PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ting, LM; Shi, WX; Lewandowicz, A; Singh, V; Mwakingwe, A; Birck, MR; Ringia, EAT; Bench, G; Madrid, DC; Tyler, PC; Evans, GB; Furneaux, RH; Schramm, VL; Kim, K				Ting, LM; Shi, WX; Lewandowicz, A; Singh, V; Mwakingwe, A; Birck, MR; Ringia, EAT; Bench, G; Madrid, DC; Tyler, PC; Evans, GB; Furneaux, RH; Schramm, VL; Kim, K			Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; BIFUNCTIONAL ORNITHINE-DECARBOXYLASE; ACCELERATOR MASS-SPECTROMETRY; DEFICIENT ERYTHROCYTE CULTURE; ADENOSYL-L-METHIONINE; NUCLEOSIDE PHOSPHORYLASE; HUMAN MALARIA; PARASITIC PROTOZOA; TOXOPLASMA-GONDII; ADENOSYLMETHIONINE DECARBOXYLASE	Plasmodium falciparum is unable to synthesize purine bases and relies upon purine salvage and purine recycling to meet its purine needs. We report that purines formed as products of polyamine synthesis are recycled in a novel pathway in which 5'-methylthioinosine is generated by adenosine deaminase. The action of P. falciparum purine nucleoside phosphorylase is a convergent step of purine salvage, converting both 5'-methylthioinosine and inosine to hypoxanthine. We used accelerator mass spectrometry to verify that 5'-methylthioinosine is an active nucleic acid precursor in P. falciparum. Prior studies have shown that inhibitors of purine salvage enzymes kill malaria, but potent malaria-specific inhibitors of these enzymes have not been described previously. 5'-Methylthio-immucillin-H, a transition state analogue inhibitor that is selective for malarial relative to human purine nucleoside phosphorylase, kills P. falciparum in culture. Immucillins are currently in clinical trials for other indications and may also have application as anti-malarials.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94551 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt, New Zealand	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Callaghan Innovation	Kim, K (corresponding author), Albert Einstein Coll Med, Dept Med, 1225 Ullmann,1300 Morris Pk Ave, Bronx, NY 10461 USA.	kkim@aecom.yu.edu	Evans, Gary/I-4123-2019; Evans, Gary/B-8343-2011; Furneaux, Richard Hubert/B-4157-2015; Taylor, Erika A./F-5635-2015	Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606; Taylor, Erika A./0000-0001-5598-640X; Bench, Graham/0000-0002-1969-6867; Kim, Kami/0000-0003-3384-152X; Lewandowicz, Andrzej/0000-0002-4207-9023				Bennett EM, 2003, J BIOL CHEM, V278, P47110, DOI 10.1074/jbc.M304622200; Berger LC, 2001, J BACTERIOL, V183, P4421, DOI 10.1128/JB.183.15.4421-4434.2001; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; Chaudhary K, 2004, J BIOL CHEM, V279, P31221, DOI 10.1074/jbc.M404232200; DADDONA PE, 1984, J BIOL CHEM, V259, P1472; DADDONA PE, 1986, J BIOL CHEM, V261, P1667; Dai Y, 2001, BIOCHEMISTRY-US, V40, P6379, DOI 10.1021/bi010110y; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; ELABBADI N, 1992, ANTIMICROB AGENTS CH, V36, P50, DOI 10.1128/AAC.36.1.50; Evans GB, 2001, J ORG CHEM, V66, P5723, DOI 10.1021/jo0155613; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; KELLEY WN, 1968, J CLIN INVEST, V47, P2281, DOI 10.1172/JCI105913; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Kilpatrick JM, 2003, INT IMMUNOPHARMACOL, V3, P541, DOI 10.1016/S1567-5769(03)00044-4; Krause T, 2000, BIOCHEM J, V352, P287, DOI 10.1042/0264-6021:3520287; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Ognibene TJ, 2003, ANAL CHEM, V75, P2192, DOI 10.1021/ac026334j; Park J, 1996, BIOORGAN MED CHEM, V4, P2179, DOI 10.1016/S0968-0896(96)00228-3; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; Sekowska A, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-8; Shi WX, 2004, J BIOL CHEM, V279, P18103, DOI 10.1074/jbc.C400068200; Striepen B, 2004, P NATL ACAD SCI USA, V101, P3154, DOI 10.1073/pnas.0304686101; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; TRACKMAN PC, 1983, J BIOL CHEM, V258, P6717; Trigg P. I., 1998, MALARIA PARASITE BIO, P11; Turteltaub KW, 2000, CURR PHARM DESIGN, V6, P991, DOI 10.2174/1381612003400047; Webster H K, 1984, Adv Exp Med Biol, V165 Pt A, P225; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Wrenger C, 2001, J BIOL CHEM, V276, P29651, DOI 10.1074/jbc.M100578200	36	106	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9547	9554		10.1074/jbc.M412693200	http://dx.doi.org/10.1074/jbc.M412693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15576366	Green Submitted, hybrid			2022-12-25	WOS:000227453100109
J	Harrison, JR; Huang, YF; Wilson, KA; Kelly, PL; Adams, DJ; Gronowicz, GA; Clark, SH				Harrison, JR; Huang, YF; Wilson, KA; Kelly, PL; Adams, DJ; Gronowicz, GA; Clark, SH			Col1a1 promoter-targeted expression of p20 CCAAT enhancer-binding protein beta (C/EBP beta), a truncated c/EBP beta isoform, causes osteopenia in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; C-FOS; REGULATED EXPRESSION; BONE-FORMATION; 3T3-L1 CELLS; I COLLAGEN; ALPHA; FAMILY	CCAAT enhancer-binding protein (C/EBP) transcription factors regulate adipocyte differentiation, and recent evidence suggests that osteoblasts and adipocytes share a common pluripotent progenitor in bone marrow. However, little is known about the role of C/EBP transcription factors in the control of osteoblast differentiation or function. In this study, the function of C/EBP transcription factors was disrupted in osteoblast lineage cells by overexpressing a naturally occurring dominant negative C/EBP isoform. Expression of FLp20C/EBPbeta was driven by a 3.6-kb Col1a1 promoter/first intron construct, and four transgenic ( TG) mouse lines were established. Northern blotting and reverse transcription-PCR indicated that the transgene was targeted to bone, with lower levels of expression in lung, skin, and adipose tissue. TG mice from two lines showed reduced body weight compared with wild type litter-mates. All TG lines showed evidence of osteopenia, ranging from mild to severe, as evidenced by reduced trabecular bone volume. Severely affected lines also showed reduced cortical bone width. Dynamic histomorphometry demonstrated an associated decrease in mineral apposition and bone formation rates. Long bones and calvariae of TG mice showed reduced COL1A1 and osteocalcin mRNA levels and increased bone sialoprotein mRNA, consistent with an inhibition of terminal osteoblast differentiation. Ex vivo analysis of primary osteoblast differentiation showed similar effects on marker expression and reduced expression of the mature osteoblast marker Col2.3-green fluorescent protein, demonstrating a cell-autonomous effect of the transgene. These data suggested that C/EBP transcription factors may be important determinants of osteoblast function and bone mass.	Univ Connecticut, Ctr Hlth, Dept Orthodont, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Orthopaed, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	Harrison, JR (corresponding author), Univ Connecticut, Ctr Hlth, Dept Orthodont, AM-049, Farmington, CT 06030 USA.	harrison@nso1.uchc.edu		Gronowicz, Gloria/0000-0001-7158-3598	NIAMS NIH HHS [AR40668, P30 AR46026] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040668, P30AR046026] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097-4644(20010401)81:1<23::AID-JCB1021>3.0.CO;2-H; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORTELL R, 1994, J CELL BIOCHEM, V54, P256, DOI 10.1002/jcb.240540214; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Fux C, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh001; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kalajzic Z, 2002, BONE, V31, P654, DOI 10.1016/S8756-3282(02)00912-2; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Orwoll ES, 2001, J BONE MINER RES, V16, P1962, DOI 10.1359/jbmr.2001.16.11.1962; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003-0868; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	41	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8117	8124		10.1074/jbc.M410076200	http://dx.doi.org/10.1074/jbc.M410076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15598659	hybrid			2022-12-25	WOS:000227395700083
J	Moskwa, P; Paclet, MN; Dagher, MC; Ligeti, E				Moskwa, P; Paclet, MN; Dagher, MC; Ligeti, E			Autoinhibition of p50 Rho GTPase-activating protein (GAP) is released by prenylated small GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE; CRYSTAL-STRUCTURE; NUCLEOTIDE EXCHANGE; BINDING PROTEIN; COMPLEX; RAC; DOMAIN; MECHANISM; 2-HYBRID	Interaction of p50 Rho GTPase-activating protein (p50RhoGAP) with Rho family small GTPases was investigated in a yeast two-hybrid system, by radioactive GAP assay, and in a Rac-regulated enzymatic reaction, through superoxide production by the phagocytic NADPH oxidase. The yeast two-hybrid system revealed an interaction between the C-terminal GAP domain and the N-terminal part of p50RhoGAP. The first 48 amino acids play a special role both in the stabilization of the intramolecular interaction and in recognition of the prenyl tail of small GTPases. The GAP assay and the NADPH oxidase activity indicate that the GTPase-activating effect of full-length p50RhoGAP is lower on nonprenylated than on prenylated small GTPase. Removal of amino acids 1-48 and 169-197 of p50RhoGAP increases the GAP effect on non-prenylated Rac, whereas prenylated Rae reacts equally well with the full-length and the truncated proteins. We suggest that p50RhoGAP is in an autoinhibited conformation stabilized by the stretches 1-48 and 169-197 and the prenyl group of the small GTPase plays a role in releasing this intramolecular restraint.	Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary; CHU Albert Michallon, Enzymol Lab, GREPI, F-38043 Grenoble, France; CEA, Lab Biochim & Biophys Syst Integres, Lab DRDC, F-38043 Grenoble, France	Semmelweis University; CHU Grenoble Alpes; CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Ligeti, E (corresponding author), Semmelweis Univ, Dept Physiol, POB 259, H-1444 Budapest, Hungary.	Ligeti@puskin.sote.hu		DAGHER, Marie-Claire/0000-0001-6878-3169	FOGARTY INTERNATIONAL CENTER [R03TW006421] Funding Source: NIH RePORTER; FIC NIH HHS [1 R03 TW006421-01A1] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		An Y, 2003, STRUCTURE, V11, P347, DOI 10.1016/S0969-2126(03)00034-0; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Batot G, 1998, BBA-MOL BASIS DIS, V1406, P188, DOI 10.1016/S0925-4439(98)00004-0; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blumenstein L, 2004, J BIOL CHEM, V279, P53419, DOI 10.1074/jbc.M409551200; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brouchon-Macari L, 2003, BIOTECHNIQUES, V35, P446, DOI 10.2144/03353bm01; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Fauchereau F, 2003, MOL CELL NEUROSCI, V23, P574, DOI 10.1016/S1044-7431(03)00078-2; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Geiszt M, 2001, BIOCHEM J, V355, P851, DOI 10.1042/bj3550851; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Low BC, 2000, J BIOL CHEM, V275, P14415, DOI 10.1074/jbc.275.19.14415; Medley QG, 2000, J BIOL CHEM, V275, P36116, DOI 10.1074/jbc.M003775200; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; Moskwa P, 2002, BIOCHEMISTRY-US, V41, P10710, DOI 10.1021/bi0257033; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9	35	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6716	6720		10.1074/jbc.M412563200	http://dx.doi.org/10.1074/jbc.M412563200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596440	hybrid			2022-12-25	WOS:000227332700060
J	Berger, AL; Randak, CO; Ostedgaard, LS; Karp, PH; Vermeer, DW; Welsh, MJ				Berger, AL; Randak, CO; Ostedgaard, LS; Karp, PH; Vermeer, DW; Welsh, MJ			Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl- channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CFTR CHLORIDE CHANNELS; WILD-TYPE; MUTATION; SECRETION; GENISTEIN; GENE; INHIBITION; ACTIVATION; EPITHELIUM	Compounds that enhance either the function or biosynthetic processing of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel may be of value in developing new treatments for cystic fibrosis (CF). Previous studies suggested that the herbal extract curcumin might affect the processing of a common CF mutant, CFTR-DeltaF508. Here, we tested the hypothesis that curcumin influences channel function. Curcumin increased CFTR channel activity in excised, inside-out membrane patches by reducing channel closed time and prolonging the time channels remained open. Stimulation was dose-dependent, reversible, and greater than that observed with genistein, another compound that stimulates CFTR. Curcumin-dependent stimulation required phosphorylated channels and the presence of ATP. We found that curcumin increased the activity of both wild-type and DeltaF508 channels. Adding curcumin also increased Cl- transport in differentiated non-CF airway epithelia but not in CF epithelia. These results suggest that curcumin may directly stimulate CFTR Cl- channels.	Univ Iowa, Dept Internal Med, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Phys & Biophys, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Dept Internal Med, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, 500 EMRB, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu		Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442; Randak, Christoph/0000-0003-3264-4137	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061234, R01HL029851, R37HL029851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062938] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29851, HL61234] Funding Source: Medline; NIDDK NIH HHS [DK062938] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ai T, 2004, MOL PHARMACOL, V65, P1415, DOI 10.1124/mol.65.6.1415; Becq F, 1999, J BIOL CHEM, V274, P27415, DOI 10.1074/jbc.274.39.27415; Berger AL, 2002, J BIOL CHEM, V277, P2125, DOI 10.1074/jbc.M109539200; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; Cotten JF, 1998, J BIOL CHEM, V273, P31873, DOI 10.1074/jbc.273.48.31873; David-Fox M, 2001, KRITIKA, V2, P1, DOI 10.1353/kri.2008.0035; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Derand R, 2002, J BIOL CHEM, V277, P35999, DOI 10.1074/jbc.M206121200; Dragomir A, 2004, BIOCHEM BIOPH RES CO, V322, P447, DOI 10.1016/j.bbrc.2004.07.146; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GRIBKOFF VK, 1994, J BIOL CHEM, V269, P10983; Grubb BR, 1999, PHYSIOL REV, V79, P193; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; Illek B, 1998, AM J PHYSIOL-LUNG C, V275, pL902, DOI 10.1152/ajplung.1998.275.5.L902; Illek B, 2000, AM J PHYSIOL-CELL PH, V279, pC1838, DOI 10.1152/ajpcell.2000.279.6.C1838; Karp Philip H, 2002, Methods Mol Biol, V188, P115; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Loo TW, 2004, BIOCHEM BIOPH RES CO, V325, P580, DOI 10.1016/j.bbrc.2004.10.070; Lukacs GL, 2003, NEW ENGL J MED, V349, P1401, DOI 10.1056/NEJMp038113; Melin P, 2004, BIOCHEM PHARMACOL, V67, P2187, DOI 10.1016/j.bcp.2004.02.022; Ostedgaard LS, 1999, J CELL SCI, V112, P2091; Randak C, 2003, CELL, V115, P837, DOI 10.1016/S0092-8674(03)00983-8; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEN BQ, 1995, AM J PHYSIOL-LUNG C, V269, pL561, DOI 10.1152/ajplung.1995.269.5.L561; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Song YL, 2004, J BIOL CHEM, V279, P40629, DOI 10.1074/jbc.M407308200; VANDOORNINCK JH, 1995, EMBO J, V14, P4403, DOI 10.1002/j.1460-2075.1995.tb00119.x; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; YAMAYA M, 1993, AM J PHYSIOL, V265, pL170, DOI 10.1152/ajplung.1993.265.2.L170; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	42	84	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5221	5226		10.1074/jbc.M412972200	http://dx.doi.org/10.1074/jbc.M412972200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15582996	hybrid			2022-12-25	WOS:000227217100015
J	Campbell, SJ; Henderson, CJ; Anthony, DC; Davidson, D; Clark, AJ; Wolf, CR				Campbell, SJ; Henderson, CJ; Anthony, DC; Davidson, D; Clark, AJ; Wolf, CR			The murine Cyp1a1 gene is expressed in a restricted spatial and temporal pattern during embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; POLYMERASE CHAIN-REACTION; C57BL/6N MOUSE EMBRYO; AH-RECEPTOR; TRANSGENIC MICE; AROMATIC-HYDROCARBON; CYTOCHROME P4501A1; RETINOIC ACID; TRANSCRIPTION FACTORS; RESPONSIVE ELEMENT	In adult mice the cytochrome P450 Cyp1a1 gene is not constitutively expressed but is highly inducible by foreign compounds acting through the aryl hydrocarbon (Ah) receptor. However, the expression profile of the Cyp1a1 gene in the developing embryo is not well understood. Using established transgenic mouse lines where 8.5 kb of the rat Cyp1A1 promoter is cloned upstream of the lacZ reporter gene (1), we describe the expression of the Cyp1A1-driven reporter gene in all tissues throughout stages E7-E14 of embryonic development. In contrast to the absence of constitutive Cyp1a1 and lacZ transgene expression in tissues of the adult mouse, a constitutive cell-specific and time-dependent pattern of Cyp1A1 promoter activity was observed in the embryo. This expression pattern was confirmed as reflecting the endogenous gene by measuring Cyp1a1 mRNA levels and protein expression by immunohistochemistry. The number of cells displaying endogenous Cyp1A1 activity could be increased in the embryo upon xenobiotic challenge, but only within areas where the Cyp1A1 promotor was already active. When reporter mice were bred onto a genetic background expressing a lower affinity form of the Ah receptor (DBA allele), transgene and murine Cyp1a1 protein expression were both attenuated in the adult mouse liver upon xenobiotic challenge. By comparison, constitutive Cyp1A1 promoter activity in the embryo was identical in the presence of either the high or low affinity Ah receptor. These novel data suggest that the Cyp1a1 protein may play a role in murine development and that regulation of the Cyp1a1 gene during this period is either through the action of a high affinity Ah receptor ligand or by an alternative regulatory pathway.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Agr & Food Res Council, Inst Anim Physiol & Genet Res, Edinburgh EH25 9PS, Midlothian, Scotland; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Dundee; University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Oxford	Wolf, CR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Level 5, Dundee DD1 9SY, Scotland.	roland.wolf@cancer.org.uk	Henderson, Colin/AAE-7141-2019; Henderson, Colin J/A-6347-2009; Anthony, Daniel/F-7765-2010	Henderson, Colin/0000-0002-4764-639X; Anthony, Daniel/0000-0003-1380-6655; Wolf, Charles Roland/0000-0002-6969-0113				ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; ABBOTT BD, 1995, DEV DYNAM, V204, P144, DOI 10.1002/aja.1002040205; ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; BORLAKOGLU JT, 1993, BIOCHEM PHARMACOL, V45, P1373, DOI 10.1016/0006-2952(93)90035-U; BORLAKOGLU JT, 1993, INT J BIOCHEM, V25, P1659, DOI 10.1016/0020-711X(93)90525-J; Bracken CP, 2003, CELL MOL LIFE SCI, V60, P1376, DOI 10.1007/s00018-003-2370-y; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 1996, J CELL SCI, V109, P2619; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; CHANG CY, 1993, PHARMACOGENETICS, V3, P312, DOI 10.1097/00008571-199312000-00005; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7; Conney AH, 2003, ANNU REV PHARMACOL, V43, P1, DOI 10.1146/annurev.pharmtox.43.100901.135754; Cowden KD, 2002, BIOCHEM BIOPH RES CO, V290, P1228, DOI 10.1006/bbrc.2001.6309; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V267, P184, DOI 10.1006/bbrc.1999.1913; Danielson PB, 2002, CURR DRUG METAB, V3, P561, DOI 10.2174/1389200023337054; Delescluse C, 2000, TOXICOLOGY, V153, P73, DOI 10.1016/S0300-483X(00)00305-X; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Gonzalez FJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P153, DOI 10.1016/S0003-9861(02)00364-8; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Harlow E., 1988, ANTIBODIES LAB MANUA; HERMISTON ML, 1995, AM J PHYSIOL-GASTR L, V268, pG813, DOI 10.1152/ajpgi.1995.268.5.G813; Johnson TN, 2002, XENOBIOTICA, V32, P595, DOI 10.1080/00498250210131888; Kantachuvesiri S, 2001, J BIOL CHEM, V276, P36727, DOI 10.1074/jbc.M103296200; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIMURA S, 1987, Journal of Experimental Pathology (New York), V3, P61; Larsen-Su SA, 2001, TOXICOL SCI, V64, P162, DOI 10.1093/toxsci/64.2.162; Ma Q, 2001, CURR DRUG METAB, V2, P149, DOI 10.2174/1389200013338603; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Nagy SR, 2002, BIOCHEMISTRY-US, V41, P861, DOI 10.1021/bi011373v; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; OMIECINSKI CJ, 1990, CANCER RES, V50, P4315; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; POLAND AP, 1974, J BIOL CHEM, V249, P5599; RICH KJ, 1993, J HISTOCHEM CYTOCHEM, V41, P915, DOI 10.1177/41.6.8315282; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; SADEK CM, 1994, J BIOL CHEM, V269, P16067; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHEN ES, 1989, BIOCHEM PHARMACOL, V38, P4075, DOI 10.1016/0006-2952(89)90689-8; SMITH G, 1993, BIOCHEM J, V289, P807, DOI 10.1042/bj2890807; Suter-Eichenberger R, 1999, TOXICOL LETT, V111, P117, DOI 10.1016/S0378-4274(99)00173-3; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Tomita S, 1996, BBA-GEN SUBJECTS, V1290, P273, DOI 10.1016/0304-4165(96)00030-X; TOMITA S, 1993, INT J BIOCHEM, V25, P1775; VECCHINI F, 1994, BIOCHEM BIOPH RES CO, V201, P1205, DOI 10.1006/bbrc.1994.1833; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; Wilson CL, 1998, TOXICOL PATHOL, V26, P657, DOI 10.1177/019262339802600510; Wu Q, 2002, TOXICOLOGY, V174, P119, DOI 10.1016/S0300-483X(02)00047-1; YANG HYL, 1995, BIOCHEM PHARMACOL, V49, P717, DOI 10.1016/0006-2952(94)00493-6; Zhou JG, 2003, ARCH BIOCHEM BIOPHYS, V416, P68, DOI 10.1016/S0003-9861(03)00274-1	58	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5828	5835		10.1074/jbc.M412899200	http://dx.doi.org/10.1074/jbc.M412899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572371	hybrid			2022-12-25	WOS:000227217100086
J	Lee, SJ; Kim, KM; Namkoong, S; Kim, CK; Kang, YC; Lee, H; Ha, KS; Han, JA; Chung, HT; Kwon, YG; Kim, YM				Lee, SJ; Kim, KM; Namkoong, S; Kim, CK; Kang, YC; Lee, H; Ha, KS; Han, JA; Chung, HT; Kwon, YG; Kim, YM			Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent noxa expression through the formation of s-nitrosohomocysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-DAMAGE; OXIDATIVE STRESS; RELAXING FACTOR; ATHEROSCLEROSIS; DYSFUNCTION; ACTIVATION; P53; INDUCTION; KINASE	Hyperhomocysteinemia is believed to induce endothelial dysfunction and promote atherosclerosis; however, the pathogenic mechanism has not been clearly elucidated. In this study, we examined the molecular mechanism by which homocysteine (HCy) causes endothelial cell apoptosis and by which nitric oxide (NO) affects HCy-induced apoptosis. Our data demonstrated that HCy caused caspase-dependent apoptosis in cultured human umbilical vein endothelial cells, as determined by cell viability, nuclear condensation, and caspase-3 activation and activity. These apoptotic characteristics were correlated with reactive oxygen species (ROS) production, lipid peroxidation, p53 and Noxa expression, and mitochondrial cytochrome c release following HCy treatment. HCy also induced p53 and Noxa expression and apoptosis in endothelial cells from wild type mice but not in the p53-deficient cells. The NO donor S-nitroso-N-acetylpenicillamine, adenoviral transfer of inducible NO synthase gene, and antioxidants (alpha-tocopherol and superoxide dismutase plus catalase) but not oxidized SNAP, 8-Br-cGMP, nitrite, and nitrate, suppressed ROS production, p53-dependent Noxa expression, and apoptosis induced by HCy. The cytotoxic effect of HCy was decreased by small interfering RNA-mediated suppression of Noxa expression, indicating that Noxa upregulation plays an important role in HCy-induced endothelial cell apoptosis. Overexpression of inducible NO synthase increased the formation of S-nitroso-HCy, which was inhibited by the NO synthase inhibitor N-monomethyl-L-arginine. Moreover, S-nitroso-HCy did not increase ROS generation, p53-dependent Noxa expression, and apoptosis. These results suggest that upregulation of p53-dependent Noxa expression may play an important role in the pathogenesis of atherosclerosis induced by HCy and that an increase in vascular NO production may prevent HCy-induced endothelial dysfunction by S-nitrosylation.	Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Vasc Syst Res Ctr, Chunchon 200701, Kangwon Do, South Korea; Wonkwang Univ, Sch Med, Dept Microbiol & Immunol, Iksan 570749, Chonbuk, South Korea; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea	Kangwon National University; Kangwon National University; Wonkwang University; Yonsei University	Kim, YM (corresponding author), Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea.	ymkim@kangwon.ae.kr	Ha, Kwon-Soo/AAU-4417-2020	Ha, Kwon-Soo/0000-0002-4219-1787; Lee, Seon-Jin/0000-0001-7214-7536; Kim, Chunki/0000-0003-2410-9118				Aoki M, 2001, HYPERTENSION, V38, P48, DOI 10.1161/01.HYP.38.1.48; Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358; Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451; Bessede G, 2001, FASEB J, V15, P1927, DOI 10.1096/fj.00-0848com; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Friebe A, 1997, BIOCHEMISTRY-US, V36, P1194, DOI 10.1021/bi962047w; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HLADOVEC J, 1979, BLOOD VESSELS, V16, P202; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; Kauser K, 2000, AM J PHYSIOL-HEART C, V278, pH1679, DOI 10.1152/ajpheart.2000.278.5.H1679; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Landmesser U, 2000, SEMIN THROMB HEMOST, V26, P529, DOI 10.1055/s-2000-13209; Lee OH, 2000, BIOCHEM BIOPH RES CO, V268, P47, DOI 10.1006/bbrc.2000.2087; Lee SJ, 2003, MOL CELLS, V16, P97; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; MONCADA S, 1991, PHARMACOL REV, V43, P109; Mujumdar VS, 2001, J CELL BIOCHEM, V82, P491, DOI 10.1002/jcb.1175; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; Rodriguez H, 1999, BIOCHEMISTRY-US, V38, P16578, DOI 10.1021/bi9918994; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; Shen YH, 2004, CIRC RES, V94, P1310, DOI 10.1161/01.RES.0000129180.13992.43; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; Suhara T, 2004, HYPERTENSION, V43, P1208, DOI 10.1161/01.HYP.0000127914.94292.76; Tawakol A, 1997, CIRCULATION, V95, P1119; Tsen CM, 2003, CHINESE J PHYSIOL, V46, P129; Tzeng E, 1997, SURGERY, V122, P255, DOI 10.1016/S0039-6060(97)90016-7; Verma S, 2002, CIRCULATION, V106, P913, DOI 10.1161/01.CIR.0000029802.88087.5E; Wang XD, 2001, GENE DEV, V15, P2922; Wattanapitayakul SK, 2000, FASEB J, V14, P271, DOI 10.1096/fasebj.14.2.271; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	46	65	76	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5781	5788		10.1074/jbc.M411224200	http://dx.doi.org/10.1074/jbc.M411224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15561702	hybrid			2022-12-25	WOS:000227217100080
J	Lindersson, E; Lundvig, D; Petersen, C; Madsen, P; Nyengaard, JR; Hojrup, P; Moos, T; Otzen, D; Gai, WP; Blumbergs, PC; Jensen, PH				Lindersson, E; Lundvig, D; Petersen, C; Madsen, P; Nyengaard, JR; Hojrup, P; Moos, T; Otzen, D; Gai, WP; Blumbergs, PC; Jensen, PH			P25 alpha stimulates a-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-SYSTEM ATROPHY; PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; LOCUS TRIPLICATION; BETA-SYNUCLEIN; PROTEIN P25; BRAIN; FILAMENTS; GENE	Aggregation of the nerve cell protein a-synuclein is a characteristic of the common neurodegenerative alpha-synucleinopathies like Parkinson's disease and Lewy body dementia, and it plays a direct pathogenic role as demonstrated by early onset diseases caused by missense mutations and multiplication of the alpha-synuclein gene. We investigated the existence of alpha-synuclein pro-aggregatory brain proteins whose dysregulation may contribute to disease progression, and we identified the brain-specific p25alpha as a candidate that preferentially binds to alpha-synuclein in its aggregated state. Functionally, purified recombinant human p25alpha strongly stimulates the aggregation of alpha-synuclein in vitro as demonstrated by thioflavin-T fluorescence and quantitative electron microscopy. p25alpha is normally only expressed in oligodendrocytes in contrast to alpha-synuclein, which is normally only expressed in neurons. This expression pattern is changed in alpha-synucleinopathies. In multiple systems atrophy, degenerating oligodendrocytes displayed accumulation of p25alpha and dystopically expressed a-synuclein in the glial cytoplasmic inclusions. In Parkinson's disease and Lewy body dementia, p25alpha was detectable in the neuronal Lewy body inclusions along with alpha-synuclein. The localization in alpha-synuclein-containing inclusions was verified biochemically by immunological detection in Lewy body inclusions purified from Lewy body dementia tissue and glial cytoplasmic inclusions purified from tissue from multiple systems atrophy. We suggest that p25alpha plays a pro-aggregatory role in the common neurodegenerative disorders hallmarked by a-synuclein aggregates.	Aarhus Univ, Dept Biochem Med, Inst Med Biochem, DK-8000 Aarhus, Denmark; Aarhus Univ, Stereol Res & Elect Microscopy Lab, DK-8000 Aarhus, Denmark; Univ So Denmark, Dept Biol Mol, DK-5000 Odense, Denmark; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Univ Aalborg, Dept Life Sci, DK-9220 Aalborg, Denmark; Flinders Univ S Australia, Sch Med, Dept Human Physiol, Bedford Pk, SA 5042, Australia; Inst Med & Vet Sci, Dept Neuropathol, Bedford Pk, SA 5042, Australia	Aarhus University; Aarhus University; University of Southern Denmark; University of Copenhagen; Aalborg University; Flinders University South Australia; Institute Medical & Veterinary Science Australia	Jensen, PH (corresponding author), Aarhus Univ, Dept Biochem Med, Inst Med Biochem, DK-8000 Aarhus, Denmark.	phj@biokemi.au.dk	Gai, Wei-Ping/A-3700-2008; Højrup, Peter/ABG-8477-2020	Otzen, Daniel/0000-0002-2918-8989; Moos, Torben/0000-0001-9989-0207; Jensen, Poul Henning/0000-0002-4439-9020; Hojrup, Peter/0000-0002-7838-6180; Madsen, Peder Sondergaard/0000-0002-8845-4802				Bodles AM, 2001, J NEUROCHEM, V78, P384, DOI 10.1046/j.1471-4159.2001.00408.x; CELIS JE, 1997, CELL BIOL LAB HDB, P222; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Gai WP, 1999, J NEUROCHEM, V73, P2093; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; Gai WP, 1995, BRAIN, V118, P1447, DOI 10.1093/brain/118.6.1447; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; Goers J, 2003, BIOCHEMISTRY-US, V42, P8465, DOI 10.1021/bi0341152; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; HERMANSON GT, 1999, BIOCONJUGATE TECHNIQ, P256; Hu RM, 2000, P NATL ACAD SCI USA, V97, P9543, DOI 10.1073/pnas.160270997; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Martin CP, 2002, BBA-MOL BASIS DIS, V1586, P113; Miller DW, 2004, NEUROLOGY, V62, P1835, DOI 10.1212/01.WNL.0000127517.33208.F4; Moos T, 1996, J HISTOCHEM CYTOCHEM, V44, P591, DOI 10.1177/44.6.8666744; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen MS, 2001, J BIOL CHEM, V276, P22680, DOI 10.1074/jbc.M101181200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; TAKAHASHI M, 1993, J NEUROCHEM, V60, P228, DOI 10.1111/j.1471-4159.1993.tb05842.x; TAKAHASHI M, 1991, FEBS LETT, V289, P37, DOI 10.1016/0014-5793(91)80903-G; Tirian L, 2003, P NATL ACAD SCI USA, V100, P13976, DOI 10.1073/pnas.2436331100; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Yokozeki T, 1998, J NEUROCHEM, V71, P410; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	48	146	154	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5703	5715		10.1074/jbc.M410409200	http://dx.doi.org/10.1074/jbc.M410409200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590652	hybrid			2022-12-25	WOS:000227217100072
J	Podesta, M; Benvenuto, F; Pitto, A; Figari, O; Bacigalupo, A; Bruzzone, S; Guida, L; Franco, L; Paleari, L; Bodrato, N; Usai, C; De Flora, A; Zocchi, E				Podesta, M; Benvenuto, F; Pitto, A; Figari, O; Bacigalupo, A; Bruzzone, S; Guida, L; Franco, L; Paleari, L; Bodrato, N; Usai, C; De Flora, A; Zocchi, E			Concentrative uptake of cyclic ADP-ribose generated by BST-1(+) stroma stimulates proliferation of human hematopoietic progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; INTRACELLULAR CALCIUM; NUCLEOSIDE TRANSPORTERS; 3T3 FIBROBLASTS; CYCLASE; INFLUX; CD38; BST-1/CD157; 3T3-CELLS; CULTURES	Cyclic ADP-ribose (cADPR) is an intracellular calcium mobilizer generated from NAD(+) by the ADP-ribosyl cyclases CD38 and BST-1. cADPR, both exogenously added and paracrinally produced by a CD38(+) feeder layer, has recently been demonstrated to stimulate the in vitro proliferation of human hemopoietic progenitors (HP) and also the in vivo expansion of hemopoietic stem cells. The low density of BST-1 expression on bone marrow (BM) stromal cells and the low specific activity of the enzyme made it unclear whether cADPR generation by a BST-1(+) stroma could stimulate HP proliferation in the BM microenvironment. We developed and characterized two BST-1(+) stromal cell lines, expressing an ectocellular cyclase activity similar to that of BST-1' human mesenchymal stem cells, the precursors of BM stromal cells. Long term co-culture of cord blood-derived HP over these BST-1' feeders determined their expansion. Influx of paracrinally generated cADPR into clonogenic HP was mediated by a concentrative, nitrobenzylthioinosine- and dipyridamole-inhibitable nucleoside transporter, this providing a possible explanation to the effectiveness of the hormone-like concentrations of the cyclic nucleotide measured in the medium conditioned by BST-1' feeders. These results suggest that the BST-1-catalyzed generation of extracellular cADPR, followed by the concentrative uptake of the cyclic nucleotide by HP, may be physiologically relevant in normal hemopoiesis.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; G Gaslini Inst Children, I-16147 Genoa, Italy; CNR, Inst Biophys, I-16149 Genoa, Italy; Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, Biotechnol Res Labs, I-27100 Pavia, Italy; San Martino Hosp, Dept Hematol, Div 2, I-16132 Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); IRCCS Fondazione San Matteo; University of Genoa; IRCCS AOU San Martino IST	Zocchi, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV-1, I-16132 Genoa, Italy.	ezocchi@unige.it	Podestà, Marina/K-3875-2016; Bruzzone, Santina/A-4264-2015	Podestà, Marina/0000-0002-6755-613X; Bruzzone, Santina/0000-0003-2034-3716; Usai, Cesare/0000-0001-8863-7759; Paleari, Laura/0000-0002-6176-2979				Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 2003, J CELL BIOL, V163, P837, DOI 10.1083/jcb.200307016; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bruzzone S, 2001, FASEB J, V15, P10; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Franco L, 1998, FASEB J, V12, P1507; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Graeff R, 2001, J BIOL CHEM, V276, P12169, DOI 10.1074/jbc.M011299200; Guida L, 2004, J BIOL CHEM, V279, P22066, DOI 10.1074/jbc.M314137200; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 2002, CYCLIC ADP RIBOSE NA, P143; LEE HC, 2002, CYCLIC ADP RIBOSE NA; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Moore BE, 2003, LEUKEMIA, V17, P1205, DOI 10.1038/sj.leu.2402956; MORGAN AJ, 2002, STRUCTURES METABOLIS, P167; Paterson A. R. P., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P14; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; Podesta M, 2002, FASEB J, V16, P310, DOI 10.1096/fj.02-0520fje; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Sato A, 1999, BIOCHEM J, V337, P491, DOI 10.1042/0264-6021:3370491; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; Soler C, 1998, J BIOL CHEM, V273, P26939, DOI 10.1074/jbc.273.41.26939; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; Wang J, 1997, PHARM RES-DORDR, V14, P1524, DOI 10.1023/A:1012113931332; Yamamoto-Katayama S, 2002, J MOL BIOL, V316, P711, DOI 10.1006/jmbi.2001.5386; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 2001, FASEB J, V15, P1610, DOI 10.1096/fj.00-0803fje	36	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5343	5349		10.1074/jbc.M408085200	http://dx.doi.org/10.1074/jbc.M408085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15574424	hybrid			2022-12-25	WOS:000227217100030
J	Stolovich, M; Lerer, T; Bolkier, Y; Cohen, H; Meyuhas, O				Stolovich, M; Lerer, T; Bolkier, Y; Cohen, H; Meyuhas, O			Lithium can relieve translational repression of TOP mRNAs elicited by various blocks along the cell cycle in a glycogen synthase kinase-3-and S6-kinase-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PROTEIN GENE; AMINO-ACIDS; C-ZETA; ACTIVATION; PHOSPHORYLATION; RAPAMYCIN; GROWTH; TRACT; EXPRESSION	TOP mRNAs are translationally controlled by mitogenic, growth, and nutritional stimuli through a 5'-terminal oligopyrimidine tract. Here we show that LiCl can alleviate the translational repression of these mRNAs when progression through the cell cycle is blocked at G., G(1)/S, or G(2)/M phases in different cell lines and by various physiological and chemical means. This derepressive effect of LiCl does not involve resumption of cell division. Unlike its efficient derepressive effect in mitotically arrested cells, LiCl alleviates inefficiently the repression of TOP mRNAs in amino acid-deprived cells and has no effect in lymphoblastoids whose TOP mRNAs are constitutively repressed even when they are proliferating. LiCl is widely used as a relatively selective inhibitor of glycogen synthase kinase-3. However, inhibition per se of this enzyme by more specific drugs failed to derepress the translation of TOP mRNAs, implying that relief of the translational repression of TOP mRNAs by LiCl is carried out in a glycogen synthase kinase-3independent manner. Moreover, this effect is apparent, at least in some cell lines, in the absence of S6-kinase 1 activation and ribosomal protein S6 phosphorylation, thus further supporting the notion that translational control of TOP mRNAs does not rely on either of these variables.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Meyuhas, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	meyuhas@cc.huji.ac.il						Agam G, 2003, PROG NEURO-PSYCHOPH, V27, P723, DOI 10.1016/S0278-5846(03)00125-8; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Armstrong JL, 2001, J BIOL CHEM, V276, P952, DOI 10.1074/jbc.M004812200; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Barth-Baus D, 2002, NUCLEIC ACIDS RES, V30, P1919, DOI 10.1093/nar/30.9.1919; Caldarola S, 2004, J BIOL CHEM, V279, P13522, DOI 10.1074/jbc.M310574200; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Hatse S, 1999, BIOCHEM PHARMACOL, V58, P539, DOI 10.1016/S0006-2952(99)00035-0; Hornstein E, 2001, COLD SPRING HARB SYM, V66, P477, DOI 10.1101/sqb.2001.66.477; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; HYMEN SE, 1995, HDB PSYCHIAT DRUG TH; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lawlor MA, 2001, J CELL SCI, V114, P2903; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; OLIVER MH, 1989, J CELL SCI, V92, P513; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Peyrollier K, 2000, BIOCHEM J, V350, P361, DOI 10.1042/0264-6021:3500361; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Wang XM, 2002, BIOCHEM J, V367, P475, DOI 10.1042/BJ20020677; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Wood NI, 2003, BRAIN RES BULL, V61, P375, DOI 10.1016/S0361-9230(03)00141-2; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	51	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5336	5342		10.1074/jbc.M412434200	http://dx.doi.org/10.1074/jbc.M412434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15569665	hybrid			2022-12-25	WOS:000227217100029
J	Fujita, H; Fukuhara, S; Sakurai, A; Yamagishi, A; Kamioka, Y; Nakaoka, Y; Masuda, M; Mochizuki, N				Fujita, H; Fukuhara, S; Sakurai, A; Yamagishi, A; Kamioka, Y; Nakaoka, Y; Masuda, M; Mochizuki, N			Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASSF1A TUMOR-SUPPRESSOR; MEDIATES RAP1-INDUCED ADHESION; FOCAL ADHESIONS; RAS; PROTEIN; GTPASE; MEMBRANE; EFFECTOR; MOTILITY; CAPTURE	Endothelial cell migration is promoted by chemoattractants and is accompanied with microtubule extension toward the leading edge. Cytoskeletal microtubules polarize to function as rails for delivering a variety of molecules by motor proteins during cell migration. It remains, however, unclear how directional migration with polarized extension of microtubules is regulated. Here we report that Rap1 controls the migration of vascular endothelial cells. We found that Rap1-associating molecule, RAPL, which belongs to the Ras association domain family (Rassf), localized on microtubules and that activated Rap1 induced dissociation of RAPL from microtubules. A Rap1 activation-monitoring probe based on the fluorescence resonance energy transfer enabled us to demonstrate that local Rap1 activation occurs at the leading edge of the cells under the two types of cell migration, chemotaxis and wound healing. Time lapse imaging of microtubules marked by enhanced green fluorescent protein-RAPL showed the directional growth of microtubules toward the leading edge of the migrating cells. Using adenovirus, inactivation of Rap1 by expression of rap1GAPII inhibited wound healing. In addition, disconnection of Rap1 and RAPL by expression of a RAPL mutant also perturbed wound healing. Collectively, the locally activated Rap1 and its association with RAPL controls the directional migration of vascular endothelial cells.	Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Mochizuki, N (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	nmochizu@ri.ncvc.go.jp						Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Gundersen GG, 2002, NAT REV MOL CELL BIO, V3, P296, DOI 10.1038/nrm777; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Krylyshkina O, 2003, J CELL BIOL, V161, P853, DOI 10.1083/jcb.200301102; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Park HO, 1999, GENE DEV, V13, P1912, DOI 10.1101/gad.13.15.1912; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wittmann T, 2001, J CELL SCI, V114, P3795	45	55	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5022	5031		10.1074/jbc.M409701200	http://dx.doi.org/10.1074/jbc.M409701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569673	hybrid			2022-12-25	WOS:000227096600124
J	Luo, W; Zou, HY; Jin, LH; Lin, SY; Li, QX; Ye, ZY; Rui, HL; Lin, SC				Luo, W; Zou, HY; Jin, LH; Lin, SY; Li, QX; Ye, ZY; Rui, HL; Lin, SC			Axin contains three separable domains that confer intramolecular, homodimeric, and heterodimeric interactions involved in distinct functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT-SIGNALING PATHWAY; CASEIN KINASE-I; DIX DOMAIN; STRUCTURAL BASIS; BETA-CATENIN; PROTEIN; WINGLESS; BINDING; ACCUMULATION; MUTATIONS	Axin is a major scaffold protein, interacting with diverse molecules involved in a number of signaling pathways. Axin can undergo dimer/oligomerization via its DIX domain. Here we show that whereas deletion of the DIX domain at the C terminus rendered Axin incapable of forming dimer, a larger deletion of the C-terminal region restored the ability of Axin to form dimers. Detailed analyses revealed that Axin actually contains two separate domains (D and 1) in addition to the DIX domain for homodimerization. The D,I, and DIX domains alone can form homodimers. Interestingly, D and I domains strongly interact with each other, suggesting that Axin can form an intramolecular structure through D and I interaction in the absence of DIX. We also found that DIX-DIX homodimeric interaction is weak but that point mutations in the DIX domain abolished Axin homodimerization. We propose a model to suggest that Axin forms homodimeric interactions through three domains, D, I, and DIX. More importantly, lack of DIX-DIX interaction caused by point mutations in the DIX domain or deletion causes Axin to form an intramolecular loop through the D and I domains, disallowing homodimer formation. Ccd1 interacts with Axin D domain yet fails to interact with AxinDeltaDIX, confirming that D is masked after D-I looping. The Axin mutants that are defective in homodimer formation fail to activate JNK but have no effect on beta-catenin signaling. Our findings have thus provided a structural basis of conformational changes in Axin, which may underlie the diversity of Axin functions.	Xiamen Univ, Dept Biomed Sci, Sch Life Sci, Xiamen 361005, Peoples R China; Xiamen Univ, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Sch Life Sci, Xiamen 361005, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Xiamen University; Xiamen University; Hong Kong University of Science & Technology	Lin, SC (corresponding author), Xiamen Univ, Dept Biomed Sci, Sch Life Sci, Xiamen 361005, Peoples R China.	linsc@mxu.edu.cn	Li, QX/G-4669-2010; Lin, Shu-Yong/B-7726-2012; Rui, Hongliang/GNM-9930-2022; Jin, Lihua/AAN-5177-2020; Lin, SC/G-4666-2010	Lin, Shu-Yong/0000-0002-4419-1713; Rui, Hongliang/0000-0002-7584-9610; Jin, Lihua/0000-0002-2685-6048; 				Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Dale TC, 1998, BIOCHEM J, V329, P209; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jin LH, 2003, INT J CANCER, V107, P696, DOI 10.1002/ijc.11435; Jones WM, 2003, CURR BIOL, V13, pR479, DOI 10.1016/S0960-9822(03)00407-X; Julius MA, 2000, BIOCHEM BIOPH RES CO, V276, P1162, DOI 10.1006/bbrc.2000.3607; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Luo W, 2003, J BIOL CHEM, V278, P37451, DOI 10.1074/jbc.M305277200; Polakis P, 2000, GENE DEV, V14, P1837; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Shiomi K, 2003, CURR BIOL, V13, P73, DOI 10.1016/S0960-9822(02)01398-2; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Vasicek TJ, 1997, GENETICS, V147, P777; Wong CK, 2004, J BIOL CHEM, V279, P39366, DOI 10.1074/jbc.M404598200; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	32	38	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5054	5060		10.1074/jbc.M412340200	http://dx.doi.org/10.1074/jbc.M412340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15579909	Green Published, hybrid			2022-12-25	WOS:000227096600127
J	Shin, D; Groisman, EA				Shin, D; Groisman, EA			Signal-dependent binding of the response regulators PhoP and PmrA to their target promoters in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MOLECULAR CHARACTERIZATION; 2-COMPONENT SYSTEM; DNA-BINDING; COGNATE SENSOR; PROTEIN; ACTIVATION; PHOSPHORYLATION; GENES	Low Mg2+ promotes phosphorylation of the response regulators PhoP and PmrA and transcription of their activated genes in Salmonella enterica. Using chromatin immunoprecipitation, we have now determined that the PhoP and PmrA proteins are recruited to the regulatory region of their target genes when bacteria experience low Mg2+ but not when they are grown in high Mg2+. Even when the PhoP protein was artificially produced at 4-fold higher levels than the wild-type strain, promoter occupancy required the low Mg2+ signal. Substitution of the predicted phosphorylation site Asp-52 with a valine residue abolished phosphorylation of the PhoP protein, resulting in loss of PhoP binding to target promoters and transcription of PhoP-activated genes. Our results indicate that the promoter binding ability of the PhoP and PmrA proteins occurring in low Mg2+ is correlated with phosphorylation of these proteins in vivo.	Washington Univ, Sch Med, Dept Mol Microbiol, Howard Hughes Med Inst, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Howard Hughes Med Inst, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu			NIAID NIH HHS [AI49561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049561] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ames SK, 1999, P NATL ACAD SCI USA, V96, P11792, DOI 10.1073/pnas.96.21.11792; Castelli ME, 2000, J BIOL CHEM, V275, P22948, DOI 10.1074/jbc.M909335199; Chamnongpol S, 2000, J MOL BIOL, V300, P291, DOI 10.1006/jmbi.2000.3848; Chen YH, 2004, J BACTERIOL, V186, P1493, DOI 10.1128/JB.186.5.1493-1502.2004; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis R., 1980, ADV BACTERIAL GENETI; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Kato A, 2004, GENE DEV, V18, P2302, DOI 10.1101/gad.1230804; Kato A, 2003, P NATL ACAD SCI USA, V100, P4706, DOI 10.1073/pnas.0836837100; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lejona S, 2004, J BACTERIOL, V186, P2476, DOI 10.1128/JB.186.8.2476-2480.2004; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; Minagawa S, 2003, J BACTERIOL, V185, P3696, DOI 10.1128/JB.185.13.3696-3702.2003; Montagne M, 2001, J BACTERIOL, V183, P1787, DOI 10.1128/JB.183.5.1787-1791.2001; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wosten MMSM, 1999, J BIOL CHEM, V274, P27185, DOI 10.1074/jbc.274.38.27185; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x	30	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4089	4094		10.1074/jbc.M412741200	http://dx.doi.org/10.1074/jbc.M412741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569664	hybrid			2022-12-25	WOS:000227096600013
J	Brusselmans, K; Bono, F; Collen, D; Herbert, JM; Carmeliet, P; Dewerchin, M				Brusselmans, K; Bono, F; Collen, D; Herbert, JM; Carmeliet, P; Dewerchin, M			A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-INDUCED APOPTOSIS; SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; FACTOR VEGF; ERYTHROPOIETIN PROTECTS; TUMOR-CELLS; ANGIOGENESIS; NEUROPILIN-1; RECEPTOR; OXYGEN	Vascular endothelial growth factor (VEGF) is best known for its angiogenic activity on endothelial cells, but it also affects neurons, pneumocytes, and other mature cell types as well as endothelial, neural, and hematopoietic progenitors. Here, we examined its effect on pluripotential embryonic stem (ES) cells under hypoxic stress. ES cells were found to produce VEGF and to express VEGF receptor-2 and neuropilin-1 (Nrp-1), a VEGF(165) isoform-specific receptor. During hypoxia, expression levels of VEGF, Flk-1, and Nrp-1 were elevated. Inhibition or targeted gene inactivation of VEGF increased ES cell apoptosis during prolonged hypoxia (48 h) by about 10-fold. The survival activity of VEGF was specific since inhibition of other growth factors (including basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet-derived growth factor, and placental growth factor) had no effect. Neuropilin-1 was involved in the VEGF-survival activity since overexpression of Nrp-1 decreased hypoxia-induced apoptosis about 3-fold. The hypoxia-response element, via which hypoxia-inducible transcription factors up-regulate VEGF expression under hypoxic conditions, was critical since targeted deletion of this element in the VEGF promoter enhanced hypoxia-induced ES cell apoptosis to the same extent as VEGF inhibition or gene inactivation. Thus, VEGF plays a critical role in survival of ES cells during prolonged hypoxia.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Sanofi Rech, Cardiovasc Thrombosis Res Dept, F-31036 Toulouse, France	Flanders Institute for Biotechnology (VIB); KU Leuven; Sanofi-Aventis; Sanofi France	Dewerchin, M (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Campus Gasthuisberg,Herestr 49 Bus 912, B-3000 Louvain, Belgium.	mieke.dewerchin@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				AKANEYA Y, 1993, J CEREBR BLOOD F MET, V13, P1029, DOI 10.1038/jcbfm.1993.130; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2002, CANCER RES, V62, P7203; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; BLACKBURN RO, 1979, TERATOLOGY, V20, P441, DOI 10.1002/tera.1420200313; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chao W, 2003, J GENE MED, V5, P277, DOI 10.1002/jgm.347; Checiu M, 1993, Rom J Morphol Embryol, V39, P87; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Czyz J, 2003, BIOL CHEM, V384, P1391, DOI 10.1515/BC.2003.155; Durao MD, 2003, RENAL FAILURE, V25, P341, DOI 10.1081/JDI-120021149; Fang JM, 2001, CANCER RES, V61, P5731; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Foster RR, 2003, AM J PHYSIOL-RENAL, V284, pF1263, DOI 10.1152/ajprenal.00276.2002; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Graham CH, 2000, PLACENTA, V21, P443, DOI 10.1053/plac.2000.0543; Han MK, 2004, NEUROREPORT, V15, P847, DOI 10.1097/00001756-200404090-00022; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HATA Y, 1995, VIRCHOWS ARCH, V426, P479; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Htun P, 1998, J MOL CELL CARDIOL, V30, P867, DOI 10.1006/jmcc.1998.0654; Ishibashi H, 2001, ORAL ONCOL, V37, P77, DOI 10.1016/S1368-8375(00)00062-2; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Kim DH, 2004, J NEUROSURG, V100, P79, DOI 10.3171/jns.2004.100.1.0079; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Krussell JS, 2001, MOL HUM REPROD, V7, P57, DOI 10.1093/molehr/7.1.57; Kubo H, 2003, GENE DEV, V17, P322, DOI 10.1101/gad.1071203; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Musallam L, 2004, J CELL PHYSIOL, V198, P62, DOI 10.1002/jcp.10389; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Ness JK, 2004, GLIA, V46, P183, DOI 10.1002/glia.10360; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Parsa CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/jbc.M314099200; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Rabbany SY, 2003, TRENDS MOL MED, V9, P109, DOI 10.1016/S1471-4914(03)00021-2; RATTNER BA, 1975, AVIAT SPACE ENVIR MD, V46, P911; Robertson SM, 2000, DEVELOPMENT, V127, P2447; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schuch G, 2003, CANCER RES, V63, P8345; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sone M, 2003, CIRCULATION, V107, P2085, DOI 10.1161/01.CIR.0000070022.78747.1B; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stalmans I, 2003, NAT MED, V9, P173, DOI 10.1038/nm819; Sylvester KG, 2004, ARCH SURG-CHICAGO, V139, P93, DOI 10.1001/archsurg.139.1.93; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; Vesey DA, 2004, NEPHROL DIAL TRANSPL, V19, P348, DOI 10.1093/ndt/gfg547; Walsh PT, 2002, IMMUNOLOGY, V107, P461, DOI 10.1046/j.1365-2567.2002.01525.x; Wang CH, 2004, BIOCHEM BIOPH RES CO, V314, P1064, DOI 10.1016/j.bbrc.2004.01.005; Wang CL, 2004, AM J PHYSIOL-HEART C, V286, pH1985, DOI 10.1152/ajpheart.00431.2003; Yamada Y, 2003, BLOOD, V101, P1801, DOI 10.1182/blood-2002-01-0119; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje	72	82	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3493	3499		10.1074/jbc.M406613200	http://dx.doi.org/10.1074/jbc.M406613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15572379	hybrid			2022-12-25	WOS:000226983900045
J	Sadasivam, S; Gupta, S; Radha, V; Batta, K; Kundu, TK; Swarup, G				Sadasivam, S; Gupta, S; Radha, V; Batta, K; Kundu, TK; Swarup, G			Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis	ONCOGENE			English	Article						p53; ipaf; caspase-1; apoptosis; transcriptional activation; gene expression	PROTEIN TYROSINE PHOSPHATASE; CELL-DEATH; P53; CANCER; PUMA; ASC; INFLAMMASOME; EXPRESSION; GENERATION; MECHANISM	The tumor suppressor protein p53 regulates transcription of many genes that mediate cell cycle arrest, apoptosis, DNA repair and other cellular responses. Here we show that Ipaf, a human CED-4 homologue and an activator of caspase-1, is induced by p53. Overexpression of p53 by transfection in U2OS and A549 cells increased Ipaf mRNA levels. Treatment of p53-positive cell lines U2OS and MCF-7 with the DNA damaging drug, doxorubicin, which increases p53 protein level, induced expression of Ipaf mRNA but similar treatment of MCF-7-mp53 ( a clone of MCF-7 cells expressing mutant p53) and p53-negative K562 cells showed much less induction of Ipaf gene expression. Expression analysis for Ipaf mRNA in doxorubicin-treated human tumor cell lines suggests that p53-dependent as well as p53-independent mechanisms are involved in the regulation of Ipaf gene expression in a cell-type-specific manner. The Ipaf promoter was activated by normal p53 but not by His(273) mutant of p53. A functional p53-binding site was identified in the Ipaf promoter. A dominant-negative mutant of Ipaf inhibited p53-induced and doxorubicin-induced apoptosis by about 50%. Ipaf-directed small hairpin RNA downregulated p53-induced Ipaf gene expression and also reduced p53-induced apoptosis. Doxorubicin-induced apoptosis was also inhibited by Ipaf-directed small hairpin RNA. Our results show that p53 can directly induce Ipaf gene transcription, which contributes to p53-dependent apoptosis in at least some human cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Swarup, G (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	gshyam@ccmb.res.in	gupta, sanjeev/B-2824-2008; Gupta, Sanjeev/AAG-9749-2020	gupta, sanjeev/0000-0002-4691-6853; Gupta, Sanjeev/0000-0002-4691-6853; Swarup, Ghanshyam/0000-0002-8098-0509; Sadasivam, Subhashini/0000-0002-7875-7180; Kundu, Tapas/0000-0001-7790-214X				Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Burns K, 2003, CURR OPIN IMMUNOL, V15, P26, DOI 10.1016/S0952-7915(02)00017-1; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200; Gutierrez O, 2004, FEBS LETT, V568, P79, DOI 10.1016/j.febslet.2004.04.095; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Matsuda K, 2002, CANCER RES, V62, P2883; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Radha V, 1999, FEBS LETT, V453, P308, DOI 10.1016/S0014-5793(99)00734-6; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shivakrupa R, 2003, J BIOL CHEM, V278, P52188, DOI 10.1074/jbc.M310656200; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	40	45	47	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					627	636		10.1038/sj.onc.1208201	http://dx.doi.org/10.1038/sj.onc.1208201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580302				2022-12-25	WOS:000226420400010
J	Tsui, J; Inagaki, M; Schulman, H				Tsui, J; Inagaki, M; Schulman, H			Calcium/calmodulin-dependent protein kinase II ( CaMKII) localization acts in concert with substrate targeting to create spatial restriction for phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; NMDA RECEPTOR; POSTSYNAPTIC DENSITY; DENDRITIC SPINES; LIPID RAFTS; HIPPOCAMPAL-NEURONS; GLUTAMATE-RECEPTOR; PLASMA-MEMBRANE; NR2B SUBUNIT; AUTOPHOSPHORYLATION	Ca2+/calmodulin-dependent protein kinase II ( CaMKII) acts in diverse cell types by phosphorylating proteins with key calcium-dependent functions such as synaptic plasticity, electrical excitability, and neurotransmitter synthesis. CaMKII displays calcium- dependent binding to proteins in vitro and translocation to synaptic sites after glutamatergic activity in neurons. We therefore hypothesized that subcellular targeting of CaMKII can direct its substrate specificity in an activity-dependent fashion. Here, we examined whether activity-dependent colocalization of CaMKII and its substrates could result in regulation of substrate phosphorylation in cells. We find that substrates localized at cellular membranes required CaMKII translocation to these compartments to achieve effective phosphorylation. Spatial barriers to phosphorylation could be overcome by translocation and anchoring to the substrate itself or to nearby target proteins within the membrane compartment. In contrast, phosphorylation of a cytoplasmic counterpart of the substrate does not require CaMKII translocation or stable protein-protein binding. Cytosolic phosphorylation is more permissive, exhibiting partial calcium-independence. Localization-dependent substrate specificity can also show more graded levels of regulation within signaling microdomains. We find that colocalization of translocated CaMKII and its substrate to lipid rafts in the plasma membrane can modulate the magnitude of phosphorylation. Thus, dynamic regulation of both substrate and kinase localization provides a powerful and nuanced way to regulate CaMKII signal specificity.	Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94304 USA; Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94304 USA; Aichi Canc Ctr, Inst Res, Div Biochem, Nagoya, Aichi 4648681, Japan; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University; Stanford University; Aichi Cancer Center; Stanford University	Schulman, H (corresponding author), SurroMed Inc, 1430 OBrien Dr, Menlo Pk, CA 94025 USA.	hschulman@surromed.com	Inagaki, Masaki/B-9920-2016		NIGMS NIH HHS [GM40600, GM30179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030179, R01GM030179, R01GM040600] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Bayer KU, 1996, MOL CELL BIOL, V16, P29; Bradshaw JM, 2003, P NATL ACAD SCI USA, V100, P10512, DOI 10.1073/pnas.1932759100; Currie S, 2004, BIOCHEM J, V377, P357, DOI 10.1042/BJ20031043; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Elion EA, 2001, J CELL SCI, V114, P3967; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gleason MR, 2003, NAT NEUROSCI, V6, P217, DOI 10.1038/nn1011; Hagemann D, 2002, TRENDS CARDIOVAS MED, V12, P51, DOI 10.1016/S1050-1738(01)00145-1; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hering H, 2003, J NEUROSCI, V23, P3262; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 2000, J BIOL CHEM, V275, P27165; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; Lu CS, 2003, NEURON, V40, P1185, DOI 10.1016/S0896-6273(03)00786-4; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Park D, 2002, J NEUROBIOL, V52, P24, DOI 10.1002/neu.10066; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Sun XX, 2004, J BIOL CHEM, V279, P10206, DOI 10.1074/jbc.M310728200; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Terry-Lorenzo RT, 2000, J BIOL CHEM, V275, P2439, DOI 10.1074/jbc.275.4.2439; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Yoshimura Y, 2002, BIOCHEM BIOPH RES CO, V290, P948, DOI 10.1006/bbrc.2001.6320; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	52	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9210	9216		10.1074/jbc.M407653200	http://dx.doi.org/10.1074/jbc.M407653200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15582994	hybrid			2022-12-25	WOS:000227453100070
J	Zhang, ZL; Tsujimura, M; Akutsu, J; Sasaki, M; Tajima, H; Kawarabayasi, Y				Zhang, ZL; Tsujimura, M; Akutsu, J; Sasaki, M; Tajima, H; Kawarabayasi, Y			Identification of an extremely thermostable enzyme with dual sugar-1-phosphate nucleotidylyltransferase activities from an acidothermophilic archaeon, Sulfolobus tokodaii strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; DTDP-RHAMNOSE; PYROPHOSPHORYLASE; GENE; CRENARCHAEON; PATHWAY	L-Rhamnose is an essential component of the cell wall and plays roles in mediating virulence and adhesion to host tissues in many microorganisms. Glucose-1-phosphate thymidylyltransferase ( RmlA, EC 2.7.7.24) catalyzes the first reaction of the four-step pathway of L-rhamnose biosynthesis, producing dTDP-D-glucose from dTTP and glucose-1-phosphate. Three RmlA homologues of varying size have been identified in the genome of a thermophilic archaeon, Sulfolobus tokodaii strain 7. In this study, we report the heterologous expression of the largest homologue (a 401 residue-long ST0452 protein) and characterization of its thermostable activity. RmlA enzymatic activity of this protein was detected from 65 to 100 degreesC, with a half- life of 60 min at 95 degreesC and 180 min at 80 degreesC. Analysis of a deletion mutant lacking the 170-residue C-terminal domain indicated that this region has an important role in the thermostability and activity of the protein. Analyses of substrate specificity indicated that the enzymatic activity of the full- length protein is capable of utilizing alpha-D-glucose-1-phosphate and N-acetyl-D-glucosamine-1-phosphate but not alpha-D glucosamine1- phosphate. However, the protein is capable of utilizing all four deoxyribonucleoside triphosphates and UTP. Thus, the ST0452 protein is an enzyme containing both glucose- 1-phosphate thymidylyltransferase and N-acetyl-D-glucosamine-1-phosphate uridylyltransferase activities. This is the first report of a thermostable enzyme with dual sugar-1-phosphate nucleotidylyltransferase activities.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan; PSS Co Ltd, Matsudo, Chiba 2710064, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Kawarabayasi, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Higashi 1-1-1, Tsukuba, Ibaraki 3058566, Japan.	kawarabayasi.yutaka@aist.go.jp						BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; Kandler O, 1998, CELL MOL LIFE SCI, V54, P305, DOI 10.1007/s000180050156; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KOPLIN R, 1993, J BACTERIOL, V175, P7786; Li Q, 2000, MICROBIOL-UK, V146, P2291, DOI 10.1099/00221287-146-9-2291; LINDQUIST L, 1993, EUR J BIOCHEM, V211, P763, DOI 10.1111/j.1432-1033.1993.tb17607.x; Ma YF, 1997, MICROBIOL-SGM, V143, P937, DOI 10.1099/00221287-143-3-937; MACPHERSON DF, 1994, MOL MICROBIOL, V11, P281, DOI 10.1111/j.1365-2958.1994.tb00308.x; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MELO A, 1965, J BIOL CHEM, V240, P398; Niemetz R, 1997, EUR J BIOCHEM, V249, P905, DOI 10.1111/j.1432-1033.1997.00905.x; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Sivaraman J, 2002, J BIOL CHEM, V277, P44214, DOI 10.1074/jbc.M206932200; THORSON JS, 1994, J BACTERIOL, V176, P1840, DOI 10.1128/jb.176.7.1840-1849.1994; Zuccotti S, 2001, J MOL BIOL, V313, P831, DOI 10.1006/jmbi.2001.5073	22	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9698	9705		10.1074/jbc.M411211200	http://dx.doi.org/10.1074/jbc.M411211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15598657	hybrid			2022-12-25	WOS:000227453100127
J	Ambrosio, ALB; Nonato, MC; de Araujo, HSS; Arni, R; Ward, RJ; Ownby, CL; de Souza, DHF; Garratt, RC				Ambrosio, ALB; Nonato, MC; de Araujo, HSS; Arni, R; Ward, RJ; Ownby, CL; de Souza, DHF; Garratt, RC			A molecular mechanism for Lys(49)-phospholipase A(2) activity based on ligand-induced conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE-49 PHOSPHOLIPASE A(2); ASPER SNAKE-VENOM; MEMBRANE-DAMAGING ACTIVITIES; BROAD-BANDED COPPERHEAD; TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; MYOTOXIN-II; PISCIVORUS PISCIVORUS; LYSOPHOSPHATIDIC ACID; PLATELET-AGGREGATION	Agkistrodon contortrix laticinctus myotoxin is a Lys(49)- phospholipase A(2) (EC 3.1.1.4) isolated from the venom of the serpent A contortrix laticinctus (broad-banded copperhead). We present here three monomeric crystal structures of the myotoxin, obtained under different crystallization conditions. The three forms present notable structural differences and reveal that the presence of a ligand in the active site (naturally presumed to be a fatty acid) induces the exposure of a hydrophobic surface (the hydrophobic knuckle) toward the C terminus. The knuckle in A contortrix laticinctus myotoxin involves the side chains of Phe(121) and Phe(124) and is a consequence of the formation of a canonical structure for the main chain within the region of residues 118-125. Comparison with other Lys(49)-phospholipase A(2) myotoxins shows that although the knuckle is a generic structural motif common to all members of the family, it is not readily recognizable by simple sequence analyses. An activation mechanism is proposed that relates fatty acid retention at the active site to conformational changes within the C-terminal region, a part of the molecule that has long been associated with Ca2+-independent membrane damaging activity and myotoxicity. This provides, for the first time, a direct structural connection between the phospholipase "active site" and the C-terminal "myotoxic site," justifying the otherwise enigmatic conservation of the residues of the former in supposedly catalytically inactive molecules.	Univ Sao Paulo, Ints Fis Sao Carlos, Ctr Biotecnol Mol Estrutural, BR-13560970 Sao Carlos, SP, Brazil; Univ Sao Paulo, FCFRP, Dept Quim & Fis, BR-14040901 Ribeirao Preto, SP, Brazil; Univ Fed Sao Carlos, Dept Ciencias Fisiol, Ctr Biotecnol Mol Estrutural, BR-13565905 Sao Carlos, SP, Brazil; UNESP, IBILCE, Dept Fis, BR-15054000 Sao Jose De Rio Preto, SP, Brazil; Univ Sao Paulo, FFCLRP, Dept Quim, BR-14040901 Ribeirao Preto, SP, Brazil; Oklahoma State Univ, Dept Physiol Sci, Stillwater, OK 74078 USA	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal de Sao Carlos; Universidade Estadual Paulista; Universidade de Sao Paulo; Oklahoma State University System; Oklahoma State University - Stillwater	Garratt, RC (corresponding author), Caixa Postal 369, BR-13560970 Sao Carlos, SP, Brazil.	richard@if.sc.usp.br	Arni, Raghuvir K/B-2222-2013; Selistre-de-Araujo, Heloisa S/A-3792-2016; Ward, Richard John/C-2460-2012; garratt, richard c/F-6921-2011; Ambrosio, Andre/C-9089-2012; Nonato, Maria Cristina C/C-5659-2012; Arni, Raghuvir K/N-9338-2018; Ambrosio, Andre/AAB-1178-2020; Souza, Dulce H.F./B-2742-2013	Arni, Raghuvir K/0000-0003-2460-1145; Ward, Richard John/0000-0003-1136-5737; Ambrosio, Andre/0000-0002-9515-930X; Nonato, Maria Cristina C/0000-0002-4916-1505; Arni, Raghuvir K/0000-0003-2460-1145; garratt, richard/0000-0002-2016-3179				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Arni RK, 1999, ARCH BIOCHEM BIOPHYS, V366, P177, DOI 10.1006/abbi.1999.1210; ARNI RK, 1995, ACTA CRYSTALLOGR D, V51, P311, DOI 10.1107/S0907444994011455; Austin SC, 1999, PROSTAG OTH LIPID M, V58, P231, DOI 10.1016/S0090-6980(99)00041-6; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bingham CO, 1999, P ASSOC AM PHYSICIAN, V111, P516, DOI 10.1046/j.1525-1381.1999.99321.x; BON C, 1979, EUR J BIOCHEM, V99, P471, DOI 10.1111/j.1432-1033.1979.tb13278.x; Bortoleto-Bugs RK, 2004, BIOCHEM BIOPH RES CO, V322, P364, DOI 10.1016/j.bbrc.2004.06.181; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calderon L, 1999, TOXICON, V37, P683, DOI 10.1016/S0041-0101(98)00211-6; Calderon L, 1998, ARCH BIOCHEM BIOPHYS, V358, P343, DOI 10.1006/abbi.1998.0853; CHANG CC, 1977, TOXICON, V15, P571, DOI 10.1016/0041-0101(77)90108-8; Chioato L, 2002, BIOCHEM J, V366, P971, DOI 10.1042/BJ20020092; da Silva Giotto MT, 1998, PROTEINS, V30, P442, DOI 10.1002/(SICI)1097-0134(19980301)30:4<442::AID-PROT11>3.0.CO;2-I; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; de Oliveira AHC, 2001, BIOCHEMISTRY-US, V40, P6912, DOI 10.1021/bi0026728; deAraujo HSS, 1996, ARCH BIOCHEM BIOPHYS, V326, P21, DOI 10.1006/abbi.1996.0042; DELAFORTELLE E, 1997, METHODS ENZYMOL, V276; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIAZ C, 1994, ARCH BIOCHEM BIOPHYS, V312, P336, DOI 10.1006/abbi.1994.1317; DIAZ C, 1991, BIOCHIM BIOPHYS ACTA, V1070, P455, DOI 10.1016/0005-2736(91)90086-N; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Fletcher J.E., 1997, VENOM PHOSPHOLIPASE, P455; FLETCHER JE, 1981, TOXICOL APPL PHARM, V59, P375, DOI 10.1016/0041-008X(81)90209-X; FRANCIS B, 1991, ARCH BIOCHEM BIOPHYS, V284, P352, DOI 10.1016/0003-9861(91)90307-5; GERRARD JM, 1993, BIOCHEM CELL BIOL, V71, P432, DOI 10.1139/o93-064; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Gutierrez JM, 2003, TOXICON, V42, P915, DOI 10.1016/j.toxicon.2003.11.005; GUTIERREZ JM, 1984, REV BIOL TROP, V32, P213; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; HOMSIBRANDEBURGO MI, 1988, TOXICON, V26, P615, DOI 10.1016/0041-0101(88)90244-9; JOHNSON EK, 1993, TOXICON, V31, P243, DOI 10.1016/0041-0101(93)90143-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNIORPERIOD WFD, 1998, TOXICON, V36, P1395; JUNIORPERIOD WFD, 1999, TOXICON, V37, P371; JUNIORPERIOD WFD, 1997, PROTEIN PEPTIDE LETT, V4, P329; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee WH, 2001, BIOCHEMISTRY-US, V40, P28, DOI 10.1021/bi0010470; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Liu Q, 2003, J BIOL CHEM, V278, P41400, DOI 10.1074/jbc.M305210200; LOMONTE B, 1990, TOXICON, V28, P1137, DOI 10.1016/0041-0101(90)90114-M; LOMONTE B, 1990, TOXICON, V28, P379, DOI 10.1016/0041-0101(90)90075-I; Lomonte B, 2003, TOXICON, V42, P885, DOI 10.1016/j.toxicon.2003.11.008; Lomonte B, 2003, TOXICON, V42, P307, DOI 10.1016/S0041-0101(03)00149-1; LOMONTE B, 1994, BIOCHEM PHARMACOL, V47, P1509, DOI 10.1016/0006-2952(94)90525-8; LOMONTE B, 1994, J BIOL CHEM, V269, P29867; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; MEBS D, 1986, TOXICON, V24, P161, DOI 10.1016/0041-0101(86)90118-2; MEBS D, 1990, PHARMACOL THERAPEUT, V48, P223, DOI 10.1016/0163-7258(90)90081-C; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Murakami MT, 2003, TOXICON, V42, P903, DOI 10.1016/j.toxicon.2003.11.014; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nunez CE, 2001, TOXICON, V39, P1587, DOI 10.1016/S0041-0101(01)00141-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ownby C.L., 1990, HDB TOXINOLOGY, p601e653; Ownby CL, 1998, J TOXICOL-TOXIN REV, V17, P213, DOI 10.3109/15569549809009250; PEDERSEN JZ, 1995, BIOCHEMISTRY-US, V34, P4670, DOI 10.1021/bi00014a021; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Polikarpov I, 1998, J SYNCHROTRON RADIAT, V5, P72, DOI 10.1107/S0909049597014684; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; RUFINI S, 1992, BIOCHEMISTRY-US, V31, P12424, DOI 10.1021/bi00164a018; Sa JM, 2004, BIOCHEM J, V382, P191, DOI 10.1042/BJ20031946; SCOTT DL, 1992, J BIOL CHEM, V267, P22645; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Sheldrick G.M, 2001, International Tables for Macromolecular Crystallography, P333; SHIMOHIGASHI Y, 1995, J BIOCHEM-TOKYO, V118, P1037, DOI 10.1093/jb/118.5.1037; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; Treharne AC, 1997, TOXICON, V35, P613, DOI 10.1016/S0041-0101(96)00162-6; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANDENBERGH CJ, 1989, J CELL BIOCHEM, V39, P379, DOI 10.1002/jcb.240390404; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; Ward RJ, 1998, TOXICON, V36, P1623, DOI 10.1016/S0041-0101(98)00155-X; Ward RJ, 2002, BIOCHEM J, V362, P89, DOI 10.1042/0264-6021:3620089; Ward RJ, 1998, PROTEIN ENG, V11, P285, DOI 10.1093/protein/11.4.285; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; Yamaguchi Y, 1997, BIOCHEM MOL BIOL INT, V43, P19; YUAN YP, 1993, THROMB RES, V70, P471, DOI 10.1016/0049-3848(93)90089-7	89	66	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7326	7335		10.1074/jbc.M410588200	http://dx.doi.org/10.1074/jbc.M410588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596433	hybrid			2022-12-25	WOS:000227332700125
J	Au, WWY; Henderson, BR				Au, WWY; Henderson, BR			The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; GENOMIC INSTABILITY; HISTONE H2AX; PROTEIN; BREAST; BINDING; REPAIR; PHOSPHOPEPTIDE; CHECKPOINT; MUTATIONS	BRCA1 accumulates in nuclear foci during S-phase and reassembles into DNA repair-associated foci after DNA damage, reflecting its role in genome maintenance. BRCA1 comprises a RING domain at the N terminus and a BRCT domain at the C terminus, through which it associates with DNA repair proteins. The key sequences that target BRCA1 to DNA damage-induced foci have not been identified. Here, we mapped the BRCA1 foci-targeting domains of yellow fluorescence protein (YFP)tagged BRCA1 in MCF-7 breast cancer cells exposed to ionizing radiation (IR). Cancer mutations specific to the BRCT domain, but not the RING domain, abolished BRCA1 recruitment to IR-induced foci. The YFP-BRCT domain itself, however, localized poorly at IR-induced foci, and the RING domain and other sequences were negative. We discovered that only when the RING and BRCT domains were combined was foci targeting restored to levels observed for wild-type BRCA1. The RING-BRCT fusion co-localized at foci with the MDC1 DNA damage response factor and inhibited entry of endogenous BRCA1 into nuclear foci. Our results explain why exon 11-deficient BRCA1 splice variants are targeted to IR-induced foci even though they are incapable of repairing DNA damage. We propose that both RING and BRCT domains together target BRCA1 to large focal assemblies at DNA double-stranded breaks.	Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au						Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1999, CANCER RES, V59, p1752S; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; Fabbro M, 2004, EXP CELL RES, V298, P661, DOI 10.1016/j.yexcr.2004.05.004; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2004, EXP CELL RES, V293, P14, DOI 10.1016/j.yexcr.2003.09.027; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu X, 2000, Science, V289, P11; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	53	56	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6993	7001		10.1074/jbc.M408879200	http://dx.doi.org/10.1074/jbc.M408879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15569676	hybrid			2022-12-25	WOS:000227332700089
J	Hoyos, B; Jiang, SL; Hammerling, U				Hoyos, B; Jiang, SL; Hammerling, U			Location and functional significance of retinol-binding sites on the serine/threonine kinase, c-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAIN; VITAMIN-A; AUTOMATED DOCKING; ACTIVATION; SPERMATOGENESIS; PROTEINS; GROWTH; DELTA; ACID	Redox activations of serine/threonine kinases represent alternate pathways in which vitamin A plays a crucial co-factor role. Vitamin A binds the zinc finger domain of c-Raf with nanomolar affinity. The retinoid-binding site has been mapped within this structure by scanning mutagenesis. The deduced contact sites were found anchored on Phe-8, counting from the 1st conserved histidine of the zinc finger. These sites agreed with contact amino acids identified by computational docking. The boundaries of a related binding pocket were identified by mutagenesis and partially confirmed by docking trials in the protein kinase Got C1A zinc finger. They comprised Phe-7, Phe-8, and Trp-22. This trio was absent from the alphaC13 domain, explaining why the latter did not bind retinol. Reconfiguring at a minimum the two corresponding amino acids of alphaC1B, Thr-7 and Tyr-22, to conform to alphaC1A converted this domain to a binder. Deletion of the predicted retinoid-binding site in the full-length molecule created a mutant c-Raf that was deficient in retinol-dependent redox activation but fully responsive to epidermal growth factor. Our findings indicate that ligation of retinol to a specific site embedded in the regulatory domain is an important feature of c-Raf regulation in the redox pathway.	Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Hoyos, B (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.	b-hoyos@ski.mskcc.org			NATIONAL CANCER INSTITUTE [R01CA089362, P30CA008748, R01CA049933] Funding Source: NIH RePORTER; NCI NIH HHS [CA89362, CA49933, CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong Robert B., 1994, P545; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; COWARD WA, 1969, BRIT J NUTR, V23, P619, DOI 10.1079/BJN19690069; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; Green HN, 1930, BRIT J EXP PATHOL, V11, P81; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Imam A, 2001, FASEB J, V15, P28; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Lassen HCA, 1930, J HYG-CAMBRIDGE, V30, P300, DOI 10.1017/S0022172400010469; MADEN M, 1993, ACTA BIOTHEOR, V41, P425, DOI 10.1007/BF00709375; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Ross A. Catharine, 1994, P521; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SPORN MB, 1994, RETINOIDS BIOL CHEM, P521; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	37	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6872	6878		10.1074/jbc.M412695200	http://dx.doi.org/10.1074/jbc.M412695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591313	hybrid			2022-12-25	WOS:000227332700076
J	Wang, JX; Fan, JN; Laschinger, C; Arora, PD; Kapus, A; Seth, A; McCulloch, CA				Wang, JX; Fan, JN; Laschinger, C; Arora, PD; Kapus, A; Seth, A; McCulloch, CA			Smooth muscle actin determines mechanical force-induced p38 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC FIBROBLASTS; PHENOTYPIC MODULATION; ALPHA-ACTIN; IN-VITRO; MYOFIBROBLAST; BINDING; KINASE; CELLS; DIFFERENTIATION; EXPRESSION	The mitogen-activated protein kinase p38 is activated by mechanical force, but the cellular elements that mediate force-induced p38 phosphorylation are not defined. As a-smooth muscle actin (SMA) is an actin isoform associated with force generation in fibroblasts, we asked if SMA participates in the activation of p38 by force. Tensile forces (0.65 pN/mum(2)) generated by magnetic fields were applied to collagen-coated magnetite beads bound to Rat-2 cells. Immunoblotting showed that p38alpha was the predominant p38 isoform. Analysis of bead-associated proteins demonstrated that SMA enrichment of collagen receptor complexes required the alpha2beta1 integrin. SMA was present almost entirely as filaments. Swinholide depolymerized SMA filaments and blocked force-induced p38 phosphorylation and force-induced increases of SMA. Knockdown of SMA (70% reduction) using RNA interference did not affect beta-actin but inhibited force-induced p38 phosphorylation by 50%. Inhibition of Rho kinase blocked SMA filament assembly, force-induced increases of SMA, and force-induced p38 activation. Force application increased SMA content and enhanced the association of phosphorylated p38 with SMA filaments. Blockade of p38 phosphorylation by SB203586 abrogated force-induced increases of SMA. In cells transfected with SMA promoter-beta-galactosidase fusion constructs, co-transfection with constitutively active p38 or MKK6 increased SMA promoter activity by 2.5-3-fold. Dominant negative p38 blocked force-induced activation of the SMA promoter. In SMA negative cells, there was no force-induced p38 phosphorylation. We conclude that force-induced p38 phosphorylation is dependent on an SMA filament-dependent pathway that uses a feed-forward amplification loop to synergize force-induced SMA expression with p38 activation.	Univ Toronto, Canadian Inst Hlth, Grp Matrix Dynam, Fac Dent, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Surg, Fac Med, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto	McCulloch, CA (corresponding author), Univ Toronto, Canadian Inst Hlth, Grp Matrix Dynam, Fac Dent, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca						Abdulhussein R, 2004, J BIOL CHEM, V279, P31462, DOI 10.1074/jbc.M400651200; ALENGHAT FJ, 2002, SCI STKE; Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; ARORA PD, 1994, J CELL PHYSIOL, V159, P161, DOI 10.1002/jcp.1041590120; BUBB MR, 1995, J BIOL CHEM, V270, P3463, DOI 10.1074/jbc.270.8.3463; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cattelino A, 1999, MOL BIOL CELL, V10, P373, DOI 10.1091/mbc.10.2.373; CHAPONNIER C, 1995, J CELL BIOL, V130, P887, DOI 10.1083/jcb.130.4.887; D'Addario M, 2003, J BIOL CHEM, V278, P53090, DOI 10.1074/jbc.M309027200; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; D'Addario M, 2002, J BIOL CHEM, V277, P47541, DOI 10.1074/jbc.M207681200; Dugina V, 2001, J CELL SCI, V114, P3285; Dugina V, 1998, EXP CELL RES, V238, P481, DOI 10.1006/excr.1997.3868; EGHBALI M, 1992, BASIC RES CARDIOL, V87, P183; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GABBIANI G, 1987, ACTA HISTOCHEM, P33; Garcia JGN, 2002, FASEB J, V16, P1064, DOI 10.1096/fj.01-0895com; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HEACOCK CS, 1983, ANAL BIOCHEM, V135, P22, DOI 10.1016/0003-2697(83)90725-X; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2003, CURR OPIN BIOTECH, V14, P538, DOI 10.1016/j.copbio.2003.08.006; Hinz B, 2003, MOL BIOL CELL, V14, P2508, DOI 10.1091/mbc.E02-11-0729; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; HOSOYA H, 1984, J CELL BIOL, V99, P994, DOI 10.1083/jcb.99.3.994; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; Nicoletti A, 1999, CARDIOVASC RES, V41, P532, DOI 10.1016/S0008-6363(98)00305-8; OWENS GK, 1995, PHYSIOL REV, V75, P487; Patel K, 2003, J CELL PHYSIOL, V195, P435, DOI 10.1002/jcp.10267; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Schildmeyer LA, 2000, FASEB J, V14, P2213, DOI 10.1096/fj.99-0927com; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Segal G, 2001, J CELL SCI, V114, P119; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Wang J, 2003, AM J PHYSIOL-HEART C, V285, pH1871, DOI 10.1152/ajpheart.00387.2003; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776; Wang JX, 2002, J BIOL CHEM, V277, P22889, DOI 10.1074/jbc.M203130200; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wilke A, 1996, BASIC RES CARDIOL, V91, P79, DOI 10.1007/BF00795367	51	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7273	7284		10.1074/jbc.M410819200	http://dx.doi.org/10.1074/jbc.M410819200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591055	hybrid			2022-12-25	WOS:000227332700119
J	Xiong, LW; Kleerekoper, QK; He, R; Putkey, JA; Hamilton, SL				Xiong, LW; Kleerekoper, QK; He, R; Putkey, JA; Hamilton, SL			Sites on calmodulin that interact with the C-terminal tail of Ca(V)1.2 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CA2+ CHANNELS; TARGET RECOGNITION; CA2+-DEPENDENT INACTIVATION; CA2+-SENSITIVE INACTIVATION; CALCIUM-BINDING; ALPHA(1C) SUBUNIT; EXONS 40-42; MOTIF; DETERMINANTS	Two fragments of the C-terminal tail of the a, subunit (CT1, amino acids 1538-1692 and CT2, amino acids 15961692) of human cardiac L-type calcium channel (Ca(v)1.2) have been expressed, refolded, and purified. A single Ca2+-calmodulin binds to each fragment, and this interaction with Ca2+-calmodulin is required for proper folding of the fragment. Ca(2+-)calmodulin, bound to these fragments, is in a more extended conformation than calmodulin bound to a synthetic peptide representing the IQ motif, suggesting that either the conformation of the IQ sequence is different in the context of the longer fragment, or other sequences within CT2 contribute to the binding of calmodulin. NMR amide chemical shift perturbation mapping shows the backbone conformation of calmodulin is nearly identical when bound to M and CT2, suggesting that amino acids 1538-1595 do not contribute to or alter calmodulin binding to amino acids 1596-1692 of Ca(v)1.2. The interaction with CT2 produces the greatest changes in the backbone amides of hydrophobic residues in the N-lobe and hydrophilic residues in the Globe of calmodulin and has a greater effect on residues located in Ca2+ binding loops I and II in the N-lobe relative to loops III and IV in the Globe. In conclusion, Ca2+-calmodulin assumes a novel conformation when part of a complex with the C-terminal tail of the Ca(v)1.2 alpha(1) subunit that is not duplicated by synthetic peptides corresponding to the putative binding motifs.	Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA	Baylor College of Medicine; University of Texas System	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Physiol & Mol Biophys, 1 Baylor Pl, Houston, TX 77030 USA.	susanh@bcm.tmc.edu		Hamilton, Susan/0000-0003-0241-9369	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044864] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44864] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson ME, 2001, J MOL CELL CARDIOL, V33, P639, DOI 10.1006/jmcc.2000.1354; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; Ishida H, 2002, BIOCHEMISTRY-US, V41, P15536, DOI 10.1021/bi020330r; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KILHOFFER MC, 1992, BIOCHEMISTRY-US, V31, P8098, DOI 10.1021/bi00149a046; Kranz JK, 2002, J BIOL CHEM, V277, P16351, DOI 10.1074/jbc.C200139200; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Mouton J, 2001, FEBS LETT, V505, P441, DOI 10.1016/S0014-5793(01)02866-6; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peersen OB, 1997, PROTEIN SCI, V6, P794; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Putkey JA, 2003, J BIOL CHEM, V278, P49667, DOI 10.1074/jbc.C300372200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Ran XY, 2003, BIOCHEMISTRY-US, V42, P5143, DOI 10.1021/bi0271751; Rodney GG, 2001, BIOCHEMISTRY-US, V40, P12430, DOI 10.1021/bi011078a; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Tang W, 2003, BIOPHYS J, V85, P1538, DOI 10.1016/S0006-3495(03)74586-X; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Walsh KB, 2004, AM J PHYSIOL-HEART C, V286, pH186, DOI 10.1152/ajpheart.00272.2003; Wu YJ, 2004, J PHYSIOL-LONDON, V554, P145, DOI 10.1113/jphysiol.2003.053314; Wu YJ, 2001, P NATL ACAD SCI USA, V98, P2877, DOI 10.1073/pnas.051449198; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Yang DM, 2003, CIRC RES, V92, P659, DOI 10.1161/01.RES.0000064566.91495.0C; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	53	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7070	7079		10.1074/jbc.M410558200	http://dx.doi.org/10.1074/jbc.M410558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15583004	hybrid			2022-12-25	WOS:000227332700097
J	Scherberich, A; Tucker, RP; Degen, M; Brown- Luedi, M; Andres, AC; Chiquet- Ehrismann, R				Scherberich, A; Tucker, RP; Degen, M; Brown- Luedi, M; Andres, AC; Chiquet- Ehrismann, R			Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38(MAPK) activity for BMP-2 and TNF-alpha induced expression in vitro	ONCOGENE			English	Article						tumor stroma; extracellular matrix; breast cancer; p38(MAPK); alpha 8 integrin	ACTIVATED PROTEIN-KINASE; C SPLICE VARIANTS; BREAST-CANCER; NECROSIS-FACTOR; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; GROWTH-FACTOR; CELL-LINES; HA-RAS; P38	Tenascins represent a family of extracellular matrix glycoproteins with distinctive expression patterns. Here we have analyzed the most recently described member, tenascin-W, in breast cancer. Mammary tumors isolated from transgenic mice expressing hormone-induced oncogenes reveal tenascin-W in the stroma around lesions with a high likelihood of metastasis. The presence of tenascin-W was correlated with the expression of its putative receptor, alpha8 integrin. HC11 cells derived from normal mammary epithelium do not express alpha8 integrin and fail to cross tenascin-W-coated filters. However, 4T1 mammary carcinoma cells do express alpha8 integrin and their migration is stimulated by tenascin-W. The expression of tenascin-W is induced by BMP-2 but not by TGF-beta1, though the latter is a potent inducer of tenascin-C. The expression of tenascin-W is dependent on p38(MAPK) and JNK signaling pathways. Since preinflammatory cytokines also act through p38MAPK and JNK signaling pathways, the possible role of TNF-alpha in tenascin-W expression was also examined. TNF-alpha induced the expression of both tenascin-W and tenascin-C, and this induction was p38(MAPK)- and cyclooxygenase-dependent. Our results show that tenascin-W may be a useful diagnostic marker for breast malignancies, and that the induction of tenascin-W in the tumor stroma may contribute to the invasive behavior of tumor cells.	Friedrich Miescher Inst, Novartis Res Fdn, CH-4058 Basel, Switzerland; Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; Univ Bern, Dept Clin Res, Fac Med, CH-3004 Bern, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis; University of California System; University of California Davis; University of Bern; University of Geneva	Chiquet- Ehrismann, R (corresponding author), Friedrich Miescher Inst, Novartis Res Fdn, Maulbeerstr 66, CH-4058 Basel, Switzerland.	ruth.chiquet@fmi.ch	Scherberich, Arnaud/H-9554-2019; Degen, Martin/H-5791-2013	Scherberich, Arnaud/0000-0003-3468-6955; Degen, Martin/0000-0002-4356-3714				Adams M, 2002, CANCER RES, V62, P3289; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P1085, DOI 10.1016/j.biocel.2004.01.007; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P986, DOI 10.1016/j.biocel.2003.12.002; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Fischer D, 1997, MOL BIOL CELL, V8, P2055, DOI 10.1091/mbc.8.10.2055; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Geffrotin C, 2000, BBA-GEN SUBJECTS, V1524, P196, DOI 10.1016/S0304-4165(00)00158-6; Goepel C, 2000, GYNECOL ONCOL, V79, P372, DOI 10.1006/gyno.2000.5978; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Hasegawa K, 1997, ACTA NEUROPATHOL, V93, P431, DOI 10.1007/s004010050636; Huang WT, 2001, CANCER RES, V61, P8586; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kaya H, 2002, EUR J GYNAECOL ONCOL, V23, P261; Latijnhouwers MAHE, 1998, MATRIX BIOL, V17, P305, DOI 10.1016/S0945-053X(98)90083-X; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; LI F, 1994, INT J CANCER, V59, P560, DOI 10.1002/ijc.2910590421; Liu LX, 2002, WORLD J GASTROENTERO, V8, P631, DOI 10.3748/wjg.v8.i4.631; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; Munarini N, 2002, J CELL SCI, V115, P25; Neidhardt J, 2003, MOL CELL NEUROSCI, V23, P193, DOI 10.1016/S1044-7431(03)00012-5; Nikolova Z, 1998, J CELL SCI, V111, P2741; Ocvirk J, 2000, MELANOMA RES, V10, P253, DOI 10.1097/00008390-200010030-00007; Pouliot F, 2003, CANCER RES, V63, P277; QIN ZH, 1993, J EXP MED, V178, P355, DOI 10.1084/jem.178.1.355; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Scherberich A, 2004, J CELL SCI, V117, P571, DOI 10.1242/jcs.00867; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schultz RM, 2003, PROG DRUG RES, V60, P59; Schwalbe M, 2003, INT J ONCOL, V23, P89; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Vinals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014-5793(01)03236-7; Weber P, 1998, J NEUROBIOL, V35, P1; Xiong SB, 2001, CANCER RES, V61, P1727; Zweers MC, 2004, J INVEST DERMATOL, V122, P885, DOI 10.1111/j.0022-202X.2004.22401.x	43	74	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1525	1532		10.1038/sj.onc.1208342	http://dx.doi.org/10.1038/sj.onc.1208342			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15592496				2022-12-25	WOS:000227218200005
J	Novoseler, M; Hershkovits, G; Katcoff, DJ				Novoseler, M; Hershkovits, G; Katcoff, DJ			Functional domains of the yeast chromatin protein Sin1p/Spt2p can bind four-way junction and crossing DNA structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HMG-BOX; HISTONES H1; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATOR; HOLLIDAY JUNCTION; SIN1 INTERACTS; CRUCIFORM DNA; URS1 REGION; IN-VIVO	Sin1p/Spt2p is a yeast chromatin protein that, when mutated or deleted, alters the transcription of a family of genes presumably by modulating local chromatin structure. In this study, we investigated the ability of different domains of this protein to bind four-way junction DNA (4WJDNA) since 4WJDNA can serve as a model for bent double helical DNA and for the crossed structure formed at the exit and entry of DNA to the nucleosomes. Sequence alignment of Sin1p/Spt2p homologues from 11 different yeast species showed conservation of several domains. We found that three domains of Sin1p/Spt2p fused to glutathione S-transferase can each bind independently in a structure-specific manner to 4WJDNA as measured in a gel mobility shift assay. A feature common to these domains is a cluster of positively charged amino acids. Modification of this cluster resulted in either abolishment of binding or a change in the binding properties. One of the domains tested clearly bound superhelical DNA, although it failed to induce bending in a circularization assay. Poly-L-lysine, which may be viewed as a cluster of positively charged amino acids, bound 4WJDNA as well. Phenotypic analysis showed that disruption of any of these domains resulted in suppression of a his4-912delta allele, indicating that each domain has functional significance. We propose that Sin1p/Spt2p is likely to modulate local chromatin structure by binding two strands of double-stranded DNA at their crossover point.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Katcoff, DJ (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	kateoff@mail.biu.ac.il						AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baxter BK, 1998, J BACTERIOL, V180, P6484, DOI 10.1128/JB.180.24.6484-6492.1998; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; Bolt EL, 1999, J MOL BIOL, V286, P403, DOI 10.1006/jmbi.1998.2499; Callejo M, 2002, J BIOL CHEM, V277, P38416, DOI 10.1074/jbc.M202050200; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; COOPER JP, 1989, P NATL ACAD SCI USA, V86, P7336, DOI 10.1073/pnas.86.19.7336; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; FEUGHELMAN M, 1955, NATURE, V175, P834, DOI 10.1038/175834a0; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Ivanchenko M, 1997, BIOPHYS J, V72, P1388, DOI 10.1016/S0006-3495(97)78785-X; KATCOFF DJ, 1993, NUCLEIC ACIDS RES, V21, P5101, DOI 10.1093/nar/21.22.5101; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRYLOV D, 1993, P NATL ACAD SCI USA, V90, P5052, DOI 10.1073/pnas.90.11.5052; LANDSMAN D, 1993, NATURE, V363, P590, DOI 10.1038/363590b0; Lee KB, 2000, J MOL BIOL, V304, P135, DOI 10.1006/jmbi.2000.4206; LEFEBVRE L, 1993, MOL CELL BIOL, V13, P5393, DOI 10.1128/MCB.13.9.5393; Liberzon A, 1996, FEBS LETT, V388, P5, DOI 10.1016/0014-5793(96)00500-5; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; Novac O, 2002, J BIOL CHEM, V277, P11174, DOI 10.1074/jbc.M107902200; Ortiz-Lombardia M, 1999, NAT STRUCT BIOL, V6, P913; Parkinson MJ, 1999, NUCLEIC ACIDS RES, V27, P682, DOI 10.1093/nar/27.2.682; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; Perez-Martin J, 1998, MOL CELL BIOL, V18, P4157, DOI 10.1128/MCB.18.7.4157; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Ristriani T, 2000, J MOL BIOL, V296, P1189, DOI 10.1006/jmbi.2000.3527; Shpungin S, 1996, P NATL ACAD SCI USA, V93, P8274, DOI 10.1073/pnas.93.16.8274; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; SUAU P, 1977, J MOL BIOL, V117, P909, DOI 10.1016/S0022-2836(77)80005-3; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; TSUBOI M, 1967, CONFORM BIOPOLYM, V2, P689; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WINSTON F, 1984, GENETICS, V107, P179; YANEVA J, 1990, FEBS LETT, V263, P225, DOI 10.1016/0014-5793(90)81379-3; YANEVA J, 1995, P NATL ACAD SCI USA, V92, P7060, DOI 10.1073/pnas.92.15.7060; Yokoyama H, 2003, J BIOL CHEM, V278, P2767, DOI 10.1074/jbc.M210899200; YONA E, 1995, MOL GEN GENET, V246, P774, DOI 10.1007/BF00290726; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	52	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5169	5177		10.1074/jbc.M406249200	http://dx.doi.org/10.1074/jbc.M406249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15563464	hybrid			2022-12-25	WOS:000227217100009
J	Wilson, MJ; Jeyasuria, P; Parker, KL; Koopman, P				Wilson, MJ; Jeyasuria, P; Parker, KL; Koopman, P			The transcription factors steroidogenic factor-1 and SOX9 regulate expression of Vanin-1 during mouse testis development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SERTOLI-CELLS; SEXUAL DEVELOPMENT; NUCLEAR RECEPTOR; OXIDATIVE STRESS; HORMONE-RECEPTOR; PROTEIN GENE; DNA-BINDING; MICE; PROMOTER	We previously showed, using differential expression screening and in situ hybridization that Vanin-1, which encodes a glycosylphosphatidylinositol-linked membrane-associated pantetheinase, is expressed in a sex-specific manner during fetal gonad development in mice (Bowles, J., Bullejos, M., and Koopman, P. (2000) Genesis 27, 124-135). In the present study we investigate in detail the expression and regulation of Vanin-1 in the fetal testis. Vanin-1 is co-expressed with the transcription factors steroidogenic factor-1 (SF-1) and SOX9 in Sertoli cells and, at a lower level, with SF-1 in Leydig cells in developing testes. SF-1 is able to activate the transcription of the Vanin-1 promoter in in vitro reporter assays, and this activation is further augmented by SOX9. We found that SF-1 is able to bind to two sites in the Vanin-1 promoter, whereas SOX9 can bind to a single interposed site defined by DNA footprinting. Mutation of the SF-1 or SOX9 sites disrupts the binding of these factors and activation of transcription. The expression of Vanin-1 was abolished in Leydig cells of a mouse mutant lacking SF-1 in that cell type. Our findings account for the sex-and cell-type-specific expression of Vanin-1 in the developing mouse gonad in vivo, which we suggest is required to provide an appropriate environment for male germ cell development.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Queensland, Australian Res Council, Ctr Excellence Biotechnol & Dev, Brisbane, Qld 4072, Australia	University of Queensland; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Queensland	Koopman, P (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	p.koopman@imb.uq.edu.au	Koopman, Peter A/C-9416-2009; Jeyasuria, Pancharatnam/B-4710-2008	Koopman, Peter A/0000-0001-6939-0914; Jeyasuria, Pancharatnam/0000-0002-1388-906X; Wilson, Megan/0000-0003-3425-5071	NICHD NIH HHS [HD046743] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046743] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albrecht KH, 2001, DEV BIOL, V240, P92, DOI 10.1006/dbio.2001.0438; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; AurrandLions M, 1996, IMMUNITY, V5, P391, DOI 10.1016/S1074-7613(00)80496-3; BAUCHE F, 1994, FEBS LETT, V349, P392, DOI 10.1016/0014-5793(94)00709-8; Berruyer C, 2004, MOL CELL BIOL, V24, P7214, DOI 10.1128/MCB.24.16.7214-7224.2004; Beverdam A, 2003, CYTOGENET GENOME RES, V101, P242, DOI 10.1159/000074344; Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; Bowles J, 2000, GENESIS, V27, P124, DOI 10.1002/1526-968X(200007)27:3<124::AID-GENE50>3.0.CO;2-E; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; CAVE DA, 1990, FUND APPL TOXICOL, V14, P199, DOI 10.1093/toxsci/14.1.199; Chaboissier MC, 2004, DEVELOPMENT, V131, P1891, DOI 10.1242/dev.01087; de Santa Barbara P, 1998, J BIOL CHEM, V273, P29654; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DUPRE S, 1973, EUR J BIOCHEM, V40, P103, DOI 10.1111/j.1432-1033.1973.tb03173.x; DUPRE S, 1970, EUR J BIOCHEM, V16, P571, DOI 10.1111/j.1432-1033.1970.tb01119.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Grimmond S, 2000, HUM MOL GENET, V9, P1553, DOI 10.1093/hmg/9.10.1553; Harley VR, 2003, ENDOCR REV, V24, P466, DOI 10.1210/er.2002-0025; HATANO O, 1994, DEVELOPMENT, V120, P2787; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; Jeyasuria P, 2004, MOL ENDOCRINOL, V18, P1610, DOI 10.1210/me.2003-0404; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Kent J, 1996, DEVELOPMENT, V122, P2813; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Maras B, 1999, FEBS LETT, V461, P149, DOI 10.1016/S0014-5793(99)01439-8; Martin F, 2004, J CLIN INVEST, V113, P591, DOI 10.1172/JCI200419557; Martin F, 2001, IMMUNOGENETICS, V53, P296, DOI 10.1007/s002510100327; Mascaro C, 2000, BIOCHEM J, V350, P785, DOI 10.1042/0264-6021:3500785; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Mruk DD, 2002, CONTRACEPTION, V65, P305, DOI 10.1016/S0010-7824(01)00320-1; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Pitari G, 2000, FEBS LETT, V483, P149, DOI 10.1016/S0014-5793(00)02110-4; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; RANGANATHAN S, 1982, ATHEROSCLEROSIS, V44, P261, DOI 10.1016/0021-9150(82)90002-8; Rao AVSK, 2000, FREE RADICAL BIO MED, V29, P1015, DOI 10.1016/S0891-5849(00)00408-1; RAO DV, 1991, RADIAT RES, V125, P89, DOI 10.2307/3577986; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; Sarkar D, 2000, ENDOCR J, V47, P63, DOI 10.1507/endocrj.47.63; Schepers G, 2003, J BIOL CHEM, V278, P28101, DOI 10.1074/jbc.M304067200; Shea-Eaton W, 2002, MOL CELL ENDOCRINOL, V188, P161, DOI 10.1016/S0303-7207(01)00715-8; Shen JHC, 2002, MOL ENDOCRINOL, V16, P529, DOI 10.1210/me.16.3.529; Sock E, 2001, MOL CELL BIOL, V21, P6951, DOI 10.1128/MCB.21.20.6951-6959.2001; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; Watanabe K, 2000, P NATL ACAD SCI USA, V97, P1624, DOI 10.1073/pnas.97.4.1624; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; YOGANATHAN T, 1989, FREE RADICAL BIO MED, V7, P355, DOI 10.1016/0891-5849(89)90121-4	50	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5917	5923		10.1074/jbc.M412806200	http://dx.doi.org/10.1074/jbc.M412806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590666	hybrid			2022-12-25	WOS:000227217100097
J	Ogino, T; Kobayashi, M; Iwama, M; Mizumoto, K				Ogino, T; Kobayashi, M; Iwama, M; Mizumoto, K			Sendai virus RNA-dependent RNA polymerase L protein catalyzes cap methylation of virus-specific mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; P-PROTEIN; METHYLTRANSFERASE DOMAIN; KINASE ACTIVITY; TRANSCRIPTION; INITIATION; COMPLEX; IDENTIFICATION; PURIFICATION; SUBUNIT	The Sendai virus (SeV) RNA-dependent RNA polymerase complex, which consists of L and P proteins, participates in the synthesis of viral mRNAs that possess a methylated cap structure. To identify the SeV protein(s) involved in mRNA cap methylation, we developed an in vitro assay system to detect mRNA (guanine-7-)methyltransferase (G-7-MTase) activity. Viral ribonucleoprotein complexes and purified recombinant L protein but not P protein exhibited G-7-MTase activity. On the other hand, mRNA synthesis in a reconstituted transcription system using purified N-RNA (N protein-genomic RNA) complex as a template required both the L and P proteins. The enzymatic properties of SeV G-7-MTase were different from those of cellular G-7-Wase. In particular, unlike cellular G-7-MTase, the SeV enzyme preferentially methylated capped RNA containing the viral mRNA 5'-end sequences (GpppApGpG-). The C-terminal part (amino acid residues 1,756-2,228) of the L protein catalyzed cap methylation, whereas the N-terminal half (residues 1-1,120) containing putative RNA polymerase subdomains did not. This is to our knowledge the first,direct biochemical evidence that supports the idea that mononegavirus L protein catalyzes cap methylation as well as RNA synthesis.	Kitasato Univ, Dept Biochem, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan; Kitasato Inst, Biol Res Ctr, Minato Ku, Tokyo 1088642, Japan	Kitasato University	Ogino, T (corresponding author), Kitasato Univ, Dept Biochem, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	mizumotok@pharm.kitasato-u.ac.jp	Ogino, Tomoaki/M-2824-2017	Ogino, Tomoaki/0000-0002-4154-1781				ABRAHAM G, 1975, CELL, V5, P51, DOI 10.1016/0092-8674(75)90091-4; AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujnicki JM, 2002, PROTEIN ENG, V15, P101, DOI 10.1093/protein/15.2.101; CURRAN J, 1992, VIROLOGY, V189, P647, DOI 10.1016/0042-6822(92)90588-G; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; DE BP, 1985, BIOCHEM BIOPH RES CO, V126, P40, DOI 10.1016/0006-291X(85)90568-6; EINBERGER H, 1990, J VIROL, V64, P4274, DOI 10.1128/JVI.64.9.4274-4280.1990; EMERSON SU, 1975, J VIROL, V15, P1348, DOI 10.1128/JVI.15.6.1348-1356.1975; Ferron F, 2002, TRENDS BIOCHEM SCI, V27, P222, DOI 10.1016/S0968-0004(02)02091-1; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; HAMAGUCHI M, 1983, VIROLOGY, V128, P105, DOI 10.1016/0042-6822(83)90322-7; HAMMOND DC, 1992, J GEN VIROL, V73, P67, DOI 10.1099/0022-1317-73-1-67; HERCYK N, 1988, VIROLOGY, V163, P222, DOI 10.1016/0042-6822(88)90253-X; Holmes DE, 2002, J VIROL, V76, P3078, DOI 10.1128/JVI.76.6.3078-3083.2002; HORIKAMI SM, 1982, P NATL ACAD SCI-BIOL, V79, P7694, DOI 10.1073/pnas.79.24.7694; HORIKAMI SM, 1994, VIROLOGY, V205, P540, DOI 10.1006/viro.1994.1676; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; HUNT DM, 1993, VIROLOGY, V193, P786, DOI 10.1006/viro.1993.1187; ITOH N, 1987, J BIOL CHEM, V262, P1989; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; LAMB R., 2001, FIELDS VIROLOGY, V1, P1305; LAMB RA, 1976, VIROLOGY, V69, P116, DOI 10.1016/0042-6822(76)90199-9; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZUMOTO K, 1979, P NATL ACAD SCI USA, V76, P4961, DOI 10.1073/pnas.76.10.4961; MIZUMOTO K, 1995, J BIOCHEM-TOKYO, V117, P527, DOI 10.1093/oxfordjournals.jbchem.a124740; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MOYER SA, 1975, CELL, V5, P59, DOI 10.1016/0092-8674(75)90092-6; Ogino T, 2003, BIOCHEM BIOPH RES CO, V311, P283, DOI 10.1016/j.bbrc.2003.09.205; PARKS GD, 1994, J VIROL, V68, P4862, DOI 10.1128/JVI.68.8.4862-4872.1994; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; POCH O, 1990, J GEN VIROL, V71, P1153, DOI 10.1099/0022-1317-71-5-1153; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SLEAT DE, 1993, J VIROL, V67, P1334, DOI 10.1128/JVI.67.3.1334-1339.1993; Stillman EA, 1999, J VIROL, V73, P7199, DOI 10.1128/JVI.73.9.7199-7209.1999; TAKAGI T, 1995, J BIOCHEM-TOKYO, V118, P390, DOI 10.1093/oxfordjournals.jbchem.a124919; TESTA D, 1977, J VIROL, V24, P786, DOI 10.1128/JVI.24.3.786-793.1977; UDEM SA, 1984, J VIROL, V49, P57, DOI 10.1128/JVI.49.1.57-65.1984; Volchkov VE, 1999, J GEN VIROL, V80, P355, DOI 10.1099/0022-1317-80-2-355; YAMADA H, 1990, ARCH VIROL, V113, P245, DOI 10.1007/BF01316677	42	82	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4429	4435		10.1074/jbc.M411167200	http://dx.doi.org/10.1074/jbc.M411167200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574411	hybrid			2022-12-25	WOS:000227096600053
J	Fu, J; Naren, AP; Gao, XP; Ahmmed, GU; Malik, AB				Fu, J; Naren, AP; Gao, XP; Ahmmed, GU; Malik, AB			Protease-activated receptor-1 activation of endothelial cells induces protein kinase Ca-dependent phosphorylation of syntaxin 4 and Munc18c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; VON-WILLEBRAND-FACTOR; WEIBEL-PALADE BODIES; MUNC-18 INTERACTS; MEMBRANE-FUSION; EXOCYTOSIS; ALPHA; SECRETION; COMPLEX; PERMEABILITY	Endothelial cells exhibit regulated exocytosis in response to inflammatory mediators such as thrombin and histamine. The exocytosis of Weibel-Palade bodies (WPBs) containing von Willebrand factor, P-selectin, and interleukin-8 within minutes after stimulation is important for vascular homeostasis. SNARE proteins are key components of the exocytic machinery in neurons and some secretory cells, but their role in regulating exocytosis in endothelial cells is not well understood. We examined the function of SNARE proteins in mediating exocytosis of WPBs in endothelial cells. We identified the presence of syntaxin 4, syntaxin 3, and the high affinity syntaxin 4-regulatory protein Munc18c in human lung microvascular endothelial cells. Small interfering RNA-induced knockdown of syntaxin 4 (but not of syntaxin 3) inhibited exocytosis of WPBs as detected by the reduction in thrombin-induced cell surface P-selectin expression. Thrombin ligation of protease-activated receptor-1 activated the phosphorylation of syntaxin 4 and Munc18c, which, in turn, disrupted the interaction between syntaxin 4 and Munc18. Protein kinase C-alpha activation was required for the phosphorylation of syntaxin 4 and Munc18c as well as the cell surface expression of P-selectin. We also observed that syntaxin 4 knockdown inhibited the adhesion of neutrophils to thrombin-activated endothelial cells, demonstrating the functional role of syntaxin 4 in promoting endothelial adhesivity. Thus, protease-activated receptor-1-induced protein kinase C-alpha activation and phosphorylation of syntaxin 4 and Munc18c are required for the cell surface expression of P-selectin and the consequent binding of neutrophils to endothelial cells.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Tennessee System; University of Tennessee Health Science Center	Malik, AB (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	abmalik@uic.edu		Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045638, R01HL046350] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46350, HL45638, HL46573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burns AR, 1999, J LEUKOCYTE BIOL, V65, P299, DOI 10.1002/jlb.65.3.299; Cabaniols JP, 1999, MOL BIOL CELL, V10, P4033, DOI 10.1091/mbc.10.12.4033; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Craig TJ, 2003, J NEUROCHEM, V86, P1450, DOI 10.1046/j.1471-4159.2003.01955.x; Datta YH, 2001, THROMB HAEMOSTASIS, V86, P1148; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; Esmon CT, 2003, J THROMB HAEMOST, V1, P1343, DOI 10.1046/j.1538-7836.2003.00261.x; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Hamilton JR, 2001, CIRC RES, V89, P92, DOI 10.1161/hh1301.092661; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; Hirano Katsuya, 2003, J Atheroscler Thromb, V10, P211; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Javaid K, 2003, CIRC RES, V92, P1089, DOI 10.1161/01.RES.0000072971.88704.CB; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Knop M, 2002, BBA-PROTEINS PROTEOM, V1600, P162, DOI 10.1016/S1570-9639(02)00457-0; Lentsch AB, 2000, J PATHOL, V190, P343; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; McIntyre TM, 2003, CURR OPIN HEMATOL, V10, P150, DOI 10.1097/00062752-200303000-00009; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michaux G, 2004, TRAFFIC, V5, P69, DOI 10.1111/j.1600-0854.2004.00157.x; Nagy G, 2002, J NEUROSCI, V22, P9278; Naren AP, 2000, J CLIN INVEST, V105, P377, DOI 10.1172/JCI8631; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Ruggeri ZM, 2003, J THROMB HAEMOST, V1, P1335, DOI 10.1046/j.1538-7836.2003.00260.x; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Takano M, 2002, AM J PHYSIOL-HEART C, V283, pH2054, DOI 10.1152/ajpheart.01001.2001; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	48	82	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3178	3184		10.1074/jbc.M410044200	http://dx.doi.org/10.1074/jbc.M410044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15576373	hybrid			2022-12-25	WOS:000226983900009
J	Tzima, E; Reader, JS; Irani-Tehrani, M; Ewalt, KL; Schwartz, MA; Schimmel, P				Tzima, E; Reader, JS; Irani-Tehrani, M; Ewalt, KL; Schwartz, MA; Schimmel, P			VE-cadherin links tRNA synthetase cytokine to anti-angiogenic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CADHERIN; FLUID SHEAR-STRESS; INTERCELLULAR-JUNCTIONS; ADHERENS JUNCTIONS; TUBE FORMATION; BLOOD-VESSELS; CELLS; PERMEABILITY; FRAGMENT; PROLIFERATION	A natural fragment of an enzyme that catalyzes the first step of protein synthesis-human tryptophanyl-tRNA synthetase (T2-TrpRS) has potent anti-angiogenic activity. A cellular receptor through which T2-TrpRS exerts its anti-angiogenic activity has not previously been identified. Here T2-TrpRS was shown to bind at intercellular junctions of endothelial cells (ECs). Using genetic knock-outs, binding was established to depend on VE-cadherin, a calcium-dependent adhesion molecule, which is selectively expressed in ECs, concentrated at adherens junctions, and is essential for normal vascular development. In contrast, T2-TrpRS binding to EC junctions was not dependent on platelet endothelial cell adhesion molecule type-1, another adhesion molecule found at EC junctions. Pull-down assays confirmed direct complex formation between T2-TrpRS and VE-cadherin. Binding of T2-TrpRS inhibited VEGF-induced ERK activation and EC migration. Thus, a VE-cadherin-dependent pathway is proposed to link T2-TrpRS to inhibition of new blood vessel formation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Virginia, Mellon Prostate Canc Res Ctr, Cardiovasc Res Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Mellon Prostate Canc Res Ctr, Cardiovasc Res Ctr, Dept Biomed Engn, Charlottesville, VA 22908 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of Virginia; University of Virginia	Tzima, E (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	etzima@scripps.edu	Tzima, Ellie/L-9256-2017	Tzima, Ellie/0000-0002-3437-0902; schwartz, martin/0000-0002-2071-1243	NCI NIH HHS [CA92577] Funding Source: Medline; NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092577] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; DeLisser HM, 1997, AM J PATHOL, V151, P671; Hashimoto H, 1998, MICROVASC RES, V55, P179, DOI 10.1006/mvre.1997.2065; Kise Y, 2004, NAT STRUCT MOL BIOL, V11, P149, DOI 10.1038/nsmb722; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Liao F, 2002, CANCER RES, V62, P2567; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; Martinis SA, 1999, BIOCHIMIE, V81, P683, DOI 10.1016/S0300-9084(99)80126-6; Matsumura T, 1997, J IMMUNOL, V158, P3408; Nagashima H, 1997, HEART VESSELS, P110; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nicosia RF, 1999, INT REV CYTOL, V185, P1; Noria S, 1999, CIRC RES, V85, P504, DOI 10.1161/01.RES.85.6.504; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744; Salvucci O, 2004, J LEUKOCYTE BIOL, V76, P217, DOI 10.1189/jlb.1203609; Schnittler HJ, 1997, AM J PHYSIOL-HEART C, V273, pH2396, DOI 10.1152/ajpheart.1997.273.5.H2396; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; TOLSTRUP AB, 1995, J BIOL CHEM, V270, P397, DOI 10.1074/jbc.270.1.397; Turpaev KT, 1996, EUR J BIOCHEM, V240, P732, DOI 10.1111/j.1432-1033.1996.0732h.x; Tzima E, 2003, P NATL ACAD SCI USA, V100, P14903, DOI 10.1073/pnas.2436330100; Ukropec JA, 2002, EXP CELL RES, V273, P240, DOI 10.1006/excr.2001.5453; Wakasugi K, 2002, J BIOL CHEM, V277, P20124, DOI 10.1074/jbc.C200126200; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Wong CWY, 2000, MOL BIOL CELL, V11, P3109, DOI 10.1091/mbc.11.9.3109; Yang XL, 2004, TRENDS BIOCHEM SCI, V29, P250, DOI 10.1016/j.tibs.2004.03.002	39	79	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2405	2408		10.1074/jbc.C400431200	http://dx.doi.org/10.1074/jbc.C400431200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15579907	hybrid			2022-12-25	WOS:000226449100004
J	Xin, BZ; Platzer, P; Fink, SP; Reese, L; Nosrati, A; Willson, JKV; Wilson, K; Markowitz, S				Xin, BZ; Platzer, P; Fink, SP; Reese, L; Nosrati, A; Willson, JKV; Wilson, K; Markowitz, S			Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia	ONCOGENE			English	Article						colon cancer; secreted proteins; serum markers	CLINICAL-PRACTICE GUIDELINES; COLORECTAL-CANCER; TUMOR-MARKERS; FECAL DNA; PREVENTION; EXPRESSION; UPDATE; BREAST; STOOL; SERUM	Cancers of the colon and rectum are the second leading cause of cancer death among adult Americans. When detected at early stages, colon cancer is highly curable. Colonoscopy, an effective but invasive screening test, has been limited in its public acceptance. The goal of this study was to identify novel serum markers of colon cancers and precancerous colon adenomas as potential candidates for noninvasive detection of early colon neoplasms. Employing expression microarrays, we identified colon cancer secreted protein-2 (CCSP-2) as a novel transcript whose expression is generally absent in normal colon and other normal body tissues, but that is induced an average of 78-fold in Stage II, III, and IV colon cancers, as well as in colon adenomas and colon cancer cell lines. These findings were validated by real-time PCR analysis in an independent panel of colon cancer cases. Moreover, CCSP-2 was shown to encode a secreted protein that circulates stably and is detectable in the blood of mice bearing human cancer xenografts transfected with epitope-tagged CCSP-2. As a novel secreted protein that is markedly induced in colon adenomas and cancers, CCSP-2 is a novel candidate for development as a diagnostic serum marker of early stage colon cancer.	Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Prot Design Labs, Fremont, CA 94555 USA	Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Markowitz, S (corresponding author), Case Western Reserve Univ, Howard Hughes Med Inst, Wolstein Res Bldg,3rd Floor,Mailstop 7285,10900 E, Cleveland, OH 44106 USA.	sxm10@cwru.edu		Fink, Stephen/0000-0003-4107-7912	NATIONAL CANCER INSTITUTE [U01CA088130, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, U01CA88130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlquist DA, 2000, GASTROENTEROLOGY, V119, P1219, DOI 10.1053/gast.2000.19580; Bast RC, 1996, J CLIN ONCOL, V14, P2843; Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865; Bond JH, 2000, MED CLIN N AM, V84, P1163, DOI 10.1016/S0025-7125(05)70281-9; Brunschwig EB, 2003, CANCER RES, V63, P1568; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Grady WM, 2001, CANCER RES, V61, P900; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hibi K, 1998, CANCER RES, V58, P1405; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Nielsen H, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P122; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Platzer P, 2002, CANCER RES, V62, P1134; Schoen RE, 2002, NAT REV CANCER, V2, P65, DOI 10.1038/nrc705; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; Traverso G, 2002, LANCET, V359, P403, DOI 10.1016/S0140-6736(02)07591-8; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	21	16	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					724	731		10.1038/sj.onc.1208134	http://dx.doi.org/10.1038/sj.onc.1208134			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580307				2022-12-25	WOS:000226420400020
J	Petre-Draviam, CE; Williams, EB; Burd, CJ; Gladden, A; Moghadam, H; Meller, J; Diehl, JA; Knudsen, KE				Petre-Draviam, CE; Williams, EB; Burd, CJ; Gladden, A; Moghadam, H; Meller, J; Diehl, JA; Knudsen, KE			A central domain of cyclin D1 mediates nuclear receptor corepressor activity	ONCOGENE			English	Article						androgen receptor; TR beta 1; ER alpha; LxxLL; corepressor; prostate cancer	ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; DEPENDENT-KINASE; TRANSCRIPTIONAL ACTIVITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GENE-EXPRESSION; CO-REPRESSOR; ACTIVATION; PHOSPHORYLATION	Regulation of nuclear receptor activity is the focus of numerous ongoing studies to develop novel therapies for the treatment of hormone-related cancer. Although cyclin D1 functions to control the activity of several nuclear receptors, the region(s) of the protein responsible for such transcriptional comodulation remain poorly defined. Herein, we map the region of cyclin D1 required for binding and repression of the androgen receptor (AR) to a central, exclusively alpha-helical domain. Deletion of this domain disrupted AR binding and corepressor activity. Further investigations showed that this domain is sufficient for AR interaction and possesses the ability to bind histone deacetylase 3. Strikingly, overexpression of this repressor region attenuates cell cycle progression in prostatic adenocarcinoma cells. The requirement of this domain for nuclear receptor repression was conserved with respect to thyroid hormone receptor beta-1, whereas cyclin D1 activation of the estrogen receptor occurred independently of the central region. Together, these data identify a minimal repression module within cyclin D1 and demonstrate that the coactivator and corepressor functions of cyclin D1 are distinct. In addition, our data suggest that properties of the cyclin D1 central domain could be exploited to develop novel prostate cancer therapeutics.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Dept Biomed Engn, Cincinnati, OH 45267 USA; Univ Penn, Ctr Canc, Abramson Family Canc Res Ctr, Philadelphia, PA 19104 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine	Knudsen, KE (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.	Karen.Knudsen@uc.edu	Meller, Jaroslaw/A-1971-2011	Meller, Jaroslaw/0000-0002-1162-8253; Burd, Craig/0000-0002-6899-6751; Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [R01CA099996, R01CA093237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA099996, CA93237] Funding Source: Medline; NICHD NIH HHS [HDO7200-15] Funding Source: Medline; NIEHS NIH HHS [P30-ES06096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamczak R, 2004, PROTEINS, V56, P753, DOI 10.1002/prot.20176; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; BURD CJ, IN PRESS MOL ENDOCRI; Card GL, 2000, EMBO J, V19, P2877, DOI 10.1093/emboj/19.12.2877; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gumbiner LM, 1999, PROSTATE, V38, P40, DOI 10.1002/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; KATO J, 1993, GENE DEV, V7, P331; Khan OY, 2003, CURR OPIN DRUG DISC, V6, P692; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Knudsen KE, 1999, CANCER RES, V59, P2297; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Maddison LA, 2004, PROSTATE, V58, P335, DOI 10.1002/pros.10341; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Maruvada P, 2004, MOL BIOL CELL, V15, P1895, DOI 10.1091/mbc.e03-09-0636; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; POROLLO A, 2004, BIOINFORMATICS  0408; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schulze-Gahmen U, 2002, NAT STRUCT BIOL, V9, P177, DOI 10.1038/nsb756; SHAO ZH, 1995, ONCOGENE, V10, P221; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Summers M. D., 1987, TEX AGR EXP STA B, V1555; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	55	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					431	444		10.1038/sj.onc.1208200	http://dx.doi.org/10.1038/sj.onc.1208200			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558026				2022-12-25	WOS:000226279700014
J	Kellermayer, MSZ; Grama, L; Karsai, A; Nagy, A; Kahn, A; Datki, ZL; Penke, B				Kellermayer, MSZ; Grama, L; Karsai, A; Nagy, A; Kahn, A; Datki, ZL; Penke, B			Reversible mechanical unzipping of amyloid beta-fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE MOLECULES; PROTEIN FIBRILLOGENESIS; MODEL; PROTOFIBRILS; ELASTICITY; DETACHMENT; OLIGOMERS; CHAIN; DNA	Amyloid fibrils are self-associating filamentous structures, the deposition of which is considered to be one of the most important factors in the pathogenesis of Alzheimer's disease and various other disorders. Here we used single molecule manipulation methods to explore the mechanics and structural dynamics of amyloid fibrils. In mechanically manipulated amyloid fibrils, formed from either amyloid beta (Abeta) peptides 1-40 or 25-35, beta-sheets behave as elastic structures that can be "unzipped" from the fibril with constant forces. The unzipping forces were different for Abeta1-40 and Abeta25-35. Unzipping was fully reversible across a wide range of stretch rates provided that coupling, via the beta-sheet, between bound and dissociated states was maintained. The rapid, cooperative zipping together of beta-sheets could be an important mechanism behind the self-assembly of amyloid fibrils. The repetitive force patterns contribute to a mechanical fingerprint that could be utilized in the characterization of different amyloid fibrils.	Univ Pecs, Fac Med, Dept Biophys, H-7624 Pecs, Hungary; Univ Szeged, Hungarian Acad Sci, Dept Med Chem, H-6720 Szeged, Hungary; Univ Szeged, Hungarian Acad Sci, Prot Res Grp, H-6720 Szeged, Hungary	University of Pecs; Hungarian Academy of Sciences; Szeged University; Hungarian Academy of Sciences; Szeged University	Kellermayer, MSZ (corresponding author), Univ Pecs, Fac Med, Dept Biophys, H-7624 Pecs, Hungary.	miklos.kellermayer.jr@aok.pte.hu		Kellermayer, Miklos/0000-0002-5553-6553				BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Brockwell DJ, 2003, NAT STRUCT BIOL, V10, P731, DOI 10.1038/nsb968; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Carrion-Vazquez M, 2003, NAT STRUCT BIOL, V10, P738, DOI 10.1038/nsb965; Case RB, 2004, SCIENCE, V305, P222, DOI 10.1126/science.1098225; Chatellier X, 1998, EUROPHYS LETT, V41, P303, DOI 10.1209/epl/i1998-00147-6; Conti M, 2001, CHEMPHYSCHEM, V2, P610, DOI 10.1002/1439-7641(20011015)2:10<610::AID-CPHC610>3.0.CO;2-6; Fisher TE, 2000, NAT STRUCT BIOL, V7, P719; Fisher TE, 1999, TRENDS BIOCHEM SCI, V24, P379, DOI 10.1016/S0968-0004(99)01453-X; Friedsam C, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/009; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Haupt BJ, 1999, LANGMUIR, V15, P3886, DOI 10.1021/la981112v; Haupt BJ, 2002, LANGMUIR, V18, P2174, DOI 10.1021/la0112514; Hugel T, 2001, MACROMOLECULES, V34, P1039, DOI 10.1021/ma0009404; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Kellermayer MSZ, 2001, BIOPHYS J, V80, P852, DOI 10.1016/S0006-3495(01)76064-X; Kellermayer MSZ, 2003, BBA-BIOENERGETICS, V1604, P105, DOI 10.1016/S0005-2728(03)00029-X; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; Liphardt J, 2002, SCIENCE, V296, P1832, DOI 10.1126/science.1071152; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Nichols MR, 2002, BIOCHEMISTRY-US, V41, P6115, DOI 10.1021/bi015985r; Oesterhelt F, 2000, SCIENCE, V288, P143, DOI 10.1126/science.288.5463.143; Palotas A, 2002, BRAIN RES BULL, V58, P203, DOI 10.1016/S0361-9230(02)00773-6; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; Seitz M, 2003, CHEMPHYSCHEM, V4, P986, DOI 10.1002/cphc.200300760; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Selkoe DJ, 1997, AM J PSYCHIAT, V154, P1198; Serpell LC, 2000, J MOL BIOL, V300, P1033, DOI 10.1006/jmbi.2000.3908; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a	46	74	77	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8464	8470		10.1074/jbc.M411556200	http://dx.doi.org/10.1074/jbc.M411556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15596431	hybrid			2022-12-25	WOS:000227395700123
J	Sommer, ME; Smith, WC; Farrens, DL				Sommer, ME; Smith, WC; Farrens, DL			Dynamics of arrestin-rhodopsin interactions - Arrestin and retinal release are directly linked events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIGHT-REGULATED BINDING; VISUAL ARRESTIN; CONFORMATIONAL-CHANGES; METARHODOPSIN-III; SYNTHETIC PHOSPHOPEPTIDE; TRYPTOPHAN RESIDUES; ACTIVATED RHODOPSIN; STRUCTURAL-ANALYSIS; SPLICE VARIANT	In this study, we address the mechanism of visual arrestin release from light-activated rhodopsin using fluorescently labeled arrestin mutants. We find that two mutants, 172C and S251C, when labeled with the small, solvent-sensitive fluorophore monobromobimane, exhibit spectral changes only upon binding light-activated, phosphorylated rhodopsin. Our analysis indicates that these changes are probably due to a burying of the probes at these sites in the rhodopsin-arrestin or phospholipid-arrestin interface. Using a fluorescence approach based on this observation, we demonstrate that arrestin and retinal release are linked and are described by similar activation energies. However, at physiological temperatures, we find that arrestin slows the rate of retinal release similar to2-fold and abolishes the pH dependence of retinal release. Using fluorescence, EPR, and biochemical approaches, we also find intriguing evidence that arrestin binds to a post-Meta 11 photodecay product, possibly Meta III. We speculate that arrestin regulates levels of free retinal in the rod cell to help limit the formation of damaging oxidative retinal adducts. Such adducts may contribute to diseases like atrophic age-related macular degeneration (AMD). Thus, arrestin may serve to both attenuate rhodopsin signaling and protect the cell from excessive retinal levels under bright light conditions.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	Oregon Health & Science University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Farrens, DL (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	farrensd@ohsu.edu	Smith, W. Clay/AAQ-1589-2021	Sommer, Martha E./0000-0003-0493-8584	NEI NIH HHS [EY12095, EY06225] Funding Source: Medline; NIDA NIH HHS [DA14896] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Chuang JZ, 2004, J CLIN INVEST, V114, P131, DOI 10.1172/JCI200421136; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dinculescu A, 2002, J BIOL CHEM, V277, P11703, DOI 10.1074/jbc.M111833200; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Elias R, 2004, MOL VIS, V10, P672; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; FARRENS DL, 1999, REC BIOCH M, P289; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; GINIGER R, 1985, CHEM PHYS LETT, V118, P240, DOI 10.1016/0009-2614(85)85308-2; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Imamoto Y, 2003, BIOPHYS J, V85, P1186, DOI 10.1016/S0006-3495(03)74554-8; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; KOSOWER EM, 1986, J PHYS CHEM-US, V90, P5552, DOI 10.1021/j100280a014; KUHN H, 1982, METHOD ENZYMOL, V81, P489; KUHN H, 1982, METHOD ENZYMOL, V81, P556; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Ling Y, 2004, BIOPHYS J, V86, P2445, DOI 10.1016/S0006-3495(04)74301-5; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Mansoor SE, 2004, BIOCHEMISTRY-US, V43, P9426, DOI 10.1021/bi036259m; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; Nair KS, 2004, J BIOL CHEM, V279, P41240, DOI 10.1074/jbc.M406768200; Neyroz P, 1996, J BIOL CHEM, V271, P27249, DOI 10.1074/jbc.271.44.27249; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Peterson JJ, 2003, EXP EYE RES, V76, P553, DOI 10.1016/S0014-4835(03)00032-0; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; ROSS JBA, 1992, BIOCHEMISTRY-US, V31, P1585, DOI 10.1021/bi00121a002; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Sachs K, 2000, METHOD ENZYMOL, V315, P238; SATO E, 1988, BIOORG CHEM, V16, P298, DOI 10.1016/0045-2068(88)90017-X; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schroder K, 2002, J BIOL CHEM, V277, P43987, DOI 10.1074/jbc.M206211200; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Shilton BH, 2002, EUR J BIOCHEM, V269, P3801, DOI 10.1046/j.1432-1033.2002.03071.x; Smith WC, 2004, MOL VIS, V10, P392; Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2004, BIOCHEMISTRY-US, V43, P9457, DOI 10.1021/bi049337u; Wilson CJ, 1997, J PROTEIN CHEM, V16, P755, DOI 10.1023/A:1026311832660; Zawadzki KM, 2003, PROTEINS, V51, P552, DOI 10.1002/prot.10326; Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200	67	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6861	6871		10.1074/jbc.M411341200	http://dx.doi.org/10.1074/jbc.M411341200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591052	hybrid			2022-12-25	WOS:000227332700075
J	Takahashi, T; Abe, H; Arai, H; Matsubara, T; Nagai, K; Matsuura, M; Iehara, N; Yokode, M; Nishikawa, S; Kita, T; Doi, T				Takahashi, T; Abe, H; Arai, H; Matsubara, T; Nagai, K; Matsuura, M; Iehara, N; Yokode, M; Nishikawa, S; Kita, T; Doi, T			Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESANGIAL CELL-PROLIFERATION; FACTOR RECEPTOR-BETA; GROWTH-FACTOR; DIABETIC-NEPHROPATHY; EXTRACELLULAR-MATRIX; RENAL-DISEASE; SMAD1; PHOSPHORYLATION; INHIBITION; CULTURE	Mesangial cell proliferation is a significant event in the development of progressive glomerular injuries. However, the issue of how cell proliferation is involved in the development of glomerulosclerosis is unclear. Recently, we showed that the overexpression of type IV collagen (Col IV), a major component of mesangial extracellular matrix, is transcriptionally regulated by Smad1 in diabetic glomeruloselerosis. In this study, we have demonstrated the effect of the administration of an anti-platelet-derived growth factor (PDGF) beta-receptor antibody (APB5) blocking activation by the PDGF-B chain on rat glomerulonephritis and have examined the signaling pathways that regulate both glomerular cell proliferation and glomeruloselerosis in vivo and in vitro. Experimental mesangial proliferative glomerulonephritis (Thy1 GN) was induced by a single intravenous injection of anti-rat Thy-1.1 monoclonal antibody. In Thy1 GN, mesangial cell proliferation and the expression of Col IV peaked at day 6. Immunohistochemical staining ;for the expression of Smad1, phospho-Smad1 (pSmad1), and phospho-STAT3 (pSTAT3) revealed that the peak for glomerular Smad1 expression occurred at day 6, consistent with the peak for mesangial proliferation. The expression of pSmad1 was up-regulated at day 1, and the peak for glomerular pSmad1 expression occurred at day 4 of the disease. When treated with AP135, both mesangial proliferation and sclerosis were reduced significantly. The expression of Smad1, pSmad1, and pSTAT3 was also significantly reduced by the administration of AP135. PDGF induced both mesangial cell replication and Col IV synthesis in association with an increased expression of pSTAT3 and pSmad1 on cultured mesangial cells. In addition, APB5 reduced mesangial cell proliferation in association with decreased pSmad1, pSTAT3, and Col IV protein expressions in vitro. The introduction of dominant negative STAT3 significantly decreased the expression of Col IV in cultured mesangial cells. These data suggest that the activation of STAT3 and Smad1 participates in the developing process of glomerulosclerosis in experimental glomerulonephritis.	Univ Tokushima, Sch Med, Course Biol Med, Dept Clin Biol & Med, Tokushima 7708503, Japan; Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Translat Res Ctr, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan; Riken Ctr Dev Biol, Kobe, Hyogo 6500047, Japan	Tokushima University; Kyoto University; Kyoto University; Kyoto University; RIKEN	Doi, T (corresponding author), Univ Tokushima, Sch Med, Course Biol Med, Dept Clin Biol & Med, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	doi@clin.med.tokushima-u.ac.jp	Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849				ABBOUD HE, 1987, J CLIN INVEST, V80, P675, DOI 10.1172/JCI113121; Abe H, 2004, J BIOL CHEM, V279, P14201, DOI 10.1074/jbc.M310427200; BARNES JL, 1990, LAB INVEST, V62, P379; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Bokemeyer D, 2000, J AM SOC NEPHROL, V11, P232, DOI 10.1681/ASN.V112232; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Choudhury GG, 1996, KIDNEY INT, V49, P19, DOI 10.1038/ki.1996.3; DAVIES M, 1994, KIDNEY INT, V45, P320, DOI 10.1038/ki.1994.41; Dick A, 1998, DEV DYNAM, V211, P293, DOI 10.1002/(SICI)1097-0177(199804)211:4<293::AID-AJA1>3.0.CO;2-C; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; FLOEGE J, 1992, KIDNEY INT, V41, P297, DOI 10.1038/ki.1992.42; FLOEGE J, 1991, KIDNEY INT, V40, P477, DOI 10.1038/ki.1991.235; FLOEGE J, 1995, MINER ELECTROL METAB, V21, P271; FOGO A, 1989, SEMIN NEPHROL, V9, P329; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; Liu ZY, 2004, J BIOL CHEM, V279, P11313, DOI 10.1074/jbc.M312731200; Makibayashi K, 2001, AM J PATHOL, V158, P1733, DOI 10.1016/S0002-9440(10)64129-6; Meloche S, 2000, MOL CELL BIOCHEM, V212, P99, DOI 10.1023/A:1007140606333; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Nagai K, 2003, J BIOL CHEM, V278, P18229, DOI 10.1074/jbc.M213266200; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; OLSON JL, 1984, KIDNEY INT, V25, P376, DOI 10.1038/ki.1984.27; Sano H, 2002, AM J PATHOL, V161, P135, DOI 10.1016/S0002-9440(10)64165-X; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; STRIKER GE, 1985, LAB INVEST, V53, P122; STRIKER LJ, 1989, SEMIN NEPHROL, V9, P318; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065	34	49	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7100	7106		10.1074/jbc.M411064200	http://dx.doi.org/10.1074/jbc.M411064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591053	Green Submitted, hybrid			2022-12-25	WOS:000227332700100
J	Blondal, T; Hjorleifsdottir, S; Aevarsson, A; Fridjonsson, OH; Skirnisdottir, S; Wheat, JO; Hermannsdottir, AG; Hreggvidsson, GO; Smith, AV; Kristjansson, JK				Blondal, T; Hjorleifsdottir, S; Aevarsson, A; Fridjonsson, OH; Skirnisdottir, S; Wheat, JO; Hermannsdottir, AG; Hreggvidsson, GO; Smith, AV; Kristjansson, JK			Characterization of a 5 '-polynucleotide kinase/3'-phosphatase from bacteriophage RM378	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 POLYNUCLEOTIDE KINASE; RNA REPAIR ENZYME; A-ADDING ENZYMES; DEINOCOCCUS-RADIODURANS; ESCHERICHIA-COLI; T4-POLYNUCLEOTIDE KINASE; RHODOTHERMUS-MARINUS; MUTATIONAL ANALYSIS; ANTICODON NUCLEASE; HD DOMAIN	polynucleotide kinase from the thermophilic bacteriophage RM378 that infects the thermophilic eubacterium Rhodothermus marinus was identified, expressed, and purified. This polynucleotide kinase was demonstrated to have a 5'-kinase domain as well as a X-phosphohydrolase domain. The RM378 polynucleotide kinase had limited sequence similarity to the 5'-kinase domain of the T4 bacteriophage polynucleotide kinase, but apparent homology was not evident within the 3'-phosphohydrolase domain. The domain order of RM378 polynucleotide kinase was reversed relative to that of the T4 polynucleotide kinase. The RM378 phosphohydrolase domain displayed some sequence similarity with the bacterial poly(A) polymerase family, including an HD motif characteristic of the diverse superfamily of metal-dependent HD phosphohydrolases. The RM378 polynucleotide kinase was biochemically characterized and shown to possess 5'-kinase activity on RNA and single- and double-stranded DNA at elevated temperatures. It also showed phosphohydrolase activity on 2':3'-cyclic adenosine monophosphate. This description of the RM378 polynucleotide kinase, along with the recently described RM378 RNA ligase, suggests that the RM378 bacteriophage has to counter a similar antiphage mechanism in R. marinus as the one that the T4 phage has to counter in Escherichia coli.	Prokaria Ltd, IS-112 Reykjavik, Iceland; Univ Iceland, IS-101 Reykjavik, Iceland; GenThor Ltd, IS-101 Reykjavik, Iceland	University of Iceland	Kristjansson, JK (corresponding author), Prokaria Ltd, Gylfaflot 5, IS-112 Reykjavik, Iceland.	jakob.krisjansson@prokaria.com	Smith, Albert Vernon/K-5150-2015	Smith, Albert Vernon/0000-0003-1942-5845; Hreggvidsson, Gudmundur Oli/0000-0002-4958-1673; AEvarsson, Arnthor/0000-0001-7910-1581				ALFREDSSON GA, 1988, J GEN MICROBIOL, V134, P299; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; ANDRESSON OS, 1994, J BACTERIOL, V176, P6165, DOI 10.1128/jb.176.20.6165-6169.1994; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Blondal T, 2003, NUCLEIC ACIDS RES, V31, P7247, DOI 10.1093/nar/gkg914; CHAN VL, 1970, MOL GEN GENET, V109, P162, DOI 10.1007/BF00269652; DAVID M, 1982, VIROLOGY, V123, P480, DOI 10.1016/0042-6822(82)90284-7; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; HAMES BD, 1990, GEL ELECTROPHORESIS, P30; HARRISON B, 1986, ANAL BIOCHEM, V158, P307, DOI 10.1016/0003-2697(86)90555-5; HARRISON B, 1986, NUCLEIC ACIDS RES, V14, P1863, DOI 10.1093/nar/14.4.1863; HJORLEIFSDOTTIR S, 2002, Patent No. 6492161; Jilani A, 1999, J CELL BIOCHEM, V73, P188, DOI 10.1002/(SICI)1097-4644(19990501)73:2<188::AID-JCB5>3.3.CO;2-8; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; LAURENT TC, 1974, EUR J BIOCHEM, V43, P231, DOI 10.1111/j.1432-1033.1974.tb03404.x; LILLEHAUG JR, 1978, BIOCHIM BIOPHYS ACTA, V525, P357, DOI 10.1016/0005-2744(78)90230-9; LILLEHAUG JR, 1977, EUR J BIOCHEM, V73, P499, DOI 10.1111/j.1432-1033.1977.tb11343.x; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1221, DOI 10.1021/bi00677a020; Liu YQ, 2003, P NATL ACAD SCI USA, V100, P4191, DOI 10.1073/pnas.0630387100; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Martins A, 2004, J BIOL CHEM, V279, P50654, DOI 10.1074/jbc.M407657200; Meijer M, 2002, J BIOL CHEM, V277, P4050, DOI 10.1074/jbc.M109383200; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; PHEIFFER BH, 1983, NUCLEIC ACIDS RES, V11, P7853, DOI 10.1093/nar/11.22.7853; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; Sambrook J., MOL CLONING LAB MANU; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; SIROTKIN K, 1978, J MOL BIOL, V123, P221, DOI 10.1016/0022-2836(78)90322-4; TESSIER DC, 1986, ANAL BIOCHEM, V158, P171, DOI 10.1016/0003-2697(86)90606-8; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomita K, 2002, J BIOL CHEM, V277, P48192, DOI 10.1074/jbc.M207527200; Tomita K, 2001, SCIENCE, V294, P1334, DOI 10.1126/science.1063816; TYNDALL C, 1994, J MOL BIOL, V237, P266, DOI 10.1006/jmbi.1994.1230; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Yakunin AF, 2004, J BIOL CHEM, V279, P36819, DOI 10.1074/jbc.M405120200; Yue DX, 1996, RNA, V2, P895; Zhu H, 2004, J BIOL CHEM, V279, P26358, DOI 10.1074/jbc.M403200200	42	24	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5188	5194		10.1074/jbc.M409211200	http://dx.doi.org/10.1074/jbc.M409211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579472	hybrid			2022-12-25	WOS:000227217100011
J	Govindarajan, B; Brat, DJ; Csete, M; Martin, WD; Murad, E; Litani, K; Cohen, C; Cerimele, F; Nunnelley, M; Lefkove, B; Yamamoto, T; Lee, C; Arbiser, JL				Govindarajan, B; Brat, DJ; Csete, M; Martin, WD; Murad, E; Litani, K; Cohen, C; Cerimele, F; Nunnelley, M; Lefkove, B; Yamamoto, T; Lee, C; Arbiser, JL			Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR-SUPPRESSOR GENE; P70 S6 KINASE; GROWTH-FACTOR; TSC2 GENE; SYSTEMIC-SCLEROSIS; MAP KINASE; IDENTIFICATION; FIBROSIS; CELLS	Tuberous sclerosis (TS) is a common autosomal dominant disorder caused by loss or malfunction of hamartin (tsc1) or tuberin (tsc2). Many lesions in TS do not demonstrate loss of heterozygosity for these genes, implying that dominant negative forms of these genes may account for some hamartomas and neoplasms in TS. To test this hypothesis, we expressed a dominant negative allele of tuberin (DeltaRG) behind the cytomegalovirus promoter in NIH3T3 cells and transgenic mice. This allele binds hamartin but has a deletion in the C terminus of tuberin, leading to constitutive activation of rap1 and rab5/rabaptin. Expression of DeltaRG in NIH3T3 cells led to a strong induction of reactive oxygen species, induction of vascular endothelial growth factor, and malignant transformation in vivo. Expression of DeltaRG driven by the constitutive cytomegalovirus promoter led to high level expression in all murine tissues examined, including skin, kidney, liver, and brain. Surprisingly, mice expressing the DeltaRG transgene developed a fibrovascular collagenoma in the dermis, which closely resembles the Shagreen patch observed in human patients with TS. In addition, numerous small subpial collections of external granule cells in the cerebellum were observed, which may be the murine equivalent of subependymal giant cell astrocytomas or tubers commonly seen in TS patients. Thus, expression of a dominant negative tuberin in multiple tissues can lead to a tissue-specific phenotype resembling some of the findings in human TS. Our data are the first to demonstrate that specific signaling abnormalities underlie specific hamartomas in a model of a human genetic disorder.	Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; Tokyo Med & Dent Univ, Dept Dermatol, Rudbeck Lab, Sch Med,Bunkyo Ku, Tokyo 1138519, Japan; Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Atlanta Vet Affairs Med Ctr, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Tokyo Medical & Dental University (TMDU); Uppsala University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Arbiser, JL (corresponding author), Emory Univ, Sch Med, Dept Dermatol, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.	jarbise@emory.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047901] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR47901] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arbiser JL, 2002, AM J PATHOL, V161, P781, DOI 10.1016/S0002-9440(10)64237-X; Arbiser JL, 2002, J AM ACAD DERMATOL, V46, P376, DOI 10.1067/mjd.2002.120530; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Beauchamp RL, 1998, HUM MUTAT, V12, P408, DOI 10.1002/(SICI)1098-1004(1998)12:6<408::AID-HUMU7>3.3.CO;2-G; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; Distler O, 2001, ARTHRITIS RHEUM-US, V44, P2665, DOI 10.1002/1529-0131(200111)44:11<2665::AID-ART446>3.0.CO;2-S; El-Hashemite N, 2003, CANCER RES, V63, P5173; Finlay GA, 2003, AM J PHYSIOL-CELL PH, V285, pC409, DOI 10.1152/ajpcell.00482.2002; Gharaee-Kermani M, 2003, CYTOKINE, V24, P266, DOI 10.1016/j.cyto.2003.08.003; Gomez MR, 1995, BRAIN DEV-JPN, V17, P55, DOI 10.1016/0387-7604(94)00130-8; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Govindarajan B, 2003, CLIN CANCER RES, V9, P3469; Henske EP, 1996, AM J HUM GENET, V59, P400; Henske EP, 1997, AM J PATHOL, V151, P1639; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kobayashi T, 1999, CANCER RES, V59, P1206; Kozawa O, 2001, J CELL BIOCHEM, V81, P430, DOI 10.1002/1097-4644(20010601)81:3<430::AID-JCB1056>3.0.CO;2-G; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Kyin R, 2001, AM J PATHOL, V159, P1541, DOI 10.1016/S0002-9440(10)62539-4; Maldonado M, 2003, NEUROBIOL DIS, V14, P279, DOI 10.1016/S0969-9961(03)00127-X; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Muhlbauer M, 2003, GASTROENTEROLOGY, V125, P1085, DOI 10.1016/S0016-5085(03)01213-7; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Orimoto K, 1998, BIOCHEM BIOPH RES CO, V247, P728, DOI 10.1006/bbrc.1998.8853; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; SAMPSON JR, 1994, HUM MOL GENET, V3, P1477, DOI 10.1093/hmg/3.suppl_1.1477; SHEPHERD CW, 1991, MAYO CLIN PROC, V66, P792, DOI 10.1016/S0025-6196(12)61196-3; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; THOMSON AW, 1989, LANCET, V2, P443; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wada T, 2004, J AM SOC NEPHROL, V15, P940, DOI 10.1097/01.ASN.0000120371.09769.80; Yamamoto T, 2001, EUR J IMMUNOL, V31, P2936, DOI 10.1002/1521-4141(2001010)31:10<2936::AID-IMMU2936>3.0.CO;2-0; Yamamoto T, 2001, J DERMATOL SCI, V26, P133, DOI 10.1016/S0923-1811(00)00169-9; Yamamoto T, 2001, J DERMATOL SCI, V26, P106, DOI 10.1016/S0923-1811(00)00164-X; Yang JQ, 2001, ANTIOXID REDOX SIGN, V3, P697, DOI 10.1089/15230860152543032	36	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5870	5874		10.1074/jbc.M411768200	http://dx.doi.org/10.1074/jbc.M411768200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15576369	hybrid			2022-12-25	WOS:000227217100091
J	Korn, C; Scholz, SR; Gimadutdinow, O; Lurz, R; Pingoud, A; Meiss, G				Korn, C; Scholz, SR; Gimadutdinow, O; Lurz, R; Pingoud, A; Meiss, G			Interaction of DNA fragmentation factor (DFF) with DNA reveals an unprecedented mechanism for nuclease inhibition and suggests that DFF can be activated in a DNA-bound state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RIBONUCLEASE INHIBITOR; CHROMATIN CONDENSATION; APOPTOTIC EXECUTION; ENDONUCLEASE-G; GRANZYME-B; COLICIN E7; ICAD-S; CLEAVAGE; PROTEIN	DNA fragmentation factor (DFF) is a complex of the DNase DFF40 (CAD) and its chaperone/inhibitor DFF45 (ICAD-L) that can be activated during apoptosis to induce DNA fragmentation. Here, we demonstrate that DFF directly binds to DNA in vitro without promoting DNA cleavage. DNA binding by DFF is mediated by the nuclease subunit, which can also form stable DNA complexes after release from DFF. Recombinant and reconstituted DFF is catalytically inactive yet proficient in DNA binding, demonstrating that the nuclease subunit in DFF is inhibited in DNA cleavage but not in DNA binding, revealing an unprecedented mode of nuclease inhibition. Activation of DFF in the presence of naked DNA or isolated nuclei stimulates DNA degradation by released DFF40 (CAD). In transfected HeLa cells transiently expressed DFF associates with chromatin, suggesting that DFF could be activated during apoptosis in a DNA-bound state.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Kazan VI Lenin State Univ, Genet Inst, Kazan 420008, Russia; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Justus Liebig University Giessen; Kazan Federal University; Max Planck Society	Meiss, G (corresponding author), Univ Giessen, Inst Biochem, Heinrich Buff ring 58, D-35392 Giessen, Germany.	gf45@uni-giessen.de						BUCKLE AM, 1994, BIOCHEMISTRY-US, V33, P8878, DOI 10.1021/bi00196a004; Cheng YS, 2002, J MOL BIOL, V324, P227, DOI 10.1016/S0022-2836(02)01092-6; COTE J, 1989, J BIOL CHEM, V264, P3301; Counis MF, 2000, BIOCHEM CELL BIOL, V78, P405, DOI 10.1139/bcb-78-4-405; DOHERTY AJ, 1995, J MOL BIOL, V251, P366, DOI 10.1006/jmbi.1995.0440; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; Dunn KL, 2003, EXP CELL RES, V288, P218, DOI 10.1016/S0014-4827(03)00185-X; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GarinotSchneider C, 1996, J MOL BIOL, V260, P731, DOI 10.1006/jmbi.1996.0433; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Haigis MC, 2003, NUCLEIC ACIDS RES, V31, P1024, DOI 10.1093/nar/gkg163; Hartley RW, 2001, METHOD ENZYMOL, V341, P599, DOI 10.1016/S0076-6879(01)41179-7; Hsia KC, 2004, STRUCTURE, V12, P205, DOI 10.1016/j.str.2004.01.004; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleanthous C, 2001, TRENDS BIOCHEM SCI, V26, P624, DOI 10.1016/S0968-0004(01)01941-7; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; Korn C, 2002, NUCLEIC ACIDS RES, V30, P1325, DOI 10.1093/nar/30.6.1325; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; Meiss G, 2001, NUCLEIC ACIDS RES, V29, P3901, DOI 10.1093/nar/29.19.3901; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Ramuz O, 2003, INT J EXP PATHOL, V84, P75, DOI 10.1046/j.1365-2613.2003.00339.x; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; Sakahira H, 2000, J BIOL CHEM, V275, P8091, DOI 10.1074/jbc.275.11.8091; Sakahira H, 2002, J BIOL CHEM, V277, P3364, DOI 10.1074/jbc.M110071200; Sakahira H, 2001, ARCH BIOCHEM BIOPHYS, V388, P91, DOI 10.1006/abbi.2000.2266; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Scholz SR, 2002, NUCLEIC ACIDS RES, V30, P3045, DOI 10.1093/nar/gkf431; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2000, ACTA BIOCHIM POL, V47, P1037; WIDLAK P, 2003, J BIOL CHEM; Woo EJ, 2004, MOL CELL, V14, P531, DOI 10.1016/S1097-2765(04)00258-8; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	49	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6005	6015		10.1074/jbc.M413035200	http://dx.doi.org/10.1074/jbc.M413035200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572351	hybrid			2022-12-25	WOS:000227217100106
J	Krishnamurthy, G; Vikram, R; Singh, SB; Patel, N; Agarwal, S; Mukhopadhyay, G; Basu, SK; Mukhopadhyay, A				Krishnamurthy, G; Vikram, R; Singh, SB; Patel, N; Agarwal, S; Mukhopadhyay, G; Basu, SK; Mukhopadhyay, A			Hemoglobin receptor in Leishmania is a hexokinase located in the flagellar pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ENDOCYTOSIS; FUSION; IDENTIFICATION; KINASE; ENDOSOME; DONOVANI; CLONING; DOMAIN	Hb endocytosis in Leishmania is mediated through a 46-kDa protein located in the flagellar pocket. To understand the nature of the Hb receptor (HbR), we have purified the 46-kDa protein to homogeneity from Leishmania promastigote membrane. Purified HbR specifically binds Hb. The gene for HbR was cloned, and sequence analysis of the full-length HbR gene indicates the presence of hexokinase (HK) signature sequences, ATP-binding domain, and PTS-II motif. Four lines of evidence indicate that HbR in Leishmania is a hexokinase: 1) the recombinant HbR binds Hb, and the Hb-binding domain resides in the N terminus of the protein; 2) recombinant proteins and cell lysate prepared from HbR-overexpressing Leishmania promastigotes show enhanced HK activity in comparison with untransfected cells; 3) immunolocalization studies using antibodies against the N-terminal fragment (Ld-HbR-DeltaC) of Ld-HbR indicate that this protein is located in the flagellar pocket of Leishmania; and 4) binding and uptake of I-125-Hb by Leishmania is significantly inhibited by anti-Ld-HbR-DeltaC antibody and Ld-HbR-DeltaC, respectively. Taken together, these results indicate that HK present in the flagellar pocket of Leishmania is involved in Hb endocytosis.	Natl Inst Immunol, New Delhi 110067, India; Jawaharlal Nehru Univ, Ctr Mol Med, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Jawaharlal Nehru University, New Delhi	Mukhopadhyay, A (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	amitabha@nii.res.in	Patel, Nitin/C-9625-2010; Mukhopadhyay, Asok/C-4051-2009					Bastin P, 1996, MOL BIOCHEM PARASIT, V76, P43, DOI 10.1016/0166-6851(95)02537-5; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Caceres AJ, 2003, MOL BIOCHEM PARASIT, V126, P251, DOI 10.1016/S0166-6851(02)00294-3; CHANG KP, 1983, INT REV CYTOL, P267; CHANG KP, 1974, SCIENCE, V183, P531, DOI 10.1126/science.183.4124.531; Chen CJ, 1996, INFECT IMMUN, V64, P5008, DOI 10.1128/IAI.64.12.5008-5014.1996; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; FRAENKEL DG, 1964, J BIOL CHEM, V239, P2765; Frommer WB, 2003, SCIENCE, V300, P261, DOI 10.1126/science.1084120; Gozalbo D, 1998, INFECT IMMUN, V66, P2052, DOI 10.1128/IAI.66.5.2052-2059.1998; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HOLMES EW, 1967, SCIENCE, V156, P646, DOI 10.1126/science.156.3775.646; Jin HF, 1996, INFECT IMMUN, V64, P3134, DOI 10.1128/IAI.64.8.3134-3141.1996; KALAB P, 1994, J BIOL CHEM, V269, P3810; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; Liu JY, 2000, J BIOL CHEM, V275, P12032, DOI 10.1074/jbc.275.16.12032; MAZUMDER S, 1992, J BIOL CHEM, V267, P18440; Modun B, 2000, TRENDS MICROBIOL, V8, P231, DOI 10.1016/S0966-842X(00)01728-5; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Mukherjee K, 2001, J BIOL CHEM, V276, P23607, DOI 10.1074/jbc.M101034200; Mukherjee K, 2000, J CELL BIOL, V148, P741, DOI 10.1083/jcb.148.4.741; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; OVERKAMP D, 1988, J IMMUNOASSAY, V9, P51, DOI 10.1080/01971528808053210; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Roy J.C., 1932, IND J MED RES, V20, P367; Sah JF, 2002, J BIOL CHEM, V277, P14902, DOI 10.1074/jbc.M200107200; SCHIRCH DM, 1987, ARCH BIOCHEM BIOPHYS, V254, P385, DOI 10.1016/0003-9861(87)90116-0; Sengupta S, 1999, J BIOL CHEM, V274, P2758, DOI 10.1074/jbc.274.5.2758; Singh SB, 2003, EMBO J, V22, P5712, DOI 10.1093/emboj/cdg557; Sinha KM, 1999, BIOCHEM J, V339, P667, DOI 10.1042/0264-6021:3390667; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; VOYIATZAKI CS, 1992, J BIOL CHEM, V267, P9112; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wiese A, 1999, FEBS LETT, V461, P13, DOI 10.1016/S0014-5793(99)01417-9; Willson M, 2002, CHEM BIOL, V9, P839, DOI 10.1016/S1074-5521(02)00169-2; Wilson ME, 1998, PARASITOL TODAY, V14, P348, DOI 10.1016/S0169-4758(98)01294-0	42	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5884	5891		10.1074/jbc.M411845200	http://dx.doi.org/10.1074/jbc.M411845200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579464	hybrid			2022-12-25	WOS:000227217100093
J	Kunkel, MT; Ni, Q; Tsien, RY; Zhang, J; Newton, AC				Kunkel, MT; Ni, Q; Tsien, RY; Zhang, J; Newton, AC			Spatio-temporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; MOLECULAR-CLONING; LIVING CELLS; ACTIVATION; AKT; PHOSPHORYLATION; BINDING; MECHANISM; DOMAIN	The serine/threonine kinase protein kinase B (PKB)/Akt is a critical regulator of insulin signaling, cell survival, and oncogenesis. The activation mechanisms of this key kinase are well characterized. In contrast, inactivation of PKB signaling by phosphatases is less well understood. To study the dynamics of PKB signaling in live cells, we generated a genetically encoded fluorescent reporter for PKB activity that reversibly responds to stimuli activating phosphatidylinositol 3-kinase. Specifically, phosphorylation of the reporter expressed in mammalian cells causes changes in fluorescence resonance energy transfer, allowing real-time imaging of phosphorylation catalyzed by PKB. Because of its reversibility, the reporter also allows termination of PKB signaling by phosphatases to be monitored. We found that PKB signaling in the cytosol was more rapid and more transient compared with that in the nucleus, suggesting the presence of differentially regulated phosphatase activity in these two compartments. Furthermore, targeting of the reporter to the plasma membrane, where PKB is activated, resulted in accelerated and prolonged response compared with the response in the cytosol, suggesting that release of PKB or its substrates from the membrane is required for desensitization of PKB signaling. These data reveal spatio-temporal gradients of both signal propagation and signal termination in PKB signaling.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins University	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	anewton@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233, P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK54441, T32 DK007233, P01 DK054441, DK07233, P01 DK054441-010003] Funding Source: Medline; NINDS NIH HHS [R01 NS027177-12, R01 NS027177, NS27177, R37 NS027177] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200; Sato M, 2004, METHODS, V32, P451, DOI 10.1016/j.ymeth.2003.10.013; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	25	166	173	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5581	5587		10.1074/jbc.M411534200	http://dx.doi.org/10.1074/jbc.M411534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15583002	Green Accepted, hybrid			2022-12-25	WOS:000227217100058
J	Hu, JX; McLarnon, SJ; Mora, S; Jiang, J; Thomas, C; Jacobson, KA; Spiegel, AM				Hu, JX; McLarnon, SJ; Mora, S; Jiang, J; Thomas, C; Jacobson, KA; Spiegel, AM			A region in the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; AUTOSOMAL-DOMINANT HYPOCALCEMIA; PROTEIN-COUPLED RECEPTORS; TRANSMEMBRANE DOMAIN; HYPOCALCIURIC HYPERCALCEMIA; CA2+-SENSING RECEPTOR; ACTIVATING MUTATIONS; IDENTIFICATION; RHODOPSIN; EXPRESSION	Of 12 naturally occurring, activating mutations in the seven-transmembrane MM) domain of the human Ca2+ receptor (CaR) identified previously in subjects with autosomal dominant hypocalcemia (ADII), five appear at the junction of TM helices 6 and 7 between residue Ile(819) and Glu(837). After identifying a sixth activating mutation in this region, V836L, in an ADH patient, we studied the remaining residues in this region to determine whether they are potential sites for activating mutations. Alanine-scanning mutagenesis revealed five additional residues in this region that when substituted by alanine led to CaR activation. We also found that, whereas E837A did not activate the receptor, E837D and E837K mutations did. Thus, region Ile(819)-Glu(837) of the 7TM domain represents a "hot spot" for naturally occurring, activating mutations of the receptor, and most of the residues in this region apparently maintain the 7TM domain in its inactive configuration. Unique among the residues in this region, Pro(823), which is highly conserved in family 3 of the G protein-coupled receptors, when mutated to either alanine or glycine, despite good expression severely impaired CaR activation by Ca2+. Both the P823A mutation and NPS 2143, a negative allosteric modulator that acts on the 7TM through a critical interaction with Glu(837), blocked activation of the CaR by various ADII mutations. These results suggest that the 7TM domain region Ile(819)-Glu(837) plays a key role in CaR activation by Ca2+. The implications of our finding that NPS 2143 corrects the molecular defect of ADH mutations for treatment of this disease are also discussed.	NIDCD, Mol Pathophysiol Sect, NIH, Bethesda, MD 20892 USA; Sci Inst H San Raffaele, Lab Pediat Endocrinol, I-20132 Milan, Italy; Sci Inst H San Raffaele, Dept Pediat, I-20132 Milan, Italy; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hu, JX (corresponding author), NIDCD, Mol Pathophysiol Sect, NIH, Bldg 10,Rm 8C-101,9000 Rockville Pike, Bethesda, MD 20892 USA.	jianxinh@intra.niddk.nih.gov	Mora, Sefano/B-2143-2013; Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493; Thomas, Craig/0000-0001-9386-9001	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031115, Z01DK070005, ZIADK031115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000061] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; D'Souza-Li L, 2002, J CLIN ENDOCR METAB, V87, P1309, DOI 10.1210/jc.87.3.1309; DELMAR EG, 2003, Patent No. 6521667; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hu JX, 2004, J BONE MINER RES, V19, P578, DOI 10.1359/JBMR.040106; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Inoue D, 1998, BONE S, V23S, pS382; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lienhardt A, 2001, J CLIN ENDOCR METAB, V86, P5313, DOI 10.1210/jc.86.11.5313; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Nagase T, 2002, J CLIN ENDOCR METAB, V87, P2681, DOI 10.1210/jc.87.6.2681; Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Pidasheva S, 2004, HUM MUTAT, V24, P107, DOI 10.1002/humu.20067; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Seki T, 1996, CHEM PHARM BULL, V44, P2061; Shiohara M, 2004, EUR J PEDIATR, V163, P94, DOI 10.1007/s00431-003-1331-7; Stewart AF, 2004, NEW ENGL J MED, V351, P324, DOI 10.1056/NEJMp048153; Yohannan S, 2004, P NATL ACAD SCI USA, V101, P959, DOI 10.1073/pnas.0306077101; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	27	70	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5113	5120		10.1074/jbc.M413403200	http://dx.doi.org/10.1074/jbc.M413403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15591042	hybrid			2022-12-25	WOS:000227096600133
J	Katsuoka, F; Motohashi, L; Engel, JD; Yamamoto, M				Katsuoka, F; Motohashi, L; Engel, JD; Yamamoto, M			Nrf2 transcriptionally activates the mafG gene through an antioxidant response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; INDUCIBLE GENES; MUTANT MICE; EXPRESSION; INDUCTION; PROTEINS; ELECTROPHILE; COMPLEXITY; LETHALITY; DEFECTS	Nrf2 accumulates in nuclei upon exposure to oxidative stress, Heterodimerizes with a small Maf protein, and activates the transcription of stress target genes through antioxidant response elements (AREs). We found that diethyl maleate (DEM), a well known activator of Nrf2, induces one of the small Maf genes, mafG. To elucidate roles MafG might play in the oxidative stress response, we examined transcriptional regulation of the mouse mafG gene. MatG utilizes three independent first exons that are each spliced to second and third coding exons. Among the small maf genes, mafG showed the strongest response to DEM, and of the three first exons, the highest -fold induction was seen with the proximal first exon (Ic). Importantly, one ARE (Ic-ARE) is conserved in the promoter flanking exon Ic of the human and mouse mafG genes. The Nrf2/MafG heterodimer bound the Ic-ARE and activated transcription, whereas DEM failed to activate mafG in nrf2-null mutant cells. Chromatin immunoprecipitation further revealed that both Nrf2 and small Maf proteins associate with the le-ARE in vivo. These results demonstrate that mafG is itself an ARE-dependent gene that is regulated by an Nrf2/small Maf heterodimer and suggest the presence of an autoregulatory feedback pathway for mafG transcriptional regulation.	Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, ERATO Environm Response Project, Tsukuba, Ibaraki 3058577, Japan; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Organogenesis, Ann Arbor, MI 48109 USA	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Motohashi, L (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan.	hozumim@tara.tsukuba.ac.jp; masi@tara.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Katsuoka, Fumiki/0000-0003-0939-7887	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028896] Funding Source: NIH RePORTER; NCI NIH HHS [CA80088] Funding Source: Medline; NIGMS NIH HHS [GM28896] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen LY, 2003, MOL CELL BIOL, V23, P4673, DOI 10.1128/MCB.23.13.4673-4686.2003; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Katsuoka F, 2003, MOL CELL BIOL, V23, P1163, DOI 10.1128/MCB.23.4.1163-1174.2003; Kotkow KJ, 1996, P NATL ACAD SCI USA, V93, P3514, DOI 10.1073/pnas.93.8.3514; Kyo M, 2004, GENES CELLS, V9, P153, DOI 10.1111/j.1356-9597.2004.00711.x; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Moran JA, 2002, BIOCHEM J, V361, P371, DOI 10.1042/0264-6021:3610371; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Motohashi H, 1998, GENES CELLS, V3, P671, DOI 10.1046/j.1365-2443.1998.00222.x; Motohashi H, 1996, GENES CELLS, V1, P223, DOI 10.1046/j.1365-2443.1996.d01-230.x; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muto A, 2004, NATURE, V429, P566, DOI 10.1038/nature02596; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Onodera K, 1999, J BIOL CHEM, V274, P21162, DOI 10.1074/jbc.274.30.21162; Onodera K, 2000, EMBO J, V19, P1335, DOI 10.1093/emboj/19.6.1335; Primiano T, 1997, Adv Pharmacol, V38, P293; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Takagi Y, 2004, BIOCHEM BIOPH RES CO, V320, P62, DOI 10.1016/j.bbrc.2004.05.131; Talalay P, 2003, ADV ENZYME REGUL, V43, P121, DOI 10.1016/S0065-2571(02)00038-9; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361	31	86	88	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4483	4490		10.1074/jbc.M411451200	http://dx.doi.org/10.1074/jbc.M411451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574414	hybrid			2022-12-25	WOS:000227096600060
J	Swales, K; Kakizaki, S; Yamamoto, Y; Inoue, K; Kobayashi, K; Negishi, M				Swales, K; Kakizaki, S; Yamamoto, Y; Inoue, K; Kobayashi, K; Negishi, M			Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P4502B6 gene in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR CAR; PROTEIN PHOSPHATASE 2A; HELIX-LOOP-HELIX; TRANSCRIPTION FACTOR; CYP2B1/B2 GENE; XENOBIOTIC INDUCTION; PRIMARY HEPATOCYTES; ENHANCER MODULE; DNA-BINDING; RAT-LIVER	The constitutive active receptor (CAR) regulates the induction of the cytochrome P450 2B6 (CYP2B6) gene by phenobarbital-type inducers, such as 1,4 bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) via the distal phenobarbital-responsive enhancer module (PBREM, at -1732/-1685 bp). Activation of the PBREM by TCPOBOP generated a 10-fold induction of CYP2B6 mRNA in HepG2 cells stably expressing mouse CAR (Ym17). Co-treatment with the protein phosphatase inhibitor okadaic acid (OA) synergistically increased this induction over 100-fold without directly activating CAR or the PBREM. Although OA synergy required the presence of PBREM, deletion assays delineated the OA-responsive activity to a proximal 24-bp (-256/-233) sequence (OARE) in the CYP2B6 promoter. CAR did not directly bind to the OARE in electrophoretic mobility shift assays. However, both DNA affinity and chromatin immunoprecipitation assays showed a significant increase in CAR association with the OARE after co-treatment with TCPOBOP and OA, indicating the indirect binding of CAR to the OARE. The two cis-acting elements, the distal PBREM and the proximal OARE, within the chromatin structure are both regulated by CAR in response to TCPOBOP and OA, respectively, to maximally induce the CYP2B6 promoter. This functional interaction between the two sites expands the current understanding of the mechanism of CAR-mediated inducible transcription.	NIEHS, NIH, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, NIH, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, POB 12233, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Satoru, Kakizaki/AAB-9521-2019; Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; Yamamoto, Yukio/0000-0002-8530-0701	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040, ZIAES080040] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alvarez M, 2003, GENE, V313, P43, DOI 10.1016/S0378-1119(03)00627-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Cheung E, 1999, BIOCHEM J, V344, P145, DOI 10.1042/0264-6021:3440145; Corcos L, 2001, PHARMACOL TOXICOL, V89, P113, DOI 10.1034/j.1600-0773.2001.d01-144.x; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Froeschle A, 1998, ONCOGENE, V16, P3369, DOI 10.1038/sj.onc.1201894; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; Galibert MD, 1997, J IMMUNOL, V159, P6176; Gutierrez S, 2004, J BIOL CHEM, V279, P43581, DOI 10.1074/jbc.M408335200; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; Huss JM, 2000, MOL PHARMACOL, V58, P48, DOI 10.1124/mol.58.1.48; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; KENDE AS, 1985, MOL PHARMACOL, V28, P445; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kobayashi K, 2003, MOL PHARMACOL, V64, P1069, DOI 10.1124/mol.64.5.1069; Marc N, 2000, EUR J BIOCHEM, V267, P963, DOI 10.1046/j.1432-1327.2000.01083.x; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Nirodi CS, 1996, ARCH BIOCHEM BIOPHYS, V331, P79, DOI 10.1006/abbi.1996.0285; Penberthy WT, 2003, GENE, V305, P205, DOI 10.1016/S0378-1119(03)00384-6; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Ramsden R, 1999, GENE, V228, P169, DOI 10.1016/S0378-1119(98)00612-X; Roe AL, 1996, BIOCHEM BIOPH RES CO, V228, P110, DOI 10.1006/bbrc.1996.1624; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Samudre KR, 2002, BIOCHEM BIOPH RES CO, V292, P312, DOI 10.1006/bbrc.2002.6665; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHUG J, 1997, ISMB, V5, P268; SETH A, 1991, J BIOL CHEM, V266, P23521; Sidhu JS, 1997, J PHARMACOL EXP THER, V282, P1122; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; WALHOUT AJM, 1997, NUCLEIC ACIDS RES, V25, P1516; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xiao QX, 2002, AM J PHYSIOL-HEART C, V283, pH213, DOI 10.1152/ajpheart.01085.2001; Yamamoto Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P207, DOI 10.1016/S0003-9861(02)00456-3; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355; Yoshinari K, 2003, FEBS LETT, V548, P17, DOI 10.1016/S0014-5793(03)00720-8	48	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3458	3466		10.1074/jbc.M411318200	http://dx.doi.org/10.1074/jbc.M411318200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15563456	hybrid			2022-12-25	WOS:000226983900041
J	Abdel-Rahman, WM; Lohi, H; Knuttila, S; Peltomaki, P				Abdel-Rahman, WM; Lohi, H; Knuttila, S; Peltomaki, P			Restoring mismatch repair does not stop the formation of reciprocal translocations in the colon cancer cell line HCA7 but further destabilizes chromosome number	ONCOGENE			English	Article						mismatch repair; MLH1; recombination; reciprocal translocations; radiation	DOUBLE-STRAND BREAKS; COLORECTAL CANCERS; MICROSATELLITE INSTABILITY; HOMOLOGOUS RECOMBINATION; GENOMIC INSTABILITY; GENETIC INSTABILITY; SOLID TUMORS; DNA-REPAIR; CARCINOMAS; INACTIVATION	An important anticarcinogenic function of the mismatch repair (MMR) system is its role in preventing recombination between similar, but nonidentical (homeologous) sequences, thus preventing chromosomal rearrangements. We recently identified a novel chromosomal instability (CIN) phenotype in an MMR defective colon cancer cell line (HCA7) characterized by an ongoing tendency to multiple reciprocal chromosomal translocations. To analyse the relation between MMR and chromosomal changes more closely, the HCA7 stem clone was divided into three stocks. The first was stably transfected with MLH1 expression plasmid, the second was regularly exposed to the demethylating agent 5-azacytidin to re-express the hypermethylated MLH1 gene, and the third was an unmanipulated control stock. All stocks were propagated in vitro for 55 - 80 passages and, furthermore, some of the early passages were irradiated to induce DNA double-strand breaks. Multiplex-fluorescent in situ hybridization (M-FISH) analysis showed that all three stocks acquired varying numbers of reciprocal translocations and other structural changes at some point. Interestingly, the control stock, which is MMR defective, maintained its numerical chromosomal stability, while some of the MMR-proficient clones showed additional numerical instability. Although the control stock was less sensitive to irradiation, its surviving clones showed marked stability of chromosome structure and number compared to the MMR-competent stocks. These results show that restoring MMR does not prevent the development of reciprocal translocations but rather predisposes cells to numerical CIN after irradiation. Thus, the accumulating data suggest that MMR defect may not be necessary for the development of reciprocal chromosomal translocations but might be permissive.	Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Zagazig Univ, Fac Med, Dept Pathol, Zagazig, Egypt; Univ Helsinki, Haartman Inst, Lab Cytomol Genet, Dept Pathol, Helsinki, Finland; Univ Helsinki, Haartman Inst, Lab Cytomol Genet, Dept Med Genet, Helsinki, Finland; Univ Helsinki, HUSLAB, Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland	University of Helsinki; Egyptian Knowledge Bank (EKB); Zagazig University; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Abdel-Rahman, WM (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Wael-Abdel-Rahman@helsinki.fi	Lohi, Hannes/F-4596-2011	Lohi, Hannes/0000-0003-1087-5532; Peltomaki, Paivi/0000-0001-8819-2980; Abdel-Rahman, Wael/0000-0002-2149-1043	NATIONAL CANCER INSTITUTE [R01CA082282] Funding Source: NIH RePORTER; NCI NIH HHS [CA82282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Bocker T, 1996, J PATHOL, V179, P15; Buermeyer AB, 1999, CANCER RES, V59, P538; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; Deans B, 2003, CANCER RES, V63, P8181; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Harfe BD, 2000, MUTAT RES-FUND MOL M, V451, P151, DOI 10.1016/S0027-5107(00)00047-6; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kim NG, 2001, CANCER RES, V61, P36; Lambert B, 1998, MUTAT RES-FUND MOL M, V405, P161, DOI 10.1016/S0027-5107(98)00133-X; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Limoli CL, 2001, BRIT J CANCER, V84, P489, DOI 10.1054/bjoc.2000.1604; Moynahan ME, 2001, CANCER RES, V61, P4842; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Risinger JI, 1998, CANCER RES, V58, P2978; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schweizer P, 2001, CANCER RES, V61, P2813; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tsuji T, 2003, J GASTROENTEROL, V38, P1185, DOI 10.1007/s00535-003-1229-1; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yu VPCC, 2000, GENE DEV, V14, P1400	34	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					706	713		10.1038/sj.onc.1208129	http://dx.doi.org/10.1038/sj.onc.1208129			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580308				2022-12-25	WOS:000226420400018
J	Reddy, J; Shivapurkar, N; Takahashi, T; Parikh, G; Stastny, V; Echebiri, C; Crumrine, K; Zochbauer-Muller, S; Drach, J; Zheng, YY; Feng, ZD; Kroft, SH; McKenna, RW; Gazdar, AF				Reddy, J; Shivapurkar, N; Takahashi, T; Parikh, G; Stastny, V; Echebiri, C; Crumrine, K; Zochbauer-Muller, S; Drach, J; Zheng, YY; Feng, ZD; Kroft, SH; McKenna, RW; Gazdar, AF			Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors	ONCOGENE			English	Article						cytokine signaling pathway; methylation; hematopoietic tumors	EPSTEIN-BARR-VIRUS; MONOCLONAL GAMMOPATHY; NEGATIVE REGULATOR; HYPERMETHYLATION; SHP1; EVENTS; SOCS-1; SYK; PCR	The perturbations of the cytokine signaling pathway play an important role in lymphoid/hematopoietic tumors. Aberrant promoter methylation is the major mechanism of gene silencing in tumors. We examined 150 lymphoid/ hematopoietic tumors or potential premalignant specimens, 55 control specimens and 12 EBV-transformed B lymphoblastoid cultures and 10 lymphoma/leukemia (L/L) or multiple myeloma ( MM) cell lines for the methylation ( and, in cell lines, of the expression status) of three genes involved in the cytokine signaling pathway. The genes were: SHP1, a protein tyrosine phosphatase; SYK, a protein kinase; and SOCS1, a suppressor of cytokine signaling. Our major findings were: ( 1) one or more of the three genes was frequently methylated in L/L and MM cell lines and there was good concordance ( 90 100%) between methylation and loss of gene expression; ( 2) treatment of L/L cell lines with a demethylating agent resulted in re-expression of SHP1 protein and downregulation of phosphorylated STAT3 in L/L cell lines; ( 3) all 55 control specimens and the lymphoblastoid cultures were negative for methylation of the three genes; ( 4) non-Hodgkin's lymphomas ( 100%), and leukemias (94%) had almost universal methylation of SHP1 and relatively less frequent (<30%) methylation of SOCS1 and SYK; ( 5) MM and monoclonal gammopathy of unknown significance (MGUS) had infrequent methylation of SHP1 (<20%), and occasional methylation of SOCS1 and SYK; and ( 6) comparable methylation frequencies for SOCS1 were observed in MM and MGUS, suggesting that SOCS1 methylation is an early event in MM pathogenesis. At least one gene was methylated in 119 of 130 (93%) of the malignant and 12 of 20 (60%) of the MGUS samples. Our findings demonstrate that the perturbations of cytokine signaling via silencing of these three genes are almost universal in lymphoid/ hematopoietic tumors but the patterns of gene methylated for L/L and plasma cell dyscrasias are different.	UT SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; UT SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Hosp, Dept Med 1, Div Clin Oncol, A-1090 Vienna, Austria; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University Hospital Vienna; Fred Hutchinson Cancer Center	Gazdar, AF (corresponding author), UT SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@utsouthwestern.edu	Kroft, Steven/AAE-2543-2020; Zöchbauer-Müller, Sabine/B-8399-2012; Parikh, Gunjan/AAS-1375-2020	Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Parikh, Gunjan/0000-0002-8447-1349	NATIONAL CANCER INSTITUTE [U01CA084971] Funding Source: NIH RePORTER; NCI NIH HHS [5U01CA8497102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Chim CS, 2004, LEUKEMIA, V18, P356, DOI 10.1038/sj.leu.2403216; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313; Guillerm G, 2001, BLOOD, V98, P244, DOI 10.1182/blood.V98.1.244; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jebbink J, 2003, J MOL DIAGN, V5, P15, DOI 10.1016/S1525-1578(10)60446-1; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Krebs DL, 2000, J CELL SCI, V113, P2813; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kyle RA, 2003, BLOOD, V102, P3759, DOI 10.1182/blood-2003-03-0801; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Oka T, 2002, CANCER RES, V62, P6390; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yuan YF, 2001, CANCER RES, V61, P5558	25	48	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					732	736		10.1038/sj.onc.1208032	http://dx.doi.org/10.1038/sj.onc.1208032			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580314				2022-12-25	WOS:000226420400021
J	Kaur, GP; Reddy, DE; Zimonjic, DB; de Riel, JK; Athwal, RS				Kaur, GP; Reddy, DE; Zimonjic, DB; de Riel, JK; Athwal, RS			Functional identification of a BAC clone from 16q24 carrying a senescence gene SEN16 for breast cancer cells	ONCOGENE			English	Article						cell senescence; breast cancer; BAC contig; BAC transfer; functional complementation	CHROMOSOME ARM 16Q; TUMOR-SUPPRESSOR GENE; CARCINOMA IN-SITU; ALLELIC IMBALANCE; HETEROZYGOSITY REGION; CELLULAR SENESCENCE; FREQUENT LOSS; DELETION; PHENOTYPE; WFDC1	We have identified an 85 kb BAC clone, 346J21, that carries a cell senescence gene (SEN16), previously mapped to 16q24.3. Transfer and retention of 346J21 in breast cancer cell lines leads to growth arrest after 8-10 cell doublings, accompanied by the appearance of characteristic senescent cell morphology and senescence-associated acid beta-galactosidase activity. Loss of transferred BAC results in reversion to the immortal growth phenotype of the parental cancer cell lines. BAC 346J21 restores senescence in the human breast cancer cell lines, MCF.7 and MDA-MB468, and the rat mammary tumor cell line LA7, but not in the human glioblastoma cell line T98G. We postulate that inactivation of both copies of SEN16 is required for the immortalization of breast epithelial cells at an early stage of tumorigenesis. Positional mapping of 346J21 shows that SEN16 is distinct from other candidate tumor suppressor genes reported at 16q24.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St,AHB Room 201, Philadelphia, PA 19140 USA.	pkaur001@temple.edu	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [Z01BC010038, R01CA074983, ZIABC010038] Funding Source: NIH RePORTER; NCI NIH HHS [CA74983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; Bando K, 2000, GENE CHROMOSOME CANC, V28, P38, DOI 10.1002/(SICI)1098-2264(200005)28:1<38::AID-GCC5>3.0.CO;2-A; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Callen DF, 2002, CANCER GENET CYTOGEN, V133, P76, DOI 10.1016/S0165-4608(01)00565-9; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9; Chin RK, 1998, CANCER GENET CYTOGEN, V103, P155, DOI 10.1016/S0165-4608(97)00407-X; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; Godfrey TE, 1997, CANCER GENET CYTOGEN, V98, P36, DOI 10.1016/S0165-4608(96)00392-5; Hansen LL, 2002, CANCER GENET CYTOGEN, V139, P1, DOI 10.1016/S0165-4608(02)00620-9; Hansen LL, 1998, CANCER RES, V58, P2166; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1974, J AM GERIATR SOC, V22, P1; Huang Y, 2001, MOL BIOL REP, V28, P185, DOI 10.1023/A:1015726217890; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; Kawakami M, 1999, INT J ONCOL, V15, P715; Kochetkova M, 2002, CANCER RES, V62, P4599; LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611; Larsen M, 2000, MAMM GENOME, V11, P767, DOI 10.1007/s003350010135; LINDBLOM A, 1993, CANCER RES, V53, P3707; Mejia JE, 1997, GENOME RES, V7, P179, DOI 10.1101/gr.7.2.179; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Powell JA, 2002, GENOMICS, V80, P303, DOI 10.1006/geno.2002.6828; RADFORD DM, 1995, CANCER RES, V55, P3399; Reddy DE, 2000, ONCOGENE, V19, P217, DOI 10.1038/sj.onc.1203264; Reddy DE, 1999, ONCOGENE, V18, P5100, DOI 10.1038/sj.onc.1202888; Saffroy R, 2002, EUR J HUM GENET, V10, P239, DOI 10.1038/sj.ejhg.5200795; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; Sato M, 1998, GENE CHROMOSOME CANC, V22, P1; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1; TSUDA H, 1994, CANCER RES, V54, P513; Vos CBJ, 1999, BRIT J CANCER, V81, P1410, DOI 10.1038/sj.bjc.6693372; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V82, P1, DOI 10.1016/0165-4608(95)91129-7	44	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					47	54		10.1038/sj.onc.1208175	http://dx.doi.org/10.1038/sj.onc.1208175			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558027				2022-12-25	WOS:000226125800007
J	Bao, XY; Chen, YY; Lee, SH; Lee, SC; Reuss, L; Altenberg, GA				Bao, XY; Chen, YY; Lee, SH; Lee, SC; Reuss, L; Altenberg, GA			Membrane transport proteins with complete replacement of transmembrane helices with polyalanine sequences remain functional	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN-1; C-MEDIATED PHOSPHORYLATION; AMINO-ACID-RESIDUES; SCANNING MUTAGENESIS; GAP; DETERMINANTS; HEMICHANNELS; CONNEXIN-43; CHANNELS; RECEPTOR	Approximately 25% of all genome coding sequences correspond to membrane proteins, which perform varied and essential functions in cells. Eukaryotic integral membrane proteins are predominantly alpha-helical proteins that span the membrane several times. The most frequent approach to identifying transmembrane-helix amino acids essential for function is to substitute native residues, one at a time, with Cys or Ala (Cys- and Ala-scanning mutagenesis). Here, we present a new approach, in which complete transmembrane-helix native sequences are substituted with poly-Ala sequences. We show that the basic functional features of two dissimilar membrane proteins, which function as a channel and a pump, respectively, are maintained when certain individual alpha-helices are replaced with poly-Ala sequences. This approach ("helix-scanning mutagenesis") allows for rapid identification of helices containing residues essential for function and can be used as a primary helix-screening tool, followed by individual amino acid substitutions when specific helix poly-Ala replacements cause functional changes in the protein.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Altenberg, GA (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	galtenbe@utmb.edu		Altenberg, Guillermo/0000-0002-8932-740X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068586] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Bao XY, 2004, J BIOL CHEM, V279, P20058, DOI 10.1074/jbc.M311137200; Bao XY, 2004, J BIOL CHEM, V279, P9689, DOI 10.1074/jbc.M311438200; Bao XY, 2004, AM J PHYSIOL-CELL PH, V286, pC647, DOI 10.1152/ajpcell.00295.2003; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Dassa E., 2003, ABC PROTEINS BACTERI, P3; Deeley RG, 2003, ABC PROTEINS BACTERI, P393; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lee SH, 2003, BIOCHEM J, V370, P357, DOI 10.1042/BJ20021452; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Miller JS, 2001, BIOCHEMISTRY-US, V40, P305, DOI 10.1021/bi0019500; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200	25	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8647	8650		10.1074/jbc.M413536200	http://dx.doi.org/10.1074/jbc.M413536200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15596437	hybrid			2022-12-25	WOS:000227453100005
J	Voskoboinik, I; Thia, MC; Fletcher, J; Ciccone, A; Browne, K; Smyth, MJ; Trapani, JA				Voskoboinik, I; Thia, MC; Fletcher, J; Ciccone, A; Browne, K; Smyth, MJ; Trapani, JA			Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; FORMING PROTEIN PERFORIN; NATURAL-KILLER-CELLS; CRYSTAL-STRUCTURE; COMPLEMENT C9; 9TH COMPONENT; T-CELLS; GENE; CYTOTOXICITY; MUTATIONS	The lymphocyte pore- forming protein perforin is essential for maintaining immune homeostasis and for effective defense against intracellular pathogens. To date, there have been no reported structure- function studies to substantiate the function of any putative domains of perforin, which have been postulated totally on primary sequence similarities with domains in other proteins. In this report, we have used recently developed modalities for expressing full- length perforin and robust functional assays to investigate one of the hallmarks of perforin function: its absolute dependence on calcium for lipid binding and cell lysis. We provide, for the first time, experimental evidence that the predicted C- terminal C2 motif constitutes a functional domain that is responsible for membrane binding of perforin. Whereas conserved aspartate residues at positions 429, 435, 483, and 485 were essential for calcium- dependent plasma membrane binding and cell lysis, the contribution of Asp- 491 was limited. Finally, after experimentally verifying an optimized three- dimensional model, we have made predictions on the impact of two inherited perforin mutations of the C2 domain on calcium- dependent lipid binding and cell lysis.	Peter MacCallum Canc Inst, Canc Immunol Program, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Peter Maccallum Cancer Center; Walter & Eliza Hall Institute	Voskoboinik, I (corresponding author), Peter MacCallum Canc Inst, Canc Immunol Program, Locked Bag 1,A Beckett St 8006, Parkville, Vic 3050, Australia.	ilia.voskoboinik@petermac.org; joe.trapani@petermac.org	Fletcher, Jamie/V-4667-2019; Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Trapani, Joseph/0000-0003-0983-1532; Fletcher, Jamie/0000-0003-2949-9469; Voskoboinik, Ilia/0000-0002-6410-009X				BLUMENTHAL R, 1984, P NATL ACAD SCI-BIOL, V81, P5551, DOI 10.1073/pnas.81.17.5551; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DENNERT G, 1983, J EXP MED, V157, P1483, DOI 10.1084/jem.157.5.1483; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Feldmann J, 2002, BRIT J HAEMATOL, V117, P965, DOI 10.1046/j.1365-2141.2002.03534.x; Forsyth WR, 2002, PROTEINS, V48, P388, DOI 10.1002/prot.10174; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kelly JM, 2004, J BIOL CHEM, V279, P22236, DOI 10.1074/jbc.M401670200; Lee SM, 2004, J MED GENET, V41, P137, DOI 10.1136/jmg.2003.011528; MASSON D, 1985, J BIOL CHEM, V260, P9069; McCormick J, 2003, AM J MED GENET A, V117A, P255, DOI 10.1002/ajmg.a.10010; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Natarajan K, 1998, CHEM BIOL, V5, P147, DOI 10.1016/S1074-5521(98)90059-X; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PERSECHINI PM, 1992, BIOCHEMISTRY-US, V31, P5017, DOI 10.1021/bi00136a015; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1983, NATURE, V302, P442, DOI 10.1038/302442a0; Ponting CP, 1996, PROTEIN SCI, V5, P162; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SHIVER JW, 1991, CELL, V64, P1175, DOI 10.1016/0092-8674(91)90272-Z; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; Trambas CM, 2003, NAT IMMUNOL, V4, P399, DOI 10.1038/ni0503-399; Trapani JA, 1998, INT REV CYTOL, V182, P111, DOI 10.1016/S0074-7696(08)62169-5; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; TSCHOPP J, 1989, NATURE, V337, P272, DOI 10.1038/337272a0; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; Voskoboinik I, 2004, J EXP MED, V200, P811, DOI 10.1084/jem.20040776; Wang S, 2002, ARCH PATHOL LAB MED, V126, P947; YOUNG JDE, 1987, J EXP MED, V165, P1371, DOI 10.1084/jem.165.5.1371; YOUNG JDE, 1986, SCIENCE, V233, P184, DOI 10.1126/science.2425429	40	116	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8426	8434		10.1074/jbc.M413303200	http://dx.doi.org/10.1074/jbc.M413303200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15576364	hybrid			2022-12-25	WOS:000227395700119
J	Bava, SV; Puliappadamba, VT; Deepti, A; Nair, A; Karunagaran, D; Anto, RJ				Bava, SV; Puliappadamba, VT; Deepti, A; Nair, A; Karunagaran, D; Anto, RJ			Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappa B and the serine/threonine kinase Akt and is independent of tubulin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER CELLS; TRANSCRIPTION FACTOR; ECTOPIC EXPRESSION; SIGNALING PATHWAY; OVARIAN-CANCER; TUMOR-CELLS; CONFERS RESISTANCE; DIETARY CURCUMIN; BREAST-CANCER; CYTOCHROME-C	Taxol is the best anticancer agent that has ever been isolated from plants, but its major disadvantage is its dose-limiting toxicity. In this study, we report with mechanism-based evidence that curcumin, a nontoxic food additive commonly used by the Indian population, sensitizes tumor cells more efficiently to the therapeutic effect of Taxol. A combination of 5 nm Taxol with 5 pm curcumin augments anticancer effects more efficiently than Taxol alone as evidenced by increased cytotoxicity and reduced DNA synthesis in HeLa cells. Furthermore, our results reveal that this combination at the cellular level augments activation of caspases and cytochrome c release. This synergistic effect was not observed in normal cervical cells, 293 cells (in which Taxol down-regulates nuclear factor-kappaB (NF-kappaB)), or HeLa cells transfected with inhibitor kappaBa double mutant (IkappaBa DM), although the transfection itself sensitized the cells to Taxol-induced cytotoxicity. Evaluation of signaling pathways common to Taxol and curcumin reveals that this synergism was in part related to down-regulation of NF-kappaB and serine/threonine kinase Akt pathways by curcumin. An electrophoretic mobility shift assay revealed that activation of NF-kappaB induced by Taxol is down-regulated by curcumin. We also noted that curcumin-down-regulated Taxol induced phosphorylation of the serine/threonine kinase AM, a survival signal which in many instances is regulated by NF-kappaB. Interestingly, tubulin polymerization and cyclin-dependent kinase Cdc2 activation induced by Taxol was not affected by curcumin. Altogether, our observations indicate that Taxol in combination with curcumin may provide a superior therapeutic index and advantage in the clinic for the treatment of refractory tumors.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Anto, RJ (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	rubyjohnanto@yahoo.com	Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; deepti, ayswaria/0000-0001-7159-6911				Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Anto RJ, 2003, J BIOL CHEM, V278, P25490, DOI 10.1074/jbc.M301790200; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Anto RJ, 2000, J BIOL CHEM, V275, P15601, DOI 10.1074/jbc.C000105200; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Chaudhury LR, 2003, J CELL BIOCHEM, V89, P1, DOI 10.1002/jcb.10495; Cheng SCS, 2001, CELL BIOL INT, V25, P261, DOI 10.1006/cbir.2000.0619; Chun EY, 2004, BIOCHEM BIOPH RES CO, V315, P771, DOI 10.1016/j.bbrc.2004.01.118; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; Holy JM, 2002, MUTAT RES-GEN TOX EN, V518, P71, DOI 10.1016/S1383-5718(02)00076-1; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG MT, 1988, CANCER RES, V48, P5941; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Huang Y, 2000, CANCER RES, V60, P4426; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; KOHN EC, 1994, J NATL CANCER I, V86, P18, DOI 10.1093/jnci/86.1.18; Krauss T, 2001, ONKOLOGIE, V24, P340, DOI 10.1159/000055105; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kumar AP, 2003, NEOPLASIA, V5, P255, DOI 10.1016/S1476-5586(03)80057-X; KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4; Lee M, 2001, MOL PHARMACOL, V59, P248, DOI 10.1124/mol.59.2.248; Lin HL, 2003, BRIT J CANCER, V88, P973, DOI 10.1038/sj.bjc.6600788; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Locke V, 2001, CYTOMETRY, V43, P170, DOI 10.1002/1097-0320(20010301)43:3<170::AID-CYTO1045>3.3.CO;2-N; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; MAIERLENZ H, 1997, SEMIN ONCOL, V24, P19; Makino K, 2001, ONCOGENE, V20, P2537, DOI 10.1038/sj.onc.1204366; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Nguyen DM, 2004, J THORAC CARDIOV SUR, V127, P365, DOI 10.1016/j.jtcvs.2003.09.033; Ozes ON, 1999, NATURE, V401, P82; Page C, 2000, ANTICANCER RES, V20, P407; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rashmi R, 2004, CARCINOGENESIS, V25, P179, DOI 10.1093/carcin/bgh001; Rashmi R, 2003, FEBS LETT, V538, P19, DOI 10.1016/S0014-5793(03)00099-1; Shanta V, 2000, J Indian Med Assoc, V98, P49; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; TANAKA T, 1994, CANCER RES, V54, P4653; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vivat-Hannah V, 2001, CANCER RES, V61, P8703; Vorobiof DA, 2004, BREAST, V13, P219, DOI 10.1016/j.breast.2004.01.006; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Wang WX, 1999, CLIN CANCER RES, V5, P119; Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082; Zanetta G, 2000, SEMIN ONCOL, V27, P23	53	176	191	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6301	6308		10.1074/jbc.M410647200	http://dx.doi.org/10.1074/jbc.M410647200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590651	hybrid, Green Published			2022-12-25	WOS:000227332700010
J	Belfort, GM; Bakirtzi, K; Kandror, KV				Belfort, GM; Bakirtzi, K; Kandror, KV			Cellugyrin induces biogenesis of synaptic-like microvesicles in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; SYNAPTOPHYSIN; SYNAPTOGYRIN; PROTEINS; ENDOSOMES; TRANSPORT	The four-transmembrane domain proteins synaptophysin and synaptogyrin represent the major constituents of synaptic vesicles. Our previous studies in PC12 cells demonstrated that synaptogyrin or its nonneuronal paralog cellugyrin targets efficiently to synaptic-like microvesicles (SLMVs) and dramatically increases the synaptophysin content of SLMVs (Belfort, G. M., and Kandror, K. V. (2003) J. Biol. Chem. 278, 47971-47978). Here, we explored the mechanism of these phenomena and found that ectopic expression of cellugyrin increases the number of SLMVs in PC12 cells. Mutagenesis studies revealed that cellugyrin's hydrophilic cytoplasmic domains are not involved in vesicle biogenesis, whereas small conserved hydrophobic hairpins in the first luminal loop and the carboxyl terminus of cellugyrin were found to be critical for the formation of SLMVs. In addition, the length but not the primary sequence of the second luminal loop was essential for SLMV biogenesis. We suggest that changing the length of this loop similar to disruption of the short hydrophobic hairpins alters the position of the vicinal transmembrane domains that may be crucial for protein function.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K124D,715 Albany St, Boston, MA 02118 USA.	kandror@biochem.bumc.bu.edu		Kandror, Konstantin/0000-0002-8601-9313	NIDDK NIH HHS [T32 DK07201, R01 DK52057, R01 DK56736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052057, T32DK007201, R01DK056736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belfort GM, 2003, J BIOL CHEM, V278, P47971, DOI 10.1074/jbc.M304174200; Blagoveshchenskaya AD, 1999, MOL BIOL CELL, V10, P3979, DOI 10.1091/mbc.10.11.3979; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; de Wit H, 2001, MOL BIOL CELL, V12, P3703, DOI 10.1091/mbc.12.11.3703; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Haass NK, 1996, J CELL BIOL, V134, P731, DOI 10.1083/jcb.134.3.731; Hubner K, 2002, INT REV CYTOL, V214, P103; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MCS, 2004, SCIENCE, V303, P479, DOI 10.1126/science.1094231; LEUBE RE, 1995, J CELL SCI, V108, P883; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; LINSTEDT AD, 1991, J PHYSIOL-PARIS, V85, P90; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; Pennuto M, 2003, MOL BIOL CELL, V14, P4909, DOI 10.1091/mbc.E03-06-0380; Schreiber BM, 1999, BIOCHEM J, V344, P7, DOI 10.1042/0264-6021:3440007; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Verma R, 2004, BIOL PSYCHIAT, V55, P196, DOI 10.1016/j.biopsych.2003.10.012; Zhao HJ, 2001, MOL BIOL CELL, V12, P2275, DOI 10.1091/mbc.12.8.2275	27	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7262	7272		10.1074/jbc.M404851200	http://dx.doi.org/10.1074/jbc.M404851200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590695	hybrid			2022-12-25	WOS:000227332700118
J	Kario, E; Marmor, MD; Adamsky, K; Citri, A; Amit, I; Amariglio, N; Rechavi, G; Yarden, Y				Kario, E; Marmor, MD; Adamsky, K; Citri, A; Amit, I; Amariglio, N; Rechavi, G; Yarden, Y			Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; EGF-RECEPTOR; SOCS BOX; INDUCED ACTIVATION; PLASMA-MEMBRANE; STAT ACTIVATION; DEGRADATION; ENDOCYTOSIS; PROTEIN; PHOSPHORYLATION	Suppressors of cytokine signaling (SOCS) are Src homology-2-containing proteins originally identified as negative regulators of cytokine signaling. Accumulating evidence indicates a role for SOCS proteins in the regulation of additional signaling pathways including receptor tyrosine kinases. Notably, SOCS36E, the Drosophila ortholog of mammalian SOCS5, was recently implicated as a negative regulator of the Drosophila ortholog of EGFR. In this study, we aimed at characterizing the role of SOCS5 in the negative regulation of EGFR. Here we show that the expression of SOCS5 and its closest homolog SOCS4 is elevated in cells following treatment with EGF, similar to several negative feedback regulators of EGFR whose expression is up-regulated upon receptor activation. The expression of SOCS5 led to a marked reduction in EGFR expression levels by promoting EGFR degradation. The reduction in EGFR levels and EGF-induced signaling in SOCS5-expressing cells requires both the Src homology-2 and SOCS box domains of SOCS5. Interestingly, EGFR is degraded by SOCS5 prior to EGF treatment in a ligand- and c-Cbl-independent manner. SOCS5 can associate with EGFR and can also bind the ElonginBC protein complex via its SOCS box, which may recruit an E3 ubiquitin ligase to promote EGFR degradation. Thus, we have characterized a novel function for SOCS5 in regulating EGFR and discuss its potential role in controlling EGFR homeostasis.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012; Citri, Ami/R-8973-2019	Citri, Ami/0000-0002-9914-0278	NCI NIH HHS [CA72981] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Brender C, 2004, MOL CELL BIOL, V24, P6094, DOI 10.1128/MCB.24.13.6094-6103.2004; Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO;2-M; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Callus BA, 2002, ONCOGENE, V21, P4812, DOI 10.1038/sj.onc.1205618; de Melker AA, 2001, J CELL SCI, V114, P2167; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Dong JB, 2004, J BIOL CHEM, V279, P21334, DOI 10.1074/jbc.M401022200; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Kumar KGS, 2003, EMBO J, V22, P5480; Leevers SJ, 1999, NAT CELL BIOL, V1, pE10, DOI 10.1038/8969; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Seki Y, 2002, P NATL ACAD SCI USA, V99, P13003, DOI 10.1073/pnas.202477099; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	47	112	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7038	7048		10.1074/jbc.M408575200	http://dx.doi.org/10.1074/jbc.M408575200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590694	hybrid			2022-12-25	WOS:000227332700094
J	Lindner, HA; Nadeau, G; Matte, A; Michel, G; Menard, R; Cygler, M				Lindner, HA; Nadeau, G; Matte, A; Michel, G; Menard, R; Cygler, M			Site-directed mutagenesis of the active site region in the quinate/shikimate 5-dehydrogenase YdiB of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; SHIKIMATE-PATHWAY ENZYMES; NICOTINAMIDE BINDING-SITE; CRYSTAL-STRUCTURE; AROMATIC BIOSYNTHESIS; HIGHER-PLANTS; ACID; REDUCTASE; ENVIRONMENT; EVOLUTION	YdiB and its paralog AroE are members of the quinate/shikimate 5-dehdrogenase family. Enzymes from this family function in the shikimate pathway that is essential for survival of microorganisms and plants and represent potential drug targets. Recent YdiB and AroE crystal structures revealed the presence of a NAD(P)-binding and a catalytic domain. We carried out site-directed mutagenesis of 8 putative active site residues in YdiB from Escherichia coli and analyzed structural and kinetic properties of the mutant enzymes. Our data indicate critical roles for an invariant lysine and aspartate residue in substrate binding and allowed us to differentiate between two previously proposed models for the binding of the substrate in the active site. Comparison of several YdiB and AroE structures led us to conclude that, upon cofactor binding and domain closure, the 2 identified binding residues are repositioned to bind to the substrate. Although the lysine residue contributes to some extent to the stabilization of the transition state, we did not identify any residue as catalytically essential. This indicates that catalysis does not operate through a general acid-base mechanism, as thought originally. Our improved understanding of the medically and agriculturally important quinate/shikimate 5-dehydrogenase family at the molecular level may prove useful in the development of novel herbicides and antimicrobial agents.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H3G 1Y6, Canada; Univ Paris 06, CNRS, Lab Goemar, F-29682 Roscoff, France	National Research Council Canada; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Lindner, HA (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Ave, Montreal, PQ H4P 2R2, Canada.	Holger.Lindner@cnrc-nrc.gc.ca	MICHEL, Gurvan/B-3490-2008; Lindner, Holger A/C-5106-2014	Lindner, Holger A/0000-0002-6679-4355; MICHEL, Gurvan/0000-0002-3009-6205				Baerson SR, 2002, PLANT PHYSIOL, V129, P1265, DOI 10.1104/pp.001560; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BALINSKY D, 1971, BIOCHEMISTRY-US, V10, P1947; BALINSKY D, 1961, BIOCHEM J, V80, P296, DOI 10.1042/bj0800296; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Benach J, 2003, J BIOL CHEM, V278, P19176, DOI 10.1074/jbc.M301348200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown KA, 2003, BIOCHEM SOC T, V31, P543, DOI 10.1042/BST0310543; BUGG TDH, 1988, TETRAHEDRON LETT, V29, P6779, DOI 10.1016/S0040-4039(00)82453-3; Campbell SA, 2004, INT J PARASITOL, V34, P5, DOI 10.1016/j.ijpara.2003.10.006; Carpenter J, 2000, SCIENCE, V287, P803; Castle LA, 2004, SCIENCE, V304, P1151, DOI 10.1126/science.1096770; Coggins JR, 2003, BIOCHEM SOC T, V31, P548, DOI 10.1042/BST0310548; DANSETTE P, 1974, BIOCHIMIE, V56, P751, DOI 10.1016/S0300-9084(74)80046-5; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; Delano W.L, 2002, PYMOL USERS MANUAL; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAWKINS AR, 1993, J GEN MICROBIOL, V139, P2891, DOI 10.1099/00221287-139-12-2891; Herrmann KM, 1999, ANNU REV PLANT PHYS, V50, P473, DOI 10.1146/annurev.arplant.50.1.473; Hua SJ, 2002, J MOL BIOL, V320, P713, DOI 10.1016/S0022-2836(02)00467-9; Knaggs AR, 2003, NAT PROD REP, V20, P119, DOI 10.1039/b100399m; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Kramer M, 2003, METAB ENG, V5, P277, DOI 10.1016/j.ymben.2003.09.001; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; Michel G, 2003, J BIOL CHEM, V278, P19463, DOI 10.1074/jbc.M300794200; Padyana AK, 2003, STRUCTURE, V11, P1005, DOI 10.1016/S0969-2126(03)00159-X; Payne D J, 2000, Curr Opin Drug Discov Devel, V3, P177; PITTARD J, 1966, J BACTERIOL, V91, P1494, DOI 10.1128/JB.91.4.1494-1508.1966; Ringe D, 1999, NATURE, V399, P417, DOI 10.1038/20819; Rubach JK, 2003, BIOCHEMISTRY-US, V42, P2907, DOI 10.1021/bi0272656; Rubach JK, 2001, BIOCHEMISTRY-US, V40, P12686, DOI 10.1021/bi011540r; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P11003, DOI 10.1021/bi980475r; SCHMID J, 1995, PHYTOCHEMISTRY, V39, P737, DOI 10.1016/0031-9422(94)00962-S; Ye S, 2003, J BACTERIOL, V185, P4144, DOI 10.1128/JB.185.14.4144-4151.2003; Zalacain M, 2003, J MOL MICROB BIOTECH, V6, P109, DOI 10.1159/000076741	38	23	26	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7162	7169		10.1074/jbc.M412028200	http://dx.doi.org/10.1074/jbc.M412028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596430	hybrid			2022-12-25	WOS:000227332700107
J	Lu, ML; Kwan, T; Yu, CJ; Chen, F; Freedman, B; Schafer, JM; Lee, EJ; Jameson, JL; Jordan, VC; Cryns, VL				Lu, ML; Kwan, T; Yu, CJ; Chen, F; Freedman, B; Schafer, JM; Lee, EJ; Jameson, JL; Jordan, VC; Cryns, VL			Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; PPAR-GAMMA; CYTOCHROME-C; IN-VIVO; POLY(ADP-RIBOSE) POLYMERASE; TUMORICIDAL ACTIVITY; MONOCLONAL-ANTIBODY; DECOY RECEPTORS; CASPASE 8; LIGAND	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapy that preferentially induces apoptosis in cancer cells. However, many neoplasms are resistant to TRAIL by mechanisms that are poorly understood. Here we demonstrate that human breast cancer cells, but not normal mammary epithelial cells, are dramatically sensitized to TRAIL-induced apoptosis and caspase activation by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists of the thiazolidinedione (TZD) class. Although TZDs do not significantly alter the expression of components of the TRAIL signaling pathway, they profoundly reduce protein levels of cyclin D3, but not other D-type cyclins, by decreasing cyclin D3 mRNA levels and by inducing its proteasomal degradation. Importantly, both TRAIL sensitization and reduction in cyclin D3 protein levels induced by TZDs are likely PPARgamma-independent because a dominant negative mutant of PPARgamma did not antagonize these effects of TZDs, nor were they affected by the expression levels of PPARgamma. TZDs also inhibit G(1) to S cell cycle progression. Furthermore, silencing cyclin D3 by RNA interference inhibits S phase entry and sensitizes breast cancer cells to TRAIL, indicating a key role for cyclin D3 repression in these events. G, cell cycle arrest sensitizes breast cancer cells to TRAIL at least in part by reducing levels of the antiapoptotic protein survivin: ectopic expression of survivin partially suppresses apoptosis induced by TRAIL and TZDs. We also demonstrate for the first time that TZDs promote TRAIL-induced apoptosis of breast cancer in vivo, suggesting that this combination may be an effective therapy for cancer.	Northwestern Univ, Feinberg Sch Med, Cell Death Regulat Lab, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Chicago	Cryns, VL (corresponding author), Northwestern Univ, Feinberg Sch Med, Cell Death Regulat Lab, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.	v-cryns@northwestern.edu	JORDAN, V.Craig/AAX-3562-2020; Yu, Chunjiang/E-9419-2012; Jordan, V. Craig/H-4491-2011	Jameson, James/0000-0001-9538-4059	NCI NIH HHS [R01CA097198, P50CA89018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089018, R01CA097198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731; Burns TF, 2001, J BIOL CHEM, V276, P37879; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen F, 2002, J BIOL CHEM, V277, P16775, DOI 10.1074/jbc.M201322200; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Filipits M, 2002, CLIN CANCER RES, V8, P729; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Griffith TS, 2002, CANCER RES, V62, P3093; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Keane MM, 1999, CANCER RES, V59, P734; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nagane M, 2000, CANCER RES, V60, P847; Nathan DM, 2002, NEW ENGL J MED, V347, P1342, DOI 10.1056/NEJMcp021106; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park Y, 2003, DIABETOLOGIA, V46, P365, DOI 10.1007/s00125-003-1037-4; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Suh N, 1999, CANCER RES, V59, P5671; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550	63	96	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6742	6751		10.1074/jbc.M411519200	http://dx.doi.org/10.1074/jbc.M411519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15569667	hybrid			2022-12-25	WOS:000227332700063
J	Francis, K; Russell, B; Gadda, G				Francis, K; Russell, B; Gadda, G			Involvement of a flavosemiquinone in the enzymatic oxidation of nitroalkanes catalyzed by 2-nitropropane dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; HANSENULA-MRAKII; GLUCOSE-OXIDASE; ACTION MECHANISM; SUPEROXIDE; SUBSTRATE; FLAVOPROTEINS; ACTIVATION; FLAVIN	2-Nitropropane dioxygenase (EC 1.13.11.32) catalyzes the oxidation of nitroalkanes into their corresponding carbonyl compounds and nitrite. In this study, the ncd-2 gene encoding for the enzyme in Neurospora crassa was cloned, expressed in Escherichia coli, and the resulting enzyme was purified. Size exclusion chromatography, heat denaturation, and mass spectroscopic analyses showed that 2-nitropropane dioxygenase is a homodimer of 80 kDa, containing a mole of non-covalently bound FMN per mole of subunit, and is devoid of iron. With neutral nitroalkanes and anionic nitronates other than propyl-1- and propyl-2-nitronate, for which a nonenzymatic free radical reaction involving superoxide was established using superoxide dismutase, substrate oxidation occurs within the enzyme active site. The enzyme was more specific for nitronates than nitroalkanes, as suggested by the second order rate constant k(cat)/K-m determined with 2-nitropropane and primary nitroalkanes with alkyl chain lengths between 2 and 6 carbons. The steady state kinetic mechanism with 2-nitropropane, nitroethane, nitrobutane, and nitrohexane, in either the neutral or anionic form, was determined to be sequential, consistent with oxygen reacting with a reduced form of enzyme before release of the carbonyl product. Enzyme-monitored turnover with ethyl nitronate as substrate indicated that the catalytically relevant reduced form of enzyme is an anionic flavin semiquinone, whose formation requires the substrate, but not molecular oxygen, as suggested by anaerobic substrate reduction with nitroethane or ethyl nitronate. Substrate deuterium kinetic isotope effects with 1,2-[H-2(4)]nitroethane and 1,1,2-[H-2(3)]ethyl nitronate at pH 8 yielded normal and inverse effects on the k(cat)/K-m value, respectively, and were negligible on the k(cat) value. The k(cat)/K-m and k(cat) pH profiles with anionic nitronates showed the requirement of an acid, whereas those for neutral nitroalkanes were consistent with the involvement of both an acid and a base in catalysis. The kinetic data reported herein are consistent with an oxidase-style catalytic mechanism for 2-nitropropane dioxygenase, in which the flavin-mediated oxidation of the anionic nitronates or neutral nitroalkanes and the subsequent oxidation of the enzyme-bound flavin occur in two independent steps.	Georgia State Univ, Dept Chem, Atlanta, GA 30302 USA; Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA; Georgia State Univ, Ctr Biotechnol & Drug Design, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University; University System of Georgia; Georgia State University; University System of Georgia; Georgia State University	Gadda, G (corresponding author), Georgia State Univ, Dept Chem, POB 4098, Atlanta, GA 30302 USA.	ggadda@gsu.edu	Gadda, Giovanni/M-2354-2016; Hamblin, Mike/AAB-2511-2022; Hamblin, Michael R/H-2758-2019	Gadda, Giovanni/0000-0002-7508-4195; Hamblin, Michael R/0000-0001-6431-4605				Allison R D, 1979, Methods Enzymol, V63, P3; BELL RP, 1952, T FARADAY SOC, V48, P439, DOI 10.1039/tf9524800439; BORS W, 1993, CHEM RES TOXICOL, V6, P302, DOI 10.1021/tx00033a008; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONAWAY CC, 1991, CANCER RES, V51, P3143; DAVIS R, 1993, PATTYS IND HYGIENE T; DAYAL R, 1989, FUND APPL TOXICOL, V13, P341, DOI 10.1016/0272-0590(89)90270-4; ECKSTEIN JW, 1993, BIOCHEMISTRY-US, V32, P404, DOI 10.1021/bi00053a004; FIALA ES, 1987, CARCINOGENESIS, V8, P1947, DOI 10.1093/carcin/8.12.1947; Francisco WA, 1998, BIOCHEMISTRY-US, V37, P2596, DOI 10.1021/bi972266x; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gadda G, 2000, ARCH BIOCHEM BIOPHYS, V382, P138, DOI 10.1006/abbi.2000.2009; Gadda G, 1999, ARCH BIOCHEM BIOPHYS, V363, P309, DOI 10.1006/abbi.1998.1081; Gadda G, 2000, BIOCHEMISTRY-US, V39, P1406, DOI 10.1021/bi992255z; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; Gorlatova N, 1998, APPL ENVIRON MICROB, V64, P1029; HAASJOBELIUS M, 1992, ECOTOX ENVIRON SAFE, V23, P253, DOI 10.1016/0147-6513(92)90075-E; Hanessian S, 2000, ORG LETT, V2, P2975, DOI 10.1021/ol000170g; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; JORNS MS, 1987, J BIOL CHEM, V262, P486; KIDO T, 1978, J BIOL CHEM, V253, P226; KIDO T, 1976, J BIOL CHEM, V251, P6994; KIDO T, 1978, J BACTERIOL, V133, P53, DOI 10.1128/JB.133.1.53-58.1978; KUO CF, 1986, BIOCHEM J, V237, P505, DOI 10.1042/bj2370505; LEWIS TR, 1979, J ENVIRON PATHOL TOX, V2, P233; LITTLE HN, 1951, J BIOL CHEM, V193, P347; Martinez JI, 1997, BIOCHEMISTRY-US, V36, P15526, DOI 10.1021/bi971495g; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Massey V, 2000, BIOCHEM SOC T, V28, P283, DOI 10.1042/0300-5127:0280283; Matt C, 1997, J ORG CHEM, V62, P234, DOI 10.1021/jo962110n; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; Nielsen A.T., 1969, CHEM NITRO NITROSO G, V1, P349; PILONE MS, 1987, BIOCHIM BIOPHYS ACTA, V914, P136; PORTER DJT, 1983, J BIOL CHEM, V258, P9913; PORTER DJT, 1973, J BIOL CHEM, V248, P4400; PORTER DJT, 1987, J BIOL CHEM, V262, P14428; PORTER DJT, 1977, J BIOL CHEM, V252, P4361; Roth JP, 2003, P NATL ACAD SCI USA, V100, P62, DOI 10.1073/pnas.252644599; Sakano K, 2001, MUTAT RES-FUND MOL M, V479, P101, DOI 10.1016/S0027-5107(01)00158-0; SANCAR GB, 1987, J BIOL CHEM, V262, P492; Sittig M, 1985, HDB TOXIC HAZARDOUS; STREITWIESER A, 1958, J AM CHEM SOC, V80, P2326, DOI 10.1021/ja01542a075; Su QJ, 1999, BIOCHEMISTRY-US, V38, P8572, DOI 10.1021/bi990044o; TCHORZEWSKI M, 1994, EUR J BIOCHEM, V226, P841, DOI 10.1111/j.1432-1033.1994.00841.x; THEORELL H, 1956, ARCH BIOCHEM BIOPHYS, V65, P439, DOI 10.1016/0003-9861(56)90204-1; URBAN P, 1988, BIOCHEMISTRY-US, V27, P7365, DOI 10.1021/bi00419a029; Valley MP, 2003, J AM CHEM SOC, V125, P8738, DOI 10.1021/ja036045s; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; Zheng YJ, 1996, J AM CHEM SOC, V118, P9402, DOI 10.1021/ja9608151	50	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5195	5204		10.1074/jbc.M411249200	http://dx.doi.org/10.1074/jbc.M411249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15582992	hybrid			2022-12-25	WOS:000227217100012
J	Heuze, ML; Guibal, FC; Banks, CA; Conaway, JW; Conaway, RC; Cayre, YE; Benecke, A; Lutz, PG				Heuze, ML; Guibal, FC; Banks, CA; Conaway, JW; Conaway, RC; Cayre, YE; Benecke, A; Lutz, PG			ASB2 is an elongin BC-interacting protein that can assemble with cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PROMYELOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR PROTEIN; RETINOIC ACID RECEPTOR; RNA-POLYMERASE-II; SOCS-BOX MOTIF; RAR-ALPHA; DIFFERENTIATION THERAPY; MEDIATED DEGRADATION; HISTONE DEACETYLASE; HEMATOPOIETIC-CELLS	The ankyrin repeat-containing protein with a suppressor of cytokine signaling box-2 (ASB2) gene was identified as a retinoic acid-response gene and a target of the promyelocytic leukemia-retinoic acid receptor-a oncogenic protein characteristic of acute promyelocytic leukemia. Expression of AS132 in myeloid leukemia cells inhibits growth and promotes commitment, recapitulating an early step known to be critical for differentiation. Here we show that AS132, by interacting with the Elongin BC complex, can assemble with Cullin5-Rbxl to form an E3 ubiquitin ligase complex that stimulates polyubiquitination by the E2 ubiquitin-conjugating enzyme Ubc5. This is a first indication that a member of the ASB protein family, AS132, is a subunit of an ECS (Elongin C-Cullin-SOCS box)-type E3 ubiquitin ligase complex. Altogether, our results strongly suggest that AS132 targets specific proteins to destruction by the proteasome in leukemia cells that have been induced to differentiate.	Hop Robert Debre, INSERM, U417, F-75935 Paris 19, France; Stowers Inst Med Res, Kansas City, MO 64110 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Univ La Sapienza 2, I-00161 Rome, Italy; Inst Hautes Etud Sci, F-91440 Bures Sur Yvette, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Stowers Institute for Medical Research; Jefferson University; Sapienza University Rome; UDICE-French Research Universities; Universite Paris Saclay	Lutz, PG (corresponding author), Univ Paris 05, CNRS, INSERM, Inst Cochin,Dept Biol Cellulaire,U567, 22 Rue Mechain, F-75014 Paris, France.	lutz@cochin.inserm.fr	Benecke, Arndt G./T-1079-2019; Lutz, Pierre/B-8822-2009	Heuze, Melina/0000-0002-4271-2706; Conaway, Joan/0000-0002-2786-0663; Lutz, Pierre/0000-0003-0590-9101				Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BREITMAN TR, 1981, BLOOD, V57, P1000; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Burnatowska-Hledin M, 2000, AM J PHYSIOL-CELL PH, V279, pC266, DOI 10.1152/ajpcell.2000.279.1.C266; Burnatowska-Hledin M, 2001, ENDOTHELIUM-J ENDOTH, V8, P49, DOI 10.3109/10623320109063157; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guibal FC, 2002, J BIOL CHEM, V277, P218, DOI 10.1074/jbc.M108476200; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038/sj.onc.1204757; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; LABBAYE C, 1994, BLOOD, V83, P651; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lutz P, 1997, J VIROL, V71, P5102, DOI 10.1128/JVI.71.7.5102-5109.1997; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Moog-Lutz C, 2003, BLOOD, V102, P3371, DOI 10.1182/blood-2002-11-3462; Moog-Lutz C, 2001, J BIOL CHEM, V276, P22375, DOI 10.1074/jbc.M011683200; Ohta T, 2001, CANCER RES, V61, P1347; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Van Dort C, 2003, AM J PHYSIOL-CELL PH, V285, pC1386, DOI 10.1152/ajpcell.00338.2002; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang Y, 2003, EMBO J, V22, P6057, DOI 10.1093/emboj/cdg577	56	60	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5468	5474		10.1074/jbc.M413040200	http://dx.doi.org/10.1074/jbc.M413040200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590664	hybrid			2022-12-25	WOS:000227217100044
J	Nusbaum, P; Laine, C; Bouaouina, M; Seveau, S; Cramer, EM; Masse, JM; Lesavre, P; Halbwachs-Mecarelli, L				Nusbaum, P; Laine, C; Bouaouina, M; Seveau, S; Cramer, EM; Masse, JM; Lesavre, P; Halbwachs-Mecarelli, L			Distinct signaling pathways are involved in leukosialin (CD43) down-regulation, membrane blebbing, and phospholipid scambling during neutrophil apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FC-GAMMA-RIII; CELL-DEATH; IN-VITRO; POLYMORPHONUCLEAR NEUTROPHILS; MOLECULAR CHARACTERIZATION; SIALOPHORIN CD43; ROCK-I; SURFACE; ACTIVATION	Although leukosialin (CD43) membrane expression decreases during neutrophil apoptosis, the CD43 molecule, unexpectedly, is neither proteolyzed nor internalized. We thus wondered whether it could be shed on bleb-derived membrane vesicles. Membrane blebbing is a transient event, hardly appreciated during the asynchronous, spontaneous apoptosis of neutrophils. Cell pre-synchronization at 15 degreesC made it possible to observe numerous blebbing neutrophils for a short 1-h period at 37 degreesC. CD43 down-regulation co-occurred with the blebbing stage and phosphatidylserine externalization, shortly after mitochondria depolarization and before nuclear condensation. Blebs detaching from the cell body were observed by time lapse fluorescence microscopy, and the release of bleb-derived vesicles was followed by flow cytometry. Phosphatidylserine externalization required caspases and protein kinase C (PKC) but not the myosin light chain kinase (MLCK). By contrast, bleb formation and release was caspase- and PKC-independent but required an active MLCK, whereas CD43 down-regulation involved caspases but neither PKC nor MLCK Furthermore, CD43 appeared mostly excluded from membrane blebs by electron microscopy. Thus, CD43 down-regulation does not result from the release of bleb-derived vesicles. Ultracentrifugation of apoptotic cell supernatants made it possible to recover <1 mum microparticles, which contained the entire CD43 molecule. These microparticles expressed neutrophil membrane markers such as CD11b, CD66b, and CD63, together with CD43. In conclusion, we show that the three early membrane events of apoptosis, namely blebbing, phosphatidylserine externalization, and CD43 down-regulation, result from different signaling pathways and can occur independently from one another. CD43 down-regulation results from the shedding of microparticles released during apoptosis but unrelated to the blebbing.	Hop Necker Enfants Malad, INSERM, U507, F-75015 Paris, France; Inst Pasteur, Unite Interact Bacteries Cellules, F-75015 Paris, France; Inst Cochin, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Halbwachs-Mecarelli, L (corresponding author), Hop Necker Enfants Malad, INSERM, U507, 161 Rue Sevres, F-75015 Paris, France.	mecarelli@necker.fr	Seveau, Stephanie/E-4060-2011					Albertine KH, 1996, J LEUKOCYTE BIOL, V59, P631, DOI 10.1002/jlb.59.5.631; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; CAMPANERO MR, 1991, EUR J IMMUNOL, V21, P3045, DOI 10.1002/eji.1830211222; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; COLOTTA F, 1992, BLOOD, V80, P2012; Combes V, 1997, THROMB HAEMOSTASIS, V77, P220; DRANSFIELD I, 1995, BLOOD, V85, P3264, DOI 10.1182/blood.V85.11.3264.bloodjournal85113264; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FISHKIND DJ, 1991, J CELL BIOL, V114, P967, DOI 10.1083/jcb.114.5.967; Fossati G, 2003, J IMMUNOL, V170, P1964, DOI 10.4049/jimmunol.170.4.1964; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Freyssinet JM, 2003, J THROMB HAEMOST, V1, P1655, DOI 10.1046/j.1538-7836.2003.00309.x; Furie B, 2004, TRENDS MOL MED, V10, P171, DOI 10.1016/j.molmed.2004.02.008; Gasser O, 2004, BLOOD, V104, P2543, DOI 10.1182/blood-2004-01-0361; Gasser O, 2003, EXP CELL RES, V285, P243, DOI 10.1016/S0014-4827(03)00055-7; HALBWACHSMECARELLI, 1996, BLOOD, V87, P1200; Hart SP, 2000, CELL DEATH DIFFER, V7, P493, DOI 10.1038/sj.cdd.4400680; Hess C, 1999, J IMMUNOL, V163, P4564; HOMBURG CHE, 1995, BLOOD, V85, P532; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Lawen A, 2003, BIOESSAYS, V25, P888, DOI 10.1002/bies.10329; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mesri C, 1998, J IMMUNOL, V161, P4382; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nusbaum P, 2004, BIOCHEM SOC T, V32, P477, DOI 10.1042/BST0320477; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Pace KE, 1999, J IMMUNOL, V163, P3801; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Pryde JG, 2000, J BIOL CHEM, V275, P33574, DOI 10.1074/jbc.M001008200; REMOLDODONNELL E, 1994, J IMMUNOL, V152, P3595; Renshaw SA, 2000, J LEUKOCYTE BIOL, V67, P662, DOI 10.1002/jlb.67.5.662; Renshaw SA, 2003, J IMMUNOL, V170, P1027, DOI 10.4049/jimmunol.170.2.1027; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHMID K, 1992, P NATL ACAD SCI USA, V89, P663, DOI 10.1073/pnas.89.2.663; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Segundo C, 1999, BLOOD, V94, P1012, DOI 10.1182/blood.V94.3.1012.415k05_1012_1020; Seveau S, 2000, BLOOD, V95, P2462; Seveau S, 1997, J CELL SCI, V110, P1465; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; Shi JL, 1996, HEPATOLOGY, V24, P1256; Shiratsuchi A, 2002, J BIOCHEM, V132, P381, DOI 10.1093/oxfordjournals.jbchem.a003233; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Woodman RC, 1998, J EXP MED, V188, P2181, DOI 10.1084/jem.188.11.2181; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Zhang K, 1997, TUMOR BIOL, V18, P175, DOI 10.1159/000218028	61	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5843	5853		10.1074/jbc.M413405200	http://dx.doi.org/10.1074/jbc.M413405200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15576378	hybrid			2022-12-25	WOS:000227217100088
J	Spiegelberg, BD; dela Cruz, J; Law, TH; York, JD				Spiegelberg, BD; dela Cruz, J; Law, TH; York, JD			Alteration of lithium pharmacology through manipulation of phosphoadenosine phosphate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 1-PHOSPHATASE; HUMAN PAPS SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ATP SULFURYLASE; 3'-PHOSPHOADENOSINE 5'-PHOSPHOSULFATE; MOLECULAR-CLONING; SULFATE; CELLS; YEAST; INHIBITION	Bisphosphate 3'-nucleotidase (BPNT1 in mammals and Met22/Hal2 in yeast) is one of five members of a family of signaling phosphatases united through a common tertiary structure and inhibition by subtherapeutic doses of the antibipolar drug lithium. Here we report a role for 3'-nucleotidase and its substrate, 3'-phosphoadenosine 5'-phosphate (PAP), in mediating the cellular effects of lithium. Lithium-induced inhibition of growth in yeast cells may be overcome by dose-dependent heterologous expression of human BPNT1. Disruption of the yeast 3'-nucleotidase gene or treatment of cells with lithium results in a >80-fold accumulation of PAP and leads to potent growth inhibition. These data indicate that the accumulation of a 3'-nucleotidase substrate, such as PAP, mediates the toxicity of lithium. To further probe this model we examined the growth inhibitory effects of lithium under conditions in which PAP biosynthetic machinery was concomitantly down-regulated. Disruption of met3 or met14 genes (ATP sulfurylase or phosphosulfate kinase), transcriptional down-regulation of MET3 through methionine addition, or administration of chlorate, a widely used cell-permeable sulfurylase inhibitor, function to reduce lithium-induced intracellular PAP accumulation and lithium toxicity; all of these effects were reversed by heterologous expression of human sulfurylase and kinase. Collectively, our data support a role for 3'-nucleotidase activity and PAP metabolism in aspects of lithium's mechanism of action and provide a platform for development of novel pharmacological modulators aimed at improving therapies for the treatment of bipolar disorder.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	York, JD (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.	yorkj@duke.edu			NHLBI NIH HHS [R01 HL-55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharya JK, 1998, NEURON, V20, P1219, DOI 10.1016/S0896-6273(00)80502-4; ALLISON JH, 1971, NATURE-NEW BIOL, V233, P267, DOI 10.1038/newbio233267a0; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Chang CS, 1998, J IMMUNOL, V160, P4367; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; Franzon VL, 1999, INT J BIOCHEM CELL B, V31, P613, DOI 10.1016/S1357-2725(98)00155-1; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; INHORN RC, 1987, J BIOL CHEM, V262, P15946; JAKUBOWSKI H, 1993, J BACTERIOL, V175, P5469, DOI 10.1128/JB.175.17.5469-5476.1993; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; KIM HJ, 1995, DRUG METAB DISPOS, V23, P840; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Lopez-Coronado JM, 1999, J BIOL CHEM, V274, P16034, DOI 10.1074/jbc.274.23.16034; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; Masuda CA, 2001, J BIOL CHEM, V276, P37794; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3685, DOI 10.1021/bi951302u; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Schneider B, 1998, J BIOL CHEM, V273, P28773, DOI 10.1074/jbc.273.44.28773; Schriever C, 1997, BIOL CHEM, V378, P701, DOI 10.1515/bchm.1997.378.7.701; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; Ullrich TC, 2001, J MOL BIOL, V313, P1117, DOI 10.1006/jmbi.2001.5098; Ullrich TC, 2001, EMBO J, V20, P316, DOI 10.1093/emboj/20.3.316; Venkatachalam KV, 1998, J BIOL CHEM, V273, P19311, DOI 10.1074/jbc.273.30.19311; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang YS, 1996, PROTEIN EXPRES PURIF, V8, P423, DOI 10.1006/prep.1996.0120; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149	33	26	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5400	5405		10.1074/jbc.M407890200	http://dx.doi.org/10.1074/jbc.M407890200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15583009	hybrid			2022-12-25	WOS:000227217100036
J	Takahashi, H; Hatakeyama, S; Saitoh, H; Nakayama, KI				Takahashi, H; Hatakeyama, S; Saitoh, H; Nakayama, KI			Noncovalent SUMO-1 binding act ivity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED PROTEIN; COVALENT MODIFICATION; NUCLEAR-BODIES; PML; RANBP2; CONJUGATION; DAMAGE; E3; ACTIVATION; MODIFIERS	SUMO-1 is a member of a family of ubiquitin-like molecules that are post-translationally conjugated to various cellular proteins in a process that is mechanistically similar to ubiquitylation. To identify molecules that bind noncovalently to SUMO-1, we performed yeast two-hybrid screening with a SUMO-1 mutant that cannot be conjugated to target proteins as the bait. This screening resulted in the isolation of cDNAs encoding the b isoform of thymine DNA glycosylase (TDGb). A deletion mutant of TDGb (TDGb(Delta11)) that lacks a region shown to be required for noncovalent binding of SUMO-1 was also found not to be susceptible to SUMO-1 conjugation at an adjacent lysine residue, suggesting that such binding is required for covalent modification. In contrast, another mutant of TDGb (TDGb(KR)) in which the lysine residue targeted for SUMO-1 conjugation is replaced with arginine retained the ability to bind SUMO-1 noncovalently. TDGb was shown to interact with the promyelocytic leukemia protein (PML) in vitro as well as to colocalize with this protein to nuclear bodies in transfected cells. TDGb(KR) also colocalized with PML, whereas TDGb(Delta11) did not, indicating that the noncovalent SUMO-1 binding activity of TDGb is required for colocalization with PML. Furthermore, SUMO-1 modification of TDGb and PML enhanced the interaction between the two proteins. These results suggest that SUMO-1 functions to tether proteins to PML-containing nuclear bodies through post-translational modification and noncovalent protein-protein interaction.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan	Kyushu University; Japan Science & Technology Agency (JST); Kumamoto University	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Hidehisa, Takahashi/E-2175-2012; Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Uchimura Y, 2004, FEBS LETT, V564, P85, DOI 10.1016/S0014-5793(04)00321-7; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	49	86	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5611	5621		10.1074/jbc.M408130200	http://dx.doi.org/10.1074/jbc.M408130200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15569683	hybrid			2022-12-25	WOS:000227217100062
J	Bochner, BS; Alvarez, RA; Mehta, P; Bovin, NV; Blixt, O; White, JR; Schnaar, RL				Bochner, BS; Alvarez, RA; Mehta, P; Bovin, NV; Blixt, O; White, JR; Schnaar, RL			Glycan array screening reveals a candidate ligand for Siglec-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORY RECEPTOR; GENOMIC ORGANIZATION; SIALOADHESIN FAMILY; MOLECULAR-CLONING; CELL-INTERACTIONS; IMMUNE-SYSTEM; IDENTIFICATION; BINDING; SULFOTRANSFERASES; MEMBER	Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is selectively expressed on human eosinophils, basophils, and mast cells, where it regulates their function and survival. Previous studies demonstrated sialic acid-dependent binding of Siglec-8 but failed to reveal significant substructure specificity or high affinity of that binding. To test a broader range of potential ligands, a Siglec-8-Ig chimeric protein was tested for binding to 172 different glycan structures immobilized as biotinylated glycosides on a 384-well streptavidin-coated plate. Of these, similar to40 structures were sialylated Among these, avid binding was detected to a single defined glycan, NeuAcalpha-2-3(6-O-sulfo)Galbeta1-4[fucalpha1-3]GlcNAc, also referred to in the literature as 6'-sulfo-sLe(x). Notably, neither unsulfated sLe(x) (NeuAcalpha2-3Galbeta1-4[Fucalpha1-3]GlcNAc) nor an isomer with the sulfate on the 6-position of the GlcNAc residue (6-sulfo-sLe(x), NeuAcalpha2-3Galbeta1-4[Fucalpha1-3](6-O-sulfo)GlcNAc) supported detectable binding. Subsequent secondary screening was performed using surface plasmon resonance. Biotin glycosides immobilized on streptavidin biosensor chips were exposed to Siglec-8-Ig in solution. Whereas surfaces derivatized with sLe(x) and 6-sulfo-sLe(x) failed to support detectable Siglec-8 binding, 6'-sulfosLe(x) supported significant binding with a K-d of 2.3 mum. In a separate test of binding specificity, aminopropyl glycosides were covalently immobilized at different concentrations on activated (N-hydroxysuccinimidyl) glass surfaces (Schott-Nexterion Slide H). Subsequent exposure to Siglec-8-Ig precomplexed with fluorescein isothiocyanate anti-human Fc resulted in fluorescent signals at immobilized concentrations of 6'-sulfo-sLe(x) of < 5 pmol/spot. In contrast, sLe(x) and 6-sulfo-sLe(x) did not support any Siglec-8 binding at the highest concentration tested (300 pmol/spot). We conclude that Siglec-8 binds preferentially to the sLe(x) structure bearing an additional sulfate ester on the galactose 6-hydroxyl.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117901, Russia; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; GlaxoSmithKline, King Of Prussia, PA 19406 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Scripps Research Institute; GlaxoSmithKline; Johns Hopkins University	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle,Rm 2B 71, Baltimore, MD 21224 USA.	bbochner@jhmi.edu	Bovin, Nicolai/P-2948-2017; Schnaar, Ronald/S-8967-2016	Bovin, Nicolai/0000-0001-8669-4477; Blixt, Ola/0000-0003-4143-6276; Schnaar, Ronald/0000-0002-7701-5484; White, John R/0000-0003-2998-1626	NIAID NIH HHS [AI41472] Funding Source: Medline; NIGMS NIH HHS [GM62116] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041472, R21AI041472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa H, 2002, J ALLERGY CLIN IMMUN, V109, P176, DOI 10.1067/mai.2002.120550; Alphey MS, 2003, J BIOL CHEM, V278, P3372, DOI 10.1074/jbc.M210602200; Barker R, 1974, Methods Enzymol, V34, P317; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Blixt O, 2003, J BIOL CHEM, V278, P31007, DOI 10.1074/jbc.M304331200; Bowman KG, 1998, CHEM BIOL, V5, P447, DOI 10.1016/S1074-5521(98)90161-2; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; Brinkman-Vand der Linden ECM, 2003, MOL CELL BIOL, V23, P4199, DOI 10.1128/MCB.23.12.4199-4206.2003; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Dimasi N, 2004, ACTA CRYSTALLOGR D, V60, P401, DOI 10.1107/S0907444903028439; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foussias G, 2000, BIOCHEM BIOPH RES CO, V278, P775, DOI 10.1006/bbrc.2000.3866; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Galanina O, 2001, SPECTROCHIM ACTA A, V57, P2285, DOI 10.1016/S1386-1425(01)00478-4; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P13117, DOI 10.1021/bi020507h; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hemmerich S, 2001, GLYCOBIOLOGY, V11, P75, DOI 10.1093/glycob/11.1.75; Ikehara Y, 2004, J BIOL CHEM, V279, P43117, DOI 10.1074/jbc.M403538200; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; KORCHAGINA EY, 1992, BIOORG KHIM+, V18, P283; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Li XA, 1999, GENOMICS, V55, P345, DOI 10.1006/geno.1998.5653; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Mazany KD, 1998, BBA-MOL BASIS DIS, V1407, P92, DOI 10.1016/S0925-4439(98)00028-3; Mingari MC, 2001, IMMUNOL REV, V181, P260, DOI 10.1034/j.1600-065X.2001.1810122.x; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Miyazaki K, 2004, CANCER RES, V64, P4498, DOI 10.1158/0008-5472.CAN-03-3614; Nath D, 1999, IMMUNOLOGY, V98, P213; Nicoll G, 2003, EUR J IMMUNOL, V33, P1642, DOI 10.1002/eji.200323693; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; NUTKU E, 2004, P 24 S C INT ALL BIE, P130; Rapoport E, 2003, BIOORG MED CHEM LETT, V13, P675, DOI 10.1016/S0960-894X(02)00998-8; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; van den Berg TK, 2001, J IMMUNOL, V166, P3637, DOI 10.4049/jimmunol.166.6.3637; Whitney G, 2001, EUR J BIOCHEM, V268, P6083, DOI 10.1046/j.0014-2956.2001.02543.x; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200; Yousef GM, 2002, GENE, V286, P259, DOI 10.1016/S0378-1119(02)00432-8; Zaccai NR, 2003, STRUCTURE, V11, P557, DOI 10.1016/S0969-2126(03)00073-X; Zhang JQQ, 2004, EUR J IMMUNOL, V34, P1175, DOI 10.1002/eji.200324723	45	206	216	0	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4307	4312		10.1074/jbc.M412378200	http://dx.doi.org/10.1074/jbc.M412378200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563466	hybrid			2022-12-25	WOS:000227096600039
J	Chemin, J; Patel, A; Duprat, F; Zanzouri, M; Lazdunski, M; Honore, E				Chemin, J; Patel, A; Duprat, F; Zanzouri, M; Lazdunski, M; Honore, E			Lysophosphatidic acid-operated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; POTASSIUM CHANNELS; FUNCTIONAL EXPRESSION; MOLECULAR-BASIS; TREK-1; TRAAK; CELLS; ACTIVATION; LYSOPHOSPHOLIPIDS; MODULATION	Lysophosphatidic acid (LPA) is an abundant cellular lipid with a myriad of biological effects. It plays an important role in both inter- and intracellular signaling. Activation of the LPA(1-3) G-protein-coupled receptors explains many of the extracellular effects of LPA, including cell growth, differentiation, survival, and motility. However, LPA also acts intracellularly, activating the nuclear hormone receptor peroxisome proliferator-activated receptor-gamma that regulates gene transcription. This study shows that the novel subfamily of mechano-gated K-2p channels comprising TREK-1, TREK-2, and TRAAK is strongly activated by intracellular LPA. The LPA-activated 2P domain K+ channels are intracellular ligandgated K+ channels such as the Ca2+ - or the ATP-sensitive K+ channels. LPA reversibly converts these mechano-gated, pH- and voltage-sensitive channels into leak conductances. Gating conversion of the 2P domain K+ channels by intracellular LPA represents a novel form of ion channel regulation. Thus, the TREK and TRAAK channels should be included in the LPA-associated physiological and disease states.	Inst Paul Hamel, CNRS UMR 6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Honore, E (corresponding author), Inst Paul Hamel, CNRS UMR 6097, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	honore@ipmc.cnrs.fr	Duprat, Fabrice/D-1221-2013	Duprat, Fabrice/0000-0001-8774-1220; chemin, jean/0000-0002-6089-5964; HONORE, Eric/0000-0002-8007-0919				Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Chemin J, 2003, EMBO J, V22, P5403, DOI 10.1093/emboj/cdg528; Czirjak B, 2004, J BIOL CHEM, V279, P18550, DOI 10.1074/jbc.M312229200; Czirjak G, 2002, J BIOL CHEM, V277, P5426, DOI 10.1074/jbc.M107138200; Duprat F, 2000, MOL PHARMACOL, V57, P906; Enyeart JJ, 2002, J BIOL CHEM, V277, P49186, DOI 10.1074/jbc.M207233200; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Kang DW, 2004, J PHYSIOL-LONDON, V554, P64, DOI 10.1113/jphysiol.2003.054387; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P64, DOI 10.1007/s004240000496; KIM Y, 2001, PFLUGERS ARCH, P952; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; Lauritzen I, 2003, J BIOL CHEM, V278, P32068, DOI 10.1074/jbc.M302631200; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200; Lesage F, 2000, FEBS LETT, V471, P137, DOI 10.1016/S0014-5793(00)01388-0; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2002, BIOCHEM BIOPH RES CO, V292, P339, DOI 10.1006/bbrc.2002.6674; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Maylie J, 2004, J PHYSIOL-LONDON, V554, P255, DOI 10.1113/jphysiol.2003.049072; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Medhurst AD, 2001, MOL BRAIN RES, V86, P101, DOI 10.1016/S0169-328X(00)00263-1; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; Nichols CG, 2002, AM J PHYSIOL-ENDOC M, V283, pE403, DOI 10.1152/ajpendo.00168.2002; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Patel AJ, 2001, ANESTHESIOLOGY, V95, P1013, DOI 10.1097/00000542-200110000-00034; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; Punke MA, 2003, ANESTH ANALG, V96, P1665, DOI 10.1213/01.ANE.0000062524.90936.1F; Sachs F, 1998, REV PHYSIOL BIOCH P, V132, P1, DOI 10.1007/BFb0004985; Sano Y, 2003, J BIOL CHEM, V278, P27406, DOI 10.1074/jbc.M206810200; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Talley EM, 2001, J NEUROSCI, V21, P7491, DOI 10.1523/JNEUROSCI.21-19-07491.2001; Talley EM, 2003, NEUROSCIENTIST, V9, P46, DOI 10.1177/1073858402239590; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; Ye XQ, 2002, NEUROREPORT, V13, P2169, DOI 10.1097/00001756-200212030-00002; Yost CS, 2003, CURR DRUG TARGETS, V4, P347, DOI 10.2174/1389450033491091; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	56	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4415	4421		10.1074/jbc.M408246200	http://dx.doi.org/10.1074/jbc.M408246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572365	hybrid, Green Published			2022-12-25	WOS:000227096600051
J	Lacombe, MJ; Mercure, C; Dikeakos, JD; Reudelhuber, TL				Lacombe, MJ; Mercure, C; Dikeakos, JD; Reudelhuber, TL			Modulation of secretory granule-targeting efficiency by cis and trans compounding of sorting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-E; CHROMOGRANIN-A; PROINSULIN; PATHWAY; CELLS; PRORENIN; PROTEINS; RECEPTOR; INSULIN; RENIN	Several protein domains acting through seemingly different mechanisms have been reported to have the capacity to target proteins to dense core secretory granules. Because proteins enter secretory granules with different efficiencies and because some of these proteins contain more than one granule-targeting motif, we have investigated whether compounding sorting signals could alter the efficiency of protein entry into secretory granules. In the current study we demonstrate that a paired basic cleavage site from human prorenin and an a-helix-containing secretory granule-sorting signal from the prohormone convertase PC1/3 can synergize to increase granule-sorting efficiency not only when located on the same protein, but also when located on distinct proteins that associate in the secretory pathway.	Clin Res Inst Montreal, Lab Mol Biochem Hypertens, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Reudelhuber, TL (corresponding author), Clin Res Inst Montreal, Lab Mol Biochem Hypertens, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	reudelt@ircm.qc.ca						Arnaoutova I, 2003, BIOCHEMISTRY-US, V42, P10445, DOI 10.1021/bi034277y; Assadi M, 2004, BIOCHEMISTRY-US, V43, P7798, DOI 10.1021/bi036331g; Beuret N, 2004, J BIOL CHEM, V279, P20242, DOI 10.1074/jbc.M310613200; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRAKCH N, 1994, BIOCHEM BIOPH RES CO, V205, P221, DOI 10.1006/bbrc.1994.2653; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Bundgaard JR, 2004, J BIOL CHEM, V279, P5488, DOI 10.1074/jbc.M310547200; Canaff L, 1996, P NATL ACAD SCI USA, V93, P9483, DOI 10.1073/pnas.93.18.9483; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 2001, MOL CELL ENDOCRINOL, V177, P87, DOI 10.1016/S0303-7207(01)00437-3; Dhanvantari S, 2002, BIOCHEMISTRY-US, V41, P52, DOI 10.1021/bi015698n; Feliciangeli S, 2001, J BIOL CHEM, V276, P6140, DOI 10.1074/jbc.M009613200; Gomord V, 1999, BIOCHIMIE, V81, P607, DOI 10.1016/S0300-9084(99)80118-7; Halban PA, 2003, MOL BIOL CELL, V14, P1195, DOI 10.1091/mbc.E02-05-0299; Hojlund K, 2001, AM J PHYSIOL-ENDOC M, V280, pE50; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Jain RK, 2002, BIOCHEM J, V368, P605, DOI 10.1042/BJ20021195; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1986, Diabetes Metabolism Reviews, V2, P71; PRATT RE, 1987, P NATL ACAD SCI USA, V84, P7837, DOI 10.1073/pnas.84.22.7837; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; Steiner DF, 1996, DIABETES METAB, V22, P94; TAUGNER R, 1987, HISTOCHEMISTRY, V86, P249; Taylor NA, 1998, J MOL ENDOCRINOL, V21, P209, DOI 10.1677/jme.0.0210209; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; TOFFELMIRE EB, 1989, J CLIN INVEST, V83, P679, DOI 10.1172/JCI113932	36	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4803	4807		10.1074/jbc.M408658200	http://dx.doi.org/10.1074/jbc.M408658200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569678	hybrid			2022-12-25	WOS:000227096600098
J	Peng, XJ; Mehta, RG; Tonetti, DA; Christov, K				Peng, XJ; Mehta, RG; Tonetti, DA; Christov, K			Identification of novel RAR beta 2 transcript variants with short 5 '-UTRs in normal and cancerous breast epithelial cells	ONCOGENE			English	Article						RAR beta 2; 5 '-UTR; transcript variants; breast cancer; translation	ACID RECEPTOR-BETA; RETINOIC ACID; CARCINOMA; NUCLEAR; LINES; TRANSLATION; EXPRESSION; ISOFORMS; PROTEIN; TISSUE	Functional significance of RARbeta2 as a putative tumor suppressor gene has been studied in breast cancer and other tumors. The long 5'-untranslated region (5'-UTR) of its transcript with multiple open-reading frames (uORFs) is considered as a regulatory unit for translation. Here, for the first time we identified RARbeta2 transcript variants with short 5'-UTRs in both normal and malignant breast epithelial cells. The 5'-RACE analysis of RARbeta2 mRNA in these cells demonstrated the existence of short RARbeta2 transcript variants that are identical to the sequence of known RARbeta2, but lack all the uORFs present in the full-length 5'-UTR. By RT-PCR analysis, we found that the expression of both transcripts with short and full-length 5'-UTR is mediated by retinoic acid, while cellular sensitivity is preferentially correlated to upregulation of short RARbeta2 transcript variants in response to retinoic acid. The transfection and in vitro translation assay indicated that the short 5'-UTR has no inhibitory effects on translation, while the presence of full-length 5'-UTR inhibited translation by 60%. In addition, no promoter activity was detectable in RARbeta2 full-length 5'-UTR region. Our data suggest that the RARbeta2 transcript variants with short 5'-UTR may serve as major transcripts for RARbeta2 protein translation as well as potential targets for retinoids in breast cancer prevention and therapy studies.	Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Christov, K (corresponding author), Univ Illinois, Dept Surg Oncol, 840 S Wood St,M-C 820, Chicago, IL 60612 USA.	christov@uic.edu			NATIONAL CANCER INSTITUTE [R01CA082316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARMICHAEL J, 1987, CANCER RES, V47, P936; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen LI, 2002, J BIOL CHEM, V277, P35411, DOI 10.1074/jbc.M202717200; DENG G, 1996, SCIENCE, V249, P1577; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; LIPPMAN SM, 1995, J CELL BIOCHEM, P1; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; PENG X, 2004, IN PRESS CANC RES; Peng XJ, 2004, INT J ONCOL, V25, P961; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TALLMAN MS, 1992, J CLIN PHARMACOL, V32, P868, DOI 10.1002/j.1552-4604.1992.tb04633.x; Widschwendter M, 1997, CANCER RES, V57, P4158; Xu XC, 1997, CANCER RES, V57, P4992; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	22	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1296	1301		10.1038/sj.onc.1208284	http://dx.doi.org/10.1038/sj.onc.1208284			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558014				2022-12-25	WOS:000226898700018
J	Woodard, GE; Lin, L; Zhang, JH; Agarwal, SK; Marx, SJ; Simonds, WF				Woodard, GE; Lin, L; Zhang, JH; Agarwal, SK; Marx, SJ; Simonds, WF			Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression	ONCOGENE			English	Article						parathyroid; parafibromin; tumor suppressor; hyperparathyroidism; jaw tumor syndrome; parathyroid carcinoma; cyclin D1	FAMILIAL ISOLATED HYPERPARATHYROIDISM; HEREDITARY HYPERPARATHYROIDISM; PARATHYROID CARCINOMA; ADENOMAS; MUTATIONS; FIBROMAS; 1Q21-Q32; MAPS	Parafibromin is the 531-amino-acid protein product encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal dominant hyperparathyroidism-jaw tumor familial cancer syndrome, sporadic parathyroid cancer, and a minority of families with isolated hyperparathyroidism. Parafibromin contains no identified functional domains but bears sequence homology to Cdc73p, a budding yeast protein component of the RNA polymerase II-associated Paf1 complex. This study addressed the expression and functional properties of human parabromin. A survey of human and mouse tissues analysed with polyclonal antibodies to parabromin showed specific immunoreactivity in adrenal and parathyroid glands, kidney, heart, and skeletal muscle. Subcellular fractionation and laser confocal microscopy of normal human parathyroid gland demonstrated expression of parafibromin in both the cytoplasmic and nuclear compartments. Parafibromin was expressed in four parathyroid adenomas but was absent from two parathyroid carcinomas. Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant implicated in parathyroid cancer and familial isolated hyperparathyroidism, inhibited cell proliferation, and blocked expression of cyclin D1, a key cell cycle regulator previously implicated in parathyroid neoplasia. These results demonstrate that human parafibromin is a nucleocytoplasmic protein with functions consistent with its postulated role as a tumor suppressor protein.	NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simonds, WF (corresponding author), NIDDKD, Metab Dis Branch, NIH, Bldg 10,Room 8C-101,10 Ctr DR MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov	Woodard, Geoffrey/A-8608-2009; Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043012, ZIADK043012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold A, 2002, J BONE MINER RES, V17, pN30; ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; DINNEN JS, 1977, J CLIN PATHOL, V30, P966, DOI 10.1136/jcp.30.10.966; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; FIRAT D, 1968, AM J MED, V44, P421, DOI 10.1016/0002-9343(68)90112-5; Fujikawa M, 1998, EUR J ENDOCRINOL, V138, P557, DOI 10.1530/eje.0.1380557; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; INOUE H, 1995, CLIN ENDOCRINOL, V43, P225, DOI 10.1111/j.1365-2265.1995.tb01919.x; JACKSON CE, 1990, SURGERY, V108, P1006; JACKSON CE, 1958, ANN INTERN MED, V49, P829, DOI 10.7326/0003-4819-49-4-829; KAKINUMA A, 1994, INTERNAL MED, V33, P123, DOI 10.2169/internalmedicine.33.123; KENNETT S, 1971, ORAL SURG ORAL MED O, V31, P502, DOI 10.1016/0030-4220(71)90347-1; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; MALLETTE LE, 1987, ANN INTERN MED, V107, P54, DOI 10.7326/0003-4819-107-1-54; Marx SJ, 2002, GENETIC BASIS HUMAN, P475; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; ROSEN IB, 1981, AM J SURG, V142, P494, DOI 10.1016/0002-9610(81)90382-2; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; Simonds WF, 2002, MEDICINE, V81, P1, DOI 10.1097/00005792-200201000-00001; STREETEN EA, 1992, J CLIN ENDOCR METAB, V75, P362, DOI 10.1210/jc.75.2.362; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2114, DOI 10.1210/jc.83.6.2114; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Vasef MA, 1999, MODERN PATHOL, V12, P412; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Visset J, 1992, Chirurgie, V118, P223; WARNAKULASURIYA S, 1985, ORAL SURG ORAL MED O, V59, P269, DOI 10.1016/0030-4220(85)90165-3; WASSIF WS, 1993, J CLIN ENDOCR METAB, V77, P1485, DOI 10.1210/jc.77.6.1485; Yoshimoto K, 1998, CLIN ENDOCRINOL, V48, P67, DOI 10.1046/j.1365-2265.1998.00354.x	33	119	127	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1272	1276		10.1038/sj.onc.1208274	http://dx.doi.org/10.1038/sj.onc.1208274			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580289				2022-12-25	WOS:000226898700014
J	Petrella, BL; Lohi, J; Brinckerhoff, CE				Petrella, BL; Lohi, J; Brinckerhoff, CE			Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma	ONCOGENE			English	Article						von Hippel-Lindau; MT1-MMP; HIF-2 alpha; renal cell carcinoma	PAS DOMAIN PROTEIN-1; TUMOR-SUPPRESSOR; ENDOTHELIAL-CELLS; MESSENGER-RNAS; GROWTH; INVASION; EXPRESSION; CANCER; GENE; TRANSCRIPTION	Metastatic renal cell carcinoma (RCC) resulting from the hereditary loss of the von Hippel - Lindau (VHL) tumor suppressor gene is the leading cause of death in VHL patients due to the deleterious effects of the metastatic tumor(s). VHL functions in the destruction of the alpha subunits of the heterodimeric transcription factor, hypoxia-inducible factor (HIF-1alpha and HIF-2alpha), in normoxic conditions. When VHL function is lost, HIF-alpha protein is stabilized, and target hypoxia-inducible genes are transcribed. The process of tumor invasion and metastasis involves the destruction of the extracellular matrix, which is accomplished primarily by the matrix metalloproteinase (MMP) family of enzymes. Here, we describe a connection between the loss of VHL tumor suppressor function and the upregulation of membrane type-1 MMP (MT1-MMP) gene expression and protein. Specifically, MT1-MMP is upregulated in VHL -/- RCC cells through an increase in gene transcription, which is mediated by the cooperative effects of the transcription factors, HIF-2 and Sp1. Further, we identify a functional HIF-binding site in the proximal promoter of MT1-MMP. To our knowledge, this is the first report to show direct regulation of MT1-MMP by HIF-2 and to provide a direct link between the loss of VHL tumor suppressor function and an increase in MMP gene and protein expression.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Biochem, Lebanon, NH 03756 USA; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Brinckerhoff, CE (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, 1 Med Ctr Dr,Rubin Bldg,HB 7936, Lebanon, NH 03756 USA.	constance.e.brinckerhoff@dartmouth.edu			NCI NIH HHS [CA-77267, R01 CA077267] Funding Source: Medline; NIAID NIH HHS [T32 AI007363] Funding Source: Medline; NIAMS NIH HHS [AR-26599, R01 AR026599, R37 AR026599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hes FJ, 2001, NETH J MED, V59, P225, DOI 10.1016/S0300-2977(01)00165-6; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kitagawa Y, 1999, J UROLOGY, V162, P905, DOI 10.1097/00005392-199909010-00088; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maquoi E, 2004, CLIN CANCER RES, V10, P4038, DOI 10.1158/1078-0432.CCR-04-0125; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Miki N, 2004, J BIOL CHEM, V279, P15025, DOI 10.1074/jbc.M313186200; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Ottino P, 2004, MOL VIS, V10, P341; Richards FM, 1998, J INTERN MED, V243, P527; Sanchez-Elsner T, 2004, J MOL BIOL, V336, P9, DOI 10.1016/j.jmb.2003.12.023; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Singh AD, 2001, SURV OPHTHALMOL, V46, P117, DOI 10.1016/S0039-6257(01)00245-4; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Zimmer M, 2004, MOL CANCER RES, V2, P89	46	144	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2005	24	6					1043	1052		10.1038/sj.onc.1208305	http://dx.doi.org/10.1038/sj.onc.1208305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592504	Green Accepted			2022-12-25	WOS:000226749200010
J	Porta, C; Hadj-Slimane, R; Nejmeddine, M; Pampin, M; Tovey, MG; Espert, L; Alvarez, S; Chelbi-Alix, MK				Porta, C; Hadj-Slimane, R; Nejmeddine, M; Pampin, M; Tovey, MG; Espert, L; Alvarez, S; Chelbi-Alix, MK			Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively	ONCOGENE			English	Article						interferon; p53; IRF1; CD95; apoptosis	INTERACTING PROTEIN KINASE-2; TRANSCRIPTION FACTOR IRF-1; DAMAGE-INDUCED APOPTOSIS; NUCLEAR-BODIES; PREMATURE SENESCENCE; CARCINOMA-CELLS; BREAST-CANCER; HOST-DEFENSE; I INTERFERON; P53 ACTIVITY	Type I interferon (IFN) enhances the transcription of the tumor suppressor gene p53. To elucidate the molecular mechanism mediating IFN-induced apoptosis, we analysed programmed cell death in response to type I (IFNalpha) or type II (IFNgamma) treatment in relation to p53 status. In two cell lines (MCF-7, SKNSH), IFNalpha, but not IFNgamma, enhanced apoptosis in a p53-dependent manner. Furthermore, only IFNalpha upregulated p53 as well as p53 target genes (Noxa, Mdm2 and CD95). The apoptotic response to IFNalpha decreased in the presence of ZB4, an anti-CD95 antibody, suggesting that CD95 is involved in this process. When p53 was inactivated by the E6 viral protein or the expression of a p53 mutant, IFNalpha-induced apoptosis and p53 target genes upregulation were abrogated. Altogether these results demonstrate that p53 plays a pivotal role in the IFNalpha-induced apoptotic response. IFNalpha-induced PML was unable to recruit p53 into nuclear bodies and its downregulation by siRNA did not alter CD95 expression. In contrast, IFNgamma-induced apoptosis is p53-independent. CD95 and IFN-regulatory factor 1 (IRF1) are directly upregulated by this cytokine. Apoptotic response to IFNgamma is decreased in the presence of ZB4 and strongly diminished by IRF1 siRNA, implicating both CD95 and IRF1 in IFNgamma-induced apoptotic response. Taken together, these results show that in two different cell lines, IFNalpha and IFNgamma, induce p53-dependent - independent apoptosis, respectively.	Inst Andre Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France; CEA, CNRS, UMR 217, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS)	Chelbi-Alix, MK (corresponding author), Inst Andre Lwoff, CNRS, UPR 9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.	mchelbi@infobiogen.fr	Espert, Lucile/ABF-5614-2021	Nejmeddine, Mohamed/0000-0003-0160-2727; Tovey, Michael/0000-0002-3058-0494				Abadie A, 2004, ONCOGENE, V23, P4911, DOI 10.1038/sj.onc.1207614; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chelbi-alix MK, 2003, ONCOGENE, V22, P9121, DOI 10.1038/sj.onc.1207090; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FAN SJ, 1995, CANCER RES, V55, P1649; Ferbeyre G, 2002, LEUKEMIA, V16, P1918, DOI 10.1038/sj.leu.2402722; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Koshiji M, 1997, BIOCHEM BIOPH RES CO, V240, P376, DOI 10.1006/bbrc.1997.7657; Li CX, 2004, ONCOGENE, V23, P1608, DOI 10.1038/sj.onc.1207273; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Panaretakis T, 2003, ONCOGENE, V22, P4543, DOI 10.1038/sj.onc.1206503; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pfeffer LM, 1998, CANCER RES, V58, P2489; Prives C, 1999, J PATHOL, V187, P112; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sandoval R, 2004, J BIOL CHEM, V279, P32275, DOI 10.1074/jbc.M313830200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STRANDER H, 1986, ADV CANCER RES, V46, pR9; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WADLER S, 1990, CANCER RES, V50, P3473; Wang SH, 2004, ONCOGENE, V23, P928, DOI 10.1038/sj.onc.1207213; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	59	80	85	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					605	615		10.1038/sj.onc.1208204	http://dx.doi.org/10.1038/sj.onc.1208204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580300				2022-12-25	WOS:000226420400008
J	Kamada, S; Kikkawa, U; Tsujimoto, Y; Hunter, T				Kamada, S; Kikkawa, U; Tsujimoto, Y; Hunter, T			Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN CONDENSATION; ICE/CED-3 PROTEASE; DNA FRAGMENTATION; INDUCED APOPTOSIS; CELL-DEATH; INHIBITOR; LOCALIZATION; DEGRADATION; TRANSPORT; SUBUNIT	Caspase-3 is thought to play an important role(s) in the nuclear morphological changes that occur in apoptotic cells and many nuclear substrates for caspase-3 have been identified despite the cytoplasmic localization of procaspase-3. Therefore, whether activated caspase-3 is localized in the nuclei and how active caspase-3 has access to its nuclear targets are important and unresolved questions. Here we confirmed nuclear localizations for both caspase-3-p17 and caspase-3-p12 subunits of active caspase in apoptotic cells using subcellular fractionation analysis. We also prepared polyclonal and monoclonal antibodies specific for active caspase-3 to define the subcellular localization of active caspase-3. Immunocytochemical observations using anti-active caspase-3 antibodies showed nuclear accumulation of active caspase-3 during apoptosis. In addition, caspase-3, but not caspase-7, translocated from the cytoplasm into the nucleus after induction of apoptosis. Mutations at the cleavage site between the p17 and p12 subunits and the substrate recognition site for the P3 amino acid of the DXXD substrate cleavage motif inhibited nuclear translocation of caspase-3, indicating that nuclear transport of active caspase-3 required proteolytic activation and substrate recognition. These results suggest that active caspase-3 is translocated in association with a substrate-like protein( s) from the cytoplasm into the nucleus during progression through apoptosis.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan; Osaka Univ, Sch Med, Dept Postgenom & Dis, Mol Genet Lab, Suita, Osaka 5650871, Japan; Grad Sch Med, Suita, Osaka 5650871, Japan	Salk Institute; Kobe University; Osaka University	Kamada, S (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	skamada@kobe-u.ac.jp; hunter@salk.edu			NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA82863, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Chen L, 2003, MOL PHARMACOL, V64, P334, DOI 10.1124/mol.64.2.334; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Huang HK, 2000, J BIOL CHEM, V275, P26661; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Mandal M, 1999, BIOCHEM BIOPH RES CO, V260, P775, DOI 10.1006/bbrc.1999.0966; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takemoto K, 2003, J CELL BIOL, V160, P235, DOI 10.1083/jcb.200207111; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	30	191	197	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					857	860		10.1074/jbc.C400538200	http://dx.doi.org/10.1074/jbc.C400538200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15569692	hybrid			2022-12-25	WOS:000226195200002
J	Zhang, W; Qin, LY; Wang, TG; Wei, SJ; Gao, HM; Liu, J; Wilson, B; Liu, B; Zhang, WQ; Kim, HC; Hong, JS				Zhang, W; Qin, LY; Wang, TG; Wei, SJ; Gao, HM; Liu, J; Wilson, B; Liu, B; Zhang, WQ; Kim, HC; Hong, JS			3-Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity	FASEB JOURNAL			English	Article						Parkinson's disease; inflammation; neuroprotection; microglia; astroglia	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; PARKINSONS-DISEASE; RAT MODEL; MICROGLIAL ACTIVATION; INTRANIGRAL INJECTION; PROMOTES RECOVERY; MOUSE MODEL; L-DOPA; DEGENERATION	The purpose of this study was to develop a novel therapy for Parkinson's disease (PD). We recently reported that dextromethorphan (DM), an active ingredient in a variety of widely used anticough remedies, protected dopaminergic neurons in rat primary mesencephalic neuron-glia cultures against lipopolysaccharide (LPS)-mediated degeneration and provided potent protection for dopaminergic neurons in a MPTP mouse model. The underlying mechanism for the protective effect of DM was attributed to its anti-inflammatory activity through inhibition of microglia activation. In an effort to develop more potent compounds for the treatment of PD, we have screened a series of analogs of DM, and 3-hydroxymorphinan (3-HM) emerged as a promising candidate for this purpose. Our study using primary mesencephalic neuron-glia cultures showed that 3-HM provided more potent neuroprotection against LPS-induced dopaminergic neurotoxicity than its parent compound. The higher potency of 3-HM was attributed to its neurotrophic effect in addition to the anti-inflammatory effect shared by both DM and 3-HM. First, we showed that 3-HM exerted potent neuroprotective and neurotrophic effects on dopaminergic neurons in rat primary mesencephalic neuron-glia cultures treated with LPS. The neurotrophic effect of 3-HM was glia-dependent since 3-HM failed to show any protective effect in the neuron-enriched cultures. We subsequently demonstrated that it was the astroglia, not the microglia, that contributed to the neurotrophic effect of 3-HM. This conclusion was based on the reconstitution studies, in which we added different percentages of microglia ( 10 - 20%) or astroglia ( 40 - 50%) back to the neuron-enriched cultures and found that 3-HM was neurotrophic after the addition of astroglia, but not microglia. Furthermore, 3-HM-treated astroglia-derived conditioned media exerted a significant neurotrophic effect on dopaminergic neurons. It appeared likely that 3-HM caused the release of neurotrophic factor(s) from astroglia, which in turn was responsible for the neurotrophic effect. Second, the anti-inflammatory mechanism was also important for the neuroprotective activity of 3-HM because the more microglia were added back to the neuron-enriched cultures, the more significant neuroprotective effect was observed. The anti-inflammatory mechanism of 3-HM was attributed to its inhibition of LPS-induced production of an array of pro-inflammatory and neurotoxic factors, including nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), prostaglandin E-2 (PGE(2)) and reactive oxygen species (ROS). In conclusion, this study showed that 3-HM exerted potent neuroprotection by acting on two different targets: a neurotrophic effect mediated by astroglia and an anti-inflammatory effect mediated by the inhibition of microglial activation. 3-HM thus possesses these two important features necessary for an effective neuroprotective agent. In view of the well-documented very low toxicity of DM and its analogs, this report may provide an important new direction for the development of therapeutic interventions for inflammation-related diseases such as PD.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Natl Ctr Toxicogenet, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Inorgan Carcinogenesis Sect, Comparat Carcinogenesis Lab, NCI,NIH, Res Triangle Pk, NC 27709 USA; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China; Dalian Med Univ, Clin Hosp 1, Dept Neurol, Dalian, Peoples R China; Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA; Kangwon Natl Univ, Coll Pharm, Chunchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS); Dalian Medical University; Dalian Medical University; State University System of Florida; University of Florida; Kangwon National University	Zhang, W (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	zhang11@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019; liu, Bin/A-7695-2009; gao, huiming/C-8454-2012	Hong, Jau-shyong/0000-0002-3056-8401; Wei, Sung Jen/0000-0002-9810-9041	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090082, ZIAES090082] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; Aloisi F, 1999, ADV EXP MED BIOL, V468, P123; Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Asanuma M, 2001, J NEUROCHEM, V76, P1895, DOI 10.1046/j.1471-4159.2001.00205.x; Asanuma Masato, 2003, Nihon Shinkei Seishin Yakurigaku Zasshi, V23, P111; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen XW, 2003, PARKINSONISM RELAT D, V10, P1, DOI 10.1016/S1353-8020(03)00097-X; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Ciesielska A, 2003, ACTA NEUROBIOL EXP, V63, P117; Connor B, 2001, CLIN EXP PHARMACOL P, V28, P896, DOI 10.1046/j.1440-1681.2001.03544.x; Cunningham LA, 2002, EXP NEUROL, V174, P230, DOI 10.1006/exnr.2002.7877; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Depino AM, 2003, EUR J NEUROSCI, V18, P2731, DOI 10.1111/j.1460-9568.2003.03014.x; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hornykiewicz O, 2002, AMINO ACIDS, V23, P65, DOI 10.1007/s00726-001-0111-9; Hurelbrink CB, 2004, EXP NEUROL, V185, P1, DOI 10.1016/j.expneurol.2003.09.018; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jellinger KA, 2001, ADV NEUROL, V86, P55; Jeohn GH, 2000, BRAIN RES, V880, P173, DOI 10.1016/S0006-8993(00)02737-2; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Jollivet C, 2004, BIOMATERIALS, V25, P933, DOI 10.1016/S0142-9612(03)00601-X; Katzenschlager Regina, 2002, Journal of Neurology, V249, P19; Kim HC, 2001, BIOORG MED CHEM LETT, V11, P1651, DOI 10.1016/S0960-894X(01)00262-1; Kordower JH, 2003, ANN NEUROL, V53, pS120, DOI 10.1002/ana.10485; Kostrzewa RM, 2002, AMINO ACIDS, V23, P57, DOI 10.1007/s00726-001-0110-x; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEE SH, 1992, J BIOL CHEM, V267, P25934; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; McGeer PL, 2001, ADV NEUROL, V86, P83; McGrath J, 2002, CELL TRANSPLANT, V11, P215; McGuire SO, 2001, EXP NEUROL, V169, P219, DOI 10.1006/exnr.2001.7688; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miyasaki JM, 2002, NEUROLOGY, V58, P11, DOI 10.1212/WNL.58.1.11; Muller Thomas, 2002, Expert Opin Pharmacother, V3, P1393, DOI 10.1517/14656566.3.10.1393; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Pan TH, 2004, NEUROLOGY, V62, P343; Petrova PS, 2003, J MOL NEUROSCI, V20, P173, DOI 10.1385/JMN:20:2:173; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Reichmann H, 2003, J NEURAL TRANSM, V110, P1393, DOI 10.1007/s00702-003-0081-z; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; THI NAD, 2004, GENE THER, V11, P746; Wallace JL, 2003, FUND CLIN PHARMACOL, V17, P11, DOI 10.1046/j.1472-8206.2003.00125.x; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Xie Z, 2002, J NEUROSCI, V22, P3484; Zhang W, 2004, FASEB J, V18, P589, DOI 10.1096/fj.03-0983fje	63	35	48	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					395	+		10.1096/fj.04-1586fje	http://dx.doi.org/10.1096/fj.04-1586fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15596482				2022-12-25	WOS:000226091000019
J	Goetze, JP; Gore, A; Moller, CH; Steinbruchel, DA; Rehfeld, JF; Nielsen, LB				Goetze, JP; Gore, A; Moller, CH; Steinbruchel, DA; Rehfeld, JF; Nielsen, LB			Acute myocardial hypoxia increases BNP gene expression	FASEB JOURNAL			English	Article						ANP; B-type natriuretic peptide; heart failure; ischemic heart disease	BRAIN NATRIURETIC PEPTIDE; VENTRICULAR SYSTOLIC DYSFUNCTION; INCREASED PLASMA-LEVELS; RISK STRATIFICATION; CARDIAC MYOCYTES; SERINE-PROTEASE; MESSENGER-RNA; HEART-FAILURE; ATRIAL; HUMANS	It is well established that cardiac failure increases cardiac B-type natriuretic peptide (BNP) expression due to myocardial stretching. However, patients with ischemic heart disease also display increased plasma BNP and proBNP concentrations despite preserved cardiac function. In this study, we examined whether acute myocardial hypoxia increases cardiac BNP expression. Surgical reduction of the blood flow to an area of the anterior ventricular wall in pigs reduced the myocardial oxygen tension from 46 +/- 4 to 13 +/- 5 mmHg. The tissue contents of VEGF and BNP mRNA increased 1.8-fold and 3.5-fold, respectively (n=10, P<0.005) in hypoxic compared with normoxic ventricular myocardium after 2.2 +/- 0.2 h; the magnitude of the increase in BNP mRNA expression was positively correlated with that of VEGF in hypoxic myocardium (r=0.66, P<0.05). In support of a hypoxia-induced increase of BNP gene transcription, the content of a premature BNP mRNA was increased in hypoxic myocardium (4.8-fold, P<0.005) and in freshly harvested ventricular myocytes when kept in culture flasks and oxygen-deprived for 3 h (2.2-fold, P=0.002). ProBNP peptide accumulated in the medium of freshly harvested ventricular myocyte cultures but was undetectable in ventricular myocardium, indicating rapid release of the newly synthesized proBNP peptide. Accordingly, the plasma proBNP concentration increased after 2 h of myocardial hypoxia (P=0.028). Cumulatively, the data suggest that acute hypoxia stimulates cardiac BNP expression.	Univ Copenhagen, Rigshosp, KB 3011, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Thorac Surg, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Nielsen, LB (corresponding author), Univ Copenhagen, Rigshosp, KB 3011, Dept Clin Biochem, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	larsbo@rh.dk						Bibbins-Domingo K, 2003, CIRCULATION, V108, P2987, DOI 10.1161/01.CIR.0000103681.04726.9C; Christoffersen C, 2002, HYPERTENSION, V40, P54, DOI 10.1161/01.HYP.0000021780.21830.DD; CHU A, 1989, CIRCULATION, V80, P1627, DOI 10.1161/01.CIR.80.6.1627; Chun YS, 2003, BIOCHEM J, V370, P149, DOI 10.1042/BJ20021087; Davidson NC, 1996, AM J CARDIOL, V77, P828, DOI 10.1016/S0002-9149(97)89176-X; de Bold AJ, 2001, CAN J PHYSIOL PHARM, V79, P705, DOI 10.1139/cjpp-79-8-705; de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Deo Rajat, 2003, Curr Cardiol Rep, V5, P271, DOI 10.1007/s11886-003-0062-8; Durocher D, 1998, RECENT PROG HORM RES, V53, P7; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Goetze JP, 2003, FASEB J, V17, P1105, DOI 10.1096/fj.02-0796fje; HANFORD DS, 1994, J BIOL CHEM, V269, P26227; Jernberg T, 2002, J AM COLL CARDIOL, V40, P437, DOI 10.1016/S0735-1097(02)01986-1; Jiang CW, 2002, PHYSIOL GENOMICS, V8, P23, DOI 10.1152/physiolgenomics.00058.2001; Kikuta K, 1996, AM HEART J, V132, P101, DOI 10.1016/S0002-8703(96)90396-8; Kudoh S, 2003, PROG BIOPHYS MOL BIO, V82, P57, DOI 10.1016/S0079-6107(03)00005-1; Latini R, 2002, CIRCULATION, V106, P2454, DOI 10.1161/01.CIR.0000036747.68104.AC; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Luo YX, 2001, CIRCULATION, V104, P202; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORITA E, 1993, CIRCULATION, V88, P82, DOI 10.1161/01.CIR.88.1.82; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; OKUMURA K, 1995, J AM COLL CARDIOL, V25, P342, DOI 10.1016/0735-1097(94)00407-H; Perhonen M, 1997, AM J PHYSIOL-REG I, V273, pR344, DOI 10.1152/ajpregu.1997.273.1.R344; Perko MJ, 2002, CARDIOVASC SURG, V10, P590, DOI 10.1016/S0967-2109(02)00134-5; Qi W, 2000, ACTA PHYSIOL SCAND, V169, P95; Rehfeld JF, 1998, CLIN CHEM, V44, P991; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Richards AM, 2001, J AM COLL CARDIOL, V37, P1781, DOI 10.1016/S0735-1097(01)01269-4; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Stanek B, 2001, J AM COLL CARDIOL, V38, P436, DOI 10.1016/S0735-1097(01)01383-3; Supaporn T, 1996, CLIN SCI, V90, P357, DOI 10.1042/cs0900357; TOTH M, 1994, AM J PHYSIOL, V266, pH1572, DOI 10.1152/ajpheart.1994.266.4.H1572; Wiese S, 2000, CIRCULATION, V102, P3074; Yamamoto K, 2000, J CARD FAIL, V6, P194, DOI 10.1054/jcaf.2000.9676; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zellner C, 1999, AM J PHYSIOL-HEART C, V276, pH1049, DOI 10.1152/ajpheart.1999.276.3.H1049; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239	47	158	165	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1928	+		10.1096/fj.03-1336fje	http://dx.doi.org/10.1096/fj.03-1336fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15576492				2022-12-25	WOS:000224243200017
J	Kiachopoulos, S; Bracher, A; Winklhofer, KF; Tatzelt, J				Kiachopoulos, S; Bracher, A; Winklhofer, KF; Tatzelt, J			Pathogenic mutations located in the hydrophobic core of the prion protein interfere with folding and attachment of the glycosylphosphatidylinositol anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CULTURED-CELLS; IN-VIVO; EXPERIMENTAL SCRAPIE; NEUROBLASTOMA-CELLS; NMR STRUCTURE; GLYCOSYLATION; DEGRADATION; DISEASE; DOMAIN	Abnormal folding of the cellular prion protein ( PrPC) is a key feature in prion diseases. Here we show that two pathogenic mutations linked to inherited prion diseases in humans severely affect folding and maturation of PrPC in the secretory pathway of neuronal cells. PrP-T183A and PrP-F198S adopt a misfolded and partially protease-resistant conformation, lack the glycosylphosphatidylinositol anchor, and are not complex glycosylated. These misfolded PrP mutants are not retained in the endoplasmic reticulum and are not subjected to the endoplasmic reticulum-associated degradation pathway. They rather are secreted, moreover, these mutants can be internalized by heterologous cells. Structural studies indicated that the side chains of Thr(183) and Phe(198) contribute to interactions between secondary structure elements in the C-terminal globular domain of PrPC. Consequently, we reasoned that a destabilized tertiary structure of these mutants could account for the defect in maturation. Indeed, mutations predicted to interfere selectively with the packing of the hydrophobic core of PrPC prevented the addition of the glycosylphosphatidylinositol anchor. Our study reveals that formation of the C-terminal globular domain of PrPC has an impact on membrane anchoring and indicates that misfolded secreted forms of the prion protein are linked to inherited prion diseases in humans.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de		Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Blochberger TC, 1997, PROTEIN ENG, V10, P1465, DOI 10.1093/protein/10.12.1465; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Dalley JA, 2003, J BIOL CHEM, V278, P51749, DOI 10.1074/jbc.M303978200; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; Heske J, 2004, J BIOL CHEM, V279, P5435, DOI 10.1074/jbc.M309570200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kiachopoulos S, 2004, TRAFFIC, V5, P426, DOI 10.1111/j.1398-9219.2004.00185.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; LOWE ME, 1992, J CELL BIOL, V116, P799, DOI 10.1083/jcb.116.3.799; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; MCCUNE JM, 1981, P NATL ACAD SCI-BIOL, V78, P5127, DOI 10.1073/pnas.78.8.5127; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nitrini R, 1997, ANN NEUROL, V42, P138, DOI 10.1002/ana.410420203; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; SPUDICH S, 1995, MOL MED, V1, P607, DOI 10.1007/BF03401601; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tatzelt A, 2004, AMYLOID, V11, P162, DOI 10.1080/1350-612040000723; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Tatzelt J, 1999, J NEUROPATH EXP NEUR, V58, P1244, DOI 10.1097/00005072-199912000-00005; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Vanik DL, 2002, J BIOL CHEM, V277, P49065, DOI 10.1074/jbc.M207511200; Weissmann C, 1996, COLD SPRING HARB SYM, V61, P511; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	47	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9320	9329		10.1074/jbc.M412525200	http://dx.doi.org/10.1074/jbc.M412525200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15591591	hybrid			2022-12-25	WOS:000227453100084
J	Baranova, IN; Vishnyakova, TG; Bocharov, AV; Kurlander, R; Chen, ZG; Kimelman, ML; Remaley, AT; Csako, G; Thomas, F; Eggerman, TL; Patterson, AP				Baranova, IN; Vishnyakova, TG; Bocharov, AV; Kurlander, R; Chen, ZG; Kimelman, ML; Remaley, AT; Csako, G; Thomas, F; Eggerman, TL; Patterson, AP			Serum amyloid a binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SCAVENGER RECEPTOR-BI; ACUTE-PHASE RESPONSE; CELLULAR CHOLESTEROL EFFLUX; CASSETTE TRANSPORTER A1; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; SR-BI; ATHEROSCLEROTIC LESIONS; COUPLED RECEPTOR	Serum amyloid A protein (SAA) is an acute-phase reactant, known to mediate pro-inflammatory cellular responses. This study reports that CLA-1 ( CD36 and LIMPII Analogous-1; human orthologue of the Scavenger Receptor Class B Type I (SR-BI)) mediates SAA uptake and downstream SAA signaling. Flow cytometry experiments revealed more than a 5-fold increase of Alexa-488 SAA uptake in HeLa cells stably transfected with CLA-1. Alexa 488-HDL uptake directly correlated with SAA uptake when determined in several CLA-1 stably transfected HeLa cell clones expressing various levels of CLA-1. SAA directly binds to CLA-1 as determined by cross-linking and colocalization of anti-CLA-1 antibody with SAA. SAA was co-internalized with transferrin to the endocytic recycling compartment pointing to a potential site of SAA metabolism. Alexa-488 SAA uptake in the CLA-1-overexpressing HeLa cells, as well as in THP-1 monocyte cell line, can be efficiently blocked by unlabeled SAA, high density lipoprotein, and other CLA-1 ligands. At the same time, markedly enhanced levels of phosphorylation of the mitogen-activated protein kinases (MAPKs), ERK1/2, and p38, were observed in cells stably transfected with CLA-1 cells following SAA stimulation when compared with mock transfected cells. The levels of the SAA-induced interleukin-8 (IL-8) secretion by CLA-1-overexpressing cells also significantly exceeded (5- to 10-fold) those detected for control cells. Synthetic amphipathic peptides possessing a structural alpha-helical motif inhibited SAA-induced activation of both MAPKs and IL-8 secretion in THP-1 cells. The results of this study demonstrate for the first time that CLA-1 functions as an endocytic SAA receptor and is involved in SAA-mediated cell signaling events associated with the immune-related and inflammatory effects of SAA.	NHLBI, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Patterson, AP (corresponding author), Off Sci, Off Biotechnol Activ, NIH, 6705 Rockledge Dr,St 750, Rockville, MD 20892 USA.	abocharov@mail.cc.nih.gov; pattersa@od.nih.gov			CLINICAL CENTER [Z01CL010306] Funding Source: NIH RePORTER	CLINICAL CENTER		ACTON SL, 1994, J BIOL CHEM, V269, P21003; Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; BANKA CL, 1995, J LIPID RES, V36, P1058; Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002; Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555; Bocharov AV, 2004, J BIOL CHEM, V279, P36072, DOI 10.1074/jbc.M314264200; Buechler C, 1999, BIOCHEM BIOPH RES CO, V262, P251, DOI 10.1006/bbrc.1999.1193; Cabana VG, 1997, PEDIATR RES, V42, P651, DOI 10.1203/00006450-199711000-00017; Cabana VG, 2004, J LIPID RES, V45, P317, DOI 10.1194/jlr.M300414-JLR200; CABANA VG, 1989, J LIPID RES, V30, P39; Calvo D, 1998, J LIPID RES, V39, P777; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; FAIRWELL T, 1987, P NATL ACAD SCI USA, V84, P4796, DOI 10.1073/pnas.84.14.4796; Furlaneto CJ, 2000, BIOCHEM BIOPH RES CO, V268, P405, DOI 10.1006/bbrc.2000.2143; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; He R, 2003, BLOOD, V101, P1572, DOI 10.1182/blood-2002-05-1431; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; KISILEVSKY R, 1992, LAB INVEST, V66, P778; Kluve-Beckerman B, 2002, ARTHRITIS RHEUM-US, V46, P1905, DOI 10.1002/art.10335; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Kumon Y, 1997, SCAND J IMMUNOL, V46, P284, DOI 10.1046/j.1365-3083.1997.d01-128.x; Kumon Y, 2002, AMYLOID, V9, P237, DOI 10.3109/13506120209114099; Kumon Y, 1999, J RHEUMATOL, V26, P785; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; LIANG JS, 1995, J LIPID RES, V36, P37; Liang TS, 2000, BIOCHEM BIOPH RES CO, V270, P331, DOI 10.1006/bbrc.2000.2416; MALLE E, 1993, ATHEROSCLEROSIS, V102, P131, DOI 10.1016/0021-9150(93)90155-N; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEEK RL, 1992, P NATL ACAD SCI USA, V89, P7949, DOI 10.1073/pnas.89.17.7949; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nanjee MN, 2000, J LIPID RES, V41, P1317; Olsson N, 1999, BIOCHEM BIOPH RES CO, V254, P143, DOI 10.1006/bbrc.1998.9911; Patel H, 1998, SCAND J IMMUNOL, V48, P410; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Salazar A, 2000, ATHEROSCLEROSIS, V152, P497, DOI 10.1016/S0021-9150(00)00368-3; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schmitz G, 1999, PATHOBIOLOGY, V67, P236, DOI 10.1159/000028100; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SLOOP CH, 1983, ATHEROSCLEROSIS, V49, P9, DOI 10.1016/0021-9150(83)90003-5; STEINMETZ A, 1989, BIOCHIM BIOPHYS ACTA, V1006, P173, DOI 10.1016/0005-2760(89)90192-6; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Svensson PA, 1999, ENDOCRINOLOGY, V140, P2494, DOI 10.1210/en.140.6.2494; TAKAHASHI M, 1989, VIRCHOWS ARCH A, V415, P411, DOI 10.1007/BF00747742; Tam SP, 2002, J LIPID RES, V43, P1410, DOI 10.1194/jlr.M100388-JLR200; TAPE C, 1988, SCAND J IMMUNOL, V28, P317, DOI 10.1111/j.1365-3083.1988.tb01455.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Urieli-Shoval S, 2000, CURR OPIN HEMATOL, V7, P64, DOI 10.1097/00062752-200001000-00012; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; XU LL, 1995, J IMMUNOL, V155, P1184; Yamada T, 1996, PATHOL INT, V46, P797, DOI 10.1111/j.1440-1827.1996.tb03552.x; Yavin EJ, 2000, FEBS LETT, V472, P259, DOI 10.1016/S0014-5793(00)01470-8; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	69	142	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8031	8040		10.1074/jbc.M405009200	http://dx.doi.org/10.1074/jbc.M405009200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15576377	hybrid			2022-12-25	WOS:000227395700073
J	Cardounel, AJ; Xia, Y; Zweier, JL				Cardounel, AJ; Xia, Y; Zweier, JL			Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase - Differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; CORONARY-ARTERY-DISEASE; L-ARGININE; ENDOTHELIAL DYSFUNCTION; PEROXYNITRITE GENERATION; REPERFUSION INJURY; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; RAT-BRAIN; METABOLISM	The endogenous methylarginines asymmetric dimethylarginine ( ADMA) and N-G-monomethyl-L-arginine ( L-NMMA) regulate nitric oxide ( NO) production from neuronal NO synthase ( nNOS). Under conditions of L-arginine or tetrahydrobiopterin ( BH4) depletion, nNOS also generates superoxide, O-2(radical anion) ; however, the effects of methylarginines on this O-2(radical anion) generation are poorly understood. Therefore, we measured the dose-dependent effects of ADMA and L-NMMA on the rate and amount of O-2(radical anion) production from nNOS under conditions of L-arginine and/or BH4 depletion, using electron paramagnetic resonance spin trapping. In the absence of L-arginine, ADMA ( 1 muM) inhibited O-2(radical anion) generation by similar to 60% from a rate of 56 to 23 nmol/mg/min, whereas L-NMMA ( 0.1 - 100 muM) had no effect. L-Arginine markedly decreased the observed O-2(radical anion), adduct formation; however, O-2. generation from the enzyme still occurs at a low rate ( 12.1 nmol/mg/min). This O-2(radical anion) leak is NOS-derived as it is not seen in the absence of calcium and calmodulin and demonstrates that O-2(radical anion) generation from NOS occurs even when normal substrate/cofactor levels are present. Under conditions of BH4 depletion, ADMA had no effect on O-2(radical anion), whereas L-NMMA increased O-2(radical anion) production almost 3-fold. This O-2(radical anion) generation was > 90% inhibited by imidazole, indicating that it occurred at the heme center. Thus, methylarginines can profoundly shift the balance of NO and O-2(radical anion) generation from nNOS. These observations have important implications with regard to the therapeutic use of methylarginine-NOS inhibitors in the treatment of disease.	Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Div Cardiovasc Med, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Div Cardiovasc Med, Dept Pharmacol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zweier, JL (corresponding author), Davis Heart & Lung Res Inst, Rm 603,473 W 12th Ave, Columbus, OH 43210 USA.	zweier-1@medctr.osu.edu			NHLBI NIH HHS [HL77575, HL38324, HL63744, HL65608] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324, R01HL077575, R01HL063744, P01HL065608] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBINA JE, 1990, J IMMUNOL, V144, P3877; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Arima T, 1997, NEUROCHEM INT, V30, P239, DOI 10.1016/S0197-0186(96)00099-X; Boger RH, 2003, ATHEROSCLEROSIS SUPP, V4, P1, DOI 10.1016/S1567-5688(03)00027-8; Cardounel AJ, 2002, J BIOL CHEM, V277, P33995, DOI 10.1074/jbc.M108983200; Cooke JP, 2000, ARTERIOSCL THROM VAS, V20, P2032, DOI 10.1161/01.ATV.20.9.2032; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Flinspach ML, 2004, NAT STRUCT MOL BIOL, V11, P54, DOI 10.1038/nsmb704; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; HASEGAWA T, 1992, BIOCHEM INT, V26, P653; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HIBBS JB, 1987, J IMMUNOL, V138, P550; Kotsonis P, 2000, BIOCHEM J, V346, P767, DOI 10.1042/0264-6021:3460767; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Maier W, 2000, J CARDIOVASC PHARM, V35, P173, DOI 10.1097/00005344-200002000-00001; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Raman CS, 2001, BIOCHEMISTRY-US, V40, P13448, DOI 10.1021/bi010957u; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RECKELHOFF JF, 1994, LIFE SCI, V55, P1895, DOI 10.1016/0024-3205(94)00521-4; REIF DW, 1995, ARCH BIOCHEM BIOPHYS, V320, P170, DOI 10.1006/abbi.1995.1356; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Roubaud V, 1998, ANAL BIOCHEM, V257, P210, DOI 10.1006/abio.1997.2542; Rutherford RAD, 1995, BRIT J PHARMACOL, V116, P3099, DOI 10.1111/j.1476-5381.1995.tb15111.x; Setoguchi S, 2001, J AM COLL CARDIOL, V38, P493, DOI 10.1016/S0735-1097(01)01382-1; Souza HP, 2002, AM J PHYSIOL-HEART C, V282, pH466, DOI 10.1152/ajpheart.00482.2001; Tiefenbacher CP, 2000, CIRCULATION, V102, P2172; Tiefenbacher CP, 2003, PFLUG ARCH EUR J PHY, V447, P1, DOI 10.1007/s00424-003-1131-y; Tiefenbacher CP, 1996, CIRCULATION, V94, P1423, DOI 10.1161/01.CIR.94.6.1423; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Witte MB, 2002, METABOLISM, V51, P1269, DOI 10.1053/meta.2002.35185; Witte MB, 2003, WOUND REPAIR REGEN, V11, P419, DOI 10.1046/j.1524-475X.2003.11605.x; Xia Y, 2000, FREE RADICAL BIO MED, V29, P793, DOI 10.1016/S0891-5849(00)00427-5; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Yadav J, 2003, J INORG BIOCHEM, V95, P25, DOI 10.1016/S0162-0134(03)00089-8	46	87	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7540	7549		10.1074/jbc.M410241200	http://dx.doi.org/10.1074/jbc.M410241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15574418	hybrid			2022-12-25	WOS:000227395700016
J	Fulton, KF; Buckle, AM; Cabrita, LD; Irving, JA; Butcher, RE; Smith, I; Reeve, S; Lesk, AM; Bottomley, SP; Rossjohn, J; Whisstock, JC				Fulton, KF; Buckle, AM; Cabrita, LD; Irving, JA; Butcher, RE; Smith, I; Reeve, S; Lesk, AM; Bottomley, SP; Rossjohn, J; Whisstock, JC			The high resolution crystal structure of a native thermostable serpin reveals the complex mechanism underpinning the stressed to relaxed transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; ACTIVE-SITE; HUMAN ALPHA(1)-ANTITRYPSIN; TERNARY COMPLEX; PROTEIN; ANTITHROMBIN; INHIBITOR; EVOLUTION; POLYMERIZATION; STABILITY	Serpins fold into a native metastable state and utilize a complex conformational change to inhibit target proteases. An undesirable result of this conformational flexibility is that most inhibitory serpins are heat sensitive, forming inactive polymers at elevated temperatures. However, the prokaryote serpin, thermopin, from Thermobifida fusca is able to function in a heated environment. We have determined the 1.8 Angstrom x- ray crystal structure of thermopin in the native, inhibitory conformation. A structural comparison with the previously determined 1.5 Angstrom structure of cleaved thermopin provides detailed insight into the complex mechanism of conformational change in serpins. Flexibility in the shutter region and electrostatic interactions at the top of the A beta- sheet ( the breach) involving the C- terminal tail, a unique structural feature of thermopin, are postulated to be important for controlling inhibitory activity and triggering conformational change, respectively, in the native state. Here we have discussed the structural basis of how this serpin reconciles the thermodynamic instability necessary for function with the stability required to withstand elevated temperatures.	Monash Univ, Prot Crystallog Unit, Monash Ctr Synchrotron Sci,Dept Biochem & Mol Biol, Sch Biomed Sci,Fac Med, Clayton, Vic 3800, Australia; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Monash Univ, Australian Res Council, Ctr Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Monash University; Monash University; Monash University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Whisstock, JC (corresponding author), Monash Univ, Prot Crystallog Unit, Monash Ctr Synchrotron Sci,Dept Biochem & Mol Biol, Sch Biomed Sci,Fac Med, POB 53, Clayton, Vic 3800, Australia.	james.whisstock@med.monash.edu.au	; Rossjohn, Jamie/F-9032-2013	Buckle, Ashley/0000-0003-2943-9044; Rossjohn, Jamie/0000-0002-2020-7522; Whisstock, James/0000-0003-4200-5611; Cabrita, Lisa/0000-0003-2963-8078; Smith, Ian/0000-0002-4143-2892; Lesk, Arthur/0000-0002-2596-0601; Irving, James/0000-0003-3204-6356				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Cabrita LD, 2004, BIOCHEMISTRY-US, V43, P9834, DOI 10.1021/bi0491346; Cabrita LD, 2004, EUR BIOPHYS J BIOPHY, V33, P83, DOI 10.1007/s00249-003-0356-1; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Chow MKM, 2004, CURR MED CHEM, V11, P491, DOI 10.2174/0929867043455936; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; DeDecker BS, 1996, J MOL BIOL, V264, P1072, DOI 10.1006/jmbi.1996.0697; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Feng ZK, 2004, BIOINFORMATICS, V20, P2153, DOI 10.1093/bioinformatics/bth214; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Im H, 2004, PROTEIN ENG DES SEL, V17, P325, DOI 10.1093/protein/gzh036; Irving JA, 2003, J MOL EVOL, V57, P1, DOI 10.1007/s00239-002-2434-x; Irving JA, 2003, STRUCTURE, V11, P387, DOI 10.1016/S0969-2126(03)00057-1; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESK AM, 1986, PROTEIN ENG, V1, P77, DOI 10.1093/protein/1.1.77; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; Liu BB, 2004, BIOPHYS J, V86, P420, DOI 10.1016/S0006-3495(04)74118-1; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; McPherson A, 1982, PREPARATION ANAL PRO; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace C N, 1986, Methods Enzymol, V131, P266; Parfrey H, 2003, J BIOL CHEM, V278, P33060, DOI 10.1074/jbc.M302646200; Pattabiraman N, 1995, J MOL RECOGNIT, V8, P334, DOI 10.1002/jmr.300080603; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Roth LG, 1996, BIOPHYS CHEM, V60, P89, DOI 10.1016/0301-4622(96)00013-0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREIBER C, 1994, STRUCTURE, V2, P945, DOI 10.1016/S0969-2126(94)00096-4; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; Seo EJ, 2002, J BIOL CHEM, V277, P14216, DOI 10.1074/jbc.M110272200; SERRANO L, 1993, J MOL BIOL, V233, P305, DOI 10.1006/jmbi.1993.1508; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; SZILAGYI A, 1995, PROTEIN ENG, V8, P779, DOI 10.1093/protein/8.8.779; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8; Vogt G, 1997, FOLD DES, V2, pS40, DOI 10.1016/S1359-0278(97)00062-X; Wang QH, 2000, J MOL BIOL, V298, P917, DOI 10.1006/jmbi.2000.3716; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Xiang T, 2004, J MOL BIOL, V339, P437, DOI 10.1016/j.jmb.2004.03.057; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	65	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8435	8442		10.1074/jbc.M410206200	http://dx.doi.org/10.1074/jbc.M410206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15590653	hybrid			2022-12-25	WOS:000227395700120
J	Horvath, I; Harmat, V; Perczel, A; Palfi, V; Nyitray, L; Nagy, A; Hlavanda, E; Naray-Szabo, G; Ovadi, J				Horvath, I; Harmat, V; Perczel, A; Palfi, V; Nyitray, L; Nagy, A; Hlavanda, E; Naray-Szabo, G; Ovadi, J			The structure of the complex of calmodulin with KAR-2 - A novel mode of binding explains the unique pharmacology of the drug	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TARGET; RECOGNITION; PEPTIDE; TRIFLUOPERAZINE; DOMAIN; PHOSPHODIESTERASE; REFINEMENT; ANTAGONIST; MODULATION	3'-(beta- Chloroethyl)-2',4'-dioxo-3,5'-spiro-oxazolidino-4-deacetoxyvinblastine (KAR-2) is a potent anti-microtubular agent that arrests mitosis in cancer cells without significant toxic side effects. In this study we demonstrate that in addition to targeting microtubules, KAR-2 also binds calmodulin, thereby countering the antagonistic effects of trifluoperazine. To determine the basis of both properties of KAR-2, the three-dimensional structure of its complex with Ca2+-calmodulin has been characterized both in solution using NMR and when crystallized using x-ray diffraction. Heterocorrelation (H-1-N-15 heteronuclear single quantum coherence) spectra of N-15-labeled calmodulin indicate a global conformation change (closure) of the protein upon its binding to KAR-2. The crystal structure at 2.12-Angstrom resolution reveals a more complete picture; KAR-2 binds to a novel structure created by amino acid residues of both the N- and C- terminal domains of calmodulin. Although first detected by x-ray diffraction of the crystallized ternary complex, this conformational change is consistent with its solution structure as characterized by NMR spectroscopy. It is noteworthy that a similar tertiary complex forms when calmodulin binds KAR-2 as when it binds trifluoperazine, even though the two ligands contact (for the most part) different amino acid residues. These observations explain the specificity of KAR-2 as an anti-microtubular agent; the drug interacts with a novel drug binding domain on calmodulin. Consequently, KAR-2 does not prevent calmodulin from binding most of its physiological targets.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1113 Budapest, Hungary; Eotvos Lorand Univ, Hungarian Acad Sci, Prot Modeling Grp, H-1117 Budapest, Hungary; Eotvos Lorand Univ, Dept Organ Chem, H-1117 Budapest, Hungary; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; Eotvos Lorand Univ, Dept Theoret Chem, H-1117 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences; Eotvos Lorand University; Eotvos Lorand University; Eotvos Lorand University	Ovadi, J (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, Karolina Ut 29, H-1113 Budapest, Hungary.	judit@enzim.hu	Harmat, Veronika/B-8033-2016; Horvath, Istvan/B-1889-2009; Nyitray, László/AAE-5910-2020	Harmat, Veronika/0000-0002-1866-9904; Horvath, Istvan/0000-0003-4262-1430; Nyitray, László/0000-0003-4717-5994; Ovadi, Judit/0000-0002-3420-682X				BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; CHOCK SP, 1984, ANAL BIOCHEM, V138, P34, DOI 10.1016/0003-2697(84)90765-6; Comin-Anduix B, 2001, MOL PHARMACOL, V60, P1235; COOK WJ, 1994, BIOCHEMISTRY-US, V33, P15259, DOI 10.1021/bi00255a006; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; Fallon JL, 2003, STRUCTURE, V11, P1303, DOI 10.1016/j.str.2003.09.004; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; GIETZEN K, 1983, BIOCHIM BIOPHYS ACTA, V736, P109, DOI 10.1016/0005-2736(83)90175-X; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAIT WN, 1986, J CLIN ONCOL, V4, P994, DOI 10.1200/JCO.1986.4.6.994; Harmat V, 2000, J MOL BIOL, V297, P747, DOI 10.1006/jmbi.2000.3607; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1986, MED RES REV, V6, P341, DOI 10.1002/med.2610060304; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINSE S, 1986, FEBS LETT, V199, P28, DOI 10.1016/0014-5793(86)81217-0; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOLNAR A, 1995, EUR J PHARM-MOLEC PH, V291, P73; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OROSZ F, 1988, MOL PHARMACOL, V33, P678; OROSZ F, 1990, MOL PHARMACOL, V38, P910; Orosz F, 1997, BRIT J PHARMACOL, V121, P955, DOI 10.1038/sj.bjp.0701190; Orosz F, 1997, BRIT J PHARMACOL, V121, P947, DOI 10.1038/sj.bjp.0701189; OROSZ F, 1988, BIOCHIM BIOPHYS ACTA, V957, P293, DOI 10.1016/0167-4838(88)90286-5; Orosz F, 1999, BRIT J CANCER, V79, P1356, DOI 10.1038/sj.bjc.6690218; Osawa M, 1998, J MOL BIOL, V276, P165, DOI 10.1006/jmbi.1997.1524; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SOBIESZEK A, 1989, BIOCHEM J, V262, P215, DOI 10.1042/bj2620215; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; TANAKA T, 1980, J BIOL CHEM, V255, P1078; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VANDONSELAAR M, 1994, NAT STRUCT BIOL, V1, P795, DOI 10.1038/nsb1194-795; Vertessy BG, 1998, BIOCHEMISTRY-US, V37, P15300, DOI 10.1021/bi980795a; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Wall ME, 1997, STRUCTURE, V5, P1599, DOI 10.1016/S0969-2126(97)00308-0; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yamauchi E, 2003, NAT STRUCT BIOL, V10, P226, DOI 10.1038/nsb900; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	54	23	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8266	8274		10.1074/jbc.M410353200	http://dx.doi.org/10.1074/jbc.M410353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15596444	hybrid			2022-12-25	WOS:000227395700100
J	Nagy, AK; Kane, DJ; Tran, CM; Farley, RA; Faller, LD				Nagy, AK; Kane, DJ; Tran, CM; Farley, RA; Faller, LD			Evidence calcium pump binds magnesium before inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM ATPASE; ADENOSINE-TRIPHOSPHATASE; O-18 EXCHANGE; INDEPENDENT PHOSPHORYLATION; CONFORMATIONAL CHANGE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; MECHANISM; ENZYME; ION	Calcium pump-catalyzed O-18 exchange between inorganic phosphate and water was studied to test the hypothesis that all P-type pumps bind Mg2+ before P-i and validate utilization of the rate equation for ordered binding to interpret differences between site-directed mutants and wild-type enzyme. The results were remarkably similar to those obtained earlier with sodium pump ( Kasho, V. N., Stengelin, M., Smirnova, I. N., and Faller, L. D. ( 1997) Biochemistry 36, 8045 - 8052). The equation for ordered binding of Mg2+ before P-i fit the data best with only a slight chance ( 0.6%) of P-i binding to apoenzyme. Therefore, P-i is the substrate, and Mg2+ is an obligatory cofactor. The intrinsic Mg2+ dissociation constant from metalloenzyme ( K-M = 3.5 +/- 0.3 mM) was experimentally indistinguishable from the sodium pump value. However, the half-maximal concentration for P-i binding to metalloenzyme ( K'(P) = 6.3 +/- 0.6 mM) was significantly higher ( similar to 6-fold), and the probability of calcium pump forming phosphoenzyme from bound P-i ( P-c = 0.04 +/- 0.03) was significantly lower ( similar to 6-fold) than for the sodium pump. From estimates of the rate constants for phosphorylation and dephosphorylation, the calcium pump appears to catalyze phosphoryl group transfer less efficiently than the sodium pump. Ordered binding of Mg2+ before P-i implies that both calcium pump and sodium pump form a ternary enzyme(.)metal(.)phosphate complex, consistent with molecular structures of other haloacid dehalogenase superfamily members that were crystallized with Mg2+ and phosphate, or a phosphate analogue, bound.	Vet Adm Greater Los Angeles Healthcare Syst, CURE, Los Angeles, CA 90073 USA; Univ So Calif, Sch Med, Dept Physiol & Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, Sch Med, CURE, Digest Dis Res Ctr,Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Faller, LD (corresponding author), Vet Adm Greater Los Angeles Healthcare Syst, CURE, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	lfaller@ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052802] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKARI A, 1983, J BIOL CHEM, V258, P3453; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; DAHMS AS, 1983, CURR TOP MEMBR TRANS, V19, P371; DAHMS AS, 1973, J BIOL CHEM, V248, P6592; EPSTEIN M, 1980, BIOCHEMISTRY-US, V19, P5564, DOI 10.1021/bi00565a016; FALLER LD, 1984, BIOCHEMISTRY-US, V23, P6584, DOI 10.1021/bi00321a047; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6908, DOI 10.1021/bi00443a020; Faller LD, 2002, BIOPHYS J, V82, p262A; Farley RA, 2001, BIOCHEMISTRY-US, V40, P6361, DOI 10.1021/bi010270+; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; GLANTZ SA, 1990, PRIMER APPLIED REGRE, P50; HACKNEY DD, 1980, J BIOL CHEM, V255, P5320; HACKNEY DD, 1978, P NATL ACAD SCI USA, V75, P3133, DOI 10.1073/pnas.75.7.3133; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1982, ANN NY ACAD SCI, V402, P515, DOI 10.1111/j.1749-6632.1982.tb25772.x; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KANAZAWA T, 1975, J BIOL CHEM, V250, P113; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; Kasho VN, 1997, BIOCHEMISTRY-US, V36, P8045, DOI 10.1021/bi970472z; Khan YM, 1997, BIOCHEM J, V321, P671, DOI 10.1042/bj3210671; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOLASSA N, 1979, FEBS LETT, V108, P495, DOI 10.1016/0014-5793(79)80596-7; KURIKI Y, 1976, BIOCHEMISTRY-US, V15, P4956, DOI 10.1021/bi00668a002; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MARTIN DW, 1981, BIOCHEMISTRY-US, V20, P4597, DOI 10.1021/bi00519a013; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; SMIRNOVA IN, 1993, BIOCHEMISTRY-US, V32, P5967, DOI 10.1021/bi00074a007; SMIRNOVA IN, 1989, EUR J BIOCHEM, V182, P451, DOI 10.1111/j.1432-1033.1989.tb14852.x; STEMPEL KE, 1986, METHOD ENZYMOL, V64, P60; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WEAST RC, 1966, HANDBOOK CHEMISTRY P, pB192; WEBB MR, 1981, J BIOL CHEM, V256, P4884	44	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7435	7443		10.1074/jbc.M412319200	http://dx.doi.org/10.1074/jbc.M412319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591322	hybrid			2022-12-25	WOS:000227395700004
J	Xu, H; Bush, LA; Pineda, AO; Caccia, S; Di Cera, E				Xu, H; Bush, LA; Pineda, AO; Caccia, S; Di Cera, E			Thrombomodulin changes the molecular surface of interaction and the rate of complex formation between thrombin and protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASES; NA+ BINDING; ANTICOAGULANT THROMBIN; FIBRINOLYSIS INHIBITOR; HOT-SPOT; ACTIVATION; SPECIFICITY; INTERFACE; MUTANT; SITE	The interaction of thrombin with protein C triggers a key down-regulatory process of the coagulation cascade. Using a panel of 77 Ala mutants, we have mapped the epitope of thrombin recognizing protein C in the absence or presence of the cofactor thrombomodulin. Residues around the Na+ site (Thr-172, Lys-224, Tyr-225, and Gly-226), the aryl binding site (Tyr-60a), the primary specificity pocket (Asp-189), and the oxyanion hole (Gly-193) hold most of the favorable contributions to protein C recognition by thrombin, whereas a patch of residues in the 30-loop (Arg-35 and Pro-37) and 60-loop (Phe-60h) regions produces unfavorable contributions to binding. The shape of the epitope changes drastically in the presence of thrombomodulin. The unfavorable contributions to binding disappear and the number of residues promoting the thrombin-protein C interaction is reduced to Tyr-60a and Asp-189. Kinetic studies of protein C activation as a function of temperature reveal that thrombomodulin increases > 1,000-fold the rate of diffusion of protein C into the thrombin active site and lowers the activation barrier for this process by 4 kcal/mol. We propose that the mechanism of thrombomodulin action is to kinetically facilitate the productive encounter of thrombin and protein C and to allosterically change the conformation of the activation peptide of protein C for optimal presentation to the thrombin active site.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Milan, Dipartimento Sci & Technol Biomed, I-20122 Milan, Italy	Washington University (WUSTL); University of Milan	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@wustl.edu	Caccia, Sonia/G-5938-2014	Caccia, Sonia/0000-0003-0829-5379	NHLBI NIH HHS [HL49413, HL58141, HL73813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073813, R01HL058141, R01HL049413, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Dang QD, 1997, BLOOD, V89, P2220, DOI 10.1182/blood.V89.6.2220; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Esmon CT, 2003, J THROMB HAEMOST, V1, P1343, DOI 10.1046/j.1538-7836.2003.00261.x; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Fortenberry YM, 2004, J BIOL CHEM, V279, P43237, DOI 10.1074/jbc.M406716200; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; GRINNELL BW, 1994, BIOCHEM J, V303, P929, DOI 10.1042/bj3030929; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Krishnan R, 2000, ACTA CRYSTALLOGR D, V56, P406, DOI 10.1107/S0907444900001487; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; Philippou H, 2003, J BIOL CHEM, V278, P32020, DOI 10.1074/jbc.M305364200; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Rezaie AR, 2003, P NATL ACAD SCI USA, V100, P12051, DOI 10.1073/pnas.2135346100; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; Schneider M, 2002, J BIOL CHEM, V277, P9944, DOI 10.1074/jbc.M111685200; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; van Holde KE, 2002, BIOPHYS CHEM, V101, P249, DOI 10.1016/S0301-4622(02)00176-X; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Yang LK, 2004, J BIOL CHEM, V279, P38519, DOI 10.1074/jbc.M407304200; YE J, 1991, J BIOL CHEM, V266, P23016	43	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7956	7961		10.1074/jbc.M412869200	http://dx.doi.org/10.1074/jbc.M412869200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15582990	hybrid			2022-12-25	WOS:000227395700065
J	Capell, A; Beher, D; Prokop, S; Steiner, H; Kaether, C; Shearman, MS; Haass, C				Capell, A; Beher, D; Prokop, S; Steiner, H; Kaether, C; Shearman, MS; Haass, C			gamma-secretase complex assembly within the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SIGNAL PEPTIDE PEPTIDASE; ACTIVE-SITE; BETA-APP; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; C-TERMINUS; PRESENILIN; NICASTRIN; PEN-2	gamma-Secretase is an aspartyl protease complex composed of the four core components APH-1, nicastrin (NCT), presenilin (PS), and PEN-2. It catalyzes the final intramembranous cleavage of the beta-secretase-processed beta-amyloid precursor protein to liberate the neurotoxic amyloid A-peptide. Whereas unassembled complex components appear to be unstable and/or to be retained within the endoplasmic reticulum (ER), the fully assembled complex is known to exert its biological function in late secretory compartments, including the plasma membrane. We thus hypothesized that the gamma-secretase complex undergoes a stepwise assembly within the ER. We demonstrate that gamma-secretase-associated NCT can be actively retained within the ER by the addition of a retention signal. Under these conditions, complex assembly occurred in the absence of maturation of NCT, and ER-retained immature NCT associated with APH-1, PEN-2, and PS fragments. Moreover, a biotinylated transition state gamma-secretase inhibitor allowed the preferential isolation of the fully assembled complex containing immature NCT. Furthermore, we observed a conformational change in immature NCT, which is known to be selectively associated with complete gamma-secretase complex assembly. This was also observed for a small amount of immature endogenous NCT. ER-retained NCT also rescued the biochemical phenotype observed upon RNA interference-mediated NCT knockdown, viz. reduced amyloid beta-peptide production; instability of PS, PEN-2, and APH-1; and accumulation of beta-amyloid precursor protein C-terminal fragments. Finally, we demonstrate that dimeric (NCT/APH-1) and trimeric (NCT/APH-1/PS) intermediates of gamma-secretase complex assembly containing endogenous NCT are retained within the ER and that the incorporation of the fourth and last binding partner (PEN-2) also occurs on immature NCT, suggesting a complete assembly of the gamma-secretase complex within the ER.	Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany; Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Dept Mol & Cellular Neurosci, Harlow CM20 2QR, Essex, England	University of Munich; Merck & Company	Haass, C (corresponding author), Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	chaass@med.uni-muenchen.de	Prokop, Stefan/Y-1257-2019	Prokop, Stefan/0000-0002-5633-2149; Beher, Dirk/0000-0001-8005-5359				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Crystal AS, 2004, BIOCHEMISTRY-US, V43, P3555, DOI 10.1021/bi0361214; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasegawa H, 2004, J BIOL CHEM, V279, P46455, DOI 10.1074/jbc.M406289200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wrigley JDJ, 2004, J NEUROCHEM, V90, P1312, DOI 10.1111/j.1471-4159.2004.02596.x; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	53	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6471	6478		10.1074/jbc.M409106200	http://dx.doi.org/10.1074/jbc.M409106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591316	hybrid			2022-12-25	WOS:000227332700029
J	Grace, MJ; Lee, S; Bradshaw, S; Chapman, J; Spond, J; Cox, S; DeLorenzo, M; Brassard, D; Wylie, D; Cannon-Carlson, S; Cullen, C; Indelicato, S; Voloch, M; Bordens, R				Grace, MJ; Lee, S; Bradshaw, S; Chapman, J; Spond, J; Cox, S; DeLorenzo, M; Brassard, D; Wylie, D; Cannon-Carlson, S; Cullen, C; Indelicato, S; Voloch, M; Bordens, R			Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE INTERFERON; CHRONIC HEPATITIS-C; CYTO-TOXIC ACTIVITY; PEGINTERFERON ALPHA-2A; POSITIONAL ISOMERS; RECOMBINANT; RECEPTOR; PHARMACOKINETICS; PHARMACODYNAMICS; RESPONSIVENESS	Therapeutic pegylated interferon-alphas (IFN-alpha) are mixtures of positional isomers that have been monopegylated at specific sites on the core IFN-alpha molecule. The pegylation results in lower in vitro specific activity associated with the core IFN-a molecule that is related to the site of pegylation and size of polyethylene glycol (PEG) attached. We prepared purified, homogeneous, positional pegylation isomers of IFN-alpha2b that were monopegylated using 5-30-kDa linear PEG molecules attached at 7 primary reactive amino acid residues: Cys(1), His(34), Lys(31), Lys(83), Lys(121), Lys(131), and Lys(134). The isomers were evaluated for STAT translocation and antiviral and antiproliferative activity. The site of pegylation strongly influenced activity relative to an IFN-a2b control. The highest residual activity was observed with the His(34) positional isomers, and the lowest was observed with the Cys(1) positional isomers. The Lys positional isomers demonstrated intermediate activity, with a general order of Lys(134) > Lys(83) similar to Lys(131) similar to Lys(121) > Lys(31). The progressive relationship between decreased activity and increased PEG size suggests that pegylation may interfere with interaction and binding of IFN-alpha to the IFNAR1-IFNAR2 heterodimeric receptor. The higher specific activity associated with the His(34) positional isomer suggests that this site may be favorable for pegylating IFN-alpha2b molecules.	Schering Plough Res Inst, Union, NJ 07083 USA; Aventis Pharmaceut, Bridgewater, NJ 08807 USA	Merck & Company; Schering-Plough Research Institute; Sanofi-Aventis	Grace, MJ (corresponding author), 1011 Morris Ave, Union, NJ 07083 USA.	michael.grace@spcorp.com						Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Cook JR, 1996, J BIOL CHEM, V271, P13448, DOI 10.1074/jbc.271.23.13448; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; FELIX AM, 1995, INT J PEPT PROT RES, V46, P253; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FORTI RL, 1986, METHOD ENZYMOL, V119, P533; Foser S, 2003, PROTEIN EXPRES PURIF, V30, P78, DOI 10.1016/S1046-5928(03)00055-X; Glue P, 2000, CLIN PHARMACOL THER, V68, P556, DOI 10.1067/mcp.2000.110973; Grace M, 2001, J INTERF CYTOK RES, V21, P1103, DOI 10.1089/107999001317205240; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hu RQ, 2001, J IMMUNOL, V167, P1482, DOI 10.4049/jimmunol.167.3.1482; HU RQ, 1993, J BIOL CHEM, V268, P12591; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; Kozlowski A, 2001, BIODRUGS, V15, P419, DOI 10.2165/00063030-200115070-00001; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Leonard WJ, 1996, NAT MED, V2, P968, DOI 10.1038/nm0996-968; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Luxon BA, 2002, CLIN THER, V24, P1363, DOI 10.1016/S0149-2918(02)80042-X; Meager A, 2001, J IMMUNOL METHODS, V257, P17, DOI 10.1016/S0022-1759(01)00460-4; Monkarsh SP, 1997, ANAL BIOCHEM, V247, P434, DOI 10.1006/abio.1997.2128; Nagabhushan TL, 2002, CAN J CHEM, V80, P1166, DOI 10.1139/V02-158; ORTALDO JR, 1983, INT J CANCER, V31, P285, DOI 10.1002/ijc.2910310306; ORTALDO JR, 1983, J BIOL CHEM, V258, P5011; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PESTKA S, 1997, SEMIN ONCOL, V24; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; REHBERG E, 1982, J BIOL CHEM, V257, P1497; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; *SCH CORP, 2004, PEG INTR PRESCR INF; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Seeff Leonard B, 2003, Clin Liver Dis, V7, P261, DOI 10.1016/S1089-3261(02)00078-8; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; van der Auwera P, 2001, AM J HEMATOL, V66, P245, DOI 10.1002/ajh.1052; Walter MR, 1997, SEMIN ONCOL, V24, P952; Wang YS, 2000, BIOCHEMISTRY-US, V39, P10634, DOI 10.1021/bi000617t; Wylie DC, 2001, PHARM RES-DORDR, V18, P1354, DOI 10.1023/A:1013006515587; Youngster S, 2002, CURR PHARM DESIGN, V8, P2139, DOI 10.2174/1381612023393242; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	44	75	130	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6327	6336		10.1074/jbc.M412134200	http://dx.doi.org/10.1074/jbc.M412134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596441	hybrid			2022-12-25	WOS:000227332700013
J	Iwaki, S; Kihara, A; Sano, T; Igarashi, Y				Iwaki, S; Kihara, A; Sano, T; Igarashi, Y			Phosphorylation by pho85 cyclin-dependent kinase acts as a signal for the down-regulation of the yeast sphingoid long-chain base kinase Lcb4 during the stationary phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CALCIUM MOBILIZATION; MULTIVESICULAR BODY; CELL-PROLIFERATION; SHUTTLE VECTORS; KEY REGULATOR; HEAT-STRESS; PROTEIN; COMPLEX; SPHINGOSINE-1-PHOSPHATE	Sphingoid long-chain base 1-phosphates (LCBPs) act as bioactive lipid molecules in eukaryotic cells. In yeast, LCBPs are synthesized mainly by the long-chain base kinase Lcb4p. Until now, the regulatory mechanism for Lcb4p has been unclear. In the present study, we found that Lcb4p is post-translationally modified by phosphorylation. Using a protein kinase mutant yeast collection, we further demonstrated that the cyclin-dependent kinase Pho85p is involved in this phosphorylation. Pho85p functions in a number of cellular processes, especially in response to environmental changes. Two of 10 Pho85p cyclins, Pc11p and Pc12p had overlapping functions in the phosphorylation of Lcb4p. Site-directed mutagenesis identified the phosphorylation sites in Lcb4p as Ser(451) and Ser(455). Additionally, pulse-chase experiments revealed that Lcb4p is degraded via the ubiquitin-dependent pathway. The protein was stabilized in Deltapho85 cells, suggesting that phosphorylation acts as a signal for the degradation. Lcb4p is down-regulated in the stationary phase of cell growth, and both phosphorylation and ubiquitination appear to be important for this process. Moreover, we demonstrated that Lcb4p is delivered to the vacuole for degradation via the multivesicular body. Since forced accumulation of LCBPs results in prolonged growth during the stationary phase, down-regulation of Lcb4p may be physiologically important for proper cellular responses to nutrient deprivation.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Igarashi, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12jo,Nishi 6 Chome, Sapporo, Hokkaido 0600812, Japan.	yigarash@pharm.hokudai.ac.jp	Sano, Takamitsu/F-9410-2012; KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brachmann CB, 1998, YEAST, V14, P115; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; Choi OH, 1996, NATURE, V380, P634; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Hait NC, 2002, FEBS LETT, V532, P97, DOI 10.1016/S0014-5793(02)03636-0; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kim S, 2000, GENETICS, V156, P1519; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Lanterman MM, 1998, BIOCHEM J, V332, P525, DOI 10.1042/bj3320525; Lenburg ME, 2001, GENETICS, V157, P39; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Moffat J, 2000, Prog Cell Cycle Res, V4, P97; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	54	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6520	6527		10.1074/jbc.M410908200	http://dx.doi.org/10.1074/jbc.M410908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15598647	hybrid			2022-12-25	WOS:000227332700035
J	Pula, G; Crosby, D; Baker, J; Poole, AW				Pula, G; Crosby, D; Baker, J; Poole, AW			Functional interaction of protein kinase C alpha with the tyrosine kinases Syk and Src in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; MEMBRANE-TARGETING MODULES; PANCREATIC ACINAR-CELLS; PKC-DELTA; PHORBOL ESTER; GRANULE SECRETION; GLYCOPROTEIN-IB; PHOSPHORYLATION SITES; STIMULATED PLATELETS; FAMILY KINASES	There is a high degree of cross-talk between tyrosine phosphorylation and the serine/threonine phosphorylation signaling pathways. Here we show a physical and functional interaction between the classical protein kinase C isoform (cPKC), PKCalpha, and two major nonreceptor tyrosine kinases in platelets, Syk and Src. In the presence of the cPKC-selective inhibitor Go6976, platelet 5-hydroxytryptamine release was abolished in response to co-activation of glycoproteins VI and Ib-IX-V by the snake venom alboaggregin A, whereas platelet aggregation was substantially inhibited. Of the two platelet cPKCs, PKCalpha but not PKCbeta was activated, occurring in an Syk- and phospholipase C-dependent manner. Syk and PKCa associate in a stimulation-dependent manner, requiring Syk but not PKC activity. PKCa and Syk also co-translocate from the cytosol to the plasma membrane upon platelet activation, in a manner dependent upon the activities of both kinases. Although PKCa is phosphorylated on tyrosine downstream of Syk, we provide evidence against phosphorylation of Syk by PKC a, consistent with a lack of effect of PKC a inhibition on Syk activity. PKCa also associates with Src; although in contrast to interaction with Syk, PKCa activity is required for the association of these kinases but not the stimulation-induced translocation of Src to the cell membrane. Finally, the activity of Src is negatively regulated by PKC, as shown by potentiation of Src activity in the presence of the PKC inhibitors GF109203X or Go6976. Therefore, there is a complex interplay between PKCa, Syk, and Src involving physical interaction, phosphorylation, translocation within the cell, and functional activity regulation.	Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol	Poole, AW (corresponding author), Sch Med Sci, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.	a.poole@bris.ac.uk	Pula, Giordano/ABE-8596-2020	Poole, Alastair/0000-0002-0868-297X				Asazuma N, 2001, BLOOD, V97, P3989, DOI 10.1182/blood.V97.12.3989; Baker J, 2004, PLATELETS, V15, P207, DOI 10.1080/09537100410001701010; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; Ballen KK, 1996, EXP HEMATOL, V24, P1501; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; Crosby D, 2003, J BIOL CHEM, V278, P24533, DOI 10.1074/jbc.M301847200; Crosby D, 2002, J BIOL CHEM, V277, P9958, DOI 10.1074/jbc.M108965200; Crosby David, 2004, Methods Mol Biol, V272, P95; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DHAR A, 1991, J BIOL CHEM, V266, P18797; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; GERRARD JM, 1989, BLOOD, V74, P2405; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Jones ML, 2004, J BIOL CHEM, V279, P40475, DOI 10.1074/jbc.M402970200; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KHAN WA, 1993, J BIOL CHEM, V268, P5063; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; LANDGREN E, 1995, ONCOGENE, V10, P2027; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIEBENHOFF U, 1994, CELL MOL BIOL, V40, P645; LIU F, 1994, BIOCHEM BIOPH RES CO, V200, P1570, DOI 10.1006/bbrc.1994.1630; Murugappan S, 2004, J BIOL CHEM, V279, P2360, DOI 10.1074/jbc.M306960200; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Poole AAW, 2004, TRENDS PHARMACOL SCI, V25, P528, DOI 10.1016/j.tips.2004.08.006; RINK TJ, 1983, NATURE, V305, P317, DOI 10.1038/305317a0; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sun LS, 2004, BLOOD, V103, P948, DOI 10.1182/blood-2003-07-2299; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Tabuchi A, 2003, J BIOL CHEM, V278, P26374, DOI 10.1074/jbc.M212407200; Tapia JA, 2002, BBA-MOL CELL RES, V1593, P99, DOI 10.1016/S0167-4889(02)00346-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WANG F, 1993, BIOCHEM BIOPH RES CO, V191, P240, DOI 10.1006/bbrc.1993.1208; WANG HY, 1990, LIFE SCI, V47, P1419, DOI 10.1016/0024-3205(90)90520-2; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Wrenn RW, 2001, BIOCHEM BIOPH RES CO, V282, P882, DOI 10.1006/bbrc.2001.4657; WRENN RW, 1995, BIOCHEM BIOPH RES CO, V208, P978, DOI 10.1006/bbrc.1995.1430; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836; YAMADA K, 1987, BIOCHEM BIOPH RES CO, V144, P35, DOI 10.1016/S0006-291X(87)80471-0; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	69	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7194	7205		10.1074/jbc.M409212200	http://dx.doi.org/10.1074/jbc.M409212200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15583006	hybrid			2022-12-25	WOS:000227332700111
J	Schinner, S; Barthel, A; Dellas, C; Grzeskowiak, R; Sharma, SK; Oetjen, E; Blume, R; Knepel, W				Schinner, S; Barthel, A; Dellas, C; Grzeskowiak, R; Sharma, SK; Oetjen, E; Blume, R; Knepel, W			Protein kinase B activity is sufficient to mimic the effect of insulin on glucagon gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; CREB-BINDING-PROTEIN; CAMP-RESPONSIVE ELEMENT; PANCREATIC-ISLET CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE DEPOLARIZATION; 3T3-L1 ADIPOCYTES; PROMOTER ACTIVITY; PATHO-PHYSIOLOGY; BETA-CELLS	Insulin inhibits glucagon gene transcription, and insulin deficiency is associated with hyperglucagonemia that contributes to hyperglycemia in diabetes mellitus. However, the insulin signaling pathway to the glucagon gene is unknown. Protein kinase B (PKB) is a key regulator of insulin signaling and glucose homeostasis. Impaired PKB function leads to insulin resistance and diabetes mellitus. Therefore, the role of PKB in the regulation of glucagon gene transcription was investigated. After transient transfections of glucagon promoter-reporter genes into a glucagon-producing islet cell line, the use of kinase inhibitors indicated that the inhibition of glucagon gene transcription by insulin depends on phosphatidylinositol (PI) 3-kinase. Furthermore, insulin caused a PI 3-kinase-dependent phosphorylation and activation of PKB in this cell line as revealed by phospho-immunoblotting and kinase assays. Overexpression of constitutively active PKB mimicked the effect of insulin on glucagon gene transcription. Both insulin and PKB responsiveness of the glucagon promoter were abolished when the binding sites for the transcription factor Pax6 within the G1 and G3 promoter elements were mutated. Recruitment of Pax6 or its potential coactivator, the CREB-binding protein (CBP), to G1 and G3 by using the GAL4 system restored both insulin and PKB responsiveness. These data suggest that insulin inhibits glucagon gene transcription by signaling via PI 3-kinase and PKB, with the transcription factor Pax6 and its potential coactivator CBP being critical components of the targeted promoter-specific nucleoprotein complex. The present data emphasize the importance of PKB in insulin signaling and glucose homeostasis by defining the glucagon gene as a novel target gene for PKB.	Univ Gottingen, Dept Mol Pharmacol, D-37099 Gottingen, Germany; Univ Hosp Dusseldorf, Dept Endocrinol Diabet & Rheumatol, D-40225 Dusseldorf, Germany	University of Gottingen; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40, D-37099 Gottingen, Germany.	wknepel@med.uni-goettingen.de		Sharma, Sanjeev Kumar/0000-0002-3273-0708				Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Banfi C, 2001, DIABETES, V50, P1522, DOI 10.2337/diabetes.50.7.1522; BARTHEL, 2003, AM J PHYSL, V285, pE685; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Beimesche S, 1999, MOL ENDOCRINOL, V13, P718, DOI 10.1210/me.13.5.718; Chan HM, 2001, J CELL SCI, V114, P2363; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337/diacare.19.6.580; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Duval DL, 2002, ENDOCRINOLOGY, V143, P11, DOI 10.1210/en.143.1.11; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Freyse EJ, 1997, DIABETES, V46, P824, DOI 10.2337/diabetes.46.5.824; Furstenau U, 1999, J BIOL CHEM, V274, P5851, DOI 10.1074/jbc.274.9.5851; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KNEPEL W, 2001, MOL BASIS ENDOCRINE, P67; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; LEFEBVRE PJ, 1995, DIABETES CARE, V18, P715, DOI 10.2337/diacare.18.5.715; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Patel S, 2002, J BIOL CHEM, V277, P9889, DOI 10.1074/jbc.M109870200; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; Pierreux CE, 1999, MOL CELL ENDOCRINOL, V147, P1, DOI 10.1016/S0303-7207(98)00238-X; Pierreux CE, 1998, MOL ENDOCRINOL, V12, P1343, DOI 10.1210/me.12.9.1343; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Scassa ME, 2001, EXP CELL RES, V271, P201, DOI 10.1006/excr.2001.5386; Schinner S, 2002, J BIOL CHEM, V277, P1941, DOI 10.1074/jbc.M109718200; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; UNGER RH, 1981, NEW ENGL J MED, V304, P1575, DOI 10.1056/NEJM198106253042604; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7; Zhou XY, 2004, NAT MED, V10, P633, DOI 10.1038/nm1050	62	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7369	7376		10.1074/jbc.M408560200	http://dx.doi.org/10.1074/jbc.M408560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590659	hybrid			2022-12-25	WOS:000227332700129
J	Viyoch, J; Matsunaga, N; Yoshida, M; To, H; Higuchi, S; Ohdo, S				Viyoch, J; Matsunaga, N; Yoshida, M; To, H; Higuchi, S; Ohdo, S			Effect of haloperidol on mPer1 gene expression in mouse suprachiasmatic nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PHASE-SHIFTS; PHOTIC REGULATION; CIRCADIAN CLOCK; FOS PROTEIN; RECEPTOR; LIGHT; NMDA; TRANSCRIPTION; RHYTHMS	The effect of a typical neuroleptic haloperidol (Hal) on mPer1 gene expression was investigated in mouse suprachiasmatic nuclei (SCN). Hal induced mPer1 mRNA levels both in vivo and in cultured SCN cells. For mechanisms underlying Hal-induced mPer1 expression, N-methyl-D-aspartate (NMDA) glutamate receptor subtype, the phosphorylation form of the transcription factor, and the Ser-133 phosphorylation form of cAMP-responsive element-binding protein (CREB) played an important role, because the induction of mPer1 mRNA significantly decreased after pretreatment with a noncompetitive NMDA receptor antagonist, such as MK-801 or CREB antisense. These results suggest that Hal may increase CREB phosphorylation and mPer1 expression according to the activation of the NMDA receptor through the dopaminergic pathways. Although the injection of Hal during the light period increased the amplitude of mPer1 mRNA rhythmicity in a nondrug state, the injection of the drug during the dark period disturbed the rhythmic pattern of mPer1 mRNA. These results suggest that the rhythmicity of clock genes in SCN may be disturbed depending on the dosing time of Hal. On the other hand, because the induction of mPer1 mRNA by Hal seems to be at least partly caused by the NMDA receptor, showing a phase shift or resetting effect of the circadian clock, Hal may also cause such phase shift effects.	Kyushu Univ, Fac Pharmaceut Sci, Clin Pharmacokinet, Div Clin Pharm,Dept Med Pharmaceut Sci,Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Ohdo, S (corresponding author), Kyushu Univ, Fac Pharmaceut Sci, Clin Pharmacokinet, Div Clin Pharm,Dept Med Pharmaceut Sci,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	ohdo@phar.kyushu-u.ac.jp		matsunaga2, naoya2/0000-0001-6226-8473				Akiyama M, 1999, J NEUROSCI, V19, P1115; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; CAMPBELL A, 1982, PSYCHOPHARMACOLOGY, V77, P150, DOI 10.1007/BF00431938; Chartoff EH, 1999, J PHARMACOL EXP THER, V291, P531; COLWELL CS, 1991, BRAIN RES, V554, P105, DOI 10.1016/0006-8993(91)90177-W; Duncan MJ, 2000, BRAIN RES, V869, P178, DOI 10.1016/S0006-8993(00)02383-0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; GANNON RL, 1994, MOL BRAIN RES, V23, P338, DOI 10.1016/0169-328X(94)90244-5; Garcia-Sainz JA, 2004, EUR J PHARMACOL, V500, P113, DOI 10.1016/j.ejphar.2004.07.016; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Guido ME, 1999, NEUROSCIENCE, V90, P555, DOI 10.1016/S0306-4522(98)00467-9; Guido ME, 1999, MOL BRAIN RES, V67, P247, DOI 10.1016/S0169-328X(99)00074-1; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; Honma S, 1998, NEUROSCIENCE, V86, P967, DOI 10.1016/S0306-4522(98)00078-5; HYTTEL J, 1995, PSYCHOPHARMACOLOGY, V87, P9; Kako K, 1998, NEUROSCI RES, V31, P257, DOI 10.1016/S0168-0102(98)00054-6; KUMAR A, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1096; Lesch KP, 2001, J AFFECT DISORDERS, V62, P57, DOI 10.1016/S0165-0327(00)00351-7; Leveque JC, 2000, J NEUROSCI, V20, P4011; McNulty S, 1998, EUR J NEUROSCI, V10, P1063, DOI 10.1046/j.1460-9568.1998.00114.x; Mintz EM, 1999, J NEUROSCI, V19, P5124; Mintz EM, 1997, NEUROSCIENCE, V79, P563, DOI 10.1016/S0306-4522(96)00696-3; Moriya T, 2000, MOL PHARMACOL, V58, P1554, DOI 10.1124/mol.58.6.1554; NAGAYAMA H, 1987, EXPERIENTIA, V43, P625, DOI 10.1007/BF02126357; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; Ohdo S, 2001, NAT MED, V7, P356, DOI 10.1038/85507; OHTA M, 1976, PHYSIOL BEHAV, V16, P505, DOI 10.1016/0031-9384(76)90333-4; Palacios G, 1996, BRAIN RES, V742, P141, DOI 10.1016/S0006-8993(96)00975-4; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Pickard GE, 1997, BIOL CELL, V89, P513, DOI 10.1016/S0248-4900(98)80007-5; Power JM, 1995, J BIOL RHYTHM, V10, P267, DOI 10.1177/074873049501000309; Rajadhyaksha A, 1999, J NEUROSCI, V19, P6348; ROBERTSON GS, 1995, NEUROSCIENCE, V67, P325, DOI 10.1016/0306-4522(95)00049-O; SatoBigbee C, 1996, J NEUROSCI RES, V46, P98, DOI 10.1002/(SICI)1097-4547(19961001)46:1<98::AID-JNR12>3.0.CO;2-8; Schurov IL, 2002, EUR J NEUROSCI, V15, P223, DOI 10.1046/j.0953-816x.2001.01848.x; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SIRINATHSINGHJI DJS, 1994, NEUROSCIENCE, V62, P407, DOI 10.1016/0306-4522(94)90376-X; Sprouse J, 2004, SYNAPSE, V54, P111, DOI 10.1002/syn.20070; Sprouse J, 2004, NEUROPHARMACOLOGY, V46, P52, DOI 10.1016/j.neuropharm.2003.08.007; STOOL JC, 1989, DOPAMINE RECEPTORS C, P31; Sumova A, 1998, BRAIN RES, V801, P254, DOI 10.1016/S0006-8993(98)00619-2; Sun YJ, 1998, BRAIN RES, V791, P125, DOI 10.1016/S0006-8993(98)00087-0; Suzuki M, 1998, PSYCHIAT CLIN NEUROS, V52, P353, DOI 10.1046/j.1440-1819.1998.00391.x; TAMMINGA CA, 1987, NEW NEUROLEPTICS EXP, P1129; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; VISWANATHAN N, 1994, J NEUROSCI, V14, P5393; Viyoch J, 2001, J PHARMACOL EXP THER, V298, P964; WEILAND NG, 1987, ENDOCRINOLOGY, V121, P1751, DOI 10.1210/endo-121-5-1751; WEINER DM, 1991, P NATL ACAD SCI USA, V88, P1859, DOI 10.1073/pnas.88.5.1859; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8	54	24	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6309	6315		10.1074/jbc.M411704200	http://dx.doi.org/10.1074/jbc.M411704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590637	hybrid			2022-12-25	WOS:000227332700011
J	Yau, TO; Chan, CY; Chan, KL; Lee, MF; Wong, CM; Fan, ST; Ng, IOL				Yau, TO; Chan, CY; Chan, KL; Lee, MF; Wong, CM; Fan, ST; Ng, IOL			HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing	ONCOGENE			English	Article						HDPR1; Dapper; beta-catenin; WNT/beta-catenin signaling; JNK signaling	BETA-CATENIN; CYCLIN D1; C-JUN; DISHEVELLED OVEREXPRESSION; MATRIX METALLOPROTEINASE-1; TRANSCRIPTIONAL ACTIVITY; WNT PATHWAY; E-CADHERIN; EXPRESSION; CANCER	Oncogenic activation of the WNT/beta-catenin signaling pathway is common in hepatocellular carcinoma (HCC). Dishevelled (Dvl), a key activator of the pathway, inhibits the adenomatous polyposis coli complex, and this leads to the accumulation of beta-catenin and promotes tumorigenesis. Recently, a novel inhibitor of Dishevelled, namely Dapper (Dpr), was isolated in Xenopus. To explore whether HDPR1, the human homologue of Dpr, has an anti-oncogenic role in hepatocarcinogenesis, we studied the expression of this gene in HCCs. We found that there were two alternatively spliced transcripts of HDPR1, designated as alpha and beta forms, in human liver. Downregulation of the gene expression was observed in 31 (43%) of the 72 human HCC samples using the primer pair that amplified both transcripts. Furthermore, the HDPR1alpha was downregulated in 42 (58%) of 72 human HCCs and the downregulation significantly correlated with accumulation of beta-catenin. Also, downregulation of HDPR1 by RNA interference in HLE cells led to cytoplasmic accumulation of beta-catenin. Furthermore, a CpG island located at the promoter region and exon 1 of the HDPR1 gene was methylated in 22 (51%) of human HCCs. We showed that downregulation of HDPR1, in hepatoma cell lines, was associated with methylation of this CpG island using bisulfite sequencing and 5-aza-2'-deoxycytidine demethylation experiment. In addition to methylation-mediated downregulation of HDPR1, allelic loss (13-28% of informative cases) was detected using microsatellite markers flanking the HDPR1 locus. To conclude, downregulation of HDPR1 is common in HCCs, frequently involves hypermethylation of the promoter region, and allelic loss of the HDPR1 locus may also play a role.	Univ Hong Kong, Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Ctr Study Liver Dis, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Ng, IOL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Room 127B,Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.	iolng@hku.hk	WONG, Chun-Ming/A-6739-2009; Fan, Sheung Tat/C-4138-2009	WONG, Chun-Ming/0000-0002-2497-7858; Ng, Irene Oi-lin/0000-0001-7532-2029				Chan CF, 2004, CLIN CANCER RES, V10, P4140, DOI 10.1158/1078-0432.CCR-03-0574; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Katoh M, 2003, INT J ONCOL, V22, P907; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Miyoshi Y, 1998, CANCER RES, V58, P2524; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Okazaki I, 1997, HEPATOLOGY, V25, P580, DOI 10.1002/hep.510250315; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Polakis P, 2000, GENE DEV, V14, P1837; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Sugioka Y, 2004, INT J CANCER, V109, P867, DOI 10.1002/ijc.20095; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Theise Neil D, 2002, Clin Liver Dis, V6, P497, DOI 10.1016/S1089-3261(02)00006-5; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459	31	74	91	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1607	1614		10.1038/sj.onc.1208340	http://dx.doi.org/10.1038/sj.onc.1208340			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15580286				2022-12-25	WOS:000227218200014
J	Griffin, J; Roshick, C; Iliffe-Lee, E; McClarty, G				Griffin, J; Roshick, C; Iliffe-Lee, E; McClarty, G			Catalytic mechanism of Chlamydia trachomatis flavin-dependent thymidylate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; COMPLEMENTING PROTEIN; FUNCTIONAL-ANALYSIS; GENOME SEQUENCES; PNEUMONIAE TWAR; DNA; PURIFICATION; SYNTHETASE; BACTERIA	Here we report on a Chlamydia trachomatis gene that complements the growth defect of a thymidylate synthase-deficient strain of Escherichia coli. The complementing gene encodes a 60.9-kDa protein that shows low level primary sequence homology to a new class of thymidylate-synthesizing enzymes, termed flavin-dependent thymidylate synthases (FDTS). Purified recombinant chlamydial FDTS (CTThyX) contains bound flavin. Results with site-directed mutants indicate that highly conserved arginine residues are required for flavin binding. Kinetic characterization indicates that CTThyX is active as a tetramer with NADPH, methylenetetrahydrofolate, and dUMP required as substrates, serving as source of reducing equivalents, methyl donor, and methyl acceptor, respectively. dTMP and H(4)folate are products of the reaction. Production of H,folate rather than H(2)folate, as in the classical thymidylate synthase reaction, eliminates the need for dihydrofolate reductase, explaining the trimethoprim-resistant phenotype displayed by thyA(-) E. coli-expressing CTThyX. In contrast to the extensively characterized thyA-encoded thymidylate synthases, which form a ternary complex with substrates dIUMP and CH(2)H(4)folate and follow an ordered sequential mechanism, CTThyX follows a pingpong kinetic mechanism involving a methyl enzyme intermediate. Mass spectrometry was used to localize the methyl group to a highly conserved arginine, and sitedirected mutagenesis showed this arginine to be critical for thymidylate synthesizing activity. These differentiating characteristics clearly distinguish FDTS from ThyA, making this class of enzymes attractive targets for rational drug design.	Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada	Public Health Agency of Canada; University of Manitoba	McClarty, G (corresponding author), Publ Hlth Agcy Canada, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.	mcclart@cc.umanitoba.ca						Agrawal N, 2004, BIOCHEMISTRY-US, V43, P10295, DOI 10.1021/bi0490439; BISSON LF, 1981, J BIOL CHEM, V256, P2456; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585; CARRERAS CW, 1992, BIOCHEMISTRY-US, V31, P6038, DOI 10.1021/bi00141a012; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; DARON HH, 1978, J BIOL CHEM, V253, P940; DELK AS, 1980, J BIOL CHEM, V255, P4387; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FAN H, 1994, THYMIDYLATE BIOSYNTH, P1; FAN HZ, 1991, J BACTERIOL, V173, P6670, DOI 10.1128/jb.173.21.6670-6677.1991; FAN HZ, 1992, J CLIN INVEST, V90, P1803, DOI 10.1172/JCI116055; Fehlner-Gardiner C, 2002, J BIOL CHEM, V277, P26893, DOI 10.1074/jbc.M203937200; Graziani S, 2004, J BIOL CHEM, V279, P54340, DOI 10.1074/jbc.M409121200; HAERTLE T, 1979, EUR J BIOCHEM, V102, P223, DOI 10.1111/j.1432-1033.1979.tb06283.x; Hammerschlag Margaret R, 2002, Semin Pediatr Infect Dis, V13, P239, DOI 10.1053/spid.2002.127201; Hitchcock PJ, 1999, CHLAMYDIA, P297; Horn M, 2004, SCIENCE, V304, P728, DOI 10.1126/science.1096330; IVANETICH KM, 1990, EXP PARASITOL, V70, P367, DOI 10.1016/0014-4894(90)90119-W; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kuhn P, 2002, PROTEINS, V49, P142, DOI 10.1002/prot.10202; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; Leduc D, 2004, BIOCHEM SOC T, V32, P231, DOI 10.1042/BST0320231; Leduc D, 2004, P NATL ACAD SCI USA, V101, P7252, DOI 10.1073/pnas.0401365101; Liu XQ, 2004, J BACTERIOL, V186, P6316, DOI 10.1128/JB.186.18.6316-6319.2004; Mathews II, 2003, STRUCTURE, V11, P677, DOI 10.1016/S0969-2126(03)00097-2; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; McClarty G, 1999, CHLAMYDIA, P69; Mollgaard H, 1983, METABOLISM NUCLEOTID, P149; Montfort WR, 1997, PHARMACOL THERAPEUT, V76, P29, DOI 10.1016/S0163-7258(97)00099-5; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; Murzin AG, 2002, SCIENCE, V297, P61, DOI 10.1126/science.1073910; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Myllykallio H, 2003, TRENDS MICROBIOL, V11, P220, DOI 10.1016/S0966-842X(03)00101-X; Read TD, 2003, NUCLEIC ACIDS RES, V31, P2134, DOI 10.1093/nar/gkg321; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Schachter J, 1999, CHLAMYDIA, P139; Shirai M, 2000, NUCLEIC ACIDS RES, V28, P2311, DOI 10.1093/nar/28.12.2311; Stephens RS, 1999, CHLAMYDIA, P9; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPTON K F, 1992, P1	42	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5456	5467		10.1074/jbc.M412415200	http://dx.doi.org/10.1074/jbc.M412415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591067	hybrid			2022-12-25	WOS:000227217100043
J	Hendriks, BS; Orr, G; Wells, A; Wiley, HS; Lauffenburger, DA				Hendriks, BS; Orr, G; Wells, A; Wiley, HS; Lauffenburger, DA			Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; KINASE CASCADE; EGF-RECEPTOR; ERBB RECEPTORS; BREAST-CANCER; TRAFFICKING; DIVERSIFICATION; AMPLIFICATION; DIMERIZATION; ENDOCYTOSIS	HER2, a member of the epidermal growth factor receptor (EGFR) tyrosine kinase family, functions as an accessory EGFR signaling component and alters EGFR trafficking by heterodimerization. HER2 overexpression leads to aberrant cell behavior including enhanced proliferation and motility. Here we applied a combination of computational modeling and quantitative experimental studies of the dynamic interactions between EGFR and HER2 and their downstream activation of ERK to understand this complex signaling system. Using cells expressing different levels of HER2 relative to the EGFR, we could separate relative contributions of EGFR and HER2 to signaling amplitude and duration. Based on our model calculations, we demonstrated that, in contrast with previous suggestions in the literature, the intrinsic capabilities of EGFR and HER2 to activate ERK were quantitatively equivalent. We found that HER2-mediated effects on EGFR dimerization and trafficking were sufficient to explain the observed HER2-mediated amplification of epidermal growth factor-induced ERK signaling. Our model suggests that transient amplification of ERK activity by HER2 arises predominantly from the 2-to-1 stoichiometry of receptor kinase to bound ligand in EGFR/HER2 heterodimers compared with the 1-to-1 stoichiometry of the EGFR homodimer, but alterations in receptor trafficking yielding increased EGFR sparing cause the sustained HER2-mediated enhancement of ERK signaling.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Lauffenburger, DA (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	lauffen@mit.edu	Dutartre, Helene/H-8837-2016; Dutartre, Helene/L-7463-2019	Dutartre, Helene/0000-0002-2682-4302; Hendriks, Bart/0000-0002-4219-4945; Wiley, Steven/0000-0003-0232-6867; Wells, Alan/0000-0002-1637-8150	NCI NIH HHS [CA88865, CA96504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088865, R01CA096504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; Asthagiri AR, 2001, BIOTECHNOL PROGR, V17, P227, DOI 10.1021/bp010009k; Asthagiri AR, 1999, ANAL BIOCHEM, V269, P342, DOI 10.1006/abio.1999.4055; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FENDLY BM, 1990, CANCER RES, V50, P1550; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Hendriks BS, 2003, CANCER RES, V63, P1130; Hendriks BS, 2003, J BIOL CHEM, V278, P23343, DOI 10.1074/jbc.M300477200; Hendriks BS, 2003, BIOPHYS J, V85, P2732, DOI 10.1016/S0006-3495(03)74696-7; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kholodenko BN, 2002, TRENDS CELL BIOL, V12, P173, DOI 10.1016/S0962-8924(02)02251-1; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LUND KA, 1990, J BIOL CHEM, V265, P15713; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	40	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6157	6169		10.1074/jbc.M410491200	http://dx.doi.org/10.1074/jbc.M410491200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572377	hybrid			2022-12-25	WOS:000227217100123
J	Mandell, JG; Goodrich, KJ; Bahler, J; Cech, TR				Mandell, JG; Goodrich, KJ; Bahler, J; Cech, TR			Expression of a RecQ helicase homolog affects progression through crisis in fission yeast lacking telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; SYNDROME GENE; IN-VITRO; WERNER; SEQUENCE; PROTEIN; TRF2; RECOMBINATION	RecQ helicases play roles in telomere maintenance in cancerous human cells using the alternative lengthening of telomeres mechanism and in budding yeast lacking telomerase. Fission yeast lacking the catalytic subunit of telomerase (trt1(+)) up-regulate the expression of a previously uncharacterized sub-telomeric open reading frame as survivors emerge from crisis. Here we show that this open reading frame encodes a protein with homology to RecQ helicases such as the human Bloom's and Werner's syndrome proteins and that copies of the helicase gene are present on multiple chromosome ends. Characterization of the helicase transcript revealed a 7.6-kilobase RNA that was associated with polyribosomes, suggesting it is translated. A 3.6-kilobase domain of the helicase gene predicted to encode the region with catalytic activity was cloned, and both native and mutant forms of this domain were overexpressed in trt1(-) cells as they progressed through crisis. Overexpression of the native form caused cells to recover from crisis earlier than cells with a vector-only control, whereas overexpression of the mutant form caused delayed recovery from crisis. Taken together, the sequence homology, functional analysis, and site-directed mutagenesis indicate that the protein is likely a second fission yeast RecQ helicase (in addition to Rqh1) that participates in telomere metabolism during crisis. These results strengthen the notion that in multiple organisms RecQ helicases contribute to survival after telomere damage.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Wellcome Trust Sanger Institute	Cech, TR (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	thomas.cech@colorado.edu	Bahler, Jurg/B-4572-2009	Bahler, Jurg/0000-0003-4036-1532	Cancer Research UK [A6517] Funding Source: Medline; NIGMS NIH HHS [GM28039] Funding Source: Medline; Wellcome Trust [077118] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028039, R37GM028039] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA C, EXPT FISSION YEAST, P95; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Baumann P, 2000, MOL BIOL CELL, V11, P3265, DOI 10.1091/mbc.11.10.3265; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BROKER M, 1989, FEBS LETT, V248, P105, DOI 10.1016/0014-5793(89)80441-7; BROWN T, 1993, CURRENT PROTOCOLS MO; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Cech TR, 2000, ANGEW CHEM INT EDIT, V39, P34, DOI 10.1002/(SICI)1521-3773(20000103)39:1<34::AID-ANIE34>3.0.CO;2-N; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Du XB, 2004, MOL CELL BIOL, V24, P8437, DOI 10.1128/MCB.24.19.8437-8446.2004; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FAN JB, 1989, NUCLEIC ACIDS RES, V17, P2801, DOI 10.1093/nar/17.7.2801; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Gao WM, 2002, GENETICS, V162, P103; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Machwe A, 2004, ONCOGENE, V23, P149, DOI 10.1038/sj.onc.1206906; Mandell JG, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2004-6-1-r1; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MERTINS P, 1987, NUCLEIC ACIDS RES, V15, P7369, DOI 10.1093/nar/15.18.7369; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; NAKASEKO Y, 1987, NUCLEIC ACIDS RES, V15, P4705, DOI 10.1093/nar/15.12.4705; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Reddel RR, 2003, CANCER LETT, V194, P155, DOI 10.1016/S0304-3835(02)00702-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sanchez-Alonso P, 1998, GENETICS, V148, P1043; Schaffitzel C, 2001, P NATL ACAD SCI USA, V98, P8572, DOI 10.1073/pnas.141229498; Schulz VP, 1996, HUM GENET, V97, P750; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tham WH, 2002, ONCOGENE, V21, P512, DOI 10.1038/sj.onc.1205078; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang L, 2000, GENETICS, V154, P357; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yamada M, 1998, J BIOL CHEM, V273, P33360, DOI 10.1074/jbc.273.50.33360; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	62	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5249	5257		10.1074/jbc.M412756200	http://dx.doi.org/10.1074/jbc.M412756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591066	hybrid			2022-12-25	WOS:000227217100019
J	Rosenfeld, SS; Houdusse, A; Sweeney, HL				Rosenfeld, SS; Houdusse, A; Sweeney, HL			Magnesium regulates ADP dissociation from myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; KINETIC MECHANISM; MOTOR DOMAIN; CONTRACTION; NUCLEOTIDE; SKELETAL; RELEASE; COMPLEX; ATPASE; ACTIN	Processivity in myosin V is mediated through the mechanical strain that results when both heads bind strongly to an actin filament, and this strain regulates the timing of ADP release. However, what is not known is which steps that lead to ADP release are affected by this mechanical strain. Answering this question will require determining which of the several potential pathways myosin V takes in the process of ADP release and how actin influences the kinetics of these pathways. We have addressed this issue by examining how magnesium regulates the kinetics of ADP release from myosin V and actomyosin V. Our data support a model in which actin accelerates the release of ADP from myosin V by reducing the magnesium affinity of a myosin V-MgADP intermediate. This is likely a consequence of the structural changes that actin induces in myosin to release phosphate. This effect on magnesium affinity provides a plausible explanation for how mechanical strain can alter this actin-induced acceleration. For actomyosin V, magnesium release follows phosphate release and precedes ADP release. Increasing magnesium concentration to within the physiological range would thus slow both the ATPase activity and the velocity of movement of this motor.	Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Inst Curie, CNRS, UMR144, F-75248 Paris, France; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; University of Pennsylvania	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, FOT 1020,1530 3rd Ave S, Birmingham, AL 35294 USA.	stevensr@uab.edu	Sweeney, H Lee/F-1862-2010	houdusse, anne/0000-0002-8566-0336	NIAMS NIH HHS [AR048565, AR35661] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661, R01AR048565] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; EIGEN M, 1960, J AM CHEM SOC, V82, P5951, DOI 10.1021/ja01507a041; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Fujita-Becker S, 2005, J BIOL CHEM, V280, P6064, DOI 10.1074/jbc.M412473200; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HAMMES GG, 1964, BIOCHEMISTRY-US, V3, P1504, DOI 10.1021/bi00898a019; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Houdusse A, 2001, CURR OPIN STRUC BIOL, V11, P182, DOI 10.1016/S0959-440X(00)00188-3; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; MARSH DJ, 1977, BIOCHEMISTRY-US, V16, P1738, DOI 10.1021/bi00627a034; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9994; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SMITH RM, 1956, J AM CHEM SOC, V78, P2376, DOI 10.1021/ja01592a009; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	27	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6072	6079		10.1074/jbc.M412717200	http://dx.doi.org/10.1074/jbc.M412717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579901	hybrid			2022-12-25	WOS:000227217100113
J	Storf, S; Jansson, S; Schmid, VHR				Storf, S; Jansson, S; Schmid, VHR			Pigment binding, fluorescence properties, and oligomerization behavior of Lhca5, a novel light-harvesting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO RECONSTITUTION; BARLEY HORDEUM-VULGARE; PLANT PHOTOSYSTEM-I; LYCOPERSICON-ESCULENTUM; ANTENNA COMPLEXES; CHLOROPHYLL-B; PS II; ORGANIZATION; LHCI-730; SITES	A new potential light-harvesting protein, named Lhca5, was recently detected in higher plants. Because of the low amount of Lhca5 in thylakoid membranes, the isolation of a native Lhca5 pigment-protein complex has not been achieved to date. Therefore, we used in vitro reconstitution to analyze whether Lhca5 binds pigments and is actually an additional light-harvesting protein. By this approach we could demonstrate that Lhca5 binds pigments in a unique stoichiometry. Analyses of pigment requirements for light-harvesting complex formation by Lhca5 revealed that chlorophyll b is the only indispensable pigment. Fluorescence measurements showed that ligated chlorophylls and carotenoids are arranged in a way that allows directed energy transfer within the light-harvesting complex. Reconstitutions of Lhca5 together with other Lhca proteins resulted in the formation of heterodimers with Lhca1. This result demonstrates that Lhca5 is indeed a protein belonging to the light-harvesting antenna of photosystem I. The properties of Lhca5 are compared with those of previously characterized Lhca proteins, and the consequences of an additional Lhca protein for the composition of the light-harvesting antenna of photosystem I are discussed in view of the recently published photosystem I structure of the pea.	Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany; Umea Univ, Dept Plant Pathol, S-90187 Umea, Sweden	Johannes Gutenberg University of Mainz; Umea University	Schmid, VHR (corresponding author), Univ Mainz, Inst Allgemeine Bot, Mullerweg 6, D-55099 Mainz, Germany.	vschmid@uni-mainz.de	Jansson, Stefan/A-1119-2009	Jansson, Stefan/0000-0002-7906-6891				Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; Castelletti S, 2003, BIOCHEMISTRY-US, V42, P4226, DOI 10.1021/bi027398r; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Damm I, 1990, CURRENT RES PHOTOSYN, VII, P607; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1997, BBA-BIOENERGETICS, V1320, P297, DOI 10.1016/S0005-2728(97)00033-9; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; KNOETZEL J, 1992, EUR J BIOCHEM, V206, P209, DOI 10.1111/j.1432-1033.1992.tb16918.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LEE ALC, 1995, PLANT PHYSIOL, V107, P565, DOI 10.1104/pp.107.2.565; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; Melkozernov AN, 1998, J PHYS CHEM B, V102, P8183, DOI 10.1021/jp9810466; MELKOZERNOV AN, 2001, P 12 INT C PHOT AUG; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 2002, HEME CHLOROPHYLL BIL, P235; PETER GF, 1991, J BIOL CHEM, V266, P16745; PICHERSKY E, 1987, PLANT MOL BIOL, V9, P205, DOI 10.1007/BF00166457; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ros F, 1998, EUR J BIOCHEM, V253, P653, DOI 10.1046/j.1432-1327.1998.2530653.x; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; SCHMID V, 1994, PLANTA, V192, P473, DOI 10.1007/BF00203584; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, BIOCHEMISTRY-US, V41, P9126, DOI 10.1021/bi016042x; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; Schmid VHR, 2001, FEBS LETT, V499, P27, DOI 10.1016/S0014-5793(01)02509-1; SCHWARTZ E, 1991, FEBS LETT, V280, P229, DOI 10.1016/0014-5793(91)80299-I; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Storf S, 2004, BIOCHEMISTRY-US, V43, P9214, DOI 10.1021/bi0498196; Wehner A, 2004, J BIOL CHEM, V279, P26823, DOI 10.1074/jbc.M402399200	47	27	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5163	5168		10.1074/jbc.M411248200	http://dx.doi.org/10.1074/jbc.M411248200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15563470	hybrid			2022-12-25	WOS:000227217100008
J	Ye, L; Mishina, Y; Chen, D; Huang, HY; Dallas, SL; Dallas, MR; Sivakumar, P; Kunieda, T; Tsutsui, TW; Boskey, A; Bonewald, LF; Feng, JQ				Ye, L; Mishina, Y; Chen, D; Huang, HY; Dallas, SL; Dallas, MR; Sivakumar, P; Kunieda, T; Tsutsui, TW; Boskey, A; Bonewald, LF; Feng, JQ			Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTIN MATRIX PROTEIN-1; BONE-FORMATION; IN-VIVO; ACIDIC PHOSPHOPROTEIN; GROWTH-PLATE; GENE; CBFA1; DIFFERENTIATION; ANGIOGENESIS; CHONDROCYTES	Understanding the molecular mechanisms by which cartilage formation is regulated is essential toward understanding the physiology of both embryonic bone development and postnatal bone growth. Although much is known about growth factor signaling in cartilage formation, the regulatory role of noncollagenous matrix proteins in this process are still largely unknown. In the present studies, we present evidence for a critical role of DMP1 (dentin matrix protein 1) in postnatal chondrogenesis. The Dmp1 gene was originally identified from a rat incisor cDNA library and has been shown to play an important role in late stage dentinogenesis. Whereas no apparent abnormalities were observed in prenatal bone development, Dmp1-deficient (Dmp1(-I-)) mice unexpectedly develop a severe defect in cartilage formation during postnatal chondrogenesis. Vertebrae and long bones in Dmp1-deficient (Dmp1(-I-)) mice are shorter and wider with delayed and malformed secondary ossification centers and an irregular and highly expanded growth plate, results of both a highly expanded proliferation and a highly expanded hypertrophic zone creating a phenotype resembling dwarfism with chondrodysplasia. This phenotype appears to be due to increased cell proliferation in the proliferating zone and reduced apoptosis in the hypertrophic zone. In addition, blood vessel invasion is impaired in the epiphyses of Dmp1(-I-) mice. These findings show that DMP1 is essential for normal postnatal chondrogenesis and subsequent osteogenesis.	Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Rochester, Sch Med & Dent, Dept Orthopaed, Rochester, NY 14642 USA; Third Mil Med Univ, Daping Hosp, Dept Orthopaed Surg, Chongqing 400042, Peoples R China; Hosp Special Surg, Dept Biochem, New York, NY 10021 USA	University of Missouri System; University of Missouri Kansas City; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Rochester; Army Medical University	Feng, JQ (corresponding author), Univ Missouri, Sch Dent, Dept Oral Biol, 650 E 25th St, Kansas City, MO 64108 USA.	fengj@umkc.edu	Bonewald, Lynda/Q-3638-2019; Sivakumar, Pitchumani/AAA-8199-2022; Tsutsui, Takeo/ABB-4046-2020	Sivakumar, Pitchumani/0000-0002-1157-8831; Boskey, Adele/0000-0002-6181-2219	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046121, R01AR051587, P01AR046798, R03AR048920, R01AR051189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE013480, K02DE000455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071003] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR051587, AR46798, P01 AR046798, P30 AR046121, AR51587, R03 AR048920, R03 AR048920-02, R01 AR051189-01, R01 AR051189] Funding Source: Medline; NIDCR NIH HHS [R29 DE013480, DE13480, K02 DE000455, DE00455] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams CS, 2002, CRIT REV ORAL BIOL M, V13, P465, DOI 10.1177/154411130201300604; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Hirst KL, 1997, J DENT RES, V76, P754, DOI 10.1177/00220345970760030701; KIERNAN J, 1999, HISTOLOGICAL HISTOHC; Koller DL, 2003, J BONE MINER RES, V18, P1758, DOI 10.1359/jbmr.2003.18.10.1758; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; MacDougall M, 1996, CYTOGENET CELL GENET, V74, P189, DOI 10.1159/000134410; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Perlot RL, 2002, J BONE MINER RES, V17, P66, DOI 10.1359/jbmr.2002.17.1.66; Rimoin DL, 1996, AM J MED GENET, V63, P106, DOI 10.1002/(SICI)1096-8628(19960503)63:1<106::AID-AJMG20>3.0.CO;2-R; Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tartaix PH, 2004, J BIOL CHEM, V279, P18115, DOI 10.1074/jbc.M314114200; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200; Zelzer E, 2002, DEVELOPMENT, V129, P1893; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012	34	162	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6197	6203		10.1074/jbc.M412911200	http://dx.doi.org/10.1074/jbc.M412911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590631	Green Accepted, hybrid			2022-12-25	WOS:000227217100126
J	Germann, M; Swain, E; Bergman, L; Nickels, JT				Germann, M; Swain, E; Bergman, L; Nickels, JT			Characterizing the sphingolipid signaling pathway that remediates defects associated with loss of the yeast amphiphysin-like orthologs, Rvs161p and Rvs167p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; CORTICAL ACTIN CYTOSKELETON; SACCHAROMYCES-CEREVISIAE; SH3 DOMAIN; IN-VIVO; MEDIATED ENDOCYTOSIS; LIPID 2ND-MESSENGERS; PROTEIN INTERACTIONS; MEMBRANE CURVATURE; BINDING PROTEIN	Loss of function of either the RVS161 or RVS167 Saccharomyces cerevisiae amphiphysin-like gene confers similar growth phenotypes that can be suppressed by mutations in sphingolipid biosynthesis. We performed a yeast two-hybrid screen using Rvs161p as bait to uncover proteins involved in this sphingolipid-dependent suppressor pathway. In the process, we nave demonstrated a direct physical interaction between Rvs167p and the two-hybrid interacting proteins, Acf2p, Gdh3p, and Ybr108wp, while also elucidating the Rvs167p amino acid domains to which these proteins bind. By using subcellular fractionation, we demonstrate that Rvs167p, Ybr108wp, Gdh3p, and Acf2p, all localize to Rvs161p-containing lipid rafts, thus placing them within a single compartment that should facilitate their interactions. Moreover, our results suggest that Aef2p and Gdh3p functions are needed for suppressor pathway activity. To determine pathway mechanisms further, we examined the localization of Rvs167p in suppressor mutants. These studies reveal roles for Rvs161p and the very long chain fatty acid elongase, Sur4p, in the localization and/or stability of Rvs167p. Previous yeast studies showed that rvs defects could be suppressed by changes in sphingolipid metabolism brought about by deleting SUR4 (Desfarges, L., Durrens, P., Juguelin, H., Cassagne, C., Bonneu, M., and Aigle, M. (1993) Yeast 9, 267-277). Using rvs167 sur4 and rvs161 sur4 double null cells as models to study suppressor pathway activity, we demonstrate that loss of SUR4 does not remediate the steady-state actin cytoskeletal defects of rvs167 or rvs161 cells. Moreover, suppressor activity does not require the function of the actin-binding protein, Abp1p, or Sla1p, a protein that is thought to regulate assembly of the cortical actin cytoskeleton. Based on our results, we suggest that sphingolipid-dependent suppression of rvs defects may not work entirely through regulating changes in actin organization.	Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Nickels, JT (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St,NCB 11115,MS 497, Philadelphia, PA 19102 USA.	JN27@drexel.edu			NHLBI NIH HHS [HL67401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen A, 2004, BIOCHEMISTRY-US, V43, P14431, DOI 10.1021/bi048817i; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Ayscough KR, 1999, MOL BIOL CELL, V10, P1061, DOI 10.1091/mbc.10.4.1061; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Baladron V, 2002, EUKARYOT CELL, V1, P774, DOI 10.1128/EC.1.5.774-786.2002; Balguerie A, 1999, J CELL SCI, V112, P2529; Balguerie A, 2002, EUKARYOT CELL, V1, P1021, DOI 10.1128/EC.1.6.1021-1031.2002; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Bon E, 2000, YEAST, V16, P1229, DOI 10.1002/1097-0061(20000930)16:13<1229::AID-YEA618>3.0.CO;2-Q; Brizzio V, 1998, J CELL BIOL, V141, P567, DOI 10.1083/jcb.141.3.567; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Colwill K, 1999, GENETICS, V152, P881; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; Cyert MS, 2003, BIOCHEM BIOPH RES CO, V311, P1143, DOI 10.1016/S0006-291X(03)01552-3; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Jayadev S, 1996, J LIPID MEDIAT CELL, V14, P295, DOI 10.1016/0929-7855(96)00538-X; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; Kahn BB, 1998, NAT GENET, V20, P223, DOI 10.1038/3018; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Lombardi R, 2001, J BIOL CHEM, V276, P6016, DOI 10.1074/jbc.M008735200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MERRILL AH, 1993, ADV LIPID RES, V25, P1; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Navarro P, 1997, BBA-PROTEIN STRUCT M, V1343, P187, DOI 10.1016/S0167-4838(97)00108-8; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Pruyne D, 2000, J CELL SCI, V113, P571; Riego L, 2002, BIOCHEM BIOPH RES CO, V293, P79, DOI 10.1016/S0006-291X(02)00174-2; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sivadon P, 1997, FEBS LETT, V417, P21, DOI 10.1016/S0014-5793(97)01248-9; Sivadon P, 1997, YEAST, V13, P747, DOI 10.1002/(SICI)1097-0061(19970630)13:8<747::AID-YEA137>3.0.CO;2-L; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilkinson BM, 1996, MICROBIOL-UK, V142, P1667, DOI 10.1099/13500872-142-7-1667; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; Young ME, 2002, MOL CELL BIOL, V22, P927, DOI 10.1128/MCB.22.3.927-934.2002; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zelhof AC, 2001, DEVELOPMENT, V128, P5005; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x; Zhang XP, 2004, J BIOL CHEM, V279, P22030, DOI 10.1074/jbc.M400299200; Zimmerberg J, 2004, CURR BIOL, V14, pR250, DOI 10.1016/j.cub.2004.02.060	80	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4270	4278		10.1074/jbc.M412454200	http://dx.doi.org/10.1074/jbc.M412454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561700	hybrid			2022-12-25	WOS:000227096600035
J	Hannich, JT; Lewis, A; Kroetz, MB; Li, SJ; Heide, H; Emili, A; Hochstrasser, M				Hannich, JT; Lewis, A; Kroetz, MB; Li, SJ; Heide, H; Emili, A; Hochstrasser, M			Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL ANALYSIS; UBIQUITIN; YEAST; PROTEINS; CONJUGATION; IDENTIFICATION; SUMOYLATION; DISSOLUTION; COHESION; COMPLEX	SUMO, or Smt3 in Saccharomyces cerevisiae, is a ubiquitin-like protein that is post-translationally attached to multiple proteins in vivo. Many of these substrate modifications are cell cycle-regulated, and SUMO conjugation is essential for viability in most eukaryotes. However, only a limited number of SUMO-modified proteins have been definitively identified to date, and this has hampered study of the mechanisms by which SUMO ligation regulates specific cellular pathways. Here we use a combination of yeast two-hybrid screening, a high copy suppressor selection with a SUMO isopeptidase mutant, and tandem mass spectrometry to define a large set of proteins (>150) that can be modified by SUMO in budding yeast. These three approaches yielded overlapping sets of proteins with the most extensive set by far being those identified by mass spectrometry. The two-hybrid data also yielded a potential SUMO-binding motif. Functional categories of SUMO-modified proteins include SUMO conjugation system enzymes, chromatin- and gene silencing-related factors, DNA repair and genome stability proteins, stress-related proteins, transcription factors, proteins involved in translation and RNA metabolism, and a variety of metabolic enzymes. The results point to a surprisingly broad array of cellular processes regulated by SUMO conjugation and provide a starting point for detailed studies of how SUMO ligation contributes to these different regulatory mechanisms.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	Yale University; University of Toronto	Hochstrasser, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	mark.hochstrasser@yale.edu		Hochstrasser, Mark/0000-0002-1131-5484; Hannich, J. Thomas/0000-0002-2286-4956				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Biggins S, 2001, GENETICS, V159, P453; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Henikoff JG, 1999, NUCLEIC ACIDS RES, V27, P226, DOI 10.1093/nar/27.1.226; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser M, 2002, MOL CELL, V9, P453, DOI 10.1016/S1097-2765(02)00486-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; James P, 1996, GENETICS, V144, P1425; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kislinger T, 2003, MOL CELL PROTEOMICS, V2, P96, DOI 10.1074/mcp.M200074-MCP200; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sherman F., 1986, METHODS YEAST GENETI; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Stead K, 2003, J CELL BIOL, V163, P729, DOI 10.1083/jcb.200305080; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	42	314	326	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4102	4110		10.1074/jbc.M413209200	http://dx.doi.org/10.1074/jbc.M413209200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590687	hybrid			2022-12-25	WOS:000227096600015
J	Kurooka, H; Yokota, Y				Kurooka, H; Yokota, Y			Nucleo-cytoplasmic shuttling of Id2, a negative regulator of basic helix-loop-helix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNALS; MYOBLAST DIFFERENTIATION; SOMATIC HYPERMUTATION; CELL-GROWTH; PROTEINS; LOCALIZATION; DEAMINASE; PHOSPHORYLATION; DEGRADATION; INHIBITION	Id proteins function as negative regulators for basic helix-loop-helix transcriptional factors that play important roles in cell fate determination. They preferentially associate with ubiquitously expressed E proteins of the basic helix-loop-helix family and prevent them from binding to DNA and activating transcription. Although their small size suggests that Id proteins enter and exit the nucleus by passive diffusion, several studies have indicated that other pathways may regulate their subcellular localization. In this study, we obtained evidence that Id2 has the ability to shuttle between the nucleus and the cytoplasm. When passive diffusion was prevented by fusion with green fluorescent protein (GFP), Id2 was predominantly localized in the cytoplasm. Using GFP fusion constructs, we demonstrated that the C-ter-minal region is required for cytoplasmic localization. Nuclear accumulation of GFP-Id2 in cells treated with the nuclear export inhibitor leptomycin B suggests that the nuclear export receptor chromosome region maintenance protein 1 mediates the cytoplasmic localization of Id2. Id2 contains two putative leucine-rich nuclear export signals, and the nuclear export signal in the C-terminal region is essential for nuclear export. On the other hand, the helix-loop-helix domain is important for nuclear localization. Finally, experiments using reporter assays revealed an inverse correlation between nuclear export and transcriptional repression via the E-box sequence. Based on all these findings, we propose that nucleo-cytoplasmic shuttling is a novel mechanism for the regulation of Id2 function.	Univ Fukui, Sch Med, Dept Mol Genet, Fukui 9101193, Japan	University of Fukui	Yokota, Y (corresponding author), Univ Fukui, Sch Med, Dept Mol Genet, 23-3 Shimoaizuki, Fukui 9101193, Japan.	yyokota@fmsrsa.fukui-med.ac.jp						AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Brar SS, 2004, J BIOL CHEM, V279, P26395, DOI 10.1074/jbc.M403503200; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; FISHER U, 1995, CELL, V82, P475; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Fong S, 2004, TRENDS MOL MED, V10, P387, DOI 10.1016/j.molmed.2004.06.008; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Ghil SH, 2002, EXP MOL MED, V34, P367, DOI 10.1038/emm.2002.52; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HOOD JK, 2000, BIOCHIM BIOPHYS ACTA, V1471, P31; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Kilstrup-Nielsen C, 2003, EMBO J, V22, P89, DOI 10.1093/emboj/cdg010; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2004, J EXP MED, V199, P1235, DOI 10.1084/jem.20040373; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; O'Toole PJ, 2003, J BIOL CHEM, V278, P45770, DOI 10.1074/jbc.M306056200; Okazaki I, 2003, ANN NY ACAD SCI, V987, P1, DOI 10.1111/j.1749-6632.2003.tb06027.x; Rodriguez JA, 2003, BIOCHEM J, V373, P251, DOI 10.1042/BJ20030289; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Tu X, 2003, EXP CELL RES, V288, P119, DOI 10.1016/S0014-4827(03)00178-2; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; WEN W, 1995, CELL, V82, P464; Wibley J, 1996, BBA-PROTEIN STRUCT M, V1294, P138, DOI 10.1016/0167-4838(96)00008-8; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Yun K, 2004, DEVELOPMENT, V131, P5441, DOI 10.1242/dev.01430; ZHANG H, 1995, MECH DEVELOP, V50, P119, DOI 10.1016/0925-4773(94)00329-L	53	57	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4313	4320		10.1074/jbc.M412614200	http://dx.doi.org/10.1074/jbc.M412614200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563451	hybrid			2022-12-25	WOS:000227096600040
J	Mouillet-Richard, S; Pietri, M; Schneider, B; Vidal, C; Mutel, V; Launay, JM; Kellermann, O				Mouillet-Richard, S; Pietri, M; Schneider, B; Vidal, C; Mutel, V; Launay, JM; Kellermann, O			Modulation of serotonergic receptor signaling and cross-talk by prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-INFECTED RATS; CELL-LINE; PHOSPHOLIPASE-C; 5-HT RECEPTORS; 2B RECEPTOR; DIFFERENTIATION; BRAIN; TRANSDUCTION; PHARMACOLOGY; INVOLVEMENT	The inducible serotonergic 1C11(5-HT) cell line expresses a defined set of serotonergic receptors of the 5-HT2B, 5-HT1B/D, and 5-HT2A subtypes, which sustain a regulation of serotonergic associated functions through G-protein-dependent signaling. 1C11(5-HT) cells have been instrumental to assign a signaling function to the cellular prion protein PrPC. Here, we establish that antibody-mediated ligation of PrPC concomitant to agonist stimulation of 5-HT receptors modulates the couplings of all three serotonergic receptors present on 1C11(5-HT) cells. Specific impacts of PrP antibodies were monitored depending on the receptor and pathway considered. PrPC ligation selectively cancels the 5-HT2A-PLC response, decreases the 5-HT1B/D negative coupling to adenylate cyclase, and potentiates the 5-HT2B-PLA2 coupling. As a result, PrPC ligation disturbs the functional interactions occurring between the signaling pathways of the three receptor subtypes. In 1C11(5-HT) cells, antagonizing cross-talks arising from 5-HT2B and 5-HT2A receptors control the 5-HT1B/D function. PrPC ligation reinforces the negative regulation exerted by 5-HT2B on 5-HT1B/D receptors. On the other hand it abrogates the blocking action of 5-HT2A on the regulatory loop linking 5-HT2B and 5-HT1B/D receptors. We propose that the ligation of PrPC affects the potency or dynamics of G-protein activation by agonist-bound serotonergic receptors. Finally, the PrPC-dependent modulation of 5-HT receptor couplings is restricted to 1C11(5-HT) cells expressing a complete serotonergic phenotype. It critically involves a PrPC-caveolin platform implemented on the neurites of 1C11(5-HT) cells during differentiation. Our findings define PrPC as a modulator of 5-HT receptor coupling to G-proteins and thereby as a protagonist contributing to the homeostasis of serotonergic neurons. They provide a foundation for uncovering the impact of prion infection on serotonergic functions.	Inst Andre Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France; Inst Pasteur, Dept Biol Cellulaire & Infect, F-75724 Paris 15, France; Commissariat Energie Atom, Serv Neurovirol, F-92265 Fontenay Aux Roses, France; F Hoffmann La Roche Ltd, Pharma Res Dept, CH-4070 Basel, Switzerland; Hop Lariboisiere, Serv Biochem, IFR6, F-75009 Paris, France; Fac Pharm Paris 5, EA3621, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Mouillet-Richard, S (corresponding author), Inst Andre Lwoff, CNRS, UPR 1983, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.	mouillet@vjf.cnrs.fr	Mouillet, Sophie/E-4960-2017; Schneider, Benoit/AAF-3850-2019	Mouillet, Sophie/0000-0002-8950-1949; Schneider, Benoit/0000-0002-1377-2670; PIETRI, Mathea/0000-0002-1819-2878				Azmitia EC, 1999, NEUROPSYCHOPHARMACOL, V21, pS33; BASSANT MH, 1984, BRAIN RES, V308, P182, DOI 10.1016/0006-8993(84)90934-X; BASSANT MH, 1986, BRAIN RES, V367, P360, DOI 10.1016/0006-8993(86)91619-7; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Chakraborti S, 2003, CELL SIGNAL, V15, P637, DOI 10.1016/S0898-6568(02)00144-4; COX DA, 1995, J PHARMACOL EXP THER, V272, P143; Cussac D, 2002, N-S ARCH PHARMACOL, V365, P242, DOI 10.1007/s00210-001-0505-y; ELLIS ES, 1995, BRIT J PHARMACOL, V114, P400, DOI 10.1111/j.1476-5381.1995.tb13240.x; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; HOYER D, 1994, PHARMACOL REV, V46, P157; Jerman JC, 2001, EUR J PHARMACOL, V414, P23, DOI 10.1016/S0014-2999(01)00775-0; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kellermann O, 2002, CR BIOL, V325, P9, DOI 10.1016/S1631-0691(02)01387-2; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Kurrasch-Orbaugh DM, 2003, J PHARMACOL EXP THER, V304, P229, DOI 10.1124/jpet.102.042184; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LORIC S, 1995, MOL PHARMACOL, V47, P458; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; Manivet P, 2002, J BIOL CHEM, V277, P17170, DOI 10.1074/jbc.M200195200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Mouillet-Richard S, 1999, MICROBES INFECT, V1, P969, DOI 10.1016/S1286-4579(99)80514-0; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751; Rohwer R G, 1981, Adv Exp Med Biol, V134, P375; ROHWER RG, 1981, BRAIN RES, V220, P367, DOI 10.1016/0006-8993(81)91227-0; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; Wanschitz J, 2000, ANN NEUROL, V48, P788, DOI 10.1002/1531-8249(200011)48:5<788::AID-ANA13>3.0.CO;2-5	36	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4592	4601		10.1074/jbc.M406199200	http://dx.doi.org/10.1074/jbc.M406199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590675	hybrid			2022-12-25	WOS:000227096600073
J	Schmoock, G; Pfennig, F; Jewiarz, J; Schlumbohm, W; Laubinger, W; Schauwecker, F; Keller, U				Schmoock, G; Pfennig, F; Jewiarz, J; Schlumbohm, W; Laubinger, W; Schauwecker, F; Keller, U			Functional cross-talk between fatty acid synthesis and nonribosomal peptide synthesis in quinoxaline antibiotic-producing streptomycetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; COMPLETE GENOME SEQUENCE; BACILLUS-SUBTILIS; GENE-CLUSTER; QUINOXALINE-2-CARBOXYLIC ACID; MOLECULAR CHARACTERIZATION; POLYKETIDE BIOSYNTHESIS; ADENYLATION DOMAINS; ACTIVATING ENZYME; COELICOLOR A3(2)	Quinoxaline antibiotics are chromopeptide lactones embracing the two families of triostins and quinomycins, each having characteristic sulfur-containing cross-bridges. Interest in these compounds stems from their antineoplastic activities and their specific binding to DNA via bifunctional intercalation of the twin chromophores represented by quinoxaline-2-carboxylic acid (QA). Enzymatic analysis of triostin A-producing Streptomyces triostinicus and quinomycin A-producing Streptomyces echinatus revealed four nonribosomal peptide synthetase modules for the assembly of the quinoxalinoyl tetrapeptide backbone of the quinoxaline antibiotics. The modules were contained in three protein fractions, referred to as triostin synthetases (TrsII, III, and IV). TrsII is a 245-kDa bimodular nonribosomal peptide synthetase activating as thioesters for both serine and alanine, the first two amino acids of the quinoxalinoyl tetrapeptide chain. TrsIII, represented by a protein of 250 kDa, activates cysteine as a thioester. TrsIV, an unstable protein of apparent M-r about 280,000, was identified by its ability to activate and N-methylate valine, the last amino acid. QA, the chromophore, was shown to be recruited by a freestanding adenylation domain, TrsI, in conjunction with a QA-binding protein, AcpPSE. Cloning of the gene for the QA-binding protein revealed that it is the fatty acyl carrier protein, AcpPSE, of the fatty acid synthase of S. echinatus and S. triostinicus. Analysis of the acylation reaction of AcpPSE by TrsI along with other A-domains and the aroyl carrier protein AcmACP from actinomycin biosynthesis revealed a specific requirement for AcpPSE in the activation and also in the condensation of QA with serine in the initiation step of QA tetrapeptide assembly on TrsII. These data show for the first time a functional interaction between nonribosomal peptide synthesis and fatty acid synthesis.	Tech Univ Berlin, Inst Chem Arbeitsgr Biochem & Mol Biol, D-10587 Berlin, Germany	Technical University of Berlin	Keller, U (corresponding author), Tech Univ Berlin, Inst Chem Arbeitsgr Biochem & Mol Biol, Franklinstr 29, D-10587 Berlin, Germany.	ullrich.keller@tu-berlin.de						Bailly C, 2000, NUCLEOS NUCLEOT NUCL, V19, P1337, DOI 10.1080/15257770008033056; Bearden SW, 1997, INFECT IMMUN, V65, P1659, DOI 10.1128/IAI.65.5.1659-1668.1997; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; CORBAZ R, 1957, HELV CHIM ACTA, V40, P199, DOI 10.1002/hlca.19570400124; CORNISH A, 1983, ANTIMICROB AGENTS CH, V23, P221, DOI 10.1128/AAC.23.2.221; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; deCrecyLagard V, 1997, J BACTERIOL, V179, P705, DOI 10.1128/jb.179.3.705-713.1997; DELL A, 1975, J AM CHEM SOC, V97, P2497, DOI 10.1021/ja00842a029; Doekel S, 2000, CHEM BIOL, V7, P373, DOI 10.1016/S1074-5521(00)00118-6; Dreier J, 1999, J BIOL CHEM, V274, P25108, DOI 10.1074/jbc.274.35.25108; Finking R, 2004, BIOCHEMISTRY-US, V43, P8946, DOI 10.1021/bi0496891; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Florova G, 2002, BIOCHEMISTRY-US, V41, P10462, DOI 10.1021/bi0258804; GAUVREAU D, 1984, CAN J MICROBIOL, V30, P439, DOI 10.1139/m84-065; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; GLUND K, 1990, BIOCHEMISTRY-US, V29, P3522, DOI 10.1021/bi00466a015; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; Ikeda H, 2003, NAT BIOTECHNOL, V21, P526, DOI 10.1038/nbt820; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; Keller U, 2001, PROG NUCLEIC ACID RE, V70, P233, DOI 10.1016/S0079-6603(01)70019-0; KELLER U, 1995, GENETICS BIOCH ANTIB, P71; KHOSLA C, 1992, MOL MICROBIOL, V6, P3237, DOI 10.1111/j.1365-2958.1992.tb01778.x; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; KONISHI M, 1981, J AM CHEM SOC, V103, P1241, DOI 10.1021/ja00395a054; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marshall CG, 2002, BIOCHEMISTRY-US, V41, P8429, DOI 10.1021/bi0202575; MATSON JA, 1993, J ANTIBIOT, V46, P162, DOI 10.7164/antibiotics.46.162; May LG, 2004, NUCLEIC ACIDS RES, V32, P65, DOI 10.1093/nar/gkh166; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; OKUMURA Y, 1983, BIOCH GENETIC REGULA, P147; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Pfennig F, 1999, J BIOL CHEM, V274, P12508, DOI 10.1074/jbc.274.18.12508; PFENNIG F, 1998, THESIS TU BERLIN BER; PHILLIPS DR, 1990, ANTI-CANCER DRUG DES, V5, P21; Revill WP, 1996, J BACTERIOL, V178, P5660, DOI 10.1128/jb.178.19.5660-5667.1996; Rowland BM, 1996, GENE, V178, P119, DOI 10.1016/0378-1119(96)00349-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schauwecker F, 1998, J BACTERIOL, V180, P2468, DOI 10.1128/JB.180.9.2468-2474.1998; Schauwecker F, 2000, CHEM BIOL, V7, P287, DOI 10.1016/S1074-5521(00)00103-4; SCHLUMBOHM W, 1990, J BIOL CHEM, V265, P2156; SHOJI J, 1961, J ANTIBIOT, V14, P335; STAAB JF, 1989, FEMS MICROBIOL LETT, V59, P15; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; Steffensky M, 2000, ANTIMICROB AGENTS CH, V44, P1214, DOI 10.1128/AAC.44.5.1214-1222.2000; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; STINDL A, 1994, BIOCHEMISTRY-US, V33, P9358, DOI 10.1021/bi00197a041; STINDL A, 1993, THESIS TU BERLIN BER; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; UGHETTO G, 1985, NUCLEIC ACIDS RES, V13, P2305, DOI 10.1093/nar/13.7.2305; WARING MJ, 1974, NATURE, V252, P653, DOI 10.1038/252653a0; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; YOSHIDA T, 1969, BIOCHEMISTRY-US, V8, P2645, DOI 10.1021/bi00834a059; YOSHIDA T, 1961, J ANTIBIOT, V14, P330; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	60	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4339	4349		10.1074/jbc.M411026200	http://dx.doi.org/10.1074/jbc.M411026200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569690	hybrid			2022-12-25	WOS:000227096600043
J	Waterhouse, NJ; Sedelies, KA; Browne, KA; Wowk, ME; Newbold, A; Sutton, VR; Clarke, CJP; Oliaro, J; Lindemann, RK; Bird, PI; Johnstone, RW; Trapani, JA				Waterhouse, NJ; Sedelies, KA; Browne, KA; Wowk, ME; Newbold, A; Sutton, VR; Clarke, CJP; Oliaro, J; Lindemann, RK; Bird, PI; Johnstone, RW; Trapani, JA			A central role for bid in granzyme B-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CYTOKINE RESPONSE MODIFIER; MEDIATED CELL-DEATH; CASPASE ACTIVATION; CYTOTOXIC LYMPHOCYTES; T-CELLS; MITOCHONDRIA; BCL-2; PERFORIN; PATHWAY	Granzyme B, a protease released from cytotoxic lymphocytes, has been proposed to induce target cell death by cleaving and activating the pro-apoptotic Bcl-2 family member Bid. It has also been proposed that granzyme B can induce target cell death by activating caspases directly, by cleaving caspase substrates, and/or by cleaving several non-caspase substrates. The relative importance of Bid in granzyme B-induced cell death has therefore remained unclear. Here we report that cells isolated from various tissues of Bid-deficient mice were resistant to granzyme B-induced cell death. Consistent with the proposed role of Bid in regulating mitochondrial outer membrane permeabilization, cytochrome c remained in the mitochondria of Bid-deficient cells treated with granzyme B. Unlike wild type cells, Bid-deficient cells survived and were then able to proliferate normally, demonstrating the critical role for Bid in mediating granzyme B-induced apoptosis.	Peter MacCallum Canc Ctr, Immune Signaling Labs, Canc Immunol Program, Melbourne, Vic 8006, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Peter Maccallum Cancer Center; Monash University	Waterhouse, NJ (corresponding author), Peter MacCallum Canc Ctr, Immune Signaling Labs, Canc Immunol Program, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	nigel.waterhouse@petermac.org; joe.trapani@petermac.org	Waterhouse, Nigel/I-9813-2016; Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532; Oliaro, Jane/0000-0002-2097-6428; Bird, Phillip/0000-0002-6695-606X				Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Andrade F, 2001, IMMUNITY, V14, P751, DOI 10.1016/S1074-7613(01)00149-2; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Davis JE, 2000, CELL DEATH DIFFER, V7, P973, DOI 10.1038/sj.cdd.4400725; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kelso A, 2002, INT IMMUNOL, V14, P605, DOI 10.1093/intimm/dxf028; Kienzle N, 2004, IMMUNOL CELL BIOL, V82, P75, DOI 10.1111/j.1440-1711.2004.01210.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu CC, 1996, J IMMUNOL, V156, P3292; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Sutton VR, 1997, J IMMUNOL, V158, P5783; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	31	105	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4476	4482		10.1074/jbc.M410985200	http://dx.doi.org/10.1074/jbc.M410985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574417	hybrid			2022-12-25	WOS:000227096600059
J	Patzke, S; Hauge, H; Sioud, M; Finne, EF; Sivertsen, EA; Delabie, J; Stokke, T; Hans-Christian, A				Patzke, S; Hauge, H; Sioud, M; Finne, EF; Sivertsen, EA; Delabie, J; Stokke, T; Hans-Christian, A			Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization	ONCOGENE			English	Article						centrosome; MAP; mitosis; mitotic spindle; cell; cycle arrest; RNA interference	DNA-REPLICATION; ETHIDIUM-BROMIDE; MITOTIC SPINDLE; KEN BOX; S-PHASE; CENTROSOME; CHECKPOINT; CYTOKINESIS; PHOSPHORYLATION; SIMIAN-VIRUS-40	Here we describe the identication of a novel vertebrate-specific centrosome/spindle pole-associated protein (CSPP) involved in cell-cycle regulation. The protein is predicted to have a tripartite domain structure, where the N- and C-terminal domains are linked through a coiled-coil mid-domain. Experimental analysis of the identified domains revealed that spindle association is dependent on the N- terminal and the coiled-coil mid domain. The expression of CSPP at the mRNA level was detected in all tested cell lines and in testis tissue. Ectopic expression of CSPP in HEK293T cells blocked cell-cycle progression in early G(1) phase and in mitosis in a dose-dependent manner. Interestingly, mitosis-arrested cells contained aberrant spindles and showed impairment of chromosome congression. Inhibition of CSPP gene expression by small interfering RNAs induced cell-cycle arrest/delay in S phase. This phenotype was characterized by elevated levels of cyclin A, decreased levels of cyclin E and hyperphosphorylation of the S-phase checkpoint kinase Chk1. The activation of Chk1 may indicate a replication stress response due to an inappropriate G(1)/S-phase transition. Taken together, we demonstrate that CSPP is associated with centrosomes and microtubules and may play a role in the regulation of G(1)/S-phase progression and spindle assembly.	Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Radiat Biol, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Hans-Christian, A (corresponding author), Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway.	h.c.asheim@labmed.uio.no	Patzke, Sebastian/G-9909-2019	Patzke, Sebastian/0000-0001-6821-197X; Delabie, Jan/0000-0001-5023-0689; Sivertsen, Einar Andreas/0000-0003-0591-3653				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Balczon R, 2002, CELL MOTIL CYTOSKEL, V52, P183, DOI 10.1002/cm.10043; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOHMER RM, 1981, CYTOMETRY, V2, P31, DOI 10.1002/cyto.990020107; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clay-Farrace L, 2003, EMBO J, V22, P704, DOI 10.1093/emboj/cdg046; Delattre M, 2004, J CELL SCI, V117, P1619, DOI 10.1242/jcs.01128; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Gromley A, 2003, J CELL BIOL, V161, P535, DOI 10.1083/jcb.200301105; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; Leirdal M, 2002, BIOCHEM BIOPH RES CO, V295, P744, DOI 10.1016/S0006-291X(02)00736-2; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Odeberg J, 2000, BIOMOL ENG, V17, P1, DOI 10.1016/S1389-0344(00)00057-5; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Patzke S, 2002, VIROLOGY, V303, P164, DOI 10.1006/viro.2002.1615; Pfleger CM, 2000, GENE DEV, V14, P655; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	59	39	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1159	1173		10.1038/sj.onc.1208267	http://dx.doi.org/10.1038/sj.onc.1208267			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580290				2022-12-25	WOS:000226898700004
J	Langford, JK; Yang, Y; Kieber-Emmons, T; Sanderson, RD				Langford, JK; Yang, Y; Kieber-Emmons, T; Sanderson, RD			Identification of an invasion regulatory domain within the core protein of syndecan-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; EPITHELIAL-CELLS; EXPRESSION; ADHESION; BINDING; AFFINITY; SURFACE; CHAINS	Among the four members of the syndecan family there exists a high level of divergence in the ectodomain core protein sequence. This has led to speculation that these core proteins bear important functional domains. However, there is little information regarding these functions, and thus far, the biological activity of syndecans has been attributed largely to their heparan sulfate chains. We have previously demonstrated that cell surface syndecan-1 inhibits invasion of tumor cells into three-dimensional gels composed of type I collagen. Inhibition of invasion is dependent on the syndecan heparan sulfate chains, but a role for the syndecan-1 ectodomain core protein was also indicated. To more closely examine this possibility and to map the regions of the ectodomain essential for syndecan-l-mediated inhibition of invasion, a panel of syndecan-1 mutational constructs was generated, and each construct was transfected individually into myeloma tumor cells. The anti-invasive effect of syndecan-1 is dramatically reduced by deletion of an ectodomain region close to the plasma membrane. Further mutational analysis identified a stretch of 5 hydrophobic amino acids, AVAAV (amino acids 222-226); critical for syndecan-1-mediated inhibition of cell invasion. This invasion regulatory domain is 26 amino acids from the start of the transmembrane domain. Importantly, this domain is functionally specific because its mutation does not affect syndecan-1-mediated cell binding to collagen, syndecan-1-mediated cell spreading, or targeting of syndecan-1 to specific cell surface domains. This invasion regulatory domain may play an important role in inhibiting tumor cell invasion, thus explaining the observed loss of syndecan-1 in some highly invasive cancers.	Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Pathol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Sanderson, RD (corresponding author), Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Pathol, 4301 W Markham St, Little Rock, AR 72205 USA.	RDSanderson@uams.edu			NATIONAL CANCER INSTITUTE [R01CA068494] Funding Source: NIH RePORTER; NCI NIH HHS [CA68494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; Anttonen A, 2001, LUNG CANCER, V32, P297, DOI 10.1016/S0169-5002(00)00230-0; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Borset M, 2000, BLOOD, V96, P2528; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; Langford JK, 2002, METHOD CELL BIOL, V69, P297, DOI 10.1016/S0091-679X(02)69019-3; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MALI M, 1990, J BIOL CHEM, V265, P6884; McFall AJ, 1997, J BIOL CHEM, V272, P12901, DOI 10.1074/jbc.272.20.12901; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Yang Y, 2003, J BIOL CHEM, V278, P12888, DOI 10.1074/jbc.M209440200; Zako M, 2003, J BIOL CHEM, V278, P13561, DOI 10.1074/jbc.M209658200	28	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3467	3473		10.1074/jbc.M412451200	http://dx.doi.org/10.1074/jbc.M412451200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15563454	hybrid			2022-12-25	WOS:000226983900042
J	Kanzawa, T; Zhang, L; Xiao, LC; Germano, IM; Kondo, Y; Kondo, S				Kanzawa, T; Zhang, L; Xiao, LC; Germano, IM; Kondo, Y; Kondo, S			Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3	ONCOGENE			English	Article						arsenic trioxide; autophagy; BNIP3; glioma; LC3	ACUTE PROMYELOCYTIC LEUKEMIA; INDUCED CYTOTOXICITY; GROWTH-FACTOR; APOPTOSIS; EXPRESSION; INDUCTION; HYPOXIA; LINES; GENE; MODULATION	Arsenic trioxide (As2O3) has shown considerable efficacy in treating hematological malignancies with induction of programmed cell death (PCD) type I, apoptosis. However, the mechanisms underlying the antitumor effect of As2O3 on solid tumors are poorly defined. Previously, we reported that As2O3 induced autophagic cell death (PCD type II) but not apoptosis in human malignant glioma cell lines. The purpose of this study was to elucidate the molecular pathway leading to autophagic cell death. In this study, we demonstrated that the cell death was accompanied by involvement of autophagy-specific marker, microtubule-associated protein light chain 3 (LC3), and damage of mitochondrial membrane integrity, but not by caspase activation. Analysis by cDNA microarray, RT-PCR, and Western blot showed that cell death members of Bcl-2 family, Bcl-2/adenovirus E1B 19-kDa- interacting protein 3 (BNIP3) and its homologue BNIP3-like (BNIP3L), were upregulated in As2O3-induced autophagic cell death. Exogenous expression of BNIP3, but not BNIP3L, induced autophagic cell death in malignant glioma cells without As2O3 treatment. When upregulation of BNIP3 induced by As2O3 was suppressed by a dominant-negative effect of the transmembrane-deleted BNIP3 (BNIP3DTM), autophagic cell death was inhibited. In contrast, BNIP3 transfection augmented As2O3-induced autophagic cell death. These results suggest that BNIP3 plays a central role in As2O3-induced autophagic cell death in malignant glioma cells. This study adds a new concept to characterize the pathways by which As2O3 acts to induce autophagic cell death in malignant glioma cells.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 64, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10510 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Icahn School of Medicine at Mount Sinai	Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 64, 1515 Holcombe Blvd, Houston, TX 77030 USA.	seikondo@mdanderson.org	germano, isabelle m/J-8327-2017	germano, isabelle m/0000-0002-3992-373X; KANZAWA, TAKAO/0000-0002-8165-5652; Zhang, Li/0000-0003-0517-7860	NATIONAL CANCER INSTITUTE [R01CA088936] Funding Source: NIH RePORTER; NCI NIH HHS [CA88936, CA106310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akao Y, 1999, FEBS LETT, V455, P59, DOI 10.1016/S0014-5793(99)00841-8; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brandes A A, 2001, Expert Rev Anticancer Ther, V1, P357, DOI 10.1586/14737140.1.3.357; Burton E C, 2000, Curr Treat Options Oncol, V1, P459, DOI 10.1007/s11864-000-0073-2; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen GQ, 1996, BLOOD, V88, P1052; Clifford JL, 2003, MOL CANCER THER, V2, P453; Cohen I, 2002, TRENDS CELL BIOL, V12, P293, DOI 10.1016/S0962-8924(02)02299-7; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hunter M, 2003, HUM MUTAT, V22, P129, DOI 10.1002/humu.10240; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Ishitsuka K, 2002, LEUKEMIA LYMPHOMA, V43, P1107, DOI 10.1080/10428190290021461; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kitamuro T, 2000, J NEUROCHEM, V75, P1826, DOI 10.1046/j.1471-4159.2000.0751826.x; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KONDO S, 1995, CANCER RES, V55, P6166; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liau LM, 2000, CANCER RES, V60, P1353; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Maeda H, 2001, CANCER RES, V61, P5432; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; Miller WH, 2002, ONCOLOGIST, V7, P14; Miller WH, 2002, CANCER RES, V62, P3893; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sowter HM, 2001, CANCER RES, V61, P6669; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Terzis AJ, 1997, BRIT J CANCER, V75, P1744, DOI 10.1038/bjc.1997.298; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zhang L, 2003, NAT BIOTECHNOL, V21, P818, DOI 10.1038/nbt836; Zheng XH, 2003, TOXICOLOGY, V187, P39, DOI 10.1016/S0300-483X(03)00025-8; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	56	333	348	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					980	991		10.1038/sj.onc.1208095	http://dx.doi.org/10.1038/sj.onc.1208095			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592527				2022-12-25	WOS:000226749200004
J	Wasylyk, C; Criqui-Filipe, P; Wasylyk, B				Wasylyk, C; Criqui-Filipe, P; Wasylyk, B			Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net	ONCOGENE			English	Article						Ubc9; E3 ligase; ternary complex factor; Elk-3; Sap-2; Erp	UBIQUITIN-CONJUGATING ENZYME; ACTIVATED STAT; ANDROGEN RECEPTOR; PROTEIN INHIBITOR; SUMO MODIFICATION; FAMILY PROTEINS; FOS PROMOTER; NUCLEAR; REPRESSION; BINDING	Net (Elk-3, Sap-2, Erp) and the related ternary complex factors Elk-1 and Sap-1 are effectors of multiple signalling pathways at the transcriptional level and play a key role in the dynamic regulation of gene expression. Net is distinct from Elk-1 and Sap-1, in that it is a strong repressor of transcription that is converted to an activator by the Ras/Erk signalling pathway. Two autonomous repression domains of Net, the NID and the CID, mediate repression. We have previously shown that the corepressor CtBP is implicated in repression by the CID. In this report we show that repression by the NID involves a different pathway, sumoylation by Ubc9 and PIAS1. PIAS1 interacts with the NID in the two-hybrid assay and in vitro. Ubc9 and PIAS1 stimulate sumoylation in vivo of lysine 162 in the NID. Sumoylation of lysine 162 increases repression by Net and decreases the positive activity of Net. These results increase our understanding of how one of the ternary complex factors regulates transcription, and contribute to the understanding of how different domains of a transcription factor participate in the complexity of regulation of gene expression.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sharrocks AD, 2002, BIOCHEM SOC T, V30, P1; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	43	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					820	828		10.1038/sj.onc.1208226	http://dx.doi.org/10.1038/sj.onc.1208226			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580297				2022-12-25	WOS:000226577100008
J	Boulanger, CA; Wagner, KU; Smith, GH				Boulanger, CA; Wagner, KU; Smith, GH			Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta 1 expression	ONCOGENE			English	Article						mammary; transplantation; stem cells; TGF-beta 1; cell fate; pregnancy	GLAND; DIFFERENTIATION; CARCINOGENESIS; MORPHOGENESIS; POPULATION; SENESCENCE; PREGNANCY	A parity-induced mammary population, marked by beta-galactosidase expression conditionally activated through cre-lox recombinase originates in WAP-Cre/Rosa-lox-STOP- lox-LacZ (WAP-Cre/Rosa-LacZ) female mice during pregnancy, lactation and involution. During subsequent pregnancies, these parity-induced mammary epithelial cells (PI-MEC) proliferated to produce new secretory acini composed of secretory luminal cells and myoepithelium. In serial transplantation assays, PI-MEC were able to self-renew over several transplant generations and to contribute significantly to the resulting mammary outgrowths. In limiting dilution transplantation, they proliferated to produce both luminal and myoepithelial cells, comprised both lobule-limited and duct-limited epithelial outgrowths, and differentiated into all the cellular subtypes recognized in murine mammary epithelium. TGF-beta1 expression from the whey acidic protein promoter (WAP) in triply transgenic females did not prevent the appearance of PI-MEC after pregnancy despite the absence of full lactation or their ability to proliferate and produce progeny with diverse cellular fates in situ upon subsequent pregnancies. However, in transplants from triple transgenic parous females, the WAP-TGF-beta1-positive PI-MEC did not contribute to the newly recapitulated mammary outgrowths, suggesting that they were incapable of expansive cellular proliferation (self-renewal). This result is consistent with our earlier publication that WAP-TGF-beta1 expression in mammary epithelium induces premature stem cell senescence in mammary transplants and decreases mammary cancer risk in mouse mammary tumor virus (MMTV)-infected females even after multiple pregnancies.	NCI, Mammary Biol & Tumorigenesis Lab, Bethesda, MD 20892 USA; Univ Nebraska, Sch Med, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System	Smith, GH (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Bldg 10,Room 5B56,9000 Rockville Pike, Bethesda, MD 20892 USA.	gs4d@nih.gov	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [Z01BC010021, ZIABC010021] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; DEOME KB, 1978, CANCER RES, V38, P2103; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Robinson GW, 1996, DEV DYNAM, V206, P159, DOI 10.1002/(SICI)1097-0177(199606)206:2<159::AID-AJA5>3.0.CO;2-H; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; SMITH GH, 1991, J VIROL, V65, P6365, DOI 10.1128/JVI.65.11.6365-6370.1991; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6	19	154	156	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					552	560		10.1038/sj.onc.1208185	http://dx.doi.org/10.1038/sj.onc.1208185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580303	Bronze			2022-12-25	WOS:000226420400003
J	Sorli, SC; Bunney, TD; Sugden, PH; Paterson, HF; Katan, M				Sorli, SC; Bunney, TD; Sugden, PH; Paterson, HF; Katan, M			Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants	ONCOGENE			English	Article						phosphoinositide-specificc phospholipase C epsilon; splice variants; Ras; colorectal tumors; epigenetic silencing	HUMAN CANCERS; RAS EFFECTOR; CYCLIC-AMP; ACTIVATION; GENE; SUPPRESSOR; PROTEIN; PATHWAYS; PLC; PHOSPHORYLATION	Phospholipase Cepsilon (PLCepsilon) is a novel member of phosphoinositide-specific phospholipase C enzymes with a unique regulatory link to Ras GTP-ases. In the present studies, we establish existence of two splice variants (PLCepsilon1a and PLCepsilon1b) derived from human PLCepsilon1 gene. When expressed in COS or HEK293 cells, PLCepsilon1a and PLCepsilon1b have similar potential to be stimulated by diverse signaling pathways via tyrosine kinase and G-protein coupled receptors and share the ability to function as an effector of Ras. The expression pattern shows broader mRNA expression of PLCepsilon1a in normal tissues; furthermore, in most cell lines expressing PLCepsilon, PLCepsilon1a is the only splice variant present. Analysis of normal/tumor matched pairs derived from colon and rectum demonstrates greatly reduced expression levels in tumor tissues. Further studies in a colorectal tumor cell line lacking PLCepsilon show restoration of transcription of PLCepsilon1a and PLCepsilon1b by demethylating agent 5-aza-2'-deoxycytidine, suggesting epigenetic silencing through hypermethylation. In addition, expression of exogenous PLCepsilon in this cell line demonstrates inhibitory effects of PLCepsilon on cell viability and proliferation. Taken together, our findings suggest that regulatory mechanisms controlling expression of PLCepsilon, broadened by diversity introduced by splice variants, could play important role in PLCepsilon regulation in normal and tumor cells.	Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, London SW7 2AZ, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Katan, M (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, Fulham Rd, London SW3 6JB, England.	matilda@icr.ac.uk		Bunney, Tom/0000-0002-0281-8813				ALVAREZ RA, 1995, GENOMICS, V29, P53, DOI 10.1006/geno.1995.1214; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Wells A, 2000, ADV CANCER RES, V78, P31; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Wu DM, 2003, EUR J NEUROSCI, V17, P1571, DOI 10.1046/j.1460-9568.2003.02591.x	35	48	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					90	100		10.1038/sj.onc.1208168	http://dx.doi.org/10.1038/sj.onc.1208168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558028				2022-12-25	WOS:000226125800011
J	Hermann, VM; Cutfield, JF; Hubbard, MJ				Hermann, VM; Cutfield, JF; Hubbard, MJ			Biophysical characterization of ERp29 - Evidence for a key structural role of cysteine 125	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM PROTEIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONES; LUMENAL PROTEIN; BINDING DOMAIN; ER CHAPERONE; ENAMEL CELLS; RAT-LIVER; RESIDENT	ERp29 is a major resident of the endoplasmic reticulum (ER) that seemingly plays an important role in most animal cells. Although a protein-folding association is widely supported, ERp29's specific molecular function remains unknown. A chaperone activity was postulated from evidence that ERp29 forms multimers like the classical ER chaperones, but conflicting results have emerged from our recent studies. Here a biophysical approach was used to clarify this issue and also reveal a key structural role for ERp29's characteristic cysteine, Cys-125. Applying hydrodynamic parameters derived from sedimentation and dynamic light-scattering analyses, a model of ERp29's quaternary structure was assembled from existing tertiary substructures. Comparison with Windbeutel, an ERp29-like protein from fruit fly with specialized chaperone activity, revealed similar tri-lobar gross structures but some finer differences consistent with functional divergence. Solubility and hydrophobic probe assays revealed moderate surface hydrophobicity, which was reduced in mutant ERp29 in which serine replaced Cys-125. This mutant was also relatively labile to proteolytic degradation, providing two reasons for the strict conservation of Cys-125. No multimerization was observed with untagged ERp29, which existed as tight homodimers (K-d < 50 nM), whereas His-tagged ERp29 artifactually formed 670-kDa oligomers. These findings distinguish ERp29 biophysically from its peers in the ER including Windbeutel, endorsing our postulate that ERp29 adds a distinct type of folding activity to the ER machinery. By invoking novel functional associations for Cys-125 and the adjoining linker, new clues about how ERp29 might work have also arisen.	Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Melbourne, Dept Paediat, Melbourne, Vic 3052, Australia; Univ Melbourne, Sch Dent Sci, Melbourne, Vic 3052, Australia	University of Otago; University of Melbourne; University of Melbourne	Hubbard, MJ (corresponding author), Royal Childrens Hosp, Dept Paediat, Flemington Rd, Melbourne, Vic 3052, Australia.	mike.hubbard@unimelb.edu.au	Hubbard, Mike (Michael) J/AAE-6573-2022	Hubbard, Mike (Michael) J/0000-0002-5432-9421				Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Araujo APU, 2000, BIOCHEM BIOPH RES CO, V272, P480, DOI 10.1006/bbrc.2000.2802; Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; Atcliffe BW, 2001, EUR J BIOCHEM, V268, P2838, DOI 10.1046/j.1432-1327.2001.02164.x; Barnewitz K, 2004, J BIOL CHEM, V279, P39829, DOI 10.1074/jbc.M406839200; Baryshev M, 2004, J MOL ENDOCRINOL, V32, P903, DOI 10.1677/jme.0.0320903; Bertini I, 2004, P NATL ACAD SCI USA, V101, P6841, DOI 10.1073/pnas.0308641101; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Chevalier M, 1998, J BIOL CHEM, V273, P26827, DOI 10.1074/jbc.273.41.26827; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Demmer J, 1997, FEBS LETT, V402, P145, DOI 10.1016/S0014-5793(96)01513-X; Durchschlag H, 2003, EUR BIOPHYS J BIOPHY, V32, P487, DOI 10.1007/s00249-003-0293-z; EDSALL JT, 1953, PROTEINS, P549; Eisenberg E, 2003, TRENDS GENET, V19, P362, DOI 10.1016/S0168-9525(03)00140-9; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Fonda Irena, 2002, ScientificWorldJournal, V2, P1312; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Hubbard MJ, 2004, BIOCHEM J, V383, P589, DOI 10.1042/BJ20040983; Hubbard MJ, 2000, EUR J BIOCHEM, V267, P1945, DOI 10.1046/j.1432-1327.2000.01193.x; Hubbard MJ, 2002, PROTEOMICS, V2, P1069, DOI 10.1002/1615-9861(200209)2:9<1069::AID-PROT1069>3.0.CO;2-R; HUBBARD MJ, 1995, EUR J BIOCHEM, V230, P68, DOI 10.1111/j.1432-1033.1995.0068i.x; Hubbard MJ, 2000, ELECTROPHORESIS, V21, P3785, DOI 10.1002/1522-2683(200011)21:17<3785::AID-ELPS3785>3.0.CO;2-2; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; KOCH G, 1986, J CELL SCI, V86, P217; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEAVIS PC, 1974, ARCH BIOCHEM BIOPHYS, V161, P671, DOI 10.1016/0003-9861(74)90353-1; Li DY, 2004, BIOCHEM BIOPH RES CO, V318, P253, DOI 10.1016/j.bbrc.2004.04.022; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Linderoth NA, 2001, BIOCHEMISTRY-US, V40, P1483, DOI 10.1021/bi0016218; Ma QJ, 2003, J BIOL CHEM, V278, P44600, DOI 10.1074/jbc.M307966200; MacLeod JC, 2004, J COMP NEUROL, V477, P29, DOI 10.1002/cne.20222; MacRaild CA, 2003, BIOPHYS J, V84, P2562, DOI 10.1016/S0006-3495(03)75061-9; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; Martin J, 2004, TRENDS BIOCHEM SCI, V29, P455, DOI 10.1016/j.tibs.2004.07.004; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Mkrtchian S, 1998, EUR J BIOCHEM, V251, P304, DOI 10.1046/j.1432-1327.1998.2510304.x; Mkrtchiana S, 1998, FEBS LETT, V431, P322, DOI 10.1016/S0014-5793(98)00786-8; Nagano N, 1999, FEBS LETT, V458, P69, DOI 10.1016/S0014-5793(99)01122-9; Park Soojung, 2003, Korean Journal of Biological Sciences, V7, P265; Primm TP, 2001, J BIOL CHEM, V276, P281, DOI 10.1074/jbc.M007670200; Sargsyan E, 2002, J BIOL CHEM, V277, P17009, DOI 10.1074/jbc.M200539200; Sargsyan E, 2002, GENE, V285, P127, DOI 10.1016/S0378-1119(02)00417-1; Schonfeld HJ, 1998, METHOD ENZYMOL, V290, P269, DOI 10.1016/S0076-6879(98)90025-8; Sen J, 2000, DEVELOPMENT, V127, P5541; Shnyder SD, 2002, J HISTOCHEM CYTOCHEM, V50, P557, DOI 10.1177/002215540205000413; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; Vuillard L, 1998, EUR J BIOCHEM, V256, P128, DOI 10.1046/j.1432-1327.1998.2560128.x; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; YU XC, 1994, BBA-PROTEIN STRUCT M, V1207, P109, DOI 10.1016/0167-4838(94)90058-2	63	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13529	13537		10.1074/jbc.M410889200	http://dx.doi.org/10.1074/jbc.M410889200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15572350	hybrid			2022-12-25	WOS:000228095500044
J	Wheeler, PR; Coldham, NG; Keating, L; Gordon, SV; Wooff, EE; Parish, T; Hewinson, RG				Wheeler, PR; Coldham, NG; Keating, L; Gordon, SV; Wooff, EE; Parish, T; Hewinson, RG			Functional demonstration of reverse transsulfuration in the Mycobacterium tuberculosis complex reveals that methionine is the preferred sulfur source for pathogenic mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE GAMMA-LYASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; SACCHAROMYCES-CEREVISIAE; IN-VIVO; STREPTOMYCES-PHAEOCHROMOGENES; SALMONELLA-TYPHIMURIUM; AUXOTROPHIC MUTANTS; AMINO-ACIDS; BOVIS BCG; BIOSYNTHESIS	Methionine can be used as the sole sulfur source by the Mycobacterium tuberculosis complex although it is not obvious from examination of the genome annotation how these bacteria utilize methionine. Given that genome annotation is a largely predictive process, key challenges are to validate these predictions and to fill in gaps for known functions for which genes have not been annotated. We have addressed these issues by functional analysis of methionine metabolism. Transport, followed by metabolism of S-35 methionine into the cysteine adduct mycothiol, demonstrated the conversion of exogenous methionine to cysteine. Mutational analysis and cloning of the Rv1079 gene showed it to encode the key enzyme required for this conversion, cystathionine gamma-lyase (CGL). Rv1079, annotated metB, was predicted to encode cystathionine gamma-synthase (CGS), but demonstration of a gamma-elimination reaction with cystathionine as well as the gamma-replacement reaction yielding cystathionine showed it encodes a bifunctional CGL/CGS enzyme. Consistent with this, a Rv1079 mutant could not incorporate sulfur from methionine into cysteine, while a cysA mutant lacking sulfate transport and a methionine auxotroph was hypersensitive to the CGL inhibitor propargylglycine. Thus, reverse transsulfuration alone, without any sulfur recycling reactions, allows M. tuberculosis to use methionine as the sole sulfur source. Intracellular cysteine was undetectable so only the CGL reaction occurs in intact mycobacteria. Cysteine desulfhydrase, an activity we showed to be separable from CGL/CGS, may have a role in removing excess cysteine and could explain the ability of M. tuberculosis to recycle sulfur from cysteine, but not methionine.	Vet Labs Agcy, Tuberculosis Res Grp, Surrey KT15 3NB, England; Barts & London Queen Marys Sch Med & Dent, Ctr Infect Dis, London E1 2AA, England	Veterinary Laboratories Agency; University of London; Queen Mary University London	Wheeler, PR (corresponding author), Vet Labs Agcy, Tuberculosis Res Grp, Surrey KT15 3NB, England.	p.wheeler@vla.defra.gsi.gov.uk	Coldham, Nick/F-6151-2010; Hewinson, Glyn/J-1902-2014; Wheeler, Paul/C-6709-2011; Hewinson, Glyn/F-7077-2010; Hewinson, Glyn/AAA-2364-2019	Hewinson, Glyn/0000-0002-5517-4281; Gordon, Stephen/0000-0002-4833-5542				AYLING PD, 1979, J GEN MICROBIOL, V114, P227, DOI 10.1099/00221287-114-2-227; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DRAPER P, 1982, BIOL MYCOBACTERIA, V1, P9; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; Green ML, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-76; Hacham Y, 2003, MOL BIOL EVOL, V20, P1513, DOI 10.1093/molbev/msg169; Hwang BJ, 2002, J BACTERIOL, V184, P1277, DOI 10.1128/JB.184.5.1277-1286.2002; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JOHNSTON M, 1979, BIOCHEMISTRY-US, V18, P4690, DOI 10.1021/bi00588a033; Kohler S, 2002, P NATL ACAD SCI USA, V99, P15711, DOI 10.1073/pnas.232454299; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEUNG KY, 1991, P NATL ACAD SCI USA, V88, P11470, DOI 10.1073/pnas.88.24.11470; LOCKWOOD BC, 1991, BIOCHEM J, V279, P675, DOI 10.1042/bj2790675; MCADAM RA, 1995, INFECT IMMUN, V63, P1004, DOI 10.1128/IAI.63.3.1004-1012.1995; Messerschmidt A, 2003, BIOL CHEM, V384, P373, DOI 10.1515/BC.2003.043; Mougous JD, 2002, P NATL ACAD SCI USA, V99, P17037, DOI 10.1073/pnas.252514899; Nagai S., 1971, METHODS ENZYMOLOGY B, V17B, P423; NAGASAWA T, 1984, J BIOL CHEM, V259, P393; Newton GL, 2000, BIOCHEMISTRY-US, V39, P10739, DOI 10.1021/bi000356n; OHMORI S, 1992, J CHROMATOGR-BIOMED, V574, P35, DOI 10.1016/0378-4347(92)80095-8; Ono B, 1999, YEAST, V15, P1365, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1365::AID-YEA468>3.0.CO;2-U; ONO BI, 1993, YEAST, V9, P389, DOI 10.1002/yea.320090409; Parish T, 1999, MICROBIOL-SGM, V145, P3497, DOI 10.1099/00221287-145-12-3497; PEDAL H W, 1954, Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M, V51, P187; PRAMANIK BC, 1989, ANAL BIOCHEM, V176, P269, DOI 10.1016/0003-2697(89)90308-4; RAVANEL S, 1995, ARCH BIOCHEM BIOPHYS, V316, P572, DOI 10.1006/abbi.1995.1077; REED DJ, 1995, METHOD ENZYMOL, V252, P92; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; Sareen D, 2003, J BACTERIOL, V185, P6736, DOI 10.1228/JB.185.22.6736-6740.2003; Sareen D, 2002, BIOCHEMISTRY-US, V41, P6885, DOI 10.1021/bi012212u; Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Seiflein TA, 2001, J BACTERIOL, V183, P336, DOI 10.1128/JB.183.1.336-346.2001; Seth A, 2000, J BACTERIOL, V182, P919, DOI 10.1128/JB.182.4.919-927.2000; Smacchi E, 1998, FEMS MICROBIOL LETT, V166, P197, DOI 10.1016/S0378-1097(98)00332-2; Smith DA, 2001, INFECT IMMUN, V69, P1142, DOI 10.1128/IAI.69.2.1442-1150.2001; SODA K, 1987, METHOD ENZYMOL, V143, P453; Soutourina J, 2001, J BIOL CHEM, V276, P40864, DOI 10.1074/jbc.M102375200; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; SWADESH JK, 1984, ANAL BIOCHEM, V141, P397, DOI 10.1016/0003-2697(84)90060-5; Treumann A, 2002, J MOL BIOL, V316, P89, DOI 10.1006/jmbi.2001.5317; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; Wheeler Paul R., 1994, P353; WHEELER PR, 1980, J GEN MICROBIOL, V121, P457; Wooff E, 2002, MOL MICROBIOL, V43, P653, DOI 10.1046/j.1365-2958.2002.02771.x; YAMADA H, 1984, J BIOTECHNOL, V1, P205, DOI 10.1016/0168-1656(84)90006-3	49	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8069	8078		10.1074/jbc.M412540200	http://dx.doi.org/10.1074/jbc.M412540200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15576367	hybrid			2022-12-25	WOS:000227395700077
J	Andrews, D; Butler, JS; Al-Bassam, J; Joss, L; Winn-Stapley, DA; Casjens, S; Cingolani, G				Andrews, D; Butler, JS; Al-Bassam, J; Joss, L; Winn-Stapley, DA; Casjens, S; Cingolani, G			Bacteriophage P22 tail accessory factor gp26 is a long triple-stranded coiled-coil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; PHAGE-P22; DNA; SUBUNIT; HEAD; HEMAGGLUTININ; VISUALIZATION; ENCAPSULATION; PREDICTION; ECTODOMAIN	P22 is a well characterized tailed bacteriophage that infects Salmonella enterica serovar Typhimurium. It is characterized by a "short" tail, which is formed by five proteins: the dodecameric portal protein (gp1), three tail accessory factors (gp4, gp10, gp26), and six trimeric copies of the tail-spike protein (gp9). We have isolated the gene encoding tail accessory factor gp26, which is responsible for stabilization of viral DNA within the mature phage, and using a variety of biochemical and biophysical techniques we show that gp26 is very likely a triple stranded coiled-coil protein. Electron microscopic examination of purified gp26 indicates that the protein adopts a rod-like structure similar to210 Angstrom in length. This trimeric rod displays an exceedingly high intrinsic thermostability (T-m similar to85 degreesC), which suggests a potentially important structural role within the phage tail apparatus. We propose that gp26 forms the thin needlelike fiber emanating from the base of the P22 neck that has been observed by electron microscopy of negatively stained P22 virions. By analogy with viral trimeric coiled-coil class I membrane fusion proteins, gp26 may represent the membrane-penetrating device used by the phage to pierce the host outer membrane.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13078 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pathol, Sch Med, Salt Lake City, UT 84132 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Cingolani, G (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13078 USA.	cingolag@upstate.edu						BAZINET C, 1988, BIOCHEMISTRY-US, V27, P1849, DOI 10.1021/bi00406a009; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; CASJENS S, 1974, Journal of Supramolecular Structure, V2, P202, DOI 10.1002/jss.400020215; CASJENS S, IN PRESS VIRAL GENOM; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Del Angel VD, 2002, BIOCHEM BIOPH RES CO, V293, P1153; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Fokine A, 2004, P NATL ACAD SCI USA, V101, P6003, DOI 10.1073/pnas.0400444101; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; HARTWIEG E, 1986, BIOPHYS J, V49, P24, DOI 10.1016/S0006-3495(86)83579-2; ISRAEL V, 1978, J GEN VIROL, V40, P669, DOI 10.1099/0022-1317-40-3-669; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Laue TM, 1995, METHOD ENZYMOL, V259, P427; Leiman PG, 2004, CELL, V118, P419, DOI 10.1016/j.cell.2004.07.022; LENK E, 1975, VIROLOGY, V68, P182, DOI 10.1016/0042-6822(75)90160-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Moak M, 2004, MOL MICROBIOL, V51, P1169, DOI 10.1046/j.1365-2958.2003.03894.x; Molineux IJ, 2001, MOL MICROBIOL, V40, P1, DOI 10.1046/j.1365-2958.2001.02357.x; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Pedulla ML, 2003, J BACTERIOL, V185, P1475, DOI 10.1128/JB.185.4.1475-1477.2003; POTEETE AR, 1979, VIROLOGY, V95, P550, DOI 10.1016/0042-6822(79)90508-7; Przybylski D, 2002, PROTEINS, V46, P197, DOI 10.1002/prot.10029; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SAMPSON L, 1993, NUCLEIC ACIDS RES, V21, P3326, DOI 10.1093/nar/21.14.3326; STRAUSS H, 1984, J MOL BIOL, V172, P523, DOI 10.1016/S0022-2836(84)80021-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; ThumanCommike PA, 1996, J MOL BIOL, V260, P85, DOI 10.1006/jmbi.1996.0383; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; Zhang ZX, 2000, J MOL BIOL, V297, P615, DOI 10.1006/jmbi.2000.3601	37	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5929	5933		10.1074/jbc.C400513200	http://dx.doi.org/10.1074/jbc.C400513200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591072	hybrid			2022-12-25	WOS:000227217100099
J	Chandrasekar, B; Mummidi, S; Claycomb, WC; Mestril, R; Nemer, M				Chandrasekar, B; Mummidi, S; Claycomb, WC; Mestril, R; Nemer, M			Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; NEONATAL-RAT CARDIOMYOCYTES; GATA-4 TRANSCRIPTION FACTOR; PROTEIN-KINASE B; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; TRANSGENIC MICE; NITRIC-OXIDE; TRANSDUCTION PATHWAYS	In patients with congestive heart failure, high serum levels of the proinflammatory cytokine interleukin (IL)-18 were reported. A positive correlation was described between serum IL-18 levels and the disease severity. IL-18 has also been shown to induce atrial natriuretic factor (ANF) gene expression in adult cardiomyocytes. Because re-expression of the fetal gene ANF is mostly associated with hypertrophy, a hallmark of heart failure, we hypothesized that IL-18 induces cardiomyocyte hypertrophy. Treatment of the cardiomyocyte cell line HL-1 with IL-18 induced hypertrophy as characterized by increases in protein synthesis, phosphorylated p70 S6 kinase, and ribosomal S6 protein levels as well as cell surface area. Furthermore, IL-18 induced ANF gene transcription in a time-dependent manner as evidenced by increased ANF secretion and ANF promoter-driven reporter gene activity. Investigation into possible signal transduction pathways mediating IL-18 effects revealed that IL-18 activates phosphoinositide 3-kinase (PI3K), an effect that was blocked by wortmannin and LY294002. IL-18 induced Akt phosphorylation and stimulated its activity, effects that were abolished by Akt inhibitor or knockdown. IL-18 stimulated GATA4 DNA binding activity and increased transcription of a reporter gene driven by multimerized GATA4-binding DNA elements. Pharmacological inhibition or knockdown studies revealed that IL-18 induced cardiomyocyte hypertrophy and ANF gene transcription via PI3K, PDK1, Akt, and GATA4. Most importantly, IL-18 induced ANF gene transcription and hypertrophy of neonatal rat ventricular myocytes via PI3K-, Akt-, and GATA4-dependent signaling. Together these data provide the first evidence that IL-18 induces cardiomyocyte hypertrophy via PI3K-dependent signaling, defines a mechanism of IL-18-mediated ANF gene transcription, and further supports a role for IL-18 in inflammatory heart diseases including heart failure.	Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; Vet Affairs Res Ctr AIDS & HIV 1 Infect, San Antonio, TX 78229 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Loyola Univ Med Ctr, Dept Physiol, Maywood, IL 60153 USA; Loyola Univ Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA; Inst Rech Clin Montreal, Lab Dev & Differentiat Cardiaques, Montreal, PQ H2W 1RT, Canada	University of Texas System; University of Texas Health San Antonio; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Loyola University Chicago; Loyola University Chicago; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chanraseka@uthscsa.edu	Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380; Mestril, Ruben/0000-0003-3631-2236	NHLBI NIH HHS [HL68020, HL067971] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067971, R01HL068020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; BRADY AJB, 1993, AM J PHYSIOL, V265, pH176, DOI 10.1152/ajpheart.1993.265.1.H176; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Cain BS, 1999, CRIT CARE MED, V27, P1309, DOI 10.1097/00003246-199907000-00018; Chandrasekar B, 2004, BIOCHEM BIOPH RES CO, V319, P304, DOI 10.1016/j.bbrc.2004.04.185; Chandrasekar B, 2004, J BIOL CHEM, V279, P20221, DOI 10.1074/jbc.M313980200; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Chang MS, 2004, MOL PHARMACOL, V66, P561; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Cook SA, 2003, CIRCULATION, V108, P664, DOI 10.1161/01.CIR.0000086978.95976.41; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Dao T, 1996, CELL IMMUNOL, V173, P230, DOI 10.1006/cimm.1996.0272; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fairweather D, 2003, J IMMUNOL, V170, P4731, DOI 10.4049/jimmunol.170.9.4731; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Finotto S, 2004, GUT, V53, P392, DOI 10.1136/gut.2003.018572; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; Grepin C, 1997, DEVELOPMENT, V124, P2387; Griffin TM, 2004, AM J PHYSIOL-HEART C, V287, pH1081, DOI 10.1152/ajpheart.00921.2003; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Higuchi Y, 2002, J MOL CELL CARDIOL, V34, P233, DOI 10.1006/jmcc.2001.1505; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Joe EL, 1998, J MOL CELL CARDIOL, V30, P303, DOI 10.1006/jmcc.1997.0593; Kim Y, 2003, MOL PHARMACOL, V63, P368, DOI 10.1124/mol.63.2.368; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lee JK, 2004, P NATL ACAD SCI USA, V101, P8815, DOI 10.1073/pnas.0402800101; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lorell BH, 2000, CIRCULATION, V102, P470; Makiishi-Shimobayashi C, 2001, BIOCHEM BIOPH RES CO, V281, P361, DOI 10.1006/bbrc.2001.4380; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381; McMullen JR, 2004, J BIOL CHEM, V279, P4782, DOI 10.1074/jbc.M310405200; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Morel JCM, 2001, J BIOL CHEM, V276, P37069, DOI 10.1074/jbc.M103574200; Morel JCM, 2001, LAB INVEST, V81, P1371, DOI 10.1038/labinvest.3780351; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Morisco C, 2001, J MOL CELL CARDIOL, V33, P561, DOI 10.1006/jmcc.2000.1332; Muller-Werdan U, 1998, J MOL CELL CARDIOL, V30, P1027, DOI 10.1006/jmcc.1998.0667; Naito AT, 2003, EXP CELL RES, V291, P56, DOI 10.1016/S0014-4827(03)00378-1; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pomerantz BJ, 2001, P NATL ACAD SCI USA, V98, P2871, DOI 10.1073/pnas.041611398; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Purcell NH, 2001, P NATL ACAD SCI USA, V98, P6668, DOI 10.1073/pnas.111155798; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Seta Y, 2000, RES COMMUN MOL PATH, V108, P87; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Thomassen E, 1998, J INTERF CYTOK RES, V18, P1077, DOI 10.1089/jir.1998.18.1077; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Weinstock JV, 2003, J IMMUNOL, V170, P5003, DOI 10.4049/jimmunol.170.10.5003; Woldbaek PR, 2003, CARDIOVASC RES, V59, P122, DOI 10.1016/S0008-6363(03)00339-0; Wyman TH, 2002, J LEUKOCYTE BIOL, V72, P401; Yamane K, 2003, ARTHRITIS RHEUM-US, V48, P1652, DOI 10.1002/art.11029; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	75	104	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4553	4567		10.1074/jbc.M411787200	http://dx.doi.org/10.1074/jbc.M411787200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574430	hybrid			2022-12-25	WOS:000227096600069
J	York, SJ; Armbruster, BN; Greenwell, P; Petes, TD; York, JD				York, SJ; Armbruster, BN; Greenwell, P; Petes, TD; York, JD			Inositol diphosphate signaling regulates telomere length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; YEAST SACCHAROMYCES-CEREVISIAE; POLYPHOSPHATE KINASE-ACTIVITY; DIPHOSPHOINOSITOL PENTAKISPHOSPHATE; PHOSPHOLIPASE-C; DNA-PK; PROTEIN; BINDING; GENE; FAMILY	Activation of phospholipase C-dependent inositol polyphosphate signaling pathways generates distinct messengers derived from inositol 1,4,5-trisphosphate that control gene expression and mRNA export. Here we report the regulation of telomere length by production of a diphosphorylinositol tetrakisphosphate, PP-IP4, synthesized by the KCS1 gene product. Loss of PP-IP4 production results in lengthening of telomeres, whereas overproduction leads to their shortening. This effect requires the presence of Tell, the yeast homologue of ATM, the protein mutated in the human disease ataxia telangiectasia. Our data provide in vivo evidence of a regulatory link between inositol polyphosphate signaling and the checkpoint kinase family and describe a third nuclear process modulated by phospholipase C activation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University of North Carolina; University of North Carolina Chapel Hill	York, JD (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.	yorkj@duke.edu			NHLBI NIH HHS [HL-55672] Funding Source: Medline; NIGMS NIH HHS [GM-531576] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Askree SH, 2004, P NATL ACAD SCI USA, V101, P8658, DOI 10.1073/pnas.0401263101; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; DUBOIS E, 1994, MOL GEN GENET, V243, P315, DOI 10.1007/BF00301067; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; El Alami M, 2003, MOL MICROBIOL, V49, P457, DOI 10.1046/j.1365-2958.2003.03562.x; Feng YC, 2001, P NATL ACAD SCI USA, V98, P875, DOI 10.1073/pnas.021558098; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; HUANG KN, 1995, GENETICS, V141, P1275; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Stolz LE, 1998, GENETICS, V148, P1715; Vega LR, 2003, NAT REV MOL CELL BIO, V4, P948, DOI 10.1038/nrm1256; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JD, 2003, HDB CELL SIGNALING, V2, P229; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	39	116	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4264	4269		10.1074/jbc.M412070200	http://dx.doi.org/10.1074/jbc.M412070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561716	Green Published, hybrid			2022-12-25	WOS:000227096600034
J	Gonzalex-Sancho, JM; Aguilera, O; Garcia, JM; Pendas-Franco, N; Pena, C; Cal, S; de Herreros, AG; Bonilla, F; Munoz, A				Gonzalex-Sancho, JM; Aguilera, O; Garcia, JM; Pendas-Franco, N; Pena, C; Cal, S; de Herreros, AG; Bonilla, F; Munoz, A			The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer	ONCOGENE			English	Article						Wnt; DICKKOPF-1; beta-catenin; T-cell factor4; gene regulation	PROMOTER-HYPERMETHYLATION; EXPRESSION; MECHANISM; PROTEINS; RECEPTOR; DKK1; OVEREXPRESSION; INHIBITION; SUPPRESSOR; CELLS	Wnt glycoproteins regulate homeostasis and development by binding to membrane Frizzled-LRP5/6 receptor complexes. Wnt signaling includes a canonical pathway involving cytosolic beta-catenin stabilization, nuclear translocation and gene regulation, acting as a co-activator of T-cell factor (TCF) proteins, and noncanonical pathways that activate Rho, Rac, JNK and PKC, or modulate Ca2+ levels. DICKKOPF-1 (DKK-1) encodes a secreted Wnt antagonist that binds to LRP5/6 and induces its endocytosis, leading to inhibition of the canonical pathway. We show that activation of canonical signaling by Wnt1 or ectopic expression of active beta-catenin, TCF4 or LRP6 mutants induces transcription of the human DKK-1 gene. Multiple beta-catenin/TCF4 sites in the DKK-1 gene promoter contribute to this activation. In contrast, Wnt5a, which signals through noncanonical pathways, does not activate DKK-1. Northern and Western blot studies show that activation of the Wnt/beta-catenin pathway by treatment with lithium or Wnt3a-conditioned medium, or by stable expression of either Wnt1 or beta-catenin, increases DKK-1 RNA and protein, thus initiating a negative feedback loop. However, we found that DKK-1 expression decreases in human colon tumors, which suggests that DKK-1 acts as a tumor suppressor gene in this neoplasia. Our data indicate that the Wnt/beta-catenin pathway is downregulated by the induction of DKK-1 expression, a mechanism that is lost in colon cancer.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Hosp Univ Puerta Hierro, E-28035 Madrid, Spain; Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Pompeu Fabra University	Munoz, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Gonzalez-Sancho, Jose/AAA-6010-2019; Munoz, Alberto/O-6393-2014; de Herreros, A Garcia/H-3104-2014	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Munoz, Alberto/0000-0003-3890-4251; de Herreros, A Garcia/0000-0001-5270-0808				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Millar JBA, 2002, GENOME BIOL, V3; Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Roessler E, 2000, CYTOGENET CELL GENET, V89, P220, DOI 10.1159/000015618; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sambrook J., 1989, MOL CLONING LAB MANU; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shinya M, 2000, MECH DEVELOP, V98, P3, DOI 10.1016/S0925-4773(00)00433-0; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	38	315	337	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1098	1103		10.1038/sj.onc.1208303	http://dx.doi.org/10.1038/sj.onc.1208303			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592505				2022-12-25	WOS:000226749200016
J	Jose, AM; Koelle, MR				Jose, AM; Koelle, MR			Domains, amino acid residues, and new isoforms of Caenorhabditis elegans diacylglycerol kinase 1 (DGK-1) important for terminating diacylglycerol signaling in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAINS; PROTEIN-KINASE-C; PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; SPLICE VARIANTS; RAT-BRAIN; GENE; BINDING; UNC-13; THETA	Diacylglycerol kinases (DGKs) inhibit diacylglycerol (DAG) signaling by phosphorylating DAG. DGK-1, the Caenorhabditis elegans ortholog of human neuronal DGKtheta, inhibits neurotransmission to control behavior. DGK-1, like DGKtheta, has three cysteine-rich domains (CRDs), a pleckstrin homology domain, and a kinase domain. To identify DGK domains and amino acid residues critical for terminating DAG signaling in vivo, we analyzed 20 dgk-1 mutants defective in DGK-1-controlled behaviors. We found by sequencing that the mutations included nine amino acid substitutions and seven premature stop codons that impair the physiological functions of DGK-1. All nine amino acid substitutions are in the second CRD, the third CRD, or the kinase domain. Thus, these domains are important for the termination of DAG signaling by DGK-1 in vivo. Seven of the substituted amino acid residues are present in all human DGKs and likely define key residues required for the function of all DGKs. An ATP-binding site mutation expected to inactivate the kinase domain retained very little physiological function, but we found two stop codon mutants predicted to truncate DGK-1 before its kinase domain that retained significantly more function. We detected novel splice forms of dgk-1 that can reconcile this apparent conflict, as they skip exons containing the stop codons to produce DGK-1 isoforms that contain the kinase domain. Two of these isoforms lack an intact pleckstrin homology domain and yet appear to have significant function. Additional novel isoform(s) account for all of the DGK-1 function necessary for one behavior, dopamine response.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Koelle, MR (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,SHM CE-30, New Haven, CT 06520 USA.	michael.koelle@yale.edu		Jose, Antony/0000-0003-1405-0618	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036918] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS036918, R01 NS036918-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe T, 2003, BIOCHEM J, V375, P673, DOI 10.1042/BJ20031052; Bany IA, 2003, J NEUROSCI, V23, P8060; BANY IA, 2004, THESIS YALE U NEW HA; BRENNER S, 1974, GENETICS, V77, P71; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; Chase DL, 2004, NAT NEUROSCI, V7, P1096, DOI 10.1038/nn1316; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Houssa B, 1997, J BIOL CHEM, V272, P10422; Houssa B, 1998, BIOCHEM J, V331, P677; Ito T, 2004, J BIOL CHEM, V279, P23317, DOI 10.1074/jbc.M312976200; KAI M, 1994, J BIOL CHEM, V269, P18492; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; KATO M, 1990, J BIOL CHEM, V265, P794; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; Los AP, 2004, BBA-MOL CELL BIOL L, V1636, P169, DOI 10.1016/j.bbalip.2003.11.008; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Moore D.S., 2003, MATH GAZ, V4th, DOI DOI 10.2307/3619120; Murakami T, 2003, J BIOL CHEM, V278, P34364, DOI 10.1074/jbc.M301542200; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; Sakane F, 2002, J BIOL CHEM, V277, P43519, DOI 10.1074/jbc.M206895200; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; SHAHAM S, 1996, CELL, V56, P204; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shindo M, 2003, J BIOL CHEM, V278, P18448, DOI 10.1074/jbc.M300400200; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Walker AJ, 2001, BIOCHEM J, V353, P129, DOI 10.1042/bj3530129	40	19	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2730	2736		10.1074/jbc.M409460200	http://dx.doi.org/10.1074/jbc.M409460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15563467	Green Accepted, hybrid			2022-12-25	WOS:000226449100045
J	Barnes, EA; Heidtman, KJ; Donoghue, DJ				Barnes, EA; Heidtman, KJ; Donoghue, DJ			Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC	ONCOGENE			English	Article						Gli1; hedgehog; nevoid basal cell carcinoma syndrome	BASAL-CELL CARCINOMA; HUMAN EMBRYONAL CARCINOMA; SONIC-HEDGEHOG GENE; D-TYPE CYCLINS; HUMAN HOMOLOG; NUCLEAR-LOCALIZATION; MISSENSE MUTATIONS; SIGNALING PATHWAY; PREMATURE MITOSIS; RECEPTOR COMPLEX	Mutations in the transmembrane receptor patched1 (ptc1) are responsible for the majority of basal cell carcinoma (BCC) cases. Many of these mutations, including ptc1-Q688X, result in premature truncation of the ptc1 protein. ptc1-Q688X has been identified in patients with both BCC and nevoid basal cell carcinoma syndrome, an inheritable disorder causing a predisposition to cancer susceptibility. Here we describe a mechanism by which ptc1-Q688X causes constitutive cellular signaling. Cells expressing ptc1-Q688X demonstrate an increase in cell cycle progression and induce cell transformation. The ptc1-Q688X mutant enhances Gli1 activity, a downstream reporter of sonic hedgehog (shh)-ptc1 signaling, independent of shh stimulation. In contrast to wild-type ptc1, ptc1-Q688X fails to associate with endogenous cyclin B1. Expression of nuclear-targeted cyclin B1 derivatives promotes Gli1-dependent transcription, which correlates temporally with cyclin B1-cdk1 kinase activity. Coexpression of wild-type ptc1 with a nuclear-targeted cyclin B1 derivative, mutated to mimic constitutive phosphorylation, dramatically decreases Gli1 activity. In addition, the coexpression of this constitutively nuclear cyclin B1 derivative with ptc1-Q688X substantially enhances foci formation. These studies therefore describe a molecular mechanism for the aberrant activity of ptc1-Q688X that includes the premature activation of the transcription factor Gli1.	Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, 9500 Gilman Dr,Urey Hall,6114, La Jolla, CA 92093 USA.	ddonoghue@ucsd.edu			NCI NIH HHS [T32-CA09523, P30CA23100-18, T32 CA009523] Funding Source: Medline; NIGMS NIH HHS [GM65490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023100, T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey EC, 2003, CANCER RES, V63, P1636; Bailey EC, 2002, J BIOL CHEM, V277, P33632, DOI 10.1074/jbc.M202203200; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chidambaram A, 1996, CANCER RES, V56, P4599; Cimini D, 1998, CHROMOSOMA, V107, P479, DOI 10.1007/s004120050332; Cohen MM, 1999, INT J ORAL MAX SURG, V28, P216, DOI 10.1034/j.1399-0020.1999.283280314.x; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Ghosh S, 1996, EXP CELL RES, V227, P165, DOI 10.1006/excr.1996.0262; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; Green J, 1998, BRIT J DERMATOL, V139, P911; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hiwasa T, 1996, CANCER LETT, V99, P87, DOI 10.1016/0304-3835(95)04041-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; JHA MN, 1994, CANCER RES, V54, P5011; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Lowrey JA, 2002, J IMMUNOL, V169, P1869, DOI 10.4049/jimmunol.169.4.1869; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reifenberger J, 1998, CANCER RES, V58, P1798; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Satoh J, 2000, J NEUROSCI METH, V94, P155, DOI 10.1016/S0165-0270(99)00143-0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; Unden AB, 1996, CANCER RES, V56, P4562; Wicking C, 2001, CANCER LETT, V173, P1, DOI 10.1016/S0304-3835(01)00676-0; Wicking C, 1997, AM J HUM GENET, V60, P21; Wicking C, 1997, AM J MED GENET, V73, P304; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang H, 2001, AM J PATHOL, V158, P381, DOI 10.1016/S0002-9440(10)63980-6	63	42	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					902	915		10.1038/sj.onc.1208240	http://dx.doi.org/10.1038/sj.onc.1208240			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592520				2022-12-25	WOS:000226577100016
J	Desrumaux, C; Risold, PY; Schroeder, H; Deckert, V; Masson, D; Athias, A; Laplanche, H; Le Guern, N; Blache, D; Jiang, XC; Tall, A; Desor, D; Lagrost, L				Desrumaux, C; Risold, PY; Schroeder, H; Deckert, V; Masson, D; Athias, A; Laplanche, H; Le Guern, N; Blache, D; Jiang, XC; Tall, A; Desor, D; Lagrost, L			Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice.	FASEB JOURNAL			English	Article						tocopherol; neurodegenerative diseases; alpha-tocopherol; PLTP-deficient mice	TOCOPHEROL TRANSFER PROTEIN; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; MOUSE MODELS; NEURODEGENERATIVE DISEASES; PLASMA; ANTIOXIDANTS; ATHEROSCLEROSIS	Vitamin E supplementation constitutes a promising strategy in the prevention of neurodegenerative diseases. Here, we show that a phospholipid transfer protein (PLTP) is widely expressed in the brain where it appears to function as a transfer factor for alpha-tocopherol, the main isomer of vitamin E. PLTP deficiency results in significant depletion of brain alpha-tocopherol in both homozygous ( - 30.1%, P< 0.0002) and heterozygous ( - 18.0%, P< 0.05) PLTP knocked-out mice. alpha-tocopherol depletion in PLTP-deficient homozygotes is associated with the elevation of lipofuscin (+ 25% and + 450% increases in cortex and substantia nigra, respectively), cholesterol oxides (+54.5%, P< 0.05), and cellular peroxides (+ 32.3%, P< 0.01) in the brain. Complete PLTP deficiency in homozygotes is accompanied by increased anxiety as shown by fewer entries (8.3% vs. 44.4% in controls, P< 0.01) and less time spent (1.7% vs. 41.3% in controls, P< 0.05) in the open arms of an elevated plus-maze, in the absence of locomotor deterioration. Thus, the vitamin E transfer activity of PLTP appears to be a key process in preventing oxidative damage in the brain, and PLTP-deficient mice could be a new model of the contribution of oxidative brain injury in the etiology of neurodegenerative diseases.	Fac Med, INSERM, U498, IFR100,Lab Biochim Lipoprot, F-21079 Dijon, France; Fac Med & Pharm, Histol Lab, Besancon, France; Fac Sci, Lab Neurosci Comportementales, Vandoeuvre Les Nancy, France; SUNY Downstate Med Ctr, Brooklyn, NY 11203 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Lorraine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University	Lagrost, L (corresponding author), Fac Med, INSERM, U498, IFR100,Lab Biochim Lipoprot, 7 Bd Jeanne dArc,BP 87900, F-21079 Dijon, France.	Laurent.Lagrost@u-bourgogne.fr	Desrumaux, Catherine/O-1925-2018; Masson, David/R-6633-2019; MASSON, David/AAC-8896-2022; Tall, Alan/AAT-8528-2021; MASSON, David/R-4557-2017; Risold, Pierre-Yves/AAJ-9535-2021; Risold, Pierre-Yves/M-7730-2018	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; Risold, Pierre-Yves/0000-0001-6801-591X; DECKERT, Valerie/0000-0001-5728-1710				Albers JJ, 2004, CURR OPIN LIPIDOL, V15, P255, DOI 10.1097/00041433-200406000-00004; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Behl C, 2002, FREE RADICAL BIO MED, V33, P182, DOI 10.1016/S0891-5849(02)00883-3; Bertoli-Avella AM, 2004, HUM GENET, V114, P413, DOI 10.1007/s00439-004-1097-7; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Chowdhury PK, 2004, PHOTOCHEM PHOTOBIOL, V79, P21; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; Copp RP, 1999, BRAIN RES, V822, P80, DOI 10.1016/S0006-8993(99)01090-2; Di Matteo V, 2003, CNS NEUROL DISORD-DR, V2, P95, DOI 10.2174/1568007033482959; Esposito E, 2002, NEUROBIOL AGING, V23, P719, DOI 10.1016/S0197-4580(02)00078-7; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Gander R, 2002, J LIPID RES, V43, P636; GOHIL K, FREE RADIC BIOL MED, V35, P1343; Guyard-Dangremont V, 1998, COMP BIOCHEM PHYS B, V120, P517, DOI 10.1016/S0305-0491(98)10038-X; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Higgins GA, 2003, BEHAV PHARMACOL, V14, P419, DOI 10.1097/01.fbp.0000088420.18414.ff; Iuliano L, 2003, ANAL BIOCHEM, V312, P217, DOI 10.1016/S0003-2697(02)00467-0; Jiang XC, 2002, FRONT BIOSCI-LANDMRK, V7, pD1634, DOI 10.2741/jiang1; Jiang XC, 2002, J BIOL CHEM, V277, P31850, DOI 10.1074/jbc.M205077200; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Katsanidis E, 1999, FREE RADICAL BIO MED, V27, P1137, DOI 10.1016/S0891-5849(99)00205-1; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; Lie J, 2004, J LIPID RES, V45, P805, DOI 10.1194/jlr.M300487-JLR200; MONJI A, 1994, BRAIN RES, V634, P62, DOI 10.1016/0006-8993(94)90258-5; Moosmann B, 2002, EXPERT OPIN INV DRUG, V11, P1407, DOI 10.1517/13543784.11.10.1407; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Phinney AL, 2003, NEUROL RES, V25, P590, DOI 10.1179/016164103101202020; Pratico D, 2002, FASEB J, V16, P1138, DOI 10.1096/fj.02-0012fje; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972; Pratico Domenico, 2002, Sci Aging Knowledge Environ, V2002, pre5; Price DL, 1996, BRAIN PATHOL, V6, P467, DOI 10.1111/j.1750-3639.1996.tb00876.x; Rao AV, 2002, NUTR NEUROSCI, V5, P291, DOI 10.1080/1028415021000033767; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; Schlitt A, 2003, ARTERIOSCL THROM VAS, V23, P1857, DOI 10.1161/01.ATV.0000094433.98445.7F; Sun AY, 1998, J BIOMED SCI, V5, P401; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Treuting PM, 2002, EXP MOL PATHOL, V72, P49, DOI 10.1006/exmp.2001.2405; van Haperen R, 2002, J BIOL CHEM, V277, P48938, DOI 10.1074/jbc.M209128200; Vuletic S, 2003, J LIPID RES, V44, P1113, DOI 10.1194/jlr.M300046-JLR200; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Yang XP, 2003, ARTERIOSCL THROM VAS, V23, P1601, DOI 10.1161/01.ATV.0000085841.55248.13; Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098	48	101	104	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					296	+		10.1096/fj.04-2400fje	http://dx.doi.org/10.1096/fj.04-2400fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576481				2022-12-25	WOS:000226091000025
J	Rong, LL; Yan, SF; Wendt, T; Hans, D; Pachydaki, S; Bucciarelli, LG; Adebayo, A; Qu, W; Lu, Y; Kostov, K; Lalla, E; Yan, SD; Gooch, C; Szabolcs, M; Trojaborg, W; Hays, AP; Schmidt, AM				Rong, LL; Yan, SF; Wendt, T; Hans, D; Pachydaki, S; Bucciarelli, LG; Adebayo, A; Qu, W; Lu, Y; Kostov, K; Lalla, E; Yan, SD; Gooch, C; Szabolcs, M; Trojaborg, W; Hays, AP; Schmidt, AM			RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways	FASEB JOURNAL			English	Article						transgenic mice; signal transduction; sciatic nerve	GLYCATION END-PRODUCTS; ADHESION MOLECULES L1; NEURITE OUTGROWTH; IN-VITRO; N-CAM; RECEPTOR; AMPHOTERIN; PROTEINS; BINDING; INJURY	Axotomy of peripheral nerve stimulates events in multiple cell types that initiate a limited inflammatory response to axonal degeneration and simultaneous outgrowth of neurites into the distal segments after injury. We found that pharmacological blockade of RAGE impaired peripheral nerve regeneration in mice subjected to RAGE blockade and acute crush of the sciatic nerve. As our studies revealed that RAGE was expressed in axons and in infiltrating mononuclear phagocytes upon injury, we tested the role of RAGE in these distinct cell types on nerve regeneration. Transgenic mice expressing signal transduction-deficient RAGE in mononuclear phagocytes or peripheral neurons were generated and subjected to unilateral crush injury to the sciatic nerve. Transgenic mice displayed decreased functional and morphological recovery compared with littermate controls, as assessed by motor and sensory conduction velocities; and myelinated fiber density. In double transgenic mice expressing signal transduction deficient RAGE in both mononuclear phagocytes and peripheral neurons, regeneration was even further impaired, suggesting the critical interplay between RAGE-modulated inflammation and neurite outgrowth in nerve repair. These findings suggest that RAGE signaling in inflammatory cells and peripheral neurons plays an important role in plasticity of the peripheral nervous system.	Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, 630 W 168th St,P&S 17-401, New York, NY 10032 USA.	ams11@columbia.edu	Gooch, Clifton L/M-1874-2016	Gooch, Clifton L/0000-0002-2210-2038				Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Azzouz M, 1996, EXP NEUROL, V138, P189, DOI 10.1006/exnr.1996.0057; BEUCHE W, 1986, BRAIN RES, V378, P97, DOI 10.1016/0006-8993(86)90289-1; BURNHAM PA, 1974, NEUROBIOLOGY, V4, P57; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Jaffee BD, 2000, BIOCHEM BIOPH RES CO, V268, P647, DOI 10.1006/bbrc.2000.2184; Kiefer R, 2001, PROG NEUROBIOL, V64, P109, DOI 10.1016/S0301-0082(00)00060-5; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Liu RY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-17-j0003.2001; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MIDRONI G, 1995, BIOPSY DIAGNOSIS PER, P40; NIEKE J, 1985, DIFFERENTIATION, V30, P141, DOI 10.1111/j.1432-0436.1985.tb00525.x; REICHERT F, 1994, J NEUROSCI, V14, P3231; RONG LL, 2004, FASEB J; Ropert C, 2001, J IMMUNOL, V166, P3423, DOI 10.4049/jimmunol.166.5.3423; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Schwaiger FW, 2000, EUR J NEUROSCI, V12, P1165, DOI 10.1046/j.1460-9568.2000.00005.x; Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009; Sheu JY, 2000, EXP NEUROL, V166, P392, DOI 10.1006/exnr.2000.7508; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; Srikrishna G, 2002, J NEUROCHEM, V80, P998, DOI 10.1046/j.0022-3042.2002.00796.x; SVENSSON B, 1995, NEUROSCI LETT, V200, P33, DOI 10.1016/0304-3940(95)12066-D; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; VARON S, 1973, BRAIN RES, V54, P51, DOI 10.1016/0006-8993(73)90033-4; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	31	108	110	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1818	1825		10.1096/fj.04-1900com	http://dx.doi.org/10.1096/fj.04-1900com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576485				2022-12-25	WOS:000226091000032
J	Vila, G; Papazoglou, M; Stalla, J; Theodoropoulou, M; Stalla, GK; Holsboer, F; Paez-Pereda, M				Vila, G; Papazoglou, M; Stalla, J; Theodoropoulou, M; Stalla, GK; Holsboer, F; Paez-Pereda, M			Sonic hedgehog regulates CRH signal transduction in the adult pituitary	FASEB JOURNAL			English	Article						corticotropin-releasing hormone; corticotropin; pro-opiomelanocortin	CORTICOTROPIN-RELEASING-FACTOR; PROOPIOMELANOCORTIN GENE-TRANSCRIPTION; EXPRESSION; RECEPTORS; PATHWAYS; HORMONE; GLI; INVOLVEMENT; ANXIETY; PROTEIN	Sonic hedgehog (Shh) is a signaling protein that binds to Patched and mediates its effects through Gli transcription factors. Shh is important in regulating survival and growth in both the embryo and the adult. It is known to be involved in pituitary development, but its role in the adult pituitary has not been investigated. Here, we show Shh and Gli1 immunoreactivity in adult human corticotroph cells. Administration of Shh (5 mug/ml) alone and in combination with corticotrophin-releasing hormone (CRH; 100 nM) in dispersed rat anterior pituitary and AtT-20 mouse corticotrophinoma cells increased corticotrophin (ACTH) secretion and proopiomelanocortin (POMC) promoter activity. Shh and CRH act additively in increasing CRH receptor 1 (CRH-R1). Unexpectedly, we found that CRH on its own increased Gli-dependent transcription, which in turn stimulated POMC transcription. Gli1 is necessary for CRH signaling, since knocking down Gli1 by RNA interference abolished the stimulatory effect of CRH on POMC. Taken together, our results demonstrate a new role for Shh and Gli1 in corticotroph function and provide a new link between Shh and CRH signaling pathways.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Paez-Pereda, M (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 10, D-80804 Munich, Germany.	marcelo@mpipsykl.mpg.de	Theodoropoulou, Marily/S-9546-2017; Vila, Greisa/P-1335-2018	Theodoropoulou, Marily/0000-0002-7378-4374; Paez-Pereda, Marcelo/0000-0001-6029-0706; Vila, Greisa/0000-0003-1918-1959				Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; ARZT E, 1992, J CLIN INVEST, V90, P1944, DOI 10.1172/JCI116072; Arzt E, 1999, FRONT NEUROENDOCRIN, V20, P71, DOI 10.1006/frne.1998.0176; Autelitano DJ, 1996, MOL CELL ENDOCRINOL, V119, P25, DOI 10.1016/0303-7207(96)03791-4; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Boutillier A L, 1998, Pituitary, V1, P33, DOI 10.1023/A:1009966808106; BOUTILLIER AL, 1995, MOL ENDOCRINOL, V9, P745, DOI 10.1210/me.9.6.745; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; Brar BK, 2004, ENDOCRINOLOGY, V145, P1718, DOI 10.1210/en.2003-1023; Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495; GAGNER JP, 1987, MOL ENDOCRINOL, V1, P677, DOI 10.1210/mend-1-10-677; Grammatopoulos DK, 2002, TRENDS ENDOCRIN MET, V13, P436, DOI 10.1016/S1043-2760(02)00670-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; LIU B, 1992, MOL CELL BIOL, V12, P3978, DOI 10.1128/MCB.12.9.3978; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Muller MB, 2003, NAT NEUROSCI, V6, P1100, DOI 10.1038/nn1123; Muller MB, 2001, ENDOCRINOLOGY, V142, P4150, DOI 10.1210/en.142.9.4150; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Nikodemova M., 2002, Archives of Physiology and Biochemistry, V110, P123, DOI 10.1076/apab.110.1.123.901; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; Paez-Pereda M, 2001, J CLIN INVEST, V108, P1123, DOI 10.1172/JCI11098; Pereda MP, 2000, J CLIN ENDOCR METAB, V85, P263, DOI 10.1210/jc.85.1.263; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Reul JMHM, 2002, CURR OPIN PHARMACOL, V2, P23, DOI 10.1016/S1471-4892(01)00117-5; Roessler E, 2003, P NATL ACAD SCI USA, V100, P13424, DOI 10.1073/pnas.2235734100; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Scully KM, 2002, SCIENCE, V295, P2231, DOI 10.1126/science.1062736; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; Treier M, 2001, DEVELOPMENT, V128, P377	35	35	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					281	+		10.1096/fj.04-2138fje	http://dx.doi.org/10.1096/fj.04-2138fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15572433				2022-12-25	WOS:000225482100002
J	Cartron, PF; Arokium, H; Oliver, L; Meflah, K; Manon, S; Vallette, FM				Cartron, PF; Arokium, H; Oliver, L; Meflah, K; Manon, S; Vallette, FM			Distinct domains control the addressing and the insertion of Bax into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; SUBCELLULAR-LOCALIZATION; CELL-DEATH; INTRACELLULAR-LOCALIZATION; MEMBRANE-INSERTION; YEAST MITOCHONDRIA; BH3-ONLY PROTEINS; TARGETING SIGNAL; ALPHA-HELIX	The translocation of Bax from the cytosol into the mitochondrial outer membrane is a central event during apoptosis. We report that beyond the addressing step, which involves its first alpha-helix (h alpha 1), the helices alpha 5 and alpha 6 (h alpha 5 alpha 6) are responsible for the insertion of Bax into mitochondrial outer membrane bilayer. The translocation of Bax to mitochondria is associated with specific changes in the conformation of the protein that are under the control of two prolines: Pro-13, which controls the unfolding of h alpha 1, and Pro-168, a proline located immediately before the hydrophobic carboxyl-terminal end (i.e. helix alpha 9, h alpha 9), which controls the disclosure of h alpha 5 alpha 6. An additional step, the disruption of an electrostatic bond formed between Asp-33 (h alpha 1) and Lys-64 (BH3), allows the mitochondria addressing of Bax. We conclude that, although the intramolecular interactions of h alpha 1 with the BH3 region control the addressing of Bax to mitochondria, the Pro-168 is involved in the control of its membrane insertion through h alpha 5 alpha 6.	Univ Nantes, INSERM, UMR 601,Apoptosis & Tumor Progress Equipe Labelis, Inst Federatif Rech 26,Equipe 4, F-44035 Nantes, France; Univ Bordeaux 2, UMR 5095 CNRS, F-33077 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Vallette, FM (corresponding author), Univ Nantes, INSERM, UMR 601,Apoptosis & Tumor Progress Equipe Labelis, Inst Federatif Rech 26,Equipe 4, 9 Quai Moncousu, F-44035 Nantes, France.	fval@nantes.inserm.fr	Manon, Stéphen/C-7088-2017; Oliver, Lisa J/L-3070-2015; Vallette, Francois/N-2361-2018; Cartron, Pierre Francois/K-9802-2015; Vallette, Francois M/K-9047-2015	Oliver, Lisa J/0000-0002-5588-7564; Vallette, Francois M/0000-0002-3296-8572; Manon, Stephen/0000-0002-5792-1084; Vallette, Francois/0000-0003-0802-0519; Cartron, Pierre-Francois/0000-0002-3393-784X				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Arokium H, 2004, J BIOL CHEM, V279, P52566, DOI 10.1074/jbc.M408373200; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Cartron PF, 2004, J BIOL CHEM, V279, P11503, DOI 10.1074/jbc.M311922200; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Guihard G, 2004, J BIOL CHEM, V279, P46542, DOI 10.1074/jbc.M405153200; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; John GB, 2002, EXP CELL RES, V278, P198, DOI 10.1006/excr.2002.5586; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; Lalle P, 2002, BIOCHEM J, V368, P213, DOI 10.1042/BJ20020836; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P619; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shi B, 1999, BIOCHEM BIOPH RES CO, V254, P779, DOI 10.1006/bbrc.1998.0130; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Zha HB, 1996, MOL CELL BIOL, V16, P6494	52	77	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10587	10598		10.1074/jbc.M409714200	http://dx.doi.org/10.1074/jbc.M409714200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15590655	hybrid			2022-12-25	WOS:000227559600104
J	Yoshida, S; Parniske, M				Yoshida, S; Parniske, M			Regulation of plant symbiosis receptor kinase through serine and threonine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; ACTIVATION LOOP; ARABIDOPSIS; AUTOPHOSPHORYLATION; DOMAIN; GENE; RICE	We studied the biochemical properties of a plant receptor-like kinase to gain insights into the regulatory mechanism of this largest class of plant kinases. SYMRK ( symbiosis receptor kinase) is required for early signal transduction leading to plant root symbioses with nitrogen-fixing rhizobia and phosphate-acquiring arbuscular mycorrhizal fungi. Amino acid substitutions in positions critical for activity of other related kinases cause a non-symbiotic plant phenotype, suggesting that SYMRK kinase activity is required for symbiosis. SYMRK is capable of intermolecular autophosphorylation. Non-phosphorylated SYMRK is less active than the phosphorylated version, suggesting the phosphorylation status of SYMRK determines its activity. Three Ser/Thr residues were identified as residues required for full kinase activation through targeted mutagenesis. Using quadrupole time-of-flight mass spectrometry analysis, two of these were confirmed to be phosphorylated in vitro. These crucial phosphorylation sites are conserved among various plant receptor-like kinases as well as animal Pelle/interleukin-1 receptor associated kinase. Despite the distinct domain architecture of receptor-like kinases versus Pelle/interleukin-1 receptor associated kinase, our results suggest the existence of conserved activation mechanisms.	John Innes Ctr, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Parniske, M (corresponding author), Univ Munich, Inst Genet, Maria Ward Str 1a, D-80638 Munich, Germany.	martin.parniske@lrz.uni-muenchen.de	Yoshida, Satoko/G-5003-2010; Parniske, Martin/F-2202-2011; Yoshida, Satoko/AAZ-4757-2021; yoshida, satoko/AAO-4892-2020; Parniske, Martin/M-3781-2019	Yoshida, Satoko/0000-0002-9999-7861; Parniske, Martin/0000-0001-8561-747X; yoshida, satoko/0000-0002-9999-7861; Parniske, Martin/0000-0001-8561-747X				Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; CORMACK B, 1997, CURRENT PROTOCOLS MO; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Krusell L, 2002, NATURE, V420, P422, DOI 10.1038/nature01207; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li JM, 2003, CURR OPIN PLANT BIOL, V6, P494, DOI 10.1016/S1369-5266(03)00088-8; Limpens E, 2003, SCIENCE, V302, P630, DOI 10.1126/science.1090074; Liu GZ, 2002, J BIOL CHEM, V277, P20264, DOI 10.1074/jbc.M110999200; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; Nishimura R, 2002, NATURE, V420, P426, DOI 10.1038/nature01231; Nuhse TS, 2004, PLANT CELL, V16, P2394, DOI 10.1105/tpc.104.023150; Parniske M, 2004, CURR OPIN PLANT BIOL, V7, P414, DOI 10.1016/j.pbi.2004.05.011; Perry JA, 2003, PLANT PHYSIOL, V131, P866, DOI 10.1104/pp.102.017384; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sessa G, 2000, EMBO J, V19, P2257, DOI 10.1093/emboj/19.10.2257; Shah K, 2001, J BIOL CHEM, V276, P41263, DOI 10.1074/jbc.M102381200; Shen BH, 2002, DEVELOPMENT, V129, P1925; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shiu SH, 2004, PLANT CELL, V16, P1220, DOI 10.1105/tpc.020834; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Tichtinsky G, 2003, TRENDS PLANT SCI, V8, P231, DOI 10.1016/S1360-1385(03)00062-1; Wu AJ, 2004, PLANT CELL, V16, P2809, DOI 10.1105/tpc.104.024141	28	74	78	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9203	9209		10.1074/jbc.M411665200	http://dx.doi.org/10.1074/jbc.M411665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15572355	hybrid			2022-12-25	WOS:000227453100069
J	Gupta, M; Yarwood, SJ				Gupta, M; Yarwood, SJ			MAP1A light chain 2 interacts with exchange protein activated by cyclic AMP 1 (EPAC1) to enhance Rap1 GTPase activity and cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAN GTPASE; CAMP; RAP1; AMP	We have recently demonstrated that light chain 2 ( LC2) of the microtubule-associated protein MAP1A interacts with the cyclic AMP ( cAMP)-binding domain of exchange protein directly activated by cyclic AMP 1 (EPAC1). In the present study we used a simultaneous expression system and found that LC2 enhances both basal and 8-(4-chlorophenylthio)-2'-O-methyladenosine-3':5'-cyclic monophosphate (8-CPT-2Me-cAMP)-stimulated Rap1 activation by EPAC1. LC2 is known to stabilize microtubules; therefore we examined whether microtubules enhanced Rap1 activation by LC2. Nocodazole inhibited Rap1 activity in cells transfected with EPAC1 alone but had little effect on Rap1 activity in cells transfected with both EPAC1 and LC2. This indicates that part of the actions of LC2 in enhancing EPAC1 activity may be through stabilization of microtubules. We also found that in cells transfected with LC2, Rap1 was more sensitive to activation by 8-CPT2Me-cAMP. Moreover, LC2 enhanced the ability of transfected and endogenous EPAC1 to interact with cyclic AMP-agarose, indicating that LC2 elicits conformational changes in the cAMP domain of EPAC1, enhancing its ability to be activated by cyclic AMP. We also found that disruption of the interaction of endogenous EPAC1 and LC2 with antibodies to the cAMP domain of EPAC1 abolished Rap1 activity in PC12 cell lysates, demonstrating the importance of LC2 for EPAC1 activation in these cells. Consistent with a role of EPAC1 in controlling integrin activity, we found that cell adhesion to laminin was enhanced in LC2- and EPAC1-transfected cells stimulated with 8-CPT-2Me-cAMP. LC2 is therefore a biological enhancer of EPAC1 activity toward Rap1 and associated downstream signaling mechanisms.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Yarwood, SJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	syarwood@bio.gla.ac.uk		Yarwood, Stephen/0000-0001-9489-9253				Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Engh RA, 2001, ADV ENZYME REGUL, V41, P121, DOI 10.1016/S0065-2571(00)00010-8; Enserink JM, 2004, J BIOL CHEM, V279, P44889, DOI 10.1074/jbc.M404599200; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Houslay MD, 1998, SEMIN CELL DEV BIOL, V9, P161, DOI 10.1006/scdb.1997.0221; Kahana JA, 1999, J CELL BIOL, V146, P1205, DOI 10.1083/jcb.146.6.1205; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Magiera MM, 2004, BIOCHEM J, V382, P803, DOI 10.1042/BJ20040122; McPhee I, 2000, FEBS LETT, V477, P213, DOI 10.1016/S0014-5793(00)01762-2; Nishimoto T, 2000, BIOL CHEM, V381, P397, DOI 10.1515/BC.2000.052; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; Qiao JB, 2002, J BIOL CHEM, V277, P26581, DOI 10.1074/jbc.M203571200; Rehmann H, 2003, J BIOL CHEM, V278, P23508, DOI 10.1074/jbc.M301680200; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020	23	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8109	8116		10.1074/jbc.M413697200	http://dx.doi.org/10.1074/jbc.M413697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591041	hybrid			2022-12-25	WOS:000227395700082
J	Wang, Q; Downey, GP; Herrera-Abreu, MT; Kapus, A; McCulloch, CA				Wang, Q; Downey, GP; Herrera-Abreu, MT; Kapus, A; McCulloch, CA			SHP-2 modulates interleukin-1-induced Ca2+ flux and ERK activation via phosphorylation of phospholipase C gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE FUNCTION; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; CALCIUM FLUX; FIBROBLASTS; ORGANIZATION; INDUCTION; IL-1	Interleukin- 1 ( IL- 1) signaling is dependent on focal adhesions, structures that are enriched with tyrosine kinases and phosphatases. Because the non- receptor tyrosine phosphatase Src homology 2 domain- containing protein tyrosine phosphatase- 2 ( SHP- 2) is enriched in focal adhesions and IL- 1- induced ERK activation requires increased Ca2+, we determined whether SHP- 2 modulates IL- 1- induced Ca2+ signaling. In SHP- 2- deficient fibroblasts, IL- 1- induced Ca2+ signaling and ERK activation were markedly diminished compared with cells expressing SHP- 2. IL- 1- induced Ca2+ release from the endoplasmic reticulum occurred in the vicinity of focal adhesions and was strongly inhibited by the blockage of phospholipase C ( PLC) catalytic activity. Immunoprecipitation and immunostaining showed that SHP- 2, the endoplasmic reticulum- specific protein calnexin, and PLCgamma1 were associated with focal adhesions; however, these associations and IL- 1- induced ERK activation dissipated after cells were plated on non- integrin substrates. IL- 1 promoted phosphorylation of SHP- 2 and PLCgamma1. IL- 1- induced phosphorylation of PLCgamma1 was diminished in SHP- 2- deficient cells but was restored by stable transfection with SHP- 2. BAPTA/ AM ( 1,2- bis( 2aminophenoxy) ethane- N, N, N', N'- tetraacetic acid tetrakis( acetoxymethyl ester)) blocked IL- 1- induced phosphorylation of SHP- 2 and PLCgamma1, indicating mutually dependent interactive roles for Ca2+, SHP- 2, and PLCgamma1 in IL- 1 signaling. We conclude that SHP- 2 is critical for IL- 1- induced phosphorylation of PLCgamma1 and thereby enhances IL- 1- induced Ca2+ release and ERK activation. Focal adhesions co- localizing with the endoplasmic reticulum may provide molecular staging sites required for ERK activation.	Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 3E8, Canada; Univ Toronto, Dept Med, Div Resp, Toronto, ON M5G 2C4, Canada; Univ Hlth Network, Toronto Gen Hosp, Inst Res, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1G6, Canada; Toronto Gen Hosp, Div Surg, Toronto, ON M5G 1G6, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	McCulloch, CA (corresponding author), Univ Toronto, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca		Downey, Gregory P/0000-0003-3253-5862				ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Boyle DL, 1997, ARTHRITIS RHEUM, V40, P1772, DOI 10.1002/art.1780401008; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; HONIG J, 1989, J PERIODONTAL RES, V24, P362, DOI 10.1111/j.1600-0765.1989.tb00883.x; Hsu S, 2003, CELL SIGNAL, V15, P1149, DOI 10.1016/S0898-6568(03)00088-3; Ko KS, 2001, J BIOL CHEM, V276, P35967, DOI 10.1074/jbc.M104106200; Ko KSC, 1998, INFECT IMMUN, V66, P703, DOI 10.1128/IAI.66.2.703-709.1998; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Luo L, 1997, BIOCHEM J, V324, P653, DOI 10.1042/bj3240653; MacGillivray M, 2003, J BIOL CHEM, V278, P27190, DOI 10.1074/jbc.M213083200; MacGillivray MK, 2000, J BIOL CHEM, V275, P23509, DOI 10.1074/jbc.M003186200; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Petrone A, 2000, J CELL SCI, V113, P2345; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Rosado JA, 2001, J BIOL CHEM, V276, P15666, DOI 10.1074/jbc.M009217200; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Tran H, 2002, J CELL SCI, V115, P2031; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wang Q, 2003, FASEB J, V17, pA1072; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	37	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8397	8406		10.1074/jbc.M410462200	http://dx.doi.org/10.1074/jbc.M410462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15563458	hybrid			2022-12-25	WOS:000227395700116
J	Kypreos, KE; van Dijk, KW; Havekes, LM; Zannis, VI				Kypreos, KE; van Dijk, KW; Havekes, LM; Zannis, VI			Generation of a recombinant apolipoprotein E variant with improved biological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; CARBOXY-TERMINAL DOMAIN; TRANSGENIC MICE; IN-VIVO; APO-E; A-I; LIPOPROTEIN; ATHEROSCLEROSIS; CHOLESTEROL; PLASMA	To identify the residues in the carboxyl-terminal region 260-299 of human apolipoprotein E (apoE) that contribute to hypertriglyceridemia, two sets of conserved, hydrophobic amino acids between residues 261 and 283 were mutated to alanines, and recombinant adenoviruses expressing these apoE mutants were generated. Adenovirus-mediated gene transfer of apoE4-mut1 (apoE4 (L261A, W264A, F265A, L268A, V269A)) in apoE-deficient mice (apoE(-/-)) corrected plasma cholesterol levels and did not cause hypertriglyceridemia. In contrast, gene transfer of apoE4-mut2 (apoE4 (W276A, L279A, V280A, V283A)) did not correct hypercholesterolemia and induced mild hypertriglyceridemia. ApoE-induced hyperlipidemia was corrected by co-infection with a recombinant adenovirus expressing human lipoprotein lipase. Both apoE4 mutants caused only a small increase in hepatic very low density lipoprotein-triglyceride secretion. Density gradient ultracentrifugation analysis of plasma and electron microscopy showed that wild-type apoE4 and apoE4-mut2 displaced apoA-1 from the high density lipoprotein (HDL) region and promoted the formation of discoidal HDL, whereas the apoE4-mut1 did not displace apoA-I from HDL and promoted the formation of spherical HDL. The findings indicate that residues Leu-261, Trp-264, Phe-265, Leu-268, and Val-269 of apoE are responsible for hypertriglyceridemia and also interfere with the formation of HDL. Substitutions of these residues by alanine provide a recombinant apoE form with improved biological functions.	Boston Univ, Sch Med, Mol Genet Sect, Whitaker Cardiovasc Inst,Dept Med, Boston, MA 02118 USA; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2333 AL Leiden, Netherlands; TNO, Prevent Gezondheid Prevent & Hlth, Gaubius Lab, NL-2333 CK Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2333 AL Leiden, Netherlands; Univ Crete, Sch Med, Inst Mol Biol & Biotechnol, Dept Biochem, GR-71110 Iraklion, Greece	Boston University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Crete	Zannis, VI (corresponding author), Boston Univ, Sch Med, Mol Genet Sect, Whitaker Cardiovasc Inst,Dept Med, 700 Albany St,W-509, Boston, MA 02118 USA.	vzannis@bu.edu	van Dijk, Ko Willems/AAT-4681-2021; van Dijk, Ko Willems/A-1798-2008; Kypreos, Kyriakos/AAG-1745-2020; KYPREOS, KYRIAKOS/AAN-4485-2020	van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394; Kypreos, Kyriakos/0000-0001-6784-2710; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068216] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68216] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Gerritsen G, 2003, J LIPID RES, V44, P408, DOI 10.1194/jlr.M200313-JLR200; HAVEL RJ, 1980, J CLIN INVEST, V66, P1351, DOI 10.1172/JCI109988; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang YD, 1997, ARTERIOSCL THROM VAS, V17, P2010, DOI 10.1161/01.ATV.17.10.2010; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; JI ZS, 1994, J BIOL CHEM, V269, P2764; Kypreos KE, 2003, BIOCHEMISTRY-US, V42, P9841, DOI 10.1021/bi0271796; Kypreos KE, 2001, BIOCHEMISTRY-US, V40, P6027, DOI 10.1021/bi002414a; Kypreos KE, 2001, FASEB J, V15, P1598, DOI 10.1096/fj.00-0882fje; Kypreos KE, 2001, J BIOL CHEM, V276, P19778, DOI 10.1074/jbc.M100418200; Li XP, 2003, BIOCHEMISTRY-US, V42, P10406, DOI 10.1021/bi027093c; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Saito H, 2003, J BIOL CHEM, V278, P14782, DOI 10.1074/jbc.M213207200; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Zannis VI, 2004, CURR OPIN LIPIDOL, V15, P151, DOI 10.1097/00041433-200404000-00008; ZANNIS VI, 1981, AM J HUM GENET, V33, P11; ZANNIS VI, 1998, NATO ASI SER, P179	25	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6276	6284		10.1074/jbc.M413458200	http://dx.doi.org/10.1074/jbc.M413458200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15576362	hybrid			2022-12-25	WOS:000227332700007
J	Roos, AK; Burgos, E; Ericsson, DJ; Salmon, L; Mowbray, SL				Roos, AK; Burgos, E; Ericsson, DJ; Salmon, L; Mowbray, SL			Competitive inhibitors of Mycobacterium tuberculosis ribose-5-phosphate isomerase B reveal new information about the reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTOSE-PHOSPHATE PATHWAY; ESCHERICHIA-COLI; PHOSPHOGLUCOSE ISOMERASE; CRYSTAL-STRUCTURE; SPINACH; SUGARS	Ribose-5-phosphate isomerase (Rpi), an important enzyme in the pentose phosphate pathway, catalyzes the interconversion of ribulose 5-phosphate and ribose 5-phosphate. Two unrelated isomerases have been identified, RpiA and RpiB, with different structures and active site residues. The reaction catalyzed by both enzymes is thought to proceed via a high energy enediolate intermediate, by analogy to other carbohydrate isomerases. Here we present studies of RpiB from Mycobacterium tuberculosis together with small molecules designed to resemble the enediolate intermediate. The relative affinities of these inhibitors for RpiB have a different pattern than that observed previously for the RpiA from spinach. X-ray structures of RpiB in complex with the inhibitors 4-phospho-D-erythronohydroxamic acid (K-m 57 mum) and 4-phospho-D-erythronate (K-i 1.7 mm) refined to resolutions of 2.1 and 2.2 Angstrom, respectively, allowed us to assign roles for most active site residues. These results, combined with docking of the substrates in the position of the most effective inhibitor, now allow us to outline the reaction mechanism for RpiBs. Both enzymes have residues that can catalyze opening of the furanose ring of the ribose 5-phosphate and so can improve the efficiency of the reaction. Both enzymes also have an acidic residue that acts as a base in the isomerization step. A lysine residue in RpiAs provides for more efficient stabilization of the intermediate than the corresponding uncharged groups of RpiBs; this same feature lies behind the more efficient binding of RpiA to 4-phospho-D-erythronate.	Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, SE-75124 Uppsala, Sweden; CNRS, UMR 8124, Inst Chim Mol & Mat Orsay, Lab Chim Bioorgan & Bioinorgan, F-91405 Orsay, France; Swedish Univ Agr Sci, Dept Mol Biol, Biomed Ctr, SE-75124 Uppsala, Sweden	Uppsala University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Swedish University of Agricultural Sciences	Mowbray, SL (corresponding author), SLU, Dept Mol Biol, BMC,Box 590, SE-75124 Uppsala, Sweden.	mowbray@xray.bmc.uu.se	Mowbray, Sherry L/D-2141-2013; Salmon, Laurent/T-5179-2018; Ericsson, Daniel/F-7458-2011	Salmon, Laurent/0000-0003-1946-8458; Ericsson, Daniel/0000-0001-5101-9244				Arsenieva D, 2002, P NATL ACAD SCI USA, V99, P5872, DOI 10.1073/pnas.052131799; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Burgos E, 2004, TETRAHEDRON LETT, V45, P3465, DOI 10.1016/j.tetlet.2004.03.004; Burgos E, 2004, TETRAHEDRON LETT, V45, P753, DOI 10.1016/j.tetlet.2003.11.038; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; DAVID J, 1970, BIOCHIM BIOPHYS ACTA, V208, P56, DOI 10.1016/0304-4165(70)90048-6; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ESSENBERG MK, 1975, EUR J BIOCHEM, V55, P323, DOI 10.1111/j.1432-1033.1975.tb02166.x; EVANS RP, 1993, P CCP4 STUD WEEK DAT, P114; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; Hardre R, 1999, CARBOHYD RES, V318, P110, DOI 10.1016/S0008-6215(99)00100-7; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Huck JHJ, 2004, AM J HUM GENET, V74, P745, DOI 10.1086/383204; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung CH, 2000, ARCH BIOCHEM BIOPHYS, V373, P409, DOI 10.1006/abbi.1999.1554; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Lee JH, 2001, BIOCHEMISTRY-US, V40, P7799, DOI 10.1021/bi002916o; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PIERCE J, 1985, J AM CHEM SOC, V107, P2448, DOI 10.1021/ja00294a041; Roos AK, 2004, J MOL BIOL, V335, P799, DOI 10.1016/j.jmb.2003.11.021; Sorensen KI, 1996, J BACTERIOL, V178, P1003, DOI 10.1128/jb.178.4.1003-1011.1996; WOOD T, 1970, ANAL BIOCHEM, V33, P297, DOI 10.1016/0003-2697(70)90300-3; Zhang RG, 2003, J MOL BIOL, V332, P1083, DOI 10.1016/j.jmb.2003.08.009; Zhang RG, 2003, STRUCTURE, V11, P31, DOI 10.1016/S0969-2126(02)00933-4	29	33	35	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6416	6422		10.1074/jbc.M412018200	http://dx.doi.org/10.1074/jbc.M412018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590681	hybrid			2022-12-25	WOS:000227332700022
J	Shirai, T; Miyagi, S; Horiuchi, D; Okuda-Katayanagi, T; Nishimoto, M; Muramatsu, M; Sakamoto, Y; Nagata, M; Hagiwara, K; Okuda, A				Shirai, T; Miyagi, S; Horiuchi, D; Okuda-Katayanagi, T; Nishimoto, M; Muramatsu, M; Sakamoto, Y; Nagata, M; Hagiwara, K; Okuda, A			Identification of an enhancer that controls up-regulation of fibronectin during differentiation of embryonic stem cells into extraembryonic endoderm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; RETINOIC ACID; MOUSE EMBRYOS; GENE; TRANSCRIPTION; EXPRESSION; PROTEIN; COMPLEX; OCT-3/4; SOX-2	The extraembryonic endoderm is derived from inner cell mass cells of the blastocyst during early mouse embryogenesis. Formation of the extraembryonic endoderm, which later contributes to the yolk sac, appears to be a prerequisite for subsequent differentiation of the inner cell mass. While embryonic stem cells can be induced to differentiate into extraembryonic endoderm cells in vitro, the molecular mechanisms underlying this process are poorly understood. We used a promoter trap approach to search for genes that are expressed in embryonic stem cells and are highly up-regulated during differentiation to the extraembryonic endoderm fate. We showed that fibronectin fits this expression profile. Moreover we identified an enhancer in the 12th intron of the fibronectin locus that recapitulated the endogenous pattern of fibronectin expression. This enhancer carries Sox protein-binding sequences, and our analysis demonstrated that Sox7 and Sox17, which are highly expressed in the extraembryonic endoderm, were involved in enhancer activity.	Saitama Med Sch, Div Dev Biol, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan; Saitama Med Sch, Dept Resp Med, Moroyama, Saitama 3500495, Japan; Saitama Small Enterprise Promot Cooperat, Rat Evolutionary Design Adv Biomol Grp, Kawaguchi, Saitama 3330844, Japan	Saitama Medical University; Saitama Medical University	Okuda, A (corresponding author), Saitama Med Sch, Div Dev Biol, Res Ctr Genom Med, 1397-1 Yamane, Hidaka, Saitama 3501241, Japan.	akiokuda@saitama-med.ac.jp						Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; Farrington SM, 1997, MECH DEVELOP, V62, P197, DOI 10.1016/S0925-4773(97)00664-3; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hogan B, 1994, MANIPULATING MOUSE E; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Li CY, 1996, J BIOL CHEM, V271, P6810, DOI 10.1074/jbc.271.12.6810; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Miyagi S, 2004, MOL CELL BIOL, V24, P4207, DOI 10.1128/MCB.24.10.4207-4220.2004; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Murakami A, 2004, J BIOL CHEM, V279, P28564, DOI 10.1074/jbc.M313814200; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Niimi T, 2004, J BIOL CHEM, V279, P38055, DOI 10.1074/jbc.M403724200; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; OKUDA A, 1989, J BIOL CHEM, V264, P16919; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; Tanaka M, 1997, DEV BIOL, V190, P55, DOI 10.1006/dbio.1997.8685; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THORSTEINSDOTTIR S, 1992, ANAT RECORD, V232, P141, DOI 10.1002/ar.1092320116; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; WARTIOVAARA J, 1979, DEV BIOL, V69, P247, DOI 10.1016/0012-1606(79)90289-6; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; ZETTER BR, 1978, P NATL ACAD SCI USA, V75, P2324, DOI 10.1073/pnas.75.5.2324; Zietkiewicz E, 1996, J MOL EVOL, V42, P66, DOI 10.1007/BF00163213	36	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7244	7252		10.1074/jbc.M410731200	http://dx.doi.org/10.1074/jbc.M410731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590650	hybrid			2022-12-25	WOS:000227332700116
J	Levinthal, DJ; DeFranco, DB				Levinthal, DJ; DeFranco, DB			Reversible oxidation of ERK-directed protein phosphatases drives oxidative toxicity in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PHOSPHATASE; CORTICAL-NEURONS; CATALYTIC ACTIVATION; HYDROGEN-PEROXIDE; REDOX REGULATION; INHIBITION; 2A; INACTIVATION; GLUTAMATE; PHOSPHORYLATION	Oxidative stress links diverse neuropathological conditions that include stroke, Parkinson's disease, and Alzheimer's disease and has been modeled in vitro with various paradigms that lead to neuronal cell death following the increased accumulation of reactive oxygen species. For example, immortalized neurons and immature primary cortical neurons undergo cell death in response to depletion of the antioxidant glutathione, which can be elicited by administration of glutamate at high concentrations. We have demonstrated previously that this glutamate-induced oxidative toxicity requires activation of the mitogen-activated protein kinase member ERK1/2, but the mechanisms by which this activation takes place in oxidatively stressed neurons are still not fully known. In this study, we demonstrate that during oxidative stress, ERK-directed phosphatases of both the serine/threonine- and tyrosine-directed classes are selectively and reversibly inhibited via a mechanism that is dependent upon the oxidation of cysteine thiols. Furthermore, the impact of ERK-directed phosphatases on ERK1/2 activation and oxidative toxicity in neurons was tested in a neuronal cell line and in primary cortical cultures. Overexpression of the highly ERK-specific phosphatase MKP3 and its catalytic mutant, MKP3 C293S, were neuroprotective in transiently transfected HT22 cells and primary neurons. The neuroprotective effect of the MKP3 C293S mutant, which enhances ERK1/2 phosphorylation but blocks its nuclear translocation, demonstrates the necessity for active ERK1/2 nuclear localization for oxidative toxicity in neurons. Together, these data implicate the inhibition of endogenous ERK-directed phosphatases as a mechanism that leads to aberrant ERKl/2 activation and nuclear accumulation during oxidative toxicity in neurons.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DeFranco, DB (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E1352 BST, Pittsburgh, PA 15261 USA.	dod1@pitt.edu	Levinthal, David/AAJ-6606-2021	Levinthal, David/0000-0001-8453-8382	NINDS NIH HHS [NS43824, R01 NS38319] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038319, F30NS043824] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Dowd S, 1998, J CELL SCI, V111, P3389; Ferri A, 2004, J NEUROCHEM, V90, P1237, DOI 10.1111/j.1471-4159.2004.02588.x; Foley TD, 2004, BIOCHEM BIOPH RES CO, V315, P568, DOI 10.1016/j.bbrc.2004.01.096; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Guerra-Crespo M, 2003, J NEUROSCI METH, V127, P179, DOI 10.1016/S0165-0270(03)00125-0; Horbinski C, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-2; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Laakko T, 2003, J BIOL CHEM, V278, P31621, DOI 10.1074/jbc.M304700200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Levinthal DJ, 2004, J BIOL CHEM, V279, P11206, DOI 10.1074/jbc.M314261200; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lin YW, 2003, J BIOL CHEM, V278, P21534, DOI 10.1074/jbc.M301854200; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; O'Loghlen A, 2003, ARCH BIOCHEM BIOPHYS, V417, P194, DOI 10.1016/S0003-9861(03)00368-0; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Pei JJ, 2003, AM J PATHOL, V163, P845, DOI 10.1016/S0002-9440(10)63445-1; Pei JJ, 2002, MOL BRAIN RES, V109, P45, DOI 10.1016/S0169-328X(02)00488-6; Persson C, 2004, P NATL ACAD SCI USA, V101, P1886, DOI 10.1073/pnas.0304403101; RATAN RR, 1994, J NEUROCHEM, V62, P376; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sohn J, 2003, BIOCHEMISTRY-US, V42, P10060, DOI 10.1021/bi0345081; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004	42	105	108	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5875	5883		10.1074/jbc.M410771200	http://dx.doi.org/10.1074/jbc.M410771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579467	hybrid			2022-12-25	WOS:000227217100092
J	Ravassa, S; Bennaghmouch, A; Kenis, H; Lindhout, T; Hackeng, T; Narula, J; Hofstra, L; Reutelingsperger, C				Ravassa, S; Bennaghmouch, A; Kenis, H; Lindhout, T; Hackeng, T; Narula, J; Hofstra, L; Reutelingsperger, C			Annexin A5 down-regulates surface expression of tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PLACENTAL ANTICOAGULANT PROTEIN; PHOSPHOLIPID-BINDING PROTEIN; FACTOR PATHWAY INHIBITOR; PROCOAGULANT ACTIVITY; APOPTOTIC CELLS; BALLOON INJURY; MOUSE MODEL; FACTOR-VIIA; VASCULAR ANTICOAGULANT	Phosphatidylserine (PtdSer) is exposed on the external leaflet of the plasma membrane during apoptosis. The protein annexin A5 (anxA5) shows high affinity for PtdSer. When anxA5 binds to the PtdSer-expressing membranes during apoptosis, it crystallizes as an extended two-dimensional network and activates thereby a novel portal of cell entry that results in the internalization of the PtdSer-expressing membrane patches. This novel pathway of cell entry is potentially involved in the regulation of the surface expression of membrane receptors. In this study we report the regulation of surface expression of the initiator of blood coagulation tissue factor (TF) by this novel pathway of cell entry. AnxA5 induces the internalization of tissue factor expressed on the surface of apoptotic THP-1 macrophages. This down-regulation depends on the abilities of anxA5 to bind to PtdSer and to form a two-dimensional crystal at the membrane. We furthermore show that THP-1 cells produce and externalize anxA5 that cause the internalization of TF in an autocrine type of mechanism. We extended our in vitro work to the in vivo situation and show in a mouse model that anxA5 causes the down-regulation of TF expression by smooth muscle cells of the media of the carotid artery that was mechanically injured. In conclusion, anxA5 down-regulates surface-expressed TF by activating the novel portal of cell entry. This mechanism may be part of a more general autocrine function of anxA5 to regulate the plasma membrane receptor repertoir under stress conditions associated with the surface expression of PtdSer.	Univ Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Cardiovasc Res Inst, Dept Cardiol, NL-6200 MD Maastricht, Netherlands; Univ Calif Irvine, Dept Med Cardiol, Irvine, CA 92612 USA	Maastricht University; Maastricht University; University of California System; University of California Irvine	Reutelingsperger, C (corresponding author), Univ Maastricht, Dept Biochem, POB 616, NL-6200 MD Maastricht, Netherlands.	c.reutelingsperger@bioch.unimaas.nl	Ravassa, Susana/I-2567-2017	Ravassa, Susana/0000-0001-5926-5677; Hackeng, Tilman/0000-0003-0142-0843				Albuquerque MLC, 1998, EXP CELL RES, V245, P163, DOI 10.1006/excr.1998.4243; ANDREE HAM, 1995, BLOOD COAGUL FIBRIN, V6, P189, DOI 10.1097/00001721-199505000-00001; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Aupeix K, 1996, BIOCHEM J, V314, P1027, DOI 10.1042/bj3141027; Barrowcliffe TW, 2002, THROMB HAEMOSTASIS, V87, P442; Benevolensky D, 2000, LAB INVEST, V80, P123, DOI 10.1038/labinvest.3780016; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; Brachvogel B, 2003, MOL CELL BIOL, V23, P2907, DOI 10.1128/MCB.23.8.2907-2913.2003; Brisset AC, 2003, THROMB HAEMOSTASIS, V90, P511, DOI 10.1160/TH02-12-0291; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; CasciolaRosen L, 1996, P NATL ACAD SCI USA, V93, P1624, DOI 10.1073/pnas.93.4.1624; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; CORRADI A, 1995, EXP CELL RES, V217, P355, DOI 10.1006/excr.1995.1097; Courtman DW, 1998, CIRC RES, V82, P996, DOI 10.1161/01.RES.82.9.996; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; Fan XX, 2004, MOL BIOL CELL, V15, P2863, DOI 10.1091/mbc.E03-09-0670; Flynn PD, 1997, BLOOD, V89, P4378, DOI 10.1182/blood.V89.12.4378; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gertz SD, 1998, CIRCULATION, V98, P580, DOI 10.1161/01.CIR.98.6.580; GOVORUKHINA N, 2002, ANNEXINS BIOL IMPORT, P40; GRAMZINSKI RA, 1989, BLOOD, V73, P983; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hansen CB, 2001, BLOOD, V97, P1712, DOI 10.1182/blood.V97.6.1712; Hatakeyama K, 1998, ATHEROSCLEROSIS, V139, P265, DOI 10.1016/S0021-9150(98)00077-X; Iakhiaev A, 1999, J BIOL CHEM, V274, P36995, DOI 10.1074/jbc.274.52.36995; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; Kenis H, 2004, J BIOL CHEM, V279, P52623, DOI 10.1074/jbc.M409009200; KONDO S, 1987, THROMB RES, V48, P449, DOI 10.1016/0049-3848(87)90402-6; Krailadsiri P, 1997, TRANSFUS SCI, V18, P223; Kunzelmann-Marche C, 2000, THROMB HAEMOSTASIS, V83, P282, DOI 10.1055/s-0037-1613800; LIEMANN S, 1995, STRUCTURE, V3, P233, DOI 10.1016/S0969-2126(01)00152-6; LINDNER V, 1993, CIRC RES, V73, P792, DOI 10.1161/01.RES.73.5.792; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MANN KG, 1992, SEMIN HEMATOL, V29, P213; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MAURERFOGY I, 1988, EUR J BIOCHEM, V174, P585, DOI 10.1111/j.1432-1033.1988.tb14139.x; Nemerson Y, 1998, BLOOD COAGUL FIBRIN, V9, pS45; Oguchi A, 1999, INT J HEMATOL, V69, P119; Oling F, 2001, J STRUCT BIOL, V133, P55, DOI 10.1006/jsbi.2000.4337; Osterud B, 1997, THROMB HAEMOSTASIS, V78, P755; Osterud B, 1998, BLOOD COAGUL FIBRIN, V9, pS9; PAWASHE AB, 1994, CIRC RES, V74, P56, DOI 10.1161/01.RES.74.1.56; Rand JH, 1997, NEW ENGL J MED, V337, P154, DOI 10.1056/NEJM199707173370303; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Reis ED, 2000, J VASC SURG, V32, P1022, DOI 10.1067/mva.2000.109763; Reutelingsperger CPM, 2002, J IMMUNOL METHODS, V265, P123, DOI 10.1016/S0022-1759(02)00075-3; REUTELINGSPERGER CPM, 1985, EUR J BIOCHEM, V151, P625, DOI 10.1111/j.1432-1033.1985.tb09150.x; ROMISCH J, 1990, BIOCHEM J, V272, P223; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Sato H, 2000, ONCOGENE, V19, P2904, DOI 10.1038/sj.onc.1203615; Schecter AD, 2000, CIRC RES, V87, P126, DOI 10.1161/01.RES.87.2.126; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; SERRES M, 1994, CELL MOL BIOL, V40, P701; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; Sohma H, 2001, J BIOCHEM-TOKYO, V130, P449, DOI 10.1093/oxfordjournals.jbchem.a003005; Speidel CM, 1996, CORONARY ARTERY DIS, V7, P57; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; van Zandvoort M, 2004, J VASC RES, V41, P54, DOI 10.1159/000076246; VANHEERDE WL, 1995, THROMB HAEMOSTASIS, V73, P172; Wang J, 2001, BRIT J HAEMATOL, V115, P382, DOI 10.1046/j.1365-2141.2001.03095.x; Wang X, 2001, PLACENTA, V22, P837, DOI 10.1053/plac.2001.0724; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	71	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6028	6035		10.1074/jbc.M411710200	http://dx.doi.org/10.1074/jbc.M411710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15576370	hybrid			2022-12-25	WOS:000227217100108
J	Sakwe, AM; Rask, L; Gylfe, E				Sakwe, AM; Rask, L; Gylfe, E			Protein kinase C modulates agonist-sensitive release of Ca2+ from internal stores in HEK293 cells overexpressing the calcium sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; INOSITOL TRISPHOSPHATE RECEPTOR; EXTRACELLULAR CALCIUM; HORMONE RELEASE; CA2+-SENSING RECEPTOR; CYTOSOLIC CALCIUM; 2-AMINOETHOXYDIPHENYL BORATE; DIFFERENTIAL REGULATION; CYTOPLASMIC CALCIUM; PHORBOL ESTERS	This study examined the mechanism of Ca2+ entry and the role of protein kinase C (PKC) in Ca2+ signaling induced by activation of the calcium sensing receptor (CaR) in HEK293 cells stably expressing the CaR. We demonstrate that influx of Ca2+ following CaR activation exhibits store-operated characteristics in being associated with Ca2+ store depletion and inhibited by 2-aminoethoxydiphenyl borate. Inhibition of PKC with GF109203X, Go6983, or Go6976 and down-regulation of PKC activity enhanced the release of Ca2+ from internal stores in response to the polyvalent cationic Call agonist neomycin, whereas activation of PKC with acute 12-O-tetradecanoylphorbol-13-acetate treatment decreased the release. In contrast, overexpression of wild type PKC-alpha or -is an element of augmented the neomycin-induced release of Ca2+ from internal stores, whereas dominant negative PKC-is an element of strongly decreased the release, but dominant negative PKC-alpha had little effect. Prolonged treatment of cells with 12-O-tetradecanoylphorbol-13-acetate effectively down-regulated immunoreactive PKC-alpha but had little effect on the expression of PKC-is an element of. Together these results indicate that diacylglycerol-responsive PKC isoforms differentially influence CaR agonist-induced release of Ca2+ from internal stores. The fundamentally different results obtained when overexpressing or functionally down-regulating specific PKC isoforms as compared with pharmacological manipulation of PKC activity indicate the need for caution when interpreting data obtained with the latter approach.	Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, SE-75123 Uppsala, Sweden; Uppsala Univ, Dept Med Cell Biol, Biomed Ctr, SE-75123 Uppsala, Sweden	Uppsala University; Uppsala University	Rask, L (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden.	Lars.Rask@imbim.uu.se	Rask, Lars B/L-4177-2013; Sakwe, Amos/AAU-7639-2020	Sakwe, Amos/0000-0002-2283-794X; Gylfe, Erik/0000-0002-8414-2107				Albert AP, 2002, J PHYSIOL-LONDON, V544, P113, DOI 10.1113/jphysiol.2002.022574; Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; Bilmen JG, 2002, CELL SIGNAL, V14, P955, DOI 10.1016/S0898-6568(02)00042-6; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; BORNER C, 1992, J BIOL CHEM, V267, P12892; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chen LW, 2000, SHOCK, V13, P175, DOI 10.1097/00024382-200003000-00002; CLARKE BL, 1993, ENDOCRINOLOGY, V132, P1168, DOI 10.1210/en.132.3.1168; Clarke H, 2000, KIDNEY INT, V58, P1004, DOI 10.1046/j.1523-1755.2000.00258.x; Dyachok O, 2001, J CELL SCI, V114, P2179; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Gil C, 1999, NEUROCHEM INT, V35, P281, DOI 10.1016/S0197-0186(99)00076-5; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1989, ACTA PHYSIOL SCAND, V135, P107, DOI 10.1111/j.1748-1716.1989.tb08557.x; GYLFE E, 1988, J BIOL CHEM, V263, P5044; Hebert SC, 1997, J EXP BIOL, V200, P295; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200; Jiang YF, 2002, J BIOL CHEM, V277, P50543, DOI 10.1074/jbc.M205798200; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; KIFOR O, 1988, ENDOCRINOLOGY, V123, P2723, DOI 10.1210/endo-123-6-2723; Kondo I, 2000, JPN J PHARMACOL, V82, P210, DOI 10.1254/jjp.82.210; KUO TH, 1991, J BIOL CHEM, V266, P2520; LEBOFF MS, 1985, J CLIN INVEST, V75, P49, DOI 10.1172/JCI111696; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Litosch I, 2003, BIOCHEMISTRY-US, V42, P1618, DOI 10.1021/bi026414h; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma R, 2001, J BIOL CHEM, V276, P25759, DOI 10.1074/jbc.M011241200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McKay C, 1996, ENDOCRINOLOGY, V137, P2473, DOI 10.1210/en.137.6.2473; MEMBRENO L, 1989, ENDOCRINOLOGY, V124, P789, DOI 10.1210/endo-124-2-789; NYGREN P, 1988, BIOCHIM BIOPHYS ACTA, V968, P253, DOI 10.1016/0167-4889(88)90014-6; Onyango I, 1999, EXP CELL RES, V247, P9, DOI 10.1006/excr.1998.4324; Poirier SN, 2001, BIOCHEMISTRY-US, V40, P6486, DOI 10.1021/bi010207k; Putney JW, 1999, BIOESSAYS, V21, P38; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P141, DOI 10.1113/jphysiol.1993.sp019764; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P163, DOI 10.1113/jphysiol.1993.sp019765; RACKE FK, 1993, FEBS LETT, V333, P132, DOI 10.1016/0014-5793(93)80390-G; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; RIDEFELT P, 1992, ACTA ENDOCRINOL-COP, V126, P505, DOI 10.1530/acta.0.1260505; Rosado JA, 2000, J PHYSIOL-LONDON, V529, P159, DOI 10.1111/j.1469-7793.2000.00159.x; Sakwe AM, 2004, EXP CELL RES, V297, P560, DOI 10.1016/j.yexcr.2004.03.039; SHOBACK DM, 1990, ENDOCRINOLOGY, V127, P141, DOI 10.1210/endo-127-1-141; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; WALLFELT C, 1988, BIOCHIM BIOPHYS ACTA, V969, P257, DOI 10.1016/0167-4889(88)90060-2; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396; Young SH, 2002, J BIOL CHEM, V277, P46871, DOI 10.1074/jbc.M207083200	54	10	10	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4436	4441		10.1074/jbc.M411686200	http://dx.doi.org/10.1074/jbc.M411686200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572354	hybrid			2022-12-25	WOS:000227096600054
J	Zhan, MC; Yu, DH; Liu, JH; Hannay, J; Pollock, RE				Zhan, MC; Yu, DH; Liu, JH; Hannay, J; Pollock, RE			Transcriptional repression of protein kinase C alpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CARCINOMA CELLS; IN-VITRO; EXPRESSION; MODULATION; SARCOMA; GENE; ISOZYMES; PROLIFERATION; DOXORUBICIN	The protein kinase C (PKC) family consists of serine/threonine protein kinases that play important roles in signal transduction, cell proliferation, and tumor formation. Recent studies found that PKCs are commonly overexpressed in human tumors, including soft tissue sarcoma (STS). Overexpression of PKCs contributes to invasion and migration of tumor cells and induction of angiogenesis. PKC can also phosphorylate the multidrug resistance (MDR) gene-encoded P-glycoprotein and induce MDR phenotype. Our previous studies showed that mutation of p53 enhanced STS metastasis and mediated the MDR phenotype. Restoring wild type (WT) p53 in STS cells containing mutant p53 sensitized the cells to chemotherapy. In the present study, we found that PKCalpha protein expression is inhibited by WT p53 partly due to reduced PKCa mRNA expression in STS cells, but p53 does not affect PKCa mRNA stability. Deletion and mutation analysis of the PKCa promoter fused to the luciferase reporter gene identified a Sp1 binding site (-244/-234) in the PKCa promoter that is required for p53-mediated inhibition of PKCa promoter activity. More importantly, PKCa phosphorylates and activates MDR1 P-glycoprotein, whereas inhibition of PKCalpha by p53 leads to decreased MDR1 phosphorylation in STS cells, which sensitizes STS cells to chemotherapeutic agents. These data indicate that WT p53 may resensitize STS to chemotherapeutic agents by reducing MDR1 phosphorylation via transcriptional repression of PKCalpha expression. Thus, molecular-based therapies targeting mutant p53 and PKCa may be an effective new strategy to improve chemotherapeutic efficacy in STS.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, U107, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Yu, DH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, U107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyu@mdanderson.org; rpollock@mdanderson.org		Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [CA 16672, R01-CA-109570, 2R01-CA-67802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109570, R01CA067802, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1993, MOL PHARMACOL, V43, P858; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Chen LG, 1999, GYNECOL ONCOL, V72, P171, DOI 10.1006/gyno.1998.5242; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Clark JH, 2002, BIOCHEMISTRY-US, V41, P11847, DOI 10.1021/bi025600k; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; Gill PK, 2001, EUR J BIOCHEM, V268, P4151, DOI 10.1046/j.1432-1327.2001.02326.x; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; KIESER A, 1994, ONCOGENE, V9, P963; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Milas M, 2000, CANCER GENE THER, V7, P422, DOI 10.1038/sj.cgt.7700141; Nakamura K, 2000, ANTICANCER RES, V20, P1; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; O'Brian CA, 2001, CANCER METAST REV, V20, P95, DOI 10.1023/A:1013186430906; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OBRIAN CA, 1989, CANCER RES, V49, P3215; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Park MJ, 2000, NEUROSCI LETT, V290, P201, DOI 10.1016/S0304-3940(00)01358-6; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Pollock R, 1998, CLIN CANCER RES, V4, P1985; Pollock RE, 1996, ONCOGENE, V12, P2035; SCHWARTZ GK, 1990, JNCI-J NATL CANCER I, V82, P1753, DOI 10.1093/jnci/82.22.1753; Serra M, 1999, INT J ONCOL, V14, P301; Shie JL, 2004, J BIOL CHEM, V279, P25010, DOI 10.1074/jbc.M403103200; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; Tenzer A, 2001, CANCER RES, V61, P8203; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zaugg K, 2001, CANCER RES, V61, P732; Zhan MC, 2001, CANCER, V92, P1556, DOI 10.1002/1097-0142(20010915)92:6<1556::AID-CNCR1482>3.0.CO;2-S; Zhang LL, 2000, CANCER RES, V60, P3655	45	48	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4825	4833		10.1074/jbc.M407450200	http://dx.doi.org/10.1074/jbc.M407450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563462	hybrid			2022-12-25	WOS:000227096600101
J	Zhang, JW; Butland, G; Greenblatt, JF; Emili, A; Zamble, DB				Zhang, JW; Butland, G; Greenblatt, JF; Emili, A; Zamble, DB			A role for SlyD in the Escherichia coli hydrogenase biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRADYRHIZOBIUM-JAPONICUM; FK506-BINDING PROTEIN; NICKEL INCORPORATION; MUTATIONAL ANALYSIS; BINDING-PROTEIN; LYSIS PROTEIN; OPERON; GENE; ISOENZYMES; EXPRESSION	The [NiFe] centers at the active sites of the Escherichia coli hydrogenase enzymes are assembled by a team of accessory proteins that includes the products of the hyp genes. To determine whether any other proteins are involved in this process, the sequential peptide affinity system was used. The analysis of the proteins in a complex with HypB revealed the peptidyl-prolyl cis/ trans-isomerase SlyD, a metal-binding protein that has not been previously linked to the hydrogenase biosynthetic pathway. The association between HypB and SlyD was confirmed by chemical cross-linking of purified proteins. Deletion of the slyD gene resulted in a marked reduction of the hydrogenase activity in cell extracts prepared from anaerobic cultures, and an in-gel assay was used to demonstrate diminished activities of both hydrogenase 1 and 2. Western analysis revealed a decrease in the final proteolytic processing of the hydrogenase 3 HycE protein, indicating that the metal center was not assembled properly. These deficiencies were all rescued by growth in medium containing excess nickel, but zinc did not have any phenotypic effect. Experiments with radioactive nickel demonstrated that less nickel accumulated in DeltaslyD cells compared with wild type, and overexpression of SlyD from an inducible promoter doubled the level of cellular nickel. These experiments demonstrate that SlyD has a role in the nickel insertion step of the hydrogenase maturation pathway, and the possible functions of SlyD are discussed.	Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Zamble, DB (corresponding author), Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada.	dzamble@chem.utoronto.ca		Zamble, Deborah/0000-0002-8976-3375				Andrews SC, 1997, MICROBIOL-SGM, V143, P3633, DOI 10.1099/00221287-143-11-3633; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; BEGG YA, 1977, FEMS MICROBIOL LETT, V2, P47, DOI 10.1111/j.1574-6968.1977.tb00905.x; Bernhardt TG, 2002, MOL MICROBIOL, V45, P99, DOI 10.1046/j.1365-2958.2002.02984.x; Binder U, 1996, ARCH MICROBIOL, V165, P69, DOI 10.1007/s002030050299; Blokesch M, 2004, J BACTERIOL, V186, P2603, DOI 10.1128/JB.186.9.2603-2611.2004; Blokesch M, 2002, BIOCHEM SOC T, V30, P674, DOI 10.1042/BST0300674; Bloom SL, 2004, BIOCHEMISTRY-US, V43, P10029, DOI 10.1021/bi049404k; BOCK A, 1996, CELLULAR MOL BIOL, P262; BUTLAND G, 2005, IN PRESS NATURE; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Casalot L, 2001, TRENDS MICROBIOL, V9, P228, DOI 10.1016/S0966-842X(01)02009-1; Cavet JS, 2003, FEMS MICROBIOL REV, V27, P165, DOI 10.1016/S0168-6445(03)00050-0; Chan JN, 2002, COORDIN CHEM REV, V233, P319, DOI 10.1016/S0010-8545(02)00176-5; Chivers PT, 2000, J BIOL CHEM, V275, P19735, DOI 10.1074/jbc.M002232200; Clugston SL, 1998, BIOCHEMISTRY-US, V37, P8754, DOI 10.1021/bi972791w; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; Finzi A, 2003, J VIROL METHODS, V111, P69, DOI 10.1016/S0166-0934(03)00154-X; Fischer G, 2004, REV PHYSIOL BIOCH P, V148, P105, DOI 10.1007/s10254-003-0011-3; Fontecilla-Camps J. C., 2001, HYDROGEN FUEL, P93; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Furutani M, 2000, BIOCHEMISTRY-US, V39, P453, DOI 10.1021/bi9911076; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Harrar Y, 2001, TRENDS PLANT SCI, V6, P426, DOI 10.1016/S1360-1385(01)02044-1; Hottenrott S, 1997, J BIOL CHEM, V272, P15697, DOI 10.1074/jbc.272.25.15697; Hube M, 2002, J BACTERIOL, V184, P3879, DOI 10.1128/JB.184.14.3879-3885.2002; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; Kislinger T, 2003, MOL CELL PROTEOMICS, V2, P96, DOI 10.1074/mcp.M200074-MCP200; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; Maier T, 1996, ARCH MICROBIOL, V165, P333, DOI 10.1007/s002030050335; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; Messenger SL, 2003, FEMS MICROBIOL LETT, V228, P81, DOI 10.1016/S0378-1097(03)00726-2; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Nakamura T, 1998, GENOMICS, V54, P89, DOI 10.1006/geno.1998.5571; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; RAGSDALE SW, 2000, ENZYME CATALYZED ELE, V35, P487; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; Rodrigue A, 1996, J BACTERIOL, V178, P4453, DOI 10.1128/jb.178.15.4453-4460.1996; ROOF WD, 1994, J BIOL CHEM, V269, P2902; Roof WD, 1997, MOL MICROBIOL, V25, P1031, DOI 10.1046/j.1365-2958.1997.5201884.x; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; ROSSMANN R, 1994, EUR J BIOCHEM, V220, P377, DOI 10.1111/j.1432-1033.1994.tb18634.x; Sanokawa-Akakura R, 2004, J BIOL CHEM, V279, P27845, DOI 10.1074/jbc.C400118200; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; SAWERS RG, 1985, J BACTERIOL, V164, P1324, DOI 10.1128/JB.164.3.1324-1331.1985; Scholz C, 1999, FEBS LETT, V443, P367, DOI 10.1016/S0014-5793(98)01735-9; Self WT, 2004, J BACTERIOL, V186, P580, DOI 10.1128/JB.186.2.580-587.2004; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Suzuki R, 2003, J MOL BIOL, V328, P1149, DOI 10.1016/S0022-2836(03)00379-6; Theodoratou E, 2000, EUR J BIOCHEM, V267, P1995, DOI 10.1046/j.1432-1327.2000.01202.x; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; Witte A, 1997, MOL MICROBIOL, V26, P337, DOI 10.1046/j.1365-2958.1997.5781941.x; WULFING C, 1994, J BIOL CHEM, V269, P2895; YU D, 2003, P NATL ACAD SCI USA, V97, P5978; Zeghouf M, 2004, J PROTEOME RES, V3, P463, DOI 10.1021/pr034084x	62	108	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4360	4366		10.1074/jbc.M411799200	http://dx.doi.org/10.1074/jbc.M411799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569666	hybrid			2022-12-25	WOS:000227096600045
J	Zhou, RF; Snyder, PM				Zhou, RF; Snyder, PM			Nedd4-2 phosphorylation induces serum and glucocorticoid-regulated kinase (SGK) ubiquitination and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; SODIUM-CHANNEL; INDUCIBLE KINASE; PROTEIN-KINASE; MISSENSE MUTATION; LIDDLES-SYNDROME; COLLECTING DUCT; BETA-SUBUNIT; GENE; MDM2	Serum and glucocorticoid-regulated kinase (SGK) plays a key role in the regulation of epithelial Na+ transport. SGK phosphorylates Nedd4-2, an E3 ubiquitin-protein ligase that targets the epithelial Na+ channel (ENaC for degradation. Phosphorylation increases Na+ transport by reducing Nedd4-2 binding to ENaC, which increases ENaC expression at the cell surface. Thus, SGK expression must be tightly controlled to maintain Na+ homeostasis. This occurs in part by regulation of SGK transcription; a variety of signals including steroid hormones (aldosterone and glucocorticoids) increase SGK levels by inducing transcription of SGK. However, SGK has a short half-life, suggesting that SGK levels might also be controlled by regulation of SGK degradation. Here we found that SGK degradation is mediated in part by Nedd4-2. Consistent with this model, overexpression of Nedd4-2 decreased steady-state levels of SGK in a dose-dependent manner by increasing SGK ubiquitination and degradation in the 26S proteasome. Conversely, silencing of Nedd4-2 by RNA interference stabilized SGK. Nedd4-2 phosphorylation potentiates SGK degradation; degradation was reduced by Nedd4-2 and SGK mutations that disrupt phosphorylation or by inhibition of SGK kinase activity. Together with previous work, the data support a model in which SGK and Nedd4-2 regulate one another in a reciprocal manner. SGK phosphorylates Nedd4-2, which reduces Nedd4-2 binding and inhibition of ENaC. Conversely, phosphorylation increases Nedd4-2-mediated degradation of SGK. Thus, by phosphorylating Nedd4-2, SGK induces its own degradation. This feedback inhibition may fine-tune the regulation of epithelial Na+ absorption.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 371 EMRB, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072256, R29HL058812, P50HL055006, R01HL058812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55006, HL72256, HL58812] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Brickley DR, 2002, J BIOL CHEM, V277, P43064, DOI 10.1074/jbc.M207604200; Busjahn A, 2002, HYPERTENSION, V40, P256, DOI 10.1161/01.HYP.0000030153.19366.26; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen SC, 2004, HYPERTENSION, V43, P866, DOI 10.1161/01.HYP.0000121883.55722.45; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; De la Rosa DA, 2003, AM J PHYSIOL-CELL PH, V284, pC404, DOI 10.1152/ajpcell.00398.2002; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pearce D, 2003, CELL PHYSIOL BIOCHEM, V13, P13, DOI 10.1159/000070245; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shigaev A, 2000, AM J PHYSIOL-RENAL, V278, pF613, DOI 10.1152/ajprenal.2000.278.4.F613; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Uehara Y, 1998, J HYPERTENS, V16, P1131, DOI 10.1097/00004872-199816080-00008; Waldegger S, 1998, PFLUG ARCH EUR J PHY, V436, P575, DOI 10.1007/s004240050674; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	74	78	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4518	4523		10.1074/jbc.M411053200	http://dx.doi.org/10.1074/jbc.M411053200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15576372	hybrid			2022-12-25	WOS:000227096600065
J	Schmittwolf, C; Porsch, M; Greiner, A; Avots, A; Muller, AM				Schmittwolf, C; Porsch, M; Greiner, A; Avots, A; Muller, AM			HOXB4 confers a constant rate of in vitro proliferation to transduced bone marrow cells	ONCOGENE			English	Article						HOXB4; bone marrow cells; proliferation; differentiation; cell cycle regulation	HEMATOPOIETIC STEM-CELLS; CELLULAR PROLIFERATION; VIVO EXPANSION; EXPRESSION; JUNB; DIFFERENTIATION; OVEREXPRESSION; PROTEINS; DIVISION; MICE	HOXB4 overexpression mediates increased self-renewal of haematopoietic stem cells (HSCs) ex vivo. Since HOXB4-expanded HSCs retain normal differentiation potential and there is no leukaemia development from transduced HSCs, HOXB 4 represents a promising tool for human HSC therapy. However, the increased proliferation capacity of HOXB4 overexpressing fibroblasts resulting from upregulation of JunB, Fra-1 and cyclin D1 protein levels may indicate a potential risk associated with the HOXB4 overexpression approach. This prompted us to investigate the proliferation rate, differentiation and expression of cell cycle regulators directly in bone marrow cultures overexpressing HOXB4. Here we show that in comparison to neo-transduced control bone marrow cultures, HOXB4-overexpressing cultures had a more homogenous morphology and increased numbers of haematopoietic progenitor cells capable to generate primitive colonies in vitro. In contrast, neo-transduced bone marrow cells in long-term cultures showed hallmarks of myeloid differentiation and a reduced secondary colony forming activity. We further show that multilineage repopulating activity in vivo, which was present only in HOXB4 long-term cultures, declined over time. HOXB4 overexpression in vitro did not result in an increase but in a stabilization of the proliferation rate (1.4 - 1.8 cell divisions per day), while the proliferation rate of control neo-transduced bone marrow cultures gradually declined. Correspondingly, increased HOXB4 expression was paralleled by decreased expression levels of cyclins, CDKs and AP-1 family members. These results suggest that the growth rate of HOXB4- compared to neo-transduced bone marrow cells remains constant in long-term cultures along with a suppression of myeloid differentiation. In contrast to HOXB4 overexpression in fibroblasts, bone marrow cells engineered to overexpress HOXB4 do not upregulate AP-1 complex members or cyclins indicating that HOXB4 acts in a cell type-specific way.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Muller, AM (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacherstr 5, D-97078 Wurzburg, Germany.	andris@ema-avoti.de; albrecht.mueller@mail.uni-wuerzburg.de						Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Brun ACM, 2003, MOL THER, V8, P618, DOI 10.1016/S1525-0016(03)00237-5; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; Furukawa Y, 2002, LEUKEMIA LYMPHOMA, V43, P225, DOI 10.1080/10428190290005973; Israels ED, 2001, STEM CELLS, V19, P88, DOI 10.1634/stemcells.19-1-88; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Loeffler M, 2002, CELLS TISSUES ORGANS, V171, P8, DOI 10.1159/000057688; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Oostendorp RAJ, 2000, BLOOD, V95, P855, DOI 10.1182/blood.V95.3.855.003k41_855_862; Oostendorp RAJ, 2002, BLOOD, V99, P1183, DOI 10.1182/blood.V99.4.1183; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; Rowlands TM, 2004, CELL CYCLE, V3, P145; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schiedlmeier B, 2003, BLOOD, V101, P1759, DOI 10.1182/blood-2002-03-0767; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	38	14	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					561	572		10.1038/sj.onc.1208202	http://dx.doi.org/10.1038/sj.onc.1208202			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580301				2022-12-25	WOS:000226420400004
J	Yang, LC; Leung, ACC; Ko, JMY; Lo, PHY; Tang, JCO; Srivastava, G; Oshimura, M; Stanbridge, EJ; Daigo, Y; Nakamura, Y; Tang, CMC; Lau, KW; Law, S; Lung, ML				Yang, LC; Leung, ACC; Ko, JMY; Lo, PHY; Tang, JCO; Srivastava, G; Oshimura, M; Stanbridge, EJ; Daigo, Y; Nakamura, Y; Tang, CMC; Lau, KW; Law, S; Lung, ML			Tumor suppressive role of a 2.4Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma	ONCOGENE			English	Article						chromosome 9; deleted in esophageal cancer 1; tumor suppressor gene; esophageal carcinoma; microcell-mediated chromosome transfer	COMPARATIVE GENOMIC HYBRIDIZATION; NASOPHARYNGEAL CARCINOMA; HOMOZYGOUS DELETION; CHROMOSOME TRANSFER; FUNCTIONAL EVIDENCE; GENETIC ALTERATIONS; BLADDER-CANCER; ALLELE LOSS; LINES; HETEROZYGOSITY	The key genes involved in the development of esophageal squamous cell carcinoma (ESCC) remain to be elucidated. Previous studies indicate extensive genomic alterations occur on chromosome 9 in ESCC. Using a monochromosome transfer approach, this study provides functional evidence and narrows down the critical region (CR) responsible for chromosome 9 tumor suppressing activity to a 2.4 Mb region mapping to 9q33 - q34 between markers D9S1798 and D9S61. Interestingly, a high prevalence of allelic loss in this CR is also observed in primary ESCC tumors by microsatellite typing. Allelic loss is found in 30/ 34 (88%) tumors and the loss of heterozygosity (LOH) frequency ranges from 67 to 86%. Absent to low expression of a 9q32 candidate tumor suppressor gene (TSG), DEC1 ( deleted in esophageal cancer 1), is detected in four Asian ESCC cell lines. Stably expressing DEC1 transfectants provide functional evidence for inhibition of tumor growth in nude mice and DEC1 expression is decreased in tumor segregants arising after long-term selection in vivo. There is 74% LOH in the DEC1 region of ESCC primary tumors. This study provides the first functional evidence for the presence of critical tumor suppressive regions on 9q33 - q34. DEC1 is a candidate TSG that may be involved in ESCC development.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; Tottori Univ, Dept Biomed Sci, Tottori 680, Japan; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Tuen Mun Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; University of Hong Kong; Hong Kong Polytechnic University; Tottori University; University of California System; University of California Irvine; University of Tokyo; Tuen Mun Hospital; Tuen Mun Hospital; University of Hong Kong	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China.	bomaria@ust.hk	Tang, Johnny Cheuk-on/W-7214-2019; Tang, Johnny C. O./M-9639-2014; Ko, Josephine/U-2972-2019; Law, Simon/C-4324-2009; Lung, Maria Li/C-4495-2009	Tang, Johnny Cheuk-on/0000-0002-4261-3206; Tang, Johnny C. O./0000-0002-4261-3206; Ko, Josephine/0000-0002-7997-331X; Law, Simon/0000-0002-6518-5806; Daigo, Yataro/0000-0002-0915-3025; Lung, Maria Li/0000-0003-2559-3626				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Gorgoulis VG, 1998, MOL MED, V4, P807, DOI 10.1007/BF03401773; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Grady B, 2001, J UROLOGY, V166, P1088, DOI 10.1016/S0022-5347(05)65927-7; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; He CD, 1999, CHINESE MED J-PEKING, V112, P497; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; HU CP, 1984, J NATL CANCER I, V72, P577; Hu YC, 2002, CANCER GENET CYTOGEN, V135, P120, DOI 10.1016/S0165-4608(01)00580-5; HUANG Y, 1992, CANCER RES, V52, P6525; Jagasia AA, 1996, CANCER LETT, V105, P91, DOI 10.1016/0304-3835(96)04274-7; Karkera JD, 2000, CLIN CANCER RES, V6, P3565; Kwong FM, 2004, CANCER LETT, V208, P207, DOI 10.1016/j.canlet.2003.11.017; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Marshall B, 1997, CANCER GENET CYTOGEN, V96, P134, DOI 10.1016/S0165-4608(96)00300-7; Miura K, 1996, CANCER RES, V56, P1629; MORI T, 1994, HUM MOL GENET, V3, P1969, DOI 10.1093/hmg/3.11.1969; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Muzeau F, 1997, INT J CANCER, V72, P27, DOI 10.1002/(SICI)1097-0215(19970703)72:1<27::AID-IJC3>3.0.CO;2-6; Naidoo R, 1999, DIAGN MOL PATHOL, V8, P131, DOI 10.1097/00019606-199909000-00005; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U; Parker WL, 2003, J BONE MINER RES, V18, P289, DOI 10.1359/jbmr.2003.18.2.289; Parris CN, 1999, CANCER RES, V59, P516; Qin P, 2004, J CELL BIOCHEM, V92, P147, DOI 10.1002/jcb.20057; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; SAMPSON JR, 1995, J MED GENET, V32, P848, DOI 10.1136/jmg.32.11.848; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; Tada K, 2000, CANCER GENET CYTOGEN, V117, P108, DOI 10.1016/S0165-4608(99)00160-0; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Wang L, 1996, ONCOGENE, V12, P699; Wiest JS, 1997, CANCER RES, V57, P1; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; YAMADA H, 1990, ONCOGENE, V5, P1141; Yang LC, 2004, CANCER LETT, V203, P71, DOI 10.1016/j.canlet.2003.09.027; Yen CC, 2003, INT J ONCOL, V23, P871; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M	45	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					697	705		10.1038/sj.onc.1208179	http://dx.doi.org/10.1038/sj.onc.1208179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580306				2022-12-25	WOS:000226420400017
J	Li, YW; Kelly, WG; Logsdon, JM; Schurko, AM; Harfe, BD; Hill-Harfe, KL; Kahn, RA				Li, YW; Kelly, WG; Logsdon, JM; Schurko, AM; Harfe, BD; Hill-Harfe, KL; Kahn, RA			Functional genomic analysis of the ADP-ribosylation factor family of GTPases: phylogeny among diverse eukaryotes and function in C-elegans	FASEB JOURNAL			English	Article						Arf family; protein sequence; eukaryotic evolution; RAS superfamily; regulatory protein	GTP-BINDING PROTEIN; HEAT-LABILE ENTEROTOXINS; PHOSPHOLIPASE-D; FACTORS ARFS; SACCHAROMYCES-CEREVISIAE; SELECTIVE AMPLIFICATION; ENDOPLASMIC-RETICULUM; MEMBRANE TRAFFICKING; DOWNSTREAM EFFECTOR; RNA INTERFERENCE	ADP-ribosylation factor (Arf) and Arf-like (Arl) proteins are a family of highly conserved 21 kDa GTPases that emerged early in the evolution of eukaryotes. These proteins serve regulatory roles in vesicular traffic, lipid metabolism, microtubule dynamics, development, and likely other cellular processes. We found evidence for the presence of 6 Arf family members in the protist Giardia lamblia and 22 members in mammals. A phylogenetic analysis was performed to delineate the evolutionary relationships among Arf family members and to attempt to organize them by both their evolutionary origins and functions in cells and/or organisms. The similar to 100 protein sequences analyzed from animals, fungi, plants, and protists clustered into 11 groups, including Arfs, nine Arls, and Sar proteins. To begin functional analyses of the family in a metazoan model organism, we examined roles for all three C. elegans Arfs (Arf-1, Arf-3, and Arf-6) and three Arls (Arl-1, Arl-2, and Arl-3) by use of RNA-mediated interference (RNAi). Injection of double-stranded RNA ( dsRNA) encoding Arf-1 or Arf-3 into N2 hermaphrodites produced embryonic lethality in their offspring and, later, sterility in the injected animals themselves. Injection of Arl-2 dsRNA resulted in a disorganized germline and sterility in early offspring, with later offspring exhibiting an early embryonic arrest. Thus, of the six Arf family members examined in C. elegans, at least three are required for embryogenesis. These data represent the first analysis of the role(s) of multiple members of this family in the development of a multicellular organism.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biol, Atlanta, GA USA	Emory University; Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Logsdon, John M/B-7812-2009; Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [R01 GM068029, R01 GM067226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], PHYLIP PHYLOGENY INF; Antoshechkin I, 2002, DEV CELL, V2, P579, DOI 10.1016/S1534-5807(02)00146-6; Bargmann CI, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews1005; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BRENNER S, 1974, GENETICS, V77, P71; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Casanova JE, 2003, PROTEINS CELL REG, V1, P283; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hillig RC, 2000, STRUCTURE, V8, P1239, DOI 10.1016/S0969-2126(00)00531-1; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Hoyt MA, 1997, GENETICS, V146, P849; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Jackson CL, 2003, CURR BIOL, V13, pR174, DOI 10.1016/S0960-9822(03)00116-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 2004, ARF FAMILY GTPASES, V1; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LEE FJS, 1994, J BIOL CHEM, V269, P21555; Logsdon Jr J. M., 2004, ARF FAMILY GTPASES; Lu L, 2003, MOL BIOL CELL, V14, P3767, DOI 10.1091/mbc.E03-01-0864; Lu L, 2001, J CELL SCI, V114, P4543; MADDISON WP, 2003, MACCLADE; McElver J, 2000, PLANT CELL, V12, P1379, DOI 10.1105/tpc.12.8.1379; Mello C, 1995, METHOD CELL BIOL, V48, P451; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1991, MOL MICROBIOL, V5, P2621, DOI 10.1111/j.1365-2958.1991.tb01971.x; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mueller AG, 2002, MOL CELL BIOL, V22, P1488, DOI 10.1128/MCB.22.5.1488-1494.2002; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; Ota R, 2000, MOL BIOL EVOL, V17, P798, DOI 10.1093/oxfordjournals.molbev.a026358; Panic B, 2003, MOL CELL, V12, P863, DOI 10.1016/S1097-2765(03)00356-3; Panic B, 2003, CURR BIOL, V13, P405, DOI 10.1016/S0960-9822(03)00091-5; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Praitis V, 2001, GENETICS, V157, P1217; Price SR, 1996, MOL CELL BIOCHEM, V159, P15; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Radcliffe PA, 2000, FEBS LETT, V468, P84, DOI 10.1016/S0014-5793(00)01202-3; Radhakrishna H, 1999, J CELL SCI, V112, P855; Schafer DA, 2000, TRAFFIC, V1, P892; Schurmann A, 2002, MOL CELL BIOL, V22, P2761, DOI 10.1128/MCB.22.8.2761-2768.2002; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Setty SRG, 2003, CURR BIOL, V13, P401, DOI 10.1016/S0960-9822(03)00089-7; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shern JF, 2003, J BIOL CHEM, V278, P40829, DOI 10.1074/jbc.M308678200; Song J, 1998, J CELL SCI, V111, P2257; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	84	88	94	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1834	1850		10.1096/fj.04-2273com	http://dx.doi.org/10.1096/fj.04-2273com			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576487				2022-12-25	WOS:000226091000034
J	Peterson, JA; Sheibani, N; David, G; Garcia-Pardo, A; Peters, DM				Peterson, JA; Sheibani, N; David, G; Garcia-Pardo, A; Peters, DM			Heparin II domain of fibronectin uses alpha 4 beta 1 integrin to control focal adhesion and stress fiber formation, independent of syndecan-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; MELANOMA CELL-ADHESION; HUMAN TRABECULAR CELLS; EXTRACELLULAR-MATRIX; IIICS REGION; BINDING DOMAINS; AQUEOUS OUTFLOW; ACTIN; SITE; IDENTIFICATION	Co-signaling events between integrins and cell surface proteoglycans play a critical role in the organization of the cytoskeleton and adhesion forces of cells. These processes, which appear to be responsible for maintaining intraocular pressure in the human eye, involve a novel cooperative co-signaling pathway between alpha5beta1 and alpha4beta1 integrins and are independent of heparan sulfate proteoglycans. Human trabecular meshwork cells isolated from the eye were plated on type III 7-10 repeats of fibronectin (alpha5beta1 ligand) in the absence or presence of the heparin (Hep) II domain of fibronectin. In the absence of the Hep II domain, cells had a bipolar morphology with few focal adhesions and stress fibers. The addition of the Hep II domain increased cell spreading and the numbers of focal adhesions and stress fibers. Cell spreading and stress fiber formation were not mediated by heparan sulfate proteoglycans because treatment with chlorate, heparinase, or soluble heparin did not prevent Hep II domain-mediated cell spreading. Cell spreading and stress fiber formation were mediated by alpha4beta1 integrin because soluble anti-alpha4 integrin antibodies inhibited Hep II domain-mediated cell spreading and soluble vascular cell adhesion molecule-1 (alpha4beta1 ligand)induced cell spreading. This is the first demonstration of the Hep II domain mediating cell spreading and stress fiber formation through alpha4beta1 integrin. This novel pathway demonstrates a cooperative, rather than antagonistic, role between alpha5beta1 and alpha4beta1 integrins and suggests that interactions between the Hep 11 domain and alpha4beta1 integrin could modulate the strength of cytoskeleton-mediated processes in the trabecular meshwork of the human eye.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA; Univ Louvain VIB, Dept Human Genet, B-3000 Louvain, Belgium; Consejo Super Invest Cientif, Ctr Invest Biol, Dept Immunol, Madrid 28006, Spain	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Flanders Institute for Biotechnology (VIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Peters, DM (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Rm 6590 MSC,1300 Univ Ave, Madison, WI 53706 USA.	dmpeter2@faestaff.wisc.edu	Garcia Pardo, Angeles/G-5987-2015; Sheibani, Nader/AAG-2379-2020	Garcia Pardo, Angeles/0000-0001-5577-2954; Sheibani, Nader/0000-0003-2723-9217	NATIONAL EYE INSTITUTE [R01EY012515, R03EY013700] Funding Source: NIH RePORTER; NEI NIH HHS [EY12515, EY13700] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Ashkenas J, 1996, DEV BIOL, V180, P433, DOI 10.1006/dbio.1996.0317; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Bradley JMB, 2003, INVEST OPHTH VIS SCI, V44, P5174, DOI 10.1167/iovs.03-0213; Bradley JMB, 1998, INVEST OPHTH VIS SCI, V39, P2649; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Chigaev A, 2003, J BIOL CHEM, V278, P38174, DOI 10.1074/jbc.M210472200; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; IIDA J, 1995, CANCER RES, V55, P2177; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; Jeong J, 2001, BIOCHEM J, V356, P531, DOI 10.1042/0264-6021:3560531; KAUFMAN PL, 1992, ARCH OPHTHALMOL-CHIC, V110, P34, DOI 10.1001/archopht.1992.01080130036022; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; LORIES V, 1989, J BIOL CHEM, V264, P7009; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; Moyano JV, 1999, J BIOL CHEM, V274, P135, DOI 10.1074/jbc.274.1.135; Moyano JV, 1997, J BIOL CHEM, V272, P24832, DOI 10.1074/jbc.272.40.24832; Moyano JV, 2003, MOL BIOL CELL, V14, P3699, DOI 10.1091/mbc.E02-10-0667; Peterson JA, 2000, INVEST OPHTH VIS SCI, V41, P1749; POLANSKY JR, 1984, OPHTHALMOLOGY, V91, P580; POLANSKY JR, 1979, INVEST OPHTH VIS SCI, V18, P1043; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBINSON JC, 1994, ARCH OPHTHALMOL-CHIC, V112, P1610, DOI 10.1001/archopht.1994.01090240116035; ROBINSON JC, 1991, INVEST OPHTH VIS SCI, V32, P1614; Sachchidanand, 2002, J BIOL CHEM, V277, P50629, DOI 10.1074/jbc.M208956200; Santas AJ, 2003, INVEST OPHTH VIS SCI, V44, P4796, DOI 10.1167/iovs.02-1083; Santas AJ, 2002, J BIOL CHEM, V277, P13650, DOI 10.1074/jbc.M111361200; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Steffensen B, 2001, CRIT REV ORAL BIOL M, V12, P373, DOI 10.1177/10454411010120050201; Tian BH, 2000, INVEST OPHTH VIS SCI, V41, P619; Tian BH, 1998, ARCH OPHTHALMOL-CHIC, V116, P633, DOI 10.1001/archopht.116.5.633; Wehrle-Haller B, 2003, INT J BIOCHEM CELL B, V35, P39, DOI 10.1016/S1357-2725(02)00071-7; WELLICOME SM, 1993, CLIN EXP IMMUNOL, V92, P412; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, J CELL SCI, V101, P277; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6	60	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6915	6922		10.1074/jbc.M406625200	http://dx.doi.org/10.1074/jbc.M406625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15572366	hybrid			2022-12-25	WOS:000227332700081
J	Ghosh, R; Nadiminty, N; Fitzpatrick, JE; Alworth, WL; Slaga, TJ; Kumar, AP				Ghosh, R; Nadiminty, N; Fitzpatrick, JE; Alworth, WL; Slaga, TJ; Kumar, AP			Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-PROMOTING AGENTS; CELL-CYCLE CONTROL; DNA-DAMAGE; FAMILY; MEMBER; GENE; PATHWAY; PROTEIN; ACID	Metastatic malignant melanoma is an extremely aggressive cancer, with no currently viable therapy. 4-Allyl-2-methoxyphenol (eugenol) was tested for its ability to inhibit proliferation of melanoma cells. Eugenol but not its isomer, isoeugenol (2-methoxy-4-propenylphenol), was found to be a potent inhibitor of melanoma cell proliferation. In a B16 xenograft study, eugenol treatment produced a significant tumor growth delay (p = 0.0057), an almost 40% decrease in tumor size, and a 19% increase in the median time to end point. More significantly, 50% of the animals in the control group died from metastatic growth, whereas none in the treatment group showed any signs of invasion or metastasis. Eugenol was well tolerated as determined by measurement of bodyweights. Examination of the mechanism of the antiproliferative action of eugenol in the human malignant melanoma cell line, WM1205Lu, showed that it arrests cells in the S phase of the cell cycle. Flow cytometry coupled with biochemical analyses demonstrated that eugenol induced apoptosis. cDNA array analysis showed that eugenol caused deregulation of the E2F family of transcription factors. Transient transfection assays and electrophoretic mobility shift assays showed that eugenol inhibits the transcriptional activity of E2F1. Overexpression of E2F1 restored about 75% of proliferation ability in cultures. These results indicate that deregulation of E2F1 may be a key factor in eugenol-mediated melanoma growth inhibition both in vitro and in vivo. Since the E2F transcription factors provide growth impetus for the continuous proliferation of melanoma cells, these results suggest that eugenol could be developed as an E2F-targeted agent for melanoma treatment.	AMC Canc Res Ctr, Dept Canc Causat & Prevent, Denver, CO 80214 USA; Univ Colorado, Ctr Comprehens Canc, Denver, CO 80045 USA; Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Denver, CO 80045 USA; Tulane Univ, Dept Chem, New Orleans, LA 70118 USA; Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70118 USA	AMC Cancer Research Center; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tulane University; Tulane University	Ghosh, R (corresponding author), AMC Canc Res Ctr, Dept Canc Causat & Prevent, 1600 Pierce St, Denver, CO 80214 USA.	ghoshr@amc.org			NATIONAL CANCER INSTITUTE [R01CA083518] Funding Source: NIH RePORTER; NCI NIH HHS [CA83518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 1996, CANCER RES, V56, P5475; Bertrand F, 1997, CHEM RES TOXICOL, V10, P335, DOI 10.1021/tx960087v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Dennis LK, 1999, ARCH DERMATOL, V135, P275, DOI 10.1001/archderm.135.3.275; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Ghosh R, 1996, P NATL ACAD SCI USA, V93, P6918, DOI 10.1073/pnas.93.14.6918; Ghosh R, 2003, FEBS LETT, V554, P427, DOI 10.1016/S0014-5793(03)01215-8; Ghosh R, 2003, MELANOMA RES, V13, P119, DOI 10.1097/00008390-200304000-00003; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Halaban R, 1998, INT J MOL MED, V1, P419; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Huss U, 2002, J NAT PROD, V65, P1517, DOI 10.1021/np020023m; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Johnson DG, 1998, FRONT BIOSCI, V3, pd447; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Kumar AP, 2003, NEOPLASIA, V5, P255, DOI 10.1016/S1476-5586(03)80057-X; MILLER JA, 1979, NATURALLY OCCURRING, P111; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; RASHEED A, 1984, NEW ENGL J MED, V310, P50; REED JA, 1995, CANCER RES, V55, P2713; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; STICH HF, 1981, MUTAT RES, V90, P355, DOI 10.1016/0165-1218(81)90058-6; Sukumaran K., 1994, Indian Journal of Physiology and Pharmacology, V38, P306; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; VANDUUREN BL, 1976, JNCI-J NATL CANCER I, V56, P1237, DOI 10.1093/jnci/56.6.1237; VANDUUREN BL, 1966, JNCI-J NATL CANCER I, V37, P519	34	134	142	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5812	5819		10.1074/jbc.M411429200	http://dx.doi.org/10.1074/jbc.M411429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15574415	hybrid			2022-12-25	WOS:000227217100084
J	Guillot, L; Le Goffic, R; Bloch, S; Escriou, N; Akira, S; Chignard, M; Si-Tahar, M				Guillot, L; Le Goffic, R; Bloch, S; Escriou, N; Akira, S; Chignard, M; Si-Tahar, M			Involvement of toll-like receptor 3 in the immune response of lung evithelial cells to double-stranded RNA and influenza A virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; BRONCHIAL EPITHELIAL-CELLS; FACTOR-KAPPA-B; DENDRITIC CELLS; EXPRESSION; LIPOPOLYSACCHARIDE; INFECTION; MEDIATORS; TLR3; RECOGNITION	Influenza A is a highly contagious single-stranded RNA virus that infects both the upper and lower respiratory tracts of humans. The host innate immune Toll-like receptor (TLR) 3 was shown previously in cells of myeloid origin to recognize the viral replicative, intermediate double-stranded RNA (dsRNA). Thus, dsRNA may be critical for the outcome of the infection. Here we first compared the activation triggered by either influenza A virus or dsRNA in pulmonary epithelial cells. We established that TLR3 is constitutively expressed in human alveolar and bronchial epithelial cells, and we describe its intracellular localization. Expression of TLR3 was positively regulated by the influenza A virus and by dsRNA but not by other inflammatory mediators, including bacterial lipopolysaccharide, the cytokines tumor necrosis factor-alpha and interleukin (IL)-1beta, and the protein kinase C activator phorbol 12-myristate 13-acetate. We also demonstrated that TLR3 contributes directly to the immune response of respiratory epithelial cells to influenza A virus and dsRNA, and we propose a molecular mechanism by which these stimuli induce epithelial cell activation. This model involves mitogen-activated protein kinases, phosphatidylinositol 3-kinase/ Akt signaling, and the TLR3-associated adaptor molecule TRIF but not MyD88-dependent activation of the transcription factors NF-kappaB or interferon regulatory factor/interferon-sensitive response-element pathways. Ultimately, this signal transduction elicits an epithelial response that includes the secretion of the cytokines IEL-8, H.-6, RANTES (regulated on activation normal T cell expressed and secreted), and interferon-P and the up-regulation of the major adhesion molecule ICAM-1.	Inst Pasteur, INSERM, E336, Unite Def Innee & Inflammat, F-75015 Paris, France; Inst Pasteur, CNRS, URA 1966, Unite Genet Mol Virus Resp, F-75015 Paris, France; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Osaka University	Si-Tahar, M (corresponding author), Inst Pasteur, INSERM, E336, Unite Def Innee & Inflammat, 25 Rue Dr Roux, F-75015 Paris, France.	sitahar@pasteur.fr	LE GOFFIC, Ronan/M-3099-2019; LE GOFFIC, Ronan/B-7649-2008; SI-TAHAR, Mustapha/L-4149-2014; Escriou, Nicolas/A-2392-2016; Si-Tahar, Mustapha/W-8034-2019; Akira, Shizuo/C-3134-2009; Guillot, Loic/D-8893-2011; Chignard, Michel/B-4351-2008	LE GOFFIC, Ronan/0000-0002-2012-0064; LE GOFFIC, Ronan/0000-0002-2012-0064; SI-TAHAR, Mustapha/0000-0002-5792-7742; Escriou, Nicolas/0000-0002-1224-6839; Si-Tahar, Mustapha/0000-0002-5792-7742; Guillot, Loic/0000-0001-6853-7945; Chignard, Michel/0000-0003-3810-6575				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Beck-Schimmer B, 2004, NEWS PHYSIOL SCI, V19, P129, DOI 10.1152/nips.01508.2003; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Fakler CR, 2000, INFLAMM RES, V49, P63, DOI 10.1007/s000110050560; Fang JD, 1999, J MED VIROL, V57, P198; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Geiss GK, 2001, J VIROL, V75, P4321, DOI 10.1128/JVI.75.9.4321-4331.2001; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Heinz S, 2003, J BIOL CHEM, V278, P21502, DOI 10.1074/jbc.M301476200; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; HOMMA T, 2004, AM J RESP CELL MOL B; Ieki K, 2004, CLIN EXP ALLERGY, V34, P745, DOI 10.1111/j.1365-2222.2004.1941.x; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; KIMURATAKEUCHI M, 1992, J INFECT DIS, V166, P1266, DOI 10.1093/infdis/166.6.1266; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; Lamb RA, 2001, FIELDS VIROL, V1, P1487; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Majde JA, 1998, ARCH VIROL, V143, P2371, DOI 10.1007/s007050050467; Majde JA, 2000, J INTERF CYTOK RES, V20, P259, DOI 10.1089/107999000312397; MAJDE JA, 1991, MICROB PATHOGENESIS, V10, P105, DOI 10.1016/0882-4010(91)90071-H; Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; McGettrick AF, 2004, MOL IMMUNOL, V41, P577, DOI 10.1016/j.molimm.2004.04.006; Mergey M, 1995, AM J PHYSIOL-LUNG C, V269, pL855, DOI 10.1152/ajplung.1995.269.6.L855; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; MILHAUD PG, 1987, J GEN VIROL, V68, P1125, DOI 10.1099/0022-1317-68-4-1125; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Rassa JC, 2003, MICROBES INFECT, V5, P961, DOI 10.1016/S1286-4579(03)00193-X; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Reynolds HY, 2002, CURR OPIN PULM MED, V8, P154, DOI 10.1097/00063198-200205000-00002; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Tanabe M, 2003, BIOCHEM BIOPH RES CO, V311, P39, DOI 10.1016/j.bbrc.2003.09.159; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	45	541	582	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5571	5580		10.1074/jbc.M410592200	http://dx.doi.org/10.1074/jbc.M410592200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579900	hybrid, Green Published			2022-12-25	WOS:000227217100057
J	Lie, TJ; Wood, GE; Leigh, JA				Lie, TJ; Wood, GE; Leigh, JA			Regulation of nif expression in Methanococcus maripaludis - Roles of the euryarchaeal repressor NrpR, 2-oxoglutarate, and two operators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; ARCHAEAL TRANSCRIPTION; ESCHERICHIA-COLI; GEL ELECTROPHORESIS; NITROGEN-FIXATION; TFIIE-ALPHA; PROTEIN; GENE; GENOME; METHANOGENS	The methanogenic archaean Methanococcus maripaludis can use ammonia, alanine, or dinitrogen as a nitrogen source for growth. The euryarchaeal nitrogen repressor NrpR controls the expression of the nif (nitrogen fixation) operon, resulting in full repression with ammonia, intermediate repression with alanine, and derepression with dinitrogen. NrpR binds to two tandem operators in the nif promoter region, nifOR(1) and nifOR(2). Here we have undertaken both in vivo and in vitro approaches to study the way in which NrpR, nifOR(1) nifOR(2), and the effector 2-oxoglutarate (20G) combine to regulate nif expression, leading to a comprehensive understanding of this archaeal regulatory system. We show that NrpR binds as a dimer to nifOR(1) and cooperatively as two dimers to both operators. Cooperative binding occurs only with both operators present. nifOR(1) has stronger binding and by itself can mediate the repression of nif transcription during growth on ammonia, unlike the weakly binding nifOR2. However, nifOR2 in combination with nifOR(1) is critical for intermediate repression during growth on alanine. Accordingly, NrpR binds to both operators together with higher affinity than to nifOR(1) alone. NrpR responds directly to 20G, which weakens its binding to the operators. Hence, 20G is an intracellular indicator of nitrogen deficiency and acts as an inducer of nif transcription via NrpR. This model is upheld by the recent finding (J. A. Dodsworth and J. A. Leigh, submitted for publication) in our laboratory that 20G levels in M. maripaludis vary with growth on different nitrogen sources.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Leigh, JA (corresponding author), Univ Washington, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	leighj@u.washington.edu			NIGMS NIH HHS [GM-55255] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055255] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argyle JL, 1996, APPL ENVIRON MICROB, V62, P4233, DOI 10.1128/AEM.62.11.4233-4237.1996; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; Bell CE, 2001, CURR OPIN STRUC BIOL, V11, P19, DOI 10.1016/S0959-440X(00)00180-9; Bell SD, 2000, J BIOL CHEM, V275, P31624, DOI 10.1074/jbc.M005422200; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bell SD, 2001, BIOCHEM SOC T, V29, P392, DOI 10.1042/BST0290392; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; BENEKE S, 1995, MOL GEN GENET, V248, P225, DOI 10.1007/BF02190804; BLANK CE, 1995, J BACTERIOL, V177, P5773, DOI 10.1128/jb.177.20.5773-5777.1995; Brinkman AB, 2003, MOL MICROBIOL, V48, P287, DOI 10.1046/j.1365-2958.2003.03442.x; Brinkman AB, 2002, J BIOL CHEM, V277, P29537, DOI 10.1074/jbc.M203528200; Brinkman AB, 2000, J BIOL CHEM, V275, P38160, DOI 10.1074/jbc.M005916200; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CohenKupiec R, 1997, P NATL ACAD SCI USA, V94, P1316, DOI 10.1073/pnas.94.4.1316; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Dixon R, 2004, NAT REV MICROBIOL, V2, P621, DOI 10.1038/nrmicro954; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Gardner WL, 1999, GENETICS, V152, P1439; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HEINICKE I, 2004, MOL GENET GENOMICS; Hendrickson EL, 2004, J BACTERIOL, V186, P6956, DOI 10.1128/JB.186.20.6956-6969.2004; Kessler PS, 1999, GENETICS, V152, P1343; Kessler PS, 2001, J BACTERIOL, V183, P882, DOI 10.1128/JB.183.3.882-889.2001; Kessler PS, 1998, J BACTERIOL, V180, P1504, DOI 10.1128/JB.180.6.1504-1511.1998; Kruger K, 1998, J MOL BIOL, V279, P761, DOI 10.1006/jmbi.1998.1795; Lange M, 2001, FEMS MICROBIOL REV, V25, P553, DOI 10.1111/j.1574-6976.2001.tb00591.x; Lee SJ, 2003, J BIOL CHEM, V278, P983, DOI 10.1074/jbc.M210236200; Leigh JA, 1999, CURR OPIN MICROBIOL, V2, P131, DOI 10.1016/S1369-5274(99)80023-X; Leigh JA, 2000, PROKARYOTIC NITROGEN FIXATION, P657; Lie TJ, 2003, MOL MICROBIOL, V47, P235, DOI 10.1046/j.1365-2958.2003.03293.x; Lie TJ, 2002, J BACTERIOL, V184, P5301, DOI 10.1128/JB.184.19.5301-5306.2002; Martinez-Argudo I, 2004, MOL MICROBIOL, V52, P1731, DOI 10.1111/j.1365-2958.2004.04089.x; Matthews KS, 1998, PROG NUCLEIC ACID RE, V58, P127; MOORE BC, 2005, IN PRESS J BACTERIOL, V187; Muller-Hill B, 1998, MOL MICROBIOL, V29, P13, DOI 10.1046/j.1365-2958.1998.00870.x; Muller-Hill B, 1998, CURR OPIN MICROBIOL, V1, P145, DOI 10.1016/S1369-5274(98)80004-0; Ouhammouch M, 2004, CURR OPIN GENET DEV, V14, P133, DOI 10.1016/j.gde.2004.01.002; Ouhammouch M, 2003, P NATL ACAD SCI USA, V100, P5097, DOI 10.1073/pnas.0837150100; Ouhammouch M, 2001, EMBO J, V20, P146, DOI 10.1093/emboj/20.1.146; Ptashne M, 1992, GENETIC SWITCH PHAGE; Reeve JN, 2003, MOL MICROBIOL, V48, P587, DOI 10.1046/j.1365-2958.2003.03439.x; Reitzer L, 2003, ANNU REV MICROBIOL, V57, P155, DOI 10.1146/annurev.micro.57.030502.090820; Soppa J, 2001, ADV APPL MICROBIOL, V50, P171, DOI 10.1016/S0065-2164(01)50006-4; Tanigawa R, 2002, P NATL ACAD SCI USA, V99, P4251, DOI 10.1073/pnas.072587199; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TUMBULA DL, 1994, FEMS MICROBIOL LETT, V121, P309, DOI 10.1016/0378-1097(94)90309-3; Vazquez-Bermudez MF, 2002, FEBS LETT, V512, P71, DOI 10.1016/S0014-5793(02)02219-6; Vierke G, 2003, J BIOL CHEM, V278, P18, DOI 10.1074/jbc.M209250200; White MF, 2002, TRENDS GENET, V18, P621, DOI 10.1016/S0168-9525(02)02808-1; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	53	74	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5236	5241		10.1074/jbc.M411778200	http://dx.doi.org/10.1074/jbc.M411778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590692	hybrid			2022-12-25	WOS:000227217100017
J	Muramatsu, H; Mihara, H; Kakutani, R; Yasuda, M; Ueda, M; Kurihara, T; Esaki, N				Muramatsu, H; Mihara, H; Kakutani, R; Yasuda, M; Ueda, M; Kurihara, T; Esaki, N			The putative malate/lactate dehydrogenase from Pseudomonas putida is an NADPH-dependent Delta(1)-piperideine-2-carboxylate/Delta(1)-pyrroline-2-carboxylate reductase involved in the catabolism of D-lysine and D-proline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENZYMATIC-SYNTHESIS; ACID DEHYDROGENASE; OVERLAP EXTENSION; BINDING PROTEIN; L-MALATE; METABOLISM; DELTA-1-PIPERIDEINE-2-CARBOXYLATE; DELTA-1-PYRROLINE-2-CARBOXYLATE; MUTAGENESIS	A Pseudomonas putida ATCC 12633 gene, dpkA, encoding a putative protein annotated as malate/L-lactate dehydrogenase in various sequence data bases was disrupted by homologous recombination. The resultant dpkA(-) mutant was deprived of the ability to use D-lysine and also D-proline as a sole carbon source. The dpkA gene was cloned and overexpressed in Escherichia coli, and the gene product was characterized. The enzyme showed neither malate dehydrogenase nor lactate dehydrogenase activity but catalyzed the NADPH-dependent reduction of such cyclic imines as Delta(1)-piperideine-2-carboxylate and Delta(1)-pyrroline-2-carboxylate to form L-pipecolate and L-proline, respectively. NADH also served as a hydrogen donor for both substrates, although the reaction rates were less than 1% of those with NADPH. The reverse reactions were also catalyzed by the enzyme but at much lower rates. Thus, the enzyme has dual metabolic functions, and we named the enzyme Delta(1)-piperideine-2-carboxylate/Delta(1)-pyrroline-2-carboxylate reductase, the first member of a novel subclass in a large family of NAD(P)-dependent oxidoreductases.	Kyoto Univ, Chem Res Inst, Uji, Kyoto 6110011, Japan; Mitsubishi Chem Corp, Yokohama Res Ctr, Yokohama, Kanagawa 2278502, Japan	Kyoto University; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Esaki, N (corresponding author), Kyoto Univ, Chem Res Inst, Uji, Kyoto 6110011, Japan.	esaki@scl.kyoto-u.ac.jp	Mihara, Hisaaki/F-2172-2010	Mihara, Hisaaki/0000-0002-5153-4403; Ueda, Makoto/0000-0002-4503-0049				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; CHANG YF, 1974, J BACTERIOL, V117, P753, DOI 10.1128/JB.117.2.753-764.1974; CHANG YF, 1971, BIOCHEM BIOPH RES CO, V45, P570, DOI 10.1016/0006-291X(71)90455-4; Cusa E, 1999, J BACTERIOL, V181, P7479, DOI 10.1128/JB.181.24.7479-7484.1999; Forouhar F, 2004, J BIOL CHEM, V279, P13148, DOI 10.1074/jbc.M313580200; FOTHERGILL JC, 1977, J GEN MICROBIOL, V99, P139, DOI 10.1099/00221287-99-1-139; GARWEG G, 1980, J NEUROCHEM, V35, P616, DOI 10.1111/j.1471-4159.1980.tb03700.x; Graupner M, 2000, J BACTERIOL, V182, P3688, DOI 10.1128/JB.182.13.3688-3692.2000; GROVE JA, 1969, BIOCHIM BIOPHYS ACTA, V184, P329, DOI 10.1016/0304-4165(69)90035-X; HIGASHINO K, 1971, ARCH BIOCHEM BIOPHYS, V142, P606, DOI 10.1016/0003-9861(71)90525-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONKA E, 1990, EUR J BIOCHEM, V188, P623, DOI 10.1111/j.1432-1033.1990.tb15443.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUTZLER J, 1975, BIOCHIM BIOPHYS ACTA, V377, P42, DOI 10.1016/0005-2744(75)90284-3; ICHIHARA A, 1960, J BIOCHEM-TOKYO, V49, P154; Irimia A, 2004, EMBO J, V23, P1234, DOI 10.1038/sj.emboj.7600147; KEENAN MV, 1974, BIOCHEM BIOPH RES CO, V57, P500, DOI 10.1016/0006-291X(74)90960-7; Kwong SM, 2000, J BACTERIOL, V182, P81, DOI 10.1128/JB.182.1.81-90.2000; Madern D, 2002, J MOL EVOL, V54, P825, DOI 10.1007/s00239-001-0088-8; MEISTER A, 1962, METHOD ENZYMOL, V5, P878, DOI 10.1016/S0076-6879(62)05332-X; MEISTER A, 1957, J BIOL CHEM, V229, P789; MILLER DL, 1971, J BIOL CHEM, V246, P2758; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Muramatsu H, 2004, TETRAHEDRON-ASYMMETR, V15, P2841, DOI 10.1016/j.tetasy.2004.06.030; OHSHIMA T, 1990, SEIKAGAKU, V62, P283; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PAYTON CW, 1982, J BACTERIOL, V149, P864, DOI 10.1128/JB.149.3.864-871.1982; PETRAKIS PL, 1965, BIOCHIM BIOPHYS ACTA, V99, P78, DOI 10.1016/S0926-6593(65)80009-1; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Thompson H, 1998, ARCH MICROBIOL, V170, P38, DOI 10.1007/s002030050612; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yew WS, 2002, J BACTERIOL, V184, P302, DOI 10.1128/JB.184.1.302-306.2002	35	54	60	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5329	5335		10.1074/jbc.M411918200	http://dx.doi.org/10.1074/jbc.M411918200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15561717	hybrid			2022-12-25	WOS:000227217100028
J	Wang, WS; Bambara, RA				Wang, WS; Bambara, RA			Human bloom protein stimulates flap endonuclease 1 activity by resolving DNA secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; OKAZAKI FRAGMENT MATURATION; NUCLEOTIDE EXCISION-REPAIR; CAG REPEAT TRACTS; SACCHAROMYCES-CEREVISIAE; MUTATION AVOIDANCE; HELICASE ACTIVITY; ESCHERICHIA-COLI; HUMAN FEN1; IN-VIVO	Flap endonuclease 1 (FEN1) participates in removal of RNA primers of Okazaki fragments, several DNA repair pathways, and genome stability maintenance. Defects in yeast FEN1 produce chromosomal instability, hyper-recombination, and sequence duplication. These occur because flaps produced during replication are not promptly removed. Long-lived flaps sustain breaks and form misaligned bubble structures that produce duplications. Flaps that can form secondary structure inhibit even wild-type FEN1 and are more likely to form bubbles. Although proliferating cell nuclear antigen stimulates FEN1, it cannot resolve secondary structures. Bloom protein (BLM) is a 3'-5' helicase, mutated in Bloom syndrome. BLM has been reported to interact with and stimulate FEN1 independent of helicase function. We found activation of the helicase by ATP did not alter BLM stimulation of cleavage of unstructured flaps. However, BLM stimulation of FEN1 cleavage of foldback flaps, bubbles, or triplet repeats was increased by an additional increment when ATP was added. Helicase-dependent stimulation of FEN1 cleavage was robust over a range of sizes of the single-stranded part of bubbles. However, increasing the length of the 5' annealed region of the bubble ultimately counteracted the stimulatory capacity of the BLM helicase. Moderate helicase-dependent stimulation was observed with both fixed and equilibrating CTG flaps. Our results suggest that BLM suppresses genome instability by aiding FEN1 cleavage of structure-containing flaps.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NIGMS NIH HHS [GM024441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bae SH, 2002, J BIOL CHEM, V277, P26632, DOI 10.1074/jbc.M111026200; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; Debrauwere H, 2001, P NATL ACAD SCI USA, V98, P8263, DOI 10.1073/pnas.121075598; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Greene AL, 1999, HUM MOL GENET, V8, P2263, DOI 10.1093/hmg/8.12.2263; Gruber SB, 2002, SCIENCE, V297, P2013, DOI 10.1126/science.1074399; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Houlston RS, 2001, J CLIN PATHOL-MOL PA, V54, P206, DOI 10.1136/mp.54.4.206; Imamura O, 2003, P NATL ACAD SCI USA, V100, P8193, DOI 10.1073/pnas.1431624100; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LINDAHL T, 1970, METHOD ENZYMOL, V21, P148; LIU QY, 1993, P NATL ACAD SCI USA, V90, P1761, DOI 10.1073/pnas.90.5.1761; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Liu Y, 2004, MOL CELL BIOL, V24, P4049, DOI 10.1128/MCB.24.9.4049-4064.2004; Liu Y, 2003, J BIOL CHEM, V278, P13728, DOI 10.1074/jbc.M212061200; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Matsuzaki Y, 2002, NUCLEIC ACIDS RES, V30, P3273, DOI 10.1093/nar/gkf440; Maurer DJ, 1998, MOL CELL BIOL, V18, P4597, DOI 10.1128/MCB.18.8.4597; Mirkin SM, 2002, NAT GENET, V31, P5, DOI 10.1038/ng0502-5; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Schawalder J, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-15; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Sharma S, 2004, HUM MOL GENET, V13, P2247, DOI 10.1093/hmg/ddh234; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; White PJ, 1999, MOL CELL BIOL, V19, P5675; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Yankiwski V, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-11	63	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5391	5399		10.1074/jbc.M412359200	http://dx.doi.org/10.1074/jbc.M412359200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579905	hybrid			2022-12-25	WOS:000227217100035
J	Yang, FS; Lim, GP; Begum, AN; Ubeda, OJ; Simmons, MR; Ambegaokar, SS; Chen, PP; Kayed, R; Glabe, CG; Frautschy, SA; Cole, GM				Yang, FS; Lim, GP; Begum, AN; Ubeda, OJ; Simmons, MR; Ambegaokar, SS; Chen, PP; Kayed, R; Glabe, CG; Frautschy, SA; Cole, GM			Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF-KAPPA-B; ALZHEIMERS-DISEASE; CONGO RED; TRANSGENIC MICE; CHEMOPREVENTIVE AGENT; CLINICAL-TRIAL; CACHE COUNTY; MOUSE MODEL; PROTEIN	Alzheimer's disease (AD) involves amyloid beta (Abeta) accumulation, oxidative damage, and inflammation, and risk is reduced with increased antioxidant and anti-inflammatory consumption. The phenolic yellow curry pigment curcumin has potent anti-inflammatory and antioxidant activities and can suppress oxidative damage, inflammation, cognitive deficits, and amyloid accumulation. Since the molecular structure of curcumin suggested potential Abeta binding, we investigated whether its efficacy in AD models could be explained by effects on Abeta aggregation. Under aggregating conditions in vitro, curcumin inhibited aggregation (IC50 = 0.8 muM) as well as disaggregated fibrillar Abeta40 (IC50 = 1 muM), indicating favorable stoichiometry for inhibition. Curcumin was a better Abeta40 aggregation inhibitor than ibuprofen and naproxen, and prevented Abeta42 oligomer formation and toxicity between 0.1 and 1.0 muM. Under EM, curcumin decreased dose dependently Abeta fibril formation beginning with 0.125 muM. The effects of curcumin did not depend on Abeta sequence but on fibril-related conformation. AD and Tg2576 mice brain sections incubated with curcumin revealed preferential labeling of amyloid plaques. In vivo studies showed that curcumin injected peripherally into aged Tg mice crossed the blood-brain barrier and bound plaques. When fed to aged Tg2576 mice with advanced amyloid accumulation, curcumin labeled plaques and reduced amyloid levels and plaque burden. Hence, curcumin directly binds small beta-amyloid species to block aggregation and fibril formation in vitro and in vivo. These data suggest that low dose curcumin effectively disaggregates Abeta as well as prevents fibril and oligomer formation, supporting the rationale for curcumin use in clinical trials preventing or treating AD.	Univ Calif Los Angeles, Dept Med, Greater Los Angeles VA Healthcare Syst CRECC11E, Sepulveda, CA 91343 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Los Angeles; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Irvine	Cole, GM (corresponding author), Univ Calif Los Angeles, Dept Med, Greater Los Angeles VA Healthcare Syst CRECC11E, 16111 Plummer St, Sepulveda, CA 91343 USA.	gmcole@ucla.edu		Frautschy, Sally A./0000-0003-0194-0363	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT003008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010685, P50AG016570, R01AG013741] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT003008] Funding Source: Medline; NIA NIH HHS [R01 AG010685, P50 AG016570, R01 AG013741] Funding Source: Medline; NINDS NIH HHS [NS43946] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe K, 1997, NEUROSCI RES, V29, P129, DOI 10.1016/S0168-0102(97)00081-3; Agdeppa ED, 2003, NEUROSCIENCE, V117, P723, DOI 10.1016/S0306-4522(02)00907-7; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Baum L, 2004, J ALZHEIMERS DIS, V6, P367; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035; Chan MMY, 1998, BIOCHEM PHARMACOL, V55, P1955, DOI 10.1016/S0006-2952(98)00114-2; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Chun KS, 2003, CARCINOGENESIS, V24, P1515, DOI 10.1093/carcin/bgg107; Cole G. M., 2003, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V3, P15, DOI 10.2174/1568013033358761; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; Cummings JL, 1998, NEUROLOGY, V51, pS65, DOI 10.1212/WNL.51.1_Suppl_1.S65; Das P, 2001, NEUROBIOL AGING, V22, P721, DOI 10.1016/S0197-4580(01)00245-7; Etminan M, 2003, BMJ-BRIT MED J, V327, P128, DOI 10.1136/bmj.327.7407.128; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; FRAUTSCHY SA, 2003, SOC NEUR ABSTR; Gasparini L, 2004, J NEUROCHEM, V88, P337, DOI 10.1046/j.1471-4159.2003.02154.x; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Han YS, 2004, BRIT J PHARMACOL, V141, P997, DOI 10.1038/sj.bjp.0705688; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelloff GJ, 1996, J CELL BIOCHEM, P72; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; KLUNK WE, 1994, NEUROBIOL AGING, V15, P691, DOI 10.1016/0197-4580(94)90050-7; Klunk WE, 1999, ANAL BIOCHEM, V266, P66, DOI 10.1006/abio.1998.2933; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Landi F, 2003, AM J GERIAT PSYCHIAT, V11, P179, DOI 10.1176/appi.ajgp.11.2.179; Launer LJ, 2003, JAMA-J AM MED ASSOC, V289, P2865, DOI 10.1001/jama.289.21.2865; Legleiter J, 2004, J MOL BIOL, V335, P997, DOI 10.1016/j.jmb.2003.11.019; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Liu RT, 2004, J NEUROSCI RES, V75, P162, DOI 10.1002/jnr.10859; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakagami Y, 2002, BRIT J PHARMACOL, V137, P676, DOI 10.1038/sj.bjp.0704911; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Sagi SA, 2003, J BIOL CHEM, V278, P31825, DOI 10.1074/jbc.M303588200; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Soudamini K. K., 1992, Indian Journal of Physiology and Pharmacology, V36, P239; SREEJAYAN, 1994, J PHARM PHARMACOL, V46, P1013, DOI 10.1111/j.2042-7158.1994.tb03258.x; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Thomas T, 2001, NEUROREPORT, V12, P3263, DOI 10.1097/00001756-200110290-00024; Veld BAI, 1998, NEUROBIOL AGING, V19, P607, DOI 10.1016/S0197-4580(98)00096-7; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Yang FS, 1998, AM J PATHOL, V152, P379; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880; ZHAO BL, 1989, CELL BIOPHYS, V14, P175, DOI 10.1007/BF02797132	64	1757	1866	13	372	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5892	5901		10.1074/jbc.M404751200	http://dx.doi.org/10.1074/jbc.M404751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590663	hybrid			2022-12-25	WOS:000227217100094
J	Iwata, S; Souta-Kuribara, A; Yamakawa, A; Sasaki, T; Shimizu, T; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Watanabe, T; Arima, N; Morimoto, C				Iwata, S; Souta-Kuribara, A; Yamakawa, A; Sasaki, T; Shimizu, T; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Watanabe, T; Arima, N; Morimoto, C			HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L)	ONCOGENE			English	Article						ATL; Tax; HTLV-I; NF-kappa B; Cas-L; HEF1	T-CELL LEUKEMIA; VIRUS TYPE-I; MEDIATED TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; GENE-EXPRESSION; PROTEIN; ACTIVATION; TRANSACTIVATION	Crk-associated substrate lymphocyte type (Cas-L) is a docking protein that is heavily tyrosine phosphorylated by the engagement of beta1 integrins in T cells. In the present study, we attempted to evaluate the role of Cas-L in the pathophysiology of adult T-cell leukemia (ATL). Examination of peripheral blood mononuclear cells from ATL patients as well as ATL-derived T cell lines showed an elevation of Cas-L in these cells. We showed that tyrosine phosphorylation as well as expression of Cas-L was markedly elevated through the induction of human T-lymphotropic virus type I ( HTLV-I) Tax in JPX-9 cells, with these cells showing marked motile behavior on the ligands for integrins. We next performed yeast two-hybrid screening of cDNA library from an HTLV-I-transformed T cell line, which resulted in the identification of Tax as a putative binding partner for Cas-L. Co-precipitation experiments revealed that the serine-rich region of Cas-L might serve as the binding site with the highest afinity for Tax. Co-localization study showed that Tax and Cas-L partly merged in the cytoplasm. Finally, we showed that exogenous Cas-L inhibited Tax-mediated transactivation of nuclear factor kappaB ( NF-kappaB), while Tax-independent activation of NF-kappaB remained intact, hence indicating that Cas-L might specically regulate Tax-NF-kappaB pathway.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Keio Univ, Sch Med, Dept Internal Med, Shinjyuku Ku, Tokyo 1608582, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Tumor Cell Biol,Minato Ku, Tokyo 1088639, Japan; Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Host Response, Kagoshima 8908520, Japan	University of Tokyo; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Keio University; University of Texas System; UTMD Anderson Cancer Center; University of Tokyo; Kagoshima University	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp	Iwata, Satoshi/A-8819-2011					ALBRECHT H, 1992, J VIROL, V66, P6191, DOI 10.1128/JVI.66.10.6191-6193.1992; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHIKAWA T, 1993, BLOOD, V82, P1590; Ishino M, 1995, ONCOGENE, V11, P2331; Iwata S, 2002, EUR J IMMUNOL, V32, P1328, DOI 10.1002/1521-4141(200205)32:5<1328::AID-IMMU1328>3.0.CO;2-6; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Miyake-Nishijima R, 2003, ARTHRITIS RHEUM, V48, P1890, DOI 10.1002/art.11047; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; Ohashi Y, 1999, J IMMUNOL, V163, P3727; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATO T, 1995, J IMMUNOL, V155, P2938; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Uchiyama T, 1996, J CLIN IMMUNOL, V16, P305, DOI 10.1007/BF01541665; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; YAMASHITA I, 1994, BLOOD, V84, P1573; YODOI J, 1986, IMMUNOL REV, V92, P135, DOI 10.1111/j.1600-065X.1986.tb01498.x; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Zheng MZ, 2002, J BIOL CHEM, V277, P39599, DOI 10.1074/jbc.M202263200	47	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1262	1271		10.1038/sj.onc.1208261	http://dx.doi.org/10.1038/sj.onc.1208261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592516				2022-12-25	WOS:000226898700013
J	Dessauge, G; Hilaly, S; Baumgartner, M; Blumen, B; Werling, D; Langsley, G				Dessauge, G; Hilaly, S; Baumgartner, M; Blumen, B; Werling, D; Langsley, G			C-Myc activation by Theileria parasites promotes survival of infected B-lymphocytes	ONCOGENE			English	Article						apoptosis; c-Myc; STAT3; Theileria; transformation	INDUCED APOPTOSIS; CELLS; PARVA; EXPRESSION; KINASE; ANNULATA; STAT3; TRANSFORMATION; PROLIFERATION; LEUKOCYTES	Theileria parasites infect and transform bovine lymphocytes, but host cell immortalization is reversible, as upon parasite death the lymphocytes rapidly die of apoptosis. Infection leads to a marked augmentation in the levels of lymphocyte c-Myc, and the parasite achieves this by inducing increased c-myc transcription and by prolonging the half-life of the transcription factor. Reduction in c-Myc turnover can be ascribed to CK2-mediated phosphorylation of the transcription factor. A parasite-dependent GM-CSF autocrine loop activates a JAK2/ STAT3 signalling pathway that contributes to heightened c-myc transcription, and inhibition of the pathway leads to caspase 9 activation and apoptosis that can be directly ascribed to a reduction in c-Myc. An antiapoptotic role for c-Myc was clearly demonstrated by specific inhibition of c-myc expression with antisense oligonucleotides, and this correlates with loss of the antiapoptotic protein Mcl-1, and, consistently, ectopic expression of c-Myc abrogates B-cell death induced upon JAK2 inhibition. Thus, Theileria parasites ensure the survival of their host lymphocytes via specific activation of c-Myc.	Inst Pasteur, Dept Parasitol, CNRS URA CNRS 2581, Lab Signalisat Immunoparasitaire, F-75724 Paris 15, France; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Royal Vet Coll, N Mymms AL9 7TA, Herts, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California San Francisco; University of London; University of London Royal Veterinary College	Langsley, G (corresponding author), Inst Pasteur, Dept Parasitol, CNRS URA CNRS 2581, Lab Signalisat Immunoparasitaire, Batiment Elie Metchnikoff,25-28 Rue Dr Roux, F-75724 Paris 15, France.	langsley@pasteur.fr	Werling, Dirk/F-5555-2013	Werling, Dirk/0000-0001-5411-4044; Baumgartner, Martin/0000-0001-9539-7204				Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Baumgartner M, 2000, CELL MICROBIOL, V2, P329, DOI 10.1046/j.1462-5822.2000.00062.x; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cavin LG, 2003, HEPATOLOGY, V38, P1540, DOI 10.1016/j.hep.2003.09.019; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; Chaussepied M, 1996, RES IMMUNOL, V147, P127, DOI 10.1016/0923-2494(96)83165-8; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Dobbelaere D, 1999, ANNU REV MICROBIOL, V53, P1, DOI 10.1146/annurev.micro.53.1.1; DOBBELAERE DAE, 1990, INFECT IMMUN, V58, P3847, DOI 10.1128/IAI.58.12.3847-3855.1990; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Guergnon J, 2003, BIOCHIMIE, V85, P771, DOI 10.1016/j.biochi.2003.09.013; Guergnon J, 2003, CELL MICROBIOL, V5, P709, DOI 10.1046/j.1462-5822.2003.00314.x; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Heussler VT, 2002, SCIENCE, V298, P1033, DOI 10.1126/science.1075462; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kuenzi P, 2003, J IMMUNOL, V171, P1224, DOI 10.4049/jimmunol.171.3.1224; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; McGuire K, 2004, VET IMMUNOL IMMUNOP, V99, P87, DOI 10.1016/j.vetimm.2004.01.003; McKeever DJ, 1997, PARASITE IMMUNOL, V19, P319, DOI 10.1046/j.1365-3024.1997.d01-214.x; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moreau MF, 1999, INFECT IMMUN, V67, P6678; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	35	63	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1075	1083		10.1038/sj.onc.1208314	http://dx.doi.org/10.1038/sj.onc.1208314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15580287				2022-12-25	WOS:000226749200013
J	Meinhold-Heerlein, I; Bauerschlag, D; Hilpert, F; Dimitrov, P; Sapinoso, LM; Orlowska-Volk, M; Bauknecht, T; Park, TW; Jonat, W; Jacobsen, A; Sehouli, J; Luttges, J; Krajewski, M; Krajewski, S; Reed, JC; Arnold, N; Hampton, GM				Meinhold-Heerlein, I; Bauerschlag, D; Hilpert, F; Dimitrov, P; Sapinoso, LM; Orlowska-Volk, M; Bauknecht, T; Park, TW; Jonat, W; Jacobsen, A; Sehouli, J; Luttges, J; Krajewski, M; Krajewski, S; Reed, JC; Arnold, N; Hampton, GM			Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential	ONCOGENE			English	Article						microarray; cluster; cell cycle	FATTY-ACID SYNTHASE; GENE-EXPRESSION PROFILES; POLO-LIKE KINASE; BREAST-CANCER; CELL-PROLIFERATION; PROSTATE-CANCER; CDNA MICROARRAY; TUMORS; BORDERLINE; P53	Profiles of gene transcription have begun to delineate the molecular basis of ovarian cancer, including distinctions between carcinomas of differing histology, tumor progression and patient outcome. However, the similarities and differences among the most commonly diagnosed noninvasive borderline ( low malignant potential, LMP) lesions and invasive serous carcinomas of varying grade (G1, G2 and G3) have not yet been explored. Here, we used oligonucleotide arrays to pro. le the expression of 12 500 genes in a series of 57 predominantly stage III serous ovarian adenocarcinomas from 52 patients, eight with borderline tumors and 44 with adenocarcinomas of varying grade. Unsupervised and supervised analyses showed that LMP lesions were distinct from high-grade serous adenocarcinomas, as might be expected; however, well-differentiated ( G1) invasive adenocarcinomas showed a strikingly similar pro. le to LMP tumors as compared to cancers with moderate ( G2) or poor ( G3) cellular differentiation, which were also highly similar. Comparative genomic hybridization of an independent cohort of five LMP and 63 invasive carcinomas of varying grade demonstrated LMP and G1 were again similar, exhibiting significantly less chromosomal aberration than G2/G3 carcinomas. A majority of LMP and G1 tumors were characterized by high levels of p21/WAF1, with concomitant expression of cell growth suppressors, gadd34 and BTG-2. In contrast, G2/G3 cancers were characterized by the expression of genes associated with the cell cycle and by STAT-1-, STAT-3/JAK-1/2-induced gene expression. The distinction between the LMP-G1 and G2 G3 groups of tumors was highly correlated to patient outcome ( v 2 for equivalence of death rates = 7.681189; P = 0.0056, log-rank test). Our results are consistent with the recent demonstration of a poor differentiation molecular 'meta-signature' in human cancer, and underscore a number of cell-cycle- and STAT-associated targets that may prove useful as points of therapeutic intervention for those patients with aggressive disease.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany; Univ Freiburg, Dept Pathol, D-7800 Freiburg, Germany; Lilly Deutschland, Bad Homburg, Germany; Univ Bonn, Dept Gynecol & Obstet, D-5300 Bonn, Germany; Univ Hosp Charite, Dept Gynecol & Obstet, Berlin, Germany; Univ Kiel, Dept Pathol, D-24098 Kiel, Germany; Burnham Inst, La Jolla, CA 92037 USA	Novartis; University of Kiel; Schleswig Holstein University Hospital; University of Freiburg; Eli Lilly; Lilly Deutschland GmbH; University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Sanford Burnham Prebys Medical Discovery Institute	Hampton, GM (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	hampton@gnf.org	Arnold, Norbert/E-3012-2010; Jonat, Walter/E-3024-2010; Bauerschlag, Dirk/H-9393-2015; Meinhold-Heerlein, Ivo/AAK-1240-2021; Bauerschlag, Dirk/B-1958-2013; Meinhold-Heerlein, Dr. Ivo/A-8970-2015	Arnold, Norbert/0000-0003-4523-8808; Meinhold-Heerlein, Dr. Ivo/0000-0002-0331-8781; Bauerschlag, Dirk O./0000-0001-8157-6121				Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Auersperg N, 2002, INT J GYNECOL CANCER, V12, P691, DOI 10.1046/j.1525-1438.2002.01152.x; BEREK JS, 2000, CANC MED, P1687; Broggini M, 2000, ANTICANCER RES, V20, P4835; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Capranico G, 1999, Cancer Chemother Biol Response Modif, V18, P125; Chan WY, 2000, AM J PATHOL, V156, P409, DOI 10.1016/S0002-9440(10)64744-X; Collins Y, 2004, INT J MOL MED, V14, P43; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Gershenson DM, 2002, BEST PRACT RES CL OB, V16, P513, DOI 10.1053/beog.2002.0308; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HAMILTON SR, 1992, J CELL BIOCHEM, P41; HAMPTON GM, 2003, EXPRESSION PROFILING, P277; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hellstrom I, 2003, CANCER RES, V63, P3695; HENRIKSEN R, 1994, ANTICANCER RES, V14, P603; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jazaeri AA, 2003, MOL CARCINOGEN, V36, P53, DOI 10.1002/mc.10098; Kiechle M, 2001, CANCER, V91, P534, DOI 10.1002/1097-0142(20010201)91:3<534::AID-CNCR1031>3.3.CO;2-K; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kim JH, 2003, CLIN CANCER RES, V9, P4782; Korkolopoulou P, 2002, GYNECOL ONCOL, V85, P404, DOI 10.1006/gyno.2002.6627; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KREIPE H, 1993, AM J PATHOL, V142, P1689; Kuo ML, 2003, CANCER RES, V63, P1046; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luo C, 2004, DRUG DISCOV TODAY, V9, P268, DOI 10.1016/S1359-6446(03)03014-9; Marx D, 1997, ANTICANCER RES, V17, P775; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; Morice P, 2003, ANN ONCOL, V14, P592, DOI 10.1093/annonc/mdg173; Muggia Franco, 2003, Expert Opin Emerg Drugs, V8, P203, DOI 10.1517/eoed.8.1.203.21032; Nijjar T, 1999, CANCER RES, V59, P5112; Okamoto Y, 2003, CANCER RES, V63, P4167; Ortiz BH, 2001, CANCER RES, V61, P7264; Palazzo JP, 2000, HUM PATHOL, V31, P698, DOI 10.1053/hupa.2000.7641; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Seidman JD, 2003, HEMATOL ONCOL CLIN N, V17, P909, DOI 10.1016/S0889-8588(03)00061-3; Seidman JD, 2002, BEST PRACT RES CL OB, V16, P499, DOI 10.1053/beog.2002.0300; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Singer G, 2002, AM J PATHOL, V160, P1223, DOI 10.1016/S0002-9440(10)62549-7; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Su AI, 2001, CANCER RES, V61, P7388; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Terlikowski S, 1999, ARCH GYNECOL OBSTET, V263, P29, DOI 10.1007/s004040050257; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vassilopoulos I, 2003, HISTOL HISTOPATHOL, V18, P761, DOI 10.14670/HH-18.761; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wang Y, 2001, CANCER LETT, V167, P99, DOI 10.1016/S0304-3835(01)00464-5; Wang Y, 2001, CLIN CHIM ACTA, V304, P107, DOI 10.1016/S0009-8981(00)00404-6; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711	76	163	171	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1053	1065		10.1038/sj.onc.1208298	http://dx.doi.org/10.1038/sj.onc.1208298			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15558012				2022-12-25	WOS:000226749200011
J	Landgraf, P; Sieg, F; Wahle, P; Meyer, G; Kreutz, MR; Pape, HC				Landgraf, P; Sieg, F; Wahle, P; Meyer, G; Kreutz, MR; Pape, HC			A maternal blood-borne factor promotes survival of the developing thalamus	FASEB JOURNAL			English	Article						Y-P30; survival-promoting peptide; sprouting; optic nerve crush; inflammation	NEUROTROPHIC FACTORS; SUBPLATE ZONE; AXONAL INJURY; IN-VITRO; NEURONS; EXPRESSION; PEPTIDE; CORTEX; IDENTIFICATION; ISOFORMS	In this report, we describe the identification of a polypeptide survival-promoting factor that is produced by maternal and early postnatal peripheral blood mononuclear cells (PBMCs) of the immune system in Long-Evans rats and humans. The factor, termed Y-P30, most likely arises from proteolytic processing of a larger precursor protein and accumulates mainly in pyramidal neurons of the developing cortex and hippocampus but not in astrocytes. It was released from neurons grown in culture and substantially promotes survival of cells in explant monocultures of perinatal thalamus from the offspring. Y-P30 mRNA was not detectable in infant or adult brain and was present only in blood cells of pregnant rats and humans but not in nonpregnant controls. However, Y-P30 transcription could be induced in PBMCs of adult animals by a central nervous system lesion (i.e., optic nerve crush), which points to a potential role of the factor not only in neuronal development but also in neuroinflammation after white matter injury.	Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, AG Mol Mech Plast, D-39118 Magdeburg, Germany; Otto Von Guericke Univ, Inst Physiol, Magdeburg, Germany; Ruhr Univ Bochum, Fac Biol, AG Dev Biol, D-4630 Bochum, Germany; Univ La Laguna, Fac Med, Dept Anat, Tenerife, Spain	Leibniz Institut fur Neurobiologie (LIN); Otto von Guericke University; Ruhr University Bochum; Universidad de la Laguna	Kreutz, MR (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, AG Mol Mech Plast, Brenneckestr 6, D-39118 Magdeburg, Germany.	kreutz@ifn-magdeburg.de		Meyer, Gundela/0000-0002-5730-828X; Sieg, Frank/0000-0001-9637-3239				Cunningham TJ, 1998, J NEUROSCI, V18, P7047; Cunningham TJ, 2002, EXP NEUROL, V177, P32, DOI 10.1006/exnr.2002.7979; Cunningham TJ, 2000, EXP NEUROL, V163, P457, DOI 10.1006/exnr.2000.7390; Engelmann R, 2001, BRAIN RES, V889, P251, DOI 10.1016/S0006-8993(00)03145-0; Flad T, 2002, J IMMUNOL METHODS, V270, P53, DOI 10.1016/S0022-1759(02)00229-6; Garnica AD, 1996, J AM COLL NUTR, V15, P206; HENSCHEL R, 1994, EUR J NEUROSCI, V6, P1239, DOI 10.1111/j.1460-9568.1994.tb00313.x; KOSTOVIC I, 1990, J COMP NEUROL, V297, P441, DOI 10.1002/cne.902970309; Kreutz MR, 1998, J NEUROSCI, V18, P8278; Kreutz MR, 2004, EUR J NEUROSCI, V19, P247, DOI 10.1111/j.1460-9568.2004.03087.x; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Lotto RB, 1997, EUR J NEUROSCI, V9, P1940, DOI 10.1111/j.1460-9568.1997.tb00761.x; Lotto RB, 2001, J NEUROSCI, V21, P3904, DOI 10.1523/JNEUROSCI.21-11-03904.2001; MOLLIVER ME, 1973, BRAIN RES, V50, P403, DOI 10.1016/0006-8993(73)90741-5; Molnar Z, 1999, EXP NEUROL, V156, P363, DOI 10.1006/exnr.1999.7032; NAEGELE JR, 1991, P NATL ACAD SCI USA, V88, P330, DOI 10.1073/pnas.88.2.330; Obst K, 1997, EUR J NEUROSCI, V9, P2571, DOI 10.1111/j.1460-9568.1997.tb01686.x; OBST K, 1995, EUR J NEUROSCI, V7, P2139, DOI 10.1111/j.1460-9568.1995.tb00636.x; RENNIE S, 1994, NEUROSCIENCE, V61, P547, DOI 10.1016/0306-4522(94)90433-2; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Seldenbecher CI, 2004, J MOL BIOL, V336, P957, DOI 10.1016/j.jmb.2003.12.054; Sieg F, 1998, DEV BRAIN RES, V110, P83, DOI 10.1016/S0165-3806(98)00097-2; Sieg F, 1999, J NEUROTRAUM, V16, P1197, DOI 10.1089/neu.1999.16.1197; Wahle P, 2003, DEVELOPMENT, V130, P611, DOI 10.1242/dev.00224	24	22	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					225	+		10.1096/fj.04-1789fje	http://dx.doi.org/10.1096/fj.04-1789fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15583035				2022-12-25	WOS:000226091000022
J	Hudson, CD; Morris, PJ; Latchman, DS; Budhram-Mahadeo, VS				Hudson, CD; Morris, PJ; Latchman, DS; Budhram-Mahadeo, VS			Brn-3a transcription factor blocks p53-mediated activation of proapoptotic target genes Noxa and Bax in vitro and in vivo to determine cell fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING SYNAPTIC PROTEINS; PROMOTES NEURONAL SURVIVAL; P53-INDUCED APOPTOSIS; RECEPTOR EXPRESSION; DEFICIENT MICE; P53; FAMILY; DEATH; DISTINCT; DIFFERENTIATION	The Brn-3a POU transcription factor is associated with survival and the differentiation of sensory neuronal cells during development. Brn-3a mediates its effects either by the direct regulation of target genes or indirectly upon interaction with proteins such as p53. Brn-3a differentially regulates p53-mediated gene expression and modifies its effect on cell fate. Here we show that, like Bax, Brn-3a antagonizes p53-mediated transcription of another proapoptotic target, Noxa, significantly reducing transactivation of the Noxa promoter by p53. This effect requires the p53 binding site, and electrophoretic mobility shift assay studies suggest that Brn-3a is associated with p53 when it is bound to its site in the Noxa promoter. The wild type but not the mutant promoter can be immunoprecipitated with Brn-3a in chromatin immunoprecipitation assays. Thus, Brn-3a may act by preventing the recruitment of cofactors required for p53 to transactivate this promoter. The co-expression of Brn-3a and p53 results in decreased endogenous Noxa protein in the neuronal cell line, ND7, suggesting a direct functional effect of this interaction. Moreover, there is a significant elevation of both proapoptotic Bax and Noxa proteins in sensory neuronal tissue taken from Brn-3a-/- embryos during development, compared with wild type controls. Striking changes occurred at embryonic day 14.5, a time that precedes a significant loss of specific neurons in the mutant embryos, but not at embryonic day 16.5 when Brn-3a-expressing cells are already lost by apoptosis. Therefore, the lack of antagonism by Brn-3a on activation of proapoptotic p53 target genes may contribute to the increased apoptosis seen in the Brn-3a-/- embryos. These results support a crucial role for Brn-3a in determining the pathway taken by p53 when co-expressed during development and thus in controlling the fate of these cells.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Budhram-Mahadeo, VS (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guildford St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk			Medical Research Council [G9901318] Funding Source: Medline; MRC [G9901318] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Budhram-Mahadeo V, 2002, NEUROSCI LETT, V334, P1, DOI 10.1016/S0304-3940(02)00813-3; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Cregan SP, 1999, J NEUROSCI, V19, P7860; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Eng SR, 2001, J NEUROSCI, V21, P541, DOI 10.1523/JNEUROSCI.21-02-00541.2001; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Greenwood AL, 1999, DEVELOPMENT, V126, P3545; Huang EJ, 1999, DEVELOPMENT, V126, P2869; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Ma L, 2003, DEVELOPMENT, V130, P3525, DOI 10.1242/dev.00582; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Middleton G, 1996, DEVELOPMENT, V122, P695; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perez-Sanchez C, 2002, NUCLEIC ACIDS RES, V30, P4872, DOI 10.1093/nar/gkf610; Sambrook J., 1990, MOL CLONING LAB MANU; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; White FA, 1998, J NEUROSCI, V18, P1428; WOOD JN, 1992, J BIOL CHEM, V267, P17787; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014	36	56	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11851	11858		10.1074/jbc.M408679200	http://dx.doi.org/10.1074/jbc.M408679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15598651	hybrid			2022-12-25	WOS:000227761800114
J	Kyttala, A; Yliannala, K; Schu, P; Jalanko, A; Luzio, JP				Kyttala, A; Yliannala, K; Schu, P; Jalanko, A; Luzio, JP			AP-1 and AP-3 facilitate lysosomal targeting of batten disease protein CLN3 via its dileucine motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; ACIDIC AMINO-ACIDS; ADAPTER COMPLEX; SORTING SIGNALS; BETA-3A SUBUNIT; TRAFFICKING; LOCALIZATION; BINDING; CLATHRIN; LEUCINE	CLN3 is a transmembrane protein with a predominant localization in lysosomes in non-neuronal cells but is also found in endosomes and the synaptic region in neuronal cells. Mutations in the CLN3 gene result in juvenile neuronal ceroid lipofuscinosis or Batten disease, which currently is the most common cause of childhood dementia. We have recently reported that the lysosomal targeting of CLN3 is facilitated by two targeting motifs: a dileucine-type motif in a cytoplasmic loop domain and an unusual motif in the carboxyl-terminal cytoplasmic tail comprising a methionine and a glycine separated by nine amino acids (Kyttala, A., Ihrke, G., Vesa, J., Schell, M. J., and Luzio, J. P. (2004) Mol. Biol. Cell 15, 1313-1323). In the present study, we investigated the pathways and mechanisms of CLN3 sorting using biochemical binding assays and immunofluorescence methods. The dileucine motif of CLN3 bound both AP-1 and AP-3 in vitro, and expression of mutated CLN3 in AP-1- or AP-3-deficient mouse fibroblasts showed that both adaptor complexes are required for sequential sorting of CLN3 via this motif. Our data indicate the involvement of complex sorting machinery in the trafficking of CLN3 and emphasize the diversity of parallel and sequential sorting pathways in the trafficking of membrane proteins.	Biomedicum Helsinki, Dept Mol Med, Natl Publ Hlth Inst, FIN-00251 Helsinki, Finland; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	Finland National Institute for Health & Welfare; University of Cambridge; University of Cambridge; University of Gottingen	Kyttala, A (corresponding author), Biomedicum Helsinki, Dept Mol Med, Natl Publ Hlth Inst, POB 104, FIN-00251 Helsinki, Finland.	aija.kyttala@ktl.fi		Uusi-Rauva, Kristiina/0000-0003-1149-0263				Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Benmerah A, 1999, J CELL SCI, V112, P1303; Blagoveshchenskaya AD, 1998, J BIOL CHEM, V273, P2729, DOI 10.1074/jbc.273.5.2729; Boman AL, 2001, J CELL SCI, V114, P3413; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Chattopadhyay S, 2003, BIOCHEM BIOPH RES CO, V302, P534, DOI 10.1016/S0006-291X(03)00209-2; Cherqui S, 2001, J BIOL CHEM, V276, P13314, DOI 10.1074/jbc.M010562200; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Fujita H, 1999, BIOCHEM BIOPH RES CO, V255, P54, DOI 10.1006/bbrc.1998.0140; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Girotti M, 1996, J CELL SCI, V109, P2915; Haskell RE, 2000, HUM MOL GENET, V9, P735, DOI 10.1093/hmg/9.5.735; Holopainen JM, 2001, EUR J BIOCHEM, V268, P5851, DOI 10.1046/j.0014-2956.2001.02530.x; Ihrke G, 2004, TRAFFIC, V5, P946, DOI 10.1111/j.1600-0854.2004.00236.x; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jarvela I, 1999, HUM MOL GENET, V8, P1091, DOI 10.1093/hmg/8.6.1091; Jarvela I, 1998, HUM MOL GENET, V7, P85, DOI 10.1093/hmg/7.1.85; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; Kremmidiotis G, 1999, HUM MOL GENET, V8, P523, DOI 10.1093/hmg/8.3.523; Kyttala A, 2004, MOL BIOL CELL, V15, P1313, DOI 10.1091/mbc.E03-02-0120; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Luiro K, 2004, HUM MOL GENET, V13, P3017, DOI 10.1093/hmg/ddh321; Luiro K, 2001, HUM MOL GENET, V10, P2123, DOI 10.1093/hmg/10.19.2123; Mao QW, 2003, FEBS LETT, V555, P351, DOI 10.1016/S0014-5793(03)01274-2; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Ngo HM, 2003, J BIOL CHEM, V278, P5343, DOI 10.1074/jbc.M208291200; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Pearce DA, 2000, J NEUROSCI RES, V59, P19, DOI 10.1002/(SICI)1097-4547(20000101)59:1<19::AID-JNR3>3.0.CO;2-Y; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Peden AA, 2001, J BIOL CHEM, V276, P49183, DOI 10.1074/jbc.M106646200; Peden AA, 2002, J CELL BIOL, V156, P327, DOI 10.1083/jcb.200107140; Rakheja D, 2004, BIOCHEM BIOPH RES CO, V317, P988, DOI 10.1016/j.bbrc.2004.03.146; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Reusch U, 2002, TRAFFIC, V3, P752, DOI 10.1034/j.1600-0854.2002.31007.x; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Storch S, 2004, J BIOL CHEM, V279, P53625, DOI 10.1074/jbc.M410930200; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; Yang W, 2000, J CELL SCI, V113, P4077	50	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10277	10283		10.1074/jbc.M411862200	http://dx.doi.org/10.1074/jbc.M411862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15598649	hybrid			2022-12-25	WOS:000227559600066
J	Thoden, JB; Timson, DJ; Reece, RJ; Holden, HM				Thoden, JB; Timson, DJ; Reece, RJ; Holden, HM			Molecular structure of human galactokinase - Implications for type II galactosemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GHMP KINASE SUPERFAMILY; SUBSTRATE-SPECIFICITY; POLYOL ACCUMULATION; YEAST GALACTOKINASE; MEVALONATE KINASE; ALDOSE REDUCTASE; LELOIR PATHWAY; DEFICIENCY; METABOLISM; MUTATIONS	Galactokinase functions in the Leloir pathway for galactose metabolism by catalyzing the MgATP- dependent phosphorylation of the C-1 hydroxyl group of alpha-D-galactose. The enzyme is known to belong to the GHMP superfamily of small molecule kinases and has attracted significant research attention for well over 40 years. Approximately 20 mutations have now been identified in human galactokinase, which result in the diseased state referred to as Type II galactosemia. Here we report the three-dimensional architecture of human galactokinase with bound alpha-D-galactose and Mg- AMPPNP. The overall fold of the molecule can be described in terms of two domains with the active site wedged between them. The N- terminal domain is dominated by a six- stranded mixed beta-sheet whereas the C-terminal motif contains six alpha-helices and two layers of anti-parallel beta-sheet. Those residues specifically involved in sugar binding include Arg(37), Glu(43), His(44), Asp(46), Gly(183), Asp(186), and Tyr(236). The C-1 hydroxyl group of alpha-D-galactose sits within 3.3 Angstrom of the gamma-phosphorus of the nucleotide and 3.4 Angstrom of the guanidinium group of Arg37. The carboxylate side chain of Asp186 lies within similar to 3.2 Angstrom of the C-2 hydroxyl group of alpha-D-galactose and the guanidinium group of Arg37. Both Arg37 and Asp186 are strictly conserved among both prokaryotic and eukaryotic galactokinases. In addition to providing molecular insight into the active site geometry of the enzyme, the model also provides a structural framework upon which to more fully understand the consequences of the those mutations known to give rise to Type II galactosemia.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland	University of Manchester; University of Wisconsin System; University of Wisconsin Madison; Queens University Belfast	Holden, HM (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	Hazel_Holden@biochem.wisc.edu	Timson, David/I-4014-2019	Timson, David/0000-0002-0985-8818	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ai YJ, 2000, HUM MOL GENET, V9, P1821, DOI 10.1093/hmg/9.12.1821; Asada M, 1999, J HUM GENET, V44, P377, DOI 10.1007/s100380050182; BORK P, 1993, PROTEIN SCI, V2, P31; Bosch AM, 2002, J INHERIT METAB DIS, V25, P629, DOI 10.1023/A:1022875629436; CAPUTTO R, 1949, J BIOL CHEM, V179, P497; CAPUTTO R, 1950, J BIOL CHEM, V184, P333; CORNISHBOWDEN A, 2004, FUNDAMENTALS ENZYME, P209; DEY PM, 1983, EUR J BIOCHEM, V136, P155, DOI 10.1111/j.1432-1033.1983.tb07720.x; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; Hartley A, 2004, J MOL BIOL, V337, P387, DOI 10.1016/j.jmb.2004.01.043; Holden HM, 2004, CELL MOL LIFE SCI, V61, P2471, DOI 10.1007/s00018-004-4160-6; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; HOWARD SM, 1965, ARCH BIOCHEM BIOPHYS, V110, P395, DOI 10.1016/0003-9861(65)90140-2; Hunter M, 2002, PEDIATR RES, V51, P602, DOI 10.1203/00006450-200205000-00010; Hunter M, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<77::AID-HUMU20>3.3.CO;2-8; Kalaydjieva L, 1999, AM J HUM GENET, V65, P1299, DOI 10.1086/302611; KINOSHITA JH, 1962, BIOCHIM BIOPHYS ACTA, V62, P176, DOI 10.1016/0006-3002(62)90508-5; Kolosha V, 2000, HUM MUTAT, V15, P447; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIN LR, 1991, EXP EYE RES, V52, P93, DOI 10.1016/0014-4835(91)90132-X; MAGNANI M, 1982, HUM HERED, V32, P329, DOI 10.1159/000153319; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; Okano Y, 2001, AM J HUM GENET, V68, P1036, DOI 10.1086/319512; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; Reich S, 2002, PEDIATR RES, V51, P598, DOI 10.1203/00006450-200205000-00009; Sangiuolo F, 2004, HUM MUTAT, V23, DOI 10.1002/humu.9223; Segal S, 1995, METABOLIC MOL BASIS, P967; STAMBOLIAN D, 1995, NAT GENET, V10, P307, DOI 10.1038/ng0795-307; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; Timson David J, 2003, BMC Biochem, V4, P16, DOI 10.1186/1471-2091-4-16; Timson DJ, 2003, EUR J BIOCHEM, V270, P1767, DOI 10.1046/j.1432-1033.2003.03538.x; Timson DJ, 2002, BIOCHEM J, V363, P515, DOI 10.1042/0264-6021:3630515; Timson DJ, 2002, BIOCHIMIE, V84, P265, DOI 10.1016/S0300-9084(02)01399-8; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WILKINSON JF, 1949, BIOCHEM J, V44, P460, DOI 10.1042/bj0440460; WILSON DB, 1969, J BIOL CHEM, V244, P2137; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	45	87	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9662	9670		10.1074/jbc.M412916200	http://dx.doi.org/10.1074/jbc.M412916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590630	hybrid			2022-12-25	WOS:000227453100123
J	Ghosh, K; Lau, CK; Guo, F; Segall, AM; Van Duyne, GD				Ghosh, K; Lau, CK; Guo, F; Segall, AM; Van Duyne, GD			Peptide trapping of the Holliday junction intermediate in Cre-loxP site-specific recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY DNA JUNCTION; CRYSTAL-STRUCTURE; TYROSINE RECOMBINASES; FLP RECOMBINASE; INHIBITORS; RESOLUTION; MECHANISM; CLEAVAGE; COMPLEX; FAMILY	Cre recombinase is a prototypical member of the tyrosine recombinase family of site-specific recombinases. Members of this family of enzymes catalyze recombination between specific DNA sequences by cleaving and exchanging one pair of strands between the two substrate sites to form a 4-way Holliday junction (HJ) intermediate and then resolve the HJ intermediate to recombinant products by a second round of strand exchanges. Recently, hexapeptide inhibitors have been described that are capable of blocking the second strand exchange step in the tyrosine recombinase recombination pathway, leading to an accumulation of the HJ intermediate. These peptides are active in the lambda-integrase, Cre recombinase, and Flp recombinase systems and are potentially important tools for both in vitro mechanistic studies and as in vivo probes of cellular function. Here we present biochemical and crystallographic data that support a model where the peptide inhibitor binds in the center of the recombinase-bound DNA junction and interacts with solvent-exposed bases near the junction branch point. Peptide binding induces large conformational changes in the DNA strands of the HJ intermediate, which affect the active site geometries in the recombinase subunits.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Ctr Microbial Sci, San Diego, CA 92182 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; California State University System; San Diego State University; California State University System; San Diego State University	Van Duyne, GD (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	vanduyne@mail.med.upenn.edu	Lau, Terrence/ABB-7900-2021	Lau, Terrence/0000-0002-7505-7306; Segall, Anca/0000-0002-8454-5248	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055041, R01GM052847] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NIAID NIH HHS [R01 AI058253] Funding Source: Medline; NIGMS NIH HHS [GM52847, GM55041] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; Arciszewska L, 1997, EMBO J, V16, P3731, DOI 10.1093/emboj/16.12.3731; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barre FX, 2001, P NATL ACAD SCI USA, V98, P8189, DOI 10.1073/pnas.111008998; Boldt JL, 2004, J BIOL CHEM, V279, P3472, DOI 10.1074/jbc.M309361200; Bolla ML, 2003, ORG LETT, V5, P109, DOI 10.1021/ol020204f; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Cassell G, 2000, J MOL BIOL, V299, P1193, DOI 10.1006/jmbi.2000.3828; Cassell GD, 2003, J MOL BIOL, V327, P413, DOI 10.1016/S0022-2836(03)00058-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; CLEGG RM, 1994, BIOPHYS J, V66, P99, DOI 10.1016/S0006-3495(94)80765-9; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Declais AC, 2003, EMBO J, V22, P1398, DOI 10.1093/emboj/cdg132; Declais AC, 2000, J MOL BIOL, V296, P421, DOI 10.1006/jmbi.1999.3479; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P5449, DOI 10.1093/nar/gkg732; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Ghosh K, 2002, METHODS, V28, P374, DOI 10.1016/S1046-2023(02)00244-X; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUO F, 2000, THESIS U PENNSYLVANI; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klemm M, 2000, J MOL BIOL, V299, P1203, DOI 10.1006/jmbi.2000.3829; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; Lee L, 2001, J BIOL CHEM, V276, P31092, DOI 10.1074/jbc.M103739200; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; Roy S, 2003, METHOD ENZYMOL, V370, P568; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; Seibert E, 2002, BIOCHEMISTRY-US, V41, P10976, DOI 10.1021/bi026121o; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STERNBERG N, 1980, COLD SPRING HARB SYM, V45, P297, DOI 10.1101/SQB.1981.045.01.042; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87	44	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8290	8299		10.1074/jbc.M411668200	http://dx.doi.org/10.1074/jbc.M411668200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591069	hybrid			2022-12-25	WOS:000227395700103
J	Kaliman, P; Catalucci, D; Lam, JT; Kondo, R; Gutierrez, JCP; Reddy, S; Palacin, M; Zorzano, A; Chien, KR; Ruiz-Lozano, P				Kaliman, P; Catalucci, D; Lam, JT; Kondo, R; Gutierrez, JCP; Reddy, S; Palacin, M; Zorzano, A; Chien, KR; Ruiz-Lozano, P			Myotonic dystrophy protein kinase phosphorylates phospholamban and regulates calcium uptake in cardiomyocyte sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELLS; CTG REPEAT; DMPK; LOCALIZATION; HOMEOSTASIS; SUBUNIT; ATPASE; ONSET	Myotonic dystrophy (DM) is caused by a CTG expansion in the 3'-untranslated region of a protein kinase gene (DMPK). Cardiovascular disease is one of the most prevalent causes of death in DM patients. Electrophysiological studies in cardiac muscles from DM patients and from DMPK-/- mice suggested that DMPK is critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction activity. However, there are no data regarding the molecular signaling pathways involved in DM heart failure. Here we show that DMPK expression in cardiac myocytes is highly enriched in the sarcoplasmic reticulum (SR) where it colocalizes with the ryanodine receptor and phospholamban (PLN), a muscle-specific SR Ca2+-ATPase (SERCA2a) inhibitor. Coimmunoprecipitation studies showed that DMPK and PLN can physically associate. Furthermore, purified wild-type DMPK, but not a kinase-deficient mutant (K110A DMPK), phosphorylates PLN in vitro. Subsequent studies using the DMPK-/- mice demonstrated that PLN is hypo-phosphorylated in SR vesicles from DMPK-/- mice compared with wild-type mice both in vitro and in vivo. Finally, we show that Ca2+ uptake in SR is impaired in ventricular homogenates from DMPK-/- mice. Together, our data suggest the existence of a novel regulatory DMPK pathway for cardiac contractility and provide a molecular mechanism for DM heart pathology.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ So Calif, Inst Genet Med, Los Angeles, CA 90033 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Recerca Biomed, La Jolla, CA 92093 USA	University of Barcelona; University of Southern California; University of California System; University of California San Diego; University of California System; University of California San Diego	Kaliman, P (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	pkaliman@ub.edu	Catalucci, Daniele/AAA-6056-2022; Catalucci, Daniele/B-6745-2015; Palacín, Manuel/G-9786-2015; Paz, Jose Carlos/I-5783-2015; Zorzano, Antonio/R-5479-2018	Catalucci, Daniele/0000-0001-7041-6114; Catalucci, Daniele/0000-0001-7041-6114; Paz, Jose Carlos/0000-0001-9684-9735; Palacin, Manuel/0000-0002-8670-293X	NHLBI NIH HHS [HL065484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065484, R56HL065484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Arai M, 2000, JPN HEART J, V41, P1, DOI 10.1536/jhj.41.1; Benders AAGM, 1997, J CLIN INVEST, V100, P1440, DOI 10.1172/JCI119664; Benders AAGM, 1996, ACTA PHYSIOL SCAND, V156, P355, DOI 10.1046/j.1365-201X.1996.202000.x; Berul CI, 2000, J INTERV CARD ELECTR, V4, P351, DOI 10.1023/A:1009842114968; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; EDSTROM L, 1989, ACTA NEUROL SCAND, V80, P419, DOI 10.1111/j.1600-0404.1989.tb03903.x; Frank KF, 2003, CARDIOVASC RES, V57, P20, DOI 10.1016/S0008-6363(02)00694-6; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Hagemann D, 2002, TRENDS CARDIOVAS MED, V12, P51, DOI 10.1016/S1050-1738(01)00145-1; Harper P.S., 1989, MYOTONIC DYSTROPHY; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JACOBS AEM, 1990, BIOCHIM BIOPHYS ACTA, V1096, P14, DOI 10.1016/0925-4439(90)90006-B; JONES LR, 1985, J BIOL CHEM, V260, P7721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam LT, 2000, HUM MOL GENET, V9, P2167, DOI 10.1093/hmg/9.14.2167; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Mounsey JP, 2000, J BIOL CHEM, V275, P23362, DOI 10.1074/jbc.M000899200; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Mussini I, 1999, J HISTOCHEM CYTOCHEM, V47, P383, DOI 10.1177/002215549904700312; PAGANI ED, 1984, AM J PHYSIOL, V247, pH909, DOI 10.1152/ajpheart.1984.247.6.H909; Pall GS, 2003, PHYSIOL GENOMICS, V13, P139, DOI 10.1152/physiolgenomics.00107.2002; Pelargonio G, 2002, HEART, V88, P665, DOI 10.1136/heart.88.6.665; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Ruiz-Lozano P, 2003, NAT GENET, V33, P8, DOI 10.1038/ng0103-8; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; Saba S, 1999, J CARDIOVASC ELECTR, V10, P1214, DOI 10.1111/j.1540-8167.1999.tb00298.x; Sarkar PS, 2004, NEUROMUSCULAR DISORD, V14, P497, DOI 10.1016/j.nmd.2004.03.012; SORDAHL LA, 1973, AM J PHYSIOL, V224, P497, DOI 10.1152/ajplegacy.1973.224.3.497; TIMCHENKO L, 1995, P NATL ACAD SCI USA, V92, P5366, DOI 10.1073/pnas.92.12.5366; Wansink DG, 2003, MOL CELL BIOL, V23, P5489, DOI 10.1128/MCB.23.16.5489-5501.2003	43	26	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8016	8021		10.1074/jbc.M412845200	http://dx.doi.org/10.1074/jbc.M412845200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15598648	hybrid			2022-12-25	WOS:000227395700071
J	Armache, KJ; Mitterweger, S; Meinhart, A; Cramer, P				Armache, KJ; Mitterweger, S; Meinhart, A; Cramer, P			Structures of complete RNA polymerase II and its subcomplex, Rpb4/7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION COMPLEX; TRANSCRIPTION; RESOLUTION; ARCHITECTURE; INITIATION; REPLACEMENT; MACHINERY; MECHANISM; MOLSCRIPT; COCRYSTAL	We determined the x-ray structure of the RNA polymerase (Pol) II subcomplex Rpb4/7 at 2.3 Angstrom resolution, combined it with a previous structure of the 10-subunit polymerase core, and refined an atomic model of the complete 12-subunit Pol II at 3.8-Angstrom resolution. Comparison of the complete Pol II structure with structures of the Pol II core and free Rpb4/7 shows that the core-Rpb4/7 interaction goes along with formation of an a-helix in the linker region of the largest Pol II subunit and with folding of the conserved Rpb7 tip loop. Details of the core-Rpb4/7 interface explain facilitated Rpb4/7 dissociation in a temperature-sensitive Pol 11 mutant and specific assembly of Pol I with its Rpb4/7 counterpart, A43/14. The refined atomic model of Pol II serves as the new reference structure for analysis of the transcription mechanism and enables structure solution of complexes of the complete enzyme with additional factors and nucleic acids by molecular replacement.	Univ Munich, Gene Ctr, LMU, Dept Chem & Biochem, D-81377 Munich, Germany	University of Munich	Cramer, P (corresponding author), Univ Munich, Gene Ctr, LMU, Dept Chem & Biochem, Feodor Lynen Str 25, D-81377 Munich, Germany.	cramer@LMB.uni-muenchen.de	Meinhart, Anton/M-9647-2014					Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Asturias FJ, 2004, CURR OPIN STRUC BIOL, V14, P121, DOI 10.1016/j.sbi.2004.03.007; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Cramer P, 2004, ADV PROTEIN CHEM, V67, P1; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Tan Q, 2003, MOL CELL BIOL, V23, P3329, DOI 10.1128/MCB.23.9.3329-3338.2003; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3	26	175	188	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7131	7134		10.1074/jbc.M413038200	http://dx.doi.org/10.1074/jbc.M413038200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591044	Green Published, hybrid			2022-12-25	WOS:000227332700103
J	Lee, GM; Donaldson, LW; Pufall, MA; Kang, HS; Pot, I; Graves, BJ; McIntosh, LP				Lee, GM; Donaldson, LW; Pufall, MA; Kang, HS; Pot, I; Graves, BJ; McIntosh, LP			The structural and dynamic basis of Ets-1 DNA binding autoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP HYDROGEN-EXCHANGE; N-15 NMR RELAXATION; BACKBONE DYNAMICS; MURINE ETS-1; SECONDARY STRUCTURE; CHEMICAL-EXCHANGE; DIPOLAR COUPLINGS; HIGH-RESOLUTION; POINTED DOMAIN; SIDE-CHAINS	The transcription factor Ets-1 is regulated by the allosteric coupling of DNA binding with the unfolding of an alpha-helix (HI-1) within an autoinhibitory module. To understand the structural and dynamic basis for this autoinhibition, we have used NAIR spectroscopy to characterize Ets-1DeltaN301, a partially inhibited fragment of Ets-1. The NMR-derived Ets-1DeltaN301 structure reveals that the autoinhibitory module is formed predominantly by the hydrophobic packing of helices from the N-terminal (HI-1, HI-2) and C-terminal (114, 115) inhibitory sequences, along with H1 of the intervening DNA binding ETS domain. The intramolecular interactions made by HI-1 in Ets-1DeltaN301 are similar to the intermolecular contacts observed in the crystal structure of an Ets-1DeltaN300 dimer, confirming that the latter represents a domain-swapped species. N-15 relaxation studies demonstrate that the backbone of the N-terminal inhibitory sequence is mobile on the nanosecond-picosecond and millisecond-microsecond time scales. Furthermore, hydrogen exchange measurements reveal that amide protons in helices HI-I and HI-2 exchange with water at rates only similar to15- and similar to75-fold slower, respectively, than predicted for an unfolded polypeptide. These findings indicate that inhibitory helices are only marginally stable even in the absence of DNA. The energetic coupling of DNA binding with the facile unfolding of the labile HI-1 provides a mechanism for modulating Ets-1 DNA binding activity via protein partnerships, post-translational modifications, or mutations. Ets-1 autoinhibition illustrates how conformational equilibria within structural domains can regulate macromolecular interactions.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ Utah, Huntsmann Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA	University of British Columbia; University of British Columbia; University of British Columbia; Utah System of Higher Education; University of Utah	McIntosh, LP (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintosh@otter.biochem.ube.ca		Donaldson, Logan/0000-0001-5034-2699; Pufall, Miles/0000-0002-7022-6916; Kang, Hyun-Seo/0000-0003-4029-5096	NATIONAL CANCER INSTITUTE [T32CA093247, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663, R29GM038663] Funding Source: NIH RePORTER; NCI NIH HHS [CA93247, CA24014] Funding Source: Medline; NIGMS NIH HHS [GM38663] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Connelly GP, 1998, BIOCHEMISTRY-US, V37, P1810, DOI 10.1021/bi972085v; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cowley DO, 2000, GENE DEV, V14, P366; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DONALDSON LW, 1996, THESIS U BRIT COLUMB; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Garvie CW, 2002, J BIOL CHEM, V277, P45529, DOI 10.1074/jbc.M206327200; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Hwang TL, 1998, J BIOMOL NMR, V11, P221, DOI 10.1023/A:1008276004875; Ishii Y, 2001, J BIOMOL NMR, V21, P141, DOI 10.1023/A:1012417721455; Jia X, 1999, J MOL BIOL, V292, P1083, DOI 10.1006/jmbi.1999.3123; JONSEN M, 1999, THESIS U UTAH SALT L; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Loria JP, 1999, J AM CHEM SOC, V121, P2331, DOI 10.1021/ja983961a; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; McIntosh LP, 1997, J BIOMOL NMR, V9, P306, DOI 10.1023/A:1018635110491; MCINTOSH LP, 1990, Q REV BIOPHYS, V23, P1, DOI 10.1017/S0033583500005400; Millet O, 2000, J AM CHEM SOC, V122, P2867, DOI 10.1021/ja993511y; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Mulder FAA, 2001, J AM CHEM SOC, V123, P967, DOI 10.1021/ja003447g; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Pufall MA, 2002, STRUCTURE, V10, P11, DOI 10.1016/S0969-2126(01)00701-8; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; Wang H, 2002, J BIOL CHEM, V277, P2225, DOI 10.1074/jbc.M109430200; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; Willard L, 2003, NUCLEIC ACIDS RES, V31, P3316, DOI 10.1093/nar/gkg565; Wolf-Watz M, 2004, NAT STRUCT MOL BIOL, V11, P945, DOI 10.1038/nsmb821; Yan JL, 2004, NAT STRUCT MOL BIOL, V11, P901, DOI 10.1038/nsmb819; Zhang YZ, 1995, PROTEIN PEPTIDE STRU; Zwahlen C, 1998, J AM CHEM SOC, V120, P7617, DOI 10.1021/ja981205z	73	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7088	7099		10.1074/jbc.M410722200	http://dx.doi.org/10.1074/jbc.M410722200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591056	hybrid			2022-12-25	WOS:000227332700099
J	Flinterman, M; Guelen, L; Ezzati-Nik, S; Killick, R; Melino, G; Tominaga, K; Mymryk, JS; Gaken, J; Tavassoli, M				Flinterman, M; Guelen, L; Ezzati-Nik, S; Killick, R; Melino, G; Tominaga, K; Mymryk, JS; Gaken, J; Tavassoli, M			E1A activates transcription of p73 and noxa to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 HOMOLOG P73; ADENOVIRUS-5 E1A; TUMOR-SUPPRESSOR; CELL-LINES; BINDING-SITES; GENE-PRODUCTS; CANCER-CELLS; PROTEIN; EXPRESSION; ONCOGENE	p73, a member of the p53 family of proteins, transcriptionally activates a number of genes involved in the control of cell cycle and apoptosis. Overexpression of p73 was detected in a large number of primary head and neck cancers, and in the established cell lines examined, these all contained inactivating p53 mutations. The significance of p73 overexpression in the pathogenesis of head and neck cancer is currently unclear. We have shown that the expression of adenovirus 5 E1A in a panel of head and neck cancer cell lines induces apoptosis independently of their p53 status. In this study we examined the role of p73 and its transcriptional targets in E1A-mediated induction of apoptosis. E1A expression resulted in significant activation of the TAp73 promoter but had no effect on the alternative, DeltaNp73 promoter. ETA also increased expression of endogenous TAp73 mRNA and protein. E1A mutants lacking the p300-and/or pRB-binding sites showed reduced ability to activate the TAp73 promoter. Additionally, mutations in the E2F1-binding sites in the TAp73 promoter impaired activation by E1A. Importantly, expression of the 13S isoform of E1A substantially induced the p53 apoptotic target Noxa in several p53-deficient cancer cell lines. Our results indicate that E1A activation of p73 and the p53 apoptotic target Noxa can occur in the absence of a functional p53. This activation is likely to play a key role in the mechanism of p53-independent apoptosis induced by E1A in some cancers and may provide an avenue for future cancer therapies.	Guys Kings & St Thomass Sch Dent, Head & Neck Oncol Grp, London SE5 9NU, England; Kings Coll London, Dept Hematol & Mol Med, London SE5 9NU, England; Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Univ Rome, Inst Dermopat Immacolatat, Inst Ric Clin Carattere Sci Lab, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Osaka Dent Univ, Dept Oral Pathol, Osaka 5731121, Japan; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada	University of London; King's College London; University of London; King's College London; University of London; King's College London; Sapienza University Rome; University of Leicester; Western University (University of Western Ontario); Western University (University of Western Ontario)	Tavassoli, M (corresponding author), Kings Coll London, Dept Oral Med & Pathol, Head & Neck Oncol Grp, 123 Coldharbour Lane, London SE2 9NU, England.	mahvash.tavassoli@kcl.ac.uk		Killick, Richard/0000-0002-8815-3436				Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Frasca F, 2003, CANCER RES, V63, P5829; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Goldschneider D, 2004, J CELL SCI, V117, P293, DOI 10.1242/jcs.00834; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishimoto O, 2002, CANCER RES, V62, P636; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mahmoud S, 2003, BIOCHEM BIOPH RES CO, V305, P1099, DOI 10.1016/S0006-291X(03)00905-7; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Terrinoni A, 2004, ONCOGENE, V23, P3721, DOI 10.1038/sj.onc.1207342; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAN DH, 1991, ONCOGENE, V6, P343; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000	46	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5945	5959		10.1074/jbc.M406661200	http://dx.doi.org/10.1074/jbc.M406661200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572378	hybrid			2022-12-25	WOS:000227217100101
J	Syrovets, T; Gschwend, JE; Buchele, B; Laumonnier, Y; Zugmaier, W; Genze, F; Simmet, T				Syrovets, T; Gschwend, JE; Buchele, B; Laumonnier, Y; Zugmaier, W; Genze, F; Simmet, T			Inhibition of I kappa B kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PENTACYCLIC TRITERPENIC ACIDS; BCL-X-L; CYCLIN D1; ALPHA KINASE; CONSTITUTIVE ACTIVATION; P65 PHOSPHORYLATION; DOWN-REGULATION; IKK-ALPHA; TRANSCRIPTIONAL REGULATION	Signaling through NF-kappaB has been implicated in the malignant phenotype as well as the chemoresistance of various cancers. Here we show that the natural compounds acetyl-beta-boswellic acid and acetyl-11-keto-beta-boswellic acid (AKbetaBA) inhibit proliferation and elicit cell death in chemoresistant androgen-independent PC-3 prostate cancer cells in vitro and in vivo. Induction of apoptosis was demonstrated in cultured PC-3 cells by several parameters including mitochondrial cytochrome c release and DNA fragmentation. At the molecular level these compounds inhibit constitutively activated NF-kappaB signaling by intercepting the IkappaB kinase (IKK) activity; signaling through the interferon-stimulated response element remained unaffected, suggesting specificity for IKK inhibition. The impaired phosphorylation of p65 and the reduced nuclear translocation of NF-kappaB proteins were associated with down-regulation of the constitutively overexpressed and NF-kappaB-dependent oantiapoptotic proteins Bcl-2 and Bcl-x(L). In addition, expression of cyclin D1, a crucial cell cycle regulator, was reduced as well. Down-regulation of IKK by antisense oligodeoxynucleotides confirmed the essential role of IKK inhibition for the proliferation of the PC-3 cells. Both compounds tested were active in vivo, yet AKbetaBA proved to be far superior. Indeed, topical application of water-soluble AKbetaBA-gamma-cyclodextrin on PC-3 tumors xenografted onto chick chorioallantoic membranes induced concentration-dependent inhibition of proliferation as well as apoptosis. Similarly, in nude mice carrying PC-3 tumors, systemic application of AKbetaBA-gamma-cyclodextrin inhibited tumor growth and triggered apoptosis in the absence of detectable systemic toxicity. Thus, AKbetaBA and related compounds acting on IKK might provide a novel approach for the treatment of chemoresistant human tumors such as androgen-independent human prostate cancers.	Univ Ulm, Dept Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany; Univ Ulm, Dept Urol, D-89081 Ulm, Germany	Ulm University; Ulm University	Simmet, T (corresponding author), Univ Ulm, Dept Pharmacol Nat Prod & Clin Pharmacol, Helmholtzstr 20, D-89081 Ulm, Germany.	thomas.simmet@medizin.uni-ulm.de	Laumonnier, yves/F-6348-2018; Syrovets, Tatiana/J-4594-2019	Syrovets, Tatiana/0000-0002-6751-2233				Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Ammon H P T, 2002, Wien Med Wochenschr, V152, P373, DOI 10.1046/j.1563-258X.2002.02056.x; Amundson SA, 2000, CANCER RES, V60, P6101; Belsner K, 2003, MAGN RESON CHEM, V41, P115, DOI 10.1002/mrc.1138; Benimetskaya L, 2001, MOL PHARMACOL, V60, P1296, DOI 10.1124/mol.60.6.1296; Bettaieb Ali, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P307, DOI 10.2174/1568011033482396; Bey EA, 2002, METHOD ENZYMOL, V353, P421; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Buchele B, 2003, J CHROMATOGR B, V795, P355, DOI 10.1016/S1570-0232(03)00555-5; Buchele B, 2003, J CHROMATOGR B, V791, P21, DOI 10.1016/S1570-0232(03)00160-0; Burysek L, 2002, J BIOL CHEM, V277, P33509, DOI 10.1074/jbc.M201941200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen Y, 1998, ONCOGENE, V16, P1913, DOI 10.1038/sj.onc.1201719; Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; Gasparian AV, 2002, J CELL SCI, V115, P141; Glaser T, 1999, BRIT J CANCER, V80, P756, DOI 10.1038/sj.bjc.6690419; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heldt MR, 1997, N-S ARCH PHARMACOL, V355, P30; Hoernlein RF, 1999, J PHARMACOL EXP THER, V288, P613; Hosokawa Y, 1999, INT J CANCER, V81, P616, DOI 10.1002/(SICI)1097-0215(19990517)81:4<616::AID-IJC18>3.3.CO;2-J; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kikuchi E, 2003, CANCER RES, V63, P107; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; Lebedeva I, 2000, CANCER RES, V60, P6052; Lee KH, 1999, J BIOMED SCI, V6, P236, DOI 10.1007/BF02253565; Leung S, 2001, INT J CANCER, V91, P846, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1131>3.0.CO;2-Y; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li XY, 2001, CANCER RES, V61, P1699; Liu JJ, 2002, CARCINOGENESIS, V23, P2087, DOI 10.1093/carcin/23.12.2087; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Palayoor ST, 1998, CLIN CANCER RES, V4, P763; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Rosenbaum E, 2003, EXPERT OPIN PHARMACO, V4, P875, DOI 10.1517/14656566.4.6.875; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sauter ER, 2002, CANCER RES, V62, P3200; Shishodia S, 2003, CANCER RES, V63, P4375; SIMMET T, 2001, Patent No. 6174876; SIMMET T, 1999, Patent No. 5919821; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Syrovets T, 2000, MOL PHARMACOL, V58, P71, DOI 10.1124/mol.58.1.71; Syrovets T, 2002, THROMB HAEMOSTASIS, V88, P274; Syrovets T, 2001, BLOOD, V97, P3941, DOI 10.1182/blood.V97.12.3941; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Vilenchik M, 2002, CANCER RES, V62, P2175; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang SM, 2003, SEMIN ONCOL, V30, P133, DOI 10.1053/j.seminoncol.2003.08.015; Wang XZ, 1999, CANCER RES, V59, P5842; Weinmann P, 1999, BLOOD, V93, P3106; Wenk J, 2004, J BIOL CHEM, V279, P45634, DOI 10.1074/jbc.M408893200; Winking M, 2000, J NEURO-ONCOL, V46, P97, DOI 10.1023/A:1006387010528; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	69	136	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6170	6180		10.1074/jbc.M409477200	http://dx.doi.org/10.1074/jbc.M409477200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15576374	hybrid			2022-12-25	WOS:000227217100124
J	Voncken, JW; Niessen, H; Neufeld, B; Rennefahrt, U; Dahlmans, V; Kubben, N; Holzer, B; Ludwig, S; Rapp, UR				Voncken, JW; Niessen, H; Neufeld, B; Rennefahrt, U; Dahlmans, V; Kubben, N; Holzer, B; Ludwig, S; Rapp, UR			MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3; MONOCLONAL-ANTIBODIES; SAM DOMAIN; IDENTIFICATION; COMPLEX; BINDING; STRESS; TRANSCRIPTION; RECOGNITION; INHIBITION	Polycomb group (PcG) proteins form chromatin-associated, transcriptionally repressive complexes, which are critically involved in the control of cell proliferation and differentiation. Although the mechanisms involved in PcG-mediated repression are beginning to unravel, little is known about the regulation of PcG function. We showed previously that PcG complexes are phosphorylated in vivo, which regulates their association with chromatin. The nature of the responsible PcG kinases remained unknown. Here we present the novel finding that the PcG protein Bmil is phosphorylated by 3pK (MAPKAP kinase 3), a convergence point downstream of activated ERK and p38 signaling pathways and implicated in differentiation and developmental processes. We identified 3pK as an interaction partner of PcG proteins, in vitro and in vivo, by yeast two-hybrid interaction and co-immunoprecipitation, respectively. Activation or overexpression of 3pK resulted in phosphorylation of Bmil and other PcG members and their dissociation from chromatin. Phosphorylation and subsequent chromatin dissociation of PcG complexes were expected to result in de-repression of targets. One such reported Bmil target is the Cdkn2a/INK4A locus. Cells overexpressing 3pK showed PcG complex/chromatin dissociation and concomitant de-repression of p14(ARF), which was encoded by the Cdkn2a/INK4A locus. Thus, 3pK is a candidate regulator of phosphorylation-dependent PcG/chromatin interaction. We speculate that phosphorylation may not only affect chromatin association but, in addition, the function of individual complex members. Our findings linked for the first time MAPK signaling pathways to the Polycomb transcriptional memory system. This suggests a novel mechanism by which a silenced gene status can be modulated and implicates PcG-mediated repression as a dynamically controlled process.	Maastricht Univ, Res Inst Growth & Dev, NL-6200 MD Maastricht, Netherlands; Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wurzburg, Germany; Inst Mol Virol, D-48419 Munster, Germany	Maastricht University	Voncken, JW (corresponding author), Maastricht Univ, Res Inst Growth & Dev, Univ Singel 50, NL-6200 MD Maastricht, Netherlands.	w.voncken@gen.unimaas.nl; rappur@mail.uni.wuerzburg.de	Niessen, Hanneke/B-7699-2009	Niessen, Hanneke/0000-0002-2639-0938; Ludwig, Stephan/0000-0003-4490-3052; Holzer, Barbara/0000-0003-0203-0601				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Atsuta T, 2001, HYBRIDOMA, V20, P43, DOI 10.1089/027245701300060427; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brock HW, 2001, CURR OPIN GENET DEV, V11, P175, DOI 10.1016/S0959-437X(00)00176-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Core N, 2004, ONCOGENE, V23, P7660, DOI 10.1038/sj.onc.1207998; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fujisaki S, 2003, BIOCHEM BIOPH RES CO, V300, P135, DOI 10.1016/S0006-291X(02)02791-2; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Hamer KM, 2002, HYBRIDOMA HYBRIDOM, V21, P245, DOI 10.1089/153685902760213859; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Hodgson JW, 2001, MOL CELL BIOL, V21, P4528, DOI 10.1128/MCB.21.14.4528-4543.2001; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SJ, 2001, FEBS LETT, V503, P61, DOI 10.1016/S0014-5793(01)02689-8; Lessard J, 2003, EXP HEMATOL, V31, P567, DOI 10.1016/S0301-472X(03)00081-X; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Neufeld B, 2000, J BIOL CHEM, V275, P20239, DOI 10.1074/jbc.C901040199; New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538; Noguchi K, 2002, BIOCHEM BIOPH RES CO, V291, P508, DOI 10.1006/bbrc.2002.6480; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; SUZUKI M, 2002, DEV CAMB, V29, P4171; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; Voncken JW, 1999, J CELL SCI, V112, P4627; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yannoni YM, 2004, FEBS LETT, V564, P205, DOI 10.1016/S0014-5793(04)00351-5; Zakowski V, 2004, EXP CELL RES, V299, P101, DOI 10.1016/j.yexcr.2004.05.027	64	130	136	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5178	5187		10.1074/jbc.M407155200	http://dx.doi.org/10.1074/jbc.M407155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15563468	hybrid			2022-12-25	WOS:000227217100010
J	Wrenger, C; Eschbach, ML; Muller, IB; Warnecke, D; Walter, RD				Wrenger, C; Eschbach, ML; Muller, IB; Warnecke, D; Walter, RD			Analysis of the vitamin B6 biosynthesis pathway in the human malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN PYRIDOXAL KINASE; BIFUNCTIONAL ORNITHINE-DECARBOXYLASE; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ADENOSINE KINASE; GENE; OPERON; PURIFICATION; EXPRESSION; SEQUENCE	Vitamin B6 is an essential cofactor for more than 100 enzymatic reactions. Mammalian cells are unable to synthesize vitamin B6 de novo, whereas bacteria, plants, fungi, and as shown here Plasmodium falciparum possess a functional vitamin B6 synthesis pathway. P. falciparum expresses the proteins Pdx1 and Pdx2, corresponding to the yeast enzymes Snz1-p and Sno1-p, which are essential for the vitamin B6 biosynthesis. An involvement of PfPdx1 and PfPdx2 in the de novo synthesis of vitamin B6 was shown by complementation of pyridoxine auxotroph yeast cells. Both plasmodial proteins act together in the glutaminase activity with a specific activity of 209 nmol min(-1) mg(-1) and a K. value for glutamine of 1.3 mm. Incubation of the parasites with methylene blue revealed by Northern blot analysis an elevated transcriptional level of pdx1 and pdx2, suggesting a participation of these proteins in the defenses against singlet oxygen. To be an active cofactor, vitamin B6 has to be phosphorylated by the pyridoxine kinase (PdxK). The recombinant plasmodial PdxK revealed K-m values for the B6 vitamers pyridoxine and pyridoxal and for ATP of 212, 70, and 82 mum, respectively. All three enzymes expose a stage-specific transcription pattern within the trophozoite stage that guarantees the concurrent expression of Pdx1, Pdx2, and PdxK for the indispensable provision of vitamin B6. The occurrence of the vitamin B6 de novo synthesis pathway displays a potential new drug target, which can be exploited for the development of new chemotherapeutics against the human malaria parasite P. falciparum.	Bernhard Nocht Inst Trop Med, Dept Biochem, D-20359 Hamburg, Germany; Univ Hamburg, Biozentrum Klein Flottbek & Botanisher Garten, D-22609 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg	Walter, RD (corresponding author), Bernhard Nocht Inst Trop Med, Dept Biochem, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	walter@bni-hamburg.de	Wrenger, Carsten/E-4110-2013	Wrenger, Carsten/0000-0001-5987-1749				Antelmann H, 1997, ELECTROPHORESIS, V18, P1451, DOI 10.1002/elps.1150180820; Bauer JA, 2004, J BIOL CHEM, V279, P2704, DOI 10.1074/jbc.M310311200; Birkholtz LM, 2004, BIOCHEM J, V377, P439, DOI 10.1042/BJ20030614; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campobasso N, 2000, BIOCHEMISTRY-US, V39, P7868, DOI 10.1021/bi0000061; Cassera MB, 2004, J BIOL CHEM, V279, P51749, DOI 10.1074/jbc.M408360200; Dong YX, 2004, EUR J BIOCHEM, V271, P745, DOI 10.1111/j.1432-1033.2003.03973.x; Ehrenshaft M, 1998, MOL CELL, V1, P603, DOI 10.1016/S1097-2765(00)80060-X; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Galperin MY, 1997, MOL MICROBIOL, V24, P443, DOI 10.1046/j.1365-2958.1997.3671706.x; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hill RE, 1996, J BIOL CHEM, V271, P30426, DOI 10.1074/jbc.271.48.30426; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KWOK F, 1979, J BIOL CHEM, V254, P6489; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAM HM, 1992, J BACTERIOL, V174, P6033, DOI 10.1128/JB.174.19.6033-6045.1992; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Li MH, 2004, J BIOL CHEM, V279, P17459, DOI 10.1074/jbc.M312380200; Li MH, 2002, J BIOL CHEM, V277, P46385, DOI 10.1074/jbc.M208600200; Luersen K, 1999, MOL BIOCHEM PARASIT, V98, P131, DOI 10.1016/S0166-6851(98)00161-3; Lum HK, 2002, PLANTA, V215, P870, DOI 10.1007/s00425-002-0799-0; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; MEI B, 1989, J BIOL CHEM, V264, P16613; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Newton P, 1999, ANNU REV MED, V50, P179, DOI 10.1146/annurev.med.50.1.179; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Park JH, 2004, J BACTERIOL, V186, P1571, DOI 10.1128/JB.186.5.1571-1573.2004; Percudani R, 2003, EMBO REP, V4, P850, DOI 10.1038/sj.embor.embor914; ROA BB, 1989, J BACTERIOL, V171, P4767, DOI 10.1128/jb.171.9.4767-4777.1989; Said HM, 2003, AM J PHYSIOL-CELL PH, V285, pC1219, DOI 10.1152/ajpcell.00204.2003; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; Scott TC, 1997, MOL BIOCHEM PARASIT, V88, P1, DOI 10.1016/S0166-6851(97)00077-7; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; Stolz J, 2003, J BIOL CHEM, V278, P18990, DOI 10.1074/jbc.M300949200; Tanaka K, 2000, J NUTR SCI VITAMINOL, V46, P55; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UMLAS J, 1971, AM J TROP MED HYG, V20, P527, DOI 10.4269/ajtmh.1971.20.527; VANKUILENBURG ABP, 1994, ANTICANCER RES, V14, P411; VENNERSTROM JL, 1995, ANTIMICROB AGENTS CH, V39, P2671, DOI 10.1128/AAC.39.12.2671; Wetzel DK, 2004, FEBS LETT, V564, P143, DOI 10.1016/S0014-5793(04)00329-1; Wrenger C, 2001, J BIOL CHEM, V276, P29651, DOI 10.1074/jbc.M100578200; Yang Y, 1998, J BACTERIOL, V180, P4294, DOI 10.1128/JB.180.16.4294-4299.1998; Zeidler J, 2003, J ORG CHEM, V68, P3486, DOI 10.1021/jo020730k; Zeidler J, 2002, J AM CHEM SOC, V124, P4542, DOI 10.1021/ja012708z	49	76	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5242	5248		10.1074/jbc.M412475200	http://dx.doi.org/10.1074/jbc.M412475200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590634	hybrid			2022-12-25	WOS:000227217100018
J	Pingoud, V; Sudina, A; Geyer, H; Bujnicki, JM; Lurz, R; Luder, G; Morgan, R; Kubareva, E; Pingoud, A				Pingoud, V; Sudina, A; Geyer, H; Bujnicki, JM; Lurz, R; Luder, G; Morgan, R; Kubareva, E; Pingoud, A			Specificity changes in the evolution of Type II restriction endonucleases - A biochemical and bioinformatic analysis of restriction enzymes that recognize unrelated sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; OLIGONUCLEOTIDE DUPLEXES; MODIFICATION SYSTEM; STIMULATE CLEAVAGE; MASS-SPECTROMETRY; REFRACTORY DNA; NOMENCLATURE; RESIDUES; IDENTIFICATION	How restriction enzymes with their different specificities and mode of cleavage evolved has been a long standing question in evolutionary biology. We have recently shown that several Type II restriction endonucleases, namely SsoII (down arrow CCNGG), PspGI (down arrow CCWGG), Eco-RII (1 CCWGG), NgoMIV (G down arrow CCGGC), and Cfr10I (R down arrow CCGGY), which recognize similar DNA sequences (as indicated, where the downward arrows denote cleavage position), share limited sequence similarity over an interrupted stretch of similar to70 amino acid residues with MboI, a Type IIestriction endonuclease from Moraxella bovis (Pingoud, V., Conzelmann, C., Kinzebach, S., Sudina, A., Metelev, V., Kubareva, E., Bujnicki, J.M., Lurz, R., Luder, G., Xu, S. Y., and Pingoud, A. (2003) J. Mol. Biol 329, 913-929). Nevertheless, MboI has a dissimilar DNA specificity (down arrow GATC) compared with these enzymes. In this study, we characterize MboI in detail to determine whether it utilizes a mechanism of DNA recognition similar to SsoII, PspGI, EcoRII, NgoMIV, and Cfr10I. Mutational analyses and photocross-linking experiments demonstrate that MboI exploits the stretch of similar to70 amino acids for DNA recognition and cleavage. It is therefore likely that MboI shares a common evolutionary origin with SsoII, PspGI, EcoRII, NgoMIV, and Cfr10I. This is the first example of a relatively close evolutionary link between Type IIestriction enzymes of widely different specificities.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Int Inst Mol & Cell Biol, Bioinformat Lab, PL-02108 Warsaw, Poland; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; New England Biolabs Inc, Beverly, MA 01915 USA	Justus Liebig University Giessen; Lomonosov Moscow State University; Lomonosov Moscow State University; Justus Liebig University Giessen; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society	Pingoud, V (corresponding author), Univ Giessen, Inst Biochem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	vera.pingoud@chemie.bio.uni-giessen.de	Sudina, Anna/I-5753-2014; Kubareva, Elena A/I-3184-2012					AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; Bujnicki JM, 2000, J MOL EVOL, V50, P39, DOI 10.1007/s002399910005; Bujnicki JM, 2001, ACTA BIOCHIM POL, V48, P935; Bujnicki JM, 2004, NUCL ACID M, V14, P63; Bujnicki JM, 2001, J MOL MICROB BIOTECH, V3, P69; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Friedhoff P, 2003, J MOL BIOL, V325, P285, DOI 10.1016/S0022-2836(02)01224-X; Friedhoff P, 2001, J BIOL CHEM, V276, P23581, DOI 10.1074/jbc.M101694200; GELINAS RE, 1977, J MOL BIOL, V114, P169, DOI 10.1016/0022-2836(77)90290-X; Geyer H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh131; Grazulis S, 2002, NUCLEIC ACIDS RES, V30, P876, DOI 10.1093/nar/30.4.876; Halford SE, 1999, BIOCHEM SOC T, V27, P696, DOI 10.1042/bst0270696; Heitman J, 1993, Genet Eng (N Y), V15, P57; Horton Jr, 2004, NUCL ACID M, V14, P361; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; Jeltsch A, 1996, J MOL EVOL, V42, P91, DOI 10.1007/BF02198833; JELTSCH A, 1995, GENE, V160, P7, DOI 10.1016/0378-1119(95)00181-5; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Kosinski J, 2003, PROTEINS, V53, P369, DOI 10.1002/prot.10545; Kurowski MA, 2003, NUCLEIC ACIDS RES, V31, P3305, DOI 10.1093/nar/gkg557; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11086, DOI 10.1021/bi963125i; Lochnit G, 2004, BIOMED CHROMATOGR, V18, P841, DOI 10.1002/bmc.399; Lochnit G, 1998, J BIOL CHEM, V273, P466, DOI 10.1074/jbc.273.1.466; Lukacs CM, 2000, NAT STRUCT BIOL, V7, P134; Morgan R, 1998, APPL ENVIRON MICROB, V64, P3669; Mucke M, 2003, NUCLEIC ACIDS RES, V31, P6079, DOI 10.1093/nar/gkg836; NOLLING J, 1992, J BACTERIOL, V174, P5719; PEIN CD, 1989, FEBS LETT, V245, P141, DOI 10.1016/0014-5793(89)80208-X; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Pingoud V, 2003, J MOL BIOL, V329, P913, DOI 10.1016/S0022-2836(03)00523-0; Pingoud V, 2002, J BIOL CHEM, V277, P14306, DOI 10.1074/jbc.M111625200; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 2004, NUCL ACID M, V14, P261; Roberts R, 1993, NUCLEASES, P35; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P418, DOI 10.1093/nar/gkg069; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; Siksnys V, 2004, NUCL ACID M, V14, P237; SIKSNYS V, 1994, GENE, V142, P1, DOI 10.1016/0378-1119(94)90347-6; Skirgaila R, 1998, J MOL BIOL, V279, P473, DOI 10.1006/jmbi.1998.1803; Steen H, 2001, PROTEIN SCI, V10, P1989, DOI 10.1110/ps.07601; Stensballe A, 2000, RAPID COMMUN MASS SP, V14, P1793, DOI 10.1002/1097-0231(20001015)14:19<1793::AID-RCM95>3.0.CO;2-Q; STEPHENSON FH, 1989, GENE, V85, P1, DOI 10.1016/0378-1119(89)90458-7; SZYBALSKI W, 1988, GENE, V74, P279; Tamulaitis G, 2002, FEBS LETT, V518, P17, DOI 10.1016/S0014-5793(02)02621-2; UENO T, 1993, NUCLEIC ACIDS RES, V21, P2309, DOI 10.1093/nar/21.10.2309; VENCLOVAS C, 1994, PROTEINS, V20, P279, DOI 10.1002/prot.340200308; Welsh AJ, 2004, NUCL ACID M, V14, P297; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WITHERS BE, 1992, NUCLEIC ACIDS RES, V20, P6267, DOI 10.1093/nar/20.23.6267; Wuhrer M, 2004, BIOCHEM J, V378, P625, DOI 10.1042/BJ20031380; Zhou XYE, 2004, J MOL BIOL, V335, P307, DOI 10.1016/j.jmb.2003.10.030	61	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4289	4298		10.1074/jbc.M409020200	http://dx.doi.org/10.1074/jbc.M409020200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563460	hybrid			2022-12-25	WOS:000227096600037
J	Yuan, GX; Nanduri, J; Bhasker, CR; Semenza, GL; Prabhakar, NR				Yuan, GX; Nanduri, J; Bhasker, CR; Semenza, GL; Prabhakar, NR			Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; OBSTRUCTIVE SLEEP-APNEA; COLON-CANCER CELLS; TYROSINE-HYDROXYLASE; FACTOR 1-ALPHA; GENE-EXPRESSION; CAROTID-BODY; C-FOS; GENOMIC CONSEQUENCES; EPISODIC HYPOXIA	Intermittent hypoxia (IH) occurs in many pathological conditions. However, very little is known about the molecular mechanisms associated with IH. Hypoxia-inducible factor 1 (HIF-1) mediates transcriptional responses to continuous hypoxia. In the present study, we investigated whether IH activates HIF-1 and, if so, which signaling pathways are involved. PC12 cells were exposed to either to 20% O-2 (non-hypoxic control) or to 60 cycles consisting of 30 s at 1.5% O-2 followed by 4 min at 20% O-2 (IH). Western blot analysis revealed significant increases in HIF-1alpha protein in nuclear extracts of cells subjected to IH. Expression of a HIF-1-dependent reporter gene was increased 3-fold in cells subjected to IH. Although IH induced the activation of ERK1, ERK2,JNK, PKC-alpha, and PKC-gamma, inhibitors of these kinases and of phosphatidylinositol 3-kinase did not block HIF-1-mediated reporter gene expression induced by III, indicating that signaling via these kinases was not required. In contrast, addition of the intracellular Ca2+ chelator BAPTA-AM or the Ca2+/calmodulin-dependent (CaM) kinase inhibitor KN93 blocked reporter gene activation in response to III. CaM kinase activity was increased 5-fold in cells subjected to IH. KN 93 prevented IH-induced transactivation mediated by HIF-1alpha, and its coactivator p300, which was phosphorylated by CaM kinase II in vitro. Expression of the HIF-1-regulated gene encoding tyrosine hydroxylase was induced by IH and this effect was blocked by KN93. These observations suggest that IH induces HIF-1 transcriptional activity via a novel signaling pathway involving CaM kinase.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Johns Hopkins Univ, Sch Med, Program Vasc Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Prabhakar, NR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nrp@po.cwru.edu	Nanduri, Srinivas/F-3585-2018	Nanduri, Srinivas/0000-0002-6671-2022; HYDERABAD, NIPER/0000-0001-7521-1150	NHLBI NIH HHS [R01-HL-55338, P01-HL-25830] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338, P01HL025830] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bruick RK, 2002, SCIENCE, V295, P807, DOI 10.1126/science.1069825; CAHAN C, 1992, J APPL PHYSIOL, V72, P2112, DOI 10.1152/jappl.1992.72.6.2112; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CZYZYKKRZESKA MF, 2003, OXYGEN SENSING RESPO, P153; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; FLETCHER EC, 1992, HYPERTENSION, V19, P555, DOI 10.1161/01.HYP.19.6.555; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuda R, 2003, CANCER RES, V63, P2330; Gozal D, 2002, SLEEP, V25, P59, DOI 10.1093/sleep/25.1.59; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Huang HM, 1999, J NEUROSCI RES, V56, P668, DOI 10.1002/(SICI)1097-4547(19990615)56:6<668::AID-JNR13>3.3.CO;2-I; Hui AS, 2003, HYPERTENSION, V42, P1130, DOI 10.1161/01.HYP.0000101691.12358.26; Imagawa S, 2001, BLOOD, V98, P1255, DOI 10.1182/blood.V98.4.1255; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; KILEY JP, 1995, NATL COMMISSION SLEE, P10; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; Kumar GK, 2003, J APPL PHYSIOL, V95, P536, DOI 10.1152/japplphysiol.00186.2003; Kumar GK, 1998, AM J PHYSIOL-CELL PH, V274, pC1592, DOI 10.1152/ajpcell.1998.274.6.C1592; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; MAXWELL PH, 2003, OXYGEN SENSING RESPO, P47; Mishra RR, 1998, MOL BRAIN RES, V59, P74, DOI 10.1016/S0169-328X(98)00139-9; Neubauer JA, 2001, J APPL PHYSIOL, V90, P1593, DOI 10.1152/jappl.2001.90.4.1593; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Peng YJ, 2004, J APPL PHYSIOL, V96, P1236, DOI 10.1152/japplphysiol.00820.2003; Peng YJ, 2003, P NATL ACAD SCI USA, V100, P10073, DOI 10.1073/pnas.1734109100; Prabhakar NR, 2001, J APPL PHYSIOL, V90, P1986, DOI 10.1152/jappl.2001.90.5.1986; Premkumar DRD, 2000, J APPL PHYSIOL, V88, P1898, DOI 10.1152/jappl.2000.88.5.1898; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Schnell PO, 2003, J NEUROCHEM, V85, P483, DOI 10.1046/j.1471-4159.2003.01696.x; Schulz R, 2002, AM J RESP CRIT CARE, V165, P67, DOI 10.1164/ajrccm.165.1.2101062; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SETA KA, 2003, OXYGEN SENSING RESPO, P123; Sodhi A, 2000, CANCER RES, V60, P4873; Wang Y, 1996, MOL CELL BIOL, V16, P5915; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; Zhong H, 1999, CANCER RES, V59, P5830	50	193	212	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4321	4328		10.1074/jbc.M407706200	http://dx.doi.org/10.1074/jbc.M407706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569687	hybrid			2022-12-25	WOS:000227096600041
J	Wu, HY; Hamamori, Y; Xu, JM; Chang, SC; Saluna, T; Chang, MF; O'Malley, BW; Kedes, L				Wu, HY; Hamamori, Y; Xu, JM; Chang, SC; Saluna, T; Chang, MF; O'Malley, BW; Kedes, L			Nuclear hormone receptor coregulator GRIP1 suppresses, whereas SRC1A and p/CIP coactivate, by domain-specific binding of MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; MEDIATED TRANSACTIVATIONS; HISTONE ACETYLTRANSFERASE; MUSCLE DIFFERENTIATION; ESTROGEN-RECEPTOR; STEROID-RECEPTORS; RESPONSE ELEMENT; BHLH PROTEIN; P300; SRC-1	p160 coregulators were initially identified as nuclear hormone receptor coactivators. In this study, functional data demonstrate that members of the three p160 families can have opposing roles in regulating gene expression by the same transcription factor. Both SRC1A and p/CIP function as coactivators for MyoD-mediated transcription whereas GRIP1 acts negatively as a (co)repressor. SRC1A and p/CIP predominantly interact with distinct sites on the NH2-terminal activation domain of MyoD. GRIP1 binds to both these regions but it alone, and neither SRC1A nor p/CIP, also interacts with specific sites on MyoD that are critical for the binding of the essential MyoD coactivator, p300. This suggests that competition by GRIP1 for SRC1A, p/CIP, and p300 binding sites on a transcription factor may regulate the activity of the factor.	Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Natl Taiwan Univ, Coll Med, Inst Microbiol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan	University of Southern California; Baylor College of Medicine; Baylor College of Medicine; National Taiwan University; National Taiwan University	Kedes, L (corresponding author), Inst Med Genet, Suite 240,2250 Alcazar St, Los Angeles, CA 90033 USA.	kedes@hsc.usc.edu		CHANG, MING-FU/0000-0001-7062-3578	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD007857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058242] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07857] Funding Source: Medline; NIDDK NIH HHS [DK58242] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	40	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3129	3137		10.1074/jbc.M412560200	http://dx.doi.org/10.1074/jbc.M412560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15563453	hybrid			2022-12-25	WOS:000226983900003
J	Jang, JH				Jang, JH			Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis	ONCOGENE			English	Article						FGFR1; silencing; tumorigenesis; colon cancer; FGFR3	FIBROBLAST-GROWTH-FACTOR; FACTOR-RECEPTOR; MULTIPLE-MYELOMA; HEPARAN-SULFATE; HUMAN BREAST; COMMON	We have previously demonstrated that the expression of FGFR3 is frequently downregulated in colorectal carcinoma cells. Here we have shown that FGFR1 is over-expressed in colorectal carcinoma cells and the gene expressions between FGFR1 and FGFR3 are mutually exclusive. Moreover, we have also shown that the disruption of FGFR1 expression by introducing of FGFR1 siRNA was effective in elevating FGFR3 expression and tumor suppressive activities. Thus, FGFR1 may confer a selectable advantage on clones of cells in colorectal tumorigenesis, favoring proliferation, whereas FGFR3 may have the effect of an unfavorable negative regulation of progression of the carcinomas to malignancy, promoting differentiation. Our results indicate that the reciprocal relationship in gene expression between FGFR1 and FGFR3 in colorectal tissue plays an important role in the progression of the carcinomas to malignancy.	Inha Univ, Coll Med, Dept Biochem, Inchon 400712, South Korea	Inha University	Jang, JH (corresponding author), Inha Univ, Coll Med, Dept Biochem, 7-241 Shinheung Dong 3 Ga, Inchon 400712, South Korea.	juhjang@seoul.com						BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Cancilla B, 1999, KIDNEY INT, V56, P2025, DOI 10.1046/j.1523-1755.1999.00781.x; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Feng SJ, 1997, CANCER RES, V57, P5369; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Giri D, 1999, CLIN CANCER RES, V5, P1063; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; Jang JH, 2000, CANCER RES, V60, P4049; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, AM J PHYSIOL-GASTR L, V272, pG885, DOI 10.1152/ajpgi.1997.272.4.G885; Kornmann M, 2002, GASTROENTEROLOGY, V123, P301, DOI 10.1053/gast.2002.34174; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Oh LYS, 2003, J NEUROSCI, V23, P883; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; SHAOUL E, 1995, ONCOGENE, V10, P1553; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	28	21	23	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					945	948		10.1038/sj.onc.1208254	http://dx.doi.org/10.1038/sj.onc.1208254			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558020				2022-12-25	WOS:000226577100020
J	Fewlass, DC; Noboa, K; Pi-Sunyer, FX; Johnston, JM; Yan, SD; Tezapsidis, N				Fewlass, DC; Noboa, K; Pi-Sunyer, FX; Johnston, JM; Yan, SD; Tezapsidis, N			Obesity-related leptin regulates Alzheimer's A beta	FASEB JOURNAL			English	Article						leptin signaling; AD; A beta production	AMYLOID-PRECURSOR-PROTEIN; APOLIPOPROTEIN-E; PRION PROTEIN; FOOD-INTAKE; METABOLISM; PRESENILIN; EXPRESSION; RECEPTOR; PEPTIDE; NEURONS	Abeta peptide is the major proteinateous component of the amyloid plaques found in the brains of Alzheimer's disease ( AD) patients and is regarded by many as the culprit of the disorder. It is well documented that brain lipids are intricately involved in Abeta-related pathogenic pathways. An important modulator of lipid homeostasis is the pluripotent peptide leptin. Here we demonstrate leptin's ability to modify Abeta levels in vitro and in vivo. Similar to methyl-beta-cyclodextrin, leptin reduces beta-secretase activity in neuronal cells possibly by altering the lipid composition of membrane lipid rafts. This phenotype contrasts treatments with cholesterol and etomoxir, an inhibitor of carnitine-palmitoyl transferase-1. Conversely, inhibitors of acetyl CoA carboxylase and fatty acid synthase mimicked leptin's action. Leptin was also able to increase apoE-dependent Abeta uptake in vitro. Thus, leptin can modulate bidirectional Abeta kinesis, reducing its levels extracellularly. Most strikingly, chronic administration of leptin to AD-transgenic animals reduced the brain Abeta load, underlying its therapeutic potential.	Columbia Univ Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; St Lukes Roosevelt Hosp, New York Obes Res Ctr, New York, NY USA; Neurotez, W Orange, NJ USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Tezapsidis, N (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, 630 W 168th St, New York, NY 10032 USA.	nik.tezapsidis@verizon.net						BarrettConnor E, 1996, J AM GERIATR SOC, V44, P1147, DOI 10.1111/j.1532-5415.1996.tb01362.x; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BISSOLI L, 2002, J NUTR HEALTH AGING, V6, P247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chung WK, 1998, AM J PHYSIOL-REG I, V274, pR985, DOI 10.1152/ajpregu.1998.274.4.R985; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Couce ME, 1997, NEUROENDOCRINOLOGY, V66, P145, DOI 10.1159/000127232; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Isidori AM, 2000, J CLIN ENDOCR METAB, V85, P1954, DOI 10.1210/jc.85.5.1954; Johnsingh AA, 2000, FEBS LETT, V465, P53, DOI 10.1016/S0014-5793(99)01664-6; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; KEMPEN HJ, 1995, J LIPID RES, V36, P1796; LaDu MJ, 2001, NEUROCHEM INT, V39, P427, DOI 10.1016/S0197-0186(01)00050-X; Lemaire-Vieille C, 2000, P NATL ACAD SCI USA, V97, P5422, DOI 10.1073/pnas.080081197; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mobbs CV, 2002, NAT MED, V8, P335, DOI 10.1038/nm0402-335; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; PUBLIELLI L, 2001, NAT CELL BIOL, V3, P905; Qiu WQ, 1997, J BIOL CHEM, V272, P6641, DOI 10.1074/jbc.272.10.6641; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shanley LJ, 2002, NAT NEUROSCI, V5, P299, DOI 10.1038/nn824; SHIMODA K, 1992, BRAIN RES, V586, P319, DOI 10.1016/0006-8993(92)91642-R; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; TAKESHIMA T, 1994, J NEUROSCI, V14, P4769; Takeshima T, 1996, J NEUROSCI METH, V67, P27, DOI 10.1016/S0165-0270(96)00002-7; Tezapsidis N, 2003, FASEB J, V17, P1322, DOI 10.1096/fj.02-0980fje; Ur E, 2002, NEUROENDOCRINOLOGY, V75, P264, DOI 10.1159/000054718; Watson GS, 2003, CNS DRUGS, V17, P27, DOI 10.2165/00023210-200317010-00003; Wood WG, 2002, NEUROBIOL AGING, V23, P685, DOI 10.1016/S0197-4580(02)00018-0; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yu YH, 2002, J BIOL CHEM, V277, P50876, DOI 10.1074/jbc.M207353200; Yu YH, 2004, AM J PHYSIOL-ENDOC M, V286, pE402, DOI 10.1152/ajpendo.00247.2003	49	230	239	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1870	1878		10.1096/fj.04-2572com	http://dx.doi.org/10.1096/fj.04-2572com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576490				2022-12-25	WOS:000226091000037
J	Rong, LL; Trojaborg, W; Qu, W; Kostov, K; Du Yan, S; Gooch, C; Szabolcs, M; Hays, AP; Schmidt, AM				Rong, LL; Trojaborg, W; Qu, W; Kostov, K; Du Yan, S; Gooch, C; Szabolcs, M; Hays, AP; Schmidt, AM			Antagonism of RAGE suppresses peripheral nerve regeneration	FASEB JOURNAL			English	Article						inflammation; axonal regeneration; peripheral nervous system	GLYCATION END-PRODUCTS; MOUSE SCIATIC-NERVE; NEURITE OUTGROWTH; BINDING-PROTEINS; CELL-SURFACE; RECEPTOR; S100; AMPHOTERIN; BLOCKADE; MICE	Axotomy of peripheral nerve triggers events that coordinate a limited inflammatory response to axonal degeneration and initiation of neurite outgrowth. Inflammatory and neurite outgrowth-promoting roles for the receptor for advanced glycation end products (RAGE) have been suggested, so we tested its role in peripheral nerve regeneration. Analysis of immunohistochemical localization of RAGE by confocal microscopy revealed that RAGE was expressed in axons and infiltrating mononuclear phagocytes upon unilateral sciatic nerve crush in mice. Administration of soluble RAGE, the extracellular ligand binding domain of RAGE, or blocking F(ab')(2) fragments of antibodies raised to either RAGE or its ligands, S100/calgranulins or amphoterin, reduced functional recovery as assessed by motor and sensory nerve conduction velocities and sciatic functional index and reduced regeneration, as assessed by myelinated fiber density after acute crush of the sciatic nerve. In parallel, in mice subjected to RAGE blockade, decreased numbers of mononuclear phagocytes infiltrated the distal nerve segments after crush. These findings provide the first evidence of an innate function of the ligand/RAGE axis and suggest that RAGE plays an important role in regeneration of the peripheral nervous system.	Columbia Univ, Med Ctr, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA; Columbia Univ, Med Ctr, Dept Pathol, New York, NY USA; Columbia Univ, Med Ctr, Dept Physiol & Cellular Biophys, New York, NY USA	Columbia University; Columbia University; Columbia University; Columbia University	Schmidt, AM (corresponding author), Columbia Univ, Med Ctr, Dept Surg, Div Surg Sci, 530 W 168th St,P&S 17-401, New York, NY 10032 USA.	ams11@columbia.edu	Gooch, Clifton L/M-1874-2016	Gooch, Clifton L/0000-0002-2210-2038				Azzouz M, 1996, EXP NEUROL, V138, P189, DOI 10.1006/exnr.1996.0057; BEUCHE W, 1986, BRAIN RES, V378, P97, DOI 10.1016/0006-8993(86)90289-1; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Haglid KG, 1997, BRAIN RES, V753, P196, DOI 10.1016/S0006-8993(96)01463-1; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kennedy JM, 2000, BRAIN, V123, P2118, DOI 10.1093/brain/123.10.2118; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Kury P, 2001, CURR OPIN NEUROL, V14, P635, DOI 10.1097/00019052-200110000-00013; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Rammes A, 1997, J BIOL CHEM, V272, P9496; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; REICHERT F, 1994, J NEUROSCI, V14, P3231; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831; Yang Z, 2001, J LEUKOCYTE BIOL, V69, P986; Yao M, 1998, LARYNGOSCOPE, V108, P1141, DOI 10.1097/00005537-199808000-00007	27	81	82	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1812	1817		10.1096/fj.04-1899com	http://dx.doi.org/10.1096/fj.04-1899com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576484				2022-12-25	WOS:000226091000031
J	Salinas, D; Haggie, PM; Thiagarajah, JR; Song, YL; Rosbe, K; Finkbeiner, WE; Nielson, DW; Verkman, AS				Salinas, D; Haggie, PM; Thiagarajah, JR; Song, YL; Rosbe, K; Finkbeiner, WE; Nielson, DW; Verkman, AS			Submucosal gland dysfunction as a primary defect in cystic fibrosis	FASEB JOURNAL			English	Article						CFTR; airway; mucus; fluorescence microscopy; photobleaching	BRONCHIAL MUCOUS GLANDS; AIRWAY SURFACE LIQUID; LUNG-DISEASE; TRACHEAL GLANDS; ION COMPOSITION; SECRETION; PATHOGENESIS; TRANSPORT; CHLORIDE; INFANTS	It has been proposed that defective submucosal gland function in CF airways is a major determinant of CF airway disease. We tested the hypothesis that submucosal gland function is defective early in CF subjects with minimal clinical disease. Functional assays of gland fluid secretion rate and viscosity were performed on freshly obtained nasal biopsies from 6 CF subjects and 5 non-CF controls (age range 2 - 22 years). Secretions from individual submucosal glands were visualized by light/fluorescence microscopy after orienting and immobilizing biopsy specimens in a custom chamber. The viscosity of freshly secreted gland fluid after pilocarpine, measured by fluorescence recovery after photobleaching of microinjected FITC-dextran, was 4.9 +/- 0.2- vs. 2.2 +/- 0.2-fold greater than water viscosity in CF vs. non-CF specimens, respectively (SE, P< 10(-4)). Gland fluid secretion rate in CF specimens, measured by video imaging (4.5 +/- 0.5 nL/min/gland, n=6), was 2.7 - fold reduced compared to non-CF specimens ( n=3, P< 0.05). Quantitative histology revealed similar size and morphology of submucosal glands in CF and non-CF specimens. Our results suggest that defective airway submucosal gland function is an early, primary defect in CF. Therapies directed at normalizing gland fluid secretion early in CF may thus reduce lung disease.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL73854] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R01DK043840, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballard ST, 1999, AM J PHYSIOL-LUNG C, V277, pL694, DOI 10.1152/ajplung.1999.277.4.L694; CHOW CW, 1982, EUR J PEDIATR, V139, P240, DOI 10.1007/BF00442171; Donaldson SH, 2003, CURR OPIN PULM MED, V9, P486, DOI 10.1097/00063198-200311000-00007; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ESTERLY JR, 1968, JOHNS HOPKINS MED J, V122, P94; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; FINKBEINER WE, 1994, AM J PHYSIOL, V267, pL206, DOI 10.1152/ajplung.1994.267.2.L206; GERMAN VF, 1980, AM REV RESPIR DIS, V122, P413; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; JACQUOT J, 1993, EUR RESPIR J, V6, P169; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; King M, 1987, Eur J Respir Dis Suppl, V153, P165; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Konstan MW, 2002, ADV DRUG DELIVER REV, V54, P1409, DOI 10.1016/S0169-409X(02)00146-1; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; OPPENHEIMER EH, 1981, HUM PATHOL, V12, P36, DOI 10.1016/S0046-8177(81)80240-7; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; STURGESS J, 1982, AM J PATHOL, V106, P303; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Trout L, 1998, AM J PHYSIOL-LUNG C, V274, pL258, DOI 10.1152/ajplung.1998.274.2.L258; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; YAMAYA M, 1991, AM J PHYSIOL, V261, pL491, DOI 10.1152/ajplung.1991.261.6.L491	27	63	70	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					431	+		10.1096/fj.04-2879fje	http://dx.doi.org/10.1096/fj.04-2879fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15596485				2022-12-25	WOS:000226091000017
J	Sutherland, BA; Shaw, OM; Clarkson, AN; Jackson, DM; Sammut, IA; Appleton, I				Sutherland, BA; Shaw, OM; Clarkson, AN; Jackson, DM; Sammut, IA; Appleton, I			Neuroprotective effects of (-)-epigallocatechin gallate after hypoxia-ischemia-induced brain damage: novel mechanisms of action	FASEB JOURNAL			English	Article						EGCG; NOS; ROS	NITRIC-OXIDE SYNTHASE; GREEN TEA EXTRACT; EPIGALLOCATECHIN GALLATE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; 6-HYDROXYDOPAMINE-INDUCED APOPTOSIS; MITOCHONDRIAL HYPEROXIDATION; ELECTRICAL RECOVERY; HIPPOCAMPAL SLICES; NADH FLUORESCENCE	(-)-Epigallocatechin gallate (EGCG) is a potent antioxidant that is neuroprotective against ischemia-induced brain damage. However, the neuroprotective effects and possible mechanisms of action of EGCG after hypoxia-ischemia (HI) have not been investigated. Therefore, we used a modified "Levine" model of HI to determine the effects of EGCG. Wistar rats were treated with either 0.9% saline or 50 mg/kg EGCG daily for 1 day and 1 h before HI induction and for a further 2 days post-HI. At 26-days-old, both groups underwent permanent left common carotid artery occlusion and exposure to 8% oxygen/92% nitrogen atmosphere for 1 h. Histological assessment showed that EGCG significantly reduced infarct volume (38.0 +/- 16.4 mm(3)) in comparison to HI + saline (99.6 +/- 15.6 mm(3)). In addition, EGCG significantly reduced total (622.6 +/- 85.8 pmol L-[H-3]citrulline/30 min/mg protein) and inducible nitric oxide synthase (iNOS) activity (143.2 +/- 77.3 pmol L-[H-3]citrulline/30 min/mg protein) in comparison to HI+ saline controls (996.6 +/- 113.6 and 329.7 +/- 59.6 pmol L-[H-3]citrulline/30 min/mg protein for total NOS and iNOS activity, respectively). Western blot analysis demonstrated that iNOS protein expression was also reduced. In contrast, EGCG significantly increased endothelial and neuronal NOS protein expression compared with HI controls. EGCG also significantly preserved mitochondrial energetics (complex I-V) and citrate synthase activity. This study demonstrates that the neuroprotective effects of EGCG are, in part, due to modulation of NOS isoforms and preservation of mitochondrial complex activity and integrity. We therefore conclude that the in vivo neuroprotective effects of EGCG are not exclusively due to its antioxidant effects but involve more complex signal transduction mechanisms.	Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand	University of Otago	Appleton, I (corresponding author), Univ Otago, Dept Pharmacol & Toxicol, POB 913, Dunedin, New Zealand.	ian.appleton@stonebow.otago.ac.nz	Sutherland, Brad/J-3920-2014; Sutherland, Brad/AAX-2725-2020	Sutherland, Brad/0000-0002-0791-0950; Clarkson, Andrew/0000-0003-3804-3834; Sammut, Ivan/0000-0002-9217-9452; Shaw, Odette/0000-0001-7158-1074				ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Aucamp J, 1997, ANTICANCER RES, V17, P4381; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Chan MMY, 1997, BIOCHEM PHARMACOL, V54, P1281, DOI 10.1016/S0006-2952(97)00504-2; CHAN MMY, 1995, CANCER LETT, V96, P23, DOI 10.1016/0304-3835(95)03913-H; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Clarkson AN, 2004, FASEB J, V18, P1114, DOI 10.1096/fj.03-1203fje; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Endres M, 2004, TRENDS NEUROSCI, V27, P283, DOI 10.1016/j.tins.2004.03.009; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Frei B, 2003, J NUTR, V133, p3275S, DOI 10.1093/jn/133.10.3275S; GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F; Guo QN, 1996, BBA-LIPID LIPID MET, V1304, P210, DOI 10.1016/S0005-2760(96)00122-1; GUTTERIDGE JMC, 1990, ARCH BIOCHEM BIOPHYS, V283, P223, DOI 10.1016/0003-9861(90)90635-C; Hong JT, 2001, BRAIN RES, V888, P11, DOI 10.1016/S0006-8993(00)02935-8; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; HUANG Z, 1996, J CEREB BLOOD FLOW M, V15, P378; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Ikeda K, 2003, TOXICOLOGY, V189, P55, DOI 10.1016/S0300-483X(03)00152-5; Inanami O, 1998, FREE RADICAL RES, V29, P359, DOI 10.1080/10715769800300401; Jin CF, 2001, J AGR FOOD CHEM, V49, P6033, DOI 10.1021/jf010903r; Jude EB, 1999, DIABETOLOGIA, V42, P748, DOI 10.1007/s001250051224; Kakuda T, 2002, BIOL PHARM BULL, V25, P1513, DOI 10.1248/bpb.25.1513; Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Kelly MR, 2001, J CELL BIOCHEM, V81, P647, DOI 10.1002/jcb.1097; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; LEE JA, 1992, CIRC RES, V71, P58, DOI 10.1161/01.RES.71.1.58; Lee SR, 2003, PHYTOTHER RES, V17, P206, DOI 10.1002/ptr.1090; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; LEVINE S, 1960, AM J PATHOL, V36, P1; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Nagai K, 2002, BRAIN RES, V956, P319, DOI 10.1016/S0006-8993(02)03564-3; Nie GJ, 2002, ARCH BIOCHEM BIOPHYS, V397, P84, DOI 10.1006/abbi.2001.2636; Paquay JBG, 2000, J AGR FOOD CHEM, V48, P5768, DOI 10.1021/jf981316h; Perez-Pinzon MA, 1998, BRAIN RES, V786, P165, DOI 10.1016/S0006-8993(97)01438-8; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SATO Y, 1989, TOHOKU J EXP MED, V157, P337, DOI 10.1620/tjem.157.337; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; SOUSSI B, 1990, ACTA PHYSIOL SCAND, V138, P107, DOI 10.1111/j.1748-1716.1990.tb08822.x; Suzuki M, 2004, MED SCI MONITOR, V10, pBR166; Tedeschi E, 2004, MOL PHARMACOL, V65, P111, DOI 10.1124/mol.65.1.111; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Vannucci RC, 1999, J NEUROSCI RES, V55, P158, DOI 10.1002/(SICI)1097-4547(19990115)55:2<158::AID-JNR3>3.0.CO;2-1; WATANABE H, 1990, FREE RADICAL BIO MED, V8, P507, DOI 10.1016/0891-5849(90)90150-H; Wei IH, 2004, BRAIN RES, V999, P73, DOI 10.1016/j.brainres.2003.11.056; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22	61	105	112	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					258	+		10.1096/fj.04-2806fje	http://dx.doi.org/10.1096/fj.04-2806fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15569775				2022-12-25	WOS:000225482100003
J	Cho, HD; Verlinde, CL; Weiner, AM				Cho, HD; Verlinde, CL; Weiner, AM			Archaeal CCA-adding enzymes - Central role of a highly conserved beta-turn motif in RNA polymerization without translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; MAMMALIAN POLY(A) POLYMERASE; CRYSTAL-STRUCTURE; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; SULFOLOBUS-SHIBATAE; CATALYTIC DOMAIN; ACTIVE-SITE; SEQUENCE; TEMPLATE; MECHANISM	The CCA-adding enzyme (tRNA nucleotidyltransferase) builds and repairs the 3' end of tRNA. A single active site adds both CTP and ATP, but the enzyme has no nucleic acid template, and tRNA does not translocate or rotate during C75 and A76 addition. We modeled the structure of the class I archaeal Sulfolobus shibatae CCA-adding enzyme on eukaryotic poly(A) polymerase and mutated residues in the vicinity of the active site. We found mutations that specifically affected C74, C75, or A76 addition, as well as mutations that progressively impaired addition of CCA. Many of these mutations clustered in an evolutionarily versatile beta-turn located between strands 3 and 4 of the nucleotidyltransferase domain. Our mutational analysis confirms and extends recent crystallographic studies of the highly homologous Archaeoglobus fulgidus enzyme. We suggest that the unusual phenotypes of the beta-turn mutants reflect the consecutive conformations assumed by the beta-turn as it presents the discriminator base N73, then C74, and finally C75 to the active site without translocation or rotation of the tRNA acceptor stem. We also suggest that beta-turn mutants can affect nucleotide selection because the growing 3' end of tRNA must be properly positioned to serve as part of the ribonucleoprotein template that selects the incoming nucleotide.	Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Weiner, AM (corresponding author), Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.	amweiner@u.washington.edu	VERLINDE, CHRISTOPHE LMJ/J-5796-2013	VERLINDE, CHRISTOPHE LMJ/0000-0002-7790-3203	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059804] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4; Bard J, 2000, SCIENCE, V289, P1346, DOI 10.1126/science.289.5483.1346; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Cho HD, 2003, RNA, V9, P970, DOI 10.1261/rna.2110903; Cho HDD, 2004, J BIOL CHEM, V279, P40130, DOI 10.1074/jbc.M405518200; Cho HDD, 2002, J BIOL CHEM, V277, P3447, DOI 10.1074/jbc.M109559200; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELANO WL, 2002, PYMOL MOL GRAPHICS; Delarue M, 2002, EMBO J, V21, P427, DOI 10.1093/emboj/21.3.427; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; Doublie S, 2004, STRUCTURE, V12, P1749, DOI 10.1016/j.str.2004.09.002; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Fischer D, 2000, Pac Symp Biocomput, P119; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Karchin R, 1998, BIOINFORMATICS, V14, P772, DOI 10.1093/bioinformatics/14.9.772; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; LIU MS, 1994, P NATL ACAD SCI USA, V91, P10389, DOI 10.1073/pnas.91.22.10389; Martin G, 2004, RNA, V10, P899, DOI 10.1261/rna.5242304; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Martin G, 2000, EMBO J, V19, P4193, DOI 10.1093/emboj/19.16.4193; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; Okabe M, 2003, EMBO J, V22, P5918, DOI 10.1093/emboj/cdg563; Panchenko AR, 2002, PROTEIN SCI, V11, P361, DOI 10.1110/ps.19902; Raynal LC, 1998, J BACTERIOL, V180, P6276; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; Tomita K, 2004, NATURE, V430, P700, DOI 10.1038/nature02712; Tomita K, 2002, J BIOL CHEM, V277, P48192, DOI 10.1074/jbc.M207527200; Tomita K, 2001, SCIENCE, V294, P1334, DOI 10.1126/science.1063816; Weiner AM, 2004, CURR BIOL, V14, pR883, DOI 10.1016/j.cub.2004.09.069; Xiong Y, 2004, NATURE, V430, P640, DOI 10.1038/nature02711; Xiong Y, 2003, MOL CELL, V12, P1165, DOI 10.1016/S1097-2765(03)00440-4; Yue DX, 1996, RNA, V2, P895; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	52	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9555	9566		10.1074/jbc.M412594200	http://dx.doi.org/10.1074/jbc.M412594200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590678	hybrid			2022-12-25	WOS:000227453100110
J	Kubica, N; Bolster, DR; Farrell, PA; Kimball, SR; Jefferson, LS				Kubica, N; Bolster, DR; Farrell, PA; Kimball, SR; Jefferson, LS			Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2B epsilon mRNA in a mammalian target of rapamycin-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GUANINE-NUCLEOTIDE-EXCHANGE; RAT SKELETAL-MUSCLE; INITIATION FACTOR-II; FACTOR 2B EIF2B; ORNITHINE-DECARBOXYLASE; RPS6 PHOSPHORYLATION; MYOTUBE HYPERTROPHY; DIABETIC-RATS; INSULIN	The contribution of mammalian target of rapamycin (mTOR) signaling to the resistance exercise-induced stimulation of skeletal muscle protein synthesis was assessed by administering rapamycin to Sprague-Dawley rats 2 h prior to a bout of resistance exercise. Animals were sacrificed 16 h postexercise, and gastrocnemius protein synthesis, mTOR signaling, and biomarkers of translation initiation were assessed. Exercise stimulated the rate of protein synthesis; however, this effect was prevented by pretreatment with rapamycin. The stimulation of protein synthesis was mediated by an increase in translation initiation, since exercise caused an increase in polysome aggregation that was abrogated by rapamycin administration. Taken together, the data suggest that the effect of rapamycin was not mediated by reduced phosphorylation of eukaryotic initiation factor 4E (eIF4E) binding protein 1 (BP1), because exercise did not cause a significant change in 4E-BP1(Thr-70) phosphorylation, 4E-BP1-eIF4E association, or eIF4F complex assembly concomitant with increased protein synthetic rates. Alternatively, there was a rapamycinsensitive decrease in relative eIF2Bepsilon(Ser-535) phosphorylation that was explained by a significant increase in the expression of eIF2Bepsilon protein. The proportion of eIF2Bepsilon mRNA in polysomes was increased following exercise, an effect that was prevented by rapamycin treatment, suggesting that the increase in eIF2Bepsilon protein expression was mediated by an mTOR-dependent increase in translation of the mRNA encoding the protein. The increase in eIF2Bepsilon mRNA translation and protein abundance occurred independent of similar changes in other eIF2B subunits. These data suggest a novel link between mTOR signaling and eIF2Bepsilon mRNA translation that could contribute to the stimulation of protein synthesis following acute resistance exercise.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; E Carolina Univ, Dept Exercise & Sport Sci, Greenville, NC 27858 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of North Carolina; East Carolina University	Jefferson, LS (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.	jjefferson@psu.edu			NIDDK NIH HHS [DK15658] Funding Source: Medline; NIGMS NIH HHS [GM08619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anthony JC, 2000, J NUTR, V130, P2413; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2003, J PHYSIOL-LONDON, V553, P213, DOI 10.1113/jphysiol.2003.047019; Chen YW, 2002, J PHYSIOL-LONDON, V545, P27, DOI 10.1113/jphysiol.2002.021220; CHESLEY A, 1992, J APPL PHYSIOL, V73, P1383, DOI 10.1152/jappl.1992.73.4.1383; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; Fabian JR, 1998, PROTEIN EXPRES PURIF, V13, P16, DOI 10.1006/prep.1998.0860; Farrell PA, 2000, J APPL PHYSIOL, V88, P1036, DOI 10.1152/jappl.2000.88.3.1036; Farrell PA, 1999, AM J PHYSIOL-ENDOC M, V276, pE721, DOI 10.1152/ajpendo.1999.276.4.E721; Farrell PA, 1998, J APPL PHYSIOL, V85, P2291, DOI 10.1152/jappl.1998.85.6.2291; Fedele MJ, 2000, J APPL PHYSIOL, V88, P102, DOI 10.1152/jappl.2000.88.1.102; Fluckey JD, 1996, AM J PHYSIOL-ENDOC M, V270, pE313, DOI 10.1152/ajpendo.1996.270.2.E313; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hardt SE, 2004, CIRC RES, V94, P926, DOI 10.1161/01.RES.0000124977.59827.80; Hernandez JM, 2000, J APPL PHYSIOL, V88, P1142, DOI 10.1152/jappl.2000.88.3.1142; HERSHEY JWB, 1994, BIOCHIMIE, V76, P847, DOI 10.1016/0300-9084(94)90186-4; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; KIMBALL SR, 1992, BIOCHEM J, V286, P263, DOI 10.1042/bj2860263; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kostyak JC, 2001, J APPL PHYSIOL, V91, P79, DOI 10.1152/jappl.2001.91.1.79; Kubica N, 2004, J APPL PHYSIOL, V96, P679, DOI 10.1152/japplphysiol.00962.2003; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; LAURENT GJ, 1978, BIOCHEM J, V176, P407, DOI 10.1042/bj1760407; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nader GA, 2001, J APPL PHYSIOL, V90, P1936, DOI 10.1152/jappl.2001.90.5.1936; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Parkington JD, 2003, AM J PHYSIOL-REG I, V285, pR1086, DOI 10.1152/ajpregu.00324.2003; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Richardson CJ, 2004, CURR BIOL, V14, P1540, DOI 10.1016/j.cub.2004.08.061; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Shantz LM, 1996, CANCER RES, V56, P3265; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; Webb BLJ, 1997, INT J BIOCHEM CELL B, V29, P1127, DOI 10.1016/S1357-2725(97)00039-3; Welle S, 1999, J APPL PHYSIOL, V86, P1220, DOI 10.1152/jappl.1999.86.4.1220; Williams DD, 2001, J BIOL CHEM, V276, P3733, DOI 10.1074/jbc.M008041200; WONG TS, 1990, J APPL PHYSIOL, V69, P1718, DOI 10.1152/jappl.1990.69.5.1718; WONG TS, 1990, J APPL PHYSIOL, V69, P1709, DOI 10.1152/jappl.1990.69.5.1709; Yoshizawa F, 1997, BIOCHEM BIOPH RES CO, V240, P825, DOI 10.1006/bbrc.1997.7652; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	59	161	173	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7570	7580		10.1074/jbc.M413732200	http://dx.doi.org/10.1074/jbc.M413732200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591312	hybrid			2022-12-25	WOS:000227395700019
J	Crossthwaite, AJ; Seebacher, T; Masada, N; Ciruela, A; Dufraux, K; Schultz, JE; Cooper, DMF				Crossthwaite, AJ; Seebacher, T; Masada, N; Ciruela, A; Dufraux, K; Schultz, JE; Cooper, DMF			The cytosolic domains of Ca2+-sensitive adenylyl cyclases dictate their targeting to plasma membrane lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; PROTEIN-COUPLED RECEPTORS; C6-2B GLIOMA-CELLS; POTASSIUM CHANNELS; CARDIAC MYOCYTES; CAVEOLAE; LOCALIZATION; INHIBITION; CAMP; CHOLESTEROL	Lipid rafts are specialized, cholesterol-rich domains of the plasma membrane that are enriched in certain signaling proteins, including Ca2+-sensitive adenylyl cyclases. This restrictive localization plays a key role in the regulation of the Ca2+-stimulable AC8 and the Ca2+-inhibitable AC6 by capacitative calcium entry. Interestingly, AC7, a Ca2+-insensitive AC, is found in the plasma membrane but is excluded from lipid rafts (Smith, K. E., Gu, C., Fagan, K. A., Hu, B., and Cooper, D. M. F. (2002) J. Biol. Chem. 277,6025-6031). The mechanisms governing the specific membrane targeting of adenylyl cyclase isoforms remain unknown. To address this issue, a series of chimeras were produced between the raft-targeted AC5 and the non-raft-targeted AC7, involving switching of their major domains. The AC5-AC7 chimeras were expressed in HEK 293 cells and lipid rafts were isolated from the bulk plasma membrane by either detergent-based or non-detergent-based fractionation methods. Additionally, confocal imaging was used to investigate the precise cellular targeting of the chimeras. Surprisingly, the two tandem six-transmembrane domains of AC5 were not required for localization to lipid rafts. Rather, AC5 localization depended on the complete cytoplasmic loops (C1 and C2); constructs with mixed domains were either retained in the endoplasmic reticulum or degraded. Similar conclusions are drawn for the lipid raft localization of the Ca2+/calmodulin-stimulable AC8; again, the C1 and C2 domains are critical. Thus, protein-protein interactions may be more important than protein-lipid interactions in targeting these calcium-sensitive enzymes to lipid rafts.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Univ Tubingen, Inst Pharm, Tubingen, Germany; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Cambridge; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	dmfc2@cam.ac.uk						AHLIJANIAN MK, 1987, J PHARMACOL EXP THER, V241, P407; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Fagan KA, 2000, J BIOL CHEM, V275, P40187, DOI 10.1074/jbc.M006606200; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; Gu C, 2000, J BIOL CHEM, V275, P6980, DOI 10.1074/jbc.275.10.6980; Gu C, 2002, EUR J BIOCHEM, V269, P413, DOI 10.1046/j.0014-2956.2001.02708.x; Gu C, 2001, CURR BIOL, V11, P185, DOI 10.1016/S0960-9822(01)00044-6; Guillou JL, 1999, J BIOL CHEM, V274, P35539, DOI 10.1074/jbc.274.50.35539; Hering H, 2003, J NEUROSCI, V23, P3262; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Hu BA, 2002, J BIOL CHEM, V277, P33139, DOI 10.1074/jbc.M112373200; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Ostrom RS, 2003, J BIOL CHEM, V278, P24461, DOI 10.1074/jbc.M212659200; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Putney JW, 1999, BIOESSAYS, V21, P38; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Seebacher T, 2001, EUR J BIOCHEM, V268, P105, DOI 10.1046/j.1432-1327.2001.01850.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith KE, 2002, J BIOL CHEM, V277, P6025, DOI 10.1074/jbc.M109615200; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Vereb G, 2003, P NATL ACAD SCI USA, V100, P8053, DOI 10.1073/pnas.1332550100; Wu GC, 2001, J BIOL CHEM, V276, P35450, DOI 10.1074/jbc.M009704200; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	56	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6380	6391		10.1074/jbc.M411987200	http://dx.doi.org/10.1074/jbc.M411987200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15574428	hybrid			2022-12-25	WOS:000227332700018
J	Massari, S; Vanoni, C; Longhi, R; Rosa, P; Pietrini, G				Massari, S; Vanoni, C; Longhi, R; Rosa, P; Pietrini, G			Protein kinase C-mediated phosphorylation of the BGT1 epithelial gamma-aminobutyric acid transporter regulates its association with LIN7 PDZ proteins - A post-translational mechanism regulating transporter surface density	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TONICITY-RESPONSIVE ENHANCER; BETAINE TRANSPORTER; SUBCELLULAR REDISTRIBUTION; DOPAMINE TRANSPORTER; GABA TRANSPORTER; CELL-LINES; RECEPTOR; MEMBRANE; CLATHRIN; IDENTIFICATION	The Na/Cl-dependent BGT1 transporter has osmoprotective functions by importing the small osmolyte betaine into the cytosol of renal medullary epithelial cells. We have demonstrated previously that the surface localization of the transporter in Madin-Darby canine kidney cells depends on its association with the LIN7 PDZ protein through a PDZ target sequence in the last 5 residues of the transporter (-KETHL). Here we describe a protein kinase C (PKC)-mediated mechanism regulating the association between BGT1 and LIN7. Reduced transport activity paralleled by the intracellular relocalization of the transporter was observed in response to the PKC activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment. This activation caused clathrin-dependent internalization of the transporter and its targeting to a recycling compartment that contains the truncated transporter lacking the LIN7 binding motif (BGTDelta5) but not the LIN7 partner of BGT1. The decreased association between BGT1 and LIN7 was demonstrated further by coimmunoprecipitation studies and in vitro binding to recombinant LIN7 fusion protein. The TPA treatment induced phosphorylation of surface BGT1 on serine and threonine residues. However, a greater increase in phosphothreonines than phosphoserines was measured in the wild type transporter, whereas the opposite was true in the BGTSer mutant in which a serine replaced the threonine 612 in the LIN7 association motif (-KESHL). No similar increase in relative phosphoserines or phosphothreonines was found in the BGTDelta5 transporter. Moreover, phosphorylation of threonine 612 in a BGT COOH-terminal peptide impaired its association with recombinant LIN7. Taken together, these data demonstrate that the post-translational regulation of BGT1 surface density is a result of transporter phosphorylation and that threonine 612 is an essential residue in this PKC-mediated regulation.	Univ Milan, Dept Med Pharmacol, Sch Med,Cellular & Mol Pharmacol Sect, Ctr Excellence Neurodegenerat Dis,CNR,Inst Neuros, I-20129 Milan, Italy; CNR, Ist Chim Riconoscimento Mol, I-20131 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Pietrini, G (corresponding author), Univ Milan, Dept Med Pharmacol, Sch Med,Cellular & Mol Pharmacol Sect, Ctr Excellence Neurodegenerat Dis,CNR,Inst Neuros, Via Vanvitelli 32, I-20129 Milan, Italy.	grazia.pietrini@unimi.it		Rosa, Patrizia/0000-0002-2590-6955				Beckman ML, 1998, J NEUROSCI, V18, P6103; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; COREY JL, 1994, J BIOL CHEM, V269, P14759; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Deken SL, 2003, J NEUROSCI, V23, P1563; GRIFFITHS G, 1990, J CELL SCI, V95, P441; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Isidoro C, 1997, CELL GROWTH DIFFER, V8, P1029; Kempson SA, 2003, AM J PHYSIOL-CELL PH, V285, pC1091, DOI 10.1152/ajpcell.00021.2003; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; MELDOLESI J, 1980, Journal of Cell Biology, V85, P516, DOI 10.1083/jcb.85.3.516; Miyakawa H, 1999, BBA-GENE STRUCT EXPR, V1446, P359, DOI 10.1016/S0167-4781(99)00122-0; Mortensen OV, 2003, EUR J PHARMACOL, V479, P159, DOI 10.1016/j.ejphar.2003.08.066; Parker LL, 2003, J BIOL CHEM, V278, P21576, DOI 10.1074/jbc.M210973200; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Perego C, 2002, J CELL SCI, V115, P3331; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; Preston AS, 1995, J AM SOC NEPHROL, V6, P1559; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; ROSA P, 1992, J BIOL CHEM, V267, P12227; Ruiz-Tachiquin ME, 2002, J NEUROSCI RES, V69, P125, DOI 10.1002/jnr.10258; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197	37	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7388	7397		10.1074/jbc.M412668200	http://dx.doi.org/10.1074/jbc.M412668200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591048	hybrid			2022-12-25	WOS:000227332700131
J	Wang, ZP; Ramanadham, S; Ma, ZA; Bao, SZ; Mancuso, DJ; Gross, RW; Turk, T				Wang, ZP; Ramanadham, S; Ma, ZA; Bao, SZ; Mancuso, DJ; Gross, RW; Turk, T			Group VIA phospholipase A(2) forms a signalling complex with the calcium/calmodulin-dependent protein kinase II beta expressed in pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; ARACHIDONIC-ACID; BINDING DOMAIN; SARCOPLASMIC-RETICULUM; CALCIUM-CHANNEL; RAT ISLETS; ACTIVATION; CALMODULIN; CA2+; MECHANISM	Insulin-secreting pancreatic islet beta-cells express a Group VIA Ca2+ -independent phospholipase A(2) (iPLA(2)beta) that contains a calmodulin binding site and protein interaction domains. We identified Ca2+/calmodulin-dependent protein kinase IIbeta (CaMKIIbeta) as a potential iPLA(2)beta-interacting protein by yeast two-hybrid screening of a cDNA library using iPLA(2)beta cDNA as bait. Cloning CaMKIIbeta cDNA from a rat islet library revealed that one dominant CaMKIIbeta isoform mRNA is expressed by adult islets and is not observed in brain or neonatal islets and that there is high conservation of the isoform expressed by rat and human beta-cells. Binary two-hybrid assays using DNA encoding this isoform as bait and iPIA(2)beta DNA as prey confirmed interaction of the enzymes, as did assays with CaMKIIbeta as prey and iPILA(2)beta bait. His-tagged CaMKIIbeta immobilized on metal affinity matrices bound iPILA(2)beta, and this did not require exogenous calmodulin and was not prevented by a calmodulin antagonist or the Ca2+ chelator EGTA. Activities of both enzymes increased upon their association, and iPLA(2)beta reaction products reduced CaMKIIbeta activity. Both the iPIA(2)beta inhibitor bromoenol lactone and the CaMKIIbeta inhibitor KN93 reduced arachidonate release from INS-1 insulinoma cells, and both inhibit insulin secretion. CaMKIIbeta and iPLA(2)beta can be coimmunoprecipitated from INS-1 cells, and forskolin, which amplifies glucose-induced insulin secretion, increases the abundance of the immunoprecipitatable complex. These findings suggest that iPLA(2)beta and CaMKIIbeta form a signaling complex in beta-cells, consistent with reports that both enzymes participate in insulin secretion and that their expression is coinduced upon differentiation of pancreatic progenitor to endocrine progenitor cells.	Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; CUNY Mt Sinai Sch Med, Div Expt Diabet & Aging, New York, NY 10029 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Turk, T (corresponding author), Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	jturk@wustl.edu		Bao, Shunzhong/0000-0002-3427-3678	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R37DK034388, P60DK020579, R01DK069455] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR00954, P41 RR000954] Funding Source: Medline; NHLBI NIH HHS [P01-HL57278, P01 HL057278] Funding Source: Medline; NIDDK NIH HHS [R37-DK34388, P60 DK020579, P30-DK56341, P30 DK056341, R01 DK069455, P60-DK20579, R37 DK034388] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; Bhatt HS, 2000, BIOCHEM PHARMACOL, V60, P1655, DOI 10.1016/S0006-2952(00)00483-4; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dukes I. D., 1997, CURR OPIN ENDOCRINOL, V4, P262; Easom RA, 1997, ENDOCRINOLOGY, V138, P2359, DOI 10.1210/en.138.6.2359; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; FUJIMOTO WY, 1987, ENDOCRINOLOGY, V120, P1750, DOI 10.1210/endo-120-5-1750; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Herson PS, 1999, J BIOL CHEM, V274, P833, DOI 10.1074/jbc.274.2.833; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Jan CR, 1996, J BIOL CHEM, V271, P15478, DOI 10.1074/jbc.271.26.15478; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; JOLLY YC, 1993, BIOCHEMISTRY-US, V32, P12209, DOI 10.1021/bi00096a034; KONRAD RJ, 1992, BIOCHIM BIOPHYS ACTA, V1135, P215, DOI 10.1016/0167-4889(92)90139-3; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; Kordeli E, 1998, J CELL SCI, V111, P2197; Krueger KA, 1999, DIABETES, V48, P499, DOI 10.2337/diabetes.48.3.499; LANDT M, 1982, ARCH BIOCHEM BIOPHYS, V213, P148, DOI 10.1016/0003-9861(82)90449-0; LAYCHOCK SG, 1982, CELL CALCIUM, V3, P43, DOI 10.1016/0143-4160(82)90036-7; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; Loweth AC, 1996, BIOCHEM BIOPH RES CO, V218, P423, DOI 10.1006/bbrc.1996.0075; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Machaca K, 2003, J BIOL CHEM, V278, P33730, DOI 10.1074/jbc.M305023200; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Rochlitz H, 2000, DIABETOLOGIA, V43, P465, DOI 10.1007/s001250051330; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Schofl C, 1999, ENDOCRINOLOGY, V140, P5516, DOI 10.1210/en.140.12.5516; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Simonsson E, 1998, DIABETES, V47, P1436, DOI 10.2337/diabetes.47.9.1436; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; SMITH MK, 1992, J BIOL CHEM, V267, P1761; Straub SG, 2000, J BIOL CHEM, V275, P18777, DOI 10.1074/jbc.M000090200; SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7; Tabuchi H, 2000, ENDOCRINOLOGY, V141, P2350, DOI 10.1210/en.141.7.2350; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; URQUIDI V, 1995, FEBS LETT, V358, P23, DOI 10.1016/0014-5793(94)01381-A; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0; Welsby PJ, 2003, J NEUROSCI, V23, P10116, DOI 10.1523/jneurosci.23-31-10116.2003; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; WOLY JF, 1994, J BIOL CHEM, V269, P14359; Yang HC, 1999, J NEUROCHEM, V73, P1278, DOI 10.1046/j.1471-4159.1999.0731278.x	63	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6840	6849		10.1074/jbc.M405287200	http://dx.doi.org/10.1074/jbc.M405287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15576376	Green Accepted, hybrid			2022-12-25	WOS:000227332700073
J	Wang, GS; Li, YF; Li, X				Wang, GS; Li, YF; Li, X			Correlation of three-dimensional structures with the antibacterial activity of a group of peptides designed based on a nontoxic bacterial membrane anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; NMR-SPECTROSCOPY; ANTIMICROBIAL PEPTIDE; CHEMICAL-SHIFTS; PROTEINS; DODECYLPHOSPHOCHOLINE; MICELLES; H-1-NMR	To understand the functional differences between a nontoxic membrane anchor corresponding to the N-terminal sequence of the Escherichia coli enzyme IIA(Glc) and a toxic antimicrobial peptide aurein 1.2 of similar sequence, a series of peptides was designed to bridge the gap between them. An alteration of a single residue of the membrane anchor converted it into an antibacterial peptide. Circular dichroism spectra indicate that all peptides are disordered in water but helical in micelles. Structures of the peptides were determined in membrane-mimetic micelles by solution NMR spectroscopy. The quality of the distance-based structures was improved by including backbone angle restraints derived from a set of chemical shifts (H-1(alpha), N-15, C-13(alpha) and C-13(beta)) from natural abundance two-dimensional heteronuclear correlated spectroscopy. Different from the membrane anchor, antibacterial peptides possess a broader and longer hydrophobic surface, allowing a deeper penetration into the membrane, as supported by intermolecular nuclear Overhauser effect cross-peaks between the peptide and short chain dioctanoyl phosphatidylglycerol. An attempt was made to correlate the NMR structures of these peptides with their antibacterial activity. The activity of this group of peptides does not correlate exactly with helicity, amphipathicity, charge, the number of charges, the size of the hydrophobic surface, or hydrophobic transfer free energy. However, a correlation is established between the peptide activity and membrane perturbation potential, which is defined by interfacial hydrophobic patches and basic residues in the case of cationic peptides. Indeed, P-31 solid state NMR spectroscopy of lipid bilayers showed that the extent of lipid vesicle disruption by these peptides is proportional to their membrane perturbation potential.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Struct Fun Lab, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Wang, GS (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Struct Fun Lab, Rm 3018,986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	gwang@unmc.edu						BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BANERJEE U, 1985, BIOCHEMISTRY-US, V24, P7621, DOI 10.1021/bi00347a019; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bax A., 2007, ENCY NUCL MAGNETIC R, V7, P4157; Bechinger B, 1999, BIOPOLYMERS, V51, P174, DOI 10.1002/(SICI)1097-0282(1999)51:3<174::AID-BIP2>3.0.CO;2-7; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUIX M, 1990, BIOCHEM BIOPH RES CO, V167, P1009, DOI 10.1016/0006-291X(90)90623-U; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gesell J, 1997, J BIOMOL NMR, V9, P127, DOI 10.1023/A:1018698002314; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; HARTEL AJ, 1982, EUR J BIOCHEM, V129, P343, DOI 10.1111/j.1432-1033.1982.tb07057.x; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; JACKSON RL, 1973, J BIOL CHEM, V248, P5218; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Karplus PA, 1997, PROTEIN SCI, V6, P1302; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Keifer PA, 2004, ANAL BIOCHEM, V331, P33, DOI 10.1016/j.ab.2004.03.074; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Markley JL, 1998, J BIOMOL NMR, V12, P1, DOI 10.1023/A:1008290618449; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Prenner EJ, 1997, BIOCHEMISTRY-US, V36, P7906, DOI 10.1021/bi962785k; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m; Rozek T, 2000, EUR J BIOCHEM, V267, P5330, DOI 10.1046/j.1432-1327.2000.01536.x; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; SZILAGYI L, 1995, PROG NUCL MAG RES SP, V27, P325, DOI 10.1016/0079-6565(95)01011-2; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; Wang GS, 2000, J BIOL CHEM, V275, P16401, DOI 10.1074/jbc.C000167200; Wang GS, 1996, BBA-LIPID LIPID MET, V1301, P174, DOI 10.1016/0005-2760(96)00037-9; Wang GS, 2004, SPECTROSC-INT J, V18, P257, DOI 10.1155/2004/719137; Wang GS, 2003, PROTEIN SCI, V12, P1087, DOI 10.1110/ps.0301503; Wang GS, 2000, J BIOL CHEM, V275, P39811, DOI 10.1074/jbc.C000709200; Wang Z, 2004, NUCLEIC ACIDS RES, V32, pD590, DOI 10.1093/nar/gkh025; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yu K, 2002, J PEPT RES, V60, P1, DOI 10.1034/j.1399-3011.2002.01968.x; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8	56	85	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5803	5811		10.1074/jbc.M410116200	http://dx.doi.org/10.1074/jbc.M410116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572363	hybrid			2022-12-25	WOS:000227217100083
J	Carattino, MD; Sheng, SH; Kleyman, TR				Carattino, MD; Sheng, SH; Kleyman, TR			Mutations in the pore region modify epithelial sodium channel gating by shear stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; MECHANOSENSITIVE ION-CHANNEL; OOCYTE EXPRESSION SYSTEM; NA+ SELF-INHIBITION; K+-CHANNEL; SELECTIVITY FILTER; FUNCTIONAL RECONSTITUTION; HISTIDINE-RESIDUES; POTASSIUM CHANNELS; ESCHERICHIA-COLI	Previous studies have shown that epithelial Na+ channels (ENaCs) are activated by laminar shear stress (LSS). ENaCs with a high intrinsic open probability because of a mutation betaS518K) or covalent modification of an introduced Cys residue (alphaS580C) in the pre-second transmembrane domain (pre-M2) were not activated by LSS, suggesting that the pre-M2 region participates in conformational rearrangements during channel activation. We examined the role of the pore region of the alpha-subunit in channel gating by studying the kinetics of activation by LSS of wild-type ENaC and channels with Cys mutations in the tract Ser (576)-Ser(592). Whole cell Na+ currents were monitored in oocytes expressing wildtype or mutant ENaCs prior to and following application of LSS. Following a 2.2-s delay, a monoexponential increase in Na+ currents was observed with a time constant (T) of 8.1 s in oocytes expressing wild-type ENaC. C ys substitutions within the a-subunit in the tract Ser (580)-Ser(589) resulted in: (i) a reduction (Ser(580) -Trp(585), Gly(587)) or increase (Ser(589)) in delay times preceding channel activation by LSS, (ii) an increase (Gln(581), Leu(584), Trp(585), Phe(586) Ser(588)) or decrease (Ser(189)) in the rate of channel activation, or (iii) a decrease in the magnitude of the response (Ser(583), Gly(587), Leu(584)). Cys substitutions at a putative amiloride-binding site (alphaSer(583) or betaGly(525)) or within the selectivity filter (alphaGly(587)) resulted in a reduction in the LSS response, and exhibited a multiexponential time course of activation. The corresponding gamma-subunit mutant (alphabetagammaG542C had a minimal response to LSS and exhibited a high intrinsic open probability. These data suggest that residues in the pore region participate in the sensing and/or transduction of the mechanical stimulus that results in channel activation and are consistent with the hypothesis that the ENaC pore region has a key role in modulating channel gating.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038470, R37DK051391, R01DK038470, R01DK051391] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38470, DK51391] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carattino MD, 2004, J BIOL CHEM, V279, P4120, DOI 10.1074/jbc.M311783200; Chalfant ML, 1996, AM J PHYSIOL-CELL PH, V270, pC998, DOI 10.1152/ajpcell.1996.270.4.C998; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Essig M, 2003, CURR OPIN NEPHROL HY, V12, P31, DOI 10.1097/00041552-200301000-00006; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GARVIN JL, 1990, AM J PHYSIOL, V259, pF580, DOI 10.1152/ajprenal.1990.259.4.F580; GOOD DW, 1979, AM J PHYSIOL, V236, pF192, DOI 10.1152/ajprenal.1979.236.2.F192; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HILLE B, 2001, ION CHANNELS EXCITAB, P575; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; KHURI RN, 1975, AM J PHYSIOL, V228, P1249, DOI 10.1152/ajplegacy.1975.228.4.1249; Kiss L, 1999, BIOPHYS J, V76, P253, DOI 10.1016/S0006-3495(99)77194-8; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Kuhn FJP, 2002, J MEMBRANE BIOL, V185, P145; Li JQ, 2003, J BIOL CHEM, V278, P13867, DOI 10.1074/jbc.M300149200; LING BN, 1991, AM J PHYSIOL, V261, pF933, DOI 10.1152/ajprenal.1991.261.6.F933; Liu W, 2003, AM J PHYSIOL-RENAL, V285, pF998, DOI 10.1152/ajprenal.00067.2003; MALNIC G, 1989, AM J PHYSIOL, V256, pF932, DOI 10.1152/ajprenal.1989.256.5.F932; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; Molina A, 1998, J PHYSIOL-LONDON, V509, P327, DOI 10.1111/j.1469-7793.1998.327bn.x; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Satlin LM, 2001, AM J PHYSIOL-RENAL, V280, pF1010, DOI 10.1152/ajprenal.2001.280.6.F1010; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schoppa NE, 1998, J GEN PHYSIOL, V111, P271, DOI 10.1085/jgp.111.2.271; Sheng SH, 2004, J BIOL CHEM, V279, P31687, DOI 10.1074/jbc.M405224200; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; TAGLIALATELA M, 1992, BIOPHYS J, V62, P34, DOI 10.1016/S0006-3495(92)81770-8; Talavera K, 2003, J GEN PHYSIOL, V121, P529, DOI 10.1085/jgp.200308794; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; Townsend C, 1999, J GEN PHYSIOL, V113, P321, DOI 10.1085/jgp.113.2.321; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; Welsh MJ, 2002, J BIOL CHEM, V277, P2369, DOI 10.1074/jbc.R100060200; Woda CB, 2001, AM J PHYSIOL-RENAL, V280, pF786, DOI 10.1152/ajprenal.2001.280.5.F786; Wong KR, 1995, AM J PHYSIOL-RENAL, V269, pF870, DOI 10.1152/ajprenal.1995.269.6.F870; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	63	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4393	4401		10.1074/jbc.M413123200	http://dx.doi.org/10.1074/jbc.M413123200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569663	hybrid			2022-12-25	WOS:000227096600049
J	Lee, MS; Chen, LY; Leu, WM; Shiau, RJ; Hu, NT				Lee, MS; Chen, LY; Leu, WM; Shiau, RJ; Hu, NT			Associations of the major pseudopilin XpsG with XpsN (GspC) and secretin XpsD of Xanthomonas campestris pv. campestris type II secretion apparatus revealed by cross-linking analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; GRAM-NEGATIVE BACTERIA; PILIN-LIKE COMPONENT; PSEUDOMONAS-AERUGINOSA; ERWINIA-CHRYSANTHEMI; CYTOPLASMIC MEMBRANE; ESCHERICHIA-COLI; PILUS BIOGENESIS; IV PILIN; ELECTRON-MICROSCOPY	The major pseudopilin XpsG is an essential component of type II secretion apparatus of Xanthomonas campestris pv. campestris. Along with other ancillary pseudopilins, it forms a pilus-like structure spanning between cytoplasmic and outer membranes. Associations of pseudopilins with non-pseudopilin members of type II secretion apparatus were not well documented, probably due to their dynamic or unstable nature. In this study, by treating intact cells with a cleavable crosslinker dithiobis(succinimidylpropionate) (DSP), followed by metal chelating chromatography and immuno-blotting on secretion-positive strains of X. campestris pv. campestris, we discovered associations of XpsGh with XpsN (GspC), as well as XpsD. These associations were detectable in a strain missing all components, but XpsO, of the type II secretion apparatus. However, chromosomal non-polar mutation in each gene exerted different effects upon the association between the other two. The XpsGh/XpsD association is undetectable in xpsN mutant; however, it was restored to a limited extent by overproducing XpsD protein. The XpsGb/XpsN association is unaltered by a lack of XpsD protein or an elevation of its abundance. Co-immune precipitation between XpsN and XpsD, while being independent of XpsG, was nonetheless enhanced by raising XpsG protein level. These observations agree with the proposition that the type II secretion apparatus in a cell may exist as an integrated multiprotein complex with all components working in concert. Moreover, in functional machinery, the association of the major pseudopilin XpsG with secretin XpsD appears strongly dependent on the existence of XpsN, the GspC protein.	Natl Chung Hsing Univ, Inst Biochem, Taichung 402, Taiwan; Natl Chung Hsing Univ, Inst Biotechnol, Taichung 402, Taiwan; Chung Shan Med Univ, Inst Biochem, Taichung 402, Taiwan	National Chung Hsing University; National Chung Hsing University; Chung Shan Medical University	Hu, NT (corresponding author), Natl Chung Hsing Univ, Inst Biochem, 250 Kuo Kuang Rd, Taichung 402, Taiwan.	nthu@nchu.edu.tw						Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bleves S, 1999, J BACTERIOL, V181, P4012, DOI 10.1128/JB.181.13.4012-4019.1999; Bleves S, 1998, MOL MICROBIOL, V27, P31, DOI 10.1046/j.1365-2958.1998.00653.x; Bouley J, 2001, J MOL BIOL, V308, P205, DOI 10.1006/jmbi.2001.4594; Chen LY, 1996, J BIOL CHEM, V271, P2703, DOI 10.1074/jbc.271.5.2703; Craig L, 2004, NAT REV MICROBIOL, V2, P363, DOI 10.1038/nrmicro885; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; Douet V, 2004, RES MICROBIOL, V155, P71, DOI 10.1016/j.resmic.2003.10.001; Durand E, 2003, J BACTERIOL, V185, P2749, DOI 10.1128/JB.185.9.2749-2758.2003; Filloux A, 1998, FEMS MICROBIOL REV, V22, P177, DOI 10.1016/S0168-6445(98)00013-8; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; HU NT, 1992, J BACTERIOL, V174, P2679, DOI 10.1128/jb.174.8.2679-2687.1992; Hu NT, 2002, BIOCHEM J, V365, P205, DOI 10.1042/BJ20020194; Kagami Y, 1998, MOL MICROBIOL, V27, P221, DOI 10.1046/j.1365-2958.1998.00679.x; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Lee HM, 2000, J BACTERIOL, V182, P1549, DOI 10.1128/JB.182.6.1549-1557.2000; Lee HM, 2001, J BACTERIOL, V183, P528, DOI 10.1128/JB.183.2.528-535.2001; Lindeberg M, 1996, MOL MICROBIOL, V20, P175, DOI 10.1111/j.1365-2958.1996.tb02499.x; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; Lu HM, 1997, MOL MICROBIOL, V25, P247, DOI 10.1046/j.1365-2958.1997.4561818.x; MATTICK JS, 1995, TRENDS MICROBIOL, V3, P411, DOI 10.1016/S0966-842X(00)88990-8; Mattick JS, 2002, ANNU REV MICROBIOL, V56, P289, DOI 10.1146/annurev.micro.56.012302.160938; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Nunn D, 1999, TRENDS CELL BIOL, V9, P402, DOI 10.1016/S0962-8924(99)01634-7; NUNN DN, 1993, J BACTERIOL, V175, P4375, DOI 10.1128/JB.175.14.4375-4382.1993; NUNN DN, 1992, P NATL ACAD SCI USA, V89, P47, DOI 10.1073/pnas.89.1.47; Planet PJ, 2001, P NATL ACAD SCI USA, V98, P2503, DOI 10.1073/pnas.051436598; Possot OM, 2000, J BACTERIOL, V182, P2142, DOI 10.1128/JB.182.8.2142-2152.2000; Possot OM, 1999, J BACTERIOL, V181, P4004, DOI 10.1128/JB.181.13.4004-4011.1999; PUGSLEY AP, 1993, MOL MICROBIOL, V9, P295, DOI 10.1111/j.1365-2958.1993.tb01691.x; Py B, 1999, J MOL BIOL, V289, P659, DOI 10.1006/jmbi.1999.2803; Py B, 2001, EMBO REP, V2, P244, DOI 10.1093/embo-reports/kve042; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; Russel M, 1998, J MOL BIOL, V279, P485, DOI 10.1006/jmbi.1998.1791; SANDKVIST M, 1995, EMBO J, V14, P1664, DOI 10.1002/j.1460-2075.1995.tb07155.x; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; Sauvonnet N, 2000, J BACTERIOL, V182, P848, DOI 10.1128/JB.182.3.848-854.2000; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; STROM MS, 1993, P NATL ACAD SCI USA, V90, P2404, DOI 10.1073/pnas.90.6.2404; Thomas JD, 1997, MICROBIOL-UK, V143, P713, DOI 10.1099/00221287-143-3-713; Tsai RT, 2002, BIOCHEM J, V367, P865, DOI 10.1042/BJ20020909; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; Vignon G, 2003, J BACTERIOL, V185, P3416, DOI 10.1128/JB.185.11.3416-3428.2003; Wolfgang M, 1998, P NATL ACAD SCI USA, V95, P14973, DOI 10.1073/pnas.95.25.14973	47	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4585	4591		10.1074/jbc.M409362200	http://dx.doi.org/10.1074/jbc.M409362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590656	hybrid			2022-12-25	WOS:000227096600072
J	Liu, HY; Zheng, GL; Treber, M; Dai, J; Woldegiorgis, G				Liu, HY; Zheng, GL; Treber, M; Dai, J; Woldegiorgis, G			Cysteine-scanning mutagenesis of muscle carnitine palmitoyltransferase I reveals a single cysteine residue (Cys-305) important for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA INHIBITION; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-RESIDUES; N-TERMINAL REGION; RAT-LIVER; CONSERVED ARGININE; HEART; IDENTIFICATION; ACETYLTRANSFERASE; SUBSTITUTION	Carnitine palmitoyltransferase (CPT) I catalyzes the conversion of long-chain fatty acyl-CoAs to acyl carnitines in the presence of L-carnitine, a rate-limiting step in the transport of long-chain fatty acids from the cytoplasm to the mitochondrial matrix. To determine the role of the 15 cysteine residues in the heart/skeletal muscle isoform of CPTI (M-CPTI) on catalytic activity and malonyl-CoA sensitivity, we constructed a 6-residue N-terminal, a 9-residue C-terminal, and a 15-residue cysteineless M-CPTI by cysteine-scanning mutagenesis. Both the 9-residue C-terminal mutant enzyme and the complete 15-residue cysteineless mutant enzyme are inactive but that the 6-residue N-terminal cysteineless mutant enzyme had activity and malonyl-CoA sensitivity similar to those of wild-type M-CPTI. Mutation of each of the 9 C-terminal cysteines to alanine or serine identified a single residue, Cys-305, to be important for catalysis. Substitution of Cys-305 with Ala in the wild-type enzyme inactivated M-CPTI, and a single change of Ala-305 to Cys in the 9-residue C-terminal cysteineless mutant resulted in an 8-residue C-terminal cysteineless mutant enzyme that had activity and malonyl-CoA sensitivity similar to those of the wild type, suggesting that Cys-305 is the residue involved in catalysis. Sequence alignments of CPTI with the acyltransferase family of enzymes in the GenBank(TM) led to the identification of a putative catalytic triad in CPTI consisting of residues Cys-305, Asp-454, and His-473. Based on the mutagenesis and substrate labeling studies, we propose a mechanism for the acyltransferase activity of CPTI that uses a catalytic triad composed of Cys-305, His-473, and Asp-454 with Cys-305 serving as a probable nucleophile, thus acting as a site for covalent attachment of the acyl molecule and formation of a stable acyl-enzyme intermediate. This would in turn allow carnitine to act as a second nucleophile and complete the acyl transfer reaction.	Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, Beaverton, OR 97006 USA	Oregon Health & Science University	Woldegiorgis, G (corresponding author), Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	gwoldeg@ebs.ogi.edu			NHLBI NIH HHS [HL52571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Bonnefont JP, 1996, AM J HUM GENET, V58, P971; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Brown NF, 2001, J LIPID RES, V42, P1134; CORR PB, 1995, HERZ, V20, P156; Dai J, 2003, BIOCHEM BIOPH RES CO, V301, P758, DOI 10.1016/S0006-291X(03)00042-1; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Ijlst L, 1998, J CLIN INVEST, V102, P527, DOI 10.1172/JCI2927; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P5215, DOI 10.1021/bi9929554; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Napal L, 2003, J BIOL CHEM, V278, P34084, DOI 10.1074/jbc.M305826200; PAULY DF, 1988, J BIOL CHEM, V263, P18160; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; SAGGERSON ED, 1982, FEBS LETT, V137, P124, DOI 10.1016/0014-5793(82)80329-3; Sfakianos MK, 2002, J BIOL CHEM, V277, P47270, DOI 10.1074/jbc.M207463200; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Tao Bernard Y., 1994, P69; Treber M, 2003, J BIOL CHEM, V278, P11145, DOI 10.1074/jbc.M210566200; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; Woldegiorgis G, 2000, J NUTR, V130, p310S, DOI 10.1093/jn/130.2.310S; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zheng GL, 2002, J BIOL CHEM, V277, P42219, DOI 10.1074/jbc.M202914200; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314; Zhu HF, 2003, ARCH BIOCHEM BIOPHYS, V413, P67, DOI 10.1016/S0003-9861(03)00081-X	41	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4524	4531		10.1074/jbc.M400893200	http://dx.doi.org/10.1074/jbc.M400893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15579906	hybrid			2022-12-25	WOS:000227096600066
J	Simon, M; Vanes, L; Geahlen, RL; Tybulewicz, VLJ				Simon, M; Vanes, L; Geahlen, RL; Tybulewicz, VLJ			Distinct roles for the linker region tyrosines of Syk in Fc epsilon RI signaling in primary mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; ANTIGEN RECEPTOR; KINASE SYK; FAMILY KINASES; ACTIVATION; PHOSPHORYLATION; ZAP-70; VAV; TRANSFECTION; TRANSDUCTION	Stimulation of Fcis an element ofRI, the high affinity IgE receptor of mast cells results in the rapid binding of the Syk tyrosine kinase to cytoplasmic domains of Fcis an element ofRI and to its subsequent activation. Syk plays an essential role in signal transduction from Fcis an element ofRI as shown by Syk-deficient mast cells, which are defective in receptor-induced degranulation, cytokine synthesis, and intracellular pathways. However the mechanism by which Syk activates these pathways remains unclear. Activation of Syk is associated with its phosphorylation on several tyrosine residues, including the linker tyrosines Tyr(317), T yr(342), and Tyr(346). These residues have been proposed to play important roles in the transduction of signals by binding to other signaling proteins. To test these hypotheses in primary murine mast cells, we used retroviral infection of Syk-deficient mast cells to generate cells expressing Syk proteins bearing mutations in the linker tyrosines. We show that Tyr(342) and Tyr(346) contribute positively to the function of Syk and have both overlapping as well as distinct functions. Mutations in either Tyr(342) or Tyr(346) alone had no effect on Fcis an element ofRI-induced degranulation or calcium flux, whereas mutation of both residues caused a significant reduction in both pathways. In contrast, phosphorylation of PLCgamma1, PLC-gamma2, and vav1 was strongly decreased by a mutation in Tyr(312) alone, whereas phosphorylation of ERK and Akt was more dependent on Tyr(346). Finally we show that Tyr(317) functions as a negative regulatory site and that its mutation can partially compensate for the loss of both Tyr(342) and Tyr(346).	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	MRC National Institute for Medical Research; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Tybulewicz, VLJ (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Mill Hill, London NW7 1AA, England.	vtybule@nimr.mrc.ac.uk		Tybulewicz, Victor/0000-0003-2439-0798; Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Choi OH, 1996, NATURE, V380, P634; Costello PS, 1996, ONCOGENE, V13, P2595; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Djouder N, 2001, J IMMUNOL, V166, P1627, DOI 10.4049/jimmunol.166.3.1627; Hong JJ, 2002, J BIOL CHEM, V277, P31703, DOI 10.1074/jbc.M201362200; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Kimura T, 1996, MOL CELL BIOL, V16, P1471; Law CL, 1996, MOL CELL BIOL, V16, P1305; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Nadler M J, 2000, Adv Immunol, V76, P325; Onishi M, 1996, EXP HEMATOL, V24, P324; Paolini R, 2002, J BIOL CHEM, V277, P36940, DOI 10.1074/jbc.M204948200; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Sada K, 2000, J IMMUNOL, V164, P338, DOI 10.4049/jimmunol.164.1.338; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Shan XC, 2001, MOL CELL BIOL, V21, P7137, DOI 10.1128/MCB.21.21.7137-7149.2001; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Wen RR, 2002, J IMMUNOL, V169, P6743, DOI 10.4049/jimmunol.169.12.6743; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Zhang J, 2002, MOL CELL BIOL, V22, P8144, DOI 10.1128/MCB.22.23.8144-8154.2002; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhang J, 1998, J IMMUNOL, V161, P4366	33	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4510	4517		10.1074/jbc.M410326200	http://dx.doi.org/10.1074/jbc.M410326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15576379	hybrid			2022-12-25	WOS:000227096600064
J	Fischer, U; Steffens, S; Frank, S; Rainov, NG; Schulze-Osthoff, KS; Kramm, CM				Fischer, U; Steffens, S; Frank, S; Rainov, NG; Schulze-Osthoff, KS; Kramm, CM			Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells	ONCOGENE			English	Article						apoptosis; Bcl-2; CD95; cytosine deaminase; p53; thymidine kinase	INDUCED APOPTOSIS; MALIGNANT GLIOMAS; KINASE GENE; BRAIN-TUMOR; P53 GENE; VIRUS; BCL-2; ACTIVATION; GANCICLOVIR; GLIOBLASTOMA	Suicide gene transfer using thymidine kinase (TK) and ganciclovir (GCV) treatment or the cytosine deaminase (CD)/5-fluorocytosine (5-FC) system represents the most widely used approach for gene therapy of cancer. However, molecular pathways and resistance mechanisms remain controversial for GCV-mediated cytotoxicity, and are virtually unknown for the CD/5-FC system. Here, we elucidated some of the cellular pathways in glioma cell lines that were transduced to express the TK or CD gene. In wild-type p53-expressing U87 cells, exposure to GCV and 5-FC resulted in a weak p53 response, although apoptosis was efficiently induced. Cell death triggered by GCV and 5-FC was independent of death receptors, but accompanied by mitochondrial alterations. Whereas expression of Bax remained unaffected, in particular, GCV and also 5-FC caused a decline in the level of Bcl-2. Similar findings were obtained in 9L and T98G glioma cells that express mutant p53, and also underwent mitochondrial apoptosis in both the TK/GCV and CD/5-FC system. Upon treatment of 9L cells with 5-FC, Bcl-x(L) expression slowly declined, whereas exposure to GCV resulted in the rapid proapoptotic phosphorylation of Bcl-x(L). These data suggest that TK/GCV- and CD/5-FC-induced apoptosis does neither require p53 nor death receptors, but converges at a mitochondrial pathway triggered by different mechanisms of modulation of Bcl-2 proteins.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Pediat Hematol Oncol & Immunol, D-40225 Dusseldorf, Germany; Univ Liverpool, Dept Neurol Sci, Liverpool L69 3BX, Merseyside, England; Walton Ctr Neurol & Neurosurg, NHS Trust, Liverpool, Merseyside, England	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Liverpool; Walton Centre	Schulze-Osthoff, KS (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Steffens, Sabine/AAV-4551-2020; Schulze-Osthoff, Klaus/N-9025-2013	Steffens, Sabine/0000-0002-6892-9751; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Aghi M, 1998, J NATL CANCER I, V90, P370, DOI 10.1093/jnci/90.5.370; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Beltinger C, 2000, CANCER RES, V60, P3212; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FREEMAN SM, 1993, CANCER RES, V53, P5274; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Glaser T, 2001, GENE THER, V8, P469, DOI 10.1038/sj.gt.3301415; Hamel W, 1996, CANCER RES, V56, P2697; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ichikawa T, 2000, CANCER GENE THER, V7, P74, DOI 10.1038/sj.cgt.7700086; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Klatzmann D, 1996, HUM GENE THER, V7, P109, DOI 10.1089/hum.1996.7.1-109; Kramm Christof M, 2003, Methods Mol Biol, V215, P137; KRAMM CM, 1995, BRAIN PATHOL, V5, P345, DOI 10.1111/j.1750-3639.1995.tb00615.x; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; Milosevic J, 2003, ONCOGENE, V22, P6852, DOI 10.1038/sj.onc.1206716; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; Nanda D, 2001, CANCER RES, V61, P8743; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Rainov NG, 2000, HUM GENE THER, V11, P2389, DOI 10.1089/104303400750038499; Rainov Nikolai G., 2001, Current Gene Therapy, V1, P367, DOI 10.2174/1566523013348445; Schilsky RL, 1998, ONCOLOGY-NY, V12, P13; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tomicic MT, 2002, ONCOGENE, V21, P2141, DOI 10.1038/sj.onc.1205280; Totzke G, 2003, ONCOGENE, V22, P8021, DOI 10.1038/sj.onc.1206837; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallace H, 1996, ONCOGENE, V13, P55; Wei JW, 2004, CANCER CELL, V5, P477, DOI 10.1016/S1535-6108(04)00116-3; Wei SJ, 1999, GENE THER, V6, P420, DOI 10.1038/sj.gt.3300817; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xie YJ, 1999, CLIN CANCER RES, V5, P4224; Zimmer C, 1997, EXP NEUROL, V143, P61, DOI 10.1006/exnr.1996.6350	59	83	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1231	1243		10.1038/sj.onc.1208290	http://dx.doi.org/10.1038/sj.onc.1208290			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592511				2022-12-25	WOS:000226898700010
J	Singh, RP; Dhanalakshmi, S; Agarwal, C; Agarwal, R				Singh, RP; Dhanalakshmi, S; Agarwal, C; Agarwal, R			Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappa B: implications for angioprevention and antiangiogenic therapy	ONCOGENE			English	Article						endothelial cells; cell cycle arrest; apoptosis; Akt; NF-kappa B; silibinin	DEPENDENT KINASE INHIBITORS; TUMOR-NECROSIS-FACTOR; PROSTATE-CANCER; INDUCED APOPTOSIS; BCL-2 FAMILY; ANGIOGENESIS; ACTIVATION; EXPRESSION; PROLIFERATION; MITOCHONDRIA	Recently, we observed that suppression of tumor xenograft growth by silibinin was associated with reduction in tumor vasculature and an increased apoptosis. Here, we provide evidence for molecular events associated with antiangiogenic efficacy of pharmacologically achievable doses of silibinin in endothelial cell culture system. Our data show that silibinin almost completely (P<0.001) inhibits growth of human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC-dermal origin) together with induction of cell death in a dose- and time-dependent manner. Growth inhibition was associated with a strong induction of G1 arrest accompanied by an increase in Kip1/p27, Cip1/p21 and p53. Apoptosis induction (up to 14- to 17-fold in both cell lines, P<0.001) was an underlying mechanism in silibinin-induced death of endothelial cells. In the studies elucidating the molecular events involved in apoptosis, silibinin caused loss of mitochondrial membrane potential and an increase in cytochrome c release from mitochondria. An increase in Bax and a decrease in Mcl-1 proteins were also observed. Silibinin-induced apoptosis involved both caspase-dependent and -independent mechanisms. Silibinin also decreased survivin level and inhibited Akt and NF-kappaB signaling. Two different PI-3K inhibitors, wortmannin and LY294002, showed Akt-independent activation of NF-kappaB. Further, silibinin showed a concentration-dependent strong inhibition of capillary tube formation on matrigel, retraction and disintegration of preformed capillary network, inhibition of matrigel invasion and migration, and a decrease in matrix metalloproteinase-2 secretion by HUVEC. Together, these findings identify pleiotropic mechanisms for antiangiogenic efficacy of silibinin, and suggest its usefulness in angioprevention and antiangiogenic therapy.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	rajesh.agarwal@uchsc.edu		Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R01CA091883, R01CA102514] Funding Source: NIH RePORTER; NCI NIH HHS [CA91883, CA102514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158; Ali IU, 2001, UROLOGY, V57, P143, DOI 10.1016/S0090-4295(00)00961-4; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje; Brawer MK, 1996, CANCER, V78, P345, DOI 10.1002/(SICI)1097-0142(19960715)78:2<345::AID-CNCR25>3.0.CO;2-V; Brekken RA, 2002, INT J CANCER, V100, P123, DOI 10.1002/ijc.10462; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen JH, 2004, BIOCHEM PHARMACOL, V67, P1337, DOI 10.1016/j.bcp.2003.12.015; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Fotsis T, 1997, CANCER RES, V57, P2916; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; GRANA X, 1995, ONCOGENE, V11, P211; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu QY, 2004, RADIAT RES, V161, P692, DOI 10.1667/RR3158; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Jiang C, 2000, BIOCHEM BIOPH RES CO, V276, P371, DOI 10.1006/bbrc.2000.3474; Jiang C, 2000, MOL CARCINOGEN, V29, P236, DOI 10.1002/1098-2744(200012)29:4<236::AID-MC1006>3.0.CO;2-E; Jones MK, 1999, NAT MED, V5, P1418; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YW, 2002, CLIN CANCER RES, V8, P2369; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Ozes ON, 1999, NATURE, V401, P82; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Qi J H, 1999, Angiogenesis, V3, P371, DOI 10.1023/A:1026565908445; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Singh RP, 2003, CURR CANCER DRUG TAR, V3, P205, DOI 10.2174/1568009033481985; Singh RP, 2003, CANCER EPIDEM BIOMAR, V12, P933; Singh RP, 2002, CANCER RES, V62, P3063; Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yoo HY, 2004, INT J MOL MED, V13, P81; Zandi E, 1999, MOL CELL BIOL, V19, P4547	67	126	129	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1188	1202		10.1038/sj.onc.1208276	http://dx.doi.org/10.1038/sj.onc.1208276			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558015				2022-12-25	WOS:000226898700006
J	Arolas, JL; Lorenzo, J; Rovira, A; Castella, J; Aviles, FX; Sommerhoff, CP				Arolas, JL; Lorenzo, J; Rovira, A; Castella, J; Aviles, FX; Sommerhoff, CP			A carboxypeptidase inhibitor from the tick Rhipicephalus bursa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATABLE FIBRINOLYSIS INHIBITOR; LEECH HIRUDO-MEDICINALIS; HUMAN PROCARBOXYPEPTIDASE A2; AMINO-ACID-SEQUENCE; 3-DIMENSIONAL STRUCTURE; PLASMINOGEN-ACTIVATOR; PROTEIN INHIBITORS; CRYSTAL-STRUCTURE; POTATO INHIBITOR; CDNA CLONING	A novel proteinaceous metallo-carboxypeptidase inhibitor, named tick carboxypeptidase inhibitor (TCI), was isolated from the ixodid tick Rhipicephalus bursa and N-terminally sequenced. The complete cDNA encoding this protein was cloned from tick mRNA by reverse transcription-PCR and rapid amplification of cDNA ends techniques. The full-length TCI cDNA contains an open reading frame coding for a precursor protein of 97 amino acid residues that consists of a predicted signal peptide of 22 residues and of mature TCI, a 75-residue cysteine-rich protein (12 Cys). The deduced amino acid sequence shows no homology to other known proteins; the C terminus, however, resembles those of other protein metallo-carboxypeptidase inhibitors, suggesting a common mechanism of inhibition. Recombinant TCI expressed in Escherichia coli is fully functional and inhibits carboxypeptidases of the A/B subfamily with equilibrium dissociation constants in the nanomolar range. Structural analyses by circular dichroism and nuclear magnetic. resonance indicate that TCI is a protein strongly constrained by disulfide bonds, unusually stable over a wide pH range and highly resistant to denaturing conditions. As a tight binding inhibitor of plasma carboxypeptidase B, also known as thrombin-activatable fibrinolysis inhibitor, recombinant TCI stimulates fibrinolysis in vitro and thus may have potential for applications to prevent or treat thrombotic disorders.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Barcelona, Spain; Univ Autonoma Barcelona, Dept Sanitat & Anatomia Anim, Bellaterra 08193, Barcelona, Spain; Univ Munich, Klinikums Standort Innenstadt, Abt Klin Chim & Klin Biochem, D-80336 Munich, Germany	Autonomous University of Barcelona; Autonomous University of Barcelona; University of Munich	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Barcelona, Spain.	fxaviles@einstein.uab.es; sommerhoff@med.uni-muenchen.de	Aviles, Francesc Xavier/F-3482-2019; Avilés, Francesc Xavier/A-2664-2015; Rovira, Ana/ABH-5661-2020; Lorenzo, Julia/E-9015-2011	Aviles, Francesc Xavier/0000-0002-1399-6789; Avilés, Francesc Xavier/0000-0002-1399-6789; Rovira, Ana/0000-0003-1301-2599; Lorenzo, Julia/0000-0001-5659-6008; Castella, Joaquim/0000-0002-4757-0372; Lopez Arolas, Joan/0000-0002-4198-5016				Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; Arolas JL, 2004, BIOCHEMISTRY-US, V43, P7973, DOI 10.1021/bi049596j; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; Basanova AV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P143, DOI 10.1023/A:1013968618120; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOURNA BN, 2003, J THROMB HAEMOST, V1, P1566; Bowman AS, 1997, MED VET ENTOMOL, V11, P277, DOI 10.1111/j.1365-2915.1997.tb00407.x; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; Campbell WD, 2002, MICROBIOL IMMUNOL, V46, P131, DOI 10.1111/j.1348-0421.2002.tb02669.x; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; EATON DL, 1991, J BIOL CHEM, V266, P21833; Eichinger S, 2004, BLOOD, V103, P3773, DOI 10.1182/blood-2003-10-3422; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HASS GM, 1975, BIOCHEMISTRY-US, V14, P1334, DOI 10.1021/bi00677a036; HASS GM, 1981, BIOCHEMISTRY-US, V20, P2256, DOI 10.1021/bi00511a029; HOMANDBERG GA, 1989, ARCH BIOCHEM BIOPHYS, V270, P153, DOI 10.1016/0003-9861(89)90017-9; Klement P, 1999, BLOOD, V94, P2735, DOI 10.1182/blood.V94.8.2735.420k30_2735_2743; LEVIN Y, 1982, P NATL ACAD SCI-BIOL, V79, P4618, DOI 10.1073/pnas.79.15.4618; Liu Q, 2000, MOL BIOL REP, V27, P241, DOI 10.1023/A:1010971219806; Mans BJ, 2004, INSECT BIOCHEM MOLEC, V34, P1, DOI 10.1016/j.ibmb.2003.09.002; Mao SS, 2003, ANAL BIOCHEM, V319, P159, DOI 10.1016/S0003-2697(03)00252-5; Marino-Buslje C, 2000, EUR J BIOCHEM, V267, P1502, DOI 10.1046/j.1432-1327.2000.01150.x; Matthews KW, 2004, MOL IMMUNOL, V40, P785, DOI 10.1016/j.molimm.2003.10.002; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Mutch NJ, 2003, J THROMB HAEMOST, V1, P2000, DOI 10.1046/j.1538-7836.2003.00383.x; Myles T, 2003, J BIOL CHEM, V278, P51059, DOI 10.1074/jbc.M306977200; Nagashima M, 2000, THROMB RES, V98, P333, DOI 10.1016/S0049-3848(00)00184-5; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Normant E, 1995, P NATL ACAD SCI USA, V92, P12225, DOI 10.1073/pnas.92.26.12225; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Renatus M, 1997, BIOCHEMISTRY-US, V36, P13483, DOI 10.1021/bi971129x; Reverter D, 1998, J BIOL CHEM, V273, P32927, DOI 10.1074/jbc.273.49.32927; Reverter D, 1998, J BIOL CHEM, V273, P3535, DOI 10.1074/jbc.273.6.3535; Reverter D, 2000, NAT STRUCT BIOL, V7, P322, DOI 10.1038/74092; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Salzet M, 2001, FEBS LETT, V492, P187, DOI 10.1016/S0014-5793(01)02212-8; Schneider M, 2003, J THROMB HAEMOST, V1, P147, DOI 10.1046/j.1538-7836.2003.00028.x; Silveira A, 2000, THROMB HAEMOSTASIS, V84, P364; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; SPRINGMAN EB, 1995, J BIOL CHEM, V270, P1300, DOI 10.1074/jbc.270.3.1300; Turk B, 1997, BIOL CHEM, V378, P141; van Tilburg NH, 2000, BLOOD, V95, P2855, DOI 10.1182/blood.V95.9.2855.009k02_2855_2859; Vendrell J, 2000, BBA-PROTEIN STRUCT M, V1477, P284, DOI 10.1016/S0167-4838(99)00280-0; Venhudova G, 2001, J BIOL CHEM, V276, P11683, DOI 10.1074/jbc.M007927200; Ventura S, 1999, J BIOL CHEM, V274, P19925, DOI 10.1074/jbc.274.28.19925; Walker JB, 2003, J BIOL CHEM, V278, P8913, DOI 10.1074/jbc.M205006200; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176	54	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3441	3448		10.1074/jbc.M411086200	http://dx.doi.org/10.1074/jbc.M411086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15561703	hybrid			2022-12-25	WOS:000226983900039
J	Ivanov, VN; Hei, TK				Ivanov, VN; Hei, TK			Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway	ONCOGENE			English	Article						melanoma; EGFR; arsenite; ERK; AKT; TRAIL	NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; HEME OXYGENASE-1 GENE; HYPOXIA-INDUCIBLE FACTOR; TRAIL-INDUCED APOPTOSIS; CELL LUNG-CANCER; THERAPEUTIC TARGET; TRANSCRIPTION FACTOR; MEDIATED APOPTOSIS; TYROSINE KINASES	Epidermal growth factor receptor (EGFR) is expressed, albeit at low or intermediate levels, in human melanomas at the different stages of tumor progression. Coexpression of EGFR with its ligand TGFalpha indicates their role in paracrine and autocrine growth regulation of melanomas. As it was previously observed for several types of cancer, specific inhibitors of EGFR-mediated signaling may reduce antiapoptotic properties of cancer cells and sensitize them to cytotoxic drugs. We recently reported that arsenite, particularly in combination with inhibitors of the PI3K-AKT and mitogen-activated protein kinase (MAPK) kinase (MEK)-extracellular signal-regulated kinase (ERK) pathways, induces high levels of apoptosis in different melanomas. Since EGFR signaling operates via activation of the PI3K-AKTand MEK-ERK pathways, we suggested that the combination of arsenite and EGFR inhibitors might also effectively induce apoptosis in melanoma. Here, we demonstrate that a moderate concentration of arsenite (5 - 10 muM) indeed upregulates apoptosis induced by EGFR inhibitors in EGFR-positive melanomas. In contrast, induction of apoptosis in melanomas with negligible surface expression of EGFR or with defective EGFR signaling requires direct suppression of the PI3K-AKTand MAPK pathways by specific pharmacological inhibitors in the presence of arsenite. Under these conditions, metastatic melanoma cell lines undergo TNF-related apoptosis-inducing ligand ( TRAIL)and tumor necrosis factor alpha (TNFalpha)- mediated apoptosis. Taken together, these data provide additional approaches in sensitizing melanomas to the cytotoxic effects of specific inhibitors of survival pathways.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Ivanov, VN (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St,VC11-218, New York, NY 10032 USA.	vni3@columbia.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NIEHS NIH HHS [P42 ES010349, P30 ES 09089, R01 ES011804, P30 ES009089, ES 05786, ES 11804, F32 ES005786, P42 ES 10349, R01 ES005786] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011804, R01ES005786, P42ES010349, P30ES009089, F32ES005786] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; ALAM J, 1992, J BIOL CHEM, V267, P21894; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Berking C, 2001, CANCER RES, V61, P8306; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Blackledge G, 2004, BRIT J CANCER, V90, P566, DOI 10.1038/sj.bjc.6601550; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cheng HYY, 2004, ONCOGENE, V23, P3603, DOI 10.1038/sj.onc.1207466; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Dancey JE, 2004, CANCER CELL, V5, P411, DOI 10.1016/S1535-6108(04)00122-9; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hayashi T, 2003, BRIT J HAEMATOL, V120, P10, DOI 10.1046/j.1365-2141.2003.03929.x; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Hershko DD, 2002, J CELL BIOCHEM, V84, P687, DOI 10.1002/jcb.10083; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; IVANOV V, 1994, J IMMUNOL, V153, P2394; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2004, J BIOL CHEM, V279, P22747, DOI 10.1074/jbc.M314131200; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li G, 2001, CANCER RES, V61, P3819; Li MY, 2002, J CELL BIOCHEM, V87, P29, DOI 10.1002/jcb.10269; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liu J, 2001, TOXICOL SCI, V61, P314, DOI 10.1093/toxsci/61.2.314; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; MYKLEBUST AT, 1994, J NEURO-ONCOL, V21, P215, DOI 10.1007/BF01063770; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Perlis C, 2004, ONCOLOGIST, V9, P182, DOI 10.1634/theoncologist.9-2-182; Rea MA, 2003, CARCINOGENESIS, V24, P747, DOI 10.1093/carcin/bgg010; Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Satyamoorthy K, 2003, CANCER RES, V63, P756; SATYAMOORTHY K, 1997, MELANOMA RES S2, V7, P35; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; von Willebrand M, 2003, CANCER RES, V63, P1420; Wakeling AE, 1996, BREAST CANCER RES TR, V38, P67, DOI 10.1007/BF01803785; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yih LH, 2002, CARCINOGENESIS, V23, P867, DOI 10.1093/carcin/23.5.867; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zheng XH, 2003, TOXICOLOGY, V187, P39, DOI 10.1016/S0300-483X(03)00025-8	82	53	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					616	626		10.1038/sj.onc.1208125	http://dx.doi.org/10.1038/sj.onc.1208125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580309	Green Published, Green Accepted			2022-12-25	WOS:000226420400009
J	Jun, JI; Chung, CW; Lee, HJ; Pyo, JO; Lee, KN; Kim, NS; Kim, YS; Yoo, HS; Lee, TH; Kim, E; Jung, YK				Jun, JI; Chung, CW; Lee, HJ; Pyo, JO; Lee, KN; Kim, NS; Kim, YS; Yoo, HS; Lee, TH; Kim, E; Jung, YK			Role of FLASH in caspase-8-mediated activation of NF-kappa B: dominant-negative function of FLASH mutant in NF-kappa B signaling pathway	ONCOGENE			English	Article						caspase-8; FLASH; NF-kappa B; siRNA; dominant negative	TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; CELL-DEATH; INTERFERING MUTANT; IKK-ALPHA; APOPTOSIS; PROTEIN; INDUCTION; TRANSDUCTION; FADD	Caspase-8 is the most receptor-proximal, upstream caspase in the caspase cascade and plays a key role in cell death triggered by various death receptors. Here, we addressed the role of endogenous caspase-8 in tumor necrosis factor (TNF)-alpha-induced activation of NF-kappaB. Direct targeting of caspase-8 with siRNA and antisense (AS) approaches abolished TNF-alpha-induced activation of NF-kappaB in NIH3T3, HeLa, and HEK293 cells as determined with luciferase reporter gene and cell fractionation assays. Reconstitution of caspase-8-deficient C33A cells with processing-defective (P/D) mutant of caspase-8 sensitized the cells to TNF-alpha for NF-kappaB activation. In contrast to wild-type caspase-8, death effector domain mutant replacing Asp73 with Ala (caspase-8 (D73A)) failed to activate NF-kappaB and to bind FLICE-associated huge protein ( FLASH) in vitro and in vivo. Instead, caspase-8 (D73A) mutant bound to caspase-8 and blocked NF-kappaB activation triggered by TNF-alpha and caspase-8. In addition, expression of an NF-kappaB-activating domain-deletion mutant of FLASH or transfection of FLASH AS oligonucleotides abolished TNF-alpha and caspase-8, but not phorbol 12-myristate 13-acetate, - induced activation of NF-kappaB. Further, immunoprecipitation assays showed that caspase-8 formed triple complex with TRAF2 and FLASH. Taken together, these results suggest that endogenous caspase-8 mediates TNF-alpha-induced activation of NF-kappaB via FLASH.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; PaiChai Univ, Dept Life Sci, Taejon 302735, South Korea	Gwangju Institute of Science & Technology (GIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei University; Pai Chai University	Jung, YK (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	ykjung@kjist.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533				Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 2000, J BIOL CHEM, V275, P27823; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Shikama Y, 2003, EUR J IMMUNOL, V33, P1998, DOI 10.1002/eji.200324013; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	43	25	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					688	696		10.1038/sj.onc.1208186	http://dx.doi.org/10.1038/sj.onc.1208186			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15592525				2022-12-25	WOS:000226420400016
J	Kehn, K; de la Fuente, C; Strouss, K; Berro, R; Jiang, H; Brady, J; Mahieux, R; Pumfery, A; Bottazzi, ME; Kashanchi, F				Kehn, K; de la Fuente, C; Strouss, K; Berro, R; Jiang, H; Brady, J; Mahieux, R; Pumfery, A; Bottazzi, ME; Kashanchi, F			The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation	ONCOGENE			English	Review						tax; HTLV-I; Rb; proteasome; cell cycle; tumorigenesis	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; TUMOR-SUPPRESSOR PROTEIN; ONCOGENE PRODUCT TAX; KAPPA-B-ALPHA; CYCLE PROGRESSION; ADENOVIRUS E1A; RB FAMILY; TRANSCRIPTIONAL ACTIVATION; HUMAN-LYMPHOCYTES	Human T-cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T-cell leukemia (ATL), is estimated to affect 10 - 20 million people worldwide. The transforming ability of HTLV-I has been largely attributed to the viral protein Tax, which modulates the activity of several well-known cell cycle regulators. An important cell cycle regulator, the retinoblastoma (Rb) protein, is often inactivated in many cancers including virally induced cancers. Upon examination of Rb status, we observed a decrease in Rb protein expression in HTLV-1-infected cell lines as well as in ex vivo ATL patient samples. Transient transfection assays indicated that decreased Rb protein levels were Tax dependent. Here, we demonstrate for the first time that Tax directly associates with Rb. This interaction was localized within the B pocket of Rb and the C-terminus of Tax (aa 245 - 353). Within the C-terminus of Tax, we have identified an LXCXE-like motif, that when mutated resulted in the loss of Tax/Rb interaction. Furthermore, through the use of proteasome inhibitors, such as MG-132, in vivo and proteasome degradation assays in vitro, we found that Tax destabilizes the hypo-phosphorylated( active) form of Rb via the proteasome pathway. Therefore, we propose a model whereby Tax targets Rb to the proteasome by acting as a molecular bridge bringing Rb into contact with the proteasome for degradation.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; NCI, Virus Tumor Biol Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Inst Pasteur, Dept SIDA & Retrovirus, Unite Epidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; George Washington Univ, Med Ctr, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Inst Genom Res TIGR, Rockville, MD 20850 USA	George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; George Washington University; J. Craig Venter Institute	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St NW,Ross Hall,Rm 552, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	Kehn-Hall, Kylene/I-5752-2013	Bottazzi, Maria Elena/0000-0002-8429-0476; mahieux, renaud/0000-0002-5129-6804	NIAID NIH HHS [AI061560, AI44357, AI43894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI061560, R01AI043894, R29AI044357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Akagi T, 1996, ONCOGENE, V12, P1645; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Antelman D, 1997, ONCOGENE, V15, P2855, DOI 10.1038/sj.onc.1201465; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Boyer SN, 1996, CANCER RES, V56, P4620; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen WJ, 2004, J BIOL CHEM, V279, P13496, DOI 10.1074/jbc.M212390200; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; de la Fuente C, 2003, MOL CELL BIOCHEM, V245, P99, DOI 10.1023/A:1022866027585; Dunaief JL, 2002, CURR EYE RES, V24, P392, DOI 10.1076/ceyr.24.5.392.8524; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FUJII M, 1991, ONCOGENE, V6, P1023; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Grossman WJ, 1996, J ACQ IMMUN DEF SYND, V13, pS162, DOI 10.1097/00042560-199600001-00025; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128/JVI.75.22.11106-11115.2001; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Iha H, 2000, AIDS RES HUM RETROV, V16, P1633, DOI 10.1089/08892220050193074; ISHIDA S, 1995, CELL GROWTH DIFFER, V6, P229; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kalejta RF, 2003, MOL CELL BIOL, V23, P1885, DOI 10.1128/MCB.23.6.1885-1895.2003; Kashanchi F, 1996, J VIROL, V70, P5503, DOI 10.1128/JVI.70.8.5503-5510.1996; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Lee JY, 1998, BIOCHEM J, V334, P457, DOI 10.1042/bj3340457; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Li JN, 2003, BIOCHEMISTRY-US, V42, P6921, DOI 10.1021/bi034369n; Liu BY, 2003, MOL CELL BIOL, V23, P5269, DOI 10.1128/MCB.23.15.5269-5281.2003; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mori N, 1997, EUR J HAEMATOL, V58, P114; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakayama K, 2000, LEUKEMIA RES, V24, P299, DOI 10.1016/S0145-2126(99)00186-1; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; Pajonk F, 2001, RADIAT RES, V156, P447, DOI 10.1667/0033-7587(2001)156[0447:TPICBA]2.0.CO;2; Pan WJ, 2001, CANCER RES, V61, P2885; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; Petropoulos L, 1998, VIROLOGY, V252, P189, DOI 10.1006/viro.1998.9430; Plath T, 2002, J NATL CANCER I, V94, P129, DOI 10.1093/jnci/94.2.129; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Salcedo M, 1995, ARCH MED RES, V26, pS157; Sambrook J, 2001, MOL CLONING LAB MANU; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; SUZUKI T, 1995, ONCOGENE, V10, P1199; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Suzuki Takeshi, 1997, Leukemia (Basingstoke), V11, P14; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang HT, 2004, J VIROL, V78, P1503, DOI 10.1128/JVI.78.3.1503-1512.2004; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; YAMAOKA S, 1992, ONCOGENE, V7, P433; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	101	85	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					525	540		10.1038/sj.onc.1208105	http://dx.doi.org/10.1038/sj.onc.1208105			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580311				2022-12-25	WOS:000226420400001
J	Nagata, KI; Inagaki, M				Nagata, KI; Inagaki, M			Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin	ONCOGENE			English	Article						septin; sept9; RhoGEF; actin	ACUTE MYELOID-LEUKEMIA; CHROMOSOME 17Q; ALLELIC LOSS; FAMILY; GENE; OVARIAN; BREAST; EXPRESSION; REGION; MSF	Small GTPase Rho and septin family proteins are thought to be related to tumorigenesis. We have identified a Rho-guanine nucleotide exchange factor (GEF) as a binding partner for a mammalian septin Sept9b using yeast two-hybrid screening. We termed this molecule septin-associated RhoGEF (SA-RhoGEF). Molecular dissection analyses indicated that the C-terminal area of SA-RhoGEF exhibited binding to the N-terminal variable region of Sept9b. SA-RhoGEF was found by immunoprecipitation analysis to associate with septin complexes in REF52 fibroblast cells, maybe through direct interaction with Sept9b. Immunofluorescence analyses revealed the colocalization of SA-RhoGEF and Sept9b along with actin stress fibers in REF52 cells, and their colocalization along stress fibers was most likely to depend on their mutual interaction. In transient expression analyses, Sept9b inhibited SA-RhoGEF-dependent Rho activation in COS7 and HeLa cells. SA-RhoGEF and its fragments expressed in REF52 cells altered endogenous septin. lament structures. To our knowledge, SA-RhoGEF is the first molecule providing a link between septins and Rho signaling.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Inagaki, M (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya Cho, Kasugai, Aichi 4800392, Japan.	knagata@inst-hsc.jp; minagaki@aichi-cc.jp	Inagaki, Masaki/B-9920-2016					Burrows JF, 2003, J PATHOL, V201, P581, DOI 10.1002/path.1484; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; Hanai N, 2004, FEBS LETT, V568, P83, DOI 10.1016/j.febslet.2004.05.030; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAGATA KI, 1992, J BIOL CHEM, V267, P19600; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Phelan CM, 1998, CANCER RES, V58, P1004; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1993, CANCER RES, V53, P3382; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, CANCER RES, V59, P4261; THEILE M, 1995, ONCOGENE, V10, P439; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; TOKSOZ D, 1994, ONCOGENE, V9, P621; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5	38	73	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					65	76		10.1038/sj.onc.1208101	http://dx.doi.org/10.1038/sj.onc.1208101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558029				2022-12-25	WOS:000226125800009
J	Davis, MD; Clemens, JJ; Macdonald, TL; Lynch, KR				Davis, MD; Clemens, JJ; Macdonald, TL; Lynch, KR			Sphingosine 1-phosphate analogs as receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FTY720; SPHINGOSINE-1-PHOSPHATE; IMMUNOSUPPRESSANT; TRAFFICKING; DISCOVERY; MIGRATION; SURVIVAL; SUBTYPES; RATS	Sphingosine 1-phosphate (S1P) is a lysophospholipid mediator that evokes a variety of cell and tissue responses via a set of cell surface receptors. The recent development of S1P receptor agonists, led by the immunomodulatory pro-drug FTY720, has revealed that S1P signaling is an important regulator of lymphocyte trafficking. With the twin goals of understanding structure-activity relationships of S1P ligands and developing tool compounds to explore S1P biology, we synthesized and tested numerous S1P analogs. We report herein that a subset of our aryl amide-containing compounds are antagonists at the S1P(1) and S1P(3) receptors. The lead compound in the series, VPC23019, was found in broken cell and whole cell assays to behave as a competitive antagonist at the S1P1 and S1P3 receptors. The structureactivity relationship of this series is steep; for example, a slight modification of the lead compound resulted in VPC25239, which was one log order more potent at the S1P3 receptor. These new chemical entities will enable further understanding of S1P signaling and provide leads for further S1P receptor antagonist development.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Chem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Lynch, KR (corresponding author), Univ Virginia, Sch Med, Dept Pharmacol, 1300 Jefferson Pk Ave,Box 800735, Charlottesville, VA 22908 USA.	krlynch@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM064101] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM064101, R01 GM06758] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Chiba K, 1998, J IMMUNOL, V160, P5037; Clair T, 2003, CANCER RES, V63, P5446; Clemens JJ, 2003, BIOORG MED CHEM LETT, V13, P3401, DOI 10.1016/S0960-894X(03)00812-6; Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828; Fujino M, 2003, J PHARMACOL EXP THER, V305, P70, DOI 10.1124/jpet.102.045658; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3501, DOI 10.1016/j.bmcl.2004.04.070; Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3495, DOI 10.1016/j.bmcl.2004.04.069; Hoshino Y, 1999, TRANSPL P, V31, P1224, DOI 10.1016/S0041-1345(98)01973-3; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Jones L, 1997, J ORG CHEM, V62, P1388, DOI 10.1021/jo962336q; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LEW MJ, 1995, TRENDS PHARMACOL SCI, V16, P328, DOI 10.1016/S0165-6147(00)89066-5; Maki T, 2002, TRANSPLANTATION, V74, P1684, DOI 10.1097/01.TP.0000038969.72218.0F; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Suzuki S, 1996, Transpl Immunol, V4, P252, DOI 10.1016/S0966-3274(96)80026-8; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Xie JH, 2003, J IMMUNOL, V170, P3662, DOI 10.4049/jimmunol.170.7.3662; Yanagawa Y, 1999, TRANSPLANT P, V31, P1227, DOI 10.1016/S0041-1345(98)01974-5; Yanagawa Y, 2000, INT J IMMUNOPHARMACO, V22, P597, DOI 10.1016/S0192-0561(00)00022-9; Yang ZD, 2003, CLIN IMMUNOL, V107, P30, DOI 10.1016/S1521-6616(02)00054-2; Zhang T, 1997, CANCER RES, V57, P169	30	235	252	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9833	9841		10.1074/jbc.M412356200	http://dx.doi.org/10.1074/jbc.M412356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15590668	hybrid			2022-12-25	WOS:000227559600012
J	Zhang, XC; Shan, PY; Alam, J; Fu, XY; Lee, PJ				Zhang, XC; Shan, PY; Alam, J; Fu, XY; Lee, PJ			Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPERFUSION LUNG INJURY; SERINE PHOSPHORYLATION; GENE-TRANSCRIPTION; CARDIAC MYOCYTES; HEME OXYGENASE-1; FAS EXPRESSION; C-JUN; ACTIVATION; PROLIFERATION; SUPPRESSES	Carbon monoxide (CO), previously considered a toxic waste product of heme catabolism, is emerging as an important gaseous molecule. In addition to its important role in neurotransmission, exogenous CO protects against vascular injury, transplant rejection, and acute lung injury. However, little is known regarding the precise signaling mechanisms of CO. We have recently shown that CO attenuates endothelial cell apoptosis during anoxia-reoxygenation injury by activating MKK3/p38alpha mitogen-activated protein kinase (MAPK) pathways. Our current study is the first to demonstrate that CO can differentially modulate STAT1 and STAT3 activation and, specifically, that STAT3 activation by CO is responsible for the anti-apoptotic effect in endothelial cells. In addition, we show that the anti-apoptotic effects of CO depend upon both phosphatidylinositol 3-kinase/Akt and p38 MAPK signaling pathways in endothelial cells, whereas previous reports have implicated only the MKK3/p38 MAPK pathway. Using chemical inhibitors and dominant negative constructs, we show that CO enhances STAT3 activation via phosphatidylinositol 3-kinase/Akt and p38 MAPK pathways with subsequent attenuation of Fas expression and caspase 3 activity. These data highlight the anti-apoptotic signaling mechanisms of CO and, importantly, delineate potential therapeutic strategies to prevent ischemiareperfusion or anoxia-reoxygenation injury in the vasculature.	Yale Univ, Sch Med, Sect Pulm & Crit Care Med, New Haven, CT 06520 USA; Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Indiana Univ, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Yale University; Ochsner Health System; Indiana University System; Indiana University-Purdue University Indianapolis	Lee, PJ (corresponding author), Yale Univ, Sch Med, Sect Pulm & Crit Care Med, 333 Cedar St,POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	Alam, Jawed/F-2596-2010; zhang, xu/GYE-3558-2022	Alam, Jawed/0000-0001-6520-482X; Zhang, Xuchen/0000-0002-1484-4672	NHLBI NIH HHS [HL 071595-01] Funding Source: Medline; NIAID NIH HHS [AI34522] Funding Source: Medline; NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asao H, 2000, J BIOL CHEM, V275, P867, DOI 10.1074/jbc.275.2.867; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; Krause A, 2002, J IMMUNOL, V169, P6610, DOI 10.4049/jimmunol.169.11.6610; Lee HM, 2003, FEBS LETT, V549, P110, DOI 10.1016/S0014-5793(03)00800-7; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Otterbein LE, 2002, ANTIOXID REDOX SIGN, V4, P309, DOI 10.1089/152308602753666361; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Stephanou A, 2002, EUR CYTOKINE NETW, V13, P401; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zhang SSM, 2004, INVEST OPHTH VIS SCI, V45, P2407, DOI 10.1167/iovs.04-0003; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhang XC, 2002, AM J PHYSIOL-LUNG C, V283, pL815, DOI 10.1152/ajplung.00485.2001	34	170	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8714	8721		10.1074/jbc.M408092200	http://dx.doi.org/10.1074/jbc.M408092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590660	hybrid			2022-12-25	WOS:000227453100013
J	Orsini, MJ; Nesmelova, I; Young, HC; Hargittai, B; Beavers, MP; Liu, JC; Connolly, PJ; Middleton, SA; Mayo, KH				Orsini, MJ; Nesmelova, I; Young, HC; Hargittai, B; Beavers, MP; Liu, JC; Connolly, PJ; Middleton, SA; Mayo, KH			The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IMMUNOGENIC PEPTIDE-FRAGMENTS; HAMSTER OVARY CELLS; NEURONS IN-VITRO; ORPHANIN-FQ; ORL(1) RECEPTOR; WATER SOLUTION; DORSAL HORN; INHIBITION; RELEASE	Nociceptin, a 17 amino acid opioid-like peptide that has an inhibitory effect on synaptic transmission in the nervous system, is involved in learning, memory, attention, and emotion and is also implicated in the perception of pain and visual, auditory, and olfactory functions. In this study, we investigated the NMR solution structure of nociceptin in membrane-like environments (trifluoroethanol and SDS micelles) and found it to have a relatively stable helix conformation from residues 4-17 with functionally important N-terminal residues being folded aperidoically on top of the helix. In functional assays for receptor binding and calcium flux, alanine-scanning variants of nociceptin indicated that functionally important residues generally followed helix periodicity, consistent with the NMR structural model. Structure-activity relationships allowed identification of pharmacophore sites that were used in small molecule data base searches, affording hits with demonstrated nociceptin receptor binding affinities.	Univ Minnesota, Hlth Sci Ctr, Dept Biochem, Minneapolis, MN 55455 USA; Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA	University of Minnesota System; University of Minnesota Twin Cities; Johnson & Johnson; Johnson & Johnson USA	Mayo, KH (corresponding author), Univ Minnesota, Hlth Sci Ctr, Dept Biochem, 6-155 Jackson Hall,321 Church St, Minneapolis, MN 55455 USA.	mayox001@maroon.tc.umn.edu	Nesmelova, Irina/D-6033-2015	Nesmelova, Irina/0000-0002-1835-1533				Amodeo P, 2000, FEBS LETT, V473, P157, DOI 10.1016/S0014-5793(00)01513-1; Andersson A, 2004, BBA-BIOMEMBRANES, V1661, P18, DOI 10.1016/j.bbamem.2003.11.014; Balakrishnan A, 2004, J PHARM SCI-US, V93, P2064, DOI 10.1002/jps.20118; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1980, J MAGN RESON, V37, P93, DOI 10.1016/0022-2364(80)90096-7; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Butour JL, 1997, EUR J PHARMACOL, V321, P97, DOI 10.1016/S0014-2999(96)00919-3; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P979; Connor M, 1999, BRIT J PHARMACOL, V128, P1779, DOI 10.1038/sj.bjp.0702971; Connor M, 1996, BRIT J PHARMACOL, V119, P1614, DOI 10.1111/j.1476-5381.1996.tb16080.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Fukuda K, 1997, FEBS LETT, V412, P290, DOI 10.1016/S0014-5793(97)00815-6; Giuliani S, 1996, BRIT J PHARMACOL, V118, P1567, DOI 10.1111/j.1476-5381.1996.tb15576.x; Guerrini R, 1997, J MED CHEM, V40, P1789, DOI 10.1021/jm970011b; Hawes BE, 1998, J NEUROCHEM, V71, P1024; Ikeda K, 1997, MOL BRAIN RES, V45, P117, DOI 10.1016/S0169-328X(96)00252-5; Knoflach F, 1996, J NEUROSCI, V16, P6657; Kobayashi T, 1997, BRIT J PHARMACOL, V120, P986, DOI 10.1038/sj.bjp.0701068; Kwan SY, 2000, CHILD NERV SYST, V16, P87, DOI 10.1007/s003810050018; Lai CC, 1997, NEUROSCIENCE, V81, P887, DOI 10.1016/S0306-4522(97)00251-0; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; Liebel JT, 1997, BRIT J PHARMACOL, V121, P425, DOI 10.1038/sj.bjp.0701149; Lou LG, 1998, J NEUROCHEM, V70, P1316; Matthes H, 1996, MOL PHARMACOL, V50, P447; Mayo KH, 1996, PROTEIN SCI, V5, P1301, DOI 10.1002/pro.5560050709; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Meunier JC, 1998, NATURE, V393, P211, DOI 10.1038/30347; Neal MJ, 1997, BRIT J PHARMACOL, V120, P1399, DOI 10.1038/sj.bjp.0701135; Nicol B, 1996, BRIT J PHARMACOL, V119, P1081, DOI 10.1111/j.1476-5381.1996.tb16007.x; Okuda-Ashitaka E, 1998, NATURE, V392, P286, DOI 10.1038/32660; Patel HJ, 1997, BRIT J PHARMACOL, V120, P735, DOI 10.1038/sj.bjp.0701013; Pulito VL, 2000, J PHARMACOL EXP THER, V294, P224; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Salvadori S, 1997, BIOCHEM BIOPH RES CO, V233, P640, DOI 10.1006/bbrc.1997.6285; Schlicker E, 1998, N-S ARCH PHARMACOL, V358, P418, DOI 10.1007/PL00005273; SCHWYZER R, 1986, BIOCHEMISTRY-US, V25, P6335, DOI 10.1021/bi00368a075; Spadaccini R, 1999, J PEPT SCI, V5, P306, DOI 10.1002/(SICI)1099-1387(199907)5:7<306::AID-PSC199>3.0.CO;2-B; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Vangeyte P, 2004, LANGMUIR, V20, P9019, DOI 10.1021/la048848e; Vaughan CW, 1996, BRIT J PHARMACOL, V117, P1609, DOI 10.1111/j.1476-5381.1996.tb15329.x; Vaughan CW, 1997, J NEUROSCI, V17, P996; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	47	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8134	8142		10.1074/jbc.M406405200	http://dx.doi.org/10.1074/jbc.M406405200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15596448	hybrid			2022-12-25	WOS:000227395700085
J	Zhao, Q; Shepherd, EG; Manson, ME; Nelin, LD; Sorokin, A; Liu, YS				Zhao, Q; Shepherd, EG; Manson, ME; Nelin, LD; Sorokin, A; Liu, YS			The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide - Attenuation of proinflammatory cytokine biosynthesis via feedback control of p38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; INNATE IMMUNITY; STRESS; EXPRESSION; MKP-1; GENE; PHOSPHORYLATION; GLUCOCORTICOIDS; DEGRADATION	Mitogen-activated protein (MAP) kinases are critical mediators of innate immune responses. In response to lipopolysaccharide (LPS), MAP kinases are rapidly activated and play an important role in the production of proinflammatory cytokines. Although a number of MAP kinase phosphatases ( MKPs) have been identified, their roles in the control of cytokine production have not been well defined. In the present report, we investigated the role of MKP-1 in alveolar macrophages stimulated with LPS. We found that LPS triggered transient activation of three MAP kinase subfamilies, ERK, JNK, and p38, in both immortalized and primary murine alveolar macrophages. MKP-1 was rapidly induced by LPS, and its induction correlated with the dephosphorylation of these MAP kinases. Blocking MKP-1 with triptolide prolonged the activities of both JNK and p38 in immortalized alveolar macrophages. Stimulation of primary alveolar macrophages isolated from MKP-1-deficient mice with LPS resulted in a prolonged p38 phosphorylation compared with wild type alveolar macrophages. Accordingly, these MKP-1-deficient alveolar macrophages also mounted a more robust and rapid tumor necrosis factor alpha production than their wild type counterparts. Adeno-virus-mediated MKP-1 overexpression significantly attenuated tumor necrosis factor alpha production in immortalized alveolar macrophages. Finally, MKP-1 was induced by a group of corticosteroids frequently prescribed for the treatment of inflammatory lung diseases, and the anti-inflammatory potencies of these drugs closely correlated with their abilities to induce MKP-1. Our studies indicated that MKP-1 plays an important role in dampening the inflammatory responses of alveolar macrophages. We speculate that MKP-1 may represent a novel target for therapeutic intervention of inflammatory lung diseases.	Ohio State Univ, Childrens Hosp, Childrens Res Inst, Ctr Dev Pharmacol & Toxicol,Dept Pediat, Columbus, OH 43205 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Medical College of Wisconsin	Liu, YS (corresponding author), Ohio State Univ, Childrens Hosp, Childrens Res Inst, Ctr Dev Pharmacol & Toxicol,Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	liuy@pediatrics.ohio-state.edu	Liu, Yusen/E-3527-2011; Nelin, Leif/AAC-8475-2020; Shepherd, Edward/E-4080-2011	Sorokin, Andrey/0000-0002-5660-0190; Liu, Yusen/0000-0002-0994-0109	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043003] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057798] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL22563] Funding Source: Medline; NIAID NIH HHS [R01AI57798] Funding Source: Medline; NICHD NIH HHS [T32HD043003] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Beutler B, 1995, J CARDIOVASC PHARM, V25, pS1, DOI 10.1097/00005344-199500252-00002; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; Chen PL, 2002, PROTEIN EXPRES PURIF, V24, P481, DOI 10.1006/prep.2001.1599; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dorfman K, 1996, ONCOGENE, V13, P925; File T M, 2000, Semin Respir Infect, V15, P184; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; KATZ P, 2000, CECIL TXB MED, P111; Kelly HW, 1998, ANN PHARMACOTHER, V32, P220, DOI 10.1345/aph.17014; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Mizgerd JP, 2001, J IMMUNOL, V166, P4042, DOI 10.4049/jimmunol.166.6.4042; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pratt PF, 2003, J BIOL CHEM, V278, P51928, DOI 10.1074/jbc.M309256200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Septimus E J, 1989, Semin Respir Infect, V4, P245; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Zhang P, 2002, SHOCK, V17, P104, DOI 10.1097/00024382-200202000-00004; Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x	35	173	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8101	8108		10.1074/jbc.M411760200	http://dx.doi.org/10.1074/jbc.M411760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15590669	hybrid			2022-12-25	WOS:000227395700081
J	Benlloch, M; Ortega, A; Ferrer, P; Segarra, R; Obrador, E; Asensi, M; Carretero, J; Estrela, JM				Benlloch, M; Ortega, A; Ferrer, P; Segarra, R; Obrador, E; Asensi, M; Carretero, J; Estrela, JM			Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; MULTIDRUG-RESISTANCE; ANTISENSE OLIGONUCLEOTIDES; TUMOR-CYTOTOXICITY; OXIDATIVE STRESS; PROTEIN MRP; IN-VITRO; BCL-2; APOPTOSIS; CANCER	Highly metastatic B16 melanoma (B16M)-F10 cells, as compared with the low metastatic B16M-F1 line, have higher GSH content and preferentially overexpress BCL-2. In addition to its anti-apoptotic properties, BCL-2 inhibits efflux of GSH from B16M-F10 cells and thereby may facilitate metastatic cell resistance against endothelium-induced oxidative/nitrosative stress. Thus, we investigated in B16M-F10 cells which molecular mechanisms channel GSH release and whether their modulation may influence metastatic activity. GSH efflux was abolished in multidrug resistance protein 1 knock-out (MRP-/-1) B16M-F10 transfected with the Bcl-2 gene or in MRP-/-1 B16M-F10 cells incubated with L-methionine, which indicates that GSH release from B16M-F10 cells is channeled through MRP1 and a BCL-2-dependent system (likely related to an L-methionine-sensitive GSH carrier previously detected in hepatocytes). The BCL-2-dependent system was identified as the cystic fibrosis transmembrane conductance regulator, since monoclonal antibodies against this ion channel or H-89 (a protein kinase A-selective inhibitor)-induced inhibition of cystic fibrosis transmembrane conductance regulator gene expression completely blocked the BCL-2-sensitive GSH release. By using a perifusion system that mimics in vivo conditions, we found that GSH depletion in metastatic cells can be achieved by using Bcl-2 antisense oligodeoxynucleotide- and verapamil (an MRP1 activator)induced acceleration of GSH efflux, in combination with acivicin-induced inhibition of gamma-glutamyltranspeptidase (which limits GSH synthesis by preventing cysteine generation from extracellular GSH). When applied under in vivo conditions, this strategy increased tumor cytotoxicity (up to similar to90%) during B16M-F10 cell adhesion to the hepatic sinusoidal endothelium.	Univ Valencia, Fac Med & Odontol, Dept Physiol, Valencia 46010, Spain; Ctr Nacl Invest Oncol, Madrid 28029, Spain	University of Valencia	Estrela, JM (corresponding author), Univ Valencia, Fac Med & Odontol, Dept Physiol, 17 Ave Blasco Ibanez, Valencia 46010, Spain.	jose.m.estrela@uv.es	Miralles, Miguel A Asensi/I-2756-2015; Estrela, Jose/H-4449-2015; Carretero, Julian/N-5214-2014; OBRADOR, ELENA/H-4069-2015; Ortega, Angel L./A-4113-2014	Miralles, Miguel A Asensi/0000-0003-1922-7777; Estrela, Jose/0000-0002-2540-9190; Carretero, Julian/0000-0001-7269-8506; OBRADOR, ELENA/0000-0002-5934-5543; Ortega, Angel L./0000-0002-9901-3383				Akerboom T P, 1981, Methods Enzymol, V77, P373; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; AW TY, 1986, AM J PHYSIOL, V251, pG354, DOI 10.1152/ajpgi.1986.251.3.G354; AW TY, 1984, J BIOL CHEM, V259, P9355; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE SPC, 1994, CANCER RES, V54, P5902; Cullen KV, 2001, BIOCHEM PHARMACOL, V62, P417, DOI 10.1016/S0006-2952(01)00681-5; DALTON WS, 1993, CANC PRINCIPLES PRAC, P2655; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; de Menezes DEL, 2000, CLIN CANCER RES, V6, P2891; Dias N, 2002, EUR J PHARM BIOPHARM, V54, P263, DOI 10.1016/S0939-6411(02)00060-7; Eissa S, 1998, CLIN CHEM, V44, P1423; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; ESTRELA JM, 1992, BIOCHEM J, V286, P257, DOI 10.1042/bj2860257; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZCHECA JC, 1988, AM J PHYSIOL, V255, pG403, DOI 10.1152/ajpgi.1988.255.4.G403; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; Gross A, 2001, IUBMB LIFE, V52, P231, DOI 10.1080/15216540152846046; HANIGAN MH, 1995, CARCINOGENESIS, V16, P181, DOI 10.1093/carcin/16.2.181; Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0; Hidalgo M, 1998, CLIN CANCER RES, V4, P2763; Hochwald SN, 1996, J NATL CANCER I, V88, P193, DOI 10.1093/jnci/88.3-4.193; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Jungas T, 2002, J BIOL CHEM, V277, P27912, DOI 10.1074/jbc.M110288200; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAFRENIE R, 1992, CANCER METAST REV, V11, P377, DOI 10.1007/BF01307188; LINSDELL P, 1998, AM J PHYSIOL, V275, P323; LIU JH, 1994, RES COMMUN MOL PATH, V85, P261; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Lorico A, 1996, CANCER RES, V56, P5351; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; Miyake H, 1999, CANCER RES, V59, P4030; MOREADITH RW, 1984, J BIOL CHEM, V259, P6222; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0; Ortega A, 2003, J BIOL CHEM, V278, P39591, DOI 10.1074/jbc.M303753200; Ortega AL, 2003, J BIOL CHEM, V278, P13888, DOI 10.1074/jbc.M207140200; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; RADERER M, 1993, CANCER, V72, P3553, DOI 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B; Rappa G, 1997, CANCER RES, V57, P5232; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; ROSENFELD H, 1981, CANCER RES, V41, P1324; SELLAK H, 1994, BLOOD, V83, P2669; SHAW LM, 1977, CLIN CHEM, V23, P79; STOLE E, 1994, J BIOL CHEM, V269, P21435; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAKADA A, 1984, J BIOL CHEM, V259, P2441; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TSURUO T, 1981, CANCER RES, V41, P1967; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; WRIGHT TL, 1988, AM J PHYSIOL, V255, pG547, DOI 10.1152/ajpgi.1988.255.5.G547; Yaziji H, 2003, INT J SURG PATHOL, V11, P11, DOI 10.1177/106689690301100103; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624; ZHOU DC, 1995, LEUKEMIA, V9, P1661	72	71	73	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6950	6959		10.1074/jbc.M408531200	http://dx.doi.org/10.1074/jbc.M408531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15561710	hybrid			2022-12-25	WOS:000227332700085
J	Bouamr, F; Cornilescu, CC; Goff, SP; Tjandra, N; Carter, CA				Bouamr, F; Cornilescu, CC; Goff, SP; Tjandra, N; Carter, CA			Structural and dynamics studies of the D54A mutant of human T cell leukemia virus-1 capsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACKBONE DYNAMICS; NMR-SPECTROSCOPY; RELAXATION; DOMAIN; RESONANCES; DIMERS; AMIDE; H2O	The human T cell leukemia virus and the human immunodeficiency virus share a highly conserved, predominantly helical two-domain mature capsid (CA) protein structure with an N-terminal beta-hairpin. Despite overall structural similarity, differences exist in the backbone dynamic properties of the CA N-terminal domain. Since studies with other retroviruses suggest that the beta-hairpin is critical for formation of a CA-CA interface, we investigated the functional role of the human T cell leukemia virus beta-hairpin by disrupting the salt bridge between Prol and Asp 54 that stabilizes the beta-hairpin. NMR N-15 relaxation data were used to characterize the backbone dynamics of the D54A mutant in the context of the N-terminal domains, compared with the wildtype counterpart. Moreover, the effect of the mutation on proteolytic processing and release of virus-like particles (VLPs) from human cells in culture was determined. Conformational and dynamic changes resulting from the mutation were detected by NMR spectroscopy. The mutation also altered the conformation of mature CA in cells and VLPs, as reflected by differential antibody recognition of the wild-type and mutated CA proteins. In contrast, the mutation did not detectably affect antibody recognition of the CA protein precursor or release of VLPs assembled by the precursor, consistent with the fact that the hairpin cannot form in the precursor molecule. The particle morphology and size were not detectably affected. The results indicate that the beta-hairpin contributes to the overall structure of the mature CA protein and suggest that differences in the backbone dynamics of the beta-hairpin contribute to mature CA structure, possibly introducing flexibility into interface formation during proteolytic maturation.	Howard Hughes Med Inst, New York, NY USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Microbiol, New York, NY 10027 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tjandra, N (corresponding author), Howard Hughes Med Inst, New York, NY USA.	nico@heliz.nih.gov; ccater@ms.c.sunysb.edu	Goff, Stephen P/K-6337-2014; Cornilescu, Claudia/H-1959-2012; Cornilescu, Gabriel/H-3113-2011; Cornilescu, Claudia/K-1981-2015	Goff, Stephen P/0000-0003-0693-5547; Cornilescu, Gabriel/0000-0002-1204-8904; Cornilescu, Claudia/0000-0002-2401-7806	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000952, P30AI042848, Z01AI000952] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI 42848] Funding Source: Medline; NIGMS NIH HHS [GM 48294] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAX A, 1992, J MAGN RESON, V99, P638, DOI 10.1016/0022-2364(92)90221-R; Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124; BRAINARD JR, 1981, BIOCHEMISTRY-US, V20, P4618, DOI 10.1021/bi00519a016; Campos-Olivas R, 2000, J MOL BIOL, V296, P633, DOI 10.1006/jmbi.1999.3475; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; Cornilescu CC, 2001, J MOL BIOL, V306, P783, DOI 10.1006/jmbi.2000.4395; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; De Alba E, 1999, PROTEIN SCI, V8, P2234; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; HONG SS, 1993, J VIROL, V67, P2787, DOI 10.1128/JVI.67.5.2787-2798.1993; Jin ZM, 1999, J MOL BIOL, V286, P83, DOI 10.1006/jmbi.1998.2443; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; Khorasanizadeh S, 1999, J MOL BIOL, V291, P491, DOI 10.1006/jmbi.1999.2986; Kingston RL, 2000, STRUCTURE, V8, P617, DOI 10.1016/S0969-2126(00)00148-9; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; PENG JW, 1991, J MAGN RESON, V95, P421, DOI 10.1016/0022-2364(91)90233-J; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rayne F, 2001, J VIROL, V75, P5277, DOI 10.1128/JVI.75.11.5277-5287.2001; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390	35	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6792	6801		10.1074/jbc.M408119200	http://dx.doi.org/10.1074/jbc.M408119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15569685	hybrid			2022-12-25	WOS:000227332700068
J	Kim, KH; Shcheynikov, N; Wang, YX; Muallem, S				Kim, KH; Shcheynikov, N; Wang, YX; Muallem, S			SLC26A7 is a Cl- channel regulated by intracellular pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL-/HCO3-EXCHANGER; SULFATE TRANSPORTER; FUNCTIONAL-CHARACTERIZATION; INTERCALATED CELLS; PENDRED-SYNDROME; ADENOMA DRA; GENE; IDENTIFICATION; MUTATIONS; MEMBRANE	Members of the SLC26 transporter family play an essential role in several epithelial functions, as revealed by diseases associated with mutations in members of the family. Several members were shown to function as Cl- and HCO3- transporters that likely play an important role in epithelial Cl- absorption and HCO3- secretion. However, the mechanism of most transporters is not well understood. SLC26A7 is a member of the SLC26 transporter family reported to be expressed in the basolateral membrane of the cortical collecting duct and parietal cells and functions as a coupled Cl-/HCO3- exchanger. In the present work we examined the transport properties of SLC26A7 to determine its transport characteristics and electrogenicity. We found that when expressed in Xenopus oocytes or HEK293 cells SLC26A7 functions as a pH(i)-regulated Cl- channel with minimal OH-/HCO3- permeability. Expression of SLC26A7 in oocytes or HEK293 cells generated a Cl- current with linear IN and an instantaneous current that was voltage- and time-independent. Based on measurement of reversal potential the selectivity of SLC26A7 is NO3- much greater than Cl- = Br- = I- > SO42- = Glu(-), although I- partially inhibited the current. Incubating the cells with HCO3- or butyrate acidified the cytosol and increased the selectivity of SLC26A7 for Cl-. Measurement of membrane potential and pH(i) showed minimal OH- and HCO3- transport by SLC26A7 when the cells were incubated in Cl--containing or Cl--firee media. The activity of SLC26A7 was inhibited by all inhibitors of anion transporters tested, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid, diphenylamine-2-carboxylic acid, and glybenclamide. These findings reveal that SLC26A7 functions as a unique Cl- channel that is regulated by intracellular H+.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shmuel.muallem@utsouthwestern.edu						Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; DAWSON DC, 1999, PHYSIOL REV, V79, P47; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; Knauf F, 2001, P NATL ACAD SCI USA, V98, P9425, DOI 10.1073/pnas.141241098; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Lee A, 2003, DNA CELL BIOL, V22, P19, DOI 10.1089/104454903321112460; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Lohi H, 2002, J BIOL CHEM, V277, P14246, DOI 10.1074/jbc.M111802200; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; Petrovic S, 2004, AM J PHYSIOL-RENAL, V286, pF161, DOI 10.1152/ajprenal.00219.2003; Petrovic S, 2003, AM J PHYSIOL-GASTR L, V284, pG1093, DOI 10.1152/ajpgi.00454.2002; Royaux IE, 2001, P NATL ACAD SCI USA, V98, P4221, DOI 10.1073/pnas.071516798; Satoh H, 1998, J BIOL CHEM, V273, P12307, DOI 10.1074/jbc.273.20.12307; Shcheynikov N, 2004, J BIOL CHEM, V279, P21857, DOI 10.1074/jbc.M313323200; Soleimani M, 2001, AM J PHYSIOL-RENAL, V280, pF356, DOI 10.1152/ajprenal.2001.280.2.F356; Tabcharani JA, 1997, J GEN PHYSIOL, V110, P341, DOI 10.1085/jgp.110.4.341; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	26	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6463	6470		10.1074/jbc.M409162200	http://dx.doi.org/10.1074/jbc.M409162200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591059	hybrid			2022-12-25	WOS:000227332700028
J	Rahman, AS; Hothersall, J; Crosby, J; Simpson, TJ; Thomas, CM				Rahman, AS; Hothersall, J; Crosby, J; Simpson, TJ; Thomas, CM			Tandemly duplicated acyl carrier proteins, which increase polyketide antibiotic production, can apparently function either in parallel or in series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-COELICOLOR A3(2); PSEUDOMONIC ACID MUPIROCIN; ESCHERICHIA-COLI; FATTY-ACID; GENE-CLUSTER; HETEROLOGOUS EXPRESSION; ASPERGILLUS-NIDULANS; TETRACENOMYCIN-C; SYNTHASE; BIOSYNTHESIS	Polyketide biosynthesis involves the addition of subunits commonly derived from malonate or methylmalonate to a starter unit such as acetate. Type 1 polyketide synthases are multifunctional polypeptides that contain one or more modules, each of which normally contains all the enzymatic domains for a single round of extension and modification of the polyketide backbone. Acyl carrier proteins (ACP(s)) hold the extender unit to which the starter or growing chain is added. Normally there is one ACP for each ketosynthase module. However, there are an increasing number of known examples of tandemly repeated ACP domains, whose function is as yet unknown. For the doublet and triplet ACP domains in the biosynthetic pathway for the antibiotic mupirocin from Pseudomonas fluorescens NCIMB10586 we have inactivated ACP domains by inframe deletion and amino acid substitution of the active site serine. By deletion analysis each individual ACP from a cluster can provide a basic but reduced activity for the pathway. In the doublet cluster, substitution analysis indicates that the pathway may follow two parallel routes, one via each of the ACPs, thus increasing overall pathway flow. In the triplet cluster, substitution in ACP5 blocked the pathway. Thus ACP5 appears to be arranged "in series" to ACP6 and ACP7. Thus although both the doublet and triplet clusters increase antibiotic production, the mechanisms by which they do this appear to be different and depend specifically on the biosynthetic stage involved. The function of some ACPs may be determined by their location in the protein rather than absolute enzymic activity.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England	University of Birmingham; University of Bristol	Thomas, CM (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	c.m.thomas@bham.ac.uk	Simpson, Thomas J/P-5058-2015		Engineering and Physical Sciences Research Council [GR/S78124/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Beck BJ, 2002, CHEM BIOL, V9, P575, DOI 10.1016/S1074-5521(02)00146-1; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Brun Christine, 2003, Journal of Structural and Functional Genomics, V3, P213, DOI 10.1023/A:1022694824569; CHAIN EB, 1977, J CHEM SOC P1, V1, P318; Coissac E, 1997, MOL BIOL EVOL, V14, P1062, DOI 10.1093/oxfordjournals.molbev.a025712; CROSBY J, 1995, BBA-PROTEIN STRUCT M, V1251, P32, DOI 10.1016/0167-4838(95)00053-W; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; DECKER H, 1993, J BACTERIOL, V175, P3876, DOI 10.1128/JB.175.12.3876-3886.1993; DECKER H, 1994, J ANTIBIOT, V47, P54, DOI 10.7164/antibiotics.47.54; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; El-Sayed AK, 2001, MICROBIOL-SGM, V147, P2127, DOI 10.1099/00221287-147-8-2127; El-Sayed AK, 2003, CHEM BIOL, V10, P419, DOI 10.1016/S1074-5521(03)00091-7; Findlow SC, 2003, BIOCHEMISTRY-US, V42, P8423, DOI 10.1021/bi0342259; Fujii I, 2001, CHEM BIOL, V8, P189, DOI 10.1016/S1074-5521(00)90068-1; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; Hitchman TS, 1998, CHEM BIOL, V5, P35, DOI 10.1016/S1074-5521(98)90085-0; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Huang GZ, 2001, MICROBIOL-UK, V147, P631, DOI 10.1099/00221287-147-3-631; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KHOSLA C, 1992, MOL MICROBIOL, V6, P3237, DOI 10.1111/j.1365-2958.1992.tb01778.x; KHOSLA C, 1993, J BACTERIOL, V175, P2197, DOI 10.1128/JB.175.8.2197-2204.1993; LAMB YJ, 1991, J HOSP INFECT, V19, P27, DOI 10.1016/0195-6701(91)90199-I; Li Q, 2003, BIOCHEMISTRY-US, V42, P4648, DOI 10.1021/bi0274120; Lynch M, 2001, GENETICS, V159, P1789; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Marti T, 2000, J BIOL CHEM, V275, P33443, DOI 10.1074/jbc.M006766200; MARTIN FM, 1989, J CHEM SOC PERK T 1, P207, DOI 10.1039/p19890000207; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; Reed MAC, 2003, ORG BIOMOL CHEM, V1, P463, DOI 10.1039/b208941f; Revill WP, 1996, J BACTERIOL, V178, P5660, DOI 10.1128/jb.178.19.5660-5667.1996; REVILL WP, 1991, J BACTERIOL, V173, P4379, DOI 10.1128/JB.173.14.4379-4385.1991; ROCK CO, 1982, J BIOL CHEM, V257, P10759; RODE H, 1991, LANCET, V338, P578, DOI 10.1016/0140-6736(91)91149-O; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P4563; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Tang L, 1999, CHEM BIOL, V6, P553, DOI 10.1016/S1074-5521(99)80087-8; Tang LJ, 1997, J BACTERIOL, V179, P3697, DOI 10.1128/jb.179.11.3697-3705.1997; Thomas I, 2002, CHEM BIOL, V9, P781, DOI 10.1016/S1074-5521(02)00164-3; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; WHATLING CA, 1995, MICROBIOL-UK, V141, P973, DOI 10.1099/13500872-141-4-973; YU JH, 1995, J BACTERIOL, V177, P4792, DOI 10.1128/jb.177.16.4792-4800.1995	49	51	51	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6399	6408		10.1074/jbc.M409814200	http://dx.doi.org/10.1074/jbc.M409814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15583005	hybrid			2022-12-25	WOS:000227332700020
J	Sacchetto, R; Bovo, E; Donella-Deana, A; Damiani, E				Sacchetto, R; Bovo, E; Donella-Deana, A; Damiani, E			Glycogen- and PP1c-targeting subunit G(M) is phosphorylated at Ser(48) by sarcoplasmic reticulum-bound Ca2+-calmodulin protein kinase in rabbit fast twitch skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH CA2+-BINDING PROTEIN; TERMINAL CISTERNAE; MOLECULAR-MECHANISM; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; ANCHORING PROTEIN; BINDING SUBUNIT; PHOSPHATASE 1; SYNTHASE; INSULIN	Multifunctional Ca2+-calmodulin-dependent protein kinase (CaMKII) is a Ser/Thr protein kinase uniformly distributed within the sarcoplasmic reticulum (SR) of skeletal muscle. In fast twitch muscle, no specific substrates of CaMKII have yet been identified in nonjunctional SR. Previous electron microscopy data showed that glycogen particles containing glycogen synthase (GS) associate with SR at the I band level. Furthermore, recent evidence implicates CaMKII in regulation of glucose and glycogen metabolism. Here, we demonstrate that the glycogen- and protein phosphatase 1-targeting subunit, also known as Gm, selectively localizes to the SR membranes of rabbit skeletal muscle and that G(M) and GS co-localize at the level of the I band. We further show that G(M), GS, and PP1c assemble in a structural complex that selectively localizes to nonjunctional SR and that G(M) is phosphorylated by SR-bound CaMKII and dephosphorylated by PP1c. On the other hand, no evidence for a structural interaction between Gm and CaMKII was obtained. Using His-tagged Gm recombinant fragments and site-directed mutagenesis, we demonstrate that the target of CaMKII is Ser(48). Taken together, these data suggest that SR-bound CaMKII participates in the regulation of GS activity through changes in the phosphorylation state of G(M). Based on these findings, we propose that SR-bound CaMKII participates in the regulation of glycogen metabolism, under physiological conditions involving repetitive raises elevations of [Ca2+](i).	Univ Padua, Dept Expt Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, I-44100 Ferrara, Italy	University of Padua; University of Padua; University of Ferrara	Damiani, E (corresponding author), Univ Padua, Dept Expt Biomed Sci, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	damiani@civ.bio.unipd.it	damiani, ernesto/AAI-5709-2020	damiani, ernesto/0000-0002-9557-6496				Aschenbach WG, 2001, J BIOL CHEM, V276, P39959, DOI 10.1074/jbc.M105518200; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; Berrebi-Bertrand I, 1998, FEBS LETT, V439, P224, DOI 10.1016/S0014-5793(98)01364-7; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CHU A, 1987, ARCH BIOCHEM BIOPHYS, V258, P13, DOI 10.1016/0003-9861(87)90317-1; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; Cohen PTW, 2002, J CELL SCI, V115, P241; Damiani E, 1997, CELL CALCIUM, V22, P129, DOI 10.1016/S0143-4160(97)90113-5; DAMIANI E, 1981, BIOCHEM J, V197, P245, DOI 10.1042/bj1970245; DAMIANI E, 1995, BIOCHEM BIOPH RES CO, V209, P457, DOI 10.1006/bbrc.1995.1524; Damiani E, 2003, BIOCHEM BIOPH RES CO, V302, P73, DOI 10.1016/S0006-291X(03)00110-4; Damiani E, 2000, BIOCHEM BIOPH RES CO, V279, P181, DOI 10.1006/bbrc.2000.3845; Damiani E, 2000, BBA-BIOMEMBRANES, V1464, P231, DOI 10.1016/S0005-2736(00)00153-X; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ENTMAN ML, 1980, J BIOL CHEM, V255, P6245; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FRIDEN J, 1989, ACTA PHYSIOL SCAND, V135, P381, DOI 10.1111/j.1748-1716.1989.tb08591.x; GomezLechon MJ, 1996, ANAL BIOCHEM, V236, P296, DOI 10.1006/abio.1996.0170; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanner C, 2001, ARCH BIOCHEM BIOPHYS, V388, P135, DOI 10.1006/abbi.2001.2283; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; LOWRY OH, 1951, J BIOL CHEM, V265, P10118; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014-5793(88)81331-0; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Nielsen JN, 2003, ACTA PHYSIOL SCAND, V178, P309, DOI 10.1046/j.1365-201X.2003.01165.x; Nielsen JN, 2001, J PHYSIOL-LONDON, V531, P757, DOI 10.1111/j.1469-7793.2001.0757h.x; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; Rose AJ, 2003, J PHYSIOL-LONDON, V553, P303, DOI 10.1113/jphysiol.2003.054171; Sacchetto R, 1999, J MUSCLE RES CELL M, V20, P403, DOI 10.1023/A:1005580609414; Sacchetto R, 2001, J MUSCLE RES CELL M, V22, P545, DOI 10.1023/A:1015010914328; SACCHETTO R, 2005, IN PRESS BASIC APPL, V15; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Shearer J, 2004, EXERC SPORT SCI REV, V32, P120, DOI 10.1097/00003677-200407000-00008; Singh P, 2004, J BIOL CHEM, V279, P35176, DOI 10.1074/jbc.M402282200; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; TANG PM, 1991, J BIOL CHEM, V266, P15782; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Walker KS, 2000, FEBS LETT, V466, P121, DOI 10.1016/S0014-5793(99)01771-8; Wright DC, 2004, LIFE SCI, V74, P815, DOI 10.1016/j.lfs.2003.06.041; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	53	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7147	7155		10.1074/jbc.M413574200	http://dx.doi.org/10.1074/jbc.M413574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591318	hybrid			2022-12-25	WOS:000227332700105
J	Bladen, CL; Udayakumar, D; Takeda, Y; Dynan, WS				Bladen, CL; Udayakumar, D; Takeda, Y; Dynan, WS			Identification of the polypyrimidine tract binding protein-associated splicing factor p54(nrb) complex as a candidate DNA double-strand break rejoining factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; RNA RECOGNITION; FACTOR PSF; LIGASE IV; END; REPAIR; KINASE; KU; TRANSCRIPTION; CELLS	The biological effects of ionizing radiation are attributable, in large part, to induction of DNA double-strand breaks. We report here the identification of a new protein factor that reconstitutes efficient double-strand break rejoining when it is added to a reaction containing the five other polypeptides known to participate in the human nonhomologous end-joining pathway. The factor is a stable heteromeric complex of polypyrimidine tract-binding protein-associated splicing factor (PSF) and a 54-kDa nuclear RNA-binding protein (p54(nrb)). These polypeptides, to which a variety of functions have previously been attributed, share extensive homology, including tandem RNA recognition motif domains. The PSF-p54(nrb) complex cooperates with Ku protein to form a functional preligation complex with substrate DNA. Based on structural comparison with related proteins, we propose a model where the four RNA recognition motif domains in the heteromeric PSF-p54(nrb) complex cooperate to align separate DNA molecules.	Med Coll Georgia, Inst Mol Med & Genet, Program Gene Regulat & Canc Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Program Gene Regulat & Canc Biol, Rm CB-2803, Augusta, GA 30912 USA.	wdynan@mail.mcg.edu		Dynan, William/0000-0002-4045-5662	NATIONAL CANCER INSTITUTE [R01CA098239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER; NCI NIH HHS [CA 98239, R01 CA098239, R01 CA098239-01A2] Funding Source: Medline; NIGMS NIH HHS [GM 35866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmedov AT, 2000, NUCLEIC ACIDS RES, V28, P3022, DOI 10.1093/nar/28.16.3022; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Hall EJ., 2000, RADIOBIOLOGY RADIOBI, V5, P17; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Izzard RA, 1999, CANCER RES, V59, P2581; Keene JD, 1996, MOL BIOL REP, V23, P173, DOI 10.1007/BF00351166; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; METZGER L, 1991, INT J RADIAT BIOL, V59, P1325, DOI 10.1080/09553009114551201; Pang DL, 1997, CANCER RES, V57, P1412; Peng R, 2002, RNA, V8, P1334, DOI 10.1017/S1355838202022070; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Takeda Y, 1999, J IMMUNOL, V163, P6269; Udayakumar D, 2003, J BIOL CHEM, V278, P41631, DOI 10.1074/jbc.M306470200; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034; ZHANG WW, 1993, BIOCHEM J, V290, P267, DOI 10.1042/bj2900267; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zolotukhin AS, 2003, MOL CELL BIOL, V23, P6618, DOI 10.1128/MCB.23.18.6618-6630.2003	39	87	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5205	5210		10.1074/jbc.M412758200	http://dx.doi.org/10.1074/jbc.M412758200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590677	hybrid			2022-12-25	WOS:000227217100013
J	Bohm, M; Wolff, I; Scholzen, TE; Robinson, SJ; Healy, E; Luger, TA; Schwarz, T; Schwarz, A				Bohm, M; Wolff, I; Scholzen, TE; Robinson, SJ; Healy, E; Luger, TA; Schwarz, T; Schwarz, A			alpha melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; B-INDUCED APOPTOSIS; HUMAN SKIN CELLS; HUMAN KERATINOCYTES; MELANOCORTIN-1 RECEPTOR; IN-SITU; SUNBURN CELL; MC1R GENE; EXPRESSION	Ultraviolet radiation is a well established epidemiologic risk factor for malignant melanoma. This observation has been linked to the relative resistance of normal melanocytes to ultraviolet B (UVB) radiation-induced apoptosis, which consequently leads to accumulation of UVB radiation-induced DNA lesions in melanocytes. Therefore, identification of physiologic factors regulating UVB radiation-induced apoptosis and DNA damage of melanocytes is of utmost biological importance. We show that the neuropeptide a-melanocyte-stimulating hormone (alpha-MSH) blocks UVB radiation-induced apoptosis of normal human melanocytes in vitro. The antiapoptotic activity of a-MSH is not mediated by filtering or by induction of melanin synthesis in melanocytes. a-MSH neither leads to changes in the cell cycle distribution nor induces alterations in the expression of the apoptosis-related proteins Bcl(2), Bcl(x), Bax, p53, CD95 (Fas/APO-1), and CD95L (FasL). In contrast, alpha-MSH markedly reduces the formation of UVB radiation-induced DNA damage as demonstrated by reduced amounts of cyclobutane pyrimidine dimers, ultimately leading to reduced apoptosis. The reduction of UV radiation-induced DNA damage by a-MSH appears to be related to induction of nucleotide excision repair, because UV radiation-mediated apoptosis was not blocked by alpha-MSH in nucleotide excision repair-deficient fibroblasts. These data, for the first time, demonstrate regulation of UVB radiation-induced apoptosis of human melanocytes by a neuropeptide that is physiologically expressed within the epidermis. Apart from its ability to induce photoprotective melanin synthesis, alpha-MSH appears to exert the capacity to reduce UV radiation-induced DNA damage and, thus, may act as a potent protection factor against the harmful effects of UV radiation on the genomic stability of epidermal cells.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany; Univ Southampton, Southampton Gen Hosp, Dermatopharmacol Unit, Southampton SO16 6YD, Hants, England; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	University of Munster; University of Munster; University of Southampton; University of Kiel	Bohm, M (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 58, D-48149 Munster, Germany.	bohmm@uni-muenster.de	Schwarz, Thomas/A-9148-2010	Healy, Eugene/0000-0001-5591-6970				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BARKER D, 1995, CANCER RES, V55, P4041; Bohm M, 2004, J BIOL CHEM, V279, P6959, DOI 10.1074/jbc.M312549200; Bohm M, 2002, J INVEST DERMATOL, V118, P533, DOI 10.1046/j.0022-202x.2001.01704.x; Bohm M, 2000, HORM RES, V54, P287, DOI 10.1159/000053273; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bohm M, 1999, EXP DERMATOL, V8, P453, DOI 10.1111/j.1600-0625.1999.tb00303.x; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; CARREAU M, 1995, CARCINOGENESIS, V16, P1003, DOI 10.1093/carcin/16.5.1003; Curry JL, 2001, IN VITRO CELL DEV-AN, V37, P234; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; Decraene D, 2002, J BIOL CHEM, V277, P32587, DOI 10.1074/jbc.M111106200; Eipper B A, 1980, Endocr Rev, V1, P1; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Flanagan N, 2000, HUM MOL GENET, V9, P2531, DOI 10.1093/hmg/9.17.2531; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Hartmeyer M, 1997, J IMMUNOL, V159, P1930; Haycock JW, 2000, J BIOL CHEM, V275, P15629, DOI 10.1074/jbc.275.21.15629; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033; Im SB, 1998, CANCER RES, V58, P47; KLEINPARKER HA, 1994, J CUTAN PATHOL, V21, P297, DOI 10.1111/j.1600-0560.1994.tb00703.x; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; Luger TA, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P87, DOI 10.1038/jidsymp.1997.17; Mildner M, 2002, J BIOL CHEM, V277, P14146, DOI 10.1074/jbc.M110687200; MORALESDUCRET CRJ, 1995, ARCH DERMATOL, V131, P915, DOI 10.1001/archderm.131.8.915; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Moustafa M, 2002, J INVEST DERMATOL, V119, P1244, DOI 10.1046/j.1523-1747.2002.19602.x; Muotri AR, 2002, HUM GENE THER, V13, P1833, DOI 10.1089/104303402760372936; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Robinson SJ, 2002, ONCOGENE, V21, P8037, DOI 10.1038/sj.onc.1205913; ROZA L, 1988, PHOTOCHEM PHOTOBIOL, V48, P627, DOI 10.1111/j.1751-1097.1988.tb02873.x; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; Schiller M, 2004, J INVEST DERMATOL, V122, P468, DOI 10.1046/j.0022-202X.2004.22239.x; Scholzen TE, 2000, J INVEST DERMATOL, V115, P1021, DOI 10.1046/j.1523-1747.2000.00174.x; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Stander S, 2002, EXP DERMATOL, V11, P42, DOI 10.1034/j.1600-0625.2002.110105.x; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; Yasumoto J, 2004, CANCER LETT, V204, P41, DOI 10.1016/j.canlet.2003.07.005; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	54	168	171	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5795	5802		10.1074/jbc.M406334200	http://dx.doi.org/10.1074/jbc.M406334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15569680	hybrid			2022-12-25	WOS:000227217100082
J	Collins, RE; Tachibana, M; Tamaru, H; Smith, KM; Jia, D; Zhang, X; Selker, EU; Shinkai, Y; Cheng, XD				Collins, RE; Tachibana, M; Tamaru, H; Smith, KM; Jia, D; Zhang, X; Selker, EU; Shinkai, Y; Cheng, XD			In vitro and in vivo analyses of a Phe/Tyr switch controlling product specificity of histone lysine methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; H3 METHYLTRANSFERASE; ARABIDOPSIS-THALIANA; ACTIVE GENES; NEUROSPORA; G9A; COMPLEX; CHROMATIN; PROTEIN	The functional significance of mono-, di-, and tri-methylation of lysine residues within histone proteins is under investigation. Evidence from several model organisms suggests that different methylated states of H3 Lys(9) (H3K9) are generated by specific histone methyl-transferases (MTases) to mark distinct types of silent chromatin. Sequence alignment of all histone lysine AlTases with known product specificity suggested that a key residue in the active site determines how many methyl groups they add. We examined this possibility both in vitro and in vivo and found that a Phe at the position equivalent to Phe 281 of Neurospora crassa DIM-5 or Phe(1205) of human G9a allows the enzyme to perform di and tri-methylation, whereas a Tyr at this position is restrictive, inhibiting tri-methylation and thus yielding a mono- or di-MTase. Phe to Tyr mutants of both DIM-5 and G9a restrict product specificity in vitro and in vivo without compromising overall catalysis. These mutants were employed to probe the biological significance of mono-, di-, and tri-methylation of H3K9 in both mouse embryonic stem cells and N. crassa. G9a F1205Y, when expressed in G9a (-/-) embryonic stem cells, rescued only H3K9 mono-methylation, but not di-methylation, to wild-type levels yet silenced Mage-a gene expression. When expressed in dim-5 strains, DIM-5 F281Y generated significant levels of mono- and di-H3K9 methylation (which are not observed in wild type Neurospora) as well as tri-methyl H3K9. The altered DIM-5 rescued the growth defect characteristic of dim-5 N. crassa but did not fully rescue the gross DNA hypomethylation of dim-5 strains.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA; Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Sakyo Ku, Kyoto 6068507, Japan; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	Emory University; Emory University; Emory University; Kyoto University; University of Oregon	Cheng, XD (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	xcheng@emory.edu	Hu, Ruogu/B-2203-2008; Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484; Jia, Da/0000-0002-2205-1998; Collins, Robert/0000-0002-4580-5991	NIGMS NIH HHS [GM61355, R01 GM068680, GM49245, R37 GM035690, R01 GM068680-01A2, R01 GM035690, T32 GM008367, GM35690, R01 GM061355, R01 GM049245] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068680, R01GM049245, R01GM061355, T32GM008367, R01GM035690, R37GM035690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; FOSS HM, 1993, SCIENCE, V262, P1737, DOI 10.1126/science.7505062; Freitag M, 2004, MOL CELL, V13, P427, DOI 10.1016/S1097-2765(04)00024-3; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jackson JP, 2004, CHROMOSOMA, V112, P308, DOI 10.1007/s00412-004-0275-7; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Manzur KL, 2003, NAT STRUCT BIOL, V10, P187, DOI 10.1038/nsb898; Margolin BS, 1998, GENETICS, V149, P1787; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Osipovich O, 2004, NAT IMMUNOL, V5, P309, DOI 10.1038/ni1042; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7	44	145	148	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5563	5570		10.1074/jbc.M410483200	http://dx.doi.org/10.1074/jbc.M410483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590646	hybrid, Green Accepted			2022-12-25	WOS:000227217100056
J	Corpe, CP; Lee, JH; Kwon, O; Eck, P; Narayanan, J; Kirk, KL; Levine, M				Corpe, CP; Lee, JH; Kwon, O; Eck, P; Narayanan, J; Kirk, KL; Levine, M			6-bromo-6-deoxy-L-ascorbic acid - An ascorbate analog specific for Na+-dependent vitamin C transporter but not glucose transporter pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMMENDED DIETARY ALLOWANCE; DEHYDROASCORBIC ACID; HUMAN-NEUTROPHILS; XENOPUS OOCYTES; ACCUMULATION; CELLS; CLONING; BRAIN	Vitamin C intracellular accumulation is mediated by Na+-dependent vitamin C transporters SVCT1 and -2 and dehydroascorbic acid transporters GLUT1 and -3. It is unclear which pathways dominate in vivo. As a new step to resolve this issue, we identified and tested 6-bromo-6-deoxy-L-ascorbic acid as a specific candidate for SVCTs. In high performance liquid chromatography and electron paramagnetic resonance analyses, the reduced compounds ascorbic acid and 6-bromo-6-deoxy-L-ascorbic acid were similar. The oxidized products 6-bromo-6-deoxy dehydroascorbic acid (BrDHA) and dehydroascorbic acid (DHA) had comparable stabilities, based on reduction recoveries. Upon expression of GLUT1 or GLUT3 in Xenopus oocytes, BrDHA was neither transported nor bound, in contrast to robust transport of DHA. The findings were not explained by differences in the oocyte reduction of DHA and BrDHA because lysed oocytes reduced both compounds equally. Further, there was no transport of the reduced compound, 6-bromo-6-deoxy-L-ascorbic acid, by GLUT1 or GLUT3. As a prerequisite for investigating 6-bromo-6-deoxy-L-ascorbic acid transported by SVCTs, SVCT2 transport activity in oocytes was enhanced 14-fold by construction and use of a vector that added a fixed poly(A) tail to the 3' end of cRNA. For SVCT1 and SVCT2 expressed in oocytes, similar K-m and V.. values were observed for ascorbic acid and 6-bromo-6-deoxy-L-ascorbic acid. In human fibroblasts, predicted to have SVCT-mediated ascorbate accumulation, K-m and V-max values were again comparable for ascorbic acid and 6-bromo-6-deoxy-L-ascorbic acid. Using activated human neutrophils, predicted to have ascorbate accumulation mediated predominantly by DHA and GLUT transporters, 6-bromo-6-deoxy-L-ascorbic acid accumulation was <1% of accumulation when compared with ascorbic acid. We conclude that 6-bromo-6-deoxy-L-ascorbic acid is the first transport substrate identified as completely specific for SVCTs, but not GLUTs, and provide a new strategy to determine the contribution of each pathway to ascorbate accumulation.	NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Levine, M (corresponding author), NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Rm 4D52,MSC 1372, Bethesda, MD 20892 USA.	markl@intra.niddk.nih.gov		Eck, Peter/0000-0003-2371-9774; corpe, christopher/0000-0003-1994-8312	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054506, Z01DK032002, ZIADK054506] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; BARTALENA L, 1993, CLIN LAB MED, V13, P583, DOI 10.1016/S0272-2712(18)30427-X; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DILIBERTO EJ, 1983, J BIOL CHEM, V258, P2886; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; HUEZ G, 1974, P NATL ACAD SCI USA, V71, P3143, DOI 10.1073/pnas.71.8.3143; KISS J, 1980, HELV CHIM ACTA, V63, P1728, DOI 10.1002/hlca.19800630642; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MANN GV, 1974, PERSPECT BIOL MED, V17, P210; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; PATTERSON JW, 1951, AM J PHYSIOL, V167, P119, DOI 10.1152/ajplegacy.1951.167.1.119; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Rumsey SC, 1999, J BIOL CHEM, V274, P23215, DOI 10.1074/jbc.274.33.23215; Samuni AM, 2002, BBA-GEN SUBJECTS, V1571, P211, DOI 10.1016/S0304-4165(02)00218-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sotiriou S, 2002, NAT MED, V8, P514, DOI 10.1038/nm0502-514; TOLBERT BM, 1982, ADV CHEM SER, P101; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505	33	74	76	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5211	5220		10.1074/jbc.M412925200	http://dx.doi.org/10.1074/jbc.M412925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590689	hybrid			2022-12-25	WOS:000227217100014
J	Shao, BH; Bergt, C; Fu, XY; Green, P; Voss, JC; Oda, MN; Oram, JF; Heinecke, JW				Shao, BH; Bergt, C; Fu, XY; Green, P; Voss, JC; Oda, MN; Oram, JF; Heinecke, JW			Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CATALYZED OXIDATION; GENERATED HYPOCHLORITE; METHIONINE RESIDUES; HYDROGEN-PEROXIDE; HUMAN NEUTROPHILS; NITRIC-OXIDE; HDL; DOMAIN; ABCA1	High density lipoprotein (HDL) isolated from human atherosclerotic lesions and the blood of patients with established coronary artery disease contains elevated levels of 3-nitrotyrosine and 3-chlorotyrosine. Myeloperoxidase (MPO) is the only known source of 3-chlorotyrosine in humans, indicating that MPO oxidizes HDL in vivo. In the current studies, we used tandem mass spectrometry to identify the major sites of tyrosine oxidation when lipid-free apolipoprotein A-I (apoA-I), the major protein of HDL, was exposed to MPO or peroxynitrite (ONOO-). Tyrosine 192 was the predominant site of both nitration and chlorination by MPO and was also the major site of nitration by ONOO-. Electron paramagnetic spin resonance studies of spin-labeled apoA-I revealed that residue 192 was located in an unusually hydrophilic environment. Moreover, the environment of residue 192 became much more hydrophobic when apoA-I was incorporated into discoidal HDL, and Tyr(192) of HDL-associated apoA-I was a poor substrate for nitration by both myeloperoxidase and ONOO-, suggesting that solvent accessibility accounted in part for the reactivity of Tyr(192). The ability of lipid-free apoA-I to facilitate ATP-binding cassette transporter A1 cholesterol transport was greatly reduced after chlorination by MPO. Loss of activity occurred in concert with chlorination of Tyr(192). Both ONOO- and MPO nitrated Tyr(192) in high yield, but unlike chlorination, nitration minimally affected the ability of apoA-I to promote cholesterol efflux from cells. Our results indicate that Tyr(192) is the predominant site of nitration and chlorination when MPO or ONOO- oxidizes lipid-free apoA-I but that only chlorination markedly reduces the cholesterol efflux activity of apoA-I. This impaired biological activity of chlorinated apoA-I suggests that MPO-mediated oxidation of HDL might contribute to the link between inflammation and cardiovascular disease.	Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	University of Washington; University of Washington Seattle; University of California System; University of California Davis; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu		Shao, Baohai/0000-0001-8832-2845; Voss, John/0000-0001-9279-209X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075381, P01HL018645, R01HL055362, P50HL073996, P01HL030086, R01HL077268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073996, HL30086, HL55362, HL18645, HL030086, HL77268, HL75381] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Bergt C, 2003, ARTERIOSCL THROM VAS, V23, P1488, DOI 10.1161/01.ATV.0000090570.99836.9C; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Chomiki N, 2001, EUR J BIOCHEM, V268, P903, DOI 10.1046/j.1432-1327.2001.01946.x; Christison J, 1996, BIOCHEM J, V314, P739, DOI 10.1042/bj3140739; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; Fu XY, 2003, J BIOL CHEM, V278, P28403, DOI 10.1074/jbc.M304739200; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Getz GS, 2004, CURR OPIN LIPIDOL, V15, P261, DOI 10.1097/00041433-200406000-00005; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hope HR, 2000, PROTEIN EXPRES PURIF, V18, P269, DOI 10.1006/prep.1999.1197; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTIONA; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1987, J LIPID RES, V28, P719; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; SEGREST JP, 1992, J LIPID RES, V33, P141; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Voss J, 1996, BIOCHEMISTRY-US, V35, P12915, DOI 10.1021/bi9608774; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	58	200	213	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5983	5993		10.1074/jbc.M411484200	http://dx.doi.org/10.1074/jbc.M411484200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15574409	hybrid			2022-12-25	WOS:000227217100104
J	Shen, Y; Kim, JL; Song, PS				Shen, Y; Kim, JL; Song, PS			NDPK2 as a signal transducer in the phytochrome-mediated light signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; X-RAY-STRUCTURE; SITE-DIRECTED MUTAGENESIS; TUMOR-METASTASIS; CRYSTAL-STRUCTURE; ACTIVE-SITE; DICTYOSTELIUM-DISCOIDEUM; PHOTOSENSORY PERCEPTION; 2-ANGSTROM RESOLUTION; MOLECULAR-CLONING	Nucleoside-diphosphate kinase (NDPK) 2 in Arabidopsis has been identified as a phytochrome-interacting protein by using the C-terminal domain of phytochrome A (PhyA) as the bait in yeast two-hybrid screening. The far-red light-absorbing form of phytochrome (Pfr) A stimulates NDPK2 gamma-phosphate exchange activity in vitro. To better understand the multiple functions of NDPK and its role in phytochrome-mediated signaling, we characterized the interaction between phytochrome and NDPK2. Domain studies revealed that PER-ARNT-SIM domain A in the C-terminal domain of phytochrome is the binding site for NDPK2. Additionally, phytochrome recognizes both the NDPK2 C-terminal fragment and the NDPK2 hexameric structure to fulfill its binding. To illustrate the mechanism of how the Pfr form of phytochrome stimulates NDPK2, His-197-surrounding residue mutants were made and tested. Results suggested that the H-bonding with His-197 inside the nucleotide-binding pocket is critical for NDPK2 functioning. The pH dependence profiles of NDPK2 indicated that mutants with different activities from the wild type have different pK(a) values of His-197 and that NDPK2 hyperactive mutants possess lower pK(a) values. Because a lower pK(a) value of His-197 accelerates NDPK2 autophosphorylation and the phospho-transfer between the phosphorylated NDPK2 and its kinase substrate, we concluded that the Pfr form of phytochrome stimulates NDPK2 by lowering the pK(a) value of His-197.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea; Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea	University of Nebraska System; University of Nebraska Lincoln; Gyeongsang National University	Song, PS (corresponding author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.	pssong@kkpc.com						BEALE SI, 1991, J BIOL CHEM, V266, P22333; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Cervoni L, 2003, BIOCHEMISTRY-US, V42, P14599, DOI 10.1021/bi035273w; Chen YX, 2003, J MOL BIOL, V332, P915, DOI 10.1016/j.jmb.2003.07.004; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; EDGERTON MD, 1993, BIOCHEMISTRY-US, V32, P8239, DOI 10.1021/bi00083a026; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; FINAN PM, 1994, PLANT MOL BIOL, V25, P59, DOI 10.1007/BF00024198; Hamada T, 1999, BIOL PHARM BULL, V22, P122, DOI 10.1248/bpb.22.122; Hasunuma K, 2003, J BIOENERG BIOMEMBR, V35, P57, DOI 10.1023/A:1023493823368; Hisada A, 2000, PLANT CELL, V12, P1063, DOI 10.1105/tpc.12.7.1063; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Huq E, 2002, EMBO J, V21, P2441, DOI 10.1093/emboj/21.10.2441; Im YJ, 2004, J MOL BIOL, V343, P659, DOI 10.1016/j.jmb.2004.08.054; Janin J, 2000, J BIOENERG BIOMEMBR, V32, P215, DOI 10.1023/A:1005528811303; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; Khurana JP, 1998, CRIT REV PLANT SCI, V17, P465, DOI 10.1080/07352689891304258; Kim J, 2004, PLANT CELL, V16, P2629, DOI 10.1105/tpc.104.023879; Kircher S, 2002, PLANT CELL, V14, P1541, DOI 10.1105/tpc.001156; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; Ladner JE, 1999, ACTA CRYSTALLOGR D, V55, P1127, DOI 10.1107/S0907444999002528; LAPKO VN, 1995, PHOTOCHEM PHOTOBIOL, V62, P194, DOI 10.1111/j.1751-1097.1995.tb05258.x; LASCU I, 1993, J BIOL CHEM, V268, P20268; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P237, DOI 10.1023/A:1005532912212; LUBECK J, 1995, PLANTA, V196, P668, DOI 10.1007/BF01106759; Matsushita T, 2003, NATURE, V424, P571, DOI 10.1038/nature01837; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Min K, 2002, PROTEINS, V46, P340, DOI 10.1002/prot.10038; Moon H, 2003, P NATL ACAD SCI USA, V100, P358, DOI 10.1073/pnas.252641899; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ni M, 1999, NATURE, V400, P781, DOI 10.1038/23500; Ogura T, 1999, PHOTOCHEM PHOTOBIOL, V69, P397, DOI 10.1562/0031-8655(1999)069<0397:COPCCN>2.3.CO;2; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Park CM, 2000, SEMIN CELL DEV BIOL, V11, P449, DOI 10.1006/scdb.2000.0200; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PARTIS MD, 1990, Z NATURFORSCH C, V45, P987; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; ROMANOWSKI M, 1992, J PROTEIN CHEM, V11, P139, DOI 10.1007/BF01025219; Schneider B, 2001, EUR J BIOCHEM, V268, P1964, DOI 10.1046/j.1432-1327.2001.02070.x; Seravalli J, 1999, BIOCHEMISTRY-US, V38, P5736, DOI 10.1021/bi9824745; Sharrock RA, 2004, P NATL ACAD SCI USA, V101, P11500, DOI 10.1073/pnas.0404286101; Sharrock RA, 2002, PLANT PHYSIOL, V130, P442, DOI 10.1104/pp.005389; SOMMER D, 1994, BBA-MOL CELL RES, V1222, P464, DOI 10.1016/0167-4889(94)90055-8; Song PS, 1999, J BIOCHEM MOL BIOL, V32, P215; Struglics A, 1999, EUR J BIOCHEM, V262, P765, DOI 10.1046/j.1432-1327.1999.00432.x; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; Yamaguchi R, 1999, J CELL BIOL, V145, P437, DOI 10.1083/jcb.145.3.437; YANO A, 1993, PLANT MOL BIOL, V23, P1087, DOI 10.1007/BF00021824; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; ZHANG JN, 1995, BBA-PROTEIN STRUCT M, V1248, P19, DOI 10.1016/0167-4838(94)00222-3; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805; Zimmermann S, 1999, J BIOL CHEM, V274, P17017, DOI 10.1074/jbc.274.24.17017	67	36	41	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5740	5749		10.1074/jbc.M408965200	http://dx.doi.org/10.1074/jbc.M408965200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15561724	hybrid			2022-12-25	WOS:000227217100076
J	Shin, I; Rotty, J; Wu, FY; Arteaga, CL				Shin, I; Rotty, J; Wu, FY; Arteaga, CL			Phosphorylation of p27(Kip1) at Thr-157 interferes with its association with importin during G(1) and prevents nuclear re-entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; CELL-CYCLE PROGRESSION; DEPENDENT PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC LOCALIZATION; P27; ACTIVATION; AKT; INHIBITOR; SIGNAL	We have studied mechanisms of Akt-mediated phosphorylation and regulation of cellular localization of p27. Akt phosphorylates Thr-157 in p27 and retains it in the cytosol. In cells arrested in G(1) and then synchronized to enter into S phase, Akt-mediated phosphorylation of Thr-157 p27 occurred in the cytosol during G(1) phase of the cell cycle. Both T157A and S10A p27 mutants localized in the nucleus in all phases of the cell cycle regardless of the expression of active Akt. Thr-157 phosphorylation was undetectable in S10A-p27, suggesting that Ser-10 phosphorylation is required for p27 localization in the cytosol and subsequent phosphorylation at Thr-157. Phosphorylation at Thr-157 interrupted the association of p27 with importin alpha. A T157A-p27 mutant protein exhibited higher association with importin alpha than wild-type-p27. Treatment of transfected and endogenous p27 with alkaline phosphatase rescued, its association with importin a. Leptomycin B inhibited cytosolic Thr-157 P-p27 staining, implying that CRMl-dependent nuclear export is required for Akt-mediated Thr-157 phosphorylation. Heterokaryon shuttling assays with NIH3T3 (mouse) cells transfected with FLAG-p27 and HeLa (human) cells revealed that both wild type and T157A-p27 shuttled from NIH3T3 to HeLa cell nuclei with similar frequencies. However, S10A-p27 was found only in the NIH3T3 nuclei of NIH3T3-HeLa cell fusions. These results suggest that 1) Ser-10 phosphorylation is required for nuclear export of p27, 2) subsequent Akt-mediated phosphorylation at Thr-157 during G(1) phase corrals p27 in the cytosol, and 3) Thr-157 phosphorylation inhibits the association of p27 with importin a thus preventing its re-entry into the nucleus.	Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Breast Cans Res Program, Nashville, TN 37232 USA; Berea Coll, Dept Biol, Berea, KY 40404 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu						AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Borgatti P, 2003, J CELL PHYSIOL, V196, P79, DOI 10.1002/jcp.10279; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHAN TO, 2001, SCI STKE; Ciaparrone M, 1998, CANCER RES, V58, P114; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; DARBON JM, 1994, ONCOGENE, V9, P3127; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Guan TL, 2000, MOL CELL BIOL, V20, P5619, DOI 10.1128/MCB.20.15.5619-5630.2000; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; Hernan R, 2003, CANCER RES, V63, P140; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; JANS DA, 1994, ONCOGENE, V9, P2961; Lenferink AEG, 2001, CANCER RES, V61, P6583; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Muller D, 2000, EMBO J, V19, P2168, DOI 10.1093/emboj/19.10.2168; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; OHTA Y, 1989, J BIOL CHEM, V264, P16143; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Singh SP, 1998, CANCER RES, V58, P1730; Smitherman M, 2000, MOL CELL BIOL, V20, P5631, DOI 10.1128/MCB.20.15.5631-5642.2000; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Zeng Y, 2000, BIOCHEM BIOPH RES CO, V274, P37, DOI 10.1006/bbrc.2000.3098	50	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6055	6063		10.1074/jbc.M412367200	http://dx.doi.org/10.1074/jbc.M412367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579463	hybrid			2022-12-25	WOS:000227217100111
J	Wood, CD; Marklund, U; Cantrell, DA				Wood, CD; Marklund, U; Cantrell, DA			Dual phospholipase C/diacylglycerol requirement for protein kinase D1 activation in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; D-DEPENDENT ACTIVATION; TRANS-GOLGI NETWORK; PHORBOL ESTERS; IN-VIVO; D PKD; LOOP PHOSPHORYLATION; PLASMA-MEMBRANE; KAPPA-B; DIACYLGLYCEROL	The serine/threonine kinase protein kinase D1 (PKD1) is a protein kinase C (PKC) substrate that mediates antigen receptor signal transduction in lymphocytes. PKC phosphorylates serines 744/748 within the PKD1 catalytic domain, and this is proposed to be necessary and sufficient for enzyme activation. Hence, a PKD1 mutant with alanine substituted at positions 744 and 748 (PKD-S744A/S748A) is catalytically inactive. Conversely, a PKD1 mutant with glutamic residues substituted at positions 744 and 748 as phospho-mimics (PKD-S744E/S748E) is constitutively active when expressed in Cos7 or HeLa cells. The present study reveals that Ser-744/Ser-748 phosphorylation is required for PKD1 activation in lymphocytes. However, PKD-S744E/S748E is not constitutively active but, like the wild type enzyme, requires antigen receptor triggering or phorbol ester stimulation. Antigen receptor activation of wild type PKD is dependent on phospholipase C (PLC)/diacylglycerol (DAG) and PKC, whereas PKD-S744E/S748E is only dependent on PLC/DAG but no longer requires PKC. Hence, substitution of serines 744 and 748 with glutamic residues as phospho-mimics bypasses the PKC requirement for PKD1 activation but does not bypass the need for antigen receptors, PLC, or DAG. In lymphocytes, PKD1 is, thus, not regulated by PLC and PKC in a linear pathway; rather, PKD1 activation has more stringent requirements for integration of dual PLC signals, one mediated by PKCs and one that is PKC-independent.	Univ Dundee, MSI, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Canc Res UK, London Res Inst, Lincolns Inn Fields Labs, Lymphocyte Activat Lab, London WC2A 3PX, England	University of Dundee; Cancer Research UK	Cantrell, DA (corresponding author), Univ Dundee, MSI, Sch Life Sci, Div Cell Biol & Immunol, WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	d.a.cantrell@dundee.ac.uk		Cantrell, Doreen/0000-0001-7525-3350; Wood, David/0000-0002-0758-0592				Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Carnegie GK, 2004, MOL CELL, V15, P889, DOI 10.1016/j.molcel.2004.09.015; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Rey O, 2004, J BIOL CHEM, V279, P34361, DOI 10.1074/jbc.M403265200; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	37	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6245	6251		10.1074/jbc.M411564200	http://dx.doi.org/10.1074/jbc.M411564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590638	hybrid			2022-12-25	WOS:000227217100132
J	Yamada, A; Irie, K; Hirota, T; Ooshio, T; Fukuhara, A; Takai, Y				Yamada, A; Irie, K; Hirota, T; Ooshio, T; Fukuhara, A; Takai, Y			Involvement of the annexin II-S100A10 complex in the formation of E-cadherin-based adherens junctions in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; ADHESION MOLECULES; BINDING PROTEIN; TIGHT JUNCTIONS; FUNCTIONAL-ANALYSIS; ACTIN CYTOSKELETON; INDUCED ACTIVATION; ALPHA-CATENIN; NECTIN; AFADIN	E-cadherin and nectins are major cell-cell adhesion molecules at adherens junctions (AJs) in epithelial cells. When Madin-Darby canine kidney (MDCK) cells stably expressing nectin-1 (nectin-l-MDCK cells) are cultured at normal Ca2+, E-cadherin and nectin-1 are concentrated at the cell-cell contact sites. When these cells are cultured at low Ca2+, E-cadherin disappears from the cell-cell contact sites, but nectin-1 persists there. When these cells are re-cultured at normal Ca2+, E-cadherin is recruited to the pectin-based cell-cell contact sites. We found here that this recruitment was dependent on protein synthesis, because a protein synthesis inhibitor, cycloheximide, prevented the accumulation of E-cadherin. When nectin-1-MDCK cells, precultured at low Ca2+ in the presence of a proteasome inhibitor, ALLN (N-acetyl-Leu-Leu-norleucinal), were re-cultured at normal Ca2+, E-cadherin was recruited to the nectin-based cell-cell contact sites but the level of E-cadherin was reduced. Similar results were obtained when wild-type MDCK cells were used instead of nectin-1-MDCK cells. These results suggest that degradation of one or more protein factors and de novo synthesis of the same or different protein factor(s) are needed for the formation of the E-cadherin-based AJs. We biochemically identified the annexin II-S100A10 complex as such a candidate. Depletion of plasma membrane cholesterol, which abolished the localization of the annexin II-S100A10 complex at the plasma membrane, inhibited the re-concentration of E-cadherin at the pectin-based cell-cell contact sites in the Ca2+ switch experiment. Knockdown of annexin II by RNA interference also inhibited the re-concentration of E-cadherin. These results indicate that the annexin II-S100A10 complex is involved in the formation of the E-cadherin-based AJs in MDCK cells.	Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Fukuhara, Atsunori/A-9601-2018	Fukuhara, Atsunori/0000-0002-6289-3778; Ooshio, Takako/0000-0001-6508-8152				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Angst BD, 2001, J CELL SCI, V114, P629; Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Corvera S, 2000, J BIOL CHEM, V275, P31414, DOI 10.1074/jbc.M001708200; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hansen MDH, 2002, J BIOL CHEM, V277, P45371, DOI 10.1074/jbc.M207747200; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Ooshio T, 2004, J BIOL CHEM, V279, P31365, DOI 10.1074/jbc.M401957200; OYAMA T, 1994, CANCER RES, V54, P6282; Peng YF, 2002, ONCOGENE, V21, P4108, DOI 10.1038/sj.onc.1205517; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Yagi T, 2000, GENE DEV, V14, P1169; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yamamoto Y, 2002, ONCOGENE, V21, P2545, DOI 10.1038/sj.onc.1205335; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Zobiack N, 2003, MOL BIOL CELL, V14, P4896, DOI 10.1091/mbc.E03-06-0387	49	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6016	6027		10.1074/jbc.M408215200	http://dx.doi.org/10.1074/jbc.M408215200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15574423	hybrid			2022-12-25	WOS:000227217100107
J	Yin, ZQ; Jayaram, M; Pathania, S; Harshey, RM				Yin, ZQ; Jayaram, M; Pathania, S; Harshey, RM			The Mu transposase interwraps distant DNA sites within a functional transpososome in the absence of DNA supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-MU; STRAND TRANSFER; BINDING-SITE; COMPLEX; RECOMBINATION; ENHANCER; SEQUENCE; SYNAPSIS; CLEAVAGE; ORDER	A Mu transpososome assembled on negatively supercoiled DNA traps five supercoils by intertwining the left (L) and right (R) ends of Mu with an enhancer element (E). To investigate the contribution of DNA supercoiling to this elaborate synapse in which E and L cross once, E and R twice, and L and R twice, we have analyzed DNA crossings in a transpososome assembled on nicked substrates under conditions that bypass the supercoiling requirement for transposition. We find that the transposase MuA can recreate an essentially similar topology on nicked substrates, interwrapping both E-R and L-R twice but being unable to generate the single E-L crossing. In addition, we deduce that the functional MuA tetramer must contribute to three of the four observed crossings and, thus, to restraining the enhancer within the complex. We discuss the contribution of both MuA and DNA supercoiling to the 5-noded Mu synapse built at the 3-way junction.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Harshey, RM (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.	rasika@uts.cc.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033247, R01GM035654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33247, GM35654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; Alen C, 1997, EMBO J, V16, P5188, DOI 10.1093/emboj/16.17.5188; ALLISON RG, 1992, J BIOL CHEM, V267, P19963; Cantor EJ, 2001, PROTEIN EXPRES PURIF, V22, P135, DOI 10.1006/prep.2001.1428; Chaconas George, 2002, P384; CRAIG NL, 2002, MOBILE DNA, V2; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; Grainge I, 2002, J MOL BIOL, V320, P515, DOI 10.1016/S0022-2836(02)00517-X; Grainge I, 2000, J MOL BIOL, V298, P749, DOI 10.1006/jmbi.2000.3679; Grindley NDF, 2002, MOBILE DNA, P272; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; Jiang H, 1999, EMBO J, V18, P3845, DOI 10.1093/emboj/18.13.3845; Johnson RC, 2002, MOBILE DNA, P230; Kilbride E, 1999, J MOL BIOL, V289, P1219, DOI 10.1006/jmbi.1999.2864; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kobryn K, 1999, J MOL BIOL, V289, P777, DOI 10.1006/jmbi.1999.2805; Kobryn K, 2002, MOL CELL, V10, P659, DOI 10.1016/S1097-2765(02)00596-8; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Lavoie BD, 1996, CELL, V85, P761, DOI 10.1016/S0092-8674(00)81241-6; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; Lee I, 2003, J MOL BIOL, V330, P261, DOI 10.1016/S0022-2836(03)00574-6; Lee L, 2003, J MOL BIOL, V326, P397, DOI 10.1016/S0022-2836(02)01429-8; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; Morgan GJ, 2002, J MOL BIOL, V317, P337, DOI 10.1006/jmbi.2002.5437; Naigamwalla DZ, 1997, EMBO J, V16, P5227, DOI 10.1093/emboj/16.17.5227; Namgoong SY, 1998, EMBO J, V17, P3775, DOI 10.1093/emboj/17.13.3775; Pathania S, 2003, EMBO J, V22, P3725, DOI 10.1093/emboj/cdg354; Pathania S, 2002, CELL, V109, P425, DOI 10.1016/S0092-8674(02)00728-6; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Rice P. A., 2002, MOBILE DNA, P219; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; Wang ZG, 1996, J BIOL CHEM, V271, P9619, DOI 10.1074/jbc.271.16.9619; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; Yanagihara K, 2003, MOL CELL, V11, P215, DOI 10.1016/S1097-2765(02)00796-7; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x	48	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6149	6156		10.1074/jbc.M411679200	http://dx.doi.org/10.1074/jbc.M411679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15563455	hybrid			2022-12-25	WOS:000227217100122
J	Ishiko, E; Matsumura, I; Ezoe, S; Gale, K; Ishiko, J; Satoh, Y; Tanaka, H; Shibayama, H; Mizuki, M; Era, T; Enver, T; Kanakura, Y				Ishiko, E; Matsumura, I; Ezoe, S; Gale, K; Ishiko, J; Satoh, Y; Tanaka, H; Shibayama, H; Mizuki, M; Era, T; Enver, T; Kanakura, Y			Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; MAMMALIAN NEURONAL DIFFERENTIATION; CYTOKINE-DEPENDENT GROWTH; LOOP-HELIX FACTORS; HEMATOPOIETIC-CELLS; MEGAKARYOCYTIC DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; SELF-RENEWAL; DNA-BINDING	The effects of Notch signals on the erythroid/ imegakaryocytic differentiation of hematopoietic cells were examined. Activation of Notch signals by the intracellular Notch1 or an estradiol-inducible form of Notch1/ER suppressed the expression of the erythroid marker glycophorin A in an erythroid/megakaryocytic cell line K562. Although Mock-transfected K562 cells underwent megakaryocytic differentiation in response to '12-O-tetradecanoylphorbol-13-acetate (TPA), estradiol-activated Notch1/ER induced apoptosis during TPA treatment in the transfectant, which was accompanied by the reduced expression of an antiapoptotic molecule Bcl-XL. Even when apoptosis was prevented by the overexpression of Bcl-XL, activated Notch signals still inhibited TPA-induced megakaryocytic differentiation. As for this mechanism, Notch1/recombination signal binding protein J-kappa-induced HES1 but not HES5 was found to inhibit the function of an erythroid/megakaryocytic lineage-specific transcription factor GATA-1. Although HES1 did not affect the DNA binding activity of GATA-1 in gel shift and chromatin immunoprecipitation assays, it directly bound to GATA-1 and dissociated a critical transcriptional cofactor, p300, from GATA-1. Furthermore, overexpressed HES1 inhibited the development of erythroid and megakaryocytic cells in colony assays. Also, the Notch ligand Jagged1 expressed on NIH3T3 cells suppressed the development of erythroid and megakaryocytic cells from cocultured Lin(-)Sca-1(+) hematopoietic stem/progenitor cells. These results suggest that Notch1 inhibits the development of erythroid/ megakaryocytic cells by suppressing GATA-1 activity through HES1.	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; RIKEN, Ctr Dev Biol, Stem Cell Biol Grp, Tyuo Ku, Kobe, Hyogo 6500047, Japan; John Radcliffe Hosp, MRC, Mol Hematol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England	Osaka University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; RIKEN; University of Oxford	Matsumura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	matumura@bldon.med.osaka-u.ac.jp		ISHIKO, JUN/0000-0003-3518-5108				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Horak CE, 2002, P NATL ACAD SCI USA, V99, P2924, DOI 10.1073/pnas.052706999; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jones P, 1998, BLOOD, V92, P1505, DOI 10.1182/blood.V92.5.1505.417k42_1505_1511; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kawamata S, 2002, ONCOGENE, V21, P3855, DOI 10.1038/sj.onc.1205487; Kumano K, 2001, BLOOD, V98, P3283, DOI 10.1182/blood.V98.12.3283; Kunisato A, 2003, BLOOD, V101, P1777, DOI 10.1182/blood-2002-07-2051; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; LARSSON C, 1994, GENOMICS, V24, P253, DOI 10.1006/geno.1994.1613; Matsumura I, 2000, BLOOD, V96, P2440; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Tan-Pertel HT, 2000, J IMMUNOL, V165, P4428, DOI 10.4049/jimmunol.165.8.4428; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Zhang P, 2000, BLOOD, V96, P2641	51	67	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4929	4939		10.1074/jbc.M406788200	http://dx.doi.org/10.1074/jbc.M406788200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563463	hybrid			2022-12-25	WOS:000227096600114
J	Mulvihill, DJ; Edamura, KN; Hagerman, KA; Pearson, CE; Wang, YH				Mulvihill, DJ; Edamura, KN; Hagerman, KA; Pearson, CE; Wang, YH			Effect of CAT or AGG interruptions and CpG methylation on nucleosome assembly upon trinucleotide repeats on spinocerebellar ataxia, type 1 and fragile X syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; FMR1 GENE; TRIPLET REPEATS; CGG REPEATS; EXCLUDES NUCLEOSOMES; ANDROGEN RECEPTOR; DNA-REPLICATION; IN-VITRO; TRANSCRIPTION; INSTABILITY	Nucleosome packaging regulates many aspects of DNA metabolism and is thought to mediate genetic instability and transcription of expanded trinucleotide repeats. Both instability and transcription are sensitive to repeat length, tract purity, and CpG methylation. CAT or AGG interruptions within the (CAG)(n) or (CGG)(n) tracts of spinocerebellar ataxia, type 1 or fragile X syndrome, respectively, confer increased genetic stability to the repeats. We report the formation of nucleosomes on sequences containing pure and interrupted (CAG)(n) and (CGG)(n) repeats having lengths above and below the genetic stability thresholds. Increased lengths of pure repeats led to increased and decreased propensities for nucleosome assembly on the (CAG)(n) and (CGG)(n) repeats, respectively. CpG methylation of the CGG repeat further reduced assembly. CAT interruptions in (CAG)(n) tracts decreased nucleosome assembly. In contrast, AGG interruptions in (CGG)(n) tracts did not affect assembly by hypoacetylated histones. The latter observation was unaltered by CpG methylation of the repeats. However, nucleosome assembly by hyperacetylated histones on interrupted (CGG)(n) tracts was increased relative to pure tracts and this effect was abolished by CpG methylation. Thus, CAT or AGG interruptions can modulate the ability of (CAG)(n) and (CGG)(n) tracts to assemble into chromatin and the effect of the AGG interruptions is dependent upon both the methylation status of the DNA and the acetylation status of the histones. Compared with the genetically unstable pure repeats, both interruptions permit a propensity of nucleosome assembly closer to that of random (genetically stable) sequences, suggesting an association of nucleosome assembly of trinucleotide repeats and genetic instability.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Wang, YH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	wangyu@umdnj.edu		Pearson, Christopher/0000-0001-9545-4205	NCI NIH HHS [CA85826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen EG, 2004, HUM GENET, V114, P439, DOI 10.1007/s00439-004-1086-x; Beilina A, 2004, HUM MOL GENET, V13, P543, DOI 10.1093/hmg/ddh053; Brooks BP, 1997, NEUROBIOL DIS, V3, P313, DOI 10.1006/nbdi.1997.0126; Burman RW, 1999, HUM MOL GENET, V8, P2293, DOI 10.1093/hmg/8.12.2293; Chiurazzi P, 1999, HUM MOL GENET, V8, P2317, DOI 10.1093/hmg/8.12.2317; Chiurazzi P, 1998, HUM MOL GENET, V7, P109, DOI 10.1093/hmg/7.1.109; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; Choong CS, 1996, MOL ENDOCRINOL, V10, P1527, DOI 10.1210/me.10.12.1527; Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837; Coffee B, 2002, AM J HUM GENET, V71, P923, DOI 10.1086/342931; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Eberhart DE, 1996, SOMAT CELL MOLEC GEN, V22, P435, DOI 10.1007/BF02369435; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Godde JS, 1996, J BIOL CHEM, V271, P24325, DOI 10.1074/jbc.271.40.24325; Hagerman PJ, 2004, AM J HUM GENET, V74, P805, DOI 10.1086/386296; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; Jin P, 2003, NEURON, V39, P739, DOI 10.1016/S0896-6273(03)00533-6; Kenneson A, 2001, HUM MOL GENET, V10, P1449, DOI 10.1093/hmg/10.14.1449; Kirkpatrick DT, 1999, MOL CELL BIOL, V19, P7661; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Kumari D, 2001, J BIOL CHEM, V276, P4357, DOI 10.1074/jbc.M009629200; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; Malter HE, 1997, NAT GENET, V15, P165, DOI 10.1038/ng0297-165; Maurer DJ, 1998, MOL CELL BIOL, V18, P4597, DOI 10.1128/MCB.18.8.4597; Metzenberg S, 1996, AM J HUM GENET, V59, P252; Murray A, 2000, SEMIN REPROD MED, V18, P59, DOI 10.1055/s-2000-13476; Nichol K, 2002, GENOME RES, V12, P1246, DOI 10.1101/gr.74502; Oostra BA, 2003, HUM MOL GENET, V12, pR249, DOI 10.1093/hmg/ddg298; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; POMPONI MG, 1994, AM J MED GENET, V51, P447, DOI 10.1002/ajmg.1320510428; Rolfsmeier ML, 2000, MOL CELL BIOL, V20, P173, DOI 10.1128/MCB.20.1.173-180.2000; Rolfsmeier ML, 2000, MOL CELL, V6, P1501, DOI 10.1016/S1097-2765(00)00146-5; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Smith KT, 2004, HUM MOL GENET, V13, P1611, DOI 10.1093/hmg/ddh172; Takayanagi K, 1997, DNA Res, V4, P241, DOI 10.1093/dnares/4.3.241; Tassone F, 2000, AM J MED GENET, V97, P195, DOI 10.1002/1096-8628(200023)97:3<195::AID-AJMG1037>3.0.CO;2-R; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; Wang YH, 1996, P NATL ACAD SCI USA, V93, P8863, DOI 10.1073/pnas.93.17.8863; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wang YH, 1996, J BIOL CHEM, V271, P22937, DOI 10.1074/jbc.271.38.22937; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Willemsen R, 2003, HUM MOL GENET, V12, P949, DOI 10.1093/hmg/ddg114; Wohrle D, 1998, J MED GENET, V35, P103, DOI 10.1136/jmg.35.2.103; Yoshimura A, 2002, BIOCHEM BIOPH RES CO, V290, P16, DOI 10.1006/bbrc.2001.6135; ZHONG N, 1995, AM J HUM GENET, V57, P351	46	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4498	4503		10.1074/jbc.M413239200	http://dx.doi.org/10.1074/jbc.M413239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574425	hybrid			2022-12-25	WOS:000227096600062
J	May, D; Itin, A; Gal, O; Kalinski, H; Feinstein, E; Keshet, E				May, D; Itin, A; Gal, O; Kalinski, H; Feinstein, E; Keshet, E			Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer	ONCOGENE			English	Article						ero1-l alpha; VEGF; HIF1; hypoxia; disulfide bond formation	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; MESSENGER-RNA STABILITY; INDUCIBLE FACTOR-I; ENDOPLASMIC-RETICULUM; HIF-ALPHA; PROTEIN; EXPRESSION; FACTOR-1; GENES	Oxygen is the ultimate source of oxidizing power for disulfide bond formation, suggesting that under limiting oxygen proper protein folding might be compromised. We show that secretion of vascular endothelial growth factor ( VEGF), a protein with multiple disulfide bonds, was indeed impeded under hypoxia and was partially restored by artificial increase of oxidizing equivalents with diamide. Physiologically, the oxireductase endoplasmic reticulum oxidoreductin-1 (Ero1)-Lalpha, but not other proteins in the relay of disulfide formation, was strongly upregulated by hypoxia and independently by hypoglycemia, two known accompaniments of tumors. Further, we provide genetic evidence that induction of Ero1-Lalpha by hypoxia and hypoglycemia is mediated by the transcription factor hypoxia-inducible factor 1 (HIF-1) but is independent of p53. In natural human tumors, Ero1-Lalpha mRNA was specifically induced in hypoxic microenvironments coinciding with that of upregulated VEGF expression. To establish a physiological relevance to modulations in Ero1-Lalpha levels, we showed that even a modest, two- to three-fold reduction in Ero1-Lalpha production via siRNA leads to significant inhibition of VEGF secretion, a compromised proliferation capacity and enhanced apoptosis. Together, these findings demonstrate that hypoxic induction of Ero1-Lalpha is the key adaptive response in a previously unrecognized HIF-1-mediated pathway that operates to improve protein secretion under hypoxia and might be harnessed for inhibiting tumor growth via inhibiting VEGF-driven angiogenesis.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Quark Biotech Inc, QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel	Hebrew University of Jerusalem	Keshet, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel.	keshet@cc.huji.ac.il	Keshet, Eli/GQR-0445-2022					An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BARASH Y, 2004, BIOINFORMATICS  0928; BENDA P, 1968, SCIENCE, V161, P371; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; CzyzykKrzeska MF, 1997, RESP PHYSIOL, V110, P99, DOI 10.1016/S0034-5687(97)00076-5; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Endoh H, 2004, J CLIN ONCOL, V22, P811, DOI 10.1200/JCO.2004.04.109; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Ryan HE, 2000, CANCER RES, V60, P4010; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P845; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Walter DH, 1996, LAB INVEST, V74, P546; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	45	113	122	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1011	1020		10.1038/sj.onc.1208325	http://dx.doi.org/10.1038/sj.onc.1208325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592500				2022-12-25	WOS:000226749200007
J	Thiele, I; Price, ND; Vo, TD; Palsson, BO				Thiele, I; Price, ND; Vo, TD; Palsson, BO			Candidate metabolic network states in human mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUX-BALANCE ANALYSIS; MYOCARDIAL GLUCOSE-UPTAKE; EXTREME PATHWAY ANALYSIS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; KETONE-BODIES; FATTY-ACIDS; HUMAN HEART; (R)-3-HYDROXYBUTYRATE DEHYDROGENASE; ADAPTIVE EVOLUTION	The human mitochondrial metabolic network was recently reconstructed based on proteomic and biochemical data. Linear programming and uniform random sampling were applied herein to identify candidate steady states of the metabolic network that were consistent with the imposed physico-chemical constraints and available experimental data. The activity of the mitochondrion was studied under four metabolic conditions: normal physiologic, diabetic, ischemic, and dietetic. Pairwise correlations between steady-state reaction fluxes were calculated in each condition to evaluate the dependence among the reactions in the network. Applying constraints on exchange fluxes resulted in predictions for intracellular fluxes that agreed with experimental data. Analyses of the steady-state flux distributions showed that the experimentally observed reduced activity of pyruvate dehydrogenase in vivo could be a result of stoichiometric constraints and therefore would not necessarily require enzymatic inhibition. The observed changes in the energy metabolism of the mitochondrion under diabetic conditions were used to evaluate the impact of previously suggested treatments. The results showed that neither normalized glucose uptake nor decreased ketone body uptake have a positive effect on the mitochondrial energy metabolism or network flexibility. Taken together, this study showed that sampling of the steady-state flux space is a powerful method to investigate network properties under different conditions and provides a basis for in silico evaluations of effects of potential disease treatments.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Ecole Super Biotechnol Strasbourg, F-67402 Strasbourg, France	University of California System; University of California San Diego; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr 0412, La Jolla, CA 92093 USA.	palsson@ucsd.edu	Thiele, Ines/A-7629-2014	Thiele, Ines/0000-0002-8071-7110; Palsson, Bernhard/0000-0003-2357-6785; Price, Nathan/0000-0002-4157-0267				Aasum E, 2003, DIABETES, V52, P434, DOI 10.2337/diabetes.52.2.434; Apstein CS, 1998, CIRCULATION, V98, P2223, DOI 10.1161/01.CIR.98.21.2223; Belke DD, 2000, AM J PHYSIOL-ENDOC M, V279, pE1104, DOI 10.1152/ajpendo.2000.279.5.E1104; Berne R.M., 2003, PHYSIOLOGY; BITTL JA, 1985, J BIOL CHEM, V260, P208; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Burgard AP, 2003, BIOTECHNOL BIOENG, V82, P670, DOI 10.1002/bit.10617; Burgard AP, 2001, BIOTECHNOL BIOENG, V74, P364, DOI 10.1002/bit.1127; Burgard AP, 2004, GENOME RES, V14, P301, DOI 10.1101/gr.1926504; Casteels K, 2003, REV ENDOCR METAB DIS, V4, P159, DOI 10.1023/A:1022942120000; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; Dashti HM, 2003, NUTRITION, V19, P901, DOI 10.1016/S0899-9007(03)00161-8; DILISA F, 1993, AM J PHYSIOL, V264, pH2188, DOI 10.1152/ajpheart.1993.264.6.H2188; Duarte NC, 2004, GENOME RES, V14, P1298, DOI 10.1101/gr.2250904; Edwards JS, 2000, BMC BIOINFORMATICS, V1, DOI 10.1186/1471-2105-1-1; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 1999, J BIOL CHEM, V274, P17410, DOI 10.1074/jbc.274.25.17410; Edwards JS, 2002, ENVIRON MICROBIOL, V4, P133, DOI 10.1046/j.1462-2920.2002.00282.x; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; EDWARDS JS, METABOLIC ENG, P13; Famili I, 2003, P NATL ACAD SCI USA, V100, P13134, DOI 10.1073/pnas.2235812100; Fiermonte G, 2003, J BIOL CHEM, V278, P32778, DOI 10.1074/jbc.M302317200; Fong SS, 2003, J BACTERIOL, V185, P6400, DOI 10.1128/JB.185.21.6400-6408.2003; Forster Jochen, 2003, OMICS A Journal of Integrative Biology, V7, P193, DOI 10.1089/153623103322246584; Fukao T, 2004, PROSTAG LEUKOTR ESS, V70, P243, DOI 10.1016/j.plefa.2003.11.001; GARLICK PB, 1979, BIOCHEM J, V184, P547, DOI 10.1042/bj1840547; Goodwin GW, 1998, AM J PHYSIOL-HEART C, V274, pH1239, DOI 10.1152/ajpheart.1998.274.4.H1239; Green D, 1996, BIOCHEMISTRY-US, V35, P8158, DOI 10.1021/bi952807n; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; Heo KN, 2000, J NUTR, V130, P2467, DOI 10.1093/jn/130.10.2467; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Iozzo P, 2002, DIABETOLOGIA, V45, P1404, DOI 10.1007/s00125-002-0917-3; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; Kantor PF, 2000, CIRC RES, V86, P580, DOI 10.1161/01.RES.86.5.580; Kauffman KJ, 2003, CURR OPIN BIOTECH, V14, P491, DOI 10.1016/j.copbio.2003.08.001; Kaufman DE, 1998, OPER RES, V46, P84, DOI 10.1287/opre.46.1.84; King LM, 2001, AM J PHYSIOL-HEART C, V280, pH1173, DOI 10.1152/ajpheart.2001.280.3.H1173; KNUUTI MJ, 1995, J MOL CELL CARDIOL, V27, P1359; Kofoed KF, 2002, EUR J NUCL MED MOL I, V29, P991, DOI 10.1007/s00259-002-0827-0; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; MARKS AR, 1992, J BIOL CHEM, V267, P15459; Meckling KA, 2004, J CLIN ENDOCR METAB, V89, P2717, DOI 10.1210/jc.2003-031606; MURTHY MSR, 1984, J BIOL CHEM, V259, P9082; NiezenKoning KE, 1997, EUR J PEDIATR, V156, P870, DOI 10.1007/s004310050733; O'Donnell JM, 2002, BIOPHYS J, V82, P11, DOI 10.1016/S0006-3495(02)75369-1; Opie L.H., 1991, HEART PHYSL METABOLI; Osborn BA, 1997, J APPL PHYSIOL, V82, P828, DOI 10.1152/jappl.1997.82.3.828; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Ozawa T, 2003, NAT BIOTECHNOL, V21, P287, DOI 10.1038/nbt791; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Papin JA, 2003, TRENDS BIOCHEM SCI, V28, P250, DOI 10.1016/S0968-0004(03)00064-1; Papin JA, 2004, TRENDS BIOCHEM SCI, V29, P641, DOI 10.1016/j.tibs.2004.10.001; Papin JA, 2002, J THEOR BIOL, V215, P67, DOI 10.1006/jtbi.2001.2499; Papin JA, 2002, GENOME RES, V12, P1889, DOI 10.1101/gr.327702; Paternostro G, 1999, CARDIOVASC RES, V42, P246, DOI 10.1016/S0008-6363(98)00233-8; Price ND, 2004, BIOPHYS J, V87, P2172, DOI 10.1529/biophysj.104.043000; Price ND, 2002, GENOME RES, V12, P760, DOI 10.1101/gr.218002; Price ND, 2004, NAT REV MICROBIOL, V2, P886, DOI 10.1038/nrmicro1023; Ramakrishna R, 2001, AM J PHYSIOL-REG I, V280, pR695, DOI 10.1152/ajpregu.2001.280.3.R695; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54; Reed JL, 2003, J BACTERIOL, V185, P2692, DOI 10.1128/JB.185.9.2692-2699.2003; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Schilling CH, 2000, J THEOR BIOL, V203, P229, DOI 10.1006/jtbi.2000.1073; Schilling CH, 2002, J BACTERIOL, V184, P4582, DOI 10.1128/JB.184.16.4582-4593.2002; Schilling CH, 2000, BIOTECHNOL BIOENG, V71, P286, DOI 10.1002/1097-0290(2000)71:4<286::AID-BIT1018>3.0.CO;2-R; Schonekess BO, 1997, J MOL CELL CARDIOL, V29, P2725, DOI 10.1006/jmcc.1997.0504; Schuster S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786; Schuster S, 2002, BIOPROC BIOSYST ENG, V24, P363, DOI 10.1007/s004490100253; SCHUSTER S, 1995, J BIOL SYST, V2, P165; Sharov VG, 2000, J MOL CELL CARDIOL, V32, P2361, DOI 10.1006/jmcc.2000.1266; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; Taegtmeyer H, 2002, CIRCULATION, V105, P1727, DOI 10.1161/01.CIR.0000012466.50373.E8; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Veech RL, 2001, IUBMB LIFE, V51, P241; VO TD, 2004, J BIOL CHEM; Wiback SJ, 2004, J THEOR BIOL, V228, P437, DOI 10.1016/j.jtbi.2004.02.006; Wiback SJ, 2002, BIOPHYS J, V83, P808, DOI 10.1016/S0006-3495(02)75210-7; WILLIAMSON JR, 1976, CIRC RES, V38, P39	83	110	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11683	11695		10.1074/jbc.M409072200	http://dx.doi.org/10.1074/jbc.M409072200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15572364	hybrid			2022-12-25	WOS:000227761800097
J	Garcia, AF; Heindl, P; Voigt, H; Buttner, M; Butz, P; Tauber, N; Tauscher, B; Pfaff, E				Garcia, AF; Heindl, P; Voigt, H; Buttner, M; Butz, P; Tauber, N; Tauscher, B; Pfaff, E			Dual nature of the infectious prion protein revealed by high pressure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERISTICS; SCRAPIE AGENT; INACTIVATION	Crude brain homogenates of terminally diseased hamsters infected with the 263K strain of scrapie (PrPSc) and purified prion fibrils were heated or pressurized at 800 megapascals and 60 degrees C for 2 h in different buffers and in water. Prion proteins (PrP) were analyzed for their proteinase K resistance in immunoblots and for their infectivity in hamster bioassays. A notable decrease in the proteinase K resistance of unpurified prion proteins, probably because of pressure-induced changes in the protein conformation of native PrPSc or the N-truncated PrP-(27-30), could be demonstrated when pressurized at initially neutral conditions in several buffers and in water but not in a slightly acidic pH. A subsequent 6-7 log(10) reduction of infectious units/g in phosphate-buffered saline buffer, pH 7.4, was found. The proteinase K-resistant core was also not detectable after purification of prions extracted from pressurized samples, confirming pressure effects at the level of the secondary structure of prion proteins. However, opposite results were found after pressurizing purified prions, arguing for the existence of pressure-sensitive beta-structures (PrP Delta PsenSc) and extremely pressure-resistant beta-structures (PrP Delta PresSc). Remarkably, after the first centrifugation step at 540,000 x g during isolation, prions remained proteinase K-resistant when pressurized in all tested buffers and in water. It is known that purified fibrils retain infectivity, but the isolated protein (full and N-truncated) behaved differently from native PrPSc under pressure, suggesting a kind of semi-crystalline polymer structure.	Fed Res Ctr Nutr & Food, D-76131 Karlsruhe, Germany; Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, D-72076 Tubingen, Germany	Friedrich Loeffler Institute	Garcia, AF (corresponding author), Meat Technol Ctr, Inst Recerca & Tecnol Agroalimentaries, Granja Camps & Armet S-N, Monells 17121, Girona, Spain.	avelina.fernandez@bfe.uni-karlsruhe.de	Garcia, Avelina Fernandez/A-1471-2009	von Buttlar, Heiner/0000-0003-4373-0823				Balny C, 2004, J PHYS-CONDENS MAT, V16, pS1245, DOI 10.1088/0953-8984/16/14/036; Brown P, 2003, P NATL ACAD SCI USA, V100, P6093, DOI 10.1073/pnas.1031826100; Cai K, 2002, BBA-PROTEIN STRUCT M, V1597, P28, DOI 10.1016/S0167-4838(02)00282-0; Cordeiro Y, 2004, J BIOL CHEM, V279, P32354, DOI 10.1074/jbc.M404295200; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; Dubois J, 1999, SCAND J IMMUNOL, V49, P376; FernandezGarcia A, 2001, J FOOD SCI, V66, P1033, DOI 10.1111/j.1365-2621.2001.tb08231.x; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; FUNTENBERGER S, 1995, FOOD SCI TECHNOL-LEB, V28, P410; Garcia AF, 2004, J GEN VIROL, V85, P261, DOI 10.1099/vir.0.19410-0; GARCIA AF, 2004, P INT C ENG FOOD, P303; Heremans K, 1998, BBA-PROTEIN STRUCT M, V1386, P353, DOI 10.1016/S0167-4838(98)00102-2; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; Kasermann F, 2003, J GEN VIROL, V84, P3173, DOI 10.1099/vir.0.19355-0; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; MCKINLEY MP, 1986, J INFECT DIS, V154, P110, DOI 10.1093/infdis/154.1.110; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P4606, DOI 10.1073/pnas.78.7.4606; PRUSINER SB, 1985, J INFECT DIS, V152, P971, DOI 10.1093/infdis/152.5.971; Randolph TW, 2002, BBA-PROTEIN STRUCT M, V1595, P224, DOI 10.1016/S0167-4838(01)00346-6; Raso J, 2003, CRIT REV FOOD SCI, V43, P265, DOI 10.1080/10408690390826527; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riesner D, 2002, J NEUROVIROL, V8, P8, DOI 10.1080/13550280290101120; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; San Martin MF, 2002, CRIT REV FOOD SCI, V42, P627, DOI 10.1080/20024091054274; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; Taylor DM, 1999, J HOSP INFECT, V43, pS69, DOI 10.1016/S0195-6701(99)90067-1; Taylor DM, 1998, VET MICROBIOL, V64, P33, DOI 10.1016/S0378-1135(98)00257-0; Taylor DM, 1997, VET MICROBIOL, V58, P87, DOI 10.1016/S0378-1135(97)00103-X; Torrent J, 2003, BIOCHEMISTRY-US, V42, P1318, DOI 10.1021/bi0269916; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zahn R, 1999, Q REV BIOPHYS, V32, P309, DOI 10.1017/S0033583500003553	35	26	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9842	9847		10.1074/jbc.M410679200	http://dx.doi.org/10.1074/jbc.M410679200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15598650	hybrid			2022-12-25	WOS:000227559600013
J	Naik, S; Billington, CK; Pascual, RM; Deshpande, DA; Stefano, FP; Kohout, TA; Eckman, DM; Benovic, JL; Penn, RB				Naik, S; Billington, CK; Pascual, RM; Deshpande, DA; Stefano, FP; Kohout, TA; Eckman, DM; Benovic, JL; Penn, RB			Regulation of cysteinyl leukotriene type 1 receptor internalization and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AIRWAY SMOOTH-MUSCLE; KINASE-C; BETA(2)-ADRENERGIC RECEPTOR; THROMBOXANE RECEPTOR; SECRETIN RECEPTOR; CYSLT(1) RECEPTOR; MOLECULAR-CLONING; HEART-FAILURE; PHOSPHORYLATION	Cysteinyl leukotrienes activate the cysteinyl leukotriene type 1 receptor (CysLT1R) to regulate numerous cell functions important in inflammatory processes and diseases such as asthma. Despite its physiologic importance, no studies to date have examined the regulation of CysLT1R signaling or trafficking. We have established model systems for analyzing recombinant human CysLT1R and found regulation of internalization and signaling of the CysLT1R to be unique among G protein-coupled receptors. Rapid and profound LTD4-stimulated internalization was observed for the wild type (WT) CysLT1R, whereas a C-terminal truncation mutant exhibited impaired internalization yet signaled robustly, suggesting a region within amino acids 310-321 as critical to internalization. Although overexpression of WT arrestins significantly increased WT CysLT1R internalization, expression of dominant-negative arrestins had minimal effects, and WT CysLT1R internalized in murine embryonic fibroblasts lacking both arrestin-2 and arrestin-3, suggesting that arrestins are not the primary physiologic regulators of CysLT1Rs. Instead, pharmacologic inhibition of protein kinase C (PKC) was shown to profoundly inhibit CysLT1R internalization while greatly increasing both phosphoinositide (PI) production and calcium mobilization stimulated by LTD4 yet had almost no effect on H1 histamine receptor internalization or signaling. Moreover, mutation of putative PKC phosphorylation sites within the CysLT1R C-tail (CysLT1RS(313-316)A) reduced receptor internalization, increased PI production and calcium mobilization by LTD4, and significantly attenuated the effects of PKC inhibition. These findings characterized the CysLT1R as the first G protein-coupled receptor identified to date in which PKC is the principal regulator of both rapid agonist-dependent internalization and rapid agonist-dependent desensitization.	Wake Forest Univ, Hlth Sci Ctr, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Hlth Sci Ctr, Dept Internal Med, Winston Salem, NC 27157 USA; Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19104 USA; Jefferson Med Coll, Div Pulm & Crit Care Med, Dept Med, Philadelphia, PA 19104 USA; Duke Univ, Ctr Med, Dept Med, Durham, NC USA; Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Jefferson University; Jefferson University; Duke University; Wake Forest University	Penn, RB (corresponding author), Wake Forest Univ, Hlth Sci Ctr, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpenn@wfubmc.edu	Billington, Charlotte/A-2304-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065338, P01HL067663, P50HL067663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM047417] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65338, HL67663] Funding Source: Medline; NIAID NIH HHS [AI059755] Funding Source: Medline; NIGMS NIH HHS [GM47417] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; Billington CK, 2003, RESP RES, V4; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Deshpande DA, 2003, FASEB J, V17, P452, DOI 10.1096/fj.02-0450fje; Drazen JM, 1999, P ASSOC AM PHYSICIAN, V111, P547, DOI 10.1046/j.1525-1381.1999.t01-1-99242.x; Elberg G, 2002, MOL ENDOCRINOL, V16, P2502, DOI 10.1210/me.2002-0207; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Flannery PJ, 2002, PROSTAG OTH LIPID M, V70, P79, DOI 10.1016/S0090-6980(02)00013-8; FOLGATE ST, 2003, J ALLERGY CLIN IMM S, V111, pS18; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; Iacovelli L, 2003, J BIOL CHEM, V278, P12433, DOI 10.1074/jbc.M203992200; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; Johns DC, 1999, J NEUROSCI, V19, P1691; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Koch WJ, 2000, ANNU REV PHYSIOL, V62, P237, DOI 10.1146/annurev.physiol.62.1.237; Koch WJ, 2002, J CARD FAIL, V8, pS526, DOI 10.1054/jcaf.2002.129287; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Lynch KR, 1999, NATURE, V399, P789; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; METTERS KM, 1993, J BIOL CHEM, V268, P6487; Mundell SJ, 2003, J NEUROCHEM, V84, P294, DOI 10.1046/j.1471-4159.2003.01515.x; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Penn RB, 1998, HANDBK PHYS, V1, P125; Peters Stephen P., 2003, Journal of Allergy and Clinical Immunology, V111, pS62, DOI 10.1067/mai.2003.21; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Santini F, 2000, J CELL SCI, V113, P2463; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Shetzline MA, 1998, J BIOL CHEM, V273, P6756, DOI 10.1074/jbc.273.12.6756; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Spurney RF, 1998, J BIOL CHEM, V273, P28496, DOI 10.1074/jbc.273.43.28496; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Tilley SL, 2003, AM J PHYSIOL-LUNG C, V284, pL599, DOI 10.1152/ajplung.00324.2002; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; Yang GC, 2004, AM J PHYSIOL-LUNG C, V286, pL992, DOI 10.1152/ajplung.00367.2003; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	58	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8722	8732		10.1074/jbc.M413014200	http://dx.doi.org/10.1074/jbc.M413014200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590629	hybrid			2022-12-25	WOS:000227453100014
J	Estebanez-Perpina, E; Moore, JMR; Mar, E; Delgado-Rodrigues, E; Nguyen, P; Baxter, JD; Buehrer, BM; Webb, P; Fletterick, RJ; Guy, RK				Estebanez-Perpina, E; Moore, JMR; Mar, E; Delgado-Rodrigues, E; Nguyen, P; Baxter, JD; Buehrer, BM; Webb, P; Fletterick, RJ; Guy, RK			The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; BINDING DOMAIN; TERMINAL INTERACTION; CRYSTAL-STRUCTURE; ACTIVATION; SPECIFICITY; RECOGNITION; REVEALS; MOTIFS; FXXLF	Androgens drive sex differentiation, bone and muscle development, and promote growth of hormone-dependent cancers by binding the nuclear androgen receptor (AR), which recruits coactivators to responsive genes. Most nuclear receptors recruit steroid receptor coactivators ( SRCs) to their ligand binding domain (LBD) using a leucine-rich motif (LXXLL). AR is believed to recruit unique coactivators to its LBD using an aromatic-rich motif (FXXLF) while recruiting SRCs to its N-terminal domain (NTD) through an alternate mechanism. Here, we report that the AR-LBD interacts with both FXXLF motifs and a subset of LXXLL motifs and that contacts with these LXXLL motifs are both necessary and sufficient for SRC-mediated AR regulation of transcription. Crystal structures of the activated AR in complex with both recruitment motifs reveal that side chains unique to the AR-LBD rearrange to bind either the bulky FXXLF motifs or the more compact LXXLL motifs and that AR utilizes subsidiary contacts with LXXLL flanking sequences to discriminate between LXXLL motifs.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Diabet Ctr, San Francisco, CA 94143 USA; Karo Bio USA, Durham, NC 27703 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Guy, RK (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St, San Francisco, CA 94143 USA.	rguy@cgl.ucsf.edu	Guy, Rodney/J-7107-2013; Estebanez-Perpina, Eva/L-4021-2014	Guy, Rodney/0000-0002-9638-2060; Buehrer, Benjamin/0000-0001-6654-4367; Estebanez-Perpina, Eva/0000-0003-2687-5801	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK058080, R01DK058080, R01DK051281] Funding Source: NIH RePORTER; NCI NIH HHS [CA8952] Funding Source: Medline; NIDDK NIH HHS [DK58080, DK51281, R01 DK058080-05, R01 DK058080] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blaszczyk N, 2004, CLIN CANCER RES, V10, P1860, DOI 10.1158/1078-0432.CCR-0974-3; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bourguet W, 2000, PROTEIN EXPRES PURIF, V19, P284, DOI 10.1006/prep.2000.1248; Brunger AT, 1998, CURR OPIN STRUC BIOL, V8, P606, DOI 10.1016/S0959-440X(98)80152-8; Christiaens V, 2002, J BIOL CHEM, V277, P49230, DOI 10.1074/jbc.M209322200; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DeLano W, 2002, PYMOL 0 99; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Gregory CW, 2001, CANCER RES, V61, P4315; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2002, MOL GENET METAB, V75, P293, DOI 10.1016/S1096-7192(02)00009-4; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Legros JJ, 2003, ANN ENDOCRINOL-PARIS, V64, P136; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Liu PY, 2003, ENDOCR REV, V24, P313, DOI 10.1210/er.2003-0005; Ma H, 1999, MOL CELL BIOL, V19, P6164; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moore JMR, 2004, J BIOL CHEM, V279, P27584, DOI 10.1074/jbc.M403453200; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Pike JW, 2002, ADV RENAL REPLACE TH, V9, P168, DOI 10.1053/jarr.2002.34845; Powell SM, 2004, ENDOCR-RELAT CANCER, V11, P117, DOI 10.1677/erc.0.0110117; RIBEIRO RCJ, 1995, ANN NY ACAD SCI, V758, P366, DOI 10.1111/j.1749-6632.1995.tb24843.x; Santos AF, 2004, STEROIDS, V69, P79, DOI 10.1016/j.steroids.2003.10.005; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Slagsvold T, 2000, MOL ENDOCRINOL, V14, P1603, DOI 10.1210/me.14.10.1603; Wang Q, 2001, J BIOL CHEM, V276, P7493, DOI 10.1074/jbc.M009916200; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287	42	123	135	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8060	8068		10.1074/jbc.M407046200	http://dx.doi.org/10.1074/jbc.M407046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15563469	hybrid			2022-12-25	WOS:000227395700076
J	Xie, RY; Zhuang, MB; Ross, LS; Gomez, I; Oltean, DI; Bravo, A; Soberon, M; Gill, SS				Xie, RY; Zhuang, MB; Ross, LS; Gomez, I; Oltean, DI; Bravo, A; Soberon, M; Gill, SS			Single amino acid mutations in the cadherin receptor from Heliothis virescens affect its toxin binding ability to Cry1A toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; CONFERS INSECTICIDE RESISTANCE; THURINGIENSIS CRYIAC TOXIN; SEXTA BT-R-1 RECEPTOR; IN-FIELD POPULATIONS; BACILLUS-THURINGIENSIS; MANDUCA-SEXTA; AMINOPEPTIDASE-N; PINK-BOLLWORM; DOMAIN-II	Bacillus thuringiensis Cry protein exerts its toxic effect through a receptor- mediated process. Both aminopeptidases and cadherin proteins were identified as putative Cry1A receptors from Heliothis virescens and Manduca sexta. The importance of cadherin was implied by its correlation with a Cry1Ac resistant H. virescens strain ( Gahan, L. J., Gould, F., and Heckel, D. G. ( 2001) Science 293, 857 - 860). In this study, the Cry1Ac toxinbinding region in H. virescens cadherin was mapped to a 40- amino- acid fragment, from amino acids 1422 to 1440. This site overlaps with a Cry1Ab toxin- binding site, amino acids 1363 - 1464 recently reported in M. sexta ( Hua, G., Jurat- Fuentes, J. L., and Adang, M. J. ( 2004) J. Biol. Chem. 279, 28051 - 28056). Further, feeding of the anti- H. virescens cadherin antiserum or the partial cadherins, which contain the toxin- binding region, in combination with Cry1Ab/ Cry1Ac reduced insect mortality by 25.5 - 55.6% to first instar H. virescens and M. sexta larvae, suggesting a critical function for this cadherin domain in insect toxicity. Mutations in this region, to which the Cry1Ac binds through its loop 3, resulted in the loss of toxin binding. For the first time, we show that the cadherin amino acids Leu(1425) and Phe(1429) are critical for Cry1Ac toxin interaction, and if substituted with charged amino acids, result in the loss of toxin binding, with a K-D of < 10(-5) M. Mutation of Gln(1430) to an alanine, however, increased the Cry1Ac affinity 10- fold primarily due to an increase on rate. The L1425R mutant can result from a single nucleotide mutation, CTG --> CGG, suggesting that these mutants, which have decreased toxin binding, may lead to Cry1A resistance in insects.	Univ Calif Riverside, Dept Cell Biol & Neurosci, Environm Toxicol Grad Program, Riverside, CA 92521 USA; Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca 62250, Morelos, Mexico	University of California System; University of California Riverside; Universidad Nacional Autonoma de Mexico	Gill, SS (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, Environm Toxicol Grad Program, 5429 Boyce Hall, Riverside, CA 92521 USA.	sarjeet.gill@ucr.edu	de la Parra, Maria Alejandra Bravo/R-6740-2017	Bravo, Alejandra/0000-0002-7573-7475; Xie, Ruiyu/0000-0003-0518-2897				BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BOQUET D, 1995, MOL IMMUNOL, V32, P303, DOI 10.1016/0161-5890(95)00012-4; Bravo A, 2004, BBA-BIOMEMBRANES, V1667, P38, DOI 10.1016/j.bbamem.2004.08.013; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P247, DOI 10.1016/0022-2011(92)90005-O; Carriere Y, 2001, J ECON ENTOMOL, V94, P1571, DOI 10.1603/0022-0493-94.6.1571; COWLES EA, 1995, APPL ENVIRON MICROB, V61, P2738, DOI 10.1128/AEM.61.7.2738-2744.1995; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; Dorsch JA, 2002, INSECT BIOCHEM MOLEC, V32, P1025, DOI 10.1016/S0965-1748(02)00040-1; ffrench-Constant RH, 2004, TRENDS GENET, V20, P163, DOI 10.1016/j.tig.2004.01.003; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; Gill M, 2002, INSECT MOL BIOL, V11, P619, DOI 10.1046/j.1365-2583.2002.00373.x; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GILL SS, 1995, J BIOL CHEM, V270, P27277, DOI 10.1074/jbc.270.45.27277; Gomez I, 2003, BIOCHEMISTRY-US, V42, P10482, DOI 10.1021/bi034440p; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, J BIOL CHEM, V277, P30137, DOI 10.1074/jbc.M203121200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Gould F, 1997, P NATL ACAD SCI USA, V94, P3519, DOI 10.1073/pnas.94.8.3519; Harlow E., 1988, ANTIBODIES LAB MANUA; Hua G, 2004, J BIOL CHEM, V279, P28051, DOI 10.1074/jbc.M400237200; Jenkins JL, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-12; KNIGHT PJK, 1995, J BIOL CHEM, V270, P17765, DOI 10.1074/jbc.270.30.17765; LECADET MM, 1980, J GEN MICROBIOL, V121, P203; Lee MK, 1996, APPL ENVIRON MICROB, V62, P2845, DOI 10.1128/AEM.62.8.2845-2849.1996; Morin S, 2003, P NATL ACAD SCI USA, V100, P5004, DOI 10.1073/pnas.0831036100; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P718, DOI 10.1271/bbb.62.718; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P727, DOI 10.1271/bbb.62.727; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; Newcomb RD, 1997, P NATL ACAD SCI USA, V94, P7464, DOI 10.1073/pnas.94.14.7464; Rajagopal R., 2002, J BIOL CHEM, V107, P1; Rajamohan F, 1996, J BIOL CHEM, V271, P25220, DOI 10.1074/jbc.271.41.25220; Rausell C, 2004, BIOCHEMISTRY-US, V43, P166, DOI 10.1021/bi035527d; Ross LS, 1996, BIOTECHNIQUES, V21, P382; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Tabashnik BE, 2000, P NATL ACAD SCI USA, V97, P12980, DOI 10.1073/pnas.97.24.12980; Tsuda Y, 2003, BIOCHEM J, V369, P697, DOI 10.1042/BJ20021401; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; Valaitis AP, 1995, INSECT BIOCHEM MOLEC, V25, P1143, DOI 10.1016/0965-1748(95)00050-X; Valaitis AP, 2001, ARCH INSECT BIOCHEM, V46, P186, DOI 10.1002/arch.1028; Van Rie J, 2000, INT J MED MICROBIOL, V290, P463; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; Williamson MS, 1996, MOL GEN GENET, V252, P51, DOI 10.1007/BF02173204; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	46	110	131	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8416	8425		10.1074/jbc.M408403200	http://dx.doi.org/10.1074/jbc.M408403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15572369	hybrid			2022-12-25	WOS:000227395700118
J	Chang, JS; Kim, SK; Kwon, TK; Bae, SS; Min, DS; Lee, YH; Kim, SO; Seo, JK; Choi, JH; Suh, PG				Chang, JS; Kim, SK; Kwon, TK; Bae, SS; Min, DS; Lee, YH; Kim, SO; Seo, JK; Choi, JH; Suh, PG			Pleckstrin homology domains of phospholipase C-gamma 1 directly interact with beta-tubulin for activation of phospholipase C-gamma 1 and reciprocal modulation of beta-tubulin function in microtubule assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SIGNALING MOLECULES; GAMMA-SUBUNITS; PH DOMAIN; OVEREXPRESSION; MEMBRANE; BINDS; SEQUENCES	Phosphoinositide-specific phospholipase C-gamma1 (PLC-gamma1) has two pleckstrin homology (PH) domains, an N-terminal domain and a split PH domain. Here we show that pull down of NIH3T3 cell extracts with PLC-gamma1 PH domain-glutathione S-transferase fusion proteins, followed by matrix-assisted laser desorption ionization-time of flight-mass spectrometry, identified beta-tubulin as a binding protein of both PLC-gamma1 PH domains. Tubulin is a main component of microtubules and mitotic spindle fibers, which are composed of alpha- and beta-tubulin heterodimers in all eukaryotic cells. PLC-gamma1 and beta-tubulin colocalized in the perinuclear region in COS-7 cells and cotranslocated to the plasma membrane upon agonist stimulation. Membrane-targeted translocation of depolymerized tubulin by agonist stimulation was also supported by immunoprecipitation analyses. The phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolyzing activity of PLC-gamma1 was substantially increased in the presence of purified tubulin in vitro, whereas the activity was not promoted by bovine serum albumin, suggesting that beta-tubulin activates PLC-gamma1. Furthermore, indirect immunofluorescent microscopy showed that PLC-gamma1 was highly concentrated in mitotic spindle fibers, suggesting that PLC-gamma1 is involved in spindle fiber formation. The effect of PLC-gamma1 in microtubule formation was assessed by overexpression and silencing PLC-gamma1 in COS-7 cells, which resulted in altered microtubule dynamics in vivo. Cells overexpressing PLC-gamma1 showed higher microtubule densities than controls, whereas PLC-gamma1 silencing with small interfering RNAs led to decreased microtubule network densities as compared with control cells. Taken together, our results suggest that PLC-gamma1 and beta-tubulin transmodulate each other, i.e. that PLC-gamma1 modulates microtubule assembly by beta-tubulin, and beta-tubulin promotes PLC-gamma1 activity.	Daejin Univ, Coll Nat Sci, Dept Life Sci, Kyonggi Do 487711, South Korea; Keimyung Univ, Coll Med, Dept Immunol, Taegu 700712, South Korea; Pusan Natl Univ, Coll Med, Dept Pharmacol, Pusan 602739, South Korea; Pusan Natl Univ, Coll Nat Sci, Dept Biol Mol, Pusan 609735, South Korea; Hanyang Univ, Coll Sci & Technol, Div Mol & Life Sci, Kyonggi Do 426791, South Korea; Chem Tech Res Inst, Kyonggi Do 472030, South Korea; Nanodigitech Inc, Monmouth Jct, NJ 08852 USA; Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea	Daejin University; Keimyung University; Pusan National University; Pusan National University; Hanyang University; Pohang University of Science & Technology (POSTECH)	Chang, JS (corresponding author), Daejin Univ, Coll Nat Sci, Dept Life Sci, Kyonggi Do 487711, South Korea.	jchang@daejin.ac.kr	Suh, Pann-Ghill/F-3610-2010; Seo, Jeong Kon/H-4770-2016; Choi, Jang Hyun/B-3055-2012					Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Chang JS, 1996, MOL CELLS, V6, P259; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; Chang JS, 1997, CANCER RES, V57, P5465; Choi JH, 2004, J CELL SCI, V117, P3785, DOI 10.1242/jcs.01220; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Garnier C, 1998, BIOCHEM BIOPH RES CO, V250, P414, DOI 10.1006/bbrc.1998.9319; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Lee IH, 2004, J BIOL CHEM, V279, P26645, DOI 10.1074/jbc.M311525200; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; McNally FJ, 1996, J CELL SCI, V109, P561; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2003, J BIOL CHEM, V278, P34299, DOI 10.1074/jbc.M301748200; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; Tseng HC, 1999, P NATL ACAD SCI USA, V96, P9503, DOI 10.1073/pnas.96.17.9503; Vertessy BG, 1999, BIOCHEM BIOPH RES CO, V254, P430, DOI 10.1006/bbrc.1998.9957; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a	46	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6897	6905		10.1074/jbc.M406350200	http://dx.doi.org/10.1074/jbc.M406350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15579910	Green Published, hybrid			2022-12-25	WOS:000227332700079
J	Misiaszek, R; Uvaydov, Y; Crean, C; Geacintov, NE; Shafirovich, V				Misiaszek, R; Uvaydov, Y; Crean, C; Geacintov, NE; Shafirovich, V			Combination reactions of superoxide with 8-oxo-7,8-dihydroguanine radicals in DNA - Kinetics and end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-MEDIATED OXIDATION; ONE-ELECTRON OXIDATION; MAJOR PRODUCT; TRANSFORMATION REACTIONS; 8-OXOGUANINE OXIDATION; AQUEOUS-SOLUTION; OXALURIC ACID; GUANINE; SPIROIMINODIHYDANTOIN; GUANOSINE	One of the major biomarkers of oxidative stress and oxidative damage of cellular DNA is 8-oxo-7,8-dihydroguanine (8-oxoGua), which is more easily oxidized than guanine to diverse oxidative products. In this work, we have investigated further oxidative transformations of 8-oxoGua in single- and double-stranded oligonucleotides to the dehydroguanidinohydantoin, oxaluric acid, and diastereomeric spiroiminodihydantoin lesions. The relative distributions of these end products were explored by a combined kinetic laser spectroscopy and mass spectrometry approach and are shown to depend markedly on the presence of superoxide radical anions. The 8-oxaGua radicals were produced by one-electron oxidation of 8-oxoGua by 2-aminopurine radicals generated by the two-photon ionization of 2-aminopurine residues site specifically positioned in 5% d(CC[2-aminopurine]TC[8-oxoGua]CTACC). The hydrated electrons also formed in the photoionization process were trapped by dissolved molecular oxygen thus producing superoxide. A combination reaction between the 8-oxoGua and superoxide radicals occurs with the rate constant of (1.3 +/- 0.2) X 10(8) m(-1) s(-1) and (1.0 +/- 0.5) x 10(8) m(-1) s(-1) in single- and double-stranded DNA, respectively. The major end products of this reaction are the dehydroguanidinohydantoin lesions that slowly hydrolyze to oxaluric acid residues. In the presence of Cu,Zn-superoxide dismutase, an enzyme that induces the rapid catalytic dismutation of superoxide to the less reactive H2O2 and O-2, the yields of the dehydroguanidinohydantoin lesions become negligible. Under these conditions, the 8-oxoGua radicals do not exhibit any observable reactivities with oxygen (k < 10(2) M-1 s(-1)), decay on the time interval of several seconds, and the major reaction products are the spiroiminodihydantoin lesions. The possible biological implications of the 8-oxoGua oxidation are discussed.	NYU, Dept Chem, New York, NY 10003 USA; NYU, Radiat & Solid State Lab, New York, NY 10003 USA	New York University; New York University	Shafirovich, V (corresponding author), NYU, Dept Chem, 31 Washington Pl, New York, NY 10003 USA.	vs5@nyu.edu	Crean, Conor/A-6609-2010		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011589] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES11589] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BIELSKI BHJ, 1978, PHOTOCHEM PHOTOBIOL, V28, P645, DOI 10.1111/j.1751-1097.1978.tb06986.x; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Cadet J, 2002, BIOL CHEM, V383, P933, DOI 10.1515/BC.2002.100; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Candeias LP, 2000, CHEM-EUR J, V6, P475, DOI 10.1002/(SICI)1521-3765(20000204)6:3<475::AID-CHEM475>3.0.CO;2-E; DEFELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847, DOI 10.1021/bi00437a049; Duarte V, 2001, CHEM RES TOXICOL, V14, P46, DOI 10.1021/tx0001629; Duarte V, 2000, J AM CHEM SOC, V122, P12622, DOI 10.1021/ja002218r; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Grisham MB, 2000, ALIMENT PHARM THERAP, V14, P3, DOI 10.1046/j.1365-2036.2000.014s1003.x; Halliwell B, 1999, MUTAT RES-GEN TOX EN, V443, P37, DOI 10.1016/S1383-5742(99)00009-5; Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252; Hickerson RP, 1999, J AM CHEM SOC, V121, P9423, DOI 10.1021/ja991929q; Joffe A, 2003, CHEM RES TOXICOL, V16, P1528, DOI 10.1021/tx034142t; JONSSON M, 1993, J PHYS CHEM-US, V97, P8229, DOI 10.1021/j100133a018; Kobayashi K, 2003, J AM CHEM SOC, V125, P10213, DOI 10.1021/ja036211w; Kornyushyna O, 2002, BIOCHEMISTRY-US, V41, P15304, DOI 10.1021/bi0264925; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; Misiaszek R, 2004, J BIOL CHEM, V279, P32106, DOI 10.1074/jbc.M313904200; Niles JC, 2004, CHEM RES TOXICOL, V17, P1510, DOI 10.1021/tx0400048; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; Shafirovich V, 2000, PHYS CHEM CHEM PHYS, V2, P4399, DOI 10.1039/b004896h; Shafirovich V, 1999, J PHYS CHEM B, V103, P10924, DOI 10.1021/jp992002f; Shafirovich V, 2001, CHEM RES TOXICOL, V14, P233, DOI 10.1021/tx000204t; Shafirovich V, 2001, J PHYS CHEM B, V105, P586, DOI 10.1021/jp0029055; SHEN C, 1995, J AM CHEM SOC, V117, P474; Simic M. G., 1986, MECH DNA DAMAGE REPA, V38, P39; Stanbury D. M., 1989, ADV INORG CHEM RA, V33, P69, DOI 10.1016/S0898-8838(08)60194-4; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Steenken S, 2000, J AM CHEM SOC, V122, P2373, DOI 10.1021/ja993508e; Sugden KD, 2001, CHEM RES TOXICOL, V14, P1315, DOI 10.1021/tx010088+; Tretyakova NY, 1999, CHEM RES TOXICOL, V12, P459, DOI 10.1021/tx980235c; Valentine JS, 1999, ADV EXP MED BIOL, V448, P193	38	39	39	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6293	6300		10.1074/jbc.M412253200	http://dx.doi.org/10.1074/jbc.M412253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590679	hybrid			2022-12-25	WOS:000227332700009
J	Mou, TC; Gille, A; Fancy, DA; Seifert, R; Sprang, SR				Mou, TC; Gille, A; Fancy, DA; Seifert, R; Sprang, SR			Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2 '(3 ')-O-(N-methylanthraniloyl)-guanosine 5 '-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; CATALYTIC MECHANISM; NUCLEOSIDE 3-POLYPHOSPHATES; NUCLEOTIDE ANALOGS; CYTOSOLIC DOMAINS; CARDIAC-FUNCTION; HEART-FAILURE; FORSKOLIN; ADENINE; REQUIREMENTS	Membrane-bound mammalian adenylyl cyclase (mAC) catalyzes the synthesis of intracellular cyclic AMP from ATP and is activated by stimulatory G protein a subunits (Galpha(s)) and by forskolin (FSK). mACs are inhibited with high potency by 2'(3')-O-(N-methylanthraniloyl) (MANT)-substituted nucleotides. In this study, the crystal structures of the complex between Galpha(s).GTPgammaS and the catalytic Cl and C2 domains from type V and type II mAC (VC1.IIC2), bound to FSK and either MANT-GTP.Mg2+ or MANT-GTP-Mn2+ have been determined. MANT-GTP coordinates two metal ions and occupies the same position in the catalytic site as P-site inhibitors and substrate analogs. However, the orientation of the guanine ring is reversed relative to that of the adenine ring. The MANT fluorophore resides in a hydrophobic pocket at the interface between the VC1 and IIC2 domains and prevents mAC from undergoing the "open" to "closed" domain rearrangement. The K-i of MANT-GTP for inhibition of VC1.IIC2 is lower in the presence of mAC activators and lower in the presence of Mn2+ compared with Mg2+, indicating that the inhibitor binds more tightly to the catalytically most active form of the enzyme. Fluorescence resonance energy transfer-stimulated emission from the MANT fluorophore upon excitation of Trp-1020 in the MANT-binding pocket of IIC2 is also stronger in the presence of FSK. Mutational analysis of two non-conserved amino acids in the MANT-binding pocket suggests that residues outside of the binding site influence isoform selectivity toward MANT-GTP.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA; Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; Univ Texas, SW Med Ctr, Ctr Biomed Invent, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Kansas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA.	stephen.sprang@utsouthwestern.edu	Seifert, Roland/G-3189-2013; Gille, Andreas/E-1531-2011	Gille, Andreas/0000-0001-5235-8897; Fancy, David A./0000-0001-7786-936X	NIDDK NIH HHS [R01 DK046371, DK46371] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046371, R01DK046371] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; Gille A, 2004, J BIOL CHEM, V279, P19955, DOI 10.1074/jbc.M312560200; Gille A, 2003, J BIOL CHEM, V278, P12672, DOI 10.1074/jbc.M211292200; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; ISHIKAWA Y, 1994, J CLIN INVEST, V93, P2224, DOI 10.1172/JCI117219; Iwatsubo K, 2004, J BIOL CHEM, V279, P40938, DOI 10.1074/jbc.M314238200; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lakowicz J R, 1986, Methods Enzymol, V131, P518; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; Okumura S, 2003, P NATL ACAD SCI USA, V100, P9986, DOI 10.1073/pnas.1733772100; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; SANBE A, 1995, J PHARMACOL EXP THER, V274, P120; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SHAFIQ J, 1992, CIRC RES, V71, P70, DOI 10.1161/01.RES.71.1.70; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Tesmer JJG, 2002, METHOD ENZYMOL, V345, P198; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	41	63	66	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7253	7261		10.1074/jbc.M409076200	http://dx.doi.org/10.1074/jbc.M409076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591060	hybrid			2022-12-25	WOS:000227332700117
J	Lenz, O; Dittmar, MT; Wagner, A; Ferko, B; Vorauer-Uhl, K; Stiegler, G; Weissenhorn, W				Lenz, O; Dittmar, MT; Wagner, A; Ferko, B; Vorauer-Uhl, K; Stiegler, G; Weissenhorn, W			Trimeric membrane-anchored gp41 inhibits HIV membrane fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODY 2F5; FLOW INJECTION TECHNIQUE; ENVELOPE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; POTENT INHIBITORS; TRANSMEMBRANE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; OLIGOMERIC STRUCTURE; ACTIVE CONFORMATION	The HIV-1 envelope glycoprotein is composed of a receptor binding subunit, gp120 that is non-covalently linked to the membrane-anchored fusion protein, gp41. Triggered by cellular receptor binding, the trimeric envelope complex mediates the fusion of viral and cellular membranes through the rearrangement of the fusion protein subunit into a six-helical bundle core structure. Here we describe the biophysical and functional properties of a membrane-anchored fragment of gp41 (gp41ctm) that includes the complete C-terminal heptad repeat region 2, the connecting part, and the transmembrane region. We show that the transmembrane domain of the envelope glycoprotein is sufficient for trimerization in vitro, contributing most of the a-helical content of gp41ctm. Trimeric gp41ctm is protease-resistant and recognizes neutralizing antibodies 2F5 and 4E10. However, gp41ctm and gp41ctm proteoliposomes elicit no clear neutralizing immune responses in preliminary mouse studies. We further show that gp41ctm and surprisingly also gp41ctm proteoliposomes have potent anti-viral activity. Our data suggest that liposome-anchored gp41ctm exerts its inhibitory action outside of the initial fusion contact site, and its implications for the fusion reaction are discussed.	European Mol Biol Lab, F-38042 Grenoble, France; Inst Hyg, Dept Virol, D-69120 Heidelberg, Germany; Inst Appl Microbiol, A-1190 Vienna, Austria	European Molecular Biology Laboratory (EMBL)	Weissenhorn, W (corresponding author), European Mol Biol Lab, 6 Rue Jules Horowitz, F-38042 Grenoble, France.	weissen@embl-grenoble.fr		Vorauer-Uhl, Karola/0000-0003-4217-8846; FERKO, Boris/0000-0001-5340-4437				Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barbato G, 2003, J MOL BIOL, V330, P1101, DOI 10.1016/S0022-2836(03)00611-9; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; BRODER CC, 1994, P NATL ACAD SCI USA, V91, P11699, DOI 10.1073/pnas.91.24.11699; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Center RJ, 1997, J VIROL, V71, P5706, DOI 10.1128/JVI.71.7.5706-5711.1997; Center RJ, 2004, J VIROL, V78, P2265, DOI 10.1128/JVI.78.5.2265-2276.2004; Center RJ, 2001, P NATL ACAD SCI USA, V98, P14877, DOI 10.1073/pnas.261573898; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen B, 2004, J VIROL, V78, P4508, DOI 10.1128/JVI.78.9.4508-4516.2004; Chen B, 2000, J BIOL CHEM, V275, P34946, DOI 10.1074/jbc.M004905200; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Coeffier E, 2000, VACCINE, V19, P684, DOI 10.1016/S0264-410X(00)00267-X; de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004; De Rosny E, 2001, J VIROL, V75, P8859, DOI 10.1128/JVI.75.18.8859-8863.2001; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Eckhart L, 1996, J GEN VIROL, V77, P2001, DOI 10.1099/0022-1317-77-9-2001; Egelhofer M, 2004, J VIROL, V78, P568, DOI 10.1128/JVI.78.2.568-575.2004; Finnegan CM, 2002, J VIROL, V76, P12123, DOI 10.1128/JVI.76.23.12123-12134.2002; Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002; Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000; He Y, 2003, J VIROL, V77, P1666, DOI 10.1128/JVI.77.3.1666-1671.2003; Hildinger M, 2001, J VIROL, V75, P3038, DOI 10.1128/JVI.75.6.3038-3042.2001; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Joyce JG, 2002, J BIOL CHEM, V277, P45811, DOI 10.1074/jbc.M205862200; Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; LARDWHITEFORD SL, 2004, J ACQ IMMUN DEF SYND, V35, P541; Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; Leikina E, 2004, J BIOL CHEM, V279, P26526, DOI 10.1074/jbc.M401883200; Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; Lu J, 2004, J VIROL, V78, P4628, DOI 10.1128/JVI.78.9.4628-4637.2004; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; McGaughey GB, 2003, BIOCHEMISTRY-US, V42, P3214, DOI 10.1021/bi026952u; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Menendez A, 2004, J MOL BIOL, V338, P311, DOI 10.1016/j.jmb.2004.02.051; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Munoz-Barroso I, 1999, J VIROL, V73, P6089; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; PAI EF, 2002, Patent No. 6482928; Parker CE, 2001, J VIROL, V75, P10906, DOI 10.1128/JVI.75.22.10906-10911.2001; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; SALZWEDEL K, 1993, J VIROL, V67, P5279, DOI 10.1128/JVI.67.9.5279-5288.1993; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002; SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Schulke N, 2002, J VIROL, V76, P7760, DOI 10.1128/JVI.76.15.7760-7776.2002; Scianimanico S, 2000, EMBO J, V19, P6732, DOI 10.1093/emboj/19.24.6732; Stiegler G, 2002, AIDS, V16, P2019, DOI 10.1097/00002030-200210180-00006; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tatulian SA, 2000, BIOCHEMISTRY-US, V39, P496, DOI 10.1021/bi991594p; Wagner A, 2002, J LIPOSOME RES, V12, P259, DOI 10.1081/LPR-120014761; Wagner A, 2002, J LIPOSOME RES, V12, P271, DOI 10.1081/LPR-120014762; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; WEISS CD, 1993, J VIROL, V67, P7060, DOI 10.1128/JVI.67.12.7060-7066.1993; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200; Zwick MB, 2004, J VIROL, V78, P3155, DOI 10.1128/JVI.78.6.3155-3161.2004; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	86	36	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4095	4101		10.1074/jbc.M411088200	http://dx.doi.org/10.1074/jbc.M411088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574416	hybrid			2022-12-25	WOS:000227096600014
J	von Wichert, T; Haeussler, U; Greten, FR; Kliche, S; Dralle, H; Bohm, BO; Adler, G; Seufferlein, T				von Wichert, T; Haeussler, U; Greten, FR; Kliche, S; Dralle, H; Bohm, BO; Adler, G; Seufferlein, T			Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells	ONCOGENE			English	Article						IGF-I; cyclin D1; PI3-kinase; neuroendocrine tumours; NF kappa B	GROWTH-FACTOR-I; NF-KAPPA-B; CARCINOID-TUMORS; CANCER-CELLS; ANTISENSE; PATHWAYS; PROMOTER; KINASE	Constitutive expression of cyclin D1 is a frequent abnormality in human cancer and sustains the transformed phenotype. We have previously demonstrated that cyclin D1 is constitutively expressed in human BON neuroendocrine tumour cells due to an autocrine insulin-like growth factor-I (IGF-I) loop. Here we examine the regulation of cyclin D1 expression by endogenously released IGF-I in BON cells. Cyclin D1 expression in these cells was found to be dependent on phosphatidylinositol 3-kinase (PI3-K), but independent of the extracellular signal-regulated kinase cascade. Ras- and Rac-GTPases were found to be upstream activators of cyclin D1 expression, whereas protein kinase B/AKT and nuclear factor kappa B (NFkappaB) could be established as downstream mediators of cyclin D1 transcription in response to endogenously released IGF-I in these cells. In addition, the Ras/PI3-K/AKT/Rac/NFkappaB/ cyclin D1 signaling cascade triggered by endogenously released IGF-I is sufficient to sustain Rb phosphorylation and cdk4 kinase activity in BON cells. In conclusion, our data provide the first comprehensive map of the signaling events elicited by endogenously released IGF-I leading to constitutive cyclin D1 expression in human neuroendocrine tumour cells.	Univ Ulm, Med Klin, Innere Med Abt 1, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med 2, D-89081 Ulm, Germany; Univ Halle Wittenberg, Dept Surg, D-06099 Halle Saale, Germany	Ulm University; Ulm University; Martin Luther University Halle Wittenberg	Seufferlein, T (corresponding author), Univ Ulm, Med Klin, Innere Med Abt 1, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	thomas.seufferlein@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018; Greten, Florian R/AAF-5196-2020; Boehm, Bernhard Otto/F-8750-2015	Greten, Florian R/0000-0002-3928-6080; 				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Oberg K, 2002, CURR OPIN ONCOL, V14, P38, DOI 10.1097/00001622-200201000-00008; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; von Wichert G, 2000, CANCER RES, V60, P4573; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; ZHOU P, 1995, ONCOGENE, V11, P571	20	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1284	1289		10.1038/sj.onc.1208264	http://dx.doi.org/10.1038/sj.onc.1208264			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580291				2022-12-25	WOS:000226898700016
J	Matsumoto, J; Ohshima, T; Isono, O; Shimotohno, K				Matsumoto, J; Ohshima, T; Isono, O; Shimotohno, K			HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein	ONCOGENE			English	Article						HTLV-1; ATL; HBZ; AP-1; c-jun; transcription	VIRUS TYPE-I; HUMAN-PAPILLOMAVIRUS TYPE-16; CELL LEUKEMIA-CELLS; FACTOR-KAPPA-B; TAX PROTEIN; T-CELLS; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE EXPRESSION; INTERLEUKIN-8 GENE; E6 ONCOPROTEIN	Disruption of transcriptional control of cellular genes by human T-cell leukemia virus type-1 (HTLV-1) is thought to be associated, at least in part, with the development of adult T-cell leukemia. It has been reported that activating protein-1 (AP-1) is dysregulated by HTLV-1 infection. HTLV-1-encoded Tax elevates AP-1 activity through the induction of AP-1 family member gene expression, including c-Jun, JunD, c-Fos, and Fra-1. However, the precise mechanism by which HTLV-1 regulates AP-1 activity remains to be addressed. Recently, a novel viral protein named HTLV-1 basic leucine-zipper factor, HBZ, has been shown to interact with c-Jun and repress c-Jun-mediated transcription by abrogating its DNA-binding activity. In the course of investigating HBZ function, we found that HBZ reduced the steady-state levels of c-Jun, and the levels were restored by treatment with a proteasome inhibitor. Together, this indicates that HBZ promotes c-Jun degradation through a proteasome-dependent pathway. Furthermore, HBZ deletion mutants revealed that both the N-terminal and leucine-zipper region of HBZ were required for the elimination of c-Jun. These results suggest dual effects of HBZ on the suppression of AP-1 activity by inhibiting c-Jun function, which may contribute to the dysregulation of cell proliferation.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan.	tohshima@virus.kyoto-u.ac.jp; kshimoto@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fu W, 1997, J NEUROVIROL, V3, P16, DOI 10.3109/13550289709015789; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HOOPER WC, 1991, BIOCHEM BIOPH RES CO, V181, P976, DOI 10.1016/0006-291X(91)92032-F; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016/0006-291X(89)92322-X; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 2000, BLOOD, V95, P3915; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	30	104	110	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1001	1010		10.1038/sj.onc.1208297	http://dx.doi.org/10.1038/sj.onc.1208297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592508				2022-12-25	WOS:000226749200006
J	Daly, NL; Arvanitis, DA; Fairley, JA; Gomez-Roman, N; Morton, JP; Graham, SV; Spandidos, DA; White, RJ				Daly, NL; Arvanitis, DA; Fairley, JA; Gomez-Roman, N; Morton, JP; Graham, SV; Spandidos, DA; White, RJ			Deregulation of RNA polymerase III transcription in cervical epithelium in response to high-risk human papillomavirus	ONCOGENE			English	Article						cervical cancer; human papillomavirus (HPV); RNA polymerase III (pol III); TFIIIB; transcription	TATA-BINDING-PROTEIN; GENE; EXPRESSION; ACTIVATION; CANCER; INTEGRATION; SEQUENCES; TYPE-16; HPV; REPRESSION	RNA polymerase (pol) III transcription is a major determinant of biosynthetic capacity, providing essential products such as tRNA and 5S rRNA. It is controlled directly by the tumour suppressors RB and p53. High-risk types of human papillomavirus (HPV), such as HPV16, express the oncoproteins E6 and E7 that can inactivate p53 and RB, respectively. Accordingly, both E6 and E7 stimulate pol III transcription in cultured cells. HPV16-positive cervical biopsies express elevated levels of tRNA and 5S rRNA when compared to biopsies that test negative for HPV or are infected with the lower risk HPV11. Integration of viral DNA into the host cell genome stimulates expression of E6 and E7 and correlates with induction of tRNA and 5S rRNA. Expression of mRNA encoding the pol III-specific transcription factor Brf1 also correlates with the presence of integrated HPV16. Brf1 levels are limiting for tRNA and 5S rRNA synthesis in cervical cells. Furthermore, pol III-transcribed genes that do not use Brf1 are not induced in HPV16-positive biopsies. Three complementary mechanisms may therefore allow high-risk HPV to stimulate production of tRNA and 5S rRNA: E6-mediated removal of p53; E7-mediated neutralization of RB; and induction of Brf1. The resultant increase in biosynthetic capacity may contribute to deregulated cell growth.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Crete, Sch Med, Virol Lab, Iraklion 71409, Greece	University of Glasgow; University of Crete	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@udcf.gla.ac.uk	Morton, Jennifer P/E-1633-2011; Arvanitis, Demetrios A/J-6434-2017; Morton, Jennifer/AAJ-5113-2021	Morton, Jennifer P/0000-0001-5766-9141; Arvanitis, Demetrios A/0000-0003-1231-320X; Morton, Jennifer/0000-0001-5766-9141; Graham, Sheila/0000-0002-7140-8279; Spandidos, Demetrios/0000-0002-1146-931X; Gomez-Roman, Natividad/0000-0002-2325-7517				Aasen T, 2003, ONCOGENE, V22, P7969, DOI 10.1038/sj.onc.1206709; Alazawi W, 2002, CANCER RES, V62, P6959; ARENDS MJ, 1991, J PATHOL, V165, P301, DOI 10.1002/path.1711650405; BALDWIN P, 2003, NAT REV CANCER, V3, P1; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Clayton DA, 2001, NATURE, V410, P29, DOI 10.1038/35065191; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GEY GO, 1952, CANCER RES, V12, P264; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; KOFFA M, 1994, INT J ONCOL, V5, P189; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; White RJ, 2004, EUR J CANCER, V40, P21, DOI 10.1016/j.ejca.2003.09.027; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WHITE RJ, 2002, RNA POLYM 3 TRANSCRI; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; YEE C, 1985, AM J PATHOL, V119, P361; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	49	33	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					880	888		10.1038/sj.onc.1208031	http://dx.doi.org/10.1038/sj.onc.1208031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592529				2022-12-25	WOS:000226577100014
J	Yoon, T; Chakrabortty, A; Franks, R; Valli, T; Kiyokawa, H; Raychaudhuri, P				Yoon, T; Chakrabortty, A; Franks, R; Valli, T; Kiyokawa, H; Raychaudhuri, P			Tumor-prone phenotype of the DDB2-deficient mice	ONCOGENE			English	Article						DDB2; DNA repair; XP-E; UV-induced tumor; DDB2 knockout mice	DNA-BINDING-PROTEIN; PIGMENTOSUM GROUP-E; NUCLEOTIDE EXCISION-REPAIR; GLOBAL GENOMIC REPAIR; GROUP-E CELLS; XERODERMA-PIGMENTOSUM; DAMAGED-DNA; UBIQUITIN LIGASE; UV-IRRADIATION; ULTRAVIOLET-B	DDB2 is an essential subunit of the damaged-DNA recognition factor DDB, which is involved in global genomic repair in human cells. Moreover, DDB2 is mutated in the repair-deficiency disease xeroderma pigmentosum ( Group E). Expression of DDB2 in human cells is induced by P53, BRCA1 and by ionizing radiation. The DDB2 protein associates with transcriptional activator and coactivator proteins. In addition, DDB2 in conjunction with DDB1 associates with cullin 4A and the Cop9/signalosome. We generated a mouse strain deficient for DDB2 (DDB2-/-). Consistent with the human disease (XP-E), the DDB2-/- mice were susceptible to UV-induced skin carcinogenesis. We observed a significant difference in the initial rate of cyclobutane pyrimidine dimer (CPD)-removal from the skin following UV irradiation. Also, the DDB2-deficient mice exhibited a significantly reduced life span compared to their wild-type littermates. Moreover, unlike other XP-deficient mice, the DDB2-deficient mice developed spontaneous malignant tumors at a high rate between the ages of 20 and 25 months. The observations suggest that, in addition to DNA repair, the other interactions of DDB2 are significant in its tumor suppression function.	Univ Illinois, Dept Biochem & Mol Genet MC 669, Chicago, IL 60607 USA; Univ Illinois, Coll Vet Med, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.	pradip@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NATIONAL CANCER INSTITUTE [R01CA077637, R01CA100204, R01CA088863] Funding Source: NIH RePORTER; NCI NIH HHS [CA 88863, R01 CA088863, 1R01CA100204, R01 CA100204, R01 CA088863-05, R01 CA077637, CA 77637, R01 CA077637-06A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22439; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Inoki T, 2004, BIOCHEM BIOPH RES CO, V314, P1036, DOI 10.1016/j.bbrc.2004.01.003; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Itoh T, 2003, MOL CELL BIOL, V23, P7540, DOI 10.1128/MCB.23.21.7540-7553.2003; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; IWAO K, 1999, NUCL ACIDS S SER, V42, P207; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1993, J BIOL CHEM, V268, P21293; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lu YP, 1999, CANCER RES, V59, P4591; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Nag A, 2001, J VIROL, V75, P10383, DOI 10.1128/JVI.75.21.10383-10392.2001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Wijnhoven SWP, 2000, ONCOGENE, V19, P5034, DOI 10.1038/sj.onc.1203844; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	43	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					469	478		10.1038/sj.onc.1208211	http://dx.doi.org/10.1038/sj.onc.1208211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558025	Green Accepted			2022-12-25	WOS:000226279700017
J	Giangiacomo, L; Ilari, A; Boffi, A; Morea, V; Chiancone, E				Giangiacomo, L; Ilari, A; Boffi, A; Morea, V; Chiancone, E			The truncated oxygen-avid hemoglobin from Bacillus subtilis - X-ray structure and ligand binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-BOND NETWORK; MYCOBACTERIUM-TUBERCULOSIS; ESCHERICHIA-COLI; PROGRAM; MOLSCRIPT; FAMILY; PLANTS; FOLD; SITE	The group II truncated hemoglobin from Bacillus subtilis has been cloned, expressed, purified, and characterized. B. subtilis truncated hemoglobin is a monomeric protein endowed with an unusually high oxygen affinity ( in the nanomolar range) such that the apparent thermodynamic binding constant for O-2 exceeds that for CO by 1 order of magnitude. The kinetic basis of the high oxygen affinity resides mainly in the very slow rate of ligand release. The extremely stable ferrous oxygenated adduct is resistant to oxidation, which can be achieved only with oxidant in large excess, e. g. ferricyanide in 50-fold molar excess. The three-dimensional crystal structure of the cyano-Met derivative was determined at 2.15 Angstrom resolution. Although the overall fold resembles that of other truncated hemoglobins, the distal heme pocket displays a unique array of hydrophilic side chains in the topological positions that dominate the steric interaction with iron-bound ligands. In fact, the Tyr-B10, Thr-E7, and Gln-E11 oxygens on one side of the heme pocket and the Trp-G8 indole NE1 nitrogen on the other form a novel pattern of the "ligand-inclusive hydrogen bond network" described for mycobacterial HbO. On the proximal side, the histidine residue is in an unstrained conformation, and the iron-His bond is unusually short ( 1.91 Angstrom).	Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, Dept Biochem Sci, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Chiancone, E (corresponding author), Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, Dept Biochem Sci, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Ilari, Andrea/T-5501-2017; Ilari, Andrea/AAC-7670-2022; Morea, Veronica/AAS-6881-2020	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Morea, Veronica/0000-0003-2566-3049				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Davydov R, 2003, J AM CHEM SOC, V125, P16340, DOI 10.1021/ja037037e; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Freitas TAK, 2004, P NATL ACAD SCI USA, V101, P6675, DOI 10.1073/pnas.0308657101; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; Karplus K, 2003, PROTEINS, V53, P491, DOI 10.1002/prot.10540; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBETH DO, 1973, J BIOL CHEM, V248, P6059; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson J S, 1981, Methods Enzymol, V76, P631; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ouellet H, 2003, BIOCHEMISTRY-US, V42, P5764, DOI 10.1021/bi0270337; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pathania R, 2002, J BIOL CHEM, V277, P15293, DOI 10.1074/jbc.M111478200; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Samuni U, 2004, J AM CHEM SOC, V126, P2682, DOI 10.1021/ja038093i; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thorsteinsson MV, 1999, BIOCHEMISTRY-US, V38, P2117, DOI 10.1021/bi9819172; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200	35	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9192	9202		10.1074/jbc.M407267200	http://dx.doi.org/10.1074/jbc.M407267200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590662	hybrid			2022-12-25	WOS:000227453100068
J	Karla, A; Lively, MO; Paetzel, M; Dalbey, R				Karla, A; Lively, MO; Paetzel, M; Dalbey, R			The identification of residues that control signal peptidase cleavage fidelity and substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; POTENTIAL ACTIVE-SITE; ESCHERICHIA-COLI; CATALYTIC MECHANISM; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; PROTEIN; REQUIREMENTS; PREDICTION; INHIBITOR	Signal peptidase, which removes signal peptides from preproteins, has a substrate specificity for small uncharged residues at -1(P1) and small or larger aliphatic residues at the -3 (P3) position. Structures of the catalytic domain with a 5S-penem inhibitor and a lipopeptide inhibitor reveal candidate residues that make up the S1 and S3 pockets that bind the P1 and P3 specificity residues of the preprotein substrate. We have used site-directed mutagenesis, mass spectrometric analysis, and in vivo and in vitro activity assays as well as molecular modeling to examine the importance of the substrate pocket residues. Generally, we find that the S1 and S3 binding sites can tolerate changes that are expected to increase or decrease the size of the pocket without large effects on activity. One residue that contributes to the high fidelity of cleavage of signal peptidase is the Ile-144 residue. Changes of the Ile-144 residue to cysteine result in cleavage at multiple sites, as determined by mass spectrometry and Edman sequencing analysis. In addition, we find that signal peptidase is able to cleave after phenylalanine at the -1 residue in a double mutant in which both Ile-86 and Ile-144 were changed to an alanine. Also, alteration of the Ile-144 and Ile-86 residues to the corresponding residues found in the homologous Imp1 protease changes the specificity to promote cleavage following a -1 Asn residue. This work shows that Ile-144 and Ile-86 contribute to the signal peptidase substrate specificity and that Ile-144 is important for the accuracy of the cleavage reaction.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Ohio State University; Wake Forest University; Simon Fraser University	Dalbey, R (corresponding author), Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu		Paetzel, Mark/0000-0002-7408-5487	NIGMS NIH HHS [T32GM08512] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008512] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbrook AC, 1996, FEBS LETT, V398, P198, DOI 10.1016/S0014-5793(96)01239-2; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlos JL, 2000, J BIOL CHEM, V275, P38813, DOI 10.1074/jbc.M007093200; Chen XM, 1999, J BIOL CHEM, V274, P37750, DOI 10.1074/jbc.274.53.37750; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; DELANO WL, 2002, PYMOL ED 0 96; DIERSTEIN R, 1986, EMBO J, V5, P427, DOI 10.1002/j.1460-2075.1986.tb04228.x; FIKES JD, 1990, J BIOL CHEM, V265, P3417; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; Klenotic PA, 2000, J BIOL CHEM, V275, P6490, DOI 10.1074/jbc.275.9.6490; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 2004, J BIOL CHEM, V279, P30781, DOI 10.1074/jbc.M401686200; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; Rugles SW, 2004, J BIOL CHEM, V279, P30751, DOI 10.1074/jbc.M400949200; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; SUNG M, 1992, J BIOL CHEM, V267, P13154; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519	29	26	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6731	6741		10.1074/jbc.M413019200	http://dx.doi.org/10.1074/jbc.M413019200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15598653	hybrid			2022-12-25	WOS:000227332700062
J	Lee, JS; Lee, JJ; Seo, JS				Lee, JS; Lee, JJ; Seo, JS			HSP70 deficiency results in activation of c-Jun N-terminal kinase, extracellular signal-regulated kinase, and caspase-3 in hyperosmolarity-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; SHOCK-PROTEIN HSP70; HEAT-SHOCK; ULTRAVIOLET-LIGHT; PHOSPHATASE MKP-3; CYTOCHROME-C; GENES; PHOSPHORYLATION; DISRUPTION; INSIGHTS	In this study we examined the function of heat shock protein 70 (HSP70) in the hyperosmolarity-induced apoptotic pathway using hsp70.1-/- mouse embryonic fibroblasts (MEFs). When the cells were exposed to hyperosmotic stress, an absence of HSP70 negatively affected cell viability. Caspase-9 and caspase-3 were rapidly activated, and extensive cleavage occurred in focal adhesion and cytoskeletal molecules in the hsp70.1-/- MEFs. In contrast, hsp70.1+/+ MEFs exhibited no caspase-9 or caspase-3 activation and finally recovered intact cell morphology when cells were shifted back to an isosmotic state. Because HSP70 might be involved in the regulation of mitogen-activated protein kinase (MAPK) activities with regard to various cellular activities, we also monitored MAPK phosphorylation. The absence of HSP70 affected c-Jun N-terminal kinase phosphorylation. However, it had no effect on p38. Sustained phosphorylation of extracellular signal-regulated kinase (ERK) was observed during the hyperosmolarity-induced apoptosis of hsp70.1-/- MEFs. Inhibition of ERK activity by the treatment of PD98059 accelerated the apoptotic pathway. ERK phosphorylation was precisely correlated with shift of mitogen-activated protein kinase phosphatase-3 from the soluble to insoluble fraction. Our results demonstrate that the inhibitory effect of HSP70 on caspase-3 activation is sufficient to inhibit apoptosis and that HSP70 exhibits regulatory functions to c-Jun N-terminal kinase and ERK phosphorylation in hyperosmolarity-induced apoptosis.	Seoul Natl Univ, Coll Med, ILCHUN Mol Med Inst, Med Res Ctr, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Lee, JS (corresponding author), Seoul Natl Univ, Coll Med, ILCHUN Mol Med Inst, Med Res Ctr, Seoul 110799, South Korea.	jeongsun@snu.ac.kr	Seo, Jeong-Sun/J-2763-2012					Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Huang L, 2001, MOL CELL BIOL, V21, P8575, DOI 10.1128/MCB.21.24.8575-8591.2001; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Joyeux-Faure M, 2003, CARDIOVASC RES, V60, P469, DOI 10.1016/j.cardiores.2003.08.012; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lee JS, 2002, EXP MOL MED, V34, P131, DOI 10.1038/emm.2002.19; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0	39	92	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6634	6641		10.1074/jbc.M412393200	http://dx.doi.org/10.1074/jbc.M412393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590690	hybrid			2022-12-25	WOS:000227332700049
J	Zhou, JG; Ren, JL; Qiu, QY; He, H; Guan, YY				Zhou, JG; Ren, JL; Qiu, QY; He, H; Guan, YY			Regulation of intracellular Cl- concentration through volume-regulated ClC-3 chloride channels in A10 vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION CHANNELS; EPITHELIAL-CELLS; EXPRESSION; CURRENTS; VOLTAGE; PROLIFERATION; INHIBITION; MYOCYTES; OOCYTES; CLONING	We previously found that antisense oligonucleotide specific to ClC-3 (ClC-3 antisense) prevented rat aortic smooth muscle cell proliferation, which was related to cell volume regulation. In the present study, we further characterized the regulation of intracellular Cl- concentrations ([Cl-](i)) via volume-regulated ClC-3 Cl- channels in an embryo rat aortic vascular smooth muscle cell line (A10 cell) and ClC-3 cDNA-transfected A10 cells (ClC-3-A10) using multiple approaches including [Cl-](i) measurement, whole cell patch clamp, and application of ClC-3 antisense and intracellular dialysis of an anti-ClC-3 antibody. We found that hypotonic solution decreased [Cl-](i) and evoked a native I-Cl.vol in A10 cells. The responses of [Cl-](i) and I-Cl.vol to hypotonic challenge were enhanced by expression of ClC-3, and inhibited by ClC-3 antisense. The currents in A10 (I-Cl.vol) and in ClC-3-A10 cells (ICl.ClC-3) were remarkably inhibited by intracellular dialysis of anti-ClC-3 antibody. Reduction in (Cri, and activation of I-Cl.vol and ICl.ClC-3 in A10 and ClC-3-A10 cells, respectively, were significantly inhibited by activation of protein kinase C (PKC) by phorbol-12,13-dibutyrate (PDBu) and inhibition of tyrosine protein kinase by genistein. Sodium orthovanadate (vanadate), a protein-tyrosine phosphatase inhibitor, however, enhanced the cell swelling-induced reduction in [Cl-](i), accompanied by the activation of I-Cl.vol and ICl.ClC-3 in a voltage-independent manner. Our results suggest that the volume-regulated ClC-3 Cl- channels play important role in the regulation of [Cl-](i), and cell proliferation of vascular smooth muscle cells.	Sun Yat Sen Univ, Zhongshan Med Coll, Dept Pharmacol, Guangzhou 510089, Guangdong, Peoples R China	Sun Yat Sen University	Guan, YY (corresponding author), Sun Yat Sen Univ, Zhongshan Med Coll, Dept Pharmacol, 74 Zhongshan 2 Rd, Guangzhou 510089, Guangdong, Peoples R China.	yyguan@gzsums.edu.cn						Arreola J, 2002, J PHYSIOL-LONDON, V545, P207, DOI 10.1113/jphysiol.2002.021980; BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; Chipperfield AR, 2000, PROG BIOPHYS MOL BIO, V74, P175, DOI 10.1016/S0079-6107(00)00024-9; Clapham DE, 1998, J GEN PHYSIOL, V111, P623, DOI 10.1085/jgp.111.5.623; CocaPrados M, 1996, J MEMBRANE BIOL, V150, P197, DOI 10.1007/s002329900044; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Duan DY, 2001, J PHYSIOL-LONDON, V531, P437, DOI 10.1111/j.1469-7793.2001.0437i.x; Eggermont J, 2001, CELL BIOCHEM BIOPHYS, V35, P263, DOI 10.1385/CBB:35:3:263; Ellershaw DC, 2002, J PHYSIOL-LONDON, V542, P537, DOI 10.1113/jphysiol.2002.018770; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Hermoso M, 2002, J BIOL CHEM, V277, P40066, DOI 10.1074/jbc.M205132200; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Isnard-Bagnis C, 2003, AM J PHYSIOL-CELL PH, V284, pC220, DOI 10.1152/ajpcell.00374.2001; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jin NG, 2003, AM J PHYSIOL-GASTR L, V285, pG938, DOI 10.1152/ajpgi.00470.2002; Lamb FS, 1999, J MOL CELL CARDIOL, V31, P657, DOI 10.1006/jmcc.1998.0901; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411; Martens JR, 1998, P SOC EXP BIOL MED, V218, P192; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Olsen ML, 2003, J NEUROSCI, V23, P5572; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; SARDINI A, 2003, BIOCHIM BIOPHYS ACTA, V1619, P153; Schmieder S, 2001, BIOCHEM BIOPH RES CO, V286, P635, DOI 10.1006/bbrc.2001.5407; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Valverde MA, 1999, CURR OPIN CELL BIOL, V11, P509, DOI 10.1016/S0955-0674(99)80074-X; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; von Weikersthal SF, 1999, J PHYSIOL-LONDON, V516, P75, DOI 10.1111/j.1469-7793.1999.075aa.x; Wang GL, 2002, CIRC RES, V91, pE28, DOI 10.1161/01.RES.0000042062.69653.E4; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Xiao GN, 2002, LIFE SCI, V70, P2233, DOI 10.1016/S0024-3205(02)01508-4; Yamamoto-Mizuma S, 2004, J PHYSIOL-LONDON, V557, P439, DOI 10.1113/jphysiol.2003.059261	39	85	99	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7301	7308		10.1074/jbc.M412813200	http://dx.doi.org/10.1074/jbc.M412813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596438	hybrid			2022-12-25	WOS:000227332700122
J	Kempiak, SJ; Yamaguchi, H; Sarmiento, C; Sidani, M; Ghosh, M; Eddy, RJ; DesMarais, V; Way, M; Condeelis, J; Segall, JE				Kempiak, SJ; Yamaguchi, H; Sarmiento, C; Sidani, M; Ghosh, M; Eddy, RJ; DesMarais, V; Way, M; Condeelis, J; Segall, JE			A neural Wiskott-Aldrich syndrome protein-mediated pathway for localized activation of actin polymerization that is regulated by cortactin.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT NETWORK FORMATION; N-WASP; ARP2/3 COMPLEX; CELL MOTILITY; ADAPTER PROTEIN; FAMILY PROTEINS; NCK; WIP; MECHANISM; MOVEMENT	Activation of the epidermal growth factor (EGF) receptor can stimulate actin polymerization via the Arp2/3 complex using a number of signaling pathways, and specific stimulation conditions may control which pathways are activated. We have previously shown that localized stimulation of EGF receptor with EGF bound to beads results in localized actin polymerization and protrusion. Here we show that the actin polymerization is dependent upon activation of the Arp2/3 complex by neural Wiskott-Aldrich Syndrome protein (N-WASP) via Grb2 and Nck2. Suppression of Grb2 or Nck2 results in loss of localization of N-WASP at the activation site and reduced actin polymerization. Although cortactin has been found to synergize with N-WASP for Arp2/3dependent actin polymerization in vitro, we find that cortactin can restrict N-WASP localization around EGFbead-induced protrusions. In addition, cortactin-deficient cells have increased lamellipod dynamics but show reduced net translocation, suggesting that cortactin can contribute to cell polarity by controlling the extent of Arp2/3 activation by WASP family members and the stability of the F-actin network.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Canc Res UK, Lincolns Inn Fields Labs, London WC2A 3PX, England	Yeshiva University; Albert Einstein College of Medicine; Cancer Research UK	Segall, JE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	segall@aecom.yu.edu	Yamaguchi, Hideki/AAP-1767-2021	Yamaguchi, Hideki/0000-0003-2125-9655; DesMarais, Vera/0000-0002-3714-0248; Way, Michael/0000-0001-7207-2722	NATIONAL CANCER INSTITUTE [R01CA077522, T32CA009475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038511] Funding Source: NIH RePORTER; NCI NIH HHS [CA77522, 5T32-CA09475] Funding Source: Medline; NIDDK NIH HHS [5T32-DK07513] Funding Source: Medline; NIGMS NIH HHS [GM38511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailly M, 2003, CURR BIOL, V13, pR128, DOI 10.1016/S0960-9822(03)00072-1; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Helwani FM, 2004, J CELL BIOL, V164, P899, DOI 10.1083/jcb.200309034; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Kempiak SJ, 2003, J CELL BIOL, V162, P781, DOI 10.1083/jcb.200303144; KEMPIAK SJ, 2004, SCI STKE, V218, P11; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rivera GM, 2004, CURR BIOL, V14, P11, DOI 10.1016/j.cub.2003.12.033; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Sarmiere PD, 2004, J NEUROBIOL, V58, P103, DOI 10.1002/neu.10267; Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Takenawa T, 2001, J CELL SCI, V114, P1801; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Wells A, 2000, ADV CANCER RES, V78, P31; Zalevsky J, 2001, CURR BIOL, V11, P1903, DOI 10.1016/S0960-9822(01)00603-0	41	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5836	5842		10.1074/jbc.M410713200	http://dx.doi.org/10.1074/jbc.M410713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579908	hybrid			2022-12-25	WOS:000227217100087
J	Koivunen, P; Salo, KEH; Myllyharju, J; Ruddock, LW				Koivunen, P; Salo, KEH; Myllyharju, J; Ruddock, LW			Three binding sites in protein-disulfide isomerase cooperate in collagen prolyl 4-hydroxylase tetramer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; FOLDING CATALYST; CAENORHABDITIS-ELEGANS; BACULOVIRUS EXPRESSION; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; BETA-SUBUNIT; B' DOMAIN	Protein-disulfide isomerase (PDI) is a modular polypeptide consisting of four domains, a, b, b', and a'. It is a ubiquitous protein folding catalyst that in addition functions as the beta-subunit in vertebrate collagen prolyl 4-hydroxylase (C-P4H) a(2)beta(2) tetramers. We report here that point mutations in the primary peptide substrate binding site in the b' domain of PDI did not inhibit C-P4H assembly. Based on sequence conservation, additional putative binding sites were identified in the a and a' domains. Mutations in these sites significantly reduced C-P4H tetramer assembly, with the a domain mutations generally having the greater effect. When the a or a' domain mutations were combined with the b' domain mutation I272W tetramer assembly was further reduced, and more than 95% of the assembly was abolished when mutations in the three domains were combined. The data indicate that binding sites in three PDI domains, a, b', and a', contribute to efficient C-P4H tetramer assembly. The relative contributions of these sites were found to differ between Caenorhabditis elegans C-P4H alphabeta dimer and human alpha(2)beta(2) tetramer formation.	Univ Oulu, Dept Biochem, Bioctr, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr, Dept Biochem, FIN-90014 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Ruddock, LW (corresponding author), Univ Oulu, Dept Biochem, Bioctr, Collagen Res Unit, FIN-90014 Oulu, Finland.	lloyd.ruddock@oulu.fi		Ruddock, Lloyd/0000-0002-6247-686X				Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Barnewitz K, 2004, J BIOL CHEM, V279, P39829, DOI 10.1074/jbc.M406839200; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Guddat LW, 1997, PROTEIN SCI, V6, P1148, DOI 10.1002/pro.5560060603; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; Hu SH, 1997, J MOL BIOL, V268, P137, DOI 10.1006/jmbi.1997.0940; JOHN DCA, 1994, BIOCHEMISTRY-US, V33, P14018, DOI 10.1021/bi00251a009; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Klappa P, 2000, J BIOL CHEM, V275, P13213, DOI 10.1074/jbc.275.18.13213; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; Mayer M, 2004, J MOL BIOL, V341, P1077, DOI 10.1016/j.jmb.2004.06.068; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 2002, J BIOL CHEM, V277, P29187, DOI 10.1074/jbc.M203824200; NIETFELD JJ, 1981, BIOCHIM BIOPHYS ACTA, V661, P21, DOI 10.1016/0005-2744(81)90078-4; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x	45	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5227	5235		10.1074/jbc.M412480200	http://dx.doi.org/10.1074/jbc.M412480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590633	hybrid			2022-12-25	WOS:000227217100016
J	Seyfried, NT; McVey, GF; Almond, A; Mahoney, DJ; Dudhia, J; Day, AJ				Seyfried, NT; McVey, GF; Almond, A; Mahoney, DJ; Dudhia, J; Day, AJ			Expression and purification of functionally active hyaluronan-binding domains from human cartilage link protein, aggrecan and versican - Formation of ternary complexes with defined hyaluronan oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM RAT CHONDROSARCOMA; BOVINE NASAL CARTILAGE; ACID OLIGOSACCHARIDES; EXTRACELLULAR-MATRIX; EQUILIBRIUM-BINDING; ARTICULAR-CARTILAGE; PROTEOGLYCAN; MODULE; TSG-6; REGION	The chondroitin sulfate proteoglycan aggrecan forms link protein-stabilized complexes with hyaluronan (RA), via its N-terminal G1-domain, that provide cartilage with its load bearing properties. Similar aggregates (potentially containing new members of the link protein family), in which other chondroitin sulfate proteoglycans (i.e. versican, brevican, and neurocan) substitute for aggrecan, may contribute to the structural integrity of many other tissues including skin and brain. In this study, cartilage link protein (cLP) and the Gl-domains of aggrecan (AG1) and versican (VG1) were expressed in Drosophila S2 cells. The recombinant human proteins were found to have properties similar to those described for the native molecules (e.g. cLP was able to form oligomers, and RA decasaccharides were the minimum size that could compete effectively for their binding to polymeric HA). Gel filtration and protein cross-linking/ matrix-assisted laser desorption ionization time-offlight peptide fingerprinting showed that cLP and AG1 interact in the absence or presence of HA. Conversely, cLP and VG1 did not bind directly to each other in solution yet formed ternary complexes with HA24. Nlinked glycosylation of AG1 and VG1 was demonstrated to he unnecessary for either RA binding or the formation of ternary complexes. Surprisingly, the length of HA required to accommodate two G1-domains was found to be significantly larger for aggrecan than versican, which may reflect differences in the conformation of RA stabilized on binding these proteins.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England	University of Oxford; University of London; University of London Royal Veterinary College	Day, AJ (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	tony.day@bioch.ox.ac.uk	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Dudhia, Jayesh/0000-0002-2503-697X; Almond, Andrew/0000-0001-7471-6333	MRC [MC_U138274352] Funding Source: UKRI; Medical Research Council [MC_U138274352] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Almond A, 1998, J MOL BIOL, V284, P1425, DOI 10.1006/jmbi.1998.2245; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; BERTRAND P, 1985, J NEUROCHEM, V45, P434, DOI 10.1111/j.1471-4159.1985.tb04006.x; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; CATERSON B, 1978, BIOCHEM BIOPH RES CO, V80, P496, DOI 10.1016/0006-291X(78)91596-6; Chu B, 1991, LASER LIGHT SCATTERI; CLELAND RL, 1979, BIOCHEM BIOPH RES CO, V87, P1140, DOI 10.1016/S0006-291X(79)80026-1; Day AJ, 1999, BIOCHEM SOC T, V27, P115, DOI 10.1042/bst0270115; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2001, CURR OPIN STRUC BIOL, V11, P617, DOI 10.1016/S0959-440X(00)00256-6; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DUDHIA J, 1990, NUCLEIC ACIDS RES, V18, P2214, DOI 10.1093/nar/18.8.2214; FALTZ LL, 1979, J BIOL CHEM, V254, P1381; FRANZEN A, 1981, BIOCHEM J, V197, P669, DOI 10.1042/bj1970669; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDINGHAM TE, 1973, BIOCHEM J, V135, P905, DOI 10.1042/bj1350905; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LYON M, 1983, BIOCHEM J, V213, P445, DOI 10.1042/bj2130445; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1995, BIOCHEM J, V307, P595; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; Oohashi T, 2002, MOL CELL NEUROSCI, V19, P43, DOI 10.1006/mcne.2001.1061; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P10708, DOI 10.1021/bi00108a015; Rauch U, 1997, CELL TISSUE RES, V290, P349, DOI 10.1007/s004410050940; Rauch U, 2004, MATRIX BIOL, V22, P629, DOI 10.1016/j.matbio.2003.11.007; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shi SL, 2004, J BIOL CHEM, V279, P12060, DOI 10.1074/jbc.M310091200; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; Sztrolovics R, 2002, J ORTHOPAED RES, V20, P257, DOI 10.1016/S0736-0266(01)00110-3; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TANG LH, 1979, J BIOL CHEM, V254, P523; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; THORNTON DJ, 1987, BIOCHEM J, V248, P943, DOI 10.1042/bj2480943; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	53	75	78	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5435	5448		10.1074/jbc.M411297200	http://dx.doi.org/10.1074/jbc.M411297200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590670	hybrid			2022-12-25	WOS:000227217100041
J	Abazeed, ME; Blanchette, JM; Fuller, RS				Abazeed, ME; Blanchette, JM; Fuller, RS			Cell-free transport from the trans-Golgi network to late endosome requires factors involved in formation and consumption of clathrin-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN RETENTION; TGN LOCALIZATION SIGNAL; KEX2 PROTEASE; SACCHAROMYCES-CEREVISIAE; SORTING RECEPTOR; BINDING-PROTEIN; CYTOSOLIC TAIL; CONTROLS ENTRY; VACUOLAR; COMPARTMENT	Transport between the trans-Golgi network (TGN) and late endosome represents a conserved, clathrin-dependent sorting event that separates lysosomal from secretory cargo molecules and is also required for localization of integral membrane proteins to the TGN. Previously, we reported a cell-free reaction that reconstitutes transport from the yeast TGN to the late endosome/prevacuolar compartment (PVC) and requires the PVC t-SNARE Pep12p. Here, we report that factors required both for formation of clathrin-coated vesicles at the TGN (the Chclp clathrin heavy chain and the Vpslp dynamin homolog) and for vesicle fusion at the PVC (the Vps21p rab protein and Vps45p SM (Sec1/Munc18) protein) are required for cell-free transport. The marker for TGN-PVC transport, Kex2p, is initially present in a clathrin-containing membrane compartment that is competent for delivery of Kex2p to the PVC. A Kex2p chimera containing the cytosolic tail (C-tail) of the vacuolar protein sorting receptor, Vps10p, is also efficiently transported to the PVC. Antibodies against the Kex2p and Vps10p C-tails selectively block transport of Kex2p and the Kex2-Vps10p chimera. The requirements for factors involved in vesicle formation and fusion, the identification of the donor compartment as a clathrin-containing membrane, and the need for accessibility of C-tail sequences argue that the TGN-PVC transport reaction involves selective incorporation of TGN cargo molecules into clathrin-coated vesicle intermediates. Further biochemical dissection of this reaction should help elucidate the molecular requirements and hierarchy of events in TGN-to-PVC sorting and transport.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fuller, RS (corresponding author), Univ Michigan, Dept Biol Chem, 1301 E Catherine Rd, Ann Arbor, MI 48109 USA.	bfuller@umich.edu	Abazeed, Mohamed/AAN-2376-2020	Abazeed, Mohamed/0000-0002-6614-4440	NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039697, R55GM039697, R01GM050915, T32GM007544] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA46592] Funding Source: Medline; NIGMS NIH HHS [GM0786, R01 GM050915, GM07544, GM39697, GM50915, T32 GM007544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1989, METHOD CELL BIOL, V31, P127; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Bensen ES, 2000, GENETICS, V154, P83; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Blanchette JM, 2004, J BIOL CHEM, V279, P48767, DOI 10.1074/jbc.M406368200; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; Brickner JH, 2001, J CELL BIOL, V155, P969, DOI 10.1083/jcb.200104093; Bryant NJ, 2003, J CELL BIOL, V161, P691, DOI 10.1083/jcb.200212078; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Bryant NJ, 1998, EUR J CELL BIOL, V76, P43, DOI 10.1016/S0171-9335(98)80016-2; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Deloche O, 2002, MOL BIOL CELL, V13, P4296, DOI 10.1091/mbc.02-07-0105; Deloche O, 2001, MOL BIOL CELL, V12, P475, DOI 10.1091/mbc.12.2.475; Gerrard SR, 2000, MOL BIOL CELL, V11, P613, DOI 10.1091/mbc.11.2.613; Gerrard SR, 2000, TRAFFIC, V1, P259, DOI 10.1034/j.1600-0854.2000.010308.x; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lemmon MA, 1998, METH MOL B, V84, P49; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Mogelsvang S, 2003, MOL BIOL CELL, V14, P2277, DOI 10.1091/mbc.E02-10-0697; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; Paumet F, 2004, P NATL ACAD SCI USA, V101, P3376, DOI 10.1073/pnas.0400271101; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Pishvaee B, 1997, EMBO J, V16, P2227, DOI 10.1093/emboj/16.9.2227; Redding K, 1996, MOL CELL BIOL, V16, P6208; Redding K, 1996, MOL BIOL CELL, V7, P1667, DOI 10.1091/mbc.7.11.1667; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; Sipos G, 2004, MOL BIOL CELL, V15, P3196, DOI 10.1091/mbc.E03-10-0755; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x	46	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4442	4450		10.1074/jbc.M412553200	http://dx.doi.org/10.1074/jbc.M412553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572353	hybrid			2022-12-25	WOS:000227096600055
J	Cohen, L; Karbat, I; Gilles, N; Ilan, N; Benveniste, M; Gordon, D; Gurevitz, M				Cohen, L; Karbat, I; Gilles, N; Ilan, N; Benveniste, M; Gordon, D; Gurevitz, M			Common features in the functional surface of scorpion beta-toxins and elements that confer specificity for insect and mammalian voltage-gated sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TITYUS-SERRULATUS; NA+-CHANNELS; RECEPTOR-SITES; MOLECULAR-MECHANISMS; CENTRUROIDES-NOXIUS; DOMAIN-II; NEUROTOXIN; BINDING; ACTIVATION; GAMMA	Scorpion beta-toxins that affect the activation of mammalian voltage-gated sodium channels (Na(v)s) have been,studied extensively, but little is known about their functional surface and mode of interaction with the channel receptor. To enable a molecular approach to this question, we have established a successful expression system for the anti-mammalian scorpion beta-toxin, Css4, whose effects on rat brain Navs have been well characterized. A recombinant toxin, His-Css4, was obtained when fused to a His tag and a thrombin cleavage site and had similar binding affinity for and effect on Na currents of rat brain sodium channels as those of the native toxin isolated from the scorpion venom. Molecular dissection of His-Css4 elucidated a functional surface of 1245 Angstrom(2) composed of the following: 1) a cluster of residues associated with the alpha-helix, which includes a putative "hot spot" (this cluster is conserved among scorpion beta-toxins and contains their "pharmaeophore"); 2) a hydrophobic cluster associated mainly with the beta2 and beta3 strands, which is likely to confer the specificity for mammalian Na(v)s; 3) a single bioactive residue (Trp-58) in the C-tail; and 4) a negatively charged residue (Glu-15) involved in voltage sensor trapping as inferred from our ability to uncouple toxin binding from activity upon its substitution. This study expands our understanding about the mode of action of scorpion beta-toxins and illuminates differences in the functional surfaces that may dictate their specificities for mammalian versus insect sodium channels.	Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; CEA, Dept Ingn Etud Prot, CE Saclay, F-91191 Gif Sur Yvette, France	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; CEA	Gordon, D (corresponding author), Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, Sackler Sch Med, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il; mamgur@post.tau.ac.il						ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; BARHANIN J, 1982, J BIOL CHEM, V257, P2553; Benkhalifa R, 1997, LIFE SCI, V61, P819, DOI 10.1016/S0024-3205(97)00564-X; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1979, J BIOL CHEM, V254, P1379; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; COURAUD F, 1982, TOXICON, V20, P9, DOI 10.1016/0041-0101(82)90138-6; DehesaDavila M, 1996, COMP BIOCHEM PHYS B, V113, P331, DOI 10.1016/0305-0491(95)02031-4; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gilles N, 2001, BIOCHEMISTRY-US, V40, P14576, DOI 10.1021/bi010973r; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; Hassani O, 1999, EUR J BIOCHEM, V260, P76, DOI 10.1046/j.1432-1327.1999.00152.x; JAIMOVICH E, 1982, P NATL ACAD SCI-BIOL, V79, P3896, DOI 10.1073/pnas.79.12.3896; JONAS P, 1986, PFLUG ARCH EUR J PHY, V407, P92, DOI 10.1007/BF00580727; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; JOVER E, 1984, BIOCHEMISTRY-US, V23, P1147, DOI 10.1021/bi00301a018; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; Karbat I, 2004, J BIOL CHEM, V279, P31679, DOI 10.1074/jbc.M402048200; LIMA ME, 1989, INSECT BIOCHEM, V19, P413; LIMA ME, 1986, BIOCHEM BIOPH RES CO, V139, P296; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Menez A, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P175; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; Pinheiro CB, 2003, ACTA CRYSTALLOGR D, V59, P405, DOI 10.1107/S090744490202111X; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; RAY R, 1978, J BIOL CHEM, V253, P7307; REED L. J., 1938, AMER JOUR HYG, V27, P493; ROCHAT H, 1977, ANAL BIOCHEM, V82, P532, DOI 10.1016/0003-2697(77)90192-0; Sautiere P, 1998, TOXICON, V36, P1141, DOI 10.1016/S0041-0101(98)00080-4; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Tsushima RG, 1999, PFLUG ARCH EUR J PHY, V437, P661, DOI 10.1007/s004240050830; Turkov M, 1997, PROTEIN EXPRES PURIF, V10, P123, DOI 10.1006/prep.1997.0724; VIJVERBERG HP, 1984, PFLUGERS ARCH, V40, P297; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	47	85	89	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5045	5053		10.1074/jbc.M408427200	http://dx.doi.org/10.1074/jbc.M408427200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569679	hybrid			2022-12-25	WOS:000227096600126
J	Vlahakis, NE; Young, BA; Atakilit, A; Sheppard, D				Vlahakis, NE; Young, BA; Atakilit, A; Sheppard, D			The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha 9 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ATTACHMENT; INTEGRIN ALPHA(9)BETA(1); FACTOR RECEPTOR-2; III REPEAT; MIGRATION; ANGIOGENESIS; FIBRONECTIN; ACTIVATION; MECHANISM; TENASCIN	Mice homozygous for a null mutation of the integrin A subunit die 6-12 days after birth from bilateral chylothoraces suggesting an underlying defect in lymphatic development. However, until now the mechanisms by which the integrin alpha9beta1 modulates lymphangiogenesis have not been described. In this study we show that adhesion to and migration on the lymphangiogenic vascular endothelial growth factors (VEGF-C and -D) are alpha9beta1-dependent. Mouse embryonic fibroblasts and human colon carcinoma cells (SW-480) transfected to express alpha9beta1 adhered and/or migrated on both growth factors in a concentration-dependent fashion, and both adhesion and migration were abrogated by anti-alpha9beta1 function-blocking antibody. In SW-480 cells, which lack cognate receptors for VEGF-C and -D, both growth factors induced alpha9beta1-dependent Erk and paxillin phosphorylation. Human microvascular endothelial cells, which express both alpha9beta1. and VEGF-R3, also adhered to and migrated on both growth factors, and both responses were blocked by anti-alpha9beta1 antibody. Furthermore, in a solid phase binding assay recombinant VEGF-C and -D bound to purified alpha9beta1 integrin in a dose- and cation-dependent fashion showing that VEGF-C and VEGF-D are ligands for the integrin alpha9beta1. The interaction between alpha9beta1 and VEGF-C and/or -D may begin to explain the abnormal lymphatic phenotype of the alpha9 knock-out Mice.	Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Mayo Clin, Coll Med, Thorac Dis Res Unit, Rochester, MN 55905 USA	University of California System; University of California San Francisco; Mayo Clinic	Sheppard, D (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, Box 2922, San Francisco, CA 94143 USA.	deans@itsa.ucsf.edu			NHLBI NIH HHS [R01 HL064353, R01 HL64353] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064353] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Kirkin V, 2001, EUR J BIOCHEM, V268, P5530, DOI 10.1046/j.1432-1033.2001.02476.x; Majumdar M, 2004, J BIOL CHEM, V279, P37528, DOI 10.1074/jbc.M401372200; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; McColl BK, 2003, J EXP MED, V198, P863, DOI 10.1084/jem.20030361; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Smyth SS, 2002, J CELL BIOL, V158, P17, DOI 10.1083/jcb.200202100; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Tsou R, 2001, MOL CELL BIOCHEM, V224, P81, DOI 10.1023/A:1011947301849; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Young BA, 2001, MOL BIOL CELL, V12, P3214, DOI 10.1091/mbc.12.10.3214; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	49	148	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4544	4552		10.1074/jbc.M412816200	http://dx.doi.org/10.1074/jbc.M412816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590642	Green Accepted, hybrid			2022-12-25	WOS:000227096600068
J	Kramer, S; Ozaki, T; Miyazaki, K; Kato, C; Hanamoto, T; Nakagawara, A				Kramer, S; Ozaki, T; Miyazaki, K; Kato, C; Hanamoto, T; Nakagawara, A			Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells	ONCOGENE			English	Article						p53; p73; RanBPM; two-hybrid; ubiquitination	KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; BINDING-PROTEIN; P53-RELATED PROTEIN; INDUCE APOPTOSIS; NUCLEAR-PROTEIN; P53; DEGRADATION; NEUROBLASTOMA	Upon a certain DNA damage including cisplatin treatment, p73 is stabilized and exerts its growth-suppressive and/or proapoptotic function. However, the precise molecular basis by which the intracellular levels of p73 are regulated remains unclear. In the present study, we have identified RanBPM as a novel binding partner of p73alpha by yeast-based two-hybrid screening, and also found that RanBPM has an ability to stabilize p73alpha. GST pull-down assays and co-immunoprecipitation experiments revealed that RanBPM directly bound to the extreme COOH-terminal region of p73alpha, whereas it failed to interact with p53. Co-expression of RanBPM with p73alpha resulted in the nuclear translocation of RanBPM, and both proteins co-localized in cell nucleus as examined by indirect immunofluorescent staining. It is worth noting that the expression of RanBPM inhibited the ubiquitination of p73alpha, and thereby prolonged its half-life. Subsequent studies demonstrated that the proapoptotic activity of p73alpha was significantly enhanced in the presence of RanBPM. Taken together, our present findings implicate a novel role for RanBPM in the regulation of p73 stability and function.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan	Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp						Agami R, 1999, NATURE, V399, P809; Bai D, 2003, BIOCHEM BIOPH RES CO, V309, P552, DOI 10.1016/j.bbrc.2003.08.033; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Goldschneider D, 2004, J CELL SCI, V117, P293, DOI 10.1242/jcs.00834; Gong JG, 1999, NATURE, V399, P806; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lutz W, 2003, BIOCHEM BIOPH RES CO, V303, P1186, DOI 10.1016/S0006-291X(03)00499-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Stiewe T, 2002, CANCER RES, V62, P3598; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wang Y, 2002, BIOCHEM BIOPH RES CO, V297, P148, DOI 10.1016/S0006-291X(02)02020-X; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	33	60	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					938	944		10.1038/sj.onc.1208257	http://dx.doi.org/10.1038/sj.onc.1208257			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558019				2022-12-25	WOS:000226577100019
J	Sato, N; Parker, AR; Fukushima, N; Miyagi, Y; Iacobuzio-Donahue, C; Eshleman, JR; Goggins, M				Sato, N; Parker, AR; Fukushima, N; Miyagi, Y; Iacobuzio-Donahue, C; Eshleman, JR; Goggins, M			Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						methylation; pancreatic cancer; invasion; protease inhibitor	FACTOR PATHWAY INHIBITOR-2; METHYLATION-SPECIFIC PCR; MATRIX-METALLOPROTEINASE EXPRESSION; HUMAN CANCER-CELLS; HUMAN GLIOMAS; CHORIOCARCINOMA CELLS; PROTEASE INHIBITOR; MOLECULAR-CLONING; CPG-ISLANDS; IN-VITRO	Using microarrays, we have screened for genes reactivated by drugs that modify epigenetic mechanisms in pancreatic cancer cells. One of the genes identified was tissue factor pathway inhibitor 2 (TFPI-2), which encodes for a broad-spectrum serine proteinase inhibitor that negatively regulates the extracellular matrix degradation, an essential step in tumor invasion and metastasis. We therefore investigated the expression and methylation patterns of the TFPI-2 gene in pancreatic adenocarcinoma, and determined its role in tumor growth and invasion. In contrast to its abundant expression in normal pancreas, TFPI-2 mRNA was undetectable in a high fraction of pancreatic cancer cell lines and in primary pancreatic ductal neoplasms (IPMNs). Loss of TFPI-2 expression was associated with aberrant hypermethylation of its promoter CpG island. Treatment with the phorbol ester (PMA), known to stimulate the TFPI-2 promoter activity, augmented the TFPI-2 expression in cell lines with unmethylated or partially methylated TFPI-2, but failed to induce the expression in cell lines that harbored fully methylated TFPI-2. Aberrant methylation of TFPI-2 was also detected in 73% (102/140) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas, was more likely in older patients with pancreatic cancer, and significantly correlated with progression of IPMNs (P = 0.0002). Restored expression of the TFPI-2 gene in nonexpressing pancreatic cancer cells resulted in marked suppression in their proliferation, migration, and invasive potential in vitro. We thus conclude that epigenetic inactivation of TFPI-2 is a common mechanism that contributes to the aggressive phenotype of pancreatic ductal adenocarcinoma.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Kanagawa Canc Ctr, Div Tumor Pathol, Yokohama, Kanagawa 2410815, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Kanagawa Prefectural Cancer Center	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave,241-0815, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NCI NIH HHS [CA90709, CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090709, P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Ellenrieder V, 1999, ANN ONCOL, V10, P46, DOI 10.1023/A:1008380501633; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fukushima N, 2003, CANCER BIOL THER, V2, P78; HAHN SA, 1995, CANCER RES, V55, P4670; Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hube F, 2003, BIOL CHEM, V384, P1029, DOI 10.1515/BC.2003.115; Iacobuzio-Donahue CA, 2004, CANCER RES, V64, P871, DOI 10.1158/0008-5472.CAN-03-2756; Izumi H, 2000, FEBS LETT, V481, P31, DOI 10.1016/S0014-5793(00)01902-5; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jin MS, 2001, GYNECOL ONCOL, V83, P325, DOI 10.1006/gyno.2001.6394; Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Miyagi Y, 1996, GENOMICS, V35, P267, DOI 10.1006/geno.1996.0353; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 2003, INT J ONCOL, V22, P843; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka Y, 2004, INVEST OPHTH VIS SCI, V45, P245, DOI 10.1167/iovs.03-0230; Tasiou A, 2001, INT J ONCOL, V19, P591; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wojtukiewicz MZ, 2003, THROMB HAEMOSTASIS, V90, P140	41	121	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					850	858		10.1038/sj.onc.1208050	http://dx.doi.org/10.1038/sj.onc.1208050			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592528				2022-12-25	WOS:000226577100011
J	Nguyen, HD; Hall, CK				Nguyen, HD; Hall, CK			Kinetics of fibril formation by polyalanine peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; PARALLEL BETA-SHEET; X-RAY-DIFFRACTION; AMYLOID FIBRILS; ALZHEIMERS-DISEASE; SUPRAMOLECULAR STRUCTURE; COMPUTER-SIMULATIONS; SECONDARY STRUCTURE; FOLDING PATHWAYS; ALPHA-HELIX	Ordered beta-sheet complexes, termed amyloid fibrils, are the underlying structural components of the intra- and extracellular fibrillar protein deposits that are associated with a variety of human diseases, including Alzheimer's, Parkinson's, and the prion diseases. In this work, we investigated the kinetics of fibril formation using our newly developed off-lattice intermediate resolution model, PRIME. The model is simple enough to allow the treatment of large multichain systems while maintaining a fairly realistic description of protein dynamics without built-in bias toward any conformation when used in conjunction with constant temperature discontinuous molecular dynamics, a fast alternative to conventional molecular dynamics. Simulations were performed on systems containing 48 - 96 model Ac-KA(14)K-NH2 peptides. We found that fibril formation for polyalanines incorporate features that are characteristic of three models, the templated assembly, nucleated polymerization, and nucleated conformational conversion models, but that none of them gave a completely satisfactory description of the simulation kinetics. Fibril formation was nucleation-dependent, occurring after a lag time that decreased with increasing peptide concentration and increased with increasing temperature. Fibril formation appeared to be a conformational conversion process in which small amorphous aggregates --> beta-sheets --> ordered nucleus --> subsequent rapid growth of a small stable fibril or protofilament. Fibril growth in our simulations involved both beta-sheet elongation, in which the fibril grew by adding individual peptides to the end of each beta-sheet, and lateral addition, in which the fibril grew by adding already formed beta-sheets to its side. The initial rate of fibril formation increased with increasing concentration and decreased with increasing temperature.	N Carolina State Univ, Dept Chem & Biomol Engn, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Hall, CK (corresponding author), N Carolina State Univ, Dept Chem & Biomol Engn, Raleigh, NC 27695 USA.	hall@turbo.che.ncsu.edu	Nguyen, Hung/D-5346-2011	Hall, Carol/0000-0002-7425-587X	NIGMS NIH HHS [GM-56766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDER BJ, 1959, J CHEM PHYS, V31, P459, DOI 10.1063/1.1730376; ANDERSEN HC, 1980, J CHEM PHYS, V72, P2384, DOI 10.1063/1.439486; Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Balbach JJ, 2002, BIOPHYS J, V83, P1205, DOI 10.1016/S0006-3495(02)75244-2; BEAVEN GH, 1969, EUR J BIOCHEM, V11, P37, DOI 10.1111/j.1432-1033.1969.tb00735.x; BELLEMANS A, 1980, MOL PHYS, V39, P781, DOI 10.1080/00268978000100671; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Blondelle SE, 1997, BIOCHEMISTRY-US, V36, P8393, DOI 10.1021/bi963015b; Brais B, 1999, SEMIN NEUROL, V19, P59, DOI 10.1055/s-2008-1040826; Burkoth TS, 2000, J AM CHEM SOC, V122, P7883, DOI 10.1021/ja000645z; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Ding F, 2003, PROTEINS, V53, P220, DOI 10.1002/prot.10468; Ding F, 2002, J MOL BIOL, V324, P851, DOI 10.1016/S0022-2836(02)01112-9; Esler WP, 2000, J STRUCT BIOL, V130, P174, DOI 10.1006/jsbi.2000.4276; Fernandez A, 2002, FEBS LETT, V529, P298, DOI 10.1016/S0014-5793(02)03392-6; FOROOD B, 1995, BIOCHEM BIOPH RES CO, V211, P7, DOI 10.1006/bbrc.1995.1770; George AR, 1999, BIOPOLYMERS, V50, P733, DOI 10.1002/(SICI)1097-0282(199912)50:7<733::AID-BIP6>3.0.CO;2-7; Green JD, 2004, J BIOL CHEM, V279, P12206, DOI 10.1074/jbc.M312452200; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Gsponer J, 2003, P NATL ACAD SCI USA, V100, P5154, DOI 10.1073/pnas.0835307100; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harrison PM, 1999, J MOL BIOL, V286, P593, DOI 10.1006/jmbi.1998.2497; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Hwang WM, 2003, J CHEM PHYS, V118, P389, DOI 10.1063/1.1524618; Ilangovan U, 1998, BIOPOLYMERS, V45, P9, DOI 10.1002/(SICI)1097-0282(199801)45:1<9::AID-BIP2>3.0.CO;2-X; Irback A, 2000, P NATL ACAD SCI USA, V97, P13614, DOI 10.1073/pnas.240245297; Jang HB, 2004, PROTEIN SCI, V13, P40, DOI 10.1110/ps.03162804; Jang HB, 2004, BIOPHYS J, V86, P31, DOI 10.1016/S0006-3495(04)74081-3; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARVIS JA, 1993, BIOCHEM BIOPH RES CO, V192, P991, DOI 10.1006/bbrc.1993.1514; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Klimov DK, 2003, STRUCTURE, V11, P295, DOI 10.1016/S0969-2126(03)00031-5; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kortvelyesi T, 2001, J MOL STRUC-THEOCHEM, V545, P215, DOI 10.1016/S0166-1280(01)00422-5; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; Kuwata K, 2003, P NATL ACAD SCI USA, V100, P14790, DOI 10.1073/pnas.2433563100; Lakdawala AS, 2002, J AM CHEM SOC, V124, P15150, DOI 10.1021/ja0273290; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Lynn DG, 2000, J STRUCT BIOL, V130, P153, DOI 10.1006/jsbi.2000.4287; Ma BY, 2002, P NATL ACAD SCI USA, V99, P14126, DOI 10.1073/pnas.212206899; Ma BY, 2002, PROTEIN SCI, V11, P2335, DOI 10.1110/ps.4270102; Mager PP, 1998, MED RES REV, V18, P403, DOI 10.1002/(SICI)1098-1128(199811)18:6<403::AID-MED4>3.0.CO;2-C; Mager PP, 1998, MOL SIMULAT, V20, P201, DOI 10.1080/08927029808024178; Mager PP, 2001, MOL SIMULAT, V26, P367, DOI 10.1080/08927020108024511; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Massi F, 2001, BIOPHYS J, V80, P31, DOI 10.1016/S0006-3495(01)75993-0; Massi F, 2003, J COMPUT CHEM, V24, P143, DOI 10.1002/jcc.10101; Massi F, 2002, PROTEIN SCI, V11, P1639, DOI 10.1110/ps.3150102; Massi F, 2001, BIOPHYS J, V81, P697, DOI 10.1016/S0006-3495(01)75734-7; MGUYEN HD, 2004, PROTEIN SCI, V13, P2909; Moraitakis G, 2003, BIOPHYS J, V84, P2149, DOI 10.1016/S0006-3495(03)75021-8; Nguyen HD, 2004, P NATL ACAD SCI USA, V101, P16180, DOI 10.1073/pnas.0407273101; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; RAPAPORT DC, 1978, J PHYS A-MATH GEN, V11, pL213, DOI 10.1088/0305-4470/11/8/008; RAPAPORT DC, 1979, J CHEM PHYS, V71, P3299, DOI 10.1063/1.438770; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Serpell LC, 2000, J MOL BIOL, V300, P1033, DOI 10.1006/jmbi.2000.3908; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; Smith AV, 2001, PROTEINS, V44, P376, DOI 10.1002/prot.1103; Smith AV, 2001, J MOL BIOL, V312, P187, DOI 10.1006/jmbi.2001.4845; Smith AV, 2001, PROTEINS, V44, P344, DOI 10.1002/prot.1100; Smith SW, 1997, J COMPUT PHYS, V134, P16, DOI 10.1006/jcph.1996.5510; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Straub JE, 2002, ACCOUNTS CHEM RES, V35, P473, DOI 10.1021/ar010031e; SUN SJ, 1993, PROTEIN SCI, V2, P762, DOI 10.1002/pro.5560020508; SUN SJ, 1995, PROTEIN ENG, V8, P769, DOI 10.1093/protein/8.8.769; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Takada S, 1999, J CHEM PHYS, V110, P11616, DOI 10.1063/1.479101; URATANI Y, 1972, J MOL BIOL, V67, P85, DOI 10.1016/0022-2836(72)90388-9; Wilkins DK, 2000, EUR J BIOCHEM, V267, P2609, DOI 10.1046/j.1432-1327.2000.01270.x; Yang MF, 2003, PROTEIN SCI, V12, P1222, DOI 10.1110/ps.0239703; Zanuy D, 2003, BIOPHYS J, V84, P1884, DOI 10.1016/S0006-3495(03)74996-0; Zanuy D, 2003, J MOL BIOL, V329, P565, DOI 10.1016/S0022-2836(03)00491-1; Zhou YQ, 1997, J CHEM PHYS, V107, P10691, DOI 10.1063/1.474186	82	83	87	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9074	9082		10.1074/jbc.M407338200	http://dx.doi.org/10.1074/jbc.M407338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15591317	hybrid			2022-12-25	WOS:000227453100056
J	Chu, M; Guo, JJ; Chen, CY				Chu, M; Guo, JJ; Chen, CY			Long-term exposure to nicotine, via Ras pathway, induces cyclin D1 to stimulate G(1) cell cycle transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SELECTIVE-INHIBITION; RECEPTOR EXPRESSION; SIGNAL-TRANSDUCTION; HA-RAS; PHOSPHORYLATION; GROWTH; ACTIVATION; CANCER; SURVIVAL	Nicotine, a major component in tobacco, has been implicated as a potential factor that promotes the development of lung cancer. However, the molecular mechanism of its action is still unclear. In this study, we have shown that, via nicotinic acetylcholine receptors, persistent exposure of mouse epithelial cells to nicotine elicits Ras signaling and subsequent Raf/MAP kinase activity, accompanied by a significant increase in cyclin D1 promoter activity and its protein expression. AP-1 is required for activation of the cyclin D1 promoter. The induction of cyclin D1 expression and its promoter activity by nicotine is abolished by the suppression of RaVMAP kinase signaling. Furthermore, upon nicotine treatment, the cells do not arrest in the G, phase of the cell cycle following serum starvation. The perturbation of the G, cell cycle checkpoint is caused by the deregulation of retinoblastoma/E2F activity. Therefore, our data indicated that by targeting the Ras pathway, long-term exposure to nicotine disrupts cell cycle restriction machinery and thus potentiates tumor development.	Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University	Chen, CY (corresponding author), Boston Univ, Sch Med, Dept Pathol, K522,80 E Concord St, Boston, MA 02118 USA.	yanyan@bu.edu			NCI NIH HHS [1R01CA100498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1996, ONCOGENE, V12, P1903; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; Brognard J, 2001, CANCER RES, V61, P3986; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cattaneo MG, 1997, BIOCHEM J, V328, P499; CATTANEO MG, 1993, CANCER RES, V53, P5566; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; CHINI B, 1992, P NATL ACAD SCI USA, V89, P1572, DOI 10.1073/pnas.89.5.1572; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FILMUS J, 1994, ONCOGENE, V9, P3627; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; HUBLER L, 1993, MOL CELL BIOL, V13, P6274, DOI 10.1128/MCB.13.10.6274; Itier V, 2001, FEBS LETT, V504, P118, DOI 10.1016/S0014-5793(01)02702-8; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Ma PH, 2002, MOL CELL BIOL, V22, P2928, DOI 10.1128/MCB.22.9.2928-2938.2002; Macklin KD, 1998, J PHARMACOL EXP THER, V287, P435; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Maus ADJ, 1998, MOL PHARMACOL, V54, P779, DOI 10.1124/mol.54.5.779; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; QUIK M, 1994, BRAIN RES, V655, P161, DOI 10.1016/0006-8993(94)91610-1; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MJ, 1992, BLOOD, V79, P2107; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Winston JT, 1996, ONCOGENE, V12, P127; WRIGHT SC, 1993, FASEB J, V7, P1045, DOI 10.1096/fasebj.7.11.8370474; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6369	6379		10.1074/jbc.M408947200	http://dx.doi.org/10.1074/jbc.M408947200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15574422	hybrid			2022-12-25	WOS:000227332700017
J	Muller, FU; Lewin, G; Baba, HA; Boknik, P; Fabritz, L; Kirchhefer, U; Kirchhof, P; Loser, K; Matus, M; Neumann, J; Riemann, B; Schmitz, W				Muller, FU; Lewin, G; Baba, HA; Boknik, P; Fabritz, L; Kirchhefer, U; Kirchhof, P; Loser, K; Matus, M; Neumann, J; Riemann, B; Schmitz, W			Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BHLH TRANSCRIPTION FACTOR; SARCOPLASMIC-RETICULUM CA2+-ATPASE; BETA-ADRENERGIC STIMULATION; CONTRACTILE DYSFUNCTION; NEURAL CREST; SERCA2 GENE; PHOSPHOLAMBAN; PROTEIN; PHOSPHORYLATION; FAILURE	The transcriptional activation mediated by cAMP-response element (CRE) and transcription factors of the CRE-binding protein (CREB)/CRE modulator (CREM) family represents an important mechanism of cAMP-dependent gene regulation possibly implicated in detrimental effects of chronic beta-adrenergic stimulation in end-stage heart failure. We studied the cardiac role of CREM in transgenic mice with heart-directed expression of CREM-IbDeltaC-X, a human cardiac CREM isoform. Transgenic mice displayed atrial enlargement with atrial and ventricular hypertrophy, developed atrial fibrillation, and died prematurely. In vivo hemodynamic assessment revealed increased contractility of transgenic left ventricles probably due to a selective up-regulation of SERCA2, the cardiac Ca2+-ATPase of the sarcoplasmic reticulum. In transgenic ventricles, reduced phosphorylation of phospholamban and of the CREB was associated with increased activity of serine-threonine protein phosphatase 1. The density of beta(1)-adrenoreceptor was increased, and messenger RNAs encoding transcription factor dHAND and small G-protein RhoB were decreased in transgenic hearts as compared with wild-type controls. Our results indicate that heart-directed expression of CREM-IbDeltaC-X leads to complex cardiac alterations, suggesting CREM as a central regulator of cardiac morphology, function, and gene expression.	Univ Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany; Univ Essen Gesamthsch, Dept Pathol, D-45147 Essen, Germany; Univ Munster, Dept Cardiol & Angiol, D-48149 Munster, Germany; Univ Munster, Dept Nucl Med, D-48149 Munster, Germany	University of Munster; University of Duisburg Essen; University of Munster; University of Munster	Muller, FU (corresponding author), Univ Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48149 Munster, Germany.	mullerf@uni-muenster.de	Kirchhof, Paulus/AAT-7074-2021	Kirchhof, Paulus/0000-0002-1881-0197; Fabritz, Larissa/0000-0002-9241-1733				Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; Boknik P, 2001, AM J PHYSIOL-HEART C, V280, pH786, DOI 10.1152/ajpheart.2001.280.2.H786; Boknik P, 2000, N-S ARCH PHARMACOL, V362, P222, DOI 10.1007/s002100000283; Brittsan AG, 2000, J BIOL CHEM, V275, P12129, DOI 10.1074/jbc.275.16.12129; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Felker GM, 2001, AM HEART J, V142, P932, DOI 10.1067/mhj.2001.119611; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Fritz G, 1999, ANTICANCER RES, V19, P1681; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Henderson DJ, 2000, MECH DEVELOP, V95, P211, DOI 10.1016/S0925-4773(00)00333-6; Isoda T, 2003, FASEB J, V17, P144, DOI 10.1096/fj.01-0981com; Ji Y, 2000, J BIOL CHEM, V275, P38073, DOI 10.1074/jbc.M004804200; Kim YK, 2003, J BIOL CHEM, V278, P47622, DOI 10.1074/jbc.M305909200; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Liao P, 2002, CIRC RES, V90, P190, DOI 10.1161/hh0202.104220; *MERIT HF STUD GRO, 2003, JAMA-J AM MED ASSOC, V283, P1295; Mittmann C, 1998, CARDIOVASC RES, V39, P267, DOI 10.1016/S0008-6363(98)00139-4; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; Muller FU, 2000, MOL CELL BIOCHEM, V212, P11, DOI 10.1023/A:1007176030884; Muller FU, 1998, FASEB J, V12, P1191; Muller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje; Muller FU, 2001, CARDIOVASC RES, V52, P95, DOI 10.1016/S0008-6363(01)00361-3; Natarajan A, 2001, J MOL CELL CARDIOL, V33, P1607, DOI 10.1006/jmcc.2001.1434; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Quinn PG, 2002, PROG NUCLEIC ACID RE, V72, P269, DOI 10.1016/S0079-6603(02)72072-2; Ravens U, 2000, CARDIOVASC RES, V45, P245, DOI 10.1016/S0008-6363(99)00338-7; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Russell MW, 1998, BBA-GENE STRUCT EXPR, V1443, P393, DOI 10.1016/S0167-4781(98)00237-1; Schmidt U, 1999, AM J PHYSIOL-HEART C, V277, pH474, DOI 10.1152/ajpheart.1999.277.2.H474; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thattaliyath BD, 2002, J MOL CELL CARDIOL, V34, P1335, DOI 10.1006/jmcc.2002.2085; Tomita H, 2003, CIRC RES, V93, P12, DOI 10.1161/01.RES.0000079794.57578.F1; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Yamazaki T, 1997, CIRCULATION, V95, P1260; Zang MX, 2004, J BIOL CHEM, V279, P54258, DOI 10.1074/jbc.M408502200; Zang MX, 2004, J CELL BIOCHEM, V93, P1255, DOI 10.1002/jcb.20225	48	69	69	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6906	6914		10.1074/jbc.M407864200	http://dx.doi.org/10.1074/jbc.M407864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15569686	hybrid			2022-12-25	WOS:000227332700080
J	Milcamps, A; Tumaney, AW; Paddock, T; Pan, DA; Ohlrogge, J; Pollard, M				Milcamps, A; Tumaney, AW; Paddock, T; Pan, DA; Ohlrogge, J; Pollard, M			Isolation of a gene encoding a 1,2-diacylglycerol-sn-acetyl-CoA acetyltransferase from developing seeds of Euonymus alatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-DIACYLGLYCEROL ACYLTRANSFERASE; ARABIDOPSIS-THALIANA; LIPID-METABOLISM; ACID PRODUCTION; PLANT-TISSUES; FATTY-ACIDS; EXPRESSION; YEAST; TRIACYLGLYCEROL; CLONING	1,2-Diacyl-3-acetyl-sn-glycerols (ac-TAG) are unusual triacylglycerols that constitute the major storage lipid in the seeds of Euonymus alatus (Burning Bush). These acTAGs have long-chain acyl groups esterified at both the sn-1 and sn-2 positions of glycerol. Cell-free extracts of developing seeds of E. alatus contain both long-chain acyl-CoA and acetyl-CoA sn-1,2-diacylglycerol acyltransferase (DGAT) activity. We have isolated a gene from developing seeds of Euonymus alatus that shows a very high sequence similarity to the members of the DGAT1 gene family (ie. related to acyl-CoAcholesterol acyltransferases). This Euonymus DGAT1 gene, when expressed in wild type yeast, results in a 5-fold enhancement of longchain triacylglycerol (Ic-TAG) accumulation, as well as the appearance of low levels of ac-TAG. Hydrogenated ac-TAG molecular species were identified by gas chromatography-mass spectrometry. Microsomes isolated from this transformed yeast show diacylglycerol:acetyl-CoA acetyltransferase activity, which is about 40-fold higher than that measured in microsomes prepared from yeast transformed with the empty vector or with the Arabidopsis thaliana DGAT1 gene. The specific activity of this microsomal acetyltransferase activity is of the same order of magnitude as the microsomal long-chain DGAT activities measured for yeast lines transformed with the empty vector or either the Arabidopsis or Euonymus DGAT1 genes. Despite this, ac-TAG accumulation in yeast transformed with the Euonymus DGATI gene was very low (0.26% of Ic-TAG), whereas Ic-TAG accumulation was enhanced. Possible reasons for this anomaly are discussed. Expression of the Euonymus DGAT1-like gene in yeast lines where endogenous TAG synthesis has been deleted confirmed that the gene product has both long-chain and acetyltransferase activity.	Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University	Pollard, M (corresponding author), Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA.	pollard9@msu.edu		Tumaney, Ajay W./0000-0003-3708-0123				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Auerbach M. H., 1998, Structural modified food fats: synthesis, biochemistry, and use., P89, DOI 10.1201/9781439832103.ch5; Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999; Bouvier-Nave P, 2000, EUR J BIOCHEM, V267, P85, DOI 10.1046/j.1432-1327.2000.00961.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; CAO YZ, 1987, PLANT PHYSIOL, V84, P762, DOI 10.1104/pp.84.3.762; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Cheng D, 2001, BIOCHEM J, V359, P707, DOI 10.1042/0264-6021:3590707; Chung CH, 1996, MOL CELLS, V6, P108; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; FAEGERMAN NJ, 1997, BIOCHEM J, V323, P1; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Hobbs DH, 1999, FEBS LETT, V452, P145, DOI 10.1016/S0014-5793(99)00646-8; Ichihara K, 1996, LIPIDS, V31, P535, DOI 10.1007/BF02522648; ICHIHARA K, 1982, PHYTOCHEMISTRY, V21, P1895, DOI 10.1016/0031-9422(82)83010-0; Jako C, 2001, PLANT PHYSIOL, V126, P861, DOI 10.1104/pp.126.2.861; Kalscheuer R, 2003, J BIOL CHEM, V278, P8075, DOI 10.1074/jbc.M210533200; KLEIMAN R, 1967, LIPIDS, V2, P473, DOI 10.1007/BF02533174; KUO SJ, 1995, J AGR FOOD CHEM, V43, P1775, DOI 10.1021/jf00055a006; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; Limb JK, 1999, J LIPID RES, V40, P2169; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; PADLEY FB, 1986, LIPID HDB, P113; Rattray J. B. M., 1988, MICROBIAL LIPIDS, P555; Reddy AS, 1996, NAT BIOTECHNOL, V14, P639, DOI 10.1038/nbt0596-639; ROSENDAL J, 1992, ANAL BIOCHEM, V207, P63, DOI 10.1016/0003-2697(92)90500-7; Routaboul JM, 1999, PLANT PHYSIOL BIOCH, V37, P831, DOI 10.1016/S0981-9428(99)00115-1; Ruuska SA, 2001, BIOTECHNIQUES, V31, P752, DOI 10.2144/01314bm08; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P217; SMITH RE, 1994, J AGR FOOD CHEM, V42, P432, DOI 10.1021/jf00038a036; TAYLOR FR, 1978, BIOCHIM BIOPHYS ACTA, V575, P204; Tumaney AW, 2004, J PLANT PHYSIOL, V161, P485, DOI 10.1078/0176-1617-01258; Vogel G, 1996, PLANT PHYSIOL, V110, P923, DOI 10.1104/pp.110.3.923; WIBERG E, 1994, PHYTOCHEMISTRY, V36, P573, DOI 10.1016/S0031-9422(00)89777-0; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139; Zou JT, 1999, PLANT J, V19, P645, DOI 10.1046/j.1365-313x.1999.00555.x	39	47	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5370	5377		10.1074/jbc.M410276200	http://dx.doi.org/10.1074/jbc.M410276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579902	hybrid			2022-12-25	WOS:000227217100033
J	Chung, SW; Chen, YH; Perrella, MA				Chung, SW; Chen, YH; Perrella, MA			Role of Ets-2 in the regulation of heme oxygenase-1 by endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; INFLAMMATORY RESPONSES; OXIDATIVE STRESS; CARBON-MONOXIDE; INDUCTION; ACTIVATION; PATHWAY; PROTEIN	Ets proteins play a vital role in the regulation of mammalian immunity, and family members Ets-1 and Ets-2 regulate a variety of genes that participate in the propagation of an inflammatory response. Heme oxygenase (HO)-1, although acutely induced by inflammatory stimuli, has cytoprotective properties and prevents an exaggerated inflammatory response. Ets-1 and Ets-2 both induce HO-1 promoter activity; however, Ets-2 was a more potent transactivator of HO-1 in macrophages. A potent inflammatory mediator, bacterial lipopolysaccharide (LPS), induced Ets-2 at the mRNA and protein level, and this induction preceded the up-regulation of HO-1. To further delineate the role of Ets-2 in regulating HO-1 transcription, we performed HO-1 promoter analysis studies in macrophages. Deletion mutants down to -137/+74 maintained an activity analogous to that of the largest construct, -4045/+74. Further deletion constructs (starting with -117/+74) showed a significant reduction in promoter activity when co-transfected with Ets-2 or exposed to LPS. Promoter sequence analysis revealed two putative Ets binding sites (EBSs) in this region, and mutation of these sites showed that EBS -93, more than EBS -125, was critical for full HO-1 promoter activity. Additional studies showed that EBS -93 binds Ets-2 and that mutation of the DNA binding domain of Ets-2 entirely prevented transactivation. of HO-1. Finally, overexpression of a dominant negative form of Ets-2 blunted HO-1 promoter induction by LPS, and kinase inhibitors (PI3K more than JNK) that reduced Ets-2 expression markedly decreased endogenous HO-1 expression. Our data provide evidence that Ets-2 contributes to the up-regulation of HO-1 by the potent inflammatory stimulus LPS in macrophages.	Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Kaohsiung Med Univ, Div Infect Dis, Dept Internal Med, Kaohsiung 807, Taiwan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaohsiung Medical University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu	Chen, Yen-Hsu/D-5484-2009	Chen, Yen-hsu/0000-0002-8667-4844	NHLBI NIH HHS [HL60788] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Camhi SL, 1998, AM J RESP CELL MOL, V18, P226, DOI 10.1165/ajrcmb.18.2.2910; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Ejima K, 2002, ANTIOXID REDOX SIGN, V4, P569, DOI 10.1089/15230860260220067; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; Perrella MA, 2003, CURR PHARM DESIGN, V9, P2479, DOI 10.2174/1381612033453776; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Sapi E, 1998, CANCER RES, V58, P1027; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015; Wiesel P, 2000, J BIOL CHEM, V275, P24840, DOI 10.1074/jbc.M000835200; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	44	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4578	4584		10.1074/jbc.M409125200	http://dx.doi.org/10.1074/jbc.M409125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590657	hybrid			2022-12-25	WOS:000227096600071
J	Chyung, JH; Raper, DM; Selkoe, DJ				Chyung, JH; Raper, DM; Selkoe, DJ			gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-SURFACE; ALZHEIMERS-DISEASE; BETA-PROTEIN; INTRACELLULAR DOMAIN; GOLGI COMPARTMENTS; DOCKING SITE; PRE-GOLGI; IN-VIVO; PRESENILIN	Research on Alzheimer's disease led to the identification of a novel proteolytic mechanism in all metazoans, the presenilin/gamma-secretase complex. This unique intramembrane-cleaving aspartyl protease is required for the normal processing of Notch, Jagged, beta-amyloid precursor protein (APP), E-cadherin, and many other receptor-like proteins. We recently provided indirect evidence of gamma-secretase activity at the cell surface in HeLa cells following inhibition of receptor-mediated endocytosis. Here, we directly identify and isolate gamma-secretase as an intact complex (Presenilin, Nicastrin, Aph-1, and Pen-2) from the plasma membrane, both in overexpressing cell lines and endogenously. Inhibition of its proteolytic activity allowed cell surface gamma-secretase to be captured in association with its plasma membrane localized APP substrates (C83 and C99). Moreover,.non-denaturing isolation of the intact enzyme complex revealed that cell surface gamma-secretase can specifically generate amyloid P-protein from an APP substrate and similarly cleave a Notch substrate. These data directly establish the proteolytic function of gamma-secretase on the plasma membrane, independent of a hypothesized substrate trafficking role. We conclude that presenilin/gamma-secretase exists as a mature complex at the cell surface, where it interacts with and can cleave its substrates, consistent with an essential function in processing many adhesion molecules and receptors required for cell-cell interaction or intercellular signaling.	Harvard Univ, Sch Med, Inst Med 730, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Selkoe, DJ (corresponding author), Harvard Univ, Sch Med, Inst Med 730, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	Dselkoe@rics.bwh.harvard.edu			NIA NIH HHS [AG 06173, AG15379] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG015379, R01AG006173, R37AG006173] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Berezovska O, 2003, J NEUROSCI, V23, P4560; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P9926, DOI 10.1073/pnas.94.18.9926; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fortna RR, 2004, J BIOL CHEM, V279, P3685, DOI 10.1074/jbc.M310505200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Medina M, 2003, CELL SIGNAL, V15, P829, DOI 10.1016/S0898-6568(03)00041-X; Netzer WJ, 2003, P NATL ACAD SCI USA, V100, P12444, DOI 10.1073/pnas.1534745100; Ramdya P, 2003, J NEUROCHEM, V87, P843, DOI 10.1046/j.1471-4159.2003.02030.x; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Rechards M, 2003, TRAFFIC, V4, P553, DOI 10.1034/j.1600-0854.2003.t01-1-00114.x; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Singh N, 2001, EXP CELL RES, V263, P1, DOI 10.1006/excr.2000.5098; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WONG P, 1997, NATURE, V397, P288; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Yan Q, 2003, J NEUROSCI, V23, P7504; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	54	125	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4383	4392		10.1074/jbc.M409272200	http://dx.doi.org/10.1074/jbc.M409272200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569674	hybrid			2022-12-25	WOS:000227096600048
J	Contreras-Shannon, V; Lin, AP; McCammon, MT; McAlister-Henn, L				Contreras-Shannon, V; Lin, AP; McCammon, MT; McAlister-Henn, L			Kinetic properties and metabolic contributions of yeast mitochondrial and cytosolic NADP(+)-specific isocitrate dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; SACCHAROMYCES-CEREVISIAE; BINDING-SITES; FATTY-ACIDS; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION; DISRUPTION; NADPH; PURIFICATION	To compare kinetic properties of homologous isozymes of NADP(+)-specific isocitrate dehydrogenase, histidine-tagged forms of yeast mitochondrial (IDP1) and cytosolic (IDP2) enzymes were expressed and purified. The isozymes were found to share similar apparent affinities for cofactors. However, with respect to isocitrate, IDP1 had an apparent K-m value similar to7-fold lower than that of IDP2, whereas, with respect to alpha-ketoglutarate, IDP2 had an apparent K-m value similar to10-fold lower than that of IDP1. Similar K-m values for substrates and cofactors in decarboxylation and carboxylation reactions were obtained for IDP2, suggesting a capacity for bidirectional catalysis in vivo. Concentrations of isocitrate and a-ketoglutarate measured in extracts from the parental strain were found to be similar with growth on different carbon sources. For mutant strains lacking IDP1, IDP2, and/or the mitochondrial NAD(+)-specific isocitrate dehydrogenase (IDH), metabolite measurements indicated that major cellular flux is through the IDH-catalyzed reaction in glucose-grown cells and through the IDP2-catalyzed reaction in cells grown with a nonfermentable carbon source (glycerol and lactate). A substantial cellular pool of alpha-ketoglutarate is attributed to IDH function during glucose growth, and to both IDP1 and IDH function during growth on glycerol/lactate. Complementation experiments using a strain lacking IDH demonstrated that overexpression of IDP1 partially compensated for the glutamate auxotrophy associated with loss of IDH. Collectively, these results suggest an ancillary role for IDP1 in cellular glutamate synthesis and a role for IDP2 in equilibrating and maintaining cellular levels of isocitrate and alpha-ketoglutarate.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017477] Funding Source: NIH RePORTER; NIA NIH HHS [AG17477] Funding Source: Medline; NIGMS NIH HHS [GM51265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BARNES LD, 1972, BIOCHEMISTRY-US, V11, P4322, DOI 10.1021/bi00773a019; BERGMEYER H, 1983, METHOD ENZYMAT AN, V1, P1577; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Contreras-Shannon V, 2004, ARCH BIOCHEM BIOPHYS, V423, P235, DOI 10.1016/j.abb.2003.12.038; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; DeLuna A, 2001, J BIOL CHEM, V276, P43775, DOI 10.1074/jbc.M107986200; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; GOTHAM SM, 1988, ANAL BIOCHEM, V173, P353, DOI 10.1016/0003-2697(88)90199-6; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Hiltunen JK, 2003, FEMS MICROBIOL REV, V27, P35, DOI 10.1016/S0168-6445(03)00017-2; Hodges M, 2003, PLANT PHYSIOL BIOCH, V41, P577, DOI 10.1016/S0981-9428(03)00062-7; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; Koh HJ, 2004, J BIOL CHEM, V279, P39968, DOI 10.1074/jbc.M402260200; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Lin AP, 2003, J BIOL CHEM, V278, P12864, DOI 10.1074/jbc.M300154200; Lin AP, 2002, J BIOL CHEM, V277, P22475, DOI 10.1074/jbc.M202534200; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; McCammon MT, 2003, ARCH BIOCHEM BIOPHYS, V419, P222, DOI 10.1016/j.abb.2003.08.022; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; Minard KI, 1998, J BIOL CHEM, V273, P31486, DOI 10.1074/jbc.273.47.31486; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palmieri L, 2000, J BIOENERG BIOMEMBR, V32, P67, DOI 10.1023/A:1005564429242; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; RYDSTROM J, 1976, ENZYMES, V13, P1; SIKORSKI RS, 1989, GENETICS, V122, P19; Sols A., 1971, YEASTS, P271; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Uemura H, 1999, J BACTERIOL, V181, P4719, DOI 10.1128/JB.181.15.4719-4723.1999; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811; Zhao WN, 1996, BIOCHEMISTRY-US, V35, P7873, DOI 10.1021/bi9605189	51	28	29	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4469	4475		10.1074/jbc.M410140200	http://dx.doi.org/10.1074/jbc.M410140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574419	hybrid			2022-12-25	WOS:000227096600058
J	Hausmann, S; Shuman, S				Hausmann, S; Shuman, S			Specificity and mechanism of RNA cap guanine-N2 methyltransferase (Tgs1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS; CAPPING ENZYME; DOMAIN; HYPERMETHYLATION; REQUIRES; BINDING; PROTEIN; SNRNAS	The 2,2,7-trimethylguanosine (TMG) cap structure is characteristic of certain eukaryotic small nuclear and small nucleolar RNAs. Prior studies have suggested that cap trimethylation might be contingent on cis-acting elements in the RNA substrate, protein components of a ribonucleoprotein complex, or intracellular localization of the RNA substrate. However, the enzymatic requirements for TMG cap formation remain obscure because TMG synthesis has not been reconstituted in vitro from defined components. Tgs1 is a conserved eukaryal protein that was initially identified as being required for RNA cap trimethylation in vivo in budding yeast. Here we show that purified recombinant fission yeast Tgs1 catalyzes methyl transfer from S-adenosylmethionine (AdoMet) to m(7)GTP and m(7)GDP. Tgs1 also methylates the cap analog m(7)GpppA but is unreactive with GTP, GDP, GpppA, m(2,2,7)GTP, M-2,M-2,M-7 GDP, ATP, CTP, UTP, and ITP. The products of methyl transfer to m 7 GTP and m 7 GDP formed under conditions of excess methyl acceptor are 2,7-dimethyl GTP and 2,7-dimethyl GDP, respectively. Under conditions of limiting methyl acceptor, the initial M2,7 GDP product is converted to M2,2,7 GDP in the presence of excess AdoMet. We conclude that Tgs1 is guanine-specific, that N7 methylation must precede N2 methylation, that Tgs1 acts via a distributive mechanism, and that the chemical steps of TMG synthesis do not require input from RNA or protein cofactors.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org						Armengaud J, 2004, J BIOL CHEM, V279, P37142, DOI 10.1074/jbc.M403845200; BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BUSCH H, 1982, ANNU REV BIOCHEM, V51, P617, DOI 10.1146/annurev.bi.51.070182.003153; Constantinesco F, 1999, J MOL BIOL, V291, P375, DOI 10.1006/jmbi.1999.2976; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Mao XD, 1996, MOL CELL BIOL, V16, P475; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mouaikel J, 2003, NUCLEIC ACIDS RES, V31, P4899, DOI 10.1093/nar/gkg656; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Speckmann WA, 2000, NUCLEIC ACIDS RES, V28, P4467, DOI 10.1093/nar/28.22.4467; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x	16	36	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4021	4024		10.1074/jbc.C400554200	http://dx.doi.org/10.1074/jbc.C400554200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590684	hybrid			2022-12-25	WOS:000227096600005
J	Iwatsuki, K; Tanaka, K; Kaneko, T; Kazama, R; Okamoto, S; Nakayama, Y; Ito, Y; Satake, M; Takahashi, S; Miyajima, A; Watanabe, T; Hara, T				Iwatsuki, K; Tanaka, K; Kaneko, T; Kazama, R; Okamoto, S; Nakayama, Y; Ito, Y; Satake, M; Takahashi, S; Miyajima, A; Watanabe, T; Hara, T			Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3	ONCOGENE			English	Article						angiogenesis; endothelial cell; IGFBP-3; Runx1; transcriptional repression	GONAD-MESONEPHROS REGION; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; ACUTE MYELOID-LEUKEMIA; ENDOTHELIAL-CELLS; GENE-TRANSCRIPTION; CORPUS-LUTEUM; MOUSE EMBRYO; STEM-CELLS; EXPRESSION; AML1	Mouse embryos lacking the Runx1 transcription factor exhibit an angiogenic defect accompanied by the absence of hematopoietic stem cells ( HSCs). To ask whether Runx1 plays a direct role in angiogenesis, we established a novel endothelial progenitor cell line, designated AEL-DeltaR1, from the aorta-gonad-mesonephros ( AGM) region of Runx1-null mouse. We introduced Runx1 cDNA into AEL-DeltaR1 cells under the doxycycline-inducible promoter. The ability of AEL-DeltaR1 cells to form vascular networks on matrigel was highly enhanced by the restored expression of Runx1. By molecular comparison of mRNAs in AEL-DeltaR1 cells before and after the induction of Runx1, we found that mRNA expression of insulin-like growth factor-binding protein 3 (IGFBP-3) is downregulated by Runx1. Gel retardation and reporter assays revealed that Runx1 binds to the promoter region of mouse IGFBP-3 gene and represses its transcription. When IGFBP-3 was exogenously added in the matrigel assay, the angiogenesis-enhancing activity of Runx1 was suppressed in a dose-dependent manner. These results demonstrate that Runx1 is directly involved in angiogenesis by repression of IGFBP-3 mRNA expression.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Biochem, Tokyo Metropolitan Org Med Res, Bunkyo Ku, Tokyo 1138613, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Tokyo Metropolitan Institute of Medical Science; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Tohoku University; University of Tokyo; University of Tokyo	Hara, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Biochem, Tokyo Metropolitan Org Med Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	thara@rinshoken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527; Takahashi, Shin-Ichiro/0000-0002-2323-2010				BAE SC, 1993, ONCOGENE, V8, P809; Bertrand-Philippe M, 2004, J BIOL CHEM, V279, P24530, DOI 10.1074/jbc.M311804200; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Delafontaine P, 1996, BIOCHEM BIOPH RES CO, V222, P478, DOI 10.1006/bbrc.1996.0769; ERICKSON GF, 1993, ENDOCRINOLOGY, V133, P1147, DOI 10.1210/en.133.3.1147; Erondu NE, 1996, GROWTH REGULAT, V6, P1; Erondu NE, 1997, ENDOCRINOLOGY, V138, P2856, DOI 10.1210/en.138.7.2856; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 1998, HUM REPROD, V13, P2180, DOI 10.1093/humrep/13.8.2180; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Gucev ZS, 1996, CANCER RES, V56, P1545; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Iwatsuki K, 2000, BIOL REPROD, V62, P1352, DOI 10.1095/biolreprod62.5.1352; Javed A, 2000, J CELL SCI, V113, P2221; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; Keller G, 1999, EXP HEMATOL, V27, P777, DOI 10.1016/S0301-472X(99)00024-7; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; LEE GH, 1995, AM J PATHOL, V147, P1811; Lee WH, 1999, ENDOCRINE, V11, P181, DOI 10.1385/ENDO:11:2:181; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OLNEY RC, 1995, J ENDOCRINOL, V146, P279, DOI 10.1677/joe.0.1460279; Ongeri EM, 2004, ENDOCRINOLOGY, V145, P1776, DOI 10.1210/en.2003-1552; Schmid MC, 2003, INT J CANCER, V103, P577, DOI 10.1002/ijc.10874; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Sun LX, 2001, CANCER RES, V61, P4994; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tamura H, 2002, EXP HEMATOL, V30, P957, DOI 10.1016/S0301-472X(02)00822-6; Tanaka K, 2002, DEV BIOL, V246, P466, DOI 10.1006/dbio.2002.0671; Tucci M, 1998, J ENDOCRINOL, V157, P13, DOI 10.1677/joe.0.1570013; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	53	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1129	1137		10.1038/sj.onc.1208287	http://dx.doi.org/10.1038/sj.onc.1208287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592512				2022-12-25	WOS:000226898700001
J	Laxman, S; Rascon, A; Beavo, JA				Laxman, S; Rascon, A; Beavo, JA			Trypanosome cyclic nucleotide phosphodiesterase 2B binds cAMP through its GAF-A domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CGMP-BINDING; SWISS-MODEL; BRUCEI; CLONING; DIFFERENTIATION; PURIFICATION; SUBUNIT; SITES; GENE	Trypanosoma brucei, the causative agent of sleeping sickness in humans and livestock, expresses at least three cAMP-specific class I phosphodiesterases (PDEs), all of which are essential for survival of the parasite. These PDEs have either one or two N-terminal GAF domains, which in other proteins function as signaling domains. However, neither the functional roles nor ligands for these domains in trypanosome PDEs are known. The present study shows that TbPDE2B, which contains two tandem GAF domains, binds cAMP with high affinity through its GAF-A domain. A purified recombinant N terminus + GAF-A domain binds cAMP with an affinity (K-i) of similar to16 nM. It also binds cGMP but with a 15-fold lower affinity of similar to275 nM. The TbPDE2B holoenzyme; has a somewhat lower affinity (similar to55 nM) for cAMP but a greatly lower affinity (similar to10 muM) for cGMP. This suggests that both the selectivity and affinity for a ligand can be determined not only by the nature of the binding domain but also by the adjacent domains. Additionally, binding of cAMP to the holoenzyme showed positive cooperativity, with a Hill coefficient value of 1.75. However, binding of cGMP to the holoenzyme did not show any cooperativity, suggesting differences in the conformational changes caused by binding of these two cyclic nucleotides with the protein. Point mutation of a key predicted binding site residue (T317A) resulted in a complete loss of high affinity cAMP binding. This mutation increased the apparent K-m of the mutant enzyme for substrate without altering the V-max. A truncated catalytic domain construct of TbPDE2B also exhibited an increased K-m, strongly suggesting that cAMP binding to the GAF-A domain can regulate TbPDE2B by allowing the full activity of the enzyme to be expressed. These properties of the GAF-A domain of TbPDE2B thus suggest that it could be a new target for anti-trypanosomal drugs.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Cent Univ Venezuela, Inst Expt Biol, Caracas 1041A, Venezuela	University of Washington; University of Washington Seattle; University of Central Venezuela	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	beavo@u.washington.edu	Laxman, Sunil/F-9886-2018	Laxman, Sunil/0000-0002-0861-5080	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44948] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1977, BIOCHEM J, V161, P653, DOI 10.1042/bj1610653; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; Huang H, 2002, INT J PARASITOL, V32, P1107, DOI 10.1016/S0020-7519(02)00085-1; HURLEY JH, 2003, SCI STKE R003; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Keiser J, 2001, TRENDS PARASITOL, V17, P42, DOI 10.1016/S1471-4922(00)01829-8; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Martinez Sergio E, 2002, Mol Interv, V2, P317, DOI 10.1124/mi.2.5.317; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; Meima M, 1999, SEMIN CELL DEV BIOL, V10, P567, DOI 10.1006/scdb.1999.0340; Meima ME, 2003, J BIOL CHEM, V278, P14356, DOI 10.1074/jbc.M209648200; Naula C, 2000, PARASITOL TODAY, V16, P35, DOI 10.1016/S0169-4758(99)01582-3; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; Rascon A, 2002, P NATL ACAD SCI USA, V99, P4714, DOI 10.1073/pnas.002031599; REED SL, 1985, INFECT IMMUN, V49, P844, DOI 10.1128/IAI.49.3.844-847.1985; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SEGEL IH, 1975, ENZYME KINETICS, P398; Shalaby T, 2001, EUR J BIOCHEM, V268, P6197, DOI 10.1046/j.0014-2956.2001.02564.x; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STRICKLER JE, 1975, SCIENCE, V190, P1110, DOI 10.1126/science.171773; STROOP SD, 1991, J BIOL CHEM, V266, P23802; Vassella E, 1997, J CELL SCI, V110, P2661; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267; Zoraghi R, 2002, P NATL ACAD SCI USA, V99, P4343, DOI 10.1073/pnas.062716599; Zoraghi R, 2001, J BIOL CHEM, V276, P11559, DOI 10.1074/jbc.M005419200	38	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3771	3779		10.1074/jbc.M408111200	http://dx.doi.org/10.1074/jbc.M408111200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15563461	hybrid			2022-12-25	WOS:000226983900078
J	Noti, JD; Johnson, AK; Dillon, JD				Noti, JD; Johnson, AK; Dillon, JD			The leukocyte integrin gene CD11d is repressed by gut-enriched Kruppel-like factor 4 in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER REPRESSOR; TRANSCRIPTION FACTOR; IN-VIVO; PROMOTER ACTIVITY; DNA-DAMAGE; RB PROTEIN; ALPHA-D; SP1; EXPRESSION; BINDS	'The myeloid-specific leukocyte integrin CD11d encodes the a, subunit for the alpha(D)beta(2) receptor. A yeast one-hybrid screen showed that a longer isoform of gut-enriched Kruppel-like factor 4 (GKLF) we term GKLFa interacts with the CD11d promoter. Purified GST-GIKLFa protein was shown to bind within the -61 to -44 region that overlaps a binding site for the CD11d transcriptional activators Sp1 and transforming growth factor beta-inducible early gene-1 (TIEG1). Transfection of GKLF/GKLFa in myeloid cells reduced CD11d promoter activity, whereas, down-regulation of GKLF/GKLFa with small interfering RNAs led to up-regulation of CD11d expression. Differentiation of myeloid cells with phorbol ester led to activation of the CD11d promoter and reduced occupancy of the promoter by GKLF/GKLFa but an increased occupancy by TIEG1 in vivo. Binding of GKLF/GKLFa, Sp1, and TIEG1 to the CD11d promoter in vivo is dependent on their zinc finger DNA binding domains. GKLFa physically associates with the histone deacetylases (HDAC) 1 and 2, and both HDACs are bound to the CD11d promoter in vivo but released after exposure of myeloid cells to phorbol ester suggesting that GKLF/GKLFa recruits HDACs to effect repression.	Guthrie Fdn Educ & Res, Sayre, PA 18840 USA		Noti, JD (corresponding author), Guthrie Fdn Educ & Res, Sayre, PA 18840 USA.	noti_john@guthrie.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063891] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL63891] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bauer TR, 2000, CURR OPIN MOL THER, V2, P383; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; ElGabalawy H, 1996, ARTHRITIS RHEUM-US, V39, P1913, DOI 10.1002/art.1780391119; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Imhof A, 1999, MOL CELL BIOL, V19, P194; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KURZINGER K, 1981, J IMMUNOL, V127, P596; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; Noti JD, 2004, J BIOL CHEM, V279, P26948, DOI 10.1074/jbc.M310634200; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Noti JD, 2002, INT J MOL MED, V10, P721; Noti JD, 1996, MOL CELL BIOL, V16, P2940; NOTI JD, 2003, CURR GENOMICS, V4; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Park H, 2003, BLOOD, V101, P894, DOI 10.1182/blood-2002-03-0680; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Shanley TP, 1998, J IMMUNOL, V160, P1014; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1986, J IMMUNOL, V136, P240; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	50	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3449	3457		10.1074/jbc.M412627200	http://dx.doi.org/10.1074/jbc.M412627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15561714	hybrid			2022-12-25	WOS:000226983900040
J	Schmitt, TL; Hotz-Wagenblatt, A; Klein, H; Droge, W				Schmitt, TL; Hotz-Wagenblatt, A; Klein, H; Droge, W			Interdependent regulation of insulin receptor kinase activity by ADP and hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; INDUCED ACTIVATION; CYSTEINE RESIDUES; CRYSTAL-STRUCTURE; REDOX REGULATION; PHOSPHORYLATION; AGENTS; DOMAIN; H2O2; SUPPLEMENTATION	Insulin signaling requires autophosphorylation of the insulin receptor kinase (IRK) domain. Using purified recombinant IRK fragments and the isolated intact insulin receptor, we show here that autophosphorylation is inhibited by ADP and that this effect is essentially reversed by hydrogen peroxide. Autophosphorylation was inhibited by hydrogen peroxide (60 mum) in the absence of ADP but enhanced in the presence of inhibitory concentrations of ADP (67 mum). Enhancement by hydrogen peroxide required direct interaction of hydrogen peroxide with the kinase domain and was not seen in insulin receptor mutants C1245A and C1308A. A similar enhancement was obtained in intact cells in the absence of insulin upon treatment with 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea, indicating that IRK activity can be alternatively enhanced by a shift in the thiol/disulfide redox status. Molecular modeling of the IRK domain indicated that the ATP-binding site becomes distorted after releasing the nucleotide unless the IRK domain is oxidatively derivatized at Cys(1245). Recent clinical studies suggest that these effects may play a role in obesity due to the fact that cytoplasmic creatine kinase in combination with phosphocreatine normally ensures rapid removal of ADP in muscle cells but not in fat cells.	Deutsch Krebsforschungszentrum, Div Immunochem, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Biophys, D-69120 Heidelberg, Germany; Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Droge, W (corresponding author), Deutsch Krebsforschungszentrum, Div Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Droege@DKFZ.de						Arivazhagan P, 2001, CHEM-BIOL INTERACT, V138, P189, DOI 10.1016/S0009-2797(01)00268-X; Baer K, 2001, BIOCHEMISTRY-US, V40, P14268, DOI 10.1021/bi015588g; BALSOM PD, 1995, ACTA PHYSIOL SCAND, V154, P303, DOI 10.1111/j.1748-1716.1995.tb09914.x; BERG JM, 2001, BIOCHEMISTRY-US, P380; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Cann AD, 1998, BIOCHEMISTRY-US, V37, P11289, DOI 10.1021/bi9809122; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; Droge W, 2004, MECH AGEING DEV, V125, P161, DOI 10.1016/j.mad.2003.12.003; Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; Frankel M, 1999, PROTEIN SCI, V8, P2158, DOI 10.1110/ps.8.10.2158; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; Garcia De La Asuncion Jose, 1996, FASEB Journal, V10, P333; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Hack V, 1998, BLOOD, V92, P59, DOI 10.1182/blood.V92.1.59.413a05_59_67; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Hildebrandt W, 2004, J MOL MED, V82, P336, DOI 10.1007/s00109-004-0532-5; Hotz-Wagenblatt A, 2002, METHOD ENZYMOL, V348, P288, DOI 10.1016/S0076-6879(02)48647-8; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huso ME, 2002, J APPL PHYSIOL, V93, P2018, DOI 10.1152/japplphysiol.01170.2001; KADOTA S, 1987, J BIOL CHEM, V262, P8252; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kinscherf R, 1996, J MOL MED-JMM, V74, P393, DOI 10.1007/s001090050040; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lands LC, 1999, J APPL PHYSIOL, V87, P1381, DOI 10.1152/jappl.1999.87.4.1381; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; MACAULAY SL, 1995, BIOCHEM J, V306, P811, DOI 10.1042/bj3060811; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MAY JM, 1979, J BIOL CHEM, V254, P2214; McClung JP, 2004, P NATL ACAD SCI USA, V101, P8852, DOI 10.1073/pnas.0308096101; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; MUKHERJEE SP, 1982, BIOCHEM INT, V4, P305; NOY N, 1985, MECH AGEING DEV, V29, P63, DOI 10.1016/0047-6374(85)90047-8; Pallardo FV, 1998, FREE RADICAL RES, V29, P617, DOI 10.1080/10715769800300671; Pani G, 2002, METHOD ENZYMOL, V352, P91; Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Schmid E, 1998, FASEB J, V12, P863, DOI 10.1096/fasebj.12.10.863; Schmid E, 1999, FASEB J, V13, P1491, DOI 10.1096/fasebj.13.12.1491; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; Shevchenko A, 2001, ANAL BIOCHEM, V296, P279, DOI 10.1006/abio.2001.5321; Ushmorov A, 1999, CANCER RES, V59, P3527; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325	52	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3795	3801		10.1074/jbc.M410352200	http://dx.doi.org/10.1074/jbc.M410352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15563471	hybrid			2022-12-25	WOS:000226983900081
J	Yoshida, M; Minamisawa, S; Shimura, M; Komazaki, S; Kume, H; Zhang, M; Matsumura, K; Nishi, M; Saito, M; Saeki, Y; Ishikawa, Y; Yanagisawa, T; Takeshima, H				Yoshida, M; Minamisawa, S; Shimura, M; Komazaki, S; Kume, H; Zhang, M; Matsumura, K; Nishi, M; Saito, M; Saeki, Y; Ishikawa, Y; Yanagisawa, T; Takeshima, H			Impaired Ca2+ store functions in skeletal and cardiac muscle cells from sarcalumenin-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; RYANODINE-RECEPTOR; CALCIUM-RELEASE; ENDOPLASMIC-RETICULUM; MEMBRANE COMPLEX; CALSEQUESTRIN; LOCALIZATION; EXPRESSION; ENTRY	Sarealumenin (SAR), specifically expressed in striated muscle cells, is a Ca2+-binding protein localized in the sarcoplasmic reticulum (SR) of the intracellular Ca2+ store. By generating SAR-deficient mice, we herein examined its physiological role. The mutant mice were apparently normal in growth, health, and reproduction, indicating that SAR is not essential for fundamental muscle functions. SAR-deficient skeletal muscle carrying irregular SR ultrastructures retained normal force generation but showed slow relaxation phases after contractions. A weakened Ca2(+) uptake activity was detected in the SR prepared from mutant muscle, indicating that SAR contributes to Ca2+ buffering in the SR lumen and also to the maintenance of Ca2+ pump proteins. Cardiac myocytes from SAR-deficient mice showed slow contraction and relaxation accompanied by impaired Ca2+ transients, and the mutant mice exhibited a number of impairments in cardiac performance as determined in electrocardiography, ventricular catheterization, and echocardiography. The results obtained demonstrate that SAR plays important roles in improving the Ca2+ handling functions of the SR in striated muscle.	Tohoku Univ, Grad Sch Med, Dept Med Chem, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Mol Pharmacol, Sendai, Miyagi 9808575, Japan; Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Internal Med, Yokohama, Kanagawa 2360004, Japan; Saitama Med Sch, Dept Anat, Moroyama, Saitama 3500495, Japan; Tsurumi Univ, Sch Dent Med, Dept Physiol, Yokohama, Kanagawa 2308501, Japan	Tohoku University; Tohoku University; Yokohama City University; Yokohama City University; Saitama Medical University; Tsurumi University	Takeshima, H (corresponding author), Tohoku Univ, Grad Sch Med, Dept Med Chem, Sendai, Miyagi 9808575, Japan.	takeshim@mail.tains.tohoku.ac.jp		Takeshima, Hiroshi/0000-0003-4525-3725; Minamisawa, Susumu/0000-0003-4728-2116				Beard NA, 2002, BIOPHYS J, V82, P310, DOI 10.1016/S0006-3495(02)75396-4; DAMIANI E, 1991, BIOCHEM J, V277, P825, DOI 10.1042/bj2770825; Dowling P, 2004, BIOCHEM J, V379, P479, DOI 10.1042/BJ20031311; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; KIM DH, 1983, J BIOL CHEM, V258, P9662; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LEBERER E, 1990, J BIOL CHEM, V265, P10118; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Nishi M, 1999, J CELL BIOL, V147, P1473, DOI 10.1083/jcb.147.7.1473; Nori A, 1997, AM J PHYSIOL-CELL PH, V272, pC1420, DOI 10.1152/ajpcell.1997.272.5.C1420; RAEYMAEKERS L, 1993, CELL CALCIUM, V14, P581, DOI 10.1016/0143-4160(93)90058-E; Shin DW, 2003, J BIOL CHEM, V278, P3286, DOI 10.1074/jbc.M209045200; Suzuki H, 1999, BIOCHEMISTRY-US, V38, P820, DOI 10.1021/bi981809f; Tada M, 1998, ANN NY ACAD SCI, V853, P116, DOI 10.1111/j.1749-6632.1998.tb08261.x; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775	21	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3500	3506		10.1074/jbc.M406618200	http://dx.doi.org/10.1074/jbc.M406618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15569689	hybrid			2022-12-25	WOS:000226983900046
J	Menendez, JA; Vellon, L; Mehmi, I; Teng, PK; Griggs, DW; Lupu, R				Menendez, JA; Vellon, L; Mehmi, I; Teng, PK; Griggs, DW; Lupu, R			A novel CYR61-triggered 'CYR61-alpha(v)beta(3) integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway	ONCOGENE			English	Article						CYR61; CCN1; heregulin; alpha(v)beta(3); paclitaxel; taxol; ERK1/ERK2 MAPK; chemotherapy; breast cancer	TISSUE GROWTH-FACTOR; TAXOL-INDUCED APOPTOSIS; IMMEDIATE-EARLY GENE; PACLITAXEL-INDUCED CYTOTOXICITY; INTESTINAL EPITHELIAL-CELLS; KINASE KINASE INHIBITION; VEIN ENDOTHELIAL-CELLS; HUMAN SKIN FIBROBLASTS; CCN FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE	The angiogenic inducer CYR61 is differentially over-expressed in breast cancer cells exhibiting high levels of Heregulin (HRG), a growth factor closely associated with a metastatic breast cancer phenotype. Here, we examined whether CYR61, independently of HRG, actively regulates breast cancer cell survival and chemosensitivity, and the pathways involved. Forced expression of CYR61 in HRG-negative MCF-7 cells notably upregulated the expression of its own integrin receptor alpha(v)beta(3) (>200 times). Small peptidomimetic alpha(v)beta(3) integrin antagonists dramatically decreased cell viability of CYR61-overexpressing MCF-7 cells, whereas control MCF-7/V remained insensitive. Mechanistically, functional blockade of alpha(v)beta(3) specifically abolished CYR6-induced hyperactivation of ERK1/ERK2 MAPK, whereas the activation status of AKT did not decrease. Moreover, CYR61 overexpression rendered MCF-7 cells significantly resistant (>10-fold) to Taxol-induced cytotoxicity. Remarkably, alpha(v)beta(3) inhibition converted the CYR61-induced Taxol-resistant phenotype into a hypersensitive one. Thus, the augmentation of Taxol-induced apoptotic cell death in the presence of alpha(v)beta(3) antagonists demonstrated a strong synergism as verified by the terminal transferase-mediated dUTP nick-end labeling (TUNEL) assay and by flow cytometric analysis for DNA content. Indeed, functional blockade of alpha(v)beta(3), similarly to the pharmacological MAPK inhibitor U0126, synergistically increased both the proportion of CYR61-overexpressing breast cancer cells in the G(2) phase of the cell cycle and the appearance of sub-G(1) hypodiploid (apoptotic) cells caused by Taxol. Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alpha(v)beta(3) or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53. Moreover, antisense downregulation of CYR61 expression abolished the anchorage-independent growth of breast cancer cells engineered to overexpress HRG, and significantly increased their sensitivity to Taxol. Our data provide evidence that CYR61 is sufficient to promote breast cancer cell proliferation, cell survival, and Taxol resistance through a alpha(v)beta(3)-activated ERK1/ERK2 MAPK signaling. The identification of a 'CYR61-alpha(v)beta(3) autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting alpha(v)beta(3) may simultaneously prevent breast cancer angiogenesis, growth, and chemo resistance.	Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Pharmacia Corp, Discovery Res, Oncol Pharmacol, St Louis, MO USA	Northwestern University; Feinberg School of Medicine; Pfizer	Lupu, R (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561				Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Atlas E, 2003, MOL CANCER RES, V1, P165; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Griggs David William, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P263; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Hortobagyi GN, 1997, SEMIN ONCOL, V24, pS30; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MacKeigan JP, 2002, CLIN CANCER RES, V8, P2091; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Meyer Debra Mary, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P825; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OKELLY J, 2002, P AM ASS CANC RES, V42; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perez, 1998, Oncologist, V3, P373; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Reinmuth N, 2003, CANCER RES, V63, P2079; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; STAEBLER A, 1994, BREAST CANCER RES TR, V31, P175, DOI 10.1007/BF00666151; Torres K, 1998, CANCER RES, V58, P3620; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; VELLON L, 2004, P AM ASSOC CANC RES, V45, P74; Wiseman LR, 1998, DRUG AGING, V12, P305, DOI 10.2165/00002512-199812040-00005; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 2001, SEMIN ONCOL, V28, P12; Yu DH, 1996, ONCOGENE, V13, P1359; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Zhang LF, 2002, CARCINOGENESIS, V23, P1251, DOI 10.1093/carcin/23.7.1251; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	126	133	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					761	779		10.1038/sj.onc.1208238	http://dx.doi.org/10.1038/sj.onc.1208238			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592521				2022-12-25	WOS:000226577100003
J	Fackelmayer, FO				Fackelmayer, FO			A stable proteinaceous structure in the territory of inactive X chromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAFFOLD ATTACHMENT FACTOR; NUCLEAR-MATRIX PROTEIN; XIST RNA; SAF-A; FEMALE MAMMALS; IN-VIVO; HNRNP-U; METHYLATION; DNA; DOMAIN	Transcriptional inactivation of one copy of the X chromosome in female cells equalizes expression of X-linked genes between males and females. This "dosage compensation" is a multistep process that involves epigenetic modifications of chromatin and is induced by the expression of a large non-coding RNA termed Xist. In contrast to protein-coding mRNA molecules, which are free to diffuse and roam the entire nuclear interior, Xist is locally constrained to the territory of inactive X chromosomes by as yet unclear mechanisms. Recent results have suggested a contribution of scaffold attachment factor A (SAF-A) in the silencing of X-linked genes, maybe by inducing a local change in nuclear architecture. Here, in vivo mobility experiments demonstrate that SAF-A is a component of a highly stable proteinaceous structure in the territory of inactive X chromosomes, which might act as a platform for immobilizing Xist RNA during the maintenance phase of X inactivation.	Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Cell Biol, D-20251 Hamburg, Germany	Heinrich Pette Institute	Fackelmayer, FO (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Cell Biol, Martinistr 52, D-20251 Hamburg, Germany.	frank@fackelmayer.de						BARR ML, 1962, ACTA CYTOL, V6, P34; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Calapez A, 2002, J CELL BIOL, V159, P795, DOI 10.1083/jcb.200203046; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Goto Y, 2002, CYTOGENET GENOME RES, V99, P66, DOI 10.1159/000071576; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Helbig R, 2003, CHROMOSOMA, V112, P173, DOI 10.1007/s00412-003-0258-0; Herrmann F, 2004, J BIOL CHEM, V279, P48774, DOI 10.1074/jbc.M407332200; Jenke ACW, 2004, P NATL ACAD SCI USA, V101, P11322, DOI 10.1073/pnas.0401355101; Jenke BHC, 2002, EMBO REP, V3, P349, DOI 10.1093/embo-reports/kvf070; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; Martens JHA, 2002, MOL CELL BIOL, V22, P2598, DOI 10.1128/MCB.22.8.2598-2606.2002; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Shav-Tal Y, 2004, SCIENCE, V304, P1797, DOI 10.1126/science.1099754; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820	28	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1720	1723		10.1074/jbc.C400531200	http://dx.doi.org/10.1074/jbc.C400531200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15563465	hybrid			2022-12-25	WOS:000226341700003
J	Li, JL; Pircher, PC; Schulman, IG; Westin, SK				Li, JL; Pircher, PC; Schulman, IG; Westin, SK			Regulation of complement C3 expression by the bile acid receptor FXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLATION-STIMULATING PROTEIN; FARNESOID-X-RECEPTOR; NUCLEAR RECEPTOR; CHENODEOXYCHOLIC ACID; TRIGLYCERIDE LEVELS; LIGANDS; PLASMA; GROWTH; ATHEROSCLEROSIS; IDENTIFICATION	The farnesoid X receptor ( FXR; NR1H4) is an intracellular bile acid-sensing transcription factor that plays a critical role in the regulation of synthesis and transport of bile acids as well as lipid metabolism. Although the reciprocal relationship between bile acid and triglyceride levels is well known, the mechanism underlying this link is not clearly defined. In this study, we demonstrate that FXR regulates the expression of at least two secreted factors, complement component C3 and FGF15, the rat ortholog of FGF19, known to influence lipid metabolism. The analysis of the human complement C3 gene reveals the presence of functional FXR response elements in the proximal promoter of C3. Furthermore, rats given a single dose of an FXR agonist exhibit an increase in the plasma concentration of complement C3 protein. These studies demonstrate a mechanism by which FXR, a nuclear receptor with a limited tissue expression pattern, regulates secretion of factors that ultimately can affect lipid metabolism in an endocrine or paracrine manner.	X Cepto Therapeut, Dept Biol, San Diego, CA 92121 USA		Westin, SK (corresponding author), X Cepto Therapeut, Dept Biol, 4757 Nexus Ctr Dr, San Diego, CA 92121 USA.	swestin@x-ceptor.com						ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; ANGELIN B, 1978, J LIPID RES, V19, P1017; Auwerx J, 1999, CELL, V97, P161; Barbier O, 2003, GASTROENTEROLOGY, V124, P1926, DOI 10.1016/S0016-5085(03)00388-3; Barnum S R, 1989, Year Immunol, V6, P208; BATESON MC, 1978, BRIT J CLIN PHARMACO, V5, P249, DOI 10.1111/j.1365-2125.1978.tb01632.x; Boggs RD, 1998, OBES RES, V6, P361, DOI 10.1002/j.1550-8528.1998.tb00364.x; Buono C, 2002, CIRCULATION, V105, P3025, DOI 10.1161/01.CIR.0000019584.04929.83; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cianflone K, 2003, BBA-BIOMEMBRANES, V1609, P127, DOI 10.1016/S0005-2736(02)00686-7; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; HANSSON GK, 1984, ACTA PATH MICRO IM A, V92, P429; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; ISER JH, 1981, DRUGS, V21, P90, DOI 10.2165/00003495-198121020-00002; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MESSIHA N, 1989, LIFE SCI, V44, P49, DOI 10.1016/0024-3205(89)90217-8; Murray I, 1999, J LIPID RES, V40, P1671; Niculescu F, 1999, MOL IMMUNOL, V36, P949, DOI 10.1016/S0161-5890(99)00117-0; PANG ASD, 1979, J IMMUNOL, V123, P1117; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Persson L, 2004, ARTERIOSCL THROM VAS, V24, P1062, DOI 10.1161/01.ATV.0000127302.24266.40; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; SEIFERT PS, 1991, ATHEROSCLEROSIS, V91, P155, DOI 10.1016/0021-9150(91)90197-B; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; VLAICU R, 1985, ATHEROSCLEROSIS, V55, P35, DOI 10.1016/0021-9150(85)90164-9; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Weyer C, 2000, DIABETES CARE, V23, P779, DOI 10.2337/diacare.23.6.779; Wright TJ, 2004, DEV BIOL, V269, P264, DOI 10.1016/j.ydbio.2004.02.003; Ylitalo K, 2001, ARTERIOSCL THROM VAS, V21, P838, DOI 10.1161/01.ATV.21.5.838; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200; Zhao A, 2004, DNA CELL BIOL, V23, P519, DOI 10.1089/1044549041562267	39	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7427	7434		10.1074/jbc.M411473200	http://dx.doi.org/10.1074/jbc.M411473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15590640				2022-12-25	WOS:000227395700003
J	Nilius, B; Prenen, J; Tang, JS; Wang, CB; Owsianik, G; Janssens, A; Voets, T; Zhu, MX				Nilius, B; Prenen, J; Tang, JS; Wang, CB; Owsianik, G; Janssens, A; Voets, T; Zhu, MX			Regulation of the Ca2+ sensitivity of the nonselective cation channel TRPM4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; PROTEIN-KINASE-C; CALMODULIN; CALCIUM; CAPSAICIN; CA2+/CALMODULIN; CARDIOMYOCYTES; IDENTIFICATION; POTENTIATION	TRPM4, a Ca2+-activated cation channel of the transient receptor potential superfamily, undergoes a fast desensitization to Ca2+. The mechanisms underlying the alterations in Ca2+ sensitivity are unknown. Here we show that cytoplasmic ATP reversed Ca2+ sensitivity after desensitization, whereas mutations to putative ATP binding sites resulted in faster and more complete desensitization. Phorbol ester-induced activation of protein kinase C (PKC) increased the Ca2+ sensitivity of wildtype TRPM4 but not of two mutants mutated at putative PKC phosphorylation sites. Overexpression of a calmodulin mutant unable to bind Ca2+ dramatically reduced TRPM4 activation. We identified five Ca2+-calmodulin binding sites in TRPM4 and showed that deletion of any of the three C-terminal sites strongly impaired current activation by reducing Ca2+ sensitivity and shifting the voltage dependence of activation to very positive potentials. Thus, the Ca2+ sensitivity of TRPM4 is regulated by ATP, PKC-dependent phosphorylation, and calmodulin binding at the C terminus.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA	KU Leuven; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	bernd.nilius@med.kuleuven.ac.be	Voets, Thomas/E-2466-2012; Voets, Thomas/AAD-4389-2019	Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Janssens, Annelies/0000-0002-6735-8248	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042183] Funding Source: NIH RePORTER; NINDS NIH HHS [NS42183] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Guinamard R, 2004, J CARDIOVASC ELECTR, V15, P342, DOI 10.1046/j.1540-8167.2004.03477.x; Guinamard R, 2002, J MEMBRANE BIOL, V188, P127, DOI 10.1007/s00232-001-0180-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Lambers TT, 2004, J BIOL CHEM, V279, P28855, DOI 10.1074/jbc.M313637200; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; Liman ER, 2003, J PHYSIOL-LONDON, V548, P777, DOI 10.1113/jphysiol.2002.037119; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2004, J PHYSIOL-LONDON, V560, P753, DOI 10.1113/jphysiol.2004.070839; Nilius B, 2004, PFLUG ARCH EUR J PHY, V448, P70, DOI 10.1007/s00424-003-1221-x; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Petersen OH, 2001, CURR BIOL, V11, pR520, DOI 10.1016/S0960-9822(01)00309-8; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; Ren XQ, 2004, MOL PHARMACOL, V65, P1536, DOI 10.1124/mol.65.6.1536; Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SIEMEN D, 1987, PFLUG ARCH EUR J PHY, V408, P534, DOI 10.1007/BF00585082; SIEMEN W, 1994, NONSELECTIVE CATION; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; ULLRICH ND, 2005, IN PRESS CELL CALCIU; Wang CB, 2004, J BIOL CHEM, V279, P37423, DOI 10.1074/jbc.M407205200; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698	35	210	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6423	6433		10.1074/jbc.M411089200	http://dx.doi.org/10.1074/jbc.M411089200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590641	hybrid, Green Published			2022-12-25	WOS:000227332700023
J	Singhirunnusorn, P; Suzuki, S; Kawasaki, N; Saiki, I; Sakurai, H				Singhirunnusorn, P; Suzuki, S; Kawasaki, N; Saiki, I; Sakurai, H			Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MAP KINASE; PATHWAYS; IL-1; AUTOPHOSPHORYLATION; JNK; IDENTIFICATION; APOPTOSIS; CASCADE; MEKK1	Transforming growth factor-beta-activated kinase 1 (TAK1) mitogen-activated protein kinase kinase kinase has been shown to be activated by cellular stresses including tumor necrosis factor-alpha (TNF-alpha). Here, we characterized the molecular mechanisms of cellular stress-induced TAK1 activation, focusing mainly on the phosphorylation of TAK1 at Thr-187 and Ser-192 in the activation loop. Thr-187 and Ser-192 are conserved among species from Caenorhabditis elegans to human, and their replacement with Ala resulted in inactivation of TAK1. Immunoblotting with a novel phospho-TAK1 antibody revealed that TNF-alpha significantly induced the phosphorylation of endogenous TAK1 at Thr-187, and subsequently the phosphorylated forms of TAK1 rapidly disappeared. Intermolecular autophosphorylation of Thr-187 was essential for TAK1 activation. RNA interference and overexpression experiments demonstrated that TAK1-binding protein TAB1 and TAB2 were involved in the phosphorylation of TAK1, but they regulated TAK1 phosphorylation differentially. Furthermore, SB203580 and p38alpha small interfering RNA enhanced TNF-alpha-induced Thr-187 phosphorylation as well as TAK1 kinase activity, indicating that the phosphorylation is affected by p38alpha/TAB1/TAB2-mediated feedback control of TAK1. These results indicate critical roles of Thr-187 phosphorylation in the stress-induced rapid and transient activation of TAK1 in a signaling complex containing TAB1 and TAB2.	Toyama Med & Pharmaceut Univ, Inst Nat Med, Div Pathogen Biochem, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, COE Program, Toyama 9300194, Japan	University of Toyama; University of Toyama	Sakurai, H (corresponding author), Toyama Med & Pharmaceut Univ, Inst Nat Med, Div Pathogen Biochem, 2630 Sugitani, Toyama 9300194, Japan.	hsakurai@ms.toyama-mpu.ac.jp	Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Dempsey CE, 2000, BBA-GENE STRUCT EXPR, V1517, P46, DOI 10.1016/S0167-4781(00)00258-X; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Fujii K, 2004, ONCOGENE, V23, P5099, DOI 10.1038/sj.onc.1207668; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Komatsu Y, 2002, MECH DEVELOP, V119, P239, DOI 10.1016/S0925-4773(02)00391-X; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Munoz-Sanjuan I, 2002, DEVELOPMENT, V129, P5529, DOI 10.1242/dev.00097; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ono K, 2001, J BIOL CHEM, V276, P24396, DOI 10.1074/jbc.M102631200; Park JM, 2004, GENE DEV, V18, P584, DOI 10.1101/gad.1168104; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sakurai H, 2002, BIOCHEM BIOPH RES CO, V297, P1277, DOI 10.1016/S0006-291X(02)02379-3; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Sundarrajan M, 2003, ARTHRITIS RHEUM, V48, P2450, DOI 10.1002/art.11228; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tamura S, 2002, EUR J BIOCHEM, V269, P1060, DOI 10.1046/j.0014-2956.2002.02754.x; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769	60	172	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7359	7368		10.1074/jbc.M407537200	http://dx.doi.org/10.1074/jbc.M407537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590691	hybrid			2022-12-25	WOS:000227332700128
J	Xia, J; Kemper, B				Xia, J; Kemper, B			Structural determinants of constitutive androstane receptor required for its glucocorticoid receptor interacting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL INDUCTION; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; MOUSE-LIVER; CYP2B GENE; CAR; ACTIVATION; LIGAND; TRANSCRIPTION; PROTEIN	Nuclear translocation of constitutive androstane receptor (CAR) is a primary mechanism for the induction of cytochrome P450 genes by phenobarbital (PB). We have shown that exogenous expression of the p160 coactivator glucocorticoid receptor interacting protein-1 (GRIP1) in hepatocytes in vivo can mediate PB-independent nuclear accumulation of murine CAR (mCAR). To understand the mechanism of this PB-independent nuclear accumulation, we have examined the mCAR structural determinants of its GRIP1-mediated nuclear localization. Mutations of the xenobiotic response sequence (XRS), which had been shown to block PB-dependent nuclear translocation of human CAR in mouse hepatocytes in vivo, also blocked GRIP1-mediated nuclear accumulation of mCAR in mouse hepatocytes in vivo and further blocked nuclear localization in cultured HepG2 cells. A leucine 326 XRS mutant retained partial transcriptional activity, but mutations of three leucines in the XRS eliminated transcriptional activity in HepG2 cells, suggesting that the translocation function of the XRS overlaps with transcriptional functions. Mutation of the activation function 2 motif, by deletion of the C-terminal 8 amino acids, also reduced nuclear localization by both PB treatment and GRIP1 expression in hepatocytes in vivo, suggesting that either interaction with GRIP1 through this motif or active CAR was required for the nuclear localization. The localization of a DNA-binding domain mutant was essentially unchanged by coexpression of GRIP1, although without GRIP1 coexpression, this mutant expressed exhibited a more nuclear localization compared with wild type. The results are most consistent with a model in which GRIP1 interaction and activation of mCAR in the nucleus result in retention and accumulation of mCAR in the nucleus in untreated animals. The model requires that mCAR is constantly shuttling between the nucleus and cytoplasm even in untreated animals in which mCAR is predominantly cytoplasmic.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	byronkem@life.uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersin T, 2003, MOL ENDOCRINOL, V17, P234, DOI 10.1210/me.2002-0263; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Karvonen U, 2002, FEBS LETT, V523, P43, DOI 10.1016/S0014-5793(02)02929-0; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kobayashi K, 2003, MOL PHARMACOL, V64, P1069, DOI 10.1124/mol.64.5.1069; Marc N, 2000, EUR J BIOCHEM, V267, P963, DOI 10.1046/j.1432-1327.2000.01083.x; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Min GS, 2002, J BIOL CHEM, V277, P34626, DOI 10.1074/jbc.M205239200; Min GS, 2002, J BIOL CHEM, V277, P26356, DOI 10.1074/jbc.M200051200; NELSON R, 2000, P ICPR, V1, P1; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Xiao L, 2002, DRUG METAB DISPOS, V30, P951, DOI 10.1124/dmd.30.9.951; Yamamoto Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P207, DOI 10.1016/S0003-9861(02)00456-3; Yoshinari K, 2003, FEBS LETT, V548, P17, DOI 10.1016/S0014-5793(03)00720-8; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	32	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7285	7293		10.1074/jbc.M409696200	http://dx.doi.org/10.1074/jbc.M409696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591315	hybrid			2022-12-25	WOS:000227332700120
J	Basak, C; Pathak, SK; Bhattacharyya, A; Mandal, D; Pathak, S; Kundu, M				Basak, C; Pathak, SK; Bhattacharyya, A; Mandal, D; Pathak, S; Kundu, M			NF-kappa B- and C/EBP beta-driven interleukin-1 beta gene expression and PAK1-mediated caspase-1 activation play essential roles in interleukin-1 beta release from Helicobacter pylori lipopolysaccharide-stimulated macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; SIGNAL-TRANSDUCTION; KINASE; PROTEIN; MYD88; IRAK; SITE; TRANSCRIPTION; INDUCTION	Helicobacter pylori is a Gram-negative microaerophilic bacterium that causes chronic gastritis, peptic ulcer, and gastric carcinoma. Interleukin-1beta (IL-1beta) is one of the potent proinflammatory cytokines elicited by H. pylori infection. We have evaluated the role of H. pylori lipopolysaccharide (LPS) as one of the mediators of EL-1beta release and dissected the signaling pathways leading to LPS-induced IL-1beta secretion. We demonstrate that both the NF-kappaB and the C/EBPbeta-binding elements of the IL-1beta promoter drive LPS-induced IL-1beta gene expression. NF-KB activation requires the classical TLR4-initiated signaling cascade leading to IkappaB phosphorylation as well as PI-3K/Rac1/p21-activated kinase (PAK) 1 signaling, whereas C/EBP,6 activation requires PI-3K/Akt/p38 mitogen-activated protein (MAP) kinase signaling. We observed a direct interaction between activated p38 MAP kinase and C/EBPbeta, suggesting that p38 MAPK is the immediate upstream kinase responsible for activating C/EBPbeta. Most important, we observed a role of Rac1/PAK1 signaling in activation of caspase-1, which is necessary for maturation of pro-IL-1beta. K. pylori LPS induced direct interaction between PAK1 and caspase-1, which was inhibited in cells transfected with dominant-negative Rac1. PAK1 immunoprecipitated from lysates of H. pylori LPS-challenged cells was able to phosphorylate recombinant caspase-1, but not its S376A mutant. LPS-induced caspase-1 activation was abrogated in cells transfected with caspase-1(S376A). Taken together, these results suggested a role of PAKI-induced phosphorylation of caspase-1 at Ser(376) in activation of caspase-1. To the best oil our knowledge our studies show for the first time that LPS-induced Rac1/PAK1 signaling leading to caspase-1 phosphorylation is crucial for caspase-1 activation. These studies also provide detailed insight into the regulation of IL-1beta gene expression by H. pylori LPS and are particularly inaportant in the light of the observations that IL-1beta gene polymorphisms are associated with increased risk of H. pylori-associated gastric cancer.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Kundu, M (corresponding author), Bose Inst, Dept Chem, 93-1 APC Rd, Kolkata 700009, W Bengal, India.	manikuntala@vsnl.net	PATHAK, SHRESH/I-6938-2012; Bhattacharyya, Asima/J-7423-2012; mandal, debabrata/AAF-6690-2019	Bhattacharyya, Asima/0000-0001-7292-6644; PATHAK, SHRESH/0000-0001-5275-1816				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555; BIRKHOLZ S, 1993, FEMS IMMUNOL MED MIC, V6, P317, DOI 10.1016/0928-8244(93)90008-R; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Ernst PB, 2000, ANNU REV MICROBIOL, V54, P615, DOI 10.1146/annurev.micro.54.1.615; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; GODAMBE SA, 1995, MOL CELL BIOL, V15, P112, DOI 10.1128/MCB.15.1.112; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Innocenti M, 2001, INFECT IMMUN, V69, P3800, DOI 10.1128/IAI.69.6.3800-3808.2001; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moran AP, 1996, ALIMENT PHARM THER, V10, P39, DOI 10.1046/j.1365-2036.1996.22164004.x; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VAN AL, 1997, GENE DEV, V11, P2295; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; WETTENHALL R E H, 1991, Peptide Research, V4, P158; Yamaoka Y, 2001, HELICOBACTER, V6, P116, DOI 10.1046/j.1523-5378.2001.00017.x; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837	53	121	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4279	4288		10.1074/jbc.M412820200	http://dx.doi.org/10.1074/jbc.M412820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561713	hybrid			2022-12-25	WOS:000227096600036
J	Heidenreich, T; Wollers, S; Mendel, RR; Bittner, F				Heidenreich, T; Wollers, S; Mendel, RR; Bittner, F			Characterization of the NifS-like domain of ABA3 from Arabidopsis thaliana provides insight into the mechanism of molybdenum cofactor sulfuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE LYASE; CYSTEINE DESULFURASE; ESCHERICHIA-COLI; XANTHINE DEHYDROGENASE; GENE; BIOSYNTHESIS; ENCODES; PURIFICATION; EXPRESSION; MUTATION	The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form. ABA3 is a two-domain protein with an NH2-terminal domain sharing significant similarities to NifS proteins that catalyze the decomposition Of L-cysteine to L-alanine and elemental sulfur for iron-sulfur cluster synthesis. Although different in its physiological function, the mechanism of ABA3 for sulfur mobilization was found to be similar to NifS proteins. The protein binds a pyridoxal phosphate cofactor and a substrate-derived persulfide intermediate, and site-directed mutagenesis of strictly conserved binding sites for the cofactor and the persulfide demonstrated that they are essential for molybdenum cofactor sulfurase activity. In vitro, the NifS-like domain of ABA3 activates aldehyde oxidase and xanthine dehydrogenase in the absence of the C-terminal,domain, but in vivo, the C-terminal domain is required for proper activation of both target enzymes. In addition to its cysteine desulfurase activity, ABA3-NifS also exhibits selenocysteine lyase activity. Although L-seleno-cysteine is unlikely to be a natural substrate for ABA3, it is decomposed more efficiently than L-cysteine. Besides mitochondrial AtNFS1 and plastidial AtNFS2, which are both proposed to be involved in iron-sulfur cluster formation, ABA3 is proposed to be a third and cytosolic NifS-like cysteine desulfurase in A. thaliana. However, the sulfur transferase activity of ABA.3 is used for post-translational activation of molybdenum enzymes rather than for iron-sulfur cluster assembly.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany	Braunschweig University of Technology	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	R.Mendel@tu-bs.de						ADAMS E, 1969, ANAL BIOCHEM, V31, P118, DOI 10.1016/0003-2697(69)90248-6; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cutler AJ, 1999, TRENDS PLANT SCI, V4, P472, DOI 10.1016/S1360-1385(99)01497-1; ESAKI N, 1982, J BIOL CHEM, V257, P4386; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Hesberg C, 2004, J BIOL CHEM, V279, P13547, DOI 10.1074/jbc.M312929200; Koiwai H, 2000, J BIOCHEM-TOKYO, V127, P659, DOI 10.1093/oxfordjournals.jbchem.a022654; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leon S, 2002, BIOCHEM J, V366, P557, DOI 10.1042/BJ20020322; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Mendel RR, 2002, J EXP BOT, V53, P1689, DOI 10.1093/jxb/erf038; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Nakai Y, 2001, J BIOL CHEM, V276, P8314, DOI 10.1074/jbc.M007878200; Pilon-Smits EAH, 2002, PLANT PHYSIOL, V130, P1309, DOI [10.1104/pp.102.010280, 10.1104/pp.010280]; Sagi M, 2002, PLANT J, V31, P305, DOI 10.1046/j.1365-313X.2002.01363.x; Schwartz SH, 1997, PLANT PHYSIOL, V114, P161, DOI 10.1104/pp.114.1.161; Xiong LM, 2001, PLANT CELL, V13, P2063, DOI 10.1105/tpc.13.9.2063; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	24	67	69	4	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4213	4218		10.1074/jbc.M411195200	http://dx.doi.org/10.1074/jbc.M411195200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561708	hybrid			2022-12-25	WOS:000227096600028
J	Hoffmeister, M; Piotrowski, M; Nowitzki, U; Martin, W				Hoffmeister, M; Piotrowski, M; Nowitzki, U; Martin, W			Mitochondrial trans-2-enoyl-CoA reductase of wax ester fermentation from Euglena gracilis defines a new family of enzymes involved in lipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; ENOYL-COA REDUCTASE; PUTATIVE POLYKETIDE SYNTHASE; COENZYME-A REDUCTASE; ASCARIS-SUUM LARVAE; PYRUVATE-NADP(+) OXIDOREDUCTASE; ANAEROBIC MITOCHONDRIA; CRYPTOSPORIDIUM-PARVUM; NUCLEOTIDE-SEQUENCES; CHAIN DEHYDROGENASES	Under anaerobiosis, Euglena gracilis mitochondria perform a malonyl-CoA independent synthesis of fatty acids leading to accumulation of wax esters, which serve as the sink for electrons stemming from glycolytic ATP synthesis and pyruvate oxidation. An important enzyme of this unusual pathway is trans-2-enoyl-CoA reductase (EC 1.3.1.44), which catalyzes reduction of enoyl-CoA to acyl-CoA. Trans-2-enoyl-CoA reductase from Euglena was purified 1700-fold to electrophoretic homogeneity and was active with NADH and NADPH as the electron donor. The active enzyme is a monomer with molecular mass of 44 kDa. The amino acid sequence of tryptic peptides determined by electrospray ionization mass spectrometry were used to clone the corresponding eDNA, which encoded a polypeptide that, when expressed in Escherichia coli and purified by affinity chromatography, possessed trans-2-enoyl-CoA reductase activity close to that of the enzyme purified from Euglena. Trans-2-enoyl-CoA reductase activity is present in mitochondria and the mRNA is expressed under aerobic and anaerobic conditions. Using NADH, the recombinant enzyme accepted crotonyl-CoA (k(m) = 68 mum) and trans-2-hexenoyl-CoA (k(m) = 91 mum). In the crotonyl-CoA-dependent reaction, both NADH (k(m) = 109 mum) or NADPH (k(m) = 119 mum) were accepted, with 2-3-fold higher specific act ivities for NADH relative to NADPH. Trans-2-enoyl-CoA reductase homologues were not found among other eukaryotes, but are present as hypothetical reading frames of unknown function in sequenced genomes of many proteobacteria and a few Gram-positive eubacteria, where they occasionally occur next to genes involved in fatty acid and polyketide biosynthesis. Trans-2-enoyl-CoA reductase assigns a biochemical activity, NAD(P)H-dependent acyl-CoA synthesis from enoyl-CoA, to one member of this gene family of previously unknown function.	Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany; Ruhr Univ Bochum, Dept Plant Physiol, D-44801 Bochum, Germany	Heinrich Heine University Dusseldorf; Ruhr University Bochum	Martin, W (corresponding author), Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany.	w.martin@uni-duesseldorf.de	Martin, William/C-5680-2008; Martin, William F./O-5446-2015; Piotrowski, Markus/F-5419-2010	Martin, William F./0000-0003-1478-6449; Piotrowski, Markus/0000-0002-6347-3337				Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; Andersson JO, 2003, CURR BIOL, V13, P94, DOI 10.1016/S0960-9822(03)00003-4; Atteia A, 2003, PLANT MOL BIOL, V53, P175, DOI 10.1023/B:PLAN.0000009274.19340.36; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Bentley R, 1999, ANNU REV MICROBIOL, V53, P411, DOI 10.1146/annurev.micro.53.1.411; Bohnert HU, 2004, PLANT CELL, V16, P2499, DOI 10.1105/tpc.104.022715; Breitling R, 2001, MOL BIOL EVOL, V18, P2154, DOI 10.1093/oxfordjournals.molbev.a003761; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; Buetow DE, 1989, BIOL EUGLENA, V4, P247; CHANG SI, 1989, P NATL ACAD SCI USA, V86, P8373, DOI 10.1073/pnas.86.21.8373; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CUI JY, 1994, J BIOCHEM, V115, P98, DOI 10.1093/oxfordjournals.jbchem.a124312; Das AK, 2000, J BIOL CHEM, V275, P24333, DOI 10.1074/jbc.M001168200; Duran E, 1998, MOL BIOCHEM PARASIT, V91, P307, DOI 10.1016/S0166-6851(97)00212-0; DURAN E, 1993, J BIOL CHEM, V268, P22391; Embley TM, 2003, IUBMB LIFE, V55, P387, DOI 10.1080/15216540310001592834; ERNSTFONBERG ML, 1971, ARCH BIOCHEM BIOPHYS, V143, P392, DOI 10.1016/0003-9861(71)90226-8; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Gelius-Dietrich G, 2004, J EUKARYOT MICROBIOL, V51, P456, DOI 10.1111/j.1550-7408.2004.tb00394.x; GOLDBERG I, 1972, J BIOL CHEM, V247, P7349; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Green LS, 2000, J BACTERIOL, V182, P2838, DOI 10.1128/JB.182.10.2838-2844.2000; Hannaert V, 2000, MOL BIOL EVOL, V17, P989, DOI 10.1093/oxfordjournals.molbev.a026395; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HENDREN RW, 1980, J BIOL CHEM, V255, P1504; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENZE K, 1995, P NATL ACAD SCI USA, V92, P9122, DOI 10.1073/pnas.92.20.9122; Hoffmeister M, 2004, J BIOL CHEM, V279, P22422, DOI 10.1074/jbc.M400913200; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; INUI H, 1984, EUR J BIOCHEM, V142, P121, DOI 10.1111/j.1432-1033.1984.tb08258.x; INUI H, 1986, J BIOCHEM, V100, P995, DOI 10.1093/oxfordjournals.jbchem.a121813; INUI H, 1987, J BIOL CHEM, V262, P9130; INUI H, 1983, AGR BIOL CHEM TOKYO, V47, P2669, DOI 10.1080/00021369.1983.10866013; INUI H, 1982, FEBS LETT, V150, P89, DOI 10.1016/0014-5793(82)81310-0; INUI H, 1985, ARCH BIOCHEM BIOPHYS, V237, P423, DOI 10.1016/0003-9861(85)90295-4; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; KHAN AA, 1973, ARCH BIOCHEM BIOPHYS, V158, P411, DOI 10.1016/0003-9861(73)90638-3; Kitaoka S., 1989, BIOL EUGLENA, VIV, P2; KOMUNIECKI PR, 1987, MOL BIOCHEM PARASIT, V22, P241, DOI 10.1016/0166-6851(87)90055-7; KOMUNIECKI R, 1987, MOL BIOCHEM PARASIT, V24, P147, DOI 10.1016/0166-6851(87)90101-0; KOMUNIECKI R, 1985, J BIOL CHEM, V260, P4770; KOMUNIECKI R, 1981, J PARASITOL, V67, P601, DOI 10.2307/3280432; Komuniecki R., 2003, MOL MEDICAL PARASITO, P339; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Liu HB, 1999, J BACTERIOL, V181, P6806, DOI 10.1128/JB.181.21.6806-6813.1999; Martin W, 2004, NATURE, V431, P134, DOI 10.1038/431134a; Mei BS, 1997, J PARASITOL, V83, P760, DOI 10.2307/3284260; Metz JG, 2001, SCIENCE, V293, P290, DOI 10.1126/science.1059593; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Nakazawa M, 2000, FEBS LETT, V479, P155, DOI 10.1016/S0014-5793(00)01882-2; Napier JA, 2002, TRENDS PLANT SCI, V7, P51, DOI 10.1016/S1360-1385(01)02191-4; Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198; PERSSON B, 1991, BIOCHEM BIOPH RES CO, V177, P218, DOI 10.1016/0006-291X(91)91970-N; PONSGENSCHMIDT E, 1988, PLANT PHYSIOL, V86, P457, DOI 10.1104/pp.86.2.457; Rein KS, 1999, COMP BIOCHEM PHYS B, V124, P117, DOI 10.1016/S0305-0491(99)00107-8; REYNOLDS KA, 1992, J BACTERIOL, V174, P3850, DOI 10.1128/jb.174.12.3850-3854.1992; Rotte C, 2001, MOL BIOL EVOL, V18, P710, DOI 10.1093/oxfordjournals.molbev.a003853; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER T, 1985, PLANTA, V166, P67, DOI 10.1007/BF00397387; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; TAKAMIYA S, 1993, BIOCHIM BIOPHYS ACTA, V1141, P65, DOI 10.1016/0005-2728(93)90190-Q; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; Thollesson M, 2004, BIOINFORMATICS, V20, P416, DOI 10.1093/bioinformatics/btg422; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIELENS AGM, 1994, PARASITOL TODAY, V10, P346, DOI 10.1016/0169-4758(94)90245-3; Torkko JM, 2003, J BIOL CHEM, V278, P41213, DOI 10.1074/jbc.M307664200; Trenkamp S, 2004, P NATL ACAD SCI USA, V101, P11903, DOI 10.1073/pnas.0404600101; WALKER TA, 1981, BIOCHEM J, V199, P383, DOI 10.1042/bj1990383; WALLACE KK, 1995, EUR J BIOCHEM, V233, P954, DOI 10.1111/j.1432-1033.1995.954_3.x; Wallis JG, 2002, TRENDS BIOCHEM SCI, V27, P467, DOI 10.1016/S0968-0004(02)02168-0; Zhu G, 2002, GENE, V298, P79, DOI 10.1016/S0378-1119(02)00931-9	73	66	145	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4329	4338		10.1074/jbc.M411010200	http://dx.doi.org/10.1074/jbc.M411010200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569691	hybrid			2022-12-25	WOS:000227096600042
J	Kurihara, S; Oda, S; Kato, K; Kim, HG; Koyanagi, T; Kumagai, H; Suzuki, H				Kurihara, S; Oda, S; Kato, K; Kim, HG; Koyanagi, T; Kumagai, H; Suzuki, H			A novel putrescine utilization pathway involves gamma-glutamylated intermediates of Escherichia coli K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPEPTIDASE; GENE; OPERON; CATABOLISM; ORNITHINE; SYSTEM	A novel bacterial putrescine utilization pathway was discovered. Seven genes, the functions of whose products were not known, are involved in this novel pathway. Five of them encode enzymes that catabolize putrescine; one encodes a putrescine importer, and the other encodes a transcriptional regulator. This novel pathway involves six sequential steps as follows: 1) import of putrescine; 2) ATP-dependent gamma-glutamylation of putrescine; 3) oxidization of gamma-glutamylputrescine; 4) dehydrogenation of gamma-glutamyl-gamma-aminobutyraldehyde; 5) hydrolysis of the gamma-glutamyl linkage of gamma-glutamyl-gamma-aminobutyrate; and 6) transamination of gamma-aminobutyrate to form the final product of this pathway, succinate semialdehyde, which is the precursor of succinate.	Kyoto Univ, Div Integrated Life Sci, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Suzuki, H (corresponding author), Kyoto Univ, Div Integrated Life Sci, Grad Sch Biostudies, Sakyo Ku, Oiwake Cho, Kyoto 6068502, Japan.	hideyuki@lif.kyoto-u.ac.jp	KOYANAGI, Takashi/AAU-8908-2021					BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; BOYLE SM, 1984, GENE, V30, P129, DOI 10.1016/0378-1119(84)90113-6; BUENO R, 1985, J BACTERIOL, V164, P816, DOI 10.1128/JB.164.2.816-822.1985; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DEAZEVEDO WSI, 2002, APPL ENVIRON MICROB, V68, P2368; Jovanovic G, 1997, J BACTERIOL, V179, P3095, DOI 10.1128/jb.179.10.3095-3102.1997; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Katayama T, 2002, J BACTERIOL, V184, P3135, DOI 10.1128/JB.184.11.3135-3141.2002; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Koyanagi T, 2004, J BACTERIOL, V186, P343, DOI 10.1128/JB.186.2.343-350.2004; MANNERVIK B, 1989, COENZYMES COFACTORS, V3, P475; METZER E, 1979, J BACTERIOL, V137, P1111, DOI 10.1128/JB.137.3.1111-1118.1979; Miller J. H., 1992, SHORT COURSE BACTERI, P263; Minami H, 2003, ENZYME MICROB TECH, V32, P431, DOI 10.1016/S0141-0229(02)00314-9; Muse WB, 1998, J BACTERIOL, V180, P1166, DOI 10.1128/JB.180.5.1166-1173.1998; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; Sambrook J, 2001, MOL CLONING LAB MANU; Schneider BL, 2002, J BACTERIOL, V184, P6976, DOI 10.1128/JB.184.24.6976-6986.2002; SEILER N, 1974, BIOCHEM J, V144, P29, DOI 10.1042/bj1440029; SHAIBE E, 1985, J BACTERIOL, V163, P933, DOI 10.1128/JB.163.3.933-937.1985; Suzuki H, 2002, J BIOL CHEM, V277, P43536, DOI 10.1074/jbc.M207680200; SUZUKI H, 1986, J BACTERIOL, V168, P1325, DOI 10.1128/jb.168.3.1325-1331.1986; Suzuki H, 2003, APPL ENVIRON MICROB, V69, P6399, DOI 10.1128/AEM.69.11.6399-6404.2003; SUZUKI H, 1987, J BACTERIOL, V169, P3926, DOI 10.1128/jb.169.9.3926-3931.1987; SUZUKI H, 1993, J BACTERIOL, V175, P6038, DOI 10.1128/JB.175.18.6038-6040.1993; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1986, P NATL ACAD SCI USA, V83, P6040, DOI 10.1073/pnas.83.16.6040; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	30	120	163	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4602	4608		10.1074/jbc.M411114200	http://dx.doi.org/10.1074/jbc.M411114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590624	hybrid			2022-12-25	WOS:000227096600074
J	Ohnishi, A; Koshino, H; Takahashi, S; Esumi, Y; Matsumoto, S				Ohnishi, A; Koshino, H; Takahashi, S; Esumi, Y; Matsumoto, S			Isolation and characterization of a humoral factor that stimulates transcription of the acyl-CoA-binding protein in the pheromone gland of the silkmoth, Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC LIPID DROPLETS; MANDUCA-SEXTA L; TOBACCO HORNWORM; MESSENGER-RNA; COENZYME-A; INHIBITOR; CELLS; ACBP; SILKWORM; ACID	Acyl-CoA binding protein (ACBP) is a highly conserved 10-kDa intracellular lipid-binding protein that binds straight-chain (C-14-C-22) acyl-CoA esters with high affinity and is expressed in a wide variety of species ranging from yeast to mammals. Functionally, ACBP can act as an acyl-CoA carrier or as an acyl-CoA pool maker within the cell. Much work on the biochemical properties regarding the ACBP has been performed using various vertebrate and plant tissues, as well as different types of cells in culture, the regulatory mechanisms underlying ACBP gene expression have remained Poorly understood. By exploiting the unique sex pheromone production system in the moth pheromone gland,(PG), we report that transcription of a specific ACBP termed pheromone gland ACBP is triggered by a hemolymph-based humoral factor. Following purification and structure elucidation by means of high resolution electrospray ionization mass spectrometry and NMR analyses, in conjunction with stereochemical analyses using acid hydrolysates, the humoral factor was identified to be beta-D-glucosyl-O-L-tyrosine. Examination of the hemolymph titers during development revealed that the amount Of beta-D-glucosyl-O-L-tyrosine dramatically rose prior to eclosion and reached a maximum of 5 mg/ml (about 1 mg/pupa) on the day preceding eclosion, which was consistent with the effective dose of P-D-glucosyl-O-L-tyrosine in stimulating pheromone gland ACBP transcription in vivo. Furthermore, in vitro assays using trimmed PG indicated that beta-D-glucosyl-O-L-tyrosine acts directly on the PG. These results provide the first evidence that transcription of some ACBPs can be triggered by specific humoral factors.	RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	RIKEN	Matsumoto, S (corresponding author), RIKEN, Inst Phys & Chem Res, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	smatsu@riken.jp	Koshino, Hiroyuki/N-7948-2015; Koshino, Hiroyuki/ABF-4899-2021	Koshino, Hiroyuki/0000-0002-0954-9839; Koshino, Hiroyuki/0000-0002-0954-9839; Ohnishi, Atsushi/0000-0003-1213-4439				Ahmad SA, 1996, INSECT BIOCHEM MOLEC, V26, P49, DOI 10.1016/0965-1748(95)00060-7; AHMED RF, 1983, INSECT BIOCHEM, V13, P369, DOI 10.1016/0020-1790(83)90019-7; AHMED RF, 1985, J INSECT PHYSL, V36, P341; BHUIYAN AKMJ, 1994, MOL CELL BIOCHEM, V139, P109, DOI 10.1007/BF01081733; BHUIYAN J, 1995, METABOLISM, V44, P1185, DOI 10.1016/0026-0495(95)90013-6; CHEN PS, 1978, INSECT BIOCHEM, V8, P276; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FONAGY A, 1992, J PESTIC SCI, V17, P47; Fonagy A, 2000, J INSECT PHYSIOL, V46, P735, DOI 10.1016/S0022-1910(99)00162-6; Fonagy A, 2001, ARTHROPOD STRUCT DEV, V30, P113, DOI 10.1016/S1467-8039(01)00027-5; FYRST H, 1995, BIOCHEM J, V306, P793, DOI 10.1042/bj3060793; Gossett RE, 1998, ARCH BIOCHEM BIOPHYS, V350, P201, DOI 10.1006/abbi.1997.0521; HANSEN HO, 1991, BIOCHEM J, V277, P341, DOI 10.1042/bj2770341; HAYAKAWA Y, 1989, J BIOL CHEM, V264, P16165; HAYASHI T, 1993, ANAL BIOCHEM, V209, P163, DOI 10.1006/abio.1993.1097; Helledie T, 2002, J BIOL CHEM, V277, P26821, DOI 10.1074/jbc.M111295200; HORVAT S, 1986, SYNTHESIS-STUTTGART, P209; ISOBE M, 1981, AGR BIOL CHEM TOKYO, V45, P687, DOI 10.1080/00021369.1981.10864566; KNUDSEN J, 1994, BIOCHEM J, V302, P479, DOI 10.1042/bj3020479; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; Kragelund BB, 1999, BBA-MOL CELL BIOL L, V1441, P150, DOI 10.1016/S1388-1981(99)00151-1; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; MANDRUP S, 1992, J MOL BIOL, V228, P1011, DOI 10.1016/0022-2836(92)90888-Q; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; Matsumoto S, 2002, INSECT BIOCHEM MOLEC, V32, P1447, DOI 10.1016/S0965-1748(02)00065-6; Matsumoto S, 2001, INSECT BIOCHEM MOLEC, V31, P603, DOI 10.1016/S0965-1748(00)00165-X; MOGENSEN IB, 1987, BIOCHEM J, V241, P189, DOI 10.1042/bj2410189; Ozawa R, 1996, INSECT BIOCHEM MOLEC, V26, P259, DOI 10.1016/0965-1748(95)00088-7; PSARIANOS CG, 1985, INSECT BIOCHEM, V15, P129, DOI 10.1016/0020-1790(85)90053-8; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; Swinnen JV, 1996, MOL CELL ENDOCRINOL, V118, P65, DOI 10.1016/0303-7207(96)03767-7; Swinnen JV, 1998, J BIOL CHEM, V273, P19938, DOI 10.1074/jbc.273.32.19938; TILAK MA, 1968, TETRAHEDRON LETT, V9, P6323; Tillman JA, 1999, INSECT BIOCHEM MOLEC, V29, P481, DOI 10.1016/S0965-1748(99)00016-8	36	8	9	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4111	4116		10.1074/jbc.M413429200	http://dx.doi.org/10.1074/jbc.M413429200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590686	hybrid			2022-12-25	WOS:000227096600016
J	Wang, YZ; Satoh, A; Warren, G				Wang, YZ; Satoh, A; Warren, G			Mapping the functional domains of the Golgi stacking factor GRASP65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROTEIN; CISTERNAE; GM130	The Golgi reassembly stacking protein (GRASP) family has been implicated in the stacking of Golgi cisternae and the regulation of Golgi disassembly/reassembly during mitosis in mammalian cells. GRASP65 is a dimer that can directly link adjacent surfaces through trans-oligomerization in a mitotically regulated manner. Here we show that the N-terminal GRASP domain (amino acids 1-201) is both necessary and sufficient for dimerization and trans-oligomerization but is not mitotically regulated. The C-terminal serine/proline-rich domain (amino acids 202-446) cannot dimerize nor can it link adjacent surfaces. It does, however, confer mitotic regulation on the GRASP domain through multiple sites phosphorylated by the mitotic kinases, cdc2/B1, and the polo-like kinase. Transient expression corroborated these results by showing that the GRASP domain alone inhibited mitotic fragmentation of the Golgi apparatus.	Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT 06520 USA	Ludwig Institute for Cancer Research; Yale University	Wang, YZ (corresponding author), Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT 06520 USA.	yanzhuang.wang@yale.edu	Satoh, Ayano/B-2423-2011; Wang, Yanzhuang/AAE-5299-2019	Satoh, Ayano/0000-0003-3736-1283; Wang, Yanzhuang/0000-0002-1864-7094	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELSSON MA, 2004, MOL BIOL CELL; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Barr FA, 2001, J CELL BIOL, V155, P885, DOI 10.1083/jcb.200108102; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Hui N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P46; Klevecz R R, 1975, Methods Cell Biol, V10, P157, DOI 10.1016/S0091-679X(08)60735-9; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Pfeffer SR, 2001, J CELL BIOL, V155, P873, DOI 10.1083/jcb.200109095; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Rambourg A., 1997, GOLGI APPARATUS, P37; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317	18	113	115	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4921	4928		10.1074/jbc.M412407200	http://dx.doi.org/10.1074/jbc.M412407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15576368	Green Accepted, hybrid			2022-12-25	WOS:000227096600113
J	Hentges, KE; Weiser, KC; Schountz, T; Woodward, LS; Morse, HC; Justice, MJ				Hentges, KE; Weiser, KC; Schountz, T; Woodward, LS; Morse, HC; Justice, MJ			Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B-cell leukemia	ONCOGENE			English	Article						Evi3; EBF; Pax-5; mb-1; B29; B-cell leukemia	ANTIGEN RECEPTOR; FUNCTIONAL-CHARACTERIZATION; RETROVIRAL INTEGRATION; LYMPHOCYTE DEVELOPMENT; TARGET GENES; MOUSE; CD19; IDENTIFICATION; CLONING; TRANSCRIPTION	Retroviral insertions that activate proto-oncogenes are a primary cause of tumors in certain strains of mice. The AKXD recombinant inbred mice are predisposed to a variety of leukemias and lymphomas as a result of viral integration. One common insertion site, the ecotropic viral insertion site 3 ( Evi3), has been implicated in most B-cell tumors in the AKXD-27 strain. The Evi3 gene encodes a zinc-finger protein with sequence similarity to the Early B-cell Factor-Associated Zinc-finger gene (EBFAZ). We show that the Evi3 gene is overexpressed in several tumors with viral insertions at Evi3, which results in the upregulation of Early B-cell Factor (EBF)-target gene expression, suggesting that Evi3 modulates EBF activity. Reconstitution of primary leukemia cells showed that these tumors express high densities of the B-cell surface proteins CD19 and CD38, which are EBF targets. Using a transactivation assay, we show that the terminal six zinc-fingers of Evi3 are required for modi. cation of EBF activity. This is the first evidence that Evi3 expression in tumors alters the level of EBF target genes, and the first characterization of the Evi3 protein domains required for modulation of EBF activity. Further, these data imply that Evi3 misexpression initiates tumorigenesis by perturbing B-cell development via an interaction with EBF.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA; NIAID, Immunopathol Lab, NIH, Rockville, MD USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Room S413,1 Baylor Plaza, Houston, TX 77030 USA.	mjustice@bcm.tmc.edu	Schountz, Tony/I-2161-2017	Hentges, Kathryn/0000-0001-8917-3765; Morse, Herbert/0000-0002-9331-3705	NCI NIH HHS [R01 CA63229] Funding Source: Medline; NICHD NIH HHS [F32 HD42436] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD042436] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA063229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akerblad P, 1999, MOL CELL BIOL, V19, P392; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; Donis-Hernandez FR, 2001, EUR J IMMUNOL, V31, P1261, DOI 10.1002/1521-4141(200104)31:4<1261::AID-IMMU1261>3.0.CO;2-H; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Gisler R, 2000, BLOOD, V96, P1457, DOI 10.1182/blood.V96.4.1457.h8001457_1457_1464; Gisler R, 1999, MOL IMMUNOL, V36, P1067, DOI 10.1016/S0161-5890(99)00092-9; Greenbaum S, 2002, SEMIN IMMUNOL, V14, P405, DOI 10.1016/S1044532302000751; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hase H, 2004, BLOOD, V103, P2257, DOI 10.1182/blood-2003-08-2694; Hasegawa M, 2001, J IMMUNOL, V167, P3190, DOI 10.4049/jimmunol.167.6.3190; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; JUSTICE MJ, 1994, J VIROL, V68, P1293, DOI 10.1128/JVI.68.3.1293-1300.1994; KRONENBERG M, 1985, NATURE, V313, P647, DOI 10.1038/313647a0; Lund FE, 1999, J IMMUNOL, V162, P2693; Lund FE, 1996, J IMMUNOL, V157, P1455; Maier H, 2002, SEMIN IMMUNOL, V14, P415, DOI 10.1016/S1044532302000763; MUCENSKI ML, 1988, J VIROL, V62, P839, DOI 10.1128/JVI.62.3.839-846.1988; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Schountz T, 1996, J IMMUNOL, V157, P3893; Shim S, 2002, NUCLEIC ACIDS RES, V30, P3107, DOI 10.1093/nar/gkf437; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; Smith EMK, 2002, J IMMUNOL, V169, P261, DOI 10.4049/jimmunol.169.1.261; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Wang SS, 1997, J NEUROSCI, V17, P4149; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; Xu YK, 2002, J IMMUNOL, V169, P6910, DOI 10.4049/jimmunol.169.12.6910; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	39	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1220	1230		10.1038/sj.onc.1208243	http://dx.doi.org/10.1038/sj.onc.1208243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580294				2022-12-25	WOS:000226898700009
J	Kim, H; Kim, YN; Kim, H; Kim, CW				Kim, H; Kim, YN; Kim, H; Kim, CW			Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction	ONCOGENE			English	Article						hydrogen peroxide; apoptosis; Bfl-1; NF-kappa B	NF-KAPPA-B; HYDROGEN-PEROXIDE; REDOX REGULATION; HUMAN A1; GROWTH ARREST; UP-REGULATION; BCL-X; ACTIVATION; EXPRESSION; PROMOTER	Many types of mammalian cells produce ROS in response to many different stimuli to modulate a number of cellular functions, including apoptosis. However, the correlation between ROS and apoptosis remains controversial, and the mechanisms whereby ROS-induced signals are propagated to critical downstream targets remain largely undefined. Here, we demonstrate that hydrogen peroxide ( H2O2) upregulates the expression of Bfl-1, an antiapoptotic member of the Bcl-2 family, and that this is responsible for the antiapoptotic activity of ROS. When Jurkat, human leukemic T cells, were pretreated with 100 muM H2O2 and then treated with anti-Fas antibody, apoptosis was impaired without change of cell surface Fas expression. An investigation of the expression patterns of Bcl-2 family genes revealed that H2O2 treatment induced Bfl-1 gene expression, but left other genes unchanged, and this Bfl-1 expression and H2O2-induced antiapoptotic effect was inhibited by antioxidants or NF-kappaB inhibitor. In addition, an electromobility shift assay revealed that the p65/p50 subunits of NF-kappaB activated by H2O2 bound to a bfl-1 promoter. Neither the induction of Bfl-1 nor the antiapoptotic effect of H2O2 was detected in Bfl-1-knockdown Jurkat cell line containing Bfl-1 antisense (Bfl-1AS). These data indicate that oxidative stress induces the expression of Bfl-1 via NF-kappaB activation, and this early-response gene protects cells from Fas-mediated apoptosis. This may be a cellular survival mechanism of cells exposed to phagocytes-derived ROS.	Seoul Natl Univ, Coll Med, Dept Pathol, Tumor Immun Med Res Ctr, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Biochem & Mol Biol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pathol, Tumor Immun Med Res Ctr, 28 Yongon Dong, Seoul 110799, South Korea.	cwkim@plaza.snu.ac.kr	Kim, Chul-Woo/F-7008-2011	Kim, Hyungsoo/0000-0002-8189-5939				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fujita T, 2002, AM J RESP CELL MOL, V27, P542, DOI 10.1165/rcmb.4775; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilston V, 2001, FREE RADICAL RES, V35, P681, DOI 10.1080/10715760100301201; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hildeman DA, 2003, P NATL ACAD SCI USA, V100, P15035, DOI 10.1073/pnas.1936213100; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee KM, 2001, CELL SIGNAL, V13, P645, DOI 10.1016/S0898-6568(01)00178-4; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Malmberg KJ, 2001, J IMMUNOL, V167, P2595, DOI 10.4049/jimmunol.167.5.2595; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Moreb JS, 1997, LEUKEMIA, V11, P998, DOI 10.1038/sj.leu.2400719; Moreb JS, 2001, BLOOD, V97, P578, DOI 10.1182/blood.V97.2.578; Otsuji M, 1996, P NATL ACAD SCI USA, V93, P13119, DOI 10.1073/pnas.93.23.13119; Preston TJ, 2003, EXP CELL RES, V285, P146, DOI 10.1016/S0014-4827(03)00015-6; Pugazhenthi S, 2003, J NEUROCHEM, V84, P982, DOI 10.1046/j.1471-4159.2003.01606.x; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmielau J, 2001, CANCER RES, V61, P4756; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	47	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1252	1261		10.1038/sj.onc.1208282	http://dx.doi.org/10.1038/sj.onc.1208282			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592513				2022-12-25	WOS:000226898700012
J	Morris, C; Jalinot, P				Morris, C; Jalinot, P			Silencing of human Int-6 impairs mitosis progression and inhibits cyclin B-Cdk1 activation	ONCOGENE			English	Article						Int-6; mitosis; chromosome segregation; Cdk1; Wee1	MAMMARY-TUMOR VIRUS; FISSION YEAST HOMOLOG; TRANSLATION INITIATION; CELL-DIVISION; SUBUNIT; KINASES; PROTEIN; GENE; SITE; PHOSPHORYLATION	The Int-6 protein has been originally identified as the product of a mouse gene being a frequent integration site of the mouse mammary tumour virus. Here, we show that reducing Int-6 expression by RNA interference in HeLa cells markedly alters mitosis progression. Defects in spindle formation, chromosome segregation and cytokinesis were observed. These abnormalities of mitosis completion are correlated with an inhibition of cyclin B Cdk1 kinase activity, due to a prolonged inhibitory phosphorylated state of Cdk1. In line with this observation, the Wee1 tyrosine kinase that negatively controls Cdk1 was less efficiently inactivated during G2 in Int-6-depleted cells. These findings support the notion that the oncogenic properties associated with alteration of Int-6 originate from chromosomal instability.	Ecole Normale Super Lyon, CNRS, UMR5161, Lab Biol Mol Cellule,IFR 128, F-69364 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, UMR5161, Lab Biol Mol Cellule,IFR 128, 46 Allee Italie, F-69364 Lyon, France.	pjalinot@ens-lyon.fr	Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; ALVES K, 2004, THESIS ECOLE NORMALE; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; DANIELS MJ, 2004, SCIENCE, V16, P16; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; HOAREAU AK, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Kawasaki H, 2003, ONCOGENE, V22, P6839, DOI 10.1038/sj.onc.1206903; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Mizunuma M, 2001, EMBO J, V20, P1074, DOI 10.1093/emboj/20.5.1074; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1999, NATL CELL BIOL, V1, P73; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Secchiero P, 1998, BLOOD, V92, P1685, DOI 10.1182/blood.V92.5.1685.417k30_1685_1696; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Stock RP, 2003, NAT BIOTECHNOL, V21, P13, DOI 10.1038/nbt0103-13; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watkins SJ, 2004, CELL PROLIFERAT, V37, P149, DOI 10.1111/j.1365-2184.2004.00305.x; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370	39	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1203	1211		10.1038/sj.onc.1208268	http://dx.doi.org/10.1038/sj.onc.1208268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558017				2022-12-25	WOS:000226898700007
J	Schwarzer, R; Tondera, D; Arnold, W; Giese, K; Klippel, A; Kaufmann, J				Schwarzer, R; Tondera, D; Arnold, W; Giese, K; Klippel, A; Kaufmann, J			REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase	ONCOGENE			English	Article						apoptosis; hypoxia; phosphoinositide; 3-kinase; prostate cancer; gene silencing; RNA interference	INDUCIBLE FACTOR-I; CELL-GROWTH DOWNSTREAM; PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; PERICELLULAR HYPOXIA; TUMOR SUPPRESSION; CANCER-THERAPY; EXPRESSION; HIF-1-ALPHA; TARGET	Cancer cells frequently evade apoptosis during tumorigenesis by acquiring mutations in apoptotic regulators. Chronic activation of the PI 3-kinase-Akt pathway through loss of the tumor suppressor PTEN is one mechanism by which these cells can gain increased protection against apoptosis. W e report here that REDD1 ( RTP801) can act as a transcriptional downstream target of PI 3-kinase signaling in human prostate cancer cells (PC-3). REDD1 expression is markedly reduced in PC-3 cells treated with LY294002 (LY) or Rapamycin and strongly induced under hypoxic conditions in a hypoxia-inducible factor-1 (HIF-1)-dependent manner. Loss of function studies employing antisense molecules or RNA interference indicate that REDD1 is essential for invasive growth of prostate cancer cells in vitro and in vivo. Reduced REDD1 levels can sensitize cells towards apoptosis, whereas elevated levels of REDD1 induced by hypoxia or overexpression desensitize cells to apoptotic stimuli. Taken together our data designate REDD1 as a novel target for therapeutic intervention in prostate cancer.	Atugen AG, D-13125 Berlin, Germany		Kaufmann, J (corresponding author), Atugen AG, Otto Warburg Haus Nr 80,Robert Roessle Str 10, D-13125 Berlin, Germany.	kaufmann@atugen.com		Schwarzer, Rolf/0000-0002-8934-8788				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Akakura N, 2001, CANCER RES, V61, P6548; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Anastasiadis AG, 2003, CURR DRUG TARGETS, V4, P191, DOI 10.2174/1389450033491136; Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chrastina A, 2003, NEOPLASMA, V50, P251; Chun YS, 2000, EUR J BIOCHEM, V267, P4198, DOI 10.1046/j.1432-1327.2000.01453.x; Coffer PJ, 1998, BIOCHEM J, V335, P1; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Ghafar MA, 2003, PROSTATE, V54, P58, DOI 10.1002/pros.10162; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kaufmann J, 2004, BIOCHEM SOC T, V32, P355, DOI 10.1042/BST0320355; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Leenders F, 2004, EMBO J, V23, P3303, DOI 10.1038/sj.emboj.7600345; Mudgil AV, 2003, J INVEST DERMATOL, V121, P191, DOI 10.1046/j.1523-1747.2003.12320.x; Paul SAM, 2004, J CELL PHYSIOL, V200, P20, DOI 10.1002/jcp.10479; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Salnikow K, 2000, CANCER RES, V60, P3375; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Tondera D, 2004, J BIOL CHEM, V279, P31544, DOI 10.1074/jbc.M404704200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Yim S, 2003, J BIOL CHEM, V278, P38260, DOI 10.1074/jbc.M306016200; Zaman K, 1999, J NEUROSCI, V19, P9821; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	58	103	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1138	1149		10.1038/sj.onc.1208236	http://dx.doi.org/10.1038/sj.onc.1208236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592522				2022-12-25	WOS:000226898700002
J	Liu, Y; Beard, WA; Shock, DD; Prasad, R; Hou, EW; Wilson, SH				Liu, Y; Beard, WA; Shock, DD; Prasad, R; Hou, EW; Wilson, SH			DNA polymerase beta and flap endonuclease 1 enzymatic specificities sustain DNA synthesis for long patch base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE-1; AP ENDONUCLEASE-1; MAMMALIAN-CELLS; SITE REPAIR; LIGASE-I; RECONSTITUTION; HOMOLOG; URACIL; FEN-1; REPLICATION	DNA polymerase beta (pol beta) and flap endonuclease 1 (FEN1) are key players in pol beta-mediated long-patch base excision repair (LP-BER). It was proposed that this type of LP-BER is accomplished through FEN1 removal of a 2- to 11-nucleotide flap created by pol beta strand displacement DNA synthesis. To understand how these enzymes might cooperate during LP-BER, we characterized purified human pol beta DNA synthesis by utilizing various BER intermediates, including single-nucleotide-gapped DNA, nicked DNA, and nicked DNA with various lengths of flaps all with a 5'-terminal tetrahydrofuran (THF) residue. We observed that nicked DNA and nicked-THF flap DNA were poor substrates for pol beta-mediated DNA synthesis; yet, DNA synthesis was strongly stimulated by purified human FEN1. FEN1 did not improve pol beta substrate binding. FEN1 cleavage activity was required for the stimulation, suggesting that FEN1 removed a barrier to pol beta DNA synthesis. In addition, FEN1 cleavage on both nicked and nicked-THF flap DNA resulted in a one-nucleotide gapped DNA molecule that was an ideal substrate for pol beta. This study demonstrates that pol beta cooperates with FEN1 to remove DNA damage via a "Hit and Run" mechanism, involving alternating short gap production by FEN1 and gap filling by pol beta, rather than through coordinated formation and removal of a strand-displaced flap.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233,111 TW Alexander Dr,MD B2-06, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050159, ZIAES050159, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Brosh RM, 2002, BIOCHEMISTRY-US, V41, P12204, DOI 10.1021/bi026031j; Brosh RM, 2001, EMBO J, V20, P5791; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Cistulli C, 2004, DNA REPAIR, V3, P581, DOI 10.1016/j.dnarep.2003.09.012; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianova II, 2004, NUCLEIC ACIDS RES, V32, P2550, DOI 10.1093/nar/gkh567; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Donny W, 2004, J BIOL CHEM, V279, P25268, DOI 10.1074/jbc.M400804200; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREER SHELDON, 1962, JOUR MOLECULAR BIOL, V4, P123; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KORNBERG A, 1992, DNA REPLICATION, P142; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; Lawley P D, 1966, Prog Nucleic Acid Res Mol Biol, V5, P89, DOI 10.1016/S0079-6603(08)60232-9; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1975, Basic Life Sci, V5A, P31; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1973, BIOCHEMISTRY-US, V12, P5151, DOI 10.1021/bi00749a020; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; LUTZ WK, 1990, MUTAT RES, V238, P287, DOI 10.1016/0165-1110(90)90020-C; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; PAGE FL, 2003, J BIOL CHEM, V278, P18471; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Sattler U, 2003, EMBO REP, V4, P363, DOI 10.1038/sj.embor.embor796; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	67	117	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3665	3674		10.1074/jbc.M412922200	http://dx.doi.org/10.1074/jbc.M412922200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15561706	hybrid			2022-12-25	WOS:000226983900066
J	Schramm, A; von Schuetz, V; Christiansen, H; Havers, W; Papoutsi, M; Wilting, JR; Schweigerer, L				Schramm, A; von Schuetz, V; Christiansen, H; Havers, W; Papoutsi, M; Wilting, JR; Schweigerer, L			High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome	ONCOGENE			English	Article						neuroblastoma; activin A; angiogenesis; outcome	CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; CELL-PROLIFERATION; DOWN-REGULATION; IN-VITRO; INDUCTION; DIFFERENTIATION; ANGIOGENESIS; FOLLISTATIN; INHIBITORS	Amplification of the MYCN oncogene contributes to the malignant progression of human neuroblastomas, but the mechanisms have remained unclear. We have previously demonstrated that N-Myc facilitates angiogenesis by downregulating an angiogenesis inhibitor identified as the inhibin betaA homodimer activin A. Here, we have sought to define the molecular, biological and clinical consequences of activin A expression in human neuroblastoma. We report that enhanced activin A expression suppresses proliferation and colony formation of human neuroblastoma cells with amplified MYCN in vitro; that it inhibits neuroblastoma growth and angiogenesis in vivo; that it is highly expressed in differentiated, but not undifferentiated human neuroblastomas; and that it correlates with favourable outcome of neuroblastoma patients. Our results indicate that high activin A expression plays an important beneficial role in human neuroblastoma.	Klinikum Univ Gottingen, Zentrum Kinderheilkunde & Jugendmed, Abt Padiatr 1, D-37075 Gottingen, Germany; Univ Kinderklin Essen, Abt Hamatol Onkol & Endokrinol, Essen, Germany; Univ Kinderklin Marburg, Marburg, Germany	University of Gottingen; University of Duisburg Essen	Schweigerer, L (corresponding author), Klinikum Univ Gottingen, Zentrum Kinderheilkunde & Jugendmed, Abt Padiatr 1, Robert Koch Str 40, D-37075 Gottingen, Germany.	lothar.schweigerer@med.uni-goettingen.de	Schramm, Alexander/G-5688-2010	Schramm, Alexander/0000-0001-7670-7529				ALTABA AR, 1989, NATURE, V341, P33; ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cantero R, 1999, WORLD J SURG, V23, P1294, DOI 10.1007/s002689900665; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Cinatl J, 2002, INT J ONCOL, V20, P97; Fotsis T, 1997, CANCER RES, V57, P2916; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Giusti AF, 2000, EVOL DEV, V2, P294, DOI 10.1046/j.1525-142x.2000.00071.x; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; Mather JP, 1997, P SOC EXP BIOL MED, V215, P209; Rossler J, 1999, INT J CANCER, V81, P113; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Tuuri T, 1996, MOL CELL ENDOCRINOL, V121, P1, DOI 10.1016/0303-7207(96)03842-7; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wai DH, 2002, INT J ONCOL, V20, P441; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Woodruff TK, 1997, J ENDOCRINOL, V152, P167, DOI 10.1677/joe.0.1520167; Wu DD, 1999, BRAIN RES, V835, P369, DOI 10.1016/S0006-8993(99)01638-8	25	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					680	687		10.1038/sj.onc.1208087	http://dx.doi.org/10.1038/sj.onc.1208087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580313				2022-12-25	WOS:000226420400015
J	Carrizo, ME; Capaldi, S; Perduca, M; Irazoqui, FJ; Nores, GA; Monaco, HL				Carrizo, ME; Capaldi, S; Perduca, M; Irazoqui, FJ; Nores, GA; Monaco, HL			The antineoplastic lectin of the common edible mushroom (Agaricus bisporus) has two binding sites, each specific for a different configuration at a single epimeric hydroxyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THOMSEN-FRIEDENREICH-ANTIGEN; XEROCOMUS-CHRYSENTERON LECTIN; MACLURA-POMIFERA AGGLUTININ; NUCLEAR-PROTEIN IMPORT; SALINE-SOLUBLE LECTIN; CRYSTAL-STRUCTURE; CARBOHYDRATE-RECOGNITION; CELL-PROLIFERATION; PEANUT AGGLUTININ; PARASITIC FUNGUS	The lectin from the common mushroom Agaricus bisporus, the most popular edible species in Western countries, has potent antiproliferative effects on human epithelial cancer cells, without any apparent cytotoxicity. This property confers to it an important therapeutic potential as an antineoplastic agent. The three-dimensional structure of the lectin was determined by x-ray diffraction. The protein is a tetramer with 222 symmetry, and each monomer presents a novel fold with two beta sheets connected by a helix-loop-helix motif. Selectivity was studied by examining the binding of four monosaccharides and seven disaccharides in two different crystal forms. The T-antigen disaccharide, Gal beta 1-3GalNAc, mediator of the antiproliferative effects of the protein, binds at a shallow depression on the surface of the molecule. The binding of N-acetylgalactosamine overlaps with that moiety of the T antigen, but surprisingly, N-acetylglucosamine, which differs from N-acetylgalactosamine only in the configuration of epimeric hydroxyl 4, binds at a totally different site on the opposite side of the helix-loop-helix motif. The lectin thus has two distinct binding sites per monomer that recognize the different configuration of a single epimeric hydroxyl. The structure of the protein and its two carbohydrate-binding sites are described in detail in this study.	Univ Verona, Dept Sci & Technol, Biocrystallog Lab, I-37134 Verona, Italy; Univ Nacl Cordoba, Fac Chem Sci, Dept Biol Chem, RA-5000 Cordoba, Argentina	University of Verona; National University of Cordoba	Monaco, HL (corresponding author), Univ Verona, Dept Sci & Technol, Biocrystallog Lab, Strada Grazie 15, I-37134 Verona, Italy.	monaco@sci.univr.it	Perduca, Massimiliano/AAS-2666-2020	Perduca, Massimiliano/0000-0001-8291-0523; capaldi, stefano/0000-0003-4632-8100; Monaco, Hugo L./0000-0002-2067-0365; Carrizo, Maria Elena/0000-0003-0501-8894				Adhikari P, 2001, J BIOL CHEM, V276, P40734, DOI 10.1074/jbc.M103040200; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Babino A, 2003, FEBS LETT, V536, P106, DOI 10.1016/S0014-5793(03)00037-1; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BETAIL G, 1975, CR SOC BIOL, V169, P561; Birck C, 2004, J MOL BIOL, V344, P1409, DOI 10.1016/j.jmb.2004.10.007; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrizo ME, 2004, ACTA CRYSTALLOGR D, V60, P718, DOI 10.1107/S0907444904001969; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CRENSHAW RW, 1995, PLANT PHYSIOL, V107, P1465, DOI 10.1104/pp.107.4.1465; Holm L, 1999, NUCLEIC ACIDS RES, V27, P244, DOI 10.1093/nar/27.1.244; Hynes MJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-217; Irazoqui FJ, 1999, GLYCOBIOLOGY, V9, P59, DOI 10.1093/glycob/9.1.59; IRAZOQUI FJ, 1992, J IMMUNOL METHODS, V156, P199, DOI 10.1016/0022-1759(92)90026-P; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Jeyaprakash AA, 2002, J MOL BIOL, V321, P637, DOI 10.1016/S0022-2836(02)00674-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee X, 1998, J BIOL CHEM, V273, P6312, DOI 10.1074/jbc.273.11.6312; LESLIE AGW, 1992, INT CCP4 ESRF AECMB, V26, P27; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Loris R, 2000, J MOL BIOL, V301, P987, DOI 10.1006/jmbi.2000.4016; MAHANTA SK, 1992, BIOCHEM J, V284, P95, DOI 10.1042/bj2840095; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NORDBRINGHERTZ B, 1979, NATURE, V281, P477, DOI 10.1038/281477a0; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Ponstingl H, 2000, PROTEINS, V41, P47; Rosen S, 1996, EUR J BIOCHEM, V238, P830, DOI 10.1111/j.1432-1033.1996.0830w.x; Rosen S, 1996, EUR J BIOCHEM, V238, P822, DOI 10.1111/j.1432-1033.1996.0822w.x; RYDER SD, 1992, JNCI-J NATL CANCER I, V84, P1410, DOI 10.1093/jnci/84.18.1410; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; SAGE HJ, 1969, J BIOL CHEM, V244, P4713; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; Sanner M. F., 1995, Proceedings of the Eleventh Annual Symposium on Computational Geometry, pC6; Saul FA, 2000, STRUCTURE, V8, P593, DOI 10.1016/S0969-2126(00)00142-8; SHELDRICK GM, 1991, P CCP4 STUDY WEEKEND, P23; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; SUEYOSHI S, 1985, BIOL CHEM H-S, V366, P213, DOI 10.1515/bchm3.1985.366.1.213; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Transue TR, 1997, NAT STRUCT BIOL, V4, P779, DOI 10.1038/nsb1097-779; Trigueros V, 2003, BBA-GEN SUBJECTS, V1621, P292, DOI 10.1016/S0304-4165(03)00098-9; Ueda H, 1999, J BIOCHEM-TOKYO, V126, P530, DOI 10.1093/oxfordjournals.jbchem.a022482; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VandenAkker F, 1996, PROTEIN SCI, V5, P1184; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walser PJ, 2004, STRUCTURE, V12, P689, DOI 10.1016/j.str.2004.03.002; Wu AM, 2003, BIOCHEM J, V371, P311, DOI 10.1042/BJ20021361; YOUNG NM, 1991, FEBS LETT, V282, P382, DOI 10.1016/0014-5793(91)80518-8; YOUNG NM, 1991, EUR J BIOCHEM, V196, P631, DOI 10.1111/j.1432-1033.1991.tb15859.x; Yu LG, 2000, EUR J BIOCHEM, V267, P2122, DOI 10.1046/j.1432-1327.2000.01230.x; Yu LG, 2002, J BIOL CHEM, V277, P24538, DOI 10.1074/jbc.M203550200; Yu LG, 1999, J BIOL CHEM, V274, P4890, DOI 10.1074/jbc.274.8.4890; Yu LG, 2001, J CELL PHYSIOL, V186, P282, DOI 10.1002/1097-4652(200102)186:2&lt;282::AID-JCP1028&gt;3.0.CO;2-2	58	79	82	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10614	10623		10.1074/jbc.M411989200	http://dx.doi.org/10.1074/jbc.M411989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15596442	hybrid			2022-12-25	WOS:000227559600107
J	Murdoch, H; Feng, GJ; Bachner, DB; Ormiston, L; White, JH; Richter, D; Milligan, G				Murdoch, H; Feng, GJ; Bachner, DB; Ormiston, L; White, JH; Richter, D; Milligan, G			Periplakin interferes with g protein activation by the melanin-concentrating hormone receptor-1 by binding to the proximal segment of the receptor C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR; HORMONE-RECEPTOR; MOLECULAR CHARACTERIZATION; 5-HT2C RECEPTORS; MESSENGER-RNA; IDENTIFICATION; MCH; CLONING; LIGAND; EXPRESSION	In mice genetic ablation of expression of either melanin-concentrating hormone or the melanin-concentrating hormone-1 receptor results in alterations in energy metabolism and a lean phenotype. There is thus great interest in the function and regulation of this receptor. Using the yeast two-hybrid system we identified an interaction of the actin- and intermediate filament-binding protein periplakin with the intracellular C-terminal tail of the melanin-concentrating hormone-1 receptor. Direct association of these proteins was verified in pull-down and coimmunoprecipitation experiments. Truncations and internal deletions delineated the site of interaction to a group of 11 amino acids proximal to transmembrane helix VII, which was distinct from the binding site for the melanin-concentrating hormone-1 receptor-interacting zinc finger protein. Immunohistochemistry demonstrated coexpression of periplakin with melanin-concentrating hormone-1 receptor in specific cells of the piriform cortex, amygdala, and other structures of the adult mouse brain. Coexpression of the melanin-concentrating hormone-1 receptor with periplakin in human embryonic kidney 293 cells did not prevent agonist-mediated internalization of the receptor but did interfere with binding of S-35-labeled guanosine 5'-3-O-(thio)triphosphate ([S-35]GTPgammaS) to the G protein Galpha(01) and the elevation of [Ca2+](i). Coexpression of the receptor with the interacting zinc finger protein did not modulate receptor internalization or G protein activation. The interaction of periplakin with receptors was selective. Coexpression of periplakin with the IP prostanoid receptor did not result in coimmunoprecipitation nor interfere with agonist-mediated binding of [S-35]GTPgammaS to the G protein Galpha(s). Periplakin is the first protein described to modify the capacity of the melanin-concentrating hormone-1 receptor to initiate signal transduction.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Univ Klinikum Hamburg Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-22529 Hamburg, Germany; GlaxoSmithKline, Med Res Ctr, Pathway Discovery, Genom & Prote Sci, Stevenage SG1 2NY, Herts, England	University of Glasgow; University of Hamburg; University Medical Center Hamburg-Eppendorf; GlaxoSmithKline	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; An SZ, 2001, P NATL ACAD SCI USA, V98, P7576, DOI 10.1073/pnas.131200698; Audinot V, 2002, BIOCHEM BIOPH RES CO, V295, P841, DOI 10.1016/S0006-291X(02)00763-5; Bachner D, 2002, FEBS LETT, V526, P124, DOI 10.1016/S0014-5793(02)03115-0; BACHNER D, 1993, HUM MOL GENET, V2, P2043, DOI 10.1093/hmg/2.12.2043; Bachner D, 1999, FEBS LETT, V457, P522, DOI 10.1016/S0014-5793(99)01092-3; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Becamel C, 2004, J BIOL CHEM, V279, P20257, DOI 10.1074/jbc.M312106200; Becamel C, 2002, EMBO J, V21, P2332, DOI 10.1093/emboj/21.10.2332; Beekman JM, 2004, J BIOL CHEM, V279, P33875, DOI 10.1074/jbc.M401018200; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Burt AR, 1996, BIOCHEM J, V320, P227, DOI 10.1042/bj3200227; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chen CG, 1998, FEBS LETT, V441, P148, DOI 10.1016/S0014-5793(98)01547-6; Chen YY, 2002, ENDOCRINOLOGY, V143, P2469, DOI 10.1210/en.143.7.2469; Della-Zuana O, 2002, INT J OBESITY, V26, P1289, DOI 10.1038/sj.ijo.0802079; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Doggrell SA, 2003, EXPERT OPIN INV DRUG, V12, P1035, DOI 10.1517/13543784.12.6.1035; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; Forray C, 2003, CURR OPIN PHARMACOL, V3, P85, DOI 10.1016/S1471-4892(02)00013-9; Griffond B, 2002, INT REV CYTOL, V213, P233; Hervieu GJ, 2000, EUR J NEUROSCI, V12, P1194, DOI 10.1046/j.1460-9568.2000.00008.x; Hill J, 2001, J BIOL CHEM, V276, P20125, DOI 10.1074/jbc.M102068200; Kalinin AE, 2004, J BIOL CHEM, V279, P22773, DOI 10.1074/jbc.M313660200; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; Kreienkamp HJ, 2002, CURR OPIN PHARMACOL, V2, P581, DOI 10.1016/S1471-4892(02)00203-5; Lembo PMC, 1999, NAT CELL BIOL, V1, P267, DOI 10.1038/12978; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; Ludwig DS, 2001, J CLIN INVEST, V107, P379, DOI 10.1172/JCI10660; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Marsh DJ, 2002, P NATL ACAD SCI USA, V99, P3240, DOI 10.1073/pnas.052706899; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; Mori M, 2001, BIOCHEM BIOPH RES CO, V283, P1013, DOI 10.1006/bbrc.2001.4893; MULLANEY I, 1990, J NEUROCHEM, V55, P1890, DOI 10.1111/j.1471-4159.1990.tb05773.x; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pissios P, 2003, TRENDS ENDOCRIN MET, V14, P243, DOI 10.1016/S1043-2760(03)00079-1; Premont RT, 2002, METHOD ENZYMOL, V343, P611; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rodriguez M, 2001, MOL PHARMACOL, V60, P632; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shimomura Y, 1999, BIOCHEM BIOPH RES CO, V261, P622, DOI 10.1006/bbrc.1999.1104; Tan CP, 2002, GENOMICS, V79, P785, DOI 10.1006/geno.2002.6771; Tetsuka M, 2004, ENDOCRINOLOGY, V145, P3712, DOI 10.1210/en.2003-1638; Wang SK, 2001, J BIOL CHEM, V276, P34664, DOI 10.1074/jbc.M102601200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; White JH, 2002, METHODS, V27, P301, DOI 10.1016/S1046-2023(02)00087-7	56	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8208	8220		10.1074/jbc.M405215200	http://dx.doi.org/10.1074/jbc.M405215200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15590649	hybrid			2022-12-25	WOS:000227395700094
J	Dawson, PA; Hubbert, M; Haywood, J; Craddock, AL; Zerangue, N; Christian, WV; Ballatori, N				Dawson, PA; Hubbert, M; Haywood, J; Craddock, AL; Zerangue, N; Christian, WV; Ballatori, N			The heteromeric organic solute transporter alpha-beta, ost alpha-ost beta, is an ileal basolateral bile acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; LINKED GLYCANS; GENE; IDENTIFICATION; EXPRESSION; MEMBRANE; RECEPTOR; SLC10A2; CLONING; SALTS	Bile acids are transported across the ileal enterocyte brush border membrane by the well characterized apical sodium-dependent bile acid transporter (Asbt) Slc10a2; however, the carrier(s) responsible for transporting bile acids across the ileocyte basolateral membrane into the portal circulation have not been fully identified. Transcriptional profiling of wild type and Slc10a2 null mice was employed to identify a new candidate basolateral bile acid carrier, the heteromeric organic solute transporter (Ost)alpha-Ostbeta. By Northern blot analysis, Ostalpha and Ostbeta mRNA was detected only in mouse kidney and intestine, mirroring the horizontal gradient of expression of Asbt in the gastrointestinal tract. Analysis of Osta and Osto protein expression by immunohistochemistry localized both subunits to the basolateral surface of the mouse ileal enterocyte. The transport properties of Ostalpha-Ostbeta were analyzed in stably transfected Madin-Darby canine kidney cells. Coexpression of mouse Ostalpha-Ostbeta, but not the individual subunits, stimulated Na+-independent bile acid uptake and the apical-to-basolateral transport of taurocholate. In contrast, basolateral-to-apical transport was not affected by Ostalpha-Ostbeta expression. Co-expression of Osta and Ostbeta was required to convert the Osta subunit to a mature glycosylated endoglycosidase H-resistant form, suggesting that co-expression facilitates the trafficking of Osta through the Golgi apparatus. Immunolocalization studies showed that co-expression was necessary for plasma membrane expression of both Ostalpha and Ostbeta. These results demonstrate that the mouse Ostalpha-Ostbeta heteromeric transporter is a basolateral bile acid carrier and may be responsible for bile acid efflux in ileum and other ASBT-expressing tissues.	Wake Forest Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; XenoPort Inc, Santa Clara, CA 95051 USA; Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA	Wake Forest University; Wake Forest University; University of Rochester	Dawson, PA (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	pdawson@wfubmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048823, R29DK047987, R01DK047987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29 DK047987, R01 DK047987, DK47987, R01 DK048823, DK48823] Funding Source: Medline; NIEHS NIH HHS [P30 ES001247, ES01247] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adrian T E, 1997, Methods Mol Biol, V73, P239; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; Dawson PA, 2003, J BIOL CHEM, V278, P33920, DOI 10.1074/jbc.M306370200; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hakansson P, 2002, SCAND J GASTROENTERO, V37, P1089, DOI 10.1080/003655202320378301; Hallen S, 2002, BIOCHEMISTRY-US, V41, P14916, DOI 10.1021/bi0205404; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Jung D, 2004, GUT, V53, P78, DOI 10.1136/gut.53.1.78; Lazaridis KN, 2000, P NATL ACAD SCI USA, V97, P11092, DOI 10.1073/pnas.200325297; LIN MC, 1993, AM J PHYSIOL, V265, pG56, DOI 10.1152/ajpgi.1993.265.1.G56; LIN MC, 1988, J MEMBRANE BIOL, V106, P1, DOI 10.1007/BF01871762; LIN MC, 1990, J BIOL CHEM, V265, P14986; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Rius M, 2003, HEPATOLOGY, V38, P374, DOI 10.1053/jhep.2003.50331; Seward DJ, 2003, J BIOL CHEM, V278, P27473, DOI 10.1074/jbc.M301106200; Shneider BL, 2001, J PEDIATR GASTR NUTR, V32, P407, DOI 10.1097/00005176-200104000-00002; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SHOJI T, 2004, AM J PYSL, V284, pG749; Stelzner M, 2000, PFLUG ARCH EUR J PHY, V440, P157, DOI 10.1007/s004240000281; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; Walters HC, 2000, AM J PHYSIOL-GASTR L, V279, pG1188, DOI 10.1152/ajpgi.2000.279.6.G1188; Wang W, 2001, P NATL ACAD SCI USA, V98, P9431, DOI 10.1073/pnas.161099898; WEINBERG SL, 1986, J CLIN INVEST, V78, P44, DOI 10.1172/JCI112571; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Zelcer N, 2003, BIOCHEM J, V369, P23, DOI 10.1042/BJ20021081; Zeng H, 2000, CANCER RES, V60, P4779	28	275	285	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6960	6968		10.1074/jbc.M412752200	http://dx.doi.org/10.1074/jbc.M412752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15563450	hybrid, Green Accepted			2022-12-25	WOS:000227332700086
J	Normand, G; Hemmati, PG; Verdoodt, B; von Haefen, C; Wendt, J; Guner, D; May, E; Dorken, B; Daniel, PT				Normand, G; Hemmati, PG; Verdoodt, B; von Haefen, C; Wendt, J; Guner, D; May, E; Dorken, B; Daniel, PT			p14(ARF) induces G(2) cell cycle arrest in p53-and p21-deficient cells by down-regulating p34(cdc2) kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P19(ARF) TUMOR-SUPPRESSOR; HUMAN CANCER-CELLS; DNA-DAMAGE; P53; APOPTOSIS; PROTEIN; PATHWAYS; PRODUCT; GROWTH; IMMORTALIZATION	The human INK4a gene locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF). Although primarily proposed to require a functional p53(.)Mdm-2 signaling axis, recently p14(ARF) has been implicated in p53-independent cell cycle regulation. Here we show that p14(ARF) preferentially induces a G(2) arrest in tumor cells lacking functional p53 and/or p21. Expression of p14(ARF) impaired mitotic entry and enforced a primarily cytoplasmic localization of p34(cdc2) that was associated with a decrease in p34(cdc2) kinase activity and reduced p34(cdc2) protein expression. A direct physical interaction between p14(ARF) and p34(cdc2) was, nevertheless, ruled out by lack of co-immunoprecipitation. The p14(ARF)-induced depletion of p34(cdc2) was associated with impaired cdc25C phosphatase expression and a prominent shift to inhibitory Tyr-15-phosphorylation in G(2)-arrested cells lacking either p53, p21, or both. Finally, reconstitution of p34(cdc2) using a constitutively active, phosphorylation-deficient p34(cdc2AF) mutant alleviated this p14(ARF)-induced G(2) arrest, thereby allowing cell cycle progression. Taken together, these data indicate that p14(ARF) arrests cells lacking functional p53/p21 in the G(2) phase of the cell cycle by targeting p34(cdc2) kinase. This may represent an important fail-safe mechanism by which p14(ARF) protects p53/p21-deficient cells from unrestrained proliferation.	Univ Berlin, Charite, Med Ctr, Dept Hematol, D-13125 Berlin, Germany; CNRS, UPR 9045, Inst Andre Lwoff, F-94801 Villejuif, France	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Centre National de la Recherche Scientifique (CNRS)	Daniel, PT (corresponding author), Univ Berlin, Charite, Med Ctr, Dept Hematol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Normand, Guillaume/0000-0003-1228-3813				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Groth A, 2000, J BIOL CHEM, V275, P27473; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; ISAACS WB, 1991, CANCER RES, V51, P4716; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kuo ML, 2003, CANCER RES, V63, P1046; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Modestou M, 2001, CANCER RES, V61, P3145; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	38	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7118	7130		10.1074/jbc.M412330200	http://dx.doi.org/10.1074/jbc.M412330200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15582998	hybrid			2022-12-25	WOS:000227332700102
J	Fujita-Becker, S; Durrwang, U; Erent, M; Clark, RJ; Geeves, MA; Manstein, DJ				Fujita-Becker, S; Durrwang, U; Erent, M; Clark, RJ; Geeves, MA; Manstein, DJ			Changes in Mg2+ ion concentration and heavy chain phosphorylation regulate the motor activity of a class I myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE PAK; DICTYOSTELIUM-DISCOIDEUM; ADENOSINE-TRIPHOSPHATASE; INTRACELLULAR PH; BINDING-SITES; ADP RELEASE; ACTIN; DOMAIN; ACTIVATION; AFFINITY	Class I myosins are single-headed motor proteins implicated in various motile processes including organelle translocation, ion channel gating, and cytoskeleton reorganization. Dictyostelium discoideum myosin-ID belongs to subclass 1alpha, whose members are thought to be tuned for rapid sliding. The direct analysis of myosin-ID motor activity is made possible by the production of single polypeptide constructs carrying an artificial lever arm. Using these constructs, we show that the motor activity of myosin-ID is activated 80-fold by phosphorylation at the TEDS site. TEDS site phosphorylation acts by stabilizing the actomyosin complex and increasing the coupling between actin binding and the release of hydrolysis products. A surprising effect of Mg2+ ions on in vitro motility was discovered. Changes in the level of free Mg2+ ions within the physiological range are shown to modulate motor activity by inhibiting ADP release. Our results indicate that higher concentrations of free me, ions stabilize the tension-bearing actin myosin ADP state and shift the system from the production of rapid movement toward the generation of tension.	Hannover Med Sch, Inst Biophys Chem, D-30623 Hannover, Germany; Max Planck Inst Med Res, Dept Biophys, D-69120 Heidelberg, Germany; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	Hannover Medical School; Max Planck Society; University of Kent	Manstein, DJ (corresponding author), Hannover Med Sch, Inst Biophys Chem, OE 4350,Carl Neuberg Str 1, D-30623 Hannover, Germany.	manstein@bpc.mh-hannover.de	Geeves, Michael/F-7583-2011; Manstein, Dietmar J. J/M-1034-2013; Manstein, Dietmar J./AAG-2640-2019	Geeves, Michael/0000-0002-9364-8898; Manstein, Dietmar J. J/0000-0003-0763-0147; Manstein, Dietmar J./0000-0003-0763-0147				Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAIN G, 1991, MOL GEN GENET, V226, P59, DOI 10.1007/BF00273587; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Batra R, 1999, BIOCHEMISTRY-US, V38, P6126, DOI 10.1021/bi982251e; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Brzeska H, 2001, J BIOL CHEM, V276, P47468, DOI 10.1074/jbc.M108957200; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; De La Roche MA, 2003, BIOCHEM J, V374, P697, DOI 10.1042/BJ20030656; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FAULSTICH H, 1983, EXP CELL RES, V144, P73, DOI 10.1016/0014-4827(83)90443-3; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geli MI, 2000, EMBO J, V19, P4281, DOI 10.1093/emboj/19.16.4281; Ito K, 2003, BIOCHEM BIOPH RES CO, V312, P958, DOI 10.1016/j.bbrc.2003.10.202; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; Kliche W, 2001, EMBO J, V20, P40, DOI 10.1093/emboj/20.1.40; Knetsch MLW, 2002, J MUSCLE RES CELL M, V23, P605, DOI 10.1023/A:1024498805771; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; Lee SF, 1998, J BIOL CHEM, V273, P27911, DOI 10.1074/jbc.273.43.27911; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MARTIN JB, 1987, BIOCHIM BIOPHYS ACTA, V931, P16, DOI 10.1016/0167-4889(87)90045-0; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Michailova A, 2001, BIOPHYS J, V81, P614, DOI 10.1016/S0006-3495(01)75727-X; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; SATRE M, 1985, BIOCHEM BIOPH RES CO, V132, P140, DOI 10.1016/0006-291X(85)90999-4; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; Tsiavaliaris G, 2004, NATURE, V427, P558, DOI 10.1038/nature02303; Wang ZY, 1998, P NATL ACAD SCI USA, V95, P15200, DOI 10.1073/pnas.95.26.15200; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; Weiss S, 2001, J BIOL CHEM, V276, P45902, DOI 10.1074/jbc.M107434200; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787	44	47	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6064	6071		10.1074/jbc.M412473200	http://dx.doi.org/10.1074/jbc.M412473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579903	hybrid			2022-12-25	WOS:000227217100112
J	Haynes, LP; Thomas, GMH; Burgoyne, RD				Haynes, LP; Thomas, GMH; Burgoyne, RD			Interaction of neuronal calcium sensor-1 and ADP-ribosylation factor 1 allows bidirectional control of phosphatidylinositol 4-kinase beta and trans-Golgi network-plasma membrane traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CANINE KIDNEY-CELLS; ENDOPLASMIC-RETICULUM; PC12 CELLS; 4-OH KINASE; ARF; EXOCYTOSIS; CHROMAFFIN; FREQUENIN; VESICLES	We have identified a novel Ca2+-dependent interaction between neuronal calcium sensor-1 (NCS-1) and the GTPase ARF1. Both of these proteins are localized to the Golgi complex, and both regulate phosphatidylinositol 4-kinase IIIbeta (PI(4)Kbeta). Spatial and temporal control of phosphatidylinositol 4-phosphate levels through activation of PI(4)Kbeta is important for the recruitment of trafficking complexes to the traps-Golgi network (TGN) and vesicular traffic from this organelle. The NCS-1-ARF1 interaction and its specificity have been demonstrated through in vitro binding assays, in vitro enzyme assay, and through functional cellular assays. We show that NCS-1 can exert bidirectional effects to activate PI(4)Kbeta on its own or inhibit the activation by ARF1. NCS-1 was shown to modulate the effects of expression of ARF mutants that disrupt Golgi morphology and to recruit GDP-loaded ARF to the Golgi complex in a Ca2+-dependent manner. We demonstrate antagonist effects of NCS-1 and ARF on constitutive and regulated exocytosis. The NCS-1-ARF1 interaction provides evidence for functional cross-talk between Ca2+-dependent and ARF-dependent pathways in TGN to plasma membrane traffic.	Univ Liverpool, Sch Biomed Sci, Physiol Lab, Liverpool L69 3BX, Merseyside, England; UCL, Dept Physiol, London WC1E 6JJ, England	University of Liverpool; University of London; University College London	Burgoyne, RD (corresponding author), Univ Liverpool, Sch Biomed Sci, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387				BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; Burgoyne RD, 2004, TRENDS NEUROSCI, V27, P203, DOI 10.1016/j.tins.2004.01.010; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; DASCHER C, 1994, J BIOL CHEM, V269, P1437; De Matteis MA, 2004, NAT CELL BIOL, V6, P487, DOI 10.1038/ncb0604-487; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Gleeson PA, 2004, TRAFFIC, V5, P315, DOI 10.1111/j.1398-9219.2004.00182.x; Glenn DE, 1998, J NEUROCHEM, V71, P2023; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; Hama H, 1999, MOL BIOL CELL, V10, p303A; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; Haynes LP, 2004, J BIOL CHEM, V279, P547, DOI 10.1074/jbc.M309617200; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Huttner IG, 2003, J BIOL CHEM, V278, P4862, DOI 10.1074/jbc.M207920200; Ivings L, 2002, BIOCHEM J, V363, P599, DOI 10.1042/0264-6021:3630599; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Koizumi S, 2002, J BIOL CHEM, V277, P30315, DOI 10.1074/jbc.M201132200; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Mora S, 2002, J BIOL CHEM, V277, P27494, DOI 10.1074/jbc.M203669200; Munro S, 2004, NAT CELL BIOL, V6, P469, DOI 10.1038/ncb0604-469; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rajebhosale M, 2003, J BIOL CHEM, V278, P6075, DOI 10.1074/jbc.M204702200; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Taverna E, 2002, J CELL SCI, V115, P3909, DOI 10.1242/jcs.00072; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200	53	107	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6047	6054		10.1074/jbc.M413090200	http://dx.doi.org/10.1074/jbc.M413090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15576365	hybrid			2022-12-25	WOS:000227217100110
J	Kobayashi, K; Yoshioka, S; Kato, Y; Asano, Y; Aono, S				Kobayashi, K; Yoshioka, S; Kato, Y; Asano, Y; Aono, S			Regulation of aldoxime dehydratase activity by redox-dependent change in the coordination structure of the aldoxime-heme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE BOND SYNTHESIS; CYTOCHROME-C-OXIDASE; SP STRAIN OXB-1; PHENYLACETALDOXIME DEHYDRATASE; BACILLUS SP; NITRILE HYDRATASE; CONTAINING LYASE; MECHANISM; LIGATION; LIGAND	Phenylacetaldoxime dehydratase from Bacillus sp. strain OxB-1 (OxdB) catalyzes the dehydration of Z-phenylacetaldoxime (PAOx) to produce phenylacetonitrile. OxdB contains a protoheme that works as the active center of the dehydration reaction. The enzymatic activity of ferrous OxdB was 1150-fold higher than that of ferric OxdB, indicating that the ferrous heme was the active state in OxdB catalysis. Although ferric OxdB was inactive, the substrate was bound to the ferric heme iron. Electron paramagnetic resonance spectroscopy revealed that the oxygen atom of PAOx was bound to the ferric heme, whereas PAOx was bound to the ferrous heme in OxdB via the nitrogen atom of PAOx. These results show a novel mechanism by which the activity of a heme enzyme is regulated; that is, the oxidation state of the heme controls the coordination structure of a substrate-heme complex, which regulates enzymatic activity. Rapid scanning spectroscopy using stopped-flow apparatus revealed that a reaction intermediate (the PAOx-ferrous OxdB complex) showed Soret, alpha, and beta bands at 415, 555, and 524 nm, respectively. The formation of this intermediate complex was very fast, finishing within the dead time of the stopped-flow mixer (-3 ms). Site-directed mutagenesis revealed that His-306 was the catalytic residue responsible for assisting the elimination of the hydrogen atom of PAOx. The pH dependence of OxdB activity suggested that another amino acid residue that assists the elimination of the OH group of PAOx would work as a catalytic residue along with His-306.	Toyama Prefectural Univ, Fac Engn, Biotechnol Res Ctr, Toyama 9390398, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan	Toyama Prefectural University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB)	Aono, S (corresponding author), Toyama Prefectural Univ, Fac Engn, Biotechnol Res Ctr, 5180 Kurokawa, Toyama 9390398, Japan.	asano@pu-toyama.ac.jp	Aono, Shigetoshi/ABD-7618-2020; Kobayashi, Katsuaki/AAW-2734-2020; Asano, Yasuhisa/K-5898-2016	Aono, Shigetoshi/0000-0002-2870-3694; Kobayashi, Katsuaki/0000-0003-1608-2752; Asano, Yasuhisa/0000-0003-3645-3952				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; Asano Y, 2002, J BIOTECHNOL, V94, P65, DOI 10.1016/S0168-1656(01)00419-9; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BOUCHER JL, 1994, BIOCHEMISTRY-US, V33, P7811, DOI 10.1021/bi00191a008; BRAUTIGAN DL, 1977, J BIOL CHEM, V252, P574; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; Hiner ANP, 2002, J INORG BIOCHEM, V91, P27, DOI 10.1016/S0162-0134(02)00390-2; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; Kato Y, 2000, BIOCHEMISTRY-US, V39, P800, DOI 10.1021/bi991598u; Kato Y, 2003, PROTEIN EXPRES PURIF, V28, P131, DOI 10.1016/S1046-5928(02)00638-1; Kato Y, 2004, J BIOSCI BIOENG, V97, P250, DOI 10.1016/S1389-1723(04)70200-5; Kato Y, 1999, J MOL CATAL B-ENZYM, V6, P249, DOI 10.1016/S1381-1177(98)00080-0; Konishi K, 2004, J BIOL CHEM, V279, P47619, DOI 10.1074/jbc.M407223200; Lefevre-Groboillot D, 2001, BIOCHEMISTRY-US, V40, P9909, DOI 10.1021/bi010561i; LIPPARDS SJ, 1971, PRINCIPLES BIOINORGA, P283; Loewen PC, 2004, BIOCHEMISTRY-US, V43, P3089, DOI 10.1021/bi035663i; MAURUS R, 1994, J BIOL CHEM, V269, P12606; Oinuma KI, 2003, J BIOL CHEM, V278, P29600, DOI 10.1074/jbc.M211832200; Perutz MF, 1999, CHEM BIOL, V6, pR291, DOI 10.1016/S1074-5521(99)80121-5; PORTER TD, 1991, J BIOL CHEM, V266, P13469; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; SALEMME FR, 1977, ANNU REV BIOCHEM, V46, P299, DOI 10.1146/annurev.bi.46.070177.001503; Sigman JA, 1999, BIOCHEMISTRY-US, V38, P11122, DOI 10.1021/bi990815o; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; VONJAGOW G, 1980, ANNU REV BIOCHEM, V49, P281; Walker FA, 2004, CHEM REV, V104, P589, DOI 10.1021/cr020634j; WALKER FA, 1984, J AM CHEM SOC, V106, P6888, DOI 10.1021/ja00335a003; Wang CCY, 1999, J AM CHEM SOC, V121, P12094, DOI 10.1021/ja992373+; Watanabe Y, 2001, J BIOL INORG CHEM, V6, P846, DOI 10.1007/s007750100278; Woggon WD, 2001, J INORG BIOCHEM, V83, P289, DOI 10.1016/S0162-0134(00)00175-6; Xie SX, 2003, BIOCHEMISTRY-US, V42, P12056, DOI 10.1021/bi035092u; Xie SX, 2001, BIOSCI BIOTECH BIOCH, V65, P2666, DOI 10.1271/bbb.65.2666; Yoshikawa S, 2002, ADV PROTEIN CHEM, V60, P341; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9; Youngs HL, 2000, BIOCHEMISTRY-US, V39, P9994, DOI 10.1021/bi000679j	44	33	33	4	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5486	5490		10.1074/jbc.M410474200	http://dx.doi.org/10.1074/jbc.M410474200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15596434	hybrid			2022-12-25	WOS:000227217100046
J	Kim, EJ; Park, JI; Nelkin, BD				Kim, EJ; Park, JI; Nelkin, BD			IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER CELLS; HA-RAS ONCOGENE; CYCLE ARREST; NEGATIVE REGULATOR; PC12 CELLS; P53; TRANSFORMATION; FAMILY; TRANSCRIPTION; ACTIVATION	Activation of Ras or Raf in the human medullary thyroid carcinoma (MTC) cell line, TT, induces growth arrest and differentiation via two parallel, yet independent, pathways. One of these pathways is intracellular and the other is a cell-extrinsic, autocrine/paracrine pathway mediated by the leukemia inhibitory factor (LIF)/JAK/STAT pathway. Here, we show that IFI16 is a necessary and sufficient downstream effector for LIF effects in MTC cells, specifically required for the LIF/JAK/STAT pathway-induced growth inhibition in these cells. IFI16 was induced by Raf or LIF. Dominant-negative STAT3 could block the induction, indicating that Raf can induce IFI16 only via the cell-extrinsic pathway. Knock-down of IFI16 using siRNA abrogated LIF-induced changes in cellular levels of E2F1, cyclin D1, and p21(WAF/CIP1), and cell cycle arrest. In addition, adenovirus-mediated overexpression of IFI16 was sufficient to induce growth arrest. In contrast to its essential role for LIF-mediated growth arrest, IFI16 was not required for differentiation induced by LIF. Knock-down of IFI16 could not block changes in differentiation markers of the MTC cells, including calcitonin, RET, and cell morphology. Our study identifies IFI16 as an essential growth-specific effector of the cell-extrinsic growth inhibitory pathway of Ras/Raf signaling in MTC cells.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Park, JI (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB572, Baltimore, MD 21231 USA.	jpark15@jhmi.edu		Park, Jong-In/0000-0001-7248-4735	NATIONAL CANCER INSTITUTE [R01CA085567] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA85567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; CARSON EB, 1995, CANCER RES, V55, P2048; Carson-Walter EB, 1998, ONCOGENE, V17, P367, DOI 10.1038/sj.onc.1201938; Chen H, 1996, SURGERY, V120, P168, DOI 10.1016/S0039-6060(96)80284-4; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fujiuchi N, 2004, J BIOL CHEM, V279, P20339, DOI 10.1074/jbc.M400344200; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Groth A, 2000, J BIOL CHEM, V275, P27473; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Knight D, 2001, PULM PHARMACOL THER, V14, P169, DOI 10.1006/pupt.2001.0282; Kwak JC, 2003, J BIOL CHEM, V278, P40899, DOI 10.1074/jbc.M308012200; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Minna JD, 2002, CANCER J, V8, pS41; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Ravi RK, 1999, AM J RESP CELL MOL, V20, P543, DOI 10.1165/ajrcmb.20.4.3406; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	42	43	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4913	4920		10.1074/jbc.M410542200	http://dx.doi.org/10.1074/jbc.M410542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572361	hybrid			2022-12-25	WOS:000227096600112
J	Yoo, JH; Park, CY; Kim, JC; Heo, WD; Cheong, MS; Park, HC; Kim, MC; Moon, BC; Choi, MS; Kang, YH; Lee, JH; Kim, HS; Lee, SM; Yoon, HW; Lim, CO; Yun, DJ; Lee, SY; Chung, WS; Cho, MJ				Yoo, JH; Park, CY; Kim, JC; Heo, WD; Cheong, MS; Park, HC; Kim, MC; Moon, BC; Choi, MS; Kang, YH; Lee, JH; Kim, HS; Lee, SM; Yoon, HW; Lim, CO; Yun, DJ; Lee, SY; Chung, WS; Cho, MJ			Direct interaction of a divergent CaM isoform and the transcription factor, MYB2, enhances salt tolerance in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT CALMODULIN ISOFORMS; R2R3-MYB GENE FAMILY; DIFFERENTIAL ACTIVATION; SIGNAL-TRANSDUCTION; DEPENDENT ENZYMES; BINDING PROTEINS; CALCIUM; THALIANA; STRESS; RECOGNITION	Calmodulin (CaM), a ubiquitous calcium-binding protein, regulates diverse cellular functions by modulating the activity of a variety of enzymes and proteins. Plants express numerous CaM isoforms that exhibit differential activation and/or inhibition of CaM-dependent enzymes in vitro. However, the specific biological functions of plant CaM are not well known. In this study, we isolated a cDNA encoding a CaM binding transcription factor, MYB2, that regulates the expression of salt- and dehydration-responsive genes in Arabidopsis. This was achieved using a salt-inducible CaM isoform (GmCaM4) as a probe from a salt-treated Arabidopsis expression library. Using domain mapping, we identified a Ca(2+)-dependent CaM binding domain in MYB2. The specific binding of CaM to CaM binding domain was confirmed by site-directed mutagenesis, a gel mobility shift assay, split ubiquitin assay, and a competition assay using a Ca(2+)/CaM-dependent enzyme. Interestingly, the specific CaM isoform GmCaM4 enhances the DNA binding activity of AtMYB2, whereas this was inhibited by a closely related CaM isoform (GmCaM1). Overexpression of GmCaM4 in Arabidopsis up-regulates the transcription rate of AtMYB2-regulated genes, including the proline-synthesizing enzyme P5CS1 (triangle(1)-pyrroline-5-carboxylate synthetase-1), which confers salt tolerance by facilitating proline accumulation. Therefore, we suggest that a specific CaM isoform mediates salt-induced Ca(2+) signaling through the activation of an MYB transcriptional activator, thereby resulting in salt tolerance in plants.	Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci, BK21 Program, Jinju 660701, South Korea; Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea	Gyeongsang National University; Gyeongsang National University	Chung, WS (corresponding author), Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci, BK21 Program, Jinju 660701, South Korea.	chungws@gsnu.ac.kr; choslab@gsnu.ac.kr	Cho, Moo Je/F-1649-2010; Park, Chan Young/F-5696-2010	Park, Chan Young/0000-0002-5183-3665; Chung, Woo Sik/0000-0002-2297-3220; Yun, Dae-Jin/0000-0002-3638-6043				Abe H, 1997, PLANT CELL, V9, P1859, DOI 10.1105/tpc.9.10.1859; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; BOTELLA JR, 1994, PLANT MOL BIOL, V24, P757, DOI 10.1007/BF00029857; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; Chung WS, 2000, PLANT CELL, V12, P1393, DOI 10.1105/tpc.12.8.1393; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EDMAN CF, 1994, EUR J BIOCHEM, V226, P725, DOI 10.1111/j.1432-1033.1994.tb20101.x; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Heo WD, 1999, P NATL ACAD SCI USA, V96, P766, DOI 10.1073/pnas.96.2.766; Hoeren FU, 1998, GENETICS, V149, P479; HORN ME, 1983, PLANT PHYSIOL, V72, P426, DOI 10.1104/pp.72.2.426; Kao YL, 2000, BIOCHEM BIOPH RES CO, V267, P201, DOI 10.1006/bbrc.1999.1896; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kiegle E, 2000, PLANT J, V23, P267, DOI 10.1046/j.1365-313x.2000.00786.x; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Kranz HD, 1998, PLANT J, V16, P263, DOI 10.1046/j.1365-313x.1998.00278.x; Laser H, 2000, P NATL ACAD SCI USA, V97, P13732, DOI 10.1073/pnas.250400997; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Lee SH, 2000, BIOCHEM J, V350, P299, DOI 10.1042/0264-6021:3500299; Lee SH, 1999, BBA-PROTEIN STRUCT M, V1433, P56, DOI 10.1016/S0167-4838(99)00149-1; Liao BR, 1999, P NATL ACAD SCI USA, V96, P6217, DOI 10.1073/pnas.96.11.6217; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; Nuccio ML, 1999, CURR OPIN PLANT BIOL, V2, P128, DOI 10.1016/S1369-5266(99)80026-0; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; Raghothama KG, 1997, PLANT MOL BIOL, V34, P393, DOI 10.1023/A:1005812217945; Reddy VS, 2002, J BIOL CHEM, V277, P9840, DOI 10.1074/jbc.M111626200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Shinozaki K, 1997, PLANT PHYSIOL, V115, P327, DOI 10.1104/pp.115.2.327; SHINOZAKI K, 1992, PLANT MOL BIOL, V19, P493, DOI 10.1007/BF00023398; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Szymanski DB, 1996, PLANT CELL, V8, P1069, DOI 10.1105/tpc.8.6.1069; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; URAO T, 1993, PLANT CELL, V5, P1529, DOI 10.1105/tpc.5.11.1529; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Yoshiba Y, 1999, BIOCHEM BIOPH RES CO, V261, P766, DOI 10.1006/bbrc.1999.1112; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	47	187	214	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3697	3706		10.1074/jbc.M408237200	http://dx.doi.org/10.1074/jbc.M408237200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15569682	hybrid			2022-12-25	WOS:000226983900069
J	Truong, AHL; Cervi, D; Lee, J; Ben-David, Y				Truong, AHL; Cervi, D; Lee, J; Ben-David, Y			Direct transcriptional regulation of MDM2 by Fli-1	ONCOGENE			English	Article						erythroleukemia; Fli-1; MDM2; Friend Disease; p53	MULV-INDUCED-ERYTHROLEUKEMIAS; MURINE LEUKEMIA-VIRUS; DNA-BINDING; F-MULV; ERYTHROID PROLIFERATION; P53 PROTEIN; ETS FAMILY; DIFFERENTIATION; CELLS; GENE	The Ets transcription factor, Fli-1, has been shown to play a pivotal role in the induction and progression of Friend Murine Leukemia Virus (F-MuLV)-induced erythroleukemia, with its overexpression leading to erythroblast survival, proliferation, and inhibition of terminal differentiation. P53 inactivation is an additional genetic alteration that occurs in late-stage leukemic progression associated with in vivo and in vitro immortalization. Since p53 protein expression levels are low, to undetectable, in primary erythroleukemic cells that express elevated levels of Fli-1, we investigated the potential regulation of p53 by Fli-1. We assessed whether the overexpression of Fli-1 could partially regulate p53 via modulation of its well-established regulator, MDM2. In this paper, we demonstrate that the promoter of MDM2 contains a consensus binding site for Fli-1that is bound by this transcription factor in vitro and in vivo, resulting in MDM2 transcriptional regulation. We further substantiate these observations in vivo by demonstrating a positive correlation in the expression of Fli-1and MDM2, and a negative correlation with p53 in leukemic tissues obtained from mice with Friend Disease. These observations depict a significant function of Fli-1 overexpression in the indirect control of p53, evidently capable of leading to an increasingly aggressive erythroleukemic clone in vivo.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Res Bldg,Room S-216,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; CordonCardo C, 1997, CANCER RES, V57, P1217; Datta NS, 2002, EXP HEMATOL, V30, P158, DOI 10.1016/S0301-472X(01)00780-9; DAVID YB, 1988, ONCOGENE, V3, P179; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Kawada H, 2001, INT J HEMATOL, V73, P463, DOI 10.1007/BF02994008; Lee CR, 2003, ANTICANCER RES, V23, P2159; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAO XH, 1994, J BIOL CHEM, V269, P18216; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Prasher JM, 2001, ONCOGENE, V20, P2946, DOI 10.1038/sj.onc.1204395; RAO VN, 1993, ONCOGENE, V8, P2167; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	29	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					962	969		10.1038/sj.onc.1208323	http://dx.doi.org/10.1038/sj.onc.1208323			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592502				2022-12-25	WOS:000226749200002
J	Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE				Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE			Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and nonantiangiogenic mechanisms	ONCOGENE			English	Article						antiangiogenesis; VEGFR tyrosine kinase inhibitor; mammary cancer; C3(1)/Tag transgenic mice	BONE-MARROW MICROENVIRONMENT; MULTIPLE-MYELOMA CELLS; TYROSINE KINASE; MOUSE MODEL; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; BREAST-CANCER; THERAPY; ANTIGEN; ENDOSTATIN	Cancer growth and progression is often critically influenced by the production of vascular endothelial growth factor ( VEGF), a key mediator of angiogenesis. VEGF produced by tumor cells stimulates endothelial cell growth through the binding and activation of the KDR/Flk-1 receptor (VEGFR-2) on endothelial cells. Recently, some human breast cancer epithelial cells have been shown to express VEGF receptors, suggesting a potential autocrine-mediated growth stimulation of a subset of cancers by VEGF. We demonstrate that mammary tumors in the C3(1)/Tag transgenic model express VEGF and VEGF receptors and tumor growth is stimulated by this autocrine mechanism. GW654652, an indazolylpyrimidine, is a VEGFRs tyrosine kinase inhibitor that dramatically reduces both angiogenesis and tumor cell growth in this model, as demonstrated using both in vitro and in vivo assays. GW654652 significantly decreased cell proliferation and induced apoptosis in human umbilical vein endothelial cells and M6 mammary tumor cells derived from C3(1)/Tag ( Tag: simian virus 40 T-antigen) transgenic mice. A 75% reduction in VEGF-induced angiogenesis was observed with GW654652 using the chick chorioallantoic membrane assay, whereas GW654652 produced an approximately 85% reduction in angiogenesis as assessed by the Matrigel(TM) plug assay. A profound inhibitory effect on tumor growth in the C3(1)/Tag transgenic model of human breast cancer was observed with oral administration of GW654652 as measured by delayed tumor onset, decreased multiplicity, reduced tumor volume, and extended animal survival. The antitumor effects of GW654652 were associated with reduced tumor vascularization and no apparent toxicity. Tumor growth, however, rapidly advanced following cessation of treatment. This is the first demonstration that a VEGF receptor inhibitor, GW654652, has a strong inhibitory effect on angiogenesis and tumor progression in a transgenic model of mammary cancer, suggesting that this is a useful approach for preclinical testing of such agents.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Cell Biol Sect, NIH, Bethesda, MD USA; GlaxoSmithKline, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); GlaxoSmithKline	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Room C629,41 Medlars Dr, Bethesda, MD 20892 USA.	jegreen@nih.gov	Calvo, Alfonso/V-7945-2017	Calvo, Alfonso/0000-0003-4074-4242	NATIONAL CANCER INSTITUTE [Z01BC005740, ZIABC005740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000482] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Calvo A, 2002, CANCER RES, V62, P3934; Calvo A, 2002, INT J CANCER, V101, P224, DOI 10.1002/ijc.10589; Chen YL, 2003, ACTA BOT SIN, V45, P40; Ciardiello F, 2002, EXPERT OPIN INV DRUG, V11, P755; DEV I, 2003, P AM ASSOC CANC RES, V45, P4695; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Heer K, 2001, CLIN CANCER RES, V7, P3491; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holzer RG, 2003, BREAST CANCER RES TR, V77, P65, DOI 10.1023/A:1021175931177; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Itokawa T, 2002, MOL CANCER THER, V1, P295; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KUMAR R, 2003, P AM ASSOC CANC RES, V45, P39; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lin B, 2002, CANCER RES, V62, P5019; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Nakopoulou L, 2002, HUM PATHOL, V33, P863, DOI 10.1053/hupa.2002.126879; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; Presta LG, 1997, CANCER RES, V57, P4593; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Reich S, 2003, MOL VIS, V9, P210; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shibata MA, 1996, CANCER RES, V56, P2998; Spiekermann K, 2002, EXP HEMATOL, V30, P767, DOI 10.1016/S0301-472X(02)00837-8; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Traxler P, 2003, EXPERT OPIN THER TAR, V7, P215, DOI 10.1517/14728222.7.2.215; Xie B, 1999, BRIT J CANCER, V81, P1335, DOI 10.1038/sj.bjc.6692206; Yokoyama Y, 2000, CANCER RES, V60, P4362; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	38	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					790	800		10.1038/sj.onc.1208221	http://dx.doi.org/10.1038/sj.onc.1208221			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592523				2022-12-25	WOS:000226577100005
J	Birukova, AA; Birukov, KG; Smurova, K; Adyshev, D; Kaibuchi, K; Alieva, I; Garcia, JGN; Verin, AD				Birukova, AA; Birukov, KG; Smurova, K; Adyshev, D; Kaibuchi, K; Alieva, I; Garcia, JGN; Verin, AD			Novel role of microtubules in thrombin-induced endothelial barrier dysfunction	FASEB JOURNAL			English	Article						thrombin; G-proteins; Rho-kinase; tau; pulmonary endothelium	NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TAU; RHO-KINASE; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; NEURITE RETRACTION; ADENYLYL-CYCLASE; TYROSINE KINASES; MAMMALIAN-CELLS	Disturbances in endothelial cell (EC) barrier regulation are critically dependent upon rearrangements of EC actin cytoskeleton. However, the role of microtubule (MT) network in the regulation of EC permeability is not well understood. We examined involvement of MT remodeling in thrombin-induced EC permeability and explored MT regulation by heterotrimeric G12/13 proteins and by small GTPase Rho. Thrombin induced phosphorylation of MT regulatory protein tau at Ser(409) and Ser(262) and peripheral MT disassembly, which was linked to increased EC permeability. MT stabilization by taxol attenuated thrombin-induced permeability, actin remodeling, and paracellular gap formation and diminished thrombin-induced activation of Rho and Rho-kinase. Expression of activated Galpha12/13 subunits involved in thrombin-mediated signaling or their effector p115RhoGEF involved in Rho activation caused MT disassembly, whereas p115RhoGEF-specific negative regulator RGS preserved MT from thrombin-induced disassembly. Consistent with these results, expression of activated RhoA and Rho-kinase induced MT disassembly. Conversely, thrombin-induced disassembly of peripheral MT network was attenuated by expression of dominant negative RhoA and Rho-kinase mutants or by pharmacological inhibition of Rho-kinase. Collectively, our data demonstrate for the first time a critical involvement of MT disassembly in thrombin-induced EC barrier dysfunction and indicate G-protein-dependent mechanisms of thrombin-induced MT alteration.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 117234, Russia; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi, Japan	Johns Hopkins University; Lomonosov Moscow State University; Nagoya University	Birukova, AA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 5200 Eastern Ave,MFL Ctr Tower 660, Baltimore, MD 21224 USA.	abirukov@jhmi.edu	Birukov, Konstantin/FJB-5755-2022; Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [HL58064, HL67307, HL68062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107920, P01HL058064, R01HL068062, R01HL067307] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007; Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055; Birukova AA, 2004, AM J PHYSIOL-LUNG C, V287, pL86, DOI 10.1152/ajplung.00441.2003; Borbiev T, 2000, ANAL BIOCHEM, V285, P260, DOI 10.1006/abio.2000.4763; Cross D, 1996, EXP CELL RES, V229, P378, DOI 10.1006/excr.1996.0383; da Costa SR, 2000, CELL MOTIL CYTOSKEL, V47, P253, DOI 10.1002/1097-0169(200012)47:4<253::AID-CM1>3.0.CO;2-S; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Fitzpatrick FA, 2003, INT IMMUNOPHARMACOL, V3, P1699, DOI 10.1016/j.intimp.2003.08.007; Fritsche J, 1999, MOL CELL NEUROSCI, V14, P398, DOI 10.1006/mcne.1999.0777; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Groeneveld ABJ, 2002, VASC PHARMACOL, V39, P247, DOI 10.1016/S1537-1891(03)00013-2; Gupta RP, 1999, ARCH BIOCHEM BIOPHYS, V365, P268, DOI 10.1006/abbi.1999.1165; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Ingelson M, 1996, NEUROSCI LETT, V220, P9, DOI 10.1016/S0304-3940(96)13218-3; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Lee TYJ, 2003, MICROSC RES TECHNIQ, V60, P115, DOI 10.1002/jemt.10250; Leung T, 1996, MOL CELL BIOL, V16, P5313; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Manolopoulos VG, 1997, BBA-MOL CELL RES, V1356, P321, DOI 10.1016/S0167-4889(97)00002-5; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; OLESEN OF, 1994, BIOCHEM BIOPH RES CO, V201, P716, DOI 10.1006/bbrc.1994.1759; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schwer HD, 2001, CURR BIOL, V11, P579, DOI 10.1016/S0960-9822(01)00153-1; SINGH TJ, 1994, MOL CELL BIOCHEM, V131, P181; Song YH, 2000, J CELL BIOCHEM, V80, P229; Storck J, 1996, THROMB RES, V81, P121, DOI 10.1016/0049-3848(95)00220-0; Suo ZM, 2003, J BIOL CHEM, V278, P37681, DOI 10.1074/jbc.M301406200; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	55	158	165	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1879	1890		10.1096/fj.04-2328com	http://dx.doi.org/10.1096/fj.04-2328com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576491				2022-12-25	WOS:000226091000038
J	Kim, HJ; Song, EJ; Lee, YS; Kim, E; Lee, KJ				Kim, HJ; Song, EJ; Lee, YS; Kim, E; Lee, KJ			Human Fas-associated factor 1 interacts with heat shock protein 70 and negatively regulates chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; N-TERMINAL KINASE; ATPASE ACTIVITY; REACTION CYCLE; IN-VIVO; HSP70; IDENTIFICATION; APOPTOSIS; THERMOTOLERANCE; PATHWAY	We examined the cell death-inducing property of human Fas-associated factor 1 ( hFAF1) in the heat shock signaling pathway. By employing co-immunoprecipitation and peptide mass fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry, we found that hFAF1 binds to the 70-kDa heat shock protein family ( Hsc70/Hsp70). Interaction mapping indicated that the 82-180 sequence of hFAF1 directly binds to the N-terminal region containing sequence 1-120 of Hsc70/Hsp70. This binding is very tight regardless of ATP and heat shock treatment. Hsc70/ Hsp70 and hFAF1 co-localized in the cytosol and nucleus and concentrated to the perinuclear region by heat shock treatment. We examined how hFAF1 regulates Hsp70 function, and found that hFAF1 inhibited the Hsp70 chaperone activity of refolding denatured protein substrates, accelerated heat shock-induced SAPK/JNK activation, and raised heat shock-induced cell death in a binding dependent manner. These results suggest that hFAF1 prevents cells from recovery after stress by binding to and inhibiting the chaperone activity of Hsp70.	Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea; Chungnam Natl Univ, Div Life Sci, Taejon 305764, South Korea	Ewha Womans University; Ewha Womans University; Chungnam National University	Lee, KJ (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seoul 120750, South Korea.	kjl@mm.ewha.ac.kr		Lee, Kong-Joo/0000-0001-7972-6020; Song, Eun Joo/0000-0002-2420-6666				Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Guerra B, 2001, INT J ONCOL, V19, P1117; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Jensen HH, 2001, INT J BIOCHEM CELL B, V33, P577, DOI 10.1016/S1357-2725(01)00039-5; Kim HJ, 2002, J BIOL CHEM, V277, P23193, DOI 10.1074/jbc.M201007200; KIM HJ, 2000, MOL CELL BIOCHEM, V229, P139; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kusk M, 1999, MOL CELL BIOCHEM, V191, P51, DOI 10.1023/A:1006840613986; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Liossis SNC, 1997, J IMMUNOL, V158, P5668; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Park MY, 2004, J BIOL CHEM, V279, P2544, DOI 10.1074/jbc.M304565200; Ryu SW, 1999, BIOCHEM BIOPH RES CO, V262, P388, DOI 10.1006/bbrc.1999.1217; Ryu SW, 2003, J BIOL CHEM, V278, P24003, DOI 10.1074/jbc.M302200200; Ryu SW, 2001, BIOCHEM BIOPH RES CO, V286, P1027, DOI 10.1006/bbrc.2001.5505; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STEGE GJJ, 1994, EXP CELL RES, V214, P279, DOI 10.1006/excr.1994.1259; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Thress K, 2001, EMBO J, V20, P1033, DOI 10.1093/emboj/20.5.1033; Volloch V, 1999, FEBS LETT, V461, P73, DOI 10.1016/S0014-5793(99)01428-3; Volloch V, 1998, CELL STRESS CHAPERON, V3, P265, DOI 10.1054/csac.1998.0120; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	34	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8125	8133		10.1074/jbc.M406297200	http://dx.doi.org/10.1074/jbc.M406297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15596450	hybrid			2022-12-25	WOS:000227395700084
J	Leonard, R; Petersen, BO; Himly, M; Kaar, W; Wopfner, N; Kolarich, D; van Ree, R; Ebner, C; Duus, JO; Ferreira, F; Altmann, F				Leonard, R; Petersen, BO; Himly, M; Kaar, W; Wopfner, N; Kolarich, D; van Ree, R; Ebner, C; Duus, JO; Ferreira, F; Altmann, F			Two novel types of O-glycans on the mugwort pollen allergen Art v 1 and their role in antibody binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; 3-DIMENSIONAL SOLUTION STRUCTURE; BASIC GLYCOPROTEIN ALLERGEN; NUCLEAR MAGNETIC-RESONANCE; GUM-ARABIC GLYCOPROTEIN; ARABINOGALACTAN-PROTEINS; NICOTIANA-TABACUM; HYDROXYPROLINE-ARABINOSIDES; CARBOHYDRATE MOIETY; MONOCLONAL-ANTIBODY	Art v 1, the major allergen of mugwort ( Artemisia vulgaris) pollen contains galactose and arabinose. As the sera of some allergic patients react with natural but not with recombinant Art v 1 produced in bacteria, the glycosylation of Art v 1 may play a role in IgE binding and human allergic reactions. Chemical and enzymatic degradation, mass spectrometry, and 800 MHz H-1 and C-13 nuclear magnetic resonance spectroscopy indicated the proline-rich domain to be glycosylated in two ways. We found a large hydroxyproline-linked arabinogalactan composed of a short beta1,6-galactan core, which is substituted by a variable number ( 5-28) of alpha-arabinofuranose residues, which form branched side chains with 5-,2,5-,3,5-, and 2,3,5- substituted arabinoses. Thus, the design of the Art v 1 polysaccharide differs from that of the well known type II arabinogalactans, and we suggest it be named type III arabinogalactan. The other type of glycosylation was formed by single ( but adjacent) beta-arabinofuranoses linked to hydroxyproline. In contrast to the arabinosylation of Ser-Hyp(4) motifs in other hydroxyproline-rich glycoproteins, such as extensins or solanaceous lectins, no oligo-arabinosides were found in Art v 1. Art v 1 and parts thereof produced by alkaline degradation, chemical deglycosylation, proteolytic degradation, and/or digestion with alpha-arabinofuranosidase were used in enzyme-linked immunosorbent assay and immunoblot experiments with rabbit serum and with the sera of patients. Although we could not observe antibody binding by the polysaccharide, the single hydroxyproline-linked beta-arabinose residues appeared to react with the antibodies. Mono-beta-arabinosylated hydroxyproline residues thus constitute a new, potentially cross-reactive, carbohydrate determinant in plant proteins.	Univ Bodenkultur Wien, Dept Chem, Div Biochem, A-1190 Vienna, Austria; Carlsberg Lab, DK-2500 Valby, Denmark; Salzburg Univ, Dept Biol Mol, Div Allergy & Immunol, A-5020 Salzburg, Austria; Sanquin Res CLB, Dept Immunopathol, NL-1066 CX Amsterdam, Netherlands; Med Univ Vienna, Inst Pathophysiol, A-1090 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Salzburg University; Medical University of Vienna	Altmann, F (corresponding author), Univ Bodenkultur Wien, Dept Chem, Div Biochem, Muthgasse 18, A-1190 Vienna, Austria.	friedrich.altmann@boku.ac.at	Ferreira, Fatima/E-4889-2011; Kolarich, Daniel/B-6893-2012; Duus, Jens Øllgaard/N-4279-2013; Ferreira, Fatima/AAB-4321-2019; Kolarich, Daniel/AAJ-3550-2020; Himly, Martin/D-1568-2015	Ferreira, Fatima/0000-0003-0989-2335; Kolarich, Daniel/0000-0002-8452-1350; Duus, Jens Øllgaard/0000-0003-3625-1250; Ferreira, Fatima/0000-0003-0989-2335; Kolarich, Daniel/0000-0002-8452-1350; Himly, Martin/0000-0001-5416-085X; Leonard, Renaud/0000-0001-5023-1032; Altmann, Friedrich/0000-0002-0112-7877				AKIYAMA Y, 1980, AGR BIOL CHEM TOKYO, V44, P2487, DOI 10.1080/00021369.1980.10864347; ALLEN AK, 1978, BIOCHEM J, V171, P665, DOI 10.1042/bj1710665; ALTMANN F, 1991, INSECT BIOCHEM, V21, P467, DOI 10.1016/0020-1790(91)90099-Z; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; Altmann F, 2000, J GEN VIROL, V81, P1111, DOI 10.1099/0022-1317-81-4-1111; ANDERSON MA, 1984, PLANT PHYSIOL, V75, P1013, DOI 10.1104/pp.75.4.1013; ASHFORD D, 1982, BIOCHEM J, V201, P199, DOI 10.1042/bj2010199; Bencurova M, 2004, GLYCOBIOLOGY, V14, P457, DOI 10.1093/glycob/cwh058; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; Campargue C, 1998, ANAL BIOCHEM, V257, P20, DOI 10.1006/abio.1997.2526; CAPEK P, 1983, CARBOHYD RES, V117, P133, DOI 10.1016/0008-6215(83)88082-3; Cardoso SM, 2002, CARBOHYD RES, V337, P917, DOI 10.1016/S0008-6215(02)00082-4; Classen B, 2000, CARBOHYD RES, V327, P497, DOI 10.1016/S0008-6215(00)00074-4; Duus JO, 2000, CHEM REV, V100, P4589, DOI 10.1021/cr990302n; Edge ASB, 2003, BIOCHEM J, V376, P339, DOI 10.1042/BJ20030673; GANE AM, 1995, CARBOHYD RES, V277, P67, DOI 10.1016/0008-6215(95)00197-2; Gaspar Y, 2001, PLANT MOL BIOL, V47, P161, DOI 10.1023/A:1010683432529; Goodrum LJ, 2000, PHYTOCHEMISTRY, V54, P99, DOI 10.1016/S0031-9422(00)00043-1; GORIN PAJ, 1976, CARBOHYD RES, V48, P171, DOI 10.1016/S0008-6215(00)83213-9; GUILLON F, 1989, CARBOHYD RES, V190, P85, DOI 10.1016/0008-6215(89)84149-7; Gupta N, 1996, J ALLERGY CLIN IMMUN, V98, P903, DOI 10.1016/S0091-6749(96)80006-6; HAAVIK S, 1987, INT ARCH ALLER A IMM, V83, P225, DOI 10.1159/000234301; HAAVIK S, 1987, INT ARCH ALLER A IMM, V83, P231, DOI 10.1159/000234302; Hill JM, 2000, EUR J BIOCHEM, V267, P4649, DOI 10.1046/j.1432-1327.2000.01507.x; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Himly M, 2002, FASEB J, V16, P106, DOI 10.1096/fj.02-0472fje; Kieliszewski MJ, 2001, PHYTOCHEMISTRY, V57, P319, DOI 10.1016/S0031-9422(01)00029-2; KJAER M, 1994, METHODS ENZYMOL, V239, P288; KLIS FM, 1995, N COMP BIOC A, V29, P511; KNOX JP, 1991, PLANT J, V1, P317, DOI 10.1046/j.1365-313X.1991.t01-9-00999.x; LAMPORT DTA, 1973, BIOCHEM J, V133, P125, DOI 10.1042/bj1330125; LAMPORT DTA, 1969, BIOCHEMISTRY-US, V8, P1155, DOI 10.1021/bi00831a049; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; Majewska-Sawka A, 2000, PLANT PHYSIOL, V122, P3, DOI 10.1104/pp.122.1.3; PENNELL RI, 1992, J CELL BIOL, V119, P1371, DOI 10.1083/jcb.119.5.1371; QI W, 1981, PLANT PHYSIOL, V96, P848; Schmid-Grendelmeier P, 2003, J ALLERGY CLIN IMMUN, V111, P1328, DOI 10.1067/mai.2003.1495; SCHUSTER R, 1988, J CHROMATOGR-BIOMED, V431, P271, DOI 10.1016/S0378-4347(00)83096-0; Showalter AM, 2001, CELL MOL LIFE SCI, V58, P1399, DOI 10.1007/PL00000784; Shpak E, 2001, J BIOL CHEM, V276, P11272, DOI 10.1074/jbc.M011323200; STEFFAN W, 1995, CARBOHYD RES, V275, P295, DOI 10.1016/0008-6215(95)00174-R; SVOBODA I, 1995, J BIOL CHEM, V270, P2607; SWAMY NR, 1991, PHYTOCHEMISTRY, V30, P263, DOI 10.1016/0031-9422(91)84134-E; Tan L, 2003, PLANT PHYSIOL, V132, P1362, DOI 10.1104/pp.103.021766; Tan L, 2004, J BIOL CHEM, V279, P13156, DOI 10.1074/jbc.M311864200; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; Willats WGT, 1998, CARBOHYD RES, V308, P149, DOI 10.1016/S0008-6215(98)00070-6; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Yates EA, 1996, GLYCOBIOLOGY, V6, P131, DOI 10.1093/glycob/6.2.131; Zeleny R, 1997, ANAL BIOCHEM, V246, P96, DOI 10.1006/abio.1996.9973; Zhao ZD, 2002, PLANT J, V31, P431, DOI 10.1046/j.1365-313X.2002.01365.x	51	85	90	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7932	7940		10.1074/jbc.M410407200	http://dx.doi.org/10.1074/jbc.M410407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591314	hybrid			2022-12-25	WOS:000227395700062
J	Bhanot, P; Schauer, K; Coppens, I; Nussenzweig, V				Bhanot, P; Schauer, K; Coppens, I; Nussenzweig, V			A surface phospholipase is involved in the migration of Plasmodium sporozoites through cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOPLASMA-GONDII; MALARIA PARASITES; INSULIN-RECEPTOR; A(2); CYTOTOXIN; PROTEIN; EXOU; ACYLTRANSFERASE; PENETRATION; INFECTIVITY	Plasmodium sporozoites, injected by mosquitoes into the skin of the host, traverse cells during their migration to hepatocytes where they continue their life cycle. The mechanisms used by the parasite to rupture the plasma membrane of the host cells are not known. Here we report the presence of a phospholipase on the surface of Plasmodium berghei sporozoites (P. berghei phospholipase; Pb PL) and demonstrate that it is involved in the establishment of a malaria infection in vivo. Ph PL is highly conserved among the Plasmodium species. The protein is about 750 amino acids, with a predicted signal sequence and a carboxyl terminus that is 32% identical to the vertebrate lecithin:cholesterol acyltransferase, a secreted phospholipase. Pb PL contains a motif characteristic of lipases and a catalytic triad of a serine, aspartate, and histidine that is found in several phospholipases. We have verified its lipase and membrane lytic activity in vitro, using recombinant baculovirus-expressed protein. To study its role in vivo' we have disrupted the P. berghei PL open reading frame and generated mutants in its active site. During an infection through mosquito bite, the infectivity of the knock-out parasites in the liver is decreased by similar to90%. The prepatent period of the resulting blood infection is I day longer as compared with wild type. Further, the mutant sporozoites are impaired in their ability to cross epithelial cell layers. Thus, the Pb PL functions as a lipase to damage cell membranes and facilitates sporozoite passage through cells during their migration from the skin to the bloodstream.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	New York University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bhanot, P (corresponding author), Publ Hlth Res Inst, 225 Warren St,W250H, Newark, NJ 07103 USA.	bhanot@phri.org		Schauer, Kristine/0000-0002-6102-8790	NIAID NIH HHS [NIHAI04997] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abubakar MS, 2003, J BIOCHEM MOL TOXIC, V17, P53, DOI 10.1002/jbt.10060; Allewelt M, 2000, INFECT IMMUN, V68, P3998, DOI 10.1128/IAI.68.7.3998-4004.2000; BIERBAUM TJ, 1979, BIOCHIM BIOPHYS ACTA, V555, P102, DOI 10.1016/0005-2736(79)90075-0; Bruna-Romero O, 2001, INT J PARASITOL, V31, P1499, DOI 10.1016/S0020-7519(01)00265-X; Cassaing S, 2000, INT J PARASITOL, V30, P1137, DOI 10.1016/S0020-7519(00)00101-6; Dorrell N, 1999, GASTROENTEROLOGY, V117, P1098, DOI 10.1016/S0016-5085(99)70394-X; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Gonzalez-Garza MT, 2000, EXP PARASITOL, V96, P116, DOI 10.1006/expr.2000.4554; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Ishino T, 2004, PLOS BIOL, V2, P77, DOI 10.1371/journal.pbio.0020004; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Kappe SHI, 2004, ANNU REV CELL DEV BI, V20, P29, DOI 10.1146/annurev.cellbio.20.011603.150935; Matuschewski K, 2002, J BIOL CHEM, V277, P41948, DOI 10.1074/jbc.M207315200; Menard R, 1997, METHODS, V13, P148, DOI 10.1006/meth.1997.0507; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; Nunes A, 1999, MOL CELL BIOL, V19, P2895; Parks JS, 1999, METH MOL B, V109, P123; Phillips RM, 2003, J BIOL CHEM, V278, P41326, DOI 10.1074/jbc.M302472200; Pollok RCG, 2003, PARASITOL RES, V90, P181, DOI 10.1007/s00436-003-0831-8; PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N; Pradel G, 2001, HEPATOLOGY, V33, P1154, DOI 10.1053/jhep.2001.24237; SAFFER LD, 1989, AM J TROP MED HYG, V40, P145, DOI 10.4269/ajtmh.1989.40.145; SAFFER LD, 1991, J PROTOZOOL, V38, P454, DOI 10.1111/j.1550-7408.1991.tb04816.x; Sato H, 2003, EMBO J, V22, P2959, DOI 10.1093/emboj/cdg290; Sidjanski S, 1997, AM J TROP MED HYG, V57, P426, DOI 10.4269/ajtmh.1997.57.426; Sultan AA, 1999, INFECT IMMUN, V67, P2602, DOI 10.1128/IAI.67.5.2602-2606.1999; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005; Wang JC, 1997, J BIOL CHEM, V272, P280; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122	31	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6752	6760		10.1074/jbc.M411465200	http://dx.doi.org/10.1074/jbc.M411465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590623	hybrid			2022-12-25	WOS:000227332700064
J	Partridge, AW; Liu, SC; Kim, S; Bowie, JU; Ginsberg, MH				Partridge, AW; Liu, SC; Kim, S; Bowie, JU; Ginsberg, MH			Transmembrane domain helix packing stabilizes integrin aIIb beta 3 in the low affinity state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL REGION; INSIDE-OUT ACTIVATION; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; GXXXG MOTIFS; LIGAND; ALPHA-IIB-BETA-3; PROTEIN; FIBRONECTIN; TALIN	Regulated changes in the affinity of integrin adhesion receptors ("activation") play an important role in numerous biological functions including hemostasis, the immune response, and cell migration. Physiological integrin activation is the result of conformational changes in the extracellular domain initiated by the binding of cytoplasmic proteins to integrin cytoplasmic domains. The conformational changes in the extracellular domain are likely caused by disruption of intersubunit interactions between the alpha and beta transmembrane (TM) and cytoplasmic domains. Here, we reasoned that mutation of residues contributing to alpha/beta interactions that stabilize the low affinity state should lead to integrin activation. Thus, we subjected the entire intracellular domain of the beta3 integrin subunit to unbiased random mutagenesis and selected it for activated mutants. 25 unique activating mutations were identified in the TM and membrane-proximal cytoplasmic domain. In contrast, no activating mutations were identified in the more distal cytoplasmic tail, suggesting that this region is dispensable for the maintenance of the inactive state. Among the 13 novel TM domain mutations that lead to integrin activation were several informative point mutations that, in combination with computational modeling, suggested the existence of a specific TM helix-helix packing interface that maintains the low affinity state. The interactions predicted by the model were used to identify additional activating mutations in both the alpha and beta TM domains. Therefore, we propose that helical packing of the alpha and beta TM domains forms a clasp that regulates integrin activation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Nuvelo Inc, San Francisco, CA 94085 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California San Diego; University of California System; University of California Los Angeles	Ginsberg, MH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr,Leichtag 181,Mail Code 0726, La Jolla, CA 92093 USA.	mhginsberg@ucsd.edu		Kim, Sanguk/0000-0002-3449-3814				Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2003, SCIENCE, V300, P755, DOI 10.1126/science.1084854; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kim S, 2004, BIOPHYS J, V87, P792, DOI 10.1579/biophysj.103.039396; Kim S, 2004, P NATL ACAD SCI USA, V101, P5988, DOI 10.1073/pnas.0308694101; Kim S, 2003, J MOL BIOL, V329, P831, DOI 10.1016/S0022-2836(03)00521-7; KOUNS WC, 1992, BLOOD, V80, P2536; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; LI W, 2005, IN PRESS P NATL ACAD; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; LUO BH, 2005, IN PRESS P NATL ACAD; Melnyk RA, 2004, J BIOL CHEM, V279, P16591, DOI 10.1074/jbc.M313936200; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Schneider D, 2004, J BIOL CHEM, V279, P9840, DOI 10.1074/jbc.M312749200; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Stefansson A, 2004, J BIOL CHEM, V279, P21200, DOI 10.1074/jbc.M400771200; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Ulmer TS, 2003, BIOCHEMISTRY-US, V42, P8307, DOI 10.1021/bi034384s; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; XIONG JP, 2001, SCIENCE, V106, P4535	42	117	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7294	7300		10.1074/jbc.M412701200	http://dx.doi.org/10.1074/jbc.M412701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591321	hybrid			2022-12-25	WOS:000227332700121
J	Tateishi, Y; Hattori, M; Nakayama, T; Iwai, M; Bannai, H; Nakamura, T; Michikawa, T; Inoue, T; Mikoshiba, K				Tateishi, Y; Hattori, M; Nakayama, T; Iwai, M; Bannai, H; Nakamura, T; Michikawa, T; Inoue, T; Mikoshiba, K			Cluster formation of inositol 1,4,5-trisphosphate receptor requires its transition to open state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CALCIUM; PROTEIN; CELL; DYNAMICS; IP3	The inositol 1,4,5-trisphosphate (IP3) receptor (IPsR) Ca2+ channel plays pivotal roles in many aspects of physiological and pathological events. It was previously reported that IP3R forms clusters on the endoplasmic reticulum when cytosolic Ca2+ concentration ([Ca2+](C)) is elevated. However, the molecular mechanism of IP,R clustering remains largely unknown, and thus its physiological significance is far from clear. In this study we found that the time course of clustering of green fluorescent protein-tagged IP3R type 1 (GFP-IP(3)R1), evoked by IP3-generating agonists, did not correlate with [Ca2+](C) but seemed compatible with cytoplasmic IP3 concentration. IP3 production alone induced GFP-Ip(3)R1 clustering in the absence of a significant increase in [Ca2+](C) but elevated [Ca2+](C) without IP3 production did not. Moreover IP(3)R1 mutants that do not undergo an IP3-induced conformational change failed to form clusters. Thus, IP3R clustering is induced by its IP3-induced conformational change to the open state. We also found that GFP-Ip(3)R1 clusters colocalized with ERp44, a luminal protein of endoplasmic reticulum that inhibits its channel activity. This is the first example of ligand-induced clustering of a ligand-gated channel protein.	Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, NTT IMSUT, Div Neural Signal Informat, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, Precursor Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; RIKEN, Brain Sci Inst, Dev Brain Sci Grp, Wako, Saitama 3510198, Japan; JST, Int Cooperat Res Project, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); RIKEN; Japan Science & Technology Agency (JST)	Hattori, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	mhattori@ims.u-tokyo.ac.jp	Inoue, Takafumi/AAM-9533-2020; Hattori, Mitsuharu/F-3859-2010; Bannai, Hiroko/I-7130-2014; Mikoshiba, Katsuhiko/N-7943-2015	Inoue, Takafumi/0000-0002-2728-0060; Hattori, Mitsuharu/0000-0002-0503-4969; Bannai, Hiroko/0000-0002-0951-488X; 				Aihara Y, 2001, J NEUROSCI RES, V65, P236, DOI 10.1002/jnr.1147; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Delmas P, 2002, NEURON, V36, P787, DOI 10.1016/S0896-6273(02)01097-8; Higo T, 2005, CELL, V120, P85, DOI 10.1016/j.cell.2004.11.048; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; Morita M, 2003, BIOCHEM BIOPH RES CO, V308, P673, DOI 10.1016/S0006-291X(03)01457-8; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Shuai JW, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.068102; Shuai JW, 2003, P NATL ACAD SCI USA, V100, P506, DOI 10.1073/pnas.0236032100; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Swillens S, 1998, CELL CALCIUM, V23, P291, DOI 10.1016/S0143-4160(98)90025-2; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Vermassen E, 2003, J CELL SCI, V116, P1269, DOI 10.1242/jcs.00354; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	26	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6816	6822		10.1074/jbc.M405469200	http://dx.doi.org/10.1074/jbc.M405469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15583010	hybrid			2022-12-25	WOS:000227332700070
J	Bhatti, MM; Sullivan, WJ				Bhatti, MM; Sullivan, WJ			Histone acetylase GCN5 enters the nucleus via importin-alpha in protozoan parasite Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNAL; PROTEIN; CLONING; HOMOLOG; ACETYLTRANSFERASE; DISTINCT; GENE; RAN; EXPRESSION; SEQUENCES	The histone acetyltransferase GCN5 acetylates nucleosomal histones to alter gene expression. How GCN5 gains entry into the nucleus of the cell has not been determined. We have mapped a six-amino acid motif (RKRVKR) that serves as a necessary and sufficient nuclear localization signal (NLS) for GCN5 in the protozoan pathogen Toxoplasma gondii (TgGCN5). Virtually nothing is known about nucleocytoplasmic transport in these parasites (phylum Apicomplexa), and this study marks the first demonstrated NLS delineated for members of the phylum. The TgGCN5 NLS has predictive value because it successfully identifies other nuclear proteins in three different apicomplexan genomic databases. Given the basic composition of the T. gondii NLS, we hypothesized that TgGCN5 physically interacts with importin-a, the main transport receptor in the importin/karyopherin nuclear import pathway. We cloned the importin-a gene from T. gondii (TgIMPalpha), which encodes a protein of 545 amino acids that possesses an importin-beta-binding domain and armadillo/beta-catenin-like repeats. In vitro co-immunoprecipitation experiments confirm that TgIMPalpha directly interacts with TgGCN5, but this interaction is abolished if the TgGCN5 NLS is deleted. Taken together, these data argue that TgGCN5 gains access to the parasite nucleus by interacting with TgIMPalpha. Bioinformatics analysis of the T. gondii genome reveals that other components of the importin pathway are present in the organism. This study demonstrates the utility of T. gondii as a model for the study of nucleocytoplasmic trafficking in early eukaryotic cells.	Indiana Univ, Dept Pharmacol & Toxicol, Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Sullivan, WJ (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, Sch Med, 635 Barnhill Dr,MS A-525, Indianapolis, IN 46202 USA.	wjsulliv@iupui.edu			NIGMS NIH HHS [GM065051] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065051] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askjaer P, 2002, MOL BIOL CELL, V13, P4355, DOI 10.1091/mbc.E02-06-0346; Bhat RA, 2003, PLANT J, V33, P455, DOI 10.1046/j.1365-313X.2003.01642.x; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONTFRAID FF, 1994, BIOCHEM BIOPH RES CO, V201, P423, DOI 10.1006/bbrc.1994.1718; Fan Q, 2004, EUKARYOT CELL, V3, P264, DOI 10.1128/EC.3.2.264-276.2004; Geles KG, 2002, MOL BIOL CELL, V13, P3138, DOI 10.1091/mbc.E02-02-0069; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hachet V, 2004, EMBO J, V23, P1526, DOI 10.1038/sj.emboj.7600154; Hermanns B, 2001, PATHOL RES PRACT, V197, P211, DOI 10.1078/0344-0338-00036; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hettmann C, 1999, NUCLEIC ACIDS RES, V27, P4344, DOI 10.1093/nar/27.22.4344; Huang JL, 2004, INT J PARASITOL, V34, P265, DOI 10.1016/j.ijpara.2003.11.025; Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Ji DD, 1998, MOL BIOCHEM PARASIT, V95, P165, DOI 10.1016/S0166-6851(98)00107-8; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kohler M, 1999, MOL CELL BIOL, V19, P7782; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Mohmmed A, 2003, MOL BIOCHEM PARASIT, V127, P199, DOI 10.1016/S0166-6851(02)00331-6; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Ramachandran V, 2002, MOL BIOCHEM PARASIT, V123, P67, DOI 10.1016/S0166-6851(02)00119-6; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Roos DS, 1997, METHODS, V13, P112, DOI 10.1006/meth.1997.0504; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sambrook J, 2001, MOL CLONING LAB MANU; Seeber Frank, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P99, DOI 10.2174/1568008033340261; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Striepen B, 1998, MOL BIOCHEM PARASIT, V92, P325, DOI 10.1016/S0166-6851(98)00011-5; Sullivan WJ, 2000, GENE, V242, P193, DOI 10.1016/S0378-1119(99)00526-0; Vlachonasios KE, 2003, PLANT CELL, V15, P626, DOI 10.1105/tpc.007922; WONG SY, 1993, AIDS, V7, P299, DOI 10.1097/00002030-199303000-00001; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303	46	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5902	5908		10.1074/jbc.M410656200	http://dx.doi.org/10.1074/jbc.M410656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591057	hybrid			2022-12-25	WOS:000227217100095
J	Jyrkkarinne, J; Windshugel, B; Makinen, J; Ylisirnio, M; Perakyla, M; Poso, A; Sippl, W; Honkakoski, P				Jyrkkarinne, J; Windshugel, B; Makinen, J; Ylisirnio, M; Perakyla, M; Poso, A; Sippl, W; Honkakoski, P			Amino acids important for ligand specificity of the human constitutive androstane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; RESPONSIVE ENHANCER MODULE; NUCLEAR HORMONE RECEPTORS; ALPHA CRYSTAL-STRUCTURE; BINDING DOMAIN; STRUCTURAL DETERMINANTS; COACTIVATOR RECRUITMENT; MOLECULAR DETERMINANTS; DRUG-METABOLISM; GENE-EXPRESSION	The human constitutive androstane receptor (CAR., NR1I3) is an important ligand-activated regulator of oxidative and conjugative enzymes and transport proteins. Because of the lack of a crystal structure of the ligand-binding domain (LBD), wide species differences in ligand specificity and the scarcity of well characterized ligands, the factors that determine CAR ligand specificity are not clear. To address this issue, we developed highly defined homology models of human CAR LBD to identify residues lining the ligand-binding pocket and to perform molecular dynamics simulations with known human CAR modulators. The roles of 22 LBD residues for basal activity, ligand selectivity, and interactions with co-regulators were studied using sitedirected mutagenesis, mammalian co-transfection, and yeast two-hybrid assays. These studies identified several amino acids within helices 3 (Asn(165)), 5 (Val(199)), 11 (Tyr(326), Ile(330), and Gln(331)), and 12 (Leu(343) and Ile(346)) that contribute to the high basal activity of human CAR. Unique residues within helices 3 (Ile(164) and Asn(165)), 5 (Cys(202) and His(203)), and 7 (Phe(234) and Phe(238)) were found control the selectivity for CAR activators and inhibitors. A single residue in helix 7 (Phe(243)) appears to explain the human/mouse species difference in response of CAR to 17alpha-ethynyl-3,17beta-estradiol.	Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland; Univ Halle Wittenberg, Dept Pharmaceut Chem, D-06120 Halle An Der Saale, Saale, Germany	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Martin Luther University Halle Wittenberg	Honkakoski, P (corresponding author), Univ Kuopio, Dept Pharmaceut, POB 1627, FIN-70211 Kuopio, Finland.	paavo.honkakoski@uku.fi	Ylisirniö, Markku/A-4663-2010; Poso, Antti/B-5630-2014; Sippl, Wolfgang/P-5944-2014; Honkakoski, Paavo/AAJ-1278-2020	Sippl, Wolfgang/0000-0002-5985-9261; Honkakoski, Paavo/0000-0002-4332-3577; Poso, Antti/0000-0003-4196-4204				Adachi R, 2004, MOL ENDOCRINOL, V18, P43, DOI 10.1210/me.2003-0244; Andersin T, 2003, MOL ENDOCRINOL, V17, P234, DOI 10.1210/me.2002-0263; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Benko S, 2003, J BIOL CHEM, V278, P43797, DOI 10.1074/jbc.M306199200; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI [DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658-1_21]; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Collingwood TN, 1998, EMBO J, V17, P4760, DOI 10.1093/emboj/17.16.4760; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cote S, 2000, BLOOD, V96, P3200, DOI 10.1182/blood.V96.9.3200.h8003200_3200_3208; Dussault I, 2002, MOL CELL BIOL, V22, P5270, DOI 10.1128/MCB.22.15.5270-5280.2002; Fischer D, 1999, CURR OPIN STRUC BIOL, V9, P208, DOI 10.1016/S0959-440X(99)80029-3; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Frank C, 2004, J BIOL CHEM, V279, P33558, DOI 10.1074/jbc.M403946200; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Honkakoski P, 2004, BIOCHEM PHARMACOL, V67, P97, DOI 10.1016/j.bcp.2003.08.037; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jacobs MN, 2003, J STEROID BIOCHEM, V84, P117, DOI 10.1016/S0960-0760(03)00021-9; Jyrkkarinne J, 2003, J MED CHEM, V46, P4687, DOI 10.1021/jm030861t; Kawamoto T, 2000, MOL ENDOCRINOL, V14, P1897, DOI 10.1210/me.14.11.1897; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN Z, 2002, P NATL ACAD SCI USA, V99, P7940; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makinen J, 2003, BIOCHEM J, V376, P465, DOI 10.1042/BJ20030553; Makinen JM, 2002, MOL PHARMACOL, V62, P366, DOI 10.1124/mol.62.2.366; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Min GS, 2002, J BIOL CHEM, V277, P26356, DOI 10.1074/jbc.M200051200; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Robinson-Rechavi M, 2001, TRENDS GENET, V17, P554, DOI 10.1016/S0168-9525(01)02417-9; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toell A, 2002, J CELL BIOCHEM, V85, P72, DOI 10.1002/jcb.10104; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Vaisanen S, 2002, J MOL BIOL, V315, P229, DOI 10.1006/jmbi.2001.5225; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Watkins RE, 2003, J MOL BIOL, V331, P815, DOI 10.1016/S0022-2836(03)00795-2; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Windshugel B, 2005, J MOL MODEL, V11, P69, DOI 10.1007/s00894-004-0227-4; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yamamoto K, 2000, P NATL ACAD SCI USA, V97, P1467, DOI 10.1073/pnas.020522697; Yamamoto Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P207, DOI 10.1016/S0003-9861(02)00456-3; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939	69	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5960	5971		10.1074/jbc.M411241200	http://dx.doi.org/10.1074/jbc.M411241200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572376	hybrid			2022-12-25	WOS:000227217100102
J	Wang, SX; Elder, PK; Zheng, Y; Strauch, AR; Kelm, RJ				Wang, SX; Elder, PK; Zheng, Y; Strauch, AR; Kelm, RJ			Cell cycle-mediated regulation of smooth muscle alpha-actin gene transcription in fibroblasts and vascular smooth muscle cells involves multiple adenovirus E1A-interacting cofactors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; SERUM RESPONSE FACTOR; EXPRESSION IN-VIVO; RETINOBLASTOMA PROTEIN; CARG ELEMENTS; PUR-ALPHA; ADVENTITIAL FIBROBLASTS; TRANSGENIC MICE; MCAT ENHANCER; DIFFERENTIATION	Expression of smooth muscle a-actin in growth factor-induced myofibroblasts and in differentiated vascular smooth muscle cells is transcriptionally controlled by multiple positive or negative trans-acting factors interacting with distinct cis-elements in the 5'-flanking region of the gene. Because none of the transcriptional regulators reported to date is smooth muscle cell- or myofibro-blast-specific per se, the dynamic interplay among many factors interacting at specific sites along the promoter appears to be a signature feature of smooth muscle a-actin gene regulation in these cell types. Herein, the ability of the adenovirus E1A 12 S protein to bind and functionally inactivate specific cell regulatory factors has been exploited to identify several previously unknown coactivators of the mouse smooth muscle a-actin promoter in rodent fibroblasts and vascular smooth muscle cells. In transient cotransfection assays, ectopic expression of wild type E1A suppressed promoter activity in a dose- and cis-element-dependent manner. In asynchronous cells, N-terminal E1A mutants defective in CREB-binding protein (CBP) and p300 binding capacity exhibited markedly reduced inhibitory activity toward a smooth muscle alpha-actin promoter driven by a composite TEF-1-, SRF-, and Sp1/3-regulated enhancer. In synchronized cells, however, a more complex mutant E1A inhibitory pattern indicated that collaboration between CBP/p300 and the retinoblastoma family of pocket proteins was required to produce a fully functional enhancer. Cotransfection experiments conducted with Rb-I- fibroblasts demonstrated the necessity of pRB in augmenting smooth muscle alpha-actin enhancer/promoter activity. Physical interaction studies with the use of purified wild type and mutant E1A proteins confirmed that CBP, p300, and pRB were targets of E1A binding in nuclear extracts of vascular smooth muscle cells and/or fibroblasts. Collectively, these results suggest that a repertoire of E1A-interacting proteins, namely CBP/p300 and pRB, serve to integrate the activities of multiple trans-acting factors to control smooth muscle a-actin gene transcription in a cell type- and cell cycle-dependent manner.	Univ Vermont, Dept Med, Burlington, VT 05405 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Ohio State Univ, Coll Med & Publ Hlth, Dorothy M Davis Heart & Lung Res Inst, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University of Vermont; Mayo Clinic; Ohio State University	Kelm, RJ (corresponding author), Univ Vermont, Dept Med, Colchester Res Facil, 208 S Pk Dr, Colchester, VT 05446 USA.	Robert.Kelm@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker NA, 2000, J BIOL CHEM, V275, P15384, DOI 10.1074/jbc.M909687199; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; Braun-Dullaeus RC, 2004, ARTERIOSCL THROM VAS, V24, P845, DOI 10.1161/01.ATV.0000125704.28058.a2; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; Diez-Juan A, 2003, CIRC RES, V92, P402, DOI 10.1161/01.RES.0000059306.71961.ED; Engelse MA, 2002, CIRC RES, V90, P1128, DOI 10.1161/01.RES.0000021044.53156.F5; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; GETZ MJ, 1976, CELL, V7, P255, DOI 10.1016/0092-8674(76)90025-8; Goodman RH, 2000, GENE DEV, V14, P1553; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; HANSSON GK, 1989, J EXP MED, V170, P1595, DOI 10.1084/jem.170.5.1595; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hinz B, 2003, MOL BIOL CELL, V14, P2508, DOI 10.1091/mbc.E02-11-0729; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; Itoh S, 2002, CIRCULATION, V105, P2288, DOI 10.1161/01.CIR.0000015607.33345.1F; Kelm RJ, 2003, J BIOL CHEM, V278, P38749, DOI 10.1074/jbc.M306163200; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kolodgie FD, 2001, CURR OPIN CARDIOL, V16, P285, DOI 10.1097/00001573-200109000-00006; Kuang PP, 2002, AM J PHYSIOL-CELL PH, V283, pC58, DOI 10.1152/ajpcell.00314.2001; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Kumar MS, 2003, CIRC RES, V92, P840, DOI 10.1161/01.RES.0000069031.55281.7C; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; Mack CP, 1999, CIRC RES, V84, P852; Majesky MW, 2003, CIRC RES, V92, P824, DOI 10.1161/01.RES.0000071525.18323.4C; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OWENS GK, 1995, PHYSIOL REV, V75, P487; Parmacek MS, 2001, CURR TOP DEV BIOL, V51, P69, DOI 10.1016/S0070-2153(01)51002-9; Patel S, 2000, CIRCULATION, V101, P524, DOI 10.1161/01.CIR.101.5.524; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; Shikama N, 2003, EMBO J, V22, P5175, DOI 10.1093/emboj/cdg502; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; Strobeck M, 2001, J BIOL CHEM, V276, P16418, DOI 10.1074/jbc.M100631200; Subramanian SV, 2004, MOL BIOL CELL, V15, P4532, DOI 10.1091/mbc.E04-04-0348; Subramanian SV, 2002, CARDIOVASC RES, V54, P539, DOI 10.1016/S0008-6363(02)00270-5; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TRINKLE LA, 1992, AM J PHYSIOL, V262, pC828, DOI 10.1152/ajpcell.1992.262.4.C828; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; Voigtlander C, 2002, J CELL BIOCHEM, V85, P54, DOI 10.1002/jcb.10099; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Zaina S, 2002, J BIOL CHEM, V277, P4505, DOI 10.1074/jbc.M108061200; Zhang HY, 1997, J IMMUNOL, V158, P1392; Zhang MY, 2002, J BIOL CHEM, V277, P21285, DOI 10.1074/jbc.M112082200	75	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6204	6214		10.1074/jbc.M409506200	http://dx.doi.org/10.1074/jbc.M409506200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15576380	hybrid			2022-12-25	WOS:000227217100127
J	Ahmad, IM; Aykin-Burns, N; Sim, JE; Walsh, SA; Higashikubo, R; Buettner, GR; Venkataraman, S; Mackey, MA; Flanagan, SW; Oberley, LW; Spitz, DR				Ahmad, IM; Aykin-Burns, N; Sim, JE; Walsh, SA; Higashikubo, R; Buettner, GR; Venkataraman, S; Mackey, MA; Flanagan, SW; Oberley, LW; Spitz, DR			Mitochondrial O-2(-center dot) and H2O2 mediate glucose deprivation-induced cytotoxicity and oxidative stress in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-CELLS; SUPEROXIDE-DISMUTASE; METABOLISM; HYDROXYL; DNA; ORIGIN; INJURY; LINES	The hypothesis that glucose deprivation-induced cytotoxicity in transformed human cells is mediated by mitochondrial O-2(-) and H2O2 was first tested by exposing glucose-deprived SV40-transformed human fibroblasts (GM00637G) to electron transport chain blockers (ETCBs) known to increase mitochondrial O-2(-) and H2O2 production (antimycin A (AntA), myxothiazol (Myx), or rotenone (Rot)). Glucose deprivation (2-8 h) in the presence of ETCBs enhanced parameters indicative of oxidative stress (i.e. GSSG and steady-state levels of oxygen-centered radicals) as well as cytotoxicity. Glucose deprivation in the presence of AntA also significantly enhanced cytotoxicity and parameters indicative of oxidative stress in several different human cancer cell lines (PC-3, DU145, MDA-MB231, and HT-29). In addition, human osteosarcoma cells lacking functional mitochondrial electron transport chains (rho(0)) were resistant to glucose deprivation-induced cytotoxicity and oxidative stress in the presence of AntA. In the absence of ETCBs, aminotriazole-mediated inactivation of catalase in PC-3 cells demonstrated increases in intracellular steady-state levels of H2O2 during glucose deprivation. Finally, in the absence of ETCBs, overexpression of manganese containing superoxide dismutase and/or mitochondrial targeted catalase using adenoviral vectors significantly protected PC-3 cells from toxicity and oxidative stress induced by glucose deprivation with expression of both enzymes providing greater protection than was seen with either alone. Overall, these findings strongly support the hypothesis that mitochondrial O-2(-) and 11,0, significantly contribute to glucose deprivation-induced cytotoxicity and metabolic oxidative stress in human cancer cells.	Univ Iowa, Free Rad & Radiat Biol Program, Med Labs B180, Holden Comprehens Canc Ctr,Dept Radiat Oncol, Iowa City, IA 52242 USA; Washington Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, St Louis, MO 63108 USA; Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA	University of Iowa; Washington University (WUSTL); University of Iowa; University of Iowa	Spitz, DR (corresponding author), Univ Iowa, Free Rad & Radiat Biol Program, Med Labs B180, Holden Comprehens Canc Ctr,Dept Radiat Oncol, Iowa City, IA 52242 USA.	douglas-spitz@uiowa.edu		Spitz, Douglas/0000-0002-1254-8765; Buettner, Garry/0000-0002-5594-1903; Ahmad, Iman/0000-0002-8543-9084	NCI NIH HHS [P01CA66081, R33CA94801, P01CA75556, R01CA100045, P20CA91709] Funding Source: Medline; NHLBI NIH HHS [R01HL51469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA094801, P01CA075556, P20CA091709, R01CA100045, P01CA066081] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVERILLBATES DA, 1994, ARCH BIOCHEM BIOPHYS, V312, P52, DOI 10.1006/abbi.1994.1279; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Boveris A, 1977, Adv Exp Med Biol, V78, P67; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETTNER GR, 1992, J BIOCHEM BIOPH METH, V24, P147, DOI 10.1016/0165-022X(92)90054-E; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GALARRAGA J, 1986, METAB BRAIN DIS, V1, P279, DOI 10.1007/BF00999357; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GREEN MR, 1979, FEBS LETT, V100, P23, DOI 10.1016/0014-5793(79)81123-0; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hendrix MJC, 1997, AM J PATHOL, V150, P483; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKEY MA, 1992, J THEOR BIOL, V156, P133, DOI 10.1016/S0022-5193(05)80669-1; MAVIS RD, 1968, J BIOL CHEM, V243, P809; NATH KA, 1995, AM J PHYSIOL-CELL PH, V268, pC227, DOI 10.1152/ajpcell.1995.268.1.C227; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY TD, 1993, FREE RADICALS AGING; PRESS WH, 1988, NUMERICAL RECPES C; ROSEN GM, 1984, P NATL ACAD SCI-BIOL, V81, P7269, DOI 10.1073/pnas.81.23.7269; Singh G, 1999, J CELL PHYSIOL, V180, P431, DOI 10.1002/(SICI)1097-4652(199909)180:3<431::AID-JCP14>3.0.CO;2-O; SPITZ DR, 1990, BIOCHEM J, V267, P453, DOI 10.1042/bj2670453; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SPITZ DR, 1990, ARCH BIOCHEM BIOPHYS, V279, P249, DOI 10.1016/0003-9861(90)90489-L; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; STANLEY PE, 1986, METHOD ENZYMOL, V133, P14; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Voet D, 1999, FUNDAMENTALS BIOCH; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	39	205	219	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4254	4263		10.1074/jbc.M411662200	http://dx.doi.org/10.1074/jbc.M411662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561720	hybrid, Green Submitted			2022-12-25	WOS:000227096600033
J	Zhang, YX; Erdmann, F; Baumgrass, R; Schutkowski, M; Fischer, G				Zhang, YX; Erdmann, F; Baumgrass, R; Schutkowski, M; Fischer, G			Unexpected side chain effects at residue 8 of cyclosporin A derivatives allow photoswitching of immunosuppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SANGLIFEHRIN-A; CYCLOPHILIN-A; CRYSTAL-STRUCTURE; CALCINEURIN; INHIBITION; MECHANISM; ANALOGS; BINDING; ACTIVATION; COMMON	To dissect the enzyme inhibitory properties of the immunosuppressive cyclic undecapeptide cyclosporin A (CsA) and gain access to monospecific, non-calcineurin-inhibiting CsA derivatives, [D-Ser(8)]CsA was subjected to modifications at the D-Ser side chain. Thus, we modified a CsA residue flanking the calcineurin (CaN) and cyclophilin 18 (Cyp18) binding domains of CsA instead of the residues of the CaN binding domain in order to develop a new specificity-determining site within the cyclic peptide. The [O-(NH2(CH2)(5)NHC(O)CH2)-D-Ser(8)]CsA (derivative 9), with an amino group on a tether, exhibits CsA-like inhibition of the peptidyl prolyl cis/trans isomerase activity of Cyp18 with an IC50 value of 3.2 nM, whereas the CaN inhibition by the Cyp18-derivative 9 complex is completely abolished. Consequently, this compound is not able to inhibit the proliferation and cytokine production of activated T cells. Structure-activity relationship studies with a series Of [D-Ser(8)]CsA derivatives indicate that the positively charged side chain is an essential requirement for Cyp18-derivative 9 to be ineffective on CaN. Upon protecting the amino group in derivative 9 with the photolabile moiety 2-nitroveratryloxycarbonyl (NVOC), the Cyp18-[O-(NVO-CNH2(CH2),NHC(O)CH2)-D-Ser(8)]CsA (derivative 11) complex exhibits strong CaN inhibition and shows potent immunosuppressive activity. In stimulated T cells pretreated with derivative 11, a remarkable recovery of transcriptional activation of the nuclear factor of activated T cells (NFAT) has been achieved through light	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle An Der Saale, Germany; Deutsch Rheuma Forschungszentrum Berlin, D-10117 Berlin, Germany	Max Planck Society; Deutsches Rheuma-Forschungszentrum (DRFZ)	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle An Der Saale, Germany.	fischer@enzyme-halle.mpg.de	Erdmann, Frank/AAF-1091-2021	Erdmann, Frank/0000-0001-5261-0984; Baumgrass, Ria/0000-0002-3289-1608; Schutkowski, MIke/0000-0003-0919-7076				ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; Baumgrass R, 2001, J BIOL CHEM, V276, P47914, DOI 10.1074/jbc.M103273200; Baumgrass R, 2004, J BIOL CHEM, V279, P2470, DOI 10.1074/jbc.M304754200; BOREL JF, 1989, PHARMACOL REV, V41, P259; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Colgan J, 2004, IMMUNITY, V21, P189, DOI 10.1016/j.immuni.2004.07.005; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EBERLE MK, 1995, J MED CHEM, V38, P1853, DOI 10.1021/jm00011a004; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; Fanghanel J, 2003, BIOPHYS CHEM, V100, P351, DOI 10.1016/S0301-4622(02)00292-2; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Fischer G, 2004, REV PHYSIOL BIOCH P, V148, P105, DOI 10.1007/s10254-003-0011-3; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Furuta T, 1999, P NATL ACAD SCI USA, V96, P1193, DOI 10.1073/pnas.96.4.1193; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5; MARRIOTT G, 1994, BIOCHEMISTRY-US, V33, P9092, DOI 10.1021/bi00197a010; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MOSS ML, 1992, J BIOL CHEM, V267, P22054; NELSON PA, 1993, J IMMUNOL, V150, P2139; Schote U, 2002, J PHARM SCI, V91, P856, DOI 10.1002/jps.10071; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Thiel A, 1999, ARTHRITIS RES, V1, P25, DOI 10.1186/ar7; TRABER R, 1989, J ANTIBIOT, V42, P591, DOI 10.7164/antibiotics.42.591; WENGER RM, 1985, ANGEW CHEM INT EDIT, V24, P77, DOI 10.1002/anie.198500773; WENGER RM, 1988, TRANSPL P, V20, P313; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200; Zhang LH, 2001, J IMMUNOL, V166, P5611, DOI 10.4049/jimmunol.166.9.5611; Zhu J, 2000, CELL MOL LIFE SCI, V57, P411, DOI 10.1007/PL00000703; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	43	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4842	4850		10.1074/jbc.M409178200	http://dx.doi.org/10.1074/jbc.M409178200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572368	hybrid			2022-12-25	WOS:000227096600103
J	Hui, DJ; Terenzi, F; Merrick, WC; Sen, GC				Hui, DJ; Terenzi, F; Merrick, WC; Sen, GC			Mouse p56 blocks a distinct function of eukaryotic initiation factor 3 in translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; PROTEIN P56; MESSENGER-RNA; INTERFERON; COMPLEX; BINDING; GENES; EXPRESSION; SUBUNITS; FAMILY	Members of the p56 family of mammalian proteins are strongly induced in virus-infected cells and in cells treated with interferons or double-stranded RNA. Previously, we have reported that human p56 inhibits initiation of translation by binding to the "e" subunit of eukaryotic initiation factor 3 (eIF3) and subsequently interfering with the eIF3/eIF2.GTP.Met-tRNA(i) (ternary complex) interaction. Here we report that mouse p56 also interferes with eIF3 functions and inhibits translation. However, the murine protein binds to the "c" subunit, not the "e" subunit, of eIF3. Consequently, it has only a marginal effect on eIF3-ternary complex interaction. Instead, the major inhibitory effect of mouse p56 is manifested at a different step of translation initiation, namely the binding of eIF4F to the 40 S ribosomal subunit.eIF3.ternary complex. Thus, mouse and human p56 proteins block different functions of eIF3 by binding to its different subunits.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Grad Program Mol Virol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.	seng@ccf.org	Hui, Daniel J/H-8855-2013	Hui, Daniel J/0000-0003-0294-3582	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796, R01GM068079] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68782, CA62220] Funding Source: Medline; NIGMS NIH HHS [GM26796, GM68079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BLUYSSEN HAR, 1994, EUR J BIOCHEM, V220, P395, DOI 10.1111/j.1432-1033.1994.tb18636.x; BLUYSSEN HAR, 1994, GENOMICS, V24, P137, DOI 10.1006/geno.1994.1591; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; de Veer MJ, 1998, GENOMICS, V54, P267, DOI 10.1006/geno.1998.5555; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Kim TH, 2001, TRENDS PLANT SCI, V6, P379, DOI 10.1016/S1360-1385(01)02015-5; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC, 2003, BIOCHEM MOL BIOL EDU, V31, P378, DOI 10.1002/bmb.2003.494031060274; MERRICK WC, 1973, P NATL ACAD SCI USA, V70, P2220, DOI 10.1073/pnas.70.8.2220; Niikura T, 1997, BLOOD CELL MOL DIS, V23, P337, DOI 10.1006/bcmd.1997.0151; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; WATHELET MG, 1988, FEBS LETT, V231, P164, DOI 10.1016/0014-5793(88)80724-5; YODERHILL J, 1993, J BIOL CHEM, V268, P5566; Yu M, 1997, P NATL ACAD SCI USA, V94, P7406, DOI 10.1073/pnas.94.14.7406; Zhang YB, 2004, GENE, V325, P43, DOI 10.1016/j.gene.2003.09.039	36	67	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3433	3440		10.1074/jbc.M406700200	http://dx.doi.org/10.1074/jbc.M406700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15561726	hybrid			2022-12-25	WOS:000226983900038
J	Agarwal, A; Das, K; Lerner, N; Sathe, S; Cicek, M; Casey, G; Sizemore, N				Agarwal, A; Das, K; Lerner, N; Sathe, S; Cicek, M; Casey, G; Sizemore, N			The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin	ONCOGENE			English	Article						AKT; PTEN; I kappa B kinase; nuclear factor-kappa B; beta-catenin; colorectal cancer	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; IKK-BETA; SUPPRESSOR PTEN; NEMO/IKK-GAMMA; COLON-CANCER; P65 SUBUNIT; TRANSCRIPTIONAL ACTIVATION	Our laboratory has delineated that the phosphatidylinositol 30 kinase (PI3K)/AKT/IkappaB kinase (IKK) pathway positively regulates NFkappaB and beta-catenin, both important transcriptional regulators in colorectal cancer (CRC). Therefore, we investigated the effect of inhibiting the PI3K/AKT/IKKalpha pathway in regulating the inappropriate constitutive activation of NFkappaB and beta-catenin in CRC cell lines. SW480 and RKO CRC cell lines demonstrate constitutive activation of AKT as well as both NFkappaB- and beta-catenin-dependent transcription. The constitutive activation of NFkappaB- and beta-catenin-dependent transcription is inhibited by transiently transfecting either kinase dead (KD) IKKalpha, which blocks IKKalpha kinase activity, KD AKT, which blocks AKT activity, or wildtype (WT) PTEN, which inhibits PI3K and AKT activity. The ability of KD IKKalpha, KD AKT or WT PTEN to decrease beta-catenin-dependent transcription is independent of their effects on NFkappaB. Inducible expression of either KD IKKalpha or WT PTEN strongly inhibits both the constitutive NFkappaB- and beta-catenin-dependent promoter and endogenous gene activation. Targeted array-based gene expression analysis of this inducible system reveals that many of the genes downregulated upon inhibition of this pathway are involved in tumor angiogenesis and metastasis. The activation of this pathway and the expression of the three most repressed genes was further analysed in samples of CRC. These results indicate a role of this pathway in controlling gene expression important in tumor progression and metastasis.	Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sizemore, N (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	sizemon@ccf.org			NCI NIH HHS [R01 CA100748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 2003, CR BIOL, V326, P1041, DOI 10.1016/j.crvi.2003.09.007; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clauss M, 2000, CIRC RES, V86, P251, DOI 10.1161/01.RES.86.3.251; Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006; Easwaran V, 2003, CANCER RES, V63, P3145; Furudoi A, 2002, ONCOLOGY-BASEL, V62, P157, DOI 10.1159/000048262; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Haefner B, 2002, DRUG DISCOV TODAY, V7, P653, DOI 10.1016/S1359-6446(02)02309-7; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339; Haraguchi M, 2002, ONCOL REP, V9, P159; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Polakis P, 2000, GENE DEV, V14, P1837; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROTHWARF DM, 1999, SCI STKE, P5; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wigmore SJ, 2001, INT J ONCOL, V18, P467; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	67	149	157	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1021	1031		10.1038/sj.onc.1208296	http://dx.doi.org/10.1038/sj.onc.1208296			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592509				2022-12-25	WOS:000226749200008
J	Guo, Y; Harwalkar, J; Stacey, DW; Hitomi, M				Guo, Y; Harwalkar, J; Stacey, DW; Hitomi, M			Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal	ONCOGENE			English	Article						cyclin D1; cell cycle; message stability; single-cell analysis; mitogenic signaling	SMOOTH-MUSCLE-CELLS; BREAST-CANCER CELLS; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; RESTRICTION POINT; DEPENDENT KINASES; PROMOTER ACTIVITY; HUMAN FIBROBLASTS; GENE-EXPRESSION	Cyclin D1 is critical for entry into, continuation of, and exit from the cell division cycle. Mitogen stimulation of quiescent cells induces cyclin D1 expression in a transcription-dependent manner. In actively cycling cells, on the other hand, fluctuation of cyclin D1 protein levels through the cell cycle is post-transcriptionally regulated. Cyclin D1 is expressed at low levels during S phase to allow efficient DNA synthesis, and induced to high levels in G2 phase through Ras activity to commit the cells to continuing cell cycle progression. Once induced in G2 phase, cyclin D1 expression becomes Ras independent through the next G1 phase, where it promotes G1/S transition. When mitogenic signaling is abrogated, however, cyclin D1 fails to increase during G2 phase and the cell becomes arrested in the next G1 phase. In this way, the expression levels of cyclin D1 in G2 phase determine the fate of the next cell cycle. Despite its importance of the mechanism of cyclin D1 suppression upon mitogen withdrawal is unknown. Using both quantitative fluorescence microscopy and biochemical analyses, we have found that, upon serum deprivation, cyclin D1 mRNA is downmodulated without any decline in its rate of transcription. Furthermore, cyclin D1 mRNA half-life becomes shorter when serum is removed. These results demonstrate that cyclin D1 message destabilization plays a critical role in cyclin D1 suppression during G2 phase of serum-deprived cultures, and therefore in the withdrawal from the cell cycle.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, NC2-150,9500 Euclid Ave, Cleveland, OH 44195 USA.	hitomim@ccf.org			NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER; NCI NIH HHS [CA92194] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gouble A, 2002, CANCER RES, V62, P1489; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; Musa NL, 1999, AM J RESP CELL MOL, V20, P352, DOI 10.1165/ajrcmb.20.2.3160; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RIMOKH R, 1994, BLOOD, V83, P3689; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stacey D W, 1981, Methods Enzymol, V79, P76; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Winston JT, 1996, ONCOGENE, V12, P127	59	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1032	1042		10.1038/sj.onc.1208299	http://dx.doi.org/10.1038/sj.onc.1208299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592507				2022-12-25	WOS:000226749200009
J	Xi, SC; Gooding, WE; Grandis, JR				Xi, SC; Gooding, WE; Grandis, JR			In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy	ONCOGENE			English	Article						signal transducers and activators of transcription; head and neck cancer; epidermal growth factor receptor; STAT3 decoy; cisplatin	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; TUMOR ANGIOGENESIS; TYROSINE KINASE; SRC ONCOPROTEIN; NECK-CANCER; KAPPA-B	The development of more effective prevention and treatment strategies for solid tumors is limited by an incomplete understanding of the critical growth pathways that are activated in carcinogenesis. Signal transducers and activators of transcription ( STAT) proteins have been linked to transformation and tumor progression. Several approaches have been used to block STAT3 in cancer cells resulting in reduced proliferation and apoptosis. We tested the hypothesis that blocking STAT3 activation using a transcription factor decoy approach would decrease tumor growth and STAT3 target gene expression in vivo. In a xenograft model of squamous cell carcinoma of the head and neck (SCCHN), daily administration of the STAT3 decoy ( 25 mug) resulted in decreased tumor volumes, abrogation of STAT3 activation, and decreased expression of STAT3 target genes ( VEGF, Bcl-xL, and cyclin D1) compared to treatment with a mutant control decoy. Blockade of STAT3 with the STAT3 decoy also induced apoptosis and decreased proliferation, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. These results suggest that a transcription factor decoy approach may be used to target STAT3 in cancers that demonstrate increased STAT3 activation including SCCHN.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Dept Biostat, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Eye & Ear Inst Pittsburgh, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu			NCI NIH HHS [R01CA 101840-01, 1 P50 CA097190-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097190, R01CA101840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Grunstein J, 1999, CANCER RES, V59, P1592; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Kawamura I, 1999, GENE THER, V6, P91, DOI 10.1038/sj.gt.3300819; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lim R, 2000, J NEUROCHEM, V74, P596, DOI 10.1046/j.1471-4159.2000.740596.x; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Mayer F, 2003, ANN ONCOL, V14, P825, DOI 10.1093/annonc/mdg242; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Rak J, 2000, CANCER RES, V60, P490; Takeda T, 1997, J ENDOCRINOL, V153, pR1, DOI 10.1677/joe.0.153R001; Takeuchi S, 1999, MOL BRAIN RES, V74, P208, DOI 10.1016/S0169-328X(99)00298-3; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; von Knethen A, 1998, ONCOGENE, V17, P387, DOI 10.1038/sj.onc.1201926; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	50	134	148	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					970	979		10.1038/sj.onc.1208316	http://dx.doi.org/10.1038/sj.onc.1208316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592503	Bronze			2022-12-25	WOS:000226749200003
J	Houlard, M; Romero-Portillo, F; Germani, A; Depaux, A; Regnier-Ricard, F; Gisselbrecht, S; Varin-Blank, N				Houlard, M; Romero-Portillo, F; Germani, A; Depaux, A; Regnier-Ricard, F; Gisselbrecht, S; Varin-Blank, N			Characterization of VIK-1: a new Vav-interacting Kruppel-like protein	ONCOGENE			English	Article						Vav-1 proto-oncogene; Kruppel genes; cell-cycle control	ZINC-FINGER PROTEINS; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; BINDING PROTEINS; CELLS; GENE; RECEPTOR; DOMAINS; RNA; ASSOCIATION	Binding partners of the Src homology domains of Vav-1 were characterized by a two-hybrid screening of a Jurkat cell cDNA library. One of the isolated clones encoded a new protein named VIK that belongs to the Kruppel-like zinc-finger gene family. Genome mapping showed that a single gene positioned at chromosome 7q22.1 generated three possible isoforms containing alternative domains such as proline-rich and Kruppel-associated box A or B repressor domains. The isolated isoform, VIK-1, did not contain such motifs but presented six tandemly arranged zinc-fingers and consensus Kruppel H-C links. VIK-1 interacted both with Vav-1 and cyclin-dependent kinase 4 through two independent domains and corresponded to a Vav C-Src homology domain (SH)3 partner able to shuttle between the nucleus and the cytoplasm exhibiting functional nuclear addressing and export sequences. The results indicated a restricted expression of the protein during the G1 phase and its overexpression resulted in an inhibition of the cell-cycle progression that was reversed in the presence of Vav 1. Thus, this ubiquitous factor provides a first link between Vav-1 and the cell-cycle machinery.	Hop Cochin, Inst Cochin, Dept Hematol, CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Varin-Blank, N (corresponding author), Hop Cochin, Inst Cochin, Dept Hematol, CNRS,UMR 8104,INSERM,U567, Batiment G Roussy,27 Rue Faubourg St Jacques, F-75014 Paris, France.	varin@cochin.inserm.fr	Varin-Blank, Nadine/G-4396-2013; Romero, Francisco/K-2101-2014	Romero, Francisco/0000-0002-9588-6881; VARIN-BLANK, Nadine/0000-0003-2769-018X				Bertagnolo V, 1998, FEBS LETT, V441, P480, DOI 10.1016/S0014-5793(98)01593-2; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hastie ND, 2001, CELL, V106, P391, DOI 10.1016/S0092-8674(01)00469-X; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, ONCOGENE, V12, P1577; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; HUEBNER K, 1991, AM J HUM GENET, V48, P726; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Millot GA, 2002, J CELL SCI, V115, P2329; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PANDYA K, 2002, J BIOL CHEM, V13, P13; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Romero F, 1996, MOL CELL BIOL, V16, P37; Romero F, 1998, J BIOL CHEM, V273, P5923, DOI 10.1074/jbc.273.10.5923; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	43	12	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					28	38		10.1038/sj.onc.1208043	http://dx.doi.org/10.1038/sj.onc.1208043			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558030				2022-12-25	WOS:000226125800005
J	Hojjati, MR; Li, ZQ; Zhou, HW; Tang, SS; Huan, CM; Ooi, E; Lu, SD; Jiang, XC				Hojjati, MR; Li, ZQ; Zhou, HW; Tang, SS; Huan, CM; Ooi, E; Lu, SD; Jiang, XC			Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY-DISEASE; CHAIN BASE SYNTHESIS; E-KNOCKOUT MICE; SERINE PALMITOYLTRANSFERASE; SPHINGOSINE 1-PHOSPHATE; DENSITY-LIPOPROTEIN; RABBIT AORTA; SPHINGOMYELIN; GENE; INHIBITION	Sphingolipids play a very important role in cell membrane formation, signal transduction, and plasma lipoprotein metabolism, all of which may well have an impact on the development of atherosclerosis. To investigate the relationship between sphingolipid metabolism and atherosclerosis, we utilized myriocin to inhibit mouse serine palmitoyl-CoA transferase (SPT), the key enzyme for sphingolipid biosynthesis. We injected 8-week-old apoE-deficient mice with myriocin (0.3 mg/kg/ every other day, intraperitoneal) for 60 days. On a chow diet, myriocin treatment caused a significant decrease (50%) in liver SPT activity (p < 0.001), significant decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (54, 32, and 73%, respectively) (p < 0.0001), and a significant increase in plasma phosphatidylcholine levels (91%) (p < 0.0001). Plasma total cholesterol and triglyceride levels demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (42% in root and 36% in en face assays) (p < 0.01). On a high fat diet, myriocin treatment caused marked decreases in plasma sphingomyelin, ceramide, and sphingosine-1-phosphate levels (59, 66, and 81%, respectively) (p < 0.0001), and a marked increase in plasma phosphatidylcholine levels (100%) (p < 0.0001). Total cholesterol and triglyceride demonstrated no significant changes, but there was a significant decrease in atherosclerotic lesion area (39% in root and 37% in en face assays) (p < 0.01). These results indicate that, apart from cholesterol levels, sphingolipids have an effect on atherosclerotic development and that SPT has proatherogenic properties. Thus, inhibition of SPT activity could be an alternative treatment for atherosclerosis.	Suny Downstate Med Ctr, Dept Anat & Cell Biol, New York, NY 10032 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Jiang, XC (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cell Biol, 450 Clarkson Ave,Box 5, New York, NY 10032 USA.	xjiang@downstate.edu			NHLBI NIH HHS [HL-64735, HL-69817] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069817, R01HL064735] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bourbon NA, 2001, AM J PHYSIOL-CELL PH, V280, pC1403, DOI 10.1152/ajpcell.2001.280.6.C1403; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Charles R, 2000, CIRC RES, V87, P282, DOI 10.1161/01.RES.87.4.282; Chen JK, 1999, CHEM BIOL, V6, P221, DOI 10.1016/S1074-5521(99)80038-6; Deutschman DH, 2003, AM HEART J, V146, P62, DOI 10.1016/S0002-8703(03)00118-2; FUGITA T, 1995, BIOORG MED CHEM LETT, V5, P847; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; He QR, 2004, MYCOPATHOLOGIA, V157, P339, DOI 10.1023/B:MYCO.0000024182.04140.95; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; Jeong TS, 1998, J CLIN INVEST, V101, P905, DOI 10.1172/JCI870; Jiang XC, 2000, ARTERIOSCL THROM VAS, V20, P2614, DOI 10.1161/01.ATV.20.12.2614; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Johnson VJ, 2004, TOXICOLOGY, V201, P67, DOI 10.1016/j.tox.2004.04.019; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Mallampalli RK, 1996, BIOCHEM J, V318, P333, DOI 10.1042/bj3180333; Marathe S, 1999, CIRCULATION, V100, P695; MERILL AH, 1985, J LIPID RES, V26, P617; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1984, BIOCHEM BIOPH RES CO, V119, P995, DOI 10.1016/0006-291X(84)90872-6; MILLER M, 1990, AM J CARDIOL, V65, P1, DOI 10.1016/0002-9149(90)90017-U; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Okajima F, 2002, BBA-MOL CELL BIOL L, V1582, P132, DOI 10.1016/S1388-1981(02)00147-6; Osuchowski MF, 2004, TOXICOL LETT, V147, P87, DOI 10.1016/j.toxlet.2003.10.016; Park TS, 2004, CIRCULATION, V110, P3465, DOI 10.1161/01.CIR.0000148370.60535.22; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SOHAL PS, 1995, BIOCHEM J, V311, P873; Teupser D, 2003, ARTERIOSCL THROM VAS, V23, P1907, DOI 10.1161/01.ATV.0000090126.34881.B1; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WILLIAMS RD, 1986, J LIPID RES, V27, P763; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9	36	211	221	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10284	10289		10.1074/jbc.M412348200	http://dx.doi.org/10.1074/jbc.M412348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15590644	hybrid			2022-12-25	WOS:000227559600067
J	Gao, ZY; Sasaoka, T; Fujimori, T; Oya, T; Ishii, Y; Sabit, H; Kawaguchi, M; Kurotaki, Y; Naito, M; Wada, T; Ishizawa, S; Kobayashi, M; Nabeshima, YI; Sasahara, M				Gao, ZY; Sasaoka, T; Fujimori, T; Oya, T; Ishii, Y; Sabit, H; Kawaguchi, M; Kurotaki, Y; Naito, M; Wada, T; Ishizawa, S; Kobayashi, M; Nabeshima, YI; Sasahara, M			Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED LIGAND; GROWTH-FACTOR RECEPTOR; BASAL JNK ACTIVITY; IN-VIVO; CELL-PROLIFERATION; INDUCED APOPTOSIS; ANALYSIS REVEALS; EXPRESSION; KINASE; MECHANISM	This study provides new perspectives of the unique aspects of platelet-derived growth factor beta-receptor (PDGFR-beta) signaling and biological responses through the establishment of a mutant mouse strain in which two loxP sequences were inserted into the introns of PDGFR-beta genome sequences. Isolation of skin fibroblasts from the mutant mice and Cre recombinase transfection in vitro induced PDGFR-beta gene deletion ( PDGFR-beta(Delta/Delta)). The resultant depletion of the PDGFR-beta protein significantly attenuated platelet-derived growth factor ( PDGF)-BB-induced cell migration, proliferation, and protection from H2O2-induced apoptosis of the cultured PDGFR-beta(Delta/Delta) dermal fibroblasts. PDGF-AA and fetal bovine serum were mitogenic and antiapoptotic but were unable to induce the migration in PDGFR-beta(Delta/Delta) fibroblasts. Concerning the PDGF signaling, PDGF-BB-induced phosphorylation of Akt, ERK1/2, and JNK, but not p38, decreased in PDGFR-beta(Delta/Delta) fibroblasts, but PDGF-AA-induced signaling was not altered. Overexpression of the phospholipid phosphatases, SHIP2 and/or PTEN, inhibited PDGF-BB-induced phosphorylation of Akt and ERK1/2 in PDGFR-beta(Delta/Delta) fibroblasts but did not affect that of JNK and p38. These results indicate that disruption of distinct PDGFR-beta signaling pathways in PDGFR-beta(Delta/Delta) dermal fibroblasts impaired their proliferation and survival, but completely inhibits migratory response, and that PDGF-BB-induced phosphorylation of Akt and ERK1/2 possibly mediated by PDGFR-alpha is regulated, at least in part, by the lipid phosphatases SHIP2 and/or PTEN. Thus, the PDGFR-beta function on dermal fibroblasts appears to be critical in PDGF-BB action for skin wound healing and is clearly distinctive from that of PDGFR-beta in the ligand-induced biological responses and the underlying properties of cellular signaling.	Toyama Med & Pharmaceut Univ, Dept Pathol, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Dept Clin Pharmacol, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Dept Internal Med 1, Toyama 9300194, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto 6068501, Japan; Larbor Hlth & Welf Org, Niigata Rosai Hosp, Dept Pathol, Niigata 9428502, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	University of Toyama; University of Toyama; University of Toyama; Kyoto University; Japan Science & Technology Agency (JST)	Sasahara, M (corresponding author), Toyama Med & Pharmaceut Univ, Dept Pathol, 2630 Sugitani, Toyama 9300194, Japan.	sasahara@ms.toyama-mpu.ac.jp	谭, 德华 德/D-1910-2009; Wada, Tsutomu/AAY-4450-2020; Fujimori, Toshihiko/L-7711-2016	Wada, Tsutomu/0000-0001-5819-8556; Fujimori, Toshihiko/0000-0001-5200-4634				Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Crosby JR, 1999, AM J PATHOL, V154, P1315, DOI 10.1016/S0002-9440(10)65384-9; Crosby JR, 1998, NAT GENET, V18, P385, DOI 10.1038/ng0498-385; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawano H, 2003, J AM SOC NEPHROL, V14, P584, DOI 10.1097/01.ASN.0000050415.97942.2F; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411; Sasaoka T, 2003, ENDOCRINOLOGY, V144, P4204, DOI 10.1210/en.2003-0190; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; Sun Y, 2003, J BIOL CHEM, V278, P43645, DOI 10.1074/jbc.M300674200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yates S, 2002, WOUND REPAIR REGEN, V10, P5, DOI 10.1046/j.1524-475X.2002.10902.x; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199	35	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9375	9389		10.1074/jbc.M413081200	http://dx.doi.org/10.1074/jbc.M413081200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590688	hybrid			2022-12-25	WOS:000227453100090
J	Gail, R; Frank, R; Wittinghofer, A				Gail, R; Frank, R; Wittinghofer, A			Systematic peptide array-based delineation of the differential beta-catenin interaction with Tcf4, E-cadherin, and adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE ANTAGONISTS; TUMOR-SUPPRESSOR PROTEIN; CRYSTAL-STRUCTURE; HOT-SPOTS; COLORECTAL-CANCER; APC; COMPLEX; BINDING; PHOSPHORYLATION; MECHANISM	Nuclear accumulation of the complex between beta-catenin and proteins of the T-cell factor (Tcf) family is a hallmark of many cancers. Targeting this interaction for drug development is complicated by the fact that E-cadherin and adenomatous polyposis coli (APC) bind to overlapping sites on beta-catenin. Inhibiting their interactions might actually promote tumor growth. To identify selective beta-catenin binding hot spots of Tef4, E-cadherin, and APC, array technology with peptides of up to 53 amino acids length was used. Interactions were monitored by a quantitative fluorescent readout, which was shown to represent a monitor of true equilibrium binding constants. We identified minimal binding motifs in the beta-catenin ligands and showed that most of the 15-mer and 20-mer repeats of APC did not interact, at least when non-phosphorylated, and defined a consensus binding motif also present in APC. We confirmed previously found hot spots and identified new ones. The method allowed us to locate a hydrophobic pocket that was relevant for the Tcf, but not the E-cadherin interaction, and would thus constitute an ideal drug target site.	Max Planck Inst Mol Physiol, Abt Struct Biol, D-44227 Dortmund, Germany; Gesell Biotechnol Forsch mbH, Abt Chem Biol, D-38124 Braunschweig, Germany	Max Planck Society; Gesellschaft fur Biotechnologische Forschung mbH	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Struct Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de						Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Fasolini M, 2003, J BIOL CHEM, V278, P21092, DOI 10.1074/jbc.M301781200; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Kato-Stankiewicz J, 2002, P NATL ACAD SCI USA, V99, P14398, DOI 10.1073/pnas.222222699; Kim JS, 2002, MOL CANCER THER, V1, P1355; Knapp S, 2001, J MOL BIOL, V306, P1179, DOI 10.1006/jmbi.2001.4463; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2000, GENE DEV, V14, P1837; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Simcha I, 2001, MOL BIOL CELL, V12, P1177, DOI 10.1091/mbc.12.4.1177; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tickenbrock L, 2003, J MOL BIOL, V327, P359, DOI 10.1016/S0022-2836(03)00144-X; Tilley JW, 1997, J AM CHEM SOC, V119, P7589, DOI 10.1021/ja970702x; Toepert F, 2001, ANGEW CHEM INT EDIT, V40, P897, DOI 10.1002/1521-3773(20010302)40:5<897::AID-ANIE897>3.0.CO;2-X; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zander N, 2004, MOL DIVERS, V8, P189, DOI 10.1023/B:MODI.0000036253.04738.ac	49	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7107	7117		10.1074/jbc.M410215200	http://dx.doi.org/10.1074/jbc.M410215200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591320	hybrid			2022-12-25	WOS:000227332700101
J	Carriere, V; Vidal, R; Lazou, K; Lacasa, M; Delers, F; Ribeiro, A; Rousset, M; Chambaz, J; Lacorte, JM				Carriere, V; Vidal, R; Lazou, K; Lacasa, M; Delers, F; Ribeiro, A; Rousset, M; Chambaz, J; Lacorte, JM			HNF-4-dependent induction of apolipoprotein A-IV gene transcription by an apical supply of lipid micelles in intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY-ACIDS; NUCLEAR FACTOR 4-ALPHA; FARNESOID-X-RECEPTOR; PROTEIN-KINASE-A; DIFFERENTIAL EXPRESSION; SUCRASE-ISOMALTASE; DIETARY N-3; SECRETION; ENHANCER	Apolipoprotein (apo) A-IV, a component of triglyceride-rich lipoproteins secreted by the small intestine, has been shown to play an important role in the control of lipid homeostasis. Numerous studies have described the induction of apoA-IV gene expression by lipids, but the molecular mechanisms involved in this process remain unknown. In this study, we have demonstrated that a lipid bolus induced transcription of the apoA-IV gene in transgenic mice and that the regulatory region of the apoA-IV gene, composed of the apoC-III enhancer and the apoA-IV promoter (eC3-A4), was responsible for this induction. In enterocyte Caco-2/TC7 cells, a permanent supply of lipids at the basal pole induced expression of the apoA-IV gene both at the transcriptional level and through mRNA stabilization. ApoA-11V gene transcription and protein secretion were further induced by an apical supply of complex lipid micelles mimicking the composition of duodenal micelles, and this effect was not reproduced by apical delivery of different combinations of micelle components. Only induction of the apoA-IV gene by lipid micelles involved the participation of hepatic nuclear factor (HNF)-4, as demonstrated using a dominant negative form of this transcription factor. Accordingly, lipid micelles increased the DNA binding activity of HNF-4 on the eC3-A4 region. These results emphasize the importance of physiological delivery of dietary lipids on apoA-IV gene expression and the implication of HNF-4 in this regulation.	UPMC, INSERM, Ctr Rech Biomed Cordeliers, UMR505, F-75006 Paris, France; Univ Paris 06, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite	Carriere, V (corresponding author), UPMC, INSERM, Ctr Rech Biomed Cordeliers, UMR505, 15 Rue Ecole Med, F-75006 Paris, France.	Veronique.Cai-riere-u505@bhdc.jussieu.fr	Ribeiro, Agnès/Q-9702-2017; Carrière, Véronique/AAQ-5027-2021	Ribeiro, Agnès/0000-0003-2063-6084; Carrière, Véronique/0000-0002-6263-0847				BLACK DD, 1990, J LIPID RES, V31, P497; Botham KM, 2003, EXP BIOL MED, V228, P143, DOI 10.1177/153537020322800203; Carriere V, 2001, BIOCHEM J, V354, P301, DOI 10.1042/0264-6021:3540301; Carriere V, 1998, AM J PHYSIOL-GASTR L, V274, pG1101, DOI 10.1152/ajpgi.1998.274.6.G1101; CHANTRET I, 1994, J CELL SCI, V107, P213; Chateau D, 2005, J CELL PHYSIOL, V202, P767, DOI 10.1002/jcp.20173; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CLANDININ MT, 1994, J PEDIATR-US, V125, pS25, DOI 10.1016/S0022-3476(06)80733-X; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; Dyer J, 2003, BIOCHEM SOC T, V31, P1140, DOI 10.1042/BST0311140; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HAYASHI H, 1990, J LIPID RES, V31, P1613; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012; Hertz R, 2003, J BIOL CHEM, V278, P22578, DOI 10.1074/jbc.M212138200; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Heshka JT, 2001, LIFE SCI, V69, P987, DOI 10.1016/S0024-3205(01)01201-2; Hirokane H, 2004, J BIOL CHEM, V279, P45685, DOI 10.1074/jbc.M404255200; Hong YH, 2003, J BIOL CHEM, V278, P27495, DOI 10.1074/jbc.M304112200; JUMARIE C, 1991, J CELL PHYSIOL, V149, P24, DOI 10.1002/jcp.1041490105; KINSELLA JE, 1990, JPEN-PARENTER ENTER, V14, pS200, DOI 10.1177/014860719001400511; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Lacorte JM, 1996, BIOCHEM J, V318, P681, DOI 10.1042/bj3180681; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Liu M, 2003, EXP BIOL MED, V228, P1181, DOI 10.1177/153537020322801013; Lu S, 2002, J LIPID RES, V43, P1303, DOI 10.1194/jlr.M200035-JLR200; Lu S, 2003, AM J PHYSIOL-GASTR L, V284, pG248, DOI 10.1152/ajpgi.00391.2002; Morel E, 2004, MOL BIOL CELL, V15, P132, DOI 10.1091/mbc.E03-04-0215; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rodolosse A, 1998, BIOCHEM J, V336, P115, DOI 10.1042/bj3360115; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Shimamoto Y, 2004, J BIOL CHEM, V279, P7770, DOI 10.1074/jbc.M310577200; Stan S, 2003, BBA-MOL CELL BIOL L, V1631, P177, DOI 10.1016/S1388-1981(03)00004-0; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wang AB, 2003, EXP CELL RES, V290, P1, DOI 10.1016/S0014-4827(03)00313-6; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis; Zheng XZ, 2001, BIOCHEM J, V357, P481, DOI 10.1042/0264-6021:3570481	47	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5406	5413		10.1074/jbc.M408002200	http://dx.doi.org/10.1074/jbc.M408002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15583007	hybrid			2022-12-25	WOS:000227217100037
J	Fenteany, FH; Colley, KJ				Fenteany, FH; Colley, KJ			Multiple signals axe required for alpha 2,6-sialyltransferase (ST6Gal I) oligomerization and Golgi localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; MEMBRANE-SPANNING DOMAIN; N-ACETYLGLUCOSAMINYLTRANSFERASE-I; MEDIAL-GOLGI; TRANSMEMBRANE DOMAIN; PLASMA-MEMBRANE; KIN RECOGNITION; ALPHA 2,6-SIALYLTRANSFERASE; ENDOPLASMIC-RETICULUM; FLANKING SEQUENCES	A single amino acid difference in the catalytic domain of two isoforms of the alpha2,6-sialyltransferase (ST6Gal 1) leads to differences in their trafficking, processing, and oligomerization. The STtyr isoform is transiently localized in the Golgi and is ultimately cleaved and secreted, whereas the STcys isoform is stably localized in the Golgi and is not cleaved and secreted. The stable localization of STcys is correlated with its enhanced ability to oligomerize. To test the hypothesis that multiple signals can mediate Golgi localization and further evaluate the role of oligomerization in the localization process, we evaluated the effects of individually and simultaneously altering the cytosolic tail and transmembrane region of the STcys isoform. We found that the localization, processing, and oligomerization of STcys were not substantially changed when either the core amino acids of the cytosolic tail were deleted or the sequence and length of the transmembrane region were altered. In contrast, when these changes were made simultaneously, the STcys isoforin was converted into a form that was processed, secreted, and weakly oligomerized like STtyr. We propose that STcys oligomerization is a secondary event resulting from its concentration in the Golgi via mechanisms independently mediated by its cytosolic tail and transmembrane region.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	karenc@uic.edu			NIGMS NIH HHS [R01-GM48134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1992, J BIOL CHEM, V267, P24433; BURKE J, 1994, J BIOL CHEM, V269, P12049; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; Chen TLL, 2003, GLYCOBIOLOGY, V13, P109, DOI 10.1093/glycob/cwg015; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; EISNER M, 2003, MOL MEMBR BIOL, V20, P221; Fullekrug J, 1998, BBA-MOL CELL RES, V1404, P77, DOI 10.1016/S0167-4889(98)00048-2; Giraudo CG, 2003, J BIOL CHEM, V278, P40262, DOI 10.1074/jbc.M305455200; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; Ma JY, 1997, J BIOL CHEM, V272, P672; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; Milland J, 2001, J BIOL CHEM, V276, P12012, DOI 10.1074/jbc.M010018200; Milland J, 2002, J BIOL CHEM, V277, P10374, DOI 10.1074/jbc.M111799200; Mironov AA, 1998, FEBS LETT, V440, P99, DOI 10.1016/S0014-5793(98)01439-2; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; Sousa VL, 2003, J BIOL CHEM, V278, P7624, DOI 10.1074/jbc.M209325200; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TEASDALE RD, 1994, GLYCOBIOLOGY, V4, P917, DOI 10.1093/glycob/4.6.917; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YOUAKIM A, 1994, P NATL ACAD SCI USA, V91, P10913, DOI 10.1073/pnas.91.23.10913	57	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5423	5429		10.1074/jbc.M412396200	http://dx.doi.org/10.1074/jbc.M412396200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15582997	hybrid			2022-12-25	WOS:000227217100039
J	Wang, H; Song, K; Sponseller, TL; Danielpour, D				Wang, H; Song, K; Sponseller, TL; Danielpour, D			Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN PROSTATE-CANCER; RAT VENTRAL PROSTATE; TGF-BETA; MALIGNANT-TRANSFORMATION; GLUCOCORTICOID-RECEPTOR; GENE AMPLIFICATION; FOCAL ADHESIONS; DOWN-REGULATION; II RECEPTORS	Androgen receptor-associated protein 55 (ARA55/Hic-5) belongs to the LIM protein superfamily and is featured by three or four N-terminal LD motifs and four C-terminal zinc finger-like LIM domains. Both LD motifs and LIM domains can serve as protein-protein interaction interfaces. Recently, we found that enforced expression of ARA55 inhibits transforming growth factor-beta-mediated up-regulation of Smad binding element-luciferase reporter activity in NRP-154 and NRP-152 rat prostate and LNCaP human prostate cell lines. Moreover, ARA55 also inhibits the induction of Smad-binding element 4-luciferase and 3TP-luciferase (a plasminogen activator inhibitor-1 (PAI-1) promoter construct) reporters by constitutively active (CA)-Smad3 in these cell lines. Coimmunoprecipitation studies suggest an interaction between ARA55 and either CA-Smad3 or wild-type Smad3 in HEK293 cells that occurs through the MH2 domain of Smad3 and the C terminus of ARA55 with wild-type Smad3 having stronger affinity than CA-Smad3 to ARA55. Glutathione S-transferase pull-down assays demonstrate that this interaction can occur in a cell-free system. These results are consistent with the luciferase data showing that the C terminus of ARA55 is critical for suppression of Smad3 activity. Furthermore, using a mammalian two-hybrid system, we confirmed that ARA55 interacts with the MH2 domain of Smad3 and suppresses CA-Smad3-induced transcriptional responses. In conclusion, these results support that ARA55 selectively intercepts transforming growth factor-beta signaling through an interaction of the LIM domain of ARA55 with the MH2 domain of Smad3.	Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Pharmacol, Univ Hosp, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr Res Labs, Univ Hosp, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; University Hospitals of Cleveland	Danielpour, D (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Pharmacol, Univ Hosp, Wolstein Res Bldg,Rm 3532,2103 Cornell Rd, Cleveland, OH 44106 USA.	david.danielpour@case.edu			NCI NIH HHS [1R01CA102074, 1R01CA092102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092102, R01CA102074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Brodin G, 1999, CANCER RES, V59, P2731; Chipuk JE, 2002, J BIOL CHEM, V277, P26412, DOI 10.1074/jbc.M201244200; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 1999, J CELL SCI, V112, P169; Denhez F, 2002, J BIOL CHEM, V277, P12270, DOI 10.1074/jbc.M110291200; Desai KV, 2000, J MOL ENDOCRINOL, V24, P253, DOI 10.1677/jme.0.0240253; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Gerdes MJ, 1998, ENDOCRINOLOGY, V139, P3569, DOI 10.1210/en.139.8.3569; Gerdes MJ, 2004, PROSTATE, V58, P299, DOI 10.1002/pros.10327; Guerrero-Santoro J, 2004, J CELL BIOCHEM, V92, P810, DOI 10.1002/jcb.20109; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Hayes SA, 2001, CANCER RES, V61, P2112; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hsing AY, 1996, CANCER RES, V56, P5146; Ishino M, 2000, FEBS LETT, V474, P179, DOI 10.1016/S0014-5793(00)01597-0; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Koivisto P, 1996, SCAND J CLIN LAB INV, V56, P57; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kundu SD, 2000, PROSTATE, V43, P118; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; Mashimo J, 2000, GENE, V249, P99, DOI 10.1016/S0378-1119(00)00163-3; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Mestayer C, 2003, PROSTATE, V56, P192, DOI 10.1002/pros.10229; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Miyoshi Y, 2003, PROSTATE, V56, P280, DOI 10.1002/pros.10262; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nessler-Menardi C, 2000, PROSTATE, V45, P124, DOI 10.1002/1097-0045(20001001)45:2<124::AID-PROS6>3.0.CO;2-7; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishiya N, 2002, J BIOCHEM, V132, P279, DOI 10.1093/oxfordjournals.jbchem.a003222; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Song K, 2003, CANCER RES, V63, P4358; Stewart LMV, 2003, EXP CELL RES, V284, P303, DOI 10.1016/S0014(02)00037-X; Tang BW, 1999, CANCER RES, V59, P4834; Thomas SM, 1999, J CELL SCI, V112, P181; Trapman J, 1996, PATHOL RES PRACT, V192, P752, DOI 10.1016/S0344-0338(96)80097-5; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang X, 2002, J BIOL CHEM, V277, P31124, DOI 10.1074/jbc.M203896200; Williams RH, 1996, CLIN CANCER RES, V2, P635; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Yang YA, 2002, CELL GROWTH DIFFER, V13, P123	80	53	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5154	5162		10.1074/jbc.M411575200	http://dx.doi.org/10.1074/jbc.M411575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15561701	hybrid			2022-12-25	WOS:000227217100007
J	Williams, G; Williams, EJ; Maison, P; Pangalos, MN; Walsh, FS; Doherty, P				Williams, G; Williams, EJ; Maison, P; Pangalos, MN; Walsh, FS; Doherty, P			Overcoming the inhibitors of myelin with a novel neurotrophin strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RAT SPINAL-CORD; NEURITE OUTGROWTH; AXONAL REGENERATION; N-CADHERIN; GLYCOPROTEIN INTERACTS; DEPENDENT MECHANISM; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; MESSENGER-RNA	Myelin inhibitors activate a p75(NTR)-dependent signaling cascade in neurons that not only inhibits axonal growth but also prevents neurotrophins (NT) from stimulating growth. Most intriguingly, in addition to Trk receptors, neurotrophins also bind to p75(NTR). We have designed a "mini-neurotrophin" called BAG to activate TrkB in the absence of p75(NTR) binding. We find that BAG is as effective as the natural TrkB ligands (brain-derived neurotrophic factor (BDNF) and NT-4) at promoting neurite outgrowth from cerebellar neurons. Furthermore, the neurite outgrowth responses stimulated by BDNF and BAG are inhibited by a common set of reagents, including the Trk receptor inhibitor K252a, as well as protein kinase A and phosphoinositide 3-kinase inhibitors. However, in contrast to BDNF, BAG promotes growth in the presence of a myelin inhibitor or when antibodies directly activate the p75NTR inhibitory pathway. On the basis of this observation, we postulated that the binding of BDNF to the p75(NTR) might compromise the ability of BDNF to stimulate neurite outgrowth in an inhibitory environment. To test this, we used NGF, and an NGF-derived peptide, to compete for the BDNF/ p75(NTR) interaction; remarkably, in the presence of either agent, BDNF acquired the ability to promote neurite outgrowth in the presence of a myelin inhibitor. The data suggest that in an inhibitory environment, the BDNF/p75(NTR) interaction compromises regeneration. Agents that activate Trk receptors in the absence of p75(NTR) binding, or agents that inhibit neurotrophin/ p75(NTR) binding, might therefore be better therapeutic candidates than neurotrophins.	Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 1UL, England; Wyeth Ayerst Res, Discovery Res, Collegeville, PA 19426 USA	University of London; King's College London; Pfizer	Doherty, P (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, Hodgkin BLD,St Thomas St, London SE1 1UL, England.	patrick.doherty@kcl.ac.uk	Williams, Gareth/B-3202-2010; Doherty, Patrick/A-8752-2008	Doherty, Patrick/0000-0002-0407-5689; Williams, Gareth/0000-0001-9205-4943				Banfield MJ, 2001, STRUCTURE, V9, P1191, DOI 10.1016/S0969-2126(01)00681-5; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Berry M, 1982, Bibl Anat, P1; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Dergham P, 2002, J NEUROSCI, V22, P6570; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Gao Y, 2003, J NEUROSCI, V23, P11770; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; LINDSAY RM, 1993, EXP NEUROL, V124, P103, DOI 10.1006/exnr.1993.1181; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Liu Y, 1999, J NEUROSCI, V19, P4370; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; Maliartchouk S, 2000, J BIOL CHEM, V275, P9946, DOI 10.1074/jbc.275.14.9946; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Menei P, 1998, EUR J NEUROSCI, V10, P607, DOI 10.1046/j.1460-9568.1998.00071.x; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; Nonomura T, 1996, DEV BRAIN RES, V97, P42, DOI 10.1016/S0165-3806(96)00130-7; O'Leary PD, 1998, J NEUROCHEM, V70, P1712; O'Leary PD, 2003, J BIOL CHEM, V278, P25738, DOI 10.1074/jbc.M303209200; OLSON L, 1994, NEUROCHEM INT, V25, P1, DOI 10.1016/0197-0186(94)90044-2; Pattarawarapan M, 2003, J MED CHEM, V46, P5277, DOI 10.1021/jm030221q; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SEBERT ME, 1993, J NEUROSCI RES, V36, P357, DOI 10.1002/jnr.490360402; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; TAPLEY P, 1992, ONCOGENE, V7, P371; Vinson M, 2001, J BIOL CHEM, V276, P20280, DOI 10.1074/jbc.M100345200; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Williams G, 2002, J BIOL CHEM, V277, P4361, DOI 10.1074/jbc.M109185200; Xie YM, 2000, J BIOL CHEM, V275, P29868, DOI 10.1074/jbc.M005071200	52	30	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5862	5869		10.1074/jbc.M411121200	http://dx.doi.org/10.1074/jbc.M411121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572360	hybrid			2022-12-25	WOS:000227217100090
J	Grund, EM; Spyropoulos, DD; Watson, DK; Muise-Helmericks, RC				Grund, EM; Spyropoulos, DD; Watson, DK; Muise-Helmericks, RC			Interleukins 2 and 15 regulate Ets1 expression via ERK1/2 and MNK1 in human natural killer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; INITIATION-FACTOR 4E; HUMAN NK CELLS; TRANSCRIPTION FACTOR; T-CELLS; PROTEIN-SYNTHESIS; BINDING-PROTEIN; IL-2; ACTIVATION; CYTOKINE	Interleukins (IL)-2 and IL-15 regulate natural killer (NK) cell proliferation, survival, and cytolytic activity. Ets1 is a transcription factor expressed early in NK cell differentiation. Because IL-2Rbeta, IL-2Rgamma, IL-15, and Ets1 knock-out mice similarly lack NK cells, we explored a molecular connection between IL-2R signaling and Ets1. Here we report the post-transcriptional regulation of Ets1 by IL-2R signaling in human NK cells. IL-2 and IL-15 stimulation leads to increased Ets1 protein levels with no significant change in mRNA levels. Pulse and pulse-chase experiments show that IL-2 stimulation results in both a marked increase in the nascent translation of Ets1 and an increased protein half-life. Pharmacological inhibition of MEK specifically blocks IL-2- and IL-15-induced translation, whereas p38, phosphatidylinositol 3-kinase, and mTOR inhibitors had no effect on Ets1 levels. Fli1, an Ets family member, exhibited a different mechanism of regulation, illustrating the specificity of IL-2R beta and gamma subunit signaling on the regulation of Ets1 expression. Expression of a dominant negative form of MNK1, a regulator of the translation initiation factor eIF4E, blocks the expression of Ets1 as do the dominant negative forms of the common IL-2R beta and gamma chains. Expression of Ets1 is regulated similarly in normal peripheral human NK cells. Taken together, our findings provide a direct link between IL-2R subunit signaling and Ets1 expression and helps to explain the interdependence of the IL-2R subunits and Ets1 for NK cell development and function.	Med Univ S Carolina, Hollings Canc Ctr 320, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr 320, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr 320, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Muise-Helmericks, RC (corresponding author), Med Univ S Carolina, Hollings Canc Ctr 320, Dept Cell Biol & Anat, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	musehelm@muse.edu			NCI NIH HHS [P01 CA78582] Funding Source: Medline; NCRR NIH HHS [P20 RR16434] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALONSO K, 1994, AM J CLIN ONCOL-CANC, V17, P41, DOI 10.1097/00000421-199402000-00009; ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Colucci F, 2003, NAT REV IMMUNOL, V3, P413, DOI 10.1038/nri1088; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; deMagalhaes-Silverman M, 2000, J IMMUNOTHER, V23, P154, DOI 10.1097/00002371-200001000-00018; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Dunne J, 2001, J IMMUNOL, V167, P3129, DOI 10.4049/jimmunol.167.6.3129; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; GARZETTI GG, 1992, GYNECOL OBSTET INVES, V34, P49, DOI 10.1159/000292724; Gilmour KC, 2001, BLOOD, V98, P877, DOI 10.1182/blood.V98.3.877; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; Goicoa M A, 1992, Arch AIDS Res, V6, P15; Hodge DL, 2002, J IMMUNOL, V168, P6090, DOI 10.4049/jimmunol.168.12.6090; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; KONJEVIC G, 1993, NEOPLASMA, V40, P81; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Kos FJ, 1996, IMMUNOL TODAY, V17, P174, DOI 10.1016/0167-5699(96)80616-5; KUNDIG TM, 1993, SCIENCE, V262, P1059, DOI 10.1126/science.8235625; Lauwerys BR, 2000, J IMMUNOL, V165, P1847, DOI 10.4049/jimmunol.165.4.1847; Lauwerys BR, 1999, CYTOKINE, V11, P822, DOI 10.1006/cyto.1999.0501; Lian RH, 2002, SEMIN IMMUNOL, V14, P453, DOI 10.1016/S1044532302000805; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Maki G, 2001, J HEMATOTH STEM CELL, V10, P369, DOI 10.1089/152581601750288975; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rosmaraki EE, 2001, EUR J IMMUNOL, V31, P1900, DOI 10.1002/1521-4141(200106)31:6<1900::AID-IMMU1900>3.0.CO;2-M; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; SCOTTALGARA D, 1992, CLIN EXP IMMUNOL, V90, P181; See D, 2002, IMMUNOL INVEST, V31, P137, DOI 10.1081/IMM-120004804; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Sullivan KE, 2000, HUM MUTAT, V16, P49; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yan Y, 1998, CLIN CANCER RES, V4, P2859; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	57	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4772	4778		10.1074/jbc.M408356200	http://dx.doi.org/10.1074/jbc.M408356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563472	hybrid			2022-12-25	WOS:000227096600094
J	Wang, DT; De Deken, X; Milenkovic, M; Song, Y; Pirson, I; Dumont, JE; Miot, F				Wang, DT; De Deken, X; Milenkovic, M; Song, Y; Pirson, I; Dumont, JE; Miot, F			Identification of a novel partner of Duox - EFP1, a thioredoxin-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PORCINE THYROID-FOLLICLES; DEPENDENT H2O2 GENERATION; NADPH OXIDASE; H2O2-GENERATING SYSTEM; DISULFIDE-ISOMERASE; PLASMA-MEMBRANE; PRIMARY CULTURE; BINDING SITE; MAMMALIAN PEROXIREDOXIN	H2O2 is a crucial substrate of thyroproxidase (TPO) to iodinate thyroglobulin and synthesize thyroid hormones in thyroid. ThOX proteins (thyroid oxidase) also called Duox are believed to be responsible for H2O2 generation. Duoxs expressed in transfected cells do not generate an active system, nor permit their membrane localization suggesting that other proteins are required to fulfill these functions. In this study, we demonstrate interactions of Duoxs with TPO and with p22(phox) without any effect on Duox activity. By yeast two-hybrid method using EF-hand fragment of dog Duox1 as the bait we have isolated EFP1 (EF-hand binding protein 1), one partner of Duoxs that belongs to the thioredoxin-related protein family. EFP1 shares moderate similarities with other members of thioredoxin-related proteins, but the characteristic active site and the folding structures are well conserved. EFP1 can be co-immunoprecipitated with Duoxs in transfected COS cells as well as in primary cultured human thyrocytes. It interacts also with TPO but not thyroglobulin. Immunofluorescence studies show that EFP1 and Duox proteins are co-localized inside the transfected cells, suggesting that EFP1 is not sufficient to induce either the expression of Duox at the plasma membrane or to permit H2O2 production. EFP1 and Duox mRNA share similar distribution in nine different tissues. These results suggest that EFP1 could be one of the partners in the assembly of the multiprotein complex constituting the thyroid H2O2 generating system but is certainly not sufficient to permit H2O2 generation.	Free Univ Brussels, IRIBHN, Inst Rech Interdisciplinaire, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Wang, DT (corresponding author), Free Univ Brussels, IRIBHN, Inst Rech Interdisciplinaire, Campus Erasme,Bat C,808 Route Lennik, B-1070 Brussels, Belgium.	dawang@ulb.ac.be		Wang, Dantong/0000-0003-2379-8222				Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; Arsenijevic T, 2004, BIOCHEM J, V378, P673, DOI 10.1042/BJ20031765; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; BJORKMAN U, 1984, ENDOCRINOLOGY, V115, P392; BJORKMAN U, 1995, MOL CELL ENDOCRINOL, V111, P99, DOI 10.1016/0303-7207(95)03552-I; Callebaut I, 2003, J BIOL CHEM, V278, P36887, DOI 10.1074/jbc.M305725200; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Collet JF, 2003, J BIOL CHEM, V278, P45325, DOI 10.1074/jbc.M307818200; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; Corvilain B, 2000, AM J PHYSIOL-ENDOC M, V278, pE692, DOI 10.1152/ajpendo.2000.278.4.E692; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2002, EXP CELL RES, V273, P187, DOI 10.1006/excr.2001.5444; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1994, MOL CELL ENDOCRINOL, V100, P163, DOI 10.1016/0303-7207(94)90297-6; DUPUY C, 1989, EUR J BIOCHEM, V185, P597, DOI 10.1111/j.1432-1033.1989.tb15155.x; DUPUY C, 1988, FEBS LETT, V233, P74, DOI 10.1016/0014-5793(88)81358-9; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Gorin Y, 1996, EUR J BIOCHEM, V240, P807, DOI 10.1111/j.1432-1033.1996.0807h.x; Gorin Y, 1997, BIOCHEM J, V321, P383, DOI 10.1042/bj3210383; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Ivings L, 2002, BIOCHEM J, V363, P599, DOI 10.1042/0264-6021:3630599; Jeong W, 2004, J BIOL CHEM, V279, P3142, DOI 10.1074/jbc.M307932200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karimpour S, 2002, ONCOGENE, V21, P6317, DOI 10.1038/sj.onc.1205749; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Laughner BJ, 1998, PLANT PHYSIOL, V118, P987, DOI 10.1104/pp.118.3.987; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Matsuo Y, 2001, J BIOL CHEM, V276, P10032, DOI 10.1074/jbc.M011037200; Meng XF, 2003, BIOCHEM GENET, V41, P99, DOI 10.1023/A:1022073917044; Morand S, 2003, ENDOCRINOLOGY, V144, P1241, DOI 10.1210/en.2002-220981; Morand S, 2004, J BIOL CHEM, V279, P30244, DOI 10.1074/jbc.M405406200; Pachucki J, 2004, MOL CELL ENDOCRINOL, V214, P53, DOI 10.1016/j.mce.2003.11.026; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; RASPE E, 1995, ENDOCRINOLOGY, V136, P965, DOI 10.1210/en.136.3.965; RASPE E, 1991, J CELL PHYSIOL, V146, P242, DOI 10.1002/jcp.1041460208; ROGER PP, 1982, FEBS LETT, V144, P209, DOI 10.1016/0014-5793(82)80639-X; ROGER PP, 1987, BIOCHEM BIOPH RES CO, V149, P707, DOI 10.1016/0006-291X(87)90425-6; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; TAUROG A, 1996, WERNER INGBARSS THYR, P61; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Vandenbroere I, 2003, BIOCHEM BIOPH RES CO, V300, P494, DOI 10.1016/S0006-291X(02)02894-2; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; Yu W, 1997, GENOME RES, V7, P353, DOI 10.1101/gr.7.4.353; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	65	60	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3096	3103		10.1074/jbc.M407709200	http://dx.doi.org/10.1074/jbc.M407709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15561711	hybrid			2022-12-25	WOS:000226449100086
J	Mezquita, P; Parghi, SS; Brandvold, KA; Ruddell, A				Mezquita, P; Parghi, SS; Brandvold, KA; Ruddell, A			Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation	ONCOGENE			English	Article						Myc; VEGF; translational control; mammalian target of rapamycin; protein synthesis	ENDOTHELIAL GROWTH-FACTOR; RIBOSOME ENTRY SITES; C-MYC; VASCULAR-PERMEABILITY; FACTOR 4E; PROTEIN-SYNTHESIS; EXPRESSION; PHOSPHORYLATION; ANGIOGENESIS; VIRUS	Deregulated c-myc gene expression is associated with many human and animal cancers. Myc overexpression promotes the growth of blood and lymphatic vessels, which is due in part to induction of growth factors including vascular endothelial growth factor (VEGF). We determined that the P493-6 human B-cell line increases VEGF production 10-fold upon Myc overexpression. Myc overexpression in avian B cells similarly resulted in high level VEGF production. Real-time RT-PCR analyses showed that Myc did not alter the VEGF mRNA content of these cell lines, indicating that a post-transcriptional mechanism regulates VEGF production. VEGF mRNA translation was examined by RT-PCR analysis of monosome and polysome sucrose gradient fractions from Myc-on and Myc-off P493-6 cells. Myc increased VEGF mRNA translation initiation, as VEGF mRNA loading onto polysomes increased 14-fold in Myc-on cells, and the number of ribosomes loaded per VEGF mRNA increased threefold. This translational regulation is specific to VEGF mRNA, as total polysomes show the same sucrose gradient pro. le in Myc-on and Myc-off cells, with no change in the percent ribosomes in polysomes, or in the number of ribosomes per polysomal mRNA. Myc stimulates VEGF production by a rapamycin- and LY294002-sensitive pathway, which does not involve alteration of eIF4E activity.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,POB 19024,MS C2-023, Seattle, WA 98109 USA.	aruddell@fhcrc.org	Mezquita, Pau/AGN-4799-2022	Ruddell, Alanna/0000-0002-0195-5576	NATIONAL CANCER INSTITUTE [R01CA068328] Funding Source: NIH RePORTER; NCI NIH HHS [CA68328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Barr LF, 2000, CANCER RES, V60, P143; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Bellamy WT, 1999, CANCER RES, V59, P728; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brandvold KA, 2001, ONCOGENE, V20, P3226, DOI 10.1038/sj.onc.1204431; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Davies E, 1995, METHOD CELL BIOL, V50, P209, DOI 10.1016/S0091-679X(08)61032-8; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; HUMPHRIES EH, 1984, CURR TOP MICROBIOL, V113, P47; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ruddell A, 2003, AM J PATHOL, V163, P2233, DOI 10.1016/S0002-9440(10)63581-X; Satake S, 1998, BIOL CELL, V90, P161, DOI 10.1016/S0248-4900(98)80337-7; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH DR, 1985, J VIROL, V56, P969, DOI 10.1128/JVI.56.3.969-977.1985; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Willis AE, 1997, CURR TOP MICROBIOL, V224, P269	52	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					889	901		10.1038/sj.onc.1208251	http://dx.doi.org/10.1038/sj.onc.1208251			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580293	Green Accepted			2022-12-25	WOS:000226577100015
J	Chang, NS; Schultz, L; Hsu, LJ; Lewis, J; Su, M; Sze, CI				Chang, NS; Schultz, L; Hsu, LJ; Lewis, J; Su, M; Sze, CI			17 beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo	ONCOGENE			English	Article						WWOX; FOR2; WOX1; WOX2; estrogen; androgen	DOMAIN-CONTAINING OXIDOREDUCTASE; WILD-TYPE P53; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; NECROSIS-FACTOR CYTOTOXICITY; ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR; NEUROBLASTOMA-CELLS; EPITHELIAL-CELLS; DELETED REGIONS; HYALURONIC-ACID	Human WWOX gene encodes a proapoptotic WW domain-containing oxidoreductase WOX1 ( also named WWOX, FOR2 or WWOXv1). Apoptotic and stress stimuli activate WOX1 via Tyr33 phosphorylation and nuclear translocation. WOX1 possesses a tetrad NSYK motif in the C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, which may bind estrogen and androgen. Here, we determined that 17beta-estradiol (E-2) activated WOX1, p53 and ERK in COS7 fibroblasts, primary lung epithelial cells, and androgen receptor (AR)-negative prostate DU145 cells, but not in estrogen receptor ( ER)positive breast MCF7 cells. Androgen also activated WOX1 in the AR-negative DU145 cells. These observations suggest that sex hormone-mediated Tyr33 phosphorylation and nuclear translocation of WOX1 is independent of ER and AR. Stress stimuli increase physical binding of p53 with WOX1 in vivo. We determined here that E2 increased the formation of p53/WOX1 complex and their nuclear translocation in COS7 cells; however, nuclear translocation of this complex could not occur in MCF7 cells. By immunohistochemistry, we determined that progression of prostate from normal to hyperplasia, cancerous and metastatic stages positively correlate with upregulation and activation of WOX1 and WOX2 (FOR1/WWOXv2). In contrast, breast cancer development to a premetastatic state is associated with upregulation and Tyr33 phosphorylation of cytosolic WOX1 and WOX2, followed by significant downregulation or absent expression during metastasis. These Tyr33-phosphorylated proteins are mostly located in the mitochondria without translocating to the nuclei, which is comparable to those findings in cultured breast cancer cells. Together, sex steroid hormone-induced activation of WOX1 and WOX2 is independent of ER and AR, and this activation positively correlates with cancerous progression of prostate and breast to a premetastatic state.	Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, 1 Guthrie Sq, Sayre, PA 18840 USA.	chang_nanshan@guthrie.org	Hsu, Li-Jin/G-7822-2011					Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Bednarek AK, 2000, CANCER RES, V60, P2140; BRONZERT DA, 1982, ENDOCRINOLOGY, V110, P2177, DOI 10.1210/endo-110-6-2177; Burchardt M, 2001, PROSTATE, V48, P225, DOI 10.1002/pros.1101; Caligo MA, 1998, INT J ONCOL, V13, P177; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-8; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chen ST, 2004, NEUROSCIENCE, V124, P831, DOI 10.1016/j.neuroscience.2003.12.036; CHEN ST, 2004, IN PRESS NEUROSCIENC; COEZY E, 1982, CANCER RES, V42, P317; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Elo JP, 1999, BRIT J CANCER, V79, P156, DOI 10.1038/sj.bjc.6690025; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Filling C, 2001, MOL CELL ENDOCRINOL, V171, P99, DOI 10.1016/S0303-7207(00)00419-6; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Gangolli EA, 1997, J STEROID BIOCHEM, V61, P1, DOI 10.1016/S0960-0760(97)00003-4; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gartel AL, 2003, ONCOL RES, V13, P405; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Green PS, 1997, J NEUROSCI, V17, P511; Gridley KE, 1998, MOL PHARMACOL, V54, P874, DOI 10.1124/mol.54.5.874; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; He XY, 2001, EUR J BIOCHEM, V268, P4899, DOI 10.1046/j.0014-2956.2001.02421.2421.x; ISAACS WB, 1991, CANCER RES, V51, P4716; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Lau KM, 2000, CANCER RES, V60, P3175; Li CD, 1999, GENE CHROMOSOME CANC, V24, P175, DOI 10.1002/(SICI)1098-2264(199903)24:3<175::AID-GCC1>3.3.CO;2-8; Linja MJ, 2003, PROSTATE, V55, P180, DOI 10.1002/pros.10242; Lokeshwar V, 1999, PROSTATE CANCER P D, V2, pS21, DOI 10.1038/sj.pcan.4500346; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Patel S, 2002, INT J CANCER, V97, P416, DOI 10.1002/ijc.1638; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Setalo G, 2002, J NEUROBIOL, V50, P1, DOI 10.1002/neu.10000; Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; Watanabe A, 2003, CANCER RES, V63, P8629; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; WOLLIN M, 1989, RADIOTHER ONCOL, V15, P285, DOI 10.1016/0167-8140(89)90097-2; Xu Y, 1996, ENDOCRINOLOGY, V137, P5634, DOI 10.1210/en.137.12.5634	50	72	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					714	723		10.1038/sj.onc.1208124	http://dx.doi.org/10.1038/sj.onc.1208124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580310				2022-12-25	WOS:000226420400019
J	Chen, YH; Rodrik, V; Foster, DA				Chen, YH; Rodrik, V; Foster, DA			Alternative phospholipase D/mTOR survival signal in human breast cancer cells	ONCOGENE			English	Article						phospholipase D; survival signals; rapamycin; phosphatidylinositol-3-kinase; Akt; breast cancer	GROWTH-FACTOR RECEPTOR; MAMMALIAN TARGET; V-SRC; DEPENDENT ACTIVATION; TRANSFORMED-CELLS; RAT FIBROBLASTS; RAPAMYCIN; MTOR; PATHWAY; PROTEIN	Cancer cells generate survival signals to suppress default apoptotic programs that protect from cancer. Phosphatidylinositol-3-kinase (PI3K) generates a survival signal that is frequently dysregulated in human cancers. Phospholipase D (PLD) has also been implicated in signals that promote survival. One of the targets of PLD signaling is mTOR ( mammalian target of rapamycin), a critical regulator of cell cycle progression and cell growth. We report here that elevated PLD activity in the MDA-MB-231 human breast cancer cell line generates an mTOR-dependent survival signal that is independent of PI3K. In contrast, MDA-MB-435S breast cancer cells, which have very low levels of PLD activity, are dependent on PI3K for survival signals. The data presented here identify an alternative survival signal that is dependent on PLD and mTOR and is active in a breast cancer cell line where the PI3K survival pathway is not active.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foster DA, 2003, MOL CANCER RES, V1, P789; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yamada Y, 2003, J MOL MED, V81, P126, DOI 10.1007/s00109-002-0411-x; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165	52	88	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					672	679		10.1038/sj.onc.1208099	http://dx.doi.org/10.1038/sj.onc.1208099			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580312				2022-12-25	WOS:000226420400014
J	Mendias, CL; Baar, K; Faulkner, JA				Mendias, CL; Baar, K; Faulkner, JA			Myostatin increases procollagen content in tendon-derived fibroblast cells	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences	MAR 31-APR 06, 2005	San Diego, CA	Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Invest Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut, Int Union Physiol Sci					Univ Michigan, Ann Arbor, MI 48109 USA; Univ Dundee, Dundee DD1 5EH, Scotland	University of Michigan System; University of Michigan; University of Dundee			Mendias, Christopher/C-5557-2018; Arruda, Ellen M/C-3579-2009	Mendias, Christopher/0000-0002-2384-0171; Borschel, Gregory/0000-0001-7691-5264; Baar, Keith/0000-0001-9337-6186					0	57	61	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 7	2005	19	5	2	S			A1118	A1118		10.1096/fj.04-2034fje	http://dx.doi.org/10.1096/fj.04-2034fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905ZS	15574489	Green Published			2022-12-25	WOS:000227610901007
J	Golabek, AA; Walus, M; Wisniewski, KE; Kida, E				Golabek, AA; Walus, M; Wisniewski, KE; Kida, E			Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PEPSTATIN-INSENSITIVE PROTEINASE; HEPARAN-SULFATE PROTEOGLYCANS; LEUKOCYTE ELASTASE ACTIVITY; LYSOSOMAL PROTEINASE; HYDROPHOBIC PROTEIN; PROCATHEPSIN L; CATHEPSIN-L; H+-ATPASE; INHIBITION	Tripeptidyl-peptidase I (TPP I, CLN2 protein) is a lysosomal exopeptidase that sequentially removes tripeptides from the N termini of polypeptides and shows a minor endoprotease activity. Mutations in TPP I lead to classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disease. TPP I proenzyme is converted in lysosomes into a mature enzyme with the assistance of another protease and is able to autoactivate in acidic pH in vitro via a unimolecular mechanism. Because autoactivation in vitro at the pH values reported for lysosomes generated inactive enzyme, we intended to determine whether physiologically relevant factors can modify this process to also make it plausible in vivo. Here, we report that high ionic strength and glycosaminoglycans (GAGs) increase yields (ionic strength) or yields and rates (GAGs) of activation, enhance degradation of liberated TPP I prosegment fragments, and switch effective autoactivation of TPP I proenzyme toward less acidic pH values (up to pH 6.0). Although ionic strength and GAGs also inhibited TPP I activity in vitro and in living cells, the degree of inhibition (from 20 to 60%) appears to be of rather limited functional significance. Importantly, binding to GAGs improved thermal stability of TPP I and protected the enzyme against alkaline pH-induced denaturation in vitro (t(1/ 2) of mature enzyme at pH 7.4 increased by similar to 8-fold in the presence of heparin) and in vivo (similar to 2-fold higher loss of TPP I in cells deficient in GAGs than in control cells after bafilomycin A1 treatment). These findings elucidate a potent physiologically relevant mechanism of TPP I regulation by GAGs and suggest that generation of the active enzyme via autoactivation can be accomplished not only in vitro but in vivo as well.	New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Golabek, AA (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	a.golabek@att.net			NINDS NIH HHS [NS047355] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; AVILA JL, 1975, BIOCHEM J, V152, P57, DOI 10.1042/bj1520057; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; BAICI A, 1980, BIOCHEM PHARMACOL, V29, P1723, DOI 10.1016/0006-2952(80)90131-8; BAICI A, 1993, BIOCHEM PHARMACOL, V46, P1545, DOI 10.1016/0006-2952(93)90321-M; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BUTOR C, 1995, J CELL SCI, V108, P2213; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Du PG, 2001, BIOL CHEM, V382, P1715, DOI 10.1515/BC.2001.207; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Ezaki J, 1999, J NEUROCHEM, V72, P2573, DOI 10.1046/j.1471-4159.1999.0722573.x; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; Golabek AA, 2004, J BIOL CHEM, V279, P31058, DOI 10.1074/jbc.M400700200; Golabek AA, 2003, J BIOL CHEM, V278, P7135, DOI 10.1074/jbc.M211872200; Golabek AA, 2000, MOL GENET METAB, V70, P203, DOI 10.1006/mgme.2000.3006; Grabowski GA, 2003, ANNU REV GENOM HUM G, V4, P403, DOI 10.1146/annurev.genom.4.070802.110415; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Honke K, 2002, MED RES REV, V22, P637, DOI 10.1002/med.10020; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Ishidoh K, 1995, BIOCHEM BIOPH RES CO, V217, P624, DOI 10.1006/bbrc.1995.2820; Ishidoh K, 1999, J BIOCHEM-TOKYO, V125, P770, DOI 10.1093/oxfordjournals.jbchem.a022348; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; Junaid MA, 2000, INT J BIOL MARKER, V15, P129, DOI 10.1177/172460080001500201; Kida E, 2001, ADV GENET, V45, P35, DOI 10.1016/S0065-2660(01)45003-6; Kida E, 2001, J NEUROPATH EXP NEUR, V60, P280, DOI 10.1093/jnen/60.3.280; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; KRAEMER PM, 1971, BIOCHEMISTRY-US, V10, P1437, DOI 10.1021/bi00784a026; KRANE SM, 1994, SCI AM MED, V3, P1; Lecaille F, 2004, BIOL CHEM, V385, P511, DOI 10.1515/BC.2004.060; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; Liu CG, 1998, GENOMICS, V50, P206, DOI 10.1006/geno.1998.5328; MAROSSY K, 1981, BIOCHIM BIOPHYS ACTA, V659, P351, DOI 10.1016/0005-2744(81)90061-9; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; MCDONALD JK, 1985, BIOCHEM BIOPH RES CO, V126, P63, DOI 10.1016/0006-291X(85)90571-6; MCPHIE P, 1972, J BIOL CHEM, V247, P4277; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MINAMI R, 1981, TOHOKU J EXP MED, V134, P215, DOI 10.1620/tjem.134.215; MOLLER HJ, 1994, CLIN CHIM ACTA, V225, P43, DOI 10.1016/0009-8981(94)90026-4; MONTCOURRIER P, 1994, J CELL SCI, V107, P2381; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PAGE AE, 1993, ARCH BIOCHEM BIOPHYS, V306, P354, DOI 10.1006/abbi.1993.1523; Palmer DN, 1997, NEUROPEDIATRICS, V28, P45, DOI 10.1055/s-2007-973666; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; REILAND J, 1993, J CELL SCI, V105, P1085; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Sergeant N, 2003, J NEUROCHEM, V85, P1581, DOI 10.1046/j.1471-4159.2003.01818.x; Serveau C, 2003, BIOL CHEM, V384, P921, DOI 10.1515/BC.2003.103; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; SNOW AD, 1988, AM J PATHOL, V133, P456; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Suopanki J, 2000, MOL GENET METAB, V71, P190, DOI 10.1006/mgme.2000.3071; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; van Horssen J, 2002, NEUROBIOL AGING, V23, P537, DOI 10.1016/S0197-4580(02)00010-6; VandenHazel HB, 1997, BIOCHEM J, V326, P339, DOI 10.1042/bj3260339; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; VANDYKE RW, 1992, BIOCHEM BIOPH RES CO, V184, P300, DOI 10.1016/0006-291X(92)91192-S; Vergne I, 1998, ANAL BIOCHEM, V255, P127, DOI 10.1006/abio.1997.2466; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Volpi N, 1997, CHEM-BIOL INTERACT, V105, P157, DOI 10.1016/S0009-2797(97)00045-8; Volpi N, 1996, BBA-GEN SUBJECTS, V1290, P299, DOI 10.1016/0304-4165(96)00033-5; Waldburg N, 2004, PATHOL RES PRACT, V200, P147, DOI 10.1016/j.prp.2004.02.006; Warburton MJ, 2002, NEUROSCI LETT, V331, P99, DOI 10.1016/S0304-3940(02)00841-8; Wisniewski KE, 2001, ADV GENET, V45, P1, DOI 10.1016/S0065-2660(01)45002-4; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wujek P, 2004, J BIOL CHEM, V279, P12827, DOI 10.1074/jbc.M313173200; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	79	12	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7550	7561		10.1074/jbc.M412047200	http://dx.doi.org/10.1074/jbc.M412047200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15582991	hybrid			2022-12-25	WOS:000227395700017
J	Mitkova, AV; Biswas-Fiss, EE; Biswas, SB				Mitkova, AV; Biswas-Fiss, EE; Biswas, SB			Modulation of DNA synthesis in Saccharomyces cerevisiae nuclear extract by DNA polymerases and the origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; S-PHASE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; HELICASE ACTIVITY; REPLICATION INITIATION; CHROMOSOMAL REPLICATION; DROSOPHILA-MELANOGASTER; EUKARYOTIC ORIGINS; MCM PROTEINS	We have analyzed the modulation of DNA synthesis on a supercoiled plasmid DNA template by DNA polymerases (pol), minichromosome maintenance protein complex (Mcm), topoisomerases, and the origin recognition complex (ORC) using an in vitro assay system. Antisera specific against the four-subunit pol alpha, the catalytic subunit of pol delta, and the Mcm467 complex each inhibited DNA synthesis. However, DNA synthesis in this system appeared to be independent of pol epsilon. Consequently, DNA synthesis in the in vitro system appeared to depend only on two polymerases, alpha and delta, as well as the Mcm467 DNA helicase. This system requires supercoiled plasmid DNA template and DNA synthesis absolutely required DNA topoisomerase I. In addition, we also report here a novel finding that purified recombinant six subunit ORC significantly stimulated the DNA synthesis on a supercoiled plasmid DNA template containing an autonomously replicating sequence, ARSI.	Univ Med & Dent New Jersey, Dept Mol Biol, GSBS, Stratford, NJ 08084 USA; Univ Med & Dent New Jersey, SOM, Stratford, NJ 08084 USA; Thomas Jefferson Univ, Dept Biosci Technol, Program Biotechnol, Philadelphia, PA 19107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Biswas, SB (corresponding author), Univ Med & Dent New Jersey, Dept Mol Biol, GSBS, Stratford, NJ 08084 USA.	Subhasis.biswas@umdnj.edu			NIGMS NIH HHS [GM36002] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bielinsky AK, 2001, J CELL SCI, V114, P643; Biswas EE, 1995, PROTEIN EXPRES PURIF, V6, P763, DOI 10.1006/prep.1995.0007; BISWAS EE, 1993, BIOCHEMISTRY-US, V32, P13393, DOI 10.1021/bi00212a003; BISWASFISS EE, 2005, IN PRESS BIOCHEMISTR, V44; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braguglia D, 1998, J MOL BIOL, V281, P631, DOI 10.1006/jmbi.1998.1973; BREWER BJ, 1994, CURR OPIN GENET DEV, V4, P196, DOI 10.1016/S0959-437X(05)80045-0; Brill S J, 1987, NCI Monogr, P11; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; BULLOCK PA, 1994, MOL CELL BIOL, V14, P5043, DOI 10.1128/MCB.14.8.5043; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P4585, DOI 10.1073/pnas.79.15.4585; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; EKI T, 1992, J BIOL CHEM, V267, P7284; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; Forsburg SL, 1997, GENETICS, V147, P1025; FUJITA M, 1999, FRONT BIOSCI, V4, P816; Fukui T, 2004, GENES CELLS, V9, P179, DOI 10.1111/j.1356-9597.2004.00716.x; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Gerbi SA, 2002, J STRUCT BIOL, V140, P17, DOI 10.1016/S1047-8477(02)00538-5; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; Huang ME, 1999, MOL GEN GENET, V260, P541, DOI 10.1007/s004380050927; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Johansson E, 2004, J BIOL CHEM, V279, P1907, DOI 10.1074/jbc.M310362200; Kasiviswanathan R, 2004, J BIOL CHEM, V279, P28358, DOI 10.1074/jbc.M403202200; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kelman Z, 2003, NAT STRUCT BIOL, V10, P148, DOI 10.1038/nsb0303-148; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KORNBERG A, 1992, DNA REPLICATION, P215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lee JK, 2001, P NATL ACAD SCI USA, V98, P13589, DOI 10.1073/pnas.251530398; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mitkova AV, 2002, BIOCHEMISTRY-US, V41, P5255, DOI 10.1021/bi0120289; Nasheuer HP, 2002, PROG NUCLEIC ACID RE, V72, P41, DOI 10.1016/S0079-6603(02)72067-9; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Newlon CS, 2002, BIOESSAYS, V24, P300, DOI 10.1002/bies.10075; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Shechter D, 2004, J BIOL CHEM, V279, P45586, DOI 10.1074/jbc.M407772200; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; VERDIER JM, 1990, NUCLEIC ACIDS RES, V18, P7033, DOI 10.1093/nar/18.23.7033; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WOLD MS, 1989, J BIOL CHEM, V264, P2801; Wu JR, 2000, J CELL BIOCHEM, V80, P73; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	76	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6285	6292		10.1074/jbc.M410129200	http://dx.doi.org/10.1074/jbc.M410129200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590683	hybrid			2022-12-25	WOS:000227332700008
J	Vo, PA; Lad, B; Tomlinson, JAP; Francis, S; Ahluwalia, A				Vo, PA; Lad, B; Tomlinson, JAP; Francis, S; Ahluwalia, A			Autoregulatory role of endothelium-derived nitric oxide (NO) on lipopolysaccharide-induced vascular inducible NO synthase expression and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SMOOTH-MUSCLE-CELLS; SHOCK-PROTEIN 90; L-ARGININE; BACTERIAL LIPOPOLYSACCHARIDE; ACTIVATION; ENDOTOXIN; RAT; KINASE; HSP90	Nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS) is responsible for sepsis-induced hypotension and plays a major contributory role in the ensuing multiorgan failure. The present study aimed to elucidate the role of endothelial NO in lipopolysaccharide (LPS)-induced iNOS expression, in isolated rat aortic rings. Exposure to LPS (1 mug/ml, 5 h) resulted in a reversal of phenylephrine precontracted tone in aortic rings (70.7 +/- 3.2%). This relaxation was associated with iNOS expression and NF-kappaB activation. Positive immunoreactivity for iNOS protein was localized in medial and adventitial layers of LPS-treated aortic rings. Removal of the endothelium rendered aortic rings resistant to LPS-induced relaxation (8.9 +/- 4.5%). Western blotting of these rings demonstrated an absence of iNOS expression. However, treatment of endothelium-denuded rings with the NO donor, diethylamine-NONOate (0.1 mum), restored LPS-induced relaxation (61.6 +/- 6.6%) and iNOS expression to levels comparable with arteries with intact endothelium. Blockade of endothelial NOS (eNOS) activation using geldanamycin and radicicol, inhibitors of heat shock protein 90, in endothelium-intact arteries suppressed both LPS-induced relaxation and LPS-induced iNOS expression (9.0 +/- 8.0% and 2.0 +/- 6.2%, respectively). Moreover, LPS treatment (12.5 mg/kg, intravenous, 15 h) of wild-type mice resulted in profound elevation of plasma [NOx] measurements that were reduced by similar to50% in eNOS knock-out animals. Furthermore, LPS-induced changes in vascular reactivity and iNOS expression evident in wild-type tissues were profoundly suppressed in tissues taken from eNOS knockout animals. Together, these data suggest that eNOS-derived NOx in part via activation of NF-kappaB, regulates iNOS-induction by LPS. This study provides the first demonstration of a proinflammatory role of vascular eNOS in sepsis.	Barts & London, William Harvey Res Inst, London, England	University of London; Queen Mary University London	Ahluwalia, A (corresponding author), Barts & London, William Harvey Res Inst, Charterhouse Sq, London, England.	a.ahluwalia@qmul.ac.uk		AHLUWALIA, Amrita/0000-0001-7626-6399				Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; Chauhan SD, 2003, FASEB J, V17, P773, DOI 10.1096/fj.02-0668fje; Connelly L, 2003, J BIOL CHEM, V278, P26480, DOI 10.1074/jbc.M302238200; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; FLEMING I, 1991, BRIT J PHARMACOL, V103, P1047, DOI 10.1111/j.1476-5381.1991.tb12298.x; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GOMEZJIMENEZ J, 1995, CRIT CARE MED, V23, P253, DOI 10.1097/00003246-199502000-00009; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Joly GA, 1997, FEBS LETT, V403, P40, DOI 10.1016/S0014-5793(97)00004-5; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kleschyov AL, 2000, AM J PHYSIOL-HEART C, V279, pH2743, DOI 10.1152/ajpheart.2000.279.6.H2743; Kroncke KD, 2003, BIOL CHEM, V384, P1365, DOI 10.1515/BC.2003.153; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; MONCADA S, 1991, PHARMACOL REV, V43, P109; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815; Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Shastry S, 2002, AM J PHYSIOL-HEART C, V282, pH232, DOI 10.1152/ajpheart.2002.282.1.H232; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; Umansky V, 1998, EUR J IMMUNOL, V28, P2276, DOI 10.1002/(SICI)1521-4141(199808)28:08<2276::AID-IMMU2276>3.0.CO;2-H; Venema RC, 2003, AM J PHYSIOL-HEART C, V285, pH669, DOI 10.1152/ajpheart.01025.2002; Viswanathan M, 1999, J VASC RES, V36, P524, DOI 10.1159/000025696; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yoshida M, 2003, J BIOL CHEM, V278, P36953, DOI 10.1074/jbc.M305214200; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414	36	75	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7236	7243		10.1074/jbc.M411317200	http://dx.doi.org/10.1074/jbc.M411317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15583003	hybrid			2022-12-25	WOS:000227332700115
J	Wernick, NLB; Haucke, V; Simister, NE				Wernick, NLB; Haucke, V; Simister, NE			Recognition of the tryptophan-based endocytosis signal in the neonatal Fc receptor by the mu subunit of adaptor protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIUM-CHAIN SUBUNIT; FACTOR-II RECEPTOR; SORTING SIGNALS; MAMMARY-GLAND; IMMUNOGLOBULIN-G; HUMAN PLACENTA; TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; IGG TRANSPORT; BIDIRECTIONAL TRANSCYTOSIS	Endocytosis of membrane proteins is typically mediated by signals present in their cytoplasmic domains. These signals usually contain an essential tyrosine or pair of leucine residues. Both tyrosine- and dileucine-based endocytosis signals are recognized by the adaptor complex AP-2. The best understood of these interactions occurs between the tyrosine-based motif, YXXPhi, and the mu2 subunit of AP-2. We recently reported a tryptophan-based endocytosis signal, WLSL, contained within the cytoplasmic domain of the neonatal Fc receptor. This signal resembles YXXPhi. We have investigated the mechanism by which the tryptophan-based signal is recognized. Both interaction assays in vitro and endocytosis assays in vivo show that mu2 binds the tryptophan-based signal. Furthermore, the WLSL sequence binds the same site as YXXPhi. Unlike the WXXF motif, contained in stonin 2 and other endocytic proteins, WLSL does not bind the a subunit of AP-2. These observations reveal a functional similarity between the tryptophan-based endocytosis signal and the YXXPhi motif, and an unexpected versatility of mu2 function.	Brandeis Univ, Rosenstiel Ctr Basic Biomed Sci, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany	Brandeis University; Brandeis University; Free University of Berlin	Simister, NE (corresponding author), Brandeis Univ, Rosenstiel Ctr Basic Biomed Sci, MS 029, Waltham, MA 02254 USA.	simister@brandeis.edu		Haucke, Volker/0000-0003-3119-6993	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027691] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27691] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adamski FM, 2000, MOL IMMUNOL, V37, P435, DOI 10.1016/S0161-5890(00)00065-1; AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Banbury AN, 2003, J BIOL CHEM, V278, P12022, DOI 10.1074/jbc.M211966200; BERRYMAN M, 1995, J CELL SCI, V108, P2347; BLUMBERG RS, 1995, J CLIN INVEST, V95, P2397, DOI 10.1172/JCI117934; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Borvak J, 1998, INT IMMUNOL, V10, P1289, DOI 10.1093/intimm/10.9.1289; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cianga P, 1999, EUR J IMMUNOL, V29, P2515, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2515::AID-IMMU2515&gt;3.0.CO;2-D; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Crump CM, 1998, J BIOL CHEM, V273, P28073, DOI 10.1074/jbc.273.43.28073; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Ellinger I, 1999, EUR J IMMUNOL, V29, P733, DOI 10.1002/(SICI)1521-4141(199903)29:03<733::AID-IMMU733>3.0.CO;2-C; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; Gafencu A, 2003, PLACENTA, V24, P664, DOI 10.1016/S0143-4004(03)00041-9; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Haymann JP, 2000, J AM SOC NEPHROL, V11, P632, DOI 10.1681/ASN.V114632; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Israel EJ, 1997, IMMUNOLOGY, V92, P69, DOI 10.1046/j.1365-2567.1997.00326.x; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JADOT M, 1992, J BIOL CHEM, V267, P11069; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jha A, 2004, J BIOL CHEM, V279, P2281, DOI 10.1074/jbc.M305644200; JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kacskovics I, 2000, J IMMUNOL, V164, P1889, DOI 10.4049/jimmunol.164.4.1889; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kobayashi N, 2002, AM J PHYSIOL-RENAL, V282, pF358, DOI 10.1152/ajprenal.0164.2001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kristoffersen EK, 1996, EUR J IMMUNOL, V26, P1668, DOI 10.1002/eji.1830260741; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leach JL, 1996, J IMMUNOL, V157, P3317; LEACH L, 1991, HISTOCHEM J, V23, P444, DOI 10.1007/BF01041374; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Mayer B, 2002, VET IMMUNOL IMMUNOP, V87, P327, DOI 10.1016/S0165-2427(02)00059-4; Mayer B, 2002, IMMUNOLOGY, V107, P288, DOI 10.1046/j.1365-2567.2002.01514.x; McCarthy KM, 2000, J CELL SCI, V113, P1277; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Nordeng TW, 1999, J BIOL CHEM, V274, P21139, DOI 10.1074/jbc.274.30.21139; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Praetor A, 2002, J MOL BIOL, V321, P277, DOI 10.1016/S0022-2836(02)00626-5; RAGHAVAN M, 1995, P NATL ACAD SCI USA, V92, P11200, DOI 10.1073/pnas.92.24.11200; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Roopenian DC, 2003, J IMMUNOL, V170, P3528, DOI 10.4049/jimmunol.170.7.3528; Schnulle PM, 2003, VET IMMUNOL IMMUNOP, V91, P227, DOI 10.1016/S0165-2427(02)00294-5; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; Stefaner I, 1999, J BIOL CHEM, V274, P8998, DOI 10.1074/jbc.274.13.8998; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Ward ES, 2003, INT IMMUNOL, V15, P187, DOI 10.1093/intimm/dxg018; Wu Z, 2001, J BIOL CHEM, V276, P5240, DOI 10.1074/jbc.M006684200	77	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7309	7316		10.1074/jbc.M410752200	http://dx.doi.org/10.1074/jbc.M410752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15598658	hybrid			2022-12-25	WOS:000227332700123
J	Gilfillan, S; Stelzer, G; Piaia, E; Hofmann, MG; Meisterernst, M				Gilfillan, S; Stelzer, G; Piaia, E; Hofmann, MG; Meisterernst, M			Efficient binding of NC2 center dot TATA-binding protein to DNA in the absence of TATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II GENE-TRANSCRIPTION; YEAST TFIIA/TBP/DNA COMPLEX; TFIID-PROMOTER COMPLEX; IN-VIVO; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; NEGATIVE COFACTOR-2; BOX-BINDING; REPRESSES TRANSCRIPTION; PREINITIATION COMPLEX	Negative cofactor 2 (NC2) forms a stable complex with TATA-binding protein (TBP) on promoters. This prevents the assembly of transcription factor (TF) IIA and TFIIB and leads to repression of RNA polymerase II transcription. Here we have revisited the interactions of NC2-TBP with DNA. We show that NC2-TBP complexes exhibit a significantly reduced preference for TATA box sequences compared with TBP and TBP-TFIIA complexes. In chromatin immunoprecipitations, NC2 is found on a variety of human TATA-containing and TATA-less promoters. Substantial amounts of NC2 are present in a complex with TBP in bulk chromatin. A complex of NC2-TBP displays a K-D for DNA of similar to2 X 10(-9) M for a 35-bp major late promoter oligonucleotide. While preferentially recognizing promoter-bound TBP, NC2 also accelerates TBP binding to promoters and stabilizes TBP-DNA complexes. Our data suggest that NC2 controls TBP binding and maintenance on DNA that is largely independent of a canonical TATA sequence.	GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Meisterernst, M (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Marchionini Str 25, D-81377 Munich, Germany.	Meisterernst@gsf.de						Bleichenbacher M, 2003, J MOL BIOL, V332, P783, DOI 10.1016/S0022-2836(03)00887-8; Buratowski RM, 2002, MOL CELL BIOL, V22, P8735, DOI 10.1128/MCB.22.24.8735-8743.2002; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Cang Y, 2002, P NATL ACAD SCI USA, V99, P12727, DOI 10.1073/pnas.202236699; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; Chou S, 1999, GENETICS, V153, P1573; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Denko N, 2003, J BIOL CHEM, V278, P5744, DOI 10.1074/jbc.M212534200; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Geisberg JV, 2002, MOL CELL BIOL, V22, P8122, DOI 10.1128/MCB.22.23.8122-8134.2002; Geisberg JV, 2001, MOL CELL BIOL, V21, P2736, DOI 10.1128/MCB.21.8.2736-2742.2001; Gilfillan S, 2003, METHOD ENZYMOL, V370, P467; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; Gumbs OH, 2003, EMBO J, V22, P3131, DOI 10.1093/emboj/cdg304; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INOSTROZA JA, 1992, CELL, V70, P477; Iratni R, 2002, SCIENCE, V298, P1996, DOI 10.1126/science.1073405; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Klejman MP, 2004, MOL CELL BIOL, V24, P10072, DOI 10.1128/MCB.24.22.10072-10082.2004; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lemaire M, 2000, MOL MICROBIOL, V36, P163, DOI 10.1046/j.1365-2958.2000.01839.x; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; Masters KM, 2003, J BIOL CHEM, V278, P31685, DOI 10.1074/jbc.M305201200; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Powell RM, 2002, J BIOL CHEM, V277, P7776, DOI 10.1074/jbc.M110147200; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; RANISH JA, 1991, J BIOL CHEM, V266, P19320; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Song W, 2002, PLANT CELL, V14, P181, DOI 10.1105/tpc.010320; Stargell LA, 2000, J BIOL CHEM, V275, P12374, DOI 10.1074/jbc.275.17.12374; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; Stewart JJ, 2001, J BIOL CHEM, V276, P30078, DOI 10.1074/jbc.M105276200; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7	57	30	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6222	6230		10.1074/jbc.M406343200	http://dx.doi.org/10.1074/jbc.M406343200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15574413	hybrid			2022-12-25	WOS:000227217100129
J	Jonas, EA; Hickman, JA; Hardwick, JM; Kaczmarek, LK				Jonas, EA; Hickman, JA; Hardwick, JM; Kaczmarek, LK			Exposure to hypoxia rapidly induces activity within a living synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; TRANSMITTER RELEASE; CYTOCHROME-C; BCL-2; HIPPOCAMPAL; CLEAVAGE; TRANSMISSION; ACTIVATION; APOPTOSIS; NEURONS	One of the earliest effects of hypoxia on neuronal function is to produce a run-down of synaptic transmission, and more prolonged hypoxia results in neuronal death. An increase in the permeability of the outer mitochondrial membrane, controlled by BCL-2 family proteins, occurs in response to stimuli that trigger cell death. By patch clamping mitochondrial membranes inside the presynaptic terminal of a squid giant synapse, we have now found that several minutes of hypoxia trigger the opening of large multiconductance channels. The channel activity is induced concurrently with the attenuation of synaptic responses that occurs under hypoxic conditions. Hypoxia-induced channels are inhibited by NADH, an agent that inhibits large conductance channels produced by a pro-apo-ptotic fragment of BCL-xL in these synaptic mitochondria. The appearance of hypoxia-induced channels was also prevented by the caspase/cysteine protease inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone (Z-VAD-fmk), which inhibits proteolysis of BCL-xL during hypoxia. Both NADH and Z-VAD-fmk reduced significantly the rate of decline of synaptic responses during hypoxia. Our results indicate that an increase in outer mitochondrial channel activity is a very early event in the response of neurons to hypoxia and suggest that this increase in activity may contribute to the decline in synaptic function during hypoxia.	Yale Univ, Sch Med, Dept Internal Med Endo, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Inst Rech Servier, F-78290 Croissy Sur Seine, France; Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Sch Med, Baltimore, MD 21205 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Yale University; Yale University; Servier; Institut de Recherches Internationales Servier; Johns Hopkins University; Johns Hopkins University; Marine Biological Laboratory - Woods Hole	Jonas, EA (corresponding author), Yale Univ, Sch Med, Dept Internal Med Endo, 333 Cedar St, New Haven, CT 06520 USA.	elizabeth.jonas@yale.edu			NINDS NIH HHS [NS45876, NS37402, NS18496] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037402, R37NS045876, R01NS045876] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aihara H, 2002, BRAIN RES, V952, P31, DOI 10.1016/S0006-8993(02)03185-2; Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Banasiak KJ, 2000, PROG NEUROBIOL, V62, P215, DOI 10.1016/S0301-0082(00)00011-3; Bolay H, 2002, STROKE, V33, P1369, DOI 10.1161/01.STR.0000013708.54623.DE; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Colombini M, 1996, Ion Channels, V4, P169; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Fleidervish IA, 2001, J NEUROSCI, V21, P4600, DOI 10.1523/JNEUROSCI.21-13-04600.2001; Frenguelli BG, 2003, J NEUROCHEM, V86, P1506, DOI 10.1046/j.1471-4159.2003.01957.x; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Gottlieb E, 2002, P NATL ACAD SCI USA, V99, P12801, DOI 10.1073/pnas.202477599; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Howard EM, 1998, BRAIN RES, V798, P109, DOI 10.1016/S0006-8993(98)00403-X; Inoue S, 2004, ANESTHESIOLOGY, V101, P75, DOI 10.1097/00000542-200407000-00013; Jonas EA, 2004, P NATL ACAD SCI USA, V101, P13590, DOI 10.1073/pnas.0401372101; Jonas EA, 1999, SCIENCE, V286, P1347, DOI 10.1126/science.286.5443.1347; Jonas EA, 2003, J NEUROSCI, V23, P8423; Jonas EA, 1997, NEURON, V19, P7, DOI 10.1016/S0896-6273(00)80343-8; Kaczmarek LK, 2004, ADV MOL CEL, V32, P433; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LEE AC, 1994, J BIOL CHEM, V269, P30974; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Pang ZP, 2002, J NEUROSCI, V22, P10948; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Sakmann B., 1995, SINGLE CHANNEL RECOR; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Sebastiao AM, 2001, J NEUROSCI, V21, P8564, DOI 10.1523/JNEUROSCI.21-21-08564.2001; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Sugawara T, 1999, J NEUROSCI, V19, part. no.; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; Tanaka H, 2004, J NEUROSCI, V24, P2750, DOI 10.1523/JNEUROSCI.5475-03.2004; Tekkok SB, 2002, NEUROSCIENCE, V113, P11, DOI 10.1016/S0306-4522(02)00154-9; Tian GF, 2000, J NEUROPHYSIOL, V83, P1830, DOI 10.1152/jn.2000.83.4.1830; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	48	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4491	4497		10.1074/jbc.M410661200	http://dx.doi.org/10.1074/jbc.M410661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561723	Green Published			2022-12-25	WOS:000227096600061
J	Naito, J; Kaji, H; Sowa, H; Hendy, GN; Sugimoto, T; Chihara, K				Naito, J; Kaji, H; Sowa, H; Hendy, GN; Sugimoto, T; Chihara, K			Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; GROWTH-FACTOR-BETA; HISTONE METHYLTRANSFERASE COMPLEX; TYPE-1 GENE-PRODUCT; BONE-FORMATION; ACTIVATOR PROTEIN-1; PROMOTER ACTIVITY; TUMOR-SUPPRESSOR; CELL-GROWTH; TRANSCRIPTION	Mice null for menin, the product of the multiple endocrine neoplasia type 1 (MEN1) gene, exhibit cranial and facial hypoplasia suggesting a role for menin in bone formation. We have shown previously that menin is required for the commitment of multipotential mesenchymal stem cells into the osteoblast lineage in part by interacting with the bone morphogenetic protein (BMP)-2 signaling molecules Smad1/5, and the key osteoblast transcriptional regulator, Runx2 (Sowa H., Kaji, H., Hendy, G. N., Canaff, L., Komori, T., Sugimoto, T., and Chihara, K. (2004) J. Biol. Chem. 279,40267-40275). However, menin inhibits the later differentiation of committed osteoblasts. The activator protein-1 (AP-1) transcription factor, JunD, is expressed in osteoblasts and has been shown to interact with menin in other cell types. Here, we examined the consequences of menin-JunD interaction on osteoblast differentiation in mouse osteoblastic MC3T3-E1 cells. JunD expression, assessed by immunoblot, gradually increased during osteoblast differentiation. Stable expression of JunD enhanced expression of the differentiation markers, Runx2, type 1 collagen (COL1), and osteocalcin (OCN) and alkaline phosphatase (ALP) activity and mineralization. Hence, JunD promotes osteoblast differentiation. In MC3T3-E1 cells in which menin expression was reduced by stable menin antisense DNA transfection, JunD levels were increased. When JunD and menin were co-transfected in MC3T3-E1 cells, they co-immunoprecipitated. JunD overexpression increased the transcriptional activity of an AP-1 luciferase reporter construct, and this activity was reduced by co-transfection of menin. Therefore, JunD and menin interact both physically and functionally in osteoblasts. Furthermore, menin overexpression inhibited the ALP activity induced by JunD. In conclusion, the data suggest that menin suppresses osteoblast maturation, in part, by inhibiting the differentiation actions of JunD.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo K, Kobe, Hyogo 6500017, Japan; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol & Human Genet, Montreal, PQ H3A 1A1, Canada	Kobe University; McGill University; McGill University	Kaji, H (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo K, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hiroshik@med.kobe-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898-6568(02)00008-6; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hoebertz A, 2003, J BONE MINER RES, V18, pS3; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Kim H, 2003, CANCER RES, V63, P6135; Lacerte A, 2004, MOL ENDOCRINOL, V18, P1558, DOI 10.1210/me.2003-0470; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Namihira H, 2002, J MOL ENDOCRINOL, V29, P297, DOI 10.1677/jme.0.0290297; Pillebout E, 2003, J CLIN INVEST, V112, P843, DOI 10.1172/JCI200317647; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Sowa H, 2004, J BIOL CHEM, V279, P40267, DOI 10.1074/jbc.M401312200; Sowa H, 2004, CANCER RES, V64, P2222, DOI 10.1158/0008-5472.CAN-03-3334; Sowa H, 2003, J BIOL CHEM, V278, P52240, DOI 10.1074/jbc.M302566200; Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Thepot D, 2000, DEVELOPMENT, V127, P143; Tohjima E, 2003, J BONE MINER RES, V18, P1461, DOI 10.1359/jbmr.2003.18.8.1461; Varghese S, 2000, ENDOCRINOLOGY, V141, P2185, DOI 10.1210/en.141.6.2185; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200; Yazgan O, 2001, CANCER RES, V61, P916; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	47	51	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4785	4791		10.1074/jbc.M408143200	http://dx.doi.org/10.1074/jbc.M408143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563473	hybrid			2022-12-25	WOS:000227096600096
J	Selva, DM; Hogeveen, KN; Hammond, GL				Selva, DM; Hogeveen, KN; Hammond, GL			Repression of the human sex hormone-binding globulin gene in Sertoli cells by upstream stimulatory transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-BOX; PROTEIN; EXPRESSION; PROMOTER; RECEPTOR; TESTIS; LIVER; USF; INDUCTION; ELEMENTS	Expression of the sex hormone-binding globulin gene (SHBG) in the liver produces SHBG, which transports sex steroids in the blood. In rodents, the SHBG gene is also expressed in Sertoli cells giving rise to the testicular androgen-binding protein, which is secreted into the seminiferous tubule where it presumably controls testosterone action. Evidence that the SHBG gene functions in this way in the human testis is lacking, and mice containing a human SHBG transgene (shbg4) under the control of its own promoter sequence are characterized by SHBG gene expression in the liver but not in the testis. A potential cis-element, defined as footprint 4 (FP4) within the human SHBG promoter, is absent in SHBG promoters of mammals that produce the testicular androgen-binding protein, and we have produced mice harboring a shbg4 transgene in which FP4 was deleted to evaluate its functional significance. Remarkably, these mice express the modified human SHBG transgene in the testis as well as the liver. Human SHBG transcripts were found within their Sertoli cells, primary cultures of which secrete human SHBG, and this was increased by treatment with follicle-stimulating hormone, retinoic acid, and estradiol but not testosterone. We have also found that the upstream stimulatory factors (USF-1 and USF-2) bind FP4 in vitro by electromobility shift assay of Sertoli cell nuclear extracts and in vivo by chromatin immunoprecipitation assay and conclude that USF transcription factors repress human SHBG transcription in Sertoli cells through an interaction with FP4 within its proximal promoter.	BC Res Inst Childrens & Womens Hlth, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Hammond, GL (corresponding author), BC Res Inst Childrens & Womens Hlth, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	ghammond@cw.bc.ca	Selva, David Martínez/O-6444-2016	Hammond, Geoffrey/0000-0002-4639-7336				Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; CHENG CY, 1985, J BIOL CHEM, V260, P5631; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DANZO BJ, 1974, STEROIDS, V24, P107, DOI 10.1016/0039-128X(74)90049-X; Drewes T, 1996, MOL CELL BIOL, V16, P925; FRENCH FS, 1973, ENDOCRINOLOGY, V93, P88, DOI 10.1210/endo-93-1-88; GERSHAGEN S, 1989, NUCLEIC ACIDS RES, V17, P9245, DOI 10.1093/nar/17.22.9245; GUNSALUS GL, 1978, SCIENCE, V200, P65, DOI 10.1126/science.635573; Gupta AK, 2002, AM J PHYSIOL-CELL PH, V283, pC1065, DOI 10.1152/ajpcell.00100.2002; HAMMOND GL, 1987, FEBS LETT, V215, P100, DOI 10.1016/0014-5793(87)80121-7; HAMMOND GL, 1989, MOL ENDOCRINOL, V3, P1869, DOI 10.1210/mend-3-11-1869; Hammond GL, 1995, TRENDS ENDOCRIN MET, V6, P298, DOI 10.1016/1043-2760(95)00162-X; Heckert LL, 2000, MOL ENDOCRINOL, V14, P1836, DOI 10.1210/me.14.11.1836; Hogan B, 1994, MANIPULATING MOUSE E; HSU AF, 1978, J CLIN INVEST, V61, P1611, DOI 10.1172/JCI109081; Janne M, 1998, J BIOL CHEM, V273, P34105, DOI 10.1074/jbc.273.51.34105; Janne M, 1998, MOL ENDOCRINOL, V12, P123; Janne M, 1999, ENDOCRINOLOGY, V140, P4166, DOI 10.1210/en.140.9.4166; JOSEPH DR, 1994, VITAM HORM, V49, P197; Levallet J, 1998, BIOL REPROD, V58, P919, DOI 10.1095/biolreprod58.4.919; Lou DQ, 1999, J BIOL CHEM, V274, P28385, DOI 10.1074/jbc.274.40.28385; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; NIEMI S, 1988, CLIN CHEM, V34, P63; PELLINIEMI LJ, 1981, ENDOCRINOLOGY, V108, P925, DOI 10.1210/endo-108-3-925; Pickwell GV, 2003, BIOCHEM PHARMACOL, V65, P1087, DOI 10.1016/S0006-2952(03)00037-6; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; REVENTOS J, 1993, MOL CELL ENDOCRINOL, V96, P69, DOI 10.1016/0303-7207(93)90096-3; Selva DM, 2002, J BIOL CHEM, V277, P45291, DOI 10.1074/jbc.M205903200; Selva DM, 2000, ENDOCRINOLOGY, V141, P1168, DOI 10.1210/en.141.3.1168; SIERRA F, 1990, BIOMETHODS LAB GUIDE, P23; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SKINNER MK, 1989, ENDOCRINOLOGY, V124, P3015, DOI 10.1210/endo-124-6-3015; Smithwick EB, 1996, TISSUE CELL, V28, P137, DOI 10.1016/S0040-8166(96)80002-4; Tumer N, 1997, NEUROPHARMACOLOGY, V36, P1065, DOI 10.1016/S0028-3908(97)00093-2; Weiss M, 1997, BIOL REPROD, V57, P68, DOI 10.1095/biolreprod57.1.68; Westphal U, 1986, STEROID PROTEIN INTE, P276; Wistuba J, 2003, BIOL REPROD, V69, P582, DOI 10.1095/biolreprod.103.015925; Wong AST, 2001, INT J ANDROL, V24, P165, DOI 10.1046/j.1365-2605.2001.00283.x; Xing WR, 2002, BIOL REPROD, V66, P1656, DOI 10.1095/biolreprod66.6.1656; Xing WR, 2001, BIOL REPROD, V64, P579, DOI 10.1095/biolreprod64.2.579	40	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4462	4468		10.1074/jbc.M409616200	http://dx.doi.org/10.1074/jbc.M409616200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574421	hybrid			2022-12-25	WOS:000227096600057
J	Jaworski, M; Buchmann, A; Bauer, P; Riess, O; Schwarz, M				Jaworski, M; Buchmann, A; Bauer, P; Riess, O; Schwarz, M			B-Raf and Ha-ras mutations in chemically induced mouse liver tumors	ONCOGENE			English	Article						mouse hepatocarcinogenesis; B-Raf; Ha-ras; mutation analysis; pyrosequencing	SIGNALING PATHWAY; BRAF GENE; APOPTOSIS; HEPATOCARCINOGENESIS; CANCER; KINASE; MICE; MITOCHONDRIA; DOWNSTREAM; ACTIVATION	The mitogen-activated protein kinase signalling pathway is a central regulator of tumor growth, which is constitutively activated in chemically induced mouse liver tumors. In about 30-50% of cases this effect can be related to activation of the Ha-ras gene by point mutations, whereas in the remaining cases mutations may occur in other members within this pathway, such as Raf kinases. Recently, B-raf has been shown to be frequently mutated in human melanomas and certain other cancers, with a V599E amino-acid change representing the most predominant mutation type. We now screened 82 N-nitrosodiethylamine-induced liver tumors from C3H/He mice for mutations within the hotspot positions in the Ha-ras and B-raf genes. About 50% (39/82) of tumors showed Ha-ras codon 61 mutations and 16 tumors (similar to20%) harbored mutations at codon 624 of the B-raf gene, which corresponds to codon 599 in human B-raf. None of the tumors was mutated in both Ha-ras and B-raf. The high prevalence of Ha-ras and B-raf mutations in mouse liver tumors is in striking contrast to human hepatocellular cancers which very infrequently harbor mutations in the two genes. These fundamental differences between the biology of liver tumors in mice and man may be of toxicological relevance.	Univ Tubingen, Abt Toxikol, Inst Pharmakol & Toxikol, D-72074 Tubingen, Germany; Univ Tubingen, Inst Humangenet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Schwarz, M (corresponding author), Univ Tubingen, Abt Toxikol, Inst Pharmakol & Toxikol, Wilhelmstr 56, D-72074 Tubingen, Germany.	michael.schwarz@uni-tuebingen.de						BAUERHOFMANN R, 1992, MOL CARCINOGEN, V6, P60, DOI 10.1002/mc.2940060110; Berg Lars M, 2002, Expert Rev Mol Diagn, V2, P361, DOI 10.1586/14737159.2.4.361; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; Chang FM, 2003, INT J ONCOL, V22, P469; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRAGANI TA, 1991, ONCOGENE, V6, P333; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Frey S, 2000, CARCINOGENESIS, V21, P161, DOI 10.1093/carcin/21.2.161; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Kalkuhl A, 1998, HEPATOLOGY, V27, P1081, DOI 10.1002/hep.510270425; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Schwarz M, 1995, MUTAT RES-FUND MOL M, V333, P69, DOI 10.1016/0027-5107(95)00133-6; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yuen ST, 2002, CANCER RES, V62, P6451	26	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1290	1295		10.1038/sj.onc.1208265	http://dx.doi.org/10.1038/sj.onc.1208265			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592514				2022-12-25	WOS:000226898700017
J	Nittka, S; Gunther, J; Ebisch, C; Erbersdobler, A; Neumaier, M				Nittka, S; Gunther, J; Ebisch, C; Erbersdobler, A; Neumaier, M			The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis	ONCOGENE			English	Article						CEACAM1; apoptosis; ACF; APC; beta-catenin; carcinogenesis	ABERRANT CRYPT FOCI; CARCINOEMBRYONIC ANTIGEN FAMILY; PROTEIN TRUNCATION TEST; CELL-ADHESION MOLECULE; COLI APC GENE; BILIARY GLYCOPROTEIN; ADENOMATOUS-POLYPOSIS; HYPERPLASTIC POLYPOSIS; CYTOPLASMIC DOMAIN; CANCER-CELLS	Defects in the adenomatous polyposis coli (APC) tumor suppressor pathway are sufficient for neoplastic transformation as the initiating step in colorectal carcinogenesis. In contrast, hyperplastic tumors possess normal APC function, and it is unclear whether they represent significant precursor lesion in cancer development. CEA-CAM1 is a tumor suppressor whose expression is known to be lost in the great majority of early adenomas and carcinomas. We found that loss of CEACAM1 expression is more common in neoplastic tumors than APC mutations. While APC function was normal in hyperplastic aberrant cypt foci and hyperplastic polyps, loss of CEACAM1 was observed as frequently as in the neoplasias. Moreover, the presence or absence of CEACAM1 expression in the hyperplastic tumors correlates with normal or reduced apoptosis, respectively. In vitro, CEACAM1 acts as a regulator of apoptosis in CEA-CAM1-transfected Jurkat cells. Finally, in human HT29 colon cancer cells, apoptosis can be specifically restored by induction of CEACAM1 expression. These data suggest an oncodevelopmental link between neoplasia and hyperplasia and demonstrate that CEACAM1 acts as a regulator of apoptosis in the colonic epithelium. Thus, failure of the maturing colon cell to express CEACAM1 is likely to contribute to the development of hyperplastic lesions, which may eventually pave the way to neoplastic transformation and colon cancer development.	Heidelberg Univ, Med Fac Mannheim, Inst Clin Chem, D-6800 Mannheim, Germany; Univ Hamburg, Hosp Eppendorf, Dept Pathol, D-20246 Hamburg, Germany	Ruprecht Karls University Heidelberg; University of Hamburg	Neumaier, M (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Inst Clin Chem, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	michael.neumaier@ikc.ma.uni-heidelberg.de						Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bala S, 1996, HUM GENET, V98, P528, DOI 10.1007/s004390050254; Battu S, 1998, ANTICANCER RES, V18, P3579; Beauchemin N, 1999, EXP CELL RES, V252, P243; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; BRUMMER J, 1995, ONCOGENE, V11, P1649; Esteller M, 2000, CANCER RES, V60, P4366; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hawkins NJ, 2000, AM J PATHOL, V157, P385, DOI 10.1016/S0002-9440(10)64551-8; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Herter P, 1999, J CANCER RES CLIN, V125, P297, DOI 10.1007/s004320050277; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jass JR, 2000, GUT, V47, P43, DOI 10.1136/gut.47.1.43; Jass JR, 2001, DIS COLON RECTUM, V44, P163, DOI 10.1007/BF02234287; JEN J, 1994, CANCER RES, V54, P5523; Kikuchi Y, 1997, VIRCHOWS ARCH, V431, P111, DOI 10.1007/s004280050076; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirchgesser M, 1998, CLIN CHEM LAB MED, V36, P567, DOI 10.1515/CCLM.1998.097; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kunath T, 1995, ONCOGENE, V11, P2375; Launonen V, 2000, CANCER RES, V60, P546; Laurent-Puig P, 1999, EUR J CANCER PREV, V8, pS39; Michor F, 2004, CELL CYCLE, V3, P358; Mori H, 2004, MUTAT RES-REV MUTAT, V566, P191, DOI 10.1016/j.mrrev.2003.08.002; NAP M, 1992, CANCER RES, V52, P2329; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Otori K, 1998, CANCER, V83, P896, DOI 10.1002/(SICI)1097-0142(19980901)83:5<896::AID-CNCR14>3.0.CO;2-Q; OTORI K, 1995, CANCER RES, V55, P4743; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Robitaille J, 1999, EUR J BIOCHEM, V264, P534, DOI 10.1046/j.1432-1327.1999.00660.x; Roncucci L, 2000, CELL PROLIFERAT, V33, P1, DOI 10.1046/j.1365-2184.2000.00159.x; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Shpitz B, 1996, DIS COLON RECTUM, V39, P763, DOI 10.1007/BF02054441; Singer BB, 2002, J IMMUNOL, V168, P5139, DOI 10.4049/jimmunol.168.10.5139; SMITH AJ, 1994, CANCER RES, V54, P5527; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; TAKAHASHI H, 1993, CANCER RES, V53, P1612; Tan S, 2002, INT J CANCER, V98, P523, DOI 10.1002/ijc.10236; Turbide C, 1997, CANCER RES, V57, P2781; Wynter CVA, 2004, GUT, V53, P573, DOI 10.1136/gut.2003.030841; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	54	67	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9306	9313		10.1038/sj.onc.1208259	http://dx.doi.org/10.1038/sj.onc.1208259			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15568039				2022-12-25	WOS:000225764100002
J	Barron, MR; Belaguli, NS; Zhang, SX; Trinh, M; Iyer, D; Merlo, X; Lough, JW; Parmacek, MS; Bruneau, BG; Schwartz, RJ				Barron, MR; Belaguli, NS; Zhang, SX; Trinh, M; Iyer, D; Merlo, X; Lough, JW; Parmacek, MS; Bruneau, BG; Schwartz, RJ			Serum response factor, an enriched cardiac mesoderm obligatory factor, is a downstream gene target for Tbx genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-BOX PROTEINS; HEART DEVELOPMENT; TRANSCRIPTION FACTOR; MOUSE DEVELOPMENT; EXPRESSION; DIFFERENTIATION; MUTATIONS; CELL; TIP60; PROMOTER	We tested the idea that T-box factors direct serum response factor (SRF) gene activity early in development. Analysis of SRF-LacZ "knock-in" mice showed highly restricted expression in early embryonic cardiac and skeletal muscle mesoderm and neuroectoderm. Examination of the SRF gene for regulatory regions by linking the promoter and 5'-flanking sequences, up to 5.5 kb, failed to target LacZ transgene activity to the heart and the tail pre-somitic mesenchyme. However, linkage of a minimal SRF promoter with the SRF 3'-untranslated region (UTR), inundated with multimeric T-box binding sites (TBEs), restored robust reporter gene activity to embryonic heart and tail. Finer dissection of the 3'-UTR to a small cluster of TBEs also stimulated transgene activity in the cardiac forming region and the tail, however, when the TBEs contained within these DNA sequences were mutated, preventing Tbx binding, transgene activity was lost. Tbx2, Tbx5, and the cardiac-enriched MYST family histone acetyltransferase TIP60, were observed to be mutual interactive cofactors through the TIP60 zinc finger and the T-box of the Tbx factors. In SRF-null ES cells, TIP60, Tbx2, and Tbx5 were sufficient to stimulate co-transfected SRF reporter activity, however this activity required the presence of the SRF 3'-UTR. SRF gene transactivation was blocked by two distinct TIP60 mutants, in which either the histone acetyltransferase domain was inactivated or the Zn finger-protein binding domain was excised. Our study supports the idea that SRF embryonic cardiac gene expression is dependent upon the SRF 3'-UTR enhancer, Tbx2, Tbx5, and TIP60 histone acetyltransferase activity.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Univ Penn, Hlth Syst, Div Cardiovasc Med, Philadelphia, PA 19104 USA; Hosp Sick Children, Cardiovasc Res Div, Toronto, ON M5G 1X8, Canada	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Medical College of Wisconsin; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Schwartz, RJ (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe, Houston, TX 77030 USA.	rschwartz@ibt.tamhsc.edu		Bruneau, Benoit/0000-0002-0804-7597	NHLBI NIH HHS [P01-HL49953] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Basson CT, 1999, P NATL ACAD SCI USA, V96, P2919, DOI 10.1073/pnas.96.6.2919; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Horb ME, 1999, DEVELOPMENT, V126, P1739; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Liberatore CM, 2000, DEV BIOL, V223, P169, DOI 10.1006/dbio.2000.9748; Lough JW, 2002, DEV DYNAM, V223, P419, DOI 10.1002/dvdy.10058; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Nelson TJ, 2004, CIRC RES, V94, P1059, DOI 10.1161/01.RES.0000125296.14014.17; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Paxton C, 2002, GENE, V283, P117, DOI 10.1016/S0378-1119(01)00878-2; REECY JM, 1999, HEART DEV, P273; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sinha S, 2000, GENE, V258, P15, DOI 10.1016/S0378-1119(00)00417-0; Tada M, 2001, DEV GROWTH DIFFER, V43, P1; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Yamada M, 2000, DEV BIOL, V228, P95, DOI 10.1006/dbio.2000.9927; YAMOMOTO T, 1997, J BIOL CHEM, V272, P30595	38	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11816	11828		10.1074/jbc.M412408200	http://dx.doi.org/10.1074/jbc.M412408200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15591049	hybrid			2022-12-25	WOS:000227761800111
J	Hintermann, E; Yang, N; O'Sullivan, D; Higgins, JMG; Quaranta, V				Hintermann, E; Yang, N; O'Sullivan, D; Higgins, JMG; Quaranta, V			Integrin alpha 6 beta 4-erbB2 complex inhibits haptotaxis by up-regulating E-cadherin cell-cell junctions in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; BREAST-CANCER; ALPHA-3-BETA-1 INTEGRIN; INTERCELLULAR-ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; INVASIVE GROWTH; ERBB RECEPTORS; EXPRESSION; MIGRATION	Keratinocyte integrins alpha6beta4 and alpha3beta1 bind laminin-5, a component of basement membranes. We previously demonstrated that in keratinocytes, haptotactic migration on laminin-5 was stimulated by anti-beta1 integrin-activating antibody TS2/16, whereas antibodies to alpha 6 and beta4, respectively, blocked TS2/16-induced, alpha3beta1-dependent migration. Moreover, alpha6beta4-associated haptotaxis inhibition was linked to a phosphatidylinositol 3-kinase (PI3K) pathway and required erbB2 activation. erbB2, the ligand-less member of the epidermal growth factor receptor family, was shown to form a complex with the hemidesmosomal integrin alpha6beta4. Here, we demonstrate that alpha6beta4 inhibitory effects on haptotaxis are abolished by an anti-E-cadherin antibody, which interferes with cell-cell adhesion. Furthermore, antibodies to alpha6 and beta4 stimulated adhesion to an E-cadherin-Fc recombinant protein. In addition, anti-alpha6/beta4 antibodies increased colony size in plated cells, stimulated cell-cell aggregation, and up-regulated E-cadherin localization to cell-cell contacts. These effects were abolished when erbB2 or PI3K were blocked. These results indicate that stimulation of alpha6beta4 increases E-cadherin-mediated cell-cell adhesion and that this mechanism depends on erbB2 activation. The molecule that links alpha6beta4 with E-cadherin may be the small GTPase cdc42, an effector of PI3K, because dominant-negative cdc42 abolished the inhibitory effect of anti-alpha6/beta4 antibodies and increased basal migration, whereas constitutively active cdc42 prevented the TS2/16-induced increase in haptotaxis. These findings suggest a model whereby alpha6beta4 can augment cell-cell adhesion and slow down haptotaxis over laminin-5 and point to the alpha6beta4-erbB2 heterodimer as an important signaling complex for the formation of cohesive keratinocyte layers.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Vanderbilt University; Scripps Research Institute; Scripps Research Institute; Harvard University; Harvard Medical School	Quaranta, V (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 221 Kirkland Hall,771 PRB,23rd & Pierce Ave, Nashville, TN 37232 USA.	vito.quaranta@vanderbilt.edu	Quaranta, Vito/G-6512-2016	Quaranta, Vito/0000-0001-7491-8672; Higgins, Jonathan/0000-0001-6622-8268	NATIONAL CANCER INSTITUTE [R01CA047858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046902] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47858] Funding Source: Medline; NIGMS NIH HHS [GM46902] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; COSTANTINI RM, 1990, CANCER RES, V50, P6107; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304; Davis TL, 2001, PROSTATE, V46, P240; De Arcangelis A, 1999, DEVELOPMENT, V126, P3957; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Fuchs E, 1997, CURR OPIN GENET DEV, V7, P672, DOI 10.1016/S0959-437X(97)80016-0; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; Goldfinger LE, 1999, J CELL SCI, V112, P2615; GUI GPH, 1995, SURGERY, V117, P102, DOI 10.1016/S0039-6060(05)80236-3; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harabayashi T, 1999, J UROLOGY, V161, P1364, DOI 10.1016/S0022-5347(01)61685-9; Hegerfeldt Y, 2002, CANCER RES, V62, P2125; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Hintermann E, 2004, MATRIX BIOL, V23, P75, DOI 10.1016/j.matbio.2004.03.001; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ishii Y, 2000, GASTROENTEROLOGY, V118, P497, DOI 10.1016/S0016-5085(00)70255-1; JENSEN PJ, 1995, EXP CELL RES, V219, P322, DOI 10.1006/excr.1995.1235; Jones JL, 1997, EXP CELL RES, V235, P325, DOI 10.1006/excr.1997.3662; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kawano K, 2001, EXP CELL RES, V262, P180, DOI 10.1006/excr.2000.5083; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Marsden M, 2003, CURR BIOL, V13, P1182, DOI 10.1016/S0960-9822(03)00433-0; Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; OToole EA, 1997, EXP CELL RES, V233, P330, DOI 10.1006/excr.1997.3586; Owens DM, 2003, J CELL SCI, V116, P3783, DOI 10.1242/jcs.00725; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; Ren XD, 2000, J CELL SCI, V113, P3673; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Serini G, 1996, J NATL CANCER I, V88, P442, DOI 10.1093/jnci/88.7.442; SRIRAMARAO P, 1993, J BIOL CHEM, V268, P22036; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; Tan M, 1999, CANCER RES, V59, P1620; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; VANWAES C, 1995, HEAD NECK-J SCI SPEC, V17, P140, DOI 10.1002/hed.2880170212; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Whittard JD, 2001, EXP CELL RES, V263, P65, DOI 10.1006/excr.2000.5099	65	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8004	8015		10.1074/jbc.M406301200	http://dx.doi.org/10.1074/jbc.M406301200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15579904	hybrid			2022-12-25	WOS:000227395700070
J	Kumagai, K; Yasuda, S; Okemoto, K; Nishijima, M; Kobayashi, S; Hanada, K				Kumagai, K; Yasuda, S; Okemoto, K; Nishijima, M; Kobayashi, S; Hanada, K			CERT mediates intermembrane transfer of various molecular species of ceramides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE TRANSFER PROTEIN; THIN-LAYER-CHROMATOGRAPHY; ACUTE REGULATORY PROTEIN; FATTY-ACID COMPOSITION; HUMAN LENS MEMBRANES; LONG-CHAIN BASES; SPHINGOMYELIN SYNTHESIS; ENDOPLASMIC-RETICULUM; GOODPASTURE ANTIGEN; BINDING-PROTEIN	Ceramide produced at the endoplasmic reticulum is transported to the Golgi apparatus for conversion to sphingomyelin. The main pathway of endoplasmic reticulum-to-Golgi transport of ceramide is mediated by CERT, a cytosolic 68-kDa protein, in a nonvesicular manner. CERT contains a domain that catalyzes the intermembrane transfer of natural C-16-ceramide. In this study, we examined the ligand specificity of CERT in detail by using a cell-free assay system for intermembrane transfer of lipids. CERT did not mediate the transfer of sphingosine or sphingomyelin at all. The activity of CERT to transfer saturated and unsaturated diacylglycerols, which structurally resemble ceramide, was 5-10% of the activity toward C-16-ceramide. Among four stereoisomers of C-16-ceramide, CERT specifically recognized the natural D-erythro isomer. CERT efficiently transferred ceramides having C-14, C-16, C-18, and C-20 chains, but not longer acyl chains, and also mediated efficient transfer of C-16-dihydroceramide and C-16-phytoceramide. Binding assays showed that CERT also recognizes short chain fluorescent analogs of ceramide with a stoichiometry of 1:1. Moreover, (1R,3R)-N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl)dodecamide, which inhibited the CERT-dependent pathway of ceramide trafficking in intact cells, was found to be an antagonist of the CERT protein. These results indicate that CERT can mediate transfer of various types of ceramides that naturally exist and their close relatives.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	hanak@nih.go.jp	Kumagai, Keigo/AAG-1385-2021; Kobayashi, Shu/E-9214-2012	Kumagai, Keigo/0000-0002-1663-2905; Hanada, Kentaro/0000-0003-1383-2781; YASUDA, Satoshi/0000-0002-1011-0815				ALLAN D, 1988, BIOCHEM J, V254, P765, DOI 10.1042/bj2540765; Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Byrdwell WC, 1997, OPHTHALMIC RES, V29, P191; CROSSMAN MW, 1977, J BIOL CHEM, V252, P5815; de Brouwer APM, 2001, CHEM PHYS LIPIDS, V112, P109, DOI 10.1016/S0009-3084(01)00171-2; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Feng L, 1998, J LIPID RES, V39, P1862; FEX G, 1971, BIOCHIM BIOPHYS ACTA, V231, P161, DOI 10.1016/0005-2760(71)90264-5; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Funakoshi T, 2000, J BIOL CHEM, V275, P29938, DOI 10.1074/jbc.M004470200; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KARLSSON KA, 1973, BIOCHIM BIOPHYS ACTA, V316, P336, DOI 10.1016/0005-2760(73)90073-8; Lehto M, 2003, BBA-MOL CELL BIOL L, V1631, P1, DOI 10.1016/S1388-1981(02)00364-5; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; Nakamura Y, 2003, J MED CHEM, V46, P3688, DOI 10.1021/jm0300779; OBRIEN JS, 1964, J LIPID RES, V5, P339; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Panagabko C, 2003, BIOCHEMISTRY-US, V42, P6467, DOI 10.1021/bi034086v; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; RAGHAVEN S, 1973, LIPIDS, V8, P517, DOI 10.1007/BF02531987; Ramstedt B, 1999, EUR J BIOCHEM, V266, P997, DOI 10.1046/j.1432-1327.1999.00938.x; Raya A, 1999, J BIOL CHEM, V274, P12642, DOI 10.1074/jbc.274.18.12642; Raya A, 2000, J BIOL CHEM, V275, P40392, DOI 10.1074/jbc.M002769200; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SAGGERSON ED, 1980, BIOCHEM J, V190, P183, DOI 10.1042/bj1900183; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Tabunoki H, 2002, J BIOL CHEM, V277, P32133, DOI 10.1074/jbc.M204507200; TAKETOMI T, 1972, J BIOCHEM-TOKYO, V72, P791, DOI 10.1093/oxfordjournals.jbchem.a129972; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; VOELKER DR, 1991, BIOCH LIPIDS LIPOPRO, P489; Yappert MC, 2004, CHEM PHYS LIPIDS, V129, P1, DOI 10.1016/j.chemphyslip.2003.12.003; Yasuda S, 2001, J BIOL CHEM, V276, P43994, DOI 10.1074/jbc.M104884200; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	52	167	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6488	6495		10.1074/jbc.M409290200	http://dx.doi.org/10.1074/jbc.M409290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596449	hybrid			2022-12-25	WOS:000227332700031
J	Li, F; Higgs, HN				Li, F; Higgs, HN			Dissecting requirements for auto-inhibition of actin nucleation by the formin, mDia1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING PROTEIN; MOUSE FORMIN; POLYMERIZATION; MECHANISM; ELONGATION; PROFILIN; COMPLEX; DOMAIN; ENDS	The mammalian formin, mDial, is an actin nucleation factor. Experiments in cells and in vitro show that the N-terminal region potently inhibits nucleation by the formin homology 2 (FH2) domain-containing C terminus and that RhoA binding to the N terminus partially relieves this inhibition. Cellular experiments suggest that potent inhibition depends upon the presence of the diaphanous auto-regulatory domain (DAD) C-terminal to FH2. In this study, we examine in detail the N-terminal and C-terminal regions required for this inhibition and for RhoA relief. Limited proteolysis of an N-terminal construct from residues 1-548 identifies two stable truncations: 129-548 and 129-369. Analytical ultracentrifugation suggests that 1-548 and 129-548 are dimers, whereas 129-369 is monomeric. All three N-terminal constructs inhibit nucleation by the full C terminus. Although inhibition by 1-548 is partially relieved by RhoA, inhibition by 129-548 or 129-369 is RhoA-resistant. At the C terminus, DAD deletion does not affect nucleation but decreases inhibitory potency of 1-548 by 20,000-fold. Synthetic DAD peptide binds both 1-548 and 129-548 with similar affinity and partially relieves nucleation inhibition. C-terminal constructs are stable dimers. Our conclusions are as follows: 1) DAD is an affinity-enhancing motif for auto-inhibition; 2) an N-terminal domain spanning residues 129-369 (called DID for diaphanous inhibitory domain) is sufficient for autoinhibition; 3) a dimerization region C-terminal to DID increases the inhibitory ability of DID; and 4) DID alone is not sufficient for RhoA relief of auto-inhibition, suggesting that sequences N-terminal to DID are important to RhoA binding. An additional finding is that FH2 domain-containing constructs of mDial and mDia2 lose >75% nucleation activity upon freeze-thaw.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Higgs, HN (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	henry.higgs@dartmouth.edu		Higgs, Henry/0000-0002-2917-9644	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069818] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR16437] Funding Source: Medline; NIGMS NIH HHS [GM069818] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; BROMME D, 1986, ARCH BIOCHEM BIOPHYS, V244, P439, DOI 10.1016/0003-9861(86)90611-9; Copeland JW, 2004, J BIOL CHEM, V279, P50250, DOI 10.1074/jbc.M404429200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; MCRORIE DK, SELF ASSOCIATING SYS, P1; MORIHARA K, 1975, AGR BIOL CHEM TOKYO, V39, P1489, DOI 10.1080/00021369.1975.10861790; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	29	136	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6986	6992		10.1074/jbc.M411605200	http://dx.doi.org/10.1074/jbc.M411605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591319	hybrid			2022-12-25	WOS:000227332700088
J	Li, B; Nowak, NM; Kim, SK; Jacobson, KA; Bagheri, A; Schmidt, C; Wess, J				Li, B; Nowak, NM; Kim, SK; Jacobson, KA; Bagheri, A; Schmidt, C; Wess, J			Random mutagenesis of the M-3 muscarinic acetylcholine receptor expressed in yeast - Identification of second-site mutations that restore function to a coupling-deficient mutant M-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CONSERVED ASPARTATE RESIDUE; 2ND TRANSMEMBRANE DOMAIN; 3RD CYTOPLASMIC LOOP; G-PROTEIN; LIGAND-BINDING; AMINO-ACIDS; RHODOPSIN MUTANTS; C5A RECEPTOR; ACTIVATION	The M, muscarinic receptor is a prototypical member of the class A family of G protein-coupled receptors (GPCRs). To gain insight into the structural mechanisms governing agonist-mediated M, receptor activation, we recently developed a genetically modified yeast strain (Saccharomyces cerevisiae) which allows the efficient screening of large libraries of mutant M-3 receptors to identify mutant receptors with altered/novel functional properties. Class A GPCRs contain a highly conserved Asp residue located in transmembrane domain II (TM II; corresponding to Asp-113 in the rat M-3 muscarinic receptor) which is of fundamental importance for receptor activation. As observed previously with other GPCRs analyzed in mammalian expression systems, the D113N point mutation abolished agonist-induced receptor/protein coupling in yeast. We then subjected the D113N mutant M, receptor to PCR-based random mutagenesis followed by a yeast genetic screen to recover point mutations that can restore G protein coupling to the D113N mutant receptor. A large scale screening effort led to the identification of three such second-site suppressor mutations, R165W, R165M, and Y250D. When expressed in the wild-type receptor background, these three point mutations did not lead to an increase in basal activity and reduced the efficiency of receptor/G protein coupling. Similar results were obtained when the various mutant receptors were expressed and analyzed in transfected mammalian cells (COS-7 cells). Interestingly, like Asp-113, Arg-165 and Tyr-250, which are located at the cytoplasmic ends of TM III and TM V, respectively, are also highly conserved among class A GPCRs. Our data suggest a conformational link between the highly conserved Asp-113, Arg-165, and Tyr-250 residues which is critical for receptor activation.	NIDDK, Dept Mol Signaling, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Dept Mol Recognit, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Dept Mol Signaling, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05,8 Ctr Dr,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov	Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003, ZIADK031115, Z01DK031115] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGATEP R, 1998, TECHNICAL TIPS ONLIN, V1, P51; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BLUML K, 1994, J BIOL CHEM, V269, P11537; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CADWELL RC, 1994, PCR METH APPL, V3, pS136; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; Celic Andjelka, 2003, V237, P105; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; Donnelly D, 1999, BIOCHEM J, V339, P55, DOI 10.1042/0264-6021:3390055; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Fanelli F, 1999, MOL PHARMACOL, V56, P214, DOI 10.1124/mol.56.1.214; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; Javitch JA, 2004, MOL PHARMACOL, V66, P1077, DOI 10.1124/mol.104.006320; JI IH, 1991, J BIOL CHEM, V266, P14953; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nagata T, 1998, BIOCHEMISTRY-US, V37, P17216, DOI 10.1021/bi9810149; NEVE KA, 1991, MOL PHARMACOL, V39, P733; Nikiforovich GV, 2003, BIOCHEMISTRY-US, V42, P9110, DOI 10.1021/bi034586o; NUSSENZVEIG DR, 1993, MOL ENDOCRINOL, V7, P1105, DOI 10.1210/me.7.9.1105; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; RATH P, 1993, BIOCHEMISTRY-US, V32, P10277, DOI 10.1021/bi00090a001; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; Schmidt C, 2003, J BIOL CHEM, V278, P30248, DOI 10.1074/jbc.M304991200; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; SOMMERS CM, 1999, REC BIOCH M, P141; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; Tao Q, 1998, J PHARMACOL EXP THER, V285, P651; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WANG CD, 1993, MOL PHARMACOL, V43, P931; WANG CD, 1991, MOL PHARMACOL, V40, P168; Ward RJ, 2002, CELL SIGNAL, V14, P139, DOI 10.1016/S0898-6568(01)00218-2; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; ZHOU W, 1994, MOL PHARMACOL, V45, P165	70	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5664	5675		10.1074/jbc.M411623200	http://dx.doi.org/10.1074/jbc.M411623200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572356	hybrid			2022-12-25	WOS:000227217100068
J	Waletko, A; Zwicker, K; Abdrakhmanova, A; Zickermann, V; Brandt, U; Kerscher, S				Waletko, A; Zwicker, K; Abdrakhmanova, A; Zickermann, V; Brandt, U; Kerscher, S			Histidine 129 in the 75-kDa subunit of mitochondrial complex I from Yarrowia lipolytica is not a ligand for [Fe4S4] cluster N5 but is required for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; IRON-SULFUR CLUSTERS; RESPIRATORY-CHAIN; 49-KDA SUBUNIT; BACTERIAL; RESIDUES; ANGSTROM; REDOX; CORE	Respiratory chain complex I contains 8-9 iron-sulfur clusters. In several cases, the assignment of these clusters to subunits and binding motifs is still ambiguous. To test the proposed ligation of the tetranuclear iron-sulfur cluster N5 of respiratory chain complex I, we replaced the conserved histidine 129 in the 75-kDa subunit from Yarrowia lipolytica with alanine. In the mutant strain, reduced amounts of fully assembled but destabilized complex I could be detected. Deamino-NADH: ubiquinone oxidoreductase activity was abolished completely by the mutation. However, EPR spectroscopic analysis of mutant complex I exhibited an unchanged cluster N5 signal, excluding histidine 129 as a cluster N5 ligand.	Univ Frankfurt, Fachbereich Med, Inst Biochem 1, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Kerscher, S (corresponding author), Univ Frankfurt, Fachbereich Med, Inst Biochem 1, D-60590 Frankfurt, Germany.	kerscher@zbc.kgu.de	Brandt, Ulrich/GLV-1242-2022; Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; GAVRIKOVA EV, 1995, BBA-BIOENERGETICS, V1230, P23, DOI 10.1016/0005-2728(95)00015-B; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher S, 2004, EUR J BIOCHEM, V271, P3588, DOI 10.1111/j.0014-2956.2004.04296.x; Kerscher S, 2002, BBA-BIOENERGETICS, V1555, P83, DOI 10.1016/S0005-2728(02)00259-1; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 2001, J CELL SCI, V114, P3915; Mendz GL, 2000, ARCH MICROBIOL, V174, P1, DOI 10.1007/s002030000174; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; OHNISHI T, 1975, BIOCHIM BIOPHYS ACTA, V387, P475, DOI 10.1016/0005-2728(75)90087-0; Ouali M, 2000, PROTEIN SCI, V9, P1162, DOI 10.1110/ps.9.6.1162; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yano T, 2003, J BIOL CHEM, V278, P15514, DOI 10.1074/jbc.M212275200; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	26	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5622	5625		10.1074/jbc.M411488200	http://dx.doi.org/10.1074/jbc.M411488200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572358	hybrid			2022-12-25	WOS:000227217100063
J	Adrain, C; Murphy, BM; Martin, SJ				Adrain, C; Murphy, BM; Martin, SJ			Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CYTOCHROME-C; MEDIATED APOPTOSIS; CLEAVAGE; PATHWAY; SPECIFICITY; SUBSTRATE; MECHANISM; FAMILY; CPP32	Granzyme B is a major cytotoxic T lymphocyte/natural killer (CTL/NK) granule protease that can activate members of the caspase family of cysteine proteases through processing of caspase zymogens. However, the molecular order and relative importance of caspase activation events that occur in target cells during granzyme B-initiated apoptosis has not been established. Here, we have examined the hierarchy of granzyme B-initiated caspase activation events using a cell-free system where all caspases are present at physiological levels. We show that granzyme B initiates a two-tiered caspase activation cascade involving seven caspases, where caspase-3 is required for the second tier of caspase activation events. Using a two-dimensional gel-based proteomics approach we have also examined the scale of granzyme B-initiated alterations to the proteome in the presence or absence of effector caspase-3 or -7. These studies indicate that granzyme B targets a highly restricted range of substrates and orchestrates cellular demolition largely through activation of caspase-3.	Trinity Coll Dublin, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Trinity Coll Dublin, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland.	martinsj@tcd.ie	Murphy, Brona/D-4873-2012; Adrain, Colin/I-6259-2013; Murphy, Brona/P-2544-2019	Murphy, Brona/0000-0002-6740-8858; Adrain, Colin/0000-0001-7597-4393; Murphy, Brona/0000-0002-6740-8858; Martin, Seamus/0000-0002-8539-3143				Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Hill Michelle M, 2003, Mol Interv, V3, P19, DOI 10.1124/mi.3.1.19; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q; Murphy BM, 2004, J BIOL CHEM, V279, P36916, DOI 10.1074/jbc.M402039200; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; POE M, 1991, J BIOL CHEM, V266, P98; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Rotonda J, 2001, CHEM BIOL, V8, P357, DOI 10.1016/S1074-5521(01)00018-7; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Sutton VR, 1997, J IMMUNOL, V158, P5783; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Ulanet DB, 2003, P NATL ACAD SCI USA, V100, P12361, DOI 10.1073/pnas.2035245100; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598	47	110	119	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4663	4673		10.1074/jbc.M410915200	http://dx.doi.org/10.1074/jbc.M410915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569669	hybrid			2022-12-25	WOS:000227096600082
J	Chen, SJ; Operana, T; Bonzo, J; Nguyen, N; Tukey, RH				Chen, SJ; Operana, T; Bonzo, J; Nguyen, N; Tukey, RH			ERK kinase inhibition stabilizes the axyl hydrocarbon receptor - Implications for transcriptional activation and protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; DIOXIN RECEPTOR; NUCLEAR-LOCALIZATION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN-INDUCED DEGRADATION; GENE-EXPRESSION; LIGAND-BINDING; CYP1A1 GENE; PATHWAY; CELLS; TRANSACTIVATION	The ultimate carcinogen and metabolite of benzo[a]pyrene-,8-dihydrodiol, benzo[a]pyrene-r-7,t-8-dihydro-diol-t-9,10-epoxide (+/-), stimulates apoptosis, and this process can be blocked by extracellular signal-regulated kinase (Erk) kinase inhibitors. However, we show here that Erk kinase inhibitors were unable to prevent B[a]P-7,8-dihydrodiol-induced apoptosis, leading us to speculate that Erk kinases are linked to regulation of the aryl hydrocarbon (Ah) receptor. Cotreatment of hepa1c1c7 cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Erk kinase inhibitor PD98059, U0126, or SL327 led to enhanced nuclear accumulation of Ah receptor but with a reduced capacity to complement TCDD induction of Cyp1a1. This is explained in part by the ability of Erk kinase inhibitors to alter the steady-state levels of cellular Ah receptor, a result that leads to a dramatic induction in detectable receptor levels. These changes in cellular Ah receptor levels are associated with delayed degradation of the Ah receptor because TCDD-initiated degradation is reversed when cells are co-treated with TCDD and Erk kinase inhibitors. Erk kinase is linked to Ah receptor expression, as demonstrated by reductions in total Ah receptor levels after overexpression of constitutively active MEK1. In addition, Erk kinase activity modulates the transcriptional response because MEK1 overexpression enhances TCDD-initiated transactivation potential of the receptor. Thus, Erk kinase activity facilitates ligand-initiated transcriptional activation while targeting the Ah receptor for degradation. Immunoprecipitation experiments of the Ah receptor indicate that Erk kinase activity is associated with the receptor. It is interesting that the carboxyl region of the Ah receptor is associated with the transactivation region as well as the site for ubiquitination, indicating that Erk kinase-dependent phosphorylation targets the carboxyl region of the receptor.	Univ Calif San Diego, Dept Biochem & Clin Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Tukey, RH (corresponding author), Leichtag Biomed Res Bldg, La Jolla, CA 92093 USA.	rtukey@ucsd.edu		Chen, Shujuan/0000-0002-1068-195X	NIEHS NIH HHS [ES10337] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrieux L, 2004, MOL PHARMACOL, V65, P934, DOI 10.1124/mol.65.4.934; Backlund M, 2004, MOL PHARMACOL, V65, P416, DOI 10.1124/mol.65.2.416; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chen SJ, 2003, J BIOL CHEM, V278, P19526, DOI 10.1074/jbc.M300780200; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Davis JW, 2003, TOXICOL APPL PHARM, V188, P42, DOI 10.1016/S0041-008X(03)00012-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GALIJATOVIC A, 2004, J BIOL CHEM; Giannone JV, 1998, BIOCHEM PHARMACOL, V55, P489, DOI 10.1016/S0006-2952(97)00493-0; Guo M, 2001, BIOCHEM PHARMACOL, V62, P1449, DOI 10.1016/S0006-2952(01)00801-2; Hestermann EV, 2000, TOXICOL APPL PHARM, V168, P160, DOI 10.1006/taap.2000.9026; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; HOLLINGSHEAD BD, 2004, J BIOL CHEM; Ikuta T, 2004, BIOCHEM BIOPH RES CO, V317, P545, DOI 10.1016/j.bbrc.2004.03.076; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JAIN S, 1994, J BIOL CHEM, V269, P31518; Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kumar MB, 1999, GENE EXPRESSION, V8, P273; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Long WP, 1998, MOL PHARMACOL, V53, P691, DOI 10.1124/mol.53.4.691; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 2000, J BIOL CHEM, V275, P12676, DOI 10.1074/jbc.275.17.12676; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; POLAND A, 1991, MOL PHARMACOL, V39, P20; Pollenz RS, 2002, CHEM-BIOL INTERACT, V141, P41, DOI 10.1016/S0009-2797(02)00065-0; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; RUTTEN AAJJL, 1992, ARCH TOXICOL, V66, P237, DOI 10.1007/BF02307168; Santiago-Josefat B, 2001, MOL CELL BIOL, V21, P1700, DOI 10.1128/MCB.21.5.1700-1709.2001; Seidel SD, 2001, J BIOCHEM MOL TOXIC, V15, P187; Shibazaki M, 2004, J BIOL CHEM, V279, P3869, DOI 10.1074/jbc.M305880200; Song ZJ, 2003, MOL PHARMACOL, V63, P597, DOI 10.1124/mol.63.3.597; SWANSON HI, 1993, ARCH BIOCHEM BIOPHYS, V302, P167, DOI 10.1006/abbi.1993.1195; TAN Z, 2004, TOXICOL SCI; Tan ZQ, 2002, BIOCHEM PHARMACOL, V64, P771, DOI 10.1016/S0006-2952(02)01138-3; Thomas RS, 2002, METHOD ENZYMOL, V357, P198; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322	45	49	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4350	4359		10.1074/jbc.M411554200	http://dx.doi.org/10.1074/jbc.M411554200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572374	hybrid			2022-12-25	WOS:000227096600044
J	Kong, SE; Kobor, MS; Krogan, NJ; Somesh, BP; Sogaard, TMM; Greenblatt, JF; Svejstrup, JQ				Kong, SE; Kobor, MS; Krogan, NJ; Somesh, BP; Sogaard, TMM; Greenblatt, JF; Svejstrup, JQ			Interaction of Fcp1 phosphatase with elongating RNA polymerase II holoenzyme, enzymatic mechanism of action, and genetic interaction with Elongator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DOMAIN PHOSPHATASE; HISTONE DEACETYLASE COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO; TRANSCRIPTION ELONGATION; PROTEIN PHOSPHATASE; PAF1 COMPLEX; YEAST; PURIFICATION; INITIATION	Fcp1 de-phosphorylates the RNA polymerase 11 (RNAPII) C-terminal domain (CTD) in vitro, and mutation of the yeast FCP1 gene results in global transcription defects and increased CTD phosphorylation levels in vivo. Here we show that the Fcp1 protein associates with elongating RNAPII holoenzyme in vitro. Our data suggest that the association of Fcp1 with elongating polymerase results in CTD de-phosphorylation when the native ternary RNAPI10-DNA-RNA complex is disrupted. Surprisingly, highly purified yeast Fcp1 dephosphorylates serine 5 but not serine 2 of the RNAPII CTD repeat. Only free RNAPI10(Ser-5) and not RNA-PII0-DNA-RNA ternary complexes act as a good substrate in the Fcp1 CTD de-phosphorylation reaction. In contrast, TFIIH CTD kinase has a pronounced preference for RNAPII incorporated into a ternary complex. Interestingly, the Fcp1 reaction mechanism appears to entail phosphoryl transfer from RNAPII0 directly to Fcp1. Elongator fails to affect the phosphatase activity of Fcp1 in vitro, but genetic evidence points to a functional overlap between Elongator and Fcp1 in vivo. Genetic interactions between Elongator and a number of other transcription factors are also reported. Together, these results shed new light on mechanisms that drive the transcription cycle and point to a role for Fcp1 in the recycling of RNAPII after dissociation from active genes.	Canc Res UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Univ Toronto, Toronto Yeast Proteom Org, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	Cancer Research UK; University of Toronto	Svejstrup, JQ (corresponding author), Canc Res UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	J.Svejstrup@Cancer.org.UK		Svejstrup, Jesper/0000-0003-4964-6147; Sogaard, Teit Max Moscote/0000-0001-6224-4818; Kobor, Michael/0000-0003-4140-1743				Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bach I, 2003, TRENDS BIOCHEM SCI, V28, P189, DOI 10.1016/S0968-0004(03)00055-0; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; Formosa T, 2002, GENETICS, V162, P1557; Ganem C, 2003, EMBO J, V22, P1588, DOI 10.1093/emboj/cdg141; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hawkes NA, 2002, J BIOL CHEM, V277, P3047, DOI 10.1074/jbc.M110445200; HENRY NL, 1992, J BIOL CHEM, V267, P23388; Jona G, 2001, GENE, V267, P31, DOI 10.1016/S0378-1119(01)00389-4; Jones JC, 2004, J BIOL CHEM, V279, P24957, DOI 10.1074/jbc.M402218200; Kamenski T, 2004, MOL CELL, V15, P399, DOI 10.1016/j.molcel.2004.06.035; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kim JH, 2002, P NATL ACAD SCI USA, V99, P1241, DOI 10.1073/pnas.251672198; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; Kornberg RD, 2001, BIOL CHEM, V382, P1103, DOI 10.1515/BC.2001.140; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; Mandal SS, 2002, MOL CELL BIOL, V22, P7543, DOI 10.1128/MCB.22.21.7543-7552.2002; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Svetlov V, 1998, J BIOL CHEM, V273, P10827, DOI 10.1074/jbc.273.18.10827; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Van Mullem V, 2002, J BIOL CHEM, V277, P10220, DOI 10.1074/jbc.M107207200; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	62	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4299	4306		10.1074/jbc.M411071200	http://dx.doi.org/10.1074/jbc.M411071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15563457	hybrid			2022-12-25	WOS:000227096600038
J	Madrid, R; Janvier, K; Hitchin, D; Day, J; Coleman, S; Noviello, C; Bouchet, J; Benmerah, A; Guatelli, J; Benichou, S				Madrid, R; Janvier, K; Hitchin, D; Day, J; Coleman, S; Noviello, C; Bouchet, J; Benmerah, A; Guatelli, J; Benichou, S			Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD4 DOWN-REGULATION; BREFELDIN-A; GUANINE-NUCLEOTIDE; DILEUCINE MOTIF; SORTING PATHWAY; COAT PROTEINS; MHC-I; MEMBRANE; CELLS; SURFACE	human immunodeficiency virus type 1 (HIV-1) Nef interacts with the clathrin-associated AP-1 and AP-3 adaptor complexes, stabilizing their association with endosomal membranes. These findings led us to hypothesize a general impact of this viral protein on the endosomal system. Here, we have shown that Nef specifically disturbs the morphology of the early/recycling compartment, inducing a redistribution of early endosomal markers and a shortening of the tubular recycling endosomal structures. Furthermore, Nef modulates the trafficking of the transferrin receptor (TfR), the prototypical recycling surface protein, indicating that it also disturbs the function of this compartment. Nef reduces the rate of recycling of TfR to the plasma membrane, causing TfR to accumulate in early endosomes and reducing its expression at the cell surface. These effects depend on the leucine-based motif of Nef, which is required for the membrane stabilization of AP-1 and AP-3 complexes. Since we show that this motif is also required for the full infectivity of HIV-1 virions, these results indicate that the positive influence of Nef on viral infectivity may be related to its general effects on early/recycling endosomal compartments.	Univ Paris 05, Inst Cochin Genet Mol, INSERM, U567,CNRS,UMR8104,Dept Infect Dis, F-75014 Paris, France; San Diego Vet Affairs Healthcare Syst, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Diego	Benichou, S (corresponding author), Univ Paris 05, Inst Cochin Genet Mol, INSERM, U567,CNRS,UMR8104,Dept Infect Dis, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	benichou@cochin.inserm.fr	Janvier, Katy/O-7780-2017; bouchet, jerome/I-7716-2019; benmerah, alexandre/H-3742-2017	Janvier, Katy/0000-0002-3105-4736; bouchet, jerome/0000-0002-6611-4380; benmerah, alexandre/0000-0003-0188-8016; Benichou, Serge/0000-0003-3602-3530; Madrid Gonzalez, Ricardo/0000-0002-1350-9864	NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [AI38201, AI36214] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038201, R01AI038201, P30AI036214] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Erdtmann L, 2000, TRAFFIC, V1, P871, DOI 10.1034/j.1600-0854.2000.011106.x; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Geyer M, 2002, J BIOL CHEM, V277, P28521, DOI 10.1074/jbc.M200522200; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Janvier K, 2000, AIDS, V14, pS21; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Janvier K, 2003, J BIOL CHEM, V278, P8725, DOI 10.1074/jbc.M210115200; Johannes L, 2003, TRAFFIC, V4, P323, DOI 10.1034/j.1600-0854.2003.00089.x; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Liu LX, 2000, J VIROL, V74, P5310, DOI 10.1128/JVI.74.11.5310-5319.2000; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Mellman I, 1996, CURR OPIN CELL BIOL, V8, P497, DOI 10.1016/S0955-0674(96)80026-3; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Sanfridson A, 1997, P NATL ACAD SCI USA, V94, P873, DOI 10.1073/pnas.94.3.873; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stoddart CA, 2003, J VIROL, V77, P2124, DOI 10.1128/JVI.77.3.2124-2133.2003; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; STUMPTNERCUVELL.P, 2003, MOL BIOL CELL, V77, P10548; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	55	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5032	5044		10.1074/jbc.M401202200	http://dx.doi.org/10.1074/jbc.M401202200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569681	hybrid			2022-12-25	WOS:000227096600125
J	Streb, JW; Miano, JM				Streb, JW; Miano, JM			AKAP12 alpha, an atypical serum response factor-dependent target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; ANGIOTENSIN-II; SMOOTH; MYOCARDIN; EXPRESSION; ACTIVATION; DIFFERENTIATION; GATA; SRF; INACTIVATION	We recently identified three AKAP12 isoforms that are differentially regulated by distinct promoters. During a screen to identify molecular determinants distinguishing the activities of these promoters, we found a potential binding site for the serum response factor (SRF) in the promoter of the ubiquitously expressed AKAP12alpha isoform. SRF is an evolutionarily conserved transcription factor that governs disparate programs of gene expression linked to cellular growth and differentiation. Using a combination of reporter assays and RNA interference, we demonstrate that SRF is required for AKAP12alpha expression. SRF regulates the activity of the AKAP12alpha promoter through two conserved CArG boxes that bind SRF with different affinities. Unlike other SRF-dependent genes, AKAP12alpha is not regulated by growth or differentiation stimuli. Molecular analysis of the AKAP12alpha SRF-binding sites, or CArG boxes, indicates that sequences flanking these sites are the determinants of sensitivity to SRF-activating signals. Specifically, the AKAP12alpha CArG boxes are shielded from growth stimulation by the absence of a binding site for Ets transcription factors. Similarly, sensitivity to the differentiation-associated co-factor, myocardin, was also determined by responsive flanking sequence; however, unlike growth stimuli, sensitivity to myocardin was found to also be dependent on a consensus CArG box. Collectively, our data demonstrate that AKAP12a belongs to a novel class of atypical SRF-dependent target genes. Furthermore, we provide new insight into the role of flanking sequences in determining sensitivity to SRF-myocar-din activity.	Univ Rochester, Sch Med, Cardiovasc Res Ctr, Aab Inst Biomed Sci, Rochester, NY 14642 USA	University of Rochester	Miano, JM (corresponding author), Univ Rochester, Sch Med, Cardiovasc Res Ctr, Aab Inst Biomed Sci, 601 Elmwood Ave, Rochester, NY 14642 USA.	j.m.miano@rochester.edu	Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207	NHLBI NIH HHS [HL62572, T32HL07949, HL70077] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007949, R01HL062572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; CARLISLEMICHEL JJ, 2002, ANN REV PHARM TOXICO, V42, P235; Carson JA, 2000, J BIOL CHEM, V275, P39061, DOI 10.1074/jbc.M006532200; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Coats SR, 2000, J MOL CELL CARDIOL, V32, P2207, DOI 10.1006/jmcc.2000.1246; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; ELBLE R, 1991, P NATL ACAD SCI USA, V88, P10966, DOI 10.1073/pnas.88.23.10966; Escalante R, 2004, MECH DEVELOP, V121, P51, DOI 10.1016/j.mod.2003.11.001; Escalante R, 2001, DEV BIOL, V235, P314, DOI 10.1006/dbio.2001.0303; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; Groisman R, 1996, J BIOL CHEM, V271, P5258; Guillemin K, 1996, DEVELOPMENT, V122, P1353; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; Mo Y, 2001, J MOL BIOL, V314, P495, DOI 10.1006/jmbi.2001.5138; Montagne J, 1996, DEVELOPMENT, V122, P2589; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; Oh J, 2004, MOL CELL BIOL, V24, P8519, DOI 10.1128/MCB.24.19.8519-8528.2004; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Selvaraj A, 2003, J BIOL CHEM, V278, P41977, DOI 10.1074/jbc.M305679200; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Streb JW, 2004, J BIOL CHEM, V279, P56014, DOI 10.1074/jbc.M408828200; Strobeck M, 2001, J BIOL CHEM, V276, P16418, DOI 10.1074/jbc.M100631200; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4125	4134		10.1074/jbc.M412466200	http://dx.doi.org/10.1074/jbc.M412466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590635	hybrid			2022-12-25	WOS:000227096600018
J	Temple, KA; Cohen, RN; Wondisford, SR; Yu, C; Deplewski, D; Wondisford, FE				Temple, KA; Cohen, RN; Wondisford, SR; Yu, C; Deplewski, D; Wondisford, FE			An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor gamma (PPAR gamma) binding and activation on some PPAR response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; OB GENE-EXPRESSION; ACYL-COA OXIDASE; GLUCOCORTICOID-RECEPTOR; SEQUENCE REQUIREMENTS; STIMULATING HORMONE; NEGATIVE REGULATION; ESTROGEN-RECEPTOR; HIGH-AFFINITY	Peroxisome proliferator-activated receptor gamma (PPARgamma) interacts with retinoid X receptor (RXR) on PPAR response elements (PPREs) to regulate transcription of PPAR-responsive genes. To investigate the binding of PPARgamma and RXR to PPREs, three mutations were constructed in the DNA-binding domains of PPARgamma; two of the mutants maintained the structure of zinc finger I (PPARgamma-GS and PPARgamma-AA), and a third mutation disrupted the protein structure of zinc finger I (PPARgamma-CS). Results indicated that the mutations of PPARgamma that maintained intact zinc fingers were capable of binding to a variety of PPREs in the presence of RXR and could activate transcription on several PPREs. In parallel, a mutation was created in the DNA-binding domain of RXRalpha that maintained the structure of the zinc fingers (RXR-GS) but did not bind DNA and was transcriptionally inactive. Examination of the 3' half-site of several PPREs revealed that variations from the consensus sequence reduced or abolished transcriptional activity, but conversion to consensus improved transcriptional activity with PPARgamma-GS and PPARgamma-AA. Examination of the 5' half-site indicated that the upstream three nucleotides were more important for transcriptional activity than the downstream three nucleotides. Our data demonstrated that stringent binding of RXR to the 3' half-site of a PPRE is more influential on the binding of the PPARgamma/RXR heterodimer than the ability of PPARgamma to bind DNA. Thus, unlike RXR, PPARgamma exhibits promiscuity in binding on a PPRE, suggesting that the definition of a PPRE for PPARgamma may need to be expanded.	Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Wondisford, FE (corresponding author), MC1027,5841 S Maryland Ave, Chicago, IL 60637 USA.	fwondisf@medicine.bsd.uchicago.edu			NHLBI NIH HHS [HL-007237] Funding Source: Medline; NIDDK NIH HHS [DK-20595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Castelein H, 1996, MOL CELL ENDOCRINOL, V119, P11, DOI 10.1016/0303-7207(96)03794-X; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; delaBrousse FC, 1996, P NATL ACAD SCI USA, V93, P4096, DOI 10.1073/pnas.93.9.4096; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DOWHAN DH, 1994, ENDOCRINOLOGY, V135, P2595, DOI 10.1210/en.135.6.2595; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Hartman HB, 2002, J BIOL CHEM, V277, P19754, DOI 10.1074/jbc.M201451200; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; Nohammer C, 2000, EUR J BIOCHEM, V267, P1254, DOI 10.1046/j.1432-1327.2000.01128.x; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Park Y, 2003, DIABETOLOGIA, V46, P365, DOI 10.1007/s00125-003-1037-4; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rieusset J, 1999, BIOCHEM BIOPH RES CO, V265, P265, DOI 10.1006/bbrc.1999.1657; Robinson CE, 1998, BIOCHEM BIOPH RES CO, V244, P671, DOI 10.1006/bbrc.1998.8305; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; Shibusawa N, 2003, J BIOL CHEM, V278, P732, DOI 10.1074/jbc.M207264200; Song HY, 2002, BIOCHEM BIOPH RES CO, V299, P291, DOI 10.1016/S0006-291X(02)02551-2; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200; XU W, 1993, COLD SPRING HARB SYM, V58, P133, DOI 10.1101/SQB.1993.058.01.017; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	55	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3529	3540		10.1074/jbc.M411422200	http://dx.doi.org/10.1074/jbc.M411422200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15572375	hybrid			2022-12-25	WOS:000226983900050
J	Bonev, BB; Breukink, E; Swiezewska, E; De Kruijff, B; Watts, A				Bonev, BB; Breukink, E; Swiezewska, E; De Kruijff, B; Watts, A			Targeting extracellular pyrophosphates underpins the high selectivity of nisin	FASEB JOURNAL			English	Article						lantibiotic; staphylococcal resistance; penicillin binding protein; vancomycin	PRECURSOR LIPID II; STAPHYLOCOCCUS-AUREUS; LANTIBIOTIC NISIN; PORE FORMATION; PEPTIDE; PEPTIDOGLYCAN; BIOSYNTHESIS; MEMBRANE; NMR; ANTIBIOTICS	The spread of infectious diseases and the increase in antibiotic resistance represent a life-threatening global development that calls for new approaches to control microorganisms. Of all potential targets, the essential and unique pathway of bacterial cell wall synthesis, targeted by the first known antibiotic penicillin, remains a perfect candidate for the development of new antibiotics. Here we show that the lantibiotic nisin exercises its antibacterial action by targeting peptidoglycan intermediates' extracellular pyrophosphate, unique to bacterial cell wall precursors. We show that nisin sequesters cell wall precursors found in the outer leaflet of bacterial plasma membranes, Lipid II and undecaprenyl pyrophosphate, into stable complexes. We propose a model of antibacterial action for nisin in which the terminal amino group of Ile1 targets the pyrophosphate groups of the bacterial cell wall precursors, where it docks via a hydrogen bond. The pyrophosphate moiety, a highly conserved chemical group different from the L-Lys-D-Ala-D-Ala docking motif for vancomycin, has no biochemical analogs with comparable properties and is unlikely to be susceptible to bacterial adaptations akin to those responsible for resistance to penicillins and vancomycin.	Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Oxford, Dept Biochem, Biomembrane Struct Unit, Oxford OX1 3QU, England; Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Utrecht, Netherlands; Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland; Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2RD, England	University of Nottingham; University of Oxford; Utrecht University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; University of Nottingham	Bonev, BB (corresponding author), Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England.	Boyan.Bonev@nottingham.ac.uk	Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660; Swiezewska, Ewa/0000-0002-3439-8948; Bonev, Boyan/0000-0001-7156-2412				BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Bonev B, 2001, PHYS CHEM CHEM PHYS, V3, P2904, DOI 10.1039/b103352m; Bonev BB, 2000, BIOCHEMISTRY-US, V39, P11425, DOI 10.1021/bi0001170; Breukink E, 2000, BIOCHEMISTRY-US, V39, P10247, DOI 10.1021/bi000915q; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; Chan WC, 1996, FEBS LETT, V390, P129, DOI 10.1016/0014-5793(96)00638-2; DelvesBroughton J, 1996, ANTON LEEUW INT J G, V69, P193, DOI 10.1007/BF00399424; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; Garau J, 2002, LANCET INFECT DIS, V2, P404, DOI 10.1016/S1473-3099(02)00316-X; Guillion T., 1989, J MAGN RESON, V81, P196; HAEBERLEN U, 1969, PHYS REV, V185, P420, DOI 10.1103/PhysRev.185.420; HARTMANN SR, 1962, PHYS REV, V128, P2042, DOI 10.1103/PhysRev.128.2042; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; Michel M, 1997, LANCET, V349, P1901, DOI 10.1016/S0140-6736(96)11192-2; Rogers LA, 1928, J BACTERIOL, V16, P211, DOI 10.1128/JB.16.4.211-229.1928; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; Swiezewska Ewa, 1994, Acta Biochimica Polonica, V41, P221; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; van Heusden HE, 2002, BIOCHEMISTRY-US, V41, P12171, DOI 10.1021/bi026090x; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Wright GD, 2003, CURR OPIN CHEM BIOL, V7, P563, DOI 10.1016/j.cbpa.2003.08.004	30	69	73	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1862	1869		10.1096/fj.04-2358com	http://dx.doi.org/10.1096/fj.04-2358com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576489	Green Submitted			2022-12-25	WOS:000226091000036
J	Mordelet, E; Kissa, K; Cressant, A; Gray, F; Ozden, S; Vidal, C; Charneau, P; Granon, S				Mordelet, E; Kissa, K; Cressant, A; Gray, F; Ozden, S; Vidal, C; Charneau, P; Granon, S			Histopathological and cognitive defects induced by Nef in the brain	FASEB JOURNAL			English	Article						neuropathology; behavior; bone marrow-derived macrophages	HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; RESTRICTED HIV-1 INFECTION; MEDIAL PREFRONTAL LESIONS; POLYMERASE CHAIN-REACTION; AIDS DEMENTIA COMPLEX; CENTRAL DNA FLAP; NEURONAL APOPTOSIS; QUINOLINIC ACID	Complex mechanisms of human immunodeficiency virus type-1 (HIV-1) brain pathogenesis suggest the contribution of individual HIV-1 gene products. Among them, the Nef protein has been reported to harbor a major determinant of pathogenicity in AIDS-like disease. The goal of the present study was to determine whether Nef protein expressed in vivo by primary macrophages could induce a brain toxicity also affecting the behavior of the rat. To achieve this goal we grafted Nef-transduced macrophages into the rat hippocampus. Two months post-transplantation, we observed that Nef induces monocyte/macrophage recruitment, expression of TNF-alpha, and astrogliosis. No apoptotic event was detected. We further demonstrated that Nef neurotoxicity is associated with cognitive deficits.	Inst Pasteur, Unite Postulante Mycol Mol, F-75015 Paris, France; Inst Pasteur, Unite Postulante Macrophages & Dev Immun, Paris, France; Inst Pasteur, Unite Retrovirus & Transfert Genet, Paris, France; Hop Lariboisiere, Serv Anat & Cytol Pathol, F-75475 Paris, France; Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, Paris, France; EPHE, CRSSA, Serv Neurol, CEA, Fontenay Aux Roses, France; Inst Pasteur, Grp Virol Mol & Vectorol, Paris, France; Inst Pasteur, Unite Recepteurs & Cognit, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mordelet, E (corresponding author), Inst Pasteur, Unite Postulante Mycol Mol, 25 Rue Dr Roux, F-75015 Paris, France.	mordelet@pasteur.fr; granon@pasteur.fr	CHARNEAU, Pierre/M-1565-2017; Kissa, Karima/N-6801-2018	CHARNEAU, Pierre/0000-0003-1184-5773; Kissa, Karima/0000-0002-7683-3661; Granon, sylvie/0000-0001-9384-3119				ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Ambrosini E, 1999, GLIA, V27, P143; Bachis A, 2003, J NEUROSCI, V23, P5715; Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002; Balasingam V, 1996, J NEUROSCI, V16, P2945; Banda NK, 1997, APOPTOSIS, V2, P61, DOI 10.1023/A:1026439726053; BARCLAY AN, 1981, IMMUNOLOGY, V44, P727; BECKER JT, 1981, NEUROPSYCHOLOGIA, V19, P733, DOI 10.1016/0028-3932(81)90085-3; Berger JR, 2000, J PSYCHOPHARMACOL, V14, P214, DOI 10.1177/026988110001400304; Berthoz A, 1997, PHILOS T R SOC B, V352, P1437, DOI 10.1098/rstb.1997.0130; BUHOT MC, 1995, EUR J PHARMACOL, V285, P221, DOI 10.1016/0014-2999(95)00407-C; Compton DM, 1997, NEUROBIOL LEARN MEM, V68, P117, DOI 10.1006/nlme.1997.3793; Corasaniti MT, 2001, FUNCT NEUROL, V16, P31; Cressant A, 2003, BRAIN RES PROTOC, V12, P116, DOI 10.1016/j.brainresprot.2003.08.002; Cressant A, 1997, J NEUROSCI, V17, P2531; DEGANS J, 1989, CLIN NEUROL NEUROSUR, V91, P199, DOI 10.1016/0303-8467(89)90114-5; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Duzel E, 2003, J NEUROSCI, V23, P9439; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; Gendelman HE, 1997, AIDS, V11, pS35; Glass JD, 1996, ANNU REV NEUROSCI, V19, P1; Glass JD, 2001, MICROSC RES TECHNIQ, V54, P95, DOI 10.1002/jemt.1124; Granon S, 1996, BEHAV BRAIN RES, V78, P147, DOI 10.1016/0166-4328(95)00242-1; GRANON S, 1994, BEHAV NEUROSCI, V108, P883, DOI 10.1037/0735-7044.108.5.883; Gray F, 1998, REV NEUROL, V154, pS91; Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Haughey NJ, 2002, JAIDS-J ACQ IMM DEF, V31, pS55, DOI 10.1097/00126334-200210012-00005; Hodges H, 1996, COGNITIVE BRAIN RES, V3, P167, DOI 10.1016/0926-6410(96)00004-3; Kapasi AA, 2002, MOL MED, V8, P676, DOI 10.1007/BF03402031; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kedzierska Katherine, 2001, Antiviral Chemistry and Chemotherapy, V12, P133; Kelder W, 1998, ANN NEUROL, V44, P831, DOI 10.1002/ana.410440521; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Koedel U, 1999, J IMMUNOL, V163, P1237; Kohleisen B, 1999, AIDS, V13, P2331, DOI 10.1097/00002030-199912030-00004; Kramer-Hammerle S, 2001, AIDS RES HUM RETROV, V17, P597, DOI 10.1089/088922201300119699; KURE K, 1990, AM J PATHOL, V136, P1085; Liu XX, 2001, J BIOL CHEM, V276, P32763, DOI 10.1074/jbc.M101025200; Messam CA, 2000, J NEUROVIROL, V6, pS90; Mordelet E, 2002, GENE THER, V9, P46, DOI 10.1038/sj.gt.3301591; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nath A, 2000, ANN NEUROL, V47, P186, DOI 10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.3.CO;2-V; Nath Avindra, 2004, Curr Treat Options Neurol, V6, P139, DOI 10.1007/s11940-004-0023-6; Navia BA, 1997, NEUROIMAG CLIN N AM, V7, P581; Nottet HSLM, 1996, J NEUROVIROL, V2, P111, DOI 10.3109/13550289609146544; Percario Z, 2003, J LEUKOCYTE BIOL, V74, P821, DOI 10.1189/jlb.0403161; Persidsky Y, 1997, J NEUROVIROL, V3, P401, DOI 10.3109/13550289709031186; Poucet B, 1997, CRIT REV NEUROBIOL, V11, P101, DOI 10.1615/CritRevNeurobiol.v11.i2-3.10; RANKI A, 1994, ARCH VIROL, V139, P365, DOI 10.1007/BF01310798; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; Rasola A, 2001, J IMMUNOL, V166, P81, DOI 10.4049/jimmunol.166.1.81; Robichaud GA, 2000, AIDS RES HUM RETROV, V16, P1959, DOI 10.1089/088922200750054684; Rostasy K, 1999, ANN NEUROL, V46, P207, DOI 10.1002/1531-8249(199908)46:2<207::AID-ANA10>3.0.CO;2-4; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sasseville VG, 1996, AM J PATHOL, V149, P1459; SAVE E, 1992, BEHAV NEUROSCI, V106, P447, DOI 10.1037/0735-7044.106.3.447; SCHENK F, 1995, BEHAV BRAIN RES NATU, P277; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Sirven A, 2000, BLOOD, V96, P4103; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Smith DG, 2001, J NEUROVIROL, V7, P56; SPATAFORA M, 1988, Respiration, V54, P73; Sporer B, 2000, J NEUROIMMUNOL, V102, P125, DOI 10.1016/S0165-5728(99)00170-8; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; Suarez S, 2001, AIDS, V15, P195, DOI 10.1097/00002030-200101260-00008; SUAREZ S, 2000, FLAMMARION MED SCI F, P40; SUTHERLAND RJ, 1982, NEUROSCI LETT, V32, P125, DOI 10.1016/0304-3940(82)90261-0; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; Tardieu M, 1999, CURR OPIN NEUROL, V12, P377, DOI 10.1097/00019052-199908000-00002; Thinus-Blanc C., 1996, ANIMAL SPATIAL COGNI; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; Torres-Munoz J, 2001, J NEUROPATH EXP NEUR, V60, P885, DOI 10.1093/jnen/60.9.885; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yang YD, 2003, J VIROL, V77, P6700, DOI 10.1128/JVI.77.12.6700-6708.2003; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	86	30	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1851	1861		10.1096/fj.04-2308com	http://dx.doi.org/10.1096/fj.04-2308com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576488				2022-12-25	WOS:000226091000035
J	Morlot, C; Pernot, L; Le Gouellec, A; Di Guilmi, AM; Vernet, T; Dideberg, O; Dessen, A				Morlot, C; Pernot, L; Le Gouellec, A; Di Guilmi, AM; Vernet, T; Dideberg, O; Dessen, A			Crystal structure of a peptidoglycan synthesis regulatory factor (PBP3) from Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; BETA-LACTAM ANTIBIOTICS; ESCHERICHIA-COLI; ACTIVE-SITE; BIOCHEMICAL-CHARACTERIZATION; STAPHYLOCOCCUS-AUREUS; STREPTOMYCES K15; CARBOXYPEPTIDASE; TRANSPEPTIDASE; RESISTANCE	Penicillin-binding proteins (PBPs) are membrane-associated enzymes which perform critical functions in the bacterial cell division process. The single D-Ala, D-Ala ( D, D)-carboxypeptidase in Streptococcus pneumoniae, PBP3, has been shown to play a key role in control of availability of the peptidoglycal substrate during cell growth. Here, we have biochemically characterized and solved the crystal structure of a soluble form of PBP3 to 2.8 angstrom resolution. PBP3 folds into an NH2-terminal, D, D-carboxypeptidase-like domain, and a COOH-terminal, elongated beta-rich region. The carboxypeptidase domain harbors the classic signature of the penicilloyl serine transferase superfamily, in that it contains a central, five-stranded antiparallel beta-sheet surrounded by alpha-helices. As in other carboxypeptidases, which are present in species whose peptidoglycan stem peptide has a lysine residue at the third position, PBP3 has a 14-residue insertion at the level of its omega loop, a feature that distinguishes it from carboxypeptidases from bacteria whose peptidoglycan harbors a diaminopimelate moiety at this position. PBP3 performs substrate acylation in a highly efficient manner (k(cat)/K-m = 50,500 M-1 center dot s(-1)), an event that may be linked to its central role in control of pneumococcal peptidoglycan reticulation. A model that places PBP3 poised vertically on the bacterial membrane suggests that its COOH-terminal region could act as a pedestal, placing the active site in proximity to the peptidoglycan and allowing the protein to "skid" on the surface of the membrane, trimming pentapeptides during the cell growth and division processes.	UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble, France; UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Dessen, A (corresponding author), UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	dessen@ibs.fr	le gouellec, audrey/M-6072-2014; Morlot, Cecile/C-8998-2014; Le Gouellec, audrey/AAC-3013-2019; Vernet, Thierry/G-1118-2012	Morlot, Cecile/0000-0002-9295-1035; Le Gouellec, audrey/0000-0002-4905-3854; Di Guilmi, Anne Marie/0000-0001-7335-3470; Dessen, Andrea/0000-0001-6487-4020				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *COMM COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760; Davies C, 2001, J BIOL CHEM, V276, P616, DOI 10.1074/jbc.M004471200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Di Guilmi AM, 1998, J BACTERIOL, V180, P5652, DOI 10.1128/JB.180.21.5652-5659.1998; Di Guilmi AM, 1999, J BACTERIOL, V181, P2773, DOI 10.1128/JB.181.9.2773-2781.1999; Di Guilmi AM, 2003, J BACTERIOL, V185, P1650, DOI 10.1128/JB.185.5.1650-1658.2003; Diaz N, 2001, J PHYS CHEM B, V105, P11302, DOI 10.1021/jp012881h; Fonze E, 1999, J BIOL CHEM, V274, P21853, DOI 10.1074/jbc.274.31.21853; FRERE JM, 1975, EUR J BIOCHEM, V57, P343, DOI 10.1111/j.1432-1033.1975.tb02307.x; HAKENBECK R, 1982, EUR J BIOCHEM, V127, P231, DOI 10.1111/j.1432-1033.1982.tb06860.x; Hayes F, 1997, J BIOL CHEM, V272, P28833, DOI 10.1074/jbc.272.46.28833; Johnson K, 1975, Methods Enzymol, V43, P687; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; LESLIE AGM, 2002, MOSFLM USER GUIDE MO; LEYHBOUILLE M, 1986, BIOCHEM J, V235, P177, DOI 10.1042/bj2350177; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; LOBKOVSKY E, 1993, P NATL ACAD SCI USA, V90, P11257, DOI 10.1073/pnas.90.23.11257; McDonough MA, 2002, J MOL BIOL, V322, P111, DOI 10.1016/S0022-2836(02)00742-8; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; MENGINLECREULX D, 1994, J BACTERIOL, V176, P4321, DOI 10.1128/jb.176.14.4321-4327.1994; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morlot C, 2003, MOL MICROBIOL, V50, P845, DOI 10.1046/j.1365-2958.2003.03767.x; Morlot C, 2004, MOL MICROBIOL, V51, P1641, DOI 10.1046/j.1365-2958.2003.03953.x; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; Nanninga N, 1998, MICROBIOL MOL BIOL R, V62, P110, DOI 10.1128/MMBR.62.1.110-129.1998; Nelson DE, 2000, J BACTERIOL, V182, P1714, DOI 10.1128/JB.182.6.1714-1721.2000; Nelson DE, 2001, J BACTERIOL, V183, P3055, DOI 10.1128/JB.183.10.3055-3064.2001; Nicholas RA, 2003, J BIOL CHEM, V278, P52826, DOI 10.1074/jbc.M310177200; Oliva M, 2003, PROTEINS, V53, P88, DOI 10.1002/prot.10450; Pagliero E, 2004, ANTIMICROB AGENTS CH, V48, P1848, DOI 10.1128/AAC.48.5.1848-1855.2004; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Popham DL, 2003, CURR OPIN MICROBIOL, V6, P594, DOI 10.1016/j.mib.2003.10.002; Pratt RF, 2002, J CHEM SOC PERK T 2, P851, DOI 10.1039/b107097p; SCHUSTER C, 1990, J BACTERIOL, V172, P6499, DOI 10.1128/jb.172.11.6499-6505.1990; SEVERIN A, 1992, J BACTERIOL, V174, P5152, DOI 10.1128/JB.174.15.5152-5155.1992; Sheldrick G.M, 1997, SHELXL 97; Stefanova ME, 2003, BIOCHEMISTRY-US, V42, P14614, DOI 10.1021/bi0350607; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; WILLIAMSON R, 1980, ANTIMICROB AGENTS CH, V18, P629, DOI 10.1128/AAC.18.4.629; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	44	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15984	15991		10.1074/jbc.M408446200	http://dx.doi.org/10.1074/jbc.M408446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15596446	hybrid			2022-12-25	WOS:000228444800065
J	Bommer, GT; Jager, CJ; Durr, EM; Baehs, S; Eichhorst, ST; Brabletz, T; Hu, G; Frohlich, T; Arnold, G; Kress, DC; Goke, B; Fearon, ER; Kolligs, FT				Bommer, GT; Jager, CJ; Durr, EM; Baehs, S; Eichhorst, ST; Brabletz, T; Hu, G; Frohlich, T; Arnold, G; Kress, DC; Goke, B; Fearon, ER; Kolligs, FT			DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN GENE; DRS MESSENGER-RNA; LINKED RETINITIS-PIGMENTOSA; COLORECTAL-CANCER; HEPATOCELLULAR CARCINOMAS; NEOPLASTIC TRANSFORMATION; SOMATIC MUTATIONS; DOWNSTREAM TARGET; CYCLIN D1; C-MYC	Neoplastic progression in human tissues appears to be paralleled by a series of genetic and epigenetic alterations. In human colorectal cancers, defect Wnt/beta-catenin/T-cell factor and RAS/RAF signaling pathways have a major contributing role in tumor initiation and progression. To date, much of the research on the consequences of beta-catenin activation has been focused on genes whose expression is believed to be activated by beta-catenin-associated T-cell factor-dependent transcription. Little is known about genes whose expression may be down-regulated secondary to beta-catenin activation. Using a subtractive suppression hybridization approach, we identified a gene with markedly decreased expression in rat RK3E epithelial cells neoplastically transformed by beta-catenin. Because expression of this gene was also down-regulated in RK3E transformed by several other oncogenes, the gene was named DRO1 for " down-regulated by oncogenes 1." Compared with corresponding normal tissues, DRO1 expression was found to be very reduced in colon and pancreatic cancer cell lines as well as in most colorectal cancer specimens. The predicted DRO1 protein contains three repetitive elements with significant similarity to the carboxyl-terminal regions of the predicted proteins from DRS/SRPX/ETX1 and SRPUL genes, suggesting the existence of a new protein family. Ectopic expression of DRO1 in neoplastically transformed RK3E or colorectal and pancreatic cancer cell lines lacking endogenous DRO1 expression resulted in substantial inhibition of growth properties. DRO1 was found to suppress anchorage independent growth and to sensitize cells to anoikis and CD95-induced apoptosis. Our findings suggest that inhibition of DRO1 expression may be an important event in the development of colorectal and pancreatic cancers.	Univ Munich, Dept Med 2, Klinikum Grosshadern, D-81377 Munich, Germany; Univ Erlangen Nurnberg, Inst Pathol, D-91054 Erlangen, Germany; Univ Michigan, Sch Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Canc Ctr, Ann Arbor, MI 48109 USA; Univ Munich, Gene Ctr, LAFUGA, D-81377 Munich, Germany; Univ Munich, Inst Mol Anim Breeding & Biotechnol, D-81377 Munich, Germany	University of Munich; University of Erlangen Nuremberg; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Munich; University of Munich	Kolligs, FT (corresponding author), Univ Munich, Dept Med 2, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.	fkolligs@med.uni-muenchen.de	Fröhlich, Thomas/C-6735-2011; Bommer, Guido/A-8425-2011	Fröhlich, Thomas/0000-0002-4709-3211; Bommer, Guido/0000-0001-6898-4884				Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Abraham SC, 2002, AM J PATHOL, V160, P953, DOI 10.1016/S0002-9440(10)64917-6; Aoki K, 2002, BIOCHEM BIOPH RES CO, V290, P1282, DOI 10.1006/bbrc.2002.6337; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Denys H, 2004, ONCOGENE, V23, P654, DOI 10.1038/sj.onc.1207160; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; El Nemer W, 2000, EUR J IMMUNOGENET, V27, P29; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujita M, 2000, CANCER RES, V60, P6683; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Grossmann J, 2002, AM J GASTROENTEROL, V97, P1421, DOI 10.1016/S0002-9270(02)04143-6; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x; Kawasoe T, 2000, CANCER RES, V60, P3354; Kim CJ, 2003, HUM PATHOL, V34, P654, DOI 10.1016/S0046-8177(03)00240-5; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Koch A, 1999, CANCER RES, V59, P269; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Marcantonio D, 2001, J MOL ENDOCRINOL, V26, P175, DOI 10.1677/jme.0.0260175; Marcantonio D, 2001, ENDOCRINOLOGY, V142, P2409, DOI 10.1210/endo.142.6.8154; MEINDL A, 1995, HUM MOL GENET, V4, P2339, DOI 10.1093/hmg/4.12.2339; Miyoshi Y, 1998, CANCER RES, V58, P2524; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mu H, 2003, MECH DEVELOP, V120, P143, DOI 10.1016/S0925-4773(02)00423-9; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Pan J, 1996, FEBS LETT, V383, P21; Park WS, 1999, CANCER RES, V59, P4257; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Polakis P, 2000, GENE DEV, V14, P1837; QUINN LA, 1979, CANCER RES, V39, P4914; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Shimakage M, 2000, INT J CANCER, V87, P5, DOI 10.1002/1097-0215(20000701)87:1<5::AID-IJC2>3.0.CO;2-Y; Shimakage M, 2002, HUM PATHOL, V33, P615, DOI 10.1053/hupa.2002.125373; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852	65	40	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7962	7975		10.1074/jbc.M412593200	http://dx.doi.org/10.1074/jbc.M412593200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15563452	hybrid			2022-12-25	WOS:000227395700066
J	Lamkanfi, M; D'hondt, K; Vande Walle, L; van Gurp, M; Denecker, G; Demeulemeester, J; Kalai, M; Declercq, W; Saelens, X; Vandenabeele, P				Lamkanfi, M; D'hondt, K; Vande Walle, L; van Gurp, M; Denecker, G; Demeulemeester, J; Kalai, M; Declercq, W; Saelens, X; Vandenabeele, P			A novel caspase-2 complex containing TRAF2 and RIP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; DOMAIN KINASE RIP; SIGNAL-TRANSDUCTION; CELL-DEATH; MEDIATED APOPTOSIS; GENE-EXPRESSION; ACTIVATION; FAMILY; INDUCTION	The enzymatic activity of caspases is implicated in the execution of apoptosis and inflammation. Here we demonstrate a novel nonenzymatic function for caspase-2 other than its reported proteolytic role in apoptosis. Caspase-2, unlike caspase-3, -6, -7, -9, -11, -12, and -14, is a potent inducer of NF-kappaB and p38 MAPK activation in a TRAF2-mediated way. Caspase-2 interacts with TRAF1, TRAF2, and RIP1. Furthermore, we demonstrate that endogenous caspase-2 is recruited into a large and inducible protein complex, together with TRAF2 and RIP1. Structure-function analysis shows that NF-kappaB activation occurs independent of enzymatic activity of the protease and that the caspase recruitment domain of caspase-2 is sufficient for the activation of NF-kappaB and p38 MAPK. These results demonstrate the inducible assembly of a novel protein complex consisting of caspase-2, TRAF2, and RIP1 that activates NF-kappaB and p38 MAPK through the caspase recruitment domain of caspase-2 independently of its proteolytic activity.	Univ Ghent, Dept Mol Biomed Res, Unit Mol Signalling & Cell Death, B-9052 Zwijnaarde, Belgium; Flemish Interuniv Inst Biotechnol, B-9052 Zwijnaarde, Belgium	Ghent University	Vandenabeele, P (corresponding author), Technol Pk 927, B-9052 Zwijnaarde, Belgium.	peter.vandenabeele@dmbr.ugent.be	Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022; Denecker, Geertrui/E-8134-2010	Vandenabeele, Peter/0000-0002-6669-8822; , Xavier/0000-0002-3861-6965; Denecker, Geertrui/0000-0002-2515-2911				Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Ahmad M, 1997, CANCER RES, V57, P615; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bonfoco E, 2001, J BIOL CHEM, V276, P29242, DOI 10.1074/jbc.M100684200; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Dowds TA, 2001, CELL DEATH DIFFER, V8, P640, DOI 10.1038/sj.cdd.4400855; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Jabado O, 2004, CELL DEATH DIFFER, V11, P618, DOI 10.1038/sj.cdd.4401397; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lamkanfi M, 2004, J BIOL CHEM, V279, P24785, DOI 10.1074/jbc.M400985200; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morita Y, 2001, CELL DEATH DIFFER, V8, P614, DOI 10.1038/sj.cdd.4400845; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; O'Reilly SM, 2003, BIOCHEM BIOPH RES CO, V303, P586, DOI 10.1016/S0006-291X(03)00389-9; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; ROLTZ IN, 1997, J BIOL CHEM, V272, P3296; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3	77	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6923	6932		10.1074/jbc.M411180200	http://dx.doi.org/10.1074/jbc.M411180200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590671	hybrid			2022-12-25	WOS:000227332700082
J	Manna, SK; Ramesh, GT				Manna, SK; Ramesh, GT			Interleukin-8 induces nuclear transcription factor-kappa B through a TRAF6-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMET-LEU-PHE; C-X-C; MOLECULAR-MECHANISMS; GROWTH-FACTOR; CROSS-TALK; ACTIVATION; RECEPTOR; ANGIOGENESIS; EXPRESSION; CANCER	Considering the potential role of interleukin-8 (IL-8) in inflammation, angiogenesis, tumorigenesis, and metastasis, we investigated the molecular mechanism involved in IL-8-mediated signaling. In this report we provide evidence that like TNF, an inducer of NF-kappaB and also a NFkappaB-dependent gene product, IL-8 induces NF-kappaB in a unique pathway. IL-8 induces NF-kappaB activation in a dose-dependent manner in different cell types as detected by a DNA-protein binding assay. IL-8 induces NF-kappaB-dependent reporter gene expression as well as ICAM-1, VCAM-1, and Cox-2 expression. IL-8 also induces IkappaBalpha phosphorylation followed by degradation and p65 translocation. IL-8 induces c-Jun N-terminal kinase (JNK) and mitogen-acti vated protein kinase (MAPK) in a dose- and time-dependent manner. IL-8-induced NF-kappaB activation is for the most part unaltered when cells are transfected with dominantnegative TRADD, FADD, or TRAF2, but is inhibited with dominant-negative TRAF6-, NIK-, IKK-, or IkappaBalpha-transfected cells. The data suggest that IL-8-induced NF-kappaB activation proceeds through a TRAF2-independent but TRAF6-dependent pathway, followed by recruitment of IRAK and activation of IKK IL-8-induced NF-kappaB activation is not observed in a cell-permeable peptide that has TRAF6 binding motif-treated cells or IRAK-deficient cells. IL-8-induced NF-kappaB activation proceeds mostly through interaction with TRAF6 and partially through the Rho-GTPase pathways. This is the first report that IL-8 induces NF-kappaB in a distinct pathway, and activation of NF-kappaB and its dependent genes may be one of the pathways of IL-8-induced inflammation and angiogenesis.	Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India; Texas So Univ, Dept Biol, Houston, TX 77004 USA	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Texas Southern University	Manna, SK (corresponding author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.	manna@cdfd.org.in			NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003045] Funding Source: NIH RePORTER; NCRR NIH HHS [G12 RR003045-170001, G12 RR003045, RR03045-16] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; Cannon ML, 2004, ONCOGENE, V23, P514, DOI 10.1038/sj.onc.1207021; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chen LY, 2004, J BIOL CHEM, V279, P7208, DOI 10.1074/jbc.M309542200; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Collins AR, 1999, BIOESSAYS, V21, P238, DOI 10.1002/(SICI)1521-1878(199903)21:3<238::AID-BIES8>3.0.CO;2-3; Derevianko A, 1997, J LEUKOCYTE BIOL, V62, P268, DOI 10.1002/jlb.62.2.268; DEWALD B, 1988, J BIOL CHEM, V263, P16179; Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fidler IJ, 2000, CANCER J, V6, pS225; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 2001, SCIENCE, V293, P227, DOI 10.1126/science.1062892; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Karashima T, 2003, CLIN CANCER RES, V9, P2786; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Li XW, 2003, INFECT IMMUN, V71, P4414, DOI 10.1128/IAI.71.8.4414-4420.2003; Li XX, 1999, MOL CELL BIOL, V19, P4643; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1997, J IMMUNOL, V159, P5042; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; Mukaida N, 2000, INT J HEMATOL, V72, P391; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; PAN ZX, 1995, J BIOL CHEM, V270, P7787, DOI 10.1074/jbc.270.14.7787; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; RAMPART M, 1989, AM J PATHOL, V135, P21; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Sarkar A, 2004, J BIOL CHEM, V279, P33768, DOI 10.1074/jbc.M403424200; SCHNITZEL W, 1994, J LEUKOCYTE BIOL, V55, P763, DOI 10.1002/jlb.55.6.763; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Singh RK, 2000, EXP HEMATOL, V28, P499, DOI 10.1016/S0301-472X(00)00145-4; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; SMITH WB, 1993, IMMUNOLOGY, V78, P491; Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486; Stambe C, 2003, KIDNEY INT, V64, P2121, DOI 10.1046/j.1523-1755.2003.00324.x; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Takada Y, 2004, BLOOD, V104, P4113, DOI 10.1182/blood-2004-04-1607; Yang D, 2001, J LEUKOCYTE BIOL, V69, P691; Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200; Yoshizumi M, 2004, EXP CELL RES, V292, P1, DOI 10.1016/j.yexcr.2003.08.003; Zhang ZY, 2003, J IMMUNOL, V171, P3620, DOI 10.4049/jimmunol.171.7.3620	59	107	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7010	7021		10.1074/jbc.M410994200	http://dx.doi.org/10.1074/jbc.M410994200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591054	Green Accepted, hybrid			2022-12-25	WOS:000227332700091
J	Plotkin, LI; Aguirre, JI; Kousteni, S; Manolagas, SC; Bellido, T				Plotkin, LI; Aguirre, JI; Kousteni, S; Manolagas, SC; Bellido, T			Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MINERAL DENSITY; HORMONE REPLACEMENT; ERK ACTIVATION; SUBCELLULAR-LOCALIZATION; TRANSCRIPTIONAL ACTIVITY; OSTEOBLAST APOPTOSIS; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; SURVIVAL SIGNALS; SEX STEROIDS	Both estrogens and bisphosphonates attenuate osteocyte apoptosis by activating the extracellular signal-regulated kinases (ERKs). However, whereas estrogens activate ERKs via an extranuclear function of the estrogen receptor, bisphosphonates do so by opening connexin 43 hemichannels. Here, we demonstrated that the signaling events downstream of ERKs induced by these two stimuli are also distinct. Inhibition of osteocyte apoptosis by estrogens requires nuclear accumulation of ERKs and activation of downstream transcription factors. On the other hand, anti-apoptosis induced by bisphosphonates requires neither transcription nor ERK-dependent transcription factors. Instead, the effect of bisphosphonates is abolished when ERKs are restricted to the nucleus by blocking CRM1/exportin1-mediated nuclear protein export or by expressing nuclear-anchored ERKs, but it is unaffected in cells expressing cytoplasmic-anchored ERKs. Connexin 43/ERK-mediated anti-apoptosis induced by bisphosphonates requires the kinase activity of the cytoplasmic target of ERKs, p90(RSK), which in turn phosphorylates the proapoptotic protein BAD and C/EBPbeta. Phosphorylation of BAD renders it inactive, whereas phosphorylation of C/EBPbeta leads to binding of pro-caspases, thus inhibiting apoptosis independently of the transcriptional activity of this transcription factor. Consistent with the evidence that estrogens and bisphosphonates phosphorylate diverse targets of ERKs, probably resulting from activation of spatially distinct pools of these kinases, the two agents had additive effects on osteocyte survival.	Univ Arkansas Med Sci, Cent Arkansas Vet Affairs Healthcare Syst, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Bellido, T (corresponding author), Univ Arkansas Med Sci, Cent Arkansas Vet Affairs Healthcare Syst, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA.	tmbellido@uams.edu	Plotkin, Lilian/H-7188-2019	Plotkin, Lilian/0000-0002-9537-4544	NIAMS NIH HHS [K02-AR02127] Funding Source: Medline; NIA NIH HHS [P01-AG13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Ajenjo N, 2004, J BIOL CHEM, V279, P32813, DOI 10.1074/jbc.M313656200; Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Joseph DE, 1996, J BIOL CHEM, V271, P13088, DOI 10.1074/jbc.271.22.13088; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Lai JM, 2002, MOL CELL BIOL, V22, P7581, DOI 10.1128/MCB.22.21.7581-7592.2002; Lindsay R, 1999, J CLIN ENDOCR METAB, V84, P3076, DOI 10.1210/jc.84.9.3076; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003-0990; O'Rourke L, 2002, BIOCHEM J, V364, P875, DOI 10.1042/BJ20020295; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Shirakata Y, 1999, J IMMUNOL, V163, P6589; Smith ER, 2004, J CELL BIOL, V164, P689, DOI 10.1083/jcb.200312028; Sterneck E, 1998, J NEUROCHEM, V70, P2424; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Susa M, 1999, INT J MOL MED, V3, P115; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Wimalawansa SJ, 1998, AM J MED, V104, P219, DOI 10.1016/S0002-9343(98)00029-1; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zuckerbraun BS, 2003, CIRCULATION, V108, P876, DOI 10.1161/01.CIR.0000081947.00070.07	55	181	193	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7317	7325		10.1074/jbc.M412817200	http://dx.doi.org/10.1074/jbc.M412817200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590626	hybrid			2022-12-25	WOS:000227332700124
J	Putrenko, I; Zakikhani, M; Dent, JA				Putrenko, I; Zakikhani, M; Dent, JA			A family of acetylcholine-gated chloride channel subunits in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION SELECTIVITY; RECEPTOR; GABA; IDENTIFICATION; REVEALS; ENCODES; ALPHA-9; DOMAIN	The genome of the nematode Caenorhabditis elegans encodes a surprisingly large and diverse superfamily of genes encoding Cys loop ligand-gated ion channels. Here we report the first cloning, expression, and pharmacological characterization of members of a family of anion-selective acetylcholine receptor subunits. Two subunits, ACC-1 and ACC-2, form homomeric channels for which acetylcholine and arecoline, but not nicotine, are efficient agonists. These channels are blocked by D-tubocurarine but not by a-bungarotoxin. We provide evidence that two additional subunits, ACC-3 and ACC-4, interact with ACC-1 and ACC-2. The acetylcholine-binding domain of these channels appears to have diverged substantially from the acetylcholine-binding domain of nicotinic receptors.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Dent, JA (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.	joseph.dent@mcgill.ca						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bamber BA, 1999, J NEUROSCI, V19, P5348; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Beg AA, 2003, NAT NEUROSCI, V6, P1145, DOI 10.1038/nn1136; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARY RB, 1994, J CELL SCI, V107, P1609; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Garcia LR, 2001, CELL, V107, P777, DOI 10.1016/S0092-8674(01)00600-6; Gelbart WM, 1997, NUCLEIC ACIDS RES, V25, P63, DOI 10.1093/nar/25.1.63; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; HARROW ID, 1985, PESTIC SCI, V16, P662, DOI 10.1002/ps.2780160612; HILLE B, 1992, IONIC CHANNELS EXCIT, P405; Horoszok L, 2001, BRIT J PHARMACOL, V132, P1247, DOI 10.1038/sj.bjp.0703937; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P85, DOI 10.1113/jphysiol.1972.sp009930; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P115, DOI 10.1113/jphysiol.1972.sp009931; Kehoe J, 1998, J NEUROSCI, V18, P8198; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; MACONOCHIE DJ, 1992, J PHYSIOL-LONDON, V454, P129, DOI 10.1113/jphysiol.1992.sp019257; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Ranganathan R, 2000, NATURE, V408, P470, DOI 10.1038/35044083; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; TRIBUT F, 1994, J EXP BIOL, V186, P325; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Vassilatis DK, 1997, J BIOL CHEM, V272, P33167, DOI 10.1074/jbc.272.52.33167; Verbitsky M, 2000, NEUROPHARMACOLOGY, V39, P2515, DOI 10.1016/S0028-3908(00)00124-6; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; Yassin L, 2001, MOL CELL NEUROSCI, V17, P589, DOI 10.1006/mcne.2000.0944; Zheng YC, 2002, J BIOL CHEM, V277, P2000, DOI 10.1074/jbc.M107635200	42	71	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6392	6398		10.1074/jbc.M412644200	http://dx.doi.org/10.1074/jbc.M412644200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15579462	hybrid			2022-12-25	WOS:000227332700019
J	Chen, PL; Levis, M; Brown, P; Kim, KT; Allebach, J; Small, D				Chen, PL; Levis, M; Brown, P; Kim, KT; Allebach, J; Small, D			FLT3/ITD mutation signaling includes suppression of SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; SRC HOMOLOGY-2 DOMAINS; BONE-MARROW-CELLS; HEMATOPOIETIC-CELLS; KINASE INHIBITOR; IN-VIVO; C-KIT; PHOSPHOTYROSINE PHOSPHATASE	Mutations in the FLT3 gene are the most common genetic alteration found in AML patients. FLT3 internal tandem duplication (ITD) mutations result in constitutive activation of FLT3 tyrosine kinase activity. The consequences of this activation are an increase in total phosphotyrosine content, persistent downstream signaling, and ultimately transformation of hematopoietic cells to factor-independent growth. The Src homology (SH)2 domain-containing protein-tyrosine phosphatase (SHP)-1 is involved in the down-regulation of a broad range of growth factor and cytokine-driven signaling cascades. Loss-of-function or deficiency of SHP-1 activity results in a hyperproliferative response of myelomonocytic cell populations to growth factor stimulation. In this study, we examined the possible role of SHP-1 in regulating FLT3 signaling. We found that transformation of TF-1 cells with FLT3/ITD mutations suppressed the activity of SHP-1 by -3-fold. Suppression was caused by decreased SHP-1 protein expression, as analyzed at both the protein and RNA levels. In contrast, protein levels of SHP-2, a phosphatase that plays a stimulatory role in signaling through a variety of receptors, did not change significantly in FLT3 mutant cells. Suppressed SHP-1 protein levels in TF-1/ITD cells were partially overcome after cells were exposed to CEP-701, a selective FLT3 inhibitor. SHP-1 protein levels also increased in naturally occurring FLT3/ITD expressing AML cell lines and in primary FLT3/ITD AML samples after CEP-701 treatment. Furthermore, a small but reproducible growth/survival advantage was observed in both TF-1 and TF-1/ITD cells when SHP-1 expression was knocked down by RNAL Taken together, these data provide the first evidence that suppression of SHP-1 by FLT3/ITD signaling may be another mechanism contributing to the transformation by FLT3/ITD mutations.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Small, D (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg,Rm 253,1650 Orlea, Baltimore, MD 21231 USA.	donsmall@jhmi.edu			NCI NIH HHS [CA 90668, CA 91177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA091177, R01CA090668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BIRG F, 1992, BLOOD, V80, P2584; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; Bruecher-Encke B, 2001, LEUKEMIA, V15, P1424, DOI 10.1038/sj.leu.2402214; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Delibrias CC, 1997, J EXP MED, V186, P1575, DOI 10.1084/jem.186.9.1575; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Herman JG, 1996, CANCER RES, V56, P722; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Jiang XY, 2003, BLOOD, V102, P2976, DOI 10.1182/blood-2003-05-1550; Jiao HY, 1997, EXP HEMATOL, V25, P592; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kiyoi H, 2002, ONCOGENE, V21, P2555, DOI 10.1038/sj.onc.1205332; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Levis M, 2003, LEUKEMIA, V17, P1738, DOI 10.1038/sj.leu.2403099; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Levis M, 2001, BLOOD, V98, P885, DOI 10.1182/blood.V98.3.885; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Luo JM, 2003, LEUKEMIA, V17, P1, DOI 10.1038/sj.leu.2402725; Lyman S D, 1998, Curr Opin Hematol, V5, P192, DOI 10.1097/00062752-199805000-00008; Ma XZ, 2003, EXP HEMATOL, V31, P131, DOI 10.1016/S0301-472X(02)01025-1; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nakao M, 1996, LEUKEMIA, V10, P1911; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Oka T, 2002, CANCER RES, V62, P6390; Oka T, 2001, AM J PATHOL, V159, P1495, DOI 10.1016/S0002-9440(10)62535-7; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Rosnet O, 1996, LEUKEMIA, V10, P238; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 2003, SEMIN HEMATOL, V40, P4, DOI 10.1053/shem.2003.50034; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shultz LD, 1997, TRENDS BIOTECHNOL, V15, P302, DOI 10.1016/S0167-7799(97)01060-3; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tapley P, 1997, EXP HEMATOL, V25, P122; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; TSUJIMURA T, 1994, BLOOD, V83, P2619; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Uesugi Y, 2000, J EXP CLIN CANC RES, V19, P363; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Ward AC, 2000, LEUKEMIA, V14, P1284, DOI 10.1038/sj.leu.2401822; Wheadon H, 2002, CELL SIGNAL, V14, P219, DOI 10.1016/S0898-6568(01)00241-8; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yi TL, 2002, J IMMUNOL, V169, P5978, DOI 10.4049/jimmunol.169.10.5978; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, J LEUKOCYTE BIOL, V65, P372, DOI 10.1002/jlb.65.3.372; Zhao M, 2000, LEUKEMIA, V14, P374, DOI 10.1038/sj.leu.2401680; Zhao RX, 2003, J BIOL CHEM, V278, P42893, DOI 10.1074/jbc.M306136200; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978; Zheng R, 2002, BLOOD, V100, P4154, DOI 10.1182/blood-2002-03-0936	74	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5361	5369		10.1074/jbc.M411974200	http://dx.doi.org/10.1074/jbc.M411974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15574429	hybrid			2022-12-25	WOS:000227217100032
J	Hashimoto, H; Shimizu, T; Imasaki, T; Kato, M; Shichijo, N; Kita, K; Sato, M				Hashimoto, H; Shimizu, T; Imasaki, T; Kato, M; Shichijo, N; Kita, K; Sato, M			Crystal structures of type II restriction endonuclease Eco0109I and its complex with cognate DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVOLUTIONARY RELATIONSHIPS; HOMING ENDONUCLEASES; SEQUENCE; RECOGNITION; RESOLUTION; ECOO109I; PROGRAM; ENZYMES	EcoO109I is a type II restriction endonuclease that recognizes the DNA sequence of RGGNCCY. Here we describe the crystal structures of EcoO109I and its complex with DNA. A comparison of the two structures shows that the catalytic domain moves drastically to capture the DNA. One metal ion and two water molecules are observed near the active site of the DNA complex. The metal ion is a Lewis acid that stabilizes the pentavalent phosphorus atom in the transition state. One water molecule, activated by Lys-126, attacks the phosphorus atom in an S(N)2 mechanism, whereas the other water interacts with the W-leaving oxygen to donate a proton to the oxygen. EcoO109I is similar to EcoRI family enzymes in terms of its DNA cleavage pattern and folding topology of the common motif in the catalytic domain, but it differs in the manner of DNA recognition. Our findings propose a novel classification of the type II restriction endonucleases and lead to the suggestion that EcoO109I represents a new subclass of the EcoRI family.	Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Kyoto Univ, Grad Sch Agr, Uji, Kyoto 6110011, Japan	Yokohama City University; Kyoto University	Sato, M (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	msato@tsurumi.yokohama-cu.ac.jp		Hashimoto, Hiroshi/0000-0003-1503-6789; Imasaki, Tsuyoshi/0000-0001-5462-1820				Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Etzkorn C, 2004, BIOCHEMISTRY-US, V43, P13256, DOI 10.1021/bi0490082; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Grazulis S, 2002, NUCLEIC ACIDS RES, V30, P876, DOI 10.1093/nar/30.4.876; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Horton NC, 2002, NAT STRUCT BIOL, V9, P42, DOI 10.1038/nsb741; Imasaki T, 2004, ACTA CRYSTALLOGR D, V60, P1165, DOI 10.1107/S0907444904009412; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kita K, 2001, BIOSCI BIOTECH BIOCH, V65, P2512, DOI 10.1271/bbb.65.2512; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Tenno T, 2004, GENES CELLS, V9, P865, DOI 10.1111/j.1365-2443.2004.00780.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van der Woerd MJ, 2001, STRUCTURE, V9, P133, DOI 10.1016/S0969-2126(01)00564-0; VENCLOVAS C, 1994, PROTEINS, V20, P279, DOI 10.1002/prot.340200308	27	21	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5605	5610		10.1074/jbc.M411684200	http://dx.doi.org/10.1074/jbc.M411684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590682	hybrid			2022-12-25	WOS:000227217100061
J	Katanosaka, Y; Iwata, Y; Kobayashi, Y; Shibasaki, F; Wakabayashi, S; Shigekawa, M				Katanosaka, Y; Iwata, Y; Kobayashi, Y; Shibasaki, F; Wakabayashi, S; Shigekawa, M			Calcineurin inhibits Na+/Ca2+ exchange in phenylephrine-treated hypertrophic cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CARDIAC-HYPERTROPHY; NA+-CA2+ EXCHANGER; DEPENDENT REGULATION; SIGNALING PATHWAYS; PRESSURE-OVERLOAD; MYOCYTES; HEART; FAILURE; GROWTH	The cardiac Na+/Ca2+ exchanger (NCX1) is the predominant mechanism for the extrusion of Ca2+ from beating cardiomyocytes. The role of protein phosphorylation in the regulation of NCX1 function in normal and diseased hearts remains unclear. In our search for proteins that interact with NCX1 using a yeast two-hybrid screen, we found that the C terminus of calcineurin Abeta, containing the autoinhibitory domain, binds to the beta1 repeat of the central cytoplasmic loop of NCX1 that presumably constitutes part of the allosterie Ca2+ regulatory site. The association of NCX1 with calcineurin was significantly increased in the BI014.6 cardiomyopathic hamster heart compared with that in the normal control. In hypertrophic neonatal rat cardiomyocytes subjected to chronic phenylephrine treatment, we observed a marked depression of NCX activity measured as the rate of Na+ i-dependent Ca-45(2+) uptake or the rate of Na+ o-dependent Ca-45(2+) efflux. Depressed NCX activity was partially and independently reversed by the acute inhibition of calcineurin and protein kinase C activities with little effect on myocyte hypertrophic phenotypes. Studies of NCX1 deletion mutants expressed in CCL39 cells were consistent with the view that the beta1. repeat is required for the action of endogenous calcineurin and that the large cytoplasmic loop may be required to maintain the interaction of the enzyme with its substrate. Our data suggest that NCX1 is a novel regulatory target for calcineurin and that depressed NCX activity might contribute to the etiology of in vivo cardiac hypertrophy and dysfunction occurring under conditions in which both calcineurin and protein kinase C are chronically activated.	Natl Cardiovasc Ctr, Inst Res, Dept Mol Physiol, Suita, Osaka 5658565, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Bunkyo Ku, Tokyo 1138613, Japan; Senri Kinran Univ, Dept Human Life Sci, Suita, Osaka 5650873, Japan	National Cerebral & Cardiovascular Center - Japan; Tokyo Metropolitan Institute of Medical Science	Shigekawa, M (corresponding author), Natl Cardiovasc Ctr, Inst Res, Dept Mol Physiol, Fujishiro Dai 5-7, Suita, Osaka 5658565, Japan.	shigekaw@ri.nevc.go.jp						Ahmmed GU, 2000, CIRC RES, V86, P558, DOI 10.1161/01.RES.86.5.558; BAJUSZ E, 1969, ANN NY ACAD SCI, V156, P396, DOI 10.1111/j.1749-6632.1969.tb16742.x; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Condrescu M, 1999, J BIOL CHEM, V274, P33279, DOI 10.1074/jbc.274.47.33279; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Iwata Y, 2003, J CELL BIOL, V161, P957, DOI 10.1083/jcb.200301101; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK B, 1998, AM J PHYSIOL, V274, pC415; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; OROURKE N, 1999, CIRC RES, V6, P558; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Stengl M, 1998, CARDIOVASC RES, V38, P703, DOI 10.1016/S0008-6363(98)00039-X; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; TAWADAIWATA Y, 1993, AM J PHYSIOL, V264, pH1447; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang ZY, 2001, J BIOL CHEM, V276, P17706, DOI 10.1074/jbc.M100544200; Wei SK, 2003, CIRC RES, V92, P897, DOI 10.1161/01.RES.0000069701.19660.14	33	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5764	5772		10.1074/jbc.M410240200	http://dx.doi.org/10.1074/jbc.M410240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15557343	hybrid			2022-12-25	WOS:000227217100078
J	Perraud, AL; Takanishi, CL; Shen, B; Kang, S; Smith, MK; Schmitz, C; Knowles, HM; Ferraris, D; Li, WX; Zhang, J; Stoddard, BL; Scharenberg, AM				Perraud, AL; Takanishi, CL; Shen, B; Kang, S; Smith, MK; Schmitz, C; Knowles, HM; Ferraris, D; Li, WX; Zhang, J; Stoddard, BL; Scharenberg, AM			Accumulation of free ADP-ribose from mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE-ADENINE-DINUCLEOTIDE; PYRIDINE-NUCLEOTIDE HYDROLYSIS; NITRO-N-NITROSOGUANIDINE; POLY(ADP-RIBOSE) POLYMERASE; CELL-DEATH; PERMEABILITY TRANSITION; BIOLOGICAL EVALUATION; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; ISCHEMIC INJURIES	TRPM2 is a member of the transient receptor potential melastatin-related (TRPM) family of cation channels, which possesses both ion channel and ADP-ribose hydrolase functions. TRPM2 has been shown to gate in response to oxidative and nitrosative stresses, but the mechanism through which TRPM2 gating is induced by these types of stimuli is not clear. Here we show through structure-guided mutagenesis that TRPM2 gating by ADP-ribose and both oxidative and nitrosative stresses requires an intact ADP-ribose binding cleft in the C-terminal nudix domain. We also show that oxidative/nitrosative stress-induced gating can be inhibited by pharmacological reagents predicted to inhibit NAD hydrolysis to ADP-ribose and by suppression of ADP-ribose accumulation by cytosolic or mitochondrial overexpression of an enzyme that specifically hydrolyzes ADP-ribose. Overall, our data are most consistent with a model of oxidative and nitrosative stress-induced TRPM2 activation in which mitochondria are induced to produce free ADP-ribose and release it to the cytosol, where its subsequent accumulation induces TRPM2 gating via interaction within a binding cleft in the C-terminal NUDT9-H domain of TRPM2.	Univ Washington, Dept Pediat, Seattle, WA 98177 USA; Childrens Hosp, Seattle, WA 98177 USA; Reg Med Ctr, Seattle, WA 98177 USA; Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Guilford Pharmaceut Inc, Baltimore, MD 21224 USA; Genentech Inc, San Francisco, CA 94080 USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital; Fred Hutchinson Cancer Center; National Jewish Health; Roche Holding; Genentech	Scharenberg, AM (corresponding author), Univ Washington, Dept Pediat, Hlth Sci Bldg,RR309,1959 NE Pacific Ave, Seattle, WA 98177 USA.	andrewms@u.washington.edu		Ferraris, Dana/0000-0001-5791-5939				Babaei-Jadidi R, 2003, DIABETES, V52, P2110, DOI 10.2337/diabetes.52.8.2110; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CervantesLaurean D, 1996, J BIOL CHEM, V271, P10461, DOI 10.1074/jbc.271.18.10461; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P489, DOI 10.1016/S0968-0004(02)02191-6; CROMPTON M, 1988, BIOCHEM J, V255, P357; Di Simplicio P, 2003, AMINO ACIDS, V25, P323, DOI 10.1007/s00726-003-0020-1; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Dodoni G, 2004, BBA-BIOENERGETICS, V1658, P58, DOI 10.1016/j.bbabio.2004.05.005; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; EBY D, 1971, BIOCHEMISTRY-US, V10, P2677; Ferraris D, 2003, BIOORGAN MED CHEM, V11, P3695, DOI 10.1016/S0968-0896(03)00333-X; Ferraris D, 2003, J MED CHEM, V46, P3138, DOI 10.1021/jm030109s; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Giles NM, 2003, CHEM BIOL, V10, P677, DOI 10.1016/S1074-5521(03)00174-1; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; HILLYARD D, 1981, J BIOL CHEM, V256, P8491; HILLYARD D, 1973, J CELL PHYSIOL, V82, P165, DOI 10.1002/jcp.1040820205; Hour TC, 1999, TOXICOL LETT, V110, P191, DOI 10.1016/S0378-4274(99)00158-7; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; Jacobson EL, 1997, ADV EXP MED BIOL, V419, P371; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kinoshita T, 2004, FEBS LETT, V556, P43, DOI [10.1016/S0014-5793(03)01362-0, 10.5940/jcrsj.46.421]; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kroemer G, 2003, CURR MED CHEM, V10, P1469, DOI 10.2174/0929867033457232; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Lin SR, 2002, BBA-PROTEIN STRUCT M, V1594, P127, DOI 10.1016/S0167-4838(01)00296-5; Livingston BE, 1996, PEDIATR RES, V40, P59, DOI 10.1203/00006450-199607000-00011; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Mongkolsuk S, 2002, MOL MICROBIOL, V45, P9, DOI 10.1046/j.1365-2958.2002.03015.x; NIKNAHAD H, 1995, XENOBIOTICA, V25, P91, DOI 10.3109/00498259509061836; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2003, J BIOL CHEM, V278, P1794, DOI 10.1074/jbc.M205601200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; RECHSTEINER M, 1976, J CELL PHYSIOL, V88, P207, DOI 10.1002/jcp.1040880210; RICHTER C, 1984, METHOD ENZYMOL, V105, P435; RICHTER C, 1990, BIOCHEM PHARMACOL, V40, P779, DOI 10.1016/0006-2952(90)90315-C; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHWEIZER M, 1993, BIOCHEM PHARMACOL, V45, P641, DOI 10.1016/0006-2952(93)90138-M; Shen BW, 2003, J MOL BIOL, V332, P385, DOI 10.1016/S0022-2836(03)00954-9; Shen YQ, 2002, ACTA CRYSTALLOGR D, V58, P1287, DOI 10.1107/S090744490200999X; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V181, P278, DOI 10.1016/0003-9861(77)90506-9; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	57	255	265	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6138	6148		10.1074/jbc.M411446200	http://dx.doi.org/10.1074/jbc.M411446200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15561722	hybrid, Green Published			2022-12-25	WOS:000227217100121
J	Ren, XQ; Furukawa, T; Nakajima, Y; Takahashi, H; Aoki, S; Sumizawa, T; Haraguchi, M; Kobayashi, M; Chijiiwa, K; Akiyama, S				Ren, XQ; Furukawa, T; Nakajima, Y; Takahashi, H; Aoki, S; Sumizawa, T; Haraguchi, M; Kobayashi, M; Chijiiwa, K; Akiyama, S			GSH inhibits trypsinization of the C-terminal half of human MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; INDUCED CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; VINCRISTINE TRANSPORT; DEPENDENT TRANSPORT; NUCLEOTIDE-BINDING; MEMBRANE-VESICLES; LEUKOTRIENE C-4; P-GLYCOPROTEIN; AGOSTEROL-A	MRP1 is a 190-kDa membrane glycoprotein that confers multidrug resistance to tumor cells. The accumulated evidence has proved that GSH interacts with MRP1 and stimulates drug transport. However, the mechanism of GSH-dependent drug transport by MRPl remains unclear. In this study, we used limited tryptic digestion of MRPl in isolated membrane vesicles, in the presence and absence of GSH, to investigate the influence of GSH on MRPl conformation. We found that GSH inhibited the generation of an similar to35-kDa C-terminal tryptic fragment (including a C-terminal His tag) termed C2 from MRPl. This effect of GSH was not because of direct inhibition of trypsin activity, and agosterol A enhanced the inhibitory effect of GSH. The main cleavage site in MRPl for the generation of the C2 fragment by trypsin resided between TMD2 and NBD2 of MRPl. Limited tryptic digestion of membrane vesicles expressing various truncated and co-expressed MRPl fragments in the presence and absence of GSH revealed that GSH inhibited the production of the C2 fragment only in the presence of the L-O region of MRPl. Thus the L-O region is required for the inhibition of trypsinization of the C-terminal half of MRPl by GSH. These findings, together with previous reports, suggest that GSH induces a conformational change at a site within the MRPl that is indispensable for the interaction of MRPl with its substrates.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, Course Adv Therapeut,Field Oncol, Kagoshima 8908520, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; Miyazaki Univ, Sch Med, Dept Surg 1, Miyazaki 8891692, Japan	Kagoshima University; Osaka University; University of Miyazaki	Akiyama, S (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, Course Adv Therapeut,Field Oncol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	akiyamas@m3.kufm.kagoshima-u.ac.jp		Furukawa, Tatsuhiko/0000-0003-1655-4123				Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen ZS, 2001, INT J CANCER, V93, P107, DOI 10.1002/ijc.1290; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Ding GY, 1999, ANTICANCER RES, V19, P3243; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HSU CM, 1989, J BIOL CHEM, V264, P17349; Ishii S, 1998, PROTEIN SCI, V7, P1802, DOI 10.1002/pro.5560070816; Jencks WJ, 1987, CATALYSIS CHEM ENZYM, P282; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MA LD, 1995, BIOCHEMISTRY-US, V34, P3338, DOI 10.1021/bi00010a024; Manciu L, 2003, J BIOL CHEM, V278, P3347, DOI 10.1074/jbc.M207963200; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Qian YM, 2002, J BIOL CHEM, V277, P35225, DOI 10.1074/jbc.M206058200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; RAO R, 1988, J BIOL CHEM, V263, P5640; Ren XQ, 2000, BIOCHEM BIOPH RES CO, V270, P608, DOI 10.1006/bbrc.2000.2483; Ren XQ, 2002, BIOCHEMISTRY-US, V41, P14132, DOI 10.1021/bi026443s; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	36	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6231	6237		10.1074/jbc.M409498200	http://dx.doi.org/10.1074/jbc.M409498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579473	hybrid			2022-12-25	WOS:000227217100130
J	Che, FY; Yuan, Q; Kalinina, E; Fricker, LD				Che, FY; Yuan, Q; Kalinina, E; Fricker, LD			Pedtidomics of Cpe(fat/fat) mouse hypothalamus - Effect of food deprivation and exercise on peptide levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN-CONCENTRATING HORMONE; OBESE FAT/FAT MICE; CARBOXYPEPTIDASE-E; MASS-SPECTROMETRY; METALLOCARBOXYPEPTIDASE D; CPE(FAT)/CPE(FAT) MICE; PROPROTEIN CONVERTASES; MESSENGER-RNA; ATT-20 CELLS; PROSAAS	Carboxypeptidase E is a major enzyme in the biosynthesis of numerous neuroendocrine peptides. Previously, we developed a technique for the isolation of neuropeptide-processing intermediates from mice that lack carboxypeptidase E activity Cpe(fat/fat) mice) due to a naturally occurring point mutation. In the present study, we used a differential labeling procedure with stable isotopic tags and mass spectrometry to quantitate the relative changes in a number of hypothalamic peptides in Cpe(fat/fat) mice in two different paradigms that each cause an similar to10% decrease in body mass. One paradigm involved a 2-day fast under normal sedentary conditions (i.e. standard mouse cages); the other involved giving mice access to an exercise wheel for 4 weeks with free access to food. Approximately 50 peptides were detected in both studies, and over 80 peptides were detected in at least one of the two studies. Twenty-eight peptides were increased >50% by food deprivation, and some of these were increased by 2- to 3-fold. In contrast, only three peptides were increased >50% in the group with exercise wheels, and many peptides showed a slight 15-30% decrease upon exercise. Approximately one-half of the peptides detected in both studies were identified by tandem mass spectrometry. Peptides found to be elevated by food deprivation but not exercise included a number of fragments of proenkephalin, prothyrotropin-releasing hormone, secretogranin II, chromogranin B, and pro-SAAS. Taken together, the differential regulation of these peptides in the two paradigms suggests that the regulation is not due to the lower body weight but to the manner in which the paradigms achieved this lower body weight.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Prote, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China	Yeshiva University; Albert Einstein College of Medicine; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Fricker, LD (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morrris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu	Kalinina, Elena/D-9252-2012	Kalinina, Elena/0000-0003-0180-090X	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271, R21DK067350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, R21DA017665] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [DA-04494, DA-17665] Funding Source: Medline; NIDDK NIH HHS [DK-67350, DK-51271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Bennett HPJ, 1991, PEPTIDE BIOSYNTHESIS, P111; Cain BM, 1997, ENDOCRINOLOGY, V138, P4034, DOI 10.1210/en.138.9.4034; Che FY, 2001, P NATL ACAD SCI USA, V98, P9971, DOI 10.1073/pnas.161542198; Che FY, 2003, CELL MOL BIOL, V49, P713; Che FY, 2002, ANAL CHEM, V74, P3190, DOI 10.1021/ac015681a; CHE FY, 2004, IN PRESS J MASS SPEC; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; Feng Y, 2001, NEUROSCIENCE, V105, P469, DOI 10.1016/S0306-4522(01)00200-7; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V1, P848, DOI 10.1016/B978-0-12-079611-3.50259-7; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V8, P840; Gygi SP, 2000, CURR OPIN CHEM BIOL, V4, P489, DOI 10.1016/S1367-5931(00)00121-6; Herve C, 1997, NEUROPEPTIDES, V31, P237, DOI 10.1016/S0143-4179(97)90054-8; Kim EM, 1996, AM J PHYSIOL-REG I, V270, pR1019, DOI 10.1152/ajpregu.1996.270.5.R1019; Li JY, 2002, J BIOL CHEM, V277, P9069, DOI 10.1074/jbc.M110467200; MCLAUGHLIN CL, 1987, PHYSIOL BEHAV, V41, P465, DOI 10.1016/0031-9384(87)90082-5; Mzhavia N, 2002, BIOCHEM J, V361, P67, DOI 10.1042/0264-6021:3610067; Mzhavia N, 2001, J BIOL CHEM, V276, P6207, DOI 10.1074/jbc.M009067200; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; RONDEEL JMM, 1992, NEUROENDOCRINOLOGY, V56, P348, DOI 10.1159/000126248; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; Sanchez VC, 2004, J CLIN INVEST, V114, P357, DOI 10.1172/jci200421620; Sayah M, 2001, J NEUROCHEM, V76, P1833, DOI 10.1046/j.1471-4159.2001.00165.x; Seidah N.G., 2004, HDB PROTEOLYTIC ENZY, P1865; SEIDAH NG, 2004, HDB PROTEOLYTIC ENZY, P1861; Shen PJ, 1996, EUR J NEUROSCI, V8, P988, DOI 10.1111/j.1460-9568.1996.tb01586.x; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SIGAFOOS J, 1993, J ANAT, V183, P253; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Strand FL, 2003, PROG DRUG RES, V61, P1; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Svensson M, 2003, J PROTEOME RES, V2, P213, DOI 10.1021/pr020010u; Udupi V, 1997, ENDOCRINOLOGY, V138, P1959, DOI 10.1210/en.138.5.1959; VANHAASTEREN GAC, 1995, J ENDOCRINOL, V145, P143, DOI 10.1677/joe.0.1450143; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1998, J CELL SCI, V111, P877; Vilim FS, 1999, MOL PHARMACOL, V55, P804; Wei SW, 2004, J ENDOCRINOL, V180, P357, DOI 10.1677/joe.0.1800357; Yuan Q, 2004, OBES RES, V12, P1179, DOI 10.1038/oby.2004.147; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	44	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4451	4461		10.1074/jbc.M411178200	http://dx.doi.org/10.1074/jbc.M411178200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572367	hybrid			2022-12-25	WOS:000227096600056
J	Pan, WH; Mathews, W; Donohue, JM; Ramnaraine, ML; Lynch, C; Selski, DJ; Walsh, N; Cassady, AI; Clohisy, DR				Pan, WH; Mathews, W; Donohue, JM; Ramnaraine, ML; Lynch, C; Selski, DJ; Walsh, N; Cassady, AI; Clohisy, DR			Analysis of distinct tartrate-resistant acid phosphatase promoter regions in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; OSTEOCLAST DIFFERENTIATION; GENE; EXPRESSION; CLONING; BONE; RECEPTOR; TYPE-5; MOUSE	The tartrate-resistant acid phosphatase (TRAP) is present in multiple tissues, including kidney, liver, lung, spleen, and bone. Recent study of (TRAP) gene expression has provided evidence for distinct promoters within the (TRAP) gene, suggesting that the gene has alternative, tissue-preferred mRNA transcripts. Examination of endogenous (TRAP) exon 1B and 1C mRNA transcripts revealed tissue-preferred transcript abundance with increased exon 1B transcripts detected in liver and kidney and increased exon 1C transcripts detected in bone and spleen. In this investigation, we have made transgenic mice that express a marker gene driven by two candidate promoters, designated BC and C, within the (TRAP) gene. The BC and C promoters are 2.2 and 1.6 kb, respectively, measured from the translation initiation site. Evaluation of BC transgenic lines demonstrated robust expression in multiple tissues. In contrast, significant transgene expression was not detected in C transgenic lines. Evaluation of transgene mRNAs in BC transgenic lines revealed that virtually all expression was in the form of B transcripts, suggesting that the tissue-preferred pattern of endogenous (TRAP) was not replicated in the BC transgenic line. Likewise, osteoclastogenic cultures from BC, but not C, transgenic bone marrow cells expressed the transgene following receptor activator of NFkappaB ligand/macrophage colony-stimulating factor stimulation. In conclusion, when compared with the 2.2-kb BC portion of the (TRAP) promoter region, the 1.6-kb C portion does not account for significant gene expression in vivo or in vitro; production of the bone- and spleen-preferred (TRAP) C transcript must depend on regulatory elements outside of the 2.2-kb promoter. As the majority of currently investigated transcription factors that influence transcriptional regulation of osteoclast gene expression bind within the 1.6-kb C portion of the (TRAP) promoter, it is likely that transcription binding sites outside of the 2.2-kb region will have profound effects on regulation of the gene in vivo and in vitro.	Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN 55455 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Beth Israel Deaconess Medical Center; University of Queensland	Clohisy, DR (corresponding author), Univ Minnesota, Dept Orthoped Surg, 420 Delaware St,MMC 806, Minneapolis, MN 55455 USA.	clohi001@umn.edu	Cassady, Alan/AAY-2962-2021	Cassady, Alan/0000-0001-8585-5427	NCI NIH HHS [CA90434] Funding Source: Medline; NIAMS NIH HHS [AR47302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103; BOYCE BF, 1995, ENDOCRINOLOGY, V136, P5751, DOI 10.1210/en.136.12.5751; CASSADY AI, 1993, GENE, V130, P201, DOI 10.1016/0378-1119(93)90420-8; EKRYLANDER B, 1991, J BIOL CHEM, V266, P24684; Fleckenstein E, 1996, LEUKEMIA, V10, P637; Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207; Lewis VA, 2003, HUM GENE THER, V14, P1009, DOI 10.1089/104303403766682269; Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Matsumoto M, 2001, J BIOL CHEM, V276, P33086, DOI 10.1074/jbc.M104299200; Partington GA, 2004, BONE, V34, P237, DOI 10.1016/j.bone.2003.11.010; Ramnaraine M, 2003, CANCER RES, V63, P6847; REDDY SV, 1993, J BONE MINER RES, V8, P1263; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200; Vallet JL, 2000, DNA CELL BIOL, V19, P689, DOI 10.1089/10445490050199072; Walsh NC, 2003, GENE, V307, P111, DOI 10.1016/S0378-1119(03)00449-9	18	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4888	4893		10.1074/jbc.M409052200	http://dx.doi.org/10.1074/jbc.M409052200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590658	hybrid			2022-12-25	WOS:000227096600109
J	Tatsuka, M; Sato, S; Kitajima, S; Suto, S; Kawai, H; Miyauchi, M; Ogawa, I; Maeda, M; Ota, T; Takata, T				Tatsuka, M; Sato, S; Kitajima, S; Suto, S; Kawai, H; Miyauchi, M; Ogawa, I; Maeda, M; Ota, T; Takata, T			Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis	ONCOGENE			English	Article						oral cancer; susceptibility; polymorphism; Ras; Aurora-A	CENTROSOME AMPLIFICATION; LIM PROTEIN; KINASE; GENE; RAS; CANCER; CELLS; PHOSPHORYLATION; SUSCEPTIBILITY; IDENTIFICATION	Aurora kinases are known to play a key role in maintaining mitotic fidelity, and overexpression of aurora kinases has been noted in various tumors. Overexpression of aurora kinase activity is thought to promote cancer development through a loss of centrosome or chromosome number integrity. Here we observed augmentation of G12V-mutated HRAS-induced neoplastic transformation in BALB/c 3T3 A31-1-1 cells transfected with Aurora-A. Aurora-A-short hairpin RNA (shRNA) experiments showed that the expression level of Aurora-A determines susceptibility to transformation. Aurora-A gene amplification was noted in human patients with tongue or gingival squamous carcinoma (4/11). Amplification was observed even in pathologically normal epithelial tissue taken at sites distant from the tumors in two patients with tongue cancer. However, overexpression of Aurora-A mRNA was observed only within the tumors of all patients examined (11/11). Our data indicate that Aurora-A gene amplification and overexpression play a role in human carcinogenesis, largely due to the effect of Aurora-A on oncogenic cell growth, rather than a loss of maintenance of centrosomal or chromosomal integrity.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Sch Dent, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dent Hosp, Minami Ku, Hiroshima 7348553, Japan; Kanazawa Med Univ, Med Res Inst, Div Mol Oncol & Virol, Kanazawa, Ishikawa 9200293, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Kanazawa Medical University	Tatsuka, M (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	haruo@hiroshima-u.ac.jp		Kitajima, Shojiro/0000-0002-4000-0473; Kawai, Hidehiko/0000-0003-2213-7166				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; KAKUNAGA T, 1985, TRANSF ASS EST CELL; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tatsuka M, 1997, INT J CANCER, V71, P88, DOI 10.1002/(SICI)1097-0215(19970328)71:1<88::AID-IJC15>3.3.CO;2-8; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	22	92	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1122	1127		10.1038/sj.onc.1208293	http://dx.doi.org/10.1038/sj.onc.1208293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592510				2022-12-25	WOS:000226749200020
J	Andrechek, ER; White, D; Muller, WJ				Andrechek, ER; White, D; Muller, WJ			Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth	ONCOGENE			English	Article						ErbB2; mammary gland; mouse models; epithelium	TRANSGENIC MICE REVEALS; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; NEU ONCOGENE; LOBULOALVEOLAR DEVELOPMENT; EXPRESSION; AMPLIFICATION; NEU/ERBB-2; LACTATION; TUMORS	The ErbB2 receptor tyrosine kinase has been implicated as a critical growth factor receptor in both normal development and cancer. Amplification and overexpression of this receptor is observed in 20-30% of all human breast cancers and is inversely correlated with patient survival. Studies with transgenic mice have established that elevated expression of erbB2 in mammary epithelium can directly induce mammary carcinomas. Although these studies confirmed a role for ErbB2 in breast cancer induction, the precise role of ErbB2 in normal mammary gland development remained to be elucidated due to the embryonic lethality associated with the null mutation. Here, we demonstrate that the mammary-specific ablation of erbB2 through Cre-mediated recombination leads to a striking ductal elongation defect. In addition to the observed elongation defect, we noted that branching in the adult mammary gland was also reduced. Despite these perturbations in virgin mammary gland morphogenesis, targeted disruption of erbB2 had little impact on the ability of these animals to lactate. Taken together, these observations indicate that erbB2 plays a critical role in the initial stages of mammary gland morphogenesis.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Dept Biol, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada	McGill University; Royal Victoria Hospital; McMaster University; McMaster University	Muller, WJ (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca		Andrechek, Eran/0000-0002-8680-3423				Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2003, CANCER RES, V63, P4920; Andrechek ER, 2002, MOL CELL BIOL, V22, P4714, DOI 10.1128/MCB.22.13.4714-4722.2002; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHAILLET JR, 1995, GENE DEV, V9, P1177, DOI 10.1101/gad.9.10.1177; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Zhou H, 2001, ONCOGENE, V20, P6009, DOI 10.1038/sj.onc.1204830	22	49	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					932	937		10.1038/sj.onc.1208230	http://dx.doi.org/10.1038/sj.onc.1208230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580295				2022-12-25	WOS:000226577100018
J	Lebedeva, IV; Su, ZZ; Sarkar, D; Gopalkrishnan, RV; Waxman, S; Yacoub, A; Dent, P; Fisher, PB				Lebedeva, IV; Su, ZZ; Sarkar, D; Gopalkrishnan, RV; Waxman, S; Yacoub, A; Dent, P; Fisher, PB			Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis	ONCOGENE			English	Article						mda-7/IL-24; ROS; pancreatic cancer; apoptosis	DIFFERENTIATION-ASSOCIATED GENE-7; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; ARSENIC TRIOXIDE; GROWTH ARREST; MDA-7 IL-24; IN-VITRO; ENHANCES RADIOSENSITIVITY; TERMINAL DIFFERENTIATION; SELECTIVE APOPTOSIS	Pancreatic cancer is exceptionally aggressive with no long-term effective therapy. Current interventional approaches, including surgery, radiation and/or chemotherapy, have done little to quell the mortality associated with this malignancy. Subtraction hybridization identified a cancer-specific apoptosis-inducing cytokine gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/ IL-24), with a broad range of selective antitumor activity in diverse cancers both in vitro and in vivo in nude mice and recently in patients with advanced carcinomas and melanomas. Unlike most neoplasms, pancreatic cancers display innate resistance to mda-7/ IL-24-induced apoptosis, which correlates with a diminished capacity to convert mda-7/ IL-24 mRNA into protein. We presently demonstrate that this translational block can be reversed by treatment with agents that elevate reactive oxygen species (ROS). Induction of apoptosis in vitro and suppression of tumorigenesis in vivo in nude mice are induced in pancreatic cancers, irrespective of the status of their K-ras gene, only when tumor cells simultaneously express mda-7/ IL-24 and are treated with a ROS-inducer, such as arsenic trioxide (ARS), N-(4-hydroxyphenyl) retinamide (HPR) or dithiophene (NSC656240 (NSC)). In pancreatic cancer cells constitutively expressing mda-7/ IL-24 mRNA, a single treatment with arsenic trioxide, HPR or NSC656240 induces apoptosis, which correlates with production of MDA-7/IL-24 protein. The specificity of this action is documented by the ability of ROS inhibitors, including N-acetyl-L-cysteine and Tiron, to block this killing effect. Of potential clinical significance, similar treatment of normal cells does not elicit significant changes in growth nor does it induce apoptosis. Analysis of signal transduction changes in pancreatic carcinoma cells infected with Ad. mda-7 in combination with a ROS-inducer indicate that cell death correlates with modulation of discrete cassettes of multiple signaling pathways in a pancreatic cancer cell-specific manner, supporting global signaling dysregulation as a potential mediator of apoptosis induction. These findings suggest a promising combinatorial approach for safely promoting cell death in pancreatic tumors that provides a rational framework for developing a selective and effective therapy for this invariably fatal cancer.	Columbia Univ Coll Phys & Surg, Med Ctr, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Med Ctr, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Med Ctr, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Med Ctr, Dept Pathol, Herbert Irving Comprehens Canc Ctr, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [P01CA072955, R01CA088906, R01CA098712, R01CA097318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA98712, CA97318, CA72955, CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Kern SE, 2002, CANCER BIOL THER, V1, P607, DOI 10.4161/cbt.307; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Kulke Matthew H, 2002, Curr Treat Options Oncol, V3, P449, DOI 10.1007/s11864-002-0065-5; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEBEDEVA IV, 2004, IN PRESS MOL THER; Li XQ, 2003, PANCREAS, V27, P174, DOI 10.1097/00006676-200308000-00011; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; McKenna S, 2003, ONCOLOGIST, V8, P149, DOI 10.1634/theoncologist.8-2-149; Mhashilkar AM, 2003, MOL THER, V8, P207, DOI 10.1016/S1525-0016(03)00170-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miller WH, 2002, CANCER RES, V62, P3893; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Vuky J, 2002, INVEST NEW DRUG, V20, P327, DOI 10.1023/A:1016270206374; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Xia Y, 2002, INT J CANCER, V102, P7, DOI 10.1002/ijc.10664; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623; Zou CP, 2002, CANCER LETT, V180, P131, DOI 10.1016/S0304-3835(01)00864-3	50	62	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					585	596		10.1038/sj.onc.1208183	http://dx.doi.org/10.1038/sj.onc.1208183			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580305				2022-12-25	WOS:000226420400006
J	Gustafsson, AJ; Ingelman-Sundberg, H; Dzabic, M; Awasum, J; Hoa, NK; Ostenson, CG; Pierro, C; Tedeschi, P; Woolcott, O; Chiounan, S; Lund, PE; Larsson, O; Islam, MS				Gustafsson, AJ; Ingelman-Sundberg, H; Dzabic, M; Awasum, J; Hoa, NK; Ostenson, CG; Pierro, C; Tedeschi, P; Woolcott, O; Chiounan, S; Lund, PE; Larsson, O; Islam, MS			Ryanodine receptor-operated activation of TRP-like channels can trigger critical Ca2+ signaling events in pancreatic beta-cells	FASEB JOURNAL			English	Article						islets of Langerhans; Ca2+-induced Ca2+ release; transient receptor potential channels	CAPACITATIVE CALCIUM-ENTRY; SMOOTH-MUSCLE CELLS; ENDOPLASMIC-RETICULUM; K+ CHANNELS; RELEASE; STORE; CAFFEINE; INFLUX; FLUORESCENCE; MECHANISMS	There is little information available concerning the link between the ryanodine (RY) receptors and the downstream Ca2+ signaling events in beta-cells. In fura-2 loaded INS-1E cells, activation of RY receptors by 9-methyl 5,7-dibromoeudistomin D (MBED) caused a rapid rise of [Ca2+](i) followed by a plateau and repetitive [Ca2+](i) spikes on the plateau. The [Ca2+](i) plateau was abolished by omission of extracellular Ca2+ and by SKF 96365. In the presence of SKF 96365, MBED produced a transient increase of [Ca2+](i), which was abolished by thapsigargin. Activation of RY receptors caused Ca2+ entry even when the ER Ca2+ pool was depleted by thapsigargin. The [Ca2+](i) plateau was not inhibited by nimodipine or ruthenium red, but was inhibited by membrane depolarization, La3+, Gd3+, niflumic acid, and 2-aminoethoxydiphenyl borate, agents that inhibit the transient receptor potential channels. The [Ca2+](i) spikes were inhibited by nimodipine and ryanodine, indicating that they were due to Ca2+ influx through the voltage-gated Ca2+ channels and Ca2+-induced Ca2+ release (CICR). Activation of RY receptors depolarized membrane potential as measured by patch clamp. Thus, activation of RY receptors leads to coherent changes in Ca2+ signaling, which includes activation of TRP-like channels, membrane depolarization, activation of the voltage-gated Ca2+ channels and CICR.	Stockholm Soder Hosp, Dept Med, Karolinska Inst, Res Ctr, S-11883 Stockholm, Sweden; Astra Res Ctr AB, R&D, S-15185 Sodertalje, Sweden; Karolinska Univ Hosp, Dept Mol Med, S-15185 Sodertalje, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Gustafsson, AJ (corresponding author), Stockholm Soder Hosp, Dept Med, Karolinska Inst, Res Ctr, S-11883 Stockholm, Sweden.	amajab@ki.se	Woolcott, Orison O./AAQ-3440-2020; Islam, Shahidul/K-3295-2019	Woolcott, Orison O./0000-0003-2905-972X; Islam, Shahidul/0000-0002-9016-1881				Akiba Y, 2004, BIOCHEM BIOPH RES CO, V321, P219, DOI 10.1016/j.bbrc.2004.06.149; Bennett DL, 1998, BIOCHEM J, V329, P349; Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje; Dyachok O, 2001, J CELL SCI, V114, P2179; Graves TK, 2003, ENDOCRINOLOGY, V144, P3565, DOI 10.1210/en.2002-0104; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERRERO A, 1994, J GEN PHYSIOL, V104, P395, DOI 10.1085/jgp.104.2.395; Guler AD, 2002, J NEUROSCI, V22, P6408; Harper JL, 2003, BIOCHEM PHARMACOL, V65, P329, DOI 10.1016/S0006-2952(02)01488-0; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; ISLAM MS, 2000, CALCIUM MOL BASIS CA, P402; Janssen SWJ, 2002, J HISTOCHEM CYTOCHEM, V50, P789, DOI 10.1177/002215540205000605; Kang GX, 2003, J PHYSIOL-LONDON, V546, P175, DOI 10.1113/jphysiol.2002.029959; Kermode H, 1998, FEBS LETT, V431, P59, DOI 10.1016/S0014-5793(98)00725-X; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Leech CA, 1997, J BIOL CHEM, V272, P17987, DOI 10.1074/jbc.272.29.17987; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maechler P, 2000, IUBMB LIFE, V50, P27, DOI 10.1080/15216540050176557; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; Miura Y, 1997, J PHYSIOL-LONDON, V503, P387, DOI 10.1111/j.1469-7793.1997.387bh.x; Ohi Y, 2001, JPN J PHARMACOL, V85, P382, DOI 10.1254/jjp.85.382; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; Putney JW, 2003, CELL CALCIUM, V34, P339, DOI 10.1016/S0143-4160(03)00143-X; Putney JW, 2001, J CELL SCI, V114, P2223; Qian F, 2002, DIABETES, V51, pS183, DOI 10.2337/diabetes.51.2007.S183; ROE MW, 1993, J BIOL CHEM, V268, P9953; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Sakura H, 1997, DIABETOLOGIA, V40, P528, DOI 10.1007/s001250050711; Seino-Umeda A, 1998, EUR J PHARMACOL, V357, P261, DOI 10.1016/S0014-2999(98)00589-5; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Walker RL, 2002, AM J PHYSIOL-CELL PH, V283, pC1637, DOI 10.1152/ajpcell.00266.2002; WORLEY JF, 1994, J BIOL CHEM, V269, P32055; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	43	26	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					301	+		10.1096/fj.04-2621fje	http://dx.doi.org/10.1096/fj.04-2621fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15572434				2022-12-25	WOS:000225482100001
J	Lee, SC; Guan, HH; Wang, CH; Huang, WN; Tjong, SC; Chen, CJ; Wu, WG				Lee, SC; Guan, HH; Wang, CH; Huang, WN; Tjong, SC; Chen, CJ; Wu, WG			Structural basis of citrate-dependent and heparan sulfate-mediated cell surface retention of cobra cardiotoxin A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; VENOM; OLIGOSACCHARIDES; CONFORMATION; DESULFATION; DIVERSITY; RESONANCE; REVEALS	Anionic citrate is a major component of venom, but the role of venom citrate in toxicity other than its inhibitory effect on the cation-dependent action of venom toxins is poorly understood. By immobilizing Chinese hamster ovary cells in microcapillary tubes and heparin on sensor chips, we demonstrated that heparan sulfate-mediated cell retention of the major cardiotoxin (CTX) from the Taiwan cobra, CTX A3, near membrane surfaces is citrate- dependent. X-ray determination of a CTX A3-heparin hexasaccharide complex structure at 2.4 Angstrom resolution revealed a molecular mechanism for toxin retention in which heparin-induced conformational changes of CTX A3 lead to citrate-mediated dimerization. A citrate ion bound to Lys-23 and Lys-31 near the tip of loop II stabilizes hydrophobic contact of the CTX A3 homodimer at the functionally important loop I and II regions. Additionally, the heparin hexasaccharide interacts with five CTX A3 molecules in the crystal structure, providing another mechanism whereby the toxin establishes a complex network of interactions that result in a strong interaction with cell surfaces presenting heparan sulfate. Our results suggest a novel role for venom citrate in biological activity and reveal a structural model that explains cell retention of cobra CTX A3 through heparan sulfate-CTX interactions.	Natl Synchroton Radiat Res Ctr, Div Res, Biol Grp, Hsinchu 30077, Taiwan; Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 30043, Taiwan; Natl Tsing Hua Univ, Dept Phys, Hsinchu 30043, Taiwan; Natl Tsing Hua Univ, Struct Biol Program, Hsinchu 30043, Taiwan	National Synchrotron Radiation Research Center; National Tsing Hua University; National Tsing Hua University; National Tsing Hua University	Chen, CJ (corresponding author), Natl Synchroton Radiat Res Ctr, Div Res, Biol Grp, Hsinchu 30077, Taiwan.	cjchen@nsrrc.org.tw; wgwu@life.nthu.edu.tw	Chen, Chun-Jung/A-6880-2011	Chen, Chun-Jung/0000-0002-5157-4288				Batra R, 2001, NAT STRUCT BIOL, V8, P810, DOI 10.1038/nsb0901-810; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cadigan KM, 2002, SEMIN CELL DEV BIOL, V13, P83, DOI 10.1016/S1084-9521(02)00014-9; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; Edward Conrad H., 1998, HEPARIN BINDING PROT, P203; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fernig D G, 2001, Methods Mol Biol, V171, P505; Forouhar F, 2003, J BIOL CHEM, V278, P21980, DOI 10.1074/jbc.M208650200; FRANCIS B, 1992, TOXICON, V30, P1239, DOI 10.1016/0041-0101(92)90440-G; Gustafsson M, 2004, CELL MOL LIFE SCI, V61, P4, DOI 10.1007/s00018-003-3262-x; HOMANS SW, 1990, BIOCHEMISTRY-US, V29, P9110, DOI 10.1021/bi00491a003; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lai M.K, 1972, Journal Formosan med Ass, V71, P328; LANDER A, 1999, CELL SURFACE PROTEOG; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; LO TB, 1966, J CHIN CHEM SOC-TAIP, V13, P25, DOI 10.1002/jccs.196600004; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; Mikhailov D, 1997, BIOCHEM J, V328, P51, DOI 10.1042/bj3280051; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Odell GV, 1999, TOXICON, V37, P407, DOI 10.1016/S0041-0101(98)00194-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel HV, 1997, J BIOL CHEM, V272, P1484, DOI 10.1074/jbc.272.32.20185; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Sue SC, 2002, J BIOL CHEM, V277, P2666, DOI 10.1074/jbc.M104887200; Sue SC, 2001, BIOCHEMISTRY-US, V40, P10436, DOI 10.1021/bi010847n; TSENG LF, 1968, TOXICOL APPL PHARM, V12, P526, DOI 10.1016/0041-008X(68)90159-2; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Vyas AA, 1997, J BIOL CHEM, V272, P9661, DOI 10.1074/jbc.272.15.9661; Wu WG, 1997, J TOXICOL-TOXIN REV, V16, P115, DOI 10.3109/15569549709016451; Wu WG, 1998, TRENDS CARDIOVAS MED, V8, P270, DOI 10.1016/S1050-1738(98)00019-X; YAMADA S, 1995, J BIOL CHEM, V270, P8696	46	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9567	9577		10.1074/jbc.M412398200	http://dx.doi.org/10.1074/jbc.M412398200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590643	hybrid			2022-12-25	WOS:000227453100111
J	Gentry, HR; Singer, AU; Betts, L; Yang, C; Ferrara, JD; Sondek, J; Parise, LV				Gentry, HR; Singer, AU; Betts, L; Yang, C; Ferrara, JD; Sondek, J; Parise, LV			Structural and biochemical characterization of CIB1 delineates a new family of EF-hand-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-BINDING PROTEIN; CALCIUM-BINDING; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; CYTOPLASMIC DOMAIN; DNA-BINDING; RECOVERIN; INTERACTS; KINASE; SENSOR	CIB1 ( CIB) is an EF- hand- containing protein that binds multiple effector proteins, including the platelet alphaIIbbeta3 integrin and several serine/ threonine kinases and potentially modulates their function. The crystal structure for Ca2+- bound CIB1 has been determined at 2.0 Angstrom resolution and reveals a compact alpha- helical protein containing four EF- hands, the last two of which bind calcium ions in the standard fashion seen in many other EF- hand proteins. CIB1 shares high structural similarity with calcineurin B and the neuronal calcium sensor ( NCS) family of EF- hand- containing proteins. Most importantly, like calcineurin B and NCS proteins, which possess a large hydrophobic pocket necessary for ligand binding, CIB1 contains a hydrophobic pocket that has been implicated in ligand binding by previous mutational analysis. However, unlike several NCS proteins, Ca2+- bound CIB1 is largely monomeric whether bound to a relevant peptide ligand or ligand- free. Differences in structure, oligomeric state, and phylogeny define a new family of CIB1- related proteins that extends from arthropods to humans.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; MSC Inc, Rigaku, The Woodlands, TX 77381 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Rigaku Corporation	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	sondek@med.unc.edu		Sondek, John/0000-0002-1127-8310	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040, R01GM062299] Funding Source: NIH RePORTER; NHLBI NIH HHS [2-P01-HL45100] Funding Source: Medline; NIGMS NIH HHS [GM62299, 5-T32-GM07040-29] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barry WT, 2002, J BIOL CHEM, V277, P28877, DOI 10.1074/jbc.M202983200; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgoyne RD, 2001, BIOCHEM J, V353, P1; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; Hollenbach AD, 2002, BBA-GENE STRUCT EXPR, V1574, P321, DOI 10.1016/S0167-4781(02)00230-0; Hwang PM, 2000, J MOL RECOGNIT, V13, P83, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<83::AID-JMR491>3.0.CO;2-A; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kudla J, 1999, P NATL ACAD SCI USA, V96, P4718, DOI 10.1073/pnas.96.8.4718; Ma S, 2003, MOL CANCER RES, V1, P376; Michiels J, 2002, TRENDS MICROBIOL, V10, P87, DOI 10.1016/S0966-842X(01)02284-3; Nagae M, 2003, J BIOL CHEM, V278, P42240, DOI 10.1074/jbc.M303630200; Naik MU, 2003, BLOOD, V102, P3629, DOI 10.1182/blood-2003-05-1703; Naik UP, 2003, BLOOD, V102, P1355, DOI 10.1182/blood-2003-02-0591; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; Osawa M, 2001, J BIOL CHEM, V276, P41005, DOI 10.1074/jbc.M105842200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; PARKS TD, 1995, VIROLOGY, V210, P194, DOI 10.1006/viro.1995.1331; Seki N, 1999, BBA-GENE STRUCT EXPR, V1444, P143, DOI 10.1016/S0167-4781(98)00253-X; Senin II, 2002, ADV EXP MED BIOL, V514, P69; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsuboi S, 2002, J BIOL CHEM, V277, P1919, DOI 10.1074/jbc.M110643200; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yamniuk AP, 2004, BIOCHEMISTRY-US, V43, P2558, DOI 10.1021/bi035432b; Yang C, 2003, ACTA CRYSTALLOGR D, V59, P1943, DOI 10.1107/S0907444903018547; Yap Kyoko L, 2002, Methods Mol Biol, V173, P317; Yuan WP, 2003, BLOOD, V102, p160A; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5	43	84	91	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8407	8415		10.1074/jbc.M411515200	http://dx.doi.org/10.1074/jbc.M411515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15574431	Green Published, hybrid			2022-12-25	WOS:000227395700117
J	Desai, N; Lee, JH; Upadhya, R; Chu, Y; Moir, RD; Willis, IM				Desai, N; Lee, JH; Upadhya, R; Chu, Y; Moir, RD; Willis, IM			Two steps in Maf1-dependent repression of transcription by RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IN-VIVO; LIMITING STEP; FACTOR TFIIIB; HUMAN-CELLS; YEAST; DNA; PROMOTERS; SUBUNIT; BINDING	In Saccharomyces cerevisiae, Maf1 is essential for mediating the repression of transcription by RNA polymerase (pol) III in response to diverse cellular conditions. These conditions activate distinct signaling pathways that converge at or above Maf1. Thus, Maf1-dependent repression is thought to involve a common set of downstream inhibitory effects on the pol III machinery. Here we provide support for this view and define two steps in Maf1-dependent transcriptional repression. We show that chlorpromazine (CPZ)-induced repression of pol III transcription is achieved by inhibiting de novo assembly of transcription factor (TF) IIIB onto DNA as well as the recruitment of pol III to preassembled TFIIIB-DNA complexes. Additionally Brf1 was identified as a target of repression in extracts of CPZ-treated cells. Maf1-Brf1 and Maf1-pol III interactions were implicated in the inhibition of TFIIIB-DNA complex assembly and polymerase recruitment by recombinant Maf1. Co-immunoprecipitation experiments confirmed these interactions in yeast extracts and demonstrated that Maf1 does not differentially sequester Brf1 or pol III under repressing conditions. The results suggest that Maf1 functions by a non-stoichiometric mechanism to repress pol III transcription.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Willis, IM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	willis@aecom.yu.edu		Willis, Ian/0000-0001-6599-2395	NIGMS NIH HHS [GM42728, GM60631] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042728, R01GM060631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; Cloutier TE, 2001, P NATL ACAD SCI USA, V98, P9581, DOI 10.1073/pnas.161292298; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; Fairley JA, 2003, EMBO J, V22, P5841, DOI 10.1093/emboj/cdg544; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Huet J, 1996, METHOD ENZYMOL, V273, P249; HUET J, 1994, NUCLEIC ACIDS RES, V22, P2282, DOI 10.1093/nar/22.12.2282; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2004, ADV PROTEIN CHEM, V67, P93; Moir RD, 2002, J BIOL CHEM, V277, P694, DOI 10.1074/jbc.M108924200; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pluta K, 2001, MOL CELL BIOL, V21, P5031, DOI 10.1128/MCB.21.15.5031-5040.2001; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; Upadhya R, 2002, MOL CELL, V10, P1489, DOI 10.1016/S1097-2765(02)00787-6; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; White RJ, 2004, EUR J CANCER, V40, P21, DOI 10.1016/j.ejca.2003.09.027; Willis IM, 2004, PROG NUCLEIC ACID RE, V77, P323, DOI 10.1016/S0079-6603(04)77009-9; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	35	84	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6455	6462		10.1074/jbc.M412375200	http://dx.doi.org/10.1074/jbc.M412375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590667	hybrid			2022-12-25	WOS:000227332700027
J	Krasnoselsky, AL; Whiteford, CC; Wei, JS; Bilke, S; Westermann, F; Chen, QR; Khan, J				Krasnoselsky, AL; Whiteford, CC; Wei, JS; Bilke, S; Westermann, F; Chen, QR; Khan, J			Altered expression of cell cycle genes distinguishes aggressive neuroblastoma	ONCOGENE			English	Article						cDNA microarray; gene expression; principal component analysis; neuroblastoma; MYCN; gene ontology	PROLIFERATIVE ACTIVITY; MYCN; AMPLIFICATION; DIFFERENTIATION; IDENTIFICATION; PREDICTION; INDUCTION	In this study, gene expression pro. ling was performed on 103 neuroblastoma (NB) tumors, stages 1-4 with and without MYCN amplification, using cDNA microarrays containing 42578 elements. Using principal component analysis (PCA) to analyse the relationships among these samples, we confirm that the global patterns of gene expression reflect the phenotype of the tumors. To explore the biological processes that may contribute to increasing aggressive phenotype of the tumors, we utilized a statistical approach based on PCA. We identified a specific subset of the cell cycle and/or chromosome segregation genes that distinguish stage 4 NB tumors from all lower stage tumors, including stage 3. Furthermore, the control of the kinetochore assembly emerges from the Gene Ontology analysis as one of the key biological processes associated with an aggressive NB phenotype. Finally, we establish that these genes are further upregulated in the most aggressive MYCN-amplified tumors.	Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Ctr Adv Technol, Gaithersburg, MD 20877 USA; German Canc Res Ctr, Dept Tumour Genet B030, D-69120 Heidelberg, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; German Cancer Research Center (DKFZ)	Khan, J (corresponding author), Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Ctr Adv Technol, Room 134E,8717 Grovemont Circle, Gaithersburg, MD 20877 USA.	khanjav@mail.nih.gov	Westermann, Frank/F-7509-2013; Khan, Javed/P-9157-2014		NATIONAL CANCER INSTITUTE [ZIASC010366, Z01SC010366] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaminos M, 2003, CANCER RES, V63, P4538; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; COHN SL, 1990, AM J PATHOL, V136, P1043; DOMINICI C, 1992, ANTICANCER RES, V12, P59; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; McArdle L, 2004, CARCINOGENESIS, V25, P1599, DOI 10.1093/carcin/bgh173; Mora J, 2003, CANCER LETT, V197, P119, DOI 10.1016/S0304-3835(03)00094-6; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; Sugihara E, 2004, ONCOGENE, V23, P1005, DOI 10.1038/sj.onc.1207216; Takita J, 2004, GENE CHROMOSOME CANC, V40, P120, DOI 10.1002/gcc.20021; Tonini GP, 2003, CANCER LETT, V197, P69, DOI 10.1016/S0304-3835(03)00081-8; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Wei J.S., 2002, DNA MICROARRAYS MOL, P110; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Zar JH, 1999, BIOSTATISTICAL ANAL; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	32	50	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1533	1541		10.1038/sj.onc.1208341	http://dx.doi.org/10.1038/sj.onc.1208341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15592497				2022-12-25	WOS:000227218200006
J	Li, WJ; Marshall, C; Mei, LJ; Schmults, C; Dans, M; Seykora, J				Li, WJ; Marshall, C; Mei, LJ; Schmults, C; Dans, M; Seykora, J			Srcasm modulates EGF and Src-kinase signaling in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FYN TYROSINE KINASE; C-SRC; FAMILY KINASES; PROTEIN-KINASE; TUMOR PROMOTION; FACTOR RECEPTOR; ACTIVATION; DIFFERENTIATION; CELLS	The Src-activating and signaling molecule (Srcasm) is a recently described activator and substrate of Src-family tyrosine kinases (SFKs). When phosphorylated at specific tyrosines, Srcasm associates with Grb2 and p85, the regulatory subunit of phosphoinositide 3-kinase; however, little is known about the role of Srcasm in cellular signaling. Data presented here demonstrate that epidermal growth factor (EGF) receptor ligands promote the tyrosine phosphorylation of endogenous and adenovirally transduced Srcasm in keratinocytes, and that increased levels of Srcasm activate endogenous SFKs, with a preference for Fyn and Src. In addition, Srcasm potentiates EGF-dependent signals transmitted by SFKs in keratinocytes. Tyrosine phosphorylation of Srcasm is dependent on growth factors and the activity of EGFR and SFKs. Increased Srcasm expression enhances p44/42 mitogen-activated protein kinase activity and Elk-l-dependent transcriptional events. Elevated Srcasm levels inhibit keratinocyte proliferation while promoting specific aspects of keratinocyte differentiation. Lastly, Srcasm levels are decreased in human cutaneous neoplasia. Collectively, these data demonstrate that Srcasm plays a role in linking EGF receptor- and SFK-dependent signaling to differentiation in keratinocytes.	Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	University of Pennsylvania	Seykora, J (corresponding author), Univ Penn, Sch Med, Dept Dermatol, 211A Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	john.seykora@uphs.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051380, P30AR057217, K08AR047597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA98101] Funding Source: Medline; NIAMS NIH HHS [P30 AR057217, K08 AR047597, R01 AR051380, K08-AR47597] Funding Source: Medline; NIDDK NIH HHS [P30 DK050306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BANKSSCHLEGEL SP, 1986, J BIOL CHEM, V261, P4359; Bernal-Mizrachi E, 2001, AM J PHYSIOL-ENDOC M, V281, pE1286, DOI 10.1152/ajpendo.2001.281.6.E1286; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; FREEDBERG LEA, 1999, DERMATOLOGY GEN MED, P823; Gniadecki R, 1998, BIOCHEM PHARMACOL, V55, P499, DOI 10.1016/S0006-2952(97)00499-1; Hansen LA, 2000, CANCER RES, V60, P3328; Katoh Y, 2004, J BIOL CHEM, V279, P24435, DOI 10.1074/jbc.M400059200; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; Maruyama T, 1999, ENDOCRINOLOGY, V140, P2632, DOI 10.1210/en.140.6.2632; Matsumoto T, 2003, CANCER RES, V63, P4819; Matsumoto T, 2002, MOL CARCINOGEN, V33, P146, DOI 10.1002/mc.10030; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; PARK JS, 1993, ONCOGENE, V8, P2627; RAO VN, 1994, ONCOGENE, V9, P1855; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shimizu Y, 2003, ONCOGENE, V22, P884, DOI 10.1038/sj.onc.1206174; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; Wakita N, 1999, J BIOL CHEM, V274, P37285, DOI 10.1074/jbc.274.52.37285; Walker JL, 2002, DEV DYNAM, V224, P361, DOI 10.1002/dvdy.10115; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; [No title captured]	48	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6036	6046		10.1074/jbc.M406546200	http://dx.doi.org/10.1074/jbc.M406546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579470	hybrid			2022-12-25	WOS:000227217100109
J	Rencurel, F; Stenhouse, A; Hawley, SA; Friedberg, T; Hardie, DG; Sutherland, C; Wolf, CR				Rencurel, F; Stenhouse, A; Hawley, SA; Friedberg, T; Hardie, DG; Sutherland, C; Wolf, CR			AMP-activated protein kinase mediates phenobarbital induction of CYP2B gene expression in hepatocytes and a newly derived human hepatoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; DRUG-METABOLIZING-ENZYMES; ENHANCER MODULE; HUMAN LIVER; RAT-LIVER; CAR; CYTOCHROME-P-450; INVOLVEMENT; PHOSPHORYLATION; ISOFORMS	Phenobarbital (PB) administration is known to trigger pleiotropic responses, including liver hypertrophy, tumor promotion, and induction of genes encoding drug-metabolizing enzymes. The induction of human CYP2B6 and the rat (CYP2B1) and mouse (CYP2B1) homologues by PB is mediated by the nuclear receptor constitutive androstane receptor (CAR). The study of CYP2B gene regulation and CAR activity by PB has been difficult due to the lack of a cellular model. In this study, we describe a novel differentiated human hepatoma cell line (WGA), derived from HepG2, which expresses CYP2B6 and CAR. WGA cells represent a powerful system to study the regulation of CYP2B6 gene expression by PB. There is evidence that CAR activity is regulated by phosphorylation and that regulation of some CYP genes depends on the nutritional status of cells. The AMP-activated protein kinase (AMPK) functions as an energy sensor and is activated when cells experience energy-depleting stresses. In this report, we show that addition of 5-amino-imidazole carboxamide riboside, an AMPK activator, to WGA and human hepatocytes induces CYP2B6 gene expression. Expression of a constitutively active form of AMPK mimics the PB induction of CYP2B6 and CYP2B1 gene expression. Conversely, the expression of a dominant negative form of AMPK inhibits the induction of these genes by PB. Finally, we demonstrate, for the first time, that AMPK activity increases in cells cultured with PB. Our data strongly support a role for AMPK in the PB induction of CYP2B gene expression and provide new insights into the regulation of gene expression by barbiturate drugs.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Dundee, Ninewells Hosp, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee; University of Dundee; University of Dundee	Wolf, CR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Level 5, Dundee DD1 9SY, Scotland.	roland.wolf@cancer.org.uk	Hardie, David/Z-1979-2019	Sutherland, Calum/0000-0003-4398-7434; Wolf, Charles Roland/0000-0002-6969-0113; Hardie, Grahame/0000-0002-8373-7379				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; ARMBRUSTER L, 1992, DIFFERENTIATION, V50, P25, DOI 10.1111/j.1432-0436.1992.tb00482.x; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BAFFET G, 1995, BIOCHEM BIOPH RES CO, V216, P947, DOI 10.1006/bbrc.1995.2712; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLOUIN RA, 1993, ARCH BIOCHEM BIOPHYS, V303, P313, DOI 10.1006/abbi.1993.1289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conney AH, 2003, ANNU REV PHARMACOL, V43, P1, DOI 10.1146/annurev.pharmtox.43.100901.135754; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X; Ferre P, 2003, BIOCHEM SOC T, V31, P220, DOI 10.1042/bst0310220; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; Frueh FW, 1997, MOL PHARMACOL, V51, P363; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Galisteo M, 1999, J PHARMACOL EXP THER, V290, P1270; Gomez-Lechon MJ, 2001, EUR J BIOCHEM, V268, P1448, DOI 10.1046/j.1432-1327.2001.02011.x; Goodwin B, 2001, MOL PHARMACOL, V60, P427; GROBHOLZ R, 1993, CANCER RES, V53, P4204; Guillouzo A, 1997, J HEPATOL, V26, P73, DOI 10.1016/S0168-8278(97)80499-0; Hardie DG, 2000, METH MOL B, V99, P63; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hodges NJ, 2000, CARCINOGENESIS, V21, P2041, DOI 10.1093/carcin/21.11.2041; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; KARVONVN I, 1987, DIABETES RES, P195; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; LeCluyse EL, 2001, EUR J PHARM SCI, V13, P343, DOI 10.1016/S0928-0987(01)00135-X; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Longnus SL, 2003, AM J PHYSIOL-REG I, V284, pR936, DOI 10.1152/ajpregu.00319.2002; MAENPAA PH, 1968, SCIENCE, V161, P1253, DOI 10.1126/science.161.3847.1253; Marc N, 2000, EUR J BIOCHEM, V267, P963, DOI 10.1046/j.1432-1327.2000.01083.x; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; PORTER TD, 1991, J BIOL CHEM, V266, P13469; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; SABINA RL, 1985, J BIOL CHEM, V260, P6107; Sahi J, 2003, DRUG METAB DISPOS, V31, P439, DOI 10.1124/dmd.31.4.439; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Sidhu JS, 1997, J PHARMACOL EXP THER, V282, P1122; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; Wang HY, 2003, J BIOL CHEM, V278, P31547, DOI 10.1074/jbc.M212532200; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xiong H, 2002, DRUG METAB DISPOS, V30, P918, DOI 10.1124/dmd.30.8.918; Yoshida Y, 1996, BIOCHEM BIOPH RES CO, V229, P182, DOI 10.1006/bbrc.1996.1777; Zangar RC, 1997, ARCH BIOCHEM BIOPHYS, V337, P217, DOI 10.1006/abbi.1996.9785	52	87	90	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4367	4373		10.1074/jbc.M412711200	http://dx.doi.org/10.1074/jbc.M412711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572372	hybrid			2022-12-25	WOS:000227096600046
J	Jazag, A; Ijichi, H; Kanai, F; Imamura, T; Guleng, B; Ohta, M; Imamura, J; Tanaka, Y; Tateishi, K; Ikenoue, T; Kawakami, T; Arakawa, Y; Miyagishi, M; Taira, K; Kawabe, T; Omata, M				Jazag, A; Ijichi, H; Kanai, F; Imamura, T; Guleng, B; Ohta, M; Imamura, J; Tanaka, Y; Tateishi, K; Ikenoue, T; Kawakami, T; Arakawa, Y; Miyagishi, M; Taira, K; Kawabe, T; Omata, M			Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta	ONCOGENE			English	Article						Smad4; TGF-beta; stable RNAi; cDNA microarray; pancreatic cancer	TUMOR-SUPPRESSOR GENE; MAMMALIAN-CELLS; MICROSATELLITE INSTABILITY; SIGNALING PATHWAY; RECEPTOR; TARGETS; DPC4; INHIBITION; PROMOTER; MUTATION	The transforming growth factor-beta (TGF-beta)-Smad signaling pathway inhibits the growth of human epithelial cells and plays a role in tumor suppression. The Smad4 gene is mutated or deleted in 50% of pancreatic cancers. In this study, we succeeded in establishing Smad4 knockdown (S4KD) pancreatic cancer cell lines using the stable RNA interference (RNAi) method. Smad4 protein expression was reduced dramatically and TGF-beta-Smad signaling was markedly inhibited in the S4KD cell lines. The S4KD and control cells were stimulated with TGF-beta and analysed using a cDNA microarray that contained 3756 genes, in order to screen for target molecules downstream of TGF-beta. The microarray analysis revealed that 187 S4KD genes and 155 genes in the control cells were regulated immediately upon TGF-beta stimulation. Quantitative RT-PCR analysis on several of these genes produced results that corroborated the outcome of the microarray analysis. Most of the genes in the S4KD and control cells identified by the array differed, which suggests signaling pathways that differ according to Smad4 status. Of the identified genes, 246 have not been reported previously as genes that lie downstream of TGF-beta. Genes that are involved in cell proliferation, adhesion, and motility were found to be regulated differentially with respect to S4KD and control cells. Cell migration induced by TGF-beta was inhibited in the S4KD cells, which might be associated with a different regulation of integrin beta7. The knock down of a specific gene using stable RNAi appears to be a promising tool for analysing endogenous gene function.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 1138655, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba 2600870, Japan; Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Tokyo 1600023, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Ibaraki 3058562, Japan	University of Tokyo; University of Tokyo; Chiba University; Asahi Life Foundation; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Ijichi, Hideaki/AAE-6692-2022; IJICHI, Hideaki/AGZ-2874-2022; Miyagishi, Makoto/L-8174-2016; Ijichi, Hideaki/V-2720-2019	Ijichi, Hideaki/0000-0002-2379-7986; IJICHI, Hideaki/0000-0002-2379-7986; Miyagishi, Makoto/0000-0001-7654-3616; Tanaka, Yasuo/0000-0002-2917-3365				Akiyoshi S, 2001, JPN J CANCER RES, V92, P257, DOI 10.1111/j.1349-7006.2001.tb01090.x; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Grau AM, 1997, CANCER RES, V57, P3929; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Lim SP, 1998, IMMUNOGENETICS, V48, P184, DOI 10.1007/s002510050422; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MORTON DM, 1995, CANCER RES, V55, P2596; Schutte M, 1996, CANCER RES, V56, P2527; Togo G, 1996, CANCER RES, V56, P5620; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wang D, 2000, CANCER RES, V60, P4507; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	36	60	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					662	671		10.1038/sj.onc.1208102	http://dx.doi.org/10.1038/sj.onc.1208102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15592526				2022-12-25	WOS:000226420400013
J	Marreiros, A; Dudgeon, K; Dao, V; Grimm, MO; Czolij, R; Crossley, M; Jackson, P				Marreiros, A; Dudgeon, K; Dao, V; Grimm, MO; Czolij, R; Crossley, M; Jackson, P			KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells	ONCOGENE			English	Article						KAI1; transcription factor; metastasis suppressor; prostate cancer	METASTASIS-SUPPRESSOR GENE; FREQUENT DOWN-REGULATION; PROSTATE-CANCER; TRANSCRIPTION FACTOR; BLADDER-CANCER; HUMAN-MELANOMA; MESSENGER-RNA; MUTANT P53; C-JUN; LINES	A molecular mechanism to explain reduced KAI1 expression in invasive and metastatic tumour cells remains elusive. In this report, we extend an earlier study in bladder cells to confirm that a 76 bp region of the KAI1 promoter ( residues - 922 to - 847), with binding motifs for p53, AP1 and AP2, is required for high level activity of a KAI1 reporter in prostate cancer cell lines. Gel shift and supershift experiments supported binding of p53, junB and heterodimers of AP2alpha/AP2gamma or AP2beta/AP2gamma to this sequence. Introduction of mutations into specific motifs demonstrated an essential requirement for p53 and junB to reporter activity, and that functional synergy between these two factors enhanced activity. A further elevation of reporter activity required AP2. Roles of individual p53, junB and AP2 proteins, as well as functional synergy between p53 and junB, were confirmed in transfection experiments. Western blotting analysis showed that an absence of wild-type p53, and/or a loss of junB and AP2 protein expression, correlated with downregulation of KAI1 mRNA levels in a series of prostate cancer cell lines. A loss of p53 function and/or expression of junB, combined with reduced expression of specific AP2 proteins may underly downregulated KAI1 expression in tumour cells.	Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia; Univ New S Wales, Sch Med, Kensington, NSW 2033, Australia; Univ Dusseldorf, Dept Urol, D-4000 Dusseldorf, Germany; Univ Sydney, Sch Mol & Microbial Sci, Camperdown, NSW, Australia	University of New South Wales Sydney; Heinrich Heine University Dusseldorf; University of Sydney	Jackson, P (corresponding author), Prince Wales Hosp, Oncol Res Ctr, Level 2 Clin Sci Bldg,Barker St, Randwick, NSW 2031, Australia.	paul.jackson@unsw.edu.au	Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642; Grimm, Marc-Oliver/0000-0003-3084-8654				Akita H, 2000, CANCER LETT, V153, P79, DOI 10.1016/S0304-3835(00)00352-9; Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707; Bosher JM, 1996, ONCOGENE, V13, P1701; BUTZ K, 1995, ONCOGENE, V10, P927; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1997, GENOMICS, V41, P25, DOI 10.1006/geno.1997.4618; Dong JT, 1996, CANCER RES, V56, P4387; Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580; Gao AC, 2003, PROSTATE, V57, P256, DOI 10.1002/pros.10309; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jackson P, 2003, PROSTATE CANCER P D, V6, P174, DOI 10.1038/sj.pcan.4500634; Jackson P, 2002, UROL ONCOL, V7, P99, DOI 10.1016/S1078-1439(01)00175-2; Jackson P, 2000, CANCER LETT, V157, P169, DOI 10.1016/S0304-3835(00)00483-3; Jackson P, 2000, BIOCHEM BIOPH RES CO, V278, P499, DOI 10.1006/bbrc.2000.3799; JACKSON P, 2004, IN PRESS PROGR BLADD; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; Lijovic M, 2002, CANCER DETECT PREV, V26, P69, DOI 10.1016/S0361-090X(02)00012-0; Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801; Lombardi DP, 1999, CANCER RES, V59, P5724; Marreiros A, 2003, GENE, V302, P155, DOI 10.1016/S0378-1119(02)01101-0; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mashimo T, 2000, BIOCHEM BIOPH RES CO, V274, P370, DOI 10.1006/bbrc.2000.3139; MAY E, 1991, ONCOGENE, V6, P1363; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Ow K, 2000, J PATHOL, V191, P39, DOI 10.1002/(SICI)1096-9896(200005)191:1<39::AID-PATH580>3.0.CO;2-K; Ribeiro JCC, 1997, INT J RADIAT BIOL, V72, P11, DOI 10.1080/095530097143491; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schindl M, 2001, CANCER LETT, V162, P261, DOI 10.1016/S0304-3835(00)00672-8; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shinohara T, 2001, CANCER RES, V61, P673; Tagawa K, 1999, JPN J CANCER RES, V90, P970, DOI 10.1111/j.1349-7006.1999.tb00843.x; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Vandel L, 1996, MOL CELL BIOL, V16, P1881; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yardley G, 1998, FEBS LETT, V430, P171, DOI 10.1016/S0014-5793(98)00650-4; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2002, BREAST CANCER RES TR, V71, P47, DOI 10.1023/A:1013378113916	46	64	72	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					637	649		10.1038/sj.onc.1208216	http://dx.doi.org/10.1038/sj.onc.1208216			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580298				2022-12-25	WOS:000226420400011
J	Edberg, DD; Adkins, JN; Springer, DL; Reeves, R				Edberg, DD; Adkins, JN; Springer, DL; Reeves, R			Dynamic and differential in vivo modifications of the isoform HMGA1a and HMGA1b chromatin proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; DNA-BINDING DOMAIN; MASS-SPECTROMETRY; CHROMOSOMAL-PROTEINS; POSTTRANSLATIONAL MODIFICATIONS; LIQUID-CHROMATOGRAPHY; PHOSPHORYLATION SITES; PROGRESSION MARKER; PROSTATE-CANCER; LEUKEMIC-CELLS	Most naturally occurring mammalian cancers and immortalized tissue culture cell lines share a common characteristic, the overexpression of full-length HMGA1 (high mobility group A1) proteins. The HMGA1 protooncogene codes for two closely related isoform proteins, HMGA1a and HMGA1b, and causes cancerous cellular transformation when overexpressed in either transgenic mice or "normal" cultured cell lines. Previous work has suggested that the in vivo types and patterns of the HMGA1 post-translational modifications (PTMs) differ between normal and malignant cells. The present study focuses on the important question of whether HMGA1a and HMGA1b proteins isolated from the same cell type have identical or different PTM patterns and also whether these isoform patterns differ between nonmalignant and malignant cells. Two independent mass spectrometry methods were used to identify the types of PTMs found on specific amino acid residues on the endogenous HMGA1a and HMGA1b proteins isolated from a non-metastatic human mammary epithelial cell line, MCF-7, and a malignant metastatic cell line derived from MCF-7 cells that overexpressed the transgenic HMGA1a protein. Although some of the PTMs were the same on both the HMGA1a and HMGA1b proteins isolated from a given cell type, many other modifications were present on one but not the other isoform. Furthermore, we demonstrate that both HMGA1 isoforms are di-methylated on arginine and lysine residues. Most importantly, however, the PTM patterns on the endogenous HMGA1a and HMGA1b proteins isolated from non-metastatic and metastatic cells were consistently different, suggesting that the isoforms likely exhibit differences in their biological functions/activities in these cell types.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA	Washington State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Reeves, R (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	reevesr@wsu.edu	Adkins, Joshua/B-9881-2013	Adkins, Joshua/0000-0003-0399-0700	NIGMS NIH HHS [GM-46352] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe N, 2003, J GASTROENTEROL, V38, P1144, DOI 10.1007/s00535-003-1221-9; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Chong BE, 1998, RAPID COMMUN MASS SP, V12, P1986, DOI 10.1002/(SICI)1097-0231(19981230)12:24<1986::AID-RCM419>3.3.CO;2-8; Diana F, 2001, J BIOL CHEM, V276, P11354, DOI 10.1074/jbc.M009521200; Edberg DD, 2004, BIOCHEMISTRY-US, V43, P11500, DOI 10.1021/bi049833i; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fedele M, 2001, CANCER RES, V61, P4583; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Galande S, 2002, CURR CANCER DRUG TAR, V2, P157, DOI 10.2174/1568009023333917; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JANSEN E, 1999, GENE THER MOL BIOL, V3, P387; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; LUND T, 1985, FEBS LETT, V180, P275, DOI 10.1016/0014-5793(85)81085-1; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Nguyen CT, 2002, CANCER RES, V62, P6456; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Reeves R, 1995, Prog Cell Cycle Res, V1, P339; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; REEVES R, 2004, CHROMATIN STRUCTURE, P155; Reeves Raymond, 2003, Prog Cell Cycle Res, V5, P279; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Sgarra R, 2004, FEBS LETT, V574, P1, DOI 10.1016/j.febslet.2004.08.013; Sgarra R, 2003, CELL DEATH DIFFER, V10, P386, DOI 10.1038/sj.cdd.4401184; Sgarra R, 2003, BIOCHEMISTRY-US, V42, P3575, DOI 10.1021/bi027338l; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Tamimi Y, 1996, BRIT J CANCER, V74, P573, DOI 10.1038/bjc.1996.403; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wood LJ, 2000, CANCER RES, V60, P4256; Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x; Yates Jr, 1999, METH MOL B, V112, P553; YATES JR, 1996, ANAL CHEM, V68, P534; Zhang LW, 2004, J AM SOC MASS SPECTR, V15, P77, DOI 10.1016/j.jasms.2003.10.001	58	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					8961	8973		10.1074/jbc.M407348200	http://dx.doi.org/10.1074/jbc.M407348200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15591590	hybrid			2022-12-25	WOS:000227453100043
J	Uo, T; Kinoshita, Y; Morrison, RS				Uo, T; Kinoshita, Y; Morrison, RS			Neurons exclusively express N-bak, a BH3 domain-only bak isoform that promotes neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; CYTOCHROME-C RELEASE; X-DEFICIENT MICE; CELL-DEATH; BH3-ONLY PROTEINS; DNA-DAMAGE; P53; SURVIVAL; MITOCHONDRIA; ACTIVATION	Bak is generally recognized as a multidomain, proapoptotic member of the Bcl-2 family. Bak and Bax are functionally redundant in non-neuronal cells and represent a mitochondrial convergence point for cell death signaling pathways. This functional redundancy, however, may not exist in neurons in which the single deletion of Bax is sufficient to confer protection against a variety of cytotoxic insults. In the present study, we demonstrate that postnatal cortical and cerebellar granule neurons exclusively express an alternatively spliced, BH3 domain-only form of Bak (N-Bak), whereas astrocytes express only the full-length, multidomain form. Overexpression of N-Bak promotes Bax translocation in HeLa cells and induces neuronal cell death in cortical, hippocampal, and cerebellar granule neurons in a Bax-dependent manner. N-Bak interacts with Bcl-X-L but not BAX, suggesting an indirect mechanism for promoting Bax translocation to the mitochondria. N-Bak message and protein levels are elevated in cortical neurons in response to DNA damage, and subsequent induction of neuronal death is significantly delayed by expressing a full-length Bak antisense plasmid. These results demonstrate that postnatal neurons solely express a BH3 domain-only form of Bak, which contributes to DNA damage-induced neuronal apoptosis. The absence of full-length Bak expression explains the near exclusive requirement for Bax in neuronal apoptosis.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Morrison, RS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA.	yael@u.washington.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035533] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35533] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleyasin H, 2004, J NEUROSCI, V24, P2963, DOI 10.1523/JNEUROSCI.0155-04.2004; Bouillet P, 2002, J CELL SCI, V115, P1567; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chittenden T, 2002, CANCER CELL, V2, P165, DOI 10.1016/S1535-6108(02)00128-9; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2004, J NEUROSCI, V24, P10003, DOI 10.1523/JNEUROSCI.2114-04.2004; D'Sa C, 2003, J NEUROSCI RES, V74, P435, DOI 10.1002/jnr.10738; Darman J, 2004, J NEUROSCI, V24, P7566, DOI 10.1523/JNEUROSCI.2002-04.2004; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eguchi H, 2000, CELL DEATH DIFFER, V7, P439, DOI 10.1038/sj.cdd.4400675; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kitamura Y, 1998, MOL PHARMACOL, V54, P1046, DOI 10.1124/mol.54.6.1046; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Lindsten T, 2003, J NEUROSCI, V23, P11112; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; Middleton G, 1996, DEVELOPMENT, V122, P695; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Milosevic J, 2004, EXP CELL RES, V294, P9, DOI 10.1016/j.yexcr.2003.10.033; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shindler KS, 1997, J NEUROSCI, V17, P3112; Sun YF, 2001, J BIOL CHEM, V276, P16240, DOI 10.1074/jbc.M010419200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	55	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9065	9073		10.1074/jbc.M413030200	http://dx.doi.org/10.1074/jbc.M413030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590665	hybrid			2022-12-25	WOS:000227453100055
J	Habib, SJ; Waizenegger, T; Lech, M; Neupert, W; Rapaport, D				Habib, SJ; Waizenegger, T; Lech, M; Neupert, W; Rapaport, D			Assembly of the TOB complex of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT CHANNEL; OUTER-MEMBRANE; INTERMEMBRANE SPACE; BIOGENESIS; BETA; TRANSLOCATION; MACHINERY; COMPONENT; TOM40	All mitochondrial precursor proteins studied so far are recognized initially at the surface of the organelle by the translocase of the outer membrane (TOM complex). Precursors of P-barrel proteins are transferred further to another complex in the outer membrane that mediates their topogenesis (TOB complex). Tob55 is an essential component of the TOB complex in that it constitutes the core element of the protein-conducting pore. The other two components of the TOB complex are Tob38, which builds a functional TOB core complex with Tob55, and Mas37, a peripheral member of the complex. We have investigated the biogenesis of the TOB complex. Reduced insertion of the Tob55 precursor in the absence of Tom20 and Tom70 argues for initial recognition of the precursor of Tob55 by the import receptors. Next, it is transferred through the import channel formed by Tom40. Variants of the latter protein influenced the insertion of Tob55. Assembly of newly synthesized Tob55 into preexisting TOB complexes, as analyzed by blue native gel electrophoresis, depended on Tob38 but did not require Mas37. Surprisingly, both the association of Mas37 precursor with mitochondria and its assembly into the TOB complex were not affected by mutation in the TOM complex. Mas37 assembled directly with the TOB core complex. Hence, the biogenesis of Mas37 represents a novel import pathway of mitochondrial proteins.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Rapaport, D (corresponding author), Univ Munich, Inst Physiol Chem, Buntenandtstr 5,Haus B, D-81377 Munich, Germany.	rapaport@bio.med.uni-muenchen.de	Lech, Maciej/AAJ-7899-2021	Lech, Maciej/0000-0002-4293-2733; Habib, Shukry/0000-0003-3132-2216				DAUM G, 1982, J BIOL CHEM, V257, P3028; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Meisinger C, 2004, DEV CELL, V7, P61, DOI 10.1016/j.devcel.2004.06.003; Milenkovic D, 2004, J BIOL CHEM, V279, P22781, DOI 10.1074/jbc.C400120200; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schleiff E, 1999, J CELL BIOL, V145, P973, DOI 10.1083/jcb.145.5.973; Sherman F., 1986, METHODS YEAST GENETI; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200	24	65	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6434	6440		10.1074/jbc.M411510200	http://dx.doi.org/10.1074/jbc.M411510200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590639	hybrid			2022-12-25	WOS:000227332700024
J	Alvarado-Kristensson, M; Andersson, T				Alvarado-Kristensson, M; Andersson, T			Protein phosphatase 2A regulates apoptosis in neutrophils by dephosphorylating both p38 MAPK and its substrate caspase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PHOSPHORYLATION; ACTIVATION; RECEPTOR; ALPHA; DEATH; BETA	The induction of apoptosis in neutrophils is an essential event in the resolution of an inflammatory process. We found recently that the reduction of the activity of the neutrophil survival factor p38 MAPK and dephosphorylation and thus activation of caspases must occur to initiate such cell death in these leukocytes. Here, we report a previously undetected early and transient activation of protein phosphatase 2A WPM in neutrophils undergoing apoptosis. The pharmacological inhibition of this phosphatase during Fas-induced apoptosis augmented the levels of phosphorylation of both p38 MAPK and caspase 3, resulting in a decreased activity of caspase 3 and an increased neutrophil survival. The complementary finding of a time-dependent association among PP2A, p38 MAPK, and caspase 3 in intact neutrophils indicated that there is a direct regulatory link among these signaling enzymes during Fas-provoked apoptosis. Moreover, immunoprecipitated active p38 MAPK and recombinant phosphorylated caspase 3 were dephosphorylated by exposure to purified PP2A in vitro. Consequently, the early and temporary activation of PP2A in neutrophils impaired not only the p38 MAPK-mediated inhibition of caspase 3 but also restored the activity to caspase 3 that had already been phosphorylated and thereby inactivated. These findings indicate that PP2A plays a pivotal dual role in the induction of neutrophil apoptosis and therefore also in the resolution of inflammation.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Alvarado-Kristensson, M (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Entrance 78,3rd Fl, SE-20502 Malmo, Sweden.	maria.alvarado-kristensson@exppat.mas.lu.se	Alvarado-Kristensson, Maria T./C-4543-2014	Alvarado Kristensson, Maria Teresa/0000-0003-0598-7986				Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; ALVARADOKRISTEN, 2001, IN PRESS FASEB J; Aoshiba K, 1999, J IMMUNOL, V162, P1692; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CARTWRIGHT GE, 1964, BLOOD, V24, P780, DOI 10.1182/blood.V24.6.780.780; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; Hale KK, 1999, J IMMUNOL, V162, P4246; Harmala-Brasken AS, 2003, ONCOGENE, V22, P7677, DOI 10.1038/sj.onc.1207077; Haslett C, 1997, BRIT MED BULL, V53, P669; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7	25	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6238	6244		10.1074/jbc.M409718200	http://dx.doi.org/10.1074/jbc.M409718200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15569672	hybrid			2022-12-25	WOS:000227217100131
J	Huang, N; Negi, S; Szebeni, A; Olson, MOJ				Huang, N; Negi, S; Szebeni, A; Olson, MOJ			Protein NPM3 interacts with the multifunctional nucleolar protein B23/nucleophosmin and inhibits ribosome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-ACTIVITY; B23; RNA; NUCLEOPHOSMIN/B23; PHOSPHORYLATION; NUCLEOPLASMIN; ASSOCIATION; MITOSIS; KINASE; ROLES	Protein B23/nucleophosmin is a multifunctional protein that plays roles in ribosome biogenesis, control of centrosome duplication, and regulation of p53 expression. A yeast two-hybrid screen was performed in a search for interaction partners of B23. The complementary DNA for a highly acidic protein, nucleoplasmin 3 (NPM3), was found in multiple positive clones. Protein NPM3 and its interaction with B23 were further characterized. Endogenous B23 was able to be co-immunoprecipitated with NPM3, and this complex was resistant to ribonuclease treatment and high concentrations of salt. The N-terminal 35-90 amino acids of B23 were found to be required for their interaction. Separate co-immunoprecipitation studies of B23 and NPM3 suggested the existence of two different complexes, one containing B23 and 28 S ribosomal RNA (rRNA) and another composed of B23, NPM3, and other proteins, but no RNA. NPM3 was localized in the nucleolus, and its nucleolar localization depended on active rRNA transcription. In the cells overexpressing NPM3, there were decreased rates of pre-rRNA synthesis and processing. Overexpression of a mutant of NPM3 that did not interact with B23 did not alter pre-rRNA synthesis and processing, suggesting that the interaction of NPM3 with B23 plays a role in the ribosome biogenesis.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Olson, MOJ (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA.	molson@biochem.umsmed.edu						BIGGIOGERA M, 1990, DEVELOPMENT, V110, P1263; BIGGIOGERA M, 1989, J HISTOCHEM CYTOCHEM, V37, P1371, DOI 10.1177/37.9.2768807; BIGGIOGERA M, 1991, CHROMOSOMA, V100, P162, DOI 10.1007/BF00337245; Busch H., 1970, NUCLEOLUS; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; DUNDR M, 1995, J CELL SCI, V108, P2811; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; HADJIOLOV AA, 1985, CELL BIOL MONOGRAPHY; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kuriki K, 2000, CELL MOL BIOL, V46, P1147; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; MacArthur CA, 1997, GENOMICS, V42, P137, DOI 10.1006/geno.1997.4353; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; SATO K, 2004, J BIOL CHEM; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Shackleford G M, 2001, BMC Genomics, V2, P8, DOI 10.1186/1471-2164-2-8; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Szebeni A, 1999, PROTEIN SCI, V8, P905; Szebeni A, 2003, J BIOL CHEM, V278, P9107, DOI 10.1074/jbc.M204411200; WANG DR, 1994, J BIOL CHEM, V269, P30994; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; Zatsepina OV, 1999, J CELL SCI, V112, P455; ZHANG H, 2004, J BIOL CHEM; Zhang YP, 2004, CELL CYCLE, V3, P259; Zirwes RF, 1997, P NATL ACAD SCI USA, V94, P11387, DOI 10.1073/pnas.94.21.11387	37	65	69	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5496	5502		10.1074/jbc.M407856200	http://dx.doi.org/10.1074/jbc.M407856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15596447	hybrid			2022-12-25	WOS:000227217100048
J	Montagner, A; Yart, A; Dance, M; Perret, B; Salles, JP; Raynal, P				Montagner, A; Yart, A; Dance, M; Perret, B; Salles, JP; Raynal, P			A novel role for Gab1 and SHP2 in epidermal growth factor-induced ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PDGF-BETA-RECEPTOR; DOCKING PROTEIN; PHOSPHOINOSITIDE 3-KINASE; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; MOLECULAR-MECHANISM; EGF-RECEPTOR; KINASE	SHP2 was recently found to down-regulate PI3K activation by dephosphorylating Gabl but the mechanisms explaining the positive role of the Gabl/SHP2 pathway in EGF-induced Ras activation remain ill defined. Substrate trapping experiments now suggest that SHP2 dephosphorylates other Gabl phosphotyrosines located within a central region displaying four YXXP motifs. Because these sites are potential docking motifs for RasGAP, we tested whether SHP2 dephosphorylates them to facilitate Ras activation. We observed that a Gabl construct preventing SHP2 recruitment promoted membrane relocation of RasGAP. Moreover, a RasGAP-inactive mutant restored the activation of Ras in cells transfected with SHP2-inactivating Gabl mutant or in SHP2deficient fibroblasts, supporting the hypothesis that RasGAP is a downstream target of SHP2. To determine whether Gabl is a RasGAP-binding partner, a Gabl mutant deleted of four YAXP motifs was produced. The deletion suppressed RasGAP redistribution and restored the defective Ras activation caused by SHP2-inactivating mutations. Moreover, Gabl was found to interact with RasGAP SH2 domains, only under conditions where SHP2 is not activated. To identify RasGAP-binding sites, Tyr to Phe mutants of Gabl YXXP motifs were produced. Gabl constructs mutated on Tyr(317) were severely affected in RasGAP binding and were the most active in compensating for Ras-defective activation and blocking RasGAP redistribution induced by SHP2 inactivation. We have thus localized on Gabl a Ras-negative regulatory tyrosine phosphorylation site involved in RasGAP binding and showed that an important SHP2 function is to down-regulate its phosphorylation to disengage RasGAP and sustain Ras activation.	Hop Purpan, INSERM, U563, Dept Lipoprot & Mediateurs Lipid, F-31300 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Raynal, P (corresponding author), Hop Purpan, INSERM, U563, Dept Lipoprot & Mediateurs Lipid, F-31300 Toulouse, France.	raynal@toulouse.inserm.fr	YART, Armelle/A-5656-2016; SALLES, Jean Pierre/K-2998-2014; Raynal, Patrick/O-1926-2018; PERRET, Bertrand/Y-2326-2019	YART, Armelle/0000-0002-2412-9840; Montagner, Alexandra/0000-0002-4800-5105; Bertrand, PERRET/0000-0001-7568-445X; Raynal, Patrick/0000-0002-6731-3007				Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Hanafusa H, 2004, J BIOL CHEM, V279, P22992, DOI 10.1074/jbc.M312498200; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wu HY, 2003, J BIOL CHEM, V278, P40425, DOI 10.1074/jbc.C300225200; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	38	140	143	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5350	5360		10.1074/jbc.M410012200	http://dx.doi.org/10.1074/jbc.M410012200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15574420	hybrid			2022-12-25	WOS:000227217100031
J	Roberts, JA; White, MF				Roberts, JA; White, MF			An archaeal endonuclease displays key properties of both eukaryal XPF-ERCC1 and Mus81	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; ERCC1-XPF; CROSSOVERS; RESOLUTION; MECHANISM; CLEAVAGE	Structure-specific nucleases of the XPF/Mus81 family function in several DNA recombination and repair pathways in eukaryotes, cleaving a variety of flap and branched DNA substrates. Mus81 and XPF are clearly related evolutionarily but differ markedly in their substrate specificity and protein partners. We demonstrate that the XPF endonuclease from Sulfolobus solfataricus, which is dependent on the sliding clamp proliferating cell nuclear antigen for activity, represents an ancestral form of the XPF/Mus81 family, with key properties in common with both enzymes. The archaeal XPF has a domain organization and sequence preference very similar to eukaryal XPF-ERCC1. However, the archaeal enzyme has a pronounced preference for Mus81-type substrates such as D loops, nicked four-way junctions, and 3' flaps. These all have in common a 5'-DNA end next to the cleavage site. The availability of the sliding clamp proliferating cell nuclear antigen may dictate the activity of Sulfolobus XPF in vivo.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	White, MF (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	mfw2@st-and.ac.uk	White, Malcolm F/A-6055-2010	White, Malcolm F/0000-0003-1543-9342				Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Doe CL, 2004, NUCLEIC ACIDS RES, V32, P5570, DOI 10.1093/nar/gkh853; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Grogan DW, 2000, TRENDS MICROBIOL, V8, P180, DOI 10.1016/S0966-842X(00)01729-7; Hollingsworth NM, 2004, GENE DEV, V18, P117, DOI 10.1101/gad.1165904; Komori K, 2002, GENES GENET SYST, V77, P227, DOI 10.1266/ggs.77.227; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; LI L, 1995, MOL CELL BIOL, V15, P5396; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; Niedernhofer LJ, 2001, EMBO J, V20, P6540, DOI 10.1093/emboj/20.22.6540; Nishino T, 2003, STRUCTURE, V11, P445, DOI 10.1016/S0969-2126(03)00046-7; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; Roberts JA, 2003, MOL MICROBIOL, V48, P361, DOI 10.1046/j.1365-2958.2003.03444.x; Whitby MC, 2003, J BIOL CHEM, V278, P6928, DOI 10.1074/jbc.M210006200	17	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5924	5928		10.1074/jbc.M412766200	http://dx.doi.org/10.1074/jbc.M412766200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591065	hybrid			2022-12-25	WOS:000227217100098
J	Waterford, SD; Kolodecik, TR; Thrower, EC; Gorelick, FS				Waterford, SD; Kolodecik, TR; Thrower, EC; Gorelick, FS			Vacuolar ATPase regulates zymogen activation in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSINOGEN ACTIVATION; SECRETORY PATHWAY; CATHEPSIN-B; H+-ATPASES; YEAST; STIMULATION; CHLOROQUINE; COMPLEX; RAVE; MICE	Supramaximal concentrations of cholecystokinin or its analogue caerulein have been shown to stimulate the proteolytic activation of zymogens within the pancreatic acinar cell and initiate acute pancreatitis. Previous studies suggest that a low pH compartment might be required for activation. To test this hypothesis, the effects of agents that modulate intracellular pH on caerulein-induced trypsin and chymotrypsin activation were studied. Pretreatment of pancreatic acini with the proto-ionophore monensin (10 mum) and the weak base chloroquine (40 mum) inhibited activation. Pre-incubation with the vacuolar ATPase (V-ATPase) inhibitors bafilomycin A, and concanamycin A also decreased activation in a concentration-dependent manner with 50% inhibition at similar to50 and 25 nm, respectively. Caerulein stimulation caused a time- and concentration-dependent translocation of soluble V-ATPase V, subunits to a membrane fraction, a marker of V-ATPase activation. Carbachol also stimulated translocation at supramaximal concentrations. Elevation of cytosolic Ca2+ by thapsigargin was sufficient to induce translocation. Thus, stimulation of VATPase activity appears to be required for agonist-induced zymogen activation in the pancreatic acinar cell.	Vet Adm Connecticut Healthcare, Dept Internal Med, Sect Digest Dis, West Haven, CT USA; Vet Adm Connecticut Healthcare, Dept Cell Biol, West Haven, CT USA; Yale Univ, Sch Med, New Haven, CT 06510 USA	Yale University	Gorelick, FS (corresponding author), Vet Adm Med Ctr, 950 Campbell Ave,Bldg 27, West Haven, CT 06516 USA.	fred.gorelick@yale.edu		Gorelick, Fred/0000-0001-8293-6803	NIDDK NIH HHS [R01 DK54021, R01 DK054021, R01 DK054021-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054021] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Camello C, 2000, CURR BIOL, V10, P161, DOI 10.1016/S0960-9822(00)00313-4; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Drose S, 1997, J EXP BIOL, V200, P1; Grady T, 1998, AM J PHYSIOL-GASTR L, V275, pG1010, DOI 10.1152/ajpgi.1998.275.5.G1010; Guillaumes S, 1997, PANCREAS, V14, P262, DOI 10.1097/00006676-199704000-00007; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Hofbauer B, 1998, AM J PHYSIOL-GASTR L, V275, pG352, DOI 10.1152/ajpgi.1998.275.2.G352; Kane PM, 2000, J EXP BIOL, V203, P81; Kukor Z, 2002, J BIOL CHEM, V277, P21389, DOI 10.1074/jbc.M200878200; LEACH SD, 1993, PANCREAS, V8, P64, DOI 10.1097/00006676-199301000-00013; LEACH SD, 1991, J CLIN INVEST, V87, P362, DOI 10.1172/JCI114995; Lu Z, 2002, AM J PHYSIOL-GASTR L, V282, pG501, DOI 10.1152/ajpgi.00388.2001; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NIEDERAU C, 1988, J CLIN INVEST, V81, P229, DOI 10.1172/JCI113300; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Okorokov LA, 2001, FEBS LETT, V505, P321, DOI 10.1016/S0014-5793(01)02852-6; Otani T, 1998, AM J PHYSIOL-GASTR L, V275, pG999, DOI 10.1152/ajpgi.1998.275.5.G999; Roussa E, 2001, J HISTOCHEM CYTOCHEM, V49, P463, DOI 10.1177/002215540104900406; SALUJA A, 1985, AM J PHYSIOL, V249, pG702, DOI 10.1152/ajpgi.1985.249.6.G702; Saluja AK, 1997, GASTROENTEROLOGY, V113, P304, DOI 10.1016/S0016-5085(97)70108-2; Schmid SW, 1998, AM J PHYSIOL-GASTR L, V274, pG734, DOI 10.1152/ajpgi.1998.274.4.G734; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	26	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5430	5434		10.1074/jbc.M413513200	http://dx.doi.org/10.1074/jbc.M413513200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15582989	hybrid, Green Accepted			2022-12-25	WOS:000227217100040
J	Buczek, O; Yoshikami, D; Bulaj, G; Jimenez, EC; Olivera, BM				Buczek, O; Yoshikami, D; Bulaj, G; Jimenez, EC; Olivera, BM			Post-translational amino acid isomerization - A functionally important D-amino acid in an excitatory peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRUSTACEAN HYPERGLYCEMIC HORMONE; CONTAINING CONUS PEPTIDE; ORNITHORHYNCHUS-ANATINUS; NATRIURETIC PEPTIDE; ACHATINA-FULICA; AMPHIBIAN SKIN; D-SERINE; RESIDUE; VENOM; DERMORPHIN	The post-translational modification of an L- to a D-amino acid has been documented in relatively few gene products, mostly in small peptides under 10 amino acids in length. In this report, we demonstrate that a 46-amino acid polypeptide toxin has one D-phenylalanine at position 44, and that the epimerization from an L-Phe to a D-Phe has a dramatic effect on the excitatory effects of the peptide. In one electrophysiological assay carried out, the D-Phe-containing peptide was extremely potent, whereas the unmodified polypeptide had no biological activity, demonstrating that the chirality of the posttranslationally modified amino acid is functionally significant. The peptide toxin analyzed, r11a, belongs to the I-gene superfamily of conotoxins that has four disulfide cross-links. The D-Phe in r11a is at the third amino acid from the C terminus, the same relative position from the C-terminal end as the D-amino acid in to-agatoxin TK from a spider, an unrelated peptide. Thus, although post-translational amino acid isomerization appears to have no strong specificity for the chemical nature of the amino acid side chain, the few peptides where this modification has been established suggest that there may be favored positions near the N or C terminus that are preferential sites for isomerization to a D-amino acid.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Philippines, Coll Sci, Dept Phys Sci, Baguio 2600, Philippines	Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Baguio	Olivera, BM (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.	olivera@biology.utah.edu	Jimenez, Elsie/AAA-7347-2019		NIGMS NIH HHS [GM 48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILAR MB, 1995, PEPTIDES, V16, P1375, DOI 10.1016/0196-9781(95)02024-1; Atherton E., 1990, SOLID PHASE PEPTIDE; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; de Plater GM, 1998, COMP BIOCHEM PHYS C, V120, P99, DOI 10.1016/S0742-8413(98)00030-9; FUJISAWA Y, 1992, COMP BIOCHEM PHYS C, V102, P91, DOI 10.1016/0742-8413(92)90049-D; HECK SD, 1994, J AM CHEM SOC, V116, P10426, DOI 10.1021/ja00102a009; Jacobsen R, 1998, J PEPT RES, V51, P173; Jacobsen RB, 1999, J PEPT RES, V54, P93, DOI 10.1034/j.1399-3011.1999.00093.x; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; Jimenez EC, 2003, J NEUROCHEM, V85, P610, DOI 10.1046/j.1471-4159.2003.01685.x; KAMATANI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1015, DOI 10.1016/S0006-291X(89)80103-2; Kauferstein S, 2003, TOXICON, V42, P43, DOI 10.1016/S0041-0101(03)00099-0; KREIL G, 1994, J BIOL CHEM, V269, P10967; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; KUWADA M, 1994, MOL PHARMACOL, V46, P587; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1989, FEBS LETT, V255, P269, DOI 10.1016/0014-5793(89)81104-4; OHTA N, 1991, BIOCHEM BIOPH RES CO, V178, P486, DOI 10.1016/0006-291X(91)90133-R; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SOYEZ D, 1994, J BIOL CHEM, V269, P18295; Torres AM, 2002, FEBS LETT, V524, P172, DOI 10.1016/S0014-5793(02)03050-8; YASUDA A, 1994, GEN COMP ENDOCR, V95, P387, DOI 10.1006/gcen.1994.1138; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x	24	79	84	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4247	4253		10.1074/jbc.M405835200	http://dx.doi.org/10.1074/jbc.M405835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561705	hybrid			2022-12-25	WOS:000227096600032
J	Liberman, Z; Eldar-Finkelman, H				Liberman, Z; Eldar-Finkelman, H			Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-MECHANISMS; GLUCOSE-METABOLISM; GROWTH-FACTOR; TNF-ALPHA; IRS-1; MODULATION	The ability of glycogen synthase kinase-3 (GSK-3) to phosphorylate insulin receptor substrate-1 (IRS-1) is a potential inhibitory mechanism for insulin resistance in type 2 diabetes. However, the serine site(s) phosphorylated by GSK-3 within IRS-1 had not been yet identified. Using an N-terminal deleted IRS-1 mutant and two IRS-1 fragments, PTB-1(1-320) and PTB-2(1-350), we localized GSK-3 phosphorylation site(s) within amino acid sequence 320-350. Mutations of serine 332 or 336, which lie in the GSK-3 consensus motif (SXXXS) within PTB-2 or IRS-1, to alanine abolished their phosphorylation by GSK-3. This suggested that Ser(332) is a GSK-3 phosphorylation site and that Ser(336) serves as the "priming" site typically required for GSK-3 action. Indeed, dephosphorylation of IRS-1 prevented GSK-3 phosphorylation. Furthermore, the phosphorylated peptide derived from the IRS-1 sequence was readily phosphorylated by GSK-3, in contrast to the nonphosphorylated peptide, which was not phosphorylated by the enzyme. When IRS-1 mutants S332A(IRS-1), S336A(IRS-1), or S332A/336A(IRS-1) were expressed in Chinese hamster ovary cells overexpressing insulin receptors, their insulin-induced tyrosine phosphorylation levels increased compared with that of wild-type (WT) IRS-1. This effect was stronger in the double mutant S332A/336A(IRS-1) and led to enhanced insulin-mediated activation of protein kinase B. Finally, immunoblot analysis with polyclonal antibody directed against IRS-1 phosphorylated at Ser(332) confirmed IRS-1 phosphorylation in cultured cells. Moreover, treatment with the GSK-3 inhibitor lithium reduced Ser 332 phosphorylation, whereas overexpression of GSK-3 enhanced this phosphorylation. In summary, our studies identify Ser(332) as the GSK-3 phosphorylation target in IRS-1, indicating its physiological relevance and demonstrating its novel inhibitory role in insulin signaling.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Eldar-Finkelman, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel.	heldar@post.tau.ac.il		Eldar-Finkelman, Hagit/0000-0002-8460-9686				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Backer JM, 1997, EUR J BIOCHEM, V245, P91, DOI 10.1111/j.1432-1033.1997.t01-1-00091.x; Birnbaum MJ, 2001, J CLIN INVEST, V108, P655, DOI 10.1172/JCI200113714; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Gual P, 2003, DIABETOLOGIA, V46, P1532, DOI 10.1007/s00125-003-1223-4; HENRIKSON EJ, 2003, AM J PHYSIOL, pE892; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kruszynska YT, 1996, J INVEST MED, V44, P413; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Nikoulina SE, 2002, DIABETES, V51, P2190, DOI 10.2337/diabetes.51.7.2190; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Sommerfeld MR, 2004, BIOCHEMISTRY-US, V43, P5888, DOI 10.1021/bi049640v; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; van der Geer P, 1999, ONCOGENE, V18, P3071, DOI 10.1038/sj.onc.1202879; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Woodgett J. R., 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P281, DOI 10.2174/1568008033340153; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	59	136	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4422	4428		10.1074/jbc.M410610200	http://dx.doi.org/10.1074/jbc.M410610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574412	hybrid			2022-12-25	WOS:000227096600052
J	Fan, QW; Weiss, WA				Fan, QW; Weiss, WA			RNA interference against a glioma-derived allele of EGFR induces blockade at G(2)M	ONCOGENE			English	Article						siRNA; EGFR; Delta EGFR; PI3 kinase; LY294002; combination therapy	GROWTH-FACTOR RECEPTOR; G(1) ARREST; LUNG-CANCER; EXPRESSION; GENE; P27(KIP1); AMPLIFICATION; INHIBITION; PHASE; CELLS	Amplification and mutation of the epidermal growth factor receptor (EGFR) is common in astrocytoma. The most frequently occurring mutation (DeltaEGFR, EGFRvIII) deletes exons 2-7 from this receptor tyrosine kinase (RTK), and signals constitutively in the absence of ligand. DeltaEGFR is not found in normal tissue, and therefore represents an attractive therapeutic target. Here, we show that a small interfering RNA (siRNA) directed against the unique exon 1/exon 8 junction sequence of DeltaEGFR efficiently suppressed expression of DeltaEGFR in rodent fibroblasts and in two human glioblastoma cell lines. SiRNA-mediated depletion of DeltaEGFR led to reduction in the levels of phosphorylated Akt in glioma cells, was associated with increased apoptosis, and induced partial arrest at the G(2)M phase of the cell cycle. Inhibitors of PI3 kinase cooperated with siRNA treatment, leading to further increases in both cell cycle blockade and apoptosis. Importantly, cell cycle blockade could be reversed, and apoptosis rescued using a conditional allele of Akt, implicating Akt as a primary target of combination therapy. This study demonstrates the therapeutic potential of siRNA to impact DeltaEGFR as a glioma-specific target, and offers a mechanistic rationale for combining siRNA and small molecule inhibitor therapies against distinct components in the EGFR signaling pathway.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol, 533 Parnassus Ave,Room U-441O, San Francisco, CA 94143 USA.	weiss@cgl.ucsf.edu		Weiss, William/0000-0003-2230-9132	NCI NIH HHS [U01CA84290, 1P50CA097257-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097257, U01CA084290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BIGNER SH, 1990, CANCER RES, V50, P8017; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; DEL PL, 1997, SCIENCE, V278, P687; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Fan QW, 2003, CANCER RES, V63, P8930; Fan QW, 2002, CURR BIOL, V12, P1386, DOI 10.1016/S0960-9822(02)01070-9; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hansen LA, 1997, AM J PATHOL, V150, P1959; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Luwor RB, 2001, CANCER RES, V61, P5355; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peng D, 1996, CANCER RES, V56, P3666; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shir A, 2002, NAT BIOTECHNOL, V20, P895, DOI 10.1038/nbt730; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Williams JI, 2001, CLIN CANCER RES, V7, P724; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu XP, 1996, ONCOGENE, V12, P1397	48	44	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					829	837		10.1038/sj.onc.1208227	http://dx.doi.org/10.1038/sj.onc.1208227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580296				2022-12-25	WOS:000226577100009
J	Bodding, M				Bodding, M			Voltage-dependent changes of TRPV6-mediated Ca2+ currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EMBRYONIC KIDNEY; RAT PANCREATIC ACINI; TRP CHANNELS; PROSTATE-CANCER; CAT-LIKE; CELLS; PERMEATION; IDENTIFICATION; SELECTIVITY; ACTIVATION	The physiological role and activation mechanism for most proteins of the transient receptor potential (TRP) family are unknown. This is also the case for the highly Ca2+ selective transient receptor potential vanilloid type 6 (TRPV6) channel. Patch clamp experiments were performed on transiently transfected human embryonic kidney (HEK) cells to address this issue. Currents were recorded under various conditions of intracellular Ca2+ buffering and monitored at the same voltage throughout. No TRPV6-mediated Ca2+ entry was detected under in vivo Ca2+ buffering conditions at a slightly negative holding potential; however, moderate depolarization resulted in current activation. Very similar results were obtained with different Ca2+ chelators, either EGTA or BAPTA dialyzing the cell. TRPV6 channel activity showed a negative correlation with the intracellular free Ca2+ concentration ([Ca2+](i)) and was modulated by the membrane potential: Hyperpolarization decreases and depolarization increases TRPV6-mediated currents. Monovalent ions permeated TRPV6 channels in the absence of extracellular divalent cations. These currents were resistant to changes in the holding potential while the negative correlation to the [Ca2+](i) was conserved, indicating that the voltage-dependent current changes depend on blocking and unblocking the charge carrier Ca2+ within the pore. In summary, these results suggest that the voltage dependence of TRPV6-mediated Ca2+ influx is of physiological importance since it occurs at cytosolic Ca2+ buffering and takes place within a physiologically relevant membrane potential range.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Bodding, M (corresponding author), Univ Saarland, D-66421 Homburg, Germany.	matthias.boedding@uniklinik-saarland.de						Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; Bodding M, 2004, J BIOL CHEM, V279, P36546, DOI 10.1074/jbc.M404679200; Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jean K, 2002, AM J PHYSIOL-CELL PH, V282, pC665, DOI 10.1152/ajpcell.00443.2001; Kim SJ, 1999, PFLUG ARCH EUR J PHY, V438, P604; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Slawik M, 1996, PFLUG ARCH EUR J PHY, V432, P112, DOI 10.1007/s004240050112; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3	31	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7022	7029		10.1074/jbc.M410184200	http://dx.doi.org/10.1074/jbc.M410184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15582993	hybrid			2022-12-25	WOS:000227332700092
J	Futamura, M; Dhanasekaran, P; Handa, T; Phillips, MC; Lund-Katz, S; Saito, H				Futamura, M; Dhanasekaran, P; Handa, T; Phillips, MC; Lund-Katz, S; Saito, H			Two-step mechanism of binding of apolipoprotein E to heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; CHOLESTEROL TRANSPORT PROTEIN; INDUCED CONFORMATIONAL-CHANGE; SULFATE PROTEOGLYCAN-BINDING; RECEPTOR-RELATED PROTEIN; AMPHIPATHIC ALPHA-HELIX; LIPID INTERACTION; EXPERIMENTAL-DESIGN; KINETIC-ANALYSIS; CELL-MIGRATION	The interaction of apolipoprotein E (apoE) with cellsurface heparan sulfate proteoglycans is an important step in the uptake of lipoprotein remnants by the liver. ApoE interacts predominantly with heparin through the N-terminal binding site spanning the residues around 136-150. In this work, surface plasmon resonance analysis was employed to investigate how amphipathic a-helix properties and basic residue organization in this region modulate binding of apoE to heparin. The apoE/heparin interaction involves a twostep process; apoE initially binds to heparin with fast association and dissociation rates, followed by a step exhibiting much slower kinetics. Circular dichroism and surface plasmon resonance experiments using a disulfide-linked mutant, in which opening of the Nterminal helix bundle was prevented, demonstrated that there is no major secondary or tertiary structural change in apoE upon heparin binding. Mutations of Lys-146, a key residue for the heparin interaction, greatly reduced the favorable free energy of binding of the first step without affecting the second step, suggesting that electrostatic interaction is involved in the first binding step. Although lipid-free apoE2 tended to bind less than apoE3 and apoE4, there were no significant differences in rate and equilibrium constants of binding among the apoE isoforms in the lipidated state. Discoidal apoE3-phospholipid complexes using a substitution mutant (Kl43PJK146R) showed similar binding affinity to wild type apoE3, indicating that basic residue specificity is not required for the effective binding of apoE to heparin, unlike its binding to the low density lipoprotein receptor. In addition, disruption of the a-helix structure in the apoE heparin binding region led to an increased favorable free energy of binding in the second step, suggesting that hydrophobic interactions contribute to the second binding step. Based on these results, it seems that cellsurface heparan sulfate proteoglycan localizes apoEenriched remnant lipoproteins to the vicinity of receptors by fast association and dissociation.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Lipid Res Grp, Philadelphia, PA 19104 USA; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Kyoto University	Lund-Katz, S (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Lipid Res Grp, Abramson Res Bldg,Suite 1102,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	katz@email.chop.edu		Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; Bazin HG, 2002, BIOCHEMISTRY-US, V41, P8203, DOI 10.1021/bi025817e; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; Cooper AD, 1997, J LIPID RES, V38, P2173; Croy JE, 2004, BIOCHEMISTRY-US, V43, P7328, DOI 10.1021/bi036208p; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Dong J, 2001, BIOCHEMISTRY-US, V40, P2826, DOI 10.1021/bi002417n; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Hileman RE, 1998, BIOCHEMISTRY-US, V37, P15231, DOI 10.1021/bi980212x; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; Lipschultz CA, 2000, METHODS, V20, P310, DOI 10.1006/meth.1999.0924; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Lund-Katz S, 2001, J LIPID RES, V42, P894; Mahley RW, 1999, J LIPID RES, V40, P1933; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; Munoz EM, 2004, ARTERIOSCL THROM VAS, V24, P1549, DOI 10.1161/01.ATV.0000137189.22999.3f; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; OLSON ST, 1991, J BIOL CHEM, V266, P6342; Osmond RIW, 2002, ANAL BIOCHEM, V310, P199, DOI 10.1016/S0003-2697(02)00396-2; Papo N, 2004, BIOCHEMISTRY-US, V43, P6393, DOI 10.1021/bi049944h; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; Prevost M, 2004, PROTEINS, V55, P874, DOI 10.1002/prot.20080; Raussens V, 2002, J BIOL CHEM, V277, P29172, DOI 10.1074/jbc.M204043200; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; Saito H, 2003, J BIOL CHEM, V278, P14782, DOI 10.1074/jbc.M213207200; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Schedin-Weiss S, 2004, BIOCHEMISTRY-US, V43, P675, DOI 10.1021/bi030173b; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Shuvaev VV, 1999, FEBS LETT, V459, P353, DOI 10.1016/S0014-5793(99)01285-5; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Strittmatter WJ, 2002, CURR OPIN LIPIDOL, V13, P119, DOI 10.1097/00041433-200204000-00002; Swertfeger DK, 2001, FRONT BIOSCI-LANDMRK, V6, pD526, DOI 10.2741/Swertfeg; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; Wilsie LC, 2003, J BIOL CHEM, V278, P15758, DOI 10.1074/jbc.M208786200; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Zaiou M, 2000, J LIPID RES, V41, P1087; Zhu YJ, 2003, J BIOL CHEM, V278, P36257, DOI 10.1074/jbc.M303171200	56	66	66	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5414	5422		10.1074/jbc.M411719200	http://dx.doi.org/10.1074/jbc.M411719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15583000	hybrid			2022-12-25	WOS:000227217100038
J	Jacob, Y; Sharkady, SM; Bhardwaj, K; Sanda, A; Williams, KP				Jacob, Y; Sharkady, SM; Bhardwaj, K; Sanda, A; Williams, KP			Function of the SmpB tail in transfer-messenger RNA translation revealed by a nucleus-encoded form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEIN-B; ESCHERICHIA-COLI; TMRNA WEBSITE; BINDING PROTEIN; IN-VITRO; SEQUENCE; RESCUE; SYSTEM; REGION; GENES	Stalled bacterial ribosomes are freed when they switch to the translation of transfer-messenger RNA (tmRNA). This process requires the tmRNA-binding and ribosome-binding cofactor SmpB, a beta-barrel protein with a protruding C-terminal tail of unresolved structure. Some plastid genomes encode tmRNA, but smpB genes have only been reported from bacteria. Here we identify smpB in the nuclear genomes of both a diatom and a red alga encoding a signal for import into the plastid, where mature SmpB could activate tmRNA. Diatom SmpB was active for tmRNA translation with bacterial components in vivo and in vitro, although less so than Escherichia coli SmpB. The tail-truncated diatom SmpB, the hypothetical product of a misspliced mRNA, was inactive in vivo. Tail-truncated E. coli SmpB was likewise inactive for tmRNA translation but was still able to bind ribosomes, and its affinity for tmRNA was only slightly diminished. This work suggests that SmpB is a universal cofactor of tmRNA. It also reveals a tail-dependent role for SmpB in tmRNA translation that supersedes a simple role of linking tmRNA to the ribosome, which the SmpB body alone could provide.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Williams, KP (corresponding author), Indiana Univ, Dept Biol, 1001 E 3rd St, Bloomington, IN 47405 USA.	kellwill@indiana.edu	Bhardwaj, Kanchan/CAH-2291-2022	Bhardwaj, Kanchan/0000-0002-7331-7717; Sharkady, Stephen/0000-0002-4147-3555				Apt KE, 2002, J CELL SCI, V115, P4061, DOI 10.1242/jcs.00092; Armbrust EV, 2000, J PHYCOL, V36, P942, DOI 10.1046/j.1529-8817.2000.00055.x; Barends S, 2000, BIOCHEMISTRY-US, V39, P2652, DOI 10.1021/bi992439d; Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; de Novoa PG, 2004, NUCLEIC ACIDS RES, V32, pD104, DOI 10.1093/nar/gkh102; Dong G, 2002, EMBO J, V21, P1845, DOI 10.1093/emboj/21.7.1845; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Gimple O, 2001, BIOL CHEM, V382, P1421, DOI 10.1515/BC.2001.175; Gueneau P, 1999, EUR J PHYCOL, V34, P533; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Haebel PW, 2004, CURR OPIN STRUC BIOL, V14, P58, DOI 10.1016/j.sbi.2004.01.010; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Himeno H, 1997, J MOL BIOL, V268, P803, DOI 10.1006/jmbi.1997.1011; Jacob Y, 2004, RNA, V10, P605, DOI 10.1261/rna.5227904; Jiang FL, 2002, J BIOL CHEM, V277, P19281, DOI 10.1074/jbc.M110857200; Kao C, 2001, METHODS, V23, P201, DOI 10.1006/meth.2000.1131; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; Someya T, 2003, FEBS LETT, V535, P94, DOI 10.1016/S0014-5793(02)03880-2; Wall MK, 2004, P NATL ACAD SCI USA, V101, P7821, DOI 10.1073/pnas.0400836101; Wiegert T, 2001, J BACTERIOL, V183, P3885, DOI 10.1128/JB.183.13.3885-3889.2001; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1998, NUCLEIC ACIDS RES, V26, P163, DOI 10.1093/nar/26.1.163; Williams KP, 2002, NUCLEIC ACIDS RES, V30, P179, DOI 10.1093/nar/30.1.179; Wower J, 2002, BIOCHEMISTRY-US, V41, P8826, DOI 10.1021/bi0201365	34	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5503	5509		10.1074/jbc.M409277200	http://dx.doi.org/10.1074/jbc.M409277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15596445	hybrid			2022-12-25	WOS:000227217100049
J	Shouldice, SR; McRee, DE; Dougan, DR; Tari, LW; Schryvers, AB				Shouldice, SR; McRee, DE; Dougan, DR; Tari, LW; Schryvers, AB			Novel anion-independent iron coordination by members of a third class of bacterial periplasmic ferric ion-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSPORT-SYSTEM; STRUCTURAL BASIS; TRANSFERRIN; LACTOFERRIN; MECHANISM; REVEALS; MUTANT; SIDEROPHORES; REFINEMENT	The uptake of the element iron is vital for the survival of most organisms. Numerous pathogenic Gram-negative bacteria utilize a periplasm-to-cytosol ATP-binding cassette transport pathway to transport this essential atom in to the cell. In this study, we investigated the Yersinia enterocolitica (YfuA) and Serratia marceseens (SfuA) iron-binding periplasmic proteins. We have determined the 1.8-Angstrom structures of iron-loaded YfuA) and iron-free (SfuA) forms of this class of proteins. Although the sequence of these proteins varies considerably from the other members of the transferrin structural superfamily, they adopt the same three-dimensional fold. The iron-loaded YfuA structure illustrates the unique nature of this new class of proteins in that they are able to octahedrally coordinate the ferric ion in the absence of a bound anion. The iron-free SfuA structure contains a bound citrate anion in the iron-binding cleft that tethers the N- and C-terminal domains of the apo protein and stabilizes the partially open structure.	Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; ActiveSight, San Diego, CA 92121 USA; Syrrx Inc, San Diego, CA 92121 USA	University of Calgary	Schryvers, AB (corresponding author), Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada.	schryver@ucalgary.ca	Schryvers, Anthony B./AAF-3417-2020					ADHIKARI P, 1995, J BIOL CHEM, V270, P25142, DOI 10.1074/jbc.270.42.25142; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; ANGERER A, 1992, J BACTERIOL, V174, P1378, DOI 10.1128/jb.174.4.1378-1387.1992; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Baker EN, 1998, ADV EXP MED BIOL, V443, P1; Bearden SW, 1999, MOL MICROBIOL, V32, P403, DOI 10.1046/j.1365-2958.1999.01360.x; Boukhalfa H, 2003, J BIOL INORG CHEM, V8, P881, DOI 10.1007/s00775-003-0487-y; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; Cornelissen CN, 1998, MOL MICROBIOL, V27, P611, DOI 10.1046/j.1365-2958.1998.00710.x; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Gong SM, 2001, INFECT IMMUN, V69, P2829, DOI 10.1128/IAI.67.5.2829-2837.2001; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; Khun HH, 1998, INFECT IMMUN, V66, P2330, DOI 10.1128/IAI.66.5.2330-2336.1998; Kirby SD, 1998, MICROBIOL-UK, V144, P3425, DOI 10.1099/00221287-144-12-3425; Kirby SD, 1997, MOL MICROBIOL, V25, P979, DOI 10.1111/j.1365-2958.1997.mmi535.x; Korndorfer IP, 2000, J MOL BIOL, V300, P917, DOI 10.1006/jmbi.2000.3896; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Ma L, 1996, BIOCHEMISTRY-US, V35, P2394, DOI 10.1021/bi9523421; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; OH BH, 1994, J BIOL CHEM, V269, P4135; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Saken E, 2000, INT J MED MICROBIOL, V290, P51; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Shouldice SR, 2004, J BACTERIOL, V186, P3903, DOI 10.1128/JB.186.12.3903-3910.2004; Shouldice SR, 2003, J BIOL CHEM, V278, P41093, DOI 10.1074/jbc.M306821200; Shouldice SR, 2003, J BIOL CHEM, V278, P11513, DOI 10.1074/jbc.M211780200; Taboy CH, 2001, J BIOL CHEM, V276, P2719, DOI 10.1074/jbc.M004763200; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; ZIMMERMANN L, 1989, J BACTERIOL, V171, P238, DOI 10.1128/jb.171.1.238-243.1989	48	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5820	5827		10.1074/jbc.M411238200	http://dx.doi.org/10.1074/jbc.M411238200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15576371	hybrid			2022-12-25	WOS:000227217100085
J	Jala, VR; Shao, WH; Haribabu, B				Jala, VR; Shao, WH; Haribabu, B			Phosphorylation-independent beta-arrestin translocation and internalization of leukotriene B-4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PLATELET-ACTIVATING-FACTOR; B-4 RECEPTOR; FORMYL PEPTIDE; BETA(2)-ADRENERGIC RECEPTOR; CROSS-DESENSITIZATION; KINASE; ATHEROSCLEROSIS; BETA-ARRESTIN-2; TRAFFICKING	Leukotriene B-4 (LTB4) activates the G-protein-coupled receptor leukotriene B-4 receptor 1 (BLT1) to mediate a diverse array of cellular responses in leukocytes including chemotaxis, calcium mobilization, degranulation, and gene expression. To determine the role of phosphorylation in BLT1 regulation, we generated mutants of BLT1 in which all of the serine/threonine residues in the C-tail are converted to alanine or to aspartate/glutamate. These mutants expressed in rat basophilic leukemia RBL-2H3 cells bound LTB4 with similar affinity and activated all of the known functional activities of BLT1, albeit at different levels. The conversion of phosphorylation sites to alanine resulted in enhanced G-protein-mediated activities, whereas conversion to aspartate/glutamate resulted in reduced responses and a right shift in dose response, indicating that receptor phosphorylation is a critical regulator of G-protein-mediated pathways. Surprisingly, translocation of beta-arrestin and receptor internalization was completely independent of BLT1 phosphorylation. Real-time analysis of beta-arrestin translocation and receptor internalization using digital fluorescence video microscopy in cells expressing a red fluorescent protein labeled BLT1 and a green fluorescent protein-tagged beta-arrestin confirmed phosphorylation-independent beta-arrestin translocation and internalization of BLT1. In beta-arrestin-deficient mouse embryo fibroblasts, the BLT1 receptors failed to display endosomal localization upon stimulation. In these cells, co-expression of beta-arrestin-green fluorescent protein with BLT1-red fluorescent protein resulted in co-localization of BLT1 and beta-arrestin upon activation. Thus, receptor phosphorylation-dependent mechanisms regulate G-protein-mediated pathways; however, phosphorylation-independent mechanisms regulate beta-arrestin association and internalization of BLT1.	Univ Louisville, Hlth Sci Ctr, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Microbiol & Immunol, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Haribabu, B (corresponding author), Univ Louisville, Hlth Sci Ctr, James Graham Brown Canc Ctr, 580 S Preston St,Rm 119 B,Delia Baxter Bldg, Louisville, KY 40202 USA.	H0bodd01@gwise.louisville.edu	Jala, Venkatakrishna R/K-7255-2018; Bodduluri, Haribabu/A-2584-2010; Shao, Wenhai/AAI-3363-2020	Jala, Venkatakrishna R/0000-0002-4206-7305; Bodduluri, Haribabu/0000-0002-8261-3294; 	NIAID NIH HHS [AI-43184, AI-52381] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043184, R01AI052381] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; ALI H, 1994, J BIOL CHEM, V269, P24557; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Chen CH, 2004, J BIOL CHEM, V279, P10020, DOI 10.1074/jbc.M310590200; Chen ZG, 2004, MOL PHARMACOL, V66, P377; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Galliera E, 2004, J BIOL CHEM, V279, P25590, DOI 10.1074/jbc.M400363200; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Goodman MP, 2000, J AM ASSOC GYN LAP, V7, P447, DOI 10.1016/S1074-3804(05)60356-8; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Jala VR, 2004, TRENDS IMMUNOL, V25, P315, DOI 10.1016/j.it.2004.04.003; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Luttrell LM, 2002, J CELL SCI, V115, P455; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; Richardson RM, 2001, BIOCHEMISTRY-US, V40, P3583, DOI 10.1021/bi0019242; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Subbarao K, 2004, ARTERIOSCL THROM VAS, V24, P369, DOI 10.1161/01.ATV.0000110503.16605.15; van Koppen CJ, 2004, MOL PHARMACOL, V66, P365, DOI 10.1124/mol.104.003822; Vines CM, 2002, J IMMUNOL, V169, P6760, DOI 10.4049/jimmunol.169.12.6760; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	39	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4880	4887		10.1074/jbc.M409821200	http://dx.doi.org/10.1074/jbc.M409821200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561704	hybrid			2022-12-25	WOS:000227096600108
J	Rieder, G; Tessier, AJ; Qiao, XTT; Madison, B; Gumucio, DL; Merchant, JL				Rieder, G; Tessier, AJ; Qiao, XTT; Madison, B; Gumucio, DL; Merchant, JL			Helicobacter-induced intestinal metaplasia in the stomach correlates with Elk-1 and serum response factor induction of villin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; C-FOS; BARRETTS METAPLASIA; REGULATED KINASE; GENE-EXPRESSION; PROTEIN VILLIN; CANCER GROWTH; BRUSH-BORDER; PYLORI; COMPLEX	Chronic Helicobacter pylori infection results in serious sequelae, including atrophy, intestinal metaplasia, and gastric cancer. Intestinal metaplasia in the stomach is defined by the presence of intestine-like cells expressing enterocyte-specific markers, such as villin. In this study, we demonstrate that villin is expressed in intestine-like cells that develop after chronic infection with H. pylori in both human stomach and in a mouse model. Transfection studies were used to identify specific regions of the villin promoter that are inducible by exposure of the cells to H. pylori. We demonstrated that induction of the villin promoter by H. pylori in a human gastric adenocarcinoma cell line (AGS) required activation of the Erk pathway. Elk-1 and the serum response factor (SRF) are downstream transcriptional targets of the Erk pathway. We observed inducible binding of Elk-1 and the SRF after 3 and 24 h of treatment with H. pylori, suggesting that the bacteria alone are sufficient to initiate a cascade of signaling events responsible for villin expression. Thus, H. pylori induction of villin in the stomach correlates with activation and cooperative binding of Elk-1 and the SRF to the proximal promoter of villin.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Merchant, JL (corresponding author), Univ Michigan, Med Sci Res Bldg 1,1150 W Med Ctr Dr,Rm 3510, Ann Arbor, MI 48109 USA.		Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061410, P01DK062041] Funding Source: NIH RePORTER; NCI NIH HHS [CA46952] Funding Source: Medline; NIDDK NIH HHS [P01DK62041, R01DK61410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-Latif MMM, 2004, INFECT IMMUN, V72, P3549, DOI 10.1128/IAI.72.6.3549-3560.2004; ALBORESSAAVEDRA J, 1988, PATHOL RES PRACT, V183, P169, DOI 10.1016/S0344-0338(88)80044-X; Basque JR, 2001, J CELL BIOCHEM, V81, P241, DOI 10.1002/1097-4644(20010501)81:2&lt;241::AID-JCB1039&gt;3.0.CO;2-B; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunstein EM, 2002, DEV DYNAM, V224, P90, DOI 10.1002/dvdy.10091; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; CORREA P, 1992, CANCER RES, V52, P6735; EZZELL RM, 1989, DEVELOPMENT, V106, P407; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; Fox JG, 2000, NAT MED, V6, P536, DOI 10.1038/75015; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Gille H, 1996, MOL CELL BIOL, V16, P1094; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HAGEN SJ, 1994, CELL TISSUE RES, V275, P255, DOI 10.1007/BF00319423; HAMPSON SJ, 1992, BRIT J UROL, V69, P323, DOI 10.1111/j.1464-410X.1992.tb15543.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Hirata Y, 2002, GASTROENTEROLOGY, V123, P1962, DOI 10.1053/gast.2002.37044; HOUBEN GMP, 1995, SCAND J GASTROENTERO, V30, P13, DOI 10.3109/00365529509090296; Jones MK, 1999, NAT MED, V5, P1418; Keates S, 1999, J IMMUNOL, V163, P5552; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kim B, 2003, CANCER RES, V63, P8248; LANDRY C, 1994, DIFFERENTIATION, V56, P55, DOI 10.1046/j.1432-0436.1994.56120055.x; MacLennan AJ, 1999, MOL CARCINOGEN, V24, P137, DOI 10.1002/(SICI)1098-2744(199902)24:2<137::AID-MC8>3.0.CO;2-A; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; MALHOTRA S L, 1976, Medical Hypotheses, V2, P279, DOI 10.1016/S0306-9877(76)80010-2; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; Mizoshita T, 2003, J CANCER RES CLIN, V129, P727, DOI 10.1007/s00432-003-0499-6; MOLL R, 1987, VIRCHOWS ARCH B, V54, P155, DOI 10.1007/BF02899208; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; Regalado SP, 1998, MOL CARCINOGEN, V22, P182, DOI 10.1002/(SICI)1098-2744(199807)22:3<182::AID-MC6>3.0.CO;2-N; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsukamoto T, 2004, J CANCER RES CLIN, V130, P135, DOI 10.1007/s00432-003-0519-6; Zavros Y, 2002, INFECT IMMUN, V70, P2630, DOI 10.1128/IAI.70.5.2630-2639.2002	43	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4906	4912		10.1074/jbc.M413399200	http://dx.doi.org/10.1074/jbc.M413399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15576363	hybrid			2022-12-25	WOS:000227096600111
J	Muranen, T; Gronholm, MG; Renkema, GH; Carpen, O				Muranen, T; Gronholm, MG; Renkema, GH; Carpen, O			Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin	ONCOGENE			English	Article						merlin; NF2; ERM; nucleus; cell cycle	TYPE-2 GENE-PRODUCT; ERM PROTEINS; P21-ACTIVATED KINASE; NUCLEAR EXPORT; GROWTH; LOCALIZATION; PHOSPHORYLATION; INHIBITION; ADHESION; SIGNAL	The neurofibromatosis 2 tumour suppressor merlin/schwannomin is structurally related to the ezrin-radixin-moesin family of proteins, which anchor actin cytoskeleton to specific membrane proteins and participate in cell signalling. Merlin inhibits cell growth with a yet unknown mechanism. As most tumour suppressors are linked to cell cycle control, we investigated merlin's behaviour during cell cycle. In glioma and osteosarcoma cells, endogenous merlin was targeted to the nucleus in a cell cycle-specific manner. Merlin accumulated perinuclearly at the G2/M phase, and shifted to the nucleus at early G1. During mitosis, merlin localized to mitotic spindles and at the contractile ring. Nuclear merlin was strongly reduced in confluent cells. Blocking of the CRM1/exportin nuclear export pathway led to accumulation of merlin in the nucleus. Activation of the p21-activated kinase or protein kinase A, which result in phosphorylation of merlin, did not affect its nuclear localization. Merlin regulates the activity of extracellular signal-regulated kinase 2 (ERK2) and nuclear localization of both proteins was induced by cell adhesion. Unlike ERK2, nuclear localization of merlin was not, however, dependent on intact actin cytoskeleton. These results link merlin to events related to cell cycle control and may help to resolve its tumour suppressor function.	Univ Helsinki, Neurosci Program, Biomedicum Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, Helsinki 00014, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital	Muranen, T (corresponding author), Univ Helsinki, Neurosci Program, Biomedicum Helsinki, Dept Pathol, PB 63, FIN-00014 Helsinki, Finland.	taru.muranen@helsinki.fi	Renkema, Herma/L-1489-2015; Muranen, Taru/AAM-9349-2021	Renkema, Herma/0000-0002-8174-6538; Muranen, Taru/0000-0003-4158-9002; Gronholm, Mikaela/0000-0002-2378-8924				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Aplin AE, 2003, FEBS LETT, V534, P11, DOI 10.1016/S0014-5793(02)03840-1; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DENBAKKER MA, 1995, ONCOGENE, V10, P757; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Giovannini M, 2000, GENE DEV, V14, P1617; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 1999, J CELL SCI, V112, P895; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Huynh DP, 1996, ONCOGENE, V13, P73; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lallena MJ, 1997, J CELL SCI, V110, P239; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Lohez OD, 2003, J CELL BIOL, V161, P67, DOI 10.1083/jcb.200208140; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Shollar D, 2004, ONCOGENE, V23, P5459, DOI 10.1038/sj.onc.1207728; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	41	46	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2005	24	7					1150	1158		10.1038/sj.onc.1208283	http://dx.doi.org/10.1038/sj.onc.1208283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580288				2022-12-25	WOS:000226898700003
J	O'Donnell, RK; Kupferman, M; Wei, SJ; Singhal, S; Weber, R; O'Malley, B; Cheng, Y; Putt, M; Feldman, M; Ziober, B; Muschel, RJ				O'Donnell, RK; Kupferman, M; Wei, SJ; Singhal, S; Weber, R; O'Malley, B; Cheng, Y; Putt, M; Feldman, M; Ziober, B; Muschel, RJ			Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity	ONCOGENE			English	Article						lymphatic metastasis; squamous cell carcinoma; microarray; gene expression pattern	MOLECULAR CLASSIFICATION; NODE METASTASIS; CHEMOKINE RECEPTORS; CDNA MICROARRAYS; DNA MICROARRAYS; BREAST-CANCER; IDENTIFICATION; HEAD; PROFILES; VALIDATION	Metastasis via the lymphatics is a major risk factor in squamous cell carcinoma of the oral cavity (OSCC). We sought to determine whether the presence of metastasis in the regional lymph node could be predicted by a gene expression signature of the primary tumor. A total of 18 OSCCs were characterized for gene expression by hybridizing RNA to Affymetrix U133A gene chips. Genes with differential expression were identified using a permutation technique and verified by quantitative RT-PCR and immunohistochemistry. A predictive rule was built using a support vector machine, and the accuracy of the rule was evaluated using crossvalidation on the original data set and prediction of an independent set of four patients. Metastatic primary tumors could be differentiated from nonmetastatic primary tumors by a signature gene set of 116 genes. This signature gene set correctly predicted the four independent patients as well as associating five lymph node metastases from the original patient set with the metastatic primary tumor group. We concluded that lymph node metastasis could be predicted by gene expression profiles of primary oral cavity squamous cell carcinomas. The presence of a gene expression signature for lymph node metastasis indicates that clinical testing to assess risk for lymph node metastasis should be possible.	Hosp Univ Penn, Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD USA; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; University of Pennsylvania	Muschel, RJ (corresponding author), Hosp Univ Penn, Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA.	muschel@xrt.upenn.edu		O'Donnell, Rebekah/0000-0001-5878-7510				Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Bei R, 2001, J PATHOL, V195, P343, DOI 10.1002/path.965; Belbin TJ, 2002, CANCER RES, V62, P1184; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Chen BS, 2000, INT J CANCER, V88, P862, DOI 10.1002/1097-0215(20001215)88:6<862::AID-IJC4>3.0.CO;2-L; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Clare Amanda, 2002, In Silico Biology, V2, P511; Datta S, 2003, BIOINFORMATICS, V19, P459, DOI 10.1093/bioinformatics/btg025; Delilbasi CB, 2004, ORAL ONCOL, V40, P154, DOI 10.1016/S1368-8375(03)00144-1; Depondt J, 1999, EUR J ORAL SCI, V107, P442, DOI 10.1046/j.0909-8836.1999.eos107605.x; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Greenberg JS, 2003, CANCER, V97, P1464, DOI 10.1002/cncr.11202; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hong WKWR, 1995, HEAD NECK CANC BASIC; Hwang D, 2003, ORAL ONCOL, V39, P259, DOI 10.1016/S1368-8375(02)00108-2; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kim Hyoun Chull, 1993, Kurume Medical Journal, V40, P183; Leethanakul C, 2003, ORAL ONCOL, V39, P248, DOI 10.1016/S1368-8375(02)00107-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loriot A, 2003, INT J CANCER, V105, P371, DOI 10.1002/ijc.11104; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Myers LL, 1998, LARYNGOSCOPE, V108, P232, DOI 10.1097/00005537-199802000-00014; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Ohta T, 1996, BRIT J CANCER, V73, P1511, DOI 10.1038/bjc.1996.285; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Roth C, 2000, GENOMICS, V63, P384, DOI 10.1006/geno.1999.6084; Schmalbach CE, 2004, ARCH OTOLARYNGOL, V130, P295, DOI 10.1001/archotol.130.3.295; Scimone ML, 2004, J EXP MED, V199, P1113, DOI 10.1084/jem.20031645; Stringer BK, 2001, CANCER RES, V61, P582; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van Kempen LCLT, 2003, EUR J CELL BIOL, V82, P539, DOI 10.1078/0171-9335-00346; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Warner GC, 2004, INT J CANCER, V110, P857, DOI 10.1002/ijc.20197; Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	51	152	162	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1244	1251		10.1038/sj.onc.1208285	http://dx.doi.org/10.1038/sj.onc.1208285			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558013				2022-12-25	WOS:000226898700011
J	Guo, Q; Sousa, R				Guo, Q; Sousa, R			Multiple roles for the T7 promoter nontemplate strand during transcription initiation and polymerase release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ELONGATION COMPLEX; STRUCTURAL TRANSITIONS; T7-RNA POLYMERASE; KINETIC-ANALYSIS; BUBBLE COLLAPSE; STABILITY; DNA; DISPLACEMENT; CONFORMATION	Transcription initiation begins with recruitment of an RNA polymerase to a promoter. Polymerase-promoter interactions are retained until the nascent RNA is extended to 8-12 nucleotides. It has been proposed that accumulation of "strain" in the transcription complex and RNA displacement of promoter-polymerase interactions contribute to releasing the polymerase from the promoter, and it has been further speculated that too strong a promoter interaction can inhibit the release step, whereas a weak interaction may facilitate release. We examined the effects of partial deletion of the nontemplate strand on release of T7 RNA polymerase from the T7 promoter. T7 polymerase will initiate from such partially single-stranded promoters but binds them with higher affinity than duplex promoters. We found that release on partially single-stranded promoters is strongly inhibited. The inhibition of release is not due to an indirect effect on transcription complex structure or loss of specific polymerase-nontemplate strand interactions, because release on partially single-stranded templates is recovered if the interaction with the promoter is weakened by a promoter base substitution. This same substitution also appears to allow the polymerase to escape more readily from a duplex promoter. Our results further suggest that template-nontemplate strand reannealing drives dissociation of abortive transcripts during initial transcription and that loss of interactions with either the nontemplate strand or duplex DNA downstream of the RNA lead to increased transcription complex slippage during initiation.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Sousa, R (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	sousa@biochem.uthscsa.edu		Sousa, Rui/0000-0003-4314-121X	NIGMS NIH HHS [R01 GM052522, GM52522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2002, J MOL BIOL, V324, P63, DOI 10.1016/S0022-2836(02)01034-3; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; Esposito EA, 2004, J BIOL CHEM, V279, P44270, DOI 10.1074/jbc.M407688200; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; Greiner DP, 1997, BIOCONJUGATE CHEM, V8, P44, DOI 10.1021/bc9600731; He B, 1998, J BIOL CHEM, V273, P18802, DOI 10.1074/jbc.273.30.18802; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jiang ML, 2004, MOL CELL, V15, P777, DOI 10.1016/j.molcel.2004.07.019; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4281, DOI 10.1021/bi00067a017; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; Mooney RA, 1999, CELL, V98, P687, DOI 10.1016/S0092-8674(00)81483-X; Mukherjee S, 2003, EMBO J, V22, P6483, DOI 10.1093/emboj/cdg618; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; Sutton DH, 1997, BIOCHEM J, V321, P481, DOI 10.1042/bj3210481; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; Yan M, 1997, EMBO J, V16, P7457, DOI 10.1093/emboj/16.24.7457; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	36	12	14	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3474	3482		10.1074/jbc.M412287200	http://dx.doi.org/10.1074/jbc.M412287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15561715	hybrid			2022-12-25	WOS:000226983900043
J	Cai, L; de Beer, MC; de Beer, FC; van der Westhuyzen, DR				Cai, L; de Beer, MC; de Beer, FC; van der Westhuyzen, DR			Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE; SR-BI; CHOLESTEROL EFFLUX; MACROPHAGE CHOLESTEROL; PLASMA-CLEARANCE; HDL CHOLESTEROL; TRANSGENIC MICE; HEPG2 CELLS; PROTEIN; APOLIPOPROTEIN	Serum amyloid A is an acute phase protein that is carried in the plasma largely as an apolipoprotein of high density lipoprotein (HDL). In this study we investigated whether SAA is a ligand for the HDL receptor, scavenger receptor class B type I (SR-BI), and how SAA may influence SR-BI-mediated HDL binding and selective cholesteryl ester uptake. Studies using Chinese hamster ovary cells expressing SR-BI showed that I-125- labeled SAA, both in lipid-free form and in reconstituted HDL particles, functions as a high affinity ligand for SR-BI. SAA also bound with high affinity to the hepatocyte cell line, HepG2. Alexa-labeled SAA was shown by fluorescence confocal microscopy to be internalized by cells in a SR-BI-dependent manner. To assess how SAA association with HDL influences HDL interaction with SR-BI, SAA-containing HDL was isolated from mice overexpressing SAA through adenoviral gene transfer. SAA presence on HDL had little effect on HDL binding to SR-BI but decreased (30-50%) selective cholesteryl ester uptake. Lipid-free SAA, unlike lipid-free apoA-1, was an effective inhibitor of both SR-BI-dependent binding and selective cholesteryl ester uptake of HDL. We have concluded that SR-BI plays a key role in SAA metabolism through its ability to interact with and internalize SAA and, further, that SAA influences HDL cholesterol metabolism through its inhibitory effects on SR-BI-mediated selective lipid uptake.	Univ Kentucky, Med Ctr, Dept Internal Med, Grad Ctr Nutr Sci, Lexington, KY 40536 USA; Dept Vet Affairs Med Ctr, Lexington, KY 40511 USA	University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	van der Westhuyzen, DR (corresponding author), Univ Kentucky, Med Ctr, Dept Internal Med, Grad Ctr Nutr Sci, Wethington Hlth Sci Bldg 541,900 S Limestone St, Lexington, KY 40536 USA.	dvwest1@uky.edu	Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [HL-65730, HL-63763] Funding Source: Medline; NIA NIH HHS [AG-17237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065730, R01HL063763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017237] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; Artl A, 2002, INT J BIOCHEM CELL B, V34, P370, DOI 10.1016/S1357-2725(01)00132-7; Azhar S, 2002, MOL CELL ENDOCRINOL, V195, P1, DOI 10.1016/S0303-7207(02)00222-8; BANKA CL, 1995, J LIPID RES, V36, P1058; BAUSSERMAN LL, 1987, J BIOL CHEM, V262, P1583; Buechler C, 1999, BIOCHEM BIOPH RES CO, V262, P251, DOI 10.1006/bbrc.1999.1193; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; de Beer MC, 2001, J LIPID RES, V42, P309; de Beer MC, 2004, J LIPID RES, V45, P706, DOI 10.1194/jlr.M300417-JLR200; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; DEBEER MC, 1995, J LIPID RES, V36, P526; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; Hayat S, 1997, BIOCHEM SOC T, V25, pS348, DOI 10.1042/bst025348s; Hirano K, 1999, CIRC RES, V85, P108; HOFFMAN JS, 1983, J CLIN INVEST, V71, P926, DOI 10.1172/JCI110847; Hosoai H, 1999, J LIPID RES, V40, P648; Khovidhunkit W, 2001, J LIPID RES, V42, P967; Kisilevsky R, 2003, J LIPID RES, V44, P2257, DOI 10.1194/jlr.M300133-JLR200; Kisilevsky R, 2003, J MOL NEUROSCI, V20, P291, DOI 10.1385/JMN:20:3:291; Kisilevsky R, 2002, PEDIATR PATHOL MOL M, V21, P291, DOI 10.1080/02770930290056523; KISILEVSKY R, 1992, LAB INVEST, V66, P778; KluveBeckerman B, 1997, BIOCHEM J, V322, P663, DOI 10.1042/bj3220663; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Liang JS, 1996, J LIPID RES, V37, P2109; LY H, 1995, J LIPID RES, V36, P1254; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; RAMADORI G, 1985, J IMMUNOL, V135, P3645; Rhainds D, 1999, EUR J BIOCHEM, V261, P227, DOI 10.1046/j.1432-1327.1999.00264.x; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Rocken C, 1997, AMYLOID, V4, P259, DOI 10.3109/13506129709003837; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Sipe J, 1999, AMYLOID, V6, P67, DOI 10.3109/13506129908993291; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Tam SP, 2002, J LIPID RES, V43, P1410, DOI 10.1194/jlr.M100388-JLR200; TURNELL W, 1986, MOL BIOL MED, V3, P387; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Van Lenten BJ, 2001, TRENDS CARDIOVAS MED, V11, P155, DOI 10.1016/S1050-1738(01)00095-0; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 1997, J LIPID RES, V38, P1583; Webb NR, 2002, J LIPID RES, V43, P1890, DOI 10.1194/jlr.M200173-JLR200; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Wustner D, 2004, J LIPID RES, V45, P427, DOI 10.1194/jlr.M300440-JLR200; Xu SZ, 1997, J LIPID RES, V38, P1289	53	145	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2954	2961		10.1074/jbc.M411555200	http://dx.doi.org/10.1074/jbc.M411555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15561721	hybrid			2022-12-25	WOS:000226449100071
J	Olivari, S; Galli, C; Alanen, H; Ruddock, L; Molinari, M				Olivari, S; Galli, C; Alanen, H; Ruddock, L; Molinari, M			A novel stress-induced EDEM variant regulating endoplasmic reticulum-associated glycoprotein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; PLASMA-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR XBP-1; MANNOSIDASE-LIKE PROTEIN; ER-ASSOCIATED DEGRADATION; SECRETORY PATHWAY; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS; OLIGOSACCHARIDE; CALNEXIN	Proteins expressed in the endoplasmic reticulum (ER) are subjected to a tight quality control. Persistent association with ER-resident molecular chaperones prevents exit of misfolded or incompletely assembled polypeptides from the ER and forward transport along the secretory line. ER-associated degradation (ERAD) is in place to avoid ER constipation. Folding-incompetent products have to be identified to interrupt futile folding attempts and then targeted for unfolding and dislocation into the cytosol for proteasome-mediated destruction. These processes are better understood for N-glycosylated proteins that represent the majority of polypeptides expressed in the EM EDEM, a mannosidase-like chaperone, regulates the extraction of misfolded glycoproteins from the calnexin cycle. Here we identify and characterize EDEM2, a novel, stress-regulated mannosidase-like protein that operates in the ER lumen. We show that transcriptional up-regulation of EDEM2 depends on the ER stress-activated transcription factor X-bp1, that EDEM2 up-regulation selectively accelerates ERAD of terminally misfolded glycoproteins by facilitating their extraction from the calnexin cycle, and that the previously characterized homolog EDEM is also a soluble protein of the ER lumen in HEK293 cells.	Inst Res Biomed, CH-6500 Bellinzona, Switzerland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90570 Oulu, Finland	Universita della Svizzera Italiana; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Molinari, M (corresponding author), Inst Res Biomed, CH-6500 Bellinzona, Switzerland.	maurizio.molinari@irb.unisi.ch	Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829; Ruddock, Lloyd/0000-0002-6247-686X				Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Braakman I, 2001, EMBO REP, V2, P666, DOI 10.1093/embo-reports/kve162; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Eriksson KK, 2004, J BIOL CHEM, V279, P44600, DOI 10.1074/jbc.M407972200; Gnann A, 2004, MOL BIOL CELL, V15, P4125, DOI 10.1091/mbc.e04-01-0024; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; Hampton RY, 2003, DEV CELL, V4, P144, DOI 10.1016/S1534-5807(03)00032-7; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Jakob CA, 2001, EMBO REP, V2, P423; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Reimold AM, 2000, GENE DEV, V14, P152; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Wang T, 2003, NAT STRUCT BIOL, V10, P319, DOI 10.1038/nsb0503-319; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4	42	124	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2424	2428		10.1074/jbc.C400534200	http://dx.doi.org/10.1074/jbc.C400534200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15579471	hybrid			2022-12-25	WOS:000226449100007
J	Carvalho, G; Lefaucheur, C; Cherbonnier, C; Metivier, D; Chapel, A; Pallardy, M; Bourgeade, MF; Charpentier, B; Hirsch, F; Kroemer, G				Carvalho, G; Lefaucheur, C; Cherbonnier, C; Metivier, D; Chapel, A; Pallardy, M; Bourgeade, MF; Charpentier, B; Hirsch, F; Kroemer, G			Chemosensitization by erythropoietin through inhibition of the NF-kappa B rescue pathway	ONCOGENE			English	Article						apoptosis; renal carcinoma; jak; leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN GROWTH-HORMONE; CELL-DEATH; MYELODYSPLASTIC SYNDROME; PRACTICE PATTERNS; MULTIPLE-MYELOMA; GENE-EXPRESSION; IN-VIVO; CANCER; APOPTOSIS	Two cell lines that exemplify erythropoietin (EPO) receptor-positive tumors, human renal carcinoma cell lines RCC and the myelomonocytic leukemia cell line U937, were investigated for the apoptosis-modulatory potential of EPO. Cells cultured in the presence of EPO exhibited an elevated apoptotic response to cancer chemotherapeutic agents such as daunorubicin (Dauno) and vinblastine (VBL). Chemosensitization by EPO did not involve an increase in p53 activation, yet correlated with enhanced Bax/Bak-dependent mitochondrial membrane perturbation and caspase maturation. In vitro monotherapy with Dauno or VBL induced the degradation of IkappaBalpha, provoked the translocation of NF-kappaB p65/50 to the nucleus and stimulated the expression of an NF-kappaB-activatable reporter gene. All these signs of NF-kappaB activation were perturbed in the presence of EPO. Inhibition of JAK2, one of the receptor-proximal elements of EPO-mediated signal transduction, greatly diminished the EPO-mediated chemosensitization and NF-kappaB inhibition. EPO lost its death-facilitating effects in the presence of an NF-kappaB inhibitor, underscoring the cause-effect relationship between EPO-mediated chemosensitization and NF-kappaB inhibition. Altogether, these results suggest that, at least in a specific subset of tumors, EPO receptor agonists can prevent activation of the NF-kappaB pathway, thereby enhancing the propensity of EPO receptor-positive tumor cells to undergo apoptosis.	Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France; Univ Paris 11, Hop Paul Brousse, INSERM, U542, F-94802 Villejuif, France; IRSN, Fontenay Aux Roses, France; Fac Pharm Paris, INSERM, U461, F-92296 Chatenay Malabry, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	hirsch@babbage.infobiogen.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; lefaucheur, carmen/F-3502-2013	KROEMER, Guido/0000-0002-9334-4405; chapel, alain/0000-0002-4687-4120				Acs G, 2001, CANCER RES, V61, P3561; Adams JR, 2004, AM J MED, V116, P28, DOI 10.1016/j.amjmed.2003.06.004; Angevin E, 1999, LAB INVEST, V79, P879; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bunworasate U, 2001, BLOOD, V98, P3492, DOI 10.1182/blood.V98.12.3492; Castedo M, 2002, TRENDS CELL BIOL, V12, P446, DOI 10.1016/S0962-8924(02)02346-2; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chapel A, 1999, EXP HEMATOL, V27, P250, DOI 10.1016/S0301-472X(98)00009-5; Cherbonnier C, 2003, BRIT J CANCER, V89, P1108, DOI 10.1038/sj.bjc.6601223; Cherbonnier C, 2002, CANCER GENE THER, V9, P497, DOI 10.1038/sj.cgt.7700467; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Durrbach A, 1999, CANCER GENE THER, V6, P564, DOI 10.1038/sj.cgt.7700085; Fine BM, 2004, BLOOD, V103, P1043, DOI 10.1182/blood-2003-05-1518; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood T, 2002, SEMIN ONCOL, V29, P40, DOI 10.1053/sonc.2002.33532; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minet E, 2000, INT J MOL MED, V5, P253; Mittelman M, 2004, EUR J HAEMATOL, V72, P155, DOI 10.1046/j.0902-4441.2003.00190.x; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schwartzberg L, 2003, CLIN THER, V25, P2781, DOI 10.1016/S0149-2918(03)80333-8; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Takeshita A, 2002, LEUKEMIA LYMPHOMA, V43, P261, DOI 10.1080/10428190290006026; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x; Williams SA, 2003, CANCER RES, V63, P7338; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	53	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					737	745		10.1038/sj.onc.1208205	http://dx.doi.org/10.1038/sj.onc.1208205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580299	Bronze			2022-12-25	WOS:000226577100001
J	Seitz, S; Frege, R; Jacobsen, A; Weimer, R; Arnold, W; von Haefen, C; Niederacher, D; Schmutzler, R; Arnold, N; Scherneck, S				Seitz, S; Frege, R; Jacobsen, A; Weimer, R; Arnold, W; von Haefen, C; Niederacher, D; Schmutzler, R; Arnold, N; Scherneck, S			A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8	ONCOGENE			English	Article						breast tumorigenesis; microcell-mediated chromosome transfer; expression difference analysis	CLUSTERIN EXPRESSION; SUPPRESSOR GENE; ALLELIC LOSS; REGION; HETEROZYGOSITY; IDENTIFICATION; CHROMOSOME-8; ASSOCIATION; METASTASIS; PROGNOSIS	Several investigations have supposed that tumor suppressor genes might be located on human chromosome 8. We used microcell-mediated transfer of chromosome 8 into MDA-MB-231 breast cancer cells and generated independent hybrids with strongly reduced tumorigenic potential. Loss of the transferred chromosome results in reappearance of the malignant phenotype. Expression analysis identified a set of 109 genes (CT8-ps) differentially expressed in microcell hybrids as compared to the tumorigenic MDA-MB-231 and rerevertant cells. Of these, 44.9% are differentially expressed in human breast tumors. The expression pattern of CT8-ps was associated with prognostic factors such as tumor size and grading as well as loss of heterozygosity at the short arm of chromosome 8. We identified CT8-ps networks suggesting that these genes act cooperatively to cause reversion of tumorigenicity in MDA-MB-231 cells. Our findings provide a conceptual basis and experimental system to identify and evaluate genes and gene networks involved in the development and/or progression of breast cancer.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13125 Berlin, Germany; Gynecol & Obstet Clin, Oncol Lab, D-24105 Kiel, Germany; Atugen AG, D-13125 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Dept Obstet & Gynecol, D-40225 Dusseldorf, Germany; Gynecol & Obstet Clin, Dept Mol Gynecol & Oncol, D-50931 Cologne, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Heinrich Heine University Dusseldorf	Seitz, S (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, Robert Roessle Str 10, D-13125 Berlin, Germany.	sseitz@mdc-berlin.de	Arnold, Norbert/E-3012-2010; Weimer, Jörg Paul/E-3472-2010	Arnold, Norbert/0000-0003-4523-8808; Weimer, Jörg Paul/0000-0002-4528-8509				Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Borg A, 2003, NAT MED, V9, P16, DOI 10.1038/nm0103-16; Goldberg EK, 2000, AM J HUM GENET, V67, P417, DOI 10.1086/302999; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Gustafson CE, 1996, CANCER RES, V56, P5238; HOGUE DA, 1996, AM J HUM GENET, V56, pA15; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kugoh H, 2002, MOL CARCINOGEN, V35, P148, DOI 10.1002/mc.10080; Lerebours F, 2002, CRIT REV ONCOL HEMAT, V44, P121, DOI 10.1016/S1040-8428(01)00191-3; LOGAN GJ, 2002, IMMUNOLOGY, V28; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Nihei N, 2002, CANCER RES, V62, P367; Payton M, 2002, ONCOGENE, V21, P8529, DOI 10.1038/sj.onc.1206035; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Rennstam K, 2003, CANCER RES, V63, P8861; Saffer H, 2002, MODERN PATHOL, V15, P1221, DOI 10.1097/01.MP.0000036386.87517.AA; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Schlitt T, 2003, GENOME RES, V13, P2568, DOI 10.1101/gr.1111403; Seitz S, 2000, EUR J CANCER, V36, P1507, DOI 10.1016/S0959-8049(00)00135-0; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 2003, GENE CHROMOSOME CANC, V37, P29, DOI 10.1002/gcc.10196; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Suzuki A, 1999, INT J ONCOL, V15, P443; THEILE M, 1994, INT J ONCOL, V4, P1067; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Tsuneizumi M, 2002, CANCER LETT, V180, P75, DOI 10.1016/S0304-3835(02)00010-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weimer J, 1999, CHROMOSOME RES, V7, P355, DOI 10.1023/A:1009263913478; Weimer J, 2000, CYTOGENET CELL GENET, V88, P114, DOI 10.1159/000015502; Wilson P, 2003, CANCER GENET CYTOGEN, V143, P100, DOI 10.1016/S0165-4608(02)00850-6; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; ZHANG RD, 1991, INVAS METAST, V11, P204	43	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					869	879		10.1038/sj.onc.1208260	http://dx.doi.org/10.1038/sj.onc.1208260			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580292				2022-12-25	WOS:000226577100013
J	Sultan, AS; Xie, JW; LeBaron, MJ; Ealley, EL; Nevalainen, MT; Rui, H				Sultan, AS; Xie, JW; LeBaron, MJ; Ealley, EL; Nevalainen, MT; Rui, H			Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells	ONCOGENE			English	Article						Stat5; breast cancer; E-cadherin; invasion; adhesion; metastasis	MAMMARY EPITHELIAL-CELLS; PROLACTIN SIGNAL-TRANSDUCTION; E-CADHERIN EXPRESSION; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; CONDITIONAL KNOCKOUT; GLAND DEVELOPMENT; GENE-EXPRESSION; BETA-CATENIN; GROWTH	Signal transducer and activator of transcription-5 (Stat5) mediates prolactin (PRL)-induced differentiation and growth of breast epithelial cells. We have recently identified active Stat5 as a tumor marker of favorable prognosis in human breast cancer, and determined that Stat5 activation is lost during metastatic progression. Here we provide novel evidence for an invasion-suppressive role of Stat5 in human breast cancer. Activation of Stat5 by PRL in human breast cancer lines was associated with increased surface levels of the invasion-suppressive adhesion molecule E-cadherin in vitro and in xenotransplant tumors in vivo. Inducible E-cadherin was blocked by dominant-negative (Dn) Stat5 or Dn-Jak2, but not by Dn-Stat3. Further experimental data indicated a role of Stat5 as a coordinate regulator of additional invasion-related characteristics of human breast cancer cells, including cell surface association of beta-catenin, homotypic cell clustering, invasion through Matrigel, cell migration, and matrix metalloproteinase activity. A role of Stat5 as a suppressor of breast cancer invasion and metastatic progression provides a biological mechanism to explain the favorable prognosis associated with active Stat5 in human breast cancer.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Rui, H (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, NRB E504,3970 Reservoir Rd NW, Washington, DC 20057 USA.	ruih@georgetown.edu	Sultan, Prof. Ahmed S/AFH-7788-2022	Sultan, Prof. Ahmed S/0000-0001-6568-1757; Sultan, Ahmad/0000-0001-5776-1837	NCI NIH HHS [CA101841, 1P30-CA-51008] Funding Source: Medline; NIDDK NIH HHS [DK52013] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA101841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; Arihiro K, 2000, Breast Cancer, V7, P221, DOI 10.1007/BF02967464; Badache A, 2001, CANCER RES, V61, P383; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Das R, 1996, ONCOGENE, V13, P1139; DUHE RJ, 1995, GENE, V158, P281, DOI 10.1016/0378-1119(95)00041-4; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Groner B, 2000, BREAST CANCER RES, V2, P149, DOI 10.1186/bcr47; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Kabotyanski EB, 2003, J BIOL CHEM, V278, P17218, DOI 10.1074/jbc.M301578200; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Mbalaviele G, 1996, CANCER RES, V56, P4063; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nevalainen MT, 2002, MOL ENDOCRINOL, V16, P1108, DOI 10.1210/mend.16.5.0839; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Philips N, 2004, CANCER LETT, V206, P63, DOI 10.1016/j.canlet.2003.10.019; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schaber JD, 1998, CANCER RES, V58, P1914; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SHIU RPC, 1984, CANCER RES, V44, P1178; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Sultan AS, 1997, J BIOL CHEM, V272, P2866, DOI 10.1074/jbc.272.5.2866; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Wagner KU, 2004, MOL CELL BIOL, V24, P5510, DOI 10.1128/MCB.24.12.5510-5520.2004; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Xie J, 2002, J BIOL CHEM, V277, P14020, DOI 10.1074/jbc.M112399200; Yamashita H, 1999, J BIOL CHEM, V274, P14699, DOI 10.1074/jbc.274.21.14699; Yamashita H, 2003, ONCOGENE, V22, P1638, DOI 10.1038/sj.onc.1206277; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; Zhang SS, 1999, J CELL SCI, V112, P2693	58	157	163	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					746	760		10.1038/sj.onc.1208203	http://dx.doi.org/10.1038/sj.onc.1208203			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592524				2022-12-25	WOS:000226577100002
J	Nikolaev, VO; Gambaryan, S; Engelhardt, S; Walter, U; Lohse, MJ				Nikolaev, VO; Gambaryan, S; Engelhardt, S; Walter, U; Lohse, MJ			Real-time monitoring of the PDE2 activity of live cells - Hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ALDOSTERONE SECRETION; EXPRESSION; MODEL	Cyclic nucleotide phosphodiesterases (PDEs) are the enzymes that catalyze the hydrolysis of cAMP and cGMP, thereby restricting the activity of these second messengers in cells. A unique ability to shape gradients of cyclic nucleotides and compartmentalize their signaling implies a high potency and a rapid action of PDEs. However, it has not been demonstrated how fast PDEs can hydrolyze cAMP in a living system. Here we perform a real-time monitoring of PDE2 activity in aldosterone-producing adrenal cells using a recently developed genetically encoded, fluorescent cAMP sensor, which reveals enormously rapid kinetics of cAMP degradation. Activation of PDE2 results in a rapid decrease of intracellular cAMP from high micromolar to the sub-micromolar range within a few seconds. Moreover, the kinetics of atrial natriuretic peptide-stimulated PDE2 activity ( measured as decline of cAMP) are much faster than the speed of ACTH and isoprenaline-induced cAMP-synthesis ( measured as cAMP accumulation) in the cells, revealing high catalytic activity and fast action of PDEs in regulating cAMP signaling in a physiological system.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Engelhardt, Stefan/AAA-9329-2019; Nikolaev, Vyacheslav/AAT-7746-2020; Walter, ulrich/W-2478-2017; Gambaryan, Stepan/I-3940-2016; Lohse, Martin J/A-7160-2012	Engelhardt, Stefan/0000-0001-5378-8661; Walter, ulrich/0000-0001-6784-2307; Gambaryan, Stepan/0000-0002-1470-0791; Lohse, Martin J/0000-0002-0599-3510				Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; GALLOPAYET N, 1993, CELL SIGNAL, V5, P651, DOI 10.1016/0898-6568(93)90060-Y; Gambaryan S, 2003, J BIOL CHEM, V278, P29640, DOI 10.1074/jbc.M302143200; Georget M, 2003, FASEB J, V17, P1380, DOI 10.1096/fj.02-0784com; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; MERY PF, 1995, MOL PHARMACOL, V48, P121; Mongillo M, 2004, CIRC RES, V95, P67, DOI 10.1161/01.RES.0000134629.84732.11; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; PODZUWEIT T, 1995, CELL SIGNAL, V7, P733, DOI 10.1016/0898-6568(95)00042-N; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Rich TC, 2001, J GEN PHYSIOL, V118, P63, DOI 10.1085/jgp.118.1.63; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Rybalkin SD, 2003, CIRC RES, V93, P280, DOI 10.1161/01.RES.0000087541.15600.2B; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Spat A, 2004, PHYSIOL REV, V84, P489, DOI 10.1152/physrev.00030.2003; Takakusa H, 2002, J AM CHEM SOC, V124, P1653, DOI 10.1021/ja011251q	20	102	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1716	1719		10.1074/jbc.C400505200	http://dx.doi.org/10.1074/jbc.C400505200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15557342	hybrid			2022-12-25	WOS:000226341700002
J	Oliveira, HCF; Cosso, RG; Alberici, LC; Maciel, EN; Salerno, AG; Dorighello, GG; Velho, JA; de Faria, EC; Vercesi, AE				Oliveira, HCF; Cosso, RG; Alberici, LC; Maciel, EN; Salerno, AG; Dorighello, GG; Velho, JA; de Faria, EC; Vercesi, AE			Oxidative stress in atherosclerosis-prone mouse is due to low antioxidant capacity of mitochondria	FASEB JOURNAL			English	Article						hypercholesterolemia; LDL receptor; reactive oxygen species; mitochondria permeability transition; pyridine nucleotide oxidation	LOW-DENSITY-LIPOPROTEIN; PERMEABILITY TRANSITION; CHOLESTEROL-SYNTHESIS; PYRIDINE-NUCLEOTIDES; LIVER-MITOCHONDRIA; RECEPTOR; ATHEROGENESIS; STATE; FLUORESCENCE; GENERATION	Atherosclerotic disease remains a leading cause of death in westernized societies, and reactive oxygen species (ROS) play a pivotal role in atherogenesis. Mitochondria are the main intracellular sites of ROS generation and are also targets for oxidative damage. Here, we show that mitochondria from atherosclerosis-prone, hypercholesterolemic low-density lipoprotein (LDL) receptor knockout mice have oxidative phosphorylation efficiency similar to that from control mice but have a higher net production of ROS and susceptibility to develop membrane permeability transition. Increased ROS production was observed in mitochondria isolated from several tissues, including liver, heart, and brain, and in intact mononuclear cells from spleen. In contrast to control mitochondria, knockout mouse mitochondria did not sustain a reduced state of matrix NADPH, the main source of antioxidant defense against ROS. Experiments in vivo showed faster liver secretion rates and de novo synthesis of triglycerides and cholesterol in knockout than in control mice, suggesting that increased lipogenesis depleted the reducing equivalents from NADPH and generated a state of oxidative stress in hypercholesterolemic knockout mice. These data provide the first evidence of how oxidative stress is generated in LDL receptor defective cells and could explain the increased LDL oxidation, cell death, and atherogenesis seen in familiar hypercholesterolemia.	Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil; Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Fisiol & Biofis, BR-13083970 Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Estadual de Campinas	Vercesi, AE (corresponding author), Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil.	anibal@unicamp.br	Dorighello, Gabriel G/J-8708-2013; Salerno, Alessandro G/A-7891-2013; Alberici, Luciane C/J-3013-2015; Oliveira, Helena C. F./C-1343-2013; Vercesi, Aníbal E/C-8767-2012	Dorighello, Gabriel G/0000-0001-6566-4244; Salerno, Alessandro G/0000-0002-7688-5904; Alberici, Luciane C/0000-0002-7464-9385; Oliveira, Helena C. F./0000-0003-0119-6992; Cotta de Faria, Eliana/0000-0002-5208-1274; Vercesi, Anibal Eugenio/0000-0001-6671-7125				Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; DIETSCHY JM, 1984, J LIPID RES, V25, P1469; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gaylor JL, 2002, BIOCHEM BIOPH RES CO, V292, P1139, DOI 10.1006/bbrc.2001.2008; Gille L, 2001, ARCH BIOCHEM BIOPHYS, V388, P34, DOI 10.1006/abbi.2000.2257; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; LAMB DJ, 1992, ATHEROSCLEROSIS, V92, P187, DOI 10.1016/0021-9150(92)90277-N; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; RICCHELLI F, 1995, EUR J BIOCHEM, V233, P165, DOI 10.1111/j.1432-1033.1995.165_1.x; Skulachev VP, 2000, FREE RADICAL BIO MED, V29, P1056, DOI 10.1016/S0891-5849(00)00291-4; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STOKES J, 1987, CIRCULATION, V75, P65; VERCESI AE, 1987, ARCH BIOCHEM BIOPHYS, V252, P171, DOI 10.1016/0003-9861(87)90021-X; VINOGRADOV AD, 1972, J BIOENERG, V3, P203, DOI 10.1007/BF01515968; Voyiaziakis E, 1998, J LIPID RES, V39, P313; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Zago EB, 2000, FEBS LETT, V478, P29, DOI 10.1016/S0014-5793(00)01815-9	27	87	91	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2004	18	14					278	+		10.1096/fj.04-2095fje	http://dx.doi.org/10.1096/fj.04-2095fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	876FO	15569776				2022-12-25	WOS:000225482100004
J	Hirano, Y; Yoshinaga, S; Takeya, R; Suzuki, NN; Horiuchi, M; Kohjima, M; Sumimoto, H; Inagaki, F				Hirano, Y; Yoshinaga, S; Takeya, R; Suzuki, NN; Horiuchi, M; Kohjima, M; Sumimoto, H; Inagaki, F			Structure of a cell polarity regulator, a complex between atypical PKC and Par6 PB1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPITHELIAL TIGHT JUNCTION; PHAGOCYTE NADPH OXIDASE; CAENORHABDITIS-ELEGANS; PC MOTIF; RECOGNITION; BINDING; DROSOPHILA; CDC42; NEUROBLASTS	A complex of atypical PKC and Par6 is a common regulator for cell polarity- related processes, which is an essential clue to evolutionary conserved cell polarity regulation. Here, we determined the crystal structure of the complex of PKCiota and Par6alpha PB1 domains to a resolution of 1.5 Angstrom. Both PB1 domains adopt a ubiquitin fold. PKCiota PB1 presents an OPR, PC, and AID ( OPCA) motif, 28 amino acid residues with acidic and hydrophobic residues, which interacts with the conserved lysine residue of Par6alpha PB1 in a front and back manner. On the interface, several salt bridges are formed including the conserved acidic residues on the OPCA motif of PKCiota PB1 and the conserved lysine residue on the Par6alpha PB1. Structural comparison of the PKCiota and Par6alpha PB1 complex with the p40(phox) and p67(phox) PB1 domain complex, subunits of neutrophil NADPH oxidase, reveals that the specific interaction is achieved by tilting the interface so that the insertion or extension in the sequence is engaged in the specificity determinant. The PB1 domain develops the interaction surface on the ubiquitin fold to increase the versatility of molecular interaction.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; CREST, Japan Sci & Technol, Kawaguchi 3320012, Japan	Hokkaido University; Kyushu University; Japan Science & Technology Agency (JST)	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Dept Biol Struct, N-12,W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp	Hirano, Yoshinori/ABC-6876-2020; Horiuchi, Masataka/D-5491-2012; Noda, Nobuo/P-1397-2015	Hirano, Yoshinori/0000-0001-9888-1616; Noda, Nobuo/0000-0002-6940-8069				Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; CAMBILLAU C, 1997, TURBO FRODO, V1; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Hirano Y, 2004, J BIOL CHEM, V279, P31883, DOI 10.1074/jbc.M403092200; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Yoshinaga S, 2003, EMBO J, V22, P4888, DOI 10.1093/emboj/cdg475	46	59	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9653	9661		10.1074/jbc.M409823200	http://dx.doi.org/10.1074/jbc.M409823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15590654	hybrid			2022-12-25	WOS:000227453100122
J	Snyder, H; Mensah, K; Hsu, C; Hashimoto, M; Surgucheva, IG; Festoff, B; Surguchov, A; Masliah, E; Matouschek, A; Wolozin, B				Snyder, H; Mensah, K; Hsu, C; Hashimoto, M; Surgucheva, IG; Festoff, B; Surguchov, A; Masliah, E; Matouschek, A; Wolozin, B			beta-synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; 20S PROTEASOME; DEGRADATION SIGNAL; SUBSTANTIA-NIGRA; LEWY BODY; AGGREGATION; EXPRESSION; PROTEIN; MUTATION; INCLUSIONS	The accumulation of aggregated alpha-synuclein is thought to contribute to the pathogenesis of Parkinson's disease. Recent studies indicate that aggregated alpha-synuclein binds to S6', a component of the 19S subunit in the 26 S proteasome and inhibits 26 S proteasomal degradation, both ubiquitin-independent and ubiquitindependent. The IC50 of aggregated alpha-synuclein for inhibition of the 26 S ubiquitin-independent proteasomal activity is similar to 1 nM. alpha-Synuclein has two close homologues, termed beta-synuclein and gamma-synuclein. In the present study we compared the effects of the three synuclein homologues on proteasomal activity. The proteasome exists as a 26 S and a 20 S species, with the 26 S proteasome containing the 20 S core and 19 S cap. Monomeric alpha-and beta-synucleins inhibited the 20 S and 26 S proteasomal activities only weakly, but monomeric gamma- synuclein strongly inhibited ubiquitin-independent proteolysis. The IC50 of monomeric alpha-synuclein for the 20 S proteolysis was 400 nM. In monomeric form, none of the three synuclein proteins inhibited 26 S ubiquitin-dependent proteasomal activity. Although beta-synuclein had no direct effect on proteasomal activity, co-incubating monomeric beta-synuclein with aggregated alpha-synuclein antagonized the inhibition of the 26 S ubiquitin-independent proteasome by aggregated alpha-synuclein when added before the aggregated alpha-synuclein. Co-incubating beta-synuclein with gamma-synuclein had no effect on the inhibition of the 20 S proteasome by monomeric gamma-synuclein. Immunoprecipitation and pull-down experiments suggested that antagonism by beta-synuclein resulted from binding to alpha-synuclein rather than binding to S6'. Pull-down experiments demonstrated that recombinant monomeric beta-synuclein does not interact with the proteasomal subunit S6', unlike alpha-synuclein, but beta-synuclein does bind alpha-synuclein and competes with S6' for binding to alpha-synuclein. Based on these data, we hypotesize that the alpha-and gamma-synucleins regulate proteasomal function and that beta-synuclein acts as a negative regulator of alpha-synuclein.	Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA; Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, Neurobiol Res Lab, Kansas City, MO 64128 USA; Univ Kansas, Sch Med, Dept Neurol, Kansas City, KS 66160 USA	Boston University; Loyola University Chicago; Northwestern University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas Medical Center	Wolozin, B (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, 715 Albany St,R614, Boston, MA 02118 USA.	bwolozin@bu.edu	Matouschek, Andreas/L-9379-2013	Matouschek, Andreas/0000-0001-6016-2341; Hsu, Cindy/0000-0002-8192-6969	NINDS NIH HHS [NS41786] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Giasson BI, 2001, EXP NEUROL, V172, P354, DOI 10.1006/exnr.2001.7805; Golts N, 2002, J BIOL CHEM, V277, P16116, DOI 10.1074/jbc.M107866200; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Li J, 2001, BIOCHIMIE, V83, P373, DOI 10.1016/S0300-9084(01)01236-6; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Martin-Clemente B, 2004, J BIOL CHEM, V279, P52984, DOI 10.1074/jbc.M409028200; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Mori F, 2003, NEUROREPORT, V14, P1783, DOI 10.1097/00001756-200310060-00005; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Surgucheva IG, 2003, ARCH BIOCHEM BIOPHYS, V410, P167, DOI 10.1016/S0003-9861(02)00664-1; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Windisch M, 2002, J MOL NEUROSCI, V19, P63, DOI 10.1007/s12031-002-0012-8; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	37	43	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7562	7569		10.1074/jbc.M412887200	http://dx.doi.org/10.1074/jbc.M412887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591046	hybrid			2022-12-25	WOS:000227395700018
J	Heymann, JB; Iwasaki, K; Yim, YI; Cheng, NQ; Belnap, DM; Greene, LE; Eisenberg, E; Steven, AC				Heymann, JB; Iwasaki, K; Yim, YI; Cheng, NQ; Belnap, DM; Greene, LE; Eisenberg, E; Steven, AC			Visualization of the binding of Hsc70 ATPase to clathrin baskets - Implications for an uncoating mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; BIOLOGICAL MACROMOLECULES; BETA-PROPELLER; AUXILIN; ENDOCYTOSIS; DOMAIN; PROTEIN; MICROSCOPY; RESOLUTION; LOCATION	Clathrin assembly into coated pits and vesicles is promoted by accessory proteins such as auxilin and AP180, and disassembly is effected by the Hsc70 ATPase. These interactions may be mimicked in vitro by the assembly and disassembly of clathrin "baskets." The chimera C58J is a minimal construct capable of supporting both reactions; it consists of the C58 moiety of AP180, which facilitates clathrin assembly, fused with the J domain of auxilin, which recruits Hsc70 to baskets. We studied the process of disassembly by using cryo-electron microscopy to identify the initial binding site of Hsc70 on clathrin-C58J baskets at pH 6, under which conditions disassembly does not proceed further. Hsc70 interactions involve two sites: (i) its major interaction is with the sides of spars of the clathrin lattice, close to the triskelion hubs and GO there is another interaction at a site at the N-terminal hooks of the clathrin heavy chains, presumably via the J domain of C58J. We propose that individual triskelions may be extricated from the clathrin lattice by the concerted action of up to six Hsc70 molecules, which intercalate between clathrin leg segments, prying them apart. Three Hsc70s remain bound to the dissociated triskelion, close to its trimerization hub.	NHLBI, Struct Biol Lab, NIAMS, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Cell Biol Lab, Bethesda, MD 20892 USA; Osaka Univ, Res Ctr Ultra High Voltage Electron Microscopy, Osaka 5670047, Japan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Osaka University	Steven, AC (corresponding author), NHLBI, Struct Biol Lab, NIAMS, NIH, Bldg 50,Rm 1517,50 South Dr,MSC 8025, Bethesda, MD 20892 USA.	Alasdair_Steven@nih.gov	Gimenez, Luis E Diaz/D-9291-2011; Heymann, Bernard/F-6825-2011; Heymann, Bernard/H-8265-2019	Heymann, Bernard/0000-0002-8872-5326	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000516, Z01HL000516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027015, ZIAAR027015] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BAROUCH W, 1994, J BIOL CHEM, V269, P28563; Belnap DM, 1997, J STRUCT BIOL, V120, P44, DOI 10.1006/jsbi.1997.3896; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chang HC, 2002, J CELL BIOL, V159, P477, DOI 10.1083/jcb.200205086; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; CROWTHER RA, 1981, J CELL BIOL, V91, P790, DOI 10.1083/jcb.91.3.790; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Fotin A, 2004, NATURE, V432, P649, DOI 10.1038/nature03078; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Greener T, 2001, NAT CELL BIOL, V3, P215, DOI 10.1038/35055137; Gruschus JM, 2004, BIOCHEMISTRY-US, V43, P3111, DOI 10.1021/bi0354740; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; Heymann JB, 2001, J STRUCT BIOL, V133, P156, DOI 10.1006/jsbi.2001.4339; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KOCSIS E, 1991, J STRUCT BIOL, V107, P6, DOI 10.1016/1047-8477(91)90025-R; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Ma YC, 2002, J BIOL CHEM, V277, P49267, DOI 10.1074/jbc.M203695200; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Morgan JR, 2000, J NEUROSCI, V20, P8667; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; Nossal R, 2001, TRAFFIC, V2, P138, DOI 10.1034/j.1600-0854.2001.020208.x; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; Scheele U, 2003, J BIOL CHEM, V278, P25357, DOI 10.1074/jbc.M303738200; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; Smith CJ, 2004, J MOL BIOL, V336, P461, DOI 10.1016/j.jmb.2003.12.006; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; TARNAI T, 1991, J MOL BIOL, V218, P485, DOI 10.1016/0022-2836(91)90691-X; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; Wakeham DE, 2003, EMBO J, V22, P4980, DOI 10.1093/emboj/cdg511	37	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7156	7161		10.1074/jbc.M411712200	http://dx.doi.org/10.1074/jbc.M411712200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596443	hybrid			2022-12-25	WOS:000227332700106
J	Isoda, K; Sawada, S; Ayaori, M; Matsuki, T; Horai, R; Kagata, Y; Miyazaki, K; Kusuhara, M; Okazaki, M; Matsubara, O; Iwakura, Y; Ohsuzu, F				Isoda, K; Sawada, S; Ayaori, M; Matsuki, T; Horai, R; Kagata, Y; Miyazaki, K; Kusuhara, M; Okazaki, M; Matsubara, O; Iwakura, Y; Ohsuzu, F			Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; NEGATIVE FEEDBACK-REGULATION; ACUTE-PHASE RESPONSE; MESSENGER-RNA LEVELS; NUCLEAR RECEPTORS; ATHEROGENIC DIET; LIPID-METABOLISM; GENE-EXPRESSION; IN-VIVO; 7-ALPHA-HYDROXYLASE	Although the anti-inflammatory effect of interleukin-1 (IL-1) receptor antagonist (IL-1Ra) has been described, the contribution of this cytokine to cholesterol metabolism remains unclear. Our aim was to ascertain whether deficiency of IL-1Ra deteriorates cholesterol metabolism upon consumption of an atherogenic diet. IL-1Ra-deficient mice (IL-1Ra(-/-)) showed severe fatty liver and portal fibrosis containing many inflammatory cells following 20 weeks of an atherogenic diet when compared with wild type (WT) mice. Expectedly, the levels of total cholesterol in IL-1Ra(-/-) mice were significantly increased, and the start of lipid accumulation in liver was observed earlier when compared with WT mice. Real-time PCR analysis revealed that IL-1Ra(-/-) mice failed to induce mRNA expression of cholesterol 7alpha-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis, with concurrent up-regulation of small heterodimer partner 1 mRNA expression. Indeed, IL-1Ra(-/-) mice showed markedly decreased bile acid excretion, which is elevated in WT mice to maintain cholesterol level under atherogenic diet feeding. Therefore, we conclude that the lack of IL-1Ra deteriorates cholesterol homeostasis under atherogenic diet-induced inflammation.	Natl Def Med Coll, Dept Pathol 2, Tokorozawa, Saitama D3598513, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Tokyo 1088639, Japan; Tokyo Med & Dent Univ, Coll Liberal Arts & Sci, Chem Lab, Chiba 2720827, Japan	National Defense Medical College - Japan; University of Tokyo; Tokyo Medical & Dental University (TMDU)	Isoda, K (corresponding author), Natl Def Med Coll, Dept Pathol 2, 3-2 Namiki, Tokorozawa, Saitama D3598513, Japan.	isoda@me.ndme.ac.jp	Iwakura, Yoichiro/E-5457-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Matsuki, Taizo/0000-0002-0591-4261				Baroni GS, 1996, HEPATOLOGY, V23, P1189; Bohan A, 2003, J BIOL CHEM, V278, P36688, DOI 10.1074/jbc.M304011200; Boros DL, 1999, INFECT IMMUN, V67, P1187, DOI 10.1128/IAI.67.3.1187-1193.1999; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Devlin CM, 2002, P NATL ACAD SCI USA, V99, P6280, DOI 10.1073/pnas.092324399; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dinarello CA, 2000, NEW ENGL J MED, V343, P732, DOI 10.1056/NEJM200009073431011; Fan Jan Gao, 2003, Zhonghua Gan Zang Bing Za Zhi, V11, P73; Feingold KR, 1996, J LIPID RES, V37, P223; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gabay C, 2001, EUR J IMMUNOL, V31, P490, DOI 10.1002/1521-4141(200102)31:2<490::AID-IMMU490>3.0.CO;2-H; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jin WJ, 2003, CIRC RES, V92, P644, DOI 10.1161/01.RES.0000064502.47539.6D; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200; Kim MS, 2003, J BIOL CHEM, V278, P8988, DOI 10.1074/jbc.M212633200; Laskin DL, 2001, J LEUKOCYTE BIOL, V70, P163; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li XX, 1999, MOL CELL BIOL, V19, P4643; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; LY H, 1995, J LIPID RES, V36, P1254; MACLIEWICZ A, 1993, ACUTE PHASE PROTEINS; Matsuki T, 2003, J EXP MED, V198, P877, DOI 10.1084/jem.20030299; McClain CJ, 1999, SEMIN LIVER DIS, V19, P205, DOI 10.1055/s-2007-1007110; Memon RA, 2001, J BIOL CHEM, V276, P30118, DOI 10.1074/jbc.M102516200; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; OKAZAKI M, 2000, HDB LIPOPROTEIN TEST, P647; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; Porter JL, 2003, J LAB CLIN MED, V141, P411, DOI 10.1016/S0022-2143(03)00040-4; PRUZANSKI W, 1993, J LIPID MEDIATOR, V8, P161; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; THOMPSON JS, 1969, J ATHEROSCLER RES, V10, P113, DOI 10.1016/S0368-1319(69)80090-6; Thurman R. G., 1999, Frontiers in Bioscience, V4, pe42, DOI 10.2741/Thurman; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Usui S, 2002, J LIPID RES, V43, P805; Vergnes L, 2003, J BIOL CHEM, V278, P42774, DOI 10.1074/jbc.M306022200; VESSELIN.D, 1968, J ATHEROSCLER RES, V8, P497, DOI 10.1016/S0368-1319(68)80105-X; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9	49	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7002	7009		10.1074/jbc.M412220200	http://dx.doi.org/10.1074/jbc.M412220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15574426	hybrid			2022-12-25	WOS:000227332700090
J	Suzuki, M; Shiraha, H; Fujikawa, T; Takaoka, N; Ueda, N; Nakanishi, Y; Koike, K; Takaki, A; Shiratori, Y				Suzuki, M; Shiraha, H; Fujikawa, T; Takaoka, N; Ueda, N; Nakanishi, Y; Koike, K; Takaki, A; Shiratori, Y			Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; C-MET; ABNORMAL PROTHROMBIN; ALPHA-FETOPROTEIN; FACTOR-RECEPTOR; SERINE PHOSPHORYLATION; CELL-LINES; VITAMIN-K; SIGNAL TRANSDUCERS; MOLECULAR-CLONING	Des-gamma-carboxyl prothrombin (DCP) is a well recognized tumor marker for hepatocellular carcinoma (HCC). In the present study, we demonstrate that DCP has a mitogenic effect on HCC cell lines. Purified DCP stimulated DNA synthesis of Hep3B and SK-Hep-1 cells in a dose-dependent manner. DCP was found to bind with cell surface receptor Met causing Met autophosphorylation and also to activate STAT3 signaling pathway through Janus kinase 1. Luciferase gene reporter analysis showed that DCP induced STAT3-related transcription. Small interfering RNAs against both STAT3 and Met abrogated DCP-induced cell proliferation. DCP did not affect the mitogen-activated protein kinase pathway, Myc signaling pathway, or phosphoinositide 3-kinase/Akt pathway. Based on these results, we believe that DCP acts as an autologous mitogen for HCC cell lines. The Met-Janus kinase 1-STAT3 signaling pathway may be a major signaling pathway for DCP-induced cell proliferation.	Okayama Univ, Grad Sch Med & Dent, Dept Med & Med Sci, Okayama 7008558, Japan	Okayama University	Shiraha, H (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Med & Med Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	hshiraha@md.okayama-u.ac.jp						Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; BARDELLI A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P41; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Chen QY, 1997, HEPATOLOGY, V26, P59; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Luca A, 1999, J CELL PHYSIOL, V180, P365, DOI 10.1002/(SICI)1097-4652(199909)180:3<365::AID-JCP7>3.0.CO;2-B; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; FURUKAWA M, 1992, CANCER-AM CANCER SOC, V69, P31, DOI 10.1002/1097-0142(19920101)69:1<31::AID-CNCR2820690108>3.0.CO;2-6; Gotoh M, 2003, JPN J CLIN ONCOL, V33, P522, DOI 10.1093/jjco/hyg096; Hayashi S, 1996, BIOCHEM BIOPH RES CO, V220, P539, DOI 10.1006/bbrc.1996.0440; HUISSE MG, 1994, CANCER, V74, P1533, DOI 10.1002/1097-0142(19940901)74:5<1533::AID-CNCR2820740507>3.0.CO;2-V; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; INOUE S, 1994, AM J GASTROENTEROL, V89, P2222; Jeffers M, 1996, ONCOGENE, V13, P853; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Koike Y, 2001, CANCER, V91, P561, DOI 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N; Kuromatsu R, 1997, J GASTROENTEROL, V32, P507, DOI 10.1007/BF02934091; Lee KH, 2003, CLIN EXP METASTAS, V20, P499, DOI 10.1023/A:1025824816021; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIEBMAN HA, 1984, NEW ENGL J MED, V310, P1427, DOI 10.1056/NEJM198405313102204; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Ljubimova JY, 1997, J HISTOCHEM CYTOCHEM, V45, P79, DOI 10.1177/002215549704500111; Marrero JA, 2003, HEPATOLOGY, V37, P1114, DOI 10.1053/jhep.2003.50195; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Ni ZY, 2002, J UROLOGY, V167, P1859, DOI 10.1016/S0022-5347(05)65249-4; Okuda H, 1999, CANCER, V85, P812, DOI 10.1002/(SICI)1097-0142(19990215)85:4<812::AID-CNCR8>3.3.CO;2-F; OKUDA H, 1987, J HEPATOL, V4, P357, DOI 10.1016/S0168-8278(87)80546-9; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Parr C, 2001, INT J ONCOL, V19, P857; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; SAKON M, 1992, AM J SURG, V163, P251, DOI 10.1016/0002-9610(92)90111-4; Sanchez A, 2003, EUR J CANCER, V39, P2093, DOI 10.1016/S0959-8049(03)00393-9; SCHNIDLER C, 1995, ANNU REV BIOCHEM, V64, P621; Shimada M, 1996, CANCER, V78, P2094, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2094::AID-CNCR9>3.0.CO;2-O; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sriuranpong V, 2003, CANCER RES, V63, P2948; SUEHIRO T, 1994, CANCER-AM CANCER SOC, V73, P2464, DOI 10.1002/1097-0142(19940515)73:10<2464::AID-CNCR2820731004>3.0.CO;2-9; SUEHIRO T, 1995, SURGERY, V117, P682, DOI 10.1016/S0039-6060(95)80013-1; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; Tamano M, 2002, HEPATOL RES, V22, P261, DOI 10.1016/S1386-6346(01)00150-4; Uehara S, 1999, CLIN CHIM ACTA, V289, P33, DOI 10.1016/S0009-8981(99)00152-7; Warn R, 2001, EXP CELL RES, V267, P258, DOI 10.1006/excr.2001.5240; WEITZ IC, 1993, HEPATOLOGY, V18, P990, DOI 10.1002/hep.1840180434; WEN Z, 1995, CELL, V87, P241; WOUDE GFV, 1997, CIBA F SYMP, V212, P119; Xie Q, 2001, WORLD J GASTROENTERO, V7, P816, DOI 10.3748/wjg.v7.i6.816; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; YOSHINAGA Y, 1992, JPN J CANCER RES, V83, P1257, DOI 10.1111/j.1349-7006.1992.tb02755.x	64	94	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6409	6415		10.1074/jbc.M406714200	http://dx.doi.org/10.1074/jbc.M406714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15582995	hybrid			2022-12-25	WOS:000227332700021
J	Brandner, K; Rehling, P; Truscott, KN				Brandner, K; Rehling, P; Truscott, KN			The carboxyl-terminal third of the dicarboxylate carrier is crucial for productive association with the inner membrane twin-pore translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; MITOCHONDRIAL PROTEIN IMPORT; ADP/ATP CARRIER; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; MEDIATES INSERTION; OUTER-MEMBRANE; RECEPTOR TOM70; TIM22 COMPLEX; BINDING	The carrier proteins of the mitochondrial inner membrane consist of three structurally related tandem repeats (modules). Several different, and in some cases contradictory, views exist on the role individual modules play in carrier transport across the mitochondrial membranes and how they promote protein insertion into the inner membrane. Thus, by use of specific translocation intermediates, we performed a detailed analysis of carrier biogenesis and assessed the physical association of carrier modules with the inner membrane translocation machinery. Here we have reported that each module of the dicarboxylate carrier contains sufficient targeting information for its transport across the outer mitochondrial membrane. The carboxyl-terminal module possesses major targeting information to facilitate the direct binding of the carrier protein to the inner membrane twin-pore translocase and subsequent insertion into the inner membrane in a membrane potential-dependent manner. We concluded that, in this case, a single structural repeat can drive inner membrane insertion, whereas all three related units contribute targeting information for outer membrane translocation.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia	University of Freiburg; La Trobe University	Truscott, KN (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany.	K.Truscott@latrobe.edu.au	Truscott, Kaye/D-3362-2012	Truscott, Kaye/0000-0002-5352-9835				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Asai T, 2004, J BIOL CHEM, V279, P19464, DOI 10.1074/jbc.M401291200; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Rehling P, 2003, J MOL BIOL, V326, P639, DOI 10.1016/S0022-2836(02)01440-7; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Schleiff E, 2000, J CELL SCI, V113, P2267; SIKORSKI RS, 1989, GENETICS, V122, P19; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Vergnolle MAS, 2005, BIOCHEM J, V385, P173, DOI 10.1042/BJ20040650; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zara V, 2001, J MOL BIOL, V310, P965, DOI 10.1006/jmbi.2001.4833	43	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6215	6221		10.1074/jbc.M412269200	http://dx.doi.org/10.1074/jbc.M412269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591051	hybrid			2022-12-25	WOS:000227217100128
J	Sharma, S; Hoskins, JR; Wickner, S				Sharma, S; Hoskins, JR; Wickner, S			Binding and degradation of heterodimeric substrates by ClpAP and ClpXP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; PROTEASES DEGRADE; HSP100 CHAPERONE; MU-TRANSPOSASE; COMPLEX; TRANSLOCATION; RECOGNITION	CIpA and CIpX function both as molecular chaperones and as the regulatory components of CIpAP and CIpXP proteases, respectively. CIpA and ClpX bind substrate proteins through specific recognition signals, catalyze ATP-dependent protein unfolding of the substrate, and when in complexes with ClpP translocate the unfolded polypeptide into the cavity of the CIpP peptidase for degradation. To examine the mechanism of interaction of CIpAP with dimeric substrates, single round binding and degradation experiments were performed, revealing that CIpAP degraded both subunits of a RepA homodimer in one cycle of binding. Furthermore, CIpAP was able to degrade both protomers of a RepA heterodimer in which only one subunit contained the CIpA recognition signal. In contrast, ClpXP degraded both subunits of a dimeric substrate only when both protomers contained a recognition signal. These data suggest that CIpAP and ClpXP may recognize and bind substrates in significantly different ways.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 5144,37 Convent Dr, Bethesda, MD 20892 USA.	suewick@helix.nih.gov						Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gonzalez M, 2000, EMBO J, V19, P5251, DOI 10.1093/emboj/19.19.5251; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; Hoskins JR, 2002, ADV PROTEIN CHEM, V59, P413; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee S, 2004, J STRUCT BIOL, V146, P99, DOI 10.1016/j.jsb.2003.11.016; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Neher SB, 2003, P NATL ACAD SCI USA, V100, P13219, DOI 10.1073/pnas.2235804100; Neuwald AF, 1999, GENOME RES, V9, P27; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	48	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5449	5455		10.1074/jbc.M412411200	http://dx.doi.org/10.1074/jbc.M412411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591068	hybrid			2022-12-25	WOS:000227217100042
J	Till, A; Rosenstiel, P; Krippner-Heidenreich, A; Mascheretti-Croucher, S; Croucher, PJP; Schafer, H; Scheurich, P; Seegert, D; Schreiber, S				Till, A; Rosenstiel, P; Krippner-Heidenreich, A; Mascheretti-Croucher, S; Croucher, PJP; Schafer, H; Scheurich, P; Seegert, D; Schreiber, S			The met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappa B signaling and target gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FACTOR RECEPTOR-II; CELL-DEATH; T-CELLS; RHEUMATOID-ARTHRITIS; TERMINAL KINASE; ASSOCIATION; ACTIVATION; POLYMORPHISM	Tumor necrosis factor-a (TNF-alpha)-induced signaling is pivotally involved in the pathogenesis of chronic inflammatory diseases. A polymorphism in the TNF receptor 2 (TNFR2) gene resulting in a juxtamembrane inversion from methionine (TNFR2(196)MET) to arginine (TNFR2(196)ARG) has been genetically associated with an increased risk for systemic lupus erythematosus and familial rheumatoid arthritis. Albeit the mutation does not affect the TNF binding kinetics of TNFR2, the present study provides evidence that the mutation results in a significantly lower capability to induce TNFR2mediated NF-kappaB activation. Pretriggering of TNFR2 with a receptor-specific mutein leads to an enhancement of TNFR1-induced apoptosis, which is further increased in cells carrying the TNFR2(196)ARG variant. A diminished induction of NF-kappaB-dependent target genes conveying either anti-apoptotic or pro-inflammatory functions, such as cIAP1, TRAF1, IL-6, or IL-8 is observed. The mutated form TNFR2(196)ARG shows a reduction of inducible TRAF2 recruitment upon TNF-a stimulation. The findings suggest a common molecular mechanism for the involvement of the TNFR2(196)ARG variant in the etiopathogenesis of different chronic inflammatory disorders.	Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Hosp Schleswig Holstein, Dept Gen Internal Med, Lab Mol Gastroenterol, D-24105 Kiel, Germany; CONARIS Res Inst AG, D-24118 Kiel, Germany	University of Kiel; University of Stuttgart; University of Kiel; Schleswig Holstein University Hospital	Schreiber, S (corresponding author), Univ Kiel, Inst Clin Mol Biol, Schittenhelmstr 12, D-24105 Kiel, Germany.	s.schreiber@mucosa.de	Rosenstiel, Philip/A-5137-2009; Till, Andreas/AAO-6375-2021; Seegert, Dirk/B-8826-2011; Schäfer, Heiner/C-1055-2011; Till, Andreas/E-9661-2013	Rosenstiel, Philip/0000-0002-9692-8828; Till, Andreas/0000-0002-0139-9143				AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; Arlt A, 2002, CANCER RES, V62, P910; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Barton A, 2001, ARTHRITIS RHEUM, V44, P61, DOI 10.1002/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO;2-Q; Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Corredor J, 2003, AM J PHYSIOL-CELL PH, V284, pC953, DOI 10.1152/ajpcell.00309.2002; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; Dieude P, 2002, ARTHRITIS RHEUM, V46, P2039, DOI 10.1002/art.10101; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Eugster HP, 1999, EUR J IMMUNOL, V29, P626, DOI 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.3.CO;2-1; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; Haridas V, 1998, J IMMUNOL, V160, P3152; Helms ML, 2001, FEBS LETT, V505, P68, DOI 10.1016/S0014-5793(01)02779-X; Herman C, 1998, J IMMUNOL, V160, P2478; Hohjoh H, 2001, TISSUE ANTIGENS, V57, P230, DOI 10.1034/j.1399-0039.2001.057003230.x; Hohjoh H, 2000, TISSUE ANTIGENS, V56, P446, DOI 10.1034/j.1399-0039.2000.560508.x; Holtmann MH, 2002, EUR J IMMUNOL, V32, P3142, DOI 10.1002/1521-4141(200211)32:11<3142::AID-IMMU3142>3.0.CO;2-4; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Jupp OJ, 2001, BIOCHEM J, V359, P525, DOI 10.1042/0264-6021:3590525; Komata T, 1999, TISSUE ANTIGENS, V53, P527, DOI 10.1034/j.1399-0039.1999.530602.x; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krippner-Heidenreich A, 2002, J BIOL CHEM, V277, P44155, DOI 10.1074/jbc.M207399200; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Mizoguchi E, 2002, GASTROENTEROLOGY, V122, P134, DOI 10.1053/gast.2002.30347; Morita C, 2001, ARTHRITIS RHEUM-US, V44, P2819, DOI 10.1002/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Nishimura M, 2000, HUM IMMUNOL, V61, P1262, DOI 10.1016/S0198-8859(00)00182-8; Pantelidis P, 1999, TISSUE ANTIGENS, V54, P585, DOI 10.1034/j.1399-0039.1999.540608.x; Peral B, 2002, J CLIN ENDOCR METAB, V87, P3977, DOI 10.1210/jc.87.8.3977; Peschon JJ, 1998, J IMMUNOL, V160, P943; Pierik M, 2004, ALIMENT PHARM THER, V20, P303, DOI 10.1111/j.1365-2036.2004.01946.x; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; Teh HS, 2000, J IMMUNOL, V165, P4814, DOI 10.4049/jimmunol.165.9.4814; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; Tsuchiya N, 2000, GENES IMMUN, V1, P501, DOI 10.1038/sj.gene.6363700; VERCAMMEN D, 1995, CYTOKINE, V7, P463, DOI 10.1006/cyto.1995.0063; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Weingartner M, 2002, J BIOL CHEM, V277, P34853, DOI 10.1074/jbc.M205149200; Weiss T, 1998, J IMMUNOL, V161, P3136; Weiss T, 1997, J IMMUNOL, V158, P2398; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	56	72	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5994	6004		10.1074/jbc.M411541200	http://dx.doi.org/10.1074/jbc.M411541200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572357				2022-12-25	WOS:000227217100105
J	Marson, A; Rock, MJ; Cain, SA; Freeman, LJ; Morgan, A; Mellody, K; Shuttleworth, CA; Baldock, C; Kielty, CM				Marson, A; Rock, MJ; Cain, SA; Freeman, LJ; Morgan, A; Mellody, K; Shuttleworth, CA; Baldock, C; Kielty, CM			Homotypic fibrillin-1 interactions in microfibril assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIC TISSUES; MARFAN-SYNDROME; ORGANIZATION; EXPRESSION; MATRIX; COMPONENT; MODULE; ZONULE; GENE	We have defined the homotypic interactions of fibril. lin-1 to obtain new insights into microfibril assembly. Dose-dependent saturable high affinity binding was demonstrated between N-terminal fragments, between furin processed C-terminal fragments, and between these Nand C-terminal fragments. The N terminus also interacted with a downstream fragment. A post-furin cleavage site C-terminal sequence also interacted with the N terminus' with itself and with the furin-processed fragment. No other homotypic fibrillin-1 interactions were detected. Some terminal homotypic interactions were inhibited by other terminal sequences, and were strongly calcium-dependent. Treatment of an N-terminal fragment with N-ethylmaleimide reduced homotypic binding. Microfibril-associated glycoprotein-1 inhibited N- to C-terminal interactions but not homotypic N-terminal interactions. These fibrillin-1 interactions are likely to regulate pericellular fibrillin-1 microfibril assembly.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Kielty, CM (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cay.kielty@man.ac.uk	Cain, Stuart A/G-2836-2017	McGovern, Amanda/0000-0001-7727-3283; Mellody, Kieran/0000-0002-8164-9148; Baldock, Clair/0000-0003-3497-1959; Cain, Stuart/0000-0001-8417-1058				Ashworth JL, 2000, BRIT J OPHTHALMOL, V84, P1312, DOI 10.1136/bjo.84.11.1312; Ashworth JL, 1999, J CELL SCI, V112, P3549; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Bax DV, 2003, J BIOL CHEM, V278, P34605, DOI 10.1074/jbc.M303159200; CHEN YP, 1993, J BIOL CHEM, V268, P27381; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; Davis EC, 2002, J STRUCT BIOL, V139, P65, DOI 10.1016/S1047-8477(02)00559-2; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; KIELTY CM, 1991, J CELL SCI, V99, P797; Kielty CM, 2002, J CELL SCI, V115, P2817; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; MAYER U, 1994, EUR J BIOCHEM, V225, P573, DOI 10.1111/j.1432-1033.1994.00573.x; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Quondamatteo F, 2002, MATRIX BIOL, V21, P637, DOI 10.1016/S0945-053X(02)00100-2; Raghunath M, 1999, J CELL SCI, V112, P1093; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Robinson PN, 2001, CELL MOL LIFE SCI, V58, P1698, DOI 10.1007/PL00000807; Rock MJ, 2004, J BIOL CHEM, V279, P23748, DOI 10.1074/jbc.M400212200; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sherratt MJ, 1997, INT J BIOCHEM CELL B, V29, P1063, DOI 10.1016/S1357-2725(97)00028-9; Trask TM, 1999, BIOCHEM J, V340, P693, DOI 10.1042/0264-6021:3400693; WALLACE RN, 1991, CURR EYE RES, V10, P99, DOI 10.3109/02713689109007614; Wallis DD, 2003, J CELL BIOCHEM, V90, P641, DOI 10.1002/jcb.10657; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	34	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5013	5021		10.1074/jbc.M409029200	http://dx.doi.org/10.1074/jbc.M409029200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15569675	hybrid			2022-12-25	WOS:000227096600123
J	Herrin, BR; Groeger, AL; Justement, LB				Herrin, BR; Groeger, AL; Justement, LB			The adaptor protein HSH2 attenuates apoptosis in response to ligation of the B cell antigen receptor complex on the B lymphoma cell line, WEHI-231	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-3 SIGNALING PATHWAY; IGM-INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; CASPASE ACTIVATION; LINKER PROTEIN; CUTTING EDGE; CYCLE ARREST; LYMPHOCYTES; SURVIVAL; BAM32	Signals transduced by the B cell antigen receptor (BCR) play a central role in regulating the functional response of the cell to antigen. Depending on the nature of the antigenic signal and the developmental or differentiation state of the B cell, antigen receptor signaling can promote either apoptosis or survival and activation. Understanding the molecular mechanisms underlying BCR-mediated apoptosis constitutes an important area of research because aberrations in programmed cell death can result in the development of autoimmunity or cancer. Expression of the adaptor protein hematopoietic Src homology 2 (HSH2) was found to significantly decrease BCR-mediated apoptosis in the murine WEHI-231 cell line. Analysis of signal transduction pathways activated in response to BCR ligation revealed that HSH2 does not significantly alter total protein tyrosine phosphorylation or Ca2+ mobilization. HSH2 does not potentiate the activation-dependent phosphorylation of AKT either. With respect to MAPK activation, HSH2 was not observed to alter the activation of ERK or p38 in response to BCR ligation, but it does significantly potentiate JNK activation. Analysis of processes directly associated with apoptosis revealed that HSH2 inhibits mitochondrial depolarization to a significant degree, whereas it has only a slight effect on caspase activation and poly ADP-ribose polymerase cleavage. BCR-induced apoptosis of WEHI-231 cells is associated with the loss of endogenous HSH2 expression within 12 h, whereas inhibition of apoptosis in response to CD40-mediated signaling leads to stabilization of HSH2 expression. Thus, endogenous HSH2 expression correlates directly with survival of WEHI-231 cells, which supports the hypothesis that HSH2 modulates the apoptotic response through its ability to directly or indirectly promote mitochondrial stability.	Univ Alabama, Dept Microbiol, Div Dev & Clin Immunol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Justement, LB (corresponding author), Univ Alabama, Dept Microbiol, Div Dev & Clin Immunol, 378 Wallace Tumor Inst,1824 6th Ave S, Birmingham, AL 35294 USA.	lbjust@uab.edu		Justement, Louis/0000-0001-7058-867X; Herrin, Brantley/0000-0002-1842-6806				Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; BEHENS TW, 1997, IMMUNOL RES, V16, P149; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bishop GA, 2001, IMMUNOL RES, V24, P97, DOI 10.1385/IR:24:2:097; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Chung JB, 2001, J IMMUNOL, V166, P736, DOI 10.4049/jimmunol.166.2.736; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; Gold MR, 2002, TRENDS PHARMACOL SCI, V23, P316, DOI 10.1016/S0165-6147(02)02045-X; Gold MR, 1999, J IMMUNOL, V163, P1894; Gold MR, 2000, IMMUNOL REV, V176, P47; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Greene TA, 2003, J BIOL CHEM, V278, P45128, DOI 10.1074/jbc.M306283200; Han A, 2003, IMMUNITY, V19, P621, DOI 10.1016/S1074-7613(03)00275-9; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Herold MJ, 2002, J IMMUNOL, V168, P3902, DOI 10.4049/jimmunol.168.8.3902; Justement LB, 2000, CURR TOP MICROBIOL, V245, P1; Katz E, 2001, J IMMUNOL, V166, P137, DOI 10.4049/jimmunol.166.1.137; KEHY MR, 1996, J IMMUNOL, V156, P2345; Kelly ME, 2000, CURR OPIN IMMUNOL, V12, P267, DOI 10.1016/S0952-7915(00)00086-8; Koonpaew S, 2004, J BIOL CHEM, V279, P11229, DOI 10.1074/jbc.M311394200; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Kurosaki T, 2002, CURR OPIN IMMUNOL, V14, P341, DOI 10.1016/S0952-7915(02)00344-8; Lee JR, 1998, J IMMUNOL, V161, P1637; Leo A, 2001, CURR OPIN IMMUNOL, V13, P307, DOI 10.1016/S0952-7915(00)00220-X; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; MERINO R, 1995, J IMMUNOL, V155, P3830; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Mlinaric-Rascan I, 2003, FEBS LETT, V553, P51, DOI 10.1016/S0014-5793(03)00966-9; Niiro H, 2003, IMMUNITY, V19, P637, DOI 10.1016/S1074-7613(03)00303-0; Niiro H, 2002, J EXP MED, V195, P143, DOI 10.1084/jem.20011524; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Oda T, 2001, BIOCHEM BIOPH RES CO, V288, P1078, DOI 10.1006/bbrc.2001.5890; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; PAGE DM, 1990, MOL CELL BIOL, V10, P3003, DOI 10.1128/MCB.10.6.3003; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; RATHMELL JC, 2002, CELL S, V109, P97; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Sohn SJ, 2003, CURR OPIN IMMUNOL, V15, P209, DOI 10.1016/S0952-7915(03)00004-9; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; Strasser A, 2003, IMMUNOL REV, V193, P82, DOI 10.1034/j.1600-065X.2003.00036.x; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Suzuki H, 2003, NAT IMMUNOL, V4, P280, DOI 10.1038/ni890; Takada E, 2001, J IMMUNOL, V166, P1641, DOI 10.4049/jimmunol.166.3.1641; Tomayko MM, 1998, J IMMUNOL, V160, P107; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Wilkins RC, 2002, CYTOMETRY, V48, P14, DOI 10.1002/cyto.10098; Wu M, 1997, CURR TOP MICROBIOL, V224, P91; Yankee TM, 2003, J IMMUNOL, V170, P349, DOI 10.4049/jimmunol.170.1.349; Yi AK, 2003, INT IMMUNOL, V15, P577, DOI 10.1093/intimm/dxg058	60	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3507	3515		10.1074/jbc.M407690200	http://dx.doi.org/10.1074/jbc.M407690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15569688	hybrid			2022-12-25	WOS:000226983900047
J	Hwang, CC; Chang, YH; Hsu, CN; Hsu, HH; Li, CW; Pon, HI				Hwang, CC; Chang, YH; Hsu, CN; Hsu, HH; Li, CW; Pon, HI			Mechanistic roles of Ser-114, Tyr-155, and Lys-159 in 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DROSOPHILA ALCOHOL-DEHYDROGENASE; NAD(+)-DEPENDENT 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; UDP-GALACTOSE 4-EPIMERASE; HYDROXYSTEROID DEHYDROGENASE; CRITICAL RESIDUES; ESCHERICHIA-COLI; CATALYSIS; EXPRESSION	3alpha-Hydroxysteroid dehydrogenase/carbonyl reductase (3alpha-HSD/CR) from Comamonas testosteroni, a short chain dehydrogenase/reductase, catalyzes the oxidation of androsterone with NAD(+) to form androstanedione and NADH. A catalytic triad of Ser-114, Tyr-155, and Lys-159 in 3alpha-HSD/CR has been proposed based on structural analysis and sequence alignment of the short chain dehydrogenase/reductase family. The 3alpha-HSD/CR-catalyzed reaction has not been kinetically analyzed in detail, however. In this study, we combined steady-state kinetics, site-directed mutagenesis, and pH profile to explore the function of Ser-114, Tyr-155, and Lys-159 in 3alpha-HSD/CR-catalyzed reaction. The catalytic efficiency of wild-type and mutants S114A, Y155F, K159A, and Y155F/K159A is 4.3 x 10(7), 7.3 x 10(4), 1.7 x 10(4), 2.4 x 10(5), and 71 m(-1)s(-1), respectively. The values of pK(alpha) on k(cat)/K-m for the wild-type, S114A, Y155F, K159A, and Y155F/K159A are 7.2, 7.4, 8.4, 9.1, and 10.2, respectively. Mutant S114A/Y155F exhibits a pH-independent profile with 10(-5) times of wild-type activity at pH 10.5. The activity decreases as the pH lowers, which indicates that a functional group with an apparent pK(alpha) of 7.2 is involved in the general base catalysis for wild-type 3alpha-HSD/CR. The pK(alpha) shift to 9.1 for mutant K159A suggests the role of Lys-159 is to lower the pK(alpha) of the residues involved in the general base catalysis. Because pH dependence is observed for both S114A and Y155F mutants and pH independence is observed in S114A/Y155F, Tyr-155 may be important as a general base catalysis in the wild-type, whereas Ser-114 may act as a general base on mutant Y155F to catalyze the reaction.	Kaohsiung Med Univ, Dept Biochem, Kaohsiung 80731, Taiwan	Kaohsiung Medical University	Hwang, CC (corresponding author), Kaohsiung Med Univ, Dept Biochem, 100 Shih Chuan 1st Rd, Kaohsiung 80731, Taiwan.	cchwang@cc.kmu.edu.tw	Hwang, Chi-Ching/K-7933-2012	Hwang, Chi-Ching/0000-0002-8328-674X				Berger E, 2001, BIOCHEMISTRY-US, V40, P6699, DOI 10.1021/bi0104571; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUICE TC, 1962, BIOCHEMISTRY-US, V1, P7, DOI 10.1021/bi00907a002; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; COLS N, 1993, FEBS LETT, V319, P90, DOI 10.1016/0014-5793(93)80043-T; Ensor CM, 1996, BIOCHEM BIOPH RES CO, V220, P330, DOI 10.1006/bbrc.1996.0405; ENSOR CM, 1994, BBA-PROTEIN STRUCT M, V1208, P151, DOI 10.1016/0167-4838(94)90172-4; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; MARCUS PI, 1956, J BIOL CHEM, V218, P661; Maser E, 2000, BIOCHEM BIOPH RES CO, V272, P622, DOI 10.1006/bbrc.2000.2813; Maser E, 2001, CHEM-BIOL INTERACT, V130, P707, DOI 10.1016/S0009-2797(00)00302-1; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; Mobus E, 1998, J BIOL CHEM, V273, P30888, DOI 10.1074/jbc.273.47.30888; Mobus E, 1997, J BACTERIOL, V179, P5951; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; SKALHEGG BA, 1975, EUR J BIOCHEM, V50, P603, DOI 10.1111/j.1432-1033.1975.tb09901.x; Tanabe T, 1998, J BIOCHEM, V124, P634, DOI 10.1093/oxfordjournals.jbchem.a022159; Thomas JL, 2002, J BIOL CHEM, V277, P42795, DOI 10.1074/jbc.M208537200; Winberg JO, 1999, J MOL BIOL, V294, P601, DOI 10.1006/jmbi.1999.3235; Xiong GM, 2001, J BIOL CHEM, V276, P9961, DOI 10.1074/jbc.M010962200	26	34	35	7	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3522	3528		10.1074/jbc.M411751200	http://dx.doi.org/10.1074/jbc.M411751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15572373	hybrid			2022-12-25	WOS:000226983900049
J	Felli, MP; Vacca, A; Calce, A; Bellavia, D; Campese, AF; Grillo, R; Di Giovine, M; Checquolo, S; Talora, C; Palermo, R; Di Mario, G; Frati, L; Gulino, A; Screpanti, I				Felli, MP; Vacca, A; Calce, A; Bellavia, D; Campese, AF; Grillo, R; Di Giovine, M; Checquolo, S; Talora, C; Palermo, R; Di Mario, G; Frati, L; Gulino, A; Screpanti, I			PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia	ONCOGENE			English	Article						T cells; Notch3; PKC theta; NF-kappa B; leukemia	NF-KAPPA-B; KINASE-C-THETA; PROTEIN-KINASE; TRANSGENIC MICE; ACTIVATION; RECEPTOR; EXPRESSION; LEUKEMIA/LYMPHOMA; COSTIMULATION; LYMPHOCYTES	Protein kinase (PK) Ctheta is a critical regulator of mature T-cell activation and proliferation, being implicated in TCR-triggered nuclear factor (NF)-kappaB activation and providing important survival signals to leukemic T cells. We previously showed that overexpression of pTalpha/pre-TCR and constitutive activation of NF-kappaB characterize the T-cell leukemia/lymphoma developing in Notch3-IC transgenic mice. We report here that PKCtheta is a downstream target of Notch3 signaling and that its activation and membrane translocation require a functional pre-TCR in order to trigger NF-kappaB activation in thymocytes and lymphoma cells of transgenic mice. Furthermore, deletion of PKCtheta in Notch3-IC transgenic mice reduces the incidence of leukemia, correlating with decreased NF-kappaB activation. This paper therefore suggests that PKCtheta mediates the activation of NF-kappaB by pre-TCR in immature thymocytes and contributes to the development of Notch3-dependent T-cell lymphoma.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Lab Mol Pathol, I-00161 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Neuromed Inst, I-86077 Pozzilli, Italy; Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00161 Rome, Italy	Sapienza University Rome; University of L'Aquila; IRCCS Neuromed; Fondazione Cenci Bolognetti; Sapienza University Rome	Screpanti, I (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Lab Mol Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it	Frati, Luigi/ABI-7437-2020; Campese, Antonio/A-9783-2015; Bellavia, Diana/AAO-6348-2021; Palermo, Rocco/I-5140-2016; Talora, Claduio/AIC-4932-2022	Palermo, Rocco/0000-0003-0134-9370; Talora, Claduio/0000-0002-6973-2184; CHECQUOLO, Saula/0000-0001-5109-8392; VACCA, Alessandra/0000-0002-0006-5379; CAMPESE, Antonio Francesco/0000-0002-8535-6609; FELLI, MARIA PIA/0000-0002-5765-2611				Aifantis I, 2001, NAT IMMUNOL, V2, P403, DOI 10.1038/87704; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Cipriani B, 2002, J IMMUNOL, V169, P5761, DOI 10.4049/jimmunol.169.10.5761; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Maroder M, 1996, J IMMUNOL, V157, P2864; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Szamel M, 1998, J IMMUNOL, V160, P2207; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, CURR CANCER DRUG TAR, V2, P125, DOI 10.2174/1568009023333908; Villunger A, 1999, EUR J IMMUNOL, V29, P3549, DOI 10.1002/(SICI)1521-4141(199911)29:11<3549::AID-IMMU3549>3.0.CO;2-Q; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433	30	61	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					992	1000		10.1038/sj.onc.1208302	http://dx.doi.org/10.1038/sj.onc.1208302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592506				2022-12-25	WOS:000226749200005
J	Vanhorne, JB; Andrew, SD; Harrison, KJ; Taylor, SAM; Thomas, B; McDonald, TJ; Ainsworth, PJ; Mulligan, LM				Vanhorne, JB; Andrew, SD; Harrison, KJ; Taylor, SAM; Thomas, B; McDonald, TJ; Ainsworth, PJ; Mulligan, LM			A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2	ONCOGENE			English	Article						GFR alpha 4; GFRA family; thyroid tumours; multiple endocrine neoplasia type 2	MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE; TYROSINE KINASE; FAMILY LIGANDS; RECEPTOR; EXPRESSION; PERSEPHIN; MUTATION; GENE; ACTIVATION	Mutations of the RET proto-oncogene are found in the majority of patients with the inherited cancer syndrome multiple endocrine neoplasia type 2 ( MEN 2). A minority of cases, however, have no detectable RET mutation and there is considerable phenotypic variation within and among MEN 2 families with the same RET mutation, suggesting a role for other loci in this disease. A candidate for such a gene is glial cell line-derived neurotrophic factor receptor alpha 4 (GFRA4), which encodes a cell surface-bound co-receptor (GFRalpha4) required for interaction of RET with its ligand persephin. The GFRA4 gene has multiple alternative splices leading to three distinct protein isoforms that are prominently expressed in thyroid. We postulated that mutations of GFRA4 contribute to MEN 2 in the absence of RET mutations or modify the RET mutation phenotype. We screened patients with MEN 2 or MEN 2-like phenotypes, with and without RET mutations, for variants of GFRA4. We identified 10 variants, one of which was over represented in, and two of which were found exclusively in, our patient populations. One of these was a single-base substitution upstream of the GFRalpha4 coding region, where it may alter gene expression. The second was a 7 bp insertion, which results in a change in reading frame for all three GFRalpha4 isoforms. This would cause a relative shift in membrane bound and soluble forms of GFRalpha4, which would significantly alter the formation of RET signalling complexes. Our data suggest a model of wild-type GFRa4 isoform expression that includes both activating and inhibiting co-receptors for RET.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada	Queens University - Canada; Western University (University of Western Ontario); Western University (University of Western Ontario)	Mulligan, LM (corresponding author), Queens Univ, Dept Pathol, 20 Barrie St, Kingston, ON K7L 3N6, Canada.	mulligal@post.queensu.ca						Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BABU VR, 1984, P NATL ACAD SCI-BIOL, V81, P2525, DOI 10.1073/pnas.81.8.2525; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Feldman GL, 2000, SURGERY, V128, P93, DOI 10.1067/msy.2000.107103; Frohnauer MK, 2000, SURGERY, V128, P1052, DOI 10.1067/msy.2000.11/6/111080; Gil L, 2002, INT J CANCER, V99, P299, DOI 10.1002/ijc.10298; Gimm O, 2001, ONCOGENE, V20, P2161, DOI 10.1038/sj.onc.1204289; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hansford JR, 2001, AM J HUM GENET, V69, P366; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Lindahl M, 2001, J BIOL CHEM, V276, P9344, DOI 10.1074/jbc.M008279200; Lombardo F, 2002, J CLIN ENDOCR METAB, V87, P1674, DOI 10.1210/jcem.87.4.8403; Masure S, 2000, J BIOL CHEM, V275, P39427, DOI 10.1074/jbc.M003867200; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; SHANNON KE, 1999, J ENDOCR GENET, V1, P39; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Van Dyke D L, 1984, Henry Ford Hosp Med J, V32, P266; Vanhorne JB, 2001, HUM GENET, V108, P409, DOI 10.1007/s004390100506; Wiench M, 2001, J CLIN ONCOL, V19, P1374, DOI 10.1200/JCO.2001.19.5.1374	24	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1091	1097		10.1038/sj.onc.1207826	http://dx.doi.org/10.1038/sj.onc.1207826			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592530				2022-12-25	WOS:000226749200015
J	Cuevas, BD; Uhlik, MT; Garrington, TP; Johnson, GL				Cuevas, BD; Uhlik, MT; Garrington, TP; Johnson, GL			MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability	ONCOGENE			English	Article						MEKK1; AP-1; dimer	NEGATIVE C-JUN; CELL-PROLIFERATION; MOUSE DEVELOPMENT; GENE DISRUPTION; DEFICIENT MICE; PHOSPHORYLATION; PLASMINOGEN; ACTIVATION; KINASE; FOS	Activator protein 1 (AP-1) transcription factor dimers are composed of Jun, Fos, and ATF member proteins, but the mechanisms that determine AP-1 composition are not clearly de. ned and the function of specific dimers is not well understood. MEKK1 is a mitogen-activated protein kinase ( MAPK) kinase kinase and an ubiquitin ligase that regulates both the extracellular signal-regulated kinase 1/2 and the c-Jun amino-terminal kinase. Herein, we demonstrate that MEKK1 regulates the AP-1 protein repertoire. Both FGF-2 and phorbol ester-inducible urokinase-type plasminogen activator (uPA) expression requires AP-1 binding to an enhancer element in the uPA promoter, and we have previously shown that FGF-2 or PMA induction of uPA expression is strongly dependent on MEKK1. JunB mRNA is significantly increased in MEKK1-/- cells, demonstrating that MEKK1 suppresses JunB mRNA expression. Upregulation of JunB expression in MEKK1-/- cells forms an inhibitory AP-1 complex that binds to the uPA promoter and inhibits uPA transcription. MEKK1 also regulates Fra-2 protein stability by inducing Fra-2 ubiquitination and degradation. MEKK1 regulates AP-1-dependent gene expression by regulating the expression, activity and degradation of component members of the AP-1 complex. Controlling the repertoire of a transcription factor complex is a newly defined function for an MAPK kinase kinase.	Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, 1108 Mary Ellen Jones Bldg,Campus Box 7365,102 Ma, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu						Acquaviva C, 2002, ANN NY ACAD SCI, V973, P426, DOI 10.1111/j.1749-6632.2002.tb04677.x; Acquaviva C, 2001, BIOCHIMIE, V83, P357, DOI 10.1016/S0300-9084(01)01243-3; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cohen D, 2001, AM SOC HEMATOL ED PR, P1; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DECESARE D, 1995, ONCOGENE, V11, P365; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Legrand C, 2001, EXP CELL RES, V264, P326, DOI 10.1006/excr.2000.5125; Lund LR, 2000, DEVELOPMENT, V127, P4481; McHenry JZ, 1998, ONCOGENE, V17, P1131, DOI 10.1038/sj.onc.1202044; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OHagan RC, 1996, ONCOGENE, V13, P1323; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Roselli HT, 1998, AM J PHYSIOL-GASTR L, V275, pG1472, DOI 10.1152/ajpgi.1998.275.6.G1472; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Thompson EJ, 2002, CANCER RES, V62, P3044; Witowsky J, 2003, J BIOL CHEM, V278, P5941, DOI 10.1074/jbc.M212363200; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Young MR, 2002, MOL CARCINOGEN, V34, P72, DOI 10.1002/mc.10050; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	46	29	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					801	809		10.1038/sj.onc.1208239	http://dx.doi.org/10.1038/sj.onc.1208239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558021				2022-12-25	WOS:000226577100006
J	Yordy, JS; Moussa, O; Pei, HP; Chaussabel, D; Li, RZ; Watson, DK				Yordy, JS; Moussa, O; Pei, HP; Chaussabel, D; Li, RZ; Watson, DK			SP100 inhibits ETS1 activity in primary endothelial cells	ONCOGENE			English	Article						ETS1; SP100; angiogenesis; microarray; migration; transcription	TISSUE GROWTH-FACTOR; TRANSCRIPTION FACTOR ETS-1; ANGIOGENESIS IN-VIVO; NF-KAPPA-B; GENE-EXPRESSION; MICROARRAY DATA; TUMOR ANGIOGENESIS; INTERFERON-ALPHA; ANTISENSE OLIGONUCLEOTIDES; PLASMINOGEN-ACTIVATOR	SP100 was first identified as a nuclear autoimmune antigen and is a constituent of the nuclear body. SP100 interacts with the ETS1 transcription factor, and we have previously shown that SP100 reduces ETS1-DNA binding and inhibits ETS1 transcriptional activity on the MMP1 and uPA promoters. We now demonstrate that SP100 expression is upregulated by interferons, which have been shown to be antiangiogenic, in primary endothelial cells. As ETS1 is functionally important in promoting angiogenesis, we tested the hypothesis that ETS1 activity is negatively modulated by SP100 in endothelial cells. SP100 directly antagonizes ETS1-mediated morphological changes in human umbilical vein endothelial cell (HUVEC) network formation and reduces HUVEC migration and invasion. To further understand the functional relationship between ETS1 and SP100, cDNA microarray analysis was utilized to assess reprogramming of gene expression by ETS1 and SP100. A subset of the differentially regulated genes, including heat-shock proteins (HSPs) H11, HSPA1L, HSPA6, HSPA8, HSPE1 and AXIN1, BRCA1, CD14, CTGF (connective tissue growth factor), GABRE (gamma-aminobutyric acid A receptor epsilon), ICAM1, SNAI1, SRD5A1 (steroid-5-alpha-reductase 1) and THY1, were validated by real-time PCR and a majority showed reciprocal expression in response to ETS1 and SP100. Interestingly, genes that are negatively regulated by ETS1 and upregulated by SP100 have antimigratory or antiangiogenic properties. Collectively, these data indicate that SP100 negatively modulates ETS1-dependent downstream biological processes.	Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA; Baylor Inst Immunol Res, Dallas, TX USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Baylor Scott & White Health	Watson, DK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Room 332,86 Jonathan Lucas St, Charleston, SC 29425 USA.	watsondk@musc.edu	Chaussabel, Damien/AAX-1909-2020	Chaussabel, Damien/0000-0002-6131-7242	NCI NIH HHS [P01CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babic AM, 1999, MOL CELL BIOL, V19, P2958; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bell SE, 2001, J CELL SCI, V114, P2755; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Chaussabel D, 2003, BLOOD, V102, P672, DOI 10.1182/blood-2002-10-3232; Chaussabel D, 2002, GENOME BIOL, V3; Chen ZQ, 1997, CANCER RES, V57, P2013; Cui Y, 2004, OMICS, V8, P106, DOI 10.1089/1536231041388320; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dandre F, 2004, AM J PHYSIOL-HEART C, V286, pH2042, DOI 10.1152/ajpheart.00625.2003; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Edwards AD, 2003, J IMMUNOL, V171, P47, DOI 10.4049/jimmunol.171.1.47; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FOLKMAN J, 2000, CANC MED, P132; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Galea E, 2002, NEUROREPORT, V13, P1469, DOI 10.1097/00001756-200208070-00024; Gerritsen ME, 2002, PHYSIOL GENOMICS, V10, P13, DOI 10.1152/physiolgenomics.00035.2002; Goetze S, 2001, ATHEROSCLEROSIS, V159, P93, DOI 10.1016/S0021-9150(01)00497-X; Griffioen AW, 1996, CANCER RES, V56, P1111; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Hastings M M, 1997, J AAPOS, V1, P226, DOI 10.1016/S1091-8531(97)90042-2; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Igarashi T, 2001, TOHOKU J EXP MED, V194, P35, DOI 10.1620/tjem.194.35; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jang HS, 2004, MOL THER, V9, P464, DOI 10.1016/j.ymthe.2003.12.002; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kevil CG, 2004, J BIOL CHEM, V279, P19230, DOI 10.1074/jbc.M312025200; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kita D, 2001, CANCER RES, V61, P7985; Kumar P, 2002, J THORAC CARDIOV SUR, V124, P404, DOI 10.1067/mtc.2002.122540; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lee WS, 1998, CIRC RES, V82, P845; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LI WW, 1991, INVEST OPHTH VIS SCI, V32, P2906; Lincoln DW, 2003, BREAST CANCER RES TR, V78, P167, DOI 10.1023/A:1022904624054; Marler JJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e37; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Okubo T, 2001, CANCER RES, V61, P1338; Ortega A, 2003, TRENDS PHARMACOL SCI, V24, P151, DOI 10.1016/S0165-6147(03)00052-X; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Raouf A, 2000, ONCOGENE, V19, P1969, DOI 10.1038/sj.onc.1203505; Roca C, 2003, CANCER RES, V63, P1500; Roy J, 2001, J BIOL CHEM, V276, P14553, DOI 10.1074/jbc.M005067200; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shimizu S, 2004, INT J BIOCHEM CELL B, V36, P114, DOI 10.1016/S1357-2725(03)00170-5; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; St Croix B, 2000, SCIENCE, V289, P1197; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Tomita N, 2003, CIRCULATION, V107, P1411, DOI 10.1161/01.CIR.0000055331.41937.AA; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Tryfonas GI, 1998, PEDIATR SURG INT, V13, P590, DOI 10.1007/s003830050411; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wang L, 2003, J GASTROINTEST SURG, V7, P587, DOI 10.1016/S1091-255X(03)00072-6; Watanabe D, 2004, AM J PATHOL, V164, P1827, DOI 10.1016/S0002-9440(10)63741-8; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; WERNERT N, 1992, AM J PATHOL, V140, P119; Wu XX, 2003, BIOL REPROD, V69, P1308, DOI 10.1095/biolreprod.103.015420; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Yordy JS, 2004, ONCOGENE, V23, P6654, DOI 10.1038/sj.onc.1207891	92	35	39	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					916	931		10.1038/sj.onc.1208245	http://dx.doi.org/10.1038/sj.onc.1208245			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592518				2022-12-25	WOS:000226577100017
J	Yuan, XP; Curtin, J; Xiong, YZ; Liu, GT; Waschsmann-Hogiu, S; Farkas, DL; Black, KL; Yu, JS				Yuan, XP; Curtin, J; Xiong, YZ; Liu, GT; Waschsmann-Hogiu, S; Farkas, DL; Black, KL; Yu, JS			Isolation of cancer stem cells from adult glioblastoma multiforme	ONCOGENE			English	Article						cancer stem cells; adult brain tumors; glioblastoma multiforme; glioblastoma spheres; in vivo implantation	NEURAL PROGENITOR CELLS; CENTRAL-NERVOUS-SYSTEM; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; BRAIN-TUMORS; BONE-MARROW; IDENTIFICATION; MICE; PRECURSORS; GENERATION	Glioblastoma multiforme (GBM) is the most common adult primary brain tumor and is comprised of a heterogeneous population of cells. It is unclear which cells within the tumor mass are responsible for tumor initiation and maintenance. In this study, we report that brain tumor stem cells can be identified from adult GBMs. These tumor stem cells form neurospheres, possess the capacity for self-renewal, express genes associated with neural stem cells (NSCs), generate daughter cells of different phenotypes from one mother cell, and differentiate into the phenotypically diverse populations of cells similar to those present in the initial GBM. Having a distinguishing feature from normal NSCs, these tumor stem cells can reform spheres even after the induction of differentiation. Furthermore, only these tumor stem cells were able to form tumors and generate both neurons and glial cells after in vivo implantation into nude mice. The identification of tumor stem cells within adult GBM may represent a major step forward in understanding the origin and maintenance of GBM and lead to the identification and testing of new therapeutic targets.	Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Med & Surg, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Yu, JS (corresponding author), Maxine Dunitz Neurosurg Inst, Suite 800 E,8631 W 3rd St, Los Angeles, CA 90048 USA.	yuj@cshs.org	Curtin, James/B-1669-2008	Curtin, James/0000-0002-9320-9254; Black, Keith/0000-0002-0546-4934; Yu, John/0000-0003-1230-8494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS002232, R01NS048959] Funding Source: NIH RePORTER; NINDS NIH HHS [1K23NS02232, 1R01 NS048959] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Katsetos CD, 2002, J NEUROPATH EXP NEUR, V61, P307, DOI 10.1093/jnen/61.4.307; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Singh SK, 2003, CANCER RES, V63, P5821; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	26	615	689	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9392	9400		10.1038/sj.onc.1208311	http://dx.doi.org/10.1038/sj.onc.1208311			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15558011	Green Submitted			2022-12-25	WOS:000225764100010
J	Toustrup-Jensen, M; Vilsen, B				Toustrup-Jensen, M; Vilsen, B			Interaction between the catalytic site and the A-M3 linker stabilizes E-2/E2P conformational states of Na+, K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; 4TH TRANSMEMBRANE SEGMENT; FUNCTIONAL CONSEQUENCES; CATION-BINDING; ALPHA-SUBUNIT; DOMAIN-A; NA+,K+-ATPASE; NA,K-ATPASE; POTASSIUM; (NA,K)-ATPASE	The consequences of mutations Ile(265) -> Ala, Thr(267) -> Ala, Gly(271) -> Ala, and Gly(274) -> Ala for the partial reaction steps of the Na+, K+-ATPase transport cycle were analyzed. The mutated residues are part of the long loop ("A-M3 linker") connecting the cytoplasmic A-domain with transmembrane segment M3. It was found that mutation Ile265 -> Ala displaces the E-1-E-2 and E1P-E2P equilibria in favor of E-1/E1P, whereas mutations Thr(267) -> Ala, Gly(271) -> Ala, and Gly(274) -> Ala displace these conformational equilibria in favor of E-2/E2P. The mutations affect both the rearrangement of the cytoplasmic domains (seen by changes in phosphoenzyme properties and apparent ATP/vanadate affinities) and the membrane sector (indicated by change in K+/Rb+ deocclusion rate). Destabilization of E-2/E2P in Ile(265) -> Ala, as well as a direct effect on the intrinsic affinity of the E-2 form for vanadate, may be explained on the basis of the E-2 crystal structures of the Ca2+-ATPase, showing interaction of the equivalent isoleucine with conserved residues near the catalytic region of the P-domain. The rate of phosphorylation from ATP was unaffected in Ile(265) -> Ala, indicating a lack of interference with the catalytic function in E-1/E1P. The effects of mutations Thr(267) -> Ala, Gly(271) -> Ala, and Gly(274) -> Ala provide the first evidence in the literature of a relative stabilization of E-2/E2P resulting from perturbation of the A-M3 linker region. These mutations may lead to increased strain of the A-M3 linker in E-1/E1P, increased stability of the A3 helix of the A-M3 linker in E-2/E2P, and/or a change of the orientation of the A3 helix, facilitating its interaction with the P-domain.	Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus, Denmark	Aarhus University	Vilsen, B (corresponding author), Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, Ole Worms Alle 160, DK-8000 Aarhus, Denmark.	bv@fi.au.dk		Toustrup-Jensen, Mads Schak/0000-0003-2064-5861; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P1; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; HANSEN O, 1984, PHARMACOL REV, V36, P143; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KUNKEL TA, 1985, P NATL ACAD SCI USA, V85, P3314; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; SMITH RL, 1980, J BIOL CHEM, V255, P9852; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P38653, DOI 10.1074/jbc.M305521200; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toustrup-Jensen M, 2002, J BIOL CHEM, V277, P38607, DOI 10.1074/jbc.M203665200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8	36	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10210	10218		10.1074/jbc.M411214200	http://dx.doi.org/10.1074/jbc.M411214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15574410	hybrid			2022-12-25	WOS:000227559600059
J	Damek-Poprawa, M; Krouse, J; Gretzula, C; Boesze-Battaglia, K				Damek-Poprawa, M; Krouse, J; Gretzula, C; Boesze-Battaglia, K			A novel tetraspanin fusion protein, peripherin-2, requires a region upstream of the fusion domain for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; RESONANCE ENERGY-TRANSFER; MEMBRANE-FUSION; PHOTORECEPTOR PERIPHERIN/RDS; DISK MEMBRANES; HETEROLOGOUS EXPRESSION; RETINAL DEGENERATION; PLASMA-MEMBRANE; VIRAL FUSION; GP41 CORE	Peripherin-2 (also known as peripherin/rds), a photoreceptor specific tetraspanin protein, is required to maintain normal cell structure through its role in renewal processes requiring membrane fusion. It is the first tetraspanin fusogen and has been shown to directly mediate fusion between disk membranes and opposing membranes to maintain the highly ordered structure of rod outer segments. Localized to the C terminus of human, bovine, and murine peripherin-2 is an amphiphilic fusion peptide domain ( residues 312 - 326) and a highly conserved region upstream of this domain that we hypothesize is essential for fusogenic function. Our previous studies indicated that substitution of a threonine for a proline at position 296 within this highly conserved region enhanced fusion activity. In this study we wanted to determine whether this proline is essential with the introduction of three additional substitutions of proline with alanine, leucine, and glutamic acid. Wild type, P296T, P296A, P296L, and P296E mutants of peripherin-2 were expressed as His(6)-tagged full-length proteins in Madin-Darby canine kidney ( MDCK) cells. All of the proteins were localized to intracellular membranes and detected as 42-kDa monomers by Western blot analysis. The wild type, P296A, and P296L assembled into core tetramers; in contrast the P296T and P296E formed higher order oligomers. Fusogenic activity of full-length protein expressed in MDCK membranes and purified protein reconstituted in model membrane liposomes was determined using fluorescence quenching techniques. Fusion activity was decreased in the P296L, P296A, and P296E mutants both in endogenous MDCK membranes and in model liposomes. Collectively, these results suggest that the proline at position 296 is necessary for optimal function.	Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, Sch Osteopath Med, Stratford, NJ 08084 USA	University of Pennsylvania; Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Boesze-Battaglia, K (corresponding author), Univ Penn, Sch Dent Med, Dept Biochem, 240 S 40th St, Philadelphia, PA 19104 USA.	battagli@biochem.dental.upenn.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026365] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001583, R01EY010420, R29EY010420, R21EY018705] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR026365, S10 RR026365-01] Funding Source: Medline; NEI NIH HHS [R01 EY010420-15, 2-P30-EY01583-26, R21 EY018705-01A1, EY10420, R21 EY018705, R01 EY010420-06, R29 EY010420-03, R01 EY010420-07, R21 EY018705-02, R01 EY010420-09, R01 EY010420-16, R01 EY010420-10A2, R01 EY010420-13A2, R01 EY010420-08, R01 EY010420, R29 EY010420, R01 EY010420-11, R01 EY010420-12, R01 EY010420-14] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Bentz J, 2000, BIOPHYS J, V78, P886, DOI 10.1016/S0006-3495(00)76646-X; Berditchevski F, 2001, J CELL SCI, V114, P4143; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; Boesze-Battaglia K, 2002, J BIOL CHEM, V277, P41843, DOI 10.1074/jbc.M207111200; Boesze-Battaglia K, 2002, INT REV CYTOL, V217, P183; Boesze-Battaglia K, 2000, BBA-BIOMEMBRANES, V1463, P343, DOI 10.1016/S0005-2736(99)00226-6; BOESZEBATTAGLIA K, 1989, EXP EYE RES, V49, P699, DOI 10.1016/S0014-4835(89)80064-8; BoeszeBattaglia K, 1997, BIOCHEMISTRY-US, V36, P6835, DOI 10.1021/bi9627370; BOESZEBATTAGLIA K, 1992, BIOCHEMISTRY-US, V31, P3733, DOI 10.1021/bi00130a002; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; COHEN AI, 1983, INVEST OPHTH VIS SCI, V24, P832; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; Delos SE, 2000, J VIROL, V74, P1686, DOI 10.1128/JVI.74.4.1686-1693.2000; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 2001, J BIOL CHEM, V276, P42700, DOI 10.1074/jbc.M107511200; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; JANSEN HG, 1984, J COMP NEUROL, V224, P71, DOI 10.1002/cne.902240107; Kedzierski W, 1999, J BIOL CHEM, V274, P29181, DOI 10.1074/jbc.274.41.29181; Kohl S, 1998, ACTA ANAT, V162, P75; Le Naour F, 2004, CANCER IMMUNOL IMMUN, V53, P148, DOI 10.1007/s00262-003-0477-5; Liu J, 2001, BIOCHEMISTRY-US, V40, P2797, DOI 10.1021/bi0024759; Liu N, 2001, CURR PROTEIN PEPT SC, V2, P107, DOI 10.2174/1389203013381161; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; McNally N, 2002, HUM MOL GENET, V11, P1005, DOI 10.1093/hmg/11.9.1005; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mellian I, 1995, COLD SPRING HARB SYM, V60, P745, DOI 10.1101/SQB.1995.060.01.080; Miyado K, 2000, Tanpakushitsu Kakusan Koso, V45, P1728; MONSMA SA, 1995, J VIROL, V69, P2583, DOI 10.1128/JVI.69.4.2583-2595.1995; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; PARTEARROYO MA, 1994, BBA-BIOMEMBRANES, V1189, P175; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Ritter LM, 2004, J BIOL CHEM, V279, P39958, DOI 10.1074/jbc.M403943200; Shmulevitz M, 2004, J VIROL, V78, P2808, DOI 10.1128/JVI.78.6.2808-2818.2004; Stefano FP, 2002, EXP EYE RES, V74, P267, DOI 10.1006/exer.2001.1119; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Todres E, 2000, INSECT MOL BIOL, V9, P581, DOI 10.1046/j.1365-2583.2000.00222.x; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Wrigley JDJ, 2000, J BIOL CHEM, V275, P13191, DOI 10.1074/jbc.C900853199; Zemni R, 2000, NAT GENET, V24, P167, DOI 10.1038/72829	57	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	2005	280	10					9217	9224		10.1074/jbc.M407166200	http://dx.doi.org/10.1074/jbc.M407166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	903VG	15591062	Green Published, hybrid			2022-12-25	WOS:000227453100071
J	Blee, E; Summerer, S; Flenet, M; Rogniaux, H; Van Dorsselaer, A; Schuber, F				Blee, E; Summerer, S; Flenet, M; Rogniaux, H; Van Dorsselaer, A; Schuber, F			Soybean epoxide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-RADIOBACTER AD1; ALKYL-ENZYME INTERMEDIATE; TRANSITION-STATE ANALOGS; GENERAL ACID ACTIVATION; CATALYTIC MECHANISM; HALOALKANE DEHALOGENASE; BIOCHEMICAL-EVIDENCE; ESTER INTERMEDIATE; ASPERGILLUS-NIGER; STYRENE OXIDES	Soybean epoxide hydrolase catalyzes the oxirane ring opening of 9,10-epoxystearate via a two-step mechanism involving the formation of an alkylenzyme intermediate, which, in contrast to most epoxide hydrolases studied so far, was found to be the rate-limiting step. We have probed residues potentially involved in catalysis by site-directed mutagenesis. Mutation of His(320), a residue predicted from sequence analysis to belong to the catalytic triad of the enzyme, considerably slowed down the second half-reaction. This kinetic manipulation provoked an accumulation of the reaction intermediate, which could be trapped and characterized by electrospray ionization mass spectrometry. As expected, mutation of Asp(126) totally abolished the activity of the enzyme from its crucial function as nucleophile involved in the formation of the alkylenzyme. In line with its role as the partner of His(320) in the "charge relay system," mutation of Asp(285) dramatically reduced the rate of catalysis. However, the mutant D285L still exhibited a very low residual activity, which, by structural analysis and mutagenesis, has been tentatively attributed to Glu(195), another acidic residue of the active site. Our studies have also confirmed the fundamental role of the conserved Tyr(175) and Tyr(255) residues, which are believed to activate the oxirane ring. Finally, we have determined the secondary tritium kinetic isotope effects on the epoxide opening step of 9,10-epoxystearate. The large observed values, i.e. (T)(V/K-m) approximate to 1.30, can be interpreted by the occurrence of a very late transition state in which the epoxide bond is broken before the nucleophilic attack by Asp(126) takes place.	UPR 2357, CNRS, IBMP, Lab Phytooxylipines, F-67083 Strasbourg, France; Ecole Chim Polymeres & Mat, Lab Spectrometr Masse Bioorgan, F-67087 Strasbourg 2, France; ULP, CNRS, UMR 7514, Lab Chim Bioorogan,Fac Pharm, F-67400 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schuber, F (corresponding author), UPR 2357, CNRS, IBMP, Lab Phytooxylipines, 28 Rue Goethe, F-67083 Strasbourg, France.	schuber@pharma.u-strasbg.fr						Arahira M, 2000, EUR J BIOCHEM, V267, P2649, DOI 10.1046/j.1432-1327.2000.01276.x; Arand M, 1999, BIOCHEM J, V337, P37, DOI 10.1042/0264-6021:3370037; Arand M, 1999, BIOCHEM J, V344, P273, DOI 10.1042/0264-6021:3440273; ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; Archelas A, 2001, CURR OPIN CHEM BIOL, V5, P112, DOI 10.1016/S1367-5931(00)00179-4; Argiriadi MA, 2000, J BIOL CHEM, V275, P15265, DOI 10.1074/jbc.M000278200; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; ARMSTRONG RN, 1987, CRC CR REV BIOCH MOL, V22, P39, DOI 10.3109/10409238709082547; BELL PA, 1993, J BIOL CHEM, V268, P14011; Berti PJ, 1999, METHOD ENZYMOL, V308, P355; BLEE E, 1993, PLANT J, V4, P113, DOI 10.1046/j.1365-313X.1993.04010113.x; BLEE E, 1992, J BIOL CHEM, V267, P11881; BLEE E, 1990, J BIOL CHEM, V265, P12887; BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923; Chiappe C, 2000, J MOL CATAL B-ENZYM, V10, P539, DOI 10.1016/S1381-1177(00)00097-7; Cook PF, 1991, ENZYME MECH ISOTOPE; DANSETTE PM, 1978, ARCH BIOCHEM BIOPHYS, V187, P290, DOI 10.1016/0003-9861(78)90037-1; DUBOIS GC, 1978, J BIOL CHEM, V253, P2932; Edqvist J, 2003, PLANTA, V216, P403, DOI 10.1007/s00425-002-0876-4; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GILLILAN RE, 1982, J AM CHEM SOC, V104, P4482, DOI 10.1021/ja00380a028; Guo A, 1998, PLANT J, V15, P647, DOI 10.1046/j.1365-313x.1998.00241.x; HAMMOCK BD, 1994, BIOCHEM BIOPH RES CO, V198, P850, DOI 10.1006/bbrc.1994.1121; HANZLIK RP, 1980, J AM CHEM SOC, V102, P2464, DOI 10.1021/ja00527a060; Harrison MJ, 1997, J AM CHEM SOC, V119, P12285, DOI 10.1021/ja9711472; Jez JM, 2000, J BIOL CHEM, V275, P39640, DOI 10.1074/jbc.M008569200; KATSUBE T, 1995, PLANT PHYSIOL, V109, P722; KIYOSUE T, 1994, PLANT J, V6, P259, DOI 10.1046/j.1365-313X.1994.6020259.x; Kohen A, 1997, BIOCHEMISTRY-US, V36, P2603, DOI 10.1021/bi962492r; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; Laitinen T, 1998, J ORG CHEM, V63, P8157, DOI 10.1021/jo980532m; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; Matsson O, 1998, ADV PHYS ORG CHEM, V31, P143; Morisseau C, 1998, ARCH BIOCHEM BIOPHYS, V356, P214, DOI 10.1006/abbi.1998.0756; Morisseau C, 2000, ARCH BIOCHEM BIOPHYS, V378, P321, DOI 10.1006/abbi.2000.1810; Moussou P, 1998, J ORG CHEM, V63, P3532, DOI 10.1021/jo9714371; Muller F, 1997, EUR J BIOCHEM, V245, P490, DOI 10.1111/j.1432-1033.1997.00490.x; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Nardini M, 1999, J BIOL CHEM, V274, P14579, DOI 10.1074/jbc.274.21.14579; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; Oesch F, 2001, ADV EXP MED BIOL, V500, P577; Omoto K, 2000, J ORG CHEM, V65, P2464, DOI 10.1021/jo9916333; PARKER RE, 1959, CHEM REV, V59, P737, DOI 10.1021/cr50028a006; Parkin D., 1991, METHODS DETERMINATIO, P269; PINOT F, 1995, J BIOL CHEM, V270, P7968, DOI 10.1074/jbc.270.14.7968; PRIES F, 1995, J BIOL CHEM, V270, P10405, DOI 10.1074/jbc.270.18.10405; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Rink R, 1998, BIOCHEMISTRY-US, V37, P18119, DOI 10.1021/bi9817257; Rink R, 2000, BIOCHEMISTRY-US, V39, P5600, DOI 10.1021/bi9922392; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Schiott B, 2002, J AM CHEM SOC, V124, P14558, DOI 10.1021/ja021021r; Schramm VL, 1999, METHOD ENZYMOL, V308, P301; Schramm VL, 2003, ACCOUNTS CHEM RES, V36, P588, DOI 10.1021/ar0200495; STAPLETON A, 1994, PLANT J, V6, P251, DOI 10.1046/j.1365-313X.1994.6020251.x; Summerer S, 2002, BIOCHEM J, V366, P471, DOI 10.1042/BJ20011778; SUNKO DE, 1977, J AM CHEM SOC, V99, P5000, DOI 10.1021/ja00457a018; Tzeng HF, 1996, J AM CHEM SOC, V118, P9436, DOI 10.1021/ja961826x; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; Yamada T, 2000, J BIOL CHEM, V275, P23082, DOI 10.1074/jbc.M001464200; Zou JY, 2000, STRUCTURE, V8, P111, DOI 10.1016/S0969-2126(00)00087-3	62	19	20	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6479	6487		10.1074/jbc.M411366200	http://dx.doi.org/10.1074/jbc.M411366200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596432	hybrid			2022-12-25	WOS:000227332700030
J	Dutartre, H; Boretto, J; Guillemot, JC; Canard, B				Dutartre, H; Boretto, J; Guillemot, JC; Canard, B			A relaxed discrimination of 2 '-O-methyl-GTP relative to GTP between de novo and elongative RNA synthesis by the hepatitis c RNA-dependent RNA polymerase NS5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; ANTIVIRAL ACTIVITY; FULL-LENGTH; VIRUS; INITIATION; MECHANISM; RIBAVIRIN; REQUIREMENTS; INTERFERON-ALPHA-2B; REPLICATION	Several nucleotide analogues have been described as inhibitors of NS5B, the essential viral RNA-dependent RNA polymerase of hepatitis C virus. However, their precise mode of action remains poorly defined at the molecular level, much like the different steps of de novo initiation of viral RNA synthesis. Here, we show that before elongation, de novo RNA synthesis is made of at least two distinct kinetic phases, the creation of the first phosphodiester bond being the most efficient nucleotide incorporation event. We have studied 2'-O-methyl-GTP as an inhibitor of NS5B-directed RNA synthesis. As a nucleotide competitor of GTP in RNA synthesis, 2'-O-methyl-GTP is able to act as a chain terminator and inhibit RNA synthesis. Relative to GTP, we find that this analogue is strongly discriminated against at the initiation step (similar to150-fold) compared with similar to2-fold at the elongation step. Interestingly, discrimination of the 2'-O-methyl-GTP at initiation is suppressed in a variant NS5B deleted in a subdomain critical for initiation (the "flap," encompassing amino acids 443-454), but not in P495L NS5B, which shows a selective alteration of transition from initiation to elongation. Our results demonstrate that the conformational change occurring between initiation and elongation is dependent on the allosteric GTP-binding site and relaxes nucleotide selectivity. RNA elongation may represent the most probable target of 2'-modified nucleotide analogues, because it is more permissive to inhibition than initiation.	CNRS, F-13288 Marseille 9, France; Univ Aix Marseille I & II, UMR 6098, Ecole Super Ingn Luminy, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Canard, B (corresponding author), CNRS, Case 925,163 Ave Luminy, F-13288 Marseille 9, France.	bruno@afmb.cnrs-mrs.fr	; Dutartre, Helene/H-8837-2016	Canard, Bruno/0000-0003-4924-1991; Dutartre, Helene/0000-0002-2682-4302				Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; Deval J, 2004, CURR DRUG METAB, V5, P305, DOI 10.2174/1389200043335478; Gallois-Montbrun S, 2003, MOL PHARMACOL, V63, P538, DOI 10.1124/mol.63.3.538; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Liang T. Jake, 2000, Annals of Internal Medicine, V132, P296; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Menendez-Arias L, 2002, TRENDS PHARMACOL SCI, V23, P381, DOI 10.1016/S0165-6147(02)02054-0; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; MILLER JP, 1977, ANN NY ACAD SCI, V284, P211, DOI 10.1111/j.1749-6632.1977.tb21953.x; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Ranjith-Kumar CT, 2003, J MOL BIOL, V330, P675, DOI 10.1016/S0022-2836(03)00613-2; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Shim J, 2003, ANTIVIR RES, V58, P243, DOI 10.1016/S0166-3542(03)00007-X; Shim JH, 2002, J VIROL, V76, P7030, DOI 10.1128/JVI.76.14.7030-7039.2002; Somsouk MA, 2003, GASTROENTEROLOGY, V124, P1946, DOI 10.1016/S0016-5085(03)00391-3; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Tomei L, 2003, J VIROL, V77, P13225, DOI 10.1128/JVI.77.24.13225-13231.2003; Vo NV, 2004, BIOCHEMISTRY-US, V43, P10579, DOI 10.1021/bi049773g; Vo NV, 2003, BIOCHEMISTRY-US, V42, P10462, DOI 10.1021/bi0344681; Walker Michelle P., 2003, Antiviral Chemistry & Chemotherapy, V14, P1; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Wu Jim Zhen, 2003, Current Drug Targets - Infectious Disorders, V3, P207, DOI 10.2174/1568005033481114; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	42	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6359	6368		10.1074/jbc.M410191200	http://dx.doi.org/10.1074/jbc.M410191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15561709	hybrid			2022-12-25	WOS:000227332700016
J	Gonzalez, EM; Reed, CC; Bix, G; Fu, J; Zhang, Y; Gopalakrishnan, B; Greenspan, DS; Iozzo, RV				Gonzalez, EM; Reed, CC; Bix, G; Fu, J; Zhang, Y; Gopalakrishnan, B; Greenspan, DS; Iozzo, RV			BMP-1/tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; EXTRACELLULAR-MATRIX PROTEINS; HEPARAN-SULFATE PROTEOGLYCAN; ALPHA-DYSTROGLYCAN BINDING; BASEMENT-MEMBRANES; GROWTH-FACTOR; TUMOR-GROWTH; DOMAIN PAIR; NULL MICE; EXPRESSION	Endorepellin, the C-terminal domain of the heparan sulfate proteoglycan perlecan, possesses angiostatic activity. The terminal laminin-like globular (LG3) domain of endorepellin appears to possess most of the biological activity on endothelial cells. LG3 protein has been detected in the urine of patients with end-stage renal disease and in the amniotic fluid of pregnant women with premature rupture of fetal membranes. These findings suggest that proteolytic processing of endorepellin and the generation of LG3 might have biological significance. In this study, we have identified specific enzymes of the bone morphogenctic protein-1 (BMP-1)/Tolloid family of metalloproteases that cleave LG3 from recombinant endorepellin at the physiologically relevant site and that cleave LG3 from endogenous perlecan in cultured mouse and human cells. The BMP-1/Tolloid family of metalloproteases is thereby implicated in the processing of a major basement membrane proteoglycan and in the liberation of an anti-angiogenic factor. Using molecular modeling, site-directed mutagenesis and angiogenic assays, we further demonstrate that LG3 activity requires specific amino acids involved in Ca2+ coordination.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cell Biol & Signaling Program, Philadelphia, PA 19107 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Program Mol & Cellular Biol, Madison, WI 53706 USA	Jefferson University; Jefferson University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol, Rm 249 JAH,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112; Greenspan, Daniel/0000-0001-8096-7446	NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063471] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NIAMS NIH HHS [R01 AR47746] Funding Source: Medline; NIGMS NIH HHS [R01 GM63471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; Gopalakrishnan B, 2004, J BIOL CHEM, V279, P30904, DOI 10.1074/jbc.M402252200; GREENSPAN DS, 2005, IN PRESS TOP CUR CHE; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HASSELL JR, 2003, GLYCOCONJ J, V19, P263; Henry MD, 2001, J CELL SCI, V114, P1137; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Hohenester E, 2002, MATRIX BIOL, V21, P115, DOI 10.1016/S0945-053X(01)00191-3; IOZZO RV, 1987, J BIOL CHEM, V262, P11188; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Melo F, 1998, J MOL BIOL, V277, P1141, DOI 10.1006/jmbi.1998.1665; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; Oda O, 1996, CLIN CHIM ACTA, V255, P119, DOI 10.1016/0009-8981(96)06395-4; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Schenk S, 2003, TRENDS CELL BIOL, V13, P366, DOI 10.1016/S0962-8924(03)00129-6; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; STCOIX B, 2000, SCIENCE, V289, P1197; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Vuadens F, 2003, PROTEOMICS, V3, P1521, DOI 10.1002/pmic.200300455; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wizemann H, 2003, J MOL BIOL, V332, P635, DOI 10.1016/S0022-2836(03)00848-9; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; Zhou ZJ, 2004, CANCER RES, V64, P4699, DOI 10.1158/0008-5472.CAN-04-0810	45	145	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7080	7087		10.1074/jbc.M409841200	http://dx.doi.org/10.1074/jbc.M409841200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591058	hybrid			2022-12-25	WOS:000227332700098
J	McGettrick, AJ; Feener, EP; Kahn, CR				McGettrick, AJ; Feener, EP; Kahn, CR			Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID POLYMORPHISM; TYROSINE KINASE-ACTIVITY; ARG(972) POLYMORPHISM; DIABETES-MELLITUS; GENE; VARIANT; RESISTANCE; SENSITIVITY; MUTATION; SECRETION	The most commonly detected polymorphism in human insulin receptor substrate-1 (IRS-1), a glycine to arginine change at codon 972 (G972R), is associated with an increased risk of Type 2 diabetes and insulin resistance. To determine the molecular mechanism by which this polymorphism may be linked to insulin resistance, we produced recombinant peptides comprising amino acid residues 925-1008 from IRS-1 that contain either a glycine or arginine at codon 972 and the two nearby tyrosine phosphorylation consensus sites ((EYMLM)-M-941 and (DYMTM)-M-989), which are known binding sites for the p85alpha regulatory subunit of phosphatidylinositol 3-kinase. The wild type peptide could be phosphorylated at these sites in vitro by purified insulin receptor. Introduction of the G972R polymorphism into the peptide reduced the amount of tyrosine phosphorylation by >60%. Pull-down experiments indicated that there was an association between the IRS-1-(925-1008) peptide and the insulin receptor that was markedly enhanced by the presence of the G972R polymorphism. The use of additional overlapping fragments localized this interaction to domains between residues 950-986 of IRS-1 and residues 966-1271 of the insulin receptor, containing the tyrosine kinase domain of the receptor. In addition, the IRS-14925-1008) G972R peptide acted as a competitive inhibitor of insulin receptor and insulin-like growth factor-1 receptor autophosphorylation. Taken together, these data indicate that the G972R naturally occurring polymorphism of IRS-1 not only reduces phosphorylation of the substrate but allows IRS-1 to act as an inhibitor of the insulin receptor kinase, producing global insulin resistance.	Harvard Univ, Sch Med, Sect Cellular & Mol Physiol, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Proteom Core, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Sect Cellular & Mol Physiol, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34834, DK33201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almind K, 1999, DIABETOLOGIA, V42, P1244, DOI 10.1007/s001250051299; Almind K, 1998, DIABETOLOGIA, V41, P969, DOI 10.1007/s001250051015; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; Almind K, 2001, NAT MED, V7, P277, DOI 10.1038/85405; Baroni MG, 1999, ARTERIOSCL THROM VAS, V19, P2975, DOI 10.1161/01.ATV.19.12.2975; Baroni MG, 2001, DIABETOLOGIA, V44, P367, DOI 10.1007/s001250051628; Baynes KCR, 2000, DIABETOLOGIA, V43, P321, DOI 10.1007/s001250050050; Bernal D, 1998, DIABETES, V47, P976, DOI 10.2337/diabetes.47.6.976; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; Ek J, 2001, DIABETOLOGIA, V44, P1170, DOI 10.1007/s001250100629; Esposito DL, 2003, J CLIN ENDOCR METAB, V88, P1468, DOI 10.1210/jc.2002-020933; Federici M, 2003, DIABETES, V52, P887, DOI 10.2337/diabetes.52.3.887; Federici M, 2001, FASEB J, V15, P22; Federici M, 2004, CIRCULATION, V109, P399, DOI 10.1161/01.CIR.0000109498.77895.6F; Hansen T, 1997, DIABETES, V46, P494, DOI 10.2337/diabetes.46.3.494; Hara K, 2002, DIABETOLOGIA, V45, P740, DOI 10.1007/s00125-002-0803-z; HITMAN GA, 1995, DIABETOLOGIA, V38, P481, DOI 10.1007/s001250050309; Hribal ML, 2000, J CLIN ENDOCR METAB, V85, P2004, DOI 10.1210/jc.85.5.2004; Jellema A, 2003, DIABETOLOGIA, V46, P990, DOI 10.1007/s00125-003-1126-4; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Krook A, 1996, BAILLIERE CLIN ENDOC, V10, P97, DOI 10.1016/S0950-351X(96)80330-2; Marchetti P, 2002, DIABETES, V51, P1419, DOI 10.2337/diabetes.51.5.1419; Marini MA, 2003, J CLIN ENDOCR METAB, V88, P3368, DOI 10.1210/jc.2002-021716; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Morrison VA, 2004, MOL GENET METAB, V81, P291, DOI 10.1016/j.ymgme.2003.10.018; Perticone F, 2004, J CLIN ENDOCR METAB, V89, P3606, DOI 10.1210/jc.2003-032161; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Stumvoll M, 2001, DIABETES, V50, P882, DOI 10.2337/diabetes.50.4.882; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang H, 2001, DIABETES, V50, P1949, DOI 10.2337/diabetes.50.8.1949; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1997, DIABETOLOGIA, V40, P2	39	59	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6441	6446		10.1074/jbc.M412300200	http://dx.doi.org/10.1074/jbc.M412300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590636	hybrid			2022-12-25	WOS:000227332700025
J	Fey, V; Wagner, R; Brautigam, K; Wirtz, M; Hell, R; Dietzmann, A; Leister, D; Oelmuller, R; Pfannschmidt, T				Fey, V; Wagner, R; Brautigam, K; Wirtz, M; Hell, R; Dietzmann, A; Leister, D; Oelmuller, R; Pfannschmidt, T			Retrograde plastid redox signals in the expression of nuclear genes for chloroplast proteins of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; MUSTARD SINAPIS-ALBA; MESSENGER-RNA; LIGHT ENVIRONMENT; HIGHER-PLANTS; PHOTOSYSTEM STOICHIOMETRY; CHLOROPHYLL FLUORESCENCE; TRANSCRIPTIONAL CONTROL; PLASTOQUINONE POOL; EXCITATION-ENERGY	Excitation imbalances between photosystem I and II generate redox signals in the thylakoid membrane of higher plants which induce acclimatory changes in the structure of the photosynthetic apparatus. They affect the accumulation of reaction center and light-harvesting proteins as well as chlorophylls a and b. In Arabidopsis thaliana the re-adjustment of photosystem stoichiometry is mainly mediated by changes in the number of photosystem I complexes, which are accompanied by corresponding changes in transcripts for plastid reaction center genes. Because chloroplast protein complexes contain also many nuclear encoded components we analyzed the impact of such photosynthetic redox signals on nuclear genes. Light shift experiments combined with application of the electron transport inhibitor 3-(3',4'-dichlorophenyl)-1,1'-dimethyl urea have been performed to induce defined redox signals in the thylakoid membrane. Using DNA macroarrays we assessed the impact of such redox signals on the expression of nuclear genes for chloroplast proteins. In addition, studies on mutants with lesions in cytosolic photoreceptors or in chloroplast-to-nucleus communication indicate that the defective components in the mutants are not essential for the perception and/or transduction of light-induced redox signals. A stable redox state of glutathione suggest that neither glutathione itself nor reactive oxygen species are involved in the observed regulation events pointing to the thylakoid membrane as the main origin of the regulatory pathways. Our data indicate a distinct role of photosynthetic redox signals in the cellular network regulating plant gene expression. These redox signals appear to act independently and/or above of cytosolic photoreceptor or known chloroplast-to-nucleus communication avenues.	Univ Jena, Dept Plant Physiol, D-07743 Jena, Germany; Heidelberg Univ, Inst Plant Sci, D-69120 Heidelberg, Germany; Max Planck Inst Plant Breeding Res, D-50829 Cologne, Germany	Friedrich Schiller University of Jena; Ruprecht Karls University Heidelberg; Max Planck Society	Pfannschmidt, T (corresponding author), Univ Jena, Dept Plant Physiol, Dornburger Str 159, D-07743 Jena, Germany.	Thomas.Pfannschmidt@uni-jena.de	Hell, Ruediger/E-5436-2014; Leister, Dario/D-5587-2009; Pfannschmidt, Thomas/AAH-5916-2021; Wirtz, Markus/G-5917-2010	Leister, Dario/0000-0003-1897-8421; Wirtz, Markus/0000-0001-7790-4022; Fey, Vidal/0000-0003-1388-5904; Hell, Ruediger/0000-0002-6238-4818; Braeutigam, Katharina/0000-0001-5655-7156				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Alexciev K, 1997, PHYSIOL PLANTARUM, V99, P477, DOI 10.1034/j.1399-3054.1997.990317.x; Allen JF, 2000, PHILOS T R SOC B, V355, P1351, DOI 10.1098/rstb.2000.0697; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Anderson JM, 1995, PHOTOSYNTH RES, V46, P129, DOI 10.1007/BF00020423; ARO EM, 2001, ADV PHOTOSYNTHESIS R; Aukerman MJ, 1997, PLANT CELL, V9, P1317, DOI 10.1105/tpc.9.8.1317; Baginsky S, 1999, PLANT MOL BIOL, V39, P1013, DOI 10.1023/A:1006177807844; BAIER M, 1998, PROG BOT, V60, P283; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cheng MC, 1997, PLANTA, V203, P373, DOI 10.1007/s004250050203; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG XW, 1989, PLANT CELL, V1, P645, DOI 10.1105/tpc.1.6.645; Dietz KJ, 2002, PROG BOT, V63, P207; Eguchi S, 2002, PLANT CELL PHYSIOL, V43, P573, DOI 10.1093/pcp/pcf064; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; Foyer CH, 1997, PHYSIOL PLANTARUM, V100, P241, DOI 10.1034/j.1399-3054.1997.1000205.x; Fujita Y, 1997, PHOTOSYNTH RES, V53, P83, DOI 10.1023/A:1005870301868; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; GHOSH PK, 1978, J BIOL CHEM, V253, P3643; GLICK RE, 1986, P NATL ACAD SCI USA, V83, P4287, DOI 10.1073/pnas.83.12.4287; Gray JC, 2003, PHILOS T R SOC B, V358, P135, DOI 10.1098/rstb.2002.1180; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hihara Y, 2003, J BACTERIOL, V185, P1719, DOI 10.1128/JB.185.5.1719-1725.2003; Iba K, 2002, ANNU REV PLANT BIOL, V53, P225, DOI 10.1146/annurev.arplant.53.100201.160729; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Karpinski S, 1999, SCIENCE, V284, P654, DOI 10.1126/science.284.5414.654; Kelly AA, 2004, CURR OPIN PLANT BIOL, V7, P262, DOI 10.1016/j.pbi.2004.03.009; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; Kurth J, 2002, PLANTA, V215, P101, DOI 10.1007/s00425-001-0719-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; Liere K, 1997, NUCLEIC ACIDS RES, V25, P2403, DOI 10.1093/nar/25.12.2403; Liere K, 2001, ADV PHOTOSYNTH, V11, P29; LIERE K, 1995, CURR GENET, V28, P128, DOI 10.1007/BF00315778; Link G, 2003, ANTIOXID REDOX SIGN, V5, P79, DOI 10.1089/152308603321223568; Lopez-Juez E, 1998, PLANT PHYSIOL, V118, P803, DOI 10.1104/pp.118.3.803; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; Meurer J, 1996, PLANT CELL, V8, P1193, DOI 10.1105/tpc.8.7.1193; Mochizuki N, 2001, P NATL ACAD SCI USA, V98, P2053, DOI 10.1073/pnas.98.4.2053; Oswald O, 2001, P NATL ACAD SCI USA, V98, P2047, DOI 10.1073/pnas.021449998; Petracek ME, 1998, P NATL ACAD SCI USA, V95, P9009, DOI 10.1073/pnas.95.15.9009; Petracek ME, 1997, PLANT CELL, V9, P2291, DOI 10.1105/tpc.9.12.2291; Pfannschmidt T, 1999, IUBMB LIFE, V48, P271, DOI 10.1080/713803507; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Pfannschmidt T, 2003, ANTIOXID REDOX SIGN, V5, P95, DOI 10.1089/152308603321223586; Pfannschmidt T, 2001, PHYSIOL PLANTARUM, V112, P1, DOI 10.1034/j.1399-3054.2001.1120101.x; Pfannschmidt T, 2001, J BIOL CHEM, V276, P36125, DOI 10.1074/jbc.M105701200; PFANNSCHMIDT T, 2004, IN PRESS ANTIOXID RE; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; Richly E, 2003, EMBO REP, V4, P491, DOI 10.1038/sj.embor.embor828; Rintamaki E, 2000, P NATL ACAD SCI USA, V97, P11644, DOI 10.1073/pnas.180054297; Rodermel S, 2001, TRENDS PLANT SCI, V6, P471, DOI 10.1016/S1360-1385(01)02085-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sane PV, 2003, PLANT PHYSIOL, V132, P2144, DOI 10.1104/pp.103.022939; Schaller F, 2001, J EXP BOT, V52, P11, DOI 10.1093/jexbot/52.354.11; Schunemann D, 2004, CURR GENET, V44, P295, DOI 10.1007/s00294-003-0450-z; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; Shen YX, 2001, PLANT CELL PHYSIOL, V42, P1071, DOI 10.1093/pcp/pce142; Sheramati I, 2002, PLANT J, V32, P631, DOI 10.1046/j.1365-313X.2002.01452.x; Sherameti I, 2002, J BIOL CHEM, V277, P46594, DOI 10.1074/jbc.M202924200; Streatfield SJ, 1999, PLANT CELL, V11, P1609, DOI 10.1105/tpc.11.9.1609; Summer H, 2000, CURR GENET, V37, P45, DOI 10.1007/s002940050007; Surpin M, 2002, PLANT CELL, V14, pS327, DOI 10.1105/tpc.010446; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; Tang L, 2003, PLANT PHYSIOL, V133, P1979, DOI 10.1104/pp.103.029686; Tullberg A, 2000, PLANT CELL PHYSIOL, V41, P1045, DOI 10.1093/pcp/pcd031; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; Walters RG, 1999, PLANTA, V209, P517, DOI 10.1007/s004250050756; WALTERS RG, 1994, PLANTA, V195, P248, DOI 10.1007/BF00199685; Weston E, 2000, PLANTA, V211, P807, DOI 10.1007/s004250000392; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Yang DH, 2001, PHOTOSYNTH RES, V68, P163, DOI 10.1023/A:1011849919438	79	173	183	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5318	5328		10.1074/jbc.M406358200	http://dx.doi.org/10.1074/jbc.M406358200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15561727	hybrid, Green Published			2022-12-25	WOS:000227217100027
J	Martinez, M; Joffraud, M; Giraud, S; Baisse, N; Bernimoulin, MP; Schapira, M; Spertini, O				Martinez, M; Joffraud, M; Giraud, S; Baisse, N; Bernimoulin, MP; Schapira, M; Spertini, O			Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin - Role of human fucosyltransferase-IV and -VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; LEUKOCYTE ADHESION DEFICIENCY; ALPHA(1,3)FUCOSYLTRANSFERASES FUCT-IV; ELAM-1-DEPENDENT CELL-ADHESION; HEMATOPOIETIC PROGENITOR CELLS; GLYCOPROTEIN LIGAND-1 PSGL-1; IN-VIVO; O-GLYCANS; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; CARBOHYDRATE LIGANDS	P-selectin glycoprotein ligand-1 (PSGL-1) interactions with selectins regulate leukocyte migration in inflammatory lesions. In mice, selectin ligand activity regulating leukocyte recruitment and lymphocyte homing into lymph nodes results from the sum of unequal contributions of fucosyltransferase (FucT)-IV and FucT-VII, with FucT-VII playing a predominant role. Here we have examined the role of human FucT-11V and -VII in conferring L-selectin, P-selectin, and E-selectin binding activities to PSGL-1. Lewis x (Le(x)) carbohydrate was generated at the CHodhf-, cell surface by FucT-11V expression, whereas sialyl Le(x) (sLe(x)) was synthesized by FucT-VII. Both human FucT-IV and -VII had the ability to generate carbohydrate ligands that support L-selectin-, P-selectin-, and E-selectin-dependent rolling on PSGL-1, with FucT-VII playing a major role. Cooperation was observed between FucT-IV and -VII in recruiting L-, P-, or E-selectin-expressing cells on PSGL-1 and in regulating cell rolling velocity and stability. Additional rolling adhesion assays were performed to assess the role of Thr-57-linked core-2 0-glycans in supporting L-selectin-, P-selectin-, and E-selectin-dependent rolling on PSGL-1. These studies confirmed that core-2 0-glycans attached to Thr-57 play a critical role in supporting L- and P-selectin-dependent rolling and revealed that additional binding sites support >75% of E-selectin-mediated rolling. The observations presented here indicate that human FucT-IV and -VII both contribute and cooperate in regulating L-selectin-, P-selectin-, and E-selectindependent rolling on PSGL-1, with FucT-VII playing a predominant role in conferring selectin binding activity to PSGL-1.	CHU Vaudois, Serv Hematol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Cent Hematol Lab, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Spertini, O (corresponding author), CHU Vaudois, Serv Hematol, BH 18-544,Bugnon 46, CH-1011 Lausanne, Switzerland.	olivier.spertini@chuv.ch						Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Bengtson P, 2002, J IMMUNOL, V169, P3940, DOI 10.4049/jimmunol.169.7.3940; Bengtson P, 2001, J BIOL CHEM, V276, P31575, DOI 10.1074/jbc.M104165200; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; Bienvenu JG, 2001, CIRCULATION, V103, P1128, DOI 10.1161/01.CIR.103.8.1128; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; Davenpeck KL, 1997, J IMMUNOL, V159, P1977; Eppihimer MJ, 2001, MICROCIRCULATION, V8, P15, DOI 10.1080/713774013; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Hayward R, 1999, CARDIOVASC RES, V41, P65, DOI 10.1016/S0008-6363(98)00266-1; Hicks AER, 2003, BLOOD, V101, P3249, DOI 10.1182/blood-2002-07-2329; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; Hirata T, 2002, J IMMUNOL, V169, P4307, DOI 10.4049/jimmunol.169.8.4307; Homeister JW, 2004, ARTERIOSCL THROM VAS, V24, P1897, DOI 10.1161/01.ATV.0000141844.28073.df; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; Huang MC, 2002, J BIOL CHEM, V277, P47786, DOI 10.1074/jbc.M208283200; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Julita MA, 2002, J IMMUNOL, V169, P1768, DOI 10.4049/jimmunol.169.4.1768; Jung U, 1996, AM J PHYSIOL-HEART C, V271, pH2740, DOI 10.1152/ajpheart.1996.271.6.H2740; Kannagi R, 2002, CURR OPIN STRUC BIOL, V12, P599, DOI 10.1016/S0959-440X(02)00365-2; Katayama Y, 2003, BLOOD, V102, P2060, DOI 10.1182/blood-2003-04-1212; Knibbs RN, 1998, J IMMUNOL, V161, P6305; Kobzdej MMA, 2002, BLOOD, V100, P4485, DOI 10.1182/blood-2002-06-1799; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; KUMAR R, 1991, J BIOL CHEM, V266, P21777; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Leppanen A, 2003, J BIOL CHEM, V278, P26391, DOI 10.1074/jbc.M303551200; Leppanen A, 2002, J BIOL CHEM, V277, P39749, DOI 10.1074/jbc.M206281200; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Mitoma J, 2003, J BIOL CHEM, V278, P9953, DOI 10.1074/jbc.M212756200; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; Norman KE, 2000, BLOOD, V96, P3585; Phillips JW, 2003, CIRCULATION, V107, P2244, DOI 10.1161/01.CIR.0000065604.56839.18; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Rees S, 1996, BIOTECHNIQUES, V20, P102; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SMITH M, 2004, J BIOL CHEM; Snapp KR, 1997, BLOOD, V89, P896, DOI 10.1182/blood.V89.3.896; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2003, J EXP MED, V197, P1355, DOI 10.1084/jem.20021854; Sperandio M, 2001, J IMMUNOL, V167, P2268, DOI 10.4049/jimmunol.167.4.2268; SPERTINI O, 1991, J IMMUNOL, V147, P942; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; TINGBEALL HP, 1993, BLOOD, V81, P2774; Tu LL, 1996, J IMMUNOL, V157, P3995; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wagers AJ, 1997, J IMMUNOL, V159, P1917; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Winkler IG, 2004, BLOOD, V103, P1685, DOI 10.1182/blood-2003-06-1921; Xia LJ, 2002, J CLIN INVEST, V109, P939; Xie X, 2000, J BIOL CHEM, V275, P34818, DOI 10.1074/jbc.M001257200; YAGO K, 1993, CANCER RES, V53, P5559; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002; Zollner O, 1997, J CELL BIOL, V136, P707, DOI 10.1083/jcb.136.3.707	87	57	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5378	5390		10.1074/jbc.M410899200	http://dx.doi.org/10.1074/jbc.M410899200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579466	hybrid			2022-12-25	WOS:000227217100034
J	Oikawa, K; Nakamura, S; Sonoyama, T; Ohshima, A; Kobayashi, Y; Takayama, SJ; Yamamoto, Y; Uchiyama, S; Hasegawa, J; Sambongi, Y				Oikawa, K; Nakamura, S; Sonoyama, T; Ohshima, A; Kobayashi, Y; Takayama, SJ; Yamamoto, Y; Uchiyama, S; Hasegawa, J; Sambongi, Y			Five amino acid residues responsible for the high stability of Hydrogenobacter thermophilus cytochrome c(552) - Reciprocal mutation analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZING BACTERIUM; PROTEIN STABILITY; PERIPLASM; C-552; STABILIZATION; EXPRESSION; VARIANTS; SEQUENCE; C(552)	Five amino acid residues responsible for extreme stability have been identified in cytochrome c(552). (HT c(552.)) from a thermophilic bacterium, Hydrogenobacter thermophilus. The five residues, which are spatially distributed in three regions of HT C-552 were replaced with the corresponding residues in the homologous but less stable cytochrome C-551 (PA c(551)) from Pseudomonas aeruginosa. The quintuple HT c(552). variant (A7F/M13V/Y34F/Y43E/ 178V) showed the same stability against guanidine hydrochloride denaturation as that of PA C-511, suggesting that the five residues in HT C-552 necessarily and sufficiently contribute to the overall stability. In the three HT C551 variants carrying mutations in each of the three regions, the Y34F/Y43E mutations resulted in the greatest destabilization, by -13.3 kJ mol(-1), followed by A7F/M13V (-3.3 W mol(-1)) and then 178V (-1.5 W mol(-1)). The order of destabilization in HT C-552 was the same as that of stabilization in PA C-551 with reverse mutations such as F34Y/ E43Y, F7A/V13WL and V78I (13.4, 10.3, and 0.3 W mol(-1), respectively). The results of guanidine hydrochloride denaturation were consistent with those of thermal denaturation for the same variants. The present study established a method for reciprocal mutation analysis. The effects of side-chain contacts were experimentally evaluated by swapping the residues between the two homologous proteins that differ in stability. A comparative study of the two proteins was a useful tool for assessing the nmino acid contribution to the overall stability.	Hiroshima Univ, CREST Japan Sci & Technol Corp, Grad Sch Biosphere Sci, Hiroshima 7398528, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; Univ Tsukuba, Dept Chem, Tsukuba, Ibaraki 3058571, Japan; Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan; Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan	Hiroshima University; Japan Science & Technology Agency (JST); Osaka University; University of Tsukuba; Osaka University; Daiichi Sankyo Company Limited	Sambongi, Y (corresponding author), Hiroshima Univ, CREST Japan Sci & Technol Corp, Grad Sch Biosphere Sci, 1-4-4 Kagamiyama, Hiroshima 7398528, Japan.	sambongi@hiroshima-u.ac.jp	UCHIYAMA, Susumu/F-9590-2017; Nakamura, Shota/E-3033-2010	UCHIYAMA, Susumu/0000-0002-5181-179X; Nakamura, Shota/0000-0003-2058-5942				Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Hasegawa J, 2000, J BIOL CHEM, V275, P37824, DOI 10.1074/jbc.M005861200; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Ishida M, 2004, BIOCHEMISTRY-US, V43, P9823, DOI 10.1021/bi049546e; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jaenicke R, 2000, J BIOTECHNOL, V79, P193, DOI 10.1016/S0168-1656(00)00236-4; Karan EF, 2002, J BIOL INORG CHEM, V7, P260, DOI 10.1007/s007750100292; Kuroda Y, 2000, J MOL BIOL, V298, P493, DOI 10.1006/jmbi.2000.3622; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Perl D, 2000, NAT STRUCT BIOL, V7, P380; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; Sambongi Y, 2002, EUR J BIOCHEM, V269, P3355, DOI 10.1046/j.1432-1033.2002.03045.x; SAMBONGI Y, 1991, THESIS U TOKYO; SANBONGI Y, 1989, J BACTERIOL, V171, P65, DOI 10.1128/jb.171.1.65-69.1989; SANBONGI Y, 1989, BIOCHEMISTRY-US, V28, P9574, DOI 10.1021/bi00451a004; SANBONGI Y, 1991, EUR J BIOCHEM, V198, P7, DOI 10.1111/j.1432-1033.1991.tb15979.x; Terui N, 2003, J AM CHEM SOC, V125, P13650, DOI 10.1021/ja035682f; Uchiyama S, 2004, J AM CHEM SOC, V126, P14684, DOI 10.1021/ja046667t; Uchiyama S, 2002, PROTEIN ENG, V15, P455, DOI 10.1093/protein/15.6.455; Zhang Y, 1998, J FERMENT BIOENG, V85, P346, DOI 10.1016/S0922-338X(97)85688-7	24	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5527	5532		10.1074/jbc.M412392200	http://dx.doi.org/10.1074/jbc.M412392200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15598654	Green Published, hybrid			2022-12-25	WOS:000227217100052
J	Reynolds, TH; Pak, Y; Harris, TE; Manchester, J; Barrett, EJ; Lawrence, JC				Reynolds, TH; Pak, Y; Harris, TE; Manchester, J; Barrett, EJ; Lawrence, JC			Effects of insulin and transgenic overexpression of UDP-glucose pyrophosphorylase on UDP-glucose and glycogen accumulation in skeletal muscle fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT PHOSPHORYLATION; KINETIC-PROPERTIES; SYNTHASE; RAT; METABOLISM; LIVER; MICE; ACTIVATION; PROFILES; PROTEINS	UDP-glucose (UDP-Glc) and glycogen levels in skeletal muscle fibers of defined fiber type were measured using microanalytical methods. Infusing rats with insulin increased glycogen in both Type I and Type 11 fibers. Insulin was without effect on UDP-Glc in Type I fibers but decreased UDP-Glc by 35-40% in Type IIAJD and Type IIB fibers. The reduction in UDP-Glc suggested that UDP-Gle pyrophosphorylase (PPL) activity might limit glycogen synthesis in response to insulin. To explore this possibility, we generated mice overexpressing a UDP-Glc PPL transgene in skeletal muscle. The transgene increased both UDP-Glc PPL activity and levels of UDP-Glc in skeletal muscles by -3-fold. However, overexpression of UDP-Gle PPL was without effect on either the levels of skeletal muscle glycogen or glucose tolerance in vivo. The transgene was also without effect on either control or insulin-stimulated rates of C-14-glucose incorporation into glycogen in muscles incubated in vitro. The results indicate that UDP-Glc PPL activity is not limiting for glycogen synthesis.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Ithaca Coll, Dept Exercise & Sport Sci, Ithaca, NY 14850 USA; Gyeongsang Natl Univ, Dept Biochem, Jinju 666701, South Korea; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of Virginia; University of Virginia; Gyeongsang National University; Washington University (WUSTL)	Lawrence, JC (corresponding author), Univ Virginia, Sch Med, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu		Reynolds, Thomas/0000-0002-0290-528X; Pak, Yunbae/0000-0002-8594-5673	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28312, R01 DK028312, R01 DK028312-27] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Azpiazu I, 2000, AM J PHYSIOL-ENDOC M, V278, pE234, DOI 10.1152/ajpendo.2000.278.2.E234; CHALLISS RAJ, 1987, EUR J BIOCHEM, V163, P205, DOI 10.1111/j.1432-1033.1987.tb10756.x; Duggleby RG, 1996, EUR J BIOCHEM, V235, P173, DOI 10.1111/j.1432-1033.1996.00173.x; HAMALAINEN N, 1993, J HISTOCHEM CYTOCHEM, V41, P733, DOI 10.1177/41.5.8468455; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRY CG, 1985, AM J PHYSIOL, V248, pH599, DOI 10.1152/ajpheart.1985.248.5.H599; HINTZ CS, 1984, J HISTOCHEM CYTOCHEM, V32, P655, DOI 10.1177/32.6.6202737; HINTZ CS, 1980, AM J PHYSIOL, V239, pC58, DOI 10.1152/ajpcell.1980.239.3.C58; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439; Koistinen HA, 2002, ANN MED, V34, P410, DOI 10.1080/078538902321012351; KONG XM, 1994, J BIOL CHEM, V269, P12963; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LOWRY CV, 1978, J BIOL CHEM, V253, P8269; Manchester J, 1996, P NATL ACAD SCI USA, V93, P10707, DOI 10.1073/pnas.93.20.10707; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; PASSONNEAU JV, 1992, ENZYMATIC ANAL PRACT; PETER JB, 1972, BIOCHEMISTRY-US, V11, P2627, DOI 10.1021/bi00764a013; Rattigan S, 1997, DIABETES, V46, P1381, DOI 10.2337/diabetes.46.9.1381; REN JM, 1993, J BIOL CHEM, V268, P16113; ROACH PJ, 1976, J BIOL CHEM, V251, P1913; ROACH PJ, 1975, BIOCHEMISTRY-US, V14, P5445, DOI 10.1021/bi00696a010; Roden M, 1999, ANNU REV MED, V50, P277, DOI 10.1146/annurev.med.50.1.277; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Skurat AV, 1996, ARCH BIOCHEM BIOPHYS, V328, P283, DOI 10.1006/abbi.1996.0174; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sokal RR, 1994, BIOMETRY PRINCIPLES, V3rd; STEIN JM, 1962, AM J ANAT, V110, P103, DOI 10.1002/aja.1001100203; ZHANG JN, 1989, J BIOL CHEM, V264, P17513	36	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5510	5515		10.1074/jbc.M413614200	http://dx.doi.org/10.1074/jbc.M413614200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15596435	hybrid, Green Accepted			2022-12-25	WOS:000227217100050
J	Subauste, MC; Nalbant, P; Adamson, ED; Hahn, KM				Subauste, MC; Nalbant, P; Adamson, ED; Hahn, KM			Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein 6-catenin with the scaffolding protein MAGI-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; CELL-ADHESION; BETA-CATENIN; PROTEASOME PATHWAY; ALPHA-CATENIN; PDZ DOMAIN; SOMA SIZE; F9 CELLS; EXPRESSION; SURVIVAL	PTEN is a frequently mutated tumor suppressor in malignancies. Interestingly, some malignancies exhibit undetectable PTEN protein without mutations or loss of PTEN mRNA. The cause(s) for this reduction in PTEN is unknown. Cancer cells frequently exhibit loss of cadherin, beta-catenin, alpha-catenin and/or vinculin, key elements of adherens junctions. Here we show that F9 vinculin-null (vin(-/-)) cells lack PTEN protein despite normal PTEN mRNA levels. Their PTEN protein expression was restored by transfection with vinculin or by inhibition of PTEN degradation. F9 vin(-/-) cells express PTEN protein upon transfection with a vinculin fragment (amino acids 243-1066) that is capable of interacting with a-catenin but unable to target into focal adhesions. On the other hand, disruption of adherens junctions with an E-cadherin blocking antibody reduced PTEN protein to undetectable levels in wild-type F9 cells. PTEN protein levels were restored in F9 vin(-/-) cells upon transfection with an E-cadherin-a-catenin fusion protein, which targets into adherens junctions and interacts with beta-catenin in F9 vin(-/-) cells. P-Catenin is known to interact with MAGI-2. MAGI-2 interaction with PTEN in the cell membrane is known to prevent PTEN protein degradation. Thus, MAGI-2 overexpression in F9 vin(-/-) cells restored PTEN protein levels. Moreover, expression of vinculin mutants that reinstated the disrupted interactions of beta-catenin with MAGI-2 in F9 vin(-/-) cells also restored PTEN protein levels. These studies indicate that PTEN protein levels are dependent on the maintenance of beta-catenin-MAGI-2 interaction, in which vinculin plays a critical role.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; University of North Carolina; University of North Carolina Chapel Hill	Subauste, MC (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mcsub@scripps.edu			NATIONAL CANCER INSTITUTE [R01CA067888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015430] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67888] Funding Source: Medline; NIAID NIH HHS [AI 01684] Funding Source: Medline; NIA NIH HHS [AG 15430, R01 AG015430] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Bastola DR, 2002, MOL CELL BIOCHEM, V236, P75, DOI 10.1023/A:1016191913274; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Firestein BL, 2001, MOL BIOL CELL, V12, P3465, DOI 10.1091/mbc.12.11.3465; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GLUKHOVA M, 1995, AM J PATHOL, V146, P706; Goldmann WH, 1998, EXP CELL RES, V239, P235, DOI 10.1006/excr.1997.3915; Kallakury BVS, 2001, CANCER, V92, P2786, DOI 10.1002/1097-0142(20011201)92:11<2786::AID-CNCR10128>3.0.CO;2-I; Kawajiri A, 2000, BIOCHEM BIOPH RES CO, V273, P712, DOI 10.1006/bbrc.2000.3002; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Li L, 2002, MOL CELL NEUROSCI, V20, P21, DOI 10.1006/mcne.2002.1115; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Ohshima K, 2001, INT J CANCER, V92, P678, DOI 10.1002/1097-0215(20010601)92:5<678::AID-IJC1259>3.0.CO;2-R; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rudiger M, 1998, BIOESSAYS, V20, P733; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Seminario MC, 2003, ONCOGENE, V22, P8195, DOI 10.1038/sj.onc.1206872; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Xu WM, 1998, J CELL SCI, V111, P1535; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411	40	91	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5676	5681		10.1074/jbc.M405561200	http://dx.doi.org/10.1074/jbc.M405561200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579911	hybrid, Green Published			2022-12-25	WOS:000227217100069
J	Ravid, D; Maor, S; Werner, H; Liscovitch, M				Ravid, D; Maor, S; Werner, H; Liscovitch, M			Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling	ONCOGENE			English	Article						Akt; anoikis; cancer; caveolin; cell survival; IGF-I; p53; signal transduction	BREAST-CANCER-CELLS; ANCHORAGE-INDEPENDENT GROWTH; FOCAL ADHESION KINASE; ONCOGENICALLY TRANSFORMED-CELLS; PROSTATE-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN EXPRESSION; INDUCED APOPTOSIS; MATRIX ADHESION; MICE	Caveolin-1 is an essential structural constituent of caveolae that has been implicated in mitogenic signaling and oncogenesis. Utilizing MCF-7 human breast cancer cells, stably transfected with caveolin-1 (MCF-7/Cav1), we previously demonstrated that caveolin-1 expression decreases MCF-7 cell proliferation and colony formation in soft agar. However, the loss of anchor age-independent growth is associated with inhibition of anoikis, as MCF-7/ Cav1 cells exhibit increased survival after detachment. Herein we show that this phenotype is associated with suppression of detachment-induced activation of p53 and of the consequent induction of cyclin-dependent kinase inhibitor p2lWAF1/Cip1. In contrast, activation of p53 and p21 WAF1/Cipt induced by doxorubicin in MCF-7/Cav1 cells remains largely unaffected. The phenotypic changes observed in MCF-7/Cav1 cells are not accompanied by changes in caspase-6, -7, -8 and -9 and cannot be explained by changes in Bid and Bcl-2 expression. However, MCF-7/Cav1 cells exhibit a constitutively phosphorylated Akt kinase and at least one phosphorylated high molecular weight putative Akt substrate which we designated pp340. In addition, MCF-7/Cavl cells exhibit elevated expression of insulin-like growth factor-1 (IGF-1) receptor expression and increased IGF-1 signaling to Erkl/2 and to Akt, as well as IGF-1-induced stimulation of pp340 phosphorylation. The addition of IGF-I to the medium rescues the parental MCF-7 cells from anoikis, indicating that IGF-1 can act as a survival factor for suspended MCF-7 cells. Finally, the levels of caveolin-1 are dramatically elevated in a time-dependent manner upon detachment of anoikis-resistant MCF-7/ Cav1 cells and HT-29-MDR human multidrug resistant colon cancer cells. We conclude that expression of caveolin-1 in human breast cancer cells enhances matrix-independent cell survival that is mediated by upregulation of IGF-I receptor expression and signaling.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty 138,POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Cohen AW, 2003, AM J PHYSIOL-ENDOC M, V285, pE1151, DOI 10.1152/ajpendo.00324.2003; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Duxbury MS, 2004, J BIOL CHEM, V279, P23176, DOI 10.1074/jbc.M402051200; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fra AM, 1999, GENOMICS, V56, P355, DOI 10.1006/geno.1998.5723; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi K, 2001, CANCER RES, V61, P2361; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li WP, 2001, J CELL SCI, V114, P1397; LISCOVITCH M, 2004, MEMBRANE MICRODOMAIN, P161; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Scotlandi K, 2002, INT J CANCER, V101, P11, DOI 10.1002/ijc.10537; Tahir SA, 2001, CANCER RES, V61, P3882; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; WERNER H, 1994, J BIOL CHEM, V269, P12577; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	58	81	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1338	1347		10.1038/sj.onc.1208337	http://dx.doi.org/10.1038/sj.onc.1208337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15592498				2022-12-25	WOS:000227092600004
J	Gocke, CB; Yu, HT; Kang, JS				Gocke, CB; Yu, HT; Kang, JS			Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; SUMO MODIFICATION; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; SUMOYLATION; CONJUGATION; YEAST; RANGAP1; RIBONUCLEOPROTEINS	Small ubiquitin-like modifier (SUMO) regulates diverse cellular processes through its reversible, covalent attachment to target proteins. Many SUMO substrates are involved in transcription and chromatin structure. Sumoylation appears to regulate the functions of target proteins by changing their subcellular localization, increasing their stability, and/or mediating their binding to other proteins. Using an in vitro expression cloning approach, we have identified 40 human SUMO1 substrates. The spectrum of human SUMO1 substrates identified in our screen suggests general roles of sumoylation in transcription, chromosome structure, and RNA processing. We have validated the sumoylation of 24 substrates in living cells. Analysis of this panel of SUMO substrates leads to the following observations. 1) Sumoylation is more efficient in vitro than in living cells. Polysumoylation occurs on several substrates in vitro. 2) SUMO isopeptidases have little substrate specificity. 3) The SUMO ligases, PIAS1 and PIASxbeta, have broader substrate specificities than does PIASy. 4) Although SUMO1 and SUMO2 are equally efficiently conjugated to a given substrate in vitro, SUMO1 conjugation is more efficient in vivo. 5) Most SUMO substrates localize to the nucleus, and sumoylation does not generally affect their subcellular localization. Therefore, sumoylation appears to regulate the functions of its substrates through multiple, context-dependent mechanisms.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, HT (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	hongtao.yu@utsouthwestern.edu		Yu, Hongtao/0000-0002-8861-049X	NIGMS NIH HHS [GM61542] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hilgarth RS, 2004, J BIOL CHEM, V279, P53899, DOI 10.1074/jbc.R400021200; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li TW, 2004, P NATL ACAD SCI USA, V101, P8551, DOI 10.1073/pnas.0402889101; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	45	112	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5004	5012		10.1074/jbc.M411718200	http://dx.doi.org/10.1074/jbc.M411718200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561718	hybrid			2022-12-25	WOS:000227096600122
J	Lavado, A; Olivares, C; Garcia-Borron, JC; Montoliu, L				Lavado, A; Olivares, C; Garcia-Borron, JC; Montoliu, L			Molecular basis of the extreme dilution mottled mouse mutation - A combination of coding and noncoding genomic alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; OCULOCUTANEOUS ALBINISM TYPE-1; TYROSINASE GENE; TRANSGENIC MICE; MAMMALIAN TYROSINASE; ENDOPLASMIC-RETICULUM; EXPRESSION; MELANOCYTES; IDENTIFICATION; PIGMENTATION	Tyrosinase is the rate-limiting enzyme in melanin biosynthesis. It is an N-glycosylated, copper-containing transmembrane protein, whose post-translational processing involves intracytoplasmic movement from the endtoplasmic reticulum to the Golgi and, eventually, to the melanosome. The expression of the tyrosinase (Tyr) gene is controlled by several regulatory regions including a locus control region (LCR) located 15 kb upstream from the promoter region. The extreme dilution mottled mutant mice (Tyr(c-em)) arose spontaneously at the MRC Institute in Harwell (United Kingdom) from a chinchilla-mottled mutant (Tyr(c-m)) stock, whose molecular basis corresponds to a rearrangement of 5'-upstream regulatory sequences including the LCR of the Tyr gene. Tyr(c-em) mice display a variegated pigmentation pattern in coat and eyes, in agreement with the LCR translocation, but also show a generalized hypopigmented phenotype, not seen in Tyr(c-m) mice. Genomic analyses of Tyr(c-em) mice showed a C1220T nucleotide substitution within the Tyr encoding region, resulting in a T3731 amino acid change, which abolishes an N-glycosylation sequon located in the second metal ion binding site of the enzyme. Tyrosinase from Tyr(c-em) displayed a reduced enzymatic activity in vivo and in vitro, compared with wild-type enzyme. Deglycosylation studies showed that the mutant protein has an abnormal glycosylation pattern and is partially retained in the endoplasmic reticulum. We conclude that the phenotype of the extreme dilution mottled mouse mutant is caused by a combination of coding and noncoding genomic alterations resulting in several abnormalities that include suboptimal gene expression, abnormal protein processing, and reduced enzymatic activity.	Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain; Univ Murcia, Sch Med, Dept Biochem & Mol Biol & Immunol, Murcia 30100, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Murcia	Montoliu, L (corresponding author), Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, C Darwin 3, Madrid 28049, Spain.	montoliu@cnb.uam.es	Garcia-Borron, Jose Carlos/H-2247-2015; Montoliu, Lluis/I-2039-2015; Olivares, Conchi/H-2794-2015	Garcia-Borron, Jose Carlos/0000-0002-9192-588X; Montoliu, Lluis/0000-0003-3941-1176; Olivares, Conchi/0000-0001-7518-3858				[Anonymous], MOUS GEN DAT MGD MOU; BEERMANN F, 1995, EXP EYE RES, V61, P599, DOI 10.1016/S0014-4835(05)80053-3; BEERMANN F, 1992, P NATL ACAD SCI USA, V89, P2809, DOI 10.1073/pnas.89.7.2809; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Costin GE, 2003, J CELL SCI, V116, P3203, DOI 10.1242/jcs.00598; DEOL MS, 1981, PIGMENT CELL 1981 PH, P153; DONATIEN PD, 1995, EUR J BIOCHEM, V232, P159, DOI 10.1111/j.1432-1033.1995.tb20794.x; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GANSS R, 1994, J BIOL CHEM, V269, P29808; Garcia-Borron JC, 2002, PIGM CELL RES, V15, P162, DOI 10.1034/j.1600-0749.2002.02012.x; Gimenez E, 2003, EUR J NEUROSCI, V18, P2673, DOI 10.1046/j.1460-9568.2003.02992.x; Gimenez E, 2001, GENESIS, V30, P21, DOI 10.1002/gene.1028; Giraldo P, 2003, NUCLEIC ACIDS RES, V31, P6290, DOI 10.1093/nar/gkg793; Giraldo P, 2002, PIGM CELL RES, V15, P258, DOI 10.1034/j.1600-0749.2002.02030.x; Giraldo P, 2001, TRANSGENIC RES, V10, P83, DOI 10.1023/A:1008918913249; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; JACKSON IJ, 1990, P NATL ACAD SCI USA, V87, P7010, DOI 10.1073/pnas.87.18.7010; JARA JR, 1988, PIGM CELL RES, V1, P332, DOI 10.1111/j.1600-0749.1988.tb00128.x; Jeffery G, 1997, DEV BRAIN RES, V99, P95, DOI 10.1016/S0165-3806(96)00211-8; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZCERVANTES C, 1993, PIGM CELL RES, V6, P394, DOI 10.1111/j.1600-0749.1993.tb00621.x; King RA, 2003, HUM GENET, V113, P502, DOI 10.1007/s00439-003-0998-1; KLUPPEL M, 1991, P NATL ACAD SCI USA, V88, P3777, DOI 10.1073/pnas.88.9.3777; KWON BS, 1989, BIOCHEM BIOPH RES CO, V161, P252, DOI 10.1016/0006-291X(89)91588-X; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LEE ST, 1994, NEW ENGL J MED, V330, P529, DOI 10.1056/NEJM199402243300803; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Montoliu L, 1996, EMBO J, V15, P6026, DOI 10.1002/j.1460-2075.1996.tb00991.x; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Oetting WS, 2003, PIGM CELL RES, V16, P307, DOI 10.1034/j.1600-0749.2003.00045.x; OETTING WS, MOUSE COAT COLOR GEN; Olivares C, 2003, J BIOL CHEM, V278, P15735, DOI 10.1074/jbc.M300658200; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Olivares C, 2001, BIOCHEM J, V354, P131, DOI 10.1042/0264-6021:3540131; PARK KC, 1993, AM J HUM GENET, V52, P406; PHILLIPS RJS, 1970, MOUSE NEWS LETT, V42, P26; POMERANTZ SH, 1964, BIOCHEM BIOPH RES CO, V16, P188, DOI 10.1016/0006-291X(64)90359-6; PORTER S, 1991, DEV GENET, V12, P393, DOI 10.1002/dvg.1020120604; Porter SD, 1999, DEV GENET, V25, P40, DOI 10.1002/(SICI)1520-6408(1999)25:1<40::AID-DVG5>3.0.CO;2-L; PORTER SD, 1994, DEVELOPMENT, V120, P2103; Regales L, 2003, PIGM CELL RES, V16, P685, DOI 10.1046/j.1600-0749.2003.00100.x; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; SCHEDL A, 1992, GENOMICS, V14, P288, DOI 10.1016/S0888-7543(05)80218-6; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SCHMIDT A, 1994, P NATL ACAD SCI USA, V91, P4756, DOI 10.1073/pnas.91.11.4756; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Simonova M, 2000, CANCER RES, V60, P6656; Spritz RA, 1997, J INVEST DERMATOL, V109, P207, DOI 10.1111/1523-1747.ep12319351; Spritz RA, 2003, CURR OPIN GENET DEV, V13, P284, DOI 10.1016/S0959-437X(03)00059-5; Toyofuku K, 2002, PIGM CELL RES, V15, P217, DOI 10.1034/j.1600-0749.2002.02007.x; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259	58	12	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4817	4824		10.1074/jbc.M410399200	http://dx.doi.org/10.1074/jbc.M410399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572362	hybrid			2022-12-25	WOS:000227096600100
J	Wochnik, GM; Ruegg, J; Abel, GA; Schmidt, U; Holsboer, F; Rein, T				Wochnik, GM; Ruegg, J; Abel, GA; Schmidt, U; Holsboer, F; Rein, T			FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PEPTIDYLPROLYL ISOMERASE DOMAIN; TETRATRICOPEPTIDE REPEAT DOMAIN; HSP90-BINDING IMMUNOPHILINS; PROGESTERONE-RECEPTOR; CYTOPLASMIC DYNEIN; HSP90 MUTANTS; IN-VIVO; BINDING; FKBP52	We used a cellular system to elucidate the molecular determinants of the large immunophilin FK506-binding proteins (FKBP)51 and -52 for their action on the glucocorticoid receptor in mammalian cells. Increasing the levels of FKBP51 reduced the transcriptional activity of the receptor, as reported. Elevated levels of FKBP52 per se showed no effect but mitigated the inhibition of the receptor induced by FYBP51. We discovered that nuclear translocation of the glucocorticoid receptor was delayed by FKBP51. This correlates with the reduced interaction of FKBP51 with the motor protein dynein compared with FKBP52. From mutational analyses, we concluded that three features of the immunophilins are required for efficient receptor signaling in mammalian cells: hsp90 interaction, dynein association, and peptidylprolyl isomerase (PPIase) enzyme activity. The relevance of dynein for receptor function was substantiated by several experiments: 1) coexpression of dynamitin, which disrupts the transport complex and reduces receptor activity; 2) coexpression of the PPIase domain fragment of FKBP52, which is known to disrupt interaction of the receptor to dynein and reduce glucocorticoid receptor function, in contrast to the corresponding fragment of FKBP51; and 3) swapping of the PPIase domains FKBP51 and FYBP52, which reverses the respective activity. We concluded from our results that the mechanisms of the regulatory system FKBP51/FKBP52 discovered in yeast also operate in mammals to modulate hormone binding of the receptor. In addition, differential regulation of dynein association and nuclear translocation contributes to the effects of the two immunophilins on the glucocorticoid receptor in mammals.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Rein, T (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 10, D-80804 Munich, Germany.	theorein@mpipsykl.mpg.de		Ruegg, Joelle/0000-0002-6580-9201; Rein, Theo/0000-0003-2850-4289				Abel GA, 2002, MOL ENDOCRINOL, V16, P1352, DOI 10.1210/me.16.6.1352; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; BAUGHMAN G, 1991, MOL ENDOCRINOL, V5, P637, DOI 10.1210/mend-5-5-637; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOHEN SP, 1995, J BIOL CHEM, V270, P29433, DOI 10.1074/jbc.270.49.29433; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; Bronnegard M, 1996, J NEUROENDOCRINOL, V8, P405, DOI 10.1046/j.1365-2826.1996.04781.x; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CHAMBRAUD B, 1993, BIOCHEM BIOPH RES CO, V196, P160, DOI 10.1006/bbrc.1993.2229; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; de Kloet ER, 2000, EUR J PHARMACOL, V405, P187, DOI 10.1016/S0014-2999(00)00552-5; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; HARRELL JM, 2004, IN PRESS J BIOL CHEM; Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Karin M, 1987, Experientia Suppl, V52, P401; Kimberly Robert P., 1994, Current Opinion in Rheumatology, V6, P273, DOI 10.1097/00002281-199405000-00005; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; Paskitti ME, 2000, MOL BRAIN RES, V80, P142, DOI 10.1016/S0169-328X(00)00121-2; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Pirkl F, 2001, J MOL BIOL, V308, P795, DOI 10.1006/jmbi.2001.4595; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Ruegg J, 2004, MOL CELL BIOL, V24, P9371, DOI 10.1128/MCB.24.21.9371-9382.2004; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; SCHMID W, 1995, J STEROID BIOCHEM, V53, P33, DOI 10.1016/0960-0760(95)00038-2; Schmidt U, 2003, J BIOL CHEM, V278, P4926, DOI 10.1074/jbc.M212000200; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitfield GK, 1999, J CELL BIOCHEM, P110; Wochnik GM, 2004, FEBS LETT, V560, P35, DOI 10.1016/S0014-5793(04)00066-3; Zennaro MC, 1998, EUR J ENDOCRINOL, V139, P127, DOI 10.1530/eje.0.1390127	51	438	448	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4609	4616		10.1074/jbc.M407498200	http://dx.doi.org/10.1074/jbc.M407498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15591061	hybrid			2022-12-25	WOS:000227096600075
J	Wu, W; Pew, T; Zou, M; Pang, D; Conzen, SD				Wu, W; Pew, T; Zou, M; Pang, D; Conzen, SD			Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PHOSPHATASE-1; DUAL-SPECIFICITY PHOSPHATASE; MAMMARY EPITHELIAL-CELLS; FACTOR-KAPPA-B; INDUCED APOPTOSIS; TRANSCRIPTION FACTORS; MOLECULAR-MECHANISMS; DECREASED DEGRADATION; MEDIATED INHIBITION; MICROARRAY ANALYSIS	Glucocorticoid receptor (GR) activation has recently been shown to inhibit apoptosis in breast epithelial cells. We have previously described a group of genes that is rapidly up-regulated in these cells following dexatmethasone (Dex) treatment. In an effort to dissect the inechanisms of GR-mediated breast epithelial cell survival, we now examine the molecular events downstream of GR activation. Here we show that GR activation leads to both the rapid induction of MAPK phosphatase-1 (MKP-1) mRNA and its sustained expression. Induction of the MKP-1 protein in the MCF10A-Myc and MDA-MB-231 breast epithelial cell lines was also seen. Paclitaxel treatment resulted in MAPK activation and apoptosis of MDA-MB-231 breast cancer cells, and both processes were inhibited by Dex pretreatment. Furthermore, induction of MKP-1 correlated with the inhibition of extracellular signal-regulated kinase (ERK1/2) and c-Jun N-terminal kinase (JNK) activity, whereas p38 activity was minimally affected. Blocking Dex-induced MYP-1 induction using small interfering RNA increased ERK1/2 and JNK phosphorylation and decreased cell survival. ERK1/2 and JNK inactivation was associated with Ets-like transcription factor-1,(ELK-1) dephosphorylation. To explore the gene expression changes that occur downstream of ELK-1 dephosphorylation, we used a combination of temporal gene expression data and promoter element analyses. This approach revealed a previously unrecognized transcripitional target of ELK-1, the human tissue plasminogen activator (tPA). We verified the predicted ELK-1 tPA transcriptional regulatory relationship using a luciferase reporter assay. We conclude that GR-mediated MAPK inactivation contributes to cell survival and that the potential transcriptional targets of this inhibition can be identified from large scale gene array analysis.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Conzen, SD (corresponding author), Univ Chicago, Dept Med, MC 2115, Chicago, IL 60637 USA.	sconzen@medicine.bsd.uchicago.edu	wu, wei/J-2797-2019	wu, wei/0000-0002-6556-067X	NCI NIH HHS [CA90459, CA89208] Funding Source: Medline; NIEHS NIH HHS [ES0123282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA090459, R01CA089208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailly-Maitre B, 2002, CELL DEATH DIFFER, V9, P945, DOI 10.1038/sj.cdd.4401043; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Clark AR, 2003, J ENDOCRINOL, V178, P5, DOI 10.1677/joe.0.1780005; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Eberhardt W, 2002, KIDNEY INT, V62, P809, DOI 10.1046/j.1523-1755.2002.00538.x; Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002-220769; Fan WM, 2004, CURR MED CHEM, V11, P403, DOI 10.2174/0929867043455990; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; Franchimont D, 2004, ANN NY ACAD SCI, V1024, P124, DOI 10.1196/annals.1321.009; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Herr I, 2003, CANCER RES, V63, P3112; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Huang Y, 2000, CANCER RES, V60, P4426; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lipworth BJ, 2000, LANCET, V356, P87, DOI 10.1016/S0140-6736(00)02463-6; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1996, AM J PATHOL, V149, P1553; Lornejad-Schafer MR, 2003, BIOCHEM J, V371, P609, DOI 10.1042/BJ20021357; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Moran TJ, 2000, CANCER RES, V60, P867; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Obexer P, 2001, ONCOGENE, V20, P4324, DOI 10.1038/sj.onc.1204573; Oesterreicher TJ, 2004, AM J PHYSIOL-GASTR L, V286, pG947, DOI 10.1152/ajpgi.00470.2003; Pettersson F, 2004, ONCOGENE, V23, P7053, DOI 10.1038/sj.onc.1207956; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rosini P, 2004, J BIOL CHEM, V279, P14016, DOI 10.1074/jbc.M305356200; Sasson R, 2003, BIOCHEM PHARMACOL, V66, P1393, DOI 10.1016/S0006-2952(03)00489-1; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schorr K, 2000, CANCER RES, V60, P5950; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; Xu QH, 2004, FREE RADICAL BIO MED, V36, P985, DOI 10.1016/j.freeradbiomed.2004.01.009; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; Zhang HH, 2001, J CLIN ENDOCR METAB, V86, P2817, DOI 10.1210/jc.86.6.2817	57	155	161	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4117	4124		10.1074/jbc.M411200200	http://dx.doi.org/10.1074/jbc.M411200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590693	hybrid			2022-12-25	WOS:000227096600017
J	Kim, KM; Lee, YJ				Kim, KM; Lee, YJ			Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the PI3K-Akt pathway	ONCOGENE			English	Article						amiloride; TRAIL; apoptosis; caspase; Akt; PDK-1; PTEN; PP1	NF-KAPPA-B; TUMOR-SUPPRESSOR; PHOSPHOINOSITIDE 3-KINASE; IONIZING-RADIATION; INTRACELLULAR PH; TYROSINE-KINASE; CANCER-CELLS; AKT; RECEPTOR; ACTIVATION	We have previously shown that low extracellular pH (pHe) promotes cell killing by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In this study, we examined whether amiloride, an inhibitor of the Na+/H+ antiporter capable of lowering the intracellular pH (pHi), can potentiate TRAIL-induced apoptotic death. Human prostate adenocarcinoma DU-145 cells were treated with various concentrations of TRAIL (10-200 ng/ml) and/or amiloride (0.1-1 mM) for 4 h. Amiloride, which caused little or no cytotoxicity by itself, enhanced TRAIL-induced apoptosis. The TRAIL-mediated activation of caspase, and PARP (poly (ADP-ribose) polymerase) cleavage were both promoted by amiloride. Western blot analysis showed that combined treatment with TRAIL and amiloride did not change the levels of TRAIL receptors (death receptor (DR)4, DR5, and DcR2 (decoy recepter 2) or antiapoptotic proteins (FLICE-inhibitory protein ( FLIP), inhibitor of apoptosis (IAP), and Bcl-2). However, unlike pHe, amiloride promoted the dephosphorylation of Akt. Interestingly, amiloride also induced the dephosphorylation of PI3K (phosphatidylinositol 3-kinase) and PDK-1 (phosphoinositide-dependent kinase-1) kinases along with PTEN (phosphatase and tensin homolog deleted on chromosome 10) and PP1alpha phosphatases. In vitro kinase assays revealed that amiloride inhibited phosphorylation of kinases and phosphatases by competing with ATP. Taken together, the present studies suggest that amiloride enhances TRAIL-induced cytotoxicity by inhibiting phosphorylation of the PI3K-Akt pathway-associated kinases and phosphatases.	Univ Pittsburgh, Sch Med, Dept Surg & Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, 5117 Ctr Ave,G-5A, Pittsburgh, PA 15213 USA.	leeyj@msx.upmc.edu			NCI NIH HHS [CA48000, CA96989, CA95191] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA048000, R01CA096989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burow ME, 1998, CANCER RES, V58, P4940; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DEL PL, 1997, SCIENCE, V278, P687; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; ENDRICH B, 1982, J NATL CANCER I, V68, P475; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hetman M, 2000, J NEUROSCI, V20, P2567; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HOLLAND R, 1983, FEBS LETT, V154, P269, DOI 10.1016/0014-5793(83)80163-X; Kandasamy K, 2002, CANCER RES, V62, P4929; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Keane MM, 1999, CANCER RES, V59, P734; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YJ, 2004, EXP CELL RES, V293, P129, DOI 10.1016/j.yexcr.2003.09.015; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nagane M, 2000, CANCER RES, V60, P847; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RALPH RK, 1982, BIOCHEM BIOPH RES CO, V104, P1054, DOI 10.1016/0006-291X(82)91356-0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH RL, 1982, J BIOL CHEM, V257, P773; SOLTOFF SP, 1983, SCIENCE, V220, P957, DOI 10.1126/science.6302840; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Tamm I, 1998, CANCER RES, V58, P5315; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Xu WP, 2003, CANCER RES, V63, P7777	67	36	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					355	366		10.1038/sj.onc.1208213	http://dx.doi.org/10.1038/sj.onc.1208213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558024				2022-12-25	WOS:000226279700007
J	Alikhani, ZB; Alikhani, M; Boyd, CM; Nagao, K; Trackman, PC; Graves, DT				Alikhani, ZB; Alikhani, M; Boyd, CM; Nagao, K; Trackman, PC; Graves, DT			Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; FACTOR-KAPPA-B; DIABETIC MICE; ALZHEIMERS-DISEASE; RETINAL PERICYTES; OXIDATIVE STRESS; SKIN COLLAGEN; IN-VITRO; RAGE; CELL	Both aging and diabetes are characterized by the formation of advanced glycation end products (AGEs). Both exhibit other similarities including deficits in wound healing that are associated with higher rates of fibroblast apoptosis. In order to investigate a potential mechanism for enhanced fibroblast apoptosis in diabetes and aged individuals, experiments were carried out to determine whether the predominant advanced glycation end product in skin, N-epsilon-(carboxymethyl) lysine (CML)-collagen, could induce fibroblast apoptosis. In vivo experiments established that CML-collagen but not unmodified collagen induced fibroblast apoptosis and that apoptosis was dependent upon caspase-3, -8, and -9 activity. In vitro experiments demonstrated that CML-collagen but not control collagen induced a time- and dose-dependent increase in fibroblast apoptosis. By use of blocking antibodies, apoptosis was shown to be mediated through receptor for AGE signaling. AGE-induced apoptosis was largely dependent on the effector caspase, caspase-3, which was activated through both cytoplasmic (caspase-8-dependent) and mitochondrial (caspase-9) pathways. CML-collagen had a global effect of enhancing mRNA levels of pro-apoptotic genes that included several classes of molecules including ligands, receptors, adaptor molecules, mitochondrial proteins, and others. However, the pattern of expression was not identical to the pattern of apoptotic genes induced by tumor necrosis factor alpha.	Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University	Graves, DT (corresponding author), Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, 700 Albany St, Boston, MA 02118 USA.	dgraves@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NIAMS NIH HHS [AR49920] Funding Source: Medline; NIDCD NIH HHS [DC11254] Funding Source: Medline; NIDCR NIH HHS [DE07559, DE14066] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR049920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R23DE007559, R01DE007559] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agarwal C, 2002, CARCINOGENESIS, V23, P1869, DOI 10.1093/carcin/23.11.1869; Alikhani M, 2004, J DENT RES, V83, P671, DOI 10.1177/154405910408300903; Alikhani MI, 2003, J BIOL CHEM, V278, P52901, DOI 10.1074/jbc.M307638200; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; Argirov OK, 2004, J BIOL CHEM, V279, P6487, DOI 10.1074/jbc.M309090200; Belyavskyi M, 1998, ADV EXP MED BIOL, V440, P619; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BOWNLEE M, 1995, ANNU REV MED, V46, P223; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; BRUCE SA, 1991, EXP GERONTOL, V26, P17, DOI 10.1016/0531-5565(91)90058-T; Bucala R, 1992, Adv Pharmacol, V23, P1; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; Cook JL, 1997, ARCH DERMATOL, V133, P1273, DOI 10.1001/archderm.133.10.1273; Darby IA, 1997, INT J BIOCHEM CELL B, V29, P191, DOI 10.1016/S1357-2725(96)00131-8; DeGroot J, 2001, OSTEOARTHR CARTILAGE, V9, P720, DOI 10.1053/joca.2001.0469; Denis U, 2002, FREE RADICAL BIO MED, V33, P236, DOI 10.1016/S0891-5849(02)00879-1; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; GUZDEK A, 1992, FOLIA HISTOCHEM CYTO, V30, P167; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Jeanmaire C, 2001, BRIT J DERMATOL, V145, P10, DOI 10.1046/j.1365-2133.2001.04275.x; Kaji Y, 2003, INVEST OPHTH VIS SCI, V44, P521, DOI 10.1167/iovs.02-0268; Kaji Y, 2001, CURR EYE RES, V23, P469, DOI 10.1076/ceyr.23.6.469.6968; Kasper M, 2000, AM J RESP CELL MOL, V23, P485, DOI 10.1165/ajrcmb.23.4.4117; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Lalla E, 2000, J CLIN INVEST, V105, P1117, DOI 10.1172/JCI8942; Liu J, 2003, AM J PHYSIOL-HEART C, V285, pH2587, DOI 10.1152/ajpheart.00516.2003; Liu RK, 2004, ENDOCRINOLOGY, V145, P2997, DOI 10.1210/en.2003-1601; Monnier V.M., 1989, Progress in Clinical and Biological Research, V304, P1; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; Munch G, 1997, BRAIN RES REV, V23, P134, DOI 10.1016/S0165-0173(96)00016-1; Naitoh T, 2001, CELL SIGNAL, V13, P331, DOI 10.1016/S0898-6568(01)00152-8; Niwa H, 1998, BIOCHEM BIOPH RES CO, V248, P93, DOI 10.1006/bbrc.1998.8899; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; Owen WF, 1998, KIDNEY INT, V53, P1365, DOI 10.1046/j.1523-1755.1998.00882.x; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571, DOI 10.1161/01.ATV.15.5.571; Paul RG, 1996, INT J BIOCHEM CELL B, V28, P1297, DOI 10.1016/S1357-2725(96)00079-9; Reber F, 2003, GRAEF ARCH CLIN EXP, V241, P213, DOI 10.1007/s00417-002-0528-1; Santana RB, 2003, DIABETES, V52, P1502, DOI 10.2337/diabetes.52.6.1502; Saudek Deborah M, 2003, Curr Rheumatol Rep, V5, P33, DOI 10.1007/s11926-003-0081-x; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; Sell DR, 2001, J GERONTOL A-BIOL, V56, pB405, DOI 10.1093/gerona/56.9.B405; Shi ZD, 1997, P NATL ACAD SCI USA, V94, P10663, DOI 10.1073/pnas.94.20.10663; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Vasan S, 2003, ARCH BIOCHEM BIOPHYS, V419, P89, DOI 10.1016/j.abb.2003.08.016; Vlassara H, 2002, J INTERN MED, V251, P87, DOI 10.1046/j.1365-2796.2002.00932.x; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; Vu CCQ, 2001, J BIOL CHEM, V276, P37602, DOI 10.1074/jbc.M104810200; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Wendt T, 2003, J AM SOC NEPHROL, V14, P1383, DOI 10.1097/01.ASN.0000065100.17349.CA; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3; Yamagishi S, 2002, J BIOL CHEM, V277, P20309, DOI 10.1074/jbc.M202634200; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495	60	139	159	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12087	12095		10.1074/jbc.M406313200	http://dx.doi.org/10.1074/jbc.M406313200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15590648	hybrid			2022-12-25	WOS:000227922000005
J	Shirokova, E; Schmiedeberg, K; Bedner, P; Niessen, H; Willecke, K; Raguse, JD; Meyerhof, W; Krautwurst, D				Shirokova, E; Schmiedeberg, K; Bedner, P; Niessen, H; Willecke, K; Raguse, JD; Meyerhof, W; Krautwurst, D			Identification of specific ligands for orphan olfactory receptors - G protein-dependent agonism and antagonisms of odorants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; FUNCTIONAL EXPRESSION; ADENYLYL-CYCLASE; RECONSTITUTION; SENSITIVITY; VOMERONASAL; SYSTEMS; GENES; CODES; CAMP	Olfactory receptors are the largest group of orphan G protein-coupled receptors with an infinitely small number of agonists identified out of thousands of odorants. The de-orphaning of olfactory receptor (OR) is complicated by its combinatorial odorant coding and thus requires large scale odorant and receptor screening and establishing receptor-specific odorant profiles. Here, we report on the stable reconstitution of OR-specific signaling in HeLa/Olf cells via G protein alpha olf and adenylyl cyclase type-III to the Ca2+ influx-mediating olfactory cyclic nucleotide-gated CNGA2 channel. We demonstrate the central role of G alpha olf in odorant-specific signaling out of OR. The employment of the non-typical G protein alpha 15 dramatically altered the odorant specificities of 3 of 7 receptors that had been characterized previously by different groups. We further show for two OR that an odorant may be an agonist or antagonist, depending on the G protein used. HeLa/Olf cells proved suitable for high-throughput screening in fluorescence-imaging plate reader experiments, resulting in the deorphaning of two new OR for the odorant (-)citronellal from an expression library of 93 receptors. To demonstrate the G protein dependence of its odorant response pattern, we screened the most sensitive (-)citronellal receptor Olfr43 versus 94 odorants simultaneously in the presence of G alpha 15 or G alpha olf. We finally established an EC50-ranking odorant profile for Olfr43 in HeLa/Olf cells. In summary, we conclude that, in heterologous systems, odorants may function as agonists or antagonists, depending on the G protein used. HeLa/Olf cells provide an olfactory model system for functional expression and de-orphaning of OR.	German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, D-14558 Nuthetal, Germany; Univ Bonn, D-53117 Bonn, Germany; Charite, Clin & Polylcin Oral & Maxillofacial Surg & Plast, D-13353 Berlin, Germany	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Krautwurst, D (corresponding author), German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Nuthetal, Germany.	dietmark@mail.dife.de	Krautwurst, Dietmar/AAD-5579-2019	Krautwurst, Dietmar/0000-0002-3350-8682				Araneda RC, 2000, NAT NEUROSCI, V3, P1248, DOI 10.1038/81774; Araneda RC, 2004, J PHYSIOL-LONDON, V555, P743, DOI 10.1113/jphysiol.2003.058040; Barber RD, 2000, J NEUROSCI, V20, P3695, DOI 10.1523/JNEUROSCI.20-10-03695.2000; Bidlack Jean M., 2003, V237, P135; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Fagan KA, 2001, FEBS LETT, V500, P85, DOI 10.1016/S0014-5793(01)02564-9; Finn JT, 1998, BIOPHYS J, V74, P1333, DOI 10.1016/S0006-3495(98)77846-4; Gaillard I, 2002, EUR J NEUROSCI, V15, P409, DOI 10.1046/j.0953-816x.2001.01871.x; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hamana H, 2003, CHEM SENSES, V28, P87, DOI 10.1093/chemse/28.2.87; Illing N, 2002, MOL CELL NEUROSCI, V20, P225, DOI 10.1006/mcne.2002.1106; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Kenakin T, 2002, TRENDS PHARMACOL SCI, V23, P403, DOI 10.1016/S0165-6147(02)02046-1; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Malnic B, 2004, P NATL ACAD SCI USA, V101, P2584, DOI 10.1073/pnas.0307882100; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Murrell JR, 1999, J NEUROSCI, V19, P8260; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Oka Y, 2004, EMBO J, V23, P120, DOI 10.1038/sj.emboj.7600032; Pun RYK, 2003, BIOPHYS J, V84, P3425, DOI 10.1016/S0006-3495(03)70064-2; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Sanchez-Montanes MA, 2002, BIOSYSTEMS, V67, P229, DOI 10.1016/S0303-2647(02)00081-3; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; Zhang XM, 2004, GENOMICS, V83, P802, DOI 10.1016/j.ygeno.2003.10.009; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	36	111	116	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11807	11815		10.1074/jbc.M411508200	http://dx.doi.org/10.1074/jbc.M411508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15598656	hybrid			2022-12-25	WOS:000227761800110
J	Swarbrick, JD; Buyya, S; Gunawardana, D; Gayler, KR; McLennan, AG; Gooley, PR				Swarbrick, JD; Buyya, S; Gunawardana, D; Gayler, KR; McLennan, AG; Gooley, PR			Structure and substrate-binding mechanism of human Ap(4)A hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIADENOSINE TETRAPHOSPHATE HYDROLASE; BARTONELLA-BACILLIFORMIS; CAENORHABDITIS-ELEGANS; CRYSTAL-STRUCTURE; NUDIX HYDROLASES; MUTT ENZYME; PYROPHOSPHATASE; DINUCLEOSIDE; NMR; IDENTIFICATION	Asymmetric diadenosine 5',5"'-P-1,P-4-tetraphosphate (Ap(4)A) hydrolases play a major role in maintaining homeostasis by cleaving the metabolite diadenosine tetraphosphate ( Ap4A) back into ATP and AMP. The NMR solution structures of the 17-kDa human asymmetric Ap4A hydrolase have been solved in both the presence and absence of the product ATP. The adenine moiety of the nucleotide predominantly binds in a ring stacking arrangement equivalent to that observed in the x-ray structure of the homologue from Caenorhabditis elegans. The binding site is, however, markedly divergent to that observed in the plant/pathogenic bacteria class of enzymes, opening avenues for the exploration of specific therapeutics. Binding of ATP induces substantial conformational and dynamic changes that were not observed in the C. elegans structure. In contrast to the C. elegans homologue, important side chains that play a major role in substrate binding do not have to reorient to accommodate the ligand. This may have important implications in the mechanism of substrate recognition in this class of enzymes.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Melbourne; University of Liverpool	Swarbrick, JD (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	j.swarbrick@unimelb.edu.au; prg@unimelb.edu.au		Gooley, Paul/0000-0002-0323-449X; Gunawardana, Dilantha/0000-0002-5086-0215				Abdelghany HM, 2003, J BIOL CHEM, V278, P4435, DOI 10.1074/jbc.M211983200; Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; Bailey S, 2002, STRUCTURE, V10, P589, DOI 10.1016/S0969-2126(02)00746-3; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Case DA, 1995, J BIOMOL NMR, V6, P341; Conyers GB, 2000, BIOCHEMISTRY-US, V39, P2347, DOI 10.1021/bi992458n; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DIXON RM, 1989, J BIOL CHEM, V264, P2069; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fisher DI, 2002, J BIOL CHEM, V277, P47313, DOI 10.1074/jbc.M209795200; Fletcher JI, 2002, STRUCTURE, V10, P205, DOI 10.1016/S0969-2126(02)00696-2; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Garrison PN, 1992, AP4A OTHER DINUCLEOS, P29; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; Graham DL, 2002, CHEM BIOL, V9, P375, DOI 10.1016/S1074-5521(02)00112-6; Gunasekaran K, 2003, J MOL BIOL, V332, P143, DOI 10.1016/S0022-2836(03)00893-3; Guranowski A, 2003, BIOCHEM J, V373, P635, DOI 10.1042/BJ20030320; GURANOWSKI A, 1994, BIOCHEMISTRY-US, V33, P235, DOI 10.1021/bi00167a031; GURANOWSKI A, 1990, FEBS LETT, V262, P205, DOI 10.1016/0014-5793(90)80190-T; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; Ismail TM, 2003, J BIOL CHEM, V278, P32602, DOI 10.1074/jbc.M305994200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Maksel D, 2001, BIOCHEM J, V357, P399, DOI 10.1042/0264-6021:3570399; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McLennan AG, 2000, PHARMACOL THERAPEUT, V87, P73, DOI 10.1016/S0163-7258(00)00041-3; MITCHELL SJ, 1995, INFECT IMMUN, V63, P1552, DOI 10.1128/IAI.63.4.1552-1562.1995; Pintor J, 2000, PHARMACOL THERAPEUT, V87, P103, DOI 10.1016/S0163-7258(00)00049-8; Pitcher WH, 2003, ANTIVIR RES, V58, P227, DOI 10.1016/S0166-3542(03)00003-2; Ranatunga W, 2004, J MOL BIOL, V339, P103, DOI 10.1016/j.jmb.2004.01.065; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; Shen BW, 2003, J MOL BIOL, V332, P385, DOI 10.1016/S0022-2836(03)00954-9; Stavrou Brigitte Maria, 2003, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V1, P151, DOI 10.2174/1568016033477513; Swarbrick JD, 2000, J MOL BIOL, V302, P1165, DOI 10.1006/jmbi.2000.4085; Swarbrick JD, 2000, J BIOMOL NMR, V16, P269, DOI 10.1023/A:1008390811521; SWARBRICK JD, 2005, IN PRESS J BIOL NMR; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7	47	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8471	8481		10.1074/jbc.M412318200	http://dx.doi.org/10.1074/jbc.M412318200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15596429	hybrid			2022-12-25	WOS:000227395700124
J	Arcuri, C; Bianchi, R; Brozzi, F; Donato, R				Arcuri, C; Bianchi, R; Brozzi, F; Donato, R			S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RETINOBLASTOMA PROTEIN; REGULATORY DOMAIN; CDK INHIBITORS; CYCLE ARREST; CALCIUM; PHOSPHORYLATION; DIFFERENTIATION; P53; EXPRESSION	S100B is a Ca2+-modulated protein of the EF-hand type expressed in high abundance in a restricted set of cell types including certain neuronal populations. S100B has been suggested to participate in cell cycle progression, and S100B levels are high in tumor cells, compared with normal parental cells. We expressed S100B in the neuronal cell line PC12, which normally does not express the protein, by the Tet-Off technique, and found the following: W proliferation was higher in S100B(+) PC12 cells than in S100B(-) PC12 cells; (ii) nerve growth factor (NGF), which decreased the proliferation of S100B- PC12 cells, was less effective in the case of S100B(+) PC12 cells; (iii) expression of S100B made PC12 cells resistant to the differentiating effect of NGF; and (iv) interruption of S100B expression did not result in an immediate restoration of PC12 cell sensitivity to the differentiating effect of NGF. Expression of S100B in PC12 cells resulted in activation of Akt; increased levels of p21(WAF1), an inhibitor of cyclin-dependent kinase (cdk) 2 and a positive regulator of cdk4; increased p21(WAF1)-cyclin D1 complex formation; and increased phosphorylation of the retinoblastoma suppressor protein, Rb. These S100B-induced effects, as well as the reduced ability of S100B PC12 cells to respond to NGF, were dependent on Akt activation because they were remarkably reduced or abrogated in the presence of LY294002, an inhibitor of the Akt upstream kinase phosphatidylinositol 3-kinase. Thus, S100B might promote cell proliferation and interfere with NGF-induced PC12 cell differentiation by stimulating a p21(WAF1)/cyclin D1/cdk4/Rb/E2F pathway in an Akt-mediated manner.	Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, I-06122 Perugia, Italy	University of Perugia	Donato, R (corresponding author), Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, Via Giochetto Casella Postale 91 Succursale 3, I-06122 Perugia, Italy.	donato@unipg.it	Donato, Rosario/I-3943-2019	Arcuri, Cataldo/0000-0002-3114-8812				Alexanian AR, 1999, FASEB J, V13, P1611, DOI 10.1096/fasebj.13.12.1611; Bang OS, 2001, J CELL SCI, V114, P81; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DONATO R, 1988, J BIOL CHEM, V263, P106; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; FRIEND WC, 1992, J NEUROSCI, V12, P4337; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Lin J, 2004, J BIOL CHEM, V279, P34071, DOI 10.1074/jbc.M405419200; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; Lindenboim L, 2004, EXP CELL RES, V297, P392, DOI 10.1016/j.yexcr.2004.03.001; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; McClintock KA, 2000, PROTEIN SCI, V9, P2043, DOI 10.1110/ps.9.10.2043; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Musatov S, 2004, P NATL ACAD SCI USA, V101, P3627, DOI 10.1073/pnas.0308289101; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Rambotti MG, 1999, NEUROSCIENCE, V92, P1089, DOI 10.1016/S0306-4522(99)00074-3; RICKMANN M, 1995, NEUROSCIENCE, V67, P977, DOI 10.1016/0306-4522(94)00615-C; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sorci G, 1999, CELL CALCIUM, V25, P93, DOI 10.1054/ceca.1998.0012; Sorci G, 2003, MOL CELL BIOL, V23, P4870, DOI 10.1128/MCB.23.14.4870-4881.2003; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vives V, 2003, J COMP NEUROL, V457, P404, DOI 10.1002/cne.10552; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	48	59	62	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4402	4414		10.1074/jbc.M406440200	http://dx.doi.org/10.1074/jbc.M406440200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572370	hybrid			2022-12-25	WOS:000227096600050
J	Kim, E; Rundhaug, JE; Benavides, F; Yang, PY; Newman, RA; Fischer, SM				Kim, E; Rundhaug, JE; Benavides, F; Yang, PY; Newman, RA; Fischer, SM			An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis	ONCOGENE			English	Article						arachidonic acid; lipoxygenase; keratinocytes; differentiation; skin cancer	ARACHIDONIC-ACID METABOLISM; ACTIVATED RECEPTOR-ALPHA; ORNITHINE-DECARBOXYLASE ACTIVITY; PROTEIN-KINASE-C; MOUSE SKIN; TUMOR PROMOTION; KERATINOCYTE DIFFERENTIATION; INDUCE APOPTOSIS; CANCER-CELLS; IN-VIVO	The levels of 8S-lipoxygenase ( 8S-LOX) expression and of its arachidonic acid metabolite, 8-hydroxyeicosatetraenoic acid (8-HETE), are highly elevated in the early stages of mouse skin carcinogenesis. On the other hand, several reports showing that 8-HETE is also closely associated with keratinocyte differentiation raise a question concerning the role of 8S-LOX/8-HETE in skin carcinogenesis. To address that question, here we conducted a series of gain-of-function studies. Skin targeted loricrin 8S-LOX/C57BL/6J transgenic mice showed a more differentiated epidermal phenotype as well as a 64% reduced papilloma development in a two-stage skin carcinogenesis protocol. Forced expression of 8S-LOX in MT1/2 cells, a murine papilloma cell line, also caused a more differentiated appearance as well as keratin 1 expression. Overexpression of 8S-LOX in CH72 cells, a murine carcinoma cell line, inhibited cell proliferation by 30% in vitro and by 86% in in vivo xenografts. Exogenous addition of 5 muM 8-HETE to CH72 cells caused cell cycle arrest at the G1 phase. Finally, immunohistochemical analyses showed 8S-LOX protein expression was strictly confined to the differentiated compartment of mouse skin and throughout tumorigenesis. Collectively, these data suggest that 8S-LOX plays a role as a prodifferentiating, antitumorigenic, and tumor suppressing gene in mouse skin carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; Univ Texas, MD Anderson Canc Ctr, Pharmaceut Dev Ctr, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	smfischer@mdanderson.org	Benavides, Fernando/E-7872-2011; Rundhaug, Joyce E/E-9114-2011	Rundhaug, Joyce E/0000-0002-2481-6317; Benavides, Fernando/0000-0003-1275-4320	NATIONAL CANCER INSTITUTE [R01CA083794, R01CA100140, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA83794, CA100140] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Burger F, 1999, MOL CARCINOGEN, V24, P108, DOI 10.1002/(SICI)1098-2744(199902)24:2<108::AID-MC5>3.0.CO;2-R; CONTI CJ, 1988, CANCER RES, V48, P435; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DuBois RN, 2003, JNCI-J NATL CANCER I, V95, P1028, DOI 10.1093/jnci/95.14.1028; FISCHER SM, 1989, CANCER RES, V49, P6693; FISCHER SM, 1988, CANCER RES, V48, P658; FISCHER SM, 1982, CARCINOGENESIS, V3, P1243, DOI 10.1093/carcin/3.11.1243; FISCHER SM, 1987, CANCER RES, V47, P3174; Fischer SM, 2004, LIPOXYGENASES TARGET; Fosslien E, 2000, CRIT REV CL LAB SCI, V37, P431, DOI 10.1080/10408360091174286; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; Furstenberger G, 2002, PROSTAG OTH LIPID M, V68-9, P235, DOI 10.1016/S0090-6980(02)00033-3; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; Guo YJ, 1999, MOL CARCINOGEN, V26, P32, DOI 10.1002/(SICI)1098-2744(199909)26:1<32::AID-MC4>3.3.CO;2-5; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; Kashiwagi M, 2002, J BIOCHEM, V132, P853, DOI 10.1093/oxfordjournals.jbchem.a003297; Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765; Kempen EC, 2001, ANAL BIOCHEM, V297, P183, DOI 10.1006/abio.2001.5325; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Mahe YF, 1998, INT J DERMATOL, V37, P416, DOI 10.1046/j.1365-4362.1998.00514.x; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Muga SJ, 2000, CELL GROWTH DIFFER, V11, P447; Nair J, 2000, CHEM RES TOXICOL, V13, P703, DOI 10.1021/tx000045d; NAITO M, 1989, GENETIC BACKGROUND D; NAKADATE T, 1982, CARCINOGENESIS, V3, P1411, DOI 10.1093/carcin/3.12.1411; NELSON KG, 1982, CANCER RES, V42, P4176; Nie D, 1998, CANCER RES, V58, P4047; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Prigge ST, 1997, BIOCHIMIE, V79, P629, DOI 10.1016/S0300-9084(97)83495-5; Ruckert R, 2000, BRIT J DERMATOL, V143, P1036, DOI 10.1046/j.1365-2133.2000.03784.x; RUZICKA T, 1984, REV PHYSIOL BIOCH P, V100, P121; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Shappell SB, 2001, CANCER RES, V61, P497; Sheu MY, 2002, J INVEST DERMATOL, V118, P94, DOI 10.1046/j.0022-202x.2001.01626.x; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Shureiqi I, 2001, CANCER RES, V61, P4879; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; SLAGA TJ, 1984, MECH INVOLVED 2 STAG; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; Steele VE, 1999, CANCER EPIDEM BIOMAR, V8, P467; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; TANG DG, 1994, ANN NY ACAD SCI, V744, P199, DOI 10.1111/j.1749-6632.1994.tb52738.x; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Thuillier P, 2000, MOL CARCINOGEN, V29, P134, DOI 10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F; TOFTGARD R, 1985, CANCER RES, V45, P5845; VERMA AK, 1980, CANCER RES, V40, P308; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; YUSPA SH, 1985, CELLULAR MOL CHANGES; ZIETKIEWICZ E, 1994, GENOMICS, V20, P176, DOI 10.1006/geno.1994.1151	61	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1174	1187		10.1038/sj.onc.1208269	http://dx.doi.org/10.1038/sj.onc.1208269			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558016				2022-12-25	WOS:000226898700005
J	Joshi, MB; Rogers, ME; Shakarian, AM; Yamage, M; Al-Harthi, SA; Bates, PA; Dwyer, DM				Joshi, MB; Rogers, ME; Shakarian, AM; Yamage, M; Al-Harthi, SA; Bates, PA; Dwyer, DM			Molecular characterization, expression, and in vivo analysis of LmexCht1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA CHITOTRIOSIDASE ACTIVITY; ACIDIC MAMMALIAN CHITINASE; BACILLUS-CIRCULANS WL-12; LEISHMANIA-DONOVANI; CRYSTAL-STRUCTURE; INDUCIBLE EXPRESSION; FUNCTIONAL DOMAINS; MEMBRANE-PROTEINS; GENE; SEQUENCE	Chitinases have been implicated to be of importance in the life cycle development and transmission of a variety of parasitic organisms.. Using a molecular approach, we identified and characterized the structure of a single copy LmexCht1-chitinase gene from the primitive trypanosomatid pathogen of humans, Leishmania mexicana. The LmexCht1 encodes an similar to50 kDa protein, with well conserved substrate binding and catalytic domains characteristic of members of the chitinase-18 protein family. Further, we showed that LmexCht1 mRNA is constitutively expressed by both the insect vector (i.e. promastigote) and mammalian (i.e. amastigote) life cycle developmental forms of this protozoan parasite. Interestingly, however, amastigotes were found to secrete/release similar to>2-4-fold higher levels of chitinase activity during their growth in vitro than promastigotes. Moreover, a homologous episomal expression system was devised and used to express an epitope-tagged LmexCht1 chimeric construct in these parasites. Expression of the LrnexCht1 chimera was verified in these transfectants by, reverse transcription-PCR, Western blots, and indirect immunofluorescence analyses. Further, results of coupled immunoprecipitation/enzyme activity experiments demonstrated that the LntexCht1 chimeric protein was secreted/released by these transfected L mexicana parasites and that it possessed functional chitinase enzyme activity. Such transfectants were also evaluated for their infectivity both in human macrophages in vitro and in two different strains of mice. Results of those experiments demonstrated that the LmexCht1 transfectants survived significantly better in human macrophages and also produced significantly larger lesions in mice than control parasites. Taken together, our results indicate that the LmexCht1-chimera afforded a definitive survival advantage to the parasite within these mammalian hosts. Thus, the LniexCht1 could potentially represent a new virulence determinant in the mammalian phase of this important human pathogen.	NIAID, Cell Biol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Liverpool, Liverpool Sch Trop Med, Mol & Biochem Parasitol Grp, Liverpool L3 5QA, Merseyside, England	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Liverpool School of Tropical Medicine; University of Liverpool	Dwyer, DM (corresponding author), NIAID, Cell Biol Sect, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	ddwyer@niaid.nih.gov		Bates, Paul/0000-0001-6861-5421	Wellcome Trust [064945] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000162] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Aguilera B, 2003, J BIOL CHEM, V278, P40911, DOI 10.1074/jbc.M301804200; Alexander J, 1998, J IMMUNOL, V161, P6794; Barone R, 2003, CLIN CHIM ACTA, V331, P79, DOI 10.1016/S0009-8981(03)00089-5; BATES PA, 1989, EXP PARASITOL, V68, P335, DOI 10.1016/0014-4894(89)90115-X; BATES PA, 1994, PARASITOLOGY, V108, P1, DOI 10.1017/S0031182000078458; BATES PA, 1993, EXP PARASITOL, V76, P412, DOI 10.1006/expr.1993.1050; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Bokma E, 1997, FEBS LETT, V411, P161, DOI 10.1016/S0014-5793(97)00682-0; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; Buxbaum LU, 2003, J IMMUNOL, V171, P3711, DOI 10.4049/jimmunol.171.7.3711; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; Debrabant A, 2000, J BIOL CHEM, V275, P16366, DOI 10.1074/jbc.M908725199; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; Debrabant A, 2001, MOL CELL BIOCHEM, V220, P109, DOI 10.1023/A:1010809420104; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERNANDES O, 1994, MOL BIOCHEM PARASIT, V66, P261, DOI 10.1016/0166-6851(94)90153-8; FISHER KJ, 1992, J BIOL CHEM, V267, P19607; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; FUJII T, 1993, J GEN MICROBIOL, V139, P677, DOI 10.1099/00221287-139-4-677; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Ghedin E, 1998, J BIOL CHEM, V273, P22997, DOI 10.1074/jbc.273.36.22997; GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230, DOI 10.1128/CMR.6.3.230-250.1993; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; HARPSTER MH, 1989, NUCLEIC ACIDS RES, V17, P5395, DOI 10.1093/nar/17.13.5395; HEITZ T, 1994, MOL GEN GENET, V245, P246, DOI 10.1007/BF00283273; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MCCREATH KJ, 1992, J MICROBIOL METH, V14, P229, DOI 10.1016/0167-7012(92)90055-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Pimenta PFP, 1997, PARASITOLOGY, V115, P359, DOI 10.1017/S0031182097001510; RAO VH, 1995, STRUCTURE, V3, P449, DOI 10.1016/S0969-2126(01)00178-2; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453; Sambrook J., 2001, MOL CLONING LAB MANU; SCHLEIN Y, 1991, P ROY SOC B-BIOL SCI, V245, P121, DOI 10.1098/rspb.1991.0097; SCHLEIN Y, 1992, P NATL ACAD SCI USA, V89, P9944, DOI 10.1073/pnas.89.20.9944; SCHNEIDER A, 1993, J BIOL CHEM, V268, P21868; Shakarian AM, 2000, EXP PARASITOL, V94, P238, DOI 10.1006/expr.2000.4493; Shakarian AM, 1998, GENE, V208, P315, DOI 10.1016/S0378-1119(98)00011-0; Shakarian AM, 2003, MOL CELL BIOCHEM, V245, P31, DOI 10.1023/A:1022851914014; Shakarian AM, 2002, J BIOL CHEM, V277, P17994, DOI 10.1074/jbc.M200114200; Sopwith WF, 2002, INT J PARASITOL, V32, P449, DOI 10.1016/S0020-7519(01)00372-1; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torrentera FA, 2002, INFECT IMMUN, V70, P5075, DOI 10.1128/IAI.70.9.5075-5080.2002; *UNDP WORLD BANK W, 1997, TROP DIS RES PROGR 1, P100; VANROEY P, 1994, BIOCHEMISTRY-US, V33, P13989, DOI 10.1021/bi00251a005; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Watanabe A, 1999, BIOSCI BIOTECH BIOCH, V63, P251, DOI 10.1271/bbb.63.251; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1990, J BIOL CHEM, V265, P15659; YANAI K, 1992, J BACTERIOL, V174, P7398, DOI 10.1128/jb.174.22.7398-7406.1992; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; Zhang WW, 2003, J BIOL CHEM, V278, P35508, DOI 10.1074/jbc.M305030200; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	70	28	29	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3847	3861		10.1074/jbc.M412299200	http://dx.doi.org/10.1074/jbc.M412299200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15561707	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000226983900088
J	Zablocki, K; Szczepanowska, J; Duszynski, J				Zablocki, K; Szczepanowska, J; Duszynski, J			Extracellular pH modifies mitochondrial control of capacitative calcium entry in Jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED CA2+ ENTRY; STORE DEPLETION; SMOOTH-MUSCLE; INFLUX; MODULATION; ACTIVATION; GENERATION; ALKALOSIS; MECHANISM; NEURONS	It was found that a collapse of the mitochondrial calcium buffering caused by the protonophoric uncoupler CCCP, antimycin A plus oligomycin, or the inhibitor of the mitochondrial Ca2+/Na2+ exchanger led to a strong inhibition of thapsigargin-induced capacitative Ca2+ entry (CCE) into Jurkat cells suspended in a medium at pH 7.2. The effect of these inhibitors was markedly less significant at higher extracellular pH. Moreover, dysfunction of the mitochondrial calcium handling greatly decreased CCE sensitivity to extracellular Ca2+ when the pH of extracellular solution was 7.2 (apparent K-d toward extracellular Ca2+ rose from 2.3 +/- 0.6 mm in control cells to 11.0 +/- 1.7 mm in CCCP-treated cells) as compared with pH 7.8 (apparent Kd toward extracellular Ca2+ increased from 1.3 +/- 0.4 mm in control cells to 2.4 +/- 0.4 mm in uncoupler-treated cells). Changes in intracellular pH triggered by methylamine did not influence Ca2+ influx. This suggests that, in Jurkat cells, store-operated calcium channels sense extracellular pH change as a parameter that modifies their sensitivity to intracellular Ca2+. In contrast, in human osteosarcoma cells, changes in extracellular pH as well as mitochondrial uncoupling did not exert any inhibitory effects on CCE.	M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Zablocki, K (corresponding author), M Nencki Inst Expt Biol, Pasteura 3, PL-02093 Warsaw, Poland.	k.zablocki@nencki.gov.pl	Zablocki, Krzysztof/R-4181-2016	Zablocki, Krzysztof/0000-0002-9987-1257; Szczepanowska, Joanna/0000-0002-0434-1262; Duszynski, Jerzy/0000-0003-2937-6725				Austin C, 2000, CIRC RES, V86, P355, DOI 10.1161/01.RES.86.3.355; Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Bosticardo M, 2001, EUR J IMMUNOL, V31, P2829, DOI 10.1002/1521-4141(200109)31:9<2829::AID-IMMU2829>3.0.CO;2-U; Carafoli E, 1997, BASIC RES CARDIOL, V92, P59, DOI 10.1007/BF00794069; DANTHULURI NR, 1990, J BIOL CHEM, V265, P19071; Fischer B, 2000, CLIN IMMUNOL, V96, P252, DOI 10.1006/clim.2000.4904; Friel DD, 2000, CELL CALCIUM, V28, P307, DOI 10.1054/ceca.2000.0172; FRIEL DD, 1994, J NEUROSCI, V14, P4007; Gende OA, 2003, PLATELETS, V14, P9, DOI 10.1080/0953710021000034465; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GROVER AK, 1986, AM J PHYSIOL, V251, pC529, DOI 10.1152/ajpcell.1986.251.4.C529; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heming TA, 2003, CLIN SCI, V105, P21, DOI 10.1042/CS20030004; Hochstrate P, 2001, J MEMBRANE BIOL, V184, P13, DOI 10.1007/s00232-001-0069-2; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Iwasawa K, 1997, J PHYSIOL-LONDON, V503, P237, DOI 10.1111/j.1469-7793.1997.237bh.x; Makowska A, 2000, EUR J BIOCHEM, V267, P877, DOI 10.1046/j.1432-1327.2000.01066.x; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; MUALLEM S, 1989, AM J PHYSIOL, V257, pG917, DOI 10.1152/ajpgi.1989.257.6.G917; Muller B, 2000, IMMUNOLOGY, V99, P375, DOI 10.1046/j.1365-2567.2000.00975.x; NICHOLLS DG, 1978, BIOCHEM J, V176, P463, DOI 10.1042/bj1760463; Parekh AB, 2003, NEWS PHYSIOL SCI, V18, P252, DOI 10.1152/nips.01458.2003; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wakabayashi I, 1996, BIOCHEM BIOPH RES CO, V221, P762, DOI 10.1006/bbrc.1996.0670; Wakabayashi I, 1997, BIOCHEM J, V323, P567, DOI 10.1042/bj3230567; WERTH JL, 1994, J NEUROSCI, V14, P348; Yeh BI, 2003, J BIOL CHEM, V278, P51044, DOI 10.1074/jbc.M306326200; Zablocki K, 2003, CELL CALCIUM, V33, P91, DOI 10.1016/S0143-4160(02)00202-6	37	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3516	3521		10.1074/jbc.M411507200	http://dx.doi.org/10.1074/jbc.M411507200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15569668	hybrid			2022-12-25	WOS:000226983900048
J	Kim, TH; Xiong, H; Zhang, ZH; Ren, B				Kim, TH; Xiong, H; Zhang, ZH; Ren, B			beta-Catenin activates the growth factor endothelin-1 in colon cancer cells	ONCOGENE			English	Article						beta-catenin; endothelin-1; colon cancer; ChIP; promoter arrays	C-MYC; COLORECTAL-CANCER; CARCINOMA-CELLS; EMERGING ROLE; A RECEPTOR; APC; IDENTIFICATION; INHIBITION; APOPTOSIS; LITHIUM	Endothelin-1 (EDN1) is a growth factor that is frequently produced by cancer cells and plays a critical role in tumorigenesis. However, the molecular mechanism controlling the expression of EDN1 in cancers is unknown. Constitutive activation of beta-catenin pathway is responsible for the initiation of the vast majority of colon cancers. Here we show that the EDN1 gene is directly regulated by beta-catenin in colon cancer cells. A specific DNA element within the EDN1 promoter is required for activation, and is associated with beta-catenin's cognate DNA binding partner, TCF4, in vivo. Inhibition of beta-catenin signaling results in lowered expression of EDN1, while enhancement of beta-catenin signaling leads to further activation of the gene. Significantly elevated EDN1 expression occurs in 80% of primary human colon cancers, consistent with it being a direct target of beta-catenin. Furthermore, EDN1 is able to rescue colon cancer cells from growth arrest and apoptosis resulting from inhibition of beta-catenin signaling, implicating a key role of EDN1 in promoting the oncogenic function of beta-catenin. These results indicate EDN1 overexpression as a major cause in colon cancers and reveal further details of the genetic programs responsible for tumorigenesis of colon cancers.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Lab Gene Regulat, La Jolla, CA 92093 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Zhang, ZH (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Lab Gene Regulat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	benzz@burnham.org; biren@ucsd.edu		Kim, Tae Hoon/0000-0003-3950-7557	NATIONAL CANCER INSTITUTE [F32CA108313] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA108313, 1F32CA108313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3; Bagnato A, 2002, CANCER RES, V62, P6381; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cohen MM, 2003, AM J MED GENET A, V122A, P303, DOI 10.1002/ajmg.a.20473; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Eberl LP, 2003, BRIT J CANCER, V88, P788, DOI 10.1038/sj.bjc.6600810; Egidy G, 2000, AM J PATHOL, V157, P1863, DOI 10.1016/S0002-9440(10)64825-0; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KUSUHARA M, 1990, CANCER RES, V50, P3257; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2003, J UROLOGY, V170, pS65, DOI 10.1097/01.ju.0000096372.07687.86; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosano L, 2003, CANCER RES, V63, P2447; Sellers WR, 2003, J UROLOGY, V170, pS67; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100	36	73	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					597	604		10.1038/sj.onc.1208237	http://dx.doi.org/10.1038/sj.onc.1208237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15558022				2022-12-25	WOS:000226420400007
J	Papadopoulos, MC; Binder, DK; Verkman, AS				Papadopoulos, MC; Binder, DK; Verkman, AS			Enhanced macromolecular diffusion in brain extracellular space in mouse models of vasogenic edema measured by cortical surface photobleaching	FASEB JOURNAL			English	Article						brain swelling; blood brain barrier; brain tumor; fluorescence; FRAP	REACTIVE ASTROCYTES; WATER-CONTENT; INJURY; TUMORS; DEXAMETHASONE; TORTUOSITY; SOLUTE; MICE; MECHANISMS; TRANSPORT	Diffusion of solutes and macromolecules in brain extracellular space (ECS) is important for normal brain function and efficient drug delivery, and is thought to be impaired in edematous brain. Here we measured the diffusion of an inert macromolecular fluorescent marker (FITC-dextran, 70 kDa) in the ECS by fluorescence recovery after photobleaching after staining the exposed cerebral cortex in vivo. In a brain tumor model of vasogenic ( leaky capillary) edema, FITC-dextran diffusion was reduced more than fourfold in hypercellular tumor and surrounding astrogliotic tissue; however, diffusion in brain away from the tumor was similar to30% faster than in normal contralateral brain. The increased diffusion was abolished by dexamethasone pretreatment. Enhanced ECS diffusion was also found in uninjured brain near a region of leaky brain vessels produced by focal cortical freeze injury. In contrast, ECS diffusion was slowed more than sixfold in cytotoxic brain edema caused by anoxia. Diffusion results were related semiquantitatively to ECS volume fraction and matrix viscosity from in vitro photobleaching studies in a model system consisting of silica particles in a fluorescent water/glycerol matrix. Our data provide in vivo evidence for enhanced ECS diffusion in vasogenic brain edema, yet greatly slowed diffusion in cytotoxic edema and in and around tumors.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol & Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x; Bastin ME, 1999, NEUROREPORT, V10, P1385, DOI 10.1097/00001756-199905140-00001; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; BOTHE HW, 1984, ACTA NEUROPATHOL, V64, P37, DOI 10.1007/BF00695604; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chen KC, 2000, P NATL ACAD SCI USA, V97, P8306, DOI 10.1073/pnas.150338197; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hrabetova S, 2003, J NEUROSCI, V23, P8351; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; ITO U, 1988, ACTA NEUROCHIR, V90, P35, DOI 10.1007/BF01541264; Ito U, 1990, Adv Neurol, V52, P459; ITO U, 1994, ACTA NEUROCHIR, P361; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; JELSMAN R, 1967, J NEUROSURG, V27, P388, DOI 10.3171/jns.1967.27.5.0388; KAO HP, 1993, J CELL BIOL, V120, P175, DOI 10.1083/jcb.120.1.175; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1994, ACTA NEUROCHIR, P3; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; Kono K, 2001, AM J NEURORADIOL, V22, P1081; Kuroiwa T, 2000, ACT NEUR S, V76, P191; Lu S, 2003, AM J NEURORADIOL, V24, P937; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Netti PA, 2000, CANCER RES, V60, P2497; Nicholson C, 1998, TRENDS NEUROSCI, V21, P207, DOI 10.1016/S0166-2236(98)01261-2; Nicholson C, 2000, PROG BRAIN RES, V125, P129; NICHOLSON C, 1992, CAN J PHYSIOL PHARM, V70, pS314, DOI 10.1139/y92-278; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; PASH MP, 1979, CAN J NEUROL SCI, V6, P423, DOI 10.1017/S0317167100023829; Pluen A, 2001, P NATL ACAD SCI USA, V98, P4628, DOI 10.1073/pnas.081626898; Romero IA, 2003, NEUROSCI LETT, V344, P112, DOI 10.1016/S0304-3940(03)00348-3; Rusakov DA, 1998, P NATL ACAD SCI USA, V95, P8975, DOI 10.1073/pnas.95.15.8975; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; Sugahara T, 1999, AM J NEURORADIOL, V20, P1554; Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330, DOI 10.1152/ajpcell.1999.277.2.C330; Vargova L, 2003, GLIA, V42, P77, DOI 10.1002/glia.10204; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; YAMADA K, 1979, J NEUROSURG, V50, P361, DOI 10.3171/jns.1979.50.3.0361	47	37	37	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					425	+		10.1096/fj.04-2834fje	http://dx.doi.org/10.1096/fj.04-2834fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15596484				2022-12-25	WOS:000226091000018
J	Guo, M; Teng, MK; Niu, LW; Liu, Q; Huang, QQ; Hao, Q				Guo, M; Teng, MK; Niu, LW; Liu, Q; Huang, QQ; Hao, Q			Crystal structure of the cysteine-rich secretory protein stecrisp reveals that the cysteine-rich domain has a K+ channel inhibitor-like fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEIN; CONVERGENT EVOLUTION; NAJA-ATRA; RAT SPERM; CLONING; GENE; TOXIN; PURIFICATION; IDENTIFICATION; SUPERFAMILIES	Stecrisp from Trimeresurus stejnegeri snake venom belongs to a family of cysteine-rich secretory proteins ( CRISP) that have various functions related to sperm-egg fusion, innate host defense, and the blockage of ion channels. Here we present the crystal structure of stec-risp refined to 1.6-angstrom resolution. It shows that stecrisp contains three regions, namely a PR-1 (pathogenesis-related proteins of group1) domain, a hinge, and a cysteine-rich domain (CRD). A conformation of solvent-exposed and -conserved residues (His(60), Glu(75), Glu(96), and His(115)) in the PR-1 domain similar to that of their counterparts in homologous structures suggests they may share some molecular mechanism. Three flexible loops of hypervariable sequence surrounding the possible substrate binding site in the PR-1 domain show an evident difference in homologous structures, implying that a great diversity of species- and substrate-specific interactions may be involved in recognition and catalysis. The hinge is fixed by two crossed disulfide bonds formed by four of ten characteristic cysteines in the carboxyl-terminal region and is important for stabilizing the N-terminal PR-1 domain. Spatially separated from the PR-1 domain, CRD possesses a similar fold with two K+ channel inhibitors (Bgk and Shk). Several candidates for the possible functional sites of ion channel blocking are located in a solvent-exposed loop in the CRD. The structure of stecrisp will provide a prototypic architecture for a structural and functional exploration of the diverse members of the CRISP family.	Univ Sci & Technol China, Key Lab Struct Biol, Chinese Acad Sci, Dept Mol & Cell Biol,Sch Life Sci,Hefei Natl Lab, Hefei 230026, Anhui, Peoples R China; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Cornell University	Niu, LW (corresponding author), Univ Sci & Technol China, Key Lab Struct Biol, Chinese Acad Sci, Dept Mol & Cell Biol,Sch Life Sci,Hefei Natl Lab, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.	lwniu@ustc.edu.cn	Liu, Qun/A-8757-2011; Hao, Quan/C-4304-2009	Liu, Qun/0000-0002-1179-290X; Hao, Quan/0000-0002-9642-0514				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blaxter M, 1998, SCIENCE, V282, P2041, DOI 10.1126/science.282.5396.2041; Brown RL, 1999, P NATL ACAD SCI USA, V96, P754, DOI 10.1073/pnas.96.2.754; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMEO MS, 1976, J ENDOCRINOL, V69, P47, DOI 10.1677/joe.0.0690047; Cohen DJ, 2001, BIOL REPROD, V65, P1000, DOI 10.1095/biolreprod65.4.1000; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Eberle HB, 2002, J CELL SCI, V115, P827; Fernandez C, 1997, J MOL BIOL, V266, P576, DOI 10.1006/jmbi.1996.0772; Gerlt JA, 1998, CURR OPIN CHEM BIOL, V2, P607, DOI 10.1016/S1367-5931(98)80091-4; Gilquin B, 2002, J BIOL CHEM, V277, P37406, DOI 10.1074/jbc.M206205200; Gilquin B, 1999, PROTEINS, V34, P520, DOI 10.1002/(SICI)1097-0134(19990301)34:4<520::AID-PROT11>3.0.CO;2-N; Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jin Y, 2003, TOXICON, V42, P539, DOI 10.1016/S0041-0101(03)00234-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplan F, 1999, AM J PHYSIOL-LUNG C, V276, pL1027, DOI 10.1152/ajplung.1999.276.6.L1027; KASAHARA M, 1989, GENOMICS, V5, P527, DOI 10.1016/0888-7543(89)90019-0; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KOHANE AC, 1980, BIOL REPROD, V23, P737, DOI 10.1095/biolreprod23.4.737; Kordis D, 2000, GENE, V261, P43, DOI 10.1016/S0378-1119(00)00490-X; Kosari F, 2002, CANCER EPIDEM BIOMAR, V11, P1419; Kratzschmar J, 1996, EUR J BIOCHEM, V236, P827, DOI 10.1111/j.1432-1033.1996.t01-1-00827.x; LANCELIN JM, 1994, NAT STRUCT BIOL, V1, P246, DOI 10.1038/nsb0494-246; LEA OA, 1978, INT J ANDROL, P592, DOI 10.1111/j.1365-2605.1978.tb00511.x; Maeda T, 1998, BIOCHEM BIOPH RES CO, V248, P140, DOI 10.1006/bbrc.1998.8918; Milne TJ, 2003, J BIOL CHEM, V278, P31105, DOI 10.1074/jbc.M304843200; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; MURPHY EV, 1995, GENE, V159, P131, DOI 10.1016/0378-1119(95)00061-A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIDERMAN T, 1995, PLANT PHYSIOL, V108, P17, DOI 10.1104/pp.108.1.17; Nobile M, 1996, EXP BRAIN RES, V110, P15; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Olson JH, 2001, P NATL ACAD SCI USA, V98, P11205, DOI 10.1073/pnas.211316798; Orengo CA, 1999, CURR OPIN STRUC BIOL, V9, P374, DOI 10.1016/S0959-440X(99)80051-7; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ren CH, 2002, MOL CELL BIOL, V22, P3345, DOI 10.1128/MCB.22.10.3345-3357.2002; Roberts KP, 2003, BIOL REPROD, V69, P572, DOI 10.1095/biolreprod.102.013771; Roberts KP, 2002, BIOL REPROD, V67, P525, DOI 10.1095/biolreprod67.2.525; ROCHWERGER L, 1992, MOL REPROD DEV, V31, P34, DOI 10.1002/mrd.1080310107; Rost B, 2002, J MOL BIOL, V318, P595, DOI 10.1016/S0022-2836(02)00016-5; Satoh T, 2003, HUM GENE THER, V14, P91, DOI 10.1089/104303403321070793; Schambony A, 2003, MECH DEVELOP, V120, P937, DOI 10.1016/S0925-4773(03)00162-X; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; Serrano RL, 2004, J MOL BIOL, V339, P173, DOI 10.1016/j.jmb.2004.03.015; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Smith DM, 2001, MECH DEVELOP, V102, P223, DOI 10.1016/S0925-4773(01)00293-3; Szyperski T, 1998, P NATL ACAD SCI USA, V95, P2262, DOI 10.1073/pnas.95.5.2262; Tian WD, 2003, J MOL BIOL, V333, P863, DOI 10.1016/j.jmb.2003.08.057; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Udby L, 2004, BIOCHEMISTRY-US, V43, P12877, DOI 10.1021/bi048823e; Udby L, 2002, J LEUKOCYTE BIOL, V72, P462; Wang J, 2004, ACTA CRYSTALLOGR D, V60, P1108, DOI 10.1107/S0907444904005670; Yamazaki Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P133, DOI 10.1016/S0003-9861(03)00028-6; Yamazaki Y, 2002, BIOCHEMISTRY-US, V41, P11331, DOI 10.1021/bi026132h	58	116	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12405	12412		10.1074/jbc.M413566200	http://dx.doi.org/10.1074/jbc.M413566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15596436	hybrid			2022-12-25	WOS:000227922000042
J	Bramham, J; Thai, CT; Soares, DC; Uhrin, D; Ogata, RT; Barlow, PN				Bramham, J; Thai, CT; Soares, DC; Uhrin, D; Ogata, RT; Barlow, PN			Functional insights from the structure of the multifunctional C345C domain of C5 of complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; TISSUE INHIBITOR; COMPONENTS C5; NMR STRUCTURE; 2 PARTS; PROTEIN; C3; METALLOPROTEINASES-2; RECOGNITION; IMMUNOLOGY	The complement protein C5 initiates assembly of the membrane attack complex. This remarkable process results in lysis of target cells and is fundamental to mammalian defense against infection. The 150-amino acid residue domain at the C terminus of C5 ( C5-C345C) is pivotal to C5 function. It interacts with enzymes that convert C5 to C5b, the first step in the assembly of the membrane attack complex; it also binds to the membrane attack complex components C6 and C7 with high affinity. Here a recombinant version of this C5-C345C domain is shown to adopt the oligosaccharide/oligonucleotide binding fold, with two helices packed against a five-stranded beta-barrel. The structure is compared with those from the netrin-like module family that have a similar fold. Residues critical to the interaction with C5-convertase cluster on a mobile, hydrophobic inter-strand loop that protrudes from the open face of the beta-barrel. The opposite, helix-dominated face of C5-C345C carries a pair of exposed hydrophobic side chains adjacent to a striking negatively charged patch, consistent with affinity for positively charged factor I modules in C6 and C7. Modeling of homologous domains from complement proteins C3 and C4, which do not participate in membrane attack complex assembly, suggests that this provisionally identified C6/C7-interacting face is indeed specific to C5.	Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JJ, Midlothian, Scotland; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	University of Edinburgh; University of Edinburgh; Torrey Pines Institute for Molecular Studies, California	Barlow, PN (corresponding author), Univ Edinburgh, Sch Chem, Joseph Black Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Barlow, Paul N/G-2853-2011; Soares, Dinesh C/A-4425-2012	Soares, Dinesh C/0000-0001-7557-0495	NIGMS NIH HHS [GM29831] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029831] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; Bessette PH, 1999, P NATL ACAD SCI USA, V96, P13703, DOI 10.1073/pnas.96.24.13703; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Bramham J, 2004, J BIOMOL NMR, V29, P217, DOI 10.1023/B:JNMR.0000019243.25787.15; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DOLMER K, 1993, FEBS LETT, V315, P85, DOI 10.1016/0014-5793(93)81139-Q; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawabata T, 2003, NUCLEIC ACIDS RES, V31, P3367, DOI 10.1093/nar/gkg581; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liepinsh E, 2003, J BIOL CHEM, V278, P25982, DOI 10.1074/jbc.M302734200; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Low PJ, 1999, J IMMUNOL, V162, P6580; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mizuno M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P87, DOI 10.2174/1568010043483890; MULEREBERHARD HJ, 1985, BIOCH SOC S, V50, P235; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; O'Donovan Claire, 2002, Brief Bioinform, V3, P275; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sandoval A, 2000, J IMMUNOL, V165, P1066, DOI 10.4049/jimmunol.165.2.1066; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Shatsky M, 2002, LECT NOTES COMPUT SC, V2452, P235; Stetefeld J, 2001, NAT STRUCT BIOL, V8, P705, DOI 10.1038/90422; Thai CT, 2004, J IMMUNOL, V173, P4547, DOI 10.4049/jimmunol.173.7.4547; Thai CT, 2003, J IMMUNOL, V171, P6565, DOI 10.4049/jimmunol.171.12.6565; van den Elsen JMH, 2002, J MOL BIOL, V322, P1103, DOI 10.1016/S0022-2836(02)00854-9; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	40	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					10636	10645		10.1074/jbc.M413126200	http://dx.doi.org/10.1074/jbc.M413126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15598652	hybrid			2022-12-25	WOS:000227559600109
J	Beaulieu, V; Da Silva, N; Pastor-Soler, N; Brown, CR; Smith, PJS; Brown, D; Breton, S				Beaulieu, V; Da Silva, N; Pastor-Soler, N; Brown, CR; Smith, PJS; Brown, D; Breton, S			Modulation of the actin cytoskeleton via gelsolin regulates vacuolar H+-ATPase recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; MALE REPRODUCTIVE-TRACT; DOMAIN-BINDING-PROTEIN; F-ACTIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INTERCALATED CELLS; ADENYLYL-CYCLASE; CHROMAFFIN CELLS; COLLECTING DUCT; TERMINAL DOMAIN	The role of the actin cytoskeleton in regulating membrane protein trafficking is complex and depends on the cell type and protein being examined. Using the epididymis as a model system in which luminal acidification is crucial for sperm maturation and storage, we now report that modulation of the actin cytoskeleton by the calcium- activated actin- capping and - severing protein gelsolin plays a key role in regulating vacuolar H+ ATPase ( V- ATPase) recycling. Epididymal clear cells contain abundant V- ATPase in their apical pole, and an increase in their cell- surface V- ATPase expression correlates with an increase in luminal proton secretion. We have shown that apical membrane accumulation of VATPase is triggered by an elevation in cAMP following activation of bicarbonate- regulated soluble adenylyl cyclase in response to alkaline luminal pH ( Pastor- Soler, N., Beaulieu, V., Litvin, T. N., Da Silva, N., Chen, Y., Brown, D., Buck, J., Levin, L. R., and Breton, S. ( 2003) J. Biol. Chem. 278, 49523 - 49529). Here, we show that clear cells express high levels of gelsolin, indicating a potential role in the functional activity of these cells. When jasplakinolide was used to overcome the severing action of gelsolin by polymerizing actin, complete inhibition of the alkaline pH- and cAMP- induced apical membrane accumulation of V- ATPase was observed. Conversely, when gelsolin- mediated actin filament elongation was inhibited using a 10- residue peptide ( PBP10) derived from the phosphatidylinositol 4,5- bisphosphatebinding region ( phosphoinositide- binding domain 2) of gelsolin, significant V- ATPase apical membrane mobilization was induced, even at acidic luminal pH. In contrast, the calcium chelator 1,2- bis( 2- aminophenoxy) ethaneN, N, N', N'- tetraacetic acid tetrakis( acetoxymethyl ester) and the phospholipase C inhibitor U- 73122 inhibited the alkaline pH- induced V- ATPase apical accumulation. Thus, maintenance of the actin cytoskeleton in a depolymerized state by gelsolin facilitates calcium- dependent apical accumulation of V- ATPase in response to luminal pH alkalinization. Gelsolin is present in other cell types that express the V- ATPase in their plasma membrane and recycling vesicles, including kidney intercalated cells and osteoclasts. Therefore, modulation of the actin cortex by this severing and capping protein may represent a common mechanism by which these cells regulate their rate of proton secretion.	Massachusetts Gen Hosp, Program Membrane Biol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Marine Biol Lab, BioCurrents Res Ctr, Woods Hole, MA 02543 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Marine Biological Laboratory - Woods Hole	Breton, S (corresponding author), Massachusetts Gen Hosp E, Program Membrane Biol, 149 13th St, Charlestown, MA 02129 USA.	sbreton@partners.org	Da Silva, Nicolas/T-3528-2019	Smith, Peter/0000-0003-4400-6853; Brown, Christopher/0000-0001-6076-4035	NCRR NIH HHS [P41-RR001395] Funding Source: Medline; NICHD NIH HHS [HD40793, HD08684, KO8-HD45524] Funding Source: Medline; NIDDK NIH HHS [DK57521, DK43351, DK42956, DK38452] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040793] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD045524, F32HD008684] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK057521, R37DK042956, R01DK042956, P01DK038452] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Ausiello D A, 1987, Soc Gen Physiol Ser, V42, P259; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BANNO Y, 1992, J BIOL CHEM, V267, P6488; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; Biswas RS, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-19; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Breton S, 1998, J HISTOCHEM CYTOCHEM, V46, P205, DOI 10.1177/002215549804600209; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Breton S, 1998, AM J PHYSIOL-CELL PH, V275, pC1134, DOI 10.1152/ajpcell.1998.275.4.C1134; Breton S, 2000, AM J PHYSIOL-RENAL, V278, pF717, DOI 10.1152/ajprenal.2000.278.5.F717; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; Brown D, 2000, J EXP BIOL, V203, P137; BROWN D, 1992, AM J PHYSIOL, V263, pC913, DOI 10.1152/ajpcell.1992.263.4.C913; Brown D, 1996, J EXP BIOL, V199, P2345; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200; Buss F, 2001, FEBS LETT, V508, P295, DOI 10.1016/S0014-5793(01)03065-4; Cabello-Agueros JF, 2003, CELL MOTIL CYTOSKEL, V56, P94, DOI 10.1002/cm.10135; CANNON C, 1985, NATURE, V314, P443, DOI 10.1038/314443a0; Chen SH, 2004, J BIOL CHEM, V279, P7988, DOI 10.1074/jbc.M305351200; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200; Dibas A, 2000, P SOC EXP BIOL MED, V223, P203, DOI 10.1046/j.1525-1373.2000.22328.x; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Durrbach A, 1996, J CELL SCI, V109, P457; FATH KR, 1993, J CELL SCI, P65; FINIDORI J, 1992, J CELL BIOL, V116, P1145, DOI 10.1083/jcb.116.5.1145; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gluck SL, 1998, ACTA PHYSIOL SCAND, V163, P203; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; HARTWIG JH, 1990, J HISTOCHEM CYTOCHEM, V38, P1145, DOI 10.1177/38.8.2164058; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAYS RM, 1993, PEDIATR NEPHROL, V7, P672, DOI 10.1007/BF00852577; Hoekstra D, 2004, J CELL SCI, V117, P2183, DOI 10.1242/jcs.01217; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; JACKMAN MR, 1994, J CELL SCI, V107, P2547; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kjeken R, 2004, MOL BIOL CELL, V15, P345, DOI 10.1091/mbc.e03-05-0334; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; Kumar N, 2004, J BIOL CHEM, V279, P24915, DOI 10.1074/jbc.C400110200; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Lee BS, 1996, AM J PHYSIOL-CELL PH, V270, pC382, DOI 10.1152/ajpcell.1996.270.1.C382; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Litvin TN, 2003, J BIOL CHEM, V278, P15922, DOI 10.1074/jbc.M212475200; Lu H, 2004, AM J PHYSIOL-RENAL, V286, pF233, DOI 10.1152/ajprenal.00179.2003; Lueck A, 1998, J CELL SCI, V111, P3633; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MADSEN KM, 1991, KIDNEY INT, V40, pS57; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORITA K, 1988, BIOCHEM PHARMACOL, V37, P3357; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; Pastor-Soler L, 2002, BIOL REPROD, V66, P1716, DOI 10.1095/biolreprod66.6.1716; Pastor-Soler N, 2003, J BIOL CHEM, V278, P49523, DOI 10.1074/jbc.M309543200; Paunescu TG, 2004, AM J PHYSIOL-CELL PH, V287, pC149, DOI 10.1152/ajpcell.00464.2003; PAVALKO FM, 1994, P SOC EXP BIOL MED, V205, P282; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; Riezman H, 1996, EXPERIENTIA, V52, P1033, DOI 10.1007/BF01952099; SCHWARTZ JH, 2004, AM J PHYSIOL, V266, pF94; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; STEINMETZ PR, 1986, AM J PHYSIOL, V251, pF173, DOI 10.1152/ajprenal.1986.251.2.F173; Stevens AL, 2000, AM J PHYSIOL-CELL PH, V278, pC791, DOI 10.1152/ajpcell.2000.278.4.C791; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Sun TX, 2002, AM J PHYSIOL-RENAL, V282, pF998, DOI 10.1152/ajprenal.00257.2001; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; Szaszi K, 2001, J BIOL CHEM, V276, P40761, DOI 10.1074/jbc.M106724200; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Wong GK, 1997, CELL MOTIL CYTOSKEL, V36, P30, DOI 10.1002/(SICI)1097-0169(1997)36:1<30::AID-CM3>3.0.CO;2-L; WU MS, 1994, J MEMBRANE BIOL, V142, P323; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	92	81	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8452	8463		10.1074/jbc.M412750200	http://dx.doi.org/10.1074/jbc.M412750200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591047	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000227395700122
J	Crevillen, P; Ventriglia, T; Pinto, F; Orea, A; Merida, A; Romero, JM				Crevillen, P; Ventriglia, T; Pinto, F; Orea, A; Merida, A; Romero, JM			Differential pattern of expression and sugar regulation of Arabidopsis thaliana ADP-glucose pyrophosphorylase-encoding genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; STARCH SYNTHESIS; POTATO-TUBERS; SMALL-SUBUNIT; ADPGLUCOSE PYROPHOSPHORYLASE; CDNA-CLONES; SUCROSE; MODULATION; INDUCTION; ENZYME	ADP-glucose pyrophoshorylase (ADP-Glc PPase) catalyzes the first and limiting step in starch biosynthesis. In plants, the enzyme is composed of two types of subunits ( small and large) and is allosterically regulated by 3-phosphoglycerate and phosphate. The pattern of expression and sugar regulation of the six Arabidopsis thaliana ADP-Glc PPase-encoding genes ( two small subunits, ApS1 and ApS2; and four large subunits, ApL1-ApL4) has been studied. Based on mRNA expression, ApS1 is the main small subunit or catalytic isoform responsible for ADP-Glc PPase activity in all tissues of the plant. Large subunits play a regulatory role, and the data presented define a clear functional distinction among them. ApL1 is the main large subunit in source tissues, whereas ApL3 and, to a lesser extent, ApL4 are the main isoforms present in sink tissues. Thus, in source tissues, ADP-Glc PPase would be finely regulated by the 3-phosphoglycerate/phosphate ratio, whereas in sink tissues, the enzyme would be dependent on the availability of substrates for starch synthesis. Sugar regulation of ADP-Glc PPase genes is restricted to ApL3 and ApL4 in leaves. Sugar induction of ApL3 and ApL4 transcription in leaves allows the establishment of heterotetramers less sensitive to the allosteric effectors, resembling the situation in sink tissues. The results presented on the expression pattern and sugar regulation allow us to propose a gene evolution model for the Arabidopsis ADP-Glc PPase gene family.	Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; Univ Seville, CSIC, Inst Invest Quim, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-USE - Instituto de Investigaciones Quimicas (IIQ)	Romero, JM (corresponding author), Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio 49, Seville 41092, Spain.	jmromero@ibvf.csic.es	Berlanga, Ángel Mérida/E-7623-2013; Pinto, Francisco M./P-4995-2014; Crevillén, Pedro/G-7113-2012; Romero, Jose M/D-5183-2009	Berlanga, Ángel Mérida/0000-0002-0880-2329; Pinto, Francisco M./0000-0001-9694-9816; Crevillén, Pedro/0000-0003-1276-9792; Romero, Jose M/0000-0002-4621-5934				[Anonymous], 1998, Adv Food Nutr Res, V41, P1; Bae JM, 1997, MOL GEN GENET, V254, P179, DOI 10.1007/s004380050406; Ballicora MA, 1998, PLANT PHYSIOL, V118, P265, DOI 10.1104/pp.118.1.265; Ballicora MA, 2004, PHOTOSYNTH RES, V79, P1, DOI 10.1023/B:PRES.0000011916.67519.58; Ballicora MA, 2000, J BIOL CHEM, V275, P1315, DOI 10.1074/jbc.275.2.1315; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Blanc G, 2004, PLANT CELL, V16, P1679, DOI 10.1105/tpc.021410; Burgess D, 1997, PLANT MOL BIOL, V33, P431, DOI 10.1023/A:1005752311130; Burton RA, 2002, PLANT PHYSIOL, V130, P1464, DOI 10.1104/pp.010363; Cross JM, 2004, PLANT PHYSIOL, V135, P137, DOI 10.1104/pp.103.036699; Fritzius T, 2001, PLANT PHYSIOL, V126, P883, DOI 10.1104/pp.126.2.883; Geiger M, 1998, PLANTA, V206, P234, DOI 10.1007/s004250050395; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Hendriks JHM, 2003, PLANT PHYSIOL, V133, P838, DOI 10.1104/pp.103.024513; Khoshnoodi J, 1998, PLANT SCI, V135, P183, DOI 10.1016/S0168-9452(98)00093-4; Kim KN, 1999, PLANT PHYSIOL, V121, P225, DOI 10.1104/pp.121.1.225; KLECZKOWSKI LA, 1993, PLANT PHYSIOL, V101, P179, DOI 10.1104/pp.101.1.179; Kleczkowski LA, 1999, Z NATURFORSCH C, V54, P353; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; Leonhardt N, 2004, PLANT CELL, V16, P596, DOI 10.1105/tpc.019000; Li XY, 2002, PLANT SCI, V162, P239, DOI 10.1016/S0168-9452(01)00565-9; LIN TP, 1988, PLANT PHYSIOL, V86, P1131, DOI 10.1104/pp.86.4.1131; Merida A, 1999, PLANT PHYSIOL, V120, P401, DOI 10.1104/pp.120.2.401; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Pedro CN, 2003, J BIOL CHEM, V278, P28508, DOI 10.1074/jbc.M304280200; PRESCOTT A, 1987, PLANT MOL BIOL REP, V4, P219, DOI DOI 10.1007/BF02675414; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rook F, 2001, PLANT J, V26, P421, DOI 10.1046/j.1365-313X.2001.2641043.x; Siedlecka A, 2003, PLANTA, V217, P184, DOI 10.1007/s00425-003-0982-y; Simillion C, 2002, P NATL ACAD SCI USA, V99, P13627, DOI 10.1073/pnas.212522399; Sokolov LN, 1998, BIOCHEM J, V336, P681, DOI 10.1042/bj3360681; Sun CW, 1997, PLANT J, V11, P1017, DOI 10.1046/j.1365-313X.1997.11051017.x; Tiessen A, 2002, PLANT CELL, V14, P2191, DOI 10.1105/tpc.003640; VILLAND P, 1993, PLANT MOL BIOL, V23, P1279, DOI 10.1007/BF00042361; VISSER RGF, 1991, PLANT MOL BIOL, V17, P691, DOI 10.1007/BF00037054; WEBER H, 1995, PLANTA, V195, P352, DOI 10.1007/BF00202592; Wingler A, 2000, PLANT PHYSIOL, V124, P105, DOI 10.1104/pp.124.1.105; Zeeman SC, 2002, PLANT PHYSIOL, V129, P516, DOI 10.1104/pp.003756; Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8	41	78	81	2	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8143	8149		10.1074/jbc.M411713200	http://dx.doi.org/10.1074/jbc.M411713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15598655	Green Published, hybrid			2022-12-25	WOS:000227395700086
J	Gao, F; Bren, N; Burghardt, TP; Hansen, S; Henchman, RH; Taylor, P; McCammon, JA; Sine, SM				Gao, F; Bren, N; Burghardt, TP; Hansen, S; Henchman, RH; Taylor, P; McCammon, JA; Sine, SM			Agonist-mediated conformational changes in acetylcholine-binding protein revealed by simulation and intrinsic tryptophan fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURARIFORM ANTAGONISTS BIND; DIFFERENT ORIENTATIONS; NICOTINIC RECEPTORS; MOLECULAR-DYNAMICS; DOMAIN; RESIDUES; SELECTIVITY; SUBUNIT; SITE	We delineated acetylcholine ( ACh)- dependent conformational changes in a prototype of the nicotinic receptor ligand binding domain by molecular dynamics simulation and changes in intrinsic tryptophan ( Trp) fluorescence. Prolonged molecular dynamics simulation of ACh- binding protein showed that binding of ACh establishes close register of Trps from adjacent subunits, Trp(143) and Trp(53), and draws the peripheral C- loop inward to occlude the entrance to the binding cavity. Close register of Trp143 and Trp53 was demonstrated by ACh- mediated quenching of intrinsic Trp fluorescence, elimination of quenching by mutation of one or both Trps to Phe, and decreased lifetime of Trp fluorescence by bound ACh. Occlusion of the binding cavity by the C- loop was demonstrated by restricted access of an extrinsic quencher of binding site Trp fluorescence by ACh. The collective findings showed that ACh initially establishes close register of conserved Trps from adjacent subunits and then draws the C- loop inward to occlude the entrance to the binding cavity.	Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Receptor Biol Lab, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92039 USA; Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92039 USA	Mayo Clinic; Mayo Clinic; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Sine, SM (corresponding author), Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.		McCammon, J. Andrew/AAG-1832-2021; Henchman, Richard/AAY-2193-2021	Henchman, Richard/0000-0002-0461-6625	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR49277, R01 AR049277] Funding Source: Medline; NIGMS NIH HHS [GM18360] Funding Source: Medline; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badea M G, 1979, Methods Enzymol, V61, P378; Birks J.B., 1970, PHOTOPHYSICS AROMATI, P403; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Gao F, 2003, J BIOL CHEM, V278, P23020, DOI 10.1074/jbc.M301151200; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Henchman RH, 2003, BIOPHYS J, V85, P3007, DOI 10.1016/S0006-3495(03)74720-1; Hibbs RE, 2004, J BIOL CHEM, V279, P28483, DOI 10.1074/jbc.M403713200; LAKOWICZ JR, 1986, PRINCIPLES FLUORESCE, P257; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Molles BE, 2002, BIOCHEMISTRY-US, V41, P7895, DOI 10.1021/bi025732d; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Samanta U, 1999, ACTA CRYSTALLOGR D, V55, P1421, DOI 10.1107/S090744499900726X; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Wang HL, 2003, J BIOL CHEM, V278, P32284, DOI 10.1074/jbc.M304366200; Yang H, 2003, SCIENCE, V302, P262, DOI 10.1126/science.1086911	22	122	124	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8443	8451		10.1074/jbc.M412389200	http://dx.doi.org/10.1074/jbc.M412389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591050	hybrid			2022-12-25	WOS:000227395700121
J	Imai, K; Noda, Y; Adachi, H; Yoda, K				Imai, K; Noda, Y; Adachi, H; Yoda, K			A novel endoplasmic reticulum membrane protein Rcr1 regulates chitin deposition in the cell wall of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; CONGO RED; CALCOFLUOR WHITE; YEAST SACCHAROMYCES; MUTATIONAL ANALYSIS; INTEGRITY PATHWAY; SIGNALING PATHWAY; CANDIDA-ALBICANS; GENE; GOLGI	Congo red binds to the cell wall and inhibits the growth of yeast. In a screening for multicopy suppressor genes of Congo red hypersensitivity of erd1Delta mutant, we found that a previously uncharacterized gene, YBR005w, makes most of the Saccharomyces cerevisiae strains resistant to Congo red. This gene was named RCR1 ( resistance to Congo red 1). An rcr1Delta null mutant showed an increased sensitivity to Congo red. RCR1 encodes a novel ER membrane protein with a single transmembrane domain. Molecular dissection suggested that the transmembrane domain and a part of the C-terminal polypeptide are sufficient for the activity. We examined the effect of RCR1 in various null mutants of genes related to the cell wall. The resistance of mutants to Congo red correlates with a reduction of chitin content. Multicopy RCR1 caused a significant decrease in the chitin content while the amount of alkali-soluble glucan did not change. The binding of Calcofluor white to the cell wall significantly decreased in these cells. Our results show that RCR1 regulates the chitin deposition and add firm genetic and biochemical evidences that the primary target of Congo red is chitin in S. cerevisiae.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Yoda, K (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asdfg@mail.ecc.u-tokyo.ac.jp						Abe M, 2004, J CELL SCI, V117, P5687, DOI 10.1242/jcs.01491; Abeliovich H, 1998, J BIOL CHEM, V273, P11719, DOI 10.1074/jbc.273.19.11719; Alonso-Monge R, 1999, J BACTERIOL, V181, P3058, DOI 10.1128/JB.181.10.3058-3068.1999; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BROWN JL, 1993, GENETICS, V133, P837; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; Bulik DA, 2003, EUKARYOT CELL, V2, P886, DOI 10.1128/EC.2.5.886-900.2003; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; ELORZA MV, 1983, J GEN MICROBIOL, V129, P1577; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; Hashimoto H, 1997, J BIOL CHEM, V272, P16308, DOI 10.1074/jbc.272.26.16308; HONG Z, 1994, MOL CELL BIOL, V14, P1017, DOI 10.1128/MCB.14.2.1017; Jablonowski D, 2001, YEAST, V18, P1285, DOI 10.1002/yea.776; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; KOPECKA M, 1992, ARCH MICROBIOL, V158, P115, DOI 10.1007/BF00245214; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lorberg A, 2001, MOL GENET GENOMICS, V266, P514; Martin H, 1999, MICROBIOL-SGM, V145, P249, DOI 10.1099/13500872-145-1-249; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; OGAWA K, 1978, CARBOHYD RES, V67, P527, DOI 10.1016/S0008-6215(00)84144-0; OGAWA K, 1973, CARBOHYD RES, V29, P397, DOI 10.1016/S0008-6215(00)83025-6; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; Popolo L, 1997, J BACTERIOL, V179, P463, DOI 10.1128/jb.179.2.463-469.1997; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Raclavsky V, 1999, FOLIA MICROBIOL, V44, P663, DOI 10.1007/BF02825658; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; REISSIG JL, 1955, J BIOL CHEM, V217, P959; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; RONCERO C, 1985, J BACTERIOL, V163, P1180, DOI 10.1128/JB.163.3.1180-1185.1985; Santos B, 1997, J CELL BIOL, V136, P95, DOI 10.1083/jcb.136.1.95; Sekiya-Kawasaki M, 2002, GENETICS, V162, P663; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; Shedletzky E, 1997, ANAL BIOCHEM, V249, P88, DOI 10.1006/abio.1997.2162; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVERMAN SJ, 1988, P NATL ACAD SCI USA, V85, P4735, DOI 10.1073/pnas.85.13.4735; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; WOOD PJ, 1980, CARBOHYD RES, V85, P271, DOI 10.1016/S0008-6215(00)84676-5; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200	50	41	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8275	8284		10.1074/jbc.M409428200	http://dx.doi.org/10.1074/jbc.M409428200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15590673	hybrid			2022-12-25	WOS:000227395700101
J	Kerkmann, M; Costa, LT; Richter, C; Rothenfusser, S; Battiany, J; Hornung, V; Johnson, J; Englert, S; Ketterer, T; Heckl, W; Thalhammer, S; Endres, S; Hartmann, G				Kerkmann, M; Costa, LT; Richter, C; Rothenfusser, S; Battiany, J; Hornung, V; Johnson, J; Englert, S; Ketterer, T; Heckl, W; Thalhammer, S; Endres, S; Hartmann, G			Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; IN-VITRO; IMMUNE CELLS; B-CELL; DNA; OLIGONUCLEOTIDES; ACTIVATION; OLIGODEOXYNUCLEOTIDE; IFN; IDENTIFICATION	Plasmacytoid dendritic cells (PDC) represent a highly specialized immune cell subset that produces large quantities of the anti-viral cytokines type I interferons (IFN-alpha and IFN-beta) upon viral infection. PDC employ a member of the family of toll-like receptors, TLR9, to detect CpG motifs (unmethylated CG dinucleotides in certain base context) present in viral DNA. A certain group of CpG motif-containing oligodeoxynucleotides (CpG ODN), CpG-A, was the first synthetic stimulus available that induced large amounts of interferon-alpha (IFN-alpha) in PDC. However, the mechanism responsible for this activity remained elusive. CpG-A is characterized by a central palindrome and poly(G) at the 5' and 3' end. Here we demonstrate that CpG- A self-assembles to higher order tertiary structures via G-tetrad formation of their poly(G) motifs. Spontaneous G-tetrad formation of CpG-A required the palindrome sequence allowing structure formation in a physiological environment. Once formed, G-tetrad-linked structures were stable even under denaturing conditions. Atomic force microscopy revealed that the tertiary structures formed by CpG-A represent nucleic acid-based nanoparticles in the size range of viruses. Similarly sized preformed polystyrene nanoparticles loaded with a CpG ODN that is otherwise weak at inducing IFN-alpha (CpG-B) gained the potency of CpG-A to induce IFN-alpha. Higher ODN uptake in PDC was not responsible for the higher IFN-alpha-inducing activity of CpG-A or of CpG-B-coated nanoparticles as compared with CpG- B. Based on these results we propose a model in which the spatial configuration of CpG motifs as particle is responsible for the virus-like potency of CpG-A to induce IFN-alpha in PDC.	Klinikum Ludwig Maximilians Univ, Med Klin Innenstadt, Klin Pharmakol Abt, Dept Internal Med,Div Clin Pharmacol, D-80336 Munich, Germany; Univ Munich, Dept Geo & Environm Sci, D-80333 Munich, Germany; Univ Munich, Inst Immunol, D-80336 Munich, Germany; CureVac GmbH, D-72076 Tubingen, Germany; Univ Tubingen, Res Ctr Nucle Acaid & Peptide Chem, D-72076 Tubingen, Germany	University of Munich; University of Munich; University of Munich; CureVac N.V.; Eberhard Karls University of Tubingen	Hartmann, G (corresponding author), Klinikum Ludwig Maximilians Univ, Med Klin Innenstadt, Klin Pharmakol Abt, Dept Internal Med,Div Clin Pharmacol, Ziemssenstr 1, D-80336 Munich, Germany.	ghartmann@lrz.uni-muenchen.de	Hartmann, Gunther/P-7492-2017; Hornung, Veit/C-3565-2012; Heckl, Wolfgang M./S-8267-2019; Thalhammer, Stefan/C-1031-2011	Hartmann, Gunther/0000-0003-1021-2018; Hornung, Veit/0000-0002-4150-194X; 				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; Basu S, 1997, NUCLEIC ACIDS RES, V25, P1327, DOI 10.1093/nar/25.7.1327; Benimetskaya L, 1997, NUCLEIC ACIDS RES, V25, P2648, DOI 10.1093/nar/25.13.2648; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Costa LT, 2004, BIOCHEM BIOPH RES CO, V313, P1065, DOI 10.1016/j.bbrc.2003.12.041; Dalpke AH, 2002, IMMUNOLOGY, V106, P102, DOI 10.1046/j.1365-2567.2002.01410.x; Fearon K, 2003, EUR J IMMUNOL, V33, P2114, DOI 10.1002/eji.200323948; Fritz H, 1997, J COLLOID INTERF SCI, V195, P272, DOI 10.1006/jcis.1997.5172; Gursel M, 2002, J LEUKOCYTE BIOL, V71, P813; Hansma HG, 1996, NUCLEIC ACIDS RES, V24, P713, DOI 10.1093/nar/24.4.713; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Keniry MA, 2001, BIOPOLYMERS, V56, P123, DOI 10.1002/1097-0282(2000/2001)56:3<123::AID-BIP10010>3.0.CO;2-3; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; Lee SW, 2000, J IMMUNOL, V165, P3631, DOI 10.4049/jimmunol.165.7.3631; Marathias VM, 1999, BIOCHEMISTRY-US, V38, P4355, DOI 10.1021/bi982604+; MARSH TC, 1994, BIOCHEMISTRY-US, V33, P10718, DOI 10.1021/bi00201a020; MARSH TC, 1995, NUCLEIC ACIDS RES, V23, P696, DOI 10.1093/nar/23.4.696; Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630; Poeck H, 2004, BLOOD, V103, P3058, DOI 10.1182/blood-2003-08-2972; Rothenfusser S, 2004, BLOOD, V103, P2162, DOI 10.1182/blood-2003-04-1091; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Verthelyi D, 2002, J IMMUNOL, V168, P1659, DOI 10.4049/jimmunol.168.4.1659; Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wu CCN, 2004, J BIOL CHEM, V279, P33071, DOI 10.1074/jbc.M311662200; Zhu FG, 2001, IMMUNOLOGY, V103, P226, DOI 10.1046/j.1365-2567.2001.01222.x	40	146	161	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8086	8093		10.1074/jbc.M410868200	http://dx.doi.org/10.1074/jbc.M410868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591070	hybrid			2022-12-25	WOS:000227395700079
J	Zeisberg, M; Shah, AA; Kalluri, R				Zeisberg, M; Shah, AA; Kalluri, R			Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; TGF-BETA; EXPRESSION; FIBROSIS; BMP-7; NEPHROGENESIS; MECHANISMS; CONVERSION; INDUCTION; CELLS	In the kidney, a unique plasticity exists between epithelial mesenchymal cells. During kidney development, the metanephric mesenchyme contributes to emerging epithelium of the nephron via mesenchymal to epithelial transition ( MET). In the injured adult kidney, renal epithelia contribute to the generation of fibroblasts via epithelial-mesenchymal transition, facilitating renal fibrosis. Recombinant human bone morphogenic protein ( BMP)-7, a morphogen that is essential for the conversion of epithelia from condensing mesenchyme during kidney development, enhances the repair of tubular structures in the kidney. In this setting, BMP-7 inhibits epithelial-mesenchymal transition involving adult renal epithelial tubular cells and decreases secretion of type I collagen by adult renal fibroblasts. In search of a mechanism behind the ability of BMP-7 to repair damaged renal tubules, we hypothesized that systemic treatment with BMP-7 might induce MET involving adult renal fibroblasts in the injured kidney, generating functional epithelial cells. Here we report that BMP-7 induces formation of epithelial cell aggregates in adult renal fibroblasts associated with reacquisition of E-cadherin expression and decreased motility, mimicking the effect of BMP-7 on embryonic metanephric mesenchyme to generate epithelium. In addition, we provide evidence that BMP-7-mediated repair of renal injury is associated with MET involving adult renal interstitial fibroblasts in mouse models for renal fibrosis. Collectively, these findings suggest that adult renal fibroblasts might retain parts of their original embryonic imprint and plasticity, which can be re-engaged by systemic administration of BMP-7 to mediate repair of tubular injury in a fibrotic kidney.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Matrix Biol,Dept Med, Boston, MA 02215 USA; Childrens Hosp, Div Nephrol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital	Kalluri, R (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Matrix Biol,Dept Med, Sana 514,330 Brookline Ave, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062987] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Bohle A, 1979, Contrib Nephrol, V16, P109; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; Godin RE, 1998, DEVELOPMENT, V125, P3473; Godin RE, 1999, INT J DEV BIOL, V43, P405; Gould SE, 2002, KIDNEY INT, V61, P51, DOI 10.1046/j.1523-1755.2002.00103.x; Hay ED, 1995, ACTA ANAT, V154, P8; Herzlinger D, 2002, J CLIN INVEST, V110, P305, DOI 10.1172/JCI200216377; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Horster MF, 1999, PHYSIOL REV, V79, P1157, DOI 10.1152/physrev.1999.79.4.1157; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Imgrund M, 1999, KIDNEY INT, V56, P1423, DOI 10.1046/j.1523-1755.1999.00663.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; LILIE FR, 1908, DEV CHICK; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Mah SP, 2000, DEV BIOL, V223, P38, DOI 10.1006/dbio.2000.9738; Morrissey J, 2002, J AM SOC NEPHROL, V13, pS14; MULLER GA, 1995, EXP NEPHROL, V3, P127; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Ray RP, 2001, CELL, V104, P801, DOI 10.1016/S0092-8674(01)00275-6; Simon N, 1999, AM J PHYSIOL-RENAL, V276, pF382, DOI 10.1152/ajprenal.1999.276.3.F382; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Surendran K, 2002, AM J PHYSIOL-RENAL, V282, pF431, DOI 10.1152/ajprenal.0009.2001; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vanderburg CR, 1996, ACTA ANAT, V157, P87; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; Wang S, 2003, KIDNEY INT, V63, P2037, DOI 10.1046/j.1523-1755.2003.00035.x; Wang SN, 2001, J AM SOC NEPHROL, V12, P2392, DOI 10.1681/ASN.V12112392; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888	47	242	273	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8094	8100		10.1074/jbc.M413102200	http://dx.doi.org/10.1074/jbc.M413102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15591043	hybrid			2022-12-25	WOS:000227395700080
J	Macfarlan, T; Kutney, S; Altman, B; Montross, R; Yu, JJ; Chakravarti, D				Macfarlan, T; Kutney, S; Altman, B; Montross, R; Yu, JJ; Chakravarti, D			Human THAP7 is a chromatin-associated, histone tail-binding protein that represses transcription via recruitment of HDAC3 and nuclear hormone receptor corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-ELEMENT TRANSPOSASE; HP1 PROTEINS; DNA-BINDING; LYSINE 9; COMPLEX; ACETYLATION; BROMODOMAIN; DOMAIN; YEAST; H3	The identities of signal transducer proteins that integrate histone hypoacetylation and transcriptional repression are largely unknown. Here we demonstrate that THAP7, an uncharacterized member of the recently identified THAP (Thanatos-associated protein) family of proteins, is ubiquitously expressed, associates with chromatin, and represses transcription. THAP7 binds preferentially to hypoacetylated (un-, mono-, and di-acetylated) histone H4 tails in vitro via its C-terminal 77 amino acids. Deletion of this domain, or treatment of cells with the histone deacetylase inhibitor TSA, which leads to histone hyperacetylation, partially disrupts THAP7/chromatin association in living cells. THAP7 coimmunoprecipitates with histone deacetylase 3 (HDAC3) and the nuclear hormone receptor corepressor (NCoR) and represses transcription as a Gal4 fusion protein. Chromatin immunoprecipitation assays demonstrate that these corepressors are recruited to promoters in a THAP7 dependent manner and promote histone H3 hypoacetylation. The conserved THAP domain is a key determinant for full HDAC3 association in vitro, and both the THAP domain and the histone interaction domain are important for the repressive properties of THAP7. Full repression mediated by THAP7 is also dependent on NCoR expression. We hypothesize that THAP7 is a dual function repressor protein that actively targets deacetylation of histone H3 necessary to establish transcriptional repression and functions as a signal transducer of the repressive mark of hypoacetylated histone H4. This is the first demonstration of the transcriptional regulatory properties of a human THAP domain protein, and a critical identification of a potential transducer of the repressive signal of hypoacetylated histone H4 in higher eukaryotes.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Chakravarti, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	debu@pharm.med.upenn.edu	Yu, Jiujiu/H-7181-2013; Altman, Brian J./X-2783-2019; Macfarlan, Todd/S-3750-2017	Altman, Brian J./0000-0002-3954-4916; Macfarlan, Todd/0000-0003-2495-9809; Chakravarti, Debabrata/0000-0001-8446-8599	NIDDK NIH HHS [DK65148, DK57079, R01 DK065148, R01 DK057079] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM007229, 5-T32-GM-008216-16] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK065148, R01DK065148, R01DK057079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229, T32GM008216] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Boxem M, 2002, CURR BIOL, V12, P906, DOI 10.1016/S0960-9822(02)00844-8; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Glass CK, 2000, GENE DEV, V14, P121; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Reddy KC, 2004, CELL, V118, P439, DOI 10.1016/j.cell.2004.07.026; Roussigne M, 2003, ONCOGENE, V22, P2432, DOI 10.1038/sj.onc.1206271; Roussigne M, 2003, TRENDS BIOCHEM SCI, V28, P66, DOI 10.1016/S0968-0004(02)00013-0; Sabet N, 2004, MOL CELL BIOL, V24, P8823, DOI 10.1128/MCB.24.20.8823-8833.2004; Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	50	56	59	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7346	7358		10.1074/jbc.M411675200	http://dx.doi.org/10.1074/jbc.M411675200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15561719	hybrid			2022-12-25	WOS:000227332700127
J	Monastyrskaya, K; Hostettler, A; Buergi, S; Draeger, A				Monastyrskaya, K; Hostettler, A; Buergi, S; Draeger, A			The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SUBSTANCE-P; SMOOTH-MUSCLE; LOW-DENSITY; CARDIOMYOCYTE CAVEOLAE; GANGLION NEURONS; ADENYLYL-CYCLASE; BETA-ARRESTIN; EXPRESSION; RICH	The spatial targeting of receptors to discrete domains within the plasma membrane allows their preferential coupling to specific effectors, which is essential for rapid and accurate discrimination of signals. Efficiency of signaling is further increased by protein and lipid segregation within the plasma membrane. We have previously demonstrated the importance of raft-mediated signaling in the regulation of smooth and skeletal muscle cell contraction. Since G protein-coupled receptors (GPCRs) are key components in the regulation of smooth muscle contraction-relaxation cycles, it is important to determine whether GPCR signaling is mediated by lipid rafts and raft-associated molecules. Neurokinin 1 receptor (NK1R) is expressed in central and peripheral nervous system as well as in endothelial and smooth muscle cells and involved in mediation of pain, inflammation, exocrine secretion, and smooth muscle contraction. The N1KI receptor was transiently expressed in HEK293 and HepG2 cell lines and its localization in membrane microdomains investigated using biochemical methods and immunofluorescent labeling. We show that the NK1 receptor, similar to the earlier described beta(2)-adrenergic receptor and G proteins, localizes to lipid rafts and caveolae. Protein kinase C (PKC) is one of the downstream effectors of the NK1 activation. Its active form translocates from the cytoplasm to the plasma membrane. Upon stimulation of the NK1 receptor with Substance P, the activated PKC relocated to lipid rafts. Using cholesterol extraction and replenishment assays we show that activation of NK1 receptor is dependent on the microarchitecture of the plasma membrane: NK1R-mediated signaling was abolished after cholesterol depletion of the receptor-expressing cells with methyl-beta-cyclodextrin. Our results demonstrate that reorganization of the plasma membrane has an effect on the activation of the raft-associated NK1R and the downstream events such as recruitment of protein kinases.	Univ Bern, Inst Anat, Dept Cell Biol, CH-3009 Bern, Switzerland; Univ Bern, Inst Pharmacol, CH-3009 Bern, Switzerland	University of Bern; University of Bern	Monastyrskaya, K (corresponding author), Univ Bern, Inst Anat, Dept Cell Biol, Baltzerstr 2, CH-3009 Bern, Switzerland.	monastyk@ana.unibe.ch		Monastyrskaya, Katia/0000-0003-2042-1139				Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0070com; Billington CK, 2003, RESP RES, V4; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Burgueno J, 2003, J NEUROCHEM, V86, P785, DOI 10.1046/j.1471-4159.2003.01842.x; CHABRE O, 1994, J BIOL CHEM, V269, P5730; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 2001, AM J PHYSIOL-CELL PH, V280, pC1097, DOI 10.1152/ajpcell.2001.280.5.C1097; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Draeger A, 2003, DEV BIOL, V262, P324, DOI 10.1016/S0012-1606(03)00398-1; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Fielding CJ, 2004, BIOCHEM SOC T, V32, P65, DOI 10.1042/BST0320065; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fu Y, 2004, J BIOL CHEM, V279, P14140, DOI 10.1074/jbc.M311061200; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Hokfelt T, 2001, J INTERN MED, V249, P27, DOI 10.1046/j.0954-6820.2000.00773.x; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Katsumata O, 2001, J IMMUNOL, V167, P5814, DOI 10.4049/jimmunol.167.10.5814; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Lallemend F, 2003, J NEUROCHEM, V87, P508, DOI 10.1046/j.1471-4159.2003.02014.x; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; LUNDSTROM K, 1994, EUR J BIOCHEM, V224, P917, DOI 10.1111/j.1432-1033.1994.00917.x; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Parkin ET, 1996, BIOCHEM J, V319, P887, DOI 10.1042/bj3190887; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Saria A, 1999, EUR J PHARMACOL, V375, P51, DOI 10.1016/S0014-2999(99)00259-9; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Spurney RF, 1998, J BIOL CHEM, V273, P28496, DOI 10.1074/jbc.273.43.28496; VIGNA SR, 1994, J NEUROSCI, V14, P834; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Yarbrough TL, 2002, CIRC RES, V90, P443, DOI 10.1161/hh0402.105177	51	82	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7135	7146		10.1074/jbc.M405806200	http://dx.doi.org/10.1074/jbc.M405806200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590676	hybrid			2022-12-25	WOS:000227332700104
J	Polster, BM; Basanez, G; Etxebarria, A; Hardwick, JM; Nicholls, DG				Polster, BM; Basanez, G; Etxebarria, A; Hardwick, JM; Nicholls, DG			Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; FOCAL CEREBRAL-ISCHEMIA; BRAIN MITOCHONDRIA; CELL-DEATH; PERMEABILITY TRANSITION; NEURONAL CULTURES; FACTOR AIF; FACTOR TRANSLOCATION; NEURAL CELL; MOUSE MODEL	The translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus has been implicated in the mechanism of glutamate excitotoxicity in cortical neurons and has been observed in vivo following acute rodent brain injuries. However, the mechanism and time course of AIF redistribution to the nucleus is highly controversial. Because elevated intracellular calcium is one of the most ubiquitous features of neuronal cell death, this study tested the hypothesis that cleavage of AIF by the calcium-activated protease calpain mediates its release from mitochondria. Both precursor and mature forms of recombinant AIF were cleaved near the amino terminus by calpain I in vitro. Mitochondrial outer membrane permeabilization by truncated Bid induced cytochrome c release from isolated liver or brain mitochondria but only induced AIF release in the presence of active calpain. Enzymatic inhibition of calpain by calpeptin precluded AIF release, demonstrating that proteolytic activity was required for release. Calpeptin and the mitochondrial permeability transition pore antagonist cyclosporin A also inhibited calcium-induced AIF release from mouse liver mitochondria, implicating the involvement of an endogenous mitochondrial calpain in release of AIF during permeability transition. Cleavage of AIF directly decreased its association with pure lipid vesicles of mitochondrial inner membrane composition. Taken together, these results define a novel mechanism of AIF release involving calpain processing and identify a potential molecular checkpoint for cytoprotective interventions.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Basque Country, Euskal Herriko Univ, Ctr Mixto, CSIC,Unidad Biofis, E-48080 Bilbao, Spain; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunon, Baltimore, MD 21205 USA	Buck Institute for Research on Aging; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Polster, BM (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	bpolster@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012; Basanez, Gorka/L-9509-2014	Basanez, Gorka/0000-0002-7475-7861; Polster, Brian/0000-0003-2571-7510	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS044791, U01NS073581, R01NS041908] Funding Source: NIH RePORTER; NINDS NIH HHS [NS73581, NS41908, NS44791] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Baud O, 2004, EUR J NEUROSCI, V20, P1713, DOI 10.1111/j.1460-9568.2004.03616.x; Braun JS, 2002, J CLIN INVEST, V109, P19; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guerini D, 2003, J BIOL CHEM, V278, P38141, DOI 10.1074/jbc.M302400200; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; Kristian T, 2004, BRAIN RES PROTOC, V13, P176, DOI 10.1016/j.brainresprot.2004.05.001; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kushnareva YE, 2001, ARCH BIOCHEM BIOPHYS, V386, P251, DOI 10.1006/abbi.2000.2201; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; LAPIDUS RG, 1993, ARCH BIOCHEM BIOPHYS, V306, P246, DOI 10.1006/abbi.1993.1507; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Polster BM, 2003, J NEUROSCI, V23, P2735; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wei MC, 2000, GENE DEV, V14, P2060; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhao H, 2004, J CEREBR BLOOD F MET, V24, P681, DOI 10.1097/01.WCB.0000127161.89708.A5; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	54	347	361	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6447	6454		10.1074/jbc.M413269200	http://dx.doi.org/10.1074/jbc.M413269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590628	hybrid			2022-12-25	WOS:000227332700026
J	Zayzafoon, M; Fulzele, K; McDonald, JM				Zayzafoon, M; Fulzele, K; McDonald, JM			Calmodulin and calmodulin-dependent kinase II alpha regulate osteoblast differentiation by controlling c-fos expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; PARATHYROID-HORMONE; BONE-FORMATION; SMOOTH-MUSCLE; IN-VITRO; ACTIVATION; CELLS; AP-1; INDUCTION	Ca2+/calmodulin-dependent protein kinase IIalpha (alpha-CaMKII) was once thought to be exclusively expressed in neuronal tissue, but it is becoming increasingly evident that CaMKII is also expressed in various extraneural cells. CaMKII plays a critical role in regulating various signaling pathways leading to modulation of several aspects of cellular functions, including proliferation, differentiation, cytoskeletal structure, and gene expression. The purpose of this study was to examine the expression of CaMKII in osteoblast-like cells (MC4) and to elucidate its role in osteoblast differentiation. We demonstrated that CaMKII, specifically the a isoform, is expressed in osteoblasts both in vitro and in vivo. Inhibition of CaMKII by the calmodulin antagonist trifluoperazine or the CaMKII antagonist KN93 reduces alkaline phosphatase activity and mineralization, as well as causes 85 and 56% decreases in alkaline phosphatase and osteocalcin gene expression, respectively. CaM and CaMKII antagonists, using the newborn mouse calvaria in vivo model, cause a 50% decrease in osteoblast number (N.Ob-BS) and a 32% decrease in mineralization (BV/TV). Pharmacologic and genetic inhibition of a-CaMKII by using trifluoperazine, KN93, and a-CaMKII small interfering RNA decreases the phosphorylation of ERK and of cAMP-response element-binding protein, leading to a significant decrease in the transactivation of serum response element and cAMP-response element. Inhibition of a-CaMKII decreases the expression of c-fos, AP-1 transactivation, and AP-1 DNA binding activity. Our findings demonstrated that a-CaMKII is expressed in osteoblasts and is involved in c-fos expression via regulation of serum response element and cAMP-response element. Inhibition of a-CaMKII results in a decrease in c-fos expression and AP-1 activation, leading to inhibition of osteoblast differentiation.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35233 USA; Vet Adm Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McDonald, JM (corresponding author), Univ Alabama Birmingham, Dept Pathol, 220 W Pavil,619 S 19th St, Birmingham, AL 35233 USA.	mcdonald@path.uab.edu			NIAMS NIH HHS [1R01-AR050235, P30-AR46031] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050235, P30AR046031] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ansari HR, 2001, J PHARMACOL EXP THER, V299, P178; Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Bergh JJ, 2004, ENDOCRINOLOGY, V145, P426, DOI 10.1210/en.2003-0319; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Caran N, 2001, J BIOL CHEM, V276, P42514, DOI 10.1074/jbc.M103013200; Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200; CLARK G, 1981, STAINING PROCEDURES, P187; Colbran RJ, 2004, BIOCHEM J, V378, P1, DOI 10.1042/BJ20031547; Colomer JM, 2000, MOL ENDOCRINOL, V14, P1125, DOI 10.1210/me.14.8.1125; Demiralp B, 2002, ENDOCRINOLOGY, V143, P4038, DOI 10.1210/en.2002-220221; Doggett TA, 2002, ENDOCRINOLOGY, V143, P1880, DOI 10.1210/en.143.5.1880; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Farach-Carson MC, 2004, STEROIDS, V69, P543, DOI 10.1016/j.steroids.2004.05.002; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Fink CC, 2002, CURR OPIN NEUROBIOL, V12, P293, DOI 10.1016/S0959-4388(02)00327-6; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gabellini N, 2003, J NEUROCHEM, V84, P282, DOI 10.1046/j.1471-4159.2003.01511.x; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Illario M, 2003, J BIOL CHEM, V278, P45101, DOI 10.1074/jbc.M305355200; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 1999, Verh Dtsch Ges Pathol, V83, P216; Kim I, 2000, J PHYSIOL-LONDON, V526, P367, DOI 10.1111/j.1469-7793.2000.00367.x; Kukushkin AN, 2002, ONCOGENE, V21, P719, DOI 10.1038/sj.onc.1205118; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Miralem T, 1996, J BIOL CHEM, V271, P17100, DOI 10.1074/jbc.271.29.17100; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Quinn CO, 2000, J MOL ENDOCRINOL, V25, P73, DOI 10.1677/jme.0.0250073; RYSECK RP, 1991, ONCOGENE, V6, P533; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang Y, 1996, MOL CELL BIOL, V16, P5915; Wang Y, 2003, J AM SOC NEPHROL, V14, P28, DOI 10.1097/01.ASN.0000043180.18456.47; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003-1156; Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200; Zayzafoon M, 2002, J BIOL CHEM, V277, P37212, DOI 10.1074/jbc.M200129200; Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097-4644(20001101)79:2<301::AID-JCB130>3.0.CO;2-0	65	90	98	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7049	7059		10.1074/jbc.M412680200	http://dx.doi.org/10.1074/jbc.M412680200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590632	hybrid			2022-12-25	WOS:000227332700095
J	Bhattacharya, SK; Rockwood, EJ; Smith, SD; Bonilha, VL; Crabb, JS; Kuchtey, RW; Robertson, NG; Peachey, NS; Morton, CC; Crabb, JW				Bhattacharya, SK; Rockwood, EJ; Smith, SD; Bonilha, VL; Crabb, JS; Kuchtey, RW; Robertson, NG; Peachey, NS; Morton, CC; Crabb, JW			Proteomics reveal cochlin deposits associated with glaucomatous trabecular meshwork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; INNER-EAR; SENSORINEURAL DEAFNESS; HEREDITARY DEAFNESS; VESTIBULAR DISORDER; MESSENGER-RNA; DFNA9; GENE; PROTEIN; EYES	The etiology of primary open angle glaucoma, a leading cause of age-related blindness, remains poorly defined, although elevated intraocular pressure (IOP) contributes to the disease progression. To better understand the mechanisms causing elevated IOP from aqueous humor circulation, we pursued proteomic analyses of trabecular meshwork (TM) from glaucoma and age-matched control donors. These analyses demonstrated that Cochlin, a protein associated with deafness disorder DFNA9, is present in glaucomatous but absent in normal TM. Cochlin was also detected in TM from the glaucomatous DBA/2J mouse preceding elevated IOP but found to be absent in three other mouse lines that do not develop elevated IOP. Histochemical analyses revealed co-deposits of Cochlin and mucopolysaccharide in human TM around Schlemm's canal, similar to that observed in the cochlea in DFNA9 deafness. Purified Cochlin was found to aggregate after sheer stress and to induce the aggregation of TM cells in vitro. Age-dependent in vivo increases in Cochlin were observed in glaucomatous TM, concomitant with a decrease in type II collagen, suggesting that Cochlin may disrupt the TM architecture and render components like collagen more susceptible to degradation and collapse. Overall, these observations suggest that Cochlin contributes to elevated IOP in primary open angle glaucoma through altered interactions within the TM extracellular matrix, resulting in cell aggregation, mucopolysaccharide deposition, and significant obstruction of the aqueous humor circulation.	Cleveland Clin Fdn, Cole Eye Inst i31, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Louis Stokes Vet Affairs Med Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Bhattacharya, SK (corresponding author), Cleveland Clin Fdn, Cole Eye Inst i31, Cleveland, OH 44195 USA.	bhattas@ccf.org	Bhattacharya, Sanjoy K/B-2001-2008; Bonilha, Vera/AAS-8566-2020; Peachey, Neal/G-5533-2010	Bonilha, Vera/0000-0002-6166-5124; Peachey, Neal/0000-0002-4419-7226	NEI NIH HHS [R01 EY014239, R01 EY006603, EY015638, R03 EY015266, R24 EY015638, F32 EY006603, EY6603, EY14239] Funding Source: Medline; NIDCD NIH HHS [DC03402, R01 DC003402] Funding Source: Medline; NATIONAL EYE INSTITUTE [R24EY015638, R01EY014239, R03EY015266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003402] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bitner-Glindzicz M, 2002, BRIT MED BULL, V63, P73, DOI 10.1093/bmb/63.1.73; Bom SJH, 1999, BRIT J AUDIOL, V33, P335, DOI 10.3109/03005369909090117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang B, 1999, NAT GENET, V21, P405, DOI 10.1038/7741; Cohen Claudia S, 2004, Curr Opin Ophthalmol, V15, P75, DOI 10.1097/00055735-200404000-00002; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; de Kok YJM, 1999, HUM MOL GENET, V8, P361, DOI 10.1093/hmg/8.2.361; Fransen E, 1999, HUM MOL GENET, V8, P1425, DOI 10.1093/hmg/8.8.1425; Grabski R, 2003, HUM GENET, V113, P406, DOI 10.1007/s00439-003-0992-7; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Ikezono T, 2004, BIOCHEM BIOPH RES CO, V314, P440, DOI 10.1016/j.bbrc.2003.12.106; Ikezono T, 2001, BBA-MOL BASIS DIS, V1535, P258, DOI 10.1016/S0925-4439(00)00101-0; Kamarinos M, 2001, Hum Mutat, V17, P351, DOI 10.1002/humu.37; Khetarpal U, 2000, LARYNGOSCOPE, V110, P1379, DOI 10.1097/00005537-200008000-00030; Lutjen-Drecoll E, 1999, PROG RETIN EYE RES, V18, P91, DOI 10.1016/S1350-9462(98)00011-1; Lutjen-Drecoll E, 2000, J GLAUCOMA, V9, P417; LUTJENDRECOLL E, 1986, EXP EYE RES, V42, P457, DOI 10.1016/0014-4835(86)90005-9; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MCMENAMIN PG, 1991, J ANAT, V178, P65; Merchant SN, 2000, ADV OTO-RHINO-LARYNG, V56, P212; Morrison JC, 2003, GLAUCOMA SCI PRACTIC; Nam Y, 2002, CURR OPIN CHEM BIOL, V6, P501, DOI 10.1016/S1367-5931(02)00346-0; Nickla DL, 2002, INVEST OPHTH VIS SCI, V43, P2519; PARETI FI, 1987, J BIOL CHEM, V262, P13835; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; Robertson NG, 2003, J MED GENET, V40, P479, DOI 10.1136/jmg.40.7.479; Robertson NG, 1997, GENOMICS, V46, P345, DOI 10.1006/geno.1997.5067; Robertson NG, 1998, NAT GENET, V20, P299, DOI 10.1038/3118; Robertson NG, 2001, HUM MOL GENET, V10, P2493, DOI 10.1093/hmg/10.22.2493; Shankaran H, 2003, BLOOD, V101, P2637, DOI 10.1182/blood-2002-05-1550; SHERWOOD ME, 1988, EXP EYE RES, V46, P881, DOI 10.1016/S0014-4835(88)80040-X; Stamer WD, 1998, INVEST OPHTH VIS SCI, V39, P1804; Tomarev SI, 2003, INVEST OPHTH VIS SCI, V44, P2588, DOI 10.1167/iovs.02-1099; Tomarev SI, 2001, NAT MED, V7, P294, DOI 10.1038/85432; Ueda J, 2002, INVEST OPHTH VIS SCI, V43, P1068; West KA, 2003, MOL CELL PROTEOMICS, V2, P37, DOI 10.1074/mcp.D200001-MCP200	36	113	125	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6080	6084		10.1074/jbc.M411233200	http://dx.doi.org/10.1074/jbc.M411233200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579465	Green Accepted, hybrid			2022-12-25	WOS:000227217100114
J	Houndolo, T; Boulay, PL; Claing, A				Houndolo, T; Boulay, PL; Claing, A			G protein-coupled receptor endocytosis in ADP-ribosylation factor 6-depleted cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; BETA(2)-ADRENERGIC RECEPTOR; PLASMA-MEMBRANE; BETA-ARRESTIN; DEPENDENT ENDOCYTOSIS; MEDIATED ENDOCYTOSIS; CLATHRIN ADAPTER; ARF6; INTERNALIZATION; DYNAMIN	The internalization of G protein-coupled receptors is regulated by several important proteins that act in concert to finely control this complex cellular process. Here, we have applied the RNA interference approach to demonstrate that ADP-ribosylation factor 6 (ARF6) is essential for the endocytosis of a broad variety of receptors. Reduction of endogenous expression of ARF6 in HEK 293 cells resulted in a correlated inhibition of the beta(2)-adrenergic receptor internalization previously characterized as being sequestered via the clathrin-coated vesicle pathway. Furthermore, other receptors internalizing via this endocytic route, namely the angiotensin type 1 receptor and the vasopressin type 2 receptor, were also impaired in their ability to be sequestered when levels of endogenous ARF6 in cells were reduced. Interestingly, endocytosis of the endothelin type B receptor, characterized as being internalized via the caveolae pathway, was also markedly inhibited in ARF6-depleted cells. In contrast, internalization of the vasoactive intestinal peptide receptor was unaffected by reduced levels of ARF6. Finally, internalization of the acetylcholine-muscarinic type 2 receptor via the non-clathrin-coated vesicle pathway was also inhibited in ARF6-depleted cells. Taken together, our results demonstrate that ARF6 proteins play an essential role in the internalization process of most G protein-coupled receptors regardless of the endocytic route being utilized. However, this phenomenon is not general. In some cases, another ARF isoform or other proteins may be essential to regulate the endocytic process.	Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Sch Med, Membrane Prot Study Grp, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Claing, A (corresponding author), Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.	audrey.claing@umontreal.ca						Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; CLAING A, 2002, J BIOL CHEM, V66, P61; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hashimoto S, 2004, J BIOL CHEM, V279, P37677, DOI 10.1074/jbc.M404196200; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HEIN L, 1994, J BIOL CHEM, V269, P27719; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Robertson DN, 2003, MOL PHARMACOL, V64, P1239, DOI 10.1124/mol.64.5.1239; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Song J, 1998, J CELL SCI, V111, P2257; Tong HY, 2004, CIRC RES, V94, P1133, DOI 10.1161/01.RES.0000126048.32383.6B; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	36	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5598	5604		10.1074/jbc.M411456200	http://dx.doi.org/10.1074/jbc.M411456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15590645	hybrid			2022-12-25	WOS:000227217100060
J	Liu, MJ; Ge, YB; Cabelof, DC; Aboukameel, A; Heydari, AR; Mohammad, R; Matherly, LH				Liu, MJ; Ge, YB; Cabelof, DC; Aboukameel, A; Heydari, AR; Mohammad, R; Matherly, LH			Structure and regulation of the murine reduced folate carrier gene - Identification of four noncoding exons and promoters and regulation by dietary folates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-ASSOCIATED PROTEIN-3; DNA METHYLATION; TRANSCRIPTIONAL REGULATION; METHOTREXATE SENSITIVITY; TRANSPORT-DEFICIENT; MEMBRANE-TRANSPORT; MULTIPLE PROMOTERS; FOLIC-ACID; KB CELLS; EXPRESSION	The upstream structure and regulation of the mouse reduced folate carrier (mRFC) gene was characterized. By 5'-rapid amplification of cDNA ends assay and DNA sequencing from mouse tissues and 7-15-day stage embryos, mRFC transcripts with four unique 5' noncoding exons, designated mRFC-a, -b, -c, and -d, were identified mapping over 6300 bp. The 5' noncoding exons were characterized by multiple transcription starts and, for form b, two alternate splice forms. mRFC transcript forms were measured by real-time reverse transcription-PCR in mouse tissues and embryos and in L1210 leukemia and BNL CL.2 liver cell lines. The highest mRFC levels were detected in kidney and brain. mRFC-b and -c were the major transcript forms, with low levels of mRFC-a and -d. The W-flanking regions for exons a-d each exhibited promoter activity in reporter gene assays. mRFC transcripts and individual noncoding exons were measured in small intestine and kidney from mice fed folate-deficient or -replete diets. Mice fed the folate-deficient diet exhibited a significant (13.8-fold) increase in total mRFC transcripts and protein in the small intestine, reflecting increases in each of the mRFC-b, -c, and -d forms. Only minor changes in mRFC transcript levels or distributions were detected for kidney. Levels of folate-binding protein a were also increased in both small intestine and kidney in folate-deficient mice (91- and 2-fold, respectively). Multidrug resistance-associated proteins 1 and 3 were, likewise, elevated in intestine from folate-deficient mice (53- and 168-fold, respectively); however, there were no significant changes in kidney. Our results document the existence of four unique noncoding exons and promoters for mRFC and demonstrate a facile induction of mRNAs for mRFC and multidrug resistance-associated proteins 1 and 3 in intestine in response to changes in dietary folate intake.	Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Matherly, LH (corresponding author), Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	matherly@karmanos.org		Ge, Yubin/0000-0002-8748-716X	NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Brigle KE, 1997, BBA-GENE STRUCT EXPR, V1353, P191, DOI 10.1016/S0167-4781(97)00082-1; Cabelof DC, 2004, J BIOL CHEM, V279, P36504, DOI 10.1074/jbc.M405185200; Chen ZS, 2002, CANCER RES, V62, P3144; Chu E., 1996, CANC CHEMOTHERAPY BI, P109; DIXON KH, 1994, J BIOL CHEM, V269, P17; Ferreri AJM, 2004, BRIT J HAEMATOL, V126, P657, DOI 10.1111/j.1365-2141.2004.05109.x; Flatley RM, 2004, CLIN CANCER RES, V10, P5111, DOI 10.1158/1078-0432.CCR-04-0116; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hooijberg JH, 1999, CANCER RES, V59, P2532; HSUEH CT, 1993, BIOCHEM PHARMACOL, V45, P2537; HSUEH CT, 1994, BIOCHEM PHARMACOL, V47, P1019, DOI 10.1016/0006-2952(94)90413-8; Jhaveri MS, 2001, MOL PHARMACOL, V60, P1288, DOI 10.1124/mol.60.6.1288; Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511; Liu MJ, 2004, BIOCHEM J, V383, P249, DOI 10.1042/BJ20040414; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; Maddox Dennis M, 2003, BMC Dev Biol, V3, P6, DOI 10.1186/1471-213X-3-6; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; MOSCOW JA, 1995, CANCER RES, V55, P3790; Payton Scott G., 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P1067; Payton SG, 2005, BBA-GENE STRUCT EXPR, V1727, P45, DOI 10.1016/j.bbaexp.2004.11.006; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Rost D, 2002, AM J PHYSIOL-GASTR L, V282, pG720, DOI 10.1152/ajpgi.00318.2001; Roy K, 1998, CANCER GENET CYTOGEN, V105, P29, DOI 10.1016/S0165-4608(98)00005-3; Sadasivan E, 2002, GENE, V291, P149, DOI 10.1016/S0378-1119(02)00591-7; Said HM, 1996, BBA-BIOMEMBRANES, V1281, P164, DOI 10.1016/0005-2736(96)00005-3; Said HM, 2000, AM J PHYSIOL-CELL PH, V279, pC1889, DOI 10.1152/ajpcell.2000.279.6.C1889; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Tolner B, 1997, GENE, V189, P1, DOI 10.1016/S0378-1119(96)00676-2; Tolner B, 1998, GENE, V211, P331, DOI 10.1016/S0378-1119(98)00123-1; Tolner B, 1999, GENE, V231, P163, DOI 10.1016/S0378-1119(99)00078-5; Turner FB, 2000, J BIOL CHEM, V275, P35960, DOI 10.1074/jbc.M005228200; Wang YH, 2001, BBA-BIOMEMBRANES, V1513, P49, DOI 10.1016/S0005-2736(01)00340-6; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; Whetstine JR, 2002, J BIOL CHEM, V277, P43873, DOI 10.1074/jbc.M208296200; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 2000, CANCER RES, V60, P4779; Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773; Zhang L, 1998, BBA-GENE STRUCT EXPR, V1442, P389, DOI 10.1016/S0167-4781(98)00168-7; Zhao RB, 2004, CLIN CANCER RES, V10, P718, DOI 10.1158/1078-0432.CCR-1066-03; Zhao RB, 2001, J BIOL CHEM, V276, P10224, DOI 10.1074/jbc.C000905200	49	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5588	5597		10.1074/jbc.M412662200	http://dx.doi.org/10.1074/jbc.M412662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15579899	hybrid			2022-12-25	WOS:000227217100059
J	Altafaj, X; Cheng, WJ; Esteve, E; Urbani, J; Grunwald, D; Sabatier, JM; Coronado, R; De Waard, M; Ronjat, M				Altafaj, X; Cheng, WJ; Esteve, E; Urbani, J; Grunwald, D; Sabatier, JM; Coronado, R; De Waard, M; Ronjat, M			Maurocalcine and domain A of the II-III loop of the dihydropyridine receptor Ca(v)1.1 subunit share common binding sites on the skeletal ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE; CHANNEL; REGIONS; IMPERATOXIN; ACTIVATION; AFFINITY	Maurocalcine is a scorpion venom toxin of 33 residues that bears a striking resemblance to the domain A of the dihydropyridine voltage-dependent calcium channel type 1.1 (Ca(v)1.1) subunit. This domain belongs to the II-III loop of Ca(v)1.1, which is implicated in excitation-contraction coupling. Besides the structural homology, maurocalcine also modulates RyR1 channel activity in a manner akin to a synthetic peptide of domain A. Because of these similarities, we hypothesized that maurocalcine and domain A may bind onto an identical region(s) of RyR1. Using a set of RyR1 fragments, we demonstrate that peptide A and maurocalcine bind onto two discrete RyR1 regions: fragments 3 and 7 encompassing residues 1021-1631 and 32013661, respectively. The binding onto fragment 7 is of greater importance and was thus further investigated. We found that the amino acid region 3351-3507 of RyR1 (fragment 7.2) is sufficient for these interactions. Proof that peptide A and maurocalcine bind onto the same site is provided by competition experiments in which binding of fragment 7.2 to peptide A is inhibited by preincubation with maurocalcine. Moreover, when expressed in COS-7 cells, RyR1 carrying a deletion of fragment 7 shows a loss of interaction with both peptide A and maurocalcine. At the functional level, this deletion abolishes the maurocalcine induced stimulation of [H-3]ryanodine binding onto microsomes of transfected COS-7 cells without affecting the caffeine and ATP responses.	INSERM, U607, DRDC, CEA Grenoble, F-38054 Grenoble 09, France; Univ Wisconsin, Dept Physiol, Sch Med, Madison, WI 53706 USA; CNRS, UMR 6560, Fac Med Nord, F-13916 Marseille 20, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Wisconsin System; University of Wisconsin Madison; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Ronjat, M (corresponding author), INSERM, U607, DRDC, CEA Grenoble, 17 Rue Martyrs, F-38054 Grenoble 09, France.	mronjat@cea.fr	Altafaj, Xavier/K-9257-2014; De Waard, Michel/G-7406-2014; ESTEVE, Eric/M-7490-2014	Altafaj, Xavier/0000-0002-7595-0647; De Waard, Michel/0000-0002-2782-9615; SABATIER, Jean-Marc/0000-0002-9040-5647; Brocard, Julie/0000-0001-9345-5191; Ronjat, Michel/0000-0002-9728-6425; ESTEVE, Eric/0000-0002-4548-9140				Arnaud N, 1997, GENE, V199, P149, DOI 10.1016/S0378-1119(97)00362-4; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; Chen L, 2003, J BIOL CHEM, V278, P16095, DOI 10.1074/jbc.M209501200; Cheng WJ, 2004, BIOPHYS J, V86, p220A; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Esteve E, 2003, J BIOL CHEM, V278, P37822, DOI 10.1074/jbc.M305798200; Green D, 2003, BIOCHEM J, V370, P517, DOI 10.1042/BJ20021488; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lee CW, 2004, BIOCHEM J, V377, P385, DOI 10.1042/BJ20031192; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARTY I, 1994, BIOCHEM J, V298, P743, DOI 10.1042/bj2980743; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MOSHBA A, 2000, PROTEIN-STRUCT FUNCT, V40, P436; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Perez CF, 2003, J BIOL CHEM, V278, P39644, DOI 10.1074/jbc.M305160200; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wagenknecht T, 2002, FRONT BIOSCI, V7, pD1464, DOI 10.2741/wagen	26	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4013	4016		10.1074/jbc.C400433200	http://dx.doi.org/10.1074/jbc.C400433200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15591063	hybrid, Green Submitted, Green Accepted			2022-12-25	WOS:000227096600003
J	Goetzman, ES; Mohsen, AWA; Prasad, K; Vockley, J				Goetzman, ES; Mohsen, AWA; Prasad, K; Vockley, J			Convergent evolution of a 2-methylbutyryl-CoA dehydrogenase from isovaleryl-CoA dehydrogenase in Solanum tuberosum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; SUBSTRATE-SPECIFICITY; ARABIDOPSIS MUTANT; VALINE CATABOLISM; CATALYTIC RESIDUE; IDENTIFICATION; DEFICIENCY; CLONING; GENE; PURIFICATION	The potato cDNAs Solanum tuberosum isovaleryl-CoA dehydrogenases 1 and 2 (St-IVD1 and St-IVD2) encode proteins that are 84% identical to each other and 65 and 64% identical to human IVD, respectively. St-IVD2 protein was previously partially purified from potato tubers and confirmed to be an IVD. The function of St-IVD1 is unknown. In these experiments, both proteins were expressed in Escherichia coli and purified as intact homotetramers. The substrate preference profile of the St-IVD2 protein was similar to that of human IVD. However, recombinant St-IVD1 had maximal activity with 2-methylbutyryl-CoA, which in humans is dehydrogenated by short/branched-chain acyl-CoA dehydrogenase (SBCAD). Whereas molecular modeling predicts that the 2-methylbutyryl-CoA dehydrogenase (2MBCD) and IVD substrate binding pockets are nearly identical, 2MBCD has amino acid substitutions at five residues that are invariant among all of the known and putative IVDs. Site-directed mutagenesis was used to match the human IVD active site with that of potato 2MBCD. The resulting mutant IVD had detectable activity with 2-methylbutyryl-CoA and no activity with isovaleryl-CoA. The 2MBCD active site was compared with that of human SBCAD using molecular modeling. Residues Met-361 and Ala-365 of 2MBCD appear to partially substitute for the function of Tyr-380 in human SBCAD, binding the methyl branch linked to C-2 of 2-methylbutyryl-CoA, whereas residues Val-88, Val-92, and Val-96 appear to bind the distal C-4 methyl group. The presence of a 2MBCD in potato that is highly homologous to IVD is an example of convergent evolution within the acyl-CoA dehydrogenase family, leading to the independent occurrence of two enzymes (SBCAD and 2MBCD) specific for 2-methylbutyryl-CoA.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vockley, J (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, 3705 5th Ave, Pittsburgh, PA 15213 USA.	gerard.vockley@chp.edu	Vockley, Jerry/AAF-8523-2020; Mohsen, Al-Walid/D-6577-2018; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Mohsen, Al-Walid/0000-0002-0096-5959; Vockley, Jerry/0000-0002-8180-6457	NIDDK NIH HHS [R01 DK45482] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045482] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andresen BS, 2000, AM J HUM GENET, V67, P1095, DOI 10.1086/303105; Battaile KP, 2002, J BIOL CHEM, V277, P12200, DOI 10.1074/jbc.M111296200; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3922, DOI 10.1021/bi00336a017; Binzak B, 1998, BBA-PROTEIN STRUCT M, V1382, P137, DOI 10.1016/S0167-4838(97)00161-1; Daschner K, 2001, PLANT PHYSIOL, V126, P601, DOI 10.1104/pp.126.2.601; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Faivre-Nitschke SE, 2001, EUR J BIOCHEM, V268, P1332, DOI 10.1046/j.1432-1327.2001.01999.x; Fu ZJ, 2004, BIOCHEMISTRY-US, V43, P9674, DOI 10.1021/bi049290c; Gibson KM, 2000, PEDIATR RES, V47, P830, DOI 10.1203/00006450-200006000-00025; He M, 2003, J BIOL CHEM, V278, P37974, DOI 10.1074/jbc.M306882200; Kim JJP, 2004, EUR J BIOCHEM, V271, P483, DOI 10.1046/j.1432-1033.2003.03948.x; Lange PR, 2004, FEBS LETT, V571, P147, DOI 10.1016/j.febslet.2004.06.071; Matern D, 2003, PEDIATRICS, V112, P74, DOI 10.1542/peds.112.1.74; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P10146, DOI 10.1021/bi00032a007; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; Mohsen AWA, 2001, MOL GENET METAB, V73, P126, DOI 10.1006/mgme.2001.3183; Nguyen TV, 2002, MOL GENET METAB, V77, P68, DOI 10.1016/S1096-7192(02)00152-X; Reinard T, 2000, J BIOL CHEM, V275, P33738, DOI 10.1074/jbc.M004178200; ROZEN R, 1994, GENOMICS, V24, P280, DOI 10.1006/geno.1994.1617; Sweetman L., 2001, METABOLIC MOL BASES, P2125; Taylor NL, 2004, PLANT PHYSIOL, V134, P838, DOI 10.1104/pp.103.035675; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; Vockley J, 2000, AM J HUM GENET, V66, P356, DOI 10.1086/302751; WILLIAMSON G, 1982, J BIOL CHEM, V257, P4314; Zhang J, 2002, BIOCHEM BIOPH RES CO, V297, P1033, DOI 10.1016/S0006-291X(02)02336-7; Zolman BK, 2001, J BIOL CHEM, V276, P31037, DOI 10.1074/jbc.M104679200	28	11	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4873	4879		10.1074/jbc.M412640200	http://dx.doi.org/10.1074/jbc.M412640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15574432	hybrid			2022-12-25	WOS:000227096600107
J	Tefsen, B; Geurtsen, J; Beckers, F; Tommassen, J; de Cock, H				Tefsen, B; Geurtsen, J; Beckers, F; Tommassen, J; de Cock, H			Lipopolysaccharide transport to the bacterial outer membrane in spheroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SIGNAL SEQUENCE; PROTEIN; MSBA; EXPORT; LOCALIZATION; MECHANISM; LIPOPROTEINS; SURFACE	The mechanism of lipopolysaccharide (LPS) transport in Gram-negative bacteria from the inner membrane to the outer membrane is largely unknown. Here, we investigated the possibility that LPS transport proceeds via a soluble intermediate associated with a periplasmic chaperone analogous to the Lol-dependent transport mechanism of lipoproteins. Whereas newly synthesized lipoproteins could be released from spheroplasts of Escherichia coli upon addition of a periplasmic extract containing Lo1A, de novo synthesized LPS was not released. We demonstrate that LPS synthesized de novo in spheroplasts co-fractionated with the outer membranes and that this co-fractionation was dependent on the presence in the spheroplasts of a functional MsbA protein, the protein responsible for the flip-flop of LPS across the inner membrane. The outer membrane localization of the LPS was confirmed by its modification by the outer membrane enzyme CrcA (PagP). We conclude that a substantial amount of LPS was translocated to the outer membrane in spheroplasts, suggesting that transport proceeds via contact sites between the two membranes. In contrast to LPS, de novo synthesized phospholipids were not transported to the outer membrane in spheroplasts. Apparently, LPS and phospholipids have different requirements for their transport to the outer membrane.	Univ Utrecht, Dept Mol Microbiol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	de Cock, H (corresponding author), Univ Utrecht, Dept Mol Microbiol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	J.J.P.A.deCock@bio.uu.nl	de Cock, Hans/B-7790-2011; Tommassen, Jan/I-1690-2016; Tefsen, Boris/J-1503-2012	de Cock, Hans/0000-0002-8420-6764; Tommassen, Jan/0000-0001-7633-4945; Tefsen, Boris/0000-0001-6668-217X				BAYER ME, 1968, J GEN MICROBIOL, V53, P395, DOI 10.1099/00221287-53-3-395; BIRDSELL DC, 1967, J BACTERIOL, V93, P427, DOI 10.1128/JB.93.1.427-437.1967; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bos MP, 2004, P NATL ACAD SCI USA, V101, P9417, DOI 10.1073/pnas.0402340101; BOSCH D, 1989, BIOCHIM BIOPHYS ACTA, V979, P69, DOI 10.1016/0005-2736(89)90524-5; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; COLEMAN WG, 1977, J BACTERIOL, V130, P656, DOI 10.1128/JB.130.2.656-660.1977; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Foster RG, 2003, J NEUROENDOCRINOL, V15, P355, DOI 10.1046/j.1365-2826.2003.01004.x; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; JANN K, 1965, BIOCHEM Z, V342, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUGTENBERG B, 1976, MOL GEN GENET, V147, P251, DOI 10.1007/BF00582876; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; MUHLRADT PF, 1973, EUR J BIOCHEM, V35, P471, DOI 10.1111/j.1432-1033.1973.tb02861.x; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VANALPHEN L, 1978, J BACTERIOL, V134, P1089, DOI 10.1128/JB.134.3.1089-1098.1978; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	38	72	72	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4504	4509		10.1074/jbc.M409259200	http://dx.doi.org/10.1074/jbc.M409259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15576375	Green Published, hybrid			2022-12-25	WOS:000227096600063
J	Haskew-Layton, RE; Mongin, AA; Kimelberg, HK				Haskew-Layton, RE; Mongin, AA; Kimelberg, HK			Hydrogen peroxide potentiates volume-sensitive excitatory amino acid release via a mechanism involving Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY ASTROCYTE CULTURES; CEREBRAL-ARTERY OCCLUSION; REGULATED ANION CHANNELS; NIH3T3 MOUSE FIBROBLASTS; TYROSINE PHOSPHORYLATION; CELL-VOLUME; GLIAL-CELLS; RAT-BRAIN; CEREBELLAR ASTROCYTES; CYTOSOLIC CALCIUM	Excessive excitatory amino acid (EAA) release in cerebral ischemia is a major mechanism responsible for neuronal damage and death. A substantial fraction of ischemic EAA release occurs via volume-regulated anion channels (VRACs). Hydrogen peroxide (H2O2), which is abundantly produced during ischemia and reperfusion, activates a number of protein kinases critical for VRAC functioning and has recently been reported to activate VRACs. In the present study, we explored the effects of H2O2 on volume-dependent EAA release in cultured astrocytes, measured as the release of preloaded D-[H-3]aspartate. 100-1,000 mum H2O2 enhanced swelling-induced EAA release by similar to2.5-3-fold (EC50 approximate to 10 mum). The VRAC blockers ATP, phloretin, and 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB) potently inhibited both control swelling-induced and the H2O2-potentiated release, suggesting a role for VRACs. The H2O2-induced component of EAA release was attenuated by the Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester (BAPTA-AM) and completely eliminated by the calmodulin antagonists trifluoperazine and W-7 and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93. Inhibitors of tyrosine kinases, protein kinase C, and the myosin light chain kinase were ineffective in blocking the H2O2 response. H2O2 treatment of swollen astrocytes, but not swelling alone, resulted in CaMKII activation that was inhibited by KN-93, as determined by a phospho-Thr286 CaMKII antibody. These data demonstrate that H2O2 strongly up-regulates astrocytic volume-sensitive EAA release via a CaMKII-dependent mechanism and in this way may potently promote pathological EAA release and brain damage in ischemia.	Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Ctr Med Sci, Ordway Res Inst, Albany, NY 12208 USA	Albany Medical College; Ordway Research Institute	Mongin, AA (corresponding author), 47 New Scotland Ave,MC-136, Albany, NY 12208 USA.	mongina@maill.amc.edu	Mongin, Alexander A./A-5526-2008	Mongin, Alexander A./0000-0002-2501-3778	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035205, F31NS046961] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS35205, R01 NS035205, F31-NS46961, F31 NS046961] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; Cardin V, 2003, GLIA, V44, P119, DOI 10.1002/glia.10271; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Crepel V, 1998, J NEUROSCI, V18, P1196; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Deleuze C, 2000, J PHYSIOL-LONDON, V523, P291, DOI 10.1111/j.1469-7793.2000.t01-2-00291.x; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DOAN TN, 1994, BIOCHEM J, V297, P209, DOI 10.1042/bj2970209; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Evanko DS, 2004, GLIA, V47, P233, DOI 10.1002/glia.20050; Fan HT, 2001, BRIT J PHARMACOL, V133, P1096, DOI 10.1038/sj.bjp.0704159; Feustel PJ, 2004, STROKE, V35, P1164, DOI 10.1161/01.STR.0000124127.57946.a1; FRANGAKIS MV, 1984, NEUROCHEM RES, V9, P1689, DOI 10.1007/BF00968079; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Haskew RE, 2002, J NEUROCHEM, V82, P903, DOI 10.1046/j.1471-4159.2002.01037.x; Hermoso M, 2004, J BIOL CHEM, V279, P17681, DOI 10.1074/jbc.M304506200; HIDAKA H, 1981, MOL PHARMACOL, V20, P571; Howe CJ, 2002, J BIOL CHEM, V277, P30469, DOI 10.1074/jbc.M205036200; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Junankar PR, 2002, J BIOL CHEM, V277, P40324, DOI 10.1074/jbc.M204712200; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; Kimelberg HK, 2003, J NEUROSURG, V99, P138, DOI 10.3171/jns.2003.99.1.0138; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kimelberg HK, 2000, NEUROREPORT, V11, P2675, DOI 10.1097/00001756-200008210-00014; KIMELBERG HK, 1993, BRAIN RES, V622, P237, DOI 10.1016/0006-8993(93)90824-7; KINDY MS, 1993, J CEREBR BLOOD F MET, V13, P372, DOI 10.1038/jcbfm.1993.50; Kirk K, 1998, ANNU REV PHYSIOL, V60, P719, DOI 10.1146/annurev.physiol.60.1.719; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Lambert IH, 2003, J MEMBRANE BIOL, V192, P19, DOI 10.1007/s00232-002-1061-1; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lepple-Wienhues A, 2001, FASEB J, V15, P927, DOI 10.1096/fj.00-0264com; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; Liu KF, 2001, STROKE, V32, P1897, DOI 10.1161/01.STR.32.8.1897; Loveday D, 2003, J NEUROCHEM, V87, P476, DOI 10.1046/j.1471-4159.2003.02021.x; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; Matsumoto S, 2004, J CEREBR BLOOD F MET, V24, P54, DOI 10.1097/01.WCB.0000095920.70924.F5; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Mongin AA, 2005, AM J PHYSIOL-CELL PH, V288, pC204, DOI 10.1152/ajpcell.00330.2004; Mongin AA, 2002, AM J PHYSIOL-CELL PH, V283, pC569, DOI 10.1152/ajpcell.00438.2001; Mongin AA, 1999, AM J PHYSIOL-CELL PH, V277, pC823, DOI 10.1152/ajpcell.1999.277.4.C823; MONGIN AA, 2005, NEUROGLIA, P550; Morales-Mulia S, 1998, J NEUROCHEM, V71, P2330; Nilius B, 2000, FEBS LETT, V466, P346, DOI 10.1016/S0014-5793(00)01097-8; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PASANTESMORALES H, 1994, AM J PHYSIOL, V266, pC172, DOI 10.1152/ajpcell.1994.266.1.C172; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Pedersen SF, 2002, J PHYSIOL-LONDON, V541, P779, DOI 10.1113/jphysiol.2002.018887; Peuchen S, 1997, PROG NEUROBIOL, V52, P261, DOI 10.1016/S0301-0082(97)00010-5; Phillis JW, 1998, BRAIN RES, V780, P352, DOI 10.1016/S0006-8993(97)01352-8; Phillis JW, 1997, BRAIN RES, V758, P9, DOI 10.1016/S0006-8993(97)00155-8; ROBSON L, 1994, J PHYSIOL-LONDON, V480, P1; ROY G, 1995, J MEMBRANE BIOL, V147, P35; Rutledge EM, 1996, J NEUROSCI, V16, P7803; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shimizu T, 2004, P NATL ACAD SCI USA, V101, P6770, DOI 10.1073/pnas.0401604101; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Takagi N, 1997, J NEUROCHEM, V69, P1060; TILLY BC, 1993, J BIOL CHEM, V268, P19919; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; van der Wijk T, 1999, BIOCHEM J, V343, P579, DOI 10.1042/0264-6021:3430579; Varela D, 2004, J BIOL CHEM, V279, P13301, DOI 10.1074/jbc.C400020200; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zhao Y, 1998, J CELL PHYSIOL, V174, P370, DOI 10.1002/(SICI)1097-4652(199803)174:3<370::AID-JCP11>3.0.CO;2-D	80	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3548	3554		10.1074/jbc.M409803200	http://dx.doi.org/10.1074/jbc.M409803200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15569671	hybrid			2022-12-25	WOS:000226983900052
J	Mun, HC; Franks, AH; Culverston, EL; Krapcho, K; Nemeth, EF; Conigrave, AD				Mun, HC; Franks, AH; Culverston, EL; Krapcho, K; Nemeth, EF; Conigrave, AD			The Venus fly trap domain of the extracellular Ca2+-sensing receptor is required for L-amino acid sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; METABOTROPIC GLUTAMATE-RECEPTOR; CALCIMIMETIC COMPOUND; TRANSMEMBRANE DOMAIN; ACTIVATING MUTATIONS; STRUCTURAL BASIS; RECOGNITION	We previously demonstrated that the human calcium-sensing receptor (CaR) is allosterically activated by L-amino acids (Conigrave, A. D., Quinn, S. J., and Brown, E. M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4814-4819). However, the domain-based location of amino acid binding has been uncertain. We now show that the Venus Fly Trap (VFT) domain of CaR, but none of its other major domains, is required for amino acid sensing. Several constructs were informative when expressed in HEK293 cells. First, the wild-type CaR exhibited allosteric activation by L-amino acids as previously observed. Second, two CaR-mGlu chimeric receptor constructs that retained the VFT domain of CaR, one containing the extracellular Cys-rich region of CaR and the other containing the Cys-rich region of the rat metabotropic glutamate type-1 (mGlu-1) receptor, together with the rat mGlu-1 transmembrane region and C-terminal tail, retained amino acid sensing. Third, a CaR lacking residues 1-599 of the N-terminal extracellular head but retaining an intact CaR transmembrane region and a functional but truncated C terminus (headless-T903 CaR) failed to respond to L-amino acids but retained responsiveness to the type-II calcimimetic NPS R-467. Finally, a T903 CaR control that retained an intact N terminus also retained L-amino acid sensing. Taken together, the data indicate that the VFT domain of CaR is necessary for L-amino acid sensing and are consistent with the hypothesis that the VFT domain is the site of L-amino acid binding. The findings support the concept that the mGlu-1 amino acid binding site for L-glutamate is conserved as an L-amino acid binding site in its homolog, the CaR.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; NPS Pharmaceut, Salt Lake City, UT 84108 USA	University of Sydney	Conigrave, AD (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.	a.conigrave@mmb.usyd.edu.au		Conigrave, Arthur/0000-0002-7232-3891				Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bradbury RA, 1996, J ENDOCRINOL, V149, P135, DOI 10.1677/joe.0.1490135; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Kuang DH, 2003, J BIOL CHEM, V278, P42551, DOI 10.1074/jbc.M307120200; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Tan YM, 2003, J CLIN ENDOCR METAB, V88, P605, DOI 10.1210/jc.2002-020081; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2002, J BIOL CHEM, V277, P33736, DOI 10.1074/jbc.M200978200; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	21	83	87	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51739	51744		10.1074/jbc.M406164/200	http://dx.doi.org/10.1074/jbc.M406164/200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15579475	Bronze			2022-12-25	WOS:000225493400005
J	Wang, X; Zhang, JL; Kim, HP; Wang, Y; Choi, AMK; Ryter, SW				Wang, X; Zhang, JL; Kim, HP; Wang, Y; Choi, AMK; Ryter, SW			Bcl-XL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation	FASEB JOURNAL			English	Article						caspase-8; DISC; hypoxia; reoxygenation	CYTOCHROME-C RELEASE; CELL-DEATH; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; MITOCHONDRIAL-MEMBRANE; FAMILY PROTEINS; GOLGI-COMPLEX; UP-REGULATION; BH3 DOMAIN; BAX	Hypoxia/reoxygenation (H/R) causes cellular injury and death. The cell death pathways induced by H/R remain incompletely understood. H/R can induce Bid and Bax mitochondrial translocation and cytochrome c release. Using mouse lung endothelial cells (MLEC), we examined the role of Bcl-X-L, an anti-apoptotic Bcl-2-related protein, in H/R-induced cell death. The expression of Bcl-X-L protected MLEC against H/R-induced cell death by blocking Bax and Bid translocation and inhibiting mitochondrial cytochrome c release. Bcl-X-L expression inhibited caspase-8 cleavage and death-inducing signal complex (DISC) formation in plasma membrane. By isolating mitochondrial, nuclear, and Golgi fractions, we found that H/ R induced DISC formation in these organelles. Bcl-X-L expression inhibited DISC formation in the nuclear and Golgi fractions relative to LacZ-infected controls. In contrast, DISC formation was elevated in the mitochondrial fraction of Bcl-X-L-infected cells. GRASP65, a Golgi-associated protein, physically associated with Fas and caspase-8; Bcl-X-L expression decreased these associations. Bcl-X-L expression also up-regulated FLIP, a caspase-8 inhibitor. In conclusion, Bcl-X-L may inactivate caspase-8 by decreasing DISC formation in the plasma membrane, nucleus, and Golgi complex while diverting DISC formation to the mitochondria. The inhibitory effects of Bcl-X-L on DISC formation may play significant roles in protecting endothelial cells from H/R-induced cell death.	Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ryter, SW (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, 3435 5th Ave,MUN NW 628, Pittsburgh, PA 15213 USA.	Ryters@upmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R01HL060234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL60234, R01-HL55330] Funding Source: Medline; NIAID NIH HHS [R01-AI42365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], [No title captured]; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Brunelle JK, 2002, APOPTOSIS, V7, P475, DOI 10.1023/A:1020668923852; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Cao XX, 2002, MOL MED, V8, P869, DOI 10.1007/BF03402093; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clerici C, 2000, J APPL PHYSIOL, V88, P1890, DOI 10.1152/jappl.2000.88.5.1890; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gollapudi S, 2003, INT J ONCOL, V22, P597; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Haynes AP, 2002, BRIT J HAEMATOL, V118, P488, DOI 10.1046/j.1365-2141.2002.03643.x; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Igbavboa U, 2003, J BIOL CHEM, V278, P17150, DOI 10.1074/jbc.M301150200; Jeremias I, 2000, CIRCULATION, V102, P915; Jiang JG, 2001, J BIOL CHEM, V276, P25049, DOI 10.1074/jbc.M101611200; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim HP, 2004, FASEB J, V18, P1080, DOI 10.1096/fj.03-1391com; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Plesnila N, 2002, EUR SURG RES, V34, P37, DOI 10.1159/000048885; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Tang ZL, 2002, MOL CELL BIOCHEM, V234, P211, DOI 10.1023/A:1015930927407; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Wang X, 2004, J BIOL CHEM, V279, P5237, DOI 10.1074/jbc.M309271200; Wu CR, 2003, STROKE, V34, P1803, DOI 10.1161/01.STR.0000077255.15597.69; YANG J, 1997, SCIENCE, V275, P1132; Yoshimura S, 2001, J CELL SCI, V114, P4105	42	35	46	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2004	18	15					1826	1833		10.1096/fj.04-2047com	http://dx.doi.org/10.1096/fj.04-2047com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	884MZ	15576486				2022-12-25	WOS:000226091000033
J	Vaaje-Kolstad, G; Houston, DR; Riemen, AHK; Eijsink, VGH; van Aalten, DMF				Vaaje-Kolstad, G; Houston, DR; Riemen, AHK; Eijsink, VGH; van Aalten, DMF			Crystal structure and binding properties of the Serratia marcescens chitin-binding protein CBP21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHITIN; CELLULOSE; DOMAIN; MECHANISM; HYDROLYSIS; ALIGNMENT; RESIDUES; SYSTEM; CHB1; GENE	Chitin proteins are commonly found in bacteria that utilize chitin as a source of energy. CBP21 is a chitin-binding protein from Serratia marcescens, a Gram-negative soil bacterium capable of efficient chitin degradation. When grown on chitin, S. marcescens secretes large amounts of CBP21, along with chitin-degrading enzymes. In an attempt to understand the molecular mechanism of CBP21 action, we have determined its crystal structure at 1.55 resolution. This is the first structure to be solved of a family 33 carbohydrate-binding module. The structure reveals a "budded" fibronectin type III fold consisting of two beta-sheets, arranged as a beta-sheet sandwich, with a 65-residue "bud" consisting of three short helices, located between beta-strands 1 and 2. Remarkably, conserved aromatic residues that have been suggested previously to play a role in chitin binding were mainly found in the interior of the protein, seemingly incapable of interacting with chitin, whereas the structure revealed a surface patch of highly conserved, mainly hydrophilic residues. The roles of six of these conserved surface-exposed residues (Tyr-54, Glu-55, Glu-60, His-114, Asp-182, and Asn-185) were probed by site-directed mutagenesis and subsequent binding studies. All single point mutations lowered the affinity of CBP21 for beta-chitin, as shown by 3-8-fold increases in the apparent binding constant. Thus, binding of CBP21 to chitin seems to be mediated primarily by conserved, solvent-exposed, polar side chains.	Agr Univ Norway, Dept Chem Biotechnol & Food Sci, N-1432 As, Norway; Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	Norwegian University of Life Sciences; University of Dundee	van Aalten, DMF (corresponding author), Agr Univ Norway, Dept Chem Biotechnol & Food Sci, Postbox 5003, N-1432 As, Norway.	dava@davapc1.bioch.dundee.ac.uk		Riemen, Anna/0000-0003-3082-6981; van Aalten, Daan/0000-0002-1499-6908; Houston, Douglas/0000-0002-3469-1546				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; BLACKWELL J, 1988, METHOD ENZYMOL, V161, P435; Bond CS, 2003, BIOINFORMATICS, V19, P311, DOI 10.1093/bioinformatics/19.2.311; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRURBERG MB, 1995, MICROBIOL-SGM, V141, P123, DOI 10.1099/00221287-141-1-123; Carrard G, 2000, P NATL ACAD SCI USA, V97, P10342, DOI 10.1073/pnas.160216697; Chang MC, 2004, FEMS MICROBIOL LETT, V232, P61, DOI 10.1016/S0378-1097(04)00014-X; Chu HH, 2001, MICROBIOL-SGM, V147, P1793, DOI 10.1099/00221287-147-7-1793; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Flint J, 2004, J MOL BIOL, V337, P417, DOI 10.1016/j.jmb.2003.12.081; Folders J, 2000, J BACTERIOL, V182, P1257, DOI 10.1128/JB.182.5.1257-1263.2000; Gal L, 1997, APPL ENVIRON MICROB, V63, P903, DOI 10.1128/AEM.63.3.903-909.1997; GOLDSTEIN MA, 1993, J BACTERIOL, V175, P5762, DOI 10.1128/JB.175.18.5762-5768.1993; Hashimoto M, 2000, J BACTERIOL, V182, P3045, DOI 10.1128/JB.182.11.3045-3054.2000; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jee JG, 2002, J BIOL CHEM, V277, P1388, DOI 10.1074/jbc.M109726200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolbe S, 1998, MICROBIOL-SGM, V144, P1291, DOI 10.1099/00221287-144-5-1291; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehtio J, 2003, P NATL ACAD SCI USA, V100, P484, DOI 10.1073/pnas.212651999; Li ZF, 2003, VIRUS RES, V96, P113, DOI 10.1016/S0168-1702(03)00179-5; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; McLean BW, 2002, J BIOL CHEM, V277, P50245, DOI 10.1074/jbc.M204433200; MONREAL J, 1969, CAN J MICROBIOL, V15, P689, DOI 10.1139/m69-122; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; SCHNELLMANN J, 1994, MOL MICROBIOL, V13, P807, DOI 10.1111/j.1365-2958.1994.tb00473.x; Sheweita SA, 1996, GENE, V182, P163, DOI 10.1016/S0378-1119(96)00544-6; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; Suzuki K, 2002, BIOSCI BIOTECH BIOCH, V66, P1075, DOI 10.1271/bbb.66.1075; Suzuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P338, DOI 10.1271/bbb.65.338; Suzuki K, 1998, BIOSCI BIOTECH BIOCH, V62, P128, DOI 10.1271/bbb.62.128; Svergun DI, 2000, BIOCHEMISTRY-US, V39, P10677, DOI 10.1021/bi000865p; Synstad B, 2004, EUR J BIOCHEM, V271, P253, DOI 10.1046/j.1432-1033.2003.03923.x; Techkarnjanaruk S, 1999, MICROBIOL-SGM, V145, P925, DOI 10.1099/13500872-145-4-925; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Uchiyama T, 2001, J BIOL CHEM, V276, P41343, DOI 10.1074/jbc.M103610200; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Watanabe T, 1997, J BACTERIOL, V179, P7111, DOI 10.1128/jb.179.22.7111-7117.1997; Zeltins A, 1997, EUR J BIOCHEM, V246, P557, DOI 10.1111/j.1432-1033.1997.t01-1-00557.x	49	208	218	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11313	11319		10.1074/jbc.M407175200	http://dx.doi.org/10.1074/jbc.M407175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15590674	hybrid			2022-12-25	WOS:000227761800052
J	Quan, TH; He, TY; Voorhees, JJ; Fisher, GJ				Quan, TH; He, TY; Voorhees, JJ; Fisher, GJ			Ultraviolet irradiation induces SMAD7 via induction of transcription factor AP-1 in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PHOTOAGED HUMAN SKIN; TGF-BETA; IN-VIVO; BINDING-ELEMENT; NUCLEAR EXPORT; RETINOIC ACID; CELL-MEMBRANE; KEY PLAYER; C-JUN	Smad7 functions as an endogenous negative regulator of transforming growth factor-beta (TGF-beta)/SMAD signaling. The TGF-beta/SMAD pathway is a major regulator of collagen production in connective tissue. Reduced expression of SMAD7 has been reported in TGF-beta-mediated fibrotic diseases, characterized by overproduction of collagen. Solar ultraviolet (UV) irradiation reduces collagen production by fibroblasts in human skin in vivo. We have investigated regulation of Smad7 gene expression by UV irradiation in human skin fibroblasts. UV irradiation transiently increased SMAD7 mRNA and protein levels. Induction of SMAD7 mRNA and protein was maximal within 5 h and returned to initial basal levels 24 h post-UV irradiation. UV irradiation induced Smad7 promoter-reporter activity 3-fold. The Smad7 promoter contains functional enhancer sequences that bind transcription factors SMAD3 and activator protein-1 (AP-1). UV irradiation reduced protein binding to the Smad3 enhancer and increased binding to the AP-1 enhancer. Deletion of the AP-1 binding site in the Smad7 promoter completely abolished UV stimulation of SMAD7 transcription. Deletion of the Smad3 element had no effect on UV irradiation-induced promoter activity. UV irradiation increased mRNA and protein expression of the AP-1 family members, c-Jun and c-Fos, which bound to the AP-1 element in the Smad7 promoter. Furthermore, overexpression of dominant negative c-Jun substantially reduced UV irradiation induction of SMAD7 transcription. These data demonstrate that induction of Smad7 gene expression by UV irradiation is mediated via induction of the transcription factor AP-1 in human skin fibroblasts.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, 1150 W Med Ctr,Med Sch 1,Rm 6447, Ann Arbor, MI 48109 USA.	dianemch@umich.edu		Quan, Taihao/0000-0002-0954-5109	NIA NIH HHS [AG19364-02, R01 AG019364-05, R01 AG019364] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019364] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; BROWN PH, 1994, ONCOGENE, V9, P791; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fiocchi C, 2001, J CLIN INVEST, V108, P523, DOI 10.1172/JCI13863; Fisher G J, 1998, J Investig Dermatol Symp Proc, V3, P61; Fisher GJ, 2000, J CLIN INVEST, V106, P663, DOI 10.1172/JCI9362; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; Fisher GJ, 2002, J INVEST DERMATOL, V119, P723; Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; GRIFFITHS CEM, 1993, NEW ENGL J MED, V329, P530, DOI 10.1056/NEJM199308193290803; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; He W, 2002, EMBO J, V21, P2580, DOI 10.1093/emboj/21.11.2580; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; PITTELKOW MR, 1988, ANN NY ACAD SCI, V548, P211, DOI 10.1111/j.1749-6632.1988.tb18809.x; Quan T, 2002, J INVEST DERMATOL, V119, P499, DOI 10.1046/j.1523-1747.2002.01834.x; Quan TH, 2004, AM J PATHOL, V165, P741, DOI 10.1016/S0002-9440(10)63337-8; Quan TH, 2002, J INVEST DERMATOL, V118, P402, DOI 10.1046/j.0022-202x.2001.01678.x; Quan TH, 2001, J BIOL CHEM, V276, P26349, DOI 10.1074/jbc.M010835200; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840	49	69	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8079	8085		10.1074/jbc.M409647200	http://dx.doi.org/10.1074/jbc.M409647200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15579469	Green Accepted, hybrid			2022-12-25	WOS:000227395700078
J	Angenstein, F; Evans, AM; Ling, SC; Settlage, RE; Ficarro, S; Carrero-Martinez, FA; Shabanowitz, J; Hunt, DF; Greenough, WT				Angenstein, F; Evans, AM; Ling, SC; Settlage, RE; Ficarro, S; Carrero-Martinez, FA; Shabanowitz, J; Hunt, DF; Greenough, WT			Proteomic characterization of messenger ribonucleoprotein complexes bound to nontranslated or translated poly(A) mRNAs in the rat cerebral cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC PROTEIN-SYNTHESIS; BINDING-PROTEIN; PUR-ALPHA; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CYTOPLASMIC POLYADENYLATION; FUSION PROTEINS; WD-REPEAT; KINASE; IDENTIFICATION; RECEPTOR	Receptor-triggered control of local postsynaptic protein synthesis plays a crucial role for enabling long lasting changes in synaptic functions, but signaling pathways that link receptor stimulation with translational control remain poorly known. Among the putative regulatory factors are mRNA-binding proteins (messenger ribonucleoprotein, mRNP), which control the fate of cytosolic localized mRNAs. Based on the assumption that a subset of mRNA is maintained in an inactive state, mRNP-mRNA complexes were separated into polysome-bound (translated) and polysome-free (nontranslated) fractions by sucrose density centrifugation. Poly(A) mRNA-mRNP complexes were purified from a postmitochondrial extract of rat cerebral cortex by oligo(dT)-cellulose affinity chromatography. The mRNA processing proteins were characterized, from solution, by a nanoflow reverse phase-high pressure liquid chromatography-mu-electrospray ionization mass spectrometry. The majority of detected mRNA-binding proteins was found in both fractions. However, a small number of proteins appeared to be fraction-specific. This subset of proteins is by far the most interesting because the proteins are potentially involved in controlling an activity-dependent onset of translation. They include transducer proteins, kinases, and anchor proteins. This study of the mRNP proteome is the first step in allowing future experimentation to characterize individual proteins responsible for mRNA processing and translation in dendrites.	Univ Illinois, Beckman Inst Neuronal Pattern Anal, Urbana, IL 61801 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Limited Liabil Corp, Proteo MS, Charlottesville, VA 22903 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Virginia; University of Virginia	Angenstein, F (corresponding author), Univ Illinois, Beckman Inst Neuronal Pattern Anal, Urbana, IL 61801 USA.	angenstein@ifn-magdeburg.de	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; LING, Shuo-Chien/0000-0002-0300-8812	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Angenstein F, 2002, J NEUROSCI, V22, P8827; Archibald JM, 2003, J MOL BIOL, V328, P771, DOI 10.1016/S0022-2836(03)00374-7; Baum S, 2004, BIOCHEM J, V380, P823, DOI 10.1042/BJ20031962; Belyanskaya LL, 2003, EXP CELL RES, V288, P374, DOI 10.1016/S0014-4827(03)00221-0; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chansky HA, 2001, CANCER RES, V61, P3586; Chen CYA, 2003, MOL CELL BIOL, V23, P4805, DOI 10.1128/MCB.23.14.4805-4813.2003; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; Dass B, 2001, BIOL REPROD, V64, P1722, DOI 10.1095/biolreprod64.6.1722; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Dollenmaier G, 2003, J GEN VIROL, V84, P403, DOI 10.1099/VIR.0.18501-0; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Funakoshi T, 2003, MOL BRAIN RES, V118, P1, DOI 10.1016/S0169-328X(03)00328-0; Gallia GL, 2001, J CELL BIOCHEM, V83, P355, DOI 10.1002/jcb.1247; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Ginisty H, 1999, J CELL SCI, V112, P761; Grill B, 2004, J IMMUNOL, V172, P2389, DOI 10.4049/jimmunol.172.4.2389; Gu HD, 2003, NUCLEIC ACIDS RES, V31, P6264, DOI 10.1093/nar/gkg823; Heaton JH, 1998, J BIOL CHEM, V273, P14261, DOI 10.1074/jbc.273.23.14261; HESKETH JE, 1991, BIOCHEM J, V277, P1; HOLCIK M, 1997, RNA FORMATION FUNCTI, P195; Huang X, 2002, BIOCHEM J, V366, P175, DOI 10.1042/BJ20020204; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; Jin P, 2004, NAT NEUROSCI, V7, P113, DOI 10.1038/nn1174; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kennedy D, 1996, Biomed Pept Proteins Nucleic Acids, V2, P93; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Kroll TT, 2002, DEVELOPMENT, V129, P5609, DOI 10.1242/dev.00160; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Li YM, 2001, BIOL PHARM BULL, V24, P231, DOI 10.1248/bpb.24.231; Linder P, 2001, CURR BIOL, V11, pR961, DOI 10.1016/S0960-9822(01)00574-7; Lorsch JR, 2002, CELL, V109, P797, DOI 10.1016/S0092-8674(02)00804-8; Matsumoto K, 2000, NUCLEIC ACIDS RES, V28, P4689, DOI 10.1093/nar/28.23.4689; Mili S, 2004, RNA, V10, P1692, DOI 10.1261/rna.7151404; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; Mohr E, 1999, PROG NEUROBIOL, V57, P507, DOI 10.1016/S0301-0082(98)00066-5; Moraes KCM, 2003, BIOL CHEM, V384, P25, DOI 10.1515/BC.2003.004; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ohashi S, 2000, J NEUROCHEM, V75, P1781, DOI 10.1046/j.1471-4159.2000.0751781.x; Ouyang Y, 1999, J NEUROSCI, V19, P7823; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Perlick HA, 1996, P NATL ACAD SCI USA, V93, P10928, DOI 10.1073/pnas.93.20.10928; RABINOVITZ M, 1992, FEBS LETT, V302, P113, DOI 10.1016/0014-5793(92)80418-G; Rabinovitz M, 1995, Nucleic Acids Symp Ser, P182; Raymond CR, 2000, J NEUROSCI, V20, P969, DOI 10.1523/JNEUROSCI.20-03-00969.2000; Shahied L, 2001, J MOL BIOL, V305, P817, DOI 10.1006/jmbi.2000.4331; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Shor B, 2003, J BIOL CHEM, V278, P49119, DOI 10.1074/jbc.M303968200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Wang XJ, 1998, NEUROSCI LETT, V252, P191, DOI 10.1016/S0304-3940(98)00598-9; Wells DG, 2001, J NEUROSCI, V21, P9541, DOI 10.1523/JNEUROSCI.21-24-09541.2001; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Yu JY, 2003, DEV BIOL, V255, P249, DOI 10.1016/S0012-1606(02)00094-5	67	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6496	6503		10.1074/jbc.M412742200	http://dx.doi.org/10.1074/jbc.M412742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15596439	hybrid			2022-12-25	WOS:000227332700032
J	Dunand-Sauthier, I; Hohl, M; Thorel, F; Jaquier-Gubler, P; Clarkson, SG; Scharer, OD				Dunand-Sauthier, I; Hohl, M; Thorel, F; Jaquier-Gubler, P; Clarkson, SG; Scharer, OD			The spacer region of XPG mediates recruitment to nucleotide excision repair complexes and determines substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; GROUP-C PROTEIN; STRUCTURE-SPECIFIC ENDONUCLEASE; HUMAN CELL-EXTRACTS; XERODERMA-PIGMENTOSUM; DNA-REPAIR; COCKAYNE-SYNDROME; DAMAGED DNA; YEAST RAD2; TFIIH	XPG has structural and catalytic roles in nucleotide excision repair (NER) and belongs to the FEN-1 family of structure-specific nucleases. XPG contains a stretch of over 600 amino acids termed the "spacer region" between the conserved N- and I-nuclease regions. Its role is unknown, and it is not similar to any known protein. To investigate its possible functions, we generated and analyzed several deletion mutants of XPG. The spacer region is not required for endonuclease activity, but amino acids 111-550 contribute to the substrate specificity of XPG, and they are required for interaction with TFIIH and for NER activity in vitro and in vivo. Deletion of residues 184-210 and 554-730 leads only to a partial defect in NER activity and a weakened interaction with TFIIH. XPGDelta184-210 and XPGDelta554-730 are not observed at sites of local UV damage in living cells by immunofluoreseence, suggesting that the weakened interaction between XPG and TFIIH results in an NER reaction with altered kinetics. This study demonstrates that the N-terminal portion of the spacer region is particularly important for NTER progression by mediating the XPG-TFIIH interaction and XPG substrate specificity.	Univ Geneva, Med Ctr, Dept Microbiol & Mol Med, CH-1211 Geneva, Switzerland; Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland	University of Geneva; University of Zurich	Scharer, OD (corresponding author), Univ Geneva, Med Ctr, Dept Microbiol & Mol Med, CH-1211 Geneva, Switzerland.	scharer@imr.unizh.ch	Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; Araujo SJ, 2000, GENE DEV, V14, P349; Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001; Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; Biggerstaff M, 1999, METH MOL B, V113, P357; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Clarkson SG, 2003, BIOCHIMIE, V85, P1113, DOI 10.1016/j.biochi.2003.10.014; Coin F, 2004, EMBO J, V23, P4835, DOI 10.1038/sj.emboj.7600480; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Ellison AR, 1998, EXP CELL RES, V243, P22, DOI 10.1006/excr.1998.4147; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; Gervais V, 2004, NAT STRUCT MOL BIOL, V11, P616, DOI 10.1038/nsmb782; Gillet LCJ, 2002, ORG LETT, V4, P4205, DOI 10.1021/ol026474f; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hohl M, 2003, J BIOL CHEM, V278, P19500, DOI 10.1074/jbc.M213155200; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Houle JF, 1999, GENE, V234, P353, DOI 10.1016/S0378-1119(99)00185-7; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Katsumi S, 2001, J INVEST DERMATOL, V117, P1156, DOI 10.1046/j.0022-202x.2001.01540.x; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Lee SK, 2002, CELL, V109, P823, DOI 10.1016/S0092-8674(02)00795-X; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Moriwaki SI, 1996, J INVEST DERMATOL, V107, P647, DOI 10.1111/1523-1747.ep12584287; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Okinaka RT, 1997, MUTAT RES-DNA REPAIR, V385, P107, DOI 10.1016/S0921-8777(97)00031-1; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; Reardon JT, 2004, CELL CYCLE, V3, P141; Reardon JT, 2003, GENE DEV, V17, P2539, DOI 10.1101/gad.1131003; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Salmon P, 2000, BLOOD, V96, P3392; Scharer OD, 2003, ANGEW CHEM INT EDIT, V42, P2946, DOI 10.1002/anie.200200523; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shivji MKK, 1999, METH MOL B, V113, P373; Stauffer ME, 2004, J BIOL CHEM, V279, P30915, DOI 10.1074/jbc.R400015200; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tapias A, 2004, J BIOL CHEM, V279, P19074, DOI 10.1074/jbc.M312611200; Thorel F, 2004, MOL CELL BIOL, V24, P10670, DOI 10.1128/MCB.24.24.10670-10680.2004; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Yokoi M, 2000, J BIOL CHEM, V275, P9870, DOI 10.1074/jbc.275.13.9870	64	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7030	7037		10.1074/jbc.M412228200	http://dx.doi.org/10.1074/jbc.M412228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15590680	Green Published, hybrid			2022-12-25	WOS:000227332700093
J	Istvan, ES; Goldberg, DE				Istvan, ES; Goldberg, DE			Distal substrate interactions enhance plasmepsin activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM FOOD VACUOLE; HUMAN CATHEPSIN-D; PLASMODIUM-FALCIPARUM; ASPARTIC PROTEINASES; MALARIA PARASITE; HEMOGLOBIN DEGRADATION; CYSTEINE PROTEASE; CRYSTAL-STRUCTURE; SPECIFICITY; SITE	Plasmepsin II (PM II) is an aspartic protease active in hemoglobin (Hb) degradation in the protozoan parasite Plasmodium falciparum. A fluorescence-quenched octapeptide substrate based on the initial hemoglobin cleavage site is recognized well by PM II. C-terminal extension of this peptide has little effect, but N-terminal extension results in higher maximal velocity and dramatic concentration-dependent substrate inhibition. This inhibition, but not the rate stimulation, depends on the presence of a DABCYL group on the peptide N terminus. Using site-directed mutagenesis, we have identified PM 11 residues that interact with N-terminal amino acids of peptide substrates. The same residues influence degradation of Rh by PM II. Cathepsin E (CatE), a related mammalian aspartic protease, is also stimulated by N-terminally extended substrates. This suggests that distal substrate interactions as far out as P6 may be a general property of aspartic proteases and may be important in substrate and inhibitor recognition. Although PM 11 and CatE are similar in their ability to cleave Hb-based peptides and Rb alpha-chains, CatE is not able to degrade native Hb, which is a substrate for PM II. Based on these results, we propose that PM II may have the special feature of being a Hb denaturase.	Washington Univ, Sch Med, Dept Mol Microbiol, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6; Asojo OA, 2002, ACTA CRYSTALLOGR D, V58, P2001, DOI 10.1107/S0907444902014695; BAILLY E, 1992, J PROTOZOOL, V39, P593, DOI 10.1111/j.1550-7408.1992.tb04856.x; BALBAA M, 1993, ARCH BIOCHEM BIOPHYS, V306, P297, DOI 10.1006/abbi.1993.1515; Banerjee R, 2003, MOL BIOCHEM PARASIT, V129, P157, DOI 10.1016/S0166-6851(03)00119-1; Banerjee R, 2001, INFEC DIS S, P43; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bernstein NK, 2003, J MOL BIOL, V329, P505, DOI 10.1016/S0022-2836(03)00444-3; Beyer BM, 1998, PROTEIN SCI, V7, P88, DOI 10.1002/pro.5560070109; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Bucci E, 1981, Methods Enzymol, V76, P97; Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; Copeland R. A., 2004, ENZYMES PRACTICAL IN; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P385; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Dunn BM, 1998, ADV EXP MED BIOL, V436, P133; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; HOFMANN T, 1988, BIOCHEMISTRY-US, V27, P1140, DOI 10.1021/bi00404a010; Klemba M, 2004, J BIOL CHEM, V279, P43000, DOI 10.1074/jbc.M408123200; Lew VL, 2003, BLOOD, V101, P4189, DOI 10.1182/blood-2002-08-2654; Li T, 2004, MOL BIOCHEM PARASIT, V135, P101, DOI 10.1016/j.molbiopara.2004.01.010; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Luker KE, 1996, MOL BIOCHEM PARASIT, V79, P71, DOI 10.1016/0166-6851(96)02651-5; Murata CE, 2003, J BIOL CHEM, V278, P38022, DOI 10.1074/jbc.M306842200; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; Nezami A, 2003, BIOCHEMISTRY-US, V42, P8459, DOI 10.1021/bi034131z; SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; SHERMAN IW, 1969, MIL MED, V134, P954; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; Silva AM, 1998, ADV EXP MED BIOL, V436, P363; Siripurkpong P, 2002, J BIOL CHEM, V277, P41009, DOI 10.1074/jbc.M204852200; Tyas L, 1999, FEBS LETT, V454, P210, DOI 10.1016/S0014-5793(99)00805-4; VISSER S, 1987, BIOCHEM J, V244, P553, DOI 10.1042/bj2440553; Westling J, 1997, EXP PARASITOL, V87, P185, DOI 10.1006/expr.1997.4225; Westling J, 1999, PROTEIN SCI, V8, P2001, DOI 10.1110/ps.8.10.2001; Wyatt DM, 2002, FEBS LETT, V513, P159, DOI 10.1016/S0014-5793(02)02241-X	44	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6890	6896		10.1074/jbc.M412086200	http://dx.doi.org/10.1074/jbc.M412086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15574427	hybrid			2022-12-25	WOS:000227332700078
J	Kang, KJ; Kinjo, TG; Szerencsei, RT; Schnetkamp, PPM				Kang, KJ; Kinjo, TG; Szerencsei, RT; Schnetkamp, PPM			Residues contributing to the Ca2+ and K+ binding pocket of the NCKX2 Na+/Ca2+-K+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-CA; RETINAL CONE; OUTER SEGMENTS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; INSECT CELLS; TRANSPORT; STOICHIOMETRY; MUTATION; CURRENTS	The Na+/Ca2+-K+ exchanger (NCKX) extrudes Ca2+ from cells utilizing both the inward Na+ gradient and the outward K+ gradient. NCKX is thought to operate by a consecutive mechanism in which a cation binding pocket accommodates both Ca2+ and K+ and alternates between inward and outward facing conformations. Here we developed a simple fluorometric method to analyze changes in K+ and Ca2+ dependences of mutant NCKX2 proteins in which candidate residues within membrane-spanning domains were substituted. The largest shifts in both K+ and Ca2+ dependences compared with wild-type NCKX2 were observed for the charge-conservative substitutions of Glu(188) and Asp(548), whereas the size-conservative substitutions resulted in nonfunctional proteins. Substitution of several other residues including two proline residues (Pro(187) and Pro(547)), three additional acidic residues (Asp(258), Glu(265), Glu(533)), and two hydroxyl-containing residues (Ser(185) and Ser(545)) showed smaller shifts, but shifts in Ca2+ dependence were invariably accompanied by shifts in K+ dependence. We conclude that Glu(188) and Asp(548) are the central residues of a single cation binding pocket that can accommodate both K+ and Ca2+. Furthermore, a single set of residues lines a transport pathway for both K+ and Ca2+.	Univ Calgary, Fac Med, Dept Physiol & Biophys, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada	University of Calgary	Schnetkamp, PPM (corresponding author), Univ Calgary, Fac Med, Dept Physiol & Biophys, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	pschnetk@ucalgary.ca						Cai XJ, 2004, J BIOL CHEM, V279, P5867, DOI 10.1074/jbc.M310908200; Cooper CB, 2000, METHOD ENZYMOL, V315, P847; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Haug-Collet K, 1999, J CELL BIOL, V147, P659, DOI 10.1083/jcb.147.3.659; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Kang K, 2003, BIOCHEMISTRY-US, V42, P9438, DOI 10.1021/bi0342261; Kang KJ, 2005, J BIOL CHEM, V280, P6834, DOI 10.1074/jbc.M412933200; Kinjo TG, 2003, BIOCHEMISTRY-US, V42, P2485, DOI 10.1021/bi0270788; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Quednau BD, 2004, PFLUG ARCH EUR J PHY, V447, P543, DOI 10.1007/s00424-003-1065-4; REEVES JP, 1985, CURR TOP MEMBR TRANS, V25, P77; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1991, J GEN PHYSIOL, V98, P555, DOI 10.1085/jgp.98.3.555; SCHNETKAMP PPM, 1995, AM J PHYSIOL-CELL PH, V269, pC1153, DOI 10.1152/ajpcell.1995.269.5.C1153; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P198; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; Schnetkamp PPM, 2004, PFLUG ARCH EUR J PHY, V447, P683, DOI 10.1007/s00424-003-1069-0; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; SCHNETKAMP PPM, 1995, BIOCHEMISTRY-US, V34, P7282, DOI 10.1021/bi00021a045; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; Su YH, 2002, P NATL ACAD SCI USA, V99, P6743, DOI 10.1073/pnas.102186699; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Szerencsei RT, 2001, BIOCHEMISTRY-US, V40, P6009, DOI 10.1021/bi0102353; Winkfein RJ, 2004, CELL CALCIUM, V36, P147, DOI 10.1016/j.ceca.2004.01.021; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x	32	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6823	6833		10.1074/jbc.M407933200	http://dx.doi.org/10.1074/jbc.M407933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15583008	hybrid			2022-12-25	WOS:000227332700071
J	Nelson, TJ; Alkon, DL				Nelson, TJ; Alkon, DL			Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; ALZHEIMERS-DISEASE; KINASE-C; A-BETA; HYDROGEN-PEROXIDE; IN-VITRO; ALPHA-TOCOPHEROL; TRANSGENIC MICE; CEREBRAL-CORTEX	Alzheimer's disease (AD) is characterized by accumulation of the neurotoxic peptide beta-amyloid, which is produced by proteolysis of amyloid precursor protein (APP). APP is a large membrane-bound copper-binding protein that is essential in maintaining synaptic function and may play a role in synaptogenesis. beta-Amyloid has been shown to contribute to the oxidative stress that accompanies AD. Later stages of AD are characterized by neuronal apoptosis. However, the biochemical function of AIPP and the mechanism of the toxicity of beta-amyloid are still unclear. In this study, we show that both beta-amyloid and APP can oxidize cholesterol to form 7beta-hydroxycholesterol, a proapoptotic oxysterol that was neurotoxic at nanomolar concentrations. 7beta-Hydroxycholesterol inhibited secretion of soluble APP from cultured rat hippocampal H19-7/IGF-IR neuronal cells and inhibited tumor necrosis factor-alpha-converting enzyme alpha-secretase activity but had no effect on beta-site APP-cleaving enzyme 1 activity. 7beta-Hydroxycholesterol was also a potent inhibitor of alpha-protein kinase C, with a K-i of similar to0.2 nm. The rate of reaction between cholesterol and beta-amyloid was comparable to the rates of cholesterol-metabolizing enzymes (k(cat) = 0.211 min(-1)). The rate of production of 7beta-hydroxycholesterol by AIPP was similar to200 times lower than by beta-amyloid. Oxidation of cholesterol was accompanied by stoichiometric production of hydrogen peroxide and required divalent copper. The results suggest that a function of APP may be to produce low levels of 7-hydroxycholesterol. Higher levels produced by beta-amyloid could contribute to the oxidative stress and cell loss observed in Alzheimer's disease.	Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA		Nelson, TJ (corresponding author), Blanchette Rockefeller Neurosci Inst, 317 Acad & Res Bldg,9601 Med Ctr Dr, Rockville, MD 20850 USA.	tjnelson@brni-jhu.org						ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; ALTMAN PL, 1974, BIOL DATA BOOK, V3, P1815; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Biasi F, 2004, FASEB J, V18, P693, DOI 10.1096/fj.03-0401fje; BLACHE D, 1995, FEBS LETT, V357, P135, DOI 10.1016/0014-5793(94)01348-5; Bodin K, 2002, J BIOL CHEM, V277, P31534, DOI 10.1074/jbc.M201712200; Borchardt T, 2000, CELL MOL BIOL, V46, P785; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Burns M, 2003, J NEUROSCI, V23, P5645; CAO J, 1995, P SOC EXP BIOL MED, V209, P195; Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Dawson GR, 1999, NEUROSCIENCE, V90, P1, DOI 10.1016/S0306-4522(98)00410-2; DUFOUR F, 2003, NEUROBIOL LIPIDS, V1, P34; Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; Evans RM, 2004, NEUROLOGY, V62, P1869, DOI 10.1212/01.WNL.0000125323.15458.3F; Fujita T, 2002, METABOLISM, V51, P737, DOI 10.1053/meta.2002.32803; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; Hass S, 1998, J BIOL CHEM, V273, P13892; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200; Huang XD, 2004, ANN NY ACAD SCI, V1012, P153, DOI 10.1196/annals.1306.012; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; Ishii K, 2002, FREE RADICAL RES, V36, P163, DOI 10.1080/10715760290006493; Iuliano L, 2003, ANAL BIOCHEM, V312, P217, DOI 10.1016/S0003-2697(02)00467-0; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; Kolsch H, 2000, NEUROCHEM INT, V36, P507, DOI 10.1016/S0197-0186(99)00157-6; Kontush A, 2001, FREE RADICAL BIO MED, V30, P119, DOI 10.1016/S0891-5849(00)00458-5; KULIG MJ, 1973, J ORG CHEM, V38, P3639, DOI 10.1021/jo00960a050; LIANG JS, 1995, J LIPID RES, V36, P37; Liang JS, 1996, BIOCHEM BIOPH RES CO, V219, P962, DOI 10.1006/bbrc.1996.0332; LODGE JK, 1995, BBA-LIPID LIPID MET, V1256, P130, DOI 10.1016/0005-2760(94)00253-U; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Massi F, 2001, BIOPHYS J, V81, P697, DOI 10.1016/S0006-3495(01)75734-7; McLaughlin M, 1999, J NEUROCHEM, V72, P273, DOI 10.1046/j.1471-4159.1999.0720273.x; Miguet C, 2001, CELL DEATH DIFFER, V8, P83, DOI 10.1038/sj.cdd.4400792; Mileusnic R, 2000, EUR J NEUROSCI, V12, P4487, DOI 10.1046/j.1460-9568.2000.01344.x; Momynaliev KT, 1997, BIOCHEMISTRY-MOSCOW+, V62, P158; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; Multhaup G, 1998, BIOCHEMISTRY-US, V37, P7224, DOI 10.1021/bi980022m; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Nelson TJ, 2004, HIPPOCAMPUS, V14, P46, DOI 10.1002/hipo.10152; NELSON TJ, 1995, J NEUROCHEM, V65, P2350; Norlin M, 2003, J LIPID RES, V44, P1515, DOI 10.1194/jlr.M300047-JLR200; O'Callaghan YC, 2001, CELL BIOL TOXICOL, V17, P127, DOI 10.1023/A:1010914306375; O'Sullivan AJ, 2003, J APPL TOXICOL, V23, P191, DOI 10.1002/jat.906; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Osada K, 2000, METHODS ENZYMOL, V319, P188; OYAMA Y, 1994, BRAIN RES, V635, P113, DOI 10.1016/0006-8993(94)91429-X; Panini SR, 2001, J LIPID RES, V42, P1678; Patel RP, 1996, J LIPID RES, V37, P2361; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P257; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Ryan L, 2004, J BIOCHEM MOL TOXIC, V18, P50, DOI 10.1002/jbt.20007; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; Seo DW, 2004, AM J PHYSIOL-GASTR L, V287, pG1247, DOI 10.1152/ajpgi.00013.2004; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Small D H, 1999, J Alzheimers Dis, V1, P275; SMITH LL, 1978, J AM CHEM SOC, V100, P6206, DOI 10.1021/ja00487a042; Sparks DL, 2003, P NATL ACAD SCI USA, V100, P11065, DOI 10.1073/pnas.1832769100; Sponne I, 2004, FASEB J, V18, P836, DOI 10.1096/fj.03-0372fje; Subasinghe S, 2003, J NEUROCHEM, V84, P471, DOI 10.1046/j.1471-4159.2003.01552.x; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Tikkanen R, 2002, BIOL CHEM, V383, P1855, DOI 10.1515/BC.2002.209; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WYLLIE SG, 1977, J ORG CHEM, V42, P725, DOI 10.1021/jo00424a033; Yao ZX, 2002, FASEB J, V16, P1677, DOI 10.1096/fj.02-0285fje; Yao ZX, 2002, J NEUROCHEM, V83, P1110, DOI 10.1046/j.1471-4159.2002.01202.x; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zhu GF, 2001, BIOCHEM BIOPH RES CO, V285, P997, DOI 10.1006/bbrc.2001.5273; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	88	156	167	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					7377	7387		10.1074/jbc.M409071200	http://dx.doi.org/10.1074/jbc.M409071200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15591071	hybrid			2022-12-25	WOS:000227332700130
J	Collins, MO; Yu, L; Coba, MP; Husi, H; Campuzano, L; Blackstock, WP; Choudhary, JS; Grant, SGN				Collins, MO; Yu, L; Coba, MP; Husi, H; Campuzano, L; Blackstock, WP; Choudhary, JS; Grant, SGN			Proteomic analysis of in vivo phosphorylated synaptic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY; GLUTAMATE RECEPTORS; KINASE; PHOSPHOPROTEINS; IDENTIFICATION; PSD-95; POTENTIATION; SPECIFICITY; COMPLEXES; SUBSTRATE	In the nervous system, protein phosphorylation is an essential feature of synaptic function. Although protein phosphorylation is known to be important for many synaptic processes and in disease, little is known about global phosphorylation of synaptic proteins. Heterogeneity and low abundance make protein phosphorylation analysis difficult, particularly for mammalian tissue samples. Using a new approach, combining both protein and peptide immobilized metal affinity chromatography and mass spectrometry data acquisition strategies, we have produced the first large scale map of the mouse synapse phosphoproteome. We report over 650 phosphorylation events corresponding to 331 sites (289 have been unambiguously assigned), 92% of which are novel. These represent 79 proteins, half of which are novel phosphoproteins, and include several highly phosphorylated proteins such as MAP1B (33 sites) and Bassoon (30 sites). An additional 149 candidate phosphoproteins were identified by profiling the composition of the protein immobilized metal affinity chromatography enrichment. All major synaptic protein classes were observed, including components of important pre- and postsynaptic complexes as well as low abundance signaling proteins. Bioinformatic and in vitro phosphorylation assays of peptide arrays suggest that a small number of kinases phosphorylate many proteins and that each substrate is phosphorylated by many kinases. These data substantially increase existing knowledge of synapse protein phosphorylation and support a model where the synapse phosphoproteome is functionally organized into a highly interconnected signaling network.	Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Univ Edinburgh, Div Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland; Waters Corp, Manchester M22 5PP, Lancs, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Wellcome Trust Sanger Institute; University of Edinburgh; Waters UK; University of Sheffield	Grant, SGN (corresponding author), Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England.	sg3@sanger.ac.uk	Collins, Mark/A-3752-2012; Choudhary, Jyoti/S-1232-2017; Collins, Mark/AAB-7484-2021	Choudhary, Jyoti/0000-0003-0881-5477; Collins, Mark/0000-0002-7656-4975; Grant, Seth/0000-0001-8732-8735				ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chang EJ, 2004, ANAL CHEM, V76, P4472, DOI 10.1021/ac049637h; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Craig TJ, 2003, J NEUROCHEM, V86, P1450, DOI 10.1046/j.1471-4159.2003.01955.x; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Farr CD, 2004, J NEUROCHEM, V91, P438, DOI 10.1111/j.1471-4159.2004.02735.x; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gardoni F, 2003, J BIOL CHEM, V278, P44745, DOI 10.1074/jbc.M303576200; Garry EM, 2003, CURR BIOL, V13, P321, DOI 10.1016/S0960-9822(03)00084-8; Grant SGN, 2003, BIOESSAYS, V25, P1229, DOI 10.1002/bies.10381; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; Kotecha SA, 2003, J BIOL CHEM, V278, P27742, DOI 10.1074/jbc.M301946200; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Lizcano JM, 2002, J BIOL CHEM, V277, P27839, DOI 10.1074/jbc.M202042200; Lonart G, 2003, CELL, V115, P49, DOI 10.1016/S0092-8674(03)00727-X; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; Nada S, 2003, J BIOL CHEM, V278, P47610, DOI 10.1074/jbc.M303873200; NOURRY C, 2003, SCI STKE; Nuhse TS, 2004, PLANT CELL, V16, P2394, DOI 10.1105/tpc.104.023150; Nuhse TS, 2003, MOL CELL PROTEOMICS, V2, P1234, DOI 10.1074/mcp.T300006-MCP200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Rychlewski L, 2004, J MOL BIOL, V336, P307, DOI 10.1016/j.jmb.2003.12.052; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; Shapira M, 2003, NEURON, V38, P237, DOI 10.1016/S0896-6273(03)00207-1; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shu HJ, 2004, MOL CELL PROTEOMICS, V3, P279, DOI 10.1074/mcp.D300003-MCP200; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Tokuda M, 1998, MOL NEUROBIOL, V17, P137, DOI 10.1007/BF02802028; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0; Yoshimura Y, 2004, J NEUROCHEM, V88, P759, DOI 10.1046/j.1471-4159.2003.02136.x	44	266	279	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5972	5982		10.1074/jbc.M411220200	http://dx.doi.org/10.1074/jbc.M411220200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15572359	hybrid			2022-12-25	WOS:000227217100103
J	Taylor, KR; Rudisill, JA; Gallo, RL				Taylor, KR; Rudisill, JA; Gallo, RL			Structural and sequence motifs in dermatan sulfate for promoting fibroblast growth factor-2 (FGF-2) and FGF-7 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; SOLVOLYTIC DESULFATION; FACTOR/SCATTER FACTOR; HIGH-AFFINITY; CHONDROITIN; BINDING; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; INJURY	Glycosaminoglycans have been implicated in the binding and activation of a variety of growth factors, cytokines, and chemokines. In this way, glycosaminoglycans are thought to participate in events such as development and wound repair. In particular, heparin and heparan sulfate have been well studied, and specific aspects of their structure dictate their participation in a variety of activities. In contrast, although dermatan sulfate participates in many of the same biological processes as heparin and heparan sulfate, the interactions of dermatan sulfate have been less well studied. Dermatan sulfate is abundant in the wound environment and binds and activates growth factors such as fibroblast growth factor-2 (FGF-2) and FGF-7, which are present during the wound repair process. To determine the minimum size and sulfation content of active dermatan sulfate oligosaccharides, dermatan sulfate was first digested and then separated by size exclusion high pressure liquid chromatography, and the activity to facilitate FGF-2 and FGF-7 was assayed by the cellular proliferation of cell lines expressing FGFR1 or FGFR2 IIIb. The minimum size required for the activation of FGF-2 was an octasaccharide and for FGF-7 a decasaccharide. Active fractions were rich in monosulfated, primarily 4-O-sulfated, disaccharides and iduronic acid. Increasing the sulfation to primarily 2/4-O-sulfated and 2/6-O-sulfated disaccharides did not increase activity. Cell proliferation decreased or was abolished with higher sulfated dermatan sulfate preparations. This indicated a preference for specific dermatan sulfate oligosaccharides capable of promoting FGF-2- and FGF-7-dependent cell proliferation. These data identify critical oligosaccharides that promote specific members of the FGF family that are important for wound repair and angiogenesis.	Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gallo, RL (corresponding author), Mail Code 9111B,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rgallo@vapop.ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, R37AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-7261, HL-57345] Funding Source: Medline; NIAID NIH HHS [AI-52453] Funding Source: Medline; NIAMS NIH HHS [AR-45676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DENTI A, 1995, THROMB RES, V79, P187, DOI 10.1016/0049-3848(95)00104-Y; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; Pavao MSG, 2002, AN ACAD BRAS CIENC, V74, P105, DOI 10.1590/S0001-37652002000100007; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Sakai S, 2002, ANAL BIOCHEM, V302, P169, DOI 10.1006/abio.2001.5545; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; TOLLEFSEN DM, 1986, J BIOL CHEM, V261, P8854; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0	25	92	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5300	5306		10.1074/jbc.m410412200	http://dx.doi.org/10.1074/jbc.m410412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15563459	hybrid			2022-12-25	WOS:000227217100025
J	Valluru, L; Xu, J; Zhu, YL; Yang, S; Contractor, A; Swanson, GT				Valluru, L; Xu, J; Zhu, YL; Yang, S; Contractor, A; Swanson, GT			Ligand binding is a critical requirement for plasma membrane expression of heteromeric kainate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; ER RETENTION SIGNAL; ENDOPLASMIC-RETICULUM; GLUTAMATE-RECEPTOR; AMPA RECEPTORS; SURFACE EXPRESSION; SYNAPTIC-TRANSMISSION; SUBUNIT COMPOSITION; NMDA; TRAFFICKING	Intracellular trafficking of ionotropic glutamate receptors is controlled by multiple discrete determinants in receptor subunits. Most such determinants have been localized to the cytoplasmic carboxyl-terminal domain, but other domains in the subunit proteins can play roles in modulating receptor surface expression. Here we demonstrate that formation of an intact glutamate binding site also acts as an additional quality-control check for surface expression of homomeric and heteromeric kainate receptors. A key ligand-binding residue in the KA2 subunit, threonine 675, was mutated to either alanine or glutamate, which eliminated affinity for the receptor ligands kainate and glutamate. We found that plasma membrane expression of heteromeric GluR6/KA2(T675A) or GluR6/KA2(T675E) kainate receptors was markedly reduced compared with wild-type GluR6/KA2 receptors in transfected HEK 293 and COS-7 cells and in cultured neurons. Surface expression of homomeric KA2 receptors lacking a retention/retrieval determinant (KA2-R/A) was also reduced upon mutation of Thr-675 and elimination of the ligand binding site. KA2 Thr-675 mutant subunits were able to co-assemble with GluR5 and GluR6 subunits and were degraded at the same rate as wild-type KA2 subunit protein. These results suggest that glutamate binding and associated conformational changes are prerequisites for forward trafficking of intracellular kainate receptors following multimeric assembly.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA	University of Texas System; University of Texas Medical Branch Galveston; Salk Institute; Northwestern University; Feinberg School of Medicine	Swanson, GT (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	g.swanson@utmb.edu		Contractor, Anis/0000-0002-5131-2536	NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH065289, R03MH065632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044322] Funding Source: NIH RePORTER; NIMH NIH HHS [R03-MH65632, R03-MH065289] Funding Source: Medline; NINDS NIH HHS [R01-NS44322] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Bernard A, 1999, EUR J NEUROSCI, V11, P604, DOI 10.1046/j.1460-9568.1999.00479.x; BERNARD A, 1994, J NEUROCHEM, V62, P2057, DOI 10.1046/j.1471-4159.1994.62052057.x; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fleck MW, 2003, J NEUROSCI, V23, P1219; Ghetti A, 2000, J NEUROSCI, V20, P2766; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Grunwald ME, 2003, NEUROPHARMACOLOGY, V45, P768, DOI 10.1016/S0028-3908(03)00274-0; Hawkins LM, 2004, J BIOL CHEM, V279, P28903, DOI 10.1074/jbc.M402599200; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; Jaskolski F, 2004, J NEUROSCI, V24, P2506, DOI 10.1523/JNEUROSCI.5116-03.2004; Kidd FL, 1999, NATURE, V400, P569, DOI 10.1038/23040; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Matsuda I, 2000, BIOCHEM BIOPH RES CO, V275, P565, DOI 10.1006/bbrc.2000.3351; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; PASS Y, 1996, NEURON, V17, P979; Paternain AV, 1998, NEUROPHARMACOLOGY, V37, P1249, DOI 10.1016/S0028-3908(98)00098-7; Perez-Otano I, 2004, NEUROSIGNALS, V13, P175, DOI 10.1159/000077524; Prybylowski K, 2004, J BIOL CHEM, V279, P9673, DOI 10.1074/jbc.R300029200; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; Schiffer HH, 1997, NEURON, V19, P1141, DOI 10.1016/S0896-6273(00)80404-3; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Swanson GT, 1998, MOL PHARMACOL, V53, P942; Swanson GT, 1997, NEURON, V19, P913, DOI 10.1016/S0896-6273(00)80972-1; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Xia HH, 2002, J BIOL CHEM, V277, P47765, DOI 10.1074/jbc.M207122200; Yan S, 2004, J NEUROSCI, V24, P679, DOI 10.1523/JNEUROSCI.4985-03.2004; Zorumski CF, 1996, J PHYSIOL-LONDON, V494, P465, DOI 10.1113/jphysiol.1996.sp021506	41	49	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					6085	6093		10.1074/jbc.M411549200	http://dx.doi.org/10.1074/jbc.M411549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15583001	hybrid			2022-12-25	WOS:000227217100115
J	Zissimopoulos, S; Lai, FA				Zissimopoulos, S; Lai, FA			Interaction of FKBP12.6 with the cardiac ryanodine receptor C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; FK506-BINDING PROTEIN FKBP12.6; MUSCLE SARCOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; FK506 BINDING-PROTEIN; SKELETAL-MUSCLE; SELECTIVE BINDING; LIGAND-BINDING; HEART-FAILURE; HEK-293 CELLS	The ryanodine receptor-calcium release channel complex (RyR) plays a pivotal role in excitation-contraction coupling in skeletal and cardiac muscle. RyR channel activity is modulated by interaction with FK506-binding protein (FKBP), and disruption of the RyR-FKBP association has been implicated in cardiomyopathy, cardiac hypertrophy, and heart failure. Evidence for an interaction between RyR and FKBP is well documented, both in skeletal muscle (RyR1-FKBP12) and in cardiac muscle (RyR2-FKBP12.6), however definition of the FKBP-binding site remains elusive. Early reports proposed interaction of a short RyR central domain with FKBP12/12.6, however this site has been questioned, and recently an alternative FIKBP12.6 interaction site has been identified within the N-terminal half of RyR2. In this study, we report evidence for the human RyR2 C-terminal domain as a novel FKBP12.6-binding site. Using competition binding assays, we find that short C-terminal RyR2 fragments can displace bound FKBP12.6 from the native RyR2, although they are unable to exclusively support interaction with FKBP12.6. However, expression of a large RyR2 C-terminal construct in mammalian cells encompassing the pore-forming transmembrane domains exhibits rapamycin-sensitive binding specifically to FKBP12.6 but not to FKBP12. We also obtained some evidence for involvement of the RyR2 N-terminal, but not the central domain, in FKBP12.6 interaction. Our studies suggest that a novel interaction site for FKBP12.6 may be present at the RyR2 C terminus, proximal to the channel pore, a sterically appropriate location that would enable this protein to play a central role in the modulation of this critical ion channel.	Univ Wales Coll Cardiff, Coll Med, Dept Cardiol, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Zissimopoulos, S (corresponding author), Univ Wales Coll Cardiff, Coll Med, Dept Cardiol, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales.	zissimopouloss@cf.ac.uk	Zissimopoulos, Spyros/GSD-9824-2022	Lai, Tony/0000-0003-2852-8547; Zissimopoulos, Spyros/0000-0001-5196-9450				AHERN GP, 1994, FEBS LETT, V352, P369, DOI 10.1016/0014-5793(94)01001-3; Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; Alarcon CM, 1997, MOL CELL BIOL, V17, P5968, DOI 10.1128/MCB.17.10.5968; Avila G, 2003, J BIOL CHEM, V278, P22600, DOI 10.1074/jbc.M205866200; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; Carmody M, 2001, FEBS LETT, V505, P97, DOI 10.1016/S0014-5793(01)02787-9; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; Doi M, 2002, CIRCULATION, V105, P1374, DOI 10.1161/hc1102.105270; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Galat A, 2000, EUR J BIOCHEM, V267, P4945, DOI 10.1046/j.1432-1327.2000.01509.x; George CH, 2003, CIRC RES, V93, P531, DOI 10.1161/01.RES.0000091335.07574.86; George CH, 2003, BIOCHEM J, V370, P579, DOI 10.1042/BJ20021433; GRUNWALD R, 1995, J BIOL CHEM, V270, P11338, DOI 10.1074/jbc.270.19.11338; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; Llano I, 2000, NAT NEUROSCI, V3, P1256, DOI 10.1038/81781; Ma JJ, 1995, BIOPHYS J, V69, P2398, DOI 10.1016/S0006-3495(95)80109-8; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; Neye H, 2001, REGUL PEPTIDES, V97, P147, DOI 10.1016/S0167-0115(00)00206-8; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Prestle J, 2001, CIRC RES, V88, P188; Qi Y, 1998, J BIOL CHEM, V273, P34813, DOI 10.1074/jbc.273.52.34813; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Rossi D, 2002, J CELL SCI, V115, P2497; Sambrook J., 2002, MOL CLONING LAB MANU; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; SITSAPESAN R, 1990, J PHYSIOL-LONDON, V423, P425, DOI 10.1113/jphysiol.1990.sp018031; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Thomas LN, 2004, CARDIOVASC RES, V64, P52, DOI 10.1016/j.cardiores.2004.06.009; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Tong JF, 1999, BIOCHEM J, V343, P39, DOI 10.1042/0264-6021:3430039; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; Van Acker K, 2004, J CELL SCI, V117, P1129, DOI 10.1242/jcs.00948; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wehrens XHT, 2004, NAT REV DRUG DISCOV, V3, P565, DOI 10.1038/nrd1440; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Xiao BL, 2004, CIRC RES, V94, P487, DOI 10.1161/01.RES.0000115945.89741.22; Xiao BL, 2002, J BIOL CHEM, V277, P41778, DOI 10.1074/jbc.M208210200; Xin HB, 1999, J BIOL CHEM, V274, P15315, DOI 10.1074/jbc.274.22.15315; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200; Zhang J, 2003, J BIOL CHEM, V278, P14211, DOI 10.1074/jbc.M213164200; ZISSIMOPOULOS S, 2005, IN PRESS CELL BIOCH; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; Zucchi R, 1997, PHARMACOL REV, V49, P1	69	47	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2005	280	7					5475	5485		10.1074/jbc.M412954200	http://dx.doi.org/10.1074/jbc.M412954200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	900LT	15591045	hybrid			2022-12-25	WOS:000227217100045
J	Chen, CC; Chou, MY; Huang, CH; Majumder, A; Wu, HY				Chen, CC; Chou, MY; Huang, CH; Majumder, A; Wu, HY			A cis-spreading nucleoprotein filament is responsible for the gene silencing activity found in the promoter relay mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN H-NS; NUCLEOID-ASSOCIATED PROTEIN; GRAM-NEGATIVE BACTERIA; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; CURVED DNA; CHROMATIN STRUCTURE; TORSIONAL TENSION; BENDING PHENOMENA	Transcription-generated DNA supercoiling plays a decisive role in a promoter relay mechanism for the coordinated expression of genes in the Salmonella typhimurium ilvIH-leuO-leuABCD gene cluster. A similar mechanism also operates to control expression of the genes in the Escherichia coli ilvIH-leuO-leuABCD gene cluster. However, the mechanism underlying the DNA supercoiling effect remained elusive. A bacterial gene silencer AT8 was found to be important for the repression state of the leuO gene as part of the promoter relay mechanism. In this communication, we demonstrated that the gene silencer AT8 is a nucleation site for recruiting histone-like nucleoid structuring protein to form a cis-spreading nucleoprotein filament that is responsible for silencing of the leuO gene. With a DNA geometric similarity rather than a DNA sequence specificity, the E. coli gene silencer EAT6 was capable of replacing the histone-like nucleoid structuring protein nucleation function of the S. typhimurium gene silencer AT8 for the leuO gene silencing. The interchangeability between DNA geometrical elements for supporting the silencing activity in the region is consistent with a previous finding that a neighboring transcription activity determines the outcome of the gene silencing activity. The geometric requirement, which was revealed for this silencing activity, explains the decisive role of transcription-generated DNA supercoiling found in the promoter relay mechanism.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Wu, HY (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	haiwu@med.wayne.edu			NIGMS NIH HHS [GM-53617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053617, R29GM053617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; BRAHMS JG, 1985, J MOL BIOL, V181, P455, DOI 10.1016/0022-2836(85)90419-X; Caramel A, 1998, J MOL BIOL, V284, P875, DOI 10.1006/jmbi.1998.2191; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chen CC, 2003, J BIOL CHEM, V278, P38094, DOI 10.1074/jbc.M300461200; Chen CC, 2003, FRONT BIOSCI, V8, pD430, DOI 10.2741/968; Chen CC, 2001, J BIOL CHEM, V276, P9478, DOI 10.1074/jbc.M010501200; Dame RT, 2001, BIOCHIMIE, V83, P231; Dole S, 2004, MOL MICROBIOL, V52, P589, DOI 10.1111/j.1365-2958.2004.04001.x; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; Dorman CJ, 2003, CURR OPIN GENET DEV, V13, P179, DOI 10.1016/S0959-437X(03)00025-X; FALCONI M, 1993, MOL MICROBIOL, V10, P273, DOI 10.1111/j.1365-2958.1993.tb01953.x; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 2000, BIOCHEM BIOPH RES CO, V276, P64, DOI 10.1006/bbrc.2000.3440; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GAY P, 1985, J BACTERIOL, V164, P918, DOI 10.1128/JB.164.2.918-921.1985; Gowrishankar J, 1996, GENETICA, V97, P363, DOI 10.1007/BF00055322; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; Ishihama A, 1999, GENES CELLS, V4, P135, DOI 10.1046/j.1365-2443.1999.00247.x; Jordi JAM, 2000, J BIOL CHEM, V275, P12123, DOI 10.1074/jbc.275.16.12123; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Majumder A, 2001, J BIOL CHEM, V276, P19046, DOI 10.1074/jbc.M100945200; Maxam A M, 1980, Methods Enzymol, V65, P499; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; Rimsky S, 2004, CURR OPIN MICROBIOL, V7, P109, DOI 10.1016/j.mib.2004.02.001; Rimsky S, 2001, MOL MICROBIOL, V42, P1311, DOI 10.1046/j.1365-2958.2001.02706.x; Schnetz K, 1996, NUCLEIC ACIDS RES, V24, P2422, DOI 10.1093/nar/24.12.2422; Schroder O, 2002, BIOL CHEM, V383, P945, DOI 10.1515/BC.2002.101; STEINMETZ M, 1985, MOL GEN GENET, V200, P220, DOI 10.1007/BF00425427; Tendeng C, 2003, TRENDS MICROBIOL, V11, P511, DOI 10.1016/j.tim.2003.09.005; Ussery D, 2001, BIOCHIMIE, V83, P201, DOI 10.1016/S0300-9084(00)01225-6; Vlahovicek K, 1999, GENETICA, V106, P63, DOI 10.1023/A:1003724710997; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Williams RM, 1997, FEMS MICROBIOL LETT, V156, P175, DOI 10.1016/S0378-1097(97)00397-2; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; WU HY, 1991, J MOL BIOL, V219, P615, DOI 10.1016/0022-2836(91)90658-S; Wu HY, 2003, PROG NUCLEIC ACID RE, V73, P43, DOI 10.1016/S0079-6603(03)01002-X; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685; YAMASHINO T, 1994, MOL MICROBIOL, V13, P475, DOI 10.1111/j.1365-2958.1994.tb00442.x	48	39	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5101	5112		10.1074/jbc.M411840200	http://dx.doi.org/10.1074/jbc.M411840200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15582999	hybrid			2022-12-25	WOS:000227096600132
J	Han, WP; Rhee, JS; Maximov, A; Lin, WC; Hammer, RE; Rosenmund, C; Sudhof, TC				Han, WP; Rhee, JS; Maximov, A; Lin, WC; Hammer, RE; Rosenmund, C; Sudhof, TC			C-terminal ECFP fusion impairs synaptotagmin 1 function - Crowding out synaptotagmin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE VESICLE EXOCYTOSIS; SYNAPTIC PLASTICITY; C2B DOMAIN; NEUROTRANSMITTER RELEASE; PHOSPHOLIPID-BINDING; ASYNCHRONOUS RELEASE; TRANSMITTER RELEASE; TRANSGENIC MICE; CA2+ BINDING; ADULT CORTEX	To allow the monitoring of synaptotagmin 1 trafficking in vivo, we generated transgenic mice expressing a synaptotagmin 1-enhanced cyan fluorescent protein (ECFP) fusion protein under control of the Thy1 promoter. Transgenic synaptotagmin 1-ECFP is expressed throughout the brain where it localizes to synapses and marks synapses in vivo. However, when we crossed transgenic synaptotagmin 1-ECFP mice with synaptotagmin 1 knock-out mice, we detected no rescue of survival or function. Furthermore, viral overexpression of synaptotagmin 1-ECFP in synaptotagmin 1-deficient neurons failed to restore normal Ca2+-triggered release, whereas overexpression of wild type synaptotagmin I did so efficiently. To determine whether synaptotagmin 1-ECFP is non-functional because the ECFP-fusion interferes with its biochemical activities, we measured,Ca2+ -independent binding of synaptotagmin 1-ECFP to SNARE complexes, and Ca2+-dependent binding of syn-aptotagmin 1-ECFP to phospholipids and to itself. Although the apparent Ca2+ affinity of synaptotagmin 1-ECFP was decreased compared with wild type synaptotagmin 1, we observed no major changes in Ca2+-dependent or -independent activities, indicating that the non-functionality of the synaptotagmin 1-ECFP fusion protein was not because of inactivation of its biochemical properties. These data suggest that synaptotagmin 1-ECFP is suitable for monitoring synaptic vesicle traffic in vivo because the synaptotagmin 1-ECFP marks synaptic vesicles without participating in exocytosis. In addition, the data demonstrate that synaptotagmin 1 function requires a free C terminus, possibly because of spatial constraints at the release sites.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; Max Planck Inst Biophys, D-37070 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; Baylor College of Medicine; Max Planck Society	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu	Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444; Hammer, Robert E./0000-0001-5487-7551				Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Burke NV, 1997, NEURON, V19, P1095, DOI 10.1016/S0896-6273(00)80400-6; Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; De Paola V, 2003, NAT NEUROSCI, V6, P491, DOI 10.1038/nn1046; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2002, J NEUROSCI, V22, P8438; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Foeller E, 2004, CURR OPIN NEUROBIOL, V14, P89, DOI 10.1016/j.conb.2004.01.011; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1994, EMBO J, V13, P3720, DOI 10.1002/j.1460-2075.1994.tb06681.x; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hagler DJ, 2001, J NEUROPHYSIOL, V85, P2324, DOI 10.1152/jn.2001.85.6.2324; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Hogan B, 1994, MANIPULATING MOUSE E; Inoue A, 2003, CURR OPIN NEUROBIOL, V13, P332, DOI 10.1016/S0959-4388(03)00077-1; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kauer JA, 2004, ANNU REV PHYSIOL, V66, P447, DOI 10.1146/annurev.physiol.66.032102.112534; Kee Y, 1996, J NEUROSCI, V16, P1975; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lu T, 2000, NEURON, V26, P683, DOI 10.1016/S0896-6273(00)81204-0; Otsu Y, 2004, J NEUROSCI, V24, P420, DOI 10.1523/JNEUROSCI.4452-03.2004; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Poskanzer KE, 2003, NATURE, V426, P559, DOI 10.1038/nature02184; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Rickman C, 2003, J BIOL CHEM, V278, P5501, DOI 10.1074/jbc.C200692200; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sorensen JB, 2003, J GEN PHYSIOL, V122, P265, DOI 10.1085/jgp.200308855; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Tokuoka H, 2003, NEURON, V38, P521, DOI 10.1016/S0896-6273(03)00290-3; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	54	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					5089	5100		10.1074/jbc.M408757200	http://dx.doi.org/10.1074/jbc.M408757200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15561725	hybrid			2022-12-25	WOS:000227096600131
J	Kanekura, K; Hashimoto, Y; Kita, Y; Sasabe, J; Aiso, S; Nishimoto, I; Matsuoka, M				Kanekura, K; Hashimoto, Y; Kita, Y; Sasabe, J; Aiso, S; Nishimoto, I; Matsuoka, M			A Rac1/phosphatidylinositol 3-kinase/Akt3 anti-apoptotic pathway, triggered by AlsinLF, the product of the ALS2 gene, antagonizes Cu/Zn-superoxide dismutase (SOD1) mutant-induced motoneuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; AMYOTROPHIC-LATERAL-SCLEROSIS; HEREDITARY SPASTIC PARALYSIS; MOTOR-NEURON DEGENERATION; DBL HOMOLOGY DOMAIN; PROTEIN-KINASE; MICE LACKING; INHIBITS APOPTOSIS; PROLONGS SURVIVAL; RAC GTPASE	AlsinLF, the product of the ALS2 gene, inhibits Cu/Zn-superoxide dismutase (SOD1) mutant-induced neurotoxicity via its Rho guanine nucleotide-exchanging factor domain. We here identified Rac1, a Rho family small GTPase, as a target for the Rho guanine nucleotide-exchanging factor activity of alsinLF. Rac1 associates with alsinLF. The amount of the GTP form of Rac1 is up-regulated by enforced overexpression of alsinLF. We further found not only that constitutively active Rac1 suppresses motoneuronal cell death induced by SOD1 mutants but also that the neuroprotective activity of alsinLF was completely inhibited by knocking down the endogenous Rac1 expression with small interfering RNA for Rac1, indicating that Rac1 is the major effector for alsinLF-mediated neuroprotection. Such alsinLF/Rac1-mediated neuroprotection occurs specifically against the SOD1 mutant-induced cell death but not against the cell death induced by any other neurotoxic insults in motoneuronal NSC34 cells. We further demonstrated that the alsinLF/Rac1-mediated neuroprotective signal is transmitted to the phosphatidylinositol 3-kinase/Akt anti-apoptotic axis. Among three Akt family proteins, Akt3 is the major downstream mediator for alsinLF/Rac1-mediated neuroprotection, which is specifically effective against SOD1 mutant-induced neurotoxicity.	Keio Univ, Sch Med, Dept Pharmacol & Neurosci, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Anat, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University	Matsuoka, M (corresponding author), Keio Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	sakimatu@sc.itc.keio.ac.jp	Hashimoto, Yuichi/N-1508-2015	Hashimoto, Yuichi/0000-0001-5863-3618				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Benard V, 2002, METHOD ENZYMOL, V345, P349; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Embade N, 2000, MOL BIOL CELL, V11, P4347, DOI 10.1091/mbc.11.12.4347; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Franke TF, 2000, METHOD ENZYMOL, V322, P400; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; GURNEY ME, 1995, SCIENCE, V269, P149, DOI 10.1126/science.269.5221.149-a; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Hashimoto Y, 2004, J NEUROSCI RES, V75, P417, DOI 10.1002/jnr.10861; Hashimoto Y, 2002, J PHARMACOL EXP THER, V300, P736, DOI 10.1124/jpet.300.3.736; Kanekura K, 2004, J BIOL CHEM, V279, P19247, DOI 10.1074/jbc.M313236200; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lee YS, 2004, FREE RADICAL RES, V38, P405, DOI 10.1080/10715760410001665262; Lesca G, 2003, NEUROLOGY, V60, P674, DOI 10.1212/01.WNL.0000048207.28790.25; Li BL, 2003, MOL BRAIN RES, V111, P155, DOI 10.1016/S0169-328X(03)00025-1; Manabe Y, 2002, APOPTOSIS, V7, P329, DOI 10.1023/A:1016123413038; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Prieto-Sanchez RM, 2003, J BIOL CHEM, V278, P37916, DOI 10.1074/jbc.M301437200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 2000, METHOD ENZYMOL, V325, P264; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zhang BL, 2004, MOL CELL BIOL, V24, P6205, DOI 10.1128/MCB.24.14.6205-6214.2004; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	58	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4532	4543		10.1074/jbc.M410508200	http://dx.doi.org/10.1074/jbc.M410508200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15579468	hybrid			2022-12-25	WOS:000227096600067
J	Le Fourn, V; Ferrand, M; Franc, JL				Le Fourn, V; Ferrand, M; Franc, JL			Endoproteolytic cleavage of human thyroperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROID PEROXIDASE; MESSENGER-RNAS; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; PROTEIN; MYELOPEROXIDASE; EXPRESSION; IDENTIFICATION	Human thyroperoxidase (hTPO), the key enzyme involved in thyroid hormone synthesis, is synthesized in the form of a 933-amino acid polypeptide that subsequently undergoes posttranslational modifications such as N- and 0-glycosylation and heme fixation. In the present study, it was established that the N-terminal part of hTPO is cleaved during the maturation of the enzyme. In the first set of experiments performed in this study, Chines hamster ovary (CHO) cells transfected with hTPO cDNA generated four different species after deglycosylation, namely a 98-kDa species, which corresponds to the full-length deglycosylated hTPO, and two 94-kDa and one 92-kDa species, which were truncated in the N-terminal parts. The three latter forms were detected only at the cell surface. A proprotein convertase inhibitor prevented these cleavages, and experiments using monensin and brefeldin A showed that they occurred in a post-endoplasmic reticulum compartment. Site-directed mutagenesis studies were performed in which Arg(65) was identified as one of the cleavage sites. In the second part of the study, hTPO from human thyroid glands was purified using a monoclonal antibody recognizing the folded form of hTPO. Amino acid determination showed that the N-terminal part of this protein begins at Thr(109). This cleavage process differs from that observed in CHO cells. The fact that this hTPO was endoglucosaminidase H-sensitive indicated that the cleavage of the propeptide occurs in the endoplasmic reticulum. To analyze the role of the hTPO prosequence, cDNAs with and without prosequence (Cys(15)-Lys(108)) were transfected into CHO cells. hTPO propeptide deletion drastically decreased the proportion of the folded hTPO form, and under these conditions the cell surface activity disappeared completely. These results strongly suggest that the prosequence plays a crucial role as an intramolecular chaperone, facilitating the folding of hTPO.	Univ Mediterranee, Fac Med, ICNE,Inst Federat Rech Jean Roche, Lab Rech,CNRS,UMR 6544, F-13916 Marseille 20, France; Fac Pharm Marseille, INSERM, U555, F-13385 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Franc, JL (corresponding author), Univ Mediterranee, Fac Med, ICNE,Inst Federat Rech Jean Roche, Lab Rech,CNRS,UMR 6544, Bd P Dramard, F-13916 Marseille 20, France.	franc.jl@jean-roche.univ-mrs.fr	Franc, Jean-Louis/C-8861-2009	Franc, Jean-Louis/0000-0002-2900-5468				CULLY J, 1989, EXP CELL RES, V180, P440, DOI 10.1016/0014-4827(89)90070-0; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; ELISEI R, 1991, J CLIN ENDOCR METAB, V72, P700, DOI 10.1210/jcem-72-3-700; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Fayadat L, 2000, ENDOCRINOLOGY, V141, P959, DOI 10.1210/en.141.3.959; Fayadat L, 2000, J BIOL CHEM, V275, P15948, DOI 10.1074/jbc.M905763199; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Ferrand M, 2003, J BIOL CHEM, V278, P3793, DOI 10.1074/jbc.M209513200; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gardas A, 1997, J CLIN ENDOCR METAB, V82, P3752, DOI 10.1210/jc.82.11.3752; Gullberg U, 1999, J IMMUNOL METHODS, V232, P201, DOI 10.1016/S0022-1759(99)00177-5; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; Lenz O, 2000, J VIROL, V74, P11418, DOI 10.1128/JVI.74.23.11418-11421.2000; MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; Mouchantaf R, 2004, REGUL PEPTIDES, V120, P133, DOI 10.1016/j.regpep.2004.02.022; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; Sucic JF, 1998, SOMAT CELL MOLEC GEN, V24, P75, DOI 10.1023/B:SCAM.0000007111.46513.70; Takagi H, 2003, APPL MICROBIOL BIOT, V63, P1, DOI 10.1007/s00253-003-1352-1; Taurog A, 1999, BIOCHIMIE, V81, P557, DOI 10.1016/S0300-9084(99)80110-2; TAYLOR KL, 1992, BIOCHEM BIOPH RES CO, V187, P1572, DOI 10.1016/0006-291X(92)90482-Z; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7	33	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4568	4577		10.1074/jbc.M408042200	http://dx.doi.org/10.1074/jbc.M408042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15590661	hybrid			2022-12-25	WOS:000227096600070
J	Shimazu, M; Sekito, T; Akiyama, K; Ohsumi, Y; Kakinuma, Y				Shimazu, M; Sekito, T; Akiyama, K; Ohsumi, Y; Kakinuma, Y			A family of basic amino acid transporters of the vacuolar membrane from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; MAJOR FACILITATOR SUPERFAMILY; PROTON MOTIVE FORCE; MULTIDRUG TRANSPORTER; ACTIVE-TRANSPORT; COMPLETE GENOME; YEAST; VESICLES; PROTEIN; RESISTANCE	Among the members of the major facilitator superfamily of Saccharomyces cerevisiae, we identified genes involved in the transport into vacuoles of the basic amino acids histidine, lysine, and arginine. ATP-dependent uptake of histidine and lysine by isolated vacuolar membrane vesicles was impaired in YMR088c, a vacuolar basic amino acid transporter 1 (VBA1)-deleted strain, whereas uptake of tyrosine or calcium was little affacted. This defect in histidine and lysine uptake was complemented fully by introducing the VBA1 gene and partially by a gene encoding Vba1p fused with green fluorescent protein, which was determined to localize exclusively to the vacuolar membrane. A defect in the uptake of histidine, lysine, or arginine was also observed in the vacuolar membrane vesicles of mutants YBR293w (VBA2) and YCLO69w (VBA3). These three VBA genes are closely related phylogenetically and constitute a new family of basic amino acid transporters in the yeast vacuole.	Ehime Univ, Fac Agr, Matsuyama, Ehime 7908566, Japan; Ehime Univ, Integrated Ctr Sci, Matsuyama, Ehime 7908566, Japan; Muroran Inst Technol, Dept Appl Chem, Muroran, Hokkaido 0508585, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Ehime Univ, Matsuyama, Ehime 7908577, Japan	Ehime University; Ehime University; Muroran Institute of Technology; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Ehime University	Kakinuma, Y (corresponding author), Ehime Univ, Fac Agr, 3-5-7 Tarumi, Matsuyama, Ehime 7908566, Japan.	ykaki@agr.ehime-u.ac.jp	Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166				Albertsen M, 2003, J BIOL CHEM, V278, P12820, DOI 10.1074/jbc.M210715200; Dimitrov K, 1998, MOL CELL BIOL, V18, P5239, DOI 10.1128/MCB.18.9.5239; Ehrenhofer-Murray AE, 1998, YEAST, V14, P49, DOI 10.1002/(SICI)1097-0061(19980115)14:1<49::AID-YEA199>3.0.CO;2-T; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE S, 1954, J BIOL CHEM, V211, P907; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nishimura K, 1998, J BACTERIOL, V180, P1962, DOI 10.1128/JB.180.7.1962-1964.1998; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Russnak R, 2001, J BIOL CHEM, V276, P23849, DOI 10.1074/jbc.M008028200; SATO T, 1984, J BIOL CHEM, V259, P1505; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SIKORSKI RS, 1989, GENETICS, V122, P19; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tenreiro S, 2000, YEAST, V16, P1469, DOI 10.1002/1097-0061(200012)16:16&lt;1469::AID-YEA640&gt;3.0.CO;2-A; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WIEMKEN A, 1974, ARCH MICROBIOL, V101, P45, DOI 10.1007/BF00455924	27	79	85	4	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4851	4857		10.1074/jbc.M412617200	http://dx.doi.org/10.1074/jbc.M412617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15572352	hybrid			2022-12-25	WOS:000227096600104
J	Lipschutz, JH; Li, SX; Arisco, A; Balkovetz, DF				Lipschutz, JH; Li, SX; Arisco, A; Balkovetz, DF			Extracellular signal-regulated kinases 1/2 control claudin-2 expression in Madin-Darby canine kidney strain I and II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; EPITHELIAL-CELLS; MDCK CELLS; SELECTIVE CHANNELS; CONTACT INHIBITION; TIGHT JUNCTIONS; MOUSE NEPHRON; BARRIER; ACTIVATION; RESISTANCE	The tight junction of the epithelial cell determines the characteristics of paracellular permeability across epithelium. Recent work points toward the claudin family of tight junction proteins as leading candidates for the molecular components that regulate paracellular permeability properties in epithelial tissues. Madin-Darby canine kidney (MDCK) strain I and II cells are models for the study of tight junctions and based on transepithelial electrical resistance (TER) contain "tight" and "leaky" tight junctions, respectively. Overexpression studies suggest that tight junction leakiness in these two strains of MDCK cells is conferred by expression of the tight junction protein claudin-2. Extracellular signal-regulated kinase (ERK) 1/2 activation by hepatocyte growth factor treatment of MDCK strain II cells inhibited claudin-2 expression and transiently increased TER. This process was blocked by the ERK 1/2 inhibitor U0126. Transfection of constitutively active mitogen-activated protein kinase/extracellular signal-regulated kinase kinase into MDCK strain II cells also inhibited claudin-2 expression and increased TER. MDCK strain I cells have higher levels of active ERK 1/2 than do MDCK strain II cells. U0126 treatment of MDCK strain I cells decreased active ERK 1/2 levels, induced expression of claudin-2 protein, and decreased TER by similar to20-fold. U0126 treatment also induced claudin-2 expression and decreased TER in a high resistance mouse cortical collecting duct cell line (94D). These data show for the first time that the ERK 1/2 signaling pathway negatively controls claudin-2 expression in mammalian renal epithelial cells and provide evidence for regulation of tight junction paracellular transport by alterations in claudin composition within tight junction complexes.	Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Penn, Dept Med & Cell, Philadelphia, PA 19104 USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; University of Alabama System; University of Alabama Birmingham	Balkovetz, DF (corresponding author), Univ Alabama, Dept Med, LHRB 642,1530 3rd Ave S, Birmingham, AL 35294 USA.	balkovet@uab.edu						Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Balkovetz DF, 2004, AM J PHYSIOL-RENAL, V286, pF702, DOI 10.1152/ajprenal.00270.2003; Balkovetz DF, 1999, LIFE SCI, V64, P1393, DOI 10.1016/S0024-3205(99)00073-9; Balkovetz DF, 1997, J BIOL CHEM, V272, P3471, DOI 10.1074/jbc.272.6.3471; Balkovetz DF, 1999, KIDNEY INT, V56, P910, DOI 10.1046/j.1523-1755.1999.00623.x; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Colegio OR, 2003, AM J PHYSIOL-CELL PH, V284, pC1346, DOI 10.1152/ajpcell.00547.2002; Enck AH, 2001, AM J PHYSIOL-RENAL, V281, pF966, DOI 10.1152/ajprenal.0021.2001; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Inai T, 1999, EUR J CELL BIOL, V78, P849, DOI 10.1016/S0171-9335(99)80086-7; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; Kiuchi-Saishin Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134875; Li SX, 2004, AM J PHYSIOL-CELL PH, V287, pC432, DOI 10.1152/ajpcell.00020.2004; Li WY, 2004, AM J PHYSIOL-RENAL, V286, pF1063, DOI 10.1152/ajprenal.00384.2003; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; Lieske JC, 2000, AM J PHYSIOL-RENAL, V278, pF130, DOI 10.1152/ajprenal.2000.278.1.F130; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masaki T, 2004, J AM SOC NEPHROL, V15, P1835, DOI 10.1097/01.ASN.0000130623.66271.67; MUTO S, 2004, J AM SOC NEPHROL, V15, pA4; Pollack AL, 2004, AM J PHYSIOL-CELL PH, V286, pC482, DOI 10.1152/ajpcell.00377.2003; Reyes JL, 2002, KIDNEY INT, V62, P476, DOI 10.1046/j.1523-1755.2002.00479.x; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Singh AB, 2004, J BIOL CHEM, V279, P3543, DOI 10.1074/jbc.M308682200; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Yamauchi K, 2004, P NATL ACAD SCI USA, V101, P4690, DOI 10.1073/pnas.0306924101; Yoder BK, 2002, AM J PHYSIOL-RENAL, V282, pF541, DOI 10.1152/ajprenal.00273.2001; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	34	103	106	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3780	3788		10.1074/jbc.M408122200	http://dx.doi.org/10.1074/jbc.M408122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15569684	hybrid			2022-12-25	WOS:000226983900079
J	Woo, HA; Jeong, WJ; Chang, TS; Park, KJ; Park, SJ; Yang, JS; Rhee, SG				Woo, HA; Jeong, WJ; Chang, TS; Park, KJ; Park, SJ; Yang, JS; Rhee, SG			Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-Cys peroxiredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; TYROSINE-PHOSPHATASE 1B; NECROSIS-FACTOR-ALPHA; MAMMALIAN PEROXIREDOXIN; SACCHAROMYCES-CEREVISIAE; REVERSIBLE INACTIVATION; THIOREDOXIN PEROXIDASE; SITE CYSTEINE; ACTIVE-SITE; PROTEIN	Cysteine residues of certain peroxiredoxins (Prxs) undergo reversible oxidation to sulfinic acid (Cys-SO2H) and the reduction reaction is catalyzed by sulfiredoxin (Srx). Specific Cys residues of various other proteins are also oxidized to sulfinic acid, suggesting that formation Of Cys-SO2H might be a novel posttranslational. modification that contributes to regulation of protein function. To examine the susceptibility of sulfinic forms of proteins to reduction by Srx, we prepared such forms of all six mammalian Prx isoforms and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Purified sulfiredoxin reduced the sulfinic forms of the four 2-Cys members (Prx I to Prx IV) of the Prx family in vitro, but it did not affect those of Prx V, Prx VI, or GAPDH. Furthermore, Srx bound specifically to the four 2-Cys Prxs in vitro and in cells. Sulfinic forms of Prx I and Prx II, but not of Prx VI or GAPDH, present in H2O2-treated A549 cells were gradually reduced after removal of H2O2; overexpression of Srx increased the rate of the reduction of Prx I and Prx II but did not induce that of Prx VI or GAPDH. These results suggest that reduction of Cys-SO2H by Srx is specific to 2-Cys Prx isoforms. For proteins such as Prx VI and GAPDH, sulfinic acid formation might be an irreversible process that causes protein damage.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; Ewha Womans University	Rhee, SG (corresponding author), Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov	Woo, Hyun Ae/AAT-9586-2021					Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Griffiths SW, 2002, J BIOL CHEM, V277, P25486, DOI 10.1074/jbc.M203089200; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jacob C, 2004, ORG BIOMOL CHEM, V2, P1953, DOI 10.1039/b406180b; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Kristensen P, 1999, BIOCHEM BIOPH RES CO, V262, P127, DOI 10.1006/bbrc.1999.1107; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Mallis RJ, 2002, BIOL CHEM, V383, P649, DOI 10.1515/BC.2002.067; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Wang QP, 2004, BIOCHEMISTRY-US, V43, P4294, DOI 10.1021/bi035986e; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	32	240	251	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3125	3128		10.1074/jbc.C400496200	http://dx.doi.org/10.1074/jbc.C400496200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15590625	hybrid			2022-12-25	WOS:000226983900002
J	Suenaga, N; Mori, H; Itoh, Y; Seiki, M				Suenaga, N; Mori, H; Itoh, Y; Seiki, M			CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase	ONCOGENE			English	Article						MT-MMP; CD44; hemopexin-like domain	TUMOR-CELL MIGRATION; SURFACE; EXPRESSION; INVASION; MT1-MMP; MATRIX-METALLOPROTEINASE-9; ACTIVATION; CLEAVAGE	Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a potent modulator of pericellular environment through its proteolytic activity and promotes migration, invasion, and proliferation of tumor cells. During cell migration, MT1-MMP binds to CD44H, a major hyaluronan receptor, through the hemopexin-like (HPX) domain and localizes at the migration front. MT1-MMP is also responsible for shedding CD44H, which supports CD44H-mediated cell migration. In this study, we asked whether the binding of MT1-MMP to CD44H is a prerequisite step for the successive shedding. Deletion of the HPX domain deprived MT1-MMP of its shedding activity. Furthermore, disruption of the CD44H/MT1-MMP complex by overexpressing the HPX fragments resulted in inhibition of the shedding. Thus, the CD44H in the complex appears to be the direct substrate of MT1-MMP for shedding. Interestingly, other members of the MT-MMP family showed varied extents of CD44H shedding. Domain swapping between MT1-MMP and other MT-MMPs revealed that the ability of the HPX domains to bind CD44H is conserved among them. However, the shedding activity was different depending on the catalytic domains. The conserved binding ability of the HPX domains suggests that CD44H may act as a core molecule assembling multiple MT-MMPs on the cell surface.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015	Itoh, Yoshifumi/0000-0002-2128-2823				Abecassis I, 2003, EXP CELL RES, V291, P363, DOI 10.1016/j.yexcr.2003.08.006; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Goebeler M, 1996, J CELL SCI, V109, P1957; Ha HY, 2001, CANCER RES, V61, P984; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Murai T, 2004, J BIOL CHEM, V279, P4541, DOI 10.1074/jbc.M307356200; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; NAOT D, 1997, ADV CANCER RES, V71, P241; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Vivinus-Nebot M, 2004, J IMMUNOL, V172, P1397, DOI 10.4049/jimmunol.172.3.1397; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	27	83	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					859	868		10.1038/sj.onc.1208258	http://dx.doi.org/10.1038/sj.onc.1208258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558018				2022-12-25	WOS:000226577100012
J	Kishimoto, K; Liu, SM; Tsuji, T; Olson, KA; Hu, GF				Kishimoto, K; Liu, SM; Tsuji, T; Olson, KA; Hu, GF			Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis	ONCOGENE			English	Article						angiogenin; angiogenesis; rRNA transcription; ribosome biogenesis; nuclear translocation; angiogenic factors	NUCLEOLAR ORGANIZER REGIONS; GROWTH-FACTOR; BINDING-PROTEIN; TUMOR-GROWTH; EXPRESSION; CANCER; SERUM; MECHANISMS; ACTIN; MICE	Angiogenin is an angiogenic protein that undergoes nuclear translocation in endothelial cells where it accumulates in the nucleolus and stimulates rRNA transcription, a rate-limiting step in ribosome biogenesis, protein translation, and cell growth. Here, we report that angiogenin is required for cell proliferation induced by various other angiogenic proteins including acidic and basic fibroblast growth factors ( aFGF and bFGF), epidermal growth factor (EGF), and vascular endothelial growth factor ( VEGF). Downregulation of angiogenin in endothelial cells by small interfering RNA ( siRNA) and antisense results in a decrease in rRNA transcription, ribosome biogenesis, and cell proliferation induced by these angiogenic factors. Inhibitors of the nuclear translocation of angiogenin abolish the angiogenic activities of these factors. Stable angiogenin antisense transfection in HeLa cells reduces tumor angiogenesis in athymic mice despite the elevated expression level of bFGF and VEGF. Thus, nuclear angiogenin assumes an essential role in endothelial cell proliferation and is necessary for angiogenesis induced by other angiogenic factors. Angiogenin-stimulated rRNA transcription in endothelial cells may thus serve as a crossroad in the process of angiogenesis induced by various angiogenic factors.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hu, GF (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,NRB 930, Boston, MA 02115 USA.	guofu_hu@hms.harvard.edu			NATIONAL CANCER INSTITUTE [R21CA091086] Funding Source: NIH RePORTER; NCI NIH HHS [CA91086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams S A, 1999, Angiogenesis, V3, P189, DOI 10.1023/A:1009015512200; AU S, 1986, ANTIMICROB AGENTS CH, V30, P395, DOI 10.1128/AAC.30.3.395; Barton DPJ, 1997, CLIN CANCER RES, V3, P1579; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; Bodner-Adler B, 2001, ANTICANCER RES, V21, P809; Eberle K, 2000, ANTICANCER RES, V20, P1679; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; Fu XY, 1999, GROWTH FACTORS, V17, P125, DOI 10.3109/08977199909103521; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Homer JJ, 2002, CLIN OTOLARYNGOL, V27, P32, DOI 10.1046/j.0307-7772.2001.00519.x; HU GF, 1993, BIOCHEM BIOPH RES CO, V197, P682, DOI 10.1006/bbrc.1993.2533; Hu GF, 2000, J CELL BIOCHEM, V76, P452, DOI 10.1002/(SICI)1097-4644(20000301)76:3<452::AID-JCB12>3.0.CO;2-Z; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; Hu GF, 1997, P NATL ACAD SCI USA, V94, P2204, DOI 10.1073/pnas.94.6.2204; Imaizumi T, 2000, THROMB HAEMOSTASIS, V83, P949; Kinoshita M, 1999, ARTERIOSCL THROM VAS, V19, P2323, DOI 10.1161/01.ATV.19.10.2323; Kushlinskii NE, 2000, B EXP BIOL MED+, V130, P691, DOI 10.1007/BF02682107; LI DC, 1994, J PATHOL, V172, P171, DOI 10.1002/path.1711720203; Liu SM, 2001, BIOCHEM BIOPH RES CO, V287, P305, DOI 10.1006/bbrc.2001.5568; MOENNER M, 1994, EUR J BIOCHEM, V226, P483, DOI 10.1111/j.1432-1033.1994.tb20073.x; Montero S, 1998, CLIN CANCER RES, V4, P2161; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; Olson KA, 2002, INT J CANCER, V98, P923, DOI 10.1002/ijc.10282; Olson KA, 2001, CLIN CANCER RES, V7, P3598; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; Ribatti D, 2000, GEN PHARMACOL-VASC S, V35, P227, DOI 10.1016/S0306-3623(01)00112-4; Risau W, 1996, CANCER METAST REV, V15, P149, DOI 10.1007/BF00437466; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; RUSCHOFF J, 1989, PATHOL RES PRACT, V185, P878; Shimoyama S, 1999, PANCREAS, V18, P225, DOI 10.1097/00006676-199904000-00002; Shimoyama S, 2002, ANTICANCER RES, V22, P1045; TRERE D, 1989, EXP CELL RES, V184, P131, DOI 10.1016/0014-4827(89)90371-6; Ugurel S, 2001, J CLIN ONCOL, V19, P577, DOI 10.1200/JCO.2001.19.2.577; WILLIAMS PD, 1987, ANTIMICROB AGENTS CH, V31, P570, DOI 10.1128/AAC.31.4.570; WILTING J, 1991, ANAT EMBRYOL, V183, P259; Xu ZP, 2003, BIOCHEMISTRY-US, V42, P121, DOI 10.1021/bi020465x; Xu ZP, 2002, BIOCHEM BIOPH RES CO, V294, P287, DOI 10.1016/S0006-291X(02)00479-5	45	261	281	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					445	456		10.1038/sj.onc.1208223	http://dx.doi.org/10.1038/sj.onc.1208223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558023				2022-12-25	WOS:000226279700015
